PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SMYTH, GE; COLMAN, RF				SMYTH, GE; COLMAN, RF			CYSTEINYL PEPTIDES OF PIG-HEART NADP-DEPENDENT ISOCITRATE DEHYDROGENASE THAT ARE MODIFIED UPON INACTIVATION BY N-ETHYLMALEIMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; THIOCYANO ENZYME; ACTIVE-SITE; METAL-IONS; DIMERIZATION; ACID	Pig heart NADP-specific isocitrate dehydrogenase is inactivated by N-ethylmaleimide (NEM) (Colman, R. F., and Chu, R. (1970) J. Biol. Chem. 245, 601-607), and is completely protected against inactivation, but not against the incorporation of NEM, by isocitrate plus Mn2+. We have now treated the enzyme with [H-3] NEM in the absence and presence of isocitrate plus Mn2+, digested it with trypsin, and isolated and sequenced the labeled Cys peptides. In the inactive enzyme, two major peptides, SSGGFVWACK and DLAGCIHGLSNVK, and two minor peptides, CATITPDEAR and EPIICK, were labeled at Cys. Upon reaction with [H-3]NEM in the presence of isocitrate plus Mn2+, full catalytic activity was retained and only DLAGCIHGLSNVK was labeled; the Cys of this peptide is therefore not essential for catalysis. The modification of SSGGFVWACK appears to be the major cause of inactivation by NEM. The Cys in SSGGFVWACK may have a catalytic role, most likely in the strengthened binding of Mn2+ in the presence of isocitrate. Isocitrate dehydrogenase was carboxymethylated under denaturing conditions with [C-14]iodoacetate and digested with trypsin; 6 unique labeled Cys peptides, containing 6 unique Cys residues, were purified and sequenced. Six corresponding peptides were isolated from enzyme treated under denaturing conditions with [H-3]NEM. These results eliminate the previous uncertainty regarding the number of Cys residues in the enzyme. A comparison of the sequences of the NH2-terminal 30 residues and the 6 Cys peptides of the pig heart NADP-dependent isocitrate dehydrogenase with the Escherichia coli NADP enzyme provides evidence for great dissimilarity between the two enzymes.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039075] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39075] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON CR, 1981, J BIOL CHEM, V256, P6593; BAILEY JM, 1987, J BIOL CHEM, V262, P12620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1970, BIOCHEMISTRY-US, V9, P4945, DOI 10.1021/bi00827a017; COLMAN RF, 1970, J BIOL CHEM, V245, P608; COLMAN RF, 1969, BIOCHEMISTRY-US, V8, P888, DOI 10.1021/bi00831a019; COLMAN RF, 1970, J BIOL CHEM, V245, P601; COLMAN RF, 1973, J BIOL CHEM, V248, P8137; COLMAN RF, 1968, J BIOL CHEM, V243, P2454; COLMAN RF, 1972, J BIOL CHEM, V247, P215; COLMAN RF, 1983, PEPTIDE PROTEIN REV, V1, P41; DANZIEL K, 1980, FEBS LETT, V117, pK45; EGUCHI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P133, DOI 10.1016/S0304-4165(89)80024-8; EHRLICH RS, 1978, EUR J BIOCHEM, V89, P575, DOI 10.1111/j.1432-1033.1978.tb12562.x; EHRLICH RS, 1977, BIOCHEMISTRY-US, V16, P3378, DOI 10.1021/bi00634a014; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; JOHANSON RA, 1981, ARCH BIOCHEM BIOPHYS, V207, P21, DOI 10.1016/0003-9861(81)90003-5; JOHANSON RA, 1981, ARCH BIOCHEM BIOPHYS, V207, P9, DOI 10.1016/0003-9861(81)90002-3; KEILDLOUHA V, 1971, FEBS LETT, V16, P291, DOI 10.1016/0014-5793(71)80373-3; KEILDLOUHA V, 1971, FEBS LETT, V16, P287, DOI 10.1016/0014-5793(71)80372-1; KELLY JH, 1981, J BIOL CHEM, V256, P335; KELLY JH, 1981, J BIOL CHEM, V256, P330; KONIGSBERG WH, 1977, PROTEINS, V3, P1; MAROUX S, 1966, BIOCHIM BIOPHYS ACTA, V122, P147, DOI 10.1016/0926-6593(66)90098-1; NAGAOKA T, 1977, J BIOCHEM-TOKYO, V81, P71, DOI 10.1093/oxfordjournals.jbchem.a131452; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Plaut G.E.W., 1963, ENZYMES, V7, P105; Smyth DG, 1960, J AM CHEM SOC, V82, P4600, DOI 10.1021/ja01502a039; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; SMYTH GE, 1989, ABSTRACTS PROTEIN SO; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; VILLAFRANCA JJ, 1972, J BIOL CHEM, V247, P209	33	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14918	14925						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869531				2022-12-25	WOS:A1991GB09700021
J	WOOD, DA; HAPAK, LK; SIMS, SM; DIXON, SJ				WOOD, DA; HAPAK, LK; SIMS, SM; DIXON, SJ			DIRECT EFFECTS OF PLATELET-ACTIVATING-FACTOR ON ISOLATED RAT OSTEOCLASTS - RAPID ELEVATION OF INTRACELLULAR FREE CALCIUM AND TRANSIENT RETRACTION OF PSEUDOPODS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; PAF-ACETHER; EXTRACELLULAR CALCIUM; ENDOTHELIAL-CELLS; BINDING-SITES; CALCITONIN; RECEPTOR; DESENSITIZATION; MOBILIZATION; MACROPHAGES	Platelet-activating factor (PAF, 1-O-alkyl-(2R)-acetylglycero-3-phosphocholine) is a potent inflammatory mediator whose actions on bone cells have not been investigated previously. In this study, we examined effects of PAF on osteoclast morphology and intracellular free calcium. Osteoclasts, the large multinucleated cells responsible for bone resorption, were isolated from neonatal rat long bones, and the cytosolic free calcium concentration ([Ca2+]i) of individual fura-2-loaded cells was monitored by microspectrofluorimetry. In one series of experiments, PAF was applied focally to single, isolated osteoclasts (1 nM to 1-mu-M racemic mixture, in an application micropipette). Within 10 s of PAF application, [Ca2+]i increased from basal levels of 74 +/- 6 nM to peak levels of 209 +/- 28 nM (mean +/- S.E. of 24 cells responding). These results indicate that PAF acted directly on osteoclasts. In more than 75% of cells tested, PAF, at concentrations greater-than-or-equal-to 10 pm (final concentration, in the bath), induced biphasic elevation of [Ca2+]i. This response was highly specific for PAF, in that vehicle, lyso-PAF (the biologically inactive precursor/metabolite of PAF), and (S)-PAF (the inactive enantiomer of PAF) all failed to change [Ca2+]i. Moreover, [Ca2+]i elevation was blocked by the specific PAF antagonist CV-3988. To determine the source of Ca 2-, cells were bathed in Ca2+-free medium, where PAF still caused an increase in [Ca2+]i, establishing that the response to PAF arose, at least in part, by release of Ca2+ from internal stores. In addition to changes in [Ca2+]i, PAF caused retraction followed by respreading of peripheral pseudopods. These findings indicate that rat osteoclasts respond to PAF by release of internal calcium and alterations in cell morphology and suggest that PAF may regulate resorption in inflammatory bone diseases.	UNIV WESTERN ONTARIO, FAC DENT, DIV ORAL BIOL, LONDON N6A 5C1, ONTARIO, CANADA; UNIV WESTERN ONTARIO, FAC DENT, DEPT PHYSIOL, LONDON N6A 5C1, ONTARIO, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)			Sims, Stephen/G-4510-2013; Dixon, S. Jeffrey/G-3657-2013	Dixon, S. Jeffrey/0000-0001-9162-1686				AVDONIN PV, 1987, THROMB RES, V46, P29, DOI 10.1016/0049-3848(87)90204-0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANK ML, 1982, RES COMMUN CHEM PATH, V38, P3; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; CHAMBERS TJ, 1983, CALCIFIED TISSUE INT, V35, P566, DOI 10.1007/BF02405095; CHAMBERS TJ, 1984, J CELL SCI, V66, P383; CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104; CONRAD GW, 1986, J CELL BIOL, V103, P439, DOI 10.1083/jcb.103.2.439; DATTA HK, 1989, BIOSCIENCE REP, V9, P747, DOI 10.1007/BF01114813; FISHER RA, 1989, FEBS LETT, V251, P22, DOI 10.1016/0014-5793(89)81421-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAPAK LK, 1990, J DENT RES, V69, P349; HARTUNG HP, 1983, FEBS LETT, V160, P209, DOI 10.1016/0014-5793(83)80968-5; HASLAM RJ, 1985, MECHANISMS STIMULUS, P265; HIRAFUJI M, 1988, BIOCHEM BIOPH RES CO, V154, P910, DOI 10.1016/0006-291X(88)90226-4; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; HWANG SB, 1985, BIOCHEM BIOPH RES CO, V128, P972, DOI 10.1016/0006-291X(85)90142-1; KERALY CL, 1983, BRIT J HAEMATOL, V53, P513, DOI 10.1111/j.1365-2141.1983.tb02053.x; KLOPROGGE E, 1984, BIOCHEM J, V223, P901, DOI 10.1042/bj2230901; KROEGEL C, 1989, BIOCHEM BIOPH RES CO, V162, P511, DOI 10.1016/0006-291X(89)92027-5; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; NG DS, 1986, BIOCHEM BIOPH RES CO, V141, P353, DOI 10.1016/S0006-291X(86)80376-X; NICHOLSON GC, 1986, J CELL BIOCHEM, V31, P229, DOI 10.1002/jcb.240310305; NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584; NICHOLSON GC, 1987, ENDOCRINOLOGY, V120, P1902, DOI 10.1210/endo-120-5-1902; NIGAM S, 1989, J LIPID MEDIATOR, V1, P323; NOGUCHI K, 1989, ARCH ORAL BIOL, V34, P37, DOI 10.1016/0003-9969(89)90044-7; PETTIPHER ER, 1987, AGENTS ACTIONS, V21, P98, DOI 10.1007/BF01974929; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RANDRIAMAMPITA C, 1989, FEBS LETT, V249, P199, DOI 10.1016/0014-5793(89)80624-6; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SCHLONDORFF D, 1984, J CLIN INVEST, V73, P1227, DOI 10.1172/JCI111309; SCHULAM PG, 1990, BIOCHEM BIOPH RES CO, V166, P1047, DOI 10.1016/0006-291X(90)90916-B; SCHWERTSCHLAG US, 1988, J BIOL CHEM, V263, P13791; SIMS SM, 1989, AM J PHYSIOL, V256, pC1277, DOI 10.1152/ajpcell.1989.256.6.C1277; STURK A, 1989, ADV LIPID RES, V23, P219; TERASHITA Z, 1983, LIFE SCI, V32, P1975, DOI 10.1016/0024-3205(83)90049-8; TERASHITA ZI, 1985, BIOCHEM PHARMACOL, V34, P1491, DOI 10.1016/0006-2952(85)90689-6; TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235; VAES G, 1988, CLIN ORTHOP RELAT R, P239; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WARSHAWSKY H, 1980, J CELL BIOL, V85, P682, DOI 10.1083/jcb.85.3.682; WOOD D A, 1990, Calcified Tissue International, V46, pA18; WOOD DA, 1990, J DENT RES, V69, P349; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006-291X(89)91143-1	50	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15369	15376						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869559				2022-12-25	WOS:A1991GB09700081
J	SCHEIDELER, MA; BELL, RM				SCHEIDELER, MA; BELL, RM			CHARACTERIZATION OF ACTIVE AND LATENT FORMS OF THE MEMBRANE-ASSOCIATED SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; PHOSPHOLIPID-SYNTHESIS; TRITON X-100; WILD-TYPE; BIOSYNTHESIS; PURIFICATION; PLSB; DEPENDENCE; PROTEIN; GENE	The intrinsically active, sn-glycerol-3-phosphate acyltransferase present in membranes prepared from both wild type Escherichia coli and from strains which overproduce the enzyme can be kinetically distinguished from a latent enzyme species which is unmasked by solubilization and reconstitution. Both membrane-associated and solubilized/reconstituted enzyme preparations exhibited cooperativity with respect to sn-glycerol-3-phosphate and palmitoyl-coenzyme A substrates; positive cooperativity in membranes toward palmitoyl-coenzyme A (n(app) = 4) and negative cooperativity toward sn-glycerol-3-phosphate (n(app) = 0.75) were significantly altered upon solubilization and reconstitution. Since the degree of alteration increased with the amount of sn-glycerol-3-P acyltransferase present in the membranes, a detergent-dissociable homooligomerization of the sn-glycerol-3-phosphate acyltransferase was considered as an underlying mechanism. This possibility was investigated by changing the protein-to-Triton X-100 ratio of homogeneous enzyme prior to reconstitution and then analyzing the subsequent migration of samples on a Sephacryl S-300 sizing column. The elution positions were consistent with monomeric and dimeric polypeptide bound to micelles of Triton X-100. Hill coefficients for monomeric, reconstituted enzyme preparations were comparable to those obtained for the active, membrane-associated sn-glycerol-3-phosphate acyltransferase. The reduced cooperativity of dimeric, reconstituted enzyme preparations correlated closely to the Hill coefficient values obtained for latent, solubilized/reconstituted sn-glycerol-3-phosphate acyltransferase from membranes of Escherichia coli which overproduce the enzyme. The physiological significance of these findings is discussed.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM20015] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; BELL RM, 1981, J LIPID RES, V22, P391; BELL RM, 1975, J BIOL CHEM, V250, P7147; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; CHANG YY, 1967, J LIPID RES, V8, P447; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; DIXON M, 1979, ENZYMES, P426; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; EDGAR JR, 1978, J BIOL CHEM, V253, P6354; ELL RM, 1975, J BIOL CHEM, V250, P7153; GOELZ SE, 1980, J BACTERIOL, V144, P462, DOI 10.1128/JB.144.1.462-464.1980; GOELZ SE, 1982, BIOCHEMISTRY-US, V21, P189, DOI 10.1021/bi00530a032; GREEN PR, 1983, J BIOL CHEM, V258, P862; GREEN PR, 1984, BIOCHIM BIOPHYS ACTA, V795, P348, DOI 10.1016/0005-2760(84)90085-7; GREEN PR, 1981, J BIOL CHEM, V256, P1151; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; KAINUMAKURODA R, 1980, J BACTERIOL, V142, P362, DOI 10.1128/JB.142.1.362-365.1980; KITO M, 1975, EUR J BIOCHEM, V54, P55, DOI 10.1111/j.1432-1033.1975.tb04113.x; LARSON TJ, 1987, J BIOL CHEM, V262, P15869; LARSON TJ, 1984, J BACTERIOL, V160, P711, DOI 10.1128/JB.160.2.711-717.1984; LIGHTNER VA, 1983, J BIOL CHEM, V258, P856; LIGHTNER VA, 1980, J BIOL CHEM, V255, P9413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUEKING DR, 1975, J BIOL CHEM, V250, P4911; MERLIE JP, 1973, J BACTERIOL, V116, P355, DOI 10.1128/JB.116.1.355-366.1973; NUNN WD, 1976, BIOCHEMISTRY-US, V15, P2546, DOI 10.1021/bi00657a009; OKOJAMA H, 1977, BIOCHEMISTRY-US, V16, P2668; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; RICHARDS EW, 1985, FED PROC, V44, P5864; ROBINSON NC, 1986, BIOCHEMISTRY-US, V25, P2328, DOI 10.1021/bi00357a005; ROBSON RJ, 1977, J PHYS CHEM-US, V81, P1075, DOI 10.1021/j100526a010; SCHEIDELER MA, 1986, J BIOL CHEM, V261, P990; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; SEGAL IH, 1975, ENZYME KINETICS, P368; SINENSKY M, 1971, J BACTERIOL, V106, P449, DOI 10.1128/JB.106.2.449-455.1971; SNIDER MD, 1977, J BACTERIOL, V130, P1072, DOI 10.1128/JB.130.3.1072-1083.1977; SNIDER MD, 1979, J BIOL CHEM, V254, P7197; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; WILKISON WO, 1986, J BIOL CHEM, V261, P9951; WILKISON WO, 1988, J BIOL CHEM, V263, P14505	43	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14321	14327						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860841				2022-12-25	WOS:A1991FZ35100035
J	CHAKRABARTI, A; MAITRA, U				CHAKRABARTI, A; MAITRA, U			FUNCTION OF EUKARYOTIC INITIATION FACTOR-5 IN THE FORMATION OF AN 80-S RIBOSOMAL POLYPEPTIDE-CHAIN INITIATION COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; RABBIT RETICULOCYTES; FACTOR-II; CALF LIVER; PURIFICATION; RELEASE; BINDING; FORMS	Eukaryotic initiation factor 5 (eIF-5), isolated from rabbit reticulocyte lysates, is a monomeric protein of 58-62 kDa. The function of eIF-5 in the formation of an 80 S polypeptide chain initiation complex from a 40 S initiation complex has been investigated. Incubation of the isolated 40 S initiation complex (40 S.AUG.Met.tRNA(f)-eIF-2 GTP) with eIF-5 resulted in the rapid and quantitative hydrolysis of GTP bound to the 40 S initiation complex. The rate of this reaction was unaffected by the presence of 60 S ribosomal subunits. Analysis of eIF-5-catalyzed reaction products by gel filtration indicated that both eIF-2.GDP binary complex and P(i) formed were released from the ribosomal complex whereas Met-tRNA(f) remained bound to 40 S ribosomes as a Met-tRNA(f).40 S.AUG complex. Reactions carried out with biologically active P-32-labeled eIF-5 indicated that this protein was not associated with the 40 S.AUG.Met-tRNA(f) complex; similar results were obtained by immunological methods using monospecific anti-eIF-5 antibodies. The isolated 40 S.AUG.Met-RNA(f) complex, free of eIF-2.GDP binary complex and eIF-5, readily interacted with 60 S ribosomal subunits in the absence of exogenously added eIF-5 to form the 80 S initiation complex capable of transferring Met-tRNA(f) into peptide linkages. These results indicate that the sole function of eIF-5 in the initiation of protein synthesis is to mediate hydrolysis of GTP bound to the 40 S initiation complex in the absence of 60 S ribosomal subunits. This leads to formation of the intermediate 40 S.AUG.Met-tRNA(f) and dissociation of the eIF-2.GDP binary complex. Subsequent joining of 60 S ribosomal subunits to the intermediate 40 S.AUG.Met-tRNA(f) complex does not require participation of eIF-5. Thus, the formation of an 80 S ribosomal polypeptide chain initiation complex from a 40 S ribosomal initiation complex can be summarized by the following sequence of partial reactions. (40 S.AUG.Met-tRNA(f)-eIF-2-GTP) (1) eIF-5 --> (40 S.SUG.Met-tRNA(f)) + (eIF-2.GDP) + P(i) (40 S.AUG.Met-tRNA(f)) + 60 S (2) --> (80 S.AUG.Met-tTRA(f)) 80 S initiation complex			CHAKRABARTI, A (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,DIV BIOL SCI,BRONX,NY 10461, USA.				NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1978, J BIOL CHEM, V253, P3078; BENNE R, 1978, J BIOL CHEM, V253, P3070; CHAUDHURI A, 1981, J BIOL CHEM, V256, P3988; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; DHOLAKIA JN, 1987, J BIOL CHEM, V262, P10164; DUBNOFF J S, 1972, Journal of Biological Chemistry, V247, P2876; GHOSH S, 1989, J BIOL CHEM, V264, P5134; Hathaway G M, 1979, Methods Enzymol, V60, P495; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MEYER LJ, 1981, J BIOL CHEM, V256, P351; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1986, J BIOL CHEM, V261, P7723; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; Zasloff M, 1974, Methods Enzymol, V30, P197	23	57	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14039	14045						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856230				2022-12-25	WOS:A1991FY02700091
J	SARDANA, M; SARDANA, V; RODKEY, J; WOOD, T; NG, A; VLASUK, GP; WAXMAN, L				SARDANA, M; SARDANA, V; RODKEY, J; WOOD, T; NG, A; VLASUK, GP; WAXMAN, L			DETERMINATION OF DISULFIDE BOND PAIRS AND STABILITY IN RECOMBINANT TICK ANTICOAGULANT PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; INHIBITOR; PURIFICATION; CELLS	Tick anticoagulant peptide (TAP) is a potent and selective inhibitor of blood coagulation factor Xa (Waxman, L., Smith, D. E., Arcuri, K. E., and Vlasuk, G. P. (1990) Science 248, 593-596). The 60-amino acid sequence of TAP shows limited homology to Kunitz-type inhibitors, including cysteines at positions 5, 15, 33, 39, 55, and 59. For detailed biochemical and pharmacological studies, a recombinant version of TAP (rTAP) has been produced in yeast. To determine the arrangement of the disulfide bonds, rTAP was cleaved with trypsin and chymotrypsin and the purified peptides sequenced using a gas-phase sequenator. The positions of the disulfide bonds were assigned by identifying the cycle(s) at which di-phenylthiohydantoin-cystine was released. The specific disulfide bridges, Cys-5 to Cys-59, Cys-15 to Cys-39, and Cys-33 to Cys-55, are analogous to those in the prototype Kunitz-type inhibitor, bovine pancreatic trypsin inhibitor (BPTI). While treatment of BPTI with dithiothreitol rapidly and specifically reduced one disulfide bond, the reduction of disulfide bonds in rTAP proceeded at a slower rate and appeared to be nonspecific, reaching a maximum of two disulfides reduced. Reduced rTAP derivatized with either iodoacetic acid or iodoacetamide lost 59% of its inhibitory activity. In contrast, BPTI alkylated with iodoacetic acid inhibited trypsin half as well as the iodoacetamide derivative. Although the arrangement of disulfides in the two inhibitors is the same, their susceptibility to reduction is markedly different.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486; MERCK SHARP & DOHME LTD,DEPT VIRUS & CELL BIOL,W POINT,PA 19486	Merck & Company; Merck & Company								AHMED AK, 1975, J BIOL CHEM, V250, P8477; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BURMAN S, 1989, P NATL ACAD SCI USA, V86, P429, DOI 10.1073/pnas.86.2.429; CONDRA JH, 1990, J BIOL CHEM, V265, P2292; GRONKE RS, 1990, J BIOL CHEM, V265, P8558; HOLLECKER M, 1983, J MOL BIOL, V168, P409, DOI 10.1016/S0022-2836(83)80026-6; JORDAN SP, 1990, BIOCHEMISTRY-US, V29, P11095, DOI 10.1021/bi00502a012; KASSELL B, 1956, J BIOL CHEM, V219, P203; KIDO H, 1988, J BIOL CHEM, V263, P18104; KRESS LF, 1967, J BIOL CHEM, V242, P4925; MARKS CB, 1987, SCIENCE, V235, P1370, DOI 10.1126/science.2435002; NEEPER MP, 1990, J BIOL CHEM, V265, P17746; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; WANKYNG L, 1968, BIOCHEM BIOPH RES CO, V31, P467; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510	15	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13560	13563						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856193				2022-12-25	WOS:A1991FY02700019
J	VU, HK; DELBECCHI, L; BOURGAUXRAMOISY, D; BOURGAUX, P				VU, HK; DELBECCHI, L; BOURGAUXRAMOISY, D; BOURGAUX, P			THE SAME MAMMALIAN REPLICON YIELDS DISTINCT RECOMBINATION PRODUCTS IN DIFFERENT CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HYBRID REPLICON; DNA-SEQUENCE; NONHOMOLOGOUS RECOMBINATION; TRANSFECTED DNA; POLYOMAVIRUS; EXCISION; INTEGRATION; RESOLUTION; PLASMIDS	We have observed previously that some chimeric replicons inclusive of a partly duplicated polyomavirus (Py) genome yield unit-length Py DNA (P155) at high frequency when transfected into normal or Py-transformed mouse cells. We demonstrate here that one such replicon generates either P155 or illegitimate recombination products in other mouse cells, transformed by simian virus 40. Use of the polymerase chain reaction indicates that each of the illegitimate products carried a different deletion, but that all deletions mapped within a rather well defined portion of the precursor replicon. Thus, these products were organized as if two hotspots for recombination existed in the Py late-coding region, one being located within or near one of the duplicated sequences characteristic of the chimeric replicon. Since this particular hotspot has already been shown to be involved in the generation of P155, the data reported here could indicate that a single recombination mechanism can yield either homologous (P155) or illegitimate products. How the DNA interacts with certain proteins, such as papovavirus large tumor antigen, could explain why one or the other type of product is formed.			VU, HK (corresponding author), UNIV SHERBROOKE,FAC MED,DEPT MICROBIOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA.							BOURGAUX P, 1990, J VIROL, V64, P2327, DOI 10.1128/JVI.64.5.2327-2336.1990; BROUILLETTE S, 1987, MOL CELL BIOL, V7, P2248, DOI 10.1128/MCB.7.6.2248; BULLOCK P, 1984, J MOL BIOL, V174, P55, DOI 10.1016/0022-2836(84)90365-6; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P2265, DOI 10.1128/MCB.5.9.2265; CHEN S, 1982, J VIROL, V48, P492; FRAPPIER D, 1990, J VIROL, V64, P5058, DOI 10.1128/JVI.64.10.5058-5065.1990; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; KONOPKA AK, 1988, NUCLEIC ACIDS RES, V16, P1739, DOI 10.1093/nar/16.5.1739; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; PICHE A, 1987, J VIROL, V61, P840; PICHE A, 1987, J VIROL, V61, P845; ROTH DB, 1985, P NATL ACAD SCI USA, V82, P3355, DOI 10.1073/pnas.82.10.3355; ROTHWELL VM, 1983, J VIROL, V48, P472, DOI 10.1128/JVI.48.2.472-480.1983; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGEAU MA, 1983, NUCLEIC ACIDS RES, V11, P6559, DOI 10.1093/nar/11.18.6559; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRINGER JR, 1985, MOL CELL BIOL, V5, P1247, DOI 10.1128/MCB.5.6.1247; SUBRAMANI S, 1983, MOL CELL BIOL, V3, P1040, DOI 10.1128/MCB.3.6.1040; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; SYLLA BS, 1984, CELL, V37, P661, DOI 10.1016/0092-8674(84)90398-2; SYLLA BS, 1984, GENE, V29, P343, DOI 10.1016/0378-1119(84)90063-5; TOOZE J, 1980, DNA TUMOR VIRUSES, V2	24	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9320	9326						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851175				2022-12-25	WOS:A1991FM03800099
J	CHEN, WY; BAHL, OP				CHEN, WY; BAHL, OP			RECOMBINANT CARBOHYDRATE AND SELENOMETHIONYL VARIANTS OF HUMAN CHORIOGONADOTROPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; BETA-SUBUNIT; EXPRESSION; BOVINE; UNITS	Recombinant human choriogonadotropin and selenomethionyl human choriogonadotropin (rhCG and SehCG) were expressed in baculovirus expression system by coinfection of SF9 insect cells by recombinant viruses, AcMNPV-hCG-alpha and AcMNPV-hCG-beta containing hCG-alpha and hCG-beta cDNAs. The expression efficiency of both rhCG and SehCG was quite high. The association of the alpha and beta-subunits into a dimer was apparently complete since no detectable amount of rhCG-beta was found in the rhCG eluate from the monoclonal hCG-beta antibody immunoaffinity column. Both rhCG and SehCG preparations were homogeneous as indicated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reverse-phase high performance liquid chromatography. The apparent molecular mass of rhCG and SehCG on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions was about 38 kDa while under reducing conditions the heterodimer dissociated to yield beta and alpha-subunits with molecular masses of 22.5 and 18 kDa, respectively. The carbohydrate analysis of rhCG showing the presence of 2.1, 3.3, 7.38, 4.2, and 27.8 residues of Fuc, GalNAC, GlcNAC, Gal, and Man, respectively, per mole of the hormone was consistent with the presence of 4 N-linked high mannose type carbohydrate and 4 O-linked simple carbohydrate chains, probably made up of Gal-GalNAC. Despite the altered glycosylation, rhCG demonstrated close similarity to the native urinary hCG in amino acid composition, receptor binding, and in its ability to stimulate cAMP and steroidogenesis. This indicates that there is no specificity of carbohydrate required for biological activity. Furthermore, it implies that the alteration from the complex to high mannose type carbohydrates in rhCG does not affect its proper folding. Finally, amino acid analysis of SehCG showed that 84% of methione residues in rhCG were replaced by selenomethionine.			CHEN, WY (corresponding author), SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260, USA.							BAHL OP, 1969, J BIOL CHEM, V244, P567; BAHL OP, 1967, J BIOL CHEM, V244, P575; CHEN WY, 1991, J BIOL CHEM, V266, P4081; ELDEIRY S, 1989, MOL ENDOCRINOL, V3, P1523, DOI 10.1210/mend-3-10-1523; ENDO T, 1988, J BIOCHEM-TOKYO, V103, P1035, DOI 10.1093/oxfordjournals.jbchem.a122375; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; HARRIS DC, 1989, J BIOL CHEM, V264, P6705; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; KESSLER MJ, 1979, J BIOL CHEM, V254, P7909; KESSLER MJ, 1979, J BIOL CHEM, V254, P7901; LUSTBADER J, 1987, J BIOL CHEM, V262, P14204; LUSTBADER JW, 1989, BIOCHEMISTRY-US, V28, P9239, DOI 10.1021/bi00450a001; PARSONS TF, 1984, ENDOCRINOLOGY, V114, P2223, DOI 10.1210/endo-114-6-2223; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; REDDY VB, 1985, P NATL ACAD SCI USA, V82, P3644, DOI 10.1073/pnas.82.11.3644; SOJAR HT, 1989, J BIOL CHEM, V264, P2552; SUMMERS MD, 1988, TEXAS EXPT STATION B, V1555; SWAMINATHAN N, 1970, BIOCHEM BIOPH RES CO, V40, P422, DOI 10.1016/0006-291X(70)91026-0; YANG W, 1990, J BIOL CHEM, V265, P13553	19	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8192	8197						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850740				2022-12-25	WOS:A1991FK44100039
J	NELSON, MJ; BATT, DG; THOMPSON, JS; WRIGHT, SW				NELSON, MJ; BATT, DG; THOMPSON, JS; WRIGHT, SW			REDUCTION OF THE ACTIVE-SITE IRON BY POTENT INHIBITORS OF LIPOXYGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXAMIC ACID INHIBITORS; SOYBEAN LIPOXYGENASE-1; LEUKOTRIENE BIOSYNTHESIS; FATTY-ACIDS; 5-LIPOXYGENASE; MECHANISM	Lipoxygenases are non-heme iron dioxygenases that catalyze the oxygenation of polyunsaturated fatty acids. Using soybean lipoxygenase-1 as a model, we have shown that two classes of lipoxygenase inhibitors currently in development as potential antiinflammatory agents obtain a significant amount of their potency by reducing the lipoxygenase active-site iron from the active ferric state to the inactive ferrous state. It is not surprising that the members of the first of these classes, the 2-benzyl-1-naphthols, are reducing agents. The members of the second class, the N-alkyl-hydroxamic acids, were not anticipated to be sufficiently strong reducing agents to be oxidized by the lipoxygenase ferric center; that they are provides additional evidence for that iron having a high reduction potential. This brings to (at least) five the number of classes of lipoxygenase inhibitors that are capable of reducing the active-site ferric ion and suggests the generality of this approach in the rational design of lipoxygenase inhibitors.	DUPONT CO,DEPT MED PROD,WILMINGTON,DE 19880	DuPont	NELSON, MJ (corresponding author), DUPONT CO,EXPTL STN,DEPT CENT RES & DEV,328 250B,WILMINGTON,DE 19880, USA.							BATT DG, 1990, J MED CHEM, V33, P360, DOI 10.1021/jm00163a058; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; CLAPP CH, 1985, BIOCHEMISTRY-US, V24, P1826, DOI 10.1021/bi00329a004; COREY EJ, 1987, J AM CHEM SOC, V109, P8107, DOI 10.1021/ja00260a038; COREY EJ, 1989, J AM CHEM SOC, V111, P1452, DOI 10.1021/ja00186a046; COREY EJ, 1984, J AM CHEM SOC, V106, P1503, DOI 10.1021/ja00317a064; FUJIO M, 1981, J AM CHEM SOC, V103, P4017, DOI 10.1021/ja00404a008; HUANG FC, 1989, J MED CHEM, V32, P1836, DOI 10.1021/jm00128a027; HUSSAIN SA, 1979, J CHEM SOC CHEM COMM, P289, DOI 10.1039/c39790000289; KEMAL C, 1987, BIOCHEMISTRY-US, V26, P7064, DOI 10.1021/bi00396a031; MANSUY D, 1988, BIOCHEM BIOPH RES CO, V151, P339, DOI 10.1016/0006-291X(88)90599-2; NELSON MJ, 1990, BIOCHEMISTRY-US, V29, P6897, DOI 10.1021/bi00481a020; NELSON MJ, 1990, J AM CHEM SOC, V112, P2820, DOI 10.1021/ja00163a064; NELSON MJ, 1988, J AM CHEM SOC, V110, P2985, DOI 10.1021/ja00217a056; NELSON MJ, 1988, BIOCHEMISTRY-US, V27, P4273, DOI 10.1021/bi00412a011; OLIVER TR, 1971, J CHEM SOC B, P677, DOI 10.1039/j29710000677; PETERSSON L, 1985, BIOCHIM BIOPHYS ACTA, V828, P81, DOI 10.1016/0167-4838(85)90012-3; RAITHEL H, 1978, Z PHYS CHEM NEUE FOL, V111, P193, DOI 10.1524/zpch.1978.111.2.193; RAYMOND KN, 1977, BIOINORG CHEM, V2, P33; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SUMMERS JB, 1988, J MED CHEM, V31, P3, DOI 10.1021/jm00396a002; SUMMERS JB, 1987, J MED CHEM, V30, P2121, DOI 10.1021/jm00394a032; SUMMERS JB, 1988, J MED CHEM, V31, P1960, DOI 10.1021/jm00118a016; SUMMERS JB, 1987, J MED CHEM, V30, P574, DOI 10.1021/jm00386a022; TATESON JE, 1988, BRIT J PHARMACOL, V94, P528, DOI 10.1111/j.1476-5381.1988.tb11557.x; VANDERZEE J, 1989, BIOCHEMISTRY-US, V28, P8363, DOI 10.1021/bi00447a015; Veldink G A, 1984, Adv Inorg Biochem, V6, P139; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959	28	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8225	8229						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850741				2022-12-25	WOS:A1991FK44100044
J	LEE, HC				LEE, HC			SPECIFIC BINDING OF CYCLIC ADP-RIBOSE TO CALCIUM-STORING MICROSOMES FROM SEA-URCHIN EGGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; INOSITOL TRISPHOSPHATE; CELLS; RECEPTOR; RELEASE; 1,4,5-TRISPHOSPHATE; METABOLITE; ANAPHASE; ONSET; POOLS	Cyclic ADP-ribose (cADPR) is a metabolite of NAD+ which is as active as inositol triphosphate (IP3) in mobilizing intracellular Ca2+ in sea urchin eggs. The enzyme responsible for synthesizing cADPR is found not only in sea urchin eggs but also in various mammalian tissue extracts, suggesting that it may be a general messenger for Ca2+ mobilization in cells. In this study I address questions of whether an intracellular receptor for cADPR exists and, if so, whether it is different from the IP3 receptor. A procedure employing nitrogen decompression was used to homogenize sea urchin eggs, and the Ca2+-storing microsomes were separated from mitochondria and other organelles by Percoll density centrifugation. Radioactive cADPR with high specific activity was produced by incubating [P-32]NAD+ with the synthesizing enzyme and the product purified by high pressure liquid chromatography. The enzyme was membrane bound and was isolated from dog brain extracts by sucrose density gradient centrifugation. Partial purification of the enzyme was achieved by DEAE ion-exchange chromatography after solubilization with 3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonate. Specific binding of P-32-labeled cADPR to a saturable site on the Ca2+-storing microsomes was detected by a filtration assay. Scatchard analysis indicated a binding affinity of about 17 nM and a capacity of about 25 fmol/mg protein. The binding was not affected by either NAD+ (the precursor) or ADP-ribose (the hydrolysis product) at 0.5-mu-M but was eliminated by 0.3-mu-M nonlabeled cADPR. The receptor for cADPR appeared to be different from that of IP3 since IP3 was not an effective competitor at a concentration as high as 3-mu-M. Similarly, heparin at a concentration that inhibits most of the IP-3-induced calcium release from the microsomes did not effect the binding. The binding showed a prominent pH optimum at about 6.7. Calcium at 40-mu-M decreased the binding by about 50%. These dependencies of the binding on pH and Ca2+ are different from those reported for the IP3 receptor and provide further support that the intracellular receptors for cADPR and IP3 are different.			LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009		NICHD NIH HHS [HD17484] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CHOW SC, 1990, J BIOL CHEM, V265, P902; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1633; LEE HC, 1989, J BIOL CHEM, V264, P1608; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; NISHIZUKA Y, 1984, NATURE, V308, P683; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SMITH L, 1955, Methods Biochem Anal, V2, P427, DOI 10.1002/9780470110188.ch13; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SPAT A, 1986, BIOCHEM J, V233, P929; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; WELSETH TF, 1990, J CELL BIOL, V111, P467; WHITAKER MJ, 1982, Q REV BIOPHYS, V15, P593, DOI 10.1017/S0033583500003760; WILSON DB, 1985, J BIOL CHEM, V260, P3496; WOLF BA, 1986, J BIOL CHEM, V261, P3501; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	31	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2276	2281						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846622				2022-12-25	WOS:A1991EV51500042
J	GOTTSCHALL, PE; TATSUNO, I; ARIMURA, A				GOTTSCHALL, PE; TATSUNO, I; ARIMURA, A			HYPOTHALAMIC BINDING-SITES FOR PITUITARY ADENYLATE-CYCLASE ACTIVATING POLYPEPTIDE - CHARACTERIZATION AND MOLECULAR-IDENTIFICATION	FASEB JOURNAL			English	Article						PACAP; HYPOTHALAMUS; BINDING SITE; RECEPTOR; CROSS-LINKING	VASOACTIVE INTESTINAL POLYPEPTIDE; PEPTIDE RECEPTORS; VIP RECEPTORS; LUNG; MEMBRANES; CELLS; LIVER	The goal of these experiments was to identify and characterize binding sites in the rat hypothalamus for the peptide, pituitary adenylate cyclase activating polypeptide (PACAP). The 27 amino acid form of PACAP (PACAP27) was used as the radiolabeled ligand in these experiments. Binding of [I-125]PACAP27 to hypothalamic membrane preparations was rapid, reversible on addition of unlabeled peptide, and at least partially regulated by GTP. Nonhydrolyzable GTP analogs, guanosine-5'-O-(3-thiotriphosphate) (GTP-gamma-S), guanosine-5'-(2-thiodiphosphate) (GDP-beta-S), and guanylylimidophosphate (GppNHp) also displaced [I-125]PACAP27 binding to hypothalamic membrane preparations in a dose-dependent manner. The order of potency for the three analogs was GTP-gamma-S > GDP-beta-S > GppNHp. Both forms of the peptide, PACAP27 and PACAP38, were highly potent in displacing bound [I-125]PACAP27, whereas VIP or PACAP(1-23) were unable to displace binding at concentrations of up to 500 nM. Scatchard analysis of the PACAP27 and PACAP38 displacement curves revealed that the fit of both curves was consistent with a single class of high-affinity binding sites, although the site exhibited a greater affinity for PACAP38 compared with PACAP27 (PACAP27 K(d) = 1452 +/- 59 pM; PACAP38 K(d) = 175 +/- 13 pM; B(max) 23.2 +/- 1.1 pmol/mg protein). The possibility of the existence of a class of binding sites with extremely low affinity cannot be discounted. After covalent cross-linking of [I-125]PACAP27 with its receptor, the molecular weights of the complexes were estimated by electrophoresis and autoradiography. A major band of 60 K(d) was evident when membranes were incubated with VIP or PACAP(1-23). Previous incubation with unlabeled PACAP27 or PACAP38 eliminated visualization of this band. These results suggest that a specific, high-affinity binding site for PACAP27 is present in rat hypothalamus, and that this site shows a greater affinity for PACAP38 compared with PACAP27. The molecular weight of the peptide-receptor complex is 60,000 kDa, and therefore the receptor itself has an apparent molecular weight 57,000.	TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT ANAT,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT PHYSIOL,NEW ORLEANS,LA 70112	Tulane University; Tulane University; Tulane University	GOTTSCHALL, PE (corresponding author), TULANE UNIV,US JAPAN BIOMED RES LABS,HEBERT CTR,BELLE CHASSE,LA 70037, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09094] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIMURA A, 1989, 71ST ANN M END SOC S, P263; ARIMURA A, 1990, 72ND ANN M END SOC A, P340; BESSON J, 1987, ANN NY ACAD SCI, V527, P204; CLAYTON RN, 1979, ENDOCRINOLOGY, V105, P1369, DOI 10.1210/endo-105-6-1369; COUVINEAU A, 1985, BIOCHEM J, V225, P473, DOI 10.1042/bj2250473; COUVINEAU A, 1986, J NEUROCHEM, V47, P1469, DOI 10.1111/j.1471-4159.1986.tb00780.x; DICKINSON KEJ, 1986, PEPTIDES, V7, P791, DOI 10.1016/0196-9781(86)90097-5; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; KOVES K, 1990, ENDOCRINOLOGY, V127, P264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLEOD KR, 1989, ENDOCRINOLOGY, V125, P2258, DOI 10.1210/endo-125-5-2258; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1989, ANN M SOC NEUROSCIEN; OGAWA M, 1985, BIOMED RES-TOKYO, V6, P103; PATTHI S, 1988, J BIOL CHEM, V263, P19363; ROBBERECHT P, 1988, PEPTIDES, V9, P339, DOI 10.1016/0196-9781(88)90270-7; STAUNOLSEN P, 1985, BRAIN RES, V330, P317, DOI 10.1016/0006-8993(85)90691-2; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; TAYLOR DP, 1979, P NATL ACAD SCI USA, V76, P660, DOI 10.1073/pnas.76.2.660; VASILOFF J, 1986, Canadian Journal of Physiology and Pharmacology, P172; WOOD CL, 1985, REGUL PEPTIDES, V12, P237, DOI 10.1016/0167-0115(85)90065-5	22	84	84	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					194	199		10.1096/fasebj.5.2.1848519	http://dx.doi.org/10.1096/fasebj.5.2.1848519			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	1848519				2022-12-25	WOS:A1991EZ00200008
J	HOSONO, S; LEE, CS; CHOU, MJ; YANG, CS; SHIH, C				HOSONO, S; LEE, CS; CHOU, MJ; YANG, CS; SHIH, C			MOLECULAR ANALYSIS OF THE P53 ALLELES IN PRIMARY HEPATOCELLULAR CARCINOMAS AND CELL-LINES	ONCOGENE			English	Article							HEPATITIS-B VIRUS; TUMOR SUPPRESSOR GENES; SV40-TRANSFORMED CELLS; INTEGRATION SITES; ANTI-ONCOGENE; DNA; EXPRESSION; PROTEIN; PRODUCT; CANCER	We have examined p53 oncogene/anti-oncogene alleles in 10 different human heptoma cell lines and 18 primary hepatocellular carcinomas. The p53 allele in these hepatoma cell lines appears to be a frequent target of mutation as demonstrated by Southern and Northern blotting, immunoprecipitation and Western blot analysis. In general, the steady state level of p53 specific RNA or protein in these hepatoma cell lines is higher than in normal liver. However, in three out of ten cell lines, normal-sized p53 mRNA cannot be detected. In contrast, the involvement of the p53 allele in primary hepatocellular carcinoma appears to be an exceedingly rare event. Steady state levels of p53 specific RNA in primary hepatomas are practically indistinguishable from those in normal adult liver. Using the polymerase chain reaction technique, we have amplified and subcloned exons 5, 6, 7 and 8 of p53 from 10 different hepatoma samples. DNA sequence analysis of these exon subclones reveals no apparent structural alterations. Finally, synthesis of p53 specific mRNA or protein in a HepG2 human hepatoblastoma cell line does not appear to be affected by gene expression and replication of human hepatitus B virus. Surprisingly, unlike many other kinds of human solid tumors, point mutations in p53 do not appear to be important in primary tumors of hepatocellular carcinomas.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; NATL TAIWAN UNIV,COLL MED,TAIPEI,TAIWAN	University of Pennsylvania; National Taiwan University			Shih, Chiaho/S-7017-2018		NCI NIH HHS [R01 CA 48198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BEASLEY RP, 1981, LANCET, V2, P1129; BLUMBERG BS, 1981, NEW ENGL J MED, V304, P782, DOI 10.1056/NEJM198103263041312; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CANNIZARO LA, 1989, AM J HUM GENET, V38, P812; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEJEAN A, 1984, P NATL ACAD SCI-BIOL, V81, P5350, DOI 10.1073/pnas.81.17.5350; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRIMM J, 1976, INT J BIOCHEM, V64, P249; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; KORNBLUTH J, 1985, J IMMUNOL, V134, P728; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACNAB GM, 1976, BRIT J CANCER, V34, P509, DOI 10.1038/bjc.1976.205; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PAYNE GS, 1981, CELL, V23, P311, DOI 10.1016/0092-8674(81)90127-6; Robinson W.S., 1990, VIROLOGY, P2137; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SLAGLE BL, 1990, J CELL BIOCHEM, V14, P276; SOUSSI T, 1987, ONCOGENE, V1, P71; STANBRIDGE EJ, 1990, SCIENCE, V247, P12, DOI 10.1126/science.2403692; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	56	86	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					237	243						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847999				2022-12-25	WOS:A1991FZ13400009
J	PLOUG, M; RONNE, E; BEHRENDT, N; JENSEN, AL; BLASI, F; DANO, K				PLOUG, M; RONNE, E; BEHRENDT, N; JENSEN, AL; BLASI, F; DANO, K			CELLULAR RECEPTOR FOR UROKINASE PLASMINOGEN-ACTIVATOR - CARBOXYL-TERMINAL PROCESSING AND MEMBRANE ANCHORING BY GLYCOSYL-PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; THY-1 GLYCOPROTEIN; U937 MONOCYTES; SARCOMA-CELLS; PRO-UROKINASE; BINDING SITE; PROTEINS; IDENTIFICATION; PURIFICATION	The cellular receptor for human urokinase-type plasminogen activator (u-PAR) is shown by several independent criteria to be a true member of a family of integral membrane proteins, anchored to the plasma membrane exclusively by a COOH-terminal glycosyl-phosphatidylinositol moiety. 1) Amino acid analysis of u-PAR after micropurification by affinity chromatography and N-[2-hydroxy-1,1-bis(hydroxymethyl)-ethyl]glycine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed the presence of 2-3 mol of ethanolamine/mol protein. 2) Membrane-bound u-PAR is efficiently released from the surface of human U937 cells by trace amounts of purified bacterial phosphatidylinositol-specific phospholipase C. This soluble form of u-PAR retains the binding specificity toward both u-PA and its amino-terminal fragment holding the receptor-binding domain. 3) Treatment of purified u-PAR with phosphatidylinositol-specific phospholipase C or mild alkali completely alters the hydrophobic properties of the receptor as judged by temperature-induced detergent-phase separation and charge-shift electrophoresis. 4) Biosynthetic labeling of u-PAR was obtained with [H-3]ethanolamine and myo-[H-3]inositol. 5) Finally, comparison of amino acid compositions derived from cDNA sequence and amino acid analysis shows that a polypeptide of medium hydrophobicity is excised from the COOH terminus of the nascent u-PAR. A similar proteolytic processing has been reported for other proteins that are linked to the plasma membrane by a glycosyl-phosphatidylinositol membrane anchor.	UNIV COPENHAGEN,INST BIOCHEM GENET,DK-1353 COPENHAGEN,DENMARK; UNIV COPENHAGEN,INST MICROBIOL,DK-1353 COPENHAGEN,DENMARK	University of Copenhagen; University of Copenhagen	PLOUG, M (corresponding author), RIGSHOSP,FINSEN LAB,STRANDBLVD 49,DK-2100 COPENHAGEN,DENMARK.			Blasi, Francesco/0000-0001-9406-1784; Behrendt, Niels/0000-0003-1833-3922; Ploug, Michael/0000-0003-2215-4265				APPELLA E, 1987, J BIOL CHEM, V262, P4437; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BERGER J, 1988, J BIOL CHEM, V263, P10016; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOFFA LC, 1977, BIOCHEM BIOPH RES CO, V74, P969, DOI 10.1016/0006-291X(77)91613-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CARRAS IW, 1989, J CELL BIOL, V108, P1387; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DANO K, 1989, CANCER METASTASIS, P98; DANO K, 1988, DEV FUNCTION REPRODU, V2, P259; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; HELENIUS A, 1977, P NATL ACAD SCI USA, V74, P529, DOI 10.1073/pnas.74.2.529; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121	47	579	592	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1926	1933						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846368				2022-12-25	WOS:A1991EU49700085
J	ADAM, D; MAUELER, W; SCHARTL, M				ADAM, D; MAUELER, W; SCHARTL, M			TRANSCRIPTIONAL ACTIVATION OF THE MELANOMA INDUCING XMRK ONCOGENE IN XIPHOPHORUS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; EGF-RECEPTOR; AUTOPHOSPHORYLATION SITES; CELL-LINE; CANCER; GENE; SEQUENCES; LOCUS	The melanoma inducing locus of Xiphophorus encodes a tumorigenic version of a novel putative receptor tyrosine kinase (Xmrk). To elucidate the mechanism of oncogenic activation of Xmrk, we compared the structure and expression of two oncogenic loci with the corresponding proto-oncogene. Only minor structural alterations were found to be specific for the oncogenic Xmrk genes. Marked overexpression of the oncogene transcripts in melanoma, which are approximately 1 kb shorter than the proto-oncogene transcript, correlates with the malignancy of the tumors. The tumor transcripts are derived from an alternative transcription start site that is used only in the oncogenic loci. Thus, oncogenic activation of the melanoma inducing Xmrk gene appears primarily to be due to novel transcriptional control and overexpression.	MAX PLANCK INST BIOCHEM, GENZENTRUM, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY	Max Planck Society			Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1988, NUCLEIC ACIDS RES, V16, P7212, DOI 10.1093/nar/16.14.7212; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; ANDERS A, 1978, BIOCHIM BIOPHYS ACTA, V516, P61, DOI 10.1016/0304-419X(78)90004-5; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; ATZ JAMES W., 1962, ZOOLOGICA [NEW YORK], V47, P153; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CARPENTER CD, 1990, BIOTECHNIQUES, V8, P26; Chaconas G, 1980, Methods Enzymol, V65, P75; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GORDON M, 1958, ANN NY ACAD SCI, V71, P1213, DOI 10.1111/j.1749-6632.1958.tb54683.x; Gordon M, 1927, GENETICS, V12, P253; HAUSSLER G, 1928, KLINWOCHENSCHR, V33, P1561; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JEFFREYS AJ, 1982, NATURE, V296, P9, DOI 10.1038/296009a0; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KOSSWIG C, 1965, Zoologischer Anzeiger, V175, P21; Kosswig C., 1928, Zeitschrift fuer Induktive Abstammungs- und Vererbungslehre, V47, P150; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MAUELER W, 1988, ONCOGENE, V2, P421; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nei M., 1987, MOL EVOLUTIONARY GEN; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; SCHARTL M, 1988, GENETICS, V119, P679; SCHARTL M, 1990, IN PRESS GENETICS; SCHWAB M, 1987, TRENDS GENET, V3, P38, DOI 10.1016/0168-9525(87)90164-8; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SINKOVICS JG, 1988, CRC CR REV IMMUNOL, V8, P217; TRONICK SR, 1988, ADV SEC MESS PHOSPH, V21, P201; Vielkind J. R., 1989, Journal of Aquatic Animal Health, V1, P69, DOI 10.1577/1548-8667(1989)001&lt;0069:GOMIXF&gt;2.3.CO;2; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINBERG RA, 1989, CANCER RES, V49, P3713; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER C D, 1969, Mitteilungen aus dem Hamburgischen Zoologischen Museum und Institut, V66, P241; ZECHEL C, 1988, ONCOGENE, V3, P605	46	64	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1991	6	1					73	80						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846957				2022-12-25	WOS:A1991EY03900010
J	MILLER, LG; LUMPKIN, M; GREENBLATT, DJ; SHADER, RI				MILLER, LG; LUMPKIN, M; GREENBLATT, DJ; SHADER, RI			ACCELERATED BENZODIAZEPINE RECEPTOR RECOVERY AFTER LORAZEPAM DISCONTINUATION	FASEB JOURNAL			English	Note						LORAZEPAM; DISCONTINUATION; EEDQ; BENZODIAZEPINE; GABA	N-ETHOXYCARBONYL-2-ETHOXY-1,2-DIHYDROQUINOLINE EEDQ; DOWN-REGULATION; RAT-BRAIN; TOLERANCE; DEPENDENCE; BINDING; INVIVO	Benzodiazepine discontinuation can lead to a behavioral syndrome in animals and humans. In a mouse model, this syndrome is associated with benzodiazepine receptor up-regulation. The protein-modifying reagent, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), has been used to irreversibly inactivate a number of neurotransmitter receptors including benzodiazepine receptors, and thus allows estimation of receptor recovery in vivo. To assess benzodiazepine receptor recovery after benzodiazepine discontinuation, we treated mice with lorazepam (LRZ), 2 mg.kg-1.day-1 for 1 wk. After 24 h, EEDQ (12.5 mg/kg) was administered, and benzodiazepine binding in the cortex and cerebellum was determined after 4-144 h. EEDQ treatment decreased receptor density in the cortex in both LRZ- and vehicle-treated groups by approximately 50%, with no change in apparent affinity as previously reported. Binding in both groups returned to control values after 96 h. Kinetic analysis indicated a more rapid increase in binding in LRZ-compared with vehicle-treated animals, with t1/2 for LRZ 19.1 h, and for vehicle, 30.8 h (P < 0.05). Receptor density was decreased in the cerebellum after EEDQ by approximately 40% in both treatment groups, with no change in apparent affinity. Receptor density returned to control values at 96 h, with no difference in kinetics in LRZ- compared with vehicle-treated mice. The decrease in receptor t1/2 associated with lorazepam discontinuation is consistent with the observed increase in benzodiazepine receptors in this setting.	TUFTS UNIV, SCH MED, DEPT PHARMACOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02111 USA; NEW ENGLAND MED CTR HOSP, BOSTON, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center	MILLER, LG (corresponding author), TUFTS UNIV, SCH MED, DIV CLIN PHARMACOL, BOSTON, MA 02111 USA.			Shader, Richard/0000-0002-1888-7565	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH034223, R01MH034223] Funding Source: NIH RePORTER; NIA NIH HHS [AG-01006] Funding Source: Medline; NIDA NIH HHS [DA-05258] Funding Source: Medline; NIMH NIH HHS [MH-34223] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BATTAGLIA G, 1987, J PHARMACOL EXP THER, V243, P69; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; GALLAGER DW, 1984, NATURE, V308, P74, DOI 10.1038/308074a0; GALPERN WR, 1990, IN PRESS BR J PHARM; GREENBLATT DJ, 1978, DRUG METAB REV, V8, P13, DOI 10.3109/03602537808993775; HESS EJ, 1988, J NEUROSCI, V8, P2361; LOPEZ F, 1990, NEUROPHARMACOLOGY, V29, P237, DOI 10.1016/0028-3908(90)90007-E; MARLEY RJ, 1989, EUR J PHARMACOL, V159, P217, DOI 10.1016/0014-2999(89)90151-9; MILLER LG, 1989, BIOCHEM PHARMACOL, V38, P3773, DOI 10.1016/0006-2952(89)90584-4; MILLER LG, 1988, J PHARMACOL EXP THER, V246, P170; MILLER LG, 1988, J PHARMACOL EXP THER, V246, P177; MILLER LG, 1990, ADV BIOCHEM PSYCHOPH, V46, P167; MILLER LG, 1990, IN PRESS J NEUROCHEM; NORMAN AB, 1989, LIFE SCI, V44, P831, DOI 10.1016/0024-3205(89)90583-3; PETURSSON H, 1981, BRIT J ADDICT, V76, P133; PILC A, 1989, BRAIN RES, V493, P8, DOI 10.1016/0006-8993(89)90994-3; SALLER CF, 1989, LIFE SCI, V45, P917, DOI 10.1016/0024-3205(89)90206-3; SIEGHART W, 1989, TRENDS PHARMACOL SCI, V10, P407, DOI 10.1016/0165-6147(89)90189-2; TIETZ EI, 1986, J PHARMACOL EXP THER, V236, P284	19	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1991	5	1					93	97		10.1096/fasebj.5.1.1846834	http://dx.doi.org/10.1096/fasebj.5.1.1846834			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1846834				2022-12-25	WOS:A1991ET60900020
J	NES, WD; JANSSEN, GG; BERGENSTRAHLE, A				NES, WD; JANSSEN, GG; BERGENSTRAHLE, A			STRUCTURAL REQUIREMENTS FOR TRANSFORMATION OF SUBSTRATES BY THE (S)-ADENOSYL-L-METHIONINE - DELTA-24(25)-STEROL METHYL TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-ENERGY INTERMEDIATE; STEROL METHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; ERGOSTEROL BIOSYNTHESIS; S-ADENOSYLMETHIONINE; 9-BETA,19-CYCLOPROPYL STEROLS; CONFORMATIONAL-ANALYSIS; STEREOCHEMICAL ASPECTS; PLANT STEROLS; SIDE-CHAIN	The membrane-bound enzyme of microsomes obtained from sunflower embryos that catalyzes the bisubstrate transfer reaction whereby the methyl group of (S)-adenosyl-L-methionine is transferred to C-24 of the sterol side chain has been investigated. Optimal incubation conditions for assay of the microsomal (S)-adenosyl-L-methionine:sterol DELTA-24-methyl transferase (SMT) have been established for the first time. The microsomal preparation was found to catalyze the formation of a DELTA-24(28)-sterol and to be free of contaminating methyl transferase enzymes, e.g. those which form DELTA-23-24 methyl sterols (cyclosadol) and DELTA-25-24-beta-methyl sterols (cyclolaudenol) and other sterolic enzymes which might transform the acceptor molecule to metabolites which could compete in the assay with the test substrate. From a series of incubations with 27 sterol and sterol-like (triterpenoids) substrates of which 23 compounds possessed a 24,25-double bond, we observed a marked dependence on precise structural features and three-dimensional shape of the acceptor molecule in its ability to be transformed by the SMT. In contrast to the yeast SMT where cycloartenol fails to bind to the SMT and zymosterol is the best substrate for methylation, the sunflower SMT studied here utilizes cycloartenol preferentially to zymosterol and the other substrates. Of the chemical groups which distinguishes cycloartenol, a free 3-beta-OH,9-beta,19-cyclopropyl group, trimethylated saturated nucleus, and DELTA-24-double bond, only the nucleophilic centers at C-3 and C-24 were obligatory for substrate binding and methylation. Of the bent or flat conformations which cycloartenol may orient in the enzyme-substrate complex, our results indicate a selection for acceptor molecules which possess the shape that closely resembles the crystal state and solution orientation of cycloartenol which is now known to be flat rather than bent (Nes, W. D., Benson, M., Lundin, R. E., and Le, P. H. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 5759-5763).	SWEDISH UNIV AGR SCI,DEPT PLANT PHYSIOL,S-75007 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences	NES, WD (corresponding author), RICHARD B RUSSELL RES CTR,MICROBIAL PROD,PLANT & FUNGAL LIPID RES,POB 5677,950 COLL STN RD,ATHENS,GA 30613, USA.							AKIHISA T, 1989, J ORG CHEM, V54, P606, DOI 10.1021/jo00264a019; Akihisa T., 1989, ANAL STEROLS OTHER B, P251; [Anonymous], 1977, ADV LIPID RES; BACH TJ, 1986, LIPIDS, V21, P82, DOI 10.1007/BF02534307; BAILEY RB, 1974, BIOCHIM BIOPHYS ACTA, V334, P127, DOI 10.1016/0005-2744(74)90156-9; BANSAL SK, 1981, PHYTOCHEMISTRY, V20, P1269, DOI 10.1016/0031-9422(81)80020-9; BENVENISTE P, 1986, ANNU REV PLANT PHYS, V37, P275, DOI 10.1146/annurev.pp.37.060186.001423; BLADOCHA M, 1985, PLANT PHYSIOL, V79, P1098, DOI 10.1104/pp.79.4.1098; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; CASTLE M, 1963, J AM CHEM SOC, V85, P3306, DOI 10.1021/ja00903a063; DUAX WL, 1988, BIOL CHOLESTEROL, P1; FONTENEAU P, 1977, PLANT SCI LETT, V10, P147, DOI 10.1016/0304-4211(77)90122-5; GARG VK, 1985, LIPIDS, V20, P876, DOI 10.1007/BF02534771; GOAD LJ, 1983, BIOCHEM SOC T, V11, P548, DOI 10.1042/bst0110548; GOAD LJ, 1973, PROG PHYTOCHEM, V1, P113; GRUNWALD C, 1975, ANNU REV PLANT PHYS, V26, P209, DOI 10.1146/annurev.pp.26.060175.001233; HARRISON DM, 1985, NAT PROD REP, P525; HARTMANNBOUILLON MA, 1978, PHYTOCHEMISTRY, V17, P1037, DOI 10.1016/S0031-9422(00)94275-4; JANSSEN GG, 1991, IN PRESS PHYSL BIOCH; JULIA M, 1985, TETRAHEDRON, V41, P3717, DOI 10.1016/S0040-4020(01)91392-4; KALINOWSKA M, 1990, PHYTOCHEMISTRY, V29, P3427, DOI 10.1016/0031-9422(90)85251-A; MATSUMOTO T, 1984, PHYTOCHEMISTRY, V23, P921, DOI 10.1016/S0031-9422(00)85067-0; MISSO NLA, 1983, PHYTOCHEMISTRY, V22, P2473, DOI 10.1016/0031-9422(83)80143-5; MOORE JT, 1969, J BIOL CHEM, V244, P6334; MOORE JT, 1970, J BIOL CHEM, V245, P4684; NES WD, 1990, P NATL ACAD SCI USA, V87, P7565, DOI 10.1073/pnas.87.19.7565; NES WD, 1990, RECENT ADV PHYTOCHEM, V24, P283; NES WD, 1984, P NATL ACAD SCI USA, V81, P5896, DOI 10.1073/pnas.81.18.5896; NES WD, 1988, P NATL ACAD SCI USA, V85, P5759, DOI 10.1073/pnas.85.16.5759; NES WD, 1981, J NAT PROD, V44, P377, DOI 10.1021/np50016a001; NES WR, 1977, LIPIDS, V12, P511, DOI 10.1007/BF02535451; NES WR, 1974, LIPIDS, V9, P596, DOI 10.1007/BF02532509; NES WR, 1977, J AM CHEM SOC, V99, P260, DOI 10.1021/ja00443a054; NISHINO T, 1981, J BIOCHEM-TOKYO, V89, P1391, DOI 10.1093/oxfordjournals.jbchem.a133330; Patterson GW, 1984, ISOPENTENOIDS PLANTS, P293; PINTO WJ, 1983, J BIOL CHEM, V258, P4472; RAHIER A, 1984, J BIOL CHEM, V259, P5215; RAHIER A, 1986, LIPIDS, V21, P52, DOI 10.1007/BF02534303; Rahier A., 1989, ANAL STEROLS OTHER B, P223, DOI [10.1016/B978-0-12-515445-1.50016-1, DOI 10.1016/B978-0-12-515445-1.50016-1]; RUBINSTEIN I, 1976, PHYTOCHEMISTRY, V15, P195, DOI 10.1016/S0031-9422(00)89083-4; RUSSELL PT, 1967, J BIOL CHEM, V242, P5802; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHEID F, 1982, PHYTOCHEMISTRY, V21, P1956; STOILOV IL, 1986, J AM CHEM SOC, V108, P8235, DOI 10.1021/ja00286a021; TATON M, 1987, PURE APPL CHEM, V59, P287, DOI 10.1351/pac198759030287; THOMPSON ED, 1974, BIOCHIM BIOPHYS ACTA, V334, P116, DOI 10.1016/0005-2744(74)90155-7; WOJCIECHOWSKI ZA, 1973, BIOCHEM J, V136, P405, DOI 10.1042/bj1360405; XU SH, 1988, J CHROMATOGR, V452, P377, DOI 10.1016/S0021-9673(01)81462-X; YABUSAKI Y, 1979, J BIOCHEM-TOKYO, V85, P1531, DOI 10.1093/oxfordjournals.jbchem.a132483; YOSHIDA K, 1989, AGR BIOL CHEM TOKYO, V53, P1901, DOI 10.1080/00021369.1989.10869552; [No title captured]	51	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15202	15212						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869550				2022-12-25	WOS:A1991GB09700060
J	FUNNELL, BE				FUNNELL, BE			THE P1 PLASMID PARTITION COMPLEX AT PARS - THE INFLUENCE OF ESCHERICHIA-COLI INTEGRATION HOST FACTOR AND OF SUBSTRATE TOPOLOGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; UNIT-COPY MINIPLASMIDS; CENTROMERE-LIKE SITE; BINDING-SITES; DAUGHTER CELLS; DNA; PROTEIN; REGION; REPLICATION; GENE	The P1 ParB protein is required for active partition and thus stable inheritance of the plasmid prophage. ParB and the Escherichia coli protein integration host factor (IHF) participate in the assembly of a partition complex at the centromere-like site parS. In this report the role of IHF in the formation of the partition complex has been explored. First, ParB protein was purified for these studies, which revealed that ParB forms a dimer in solution. Next, the IHF binding site was mapped to a 29-base pair region within parS, including the sequence TAACTGACTGTTT (which differs from the IHF consensus in two positions). IHF induced a strong bend in the DNA at its binding site. Versions of parS which have lost or damaged the IHF binding site bound ParB with greatly reduced affinity in vitro and in vivo. Measurements of binding constants showed that IHF increased ParB affinity for the wild-type parS site by about 10,000-fold. Finally, DNA super-coiling improved ParB binding in the presence of IHF but not in its absence. These observations led to the proposal that IHF and superhelicity assist ParB by promoting its precise positioning at parS, a spatial arrangement that results in a high affinity of ParB for parS.	NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Funnell, Barbara/0000-0002-1828-6567				ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; AUSTIN S, 1983, J MOL BIOL, V169, P373, DOI 10.1016/S0022-2836(83)80056-4; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS MA, 1990, EMBO J, V9, P991, DOI 10.1002/j.1460-2075.1990.tb08201.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DRLICA K, 1990, BACTERIAL CHROMOSOME, P195; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FLAMM EL, 1985, J MOL BIOL, V183, P117, DOI 10.1016/0022-2836(85)90206-2; FRANKKAMENETSKI.MD, 1990, DNA TOPOLOGY ITS BIO, P185; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1989, J CELL BIOL D, V13, P86; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; JOHNSON RC, 1987, TRENDS GENET, V3, P262, DOI 10.1016/0168-9525(87)90261-7; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; Maniatis T., 1982, MOL CLONING; MANIS JJ, 1977, MOL GEN GENET, V152, P175, DOI 10.1007/BF00268815; MARTIN KA, 1987, P NATL ACAD SCI USA, V84, P8544, DOI 10.1073/pnas.84.23.8544; MILLER HI, 1984, COLD SPRING HARB SYM, V49, P691, DOI 10.1101/SQB.1984.049.01.078; Miller JH., 1972, EXPT MOL GENETICS; NASH HA, 1981, J BIOL CHEM, V256, P9246; OGURA T, 1983, CELL, V32, P351, DOI 10.1016/0092-8674(83)90454-3; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; ROSS W, 1982, J MOL BIOL, V156, P523, DOI 10.1016/0022-2836(82)90264-9; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STERNBERG N, 1983, J BACTERIOL, V153, P800, DOI 10.1128/JB.153.2.800-812.1983; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YARMOLINSKY MB, 1988, BACTERIOPHAGES, P291; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZWEIB C, 1989, GENE DEV, V3, P606	47	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14328	14337						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860842				2022-12-25	WOS:A1991FZ35100036
J	REED, DK; RYAN, RJ; MCCORMICK, DJ				REED, DK; RYAN, RJ; MCCORMICK, DJ			RESIDUES IN THE ALPHA-SUBUNIT OF HUMAN CHORIOTROPIN THAT ARE IMPORTANT FOR INTERACTION WITH THE LUTROPIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HUMAN LUTEINIZING-HORMONE; GLYCOPROTEIN HORMONES; METHIONINE RESIDUES; BINDING REGION; LEYDIG-CELLS; PEPTIDES; CARBOXYMETHYLATION; DERIVATIVES; INHIBITION	Synthetic peptides were used to probe the structure-function relationships between human choriotropin (hCG) and the lutropin (LH) receptor. Previously, a peptide region of the alpha-subunit of hCG, residues 26-46, had been shown to inhibit binding of I-125-hCG to the LH receptor in rat ovarian membranes (Charlesworth, M. C., McCormick, D. J., Madden, B., and Ryan, R. J. (1987) J. Biol. Chem. 262, 13409-13416). To determine which residues are important for this inhibitory activity, peptides were truncated from either the amino or carboxyl terminus, or individual residues were substituted with alanine. The amino-terminal boundary was determined to be Gly-30 and the carboxyl-terminal boundary, Lys-44. This core peptide contained all the residues needed for full activity of the parent peptide 26-46. Arg-35 and Phe-33 were particularly important residues; when they were substituted with alanine, the peptide inhibitory potencies were decreased. Ser-43, Arg-42, Cys-32, and Cys-31 were also important but to a lesser degree. These results are consistent with predictions based on chemical and enzymatic modification studies and provide insight into which residues are important for interaction between hCG and the LH receptor.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,GUGGENHEIM 1621C,ROCHESTER,MN 55905	Mayo Clinic					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 9140] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BROWN BW, 1977, STATISTICS BIOMEDICA, P112; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; CHENG KW, 1976, BIOCHEM J, V159, P71, DOI 10.1042/bj1590071; CHENG KW, 1976, BIOCHEM J, V159, P79, DOI 10.1042/bj1590079; COLOMA TAS, 1990, J BIOL CHEM, V265, P5037; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; ERICKSON LD, 1990, ENDOCRINOLOGY, V126, P2555, DOI 10.1210/endo-126-5-2555; Garnier J., 1978, STRUCTURE FUNCTION G, P381; GIUDICE LC, 1979, J BIOL CHEM, V254, P1164; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HARRIS DC, 1989, J BIOL CHEM, V264, P6705; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; LEE CY, 1973, BIOCHEMISTRY-US, V12, P4609, DOI 10.1021/bi00747a011; LEE CY, 1972, P NATL ACAD SCI USA, V69, P3520, DOI 10.1073/pnas.69.12.3520; LOWITT S, 1982, ENDOCRINOLOGY, V111, P1415, DOI 10.1210/endo-111-4-1415; LUSTBADER JW, 1989, BIOCHEMISTRY-US, V28, P9239, DOI 10.1021/bi00450a001; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P456, DOI 10.1210/endo-123-1-456; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RYAN RJ, 1987, RECENT PROG HORM RES, V43, P383; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P10; Stewart JM, 1984, SOLID PHASE PEPTIDE; SULLIVAN MHF, 1986, BIOCHEM J, V236, P45, DOI 10.1042/bj2360045; WARD DN, 1990, GLYCOPROTEIN HORMONE, P81; WEARE JA, 1979, J BIOL CHEM, V254, P6972	29	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14251	14255						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860839				2022-12-25	WOS:A1991FZ35100023
J	FORRYSCHAUDIES, S; HUGHES, SH				FORRYSCHAUDIES, S; HUGHES, SH			THE CHICKEN TROPOMYOSIN-1 GENE GENERATES 9 MESSENGER-RNAS BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEIGHT NONMUSCLE TROPOMYOSIN; MUSCLE ALPHA-TROPOMYOSIN; BETA-TROPOMYOSIN; EMBRYO FIBROBLASTS; INTRON SEQUENCES; SINGLE GENE; EXPRESSION; SKELETAL; ISOFORMS; SMOOTH	Skeletal muscle beta-tropomyosin, smooth muscle alpha-tropomyosin, and a low molecular weight fibroblast tropomyosin are generated by alternatively splicing RNA transcripts of the chicken tropomyosin 1 (TM 1) gene (Forry-Schaudies, S., Maihle, N. J., and Hughes, S. H. (1990) J. Mol. Biol. 21 1; 321-330). Two novel tropomyosin cDNAs that derive from mRNAs of the TM 1 gene have been isolated from a chicken embryo brain cDNA library. Brain cDNA BRT-1 is 2.2 kilobases in length and encodes 283 amino acids. It is identical to skeletal muscle beta-tropomyosin from amino acids 1 to 258. The sequence 3' of this point is unique to BRT-1; a comparison to genomic sequence indicates that a new carboxyl-terminal exon is used to generate this sequence. 1.4-kilobase brain cDNA BRT-2 contains sequences found in both fibroblast cDNA FT-beta (5'-end) and skeletal muscle cDNA SKT-beta (3'-end). RNase and SI nuclease assays using RNA samples from leg muscle, gizzard, fibroblasts, and brain indicate that the TM 1 gene expresses four additional tropomyosin RNAs by alternately splicing previously characterized exons. These results demonstrate that the chicken TM 1 gene encodes nine tropomyosin RNAs through the use of two promoters, two internal exons that are mutually exclusive, and three 3'-exons. Implications for the regulation of alternative splicing are discussed.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, POB B, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADAC JA, 1989, MOL CELL BIOL, V9, P185, DOI 10.1128/MCB.9.1.185; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; FATTOUM A, 1983, BIOCHEMISTRY-US, V22, P1187, DOI 10.1021/bi00274a031; FORRYSCHAUDIES S, 1990, CELL GROWTH DIFFER, V1, P473; FORRYSCHAUDIES S, 1990, J MOL BIOL, V211, P321, DOI 10.1016/0022-2836(90)90354-O; GILMAN M, 1987, CURRENT PROTOCOLS MO; GIOMETTI CS, 1984, J BIOL CHEM, V259, P4113; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HELFMAN DM, 1984, J BIOL CHEM, V259, P4136; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; LATCHMAN D S, 1990, New Biologist, V2, P297; LAZARIDES E, 1975, J CELL BIOL, V65, P549, DOI 10.1083/jcb.65.3.549; LEESMILLER JP, 1990, J MOL BIOL, V213, P399, DOI 10.1016/S0022-2836(05)80202-5; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1990, J BIOL CHEM, V265, P3471; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LINDQUESTER GJ, 1989, NUCLEIC ACIDS RES, V17, P2099, DOI 10.1093/nar/17.5.2099; MACLEOD AR, 1985, P NATL ACAD SCI USA, V82, P7835, DOI 10.1073/pnas.82.23.7835; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MACLEOD AR, 1986, NUCLEIC ACIDS RES, V14, P8413, DOI 10.1093/nar/14.21.8413; MACLEOD AR, 1987, J MOL BIOL, V194, P1, DOI 10.1016/0022-2836(87)90710-8; Maniatis T., 1982, MOL CLONING; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PAYNE MR, 1984, TRENDS BIOCHEM SCI, V9, P361, DOI 10.1016/0968-0004(84)90061-6; PEARSONWHITE SH, 1987, J BIOL CHEM, V262, P15998; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; YAJMAWAKIKATAOK.Y, 1987, J BIOL CHEM, V262, P10791	42	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13821	13827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856215				2022-12-25	WOS:A1991FY02700059
J	ASSONBATRES, MA; HARE, JF				ASSONBATRES, MA; HARE, JF			EFFECT OF OXYGEN ON THE SYNTHESIS AND ASSEMBLY OF MITOCHONDRIAL ENCODED SUBUNITS OF CYTOCHROME-OXIDASE AND CYTOCHROME-B-C1 IN MOUSE EMBRYO FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORETIC PROCEDURE; C-OXIDASE; SACCHAROMYCES-CEREVISIAE; ENZYMIC CONVERSION; RESPIRATORY-CHAIN; 13 POLYPEPTIDES; BEEF-HEART; RAT-LIVER; YEAST; HEME	Mouse embryo fibroblasts were grown in low and control O2 for 24 h (average medium oxygen tensions, 7 torr and 143 torr, respectively). Relative to controls, there was a reduction in radiolabeled subunits in immunoprecipitates of cytochrome oxidase and cytochrome b.c1 prepared from low O2 cells. Incorporation of radiolabeled amino acids into subunit I of cytochrome oxidase and the apocytochrome b protein of the b.c1 complex ranged from 51-100% of control, whereas the appearance of these pulse-labeled subunits into holoenzymes immunoprecipitated from low O2 cells was in the range of 6-39% of control. The synthesis of subunit II of cytochrome oxidase by low O2 cells ranged from 63-100% of control, and assembly of this protein into the low O2 immunoprecipitated enzyme ranged from 15-61% of control. Thus, the data suggest that O2 had an effect on the assembly of these mitochondrically translated proteins that was independent of any effect on their synthesis.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEBONOJO F, 1961, CANCER RES, V21, P252; ARCANGIOLI B, 1985, EMBO J, V4, P2627, DOI 10.1002/j.1460-2075.1985.tb03980.x; ASSONBATRES MA, 1989, RESP PHYSIOL, V77, P101, DOI 10.1016/0034-5687(89)90033-9; ASSONBATRES MA, 1989, THESIS OREGON HLTH S; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPALDI RA, 1988, J BIOENERG BIOMEMBR, V20, P291, DOI 10.1007/BF00769634; CAPALDI RA, 1986, FEBS LETT, V207, P11, DOI 10.1016/0014-5793(86)80004-7; CHIN CH, 1950, NATURE, V165, P926, DOI 10.1038/165926b0; DANNENBERG AM, 1963, J CELL BIOL, V17, P465, DOI 10.1083/jcb.17.3.465; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; HALL RE, 1990, J BIOL CHEM, V265, P16484; HARE JF, 1980, BIOCHEMISTRY-US, V19, P2023, DOI 10.1021/bi00551a003; HARE JF, 1982, J CELL PHYSIOL, V113, P23, DOI 10.1002/jcp.1041130106; HODGE MR, 1989, MOL CELL BIOL, V9, P1958, DOI 10.1128/MCB.9.5.1958; IDSTROM JP, 1985, AM J PHYSIOL, V248, pH40, DOI 10.1152/ajpheart.1985.248.1.H40; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; MAHIN DT, 1966, ANAL BIOCHEM, V16, P500, DOI 10.1016/0003-2697(66)90233-8; MAIZEL JV, 1969, FUNDAMENTAL TECHNIQU, P334; MASON T, 1983, MITOCHONDRIA 1983, P509; MURPHY BJ, 1984, SCIENCE, V223, P707, DOI 10.1126/science.6320368; PIOUS DA, 1970, P NATL ACAD SCI USA, V65, P1001, DOI 10.1073/pnas.65.4.1001; POULSON R, 1976, J BIOL CHEM, V251, P3730; POULSON R, 1975, J BIOL CHEM, V250, P1269; POULSON R, 1974, J BIOL CHEM, V249, P6367; ROSS E, 1976, J BIOL CHEM, V251, P1997; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER HH, 1957, SCIENCE, V125, P501, DOI 10.1126/science.125.3246.501; SIMON LM, 1977, J CLIN INVEST, V59, P443, DOI 10.1172/JCI108658; Tisdale HD, 1967, METHODS ENZYMOL, V10, P213, DOI DOI 10.1016/0076-6879(67)10042-6; Wharton DC., 1967, METHOD ENZYMOL, P245; WIELBURSKI A, 1984, FEBS LETT, V177, P291, DOI 10.1016/0014-5793(84)81302-2; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3; WILSON G, 1981, J BIOL CHEM, V256, P5197; WOODROW G, 1979, J BIOL CHEM, V254, P6088; WOODS JS, 1977, MOL PHARMACOL, V13, P50; ZEVIANI M, 1988, GENE, V65, P1, DOI 10.1016/0378-1119(88)90411-8	38	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9932	9938						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851760				2022-12-25	WOS:A1991FM45900088
J	SENIOR, RM; GRIFFIN, GL; FLISZAR, CJ; SHAPIRO, SD; GOLDBERG, GI; WELGUS, HG				SENIOR, RM; GRIFFIN, GL; FLISZAR, CJ; SHAPIRO, SD; GOLDBERG, GI; WELGUS, HG			HUMAN 92-KILODALTON AND 72-KILODALTON TYPE-IV COLLAGENASES ARE ELASTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; SKIN FIBROBLAST COLLAGENASE; TISSUE INHIBITOR; SUBSTRATE-SPECIFICITY; METALLOPROTEINASE; STROMELYSIN; EXPRESSION; SECRETE; CELLS; PROCOLLAGENASE	Elastin is critical to the structural integrity of a variety of connective tissues. Only a select group of enzymes has thus far been identified capable of cleaving insoluble elastin. Recently, we observed that human alveolar macrophages secrete elastase activity that is largely inhibited by the tissue inhibitor of metalloproteinases (TIMP). This finding suggested that one or more of the metalloproteinases released by alveolar macrophages has elastase activity. Accordingly, we tested pure human interstitial collagenase, stromelysin, 92-kDa type IV collagenase, and 72-kDa type IV collagenase for elastolytic activity using kappa-elastin zymography and insoluble H-3-labeled elastin. The 92- and 72-kDa type IV collagenases were found to be elastolytic in both assay systems. A recombinant preparation of 92-kDa type IV collagenase with gelatinolytic activity was also found to be elastolytic. Organomercurial activation was essential to detect elastolytic activity of the native 92- and 72-kDa type IV collagenases and enhanced the elastase activity of the recombinant 92-kDa enzyme. On a molar basis the recombinant 92-kDa type IV collagenase was approximately 30% as active as human leukocyte elastase in solubilizing H-3-labeled elastin. Exogenously added TIMP in significant molar excess abolished the elastase activity of the 92- and 72-kDa type IV collagenases. Stromelysin and interstitial collagenase showed no significant elastolytic activity, although both were catalytically active against susceptible substrates. Conditioned media from cultures of human mononuclear phagocytes containing the 92-kDa enzyme produced a distinct zone of lysis in the kappa-elastin zymograms at this molecular mass. These results definitively extend the spectrum of human proteinases with elastolytic activity to metalloproteinases and suggest the enzymatic basis for elastase activity observed with certain cell types such as human alveolar macrophages.	JEWISH HOSP ST LOUIS,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,SCH MED,ST LOUIS,MO 63130	Barnes-Jewish Hospital; Washington University (WUSTL)	SENIOR, RM (corresponding author), JEWISH HOSP ST LOUIS,DEPT MED,DIV RESP & CRIT CARE,216 S KINGSHIGHWAY,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805, R01AR039472] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29594] Funding Source: Medline; NIAMS NIH HHS [AR 35805, AR 39472] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBIN RJ, 1987, AM REV RESPIR DIS, V135, P1281; BANDA MJ, 1987, METHOD ENZYMOL, V144, P288; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BIETH JG, 1986, BIOL EXTRACELLULAR M, P217; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; CAMPBELL EJ, 1987, J BIOL CHEM, V262, P15862; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GRANDA JL, 1990, CONNECT TISSUE RES, V24, P249, DOI 10.3109/03008209009152153; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HERRON GS, 1986, J BIOL CHEM, V261, P2810; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; PIPOLY DJ, 1987, BIOCHEMISTRY-US, V26, P5748, DOI 10.1021/bi00392a025; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493; SANDERSON RJ, 1977, J IMMUNOL, V118, P1409; SENIOR RM, 1989, AM REV RESPIR DIS, V139, P1251, DOI 10.1164/ajrccm/139.5.1251; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STONE PJ, 1982, METHOD ENZYMOL, V82, P588; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; SZENDROI M, 1984, J INVEST DERMATOL, V83, P224, DOI 10.1111/1523-1747.ep12263609; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WELGUS HG, 1980, J BIOL CHEM, V255, P6806; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918	37	514	519	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7870	7875						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850424				2022-12-25	WOS:A1991FJ34200086
J	JOYCEBRADY, M; RUBINS, JB; PANCHENKO, MP; BERNARDO, J; STEELE, MP; KOLM, L; SIMONS, ER; DICKEY, BF				JOYCEBRADY, M; RUBINS, JB; PANCHENKO, MP; BERNARDO, J; STEELE, MP; KOLM, L; SIMONS, ER; DICKEY, BF			MECHANISMS OF MASTOPARAN-STIMULATED SURFACTANT SECRETION FROM ISOLATED PULMONARY ALVEOLAR TYPE-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II EPITHELIAL-CELLS; GTP-BINDING PROTEIN; WASP VENOM; PHOSPHATIDYLCHOLINE SECRETION; PHOSPHOLIPASE-A2 ACTIVITY; PERTUSSIS TOXIN; DISATURATED PHOSPHATIDYLCHOLINE; BIOCHEMICAL ASPECTS; ADENYLATE-CYCLASE; LUNG SURFACTANT	Mastoparan, a tetradecapeptide component of wasp venom, is a potent activator of secretion in a variety of cell types, and has been shown to activate purified G-proteins reconstituted into phospholipid vesicles with a preferential activation of G(i) over G(s) (Higashijima, T., Uzu, S., Nakajima, T., and Ross, E. R. (1988) J. Biol. Chem. 263, 6491-6494). To identify the biochemical activities of mastoparan in a cellular system, we characterized the effects of mastoparan on signal transduction pathways in rat pulmonary alveolar type 2 epithelial cells, which synthesize and secrete pulmonary surfactant. Mastoparan inhibited adenylylcyclase activity in a manner that was dose-dependent (IC50 = 30-mu-M), but sensitive to neither guanine nucleotide nor pertussis toxin (PT). Mastoparan induced a PT-sensitive increase in cellular inositol trisphosphate and a rapid rise in cytosolic calcium released from intracellular stores; the time to onset of the calcium rise, but neither the rate nor the amplitude of the rise, were PT-sensitive. Mastoparan also caused a dose-(EC50 = 16-mu-M) and time-dependent activation of arachidonic acid release that was completely insensitive to pretreatment with PT. Secretion of pulmonary surfactant was increased by mastoparan approximately 8-fold over constitutive levels at 1 h with an EC50 = 20-mu-M, and mastoparan-stimulated secretion was partially sensitive to PT at late time points and to inhibitors of arachidonic acid metabolism, but not to the protein kinase C inhibitor H7. These findings are consistent with the activation of G(i) proteins in type 2 cells by mastoparan, although the lack of predicted triphosphoguanine nucleotide and PT sensitivity for some activities indicates that mastoparan does not act in a manner strictly analogous to liganded receptors or that some activities are not mediated by activation of G(i). While mastoparan is a potent secretagogue in several cell types, its secretory activity appears to have only a limited dependence on the activation of G(i) proteins in type 2 cells.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; MOSCOW CARDIOVASC SURG RES INST,MOLEC ENDOCRINOL LAB,MOSCOW,USSR	Boston University	JOYCEBRADY, M (corresponding author), BOSTON UNIV,SCH MED,PULM CTR K603,80 E CONCORD ST,BOSTON,MA 02118, USA.			Bernardo, John/0000-0002-3922-0559; Joyce-Brady, Martin/0000-0002-1898-6002	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031056] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07864, HL19717] Funding Source: Medline; NIDDK NIH HHS [DK31056] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; ASANO T, 1984, J BIOL CHEM, V259, P9351; BERRIDGE MJ, 1989, JAMA-J AM MED ASSOC, V262, P1834; BROWN LAS, 1981, J BIOL CHEM, V256, P66; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHAUNCEY JB, 1988, LAB INVEST, V58, P133; CHOW SC, 1990, J BIOL CHEM, V265, P902; CLAYPOOL WD, 1984, EXP LUNG RES, V6, P215, DOI 10.3109/01902148409109249; CLEMENTS JA, 1977, AM REV RESPIR DIS, V115, P67; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; COTT GR, 1990, AM J PHYSIOL, V258, pL179, DOI 10.1152/ajplung.1990.258.4.L179; DOBBS LG, 1986, BIOCHIM BIOPHYS ACTA, V877, P305, DOI 10.1016/0005-2760(86)90308-5; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DOBBS LG, 1978, AM REV RESPIR DIS, V118, P705, DOI 10.1164/arrd.1978.118.4.705; DORN CC, 1989, BRIT J PHARMACOL, V97, P163, DOI 10.1111/j.1476-5381.1989.tb11938.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; FANESTIL DD, 1965, J GERONTOL, V20, P462; FISHER AB, 1989, AM J PHYSIOL, V257, pL248, DOI 10.1152/ajplung.1989.257.4.L248; GIETZEN K, 1983, BIOCHIM BIOPHYS ACTA, V736, P109, DOI 10.1016/0005-2736(83)90175-X; GILFILLAN AM, 1987, BIOCHIM BIOPHYS ACTA, V917, P18, DOI 10.1016/0005-2760(87)90278-5; GILFILLAN AM, 1987, J PHARMACOL EXP THER, V241, P907; GILFILLAN AM, 1985, BIOCHIM BIOPHYS ACTA, V833, P336, DOI 10.1016/0005-2760(85)90207-3; GILFILLAN AM, 1986, BIOCHIM BIOPHYS ACTA, V876, P22, DOI 10.1016/0005-2760(86)90313-9; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1987, PEPTIDE CHEM 1986, P75; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JOYCEBRADY M, 1989, J CELL BIOL, V107, P349; JOYCEBRADY MF, 1990, DEV BIOL, V137, P331, DOI 10.1016/0012-1606(90)90258-K; KIKKAWA Y, 1983, LAB INVEST, V49, P122; KOLESNICK RN, 1984, AM J PHYSIOL, V246, pE458, DOI 10.1152/ajpendo.1984.246.5.E458; KURIHARA H, 1986, CELL TISSUE RES, V243, P311; KURODA Y, 1980, P JPN ACAD B-PHYS, V56, P660, DOI 10.2183/pjab.56.660; LIMBIRD LE, 1981, BIOCHEM J, V195, P1; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MASON RJ, 1977, AM REV RESPIR DIS, V115, P1015; MASON RJ, 1985, AM REV RESPIR DIS, V131, P786; MASON RJ, 1976, J LIPID RES, V17, P281; MESCHER EJ, 1983, EXP LUNG RES, V5, P173, DOI 10.3109/01902148309061512; METTLER NR, 1981, LAB INVEST, V45, P575; METZ SA, 1987, BIOCHEM BIOPH RES CO, V142, P251, DOI 10.1016/0006-291X(87)90478-5; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; NAKASHIMA S, 1987, BIOCHEM BIOPH RES CO, V146, P820, DOI 10.1016/0006-291X(87)90604-8; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKANO Y, 1985, FEBS LETT, V188, P363, DOI 10.1016/0014-5793(85)80403-8; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERIANIN A, 1989, J IMMUNOL, V143, P1669; PIAN MS, 1988, BIOCHIM BIOPHYS ACTA, V960, P43, DOI 10.1016/0005-2760(88)90007-0; RESINK TJ, 1988, EUR J BIOCHEM, V174, P531, DOI 10.1111/j.1432-1033.1988.tb14131.x; RICE WR, 1984, BIOCHIM BIOPHYS ACTA, V805, P261, DOI 10.1016/0167-4889(84)90081-8; RICE WR, 1986, BRIT J PHARMACOL, V89, P485, DOI 10.1111/j.1476-5381.1986.tb11148.x; RICE WR, 1987, BRIT J PHARMACOL, V91, P833, DOI 10.1111/j.1476-5381.1987.tb11282.x; RICE WR, 1985, EXP LUNG RES, V9, P135, DOI 10.3109/01902148509061533; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANO K, 1987, AM J PHYSIOL, V253, pC679, DOI 10.1152/ajpcell.1987.253.5.C679; SANO K, 1985, J BIOL CHEM, V260, P2725; SEISHIMA M, 1988, BIOCHEM BIOPH RES CO, V156, P1077, DOI 10.1016/S0006-291X(88)80742-3; SILK ST, 1989, J BIOL CHEM, V264, P21466; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; TOUCHSTONE JC, 1980, LIPIDS, V15, P61, DOI 10.1007/BF02534120; VANDOP C, 1984, J BIOL CHEM, V259, P23; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374; WALLACE MA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P311, DOI 10.1016/0005-2760(89)90018-0; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; White A A, 1974, Methods Enzymol, V38, P41; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426; YANG CY, 1987, ENDOCRINOLOGY, V120, P63, DOI 10.1210/endo-120-1-63; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4; YOSHINO H, 1989, J BIOL CHEM, V264, P19706; ZEITLER P, 1985, MOL PHARMACOL, V28, P549	76	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6859	6865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849893				2022-12-25	WOS:A1991FG72700036
J	MILLIGAN, G; CARR, C; GOULD, GW; MULLANEY, I; LAVAN, BE				MILLIGAN, G; CARR, C; GOULD, GW; MULLANEY, I; LAVAN, BE			AGONIST-DEPENDENT, CHOLERA TOXIN-CATALYZED ADP-RIBOSYLATION OF PERTUSSIS TOXIN-SENSITIVE G-PROTEINS FOLLOWING TRANSFECTION OF THE HUMAN ALPHA-2-C10 ADRENERGIC-RECEPTOR INTO RAT-1 FIBROBLASTS - EVIDENCE FOR THE DIRECT INTERACTION OF A SINGLE RECEPTOR WITH 2 PERTUSSIS TOXIN-SENSITIVE G-PROTEINS, GI2 AND GI3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; PLATELET ALPHA-2-ADRENERGIC RECEPTOR; ISLET-ACTIVATING PROTEIN; C6 BU1 CELLS; ADENYLYL CYCLASE; HYBRID-CELLS; SIGNAL TRANSDUCTION; HL-60 CELLS; EXPRESSION; IDENTIFICATION	A DNA encoding the human alpha-2-C10 adrenergic receptor was transfected into Rat 1 fibroblasts and clones selected on the basis of resistance to G418 sulfate. Two clones, one of which (1C) expressed some 3.5 pmol/mg membrane protein of the receptor as assessed by the specific binding of [H-3]yohimbine and one (4D) which did not express detectable amounts of the receptor were selected for further study. When cholera toxin-catalyzed ADP-ribosylation was performed with [P-32]NAD on membranes of these cells in the absence of added guanine nucleotides, radioactivity was incorporated into a polypeptide(s) of 40 kDa in addition to the 45- and 42-kDa forms of G(s)alpha. Addition of the selective alpha-2 receptor agonist U.K.14304 enhanced markedly, in a dose-dependent manner, the cholera toxin-catalyzed [P-32]ADP-ribosylation of the 40-kDa polypeptide(s), but not the 45- or 42-kDa polypeptides, in membranes of the 1C cells. Dose response curves for U.K.14304 enhancement of cholera toxin-labeling of the 40-kDa polypeptide(s) and stimulation of high affinity GTPase activity were identical. By contrast, U.K.14304 was ineffective in either assay in membranes from the 4D cells, demonstrating this effect to be dependent upon receptor activation. Furthermore, the alpha-2 receptor antagonist yohimbine blocked all effects of U.K.14304. The agonist promotion of cholera toxin-catalyzed ADP-ribosylation of G(i) was completely blocked by guanine nucleotides. Whether GDP or GDP + fluoroaluminate (as a mimic of GTP) was used, blockade of the agonist effect was complete and indeed both conditions prevented agonist-independent labeling by cholera toxin of the 40-kDa polypeptide(s). Mg2+ produced an agonist-independent cholera toxin-catalyzed [P-32]ADP-ribosylation of the 40-kDa polypeptide(s) but even in the presence of [Mg2+], agonist-stimulation of cholera toxin-labeling of the 40-kDa polypeptide(s) was observed and was additive with the effect of [Mg2+]. Agonist stimulation of cholera toxin-catalyzed ADP-ribosylation of G(i) was completely attenuated by pretreatment of the cells with pertussis toxin, which prevents contact between receptors and G-proteins which are substrates for this toxin. By contrast, pretreatment of the cells with concentrations of cholera toxin able to "down-regulate" essentially all of the membrane-associated G(s)alpha did not prevent agonist stimulation of cholera toxin-catalyzed ADP-ribosylation of G(i). Immunoprecipitation of the 40-kDa polypeptide(s) radiolabeled by cholera toxin, with selective anti-G-protein antisera, demonstrated that both G(i)2 and G(i)3 were modified in an agonist-dependent manner. These results demonstrate that agonist stimulation of the cholera toxin-catalyzed ADP-ribosylation of "inappropriate" G-proteins can define interactions of receptors with pertussis toxin-sensitive G-proteins and that to achieve such results the guanine nucleotide-binding pocket of the G-protein must lack either GDP or GTP. Furthermore, these results indicate that the alpha-2-C10 adrenergic receptor can interact functionally in these membranes with both G(i)2 and G(i)3. This is the first demonstration that a single molecularly defined receptor can activate multiple pertussis toxin-sensitive G-proteins in a native membrane.	UNIV GLASGOW,DEPT PHARMACOL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow	MILLIGAN, G (corresponding author), UNIV GLASGOW,DEPT BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND.		Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Gould, Gwyn/0000-0001-6571-2875				AKSAMIT RR, 1985, P NATL ACAD SCI USA, V82, P7475, DOI 10.1073/pnas.82.22.7475; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; CHANG FH, 1989, J BIOL CHEM, V264, P5352; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1990, MOL PHARMACOL, V37, P383; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FRASER CM, 1989, J BIOL CHEM, V264, P11754; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HINGORANI VN, 1990, G PROTEINS MEDIATORS, P95; IIRI T, 1989, J BIOL CHEM, V264, P21394; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAZIRO Y, 1990, G PROTEINS MEDIATORS, P47; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIMBIRD LE, 1988, ALPHA 2 ADRENERGIC R; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1989, CELL SIGNAL, V1, P411, DOI 10.1016/0898-6568(89)90027-2; MILLIGAN G, 1989, CELL SIGNAL, V1, P65, DOI 10.1016/0898-6568(89)90021-1; MILLIGAN G, 1987, BIOCHEM J, V245, P501, DOI 10.1042/bj2450501; MILLIGAN G, 1987, BIOCHIM BIOPHYS ACTA, V929, P197, DOI 10.1016/0167-4889(87)90176-5; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; MITCHELL FM, 1989, BIOCHEM J, V262, P403, DOI 10.1042/bj2620403; OBRIEN RM, 1987, FEBS LETT, V212, P281, DOI 10.1016/0014-5793(87)81361-3; OFFERMANS S, 1990, FEBS LETT, V260, P14, DOI 10.1016/0014-5793(90)80054-M; OWENS JR, 1985, J BIOL CHEM, V260, P5946; REGAN JW, 1986, J BIOL CHEM, V261, P3894; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4	42	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6447	6455						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848855				2022-12-25	WOS:A1991FE37300067
J	ADNANE, J; GAUDRAY, P; DIONNE, CA; CRUMLEY, G; JAYE, M; SCHLESSINGER, J; JEANTEUR, P; BIRNBAUM, D; THEILLET, C				ADNANE, J; GAUDRAY, P; DIONNE, CA; CRUMLEY, G; JAYE, M; SCHLESSINGER, J; JEANTEUR, P; BIRNBAUM, D; THEILLET, C			BEK AND FLG, 2 RECEPTORS TO MEMBERS OF THE FGF FAMILY, ARE AMPLIFIED IN SUBSETS OF HUMAN BREAST CANCERS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; HER-2 NEU ONCOGENE; PROTO-ONCOGENE; AMPLIFICATION; GENE; CARCINOMAS; TUMORS; DNA; EXPRESSION; PHENOTYPE	Tumor DNA samples from 387 breast carcinomas have been investigated for amplification of BEK and FLG genes, both of which have been shown to code for cell surface receptors to FGFs. BEK and FLG were found amplified in 11.5 and 12.7% of breast tumors respectively. Statistical analysis, performed on the subset of 297 primary cancers without presurgical therapy, showed for BEK a trend of preferential amplification in patients above 50 years (P = 0.055), whereas amplification of FLG could significantly be correlated with nodal involvement (P = 0.032) and seemed prevalent in steroid hormones receptor positive tumors. Since the same tumors were previously analysed for the amplification of MYC, ERBB2 and HST/INT2/BCL1 possible associations with BEK and FLG amplifications were looked for. BEK was found significantly correlated with MYC and FLG with HST/INT2/BCL1. The amplification of these two FGF receptor genes may therefore represent additional steps in the molecular phenotyping of breast cancer.	FAC MED NICE,LGMCH,AV VALOMBROSE,F-06034 NICE,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE; RHONE POULENC RORER CENT RES,KING OF PRUSSIA,PA 19406; UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,UA 1191,F-34095 MONTPELLIER 2,FRANCE; CTR PAUL LAMARQUE,BIOCHIM LAB,F-34094 MONTPELLIER 2,FRANCE; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; New York University			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Birnbaum, Daniel/0000-0001-7920-9883				ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1988, BREAST CANCER CELLUL, P25; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GOMPEL C, 1983, PRINCIPLES PRACTICES, V1, P245; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINTRUF C, 1990, GENE CHROMOSOME CANC, V2, P18, DOI 10.1002/gcc.2870020105; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THEILLET C, 1989, ONCOGENE, V4, P915; VARLEY JM, 1988, ONCOGENE, V3, P87; WILLIAMS BP, 1988, ONCOGENE, V3, P345; ZEILLINGER R, 1989, ONCOGENE, V4, P109; 1982, TUMORI, V68, P181	24	246	267	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					659	663						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851551				2022-12-25	WOS:A1991FR93900023
J	FUKUI, Y; SALTIEL, AR; HANAFUSA, H				FUKUI, Y; SALTIEL, AR; HANAFUSA, H			PHOSPHATIDYLINOSITOL-3 KINASE IS ACTIVATED IN V-SRC, V-YES, AND V-FPS TRANSFORMED CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							MIDDLE T-ANTIGEN; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; TYROSINE KINASE; SARCOMA-VIRUS; BOVINE BRAIN; ASSOCIATION; PP60C-SRC; 3-KINASE; PROTEIN	PI-3 kinase activity has been shown to associate with p60v-src. We found that immunoprecipitates of p60v-src exhibit an activity that catalyzes the formation of PI-3-P, PI-3,4-P2 and PIP3 from PI, PI-4-P, and PI-4,5-P2, respectively. Transformation of chicken embryo fibroblasts (CEF) by p60v-src of Rous sarcoma virus (RSV) caused elevation of PI-3-P, PI-3,4-P2, and PIP3, suggesting that the PI-3 kinase may be activated in these cells. Similar elevations were seen in cells transformed with the v-yes or v-fps oncogenes, but not with v-ros or v-ras. We have established also a system that allows the binding of PI-3 kinase to purified p60v-src in vitro, reproducing the binding seen in vivo. This assay indicated that more PI-3 kinase activity binds to purified p60v-src in cell lysates from CEF transformed with v-yes or v-fps, suggesting that some modification or overexpression of PI-3 kinase takes place in these cells.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University			Saltiel, Alan/L-3632-2019; Fukui, Yasuhisa/E-8806-2010	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA44356] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK033804, R01DK033804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FELDMAN RA, 1985, J VIROL, V42, P228; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALTIEL AR, 1987, BIOCHEM J, V241, P759, DOI 10.1042/bj2410759; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SUMMERS MD, 1985, BANBURY REPORT, V22, P319; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	29	70	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					407	411						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849246				2022-12-25	WOS:A1991FT34400009
J	FOSKETT, JK; ROIFMAN, CM; WONG, D				FOSKETT, JK; ROIFMAN, CM; WONG, D			ACTIVATION OF CALCIUM OSCILLATIONS BY THAPSIGARGIN IN PAROTID ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; PLASMA-MEMBRANE; TUMOR PROMOTER; CA-2+; RECEPTOR; TRISPHOSPHATE; PHOSPHATES; RELEASE	The tumor promoter Thapsigargin releases Ca2+ from intracellular stores by specific inhibition of microsomal Ca-ATPase activity without inositol phosphate formation. Recent studies of the actions of thapsigargin support the concept that the level of Ca2+ within the inositol (1,4,5)-trisphosphate (IP3)-sensitive intracellular pool regulates the Ca2+ permeability of the plasma membrane. We examined the effects of thapsigargin on intracellular Ca2+ concentration ([Ca2+]i) in single rat parotid cells using digital fluorescence microscopy. In the absence of extracellular Ca2+ (Ca2+o), thapsigargin transiently increased [Ca2+]i. Following the thapsigargin-induced [Ca2+]i transient, carbachol in the continued absence of Ca2+o was unable to raise [Ca2+]i, indicating that thapsigargin mobilizes Ca2+ from the IP3-sensitive store. In the converse experiment, carbachol prevented a rise of [Ca2+]i by thapsigargin, suggesting that the IP3- and thapsigargin-sensitive Ca2+ pools are the same. Depletion of Ca2+ from the IP3-sensitive pool by thapsigargin enhanced plasma membrane Ca2+ permeability. Thapsigargin triggered sustained Ca2+ oscillations in Ca2+-containing medium which are highly reminiscent of agonist-induced oscillations in these cells. Carbachol addition rapidly raised IP3 levels during oscillations triggered by thapsigargin but did not elevate [Ca2+]i, indicating that the IP3-sensitive pool remains continuously depleted during [Ca2+]i fluctuations. The results from this study rule out the involvement of the IP3-sensitive pool in the mechanisms involved in thapsigargin-induced (and by analogy, agonist-induced) oscillations in parotid cells.	HOSP SICK CHILDREN, DIV IMMUNOL ALLERGY, TORONTO M5G 1X8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	FOSKETT, JK (corresponding author), HOSP SICK CHILDREN, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA.		Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268	NIDDK NIH HHS [DK41980-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK041980] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI H, 1985, BRIT J PHARMACOL, V85, P705, DOI 10.1111/j.1476-5381.1985.tb10567.x; AUB DL, 1987, J DENT RES, V66, P547, DOI 10.1177/00220345870660022701; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; DOUGLAS WW, 1963, J PHYSIOL-LONDON, V165, P528, DOI 10.1113/jphysiol.1963.sp007076; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; Foskett J.K., 1990, NONINVASIVE TECHNIQU, P237; FOSKETT JK, 1988, AM J PHYSIOL, V255, pC566, DOI 10.1152/ajpcell.1988.255.4.C566; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWORTH RA, 1989, CELL CALCIUM, V10, P263, DOI 10.1016/0143-4160(89)90009-2; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1989, BIOCHEM SOC T, V17, P6, DOI 10.1042/bst0170006; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KANO S, 1987, BIOCHEM BIOPH RES CO, V143, P672, DOI 10.1016/0006-291X(87)91406-9; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NAUNTOFTE B, 1987, AM J PHYSIOL, V253, pG290, DOI 10.1152/ajpgi.1987.253.3.G290; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PUTNEY JW, 1986, FASEB J, V45, P2634; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROIFMAN CM, 1987, EUR J IMMUNOL, V17, P1737, DOI 10.1002/eji.1830171209; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SORIMACHI M, 1990, NEUROSCI LETT, V111, P333, DOI 10.1016/0304-3940(90)90284-G; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W	51	104	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2778	2782						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847134				2022-12-25	WOS:A1991EX60000020
J	BLISKA, JB; BENJAMIN, HW; COZZARELLI, NR				BLISKA, JB; BENJAMIN, HW; COZZARELLI, NR			MECHANISM OF TN3 RESOLVASE RECOMBINATION INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; TOPOISOMERASE-I; DNA; TRANSPOSITION; SEQUENCES; TOPOLOGY; PROTEINS; ENCODES; PBR322; KNOTS	To determine the physiologically important features of site-specific recombination by Escherichia coli Tn3 resolvase we analyzed the salient properties of the reaction in vivo. A two-plasmid system in which one plasmid served as substrate while the other encoded both resolvase and a thermolabile repressor of resolvase transcription provided controlled, synchronous recombination. Recombination proceeded rapidly and was promoted by (-) DNA supercoiling. These structures of the in vivo recombination products were predominantly the same as those previously identified in vitro. By examination of the products of successive rounds of recombination of a four-site substrate, we ruled out a tracking mechanism for site alignment. Inversion and plasmid fusion occurred in vivo at a much lower rate than resolution but ultimately reached a higher extent than found in vitro. We propose that inversion and fusion exploit topologically interlinked substrates that occur at low levels in vivo. This proposal is supported by the unexpected specificity of fusion. Our data imply that supercoiled DNA, the resolvase synaptic complex, and the mechanism of strand exchange are fundamentally similar in vivo and in vitro, but that the repertoire of resolvase substrates and products is expanded in vivo by the action of other enzymes that alter DNA topology.	UNIV CALIF BERKELEY,DEPT MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BENJAMIN HW, 1985, CELL, V40, P147, DOI 10.1016/0092-8674(85)90318-6; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; Bernard H U, 1979, Methods Enzymol, V68, P482; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHIANG SJ, 1982, MOL GEN GENET, V185, P169, DOI 10.1007/BF00333809; COZZARELLI NR, 1968, P NATL ACAD SCI USA, V60, P992, DOI 10.1073/pnas.60.3.992; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DEAN FB, 1985, J BIOL CHEM, V260, P4975; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DROGE P, 1989, P NATL ACAD SCI USA, V86, P6062, DOI 10.1073/pnas.86.16.6062; DUNGAN JM, 1983, THESIS U CALIFORNIA; GRINDLEY NDF, 1983, CELL, V32, P3, DOI 10.1016/0092-8674(83)90490-7; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KOSTRIKEN R, 1981, P NATL ACAD SCI-BIOL, V78, P4041, DOI 10.1073/pnas.78.7.4041; KRASNOW MA, 1983, CELL, V32, P131; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V1, P3; Ptashne M., 1971, BACTERIOPHAGE LAMBDA, P221; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; SHEN LL, 1985, P NATL ACAD SCI USA, V82, P307, DOI 10.1073/pnas.82.2.307; Sherratt D. J., 1987, DNA REPLICATION RECO, P703; SHISHIDO K, 1989, NUCLEIC ACIDS RES, V17, P9749, DOI 10.1093/nar/17.23.9749; SHISHIDO K, 1987, J MOL BIOL, V195, P215, DOI 10.1016/0022-2836(87)90338-X; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WHITE JH, 1987, J MOL BIOL, V197, P585, DOI 10.1016/0022-2836(87)90566-3	31	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2041	2047						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846609				2022-12-25	WOS:A1991EV51500008
J	CHERN, YJ; SPANGLER, R; CHOI, HS; SYTKOWSKI, AJ				CHERN, YJ; SPANGLER, R; CHOI, HS; SYTKOWSKI, AJ			ERYTHROPOIETIN ACTIVATES THE RECEPTOR IN BOTH RAUSCHER AND FRIEND MURINE ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-MYB CDNA; ERYTHROID-DIFFERENTIATION; GENE-EXPRESSION; VIRUS; LEUKEMIA; INVITRO; CLONING; PROTEIN; ACID; RNA	Alterations in the expression of two proto-oncogenes, c-myb and c-myc, have been implicated in the differentiation of transformed erythroid cells induced by chemical inducers, such as dimethyl sulfoxide (Me2SO). In the present study, we compared the expression of c-myb and c-myc during erythropoietin (Epo) and Me2SO induction of Rauscher erythroleukemia cells, which differentiate in response to both inducers, and Friend erythroleukemia cells, in which Epo-induced differentiation is blocked. Our results demonstrate that Epo induces specific changes in expression of c-myb and c-myc in both Rauscher and Friend cells. Epo increases c-myc transcript, in contrast to a decreased caused Me2SO, indicating that the biphasic mode of c-myc regulation seen with Me2SO is not required for erythropoiesis. The Epo-induced changes in c-myb and c-myc do not require new protein synthesis, thus identifying these proto-oncogenes as early response genes for Epo. Both cell types also exhibit rapid changes in membrane protein phosphorylation in response to Epo. Since the signal pathway from Epo receptor activation to the nucleus appears equally functional in both Rauscher and Friend cells, the data suggest that the inability of Friend cells to differentiate in response to Epo is due to a block at a later step in the induction process.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,BOSTON,MA 02215; ACAD SINICA,INST BIOMED SCI,TAIPEI 115,TAIWAN	Harvard University; Harvard Medical School; Academia Sinica - Taiwan			chern, yijuang/S-7013-2018	chern, yijuang/0000-0002-5842-5429	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038841] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK38841] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BESTWICK RK, 1984, J VIROL, V51, P695, DOI 10.1128/JVI.51.3.695-705.1984; BRAELL WA, 1981, J BIOL CHEM, V256, P1337; CASTLE S, 1985, BIOCHEM BIOPH RES CO, V132, P688, DOI 10.1016/0006-291X(85)91187-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI HS, 1987, J BIOL CHEM, V262, P2933; CHOI HS, 1990, J BIOL CHEM, V265, P4143; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANDREA A, 1990, NATURE, V343, P762; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; de Both N J, 1978, Nature, V272, P626, DOI 10.1038/272626a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HANKINS WD, 1980, CELL, V22, P693; IMAGAWA S, 1989, BLOOD, V73, P1452; KOURY MJ, 1982, P NATL ACAD SCI-BIOL, V79, P635, DOI 10.1073/pnas.79.2.635; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MAGER D, 1981, MOL CELL BIOL, V1, P721, DOI 10.1128/MCB.1.8.721; MCMAHON J, 1988, ONCOGENE, V3, P717; MILLER BA, 1989, BLOOD, V73, P1188; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PREISLER HD, 1974, NATURE, V251, P645, DOI 10.1038/251645a0; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RIFKIND RA, 1978, BLOOD CELLS, V4, P189; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SYTKOWSKI AJ, 1984, BLOOD, V64, P84; SYTKOWSKI AJ, 1980, SCIENCE, V210, P74, DOI 10.1126/science.6932101; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOJO A, 1989, BLOOD, V74, P124	34	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2009	2012						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846607				2022-12-25	WOS:A1991EV51500002
J	HIGASHI, K; HOEK, JB				HIGASHI, K; HOEK, JB			ETHANOL CAUSES DESENSITIZATION OF RECEPTOR-MEDIATED PHOSPHOLIPASE-C ACTIVATION IN ISOLATED HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PROTEIN KINASE-C; ADENOSINE CYCLIC 3',5'-PHOSPHOROTHIOATE; PHORBOL-MYRISTATE ACETATE; GLUCAGON-INDUCED INCREASE; FREE CA-2+ CONCENTRATION; HETEROLOGOUS DESENSITIZATION; SIGNAL-TRANSDUCTION; INDUCED STIMULATION; HUMAN-PLATELETS	The effect of ethanol on receptor-mediated phospholipase C-linked signal transduction processes was investigated in isolated rat hepatocytes. Pretreatment of the cells with ethanol (6-300 mM) markedly inhibited a subsequent stimulation of phospholipase C by vasopressin, angiotensin II, or epidermal growth factor. By contrast, the effects of the alpha-1-adrenergic agonist phenylephrine and of glucagon were not affected by ethanol pretreatment. Ethanol inhibited the agonist-induced decrease in polyphosphoinositides, the formation of inositol phosphates, and the increase in cytosolic free Ca2+ levels, as detected with the intracellular Ca2+ indicator indo-1. The effects of ethanol were concentration dependent and were pronounced at low concentrations of agonists but were not significant at saturating levels. Pretreatment of the cells with the protein kinase C inhibitor H7 partly prevented the inhibition by ethanol of vasopressin-induced phospholipase C activation. By contrast, pretreatment of the cells with (R(p))-adenosine cyclic 3':5'-phosphorothioate ((R(p))-cAMP-S), a competitive inhibitor of protein kinase A, potentiated the inhibitory effect of ethanol on the Ca2+ mobilization by vasopressin. (R(p))-cAMP-S similarly potentiated the inhibition of phospholipase C by the protein kinase C-activating phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA). The kinase A inhibitor also made the Ca2+ mobilization by phenylephrine sensitive to ethanol, indicating that the formation of cAMP in the cells played a role in suppressing the sensitivity to ethanol. Pretreatment of the cells with ethanol enhanced the inhibitory effects of TPA on the vasopressin-induced phospholipase C activation at all concentrations of the hormone; however, these synergistic effects were prevented when TPA was added prior to ethanol, a condition that prevents the activation of phospholipase C by ethanol. The data indicate that ethanol causes desensitization of the receptor-mediated phospholipase C secondary to the ethanol-induced activation of phospholipase C and activation of protein kinase C. Ethanol treatment also affects the sensitivity of the phospholipase C system to control by protein kinases A and C. The data indicate that ethanol can affect the control of intracellular signal transduction processes in liver cells under physiologically relevant conditions.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University				Hoek, Jan/0000-0001-7127-4218	NIAAA NIH HHS [AA07215, AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38461] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CHAN TM, 1977, J BIOL CHEM, V252, P8645; COMBETTES L, 1986, BIOCHEM J, V237, P675, DOI 10.1042/bj2370675; CONNELLY PA, 1987, J BIOL CHEM, V262, P4324; COOPER RH, 1985, J BIOL CHEM, V260, P3281; DORIO RJ, 1988, BIOCHEM PHARMACOL, V37, P3528, DOI 10.1016/0006-2952(88)90708-3; FORSLING ML, 1988, J ENDOCRINOL, V116, P217, DOI 10.1677/joe.0.1160217; HIDAKA H, 1987, TRENDS PHARMACOL SCI, V8, P162, DOI 10.1016/0165-6147(87)90155-6; Hoek J B, 1988, Adv Exp Med Biol, V232, P25; HOEK JB, 1988, INT CONGR SER, V805, P651; HOEK JB, 1987, ANN NY ACAD SCI, V492, P212, DOI 10.1111/j.1749-6632.1987.tb48671.x; HOEK JB, 1988, TRENDS BIOCHEM SCI, V13, P269, DOI 10.1016/0968-0004(88)90161-2; HOEK JB, 1988, BIOCHEM J, V251, P865, DOI 10.1042/bj2510865; HOEK JB, 1987, J BIOL CHEM, V262, P682; HOFFMAN PL, 1990, FASEB J, V4, P2612, DOI 10.1096/fasebj.4.9.2161371; IRVINE RF, 1985, BIOCHEM J, V229, P505, DOI 10.1042/bj2290505; KIKUCHI A, 1987, J BIOL CHEM, V262, P6766; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; MARKS JS, 1986, J BIOL CHEM, V261, P5895; MOCHLYROSEN D, 1988, NATURE, V333, P848, DOI 10.1038/333848a0; NAGY LE, 1989, MOL PHARMACOL, V36, P744; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; ROONEY TA, 1989, J BIOL CHEM, V264, P6817; ROTHERMEL JD, 1984, J BIOL CHEM, V259, P8151; ROTHERMEL JD, 1984, J BIOL CHEM, V259, P5294; RUBIN R, 1988, BIOCHEM PHARMACOL, V37, P2461, DOI 10.1016/0006-2952(88)90374-7; RUBIN R, 1988, BIOCHEM J, V254, P147, DOI 10.1042/bj2540147; RUBIN R, 1988, ARCH BIOCHEM BIOPHYS, V260, P480, DOI 10.1016/0003-9861(88)90472-9; STADDON JM, 1989, EUR J BIOCHEM, V179, P47, DOI 10.1111/j.1432-1033.1989.tb14519.x; STADDON JM, 1986, BIOCHEM J, V238, P737, DOI 10.1042/bj2380737; STEINER AL, 1969, P NATL ACAD SCI USA, V64, P367, DOI 10.1073/pnas.64.1.367; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	38	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2178	2190						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846616				2022-12-25	WOS:A1991EV51500028
J	OEMAR, BS; FOELLMER, HG; HODGDONANANDANT, L; ROSENZWEIG, SA				OEMAR, BS; FOELLMER, HG; HODGDONANANDANT, L; ROSENZWEIG, SA			REGULATION OF INSULIN-LIKE GROWTH FACTOR-I RECEPTORS IN DIABETIC MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE GLOMERULOSCLEROSIS; RIBONUCLEIC-ACID; BINDING; KIDNEY; MECHANISM; HORMONE; CULTURE; RATS	Mesangial cells are thought to play a central role in the renal complications of diabetes mellitus. Insulin-like growth factor I(IGF-I) has been found to promote mesangial cell proliferation and regulate normal mesangial cell function in an autocrine and/or paracrine fashion. To gain further insight into the potential regulatory role IGF-I may play in mesangial cell function in diabetes, IGF-I receptors were analyzed in mesangial cells isolated from diabetic mice (db/db) and their control littermates (db/m). Mesangial cells isolated from db/db mice exhibited higher levels of IGF-I receptors compared to cells from db/m mice. Insulin receptors were not detectable in either cell type by binding analyses; however, immunoblot analysis revealed insulin receptor alpha-subunits in wheat germ agglutinin-Sepharose-purified membranes from db/db cells. Northern blot analysis further indicated a lack of detectable insulin receptor mRNA in db/m cells, whereas db/db cells expressed multiple insulin receptor mRNA transcripts. Both IGF-1 and insulin receptor mRNA levels were increased in db/db cells grown in the presence of high glucose (28 mM), whereas the receptor protein levels remained relatively constant or increased, respectively. This increased expression of IGF-I and insulin receptors in diabetic mesangial cells may have an important role in the development of diabetic nephropathy.	YALE UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,330 CEDAR ST,POB 3333,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Yale University			Rosenzweig, Steven A/O-5062-2018	Rosenzweig, Steven/0000-0002-7022-6086; Oemar, Barry/0000-0003-1996-5817	NATIONAL EYE INSTITUTE [P30EY000785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034389, R23DK034389] Funding Source: NIH RePORTER; NEI NIH HHS [EY-06581, EY-00785] Funding Source: Medline; NIDDK NIH HHS [DK-34389] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRASS CK, 1988, ENDOCRINOLOGY, V123, P2432, DOI 10.1210/endo-123-5-2432; ARON DC, 1989, J CLIN ENDOCR METAB, V68, P585, DOI 10.1210/jcem-68-3-585; BOWER G, 1980, LAB INVEST, V43, P333; BRIATA P, 1989, BIOCHEM BIOPH RES CO, V160, P1415, DOI 10.1016/S0006-291X(89)80162-7; BRITA P, 1989, BIOCHEM BIOPH RES CO, V165, P1123; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONTI FG, 1988, ENDOCRINOLOGY, V122, P2788, DOI 10.1210/endo-122-6-2788; DIAMOND MP, 1990, METABOLISM, V39, P220, DOI 10.1016/0026-0495(90)90039-F; DOI T, 1988, AM J PATHOL, V131, P398; GUENTHER HL, 1982, EXPERIENTIA, V38, P979, DOI 10.1007/BF01953688; HAMMERMAN MR, 1989, AM J PHYSIOL, V257, pF503, DOI 10.1152/ajprenal.1989.257.4.F503; HOROVITZ O, 1989, J CELL BIOL, V108, P1817, DOI 10.1083/jcb.108.5.1817; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD CM, 1989, P NATL ACAD SCI USA, V86, P10113, DOI 10.1073/pnas.86.24.10113; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; OLEARY NE, 1987, AM J PHYSIOL, V253, pE81, DOI 10.1152/ajpendo.1987.253.1.E81; ROSENZWEIG SA, 1990, J BIOL CHEM, V265, P18030; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; SEGAL R, 1989, KIDNEY INT, V36, pS2; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; STERZEL RB, 1986, AM J PATHOL, V125, P130; STRIKER LJ, 1989, SEMIN NEPHROL, V9, P318; WERNER H, 1990, DIABETES S1, V39, pA77	27	78	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2369	2373						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846626				2022-12-25	WOS:A1991EV51500055
J	ZHANG, B; TAVARE, JM; ELLIS, L; ROTH, RA				ZHANG, B; TAVARE, JM; ELLIS, L; ROTH, RA			THE REGULATORY ROLE OF KNOWN TYROSINE AUTOPHOSPHORYLATION SITES OF THE INSULIN-RECEPTOR KINASE DOMAIN - AN ASSESSMENT BY REPLACEMENT WITH NEUTRAL AND NEGATIVELY CHARGED AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BETA-SUBUNIT; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; EXPRESSION SYSTEM; HEPATOMA-CELLS; PHOSPHORYLATION; ACTIVATION; RESIDUES; INVITRO	Autophosphorylation of the insulin receptor has been previously documented to activate the phosphotransferase activity of the receptor from 20- to 200-fold. Biochemical studies have correlated activation of the receptor kinase with the autophosphorylation of tryosines residues 1158, 1162, and 1163. To further assess the role of these 3 tyrosines in the activation process, we have studied the effect of their substitution with either the neutral amino acids phenylalanine or alanine or with the negatively charged amino acids aspartate and glutamate. In several other proteins, it has been shown that substitution of phosphorylated residues with negatively charged amino acids can mimic the phosphorylation state of the protein. In agreement with previous studies, tyrosines at positions 1162 and 1163 were found to be crucial in the kinase activation process. In contrast, mutant receptors with tyrosine 1158 changed to either phenylalanine or aspartate were still activated to the same extent as the wild-type receptor. An increased basal exogenous kinase activity was observed upon replacement of tyrosines 1162 and 1163 with, in increasing order of potency, aspartate = glutamate < alanine = phenylalanine. These results indicate that phosphorylation of tyrosines 1162/1163 but not 1158 play a critical role in the activation of the receptor kinase and that the mechanism of activation of the receptor kinase by autophosphorylation is more complex than just an introduction of a cluster of negative charges in this region of the receptor. In addition, the finding of an increased basal kinase activity in receptors lacking tyrosines 1162 and 1163 could explain the reported ability of this receptor to mediate certain biological responses.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK 40511, DK 34926, DK 41765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041765, R01DK040511, R37DK034926, R01DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1990, J EXPT PHARM INSULIN, V92, P313; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; COBB MH, 1989, J BIOL CHEM, V264, P18701; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FONG YL, 1989, J BIOL CHEM, V264, P16759; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOREN HJ, 1987, BIOCHEMISTRY-US, V26, P2374, DOI 10.1021/bi00382a044; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HOLLENBERG MD, 1990, HDB EXPT PHARM INSUL, V92, P183; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KLEIN HH, 1986, J BIOL CHEM, V261, P4691; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MORGAN DO, 1985, ENDOCRINOLOGY, V116, P1224, DOI 10.1210/endo-116-3-1224; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; RAMOS P, 1989, MOL BRAIN RES, V6, P61, DOI 10.1016/0169-328X(89)90029-6; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTH RA, 1990, HDB EXPT PHARM INSUL, V92, P169; ROTHENBERG P, 1990, HDB EXPT PHARM INSUL, V92, P209; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; YONEZAWA K, 1990, FASEB J, V4, P194, DOI 10.1096/fasebj.4.2.2153593; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P4715	45	124	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					990	996						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1846000				2022-12-25	WOS:A1991ET17700051
J	ZELEZNIKAR, RJ; GOLDBERG, ND				ZELEZNIKAR, RJ; GOLDBERG, ND			KINETICS AND COMPARTMENTATION OF ENERGY-METABOLISM IN INTACT SKELETAL-MUSCLE DETERMINED FROM O-18 LABELING OF METABOLITE PHOSPHORYLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE ALPHA-PHOSPHORYLS; OXYGEN-EXCHANGE; PHOSPHATE; HYDROLYSIS; SHUTTLE; MYOSIN; ATPASE; CELLS; WATER	Analyses of isolated intact diaphragm muscle show that at rest only about 30% of the total cellular P(i) is metabolically reactive as indicated by O-18 incorporation from [O-18]water, whereas up to 90% becomes metabolically active incrementally with contractile frequency. Kinetics of [gamma-O-18]ATP appearance show that about 90% of the cellular ATP is metabolically active and suggest slowly and rapidly metabolizing compartments of ATP in resting muscle and only rapidly metabolizing compartments in contracting muscle. Rates of [O-18]creatine phosphate ([O-18]CrP) appearance are consistent with creatine kinase-catalyzed phosphoryl exchange functioning in an obligatory phosphoryl shuttle system. In noncontracting muscle, ATP turnover rate was 83 nmol.mg protein-1.min-1, and the P/O ratio was determined to be 3.2. ATP utilization increases in direct proportion to contractile frequency with each contracture consuming the equivalent of 0.96 nmol of ATP.mg protein-1 or 2.5-3.5 molecules of ATP/myosin active site. Basal concentrations of nucleotide polyphosphates are not altered when ATP utilization rates increase during contraction. At high contractile frequencies, decreases in CrP concentration occur, but this accounts for less than 4% of total high energy phosphoryls consumed. If metabolic intermediates are free in the aqueous cellular cytosol, each twitch contracture would result in a decrease in ATP concentration of no more than 2% and increases in ADP and AMP concentrations of less than 20 and 7%, respectively. Thus, changes in metabolite concentration must be highly localized or metabolic regulation can be accomplished by a nonallosteric mechanism.	UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL EYE INSTITUTE [R01EY004877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028818] Funding Source: NIH RePORTER; NEI NIH HHS [EY 04877] Funding Source: Medline; NIGMS NIH HHS [GM 28818] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BUSBY SJW, 1978, BIOCHEM J, V170, P103, DOI 10.1042/bj1700103; DAWIS SM, 1989, BIOPHYS J, V55, P79, DOI 10.1016/S0006-3495(89)82782-1; DEMPSEY ME, 1971, CONTRACTILE PROTEINS, P569; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; GADIAN DG, 1981, ANNU REV BIOCHEM, V50, P69, DOI 10.1146/annurev.bi.50.070181.000441; GEEVES MA, 1980, BIOCHEMISTRY-US, V19, P4748, DOI 10.1021/bi00562a005; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goldberg A L, 1975, Methods Enzymol, V39, P82; GOLDBERG ND, 1983, J BIOL CHEM, V258, P9213; HITZIG BM, 1987, FASEB J, V1, P22, DOI 10.1096/fasebj.1.1.3301494; LEMASTERS JJ, 1984, J BIOL CHEM, V259, P3123; Lindberg B., 1975, ADV CARBOHYD CHEM BI, V31, P185; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND J, 1987, J BIOL CHEM, V262, P8584; MATHEWS PM, 1982, BIOCHIM BIOPHYS ACTA, V720, P163; MEYER RA, 1979, AM J PHYSIOL, V237, pC111, DOI 10.1152/ajpcell.1979.237.3.C111; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; SAKS VA, 1978, CAN J PHYSIOL PHARM, V56, P691, DOI 10.1139/y78-113; SLEEP JA, 1980, J BIOL CHEM, V255, P4094; SLEEP JA, 1978, BIOCHEMISTRY-US, V17, P5417, DOI 10.1021/bi00618a015; SRIVASTAVA DK, 1986, SCIENCE, V234, P1081, DOI 10.1126/science.3775377; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; WALSETH TF, 1988, METHOD ENZYMOL, V159, P60; WALSETH TF, 1983, J BIOL CHEM, V258, P1544; WALSETH TF, 1981, J BIOL CHEM, V256, P2176; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300	29	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15110	15119						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869545				2022-12-25	WOS:A1991GB09700049
J	GAESTEL, M; SCHRODER, W; BENNDORF, R; LIPPMANN, C; BUCHNER, K; HUCHO, F; ERDMANN, VA; BIELKA, H				GAESTEL, M; SCHRODER, W; BENNDORF, R; LIPPMANN, C; BUCHNER, K; HUCHO, F; ERDMANN, VA; BIELKA, H			IDENTIFICATION OF THE PHOSPHORYLATION SITES OF THE MURINE SMALL HEAT-SHOCK PROTEIN HSP25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; EHRLICH ASCITES TUMOR; SUBSTRATE RECOGNITION REQUIREMENTS; MAMMALIAN STRESS PROTEINS; KINASE-C; 27 KDA; RAPID PHOSPHORYLATION; PHYSIOLOGICAL SITES; CELLS; SEQUENCE	Native phosphorylated mouse small heat shock protein hsp25 from Ehrlich ascites tumor cells was isolated and the in vivo phosphorylation sites of the protein were determined. Furthermore, native hsp25 was phosphorylated by the endogenous kinase(s) in a cell-free system as well as recombinant hsp25 was phosphorylated in vitro by protein kinase C and catalytic subunit of cAMP-dependent protein kinase. The two major phosphorylation sites of native and recombinant hsp25 were determined as Ser-15 and Ser-86. There are no differences in the hsp25 phosphorylation sites phosphorylated by the protein kinase C, the catalytic subunit of cAMP-dependent protein kinase and the unknown intracellular kinase(s). The serine residues identified exist in all known small mammalian stress proteins and are located in the conserved kinase recognition sequence Arg-X-X-Ser.	FREE UNIV BERLIN,INST BIOCHEM,W-1000 BERLIN 33,GERMANY	Free University of Berlin	GAESTEL, M (corresponding author), INST MOLEC BIOL,ZELLPHYSIOL ABT,O-1115 BERLIN,GERMANY.		Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652				APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENNDORF R, 1988, BIOCHEM INT, V17, P225; BENNDORF R, 1988, EXP CELL RES, V174, P130, DOI 10.1016/0014-4827(88)90148-6; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; DAILE P, 1975, NATURE, V257, P416, DOI 10.1038/257416a0; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; ERIKSON E, 1988, 2ND MESSENGERS PHOSP, V12, P135; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FUQUA SAW, 1989, CANCER RES, V49, P4126; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HEPBURN A, 1988, FEBS LETT, V227, P175, DOI 10.1016/0014-5793(88)80892-5; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HOUSE C, 1987, J BIOL CHEM, V262, P772; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE J, 1990, NUCLEIC ACIDS RES, V18, P1637, DOI 10.1093/nar/18.6.1637; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; OESTERREICH S, 1990, BIOMED BIOCHIM ACTA, V49, P219; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; SCHLESINGER MJ, 1989, STRESS INDUCED PROTE, P137; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; SEYMOUR L, 1990, BRIT J CANCER, V61, P886, DOI 10.1038/bjc.1990.198; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989	38	184	189	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14721	14724						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860870				2022-12-25	WOS:A1991FZ35100094
J	SCHRODER, I; GUNSALUS, RP; ACKRELL, BAC; COCHRAN, B; CECCHINI, G				SCHRODER, I; GUNSALUS, RP; ACKRELL, BAC; COCHRAN, B; CECCHINI, G			IDENTIFICATION OF ACTIVE-SITE RESIDUES OF ESCHERICHIA-COLI FUMARATE REDUCTASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE FRAMEWORK; COVALENTLY-BOUND FLAVIN; LIGAND-BINDING SITES; IRON-SULFUR CENTER; SUCCINATE-DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; ELECTRON-TRANSPORT; ARGININE RESIDUE; MEMBRANE; COMPLEX	Menaquinol-fumarate oxidoreductase of Escherichia coli is a four-subunit membrane-bound complex that catalyzes the final step in anaerobic respiration when fumarate is the terminal electron acceptor. The enzyme is structurally and catalytically similar to succinate dehydrogenase (succinate-ubiquinone oxidoreductase) from both procaryotes and eucaryotes. Both enzymes have been proposed to contain an essential cysteine residue at the active site based on studies with thiol-specific reagents. Chemical modification studies have also suggested roles for essential histidine and arginine residues in catalysis by succinate dehydrogenase. In the present study, a combination of site-directed mutagenesis and chemical modification techniques have been used to investigate the role(s) of the conserved histidine 232, cysteine 247, and arginine 248 residues of the flavoprotein subunit (FrdA) in active site function. A role for His-232 and Arg-248 of FrdA is shown by loss of both fumarate reductase and succino-oxidase activities following site-directed substitution of these particular amino acids. Evidence is also presented that suggests a second arginine residue may form part of the active site. Potential catalytic and substrate-binding roles for arginine are discussed. The effects of removing histidine-232 of FrdA are consistent with its proposed role as a general acid-base catalyst. The fact that succinate oxidation but not fumarate reduction was completely lost, however, might suggest that alternate proton donors substitute for His-232. The data confirm that cysteine 247 of FrdA is responsible for the N-ethylmaleimide sensitivity shown bv fumarate reductase but is not required for catalytic activity or the tight-binding of oxalacetate, as previously thought.	VET AFFAIRS MED CTR,DIV MOLEC BIOL 151-S,4150 CLEMENT ST,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NHLBI NIH HHS [HL-16251] Funding Source: Medline; NIAID NIH HHS [AI-21678] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021678] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; ACKRELL BAC, 1975, J BIOL CHEM, V250, P7114; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BLAUT M, 1989, J BIOL CHEM, V264, P13599; CAMMACK R, 1986, BIOCHIM BIOPHYS ACTA, V870, P545, DOI 10.1016/0167-4838(86)90264-5; CECCHINI G, 1986, P NATL ACAD SCI USA, V83, P8898, DOI 10.1073/pnas.83.23.8898; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P145, DOI 10.1016/0968-0004(89)90147-3; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P101, DOI 10.1016/0968-0004(89)90131-X; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; COLE ST, 1987, EUR J BIOCHEM, V167, P481, DOI 10.1111/j.1432-1033.1987.tb13362.x; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DERVARTANIAN D. V., 1965, BIOCHIM BIOPHYS ACTA, V105, P424; FERSHT AR, 1973, J MOL BIOL, V74, P137, DOI 10.1016/0022-2836(73)90103-4; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; HANNAHAN D, 1983, J MOL BIOL, V166, P557; HEDERSTEDT L, 1986, ARCH BIOCHEM BIOPHYS, V247, P346, DOI 10.1016/0003-9861(86)90593-X; HEDERSTEDT L, 1989, BIOCHEM J, V260, P491, DOI 10.1042/bj2600491; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JOHNSON MK, 1988, J BIOL CHEM, V263, P14732; JOHNSON MK, 1985, BIOCHEM BIOPH RES CO, V131, P653, DOI 10.1016/0006-291X(85)91287-2; JOHNSON MK, 1985, BIOCHEM BIOPH RES CO, V131, P756, DOI 10.1016/0006-291X(85)91303-8; JOHNSON MK, 1987, CYTOCHROME SYSTEMS M, P473; JURSA M, 1962, NATURE, V195, P110; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KENNEY WC, 1975, J BIOL CHEM, V250, P3089; KOTLYAR AB, 1984, BIOCHEM INT, V8, P545; KROGER A, 1978, BIOCHIM BIOPHYS ACTA, V505, P129, DOI 10.1016/0304-4173(78)90010-1; LAUTERBACH F, 1990, ARCH MICROBIOL, V154, P386, DOI 10.1007/BF00276536; LEMIRE BD, 1982, J BACTERIOL, V152, P1126; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORNINGSTAR JE, 1985, J BIOL CHEM, V260, P3631; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PADDOCK ML, 1989, P NATL ACAD SCI USA, V86, P6602, DOI 10.1073/pnas.86.17.6602; PHILLIPS MK, 1987, J BACTERIOL, V169, P864, DOI 10.1128/jb.169.2.864-873.1987; Riordan J.F., 1967, METHOD ENZYMOL, V11, P541; ROBINSON JJ, 1982, CAN J BIOCHEM CELL B, V60, P811, DOI 10.1139/o82-101; SALACH J, 1972, EUR J BIOCHEM, V26, P267, DOI 10.1111/j.1432-1033.1972.tb01765.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UNDEN G, 1980, FEBS LETT, V177, P323; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P6749, DOI 10.1073/pnas.78.11.6749; VINOGRAD.AD, 1972, BIOCHEM BIOPH RES CO, V49, P441, DOI 10.1016/0006-291X(72)90430-5; VINOGRADOV A D, 1986, Biokhimiya, V51, P1944; WEINER JH, 1986, P NATL ACAD SCI USA, V83, P2056, DOI 10.1073/pnas.83.7.2056; WEINER JH, 1979, J BIOL CHEM, V254, P8590; WERTH MT, 1990, P NATL ACAD SCI USA, V87, P8965, DOI 10.1073/pnas.87.22.8965; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519	49	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13572	13579						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856194				2022-12-25	WOS:A1991FY02700021
J	STORCH, J; LECHENE, C; KLEINFELD, AM				STORCH, J; LECHENE, C; KLEINFELD, AM			DIRECT DETERMINATION OF FREE FATTY-ACID TRANSPORT ACROSS THE ADIPOCYTE PLASMA-MEMBRANE USING QUANTITATIVE FLUORESCENCE MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING-PROTEIN; UNILAMELLAR VESICLES; CELLULAR UPTAKE; LONG; LIVER; PHOSPHATIDYLCHOLINE; PERMEATION; MECHANISM; LIPOSOMES; KINETICS	Movement of free fatty acids (FFA) across the plasma membrane has been directly measured for the first time, using fluorescent FFA analogs and quantitative fluorescence microscopy. The rate of short chain FFA (less-than-or-equal-to 12 carbons) transport from the extracellular medium into intracellular lipid droplets of 3T3F442A adipocytes was more than 40-fold faster than long chain FFA (16 and 18 carbons). The membrane-impermeable amino reagent 4,4'-diisothiocyanostilbene-2,2'-disulfonate, inhibited greater-than-or-equal-to 50% of the long chain FFA transport but had no effect on short chain FFA transport. Oleic acid (2-mu-M) inhibited 90% of the fluorescent oleate transport but had no effect on the 11-carbon analog. These results indicate that a large fraction of long chain FFA uptake is mediated by a plasma membrane protein (s).	HARVARD UNIV,SCH MED,DEPT MED,CELLULAR PHYSIOL LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; MED BIOL INST,DIV MEMBRANE BIOL,LA JOLLA,CA 92037	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	STORCH, J (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115, USA.			Storch, Judith/0000-0001-5482-1777	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, R01DK038389, R29DK038389] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02604] Funding Source: Medline; NIDDK NIH HHS [DK34854, DK38389, R01 DK038389] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRECHER P, 1984, J BIOL CHEM, V259, P3395; Cantor C.R., 1980, BIOPHYS CHEM; CHALPIN DB, 1983, BIOCHIM BIOPHYS ACTA, V731, P465, DOI 10.1016/0005-2736(83)90042-1; COOPER R, 1987, BIOCHEMISTRY-US, V26, P5890, DOI 10.1021/bi00392a047; DANIELS C, 1985, BIOCHEMISTRY-US, V24, P3286, DOI 10.1021/bi00334a032; DEGRELLA RF, 1980, J BIOL CHEM, V255, P9739; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; Kates M., 1986, TECHNIQUES LIPIDOLOG; Kleinfeld A. M., 1990, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V6, P361; MALOY SR, 1981, J BIOL CHEM, V256, P3735; MCCORMACK M, 1987, BIOCHEM J, V244, P717, DOI 10.1042/bj2440717; MORAND O, 1982, BIOCHIM BIOPHYS ACTA, V711, P539, DOI 10.1016/0005-2760(82)90070-4; MORAND O, 1985, BIOCHIM BIOPHYS ACTA, V835, P68, DOI 10.1016/0005-2760(85)90031-1; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; SCHWARTZ SE, 1980, BIOCHIM BIOPHYS ACTA, V600, P961, DOI 10.1016/0005-2736(80)90498-8; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SHOHET SB, 1968, J CLIN INVEST, V47, P1096, DOI 10.1172/JCI105799; Stein W., 2012, TRANSPORT DIFFUSION; STORCH J, 1985, BIOCHIM BIOPHYS ACTA, V812, P473, DOI 10.1016/0005-2736(85)90322-0; STORCH J, 1990, J BIOL CHEM, V265, P7827; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P10527; STORCH J, 1987, BIOCHEMISTRY-US, V26, P332; STREMMEL W, 1985, J CLIN INVEST, V75, P1068, DOI 10.1172/JCI111769; STREMMEL W, 1986, BIOCHIM BIOPHYS ACTA, V7877, P191	30	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13473	13476						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856185				2022-12-25	WOS:A1991FY02700002
J	TESHIMA, G; STULTS, JT; LING, V; CANOVADAVIS, E				TESHIMA, G; STULTS, JT; LING, V; CANOVADAVIS, E			ISOLATION AND CHARACTERIZATION OF A SUCCINIMIDE VARIANT OF METHIONYL HUMAN GROWTH-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; ELECTROSPRAY IONIZATION; SEQUENCE IONS; PEPTIDES; DEAMIDATION	Deamidation of asparagine and glutamine residues, isomerization of aspartic acid side chains, and racemization of the L- to the D-form of the amino acids are common spontaneous chemical reactions known to occur in proteins. Previous studies have implicated succinimides as intermediates in these reactions; however, the evidence has been indirect. Our results demonstrate, for the first time, the presence of a succinimide intermediate in an intact protein. The succinimide (cyclic imide) variant was isolated from thermally stressed recombinant methionyl human growth hormone (hGH) by high performance anion-exchange chromatography, further purified by reversed-phase high performance liquid chromatography, and analyzed by tryptic mapping. A later eluting tryptic peptide, compared with the native T12 peptide (residues 128-134, Leu-Glu-Asp-Gly-Ser-Pro-Arg), was analyzed by mass spectrometry (MS). This variant had a protonated molecular mass of 755.3 atomic mass units (u), as compared with 773.3 u for the native T12 peptide. A difference of 18 u, a loss of water, is consistent with the formation of a succinimide intermediate at Asp-130 of methionyl hGH. MS/MS analysis of the cyclic imide-containing peptide verified that the modification occurred at Asp-130. A difference of 18 u was also observed for the intact cyclic imide methionyl hGH variant (22,238 u), as measured by electrospray mass spectrometry, compared with native methionyl hGH (22,256 u).	GENENTECH INC,DEPT PROT CHEM,SAN FRANCISCO,CA 94080	Roche Holding; Genentech	TESHIMA, G (corresponding author), GENENTECH INC,DEPT MED & ANALYT CHEM,SAN FRANCISCO,CA 94080, USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; AHERN TJ, 1987, P NATL ACAD SCI USA, V84, P675, DOI 10.1073/pnas.84.3.675; AHERN TJ, 1985, SCIENCE, V228, P1280, DOI 10.1126/science.4001942; BECKER GW, 1988, BIOTECHNOL APPL BIOC, V10, P326; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BODANSZKY M, 1978, INT J PEPT PROT RES, V12, P69; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GEIGER T, 1987, J BIOL CHEM, V262, P785; HANCOCK WS, 1988, BANBURY REPORT, V29, P95; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; JOHNSON RS, 1988, INT J MASS SPECTROM, V86, P137, DOI 10.1016/0168-1176(88)80060-0; KOHR WJ, 1982, ANAL BIOCHEM, V122, P348, DOI 10.1016/0003-2697(82)90294-9; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SATO K, 1987, ANAL CHEM, V59, P1652, DOI 10.1021/ac00140a016; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; SMYTH DG, 1962, J BIOL CHEM, V237, P1845; TESHIMA G, 1991, IN PRESS BIOCHEMISTR; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	20	57	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13544	13547						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856190				2022-12-25	WOS:A1991FY02700016
J	JAHNER, D; HUNTER, T				JAHNER, D; HUNTER, T			THE STIMULATION OF QUIESCENT RAT FIBROBLASTS BY V-SRC AND V-FPS ONCOGENIC PROTEIN-TYROSINE KINASES LEADS TO THE INDUCTION OF A SUBSET OF IMMEDIATE EARLY GENES	ONCOGENE			English	Article								The stimulation of quiescent murine fibroblasts by growth factors and by phorbol esters results in a rapid and transient transcriptional activation of a large group of so-called immediate early genes. Several such genes were found to be induced in chicken embryo fibroblasts following activation of a temperature sensitive (ts) Rous sarcoma virus v-src mutant following temperature shift (Simmons et al., 1989). In contrast, the classical immediate early genes c-myc, c-fos and c-jun were essentially uninducible upon activation of a ts v-src mutant in rat-1 fibroblasts (Welham et al., 1990). We have cloned 9 cDNAs of genes that are rapidly and transiently inducible in rat fibroblasts by ts v-src mutants, and by a ts Fujinami sarcoma virus v-fps mutant. Six of these cDNAs are derived from the known immediate early genes NGFI-A, KC, c-fos, tissue factor, PC4 and ornithine decarboxylase; the other three cDNAs have not been described before. These 9 genes showed individual profiles of inducibility by fetal calf serum, epidermal growth factor (EGF) and by phorbol esters. Their response to the retroviral oncogenic protein-tyrosine kinases correlated best with the one to EGF, suggesting a common pathway of signal transduction. c-fos did not respond strongly to this pathway but was well induced by fetal calf serum. NGFI-A, however, was induced to a similar extent by all activators tested. Furthermore, we demonstrated that the induction of several of these genes by the retroviral oncogenic protein-tyrosine kinases is rapid, direct and occurs at the transcriptional level.	SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA	Salk Institute	HUNTER, T (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.				NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14195, CA-39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; Bogenberger J, 1988, Oncogene Res, V3, P301; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHEN YC, 1977, CELL, V11, P513, DOI 10.1016/0092-8674(77)90069-1; CHIARUGI V, 1987, ONCOGENE, V2, P37; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; DURKIN JP, 1984, J CELL PHYSIOL, V120, P135, DOI 10.1002/jcp.1041200205; DURKIN JP, 1991, IN PRESS CELL SIGNAL; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GILMAN MZ, 1988, COLD SPRING HARB SYM, V53, P761, DOI 10.1101/SQB.1988.053.01.086; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; JAHNER D, 1991, IN PRESS MOL CELL BI; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINS TJ, 1989, J CELL BIOL, V108, P683, DOI 10.1083/jcb.108.2.683; MARTINSGREEN M, 1990, J CELL BIOL, V110, P581, DOI 10.1083/jcb.110.3.581; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; ROLLINS BJ, 1987, SCIENCE, V238, P1269, DOI 10.1126/science.3685976; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STOECKLE M Y, 1990, New Biologist, V2, P313; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; VARNUM BC, 1989, ONCOGENE, V4, P1263; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WEINMASTER GA, 1988, J VIROL, V62, P3849, DOI 10.1128/JVI.62.10.3849-3854.1988; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1	85	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1259	1268						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861868				2022-12-25	WOS:A1991GV26000023
J	BRENOWITZ, S; KWACK, S; GOODMAN, MF; ODONNELL, M; ECHOLS, H				BRENOWITZ, S; KWACK, S; GOODMAN, MF; ODONNELL, M; ECHOLS, H			SPECIFICITY AND ENZYMATIC MECHANISM OF THE EDITING EXONUCLEASE OF ESCHERICHIA-COLI DNA POLYMERASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS MUTATION; EPSILON-SUBUNIT; MISMATCH REPAIR; REPLICATION; HOLOENZYME; FIDELITY; IDENTIFICATION; GENE; PURIFICATION; FRAGMENT	Exonucleolytic editing is a major contributor to the fidelity of DNA replication by the multisubunit DNA polymerase (pol) III holoenzyme. To investigate the source of editing specificity, we have studied the isolated exonuclease subunit, epsilon, and the pol III core subassembly, which carries the epsilon, theta, and alpha (polymerase) subunits. Using oligonucleotides with specific terminal mismatches, we have found that both epsilon and pol III core preferentially excise a mispaired 3' terminus and therefore have intrinsic editing specificity. For both epsilon and pol III core, exonuclease activity is much more effective with single-strand DNA; with a double-strand DNA, the exonuclease is strongly temperature-dependent. We conclude that the epsilon-subunit of pol III holoenzyme is itself a specific editing exonuclease and that the source of specificity is the greater melting capacity of a mispaired 3' terminus.	UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089; CORNELL UNIV,MED CTR,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021	University of Southern California; Cornell University	BRENOWITZ, S (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NCI NIH HHS [CA 41655] Funding Source: Medline; NIGMS NIH HHS [GM 21422, GM 38831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; COX EC, 1982, GENETICS, V100, P7; DEGNEN GE, 1974, J BACTERIOL, V117, P477, DOI 10.1128/JB.117.2.477-487.1974; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; ECHOLS H, 1982, BIOCHIMIE, V64, P571, DOI 10.1016/S0300-9084(82)80089-8; ECHOLS H, 1991, IN PRESS ANN REV BIO; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; JOYCE CM, 1988, DNA REPLICATION MUTA, P220; KORNBERG A, 1988, J BIOL CHEM, V263, P1; Kornberg A., 1980, DNA REPLICATION; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1985, J BIOL CHEM, V260, P2987; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MESSING J, 1983, METHOD ENZYMOL, V101, P20; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STEITZ TA, 1987, COLD SPRING HARB SYM, V52, P465, DOI 10.1101/SQB.1987.052.01.053; WELCH MM, 1982, J BACTERIOL, V152, P351	29	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7888	7892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850425				2022-12-25	WOS:A1991FJ34200089
J	VIGNE, P; LADOUX, A; FRELIN, C				VIGNE, P; LADOUX, A; FRELIN, C			ENDOTHELINS ACTIVATE NA+/H+ EXCHANGE IN BRAIN CAPILLARY ENDOTHELIAL-CELLS VIA A HIGH-AFFINITY ENDOTHELIN-3 RECEPTOR THAT IS NOT COUPLED TO PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; INDEPENDENT PATHWAYS; POTENT; RAT; INHIBITION; AMILORIDE; FAMILY	Endothelial cells from brain microvessels (BCEC) express high affinity receptor sites for endothelin-1 that recognize endothelin-3 with a low affinity (Vigne, P., Marsault, R., Breittmayer, J. P. & Frelin, C. (1990) Biochem. J. 266, 415-420). Binding experiments using I-125-endothelin-3 showed the presence in BCEC of a new class of receptor sites that had a high affinity for endothelin-3 (K(d) = 0.8 nM), endothelin-1 (K(d) = 0.8 nM), and sarafotoxin S6b (K(d) = 0.3 nM). Endothelins activated phospholipase C in BCEC and produced transient increases in intracellular Ca2+ with properties of a low affinity endothelin-3 receptor. Endothelins also increased Na-22+ uptake via the Na+/H+ antiporter in BCEC. Concentrations for half-maximum activation (endothelin-1, 0.5 nM; sarafotoxin S6b, 1 nM; endothelin-3, 2 nM) were close to the K(d) values determined in I-125-endothelin-3-binding experiments. The action of endothelins on Na+/H+ exchange was not mimicked by phorbol myristate acetate, it was not reversed by staurosporine, and it did not correlate with the phosphorylation of the 80-kDa protein. These results indicated that the action of endothelins on Na+/H+ exchange did not involve protein kinase C. It is concluded that BCEC coexpress two types of functional receptor sites for endothelins: (i) a high affinity endothelin-1, low affinity endothelin-3 receptor that is coupled to phospholipase C and to intracellular Ca2+ mobilization, and (ii) a high affinity endothelin-1, high affinity endothelin-3 receptor that controls Na+/H+ exchange activity via a protein kinase C-independent mechanism.			VIGNE, P (corresponding author), CNRS,INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE.		LADOUX, ANNIE/O-4267-2016; LADOUX, ANNIE/S-2077-2019	LADOUX, ANNIE/0000-0003-3857-2621; LADOUX, ANNIE/0000-0003-3857-2621				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BERK BC, 1987, J BIOL CHEM, V262, P5057; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KLOOG Y, 1989, FEBS LETT, V253, P199, DOI 10.1016/0014-5793(89)80958-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; MARSAULT R, 1990, J NEUROCHEM, V54, P2142, DOI 10.1111/j.1471-4159.1990.tb04921.x; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; MITSUHASHI T, 1988, J BIOL CHEM, V263, P8790; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REDONDO JM, 1988, J BIOL CHEM, V263, P17467; RESINK TJ, 1988, BIOCHEM BIOPH RES CO, V157, P1360, DOI 10.1016/S0006-291X(88)81025-8; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; STANTON TH, 1988, J BIOL CHEM, V263, P13786; SUPATTAPONE S, 1989, BIOCHEM BIOPH RES CO, V165, P1115, DOI 10.1016/0006-291X(89)92718-6; VANRENTERGHEM C, 1988, BIOCHEM BIOPH RES CO, V157, P977, DOI 10.1016/S0006-291X(88)80970-7; VARA F, 1985, BIOCHEM BIOPH RES CO, V145, P111; VIGNE P, 1985, J BIOL CHEM, V260, P8008; VIGNE P, 1990, J BIOL CHEM, V265, P6782; VIGNE P, 1983, BIOCHEM BIOPH RES CO, V116, P86, DOI 10.1016/0006-291X(83)90384-4; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; WARNER TD, 1989, EUR J PHARMACOL, V159, P325, DOI 10.1016/0014-2999(89)90167-2; WOLLBERG Z, 1988, TOXICON, V26, P525, DOI 10.1016/0041-0101(88)90232-2; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211	32	96	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5925	5928						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848560				2022-12-25	WOS:A1991FD37000088
J	FINK, JS; VERHAVE, M; WALTON, K; MANDEL, G; GOODMAN, RH				FINK, JS; VERHAVE, M; WALTON, K; MANDEL, G; GOODMAN, RH			CYCLIC AMP-INDUCED AND PHORBOL ESTER-INDUCED TRANSCRIPTIONAL ACTIVATION ARE MEDIATED BY THE SAME ENHANCER ELEMENT IN THE HUMAN VASOACTIVE-INTESTINAL-PEPTIDE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAYS; DNA-BINDING PROTEIN; TRANS-ACTING FACTOR; NUCLEAR FACTOR CREB; FACTOR AP-1; METALLOTHIONEIN GENE; SOMATOSTATIN GENE; ADENYLATE-CYCLASE; CATALYTIC SUBUNIT	Transcription of the human vasoactive intestinal peptide (VIP) gene is regulated by both cyclic AMP and phorbol esters. A 17-nucleotide enhancer element within the human VIP gene mediates transcriptional activation by both phorbol esters and forskolin. Mutations of this element decrease responses to both agents, suggesting that the trans-acting proteins that mediate both modes of transcriptional regulation have similar DNA-binding characteristics. The response of the VIP enhancer element to forskolin, but not to 12-O-tetradecanoylphorbol-13-acetate, was attenuated by treatment with a recombinant inhibitor of the cAMP-dependent protein kinase, suggesting that the cAMP-dependent protein kinase and protein kinase C second messenger pathways that converge on this single enhancer element are distinct. The transcriptional activator cAMP-responsive element-binding (CREB) proteins and the c-fos.c-Jun complex interact with the VIP enhancer. The dual second messenger responses of the VIP gene may result from the interaction of this second messenger enhancer with different transcriptional activator proteins.	MASSACHUSETTS GEN HOSP, MOLEC NEUROBIOL LAB, BOSTON, MA 02114 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; NEW ENGLAND MED CTR HOSP, DIV PEDIAT GASTROENTEROL & NUTR, BOSTON, MA 02111 USA; SUNY STONY BROOK, DEPT NEUROBIOL & BEHAV, STONY BROOK, NY 11794 USA	Harvard University; Massachusetts General Hospital; Oregon Health & Science University; Tufts Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	FINK, JS (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA037370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027514, K07NS000885] Funding Source: NIH RePORTER; NCI NIH HHS [CA37370] Funding Source: Medline; NINDS NIH HHS [R01 NS27514, KO7 NS00885] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BELL JD, 1985, J BIOL CHEM, V260, P2625; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COMB M, 1987, TRENDS NEUROSCI, V10, P473, DOI 10.1016/0166-2236(87)90103-2; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROVE JR, 1987, SCIENCE, V238, P530; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; NAGHSHINEH S, 1986, J BIOL CHEM, V261, P4534; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OHSAWA K, 1985, BIOCHEM BIOPH RES CO, V132, P885, DOI 10.1016/0006-291X(85)91890-X; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SUGDEN D, 1985, NATURE, V314, P359, DOI 10.1038/314359a0; TSUKADA T, 1985, DNA-J MOLEC CELL BIO, V4, P293, DOI 10.1089/dna.1985.4.293; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	49	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3882	3887						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847391				2022-12-25	WOS:A1991EY68200080
J	KLEYMAN, TR; KRAEHENBUHL, JP; ERNST, SA				KLEYMAN, TR; KRAEHENBUHL, JP; ERNST, SA			CHARACTERIZATION AND CELLULAR-LOCALIZATION OF THE EPITHELIAL NA+ CHANNEL - STUDIES USING AN ANTI-NA+ CHANNEL ANTIBODY RAISED BY AN ANTIIDIOTYPIC ROUTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY COLLECTING DUCT; TOAD URINARY-BLADDER; SODIUM-CHANNEL; MONOCLONAL-ANTIBODIES; BASOLATERAL MEMBRANE; AMILORIDE ANTIBODIES; APICAL MEMBRANE; KIDNEY-CELLS; RECEPTOR; TRANSPORT	Amiloride-sensitive Na+ channels are expressed at the apical membrane of high resistance, Na+-transporting epithelial. The specific interaction of amiloride with this transport protein suggested the feasibility of raising anti-Na+ channel antibodies by an antiidiotypic approach designed to generate antibodies directed against the amiloride-binding domain on the channel. Antiidiotypic monoclonal antibody RA6.3 mimicked the effect of amiloride by inhibiting Na+ transport across A6 cell monolayers when applied to the apical cell surface. Inhibition of transport required pretreatment of the apical cell surface with trypsin in the presence of amiloride in order to enhance accessibility of the antibody to the amiloride-binding site. This antibody specifically immunoprecipitated a large 750,000-700,000 Da protein from [S-35]methionine-labeled A6 cell cultures, which was resolved further under reducing conditions as a set of polypeptides with apparent molecular masses of 260,000-230,000, 180,000, 140,000-110,000, and 70,000 Da. The antibody recognized the 140,000-Da subunit, known to contain the amiloride-binding domain, on immunoblots of purified A6 cell Na+ channel. Immunoprecipitation of apical or basolateral plasma membrane proteins selectively labeled with I-125 demonstrated that expression of the oligomeric Na+ channel was restricted to the apical plasma membrane. Immunocytochemical localization in A6 cultures revealed apical membrane as well as cytosolic immunoreactive sites. Immunostaining was also observed at or near the basolateral plasma membrane.	VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA; SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; UNIV MICHIGAN, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; UNIV LAUSANNE, DEPT BIOCHEM, CH-1000 LAUSANNE 17, SWITZERLAND	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Swiss Institute Experimental Cancer Research; University of Michigan System; University of Michigan; University of Pennsylvania; University of Lausanne	KLEYMAN, TR (corresponding author), UNIV PENN, DEPT MED, RENAL SECT, 700 CLIN RES BLDG, PHILADELPHIA, PA 19104 USA.				NCRR NIH HHS [RR05385] Funding Source: Medline; NIDDK NIH HHS [DK27559] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027559] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHER C, 1988, P NATL ACAD SCI USA, V85, P7413, DOI 10.1073/pnas.85.19.7413; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BARBRY P, 1990, BIOCHEMISTRY-US, V29, P1039, DOI 10.1021/bi00456a028; BARBRY P, 1987, P NATL ACAD SCI USA, V84, P4836, DOI 10.1073/pnas.84.14.4836; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BROWN D, 1989, AM J PHYSIOL, V256, pF366, DOI 10.1152/ajprenal.1989.256.2.F366; CAYANIS E, 1986, J BIOL CHEM, V261, P5094; CHASE HS, 1981, J GEN PHYSIOL, V77, P693, DOI 10.1085/jgp.77.6.693; CLEVELAND WL, 1983, NATURE, V305, P56, DOI 10.1038/305056a0; CUTHBERT AW, 1978, BRIT J PHARMACOL, V63, P139, DOI 10.1111/j.1476-5381.1978.tb07783.x; ERLANGER BF, 1986, IMMUNOL REV, V94, P23, DOI 10.1111/j.1600-065X.1986.tb01162.x; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; GARTY H, 1987, J MEMBRANE BIOL, V95, P91, DOI 10.1007/BF01869154; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; HAMILTON KL, 1986, FASEB J, V45, P2713; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; HILL BL, 1988, ENDOCRINOLOGY, V122, P2840, DOI 10.1210/endo-122-6-2840; HOMCY CJ, 1982, J CLIN INVEST, V69, P1147, DOI 10.1172/JCI110550; KLEYMAN TR, 1986, AM J PHYSIOL, V250, pC165, DOI 10.1152/ajpcell.1986.250.1.C165; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KLEYMAN TR, 1986, KIDNEY INT, V29, P400; KOEPPEN BM, 1986, AM J PHYSIOL, V250, pF70, DOI 10.1152/ajprenal.1986.250.1.F70; KU HH, 1987, J IMMUNOL, V139, P2376; LEWIS SA, 1982, NATURE, V297, P685, DOI 10.1038/297685a0; LIGHT DB, 1988, AM J PHYSIOL, V255, pF278, DOI 10.1152/ajprenal.1988.255.2.F278; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; Maizel JV, 1971, METHOD VIROL, V5, P179; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PERKINS FM, 1981, AM J PHYSIOL, V241, pC154, DOI 10.1152/ajpcell.1981.241.3.C154; SARIBANSOHRABY S, 1986, AM J PHYSIOL, V250, pC175, DOI 10.1152/ajpcell.1986.250.2.C175; SARIBANSOHRABY S, 1983, AM J PHYSIOL, V245, pC167, DOI 10.1152/ajpcell.1983.245.3.C167; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; SEIFTER JL, 1986, J CLIN INVEST, V78, P859, DOI 10.1172/JCI112671; SORSCHER EJ, 1988, AM J PHYSIOL, V255, pC835, DOI 10.1152/ajpcell.1988.255.6.C835; TOKUYASU KT, 1976, J CELL BIOL, V71, P894, DOI 10.1083/jcb.71.3.894; TOUSSON A, 1989, J CELL SCI, V93, P349; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; WASSERMANN NH, 1982, P NATL ACAD SCI-BIOL, V79, P4810, DOI 10.1073/pnas.79.15.4810; ZHUANG YX, 1984, BIOCHEMISTRY-US, V23, P4481, DOI 10.1021/bi00314a038	43	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3907	3915						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847393				2022-12-25	WOS:A1991EY68200084
J	LIM, SK; GARDELLA, T; THOMPSON, A; ROSENBERG, J; KEUTMANN, H; POTTS, J; KRONENBERG, H; NUSSBAUM, S				LIM, SK; GARDELLA, T; THOMPSON, A; ROSENBERG, J; KEUTMANN, H; POTTS, J; KRONENBERG, H; NUSSBAUM, S			FULL-LENGTH CHICKEN PARATHYROID-HORMONE - BIOSYNTHESIS IN ESCHERICHIA-COLI AND ANALYSIS OF BIOLOGIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL 1-34 FRAGMENT; ADRENOCORTICAL-CELLS; STIMULATION; PEPTIDE	Chicken parathyroid hormone (cPTH) has been reported to stimulate adrenal steroidogenesis and to have unusual potency on traditional PTH target tissues. To evaluate these properties, chicken PTH-(1-88) has been expressed in Escherichia coli using a plasmid encoding a fusion protein which links together growth hormone, a factor Xa recognition site, and chicken PTH-(1-88). The growth hormone-cPTH fusion protein required the presence of 0.02% sodium dodecyl sulfate to remain in solution and be cleaved by factor Xa. The high performance liquid chromatography-purified recombinant cPTH-(1-88) and chemically synthesized cPTH-(1-34) had similar potency in rat osteosarcoma (ROS 17/2.8) cells, opossum kidney (OK) cells, and dispersed primary chicken kidney cells. The biologic potencies of cPTH-(1-34) and cPTH-(1-88) in radioreceptor binding and cAMP generation in both bone- and kidney-derived cell lines were less than those of human (h)PTH-(1-34). In dispersed chicken kidney cells, cAMP production by cPTH-(1-34) and cPTH-(1-88) was similar to that stimulated by human PTH-(1-34). No stimulation of steroidogenesis could be detected when recombinant chicken PTH-(1-88) was added to dispersed chicken adrenal cells. The biologic activity of recombinant chicken PTH-(1-88) purified from E. coli was comparable with that of chicken PTH-(1-88) expressed by mammalian COS cells. Thus, the full-length chicken PTH did not exhibit enhanced potency, when compared with human PTH in ROS 17/2.8, OK cell lines, and dispersed chicken kidney cells and did not demonstrate the novel steroidogenic action previously reported in adrenal cells. The successful production of chicken PTH-(1-88) will enhance our understanding of the structure-activity relationships for PTH, particularly the sequence-dependent metabolism of the hormone.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	LIM, SK (corresponding author), MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA.							ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; BRINGHURST FR, 1988, AM J PHYSIOL, V255, pE886, DOI 10.1152/ajpendo.1988.255.6.E886; CAULFIELD MP, 1988, ENDOCRINOLOGY, V123, P2949, DOI 10.1210/endo-123-6-2949; GARDELLA TJ, 1990, J BIOL CHEM, V265, P15854; HINSON J, 1987, J ENDOCRINOL, V115, P61, DOI 10.1677/joe.0.1150061; IKEHARA M, 1984, P NATL ACAD SCI-BIOL, V81, P5956, DOI 10.1073/pnas.81.19.5956; KHOSLA S, 1988, J BONE MINER RES, V3, P689; MARTIN TJ, 1987, HORM RES, V32, P84; MERRIFIELD RB, 1969, ADV ENZYMOL RAMB, V32, P221; MORELLE G, 1988, BIOCHIM BIOPHYS ACTA, V950, P459, DOI 10.1016/0167-4781(88)90146-7; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; RAFFERTY B, 1983, ENDOCRINOLOGY, V113, P1036, DOI 10.1210/endo-113-3-1036; ROSENBERG J, 1988, J ENDOCRINOL, V116, P91, DOI 10.1677/joe.0.1160091; ROSENBERG J, 1987, J ENDOCRINOL, V112, P431, DOI 10.1677/joe.0.1120431; RUSSELL J, 1989, MOL ENDOCRINOL, V3, P325, DOI 10.1210/mend-3-2-325; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TREGEAR GW, 1977, BIOCHEMISTRY-US, V16, P2817, DOI 10.1021/bi00632a002; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo-122-4-1208	19	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3709	3714						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847386				2022-12-25	WOS:A1991EY68200056
J	PARKER, EM; KAMEYAMA, K; HIGASHIJIMA, T; ROSS, EM				PARKER, EM; KAMEYAMA, K; HIGASHIJIMA, T; ROSS, EM			RECONSTITUTIVELY ACTIVE G-PROTEIN-COUPLED RECEPTORS PURIFIED FROM BACULOVIRUS-INFECTED INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; NUCLEOTIDE REGULATORY PROTEINS; TURKEY ERYTHROCYTE-MEMBRANES; GTP-BINDING PROTEINS; PERTUSSIS TOXIN; PHOSPHOLIPID-VESICLES; EXPRESSION VECTORS; ADENYLATE-CYCLASE; LIGAND-BINDING	The turkey beta-adrenergic receptor (beta-AR), the m1 and m2 forms of the human muscarinic cholinergic receptor (MAChR) and several other mutant and wild-type G protein-coupled receptors were produced in insect Sf9 cells by infection with recombinant baculoviruses. Maximal expression for most receptors was 5-30 pmol receptor/mg protein (2-15 nmol/liter culture). The receptors displayed typical ligand binding characteristics. The beta-AR was glycosylated; electrophoretic behavior of the two MAChRs also suggested glycosylation. The beta-AR stimulated endogenous adenylyl cyclase in response to beta-adrenergic agonists. The beta-AR and both MAChRs were purified and coreconstituted with various purified G proteins in phospholipid vesicles. The recombinant beta-AR catalyzed the agonist-dependent activation of G(s) by guanosine5'-O-(thiotriphosphate) (GTP-gamma-S) with the same efficiency as did the natural beta-AR. The m2 MAChR efficiently catalyzed GTP-gamma-S binding to G(o) and to the recently identified G protein G(z) (G(x)). The m2 MAChR also catalyzed the activation of G(i),1 and G(i),3 weakly. Activation of these same G proteins by the ml MAChR was much less efficient, consistent with its known selectivity for pertussis toxin-insensitive G proteins ("G(p)") that have not yet been isolated. The beta-AR and m2 MAChR were characteristically stimulated by reduction of disulfides. These results demonstrate the general utility of the baculovirus system for production of large quantities of native G protein-coupled receptors.	UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	PARKER, EM (corresponding author), UNIV TEXAS,SW MED CTR,SW GRAD SCH BIOMED SCI,DEPT PHARMACOL,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM 11943, GM 30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355, F32GM011943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1987, J RECEPTOR RES, V7, P257, DOI 10.3109/10799898709054989; BOEGE F, 1988, J BIOL CHEM, V263, P9040; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; BURGERMEISTER W, 1983, BIOCHIM BIOPHYS ACTA, V729, P219, DOI 10.1016/0005-2736(83)90488-1; CARON MG, 1979, J BIOL CHEM, V254, P2923; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHAPOT MP, 1990, EUR J BIOCHEM, V187, P137, DOI 10.1111/j.1432-1033.1990.tb15287.x; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FLEMING JW, 1980, J CYCLIC NUCL PROT, V6, P407; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GEORGE ST, 1986, J BIOL CHEM, V261, P6559; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAGA K, 1983, J BIOL CHEM, V258, P3575; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HUFF RM, 1985, J BIOL CHEM, V260, P864; KATADA T, 1986, J BIOL CHEM, V261, P8182; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAD PM, 1980, J BIOL CHEM, V255, P988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MAGUIRE ME, 1976, J BIOL CHEM, V251, P1221; MAIORELLA B, 1988, BIO-TECHNOL, V6, P1406, DOI 10.1038/nbt1288-1406; MASTERS SB, 1985, BIOCHEM J, V227, P933, DOI 10.1042/bj2270933; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOXHAM CP, 1988, MOL PHARMACOL, V33, P486; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARKER EM, 1990, CURR TOP MEMBR TRANS, V36, P131; PATERSON GL, 1984, P NATL ACAD SCI USA, V81, P4993; PEDERSEN SE, 1985, J BIOL CHEM, V260, P4150; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1977, J BIOL CHEM, V252, P5761; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SHORR RGL, 1982, J BIOL CHEM, V257, P2341; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRADER CD, 1908, J CELL BIOL, V107, P64; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; UCHIYAMA H, 1990, J NEUROCHEM, V54, P1870, DOI 10.1111/j.1471-4159.1990.tb04885.x; WEILAND GA, 1979, NATURE, V281, P114, DOI 10.1038/281114a0; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6795, DOI 10.1073/pnas.83.18.6795; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; 1990, TRENDS PHARM SCI; MCCUTCHEONS DETERGEN	71	309	318	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					519	527						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845979				2022-12-25	WOS:A1991EQ33900077
J	BRICKNER, HE; ZHU, XX; ATWEH, GF				BRICKNER, HE; ZHU, XX; ATWEH, GF			A NOVEL REGULATORY ELEMENT OF THE HUMAN ALPHA-GLOBIN GENE RESPONSIBLE FOR ITS CONSTITUTIVE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-HYPERSENSITIVE SITES; BETA-GLOBIN; GAMMA-GLOBIN; TRANSGENIC MICE; DNA-SEQUENCES; ERYTHROLEUKEMIA-CELLS; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; FINE-STRUCTURE; TRANSCRIPTION	The alpha-globin gene is expressed at a constitutively high level upon gene transfer into both erythroid and nonerythroid cells. The beta-globin gene, on the other hand, is dependent on the presence of a linked viral enhancer for its efficient expression upon transfer into heterologous cells. In this report, we describe a novel regulatory element within the structural alpha-globin gene which can activate its own promoter to result in a high level of expression in both erythroid and non-erythroid cells. This regulatory element does not appear to have the properties of a classical enhancer. While this element exerts a positive effect on its own promoter, we have demonstrated in a previous study that the same element exerts a negative effect on heterologous genes such as the beta- and gamma-globin genes. In this study, we localize this element to a 259-nucleotide fragment immediately downstream from the translation initiation codon which is partially overlapped by a DNase I hypersensitive domain only in erythroid cells. We propose that this element may activate the alpha-globin gene promoter in all cell types in vivo as it does in vitro. The specificity of erythroid expression of the alpha-globin gene in vivo is probably determined by a ''permissive'' chromatin configuration in erythroid cells and a ''nonpermissive'' configuration in non-erythroid cells.	VET ADM MED CTR,800 POLY PL,BROOKLYN,NY 11209; SUNY HLTH SCI CTR,DEPT MED,BROOKLYN,NY 11209	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center				Zhu, Charles/0000-0003-2922-0042	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL016008, R01HL042919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16008, HL-42919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGNOU NP, 1986, EMBO J, V5, P121, DOI 10.1002/j.1460-2075.1986.tb04185.x; ANTONIOU M, 1988, EMBO J, V7, P377, DOI 10.1002/j.1460-2075.1988.tb02824.x; ATWEH GF, 1985, NUCLEIC ACIDS RES, V13, P777, DOI 10.1093/nar/13.3.777; ATWEH GF, 1988, MOL CELL BIOL, V8, P5047, DOI 10.1128/MCB.8.11.5047; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BEHRINGER RR, 1987, P NATL ACAD SCI USA, V84, P7056, DOI 10.1073/pnas.84.20.7056; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; CHUNG SY, 1983, P NATL ACAD SCI-BIOL, V80, P2427, DOI 10.1073/pnas.80.9.2427; CREMISI C, 1981, NUCLEIC ACIDS RES, V9, P5949, DOI 10.1093/nar/9.22.5949; DERSE D, 1986, SCIENCE, V231, P1437, DOI 10.1126/science.3006241; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; Favaloro J, 1980, Methods Enzymol, V65, P718; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD GC, 1982, NATURE, V295, P120, DOI 10.1038/295120a0; HATTON CSR, 1990, BLOOD, V76, P221; HERBOMEL P, 1981, CELL, V25, P651, DOI 10.1016/0092-8674(81)90172-0; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HUMPHRIES RK, 1982, CELL, V30, P173; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; TRUDEL M, 1987, MOL CELL BIOL, V7, P4024, DOI 10.1128/MCB.7.11.4024; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; ULRICH MJ, 1990, BLOOD, V75, P990; WHITELAW E, 1989, MOL CELL BIOL, V9, P241, DOI 10.1128/MCB.9.1.241; WU R, 1971, J MOL BIOL, V57, P491, DOI 10.1016/0022-2836(71)90105-7; YAGI M, 1986, MOL CELL BIOL, V6, P1108, DOI 10.1128/MCB.6.4.1108; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; ZHU XX, 1989, J BIOL CHEM, V264, P14556	43	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15363	15368						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869558				2022-12-25	WOS:A1991GB09700080
J	HURWITZ, R; HOLCOMBE, V				HURWITZ, R; HOLCOMBE, V			AFFINITY PURIFICATION OF THE PHOTORECEPTOR CGMP-GATED CATION CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLIC-GMP; ROD PHOTORECEPTORS; PHOSPHODIESTERASE; MECHANISM; CONDUCTANCE; PROTEINS; BINDING	The cGMP-gated cation channel is a member of a new family of channel proteins that appear to be directly regulated by cyclic nucleotides. A protein with a subunit molecular mass of 78 kDa that exhibits cGMP-gated calcium flux when reconstituted into phospholipid-containing vesicles has been purified using 8-bromo-cGMP-agarose affinity chromatography. This channel activity is sensitive to the inhibitor l-cis-diltiazem. Treatment of the reconstituted channel with trypsin abolishes the l-cis-diltiazem sensitivity. Apparent endogenous proteolysis can also result in smaller molecular weight polypeptides that exhibit cGMP-gated channel activity but are insensitive to l-cis-diltiazem. These results show that the channel can bind cGMP and that it contains a l-cis-diltiazem inhibitory domain that is distinct from the cGMP-binding domain.			HURWITZ, R (corresponding author), BAYLOR UNIV,DEPT PEDIAT & CELL BIOL,HOUSTON,TX 77030, USA.				NEI NIH HHS [EY06656] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COOK NJ, 1989, J BIOL CHEM, V264, P6996; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIXSON CS, 1981, J BIOL CHEM, V256, P1122; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KOCH KW, 1985, J BIOL CHEM, V260, P6788; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STERN JH, 1986, P NATL ACAD SCI USA, V83, P1163, DOI 10.1073/pnas.83.4.1163; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	18	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					7975	7977						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850731				2022-12-25	WOS:A1991FK44100004
J	KROLL, DJ; ROWE, TC				KROLL, DJ; ROWE, TC			PHOSPHORYLATION OF DNA TOPOISOMERASE-II IN A HUMAN TUMOR-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; LEUKEMIA-CELLS; PHORBOL ESTER; PROTEINS; FORMS; DIFFERENTIATION; CHROMOSOMES; COMPLEX; MITOSIS; INVIVO	The phosphorylation of the nuclear enzyme DNA topoisomerase II was characterized from HeLa human cervical carcinoma cells labeled with P-32(i). Analysis of topoisomerase II immunoprecipitates from P-32-labeled HeLa cells indicated that phosphorylation of the enzyme occurred at serine residues. Incorporation of P-32 into topoisomerase II was not due to other types of phosphomodifications such as poly(ADP-ribosylation) or covalent interactions of the enzyme with nucleic acids. The stability of topoisomerase II protein and topoisomerase II phosphorylation was also investigated in HeLa cells. Topoisomerase II protein was relatively stable, having a half-life of approximately 27 h. Phosphorylation of HeLa topoisomerase II was also remarkably stable with a T1/2 of 17 h.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,COLL MED,DEPT PHARMACOL & THERAPEUT,BOX J-267,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038859] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38859] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; BERG P, 1956, J BIOL CHEM, V222, P1015; BROUGHAM MJ, 1986, BIOCHEMISTRY-US, V25, P7362, DOI 10.1021/bi00371a018; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CONSTANTINOU A, 1989, CANCER RES, V49, P1110; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; DESIDERIO SV, 1981, J MOL BIOL, V145, P319, DOI 10.1016/0022-2836(81)90208-4; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HSIANG YH, 1988, CANCER RES, V48, P3230; Hsieh T, 1990, CURR OPIN CELL BIOL, V2, P461, DOI 10.1016/0955-0674(90)90128-2; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; ILSHIDA T, 1965, J MOL BIOL, V11, P341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; OHTA T, 1990, P NATL ACAD SCI USA, V87, P5307, DOI 10.1073/pnas.87.14.5307; PIGIET V, 1978, J BIOL CHEM, V253, P1910; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; ROWE TC, 1986, CANCER RES, V46, P2021; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	36	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7957	7961						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850428				2022-12-25	WOS:A1991FJ34200098
J	FRANCO, PJ; BROOKER, RJ				FRANCO, PJ; BROOKER, RJ			EVIDENCE THAT THE ASPARAGINE-322 MUTANT OF THE LACTOSE PERMEASE TRANSPORTS PROTONS AND LACTOSE WITH A NORMAL STOICHIOMETRY AND ACCUMULATES LACTOSE AGAINST A CONCENTRATION GRADIENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LAC PERMEASE; CARRIER PROTEIN; ENHANCED RECOGNITION; CHLORELLA-VULGARIS; HISTIDINE-RESIDUES; ACTIVE-TRANSPORT; PLASMA-MEMBRANE; MALTOSE; TYROSINE	The single asparagine 322 mutant of the lactose permease was made by constructing a hybrid plasmid which contained the amino-terminal coding sequence from the wild-type permease gene and the carboxyl-terminal coding sequence from a previously characterized double mutant permease which contained an asparagine residue at position 322. Since histidine at position 322 has been postulated to be critically involved with H+ transport and the active accumulation of sugars, the ability of the Asn-322 mutant to couple H+ and sugar transport was carefully examined. Measurements of proton/lactose stoichiometries gave very similar values for the wild-type (0.78) and the Asn-322 strain (0.82). Moreover, the Asn-322 mutant was able to effectively accumulate lactose against a concentration gradient although the levels of accumulation in the Asn-322 mutant (approximately 5-7-fold) were significantly less than that of the wild-type strain (approximately 30-40-fold). Overall, these results are inconsistent with the notion that an ionizable histidine residue at position 322 is obligatorily required for H+ transport or the active accumulation of galactosides against a concentration gradient. The ability of the Asn-322 mutant to recognize a variety of sugars was compared with wild-type, Val-177, and Val-177/Asn-322 strains. The Asn-322 mutant exhibited an ability to recognize and transport maltose (an alpha-glucoside) which was significantly better than the wild-type strain but not as good as either the single Val-177 mutant or the double Val-177/Asn-322 mutant. Both the Asn-322 and the Val-177/Asn-322 strain showed a relatively poor recognition for alpha-galactosides (i.e. melibiose), beta-galactosides (lactose and thiodigalactoside), and beta-glucosides (cellobiose). In contrast, the single Val-177 strain exhibited a normal recognition for these sugars.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV MINNESOTA,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024204] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24204] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BROOKER RJ, 1985, J BIOL CHEM, V260, P6181; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COHEN GN, 1956, ANN IN PASTEUR PARIS, V91, P683; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; CRANE RK, 1962, FED PROC, V21, P891; CRANE RK, 1960, PHYSIOL REV, V40, P784; EDDY AA, 1971, BIOCHEM J, V122, P701, DOI 10.1042/bj1220701; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1989, BIOCHIM BIOPHYS ACTA, V982, P253, DOI 10.1016/0005-2736(89)90062-X; KING SC, 1990, J BIOL CHEM, V265, P9645; KOMOR E, 1973, FEBS LETT, V38, P16, DOI 10.1016/0014-5793(73)80501-0; KOMOR E, 1974, EUR J BIOCHEM, V44, P219, DOI 10.1111/j.1432-1033.1974.tb03476.x; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Mandel M, 1970, J MOL BIOL, V53, P154; MARKGRAF M, 1985, MOL GEN GENET, V198, P473, DOI 10.1007/BF00332941; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P1132, DOI 10.1021/bi00378a022; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; Miller J. H., 1972, EXPT MOL GENETICS, P433; MITCHELL P, 1963, BIOCH SOC S, V2, P142; PADAN E, 1985, P NATL ACAD SCI USA, V82, P6765, DOI 10.1073/pnas.82.20.6765; PUTTNER IB, 1989, BIOCHEMISTRY-US, V28, P2525, DOI 10.1021/bi00432a027; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; ROEPE PD, 1989, BIOCHEMISTRY-US, V28, P6127, DOI 10.1021/bi00440a060; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; SLAYMAN CL, 1974, P NATL ACAD SCI USA, V71, P1935, DOI 10.1073/pnas.71.5.1935; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1973, BIOCHEM J, V132, P587, DOI 10.1042/bj1320587; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON TH, 1983, CELL MEMBR METH REV, V1, P1	42	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6693	6699						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849889				2022-12-25	WOS:A1991FG72700010
J	PAGE, DM; GOLD, MR; FAHEY, KA; MATSUUCHI, L; DEFRANCO, AL				PAGE, DM; GOLD, MR; FAHEY, KA; MATSUUCHI, L; DEFRANCO, AL			MUTATIONAL ANALYSIS OF ANTIGEN RECEPTOR REGULATION OF LYMPHOCYTE-B GROWTH - EVIDENCE FOR INVOLVEMENT OF THE PHOSPHOINOSITIDE SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL-MYRISTATE ACETATE; CELL ACTIVATION; INOSITOL TRISPHOSPHATE; CALCIUM IONOPHORE; IMMUNOGLOBULIN; WEHI-231; MURINE; PROLIFERATION; TRANSDUCTION; TOLERANCE	Stimulation of the antigen receptor of WEHI-231 B lymphoma cells with anti-receptor antibodies (anti-IgM) induces irreversible growth arrest. Anti-IgM stimulates two kinds of transmembrane signaling events, phosphorylation of proteins on tyrosyl residues and breakdown of inositol phospholipids, which results in increases of inositol phosphates, diacylglycerol, and calcium. The roles of these reactions in mediating the growth arrest of the B lymphoma cells have not been established. To examine this issue, we took a genetic approach. Mutants of WEHI-231 cells were isolated that were resistant to anti-IgM-induced growth arrest. Five out of seven independent mutants analyzed had normal cell-surface expression of antigen receptors. Although each of these five mutants had tyrosine protein phosphorylation patterns comparable to wild-type cells, they exhibited alterations in the phosphoinositide signaling pathway. Four of the mutants had decreased phosphoinositide breakdown, probably due to an alteration in phospholipase C. Decreased second messenger production may be responsible for the growth-resistant phenotype. Full growth arrest was restored upon addition of the calcium ionophore ionomycin, suggesting that the limiting second messenger was intracellular free calcium. The final mutant appeared to be altered in a component(s) that responds to diacylglycerol and calcium. Taken together, these results provide further evidence that the phosphoinositide pathway is at least partly responsible for mediating antigen receptor regulation of B lymphoma cell growth.	UNIV CALIF SAN FRANCISCO,GEORGE W HOOPER FDN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Gold, Michael/0000-0003-1222-3191	NCI NIH HHS [5T32 CA-09270] Funding Source: Medline; NIADDK NIH HHS [AM-35895] Funding Source: Medline; NIAID NIH HHS [AI-20038] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R23AM035895] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020038, R37AI020038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BRAMMAR WJ, 1967, P NATL ACAD SCI USA, V58, P1499, DOI 10.1073/pnas.58.4.1499; BRUNSWICK M, 1989, P NATL ACAD SCI USA, V86, P6724, DOI 10.1073/pnas.86.17.6724; BRUNSWICK M, 1991, IN PRESS P NATL ACAD; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; DEFRANCO AL, 1982, B T CELL TUMORS BIOL, P445; Del Guidice RA, 1978, MYCOPLASMA INFECTION, P57; DENNIS GJ, 1987, J IMMUNOL, V138, P4307; FAHEY KA, 1987, J IMMUNOL, V138, P3935; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLD MR, 1987, J IMMUNOL, V138, P868; GOLD MR, 1987, J IMMUNOL, V139, P3604; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; JAKWAY JP, 1986, J IMMUNOL, V137, P2225; KISHIMOTO T, 1985, ANNU REV IMMUNOL, V3, P133, DOI 10.1146/annurev.iy.03.040185.001025; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNG JT, 1981, J IMMUNOL, V127, P873; LABAER J, 1986, J IMMUNOL, V137, P1836; LANE PJL, 1990, J IMMUNOL, V144, P3684; LIU CM, 1978, J BIOL CHEM, V253, P5892; MACDOUGALL SL, 1988, CELL, V54, P229, DOI 10.1016/0092-8674(88)90555-7; MALLING HV, 1968, MUTAT RES, V6, P181, DOI 10.1016/0027-5107(68)90033-X; MONROE JG, 1989, J EXP MED, V169, P1059, DOI 10.1084/jem.169.3.1059; MONROE JG, 1985, J IMMUNOL, V135, P1674; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PAGE DM, 1990, MOL CELL BIOL, V10, P3003, DOI 10.1128/MCB.10.6.3003; PAGE DM, 1988, J IMMUNOL, V140, P3717; PAGE DM, 1989, THESIS U CALIFORNIA; PAUL WE, 1986, CELL IMMUNOL, V99, P7, DOI 10.1016/0008-8749(86)90209-1; RALPH P, 1979, IMMUNOL REV, V48, P107, DOI 10.1111/j.1600-065X.1979.tb00300.x; RANSOM JT, 1986, J IMMUNOL, V137, P708; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROTHSTEIN TL, 1986, CELL IMMUNOL, V102, P364, DOI 10.1016/0008-8749(86)90430-2; SCOTT DW, 1987, J MOL CELL IMMUNOL, V3, P109; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; TISCH R, 1988, P NATL ACAD SCI USA, V85, P6914, DOI 10.1073/pnas.85.18.6914; VANDUUREN BL, 1967, JNCI-J NATL CANCER I, V39, P1217; WARNER NL, 1979, IMMUNOL REV, V48, P197, DOI 10.1111/j.1600-065X.1979.tb00304.x	49	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5563	5574						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848555				2022-12-25	WOS:A1991FD37000034
J	WEI, L; ALHENCGELAS, F; SOUBRIER, F; MICHAUD, A; CORVOL, P; CLAUSER, E				WEI, L; ALHENCGELAS, F; SOUBRIER, F; MICHAUD, A; CORVOL, P; CLAUSER, E			EXPRESSION AND CHARACTERIZATION OF RECOMBINANT HUMAN ANGIOTENSIN I-CONVERTING ENZYME - EVIDENCE FOR A C-TERMINAL TRANSMEMBRANE ANCHOR AND FOR A PROTEOLYTIC PROCESSING OF THE SECRETED RECOMBINANT AND PLASMA ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; KIDNEY MICROVILLAR MEMBRANE; RABBIT LUNG; SPECTROPHOTOMETRIC ASSAY; MOLECULAR-CLONING; AMINOPEPTIDASE-N; ECTO-ENZYMES; KININASE-II; PURIFICATION; LOCALIZATION	Chinese hamster ovary (CHO) cells have been transfected with either a full-length cDNA encoding human angiotensin I-converting enzyme (kininase II; EC 3.4.15.1) (ACE) or a mutated cDNA, in which the last C-terminal 47 amino acids, including the putative transmembrane domain, are not translated. Cell lines expressing high levels of the wild-type ACE or the mutant were established. The cells transfected with the wild-type cDNA (CHO-ACE) express a membrane-bound ectoenzyme with an intracellular C terminus, as shown by indirect immunofluorescence using an antiserum (28A7) raised against a synthetic peptide corresponding to the deduced C terminus of ACE. This enzyme is structurally, immunologically, and enzymatically identical to human kidney ACE. In addition, CHO-ACE cells also produce a secreted form of the enzyme. Neither this secreted form nor the enzyme purified from human plasma is recognized by the antiserum 28A7, indicating that they undergo a truncation in the C-terminal region. On the other hand, the transfected cells expressing the C-terminally truncated mutant (CHO-ACE(DELTA-COOH)) do not retain ACE in the plasma membrane, but secrete it into the medium. These results indicate that ACE is anchored to the plasma membrane by the predicted C-terminal transmembrane domain, and the secreted form is derived from the membrane-bound form by a post-translational proteolytic cleavage of the C-terminal region.			WEI, L (corresponding author), COLL FRANCE,INSERM,U36,3 RUE ULM,F-75231 PARIS 05,FRANCE.		Alhenc-Gelas, Francois/F-9511-2017					ALHENCGELAS F, 1983, J LAB CLIN MED, V101, P83; BRUNEVAL P, 1986, HISTOCHEMISTRY, V85, P73, DOI 10.1007/BF00508656; BULL HG, 1985, J BIOL CHEM, V260, P2963; BULL HG, 1985, J BIOL CHEM, V260, P2952; CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444; CUMIN F, 1989, BIOCHEM BIOPH RES CO, V163, P718, DOI 10.1016/0006-291X(89)92282-1; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DAS M, 1977, J BIOL CHEM, V252, P1316; DEFENDINI R, 1983, NEUROENDOCRINOLOGY, V37, P32, DOI 10.1159/000123512; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; EHLERS MRW, 1986, BIOCHIM BIOPHYS ACTA, V883, P361, DOI 10.1016/0304-4165(86)90329-6; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERDOS EG, 1987, LAB INVEST, V56, P345; FERACCI H, 1982, BIOCHIM BIOPHYS ACTA, V684, P133, DOI 10.1016/0005-2736(82)90057-8; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; HAYES LW, 1978, BIOCHEM BIOPH RES CO, V82, P1147, DOI 10.1016/0006-291X(78)90306-6; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; HOOPER NM, 1988, FEBS LETT, V229, P340, DOI 10.1016/0014-5793(88)81152-9; HOOPER NM, 1987, BIOCHEM J, V244, P465, DOI 10.1042/bj2440465; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; HORIUCHI M, 1982, J CHROMATOGR, V233, P123, DOI 10.1016/S0378-4347(00)81738-7; HUANG H, 1989, CLIN EXP HYPERTENS A, V11, P1535, DOI 10.3109/10641968909038181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1987, BIOCHEM J, V244, P1; MACNAIR RDC, 1979, BIOCHEM J, V179, P379, DOI 10.1042/bj1790379; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; PINET F, 1988, J CLIN ENDOCR METAB, V67, P1211, DOI 10.1210/jcem-67-6-1211; RYAN US, 1976, TISSUE CELL, V8, P125, DOI 10.1016/0040-8166(76)90025-2; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STEWART TA, 1981, PEPTIDES, V2, P145, DOI 10.1016/S0196-9781(81)80027-7; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WHITE BA, 1982, J BIOL CHEM, V257, P8569; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	40	208	211	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5540	5546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848554				2022-12-25	WOS:A1991FD37000030
J	MUNDINAWEILENMANN, C; CHANG, CF; GUTIERREZ, LM; HOSEY, MM				MUNDINAWEILENMANN, C; CHANG, CF; GUTIERREZ, LM; HOSEY, MM			DEMONSTRATION OF THE PHOSPHORYLATION OF DIHYDROPYRIDINE-SENSITIVE CALCIUM CHANNELS IN CHICK SKELETAL-MUSCLE AND THE RESULTANT ACTIVATION OF THE CHANNELS AFTER RECONSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; DEPENDENT CA-2+ CHANNEL; 1,4-DIHYDROPYRIDINE RECEPTOR; TRANSVERSE TUBULES; CYCLIC-AMP; PHENYLALKYLAMINE RECEPTOR; ANTAGONIST RECEPTOR; PURIFIED RECEPTOR; PURIFICATION; MODULATION	We have examined the effects of cAMP elevating agents on the phosphorylation of dihydropyridine-sensitive Ca2+ channels in intact newborn chick skeletal muscle. In situ treatment with the beta-adrenergic receptor agonist isoproterenol resulted in the phosphorylation of the 170-kDa alpha-1-subunit in the intact cells, as evidenced by a marked decrease in the ability of the alpha-1-peptide to serve as a substrate in in vitro back phosphorylation reactions with [gamma-P-32]ATP and the purified catalytic subunit of cAMP-dependent protein kinase. The phosphorylation of the 52-kDa beta-subunit was not affected. The effects of isoproterenol were time- and concentration-dependent and were mimicked by other cAMP elevating agents but not by the Ca2+ ionophore A23187 or a protein kinase C activator. To test for functional effects of the observed phosphorylation, purified channels were reconstituted into liposomes containing entrapped fluo-3, and depolarization-sensitive and dihydropyridine-sensitive Ca2+ influx was measured. Channels from isoproterenol-treated muscle exhibited an increased rate and extent of Ca2+ influx compared to control preparations. The effects of isoproterenol pretreatment could be mimicked by phosphorylating the channels with cAMP-dependent protein kinase in vitro. These results demonstrate that the alpha-1-subunit of the dihydropyridine-sensitive Ca2+-channels is the primary target of cAMP-dependent phosphorylation in intact muscle and that the phosphorylation of this protein leads to activation of channel activity.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University			Gutierrez, Luis/K-8633-2014	Gutierrez, Luis/0000-0002-0512-7858	NHLBI NIH HHS [HL-23306] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL023306, R01HL023306] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; BLAU L, 1988, BIOCHEMISTRY-US, V27, P5661, DOI 10.1021/bi00415a040; BORSOTTO M, 1985, J BIOL CHEM, V260, P4255; CHANG CF, 1990, BIOCHEM BIOPH RES CO, V172, P751, DOI 10.1016/0006-291X(90)90738-9; CHANG CF, 1989, BIOPHYS J, V57, pA315; CHANG FC, 1988, J BIOL CHEM, V263, P18929; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; CURTIS BM, 1986, BIOCHEMISTRY-US, V25, P3077, DOI 10.1021/bi00359a002; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DUNN SMJ, 1989, J BIOL CHEM, V264, P11053; FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6; GALIZZI JP, 1986, J BIOL CHEM, V261, P1393; GUTIERREZ LM, 1989, BIOCHEM J, V264, P589, DOI 10.1042/bj2640589; HORNE WA, 1988, P NATL ACAD SCI USA, V85, P3718, DOI 10.1073/pnas.85.11.3718; HOSEY MM, 1986, P NATL ACAD SCI USA, V83, P3733, DOI 10.1073/pnas.83.11.3733; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; HOSEY MM, 1987, BIOCHEM BIOPH RES CO, V147, P1137; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; KAMEYAMA A, 1988, BIOCHEM BIOPH RES CO, V154, P1067, DOI 10.1016/0006-291X(88)90249-5; KAO JPY, 1989, J BIOL CHEM, V264, P8179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NAKAO S, 1988, BIOCHIM BIOPHYS ACTA, V944, P337, DOI 10.1016/0005-2736(88)90503-2; NASTAINCZYK W, 1987, EUR J BIOCHEM, V169, P137, DOI 10.1111/j.1432-1033.1987.tb13590.x; NORMAN JA, 1982, MOL PHARMACOL, V22, P395; NUMOKI K, 1989, P NATL ACAD SCI USA, V86, P6816; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; OCALLAHAN CM, 1988, J BIOL CHEM, V263, P17342; OCALLAHAN CM, 1988, BIOCHEMISTRY-US, V27, P6071, DOI 10.1021/bi00416a036; OSTERRIEDER W, 1982, NATURE, V298, P576, DOI 10.1038/298576a0; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; SCHILLING WP, 1984, J MEMBRANE BIOL, V79, P163, DOI 10.1007/BF01872120; SCHMID A, 1985, J BIOL CHEM, V260, P3041; SIEBER M, 1987, EUR J BIOCHEM, V167, P117, DOI 10.1111/j.1432-1033.1987.tb13311.x; STRIESSNIG J, 1987, FEBS LETT, V212, P247, DOI 10.1016/0014-5793(87)81354-6; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; VAGHY PL, 1987, J BIOL CHEM, V262, P14337; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YUAN SH, 1987, CIRC RES, V61, P372, DOI 10.1161/01.RES.61.3.372	47	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4067	4073						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847914				2022-12-25	WOS:A1991FA69400010
J	LANGERSAFER, PR; AHERN, TJ; ANGUS, LB; BARONE, KM; BRENNER, MJ; HORGAN, PG; MORRIS, GE; STOUDEMIRE, JB; TIMONY, GA; LARSEN, GR				LANGERSAFER, PR; AHERN, TJ; ANGUS, LB; BARONE, KM; BRENNER, MJ; HORGAN, PG; MORRIS, GE; STOUDEMIRE, JB; TIMONY, GA; LARSEN, GR			REPLACEMENT OF FINGER AND GROWTH-FACTOR DOMAINS OF TISSUE PLASMINOGEN-ACTIVATOR WITH PLASMINOGEN KRINGLE-1 - BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF A NOVEL CHIMERA CONTAINING A HIGH-AFFINITY FIBRIN-BINDING DOMAIN LINKED TO A HETEROLOGOUS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT MOLECULAR-WEIGHT; STRUCTURAL DOMAINS; UROKINASE; CHAIN; ACID; DEGRADATION; EXPRESSION; DIGESTION; VARIANTS; DELETION	A novel triple-kringle plasminogen activator protein, PK1-DELTA-FE1X, has been produced which is a genetic chimera between the fibrin binding kringle 1 domain of plasminogen and the two kringles and serine protease domains of naturally occurring wild-type tissue plasminogen activator (wt t-PA). This chimera also contains a modification to prevent high mannose type N-linked glycosylation on kringle 1 of t-PA. PK1-DELTA-FE1X is biochemically and fibrinolytically similar to wt t-PA in vitro but retains the decreased plasma clearance rate characteristic of other t-PA variants which lack fibronectin finger-like and epidermal growth factor domains. The serine protease domain of PK1-DELTA-FE1X exhibits the amidolytic activity characteristic of wt t-PA. In an indirect coupled plasminogen activator assay, the specific activity of PK1-DELTA-FE1X is approximately 1.4 times greater than that of wt t-PA. In a fibrin film-binding assay, greater binding to untreated fibrin is observed with wt t-PA than with PK1-DELTA-FE1X. However, following limited plasmin digestion of the fibrin film, PK1-DELTA-FE1X binding increases to the level observed with wt t-PA. The incremental binding to plasmin-digested fibrin observed with PK1-DELTA-FE1X is eliminated if plasmin digestion of the fibrin film is followed by carboxypeptidase B treatment. This result suggests that plasminogen kringle 1 binds plasmin-digested fibrin even after recombination with a heterologous protein. The fibrinolytic activity of PK1-DELTA-FE1X in human plasma clot lysis assays was similar to that of wt t-PA at activator concentrations of approximately 1-mu-g/ml. At substantially lower concentrations, approximately 0.1-mu-g/ml, PK1-DELTA-FE1X was only slightly less active than wt t-PA. Pharmacokinetic analysis showed that wt t-PA activity is cleared approximately 15 times as rapidly as PK1-DELTA-FE1X following intravenous bolus injection. In a rabbit jugular vein clot lysis model, intravenous bolus injection of 0.06 mg/kg of PK1-DELTA-FE1X showed greater thrombolytic potency than a similar administration of 0.5 mg/kg of wt t-PA. Thus it appears that in vitro exon shuffling techniques can be used to generate novel fibrinolytic agents which biochemically and pharmacologically represent the combination of individual domains of naturally occurring proteins.	GENET INST,CAMBRIDGE,MA 02140									AHERN TJ, 1990, J BIOL CHEM, V265, P5540; CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9; COLLEN D, 1983, J CLIN INVEST, V71, P368, DOI 10.1172/JCI110778; COLLEN D, 1988, BLOOD, V71, P216; COTTRELL BA, 1976, BIOCHEM BIOPH RES CO, V71, P754, DOI 10.1016/0006-291X(76)90895-0; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EHRLICH H J, 1987, Fibrinolysis, V1, P75, DOI 10.1016/0268-9499(87)90013-0; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; Gibaldi M., 1982, PHARMACOKINETICS, P445; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; HANSEN L, 1988, J BIOL CHEM, V263, P15713; HARRIS TJR, 1987, PROTEIN ENG, V1, P449, DOI 10.1093/protein/1.6.449; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KAGITANI H, 1985, FEBS LETT, V189, P145, DOI 10.1016/0014-5793(85)80860-7; KALYAN NK, 1988, J BIOL CHEM, V263, P3971; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LEE SG, 1988, J BIOL CHEM, V263, P2917; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LIJNEN HR, 1988, THROMB RES, V52, P431, DOI 10.1016/0049-3848(88)90027-8; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; PANNEKOEK H, 1988, Fibrinolysis, V2, P123, DOI 10.1016/0268-9499(88)90025-2; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; ROBBINS KC, 1986, BIOCHEMISTRY-US, V25, P3603, DOI 10.1021/bi00360a019; ROBBINS KC, 1987, BIOCHEMISTRY-US, V26, P4661, DOI 10.1021/bi00389a011; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; THORSEN S, 1972, THROMB DIATH HAEMOST, V28, P65; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; VALI Z, 1984, J BIOL CHEM, V259, P3690; VALI Z, 1982, J BIOL CHEM, V257, P2104; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J CELL BIOCHEM, V32, P169, DOI 10.1002/jcb.240320302; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WALLEN P, 1983, EUR J BIOCHEM, V132, P681, DOI 10.1111/j.1432-1033.1983.tb07418.x; WIMAN B, 1977, THROMB RES, V10, P213, DOI 10.1016/0049-3848(77)90003-2	40	15	15	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3715	3723						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847387				2022-12-25	WOS:A1991EY68200057
J	JAWORSKI, A; HIGGINS, NP; WELLS, RD; ZACHARIAS, W				JAWORSKI, A; HIGGINS, NP; WELLS, RD; ZACHARIAS, W			TOPOISOMERASE MUTANTS AND PHYSIOLOGICAL CONDITIONS CONTROL SUPERCOILING AND Z-DNA FORMATION INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANDED Z-DNA; ESCHERICHIA-COLI; I MUTANTS; GENE-EXPRESSION; SALMONELLA-TYPHIMURIUM; GYRASE INHIBITORS; LINKING NUMBER; PLASMID DNA; B-DNA; TRANSCRIPTION	The influence of topoisomerase I and gyrase mutations in Escherichia coli on the supercoil density of recombinant plasmids and the stability of left-handed Z-DNA was investigated. The formation of Z-DNA in vivo by dC-dG sequences of different lengths was used to determine the effective plasmid supercoil densities in the mutant strains. The presence of Z-DNA in the cells was detected by linking number and EcoRI methylase inhibition assays. A change in the unrestrained superhelical tension in vivo directly effects the B- to Z-DNA transition. Alterations in the internal or external environment of the cells, such as the inactivation of gyrase or topoisomerase I, a gyrase temperature-sensitive mutant, or starvation of cells, have a dramatic influence on the topology of plasmids. Also, E. coli has significantly more superhelical strain than Klebsiella, Morganella, or Enterobacter. These studies indicate that linking deficiency and effective supercoil density are mutually independent variables of plasmid tertiary structure. A variety of factors, such as protein-DNA interactions, activity of topoisomerases, and the resulting supercoil density, contribute to the B to Z transition inside living cells.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIAMS NIH HHS [2P60 AR20614] Funding Source: Medline; NIGMS NIH HHS [GM30822, GM33143] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033143, R01GM030822] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON P, 1978, BIOCHEMISTRY-US, V17, P594, DOI 10.1021/bi00597a006; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BRADY GW, 1987, J MOL BIOL, V195, P185, DOI 10.1016/0022-2836(87)90335-4; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; COOK DN, 1989, J BACTERIOL, V171, P4836, DOI 10.1128/jb.171.9.4836-4843.1989; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DORMAN CJ, 1988, J BACTERIOL, V170, P2816, DOI 10.1128/jb.170.6.2816-2826.1988; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; ESPOSITO F, 1987, NUCLEIC ACIDS RES, V15, P5105, DOI 10.1093/nar/15.13.5105; FIGUEROA N, 1988, P NATL ACAD SCI USA, V85, P9416, DOI 10.1073/pnas.85.24.9416; FRANCO RJ, 1989, J BACTERIOL, V171, P6573, DOI 10.1128/jb.171.12.6573-6579.1989; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GIAVER NG, 1988, BIOPHYS CHEM, V29, P7; GOLDSTEIN E, 1984, P NATL ACAD SCI-BIOL, V81, P4046, DOI 10.1073/pnas.81.13.4046; HANIFORD DB, 1983, J BIOMOL STRUCT DYN, V1, P593, DOI 10.1080/07391102.1983.10507467; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HORBACH E, 1988, J MOL BIOL, V202, P157, DOI 10.1016/0022-2836(88)90527-X; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1989, J MOL BIOL, V207, P513, DOI 10.1016/0022-2836(89)90461-0; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LILLEY D, 1986, NATURE, V320, P14, DOI 10.1038/320014a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; LODGE JK, 1989, J BACTERIOL, V171, P2181, DOI 10.1128/jb.171.4.2181-2187.1989; MENZEL R, 1983, CELL, V34, P105, DOI 10.1016/0092-8674(83)90140-X; MENZEL R, 1987, J BACTERIOL, V169, P1272, DOI 10.1128/jb.169.3.1272-1278.1987; NICHOLSON WL, 1990, J BACTERIOL, V172, P7, DOI 10.1128/JB.172.1.7-14.1990; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; PRUSS GJ, 1985, J BACTERIOL, V164, P947, DOI 10.1128/JB.164.2.947-949.1985; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; SINDEN RR, 1987, BIOCHEMISTRY-US, V26, P1343, DOI 10.1021/bi00379a021; SINDEN RR, 1987, J CHEM EDUC, V64, P294, DOI 10.1021/ed064p294; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; Wells R.D., 1988, UNUSUAL DNA STRUCTUR; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WITTIG B, 1989, J CELL BIOL, V108, P755, DOI 10.1083/jcb.108.3.755; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YAMAMOTO N, 1985, P NATL ACAD SCI USA, V82, P2077, DOI 10.1073/pnas.82.7.2077; ZACHARIAS W, 1990, J BACTERIOL, V172, P3278, DOI 10.1128/jb.172.6.3278-3283.1990; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069	48	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2576	2581						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846630				2022-12-25	WOS:A1991EV51500086
J	OBERHUBER, H; MALY, K; UBERALL, F; HOFLACHER, J; KIANI, A; GRUNICKE, HH				OBERHUBER, H; MALY, K; UBERALL, F; HOFLACHER, J; KIANI, A; GRUNICKE, HH			MECHANISM OF DESENSITIZATION OF THE CA2+-MOBILIZING SYSTEM TO BOMBESIN BY HA-RAS - INDEPENDENCE FROM DOWN-MODULATION OF AGONIST-STIMULATED INOSITOL PHOSPHATE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR; NIH-3T3 CELLS; V-MOS; ONCOGENE; MOBILIZATION; CALCIUM; HYDROLYSIS; BRADYKININ	Expression of a transforming Ha-ras gene in NIH 3T3 cells transfected with an inducible Ha-ras construct leads to a rapid desensitization of the intracellular Ca2+-mobilizing system to bombesin and serum growth factors. Half-maximal depression of the Ca2+ response is observed 2 h after induction of p21ras. A maximum is obtained after 6 h. Bombesin-induced elevation of inositol 1,4,5-trisphosphate formation is also depressed in cells expressing Ha-ras. This, however, is a relatively late phenomenon and not yet detectable when maximal depression of the Ca2+ signal is observed. We conclude that the rapid densensitization of the Ca2+-releasing system to bombesin by Ha-ras is not caused by down-modulation or uncoupling of phospholipase C-coupled bombesin receptors. The inositol 1,4,5-trisphosphate-mediated release of intracellular Ca2+ is reduced in permeabilized cells expressing the Ha-ras oncogene. A depletion of intracellular Ca2+ stores by Ha-ras is unlikely since (i) the Ha-ras-induced growth factor-independent stimulation of inositol phosphate formation occurs several hours after reduction of the Ca2+ response and (ii) the Ca2+ load of intracellular nonmitochondrial Ca2+ stores was found to be unaffected by Ha-ras. We conclude that the desensitization of the Ca2+-mobilizing system is caused either by partial inhibition of inositol 1,4,5-trisphosphate-regulated Ca2+ channels or by interference of Ha-ras with Ca2+ translocation between intracellular Ca2+ compartments.			OBERHUBER, H (corresponding author), UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA.							ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; EBERL G, 1987, FEBS LETT, V222, P349, DOI 10.1016/0014-5793(87)80400-3; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANCOCK JF, 1988, ONCOGENE, V3, P187; HESLOP JP, 1985, J EXP BIOL, V119, P395; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALY K, 1988, MOL CELL BIOL, V8, P4212, DOI 10.1128/MCB.8.10.4212; MALY K, 1988, ADV ENZYME REGUL, V27, P121; MALY K, 1989, J BIOL CHEM, V264, P11839; OLINGER PL, 1989, J CELL PHYSIOL, V139, P335, DOI 10.1002/jcp.1041390216; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; Peferoen M, 1988, Methods Mol Biol, V3, P395, DOI 10.1385/0-89603-126-8:395; PRICE BD, 1989, BIOCHEM J, V260, P157, DOI 10.1042/bj2600157	25	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1437	1442						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846354				2022-12-25	WOS:A1991EU49700016
J	SHUMAN, S				SHUMAN, S			SITE-SPECIFIC DNA CLEAVAGE BY VACCINIA VIRUS-DNA TOPOISOMERASE-I - ROLE OF NUCLEOTIDE-SEQUENCE AND DNA SECONDARY STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; NICKING-CLOSING ENZYME; COLI PROTEIN-OMEGA; ESCHERICHIA-COLI; RAT-LIVER; TYPE-1 TOPOISOMERASE; SUPERHELICAL DNA; BINDING SEQUENCE; RIBOSOMAL-RNA; SV40 DNA	Cleavage of linear duplex DNA by purified vaccinia virus DNA topoisomerase I occurs at a conserved sequence element (5'-(C/T)CCTT down) in the incised DNA strand. Oligonucleotides spanning the high affinity cleavage site CCCTT at nucleotide 2457 in pUC19 DNA are cleaved efficiently in vitro, but only when hybridized to a complementary DNA molecule. As few as 6 nucleotides proximal to the cleavage site and 6 nucleotides downstream of the site are sufficient to support exclusive cleavage at the high affinity site (position +1). Single nucleotide substitutions within the consensus pentamer have deleterious effects on the equilibria of the topoisomerase binding and DNA cleavage reactions. The effects of base mismatch within the pentamer are more dramatic than are the effects of mutations that preserve base complementarity. Competition experiments indicate that topoisomerase binds preferentially to DNA sites containing the wild-type pentamer element. Single-stranded DNA containing the sequence CCCTT in the cleaved stand is a more effective competitor than is single-stranded DNA containing the complementary sequence in the noncleaved strand.			SHUMAN, S (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42498-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER WR, 1977, P NATL ACAD SCI USA, V74, P1841, DOI 10.1073/pnas.74.5.1841; BEEN MD, 1984, BIOCHIM BIOPHYS ACTA, V782, P304, DOI 10.1016/0167-4781(84)90066-6; BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8463, DOI 10.1093/nar/17.21.8463; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P3800, DOI 10.1073/pnas.74.9.3800; CHAMPOUX JJ, 1972, P NATL ACAD SCI USA, V69, P143, DOI 10.1073/pnas.69.1.143; CHAMPOUX JJ, 1984, COLD SPRING HARB SYM, V49, P435, DOI 10.1101/SQB.1984.049.01.049; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHAMPOUX JJ, 1988, GENETIC RECOMBINATIO, P655; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; DEPEW RE, 1978, J BIOL CHEM, V253, P511; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; EGYHAZI E, 1987, MOL CELL BIOL, V7, P4308, DOI 10.1128/MCB.7.12.4308; ENG WK, 1989, J BIOL CHEM, V264, P13373; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; HALLIGAN BD, 1982, J BIOL CHEM, V257, P3995; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHISHIDO K, 1983, BIOCHIM BIOPHYS ACTA, V740, P108, DOI 10.1016/0167-4781(83)90127-6; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, VIROLOGY, V170, P302, DOI 10.1016/0042-6822(89)90384-X; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; THIELKING V, 1990, BIOCHEMISTRY-US, V29, P4682, DOI 10.1021/bi00471a024; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; TSEDINH YC, 1983, NUCLEIC ACIDS RES, V11, P8691, DOI 10.1093/nar/11.24.8691; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	46	65	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1796	1803						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846364				2022-12-25	WOS:A1991EU49700068
J	CARROLL, MP; SPIVAK, JL; MCMAHON, M; WEICH, N; RAPP, UR; MAY, WS				CARROLL, MP; SPIVAK, JL; MCMAHON, M; WEICH, N; RAPP, UR; MAY, WS			ERYTHROPOIETIN INDUCES RAF-1 ACTIVATION AND RAF-1 IS REQUIRED FOR ERYTHROPOIETIN-MEDIATED PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; GENE-EXPRESSION; CELL-GROWTH; PHOSPHORYLATION; RECEPTOR; RNA; INTERLEUKIN-3; PROTOONCOGENE; COMPLEMENTARY; MEMBRANE	Erythropoietin mediates the rapid phosphorylation of Raf-1 in the murine cell lines HCD-57 and FDC-P1/ER, which proliferate in response to this cytokine. Phosphorylation occurs at both serine and tyrosine residues and as such is similar to the Raf-1 phosphorylation seen after interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor, and interleukin-2 stimulation in other murine cell lines. Such data suggest that these growth factors may share a common mechanism(s) of Raf-1 phosphorylation. Furthermore, in association with Raf-1 phosphorylation, erythropoietin induces a 2-3-fold increase in Raf-1 kinase activity as measured in immune complex kinase assays in vitro. Finally, a c-raf antisense oligodeoxyribonucleotide, which specifically decreases intracellular Raf-I levels, also substantially inhibits both erythropoietin and IL-3-directed DNA synthesis. Together, these results provide evidence that activated Raf-1 is a necessary component of erythropoietin and IL-3 growth signaling pathways.	JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ONCOL CTR, 424 N BOND ST, BALTIMORE, MD 21231 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV HEMATOL, BALTIMORE, MD 21231 USA; JOHNSON & JOHNSON, RW JOHNSON PHARMACEUT RES INST, RARITAN, NJ 08869 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johnson & Johnson; Johnson & Johnson USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL CANCER INSTITUTE [R01CA044649, R01CA047993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016702, R01DK016702] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44649, CA 47993] Funding Source: Medline; NIDDK NIH HHS [DK 16702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CARROLL MP, 1990, EXP HEMATOL, V18, pA625; CHOI HS, 1987, J BIOL CHEM, V262, P2933; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KRANTZ SB, 1991, BLOOD, V77, P419; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Neckers L. M., 1989, OLIGODEOXYNUCLEOTIDE, P211; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1987, ONCOGENES CANCER, P55; REED JC, 1990, CANCER RES, V50, P6565; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SPIVAK JL, 1991, BLOOD, V77, P1228; STEIN CA, 1988, CANCER RES, V48, P2659; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STORM SM, 1990, ONCOGENE, V5, P345; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VALTIERI M, 1991, BLOOD, V77, P1181; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WEINTRAUB H, 1985, TRENDS GENET, V1, P22, DOI 10.1016/0168-9525(85)90010-1; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	47	176	181	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14964	14969						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869534				2022-12-25	WOS:A1991GB09700028
J	TYAGI, SC; SIMON, SR				TYAGI, SC; SIMON, SR			PARINARIC ACIDS AS PROBES OF BINDING DOMAINS IN NEUTROPHIL ELASTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; POLYENE FATTY-ACIDS; FLUORESCENT-PROBES; INHIBITORS; MEMBRANE; ACTIVATION; KINETICS; PROTEINS; ENZYMES	Human neutrophil elastase has an extended hydrophobic substrate binding site which serves as a target for a number of hydrophobic inhibitors. We show here that the parinaric acids, fluorescent-conjugated tetraenoic fatty acids of plant origin, are inhibitors of neutrophil elastase. cis-Parinaric acid (cis-PA) interacts with the enzyme in two inhibitory modes. The high affinity interaction (K(i) = 55 +/- 6 nM) results in partial noncompetitive inhibition of amidolytic activity, with 82% residual activity. A lower affinity interaction with cis-PA (K(i) = 4 +/- 1-mu-M) results in competitive inhibition. trans-PA also acts as a high affinity partial noncompetitive inhibitor of elastase with a K(i) equal to that for cis-PA but has no low affinity competitive inhibitory action. The endogenous fluorescence from the 3 tryptophan residues in elastase is partially quenched on binding cis- or trans-PA. Dependence of quenching of tryptophan fluorescence on PA concentration is consistent with binding to a single site with an apparent K(d) of 26 +/- 3 nM, which may be equivalent to the high affinity partial noncompetitive inhibitory binding mode. Analysis of quenching according to the modified Forster theory of energy transfer developed by Snyder and Freire (Snyder, B., and Freire, E. (1982) Biophys. J. 40, 137-148) leads to an estimate of apparent closest indole-PA distance of 13 +/- 3 angstrom. Fluorescence of either cis- or trans-PA is apparently unperturbed upon binding in the high affinity mode to elastase, but at micromolar cis-PA concentrations, binding to elastase results in a blue shift and 20% increase in intensity of PA emission, suggesting that the lower affinity competitive inhibitory binding mode of binding to elastase provides a hydrophobic environment for cis-PA.	SUNY STONY BROOK,DEPT ENTOMOL,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	TYAGI, SC (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014262, R37HL014262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHE BM, 1977, BIOCHEM BIOPH RES CO, V75, P194, DOI 10.1016/0006-291X(77)91308-0; BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; Bieth J., 1974, BAYER S, P463; BIETH JG, 1986, BIOL EXTRACELLULAR M, P217; Bieth JG, 1989, ELASTIN ELASTASES, VII, P23; BIETH JG, 1989, ELASTIN ELASTASES, V2, P13; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; CLARK JM, 1980, J CELL BIOL, V84, P102, DOI 10.1083/jcb.84.1.102; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COOK L, 1988, BIOL CHEM H-S, V369, P627, DOI 10.1515/bchm3.1988.369.2.627; COOK L, 1989, BIOL CHEM H-S, V370, P11, DOI 10.1515/bchm3.1989.370.1.11; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DOHERTY JB, 1986, NATURE, V322, P192, DOI 10.1038/322192a0; EISINGER J, 1969, BIOCHEMISTRY-US, V8, P3908, DOI 10.1021/bi00838a005; EMPIE MW, 1982, BIOCHEMISTRY-US, V21, P2274, DOI 10.1021/bi00539a002; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FOURNEL MA, 1988, AM J MED, V84, P43; GREEN NM, 1953, BIOCHEM J, V54, P347, DOI 10.1042/bj0540347; HANCE AJ, 1975, AM REV RESPIR DIS, V112, P656; HARPER JW, 1983, J AM CHEM SOC, V21, P6518; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JANOFF A, 1985, ANNU REV MED, V36, P207; Maksimov M. Z., 1962, OPT SPECTROSC, V12, P337; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; OLEKSYSZYN J, 1991, BIOCHEMISTRY-US, V30, P485, DOI 10.1021/bi00216a026; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; SANDBORG RR, 1988, LAB INVEST, V59, P300; SEGEL IH, 1975, ENZYME KINETICS BEHA, P166; SILVERMAN R, 1988, MECHANISM BASED ENZY, P22; SKLAR LA, 1980, FEBS LETT, V118, P308, DOI 10.1016/0014-5793(80)80245-6; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P819, DOI 10.1021/bi00624a002; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P813, DOI 10.1021/bi00624a001; SKLAR LA, 1975, P NATL ACAD SCI USA, V72, P1649, DOI 10.1073/pnas.72.5.1649; SNYDER B, 1982, BIOPHYS J, V40, P137, DOI 10.1016/S0006-3495(82)84468-8; STARKEY PM, 1977, PROTEINASES MAMMALIA, P57; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; TECOMA ES, 1977, BIOCHEMISTRY-US, V16, P829, DOI 10.1021/bi00624a003; TRAINOR DA, 1987, TRENDS PHARMACOL SCI, V8, P300; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1988, AM J MED, V84, P37; TYAGI SC, 1990, BIOCHEMISTRY-US, V29, P9970, DOI 10.1021/bi00494a030	44	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15185	15191						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869548				2022-12-25	WOS:A1991GB09700058
J	OHNISHI, T; ARAKAKI, N; NAKAMURA, O; HIRONO, S; DAIKUHARA, Y				OHNISHI, T; ARAKAKI, N; NAKAMURA, O; HIRONO, S; DAIKUHARA, Y			PURIFICATION, CHARACTERIZATION, AND STUDIES ON BIOSYNTHESIS OF A 59-KDA BONE SIALIC ACID-CONTAINING PROTEIN (BSP) FROM RAT MANDIBLE USING A MONOCLONAL-ANTIBODY - EVIDENCE THAT 59-KDA BSP MAY BE THE RAT COUNTERPART OF HUMAN ALPHA-2-HS GLYCOPROTEIN AND IS SYNTHESIZED BY BOTH HEPATOCYTES AND OSTEOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEOGLYCAN-I; SIALOPROTEIN-II; PHOSPHORYLATED GLYCOPROTEIN; MINERAL COMPARTMENT; A-CHAIN; B-CHAIN; PLASMA; ALPHA-2HS-GLYCOPROTEIN; SEQUENCE; MATRIX	A monoclonal antibody was raised against a mineralized tissue-specific sialoprotein containing no phosphorus using partially purified noncollagenous bone matrix proteins from rats as antigen. Then the sialoprotein was purified by high performance liquid chromatography from rat mandibulae using the monoclonal antibody as a marker. The sialoprotein (59-kDa bone sialoprotein (BSP)) with a molecular weight of 59,000 contained 1.4% sialic acid but no detectable phosphorus. Immunohistochemical studies with the antibody showed that the protein was specific to mineralized tissues such as bone and dentin, and present in osteoblasts, osteocytes, and bone matrix. No other soft tissues, such as the cartilage, liver, kidney, and periosteum, were stained. However, Western blot analysis showed that plasma contained immunoreactive 59-kDa BSP. The quantitative amino acid composition of 59-kDa BSP resembled that of human alpha-2-HS glycoprotein (alpha-2-HSG) (Lee, C.-C., Bowman, B. H., and Yang, F. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 4403-4407; Kellermann, J., Haupt, H., Auerswald, E.-A., and Muller-Esterl, W. (1989) J. Biol. Chem. 264, 14121-14128) and rat 64-kDa protein (Franzen, A., and Heinegard, D. (1985) in The Chemistry and Biology of Mineralized Tissues (Butler, W. T., ed), p. 132, EBSCO Media, Birmingham, AL). Amino acid sequence analyses of the amino-terminal region and four peptide fragments of 59-kDa BSP revealed that about 50% of the amino acids were homologous with those of human alpha-2-HSG, which is known to be synthesized by the liver, transported in the bloodstream, and incorporated into calcified tissues. But when newborn rat calvaria, primary cultures of osteoblast-rich cells, and adult rat hepatocytes were incubated with radioactive leucine, immunoreactive 59-kDa BSP was detected in their conditioned medium by fluorography. Several characteristics, including the amino acid sequence, suggest that 59-kDa BSP may be the rat counterpart of human alpha-2-HSG. However, rat 59-kDa BSP is a single peptide and synthesized by both osteoblasts and hepatocytes, whereas human alpha-2-HSG is known to be a heterodimer and to be synthesized by the liver.	KAGOSHIMA UNIV, SCH DENT, DEPT BIOCHEM, 35-1 SAKURAGAOKA 8, KAGOSHIMA 890, JAPAN	Kagoshima University								ARNAUD P, 1988, METHOD ENZYMOL, V163, P431; ASHTON BA, 1976, CALC TISS RES, V22, P27; BERESFORD JN, 1987, J BIOL CHEM, V262, P17164; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BUTLER WT, 1987, METHOD ENZYMOL, V145, P255; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; COLCLASURE GC, 1988, J CLIN ENDOCR METAB, V66, P187, DOI 10.1210/jcem-66-1-187; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; DICKSON IR, 1975, NATURE, V256, P430, DOI 10.1038/256430a0; DIETRICH JW, 1976, ENDOCRINOLOGY, V98, P943, DOI 10.1210/endo-98-4-943; ECAROTCHARRIER B, 1989, J BIOL CHEM, V264, P20049; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FISHER LW, 1985, CLIN ORTHOP RELAT R, P362; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; FRANZEN A, 1985, CHEM BIOL MINERALIZE, P132; GEJYO F, 1983, J BIOL CHEM, V258, P4966; GERLACH U, 1974, METHOD ENZYMAT AN, V2, P871; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HEREMANS JF, 1960, GLOBULINES SERIQUES, P103; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; HURRELL JGR, 1982, MONOCLONAL HYBRIDOMA, P1; ISHIKAWA E, 1979, TECHNIQUES METABOL B, V217, P1; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRETON JP, 1977, FEBS LETT, V80, P351, DOI 10.1016/0014-5793(77)80474-2; LEE CC, 1987, P NATL ACAD SCI USA, V84, P4403, DOI 10.1073/pnas.84.13.4403; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN TJ, 1987, METHOD ENZYMOL, V145, P324; MARTINI OHW, 1971, J MOL BIOL, V62, P403, DOI 10.1016/0022-2836(71)90435-9; NAKAMA T, 1988, CALCIFIED TISSUE INT, V43, P263, DOI 10.1007/BF02555145; NAKAMURA O, 1985, CALCIFIED TISSUE INT, V37, P491, DOI 10.1007/BF02557832; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; PLANK J, 1952, Zentralbl Allg Pathol, V89, P252; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; READING CL, 1982, J IMMUNOL METHODS, V53, P261, DOI 10.1016/0022-1759(82)90175-2; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID K, 1961, BIOCHIM BIOPHYS ACTA, V47, P440, DOI 10.1016/0006-3002(61)90539-X; SCHNEIDER WC, 1957, METHOD ENZYMOL, V3, P680, DOI 10.1016/S0076-6879(57)03442-4; SCHULTZE HE, 1962, NATURWISSENSCHAFTEN, V49, P15, DOI 10.1007/BF00632835; TAKAGI Y, 1990, CALCIFIED TISSUE INT, V47, P40, DOI 10.1007/BF02555864; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; TRIFFITT JT, 1987, CLIN SCI, V72, P399, DOI 10.1042/cs0720399; TRIFFITT JT, 1978, CALC TISS RES, V26, P155, DOI 10.1007/BF02013251; UCHIYAMA A, 1986, BIOCHEMISTRY-US, V25, P7572, DOI 10.1021/bi00371a047; Veis A, 1985, CHEM BIOL MINERALIZE, P170; WARY W, 1981, ANAL BIOCHEM, V105, P361; YOSHIOKA Y, 1986, J BIOL CHEM, V261, P1665	56	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14636	14645						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860865				2022-12-25	WOS:A1991FZ35100081
J	RAYMOND, JR				RAYMOND, JR			PROTEIN-KINASE-C INDUCES PHOSPHORYLATION AND DESENSITIZATION OF THE HUMAN 5-HT1A RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC CHOLINERGIC RECEPTORS; NUCLEOTIDE REGULATORY PROTEINS; SMOOTH-MUSCLE CELLS; ADENYLATE-CYCLASE; PHORBOL ESTER; HELA-CELLS; AGONIST; BINDING; ERYTHROCYTES	The effects of short-term phorbol ester treatment of CHO cells that stably express 900 fmol of recombinant human serotonin 5-HT1A receptor/mg of protein on coupling to the inhibition of adenylyl cyclase and on phosphorylation of the receptor were studied. Pretreatment of cell monolayers with phorbol 12-myristate 13-acetate (PMA) caused a dose- and time-dependent shift of the half-maximal dose of serotonin (5-HT) required to inhibit membrane adenylyl cyclase (from IC50 almost-equal-to 100 nM to almost-equal-to 400 nM). This desensitization (shift in IC50) was rapid, occurring with 5 min of pretreatment and being maximal by 10-15 min; it was also dose-dependent, being half-maximal at almost-equal-to 300 nM PMA. Desensitization was also induced by sn-dioctanoylglycerol (DiC8) and blocked by the protein kinase C (PKC) inhibitors sphingosine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7). In detached permeabilized cells, PMA pretreatment caused a rapid phosphorylation of immunoprecipitated 5-HT1A receptors, with an almost-equal-to 3-4-fold increase that was maximal after 15 min and persisted for 90 min. The phosphorylation occurred at a similar dose of PMA as that which induced desensitization (half-maximal at almost-equal-to 300 nM, maximal at 500 nM to 1-mu-M), could be reproduced by pretreatment with the PKC activators DiC8 or phorbol 12,13-dibutyrate (PDBu), and could be blocked by the PKC inhibitors sphingosine or H-7. The stoichiometry of the phosphorylation was almost-equal-to 2 mol of [P-32]ATP/mol of receptor, suggesting the involvement at least two of three putative PKC sites within the 5-HT1A receptor. The close concordance between the PKC-induced desensitization and phosphorylation suggests a potential causative link between these two effects of PKC on the human 5-HT1A receptor.	DEPT VET AFFAIRS MED CTR,MED NEPHROL SERV,DURHAM,NC 27705		RAYMOND, JR (corresponding author), DUKE UNIV,MED CTR,DEPT MED NEPHROL,BOX 3459,DURHAM,NC 27710, USA.							ANDRADE R, 1987, J PHYSIOL-LONDON, V394, P99, DOI 10.1113/jphysiol.1987.sp016862; AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P53, DOI 10.1016/0019-2791(69)90178-5; BLIER P, 1990, J CARDIOVASC PHARM, V15, pS42, DOI 10.1097/00005344-199000157-00006; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; ELMESTIKAWY S, 1988, J NEUROCHEM, V51, P1031; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1989, J BIOL CHEM, V264, P14848; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MERRIFIELD RB, 1965, SCIENCE, V150, P175; MIDDLETON JP, 1990, J CLIN INVEST, V86, P1799, DOI 10.1172/JCI114909; PAUWELS PJ, 1990, LIFE SCI, V47, P2009, DOI 10.1016/0024-3205(90)90435-T; RAYMOND JR, 1989, MOL PHARMACOL, V36, P15; RAYMOND JR, 1991, J BIOL CHEM, V266, P372; RAYMOND JR, 1989, J BIOL CHEM, V264, P21943; RAYMOND JR, 1991, IN PRESS MOL BIOL RE; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIBLEY DR, 1984, BIOCHEM BIOPH RES CO, V121, P973, DOI 10.1016/0006-291X(84)90772-1	35	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14747	14753						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860872				2022-12-25	WOS:A1991FZ35100098
J	VLESSIS, AA; MULLER, P; BARTOS, D; TRUNKEY, D				VLESSIS, AA; MULLER, P; BARTOS, D; TRUNKEY, D			MECHANISM OF PEROXIDE-INDUCED CELLULAR INJURY IN CULTURED ADULT CARDIAC MYOCYTES	FASEB JOURNAL			English	Note						PEROXIDE METABOLISM; CARDIOMYOCYTES; REPERFUSION INJURY; PYRUVATE DEHYDROGENASE; CELLULAR METABOLISM	MYOCARDIAL INFARCT SIZE; REPERFUSION INJURY; FREE-RADICALS; GLUTATHIONE PEROXIDASE; LIPID-PEROXIDATION; POTENTIAL ROLE; BLOOD-FLOW; RAT-HEART; ISCHEMIA; METABOLISM	Reactive oxygen species contribute to the tissue injury seen after reperfusion of ischemic myocardium. We propose that toxicity originates from the effect that mitochondrial peroxide metabolism has on substrate entry into oxidative pathways. To support our contention, cultured adult rat cardiomyocytes were incubated with physiological concentrations of peroxide. The cellular extract and incubation medium were analyzed for adenine nucleotides and purines by reverse-phase high-pressure liquid chromatography. Cellular glutathione efflux was determined by enzymatic analysis of the incubation medium. Pyruvate dehydrogenase (PDH) activity was determined in the cultured myocytes as well as in freshly isolated cardiac mitochondria using [1-C-14]pyruvate. Extracellular glutathione rose 3.3-fold in response to small doses of peroxide (almost-equal-to 108 nmol/mg protein). Likewise, small quantities of peroxide reduced total cellular adenine nucleotides to 50-60% of control values with only a modest (0.95-0.91) reduction in energy charge ((ATP + 1/2 ADP)/(ATP + ADP + AMP)). Peroxide-treated myocytes selectively release inosine and adenosine, as only these two purine degradation products were detected in the incubation medium. The most dramatic response was a peroxide dose-dependent inhibition of PDH activity in cultured myocytes as well as freshly isolated mitochondria; just 65 and 30 nmol peroxide/mg protein induced a 50% reduction in cellular and mitochondrial PDH activity, respectively. In conclusion, physiological quantities of peroxide potently inhibit PDH in cultured cardiomyocytes and isolated cardiac mitochondria. PDH inhibition blocks the aerobic oxidation of glucose and inhibits the oxidative phosphorylation of ADP, which in turn leads to cellular adenine nucleotide degradation.	OREGON HLTH SCI UNIV,DEPT SURG BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								ACHTERBERG PW, 1988, AM J PHYSIOL, V254, pH1091, DOI 10.1152/ajpheart.1988.254.6.H1091; ARNOLD PE, 1986, AM J PHYSIOL, V250, pF357, DOI 10.1152/ajprenal.1986.250.2.F357; BANDO K, 1989, J SURG RES, V46, P152, DOI 10.1016/0022-4804(89)90219-9; BERNE RM, 1980, CIRC RES, V47, P807, DOI 10.1161/01.RES.47.6.807; BRASCH H, 1989, J MOL CELL CARDIOL, V21, P697, DOI 10.1016/0022-2828(89)90611-1; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; BULKLEY BH, 1977, CIRCULATION, V56, P906, DOI 10.1161/01.CIR.56.6.906; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; CHATHAM JC, 1989, EUR J BIOCHEM, V184, P657, DOI 10.1111/j.1432-1033.1989.tb15063.x; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; FERRARI R, 1990, J THORAC CARDIOV SUR, V99, P919; GAMELIN LM, 1988, AM J PHYSIOL, V255, pF450, DOI 10.1152/ajprenal.1988.255.3.F450; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; ISHIKAWA T, 1984, J BIOL CHEM, V259, P3838; JENNINGS RB, 1969, LAB INVEST, V20, P548; JENNINGS RB, 1986, J MOL CELL CARDIOL, V18, P769, DOI 10.1016/S0022-2828(86)80952-X; JONES DP, 1983, FUNCTIONS GLUTATHION, P109; KLONER RA, 1974, AM J PATHOL, V74, P399; KOYAMA I, 1985, TRANSPLANTATION, V40, P590, DOI 10.1097/00007890-198512000-00003; LITT MR, 1989, CIRCULATION, V80, P1816, DOI 10.1161/01.CIR.80.6.1816; LITTLE C, 1970, J BIOL CHEM, V245, P3632; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCCHESI BR, 1990, ANNU REV PHYSIOL, V52, P561, DOI 10.1146/annurev.ph.52.030190.003021; McCord J M, 1985, Adv Myocardiol, V5, P183; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1978, ANN INTERN MED, V89, P122, DOI 10.7326/0003-4819-89-1-122; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MENASCHE P, 1989, ANN THORAC SURG, V47, P939, DOI 10.1016/0003-4975(89)90047-7; NAG AC, 1981, TISSUE CELL, V13, P515, DOI 10.1016/0040-8166(81)90023-9; Novelli G P, 1988, Prog Clin Biol Res, V264, P397; OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4; PRZYKLENK K, 1989, CIRC RES, V64, P86, DOI 10.1161/01.RES.64.1.86; REED DJ, 1986, BIOCHEM PHARMACOL, V35, P7, DOI 10.1016/0006-2952(86)90545-9; RENSTROM B, 1990, CIRC RES, V66, P282, DOI 10.1161/01.RES.66.2.282; SIES H, 1978, EUR J BIOCHEM, V84, P377, DOI 10.1111/j.1432-1033.1978.tb12178.x; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SINGH A, 1989, CIRCULATION, V80, P1795, DOI 10.1161/01.CIR.80.6.1795; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; VLADIMIROV YA, 1980, ADV LIPID RES, V17, P173; VLESSIS AA, 1989, PEDIATR RES, V26, P220, DOI 10.1203/00006450-198909000-00013; VLESSIS AA, 1989, AM J PHYSIOL, V256, pC1196, DOI 10.1152/ajpcell.1989.256.6.C1196; VLESSIS AA, 1990, J BIOL CHEM, V265, P1448; VLESSIS AA, 1990, J NEUROCHEM, V54, P1412, DOI 10.1111/j.1471-4159.1990.tb01977.x; VLESSIS AA, 1990, BIOCHEM BIOPH RES CO, V170, P1281, DOI 10.1016/0006-291X(90)90532-R; WIELAND OH, 1982, REV PHYSIOL BIOCH P, V96, P123, DOI 10.1007/BFb0031008; WOOD JM, 1979, CIRC RES, V44, P52, DOI 10.1161/01.RES.44.1.52; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	47	63	63	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2600	2605		10.1096/fasebj.5.11.1868984	http://dx.doi.org/10.1096/fasebj.5.11.1868984			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868984				2022-12-25	WOS:A1991GB09400015
J	DENZIN, LK; WHITLOW, M; VOSS, EW				DENZIN, LK; WHITLOW, M; VOSS, EW			SINGLE-CHAIN SITE-SPECIFIC MUTATIONS OF FLUORESCEIN-AMINO ACID CONTACT RESIDUES IN HIGH-AFFINITY MONOCLONAL-ANTIBODY 4-4-20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; IDIOTYPE FAMILY; IGG ANTIBODIES; BINDING; DNA; PROTEIN; EXPRESSION; REPERTOIRE; DIVERSITY	Previous crystallographic studies of high affinity anti-fluorescein monoclonal antibody 4-4-20 (K-(a) = 1.7 x 10(10) M-1) complexed with fluorescyl ligand resolved active site contact residues involved in binding. For better definition of the relative roles of three light chain antigen contact residues (L27d(his), L32tyr and L34arg), four site-specific mutations (L27d(his) to L27d(lys), L32tyr to L32phe, and L34arg to L34lys and L34his) were generated and expressed in single-chain antigen binding derivatives of monoclonal antibody 4-4-20 containing two different polypeptide linkers (SCA 4-4-20/205c, 25 amino acids and SCA 4-4-20/212, 14 amino acids). Results showed that L27d(his) and L32tyr were necessary for wild type binding affinities, however, were not required for near-wild type Q(max) values (where Q(max) is the maximum fluorescein fluorescence quenching expressed as percent). Tyrosine L32 which hydrogen bonds with ligand was also characterized at the haptenic level through the use of 9-hydroxyphenylfluoron which lacks the carboxyl group to which L32 tyrosine forms a hydrogen bond. Results demonstrated that wild type SCA and mutant L32phe possessed similar HPF binding characteristics. Active site contact residue L34arg was important for fluorescein quenching maxima and binding affinity (L34his mutant), however, substitution of lysine for arginine at L34 did not have a significant effect on observed Q(max) value. In addition, substitutions had no effect on structural and topological characteristics, since all mutants retained similar idiotypic and metatypic properties. Finally, two linkers were comparatively examined to determine relative contributions to mutant binding properties and stability. No linker effects were observed. Collectively, these results verified the importance of these light chain fluorescein contact residues in the binding pocket of monoclonal antibody 4-4-20.	UNIV ILLINOIS,DEPT MICROBIOL,131 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801; GENEX CORP,GAITHERSBURG,MD 20877	University of Illinois System; University of Illinois Urbana-Champaign								AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BATRA JK, 1990, J BIOL CHEM, V265, P15198; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEDZYK WD, 1989, J BIOL CHEM, V264, P1565; BEDZYK WD, 1991, MOL IMMUNOL, V28, P27, DOI 10.1016/0161-5890(91)90083-V; BEDZYK WD, 1986, MOL IMMUNOL, V23, P1319, DOI 10.1016/0161-5890(86)90017-9; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CLEVINGER B, 1980, J EXP MED, V151, P1059, DOI 10.1084/jem.151.5.1059; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; FIELD H, 1990, PROTEIN ENG, V3, P641, DOI 10.1093/protein/3.7.641; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KRANZ DM, 1983, MOL IMMUNOL, V20, P1313, DOI 10.1016/0161-5890(83)90162-1; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN MM, 1975, J LUMIN, V10, P381, DOI 10.1016/0022-2313(75)90003-4; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; NISHINARITA S, 1985, J IMMUNOL, V134, P436; PERLMUTTER RM, 1984, BIOL IDIOTYPES, P59; POLJAK RJ, 1984, BIOL IDIOTYPES, P131; REINITZ DM, 1984, MOL IMMUNOL, V21, P775, DOI 10.1016/0161-5890(84)90164-0; REINITZ DM, 1985, J IMMUNOL, V135, P3365; RUDIKOFF S, 1983, J EXP MED, V158, P1385, DOI 10.1084/jem.158.5.1385; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SCHILLING J, 1980, NATURE, V283, P35, DOI 10.1038/283035a0; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SMITH RA, 1983, APPL ENVIRON MICROB, V45, P586, DOI 10.1128/AEM.45.2.586-590.1983; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; TEMPLETON EFG, 1985, MOL IMMUNOL, V22, P45, DOI 10.1016/0161-5890(85)90033-1; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VOSS EW, 1988, MOL IMMUNOL, V26, P971; VOSS EW, 1990, COMMENTS MOL CELL BI, V6, P197; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; WATT RM, 1978, IMMUNOCHEMISTRY, V15, P875, DOI 10.1016/0161-5890(78)90121-9; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513	46	57	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14095	14103						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856233				2022-12-25	WOS:A1991FY02700098
J	GRECO, NJ; YAMAMOTO, N; JACKSON, BW; TANDON, NN; MOOS, M; JAMIESON, GA				GRECO, NJ; YAMAMOTO, N; JACKSON, BW; TANDON, NN; MOOS, M; JAMIESON, GA			IDENTIFICATION OF A NUCLEOTIDE-BINDING SITE ON GLYCOPROTEIN-IIB - RELATIONSHIP TO ADP-INDUCED PLATELET ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD-PLATELETS; INHIBITS ADENYLATE-CYCLASE; ULTRAVIOLET-LIGHT; 5'-PARA-FLUOROSULFONYLBENZOYL ADENOSINE; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; RECEPTOR PROTEIN; PLASMA-MEMBRANE; IIIA COMPLEX; SHAPE CHANGE	Formalin-fixed platelets have been used to study the binding of adenine nucleotides in order to avoid the complications of nucleotide metabolism and to achieve steady-state binding. S(p)-adenosine-5'-(1-thiotriphosphate) (S(p)-ATP-alpha-S) binds to platelets at two sites (K(d1) 3 nm; 31,000 sites/platelet; K(d2) 200 nm; 300,000 sites/ platelet) as compared with values for ADP under these conditions (K(d1) 30 nm; 25,000 sites/platelet and K(d2) 3-mu-m; 400,000 sites/platelet) (bound/total approximately 0.1). Competition binding experiments showed that both of the ATP-alpha-S sites were accessible to ADP and vice versa. [S-35]ATP-alpha-S was photoaffinity cross-linked to unfixed platelets by direct irradiation with ultraviolet light. A single radiolabeled component (120 kDa) was identified and shown to be identical with the alpha subunit of GPIIb based on two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by Western blotting with anti-GPIIb monoclonal antibodies, by isoelectric focusing (pI 4.5-5.5), by immunoaffinity adsorption using monoclonal anti-GPIIb/ IIIa antibodies coupled to Sepharose, and by crossed immunoelectrophoresis. Amino-terminal sequencing of a tryptic fragment labeled with [S-35]ATP-alpha-S identified an 18-kDa domain beginning at Tyr-198 in the primary sequence of GPIIb-alpha. These studies demonstrate the presence of an adenine nucleotide-binding site on GPIIb-alpha.	US FDA,CTR BIOL EVALUAT & RES,DIV BIOCHEM,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DIV BIOPHYS,BETHESDA,MD 20892	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	GRECO, NJ (corresponding author), AMER RED CROSS,CELL BIOL LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.		Moos, Malcolm C/F-3673-2011	Moos, Malcolm C/0000-0002-9575-9938	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039438] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39438] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRAWAL AK, 1989, THROMB HAEMOSTASIS, V62, P1103; ANTONOFF RS, 1974, J BIOL CHEM, V249, P3319; BARBER AJ, 1970, J BIOL CHEM, V245, P6357; BENNETT JS, 1978, J BIOL CHEM, V253, P7346; BENNETT JS, 1982, BLOOD S, V60, pA194; BISWAS SB, 1987, J BIOL CHEM, V262, P7831; BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BLAUSTEIN MP, 1983, P NATL ACAD SCI-BIOL, V80, P3855, DOI 10.1073/pnas.80.12.3855; BRASS LF, 1985, J BIOL CHEM, V260, P2231; Bylund D.B., 1990, METHODS NEUROTRANSMI, P1; CHOWDHRY V, 1979, ANNU REV BIOCHEM, V48, P293, DOI 10.1146/annurev.bi.48.070179.001453; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; COLMAN RW, 1988, PLATELET MEMBRANE RE, P263; CUSACK NJ, 1982, BRIT J PHARMACOL, V77, P329, DOI 10.1111/j.1476-5381.1982.tb09302.x; CUSACK NJ, 1982, BRIT J PHARMACOL, V76, P221, DOI 10.1111/j.1476-5381.1982.tb09210.x; DAVIS CB, 1990, J BIOL CHEM, V265, P1300; DICKSON RC, 1971, SCIENCE, V172, P1140, DOI 10.1126/science.172.3988.1140; DOERY JCG, 1973, BLOOD, V42, P551, DOI 10.1182/blood.V42.4.551.551; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ERIKSSON S, 1982, P NATL ACAD SCI-BIOL, V79, P81, DOI 10.1073/pnas.79.1.81; FIGURES WR, 1987, BLOOD, V70, P796; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GRECO NJ, 1990, BLOOD, V75, P1983; GULINO D, 1990, J BIOL CHEM, V265, P9575; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARMON JT, 1991, IN PRESS METHODS ENZ; Haslam R. J., 1981, PURINERGIC RECEPTORS, P223; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; JEFFERSON JR, 1987, J MED CHEM, V30, P2013, DOI 10.1021/jm00394a015; JEFFERSON JR, 1988, BLOOD, V71, P110; KUNICKI TJ, 1981, BLOOD, V58, P268; MACFARLANE DE, 1982, BIOCHEMISTRY-US, V21, P544, DOI 10.1021/bi00532a020; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; MCGOWAN EB, 1986, J BIOL CHEM, V261, P739; MILLS DCB, 1985, J BIOL CHEM, V260, P8078; MILLS DCB, 1977, THROMB HAEMOSTASIS, V38, P82; MODAK MJ, 1982, J BIOL CHEM, V257, P5105; MOHLER H, 1980, P NATL ACAD SCI-BIOL, V77, P1666, DOI 10.1073/pnas.77.3.1666; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBRIG TG, 1975, BIOCHEM BIOPH RES CO, V66, P437, DOI 10.1016/S0006-291X(75)80347-0; OSWALD R, 1981, P NATL ACAD SCI-BIOL, V78, P3925, DOI 10.1073/pnas.78.6.3925; PEERSCHKE EI, 1981, BLOOD, V57, P663; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; PLOW EF, 1985, BLOOD, V66, P724; PONCZ M, 1987, J BIOL CHEM, V262, P8476; POWLING MJ, 1985, BLOOD, V66, P731; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; YAMAMOTO N, 1990, THROMB HAEMOSTASIS, V63, P97; YAMAMOTO N, 1989, BLOOD, V73, P1552	57	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13627	13633						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856198				2022-12-25	WOS:A1991FY02700030
J	HERMANS, MMP; KROOS, MA; VANBEEUMEN, J; OOSTRA, BA; REUSER, AJJ				HERMANS, MMP; KROOS, MA; VANBEEUMEN, J; OOSTRA, BA; REUSER, AJJ			HUMAN LYSOSOMAL ALPHA-GLUCOSIDASE - CHARACTERIZATION OF THE CATALYTIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE COMPLEX; GLYCOGENOSIS TYPE-II; AMINO-ACID-SEQUENCE; CONDURITOL-B-EPOXIDE; ACTIVE-SITE; BETA-GLUCOSIDASE; ESSENTIAL CARBOXYLATE; PROTEINS; PHOSPHORYLATION; BIOSYNTHESIS	The substrate analogue conduritol B epoxide (CBE) is demonstrated to be an active site-directed inhibitor of human lysosomal alpha-glucosidase. A competitive mode of inhibition is obtained with glycogen as natural and 4-methylumbelliferyl-alpha-D-glucopyranoside as artificial substrate. The inactivation of the enzyme is time and concentration dependent and results in the covalent binding of CBE. Catalytic activity is required for binding to occur. CBE-labeled peptides containing the catalytic residue of lysosomal alpha-glucosidase were isolated and identified by microsequencing and amino acid analysis. The peptides appeared to originate from a protein domain which is highly conserved among alpha-amylases, maltase, glucoamylases, and transglucanosylases. Based on the sequence similarity and the mechanism of CBE binding, Asp-518 is predicted to be the essential carboxylate in the active site of lysosomal alpha-glucosidase. The functional importance of Asp-518 and other residues around the catalytic site was studied by expression of in vitro mutagenized alpha-glucosidase cDNA in transiently transfected COS cells. Substitution of Asp-513 by Glu-513 is shown to interfere with the posttranslational modification and the intracellular transport of the alpha-glucosidase precursor. The residues Trp-516 and Asp-518 are demonstrated to be critical for catalytic function.	ERASMUS UNIV,DEPT CELL BIOL & GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS; STATE UNIV GHENT,MICROBIOL LAB,B-9000 GHENT,BELGIUM	Erasmus University Rotterdam; Ghent University								BAUSE E, 1980, BIOCHIM BIOPHYS ACTA, V626, P459, DOI 10.1016/0005-2795(80)90142-7; BRAUN H, 1977, BIOCHIM BIOPHYS ACTA, V483, P135, DOI 10.1016/0005-2744(77)90015-8; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; ELFERINK RPJO, 1985, EUR J BIOCHEM, V153, P55, DOI 10.1111/j.1432-1033.1985.tb09266.x; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRABOWSKI GA, 1984, ARCH BIOCHEM BIOPHYS, V231, P144, DOI 10.1016/0003-9861(84)90371-0; GRABOWSKI GA, 1986, J BIOL CHEM, V261, P8263; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HASILIK A, 1980, J BIOL CHEM, V255, P4946; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HERS HG, 1963, BIOCHEM J, V86, P11, DOI 10.1042/bj0860011; HOEFSLOOT LH, 1990, BIOCHEM J, V272, P493, DOI 10.1042/bj2720493; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HOEFSLOOT LH, 1990, BIOCHEM J, V272, P485, DOI 10.1042/bj2720485; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; JEFFREY PL, 1970, BIOCHEMISTRY-US, V9, P1403, DOI 10.1021/bi00808a015; JEFFREY PL, 1970, BIOCHEMISTRY-US, V9, P1416, DOI 10.1021/bi00808a016; KOSTER JF, 1972, EUR J CLIN INVEST, V2, P467, DOI 10.1111/j.1365-2362.1972.tb00678.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGLER G, 1978, BIOCHIM BIOPHYS ACTA, V524, P102, DOI 10.1016/0005-2744(78)90108-0; LEGLER G, 1973, MOL CELL BIOCHEM, V2, P31, DOI 10.1007/BF01738676; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ONODERA S, 1989, J BIOCHEM, V105, P611, DOI 10.1093/oxfordjournals.jbchem.a122713; QUARONI A, 1974, J BIOL CHEM, V249, P6424; QUARONI A, 1976, J BIOL CHEM, V251, P3250; REUSER AJJ, 1978, AM J HUM GENET, V30, P132; REUSER AJJ, 1985, J BIOL CHEM, V260, P8336; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERHORST GTJ, 1987, BIOCHIM BIOPHYS ACTA, V910, P123, DOI 10.1016/0167-4781(87)90064-9; WALLACE RB, 1981, NUCLEIC ACIDS RES, V9, P879, DOI 10.1093/nar/9.4.879; Wilkinson J., 1986, PRACTICAL PROTEIN CH, P121	36	141	145	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13507	13512						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856189				2022-12-25	WOS:A1991FY02700011
J	LEBONNIEC, BF; MACGILLIVRAY, RTA; ESMON, CT				LEBONNIEC, BF; MACGILLIVRAY, RTA; ESMON, CT			THROMBIN GLU-39 RESTRICTS THE P'3 SPECIFICITY TO NONACIDIC RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; FIBRINOGEN-LIKE PEPTIDES; HUMAN FACTOR-IX; PROTEIN-C; PLASMINOGEN-ACTIVATOR; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; SERINE PROTEASES; CLEAVAGE SITE; EXPRESSION	Residue 39 of serine proteases neighbors positions P'2 to P'4 of the substrate. When Glu-39 of thrombin is replaced with Lys, the resultant enzyme (E39K) retains similar P1, P2, and P3 specificities but has altered P'3 and/or P'4 specificities. These conclusions are based on analysis of both p-nitroanilide and synthetic peptide hydrolysis. The activity of E39K is nearly normal toward 17 p-nitroanilide substrates. In peptide substrates, an acidic residue at either the P3 or P'3 position reduces the rate of cleavage by thrombin. A single substitution of Asp with Gly in either the P3 or P'3 position of a peptide corresponding to the P7-P'5 residues of protein C increases the rate of cleavage by thrombin 2-3-fold. Replacement of both Asp residues with Gly increases the rate of cleavage 30-fold. With E39K, the inhibitory effect of Asp in P3 remains unchanged, but Asp in the P'3 site is no longer inhibitory. Significant differences in the catalytic activity of E39K are also seen with respect to protein C activation. In the absence of thrombomodulin, E39K activates protein C 2.2 times faster than thrombin. In the presence of thrombomodulin, the rate of protein C activation is similar for E39K and thrombin. The second order rate constant of inhibition by antithrombin III, where P'4 is a Glu, is slightly increased (1.4-fold). The clotting activity is reduced 2.4-fold due to a lower rate of fibrinopeptides A and B release where P'3 is Arg. These data show that the P'3 position is a determinant of thrombin specificity and suggest that thrombomodulin may function in part by alleviating the inhibitory effects that may arise from the proximity of the Asp in P'3 of protein C with Glu-39 of thrombin.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1W5, BC, CANADA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM, OKLAHOMA CITY, OK 73104 USA; HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA	University of British Columbia; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute			Le Bonniec, Bernard/ABA-1366-2020; Le Bonniec, Bernard/S-5756-2016	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363	NHLBI NIH HHS [R01-HL29807, R37-HL30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSON DS, 1985, NATURE, V315, P683, DOI 10.1038/315683a0; BERGER SL, 1987, GUIDE MOL CLONIONG T, V152; BERTINA RM, 1990, J BIOL CHEM, V265, P10876; BEZEAUD A, 1988, J BIOL CHEM, V263, P3576; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; BUSBY S, 1985, NATURE, V316, P271, DOI 10.1038/316271a0; CHANG JY, 1986, BIOCHEM J, V240, P797, DOI 10.1042/bj2400797; CHANG JY, 1985, EUR J BIOCHEM, V151, P225, DOI 10.1111/j.1432-1033.1985.tb09092.x; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CHASE T, 1970, METHOD ENZYMOL, V19, P21; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DANGELO A, 1988, J CLIN INVEST, V81, P1445, DOI 10.1172/JCI113475; DELASALLE H, 1985, NATURE, V316, P268, DOI 10.1038/316268a0; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P1654, DOI 10.1021/bi00458a043; FURIE B, 1982, J BIOL CHEM, V257, P3875; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; Hartley BS, 1971, ENZYMES, V3, P323; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; IRWIN DM, 1986, THESIS U BRIT COLUMB; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUNDBLAD RL, 1988, J BIOL CHEM, V263, P3729; MACGILLIVRAY RTA, 1986, ANN NY ACAD SCI, V485, P73, DOI 10.1111/j.1749-6632.1986.tb34569.x; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; Maniatis T., 1982, MOL CLONING; MARSH HC, 1982, BIOCHEMISTRY-US, V21, P6167, DOI 10.1021/bi00267a022; MARSH HC, 1983, BIOCHEMISTRY-US, V22, P4170, DOI 10.1021/bi00287a002; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; NOE G, 1988, J BIOL CHEM, V263, P11729; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; OWEN WG, 1974, J BIOL CHEM, V249, P594; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALZ DA, 1986, BIOREGULATORY FUNCTI, V485; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	59	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13796	13803						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856211				2022-12-25	WOS:A1991FY02700055
J	PUGSLEY, AP; KORNACKER, MG				PUGSLEY, AP; KORNACKER, MG			SECRETION OF THE CELL-SURFACE LIPOPROTEIN PULLULANASE IN ESCHERICHIA-COLI - COOPERATION OR COMPETITION BETWEEN THE SPECIFIC SECRETION PATHWAY AND THE LIPOPROTEIN SORTING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; OUTER-MEMBRANE; BETA-LACTAMASE; PROTEIN EXPORT; GENES; LOCALIZATION; EXPRESSION; UNF5023; ENZYME; OPERON	The fatty acid-acylated enzyme pullulanase is normally found in either of two locations in Escherichia coli, depending on whether or not the producing strains also express the genes specifically required for the second step in pullulanase secretion. When they are expressed, the enzyme is localized to the cell surface, while in their absence, it is directed to an unidentified location in the cell envelope which, upon lysis, forms vesicles whose density is intermediate between those of outer and cytoplasmic membrane vesicles. In order to test the role of the putative lipoprotein sorting signal, Asp2, in pullulanase sorting and secretion, the structural gene (pulA) was subjected to site-directed mutagenesis. Replacement of the Asp2 residue by Asn, Glu, or Ser caused the enzyme to fractionate with outer membrane-derived vesicles rather than with intermediate density vesicles from E. coli cells devoid of pullulanase secretion genes. A pronounced secretion defect was observed in a two-step secretion assay in which the first (sec gene-dependent) and second (pul gene-dependent) secretion steps were uncoupled. We propose that the Asp residue increases the efficiency of pullulanase secretion by allowing the enzyme to be initially sorted to a region of the cell envelope wherein most of the pullulase-specific secretion factors are located.			PUGSLEY, AP (corresponding author), INST PASTEUR,CNRS,UA 1149,UNITE GENET MOLEC,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; DENFERT C, 1989, J BIOL CHEM, V264, P17462; DENFERT C, 1987, MOL MICROBIOL, V1, P107, DOI 10.1111/j.1365-2958.1987.tb00534.x; DENFERT C, 1987, EMBO J, V6, P3531, DOI 10.1002/j.1460-2075.1987.tb02679.x; FUTAI M, 1974, J MEMBRANE BIOL, V15, P15, DOI 10.1007/BF01870079; KORNACKER MG, 1990, MOL MICROBIOL, V4, P73, DOI 10.1111/j.1365-2958.1990.tb02016.x; KORNACKER MG, 1990, MOL MICROBIOL, V4, P1101, DOI 10.1111/j.1365-2958.1990.tb00684.x; MICHAELIS S, 1985, J BACTERIOL, V164, P633, DOI 10.1128/JB.164.2.633-638.1985; Miller J.H., 1972, EXPT MOL GENETICS; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Perbal B., 1988, PRACTICAL GUIDE MOL; PUGSLEY AP, 1991, MOL MICROBIOL, V5, P865, DOI 10.1111/j.1365-2958.1991.tb00760.x; PUGSLEY AP, 1990, ANNU REV GENET, V24, P67; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P365, DOI 10.1111/j.1365-2958.1990.tb00604.x; PUGSLEY AP, 1986, J BACTERIOL, V166, P1083, DOI 10.1128/jb.166.3.1083-1088.1986; PUGSLEY AP, 1991, MOL MICROBIOL, V5, P343, DOI 10.1111/j.1365-2958.1991.tb02115.x; PUGSLEY AP, 1987, PLASMIDS PRACTICAL A, P106; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P52; REYSS I, 1990, MOL GEN GENET, V222, P176, DOI 10.1007/BF00633815; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; WATANABE T, 1988, J BACTERIOL, V170, P4001, DOI 10.1128/jb.170.9.4001-4007.1988; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; [No title captured]	23	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13640	13645						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856199				2022-12-25	WOS:A1991FY02700032
J	TESTA, U; KUHN, L; PETRINI, M; QUARANTA, MT; PELOSI, E; PESCHLE, C				TESTA, U; KUHN, L; PETRINI, M; QUARANTA, MT; PELOSI, E; PESCHLE, C			DIFFERENTIAL REGULATION OF IRON REGULATORY ELEMENT-BINDING PROTEIN(S) IN CELL-EXTRACTS OF ACTIVATED LYMPHOCYTES VERSUS MONOCYTES-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR GENE; 3' UNTRANSLATED REGION; HUMAN APOFERRITIN-H; RESPONSIVE ELEMENTS; AFFINITY PURIFICATION; CYTOSOLIC PROTEIN; TRANSLATION; EXPRESSION; LINES	The intracellular iron level exerts a negative feedback on transferrin receptor (TfR) expression in cells requiring iron for their proliferation, in contrast to the positive feedback observed in monocytes-macrophages. It has been suggested recently that modulation of TfR and ferritin synthesis by iron is mediated through a cytoplasmic protein(s) (iron regulatory element-binding protein(s) (IRE-BP)), which interacts with ferritin and TfR mRNA at the level of hairpin structures (IRE), thus leading to inhibition of transferrin mRNA degradation and repression of ferritin mRNA translation. In the present study we have evaluated in parallel the level of TfR expression, ferritin, and IRE-BP in cultures of: (i) circulating human lymphocytes stimulated to proliferate by phytohemagglutinin (PHA) and (ii) circulating human monocytes maturing in vitro to macrophages. The cells were grown in either standard or iron-supplemented culture. TfR and ferritin expression was evaluated at both the protein and mRNA level. IRE-BP activity was measured by gel retardation assay in the absence or presence of beta-mercaptoethanol (spontaneous or total IRE-BP activity, respectively). Spontaneous IRE-BP activity, already present at low level in quiescent T lymphocytes, shows a gradual and marked increase in PHA-stimulated T cells from day 1 of culture onward. This increase is directly and strictly correlated with the initiation and gradual rise of TfR expression, which is in turn associated with a decrease of ferritin content. Both the rise of TfR and spontaneous IRE-BP activity are completely inhibited in iron-supplemented T cell cultures. In contrast, the total IRE-BP level is similar in both quiescent and PHA-stimulated lymphocytes, grown in cultures supplemented or not with iron salts. Monocytes maturing in vitro to macrophages show a sharp increase of spontaneous and, to a lesser extent, total IRE-BP; the addition of iron moderately stimulates the spontaneous IRE-BP activity but not the total one. Here again, the rise of spontaneous IRE-BP from very low to high activity is strictly related to the parallel increase of TfR expression and, surprisingly, also with a very pronounced rise of ferritin expression observed at both the mRNA and protein level. It is noteworthy the effect of beta-mercaptoethanol is cell specific, i.e. the ratio of total versus spontaneous IRE-BP activity is different in activated lymphocytes and maturing monocytes. In conclusion, our studies provide evidence that the levels of spontaneous IRE-BP activity and TfR expression are directly correlated in both a cell proliferation model (PHA-stimulated T lymphocytes) and a cell differentiation model (monocytes maturing to macrophages). Furthermore, both parameters are either down- or up-modulated by iron in lymphocytes or monocytes-macrophages, respectively. The linkage between TfR expression and spontaneous IRE-BP activity strongly suggests that this binding protein plays a crucial role in the modulation of TfR expression.	SWISS INST EXPTL CANC RES,GENET UNIT,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research	TESTA, U (corresponding author), IST SUPER SANITA,DEPT HEMATOL ONCOL,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		Testa, Ugo/J-6472-2016; pelosi, elvira/J-7298-2016; Quaranta, Maria Teresa/AAC-2134-2019	Testa, Ugo/0000-0001-7900-8942; pelosi, elvira/0000-0002-3043-6249; Quaranta, Maria Teresa/0000-0002-5886-507X; petrini, marina/0000-0003-4891-3389				AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSTANZO F, 1984, EMBO J, V3, P23, DOI 10.1002/j.1460-2075.1984.tb01756.x; COSTANZO F, 1986, NUCLEIC ACIDS RES, V14, P721, DOI 10.1093/nar/14.2.721; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KUCERA R, 1983, J CELL PHYSIOL, V117, P158, DOI 10.1002/jcp.1041170205; KUHN LC, 1984, CELL, V37, P95, DOI 10.1016/0092-8674(84)90304-0; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LOUACHE F, 1984, J BIOL CHEM, V259, P1576; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PELOSI E, 1986, J BIOL CHEM, V261, P3036; PELOSITESTA E, 1986, CANCER RES, V46, P5330; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; TESTA U, 1989, J BIOL CHEM, V264, P13181; TESTA U, 1985, BRIT J HAEMATOL, V60, P491, DOI 10.1111/j.1365-2141.1985.tb07446.x; Testa U, 1985, Curr Top Hematol, V5, P127; TESTA U, 1982, EXP CELL RES, V140, P251, DOI 10.1016/0014-4827(82)90112-4; THEIL EC, 1990, J BIOL CHEM, V265, P4771; THEIL EC, 1987, ANN REV BIOCH, V56, P287; THELANDER L, 1983, J BIOL CHEM, V258, P4063; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TITEUX M, 1984, J CELL PHYSIOL, V121, P251, DOI 10.1002/jcp.1041210131; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WARD JH, 1982, BIOCHEM J, V28, P19	40	55	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13925	13930						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856222				2022-12-25	WOS:A1991FY02700074
J	BALENTIEN, E; MUFSON, BE; SHATTUCK, RL; DERYNCK, R; RICHMOND, A				BALENTIEN, E; MUFSON, BE; SHATTUCK, RL; DERYNCK, R; RICHMOND, A			EFFECTS OF MGSA GRO-ALPHA ON MELANOCYTE TRANSFORMATION	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; STIMULATORY ACTIVITY; CELL-LINES; MONOCLONAL-ANTIBODY; MURINE MELANOCYTES; MALIGNANT-MELANOMA; TUMOR PROGRESSION; AUTOCRINE GROWTH; TRANSGENIC MICE; FACTOR CDNA	In the work described here we demonstrate that the clonal cell line Mel-a-6, produced by transfection of mouse Melan-a cells with human MGSA, had an increased ability to form large colonies in soft agar and increased ability to form tumors when injected into nude mice as compared to cells transfected with the neomycin resistance gene alone. This effect appeared to be dependent on the levels of MGSA produced since another transfected clone, Mel-a-l, produced only a low level of MGSA transgene mRNA, formed only minimal large colonies in soft agar and had a tumorigenic rate equal to that of neomycin resistant controls. The histology of the Mel-a-6 tumors is compatible with features normally exhibited by melanoma tumors. The cells do not stain for melanin, and they are positive for the neural crest marker protein S-100 as well as the HMB 45 melanoma specific antigen. Immunohistochemical studies revealed expression of the human MGSA in tumor cells from tissues, excised from animals injected with cells from clone Mel-a-6. Whereas DNA ploidy analysis suggests that in vitro the Mel-a parent cell line, control Mel-a-neo, Mel-a-1 and Mel-a-6 cells show no evidence of aneuploidy, the nuclei isolated from the tumors from animals injected with Mel-a-6 do exhibit aneuploidy. These data suggest that over-expression of MGSA in immortalized melanocytes contributes to transformation.	VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37240; DEPT VET AFFAIRS,NASHVILLE,TN; GENENTECH INC,DEPT DEV BIOL,S SAN FRANCISCO,CA; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,DEPT MED,ATLANTA,GA 30322; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37240	Vanderbilt University; Roche Holding; Genentech; Emory University; Emory University; Vanderbilt University	RICHMOND, A (corresponding author), VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37240, USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X				ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; BAKER N, 1990, NUCLEIC ACIDS RES, V18, P21; BALENTIEN F, 1990, BIOCHEM, V29, P10225; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BORDONI R, 1990, J CELL BIOCHEM, V44, P207, DOI 10.1002/jcb.240440403; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; DERYNCK R, 1987, CANCER RES, V47, P707; DICKER P, 1981, EXP CELL RES, V135, P221, DOI 10.1016/0014-4827(81)90314-1; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ERISMAN MD, 1982, P NATL ACAD SCI-BIOL, V79, P2379, DOI 10.1073/pnas.79.7.2379; FINZI E, 1990, J INVEST DERMATOL, V95, P382, DOI 10.1111/1523-1747.ep12555464; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GATTUSO P, 1990, SURGERY, V108, P702; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIANGASPERO F, 1987, CANCER, V60, P59, DOI 10.1002/1097-0142(19870701)60:1<59::AID-CNCR2820600111>3.0.CO;2-4; GOWN AM, 1986, AM J PATHOL, V123, P195; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HERLYN M, 1987, LAB INVEST, V56, P461; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KHEIR S M, 1988, Annals of Surgery, V207, P455, DOI 10.1097/00000658-198804000-00014; LAWSON DH, 1987, J CELL BIOCHEM, V34, P169, DOI 10.1002/jcb.240340304; LINDGREN V, 1989, P NATL ACAD SCI USA, V86, P5025, DOI 10.1073/pnas.86.13.5025; MANIATIS T, 1987, MOL CLONING; Masson P, 1928, AM J PATHOL, V4, P181; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; NAKAJIMA T, 1982, CANCER, V50, P912, DOI 10.1002/1097-0142(19820901)50:5<912::AID-CNCR2820500519>3.0.CO;2-U; NAKANISHI Y, 1988, EXP CELL BIOL, V56, P74; ORDONEZ NG, 1988, AM J CLIN PATHOL, V90, P385, DOI 10.1093/ajcp/90.4.385; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RICHMOND A, 1985, CANCER RES, V45, P6390; RICHMOND A, 1982, COLD SPRING HARBOR C, V9, P885; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TODARO GJ, 1977, NATURE, V267, P526, DOI 10.1038/267526a0; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WILSON RE, 1989, CANCER RES, V49, P711	47	96	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1115	1124						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861861				2022-12-25	WOS:A1991GV26000004
J	FUTREAL, PA; BARRETT, JC				FUTREAL, PA; BARRETT, JC			FAILURE OF SENESCENT CELLS TO PHOSPHORYLATE THE RB PROTEIN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN-DIPLOID FIBROBLASTS; SYRIAN-HAMSTER TUMORS; CELLULAR SENESCENCE; PRODUCT; EXPRESSION; CYCLE; IDENTIFICATION; SUPPRESSION; CARCINOMA	The product of the RB susceptibility gene has been shown to be differentially phosphorylated during the cell cycle, suggesting a role in the regulation of cell cycle progression. We examined the expression and phosphorylation status of the RB protein in senescent Syrian hamster embryo cells. Both phosphorylated and unphosphorylated forms of the RB protein were observed in cells at early passages; however, only unphosphorylated RB protein was found in senescent cells. When nonsenescent cells at low population doubling levels were made quiescent by reducing the serum concentration of the media, the RB protein in these cells was mostly in the unphosphorylated protein in these cells was mostly in the unphosphorylated form. When stimulated with serum, phosphorylation of the RB protein occurred between 10-20 h after stimulation, which corresponded with the induction of DNA synthesis. Senescent cells, in contrast, did not show any phosphorylation of the RB protein in response to serum. In addition, cell lines that had escaped cellular senescence at various stages of neoplastic progression were examined; all 25 cell lines examined expressed RB protein, which was phosphorylated normally. These results suggest that the RB protein plays a role in cellular senescence with phosphorylation status determining this role. Factors controlling this phosphorylation are potential key factors in controlling cellular life span in culture.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill	FUTREAL, PA (corresponding author), NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709, USA.							BARRETT JC, 1987, MECHANISMS ENV CARCI, P73; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6464; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRISTOFALO VJ, 1985, TESTING THEORIES AGI, P201; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIORDANO T, 1989, EXP CELL RES, V185, P399, DOI 10.1016/0014-4827(89)90310-8; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1980, ANN REV GERONTOLOGY, V1, P26; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OSHIMURA M, 1988, CANCER RES, V48, P1623; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; Smith J R, 1990, Adv Cancer Res, V54, P63, DOI 10.1016/S0065-230X(08)60808-8; SMITH JR, 1989, GENOME, V31, P386, DOI 10.1139/g89-058; SMITH JR, 1989, EXP GERONTOL, V24, P377, DOI 10.1016/0531-5565(89)90045-4; STEIN GH, 1986, P NATL ACAD SCI USA, V83, P9030, DOI 10.1073/pnas.83.23.9030; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XU HJ, 1989, ONCOGENE, V4, P807; [No title captured]	45	74	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1109	1113						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861860				2022-12-25	WOS:A1991GV26000003
J	FAUSSNER, A; HEINZERIAN, P; KLIER, C; ROSCHER, AA				FAUSSNER, A; HEINZERIAN, P; KLIER, C; ROSCHER, AA			SOLUBILIZATION AND CHARACTERIZATION OF B2-BRADYKININ RECEPTORS FROM CULTURED HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRADYKININ RECEPTORS; BINDING-SITES; PROTEIN; INHIBITOR; KININS; ENZYME	Active B2 bradykinin (BK) receptors were solubilized in high yields from intact monolayers or particulate fractions of cultured human foreskin fibroblasts using 4 mM of the non-denaturing zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS). Other detergents showed only minor (digitonin) or no (Triton X-100, n-octyl glucopyranosid) efficacy at all. The stability of CHAPS-solubilized BK binding activity was temperature dependent being reduced to 30% of initial binding after 3 days of storage at 4-degrees-C. CHAPS extracts, however, retained BK binding activity for at least several days when they were stored at -20-degrees-C in the presence of 10% glycerol. The pharmacological characterization gave a rank order of potency for unlabeled BK, BK agonists, and antagonists to compete with [H-3]BK for specific binding very similar to that observed in intact fibroblasts. Association and dissociation kinetics demonstrated that the binding of [H-3]BK to the soluble CHAPS extracts was time dependent and reversible. Scatchard analysis of equilibrium binding data exhibited saturable binding of a single class of high affinity BK-binding sites with a K(d) of 1.68 +/- 0.8 nM. Gel filtration revealed an apparent molecular weight of 250,000 for the solubilized BK receptor complex in CHAPS extracts. The ability to solubilize the B2 BK receptor in an active and stable form should allow for its future purification and for the characterization of its chemical properties.	UNIV MUNICH, DR HAUNERSCHEN KINDERSPITAL, KINDERKLIN, KLIN BIOCHEM ABT, W-8000 MUNICH 2, GERMANY	University of Munich								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DENGLER R, 1990, FEBS LETT, V262, P111, DOI 10.1016/0014-5793(90)80166-G; ETSCHEID BG, 1989, J CELL PHYSIOL, V140, P264, DOI 10.1002/jcp.1041400211; FREDRICK MJ, 1987, EUR J PHARMACOL, V134, P45, DOI 10.1016/0014-2999(87)90129-4; FURUTOKATO S, 1985, J BIOL CHEM, V260, P2054; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; LORKOWSKI G, 1987, BIOCHEM J, V248, P345, DOI 10.1042/bj2480345; MANNING DC, 1986, J PHARMACOL EXP THER, V237, P504; ODYA CE, 1987, BIOCHEM PHARMACOL, V36, P39, DOI 10.1016/0006-2952(87)90380-7; ODYA CE, 1983, BIOCHEM PHARMACOL, V32, P3839, DOI 10.1016/0006-2952(83)90158-2; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; REGOLI D, 1980, PHARMACOL REV, V32, P1; ROBERTS RA, 1989, J CELL SCI, V94, P527; ROSCHER AA, 1984, J CLIN INVEST, V74, P552, DOI 10.1172/JCI111452; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; ROSCHER AA, 1990, J CARDIOVASC PHARM, V15, pS39, DOI 10.1097/00005344-199015061-00008; SNELL PH, 1990, BIOCHEM PHARMACOL, V39, P1921, DOI 10.1016/0006-2952(90)90610-W; STEWART JM, 1990, J CARDIOVASC PHARM, V15, pS69, DOI 10.1097/00005344-199000156-00013; ZEGGARI M, 1987, EUR J BIOCHEM, V164, P667, DOI 10.1111/j.1432-1033.1987.tb11178.x	22	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9442	9446						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851746				2022-12-25	WOS:A1991FM45900020
J	LANDERS, JP; WINHALL, MJ; MCCREADY, TL; SANDERS, DAR; RASPER, D; NAKAI, JS; BUNCE, NJ				LANDERS, JP; WINHALL, MJ; MCCREADY, TL; SANDERS, DAR; RASPER, D; NAKAI, JS; BUNCE, NJ			CHARACTERIZATION OF AN INDUCIBLE ARYL-HYDROCARBON RECEPTOR-LIKE PROTEIN IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC AH RECEPTOR; GENE-EXPRESSION; CYTOCHROME-P1-450 GENE; CYTOSOLIC RECEPTOR; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; INDUCTION; BINDING; MOUSE; DIOXIN; CELLS	The individual pretreatment of Sprague-Dawley rats with either 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 2,2',4,4',5,5'-hexachlorobiphenyl (HCB) has been previously shown to result in the "induction" of [H-3]TCDD specific binding activity in hepatic tissue. In the present work, the coadministration of TCDD and HCB increased the concentration of hepatic proteins capable of binding [H-3]TCDD specifically by at least 2-3-fold. This increase was shown not to be the result of activation, by HCB, of a form of the receptor having low affinity toward [H-3]TCDD into a form with high affinity. Kinetic analysis of the time course of binding of [H-3]TCDD to induced cytosol was consistent with the presence of an "inducible" binding protein in addition to the "constitutive" aryl hydrocarbon (Ah) receptor present in cytosol from untreated animals. The liganded ([H-3]TCDD) form of the inducible binding component lost its ligand much faster than the liganded form of the constitutive Ah receptor at 37-degrees-C; apparent first order rate constants for loss of [H-3]TCDD were 0.55 min-1 and < 0.0024 min-1, respectively. Conversely, the unliganded form of the induced binding component was slightly more stable (almost-equal-to 2-fold) toward thermal inactivation than the unbound constitutive Ah receptor. The [H-3]TCDD-bound protein(s) in uninduced and induced cytosols behaved identically in a sucrose gradient; 8.7-8.9 S in the absence of salt, shifted to 5.5 S by 0.4 M KCl. They were also indistinguishable by gel permeation chromatography, and by photoaffinity labeling their TCDD-binding subunits, approximate molecular weights 105,000. These results show the hepatic TCDD-binding protein(s) induced upon pretreatment of Sprague-Dawley rats with TCDD/HCB to be kinetically distinct from the Ah receptor, but structurally very similar.	UNIV GUELPH,DEPT CHEM & BIOCHEM,GUELPH N1G 2W1,ONTARIO,CANADA	University of Guelph			Sanders, David A.R./I-5668-2016					Andrews P, 1970, Methods Biochem Anal, V18, P1, DOI 10.1002/9780470110362.ch1; BANDIERA S, 1984, TOXICOLOGY, V32, P131, DOI 10.1016/0300-483X(84)90132-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNCE NJ, 1990, TOXICOL IN VITRO, V4, P87, DOI 10.1016/0887-2333(90)90028-R; BUNCE NJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P384, DOI 10.1016/0003-9861(88)90044-6; CHEN TL, 1983, J BIOL CHEM, V258, P4350; COOK JC, 1986, BIOCHEM PHARMACOL, V35, P167, DOI 10.1016/0006-2952(86)90510-1; DENISON MS, 1986, CHEMOSPHERE, V15, P1665, DOI 10.1016/0045-6535(86)90452-2; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DENISON MS, 1986, J BIOL CHEM, V261, P189; DENOMME MA, 1986, BIOCHEM PHARMACOL, V35, P277, DOI 10.1016/0006-2952(86)90526-5; EDELHOCH H, 1960, J BIOL CHEM, V235, P1326; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; GASIEWICZ TA, 1987, J BIOL CHEM, V262, P2116; GASIEWICZ TA, 1984, MOL PHARMACOL, V26, P90; GASIEWICZ TA, 1982, ANAL BIOCHEM, V124, P1, DOI 10.1016/0003-2697(82)90212-3; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GOTTLICHER M, 1987, CARCINOGENESIS, V8, P1021, DOI 10.1093/carcin/8.7.1021; GRUOL DJ, 1989, BIOCHEMISTRY-US, V28, P2929, DOI 10.1021/bi00433a028; HENRY EC, 1989, BIOCHEMISTRY-US, V28, P6430, DOI 10.1021/bi00441a041; HIRST M, 1982, ENDOCRINOLOGY, V111, P1400, DOI 10.1210/endo-111-4-1400; JONES PBC, 1986, J BIOL CHEM, V261, P6647; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; JORDAN VC, 1985, ENDOCRINOLOGY, V116, P1845, DOI 10.1210/endo-116-5-1845; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JP, 1990, TOXICOL LETT, V51, P295, DOI 10.1016/0378-4274(90)90072-T; LANDERS JP, 1990, J BIOCHEM TOXICOL, V5, P33, DOI 10.1002/jbt.2570050106; LANDERS JP, 1989, J BIOL CHEM, V264, P18463; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NAITO K, 1985, BIOCHEM BIOPH RES CO, V129, P447, DOI 10.1016/0006-291X(85)90171-8; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OKEY AB, 1979, J BIOL CHEM, V254, P1636; OKEY AB, 1984, BIOCHEM PHARMACOL, V33, P531, DOI 10.1016/0006-2952(84)90303-4; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; PERDEW GH, 1990, BIOCHEMISTRY-US, V29, P6210, DOI 10.1021/bi00478a014; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1987, BIOCHEM BIOPH RES CO, V146, P1439, DOI 10.1016/0006-291X(87)90811-4; POLAND A, 1976, J BIOL CHEM, V251, P4936; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; Rothen A, 1944, J BIOL CHEM, V152, P679; RUCCI G, 1988, ARCH BIOCHEM BIOPHYS, V265, P197, DOI 10.1016/0003-9861(88)90385-2; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SAFE SH, 1988, ISI ATLAS-PHARMACOL, P78; SLOOP TC, 1987, TOXICOL APPL PHARM, V88, P329, DOI 10.1016/0041-008X(87)90208-0; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; TAYLOR JF, 1948, J BIOL CHEM, V173, P591; TSUI HW, 1981, CAN J PHYSIOL PHARM, V59, P927, DOI 10.1139/y81-143; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WOLLENBERG GK, 1989, LAB INVEST, V60, P254	50	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9471	9480						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851747				2022-12-25	WOS:A1991FM45900025
J	PARKER, EM; ROSS, EM				PARKER, EM; ROSS, EM			TRUNCATION OF THE EXTENDED CARBOXYL-TERMINAL DOMAIN INCREASES THE EXPRESSION AND REGULATORY ACTIVITY OF THE AVIAN BETA-ADRENERGIC-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOLAMINE-INDUCED DESENSITIZATION; HUMAN BETA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE ACTIVATION; CYCLIC-AMP LEVELS; LIGAND-BINDING; PHOSPHOLIPID-VESICLES; DIRECTED MUTAGENESIS; TURKEY ERYTHROCYTES; CHOLERA-TOXIN; PROTEIN	A series of mutant avian beta-adrenergic receptors with progressively truncated carboxyl termini have been expressed in insect and mammalian cells. Removal of 18-124 amino acid residues caused multiple phenotypic changes in the receptor. Membranes from cells that expressed the truncated receptors displayed elevated basal (2- to 3-fold) and agonist-stimulated adenylylcyclase activities. Adenylylcyclase activity in these membranes also displayed greater stimulation in response to partial agonists. Activity was also markedly stimulated by beta-adrenergic ligands that are usually considered to be antagonists (alprenolol, > 4-fold; propranolol, approximately 2-fold). Wild type receptor did not mediate a response to these classical antagonists. After purification and reconstitution with G(s), the truncated receptors did not appear to be more active than the wild type. Guanine nucleotides modulated the affinity of agonist for the truncated receptors, whereas the affinity of agonist for the wild type receptor was not altered by guanine nucleotides. The truncated receptors were solubilized from the membrane more efficiently and were more susceptible to amino-terminal proteolysis than was the wild type protein. These results suggest interaction of the carboxyl terminus of the avian beta-adrenergic receptor with cellular regulatory or structural elements.			PARKER, EM (corresponding author), UNIV TEXAS, SW GRAD SCH BIOMED SCI, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355, F32GM011943] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355, GM 11943] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; BOEGE F, 1988, J BIOL CHEM, V263, P9040; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BROWN EM, 1976, J BIOL CHEM, V251, P1239; CARON MG, 1979, J BIOL CHEM, V254, P2923; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DUNKEL FG, 1989, BIOCHEM BIOPH RES CO, V165, P264, DOI 10.1016/0006-291X(89)91064-4; FLEMING JW, 1980, J CYCLIC NUCL PROT, V6, P407; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAGMANN J, 1980, J BIOL CHEM, V255, P2659; HANSKI E, 1979, BIOCHEMISTRY-US, V18, P846, DOI 10.1021/bi00572a017; HARDEN TK, 1979, J CYCLIC NUCL PROT, V5, P99; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERTEL C, 1990, J BIOL CHEM, V265, P17988; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; JASPER JR, 1990, MOL PHARMACOL, V37, P44; KENNEDY MS, 1979, MOL PHARMACOL, V16, P215; LAD PM, 1980, J BIOL CHEM, V255, P988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE H, 1982, J MEMBRANE BIOL, V64, P225, DOI 10.1007/BF01870889; MAGUIRE ME, 1976, J BIOL CHEM, V251, P1221; MAIORELLA B, 1988, BIO-TECHNOL, V6, P1406, DOI 10.1038/nbt1288-1406; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUBIG RR, 1985, MOL PHARMACOL, V28, P475; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PARKER EM, 1991, J BIOL CHEM, V266, P519; PARKER EM, 1990, CURR TOP MEMBR TRANS, V36, P131; PEDERSEN SE, 1985, J BIOL CHEM, V260, P4150; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RIMON G, 1980, BIOCHEMISTRY-US, V19, P4451, DOI 10.1021/bi00560a011; RIMON G, 1978, NATURE, V276, P394, DOI 10.1038/276394a0; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; RUDOLPH SA, 1977, P NATL ACAD SCI USA, V74, P3404, DOI 10.1073/pnas.74.8.3404; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMANTOV R, 1978, FEBS LETT, V90, P69, DOI 10.1016/0014-5793(78)80300-7; SIMPSON IA, 1980, FEBS LETT, V115, P113, DOI 10.1016/0014-5793(80)80738-1; STADEL JM, 1982, ADV ENZYMOL RAMB, V53, P1; STADEL JM, 1981, J CYCLIC NUCL PROT, V7, P37; STADEL JM, 1983, J BIOL CHEM, V258, P3032; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; SUMMERS MD, 1987, TEX AGR EXP ST B, V1555; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6795, DOI 10.1073/pnas.83.18.6795; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	61	65	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9987	9996						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851762				2022-12-25	WOS:A1991FM45900097
J	FIELD, MC; MENON, AK; CROSS, GAM				FIELD, MC; MENON, AK; CROSS, GAM			DEVELOPMENTAL VARIATION OF GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS IN TRYPANOSOMA-BRUCEI - IDENTIFICATION OF A CANDIDATE BIOSYNTHETIC PRECURSOR OF THE GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR OF THE MAJOR PROCYCLIC STAGE SURFACE GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; PROTEINS	The major surface antigen of the mammalian bloodstream form of Trypanosoma brucei, the variant surface glycoprotein (VSG), is attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. The VSG anchor is susceptible to phosphatidylinositol-specific phospholipase C (PI-PLC). Candidate precursor glycolipids, P2 and P3, which are PI-PLC-sensitive and -resistant respectively, have been characterized in the bloodstream stage. In the insect midgut stage, the major surface glycoprotein, procyclic acidic repetitive glycoprotein, is also GPI-anchored but is resistant to PI-PLC. To determine how the structure of the GPI anchor is altered at different life stages, we characterized candidate GPI molecules in procyclic T. brucei. The structure of a major procyclic GPI, PP1, is ethanolamine-PO4 - Man-alpha-1 - 2Man-alpha-1 - 6Man-alpha-1 - GlcN - acylinositol, linked to lysophosphatidic acid. The inositol can be labeled with [H-3]palmitic acid, and the glyceride with [H-3]stearic acid. We have also found that all detectable ethanolamine-containing GPIs from procyclic cells contain acylinositol and are resistant to cleavage by PI-PLC. This suggests that the procyclic acidic repetitive glycoprotein GPI anchor structure differs from that of the VSG by virtue of the structures of the GPIs available for transfer.			FIELD, MC (corresponding author), ROCKEFELLER UNIV, MOLEC PARASITOL LAB, NEW YORK, NY 10021 USA.		Cross, George A M/B-7444-2011; Field, Mark/AAD-6455-2021	Cross, George A M/0000-0003-1374-6955; Field, Mark/0000-0002-4866-2885; Menon, Anant Kumar/0000-0001-6924-2698	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1988, J BIOL CHEM, V263, P17697; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BELLOFATTO V, 1990, PARASITOL TODAY, V6, P299, DOI 10.1016/0169-4758(90)90260-B; BRUN R, 1979, ACTA TROP, V36, P289; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1989, BIOCHEM SOC T, V17, P1034, DOI 10.1042/bst0171034; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MAYOR S, 1991, IN PRESS J CELL BIOL; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MOMANS S, 1988, NATURE, V333, P269; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001	31	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8392	8400						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850744				2022-12-25	WOS:A1991FK44100067
J	KINSELLA, BT; MALTESE, WA				KINSELLA, BT; MALTESE, WA			RAB GTP-BINDING PROTEINS IMPLICATED IN VESICULAR TRANSPORT ARE ISOPRENYLATED INVITRO AT CYSTEINES WITHIN A NOVEL CARBOXYL-TERMINAL MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YPT1 PROTEIN; YEAST; SECRETION; PRODUCT; RESIDUE; GENES	Low molecular mass GTP-binding proteins encoded by the mammalian rab genes are found in membranes of the Golgi complex and endosomes, suggesting that they play a role in the movement of exocytic and endocytic vesicles. The basis for the membrane association of these proteins has not been defined. Herein, we demonstrate that terminal cysteine residues in the rab1B, rab2, and rab5 proteins undergo thioether modification by isoprenyl groups when these proteins are translated in vitro in the presence of a radiolabeled isoprenoid precursor, [H-3]mevalonate. Results of gel permeation chromatography of the radiolabeled hydrocarbons suggest that these proteins are modified specifically by isoprenyl groups of the 20-carbon diterpene class, rather than the 15-carbon farnesyl class known to be involved in modification of ras proteins. The rab1 and rab2 proteins lack the carboxyl-terminal amino acid motif common to all previously identified isoprenylated proteins, i.e. CXXX, where X is an unspecified amino acid. Analysis of altered translation products generated by site-directed mutagenesis indicates that modification of rab1B protein requires an intact carboxyl-terminal sequence consisting of GGCC. This represents a new amino acid motif for isoprenylation.	GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822	Geisinger Medical Center				Kinsella, B. Therese/0000-0003-3072-941X	NCI NIH HHS [R01 CA 34569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; KELLER RK, 1986, J BIOL CHEM, V261, P2053; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P1770, DOI 10.1093/nar/17.4.1770; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	38	107	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8540	8544						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850747				2022-12-25	WOS:A1991FK44100087
J	RONGNOPARUT, P; VERDON, CP; GEHNRICH, SC; SUL, HS				RONGNOPARUT, P; VERDON, CP; GEHNRICH, SC; SUL, HS			ISOLATION AND CHARACTERIZATION OF THE TRANSCRIPTIONALLY REGULATED MOUSE-LIVER (B-TYPE) PHOSPHOFRUCTOKINASE GENE AND ITS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE PHOSPHOFRUCTOKINASE; EXPRESSION; PROTEIN; BINDING; ASSIGNMENT; ISOZYMES; SEQUENCE; REGIONS; HEART	We have isolated and characterized a mouse gene encoding liver (B-type) phosphofructokinase, a key regulatory enzyme in glycolysis. The gene spans approximately 21.5 kilobase pairs and consists of 22 exons. Compared with the muscle (A-type) phosphofructokinase gene, the sizes of the introns are different although exon lengths are highly conserved. Two transcription start sites 10 bases apart were determined by primer extension experiments. The immediate 5' sequence does not possess a TATA or CCAAT box but contains multiple GC boxes (positions -10, -43, -50, -62, and +28 in the 5'-untranslated region) which may be Sp1-binding sites. An unusual feature of 200 base stretches of CT repeats is present at position -480 to -693. In addition, direct repeats of CTCGAAGGAG are found at positions -447 and -478. DNase I footprinting showed five regions where liver nuclear proteins may interact. Two proximal 5'-flanking regions spanning -1 to -20 and -30 to -70, which contain GC boxes. Also protected was a region spanning -70 to -90, which contains an AP-1 like sequence (TCAGTCA). The consensus AP-1 sequence, however, did not inhibit footprinting, indicating involvement of a distinct protein. Two distal regions spanning from -450 to -470 and from -500 to -520 were also protected. The former is positioned between the direct repeats and the latter is at the start of the CT repeats. The rate of transcription of the liver phosphofructokinase gene, as measured by run-on assays, increased 5-fold in livers of previously starved mice fed a high carbohydrate diet compared to starved controls. Administration of dibutyryl cAMP blocked the increase in transcription caused by refeeding. Functional analysis of the promoter region of the gene will be necessary to elucidate the mechanisms of transcriptional regulation by fasting/refeeding and by cAMP. These results provide a useful system for the study of regulatory elements in liver phosphofructokinase gene transcription.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Han, Zaiqi/AAI-2233-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36264] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHOATE GL, 1985, J BIOL CHEM, V260, P4815; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOE LG, 1985, J BIOL CHEM, V260, P726; FUJITA T, 1983, P NATL ACAD SCI-BIOL, V80, P7437, DOI 10.1073/pnas.80.24.7437; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GEKAKIS N, 1988, J BIOL CHEM, V263, P11755; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; KEMP RG, 1983, MOL CELL BIOCHEM, V57, P147, DOI 10.1007/BF00849191; LEE CP, 1987, J BIOL CHEM, V262, P4195; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1477, DOI 10.1021/bi00548a034; RILEY DE, 1986, NUCLEIC ACIDS RES, V14, P9407, DOI 10.1093/nar/14.23.9407; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; THRASHER JR, 1981, J BIOL CHEM, V256, P7844; TSAI MY, 1972, J BIOL CHEM, V248, P785; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VORA S, 1981, P NATL ACAD SCI-BIOL, V78, P3738, DOI 10.1073/pnas.78.6.3738; VORA S, 1981, BLOOD, V57, P724; WEIL D, 1980, ANN HUM GENET, V44, P11, DOI 10.1111/j.1469-1809.1980.tb00941.x	27	29	30	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8086	8091						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850735				2022-12-25	WOS:A1991FK44100023
J	HORTIN, GL; TRIMPE, BL				HORTIN, GL; TRIMPE, BL			ALLOSTERIC CHANGES IN THROMBINS ACTIVITY PRODUCED BY PEPTIDES CORRESPONDING TO SEGMENTS OF NATURAL INHIBITORS AND SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; HEPARIN COFACTOR-II; ANTITHROMBIN ACTIVITY; LYSYL RESIDUES; BINDING-SITE; HIRUDIN; IDENTIFICATION; COMPLEX; FIBRIN; THROMBOMODULIN	Acidic synthetic peptides corresponding to segments of several nonhomologous proteins (hirudin, residues 54-65; heparin cofactor II, residues 54-75; and fibrinogen, residues 410-427 of the gamma-B-chain) inhibit thrombin's cleavage of fibrinogen without blocking the enzyme's active site. Here, we examined effects of these peptides on thrombin's cleavage of protein C and small peptides. Activation of protein C by thrombin in the absence of calcium was inhibited by all of the peptides. Maximal inhibition was 60%, and no greater inhibition was produced by higher peptide concentrations. This differed from progressive inhibition of protein C activation by increasing peptide concentrations in the presence of thrombomodulin and calcium. Potencies of the peptides were in the order hirudin-(54-65) > heparin cofactor II-(54-75) > gamma-B-chain-(410-427). Sulfation of the tyrosine residue in hirudin-(54-65) increased its potency about 10-fold, similar to changes in anticlotting activity. The peptides were activators rather than inhibitors of the cleavage of small chromogenic substrates. In the presence of the peptides, the affinity of thrombin for the substrates S-2366 (pyro-Glu-Pro-Arg-4-nitroanilide), Chromozyme TH (tosyl-Gly-Pro-Arg-4-nitroanilide), and S-2251 (D-Val-Leu-Lys-4-nitroanilide) increased 1.5-2-fold with little change in the V(max) of substrate cleavage. Potencies of peptides in these allosteric effects on thrombin was in the same order as for their other effects. The similar actions of these nonhomologus peptides, which are believed to bind to thrombin's anion-binding exosite, suggest that binding of any peptide to this site exerts the same allosteric effect on thrombin's active site. Interactions of these peptides with thrombin may serve as models for regulation of thrombin's interactions with natural substrates and inhibitors.			HORTIN, GL (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,BOX 8116,400 S KINGSHIGHWAY,ST LOUIS,MO 63110, USA.				NIGMS NIH HHS [GM 38280] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038280, R01GM038280] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DECRISTOFARO R, 1990, BIOPHYS CHEM, V36, P77, DOI 10.1016/0301-4622(90)85010-4; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1989, SEMIN THROMB HEMOST, V15, P265, DOI 10.1055/s-2007-1002718; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FENTON JW, 1986, SEMIN THROMB HEMOST, V12, P200, DOI 10.1055/s-2007-1003551; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HOFSTEENGE J, 1987, EUR J BIOCHEM, V168, P49, DOI 10.1111/j.1432-1033.1987.tb13385.x; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HORTIN G, 1986, J BIOL CHEM, V261, P5827; HORTIN GL, 1990, BIOCHEM BIOPH RES CO, V169, P437, DOI 10.1016/0006-291X(90)90350-V; HORTIN GL, 1989, BIOCHEM INT, V19, P1355; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HORTIN GL, 1990, BLOOD, V76, P946; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; KAMINSKI M, 1987, BIOCHEM J, V242, P881, DOI 10.1042/bj2420881; KANE WH, 1988, BLOOD, V71, P539; KRSTENANSKY JL, 1988, THROMB RES, V52, P137, DOI 10.1016/0049-3848(88)90092-8; KRSTENANSKY JL, 1988, BIOCHIM BIOPHYS ACTA, V957, P53, DOI 10.1016/0167-4838(88)90156-2; KRSTENANSKY JL, 1990, THROMB HAEMOSTASIS, V63, P208; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V481, P297; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; NASKI MC, 1990, J BIOL CHEM, V265, P13484; OWEN TJ, 1988, J MED CHEM, V31, P1009, DOI 10.1021/jm00400a020; PRESCOTT SM, 1990, J BIOL CHEM, V265, P9614; RAGG H, 1990, J BIOL CHEM, V265, P5211; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; STONE SR, 1989, BIOCHEMISTRY-US, V28, P6857, DOI 10.1021/bi00443a012; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; SUZUKI K, 1990, J BIOL CHEM, V265, P13263; VALI Z, 1988, BIOCHEMISTRY-US, V27, P1956, DOI 10.1021/bi00406a023	47	77	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6866	6871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849894				2022-12-25	WOS:A1991FG72700037
J	GARLID, KD; SHARIATMADAR, Z; NATH, S; JEZEK, P				GARLID, KD; SHARIATMADAR, Z; NATH, S; JEZEK, P			RECONSTITUTION AND PARTIAL-PURIFICATION OF THE NA+-SELECTIVE NA+/H+ ANTIPORTER OF BEEF-HEART MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SUBMITOCHONDRIAL PARTICLES; CATION-TRANSPORT; H+ EXCHANGER; SODIUM; MEMBRANE; PROTEIN; CALCIUM; PROTON; VESICLES	Na+/H+ antiporters play important physiological roles in most biological membranes. Although they were first discovered in mitochondria (Mitchell, P., and Moyle, J. (1969) Eur. J. Biochem. 9, 149-155), the mitochondrial Na+/H+ antiporter has not yet been reconstituted nor has the protein responsible for its activity been identified. We used detergents to extract proteins from beef heart mitochondria and reconstituted these proteins into lipid vesicles loaded with the fluorescent probe, sodium-binding benzofuran isophthalate. The vesicles exhibited spontaneous, electroneutral Na+ transport that was inhibited by Li+ and Mn2+ with appropriate kinetic constants. These protocols were then used to follow fractionation of the solubilized proteins with DEAE-cellulose columns. We obtained a fraction that catalyzed Na+/H+ antiport with V(max) values of 75-120-mu-mol/mg protein/min, 500-700 times faster than observed in intact mitochondria. Na+ transport was inhibited by Li+ with I50 values of 0.5-1.0 mM and by Mn2+ with I50 value of 0.5 mM. The K(m) for Na+ was 31 mM. These values correspond to those found in intact mitochondria, and we conclude that the solubilized mitochondrial Na+/H+ antiporter has been partially purified in a reconstitutively active state.			GARLID, KD (corresponding author), MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699, USA.		Jezek, Petr/B-9264-2012	Jezek, Petr/0000-0002-2720-9395; Garlid, Keith/0000-0002-6777-1235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36573] Funding Source: Medline; NIGMS NIH HHS [GM 31086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON PS, 1986, CURR TOP MEMBR TRANS, V26, P57; BERNARDI P, 1990, EUR J BIOCHEM, V188, P91, DOI 10.1111/j.1432-1033.1990.tb15375.x; BRIERLEY GP, 1988, ARCH BIOCHEM BIOPHYS, V264, P417, DOI 10.1016/0003-9861(88)90307-4; BRIERLEY GP, 1989, BIOCHEMISTRY-US, V28, P4347, DOI 10.1021/bi00436a034; BRIERLEY GP, 1980, PHARMACOL THERAPEUT, V8, P193, DOI 10.1016/0163-7258(80)90065-0; BRIERLEY GP, 1988, CELLULAR CALCIUM REG, P47; BRIERLEY GP, 1978, ARCH BIOCHEM BIOPHYS, V190, P203; CROMPTON M, 1977, EUR J BIOCHEM, V79, P549, DOI 10.1111/j.1432-1033.1977.tb11839.x; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; CROMPTON M, 1978, EUR J BIOCHEM, V91, P599, DOI 10.1111/j.1432-1033.1978.tb12713.x; DOUGLAS MG, 1974, J BIOL CHEM, V249, P5464; GARLID KD, 1988, CELLULAR CALCIUM REG, P37; GARLID KD, 1988, INTEGRATION MITOCHON, P257; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAROLD FM, 1972, J MEMBRANE BIOL, V8, P45, DOI 10.1007/BF01868094; JEZEK P, 1990, J BIOL CHEM, V265, P10522; KAKAR SS, 1989, J BIOL CHEM, V264, P5846; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KAPUS A, 1988, BIOCHIM BIOPHYS ACTA, V944, P383, DOI 10.1016/0005-2736(88)90509-3; KINSELLA JL, 1981, AM J PHYSIOL, V241, pC220, DOI 10.1152/ajpcell.1981.241.5.C220; KLINGENBERG M, 1986, METHOD ENZYMOL, V127, P772; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XQ, 1990, J BIOL CHEM, V265, P15316; MARTIN WH, 1984, J BIOL CHEM, V259, P2062; MINTA A, 1989, J BIOL CHEM, V264, P19449; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MITCHELL P, 1969, EUR J BIOCHEM, V9, P149, DOI 10.1111/j.1432-1033.1969.tb00588.x; MITCHELL P, 1967, BIOCHEM J, V105, P1147, DOI 10.1042/bj1051147; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; NAKASHIMA RA, 1982, J BIOL CHEM, V257, P9252; NATH S, 1990, KINETIC PROPERTIES M; Nath S., 1988, INTEGRATION MITOCHON, P357; ROSEN BP, 1980, FEBS LETT, V117, P39, DOI 10.1016/0014-5793(80)80909-4; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SETTLEMIRE CT, 1968, BIOCHIM BIOPHYS ACTA, V162, P487, DOI 10.1016/0005-2728(68)90055-8	37	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6518	6523						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848857				2022-12-25	WOS:A1991FE37300077
J	MIURA, S; ICHIKAWA, Y				MIURA, S; ICHIKAWA, Y			CONFORMATIONAL CHANGE OF ADRENODOXIN INDUCED BY REDUCTION OF IRON-SULFUR CLUSTER - PROTON NUCLEAR-MAGNETIC-RESONANCE STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC ELECTRON-TRANSPORT; AMINO-ACID SEQUENCE; MITOCHONDRIAL CYTOCHROME-P-450SCC; BOVINE ADRENODOXIN; 2FE-2S FERREDOXIN; PROTEINS; SPECTRA; SPECTROSCOPY; COMPLEX; CHOLESTEROL	Bovine adrenodoxin in the reduced form has been measured by one- and two-dimensional H-1 NMR spectroscopy. By comparing the spectrum of reduced adrenodoxin with that of the oxidized protein, resonances have been assigned for the aromatic residues. The spin-lattice relaxation time for the resonances due to histidine residues was found to depend on the reduction state of adrenodoxin. The distance from the paramagnetic center is calculated by using the Solomone-Bloembergen equation. The resonances from Tyr-82 and Ala-81 show large chemical shift changes upon reduction of adrenodoxin. The conformational change of adrenodoxin manifested by chemical shift difference between reduced and oxidized forms is found in the sequence around Tyr-82 and Ala-81. Modification with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide at Glu-74, Asp-79, and Asp-86 inhibited the interaction with both adrenodoxin reductase and cytochrome P-450scc (Lambeth, D. J., Geren, L. M., and Millett, F. (1984) J. Biol. Chem. 259, 10025-10029; Geren, L. M., O'Brien, P., Stonehuerner, J., and Millett, F. (1984) J. Biol. Chem. 259, 2155-2160). Thus, the sequence of these amino acids was assigned to the interaction site with the redox partners. The present H-1 NMR investigation of adrenodoxin demonstrates that a conformational change upon reduction of the iron-sulfur cluster occurs in the sequence of negatively charged amino acids that is a putative site for interaction with redox partners. This could offer the structural basis of the electron transfer mechanism in which adrenodoxin functions as a mobile electron carrier.			MIURA, S (corresponding author), KAGAWA MED SCH,DEPT BIOCHEM,MIKI CHO,KAGAWA 76107,JAPAN.							BERTRAND P, 1987, BIOCHIM BIOPHYS ACTA, V916, P24, DOI 10.1016/0167-4838(87)90206-8; BLOEMBERGEN N, 1957, J CHEM PHYS, V27, P527; CHAN TM, 1983, BIOCHEMISTRY-US, V22, P6008, DOI 10.1021/bi00294a048; DUGAD LB, 1990, BIOCHEMISTRY-US, V29, P2263, DOI 10.1021/bi00461a009; DUNHAM WR, 1971, BIOCHIM BIOPHYS ACTA, V253, P373, DOI 10.1016/0005-2728(71)90041-7; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; GEREN LM, 1984, J BIOL CHEM, V259, P2155; GLICKSON JD, 1971, BIOCHEM BIOPH RES CO, V42, P271, DOI 10.1016/0006-291X(71)90098-2; GREENFIELD NJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P246, DOI 10.1016/0167-4838(89)90042-3; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4321, DOI 10.1016/S0021-9258(19)69436-6; HANUKOGLU I, 1980, J BIOL CHEM, V255, P3057, DOI 10.1016/S0021-9258(19)85851-9; HIWATASHI A, 1986, FEBS LETT, V209, P311, DOI 10.1016/0014-5793(86)81133-4; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAMBETH JD, 1983, J BIOL CHEM, V258, P5596; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1985, J BIOL CHEM, V260, P8810; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; LIGHT DR, 1981, J BIOL CHEM, V256, P343; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; NAGAYAMA K, 1983, J BIOCHEM-TOKYO, V94, P893, DOI 10.1093/oxfordjournals.jbchem.a134432; OH BH, 1990, BIOCHEMISTRY-US, V29, P3993, DOI 10.1021/bi00468a029; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; POE M, 1971, P NATL ACAD SCI USA, V68, P68, DOI 10.1073/pnas.68.1.68; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SALMEEN I, 1972, ARCH BIOCHEM BIOPHYS, V150, P767, DOI 10.1016/0003-9861(72)90096-3; SEYBERT DW, 1978, J BIOL CHEM, V253, P8355; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; SOLOMON I, 1956, J CHEM PHYS, V25, P261, DOI 10.1063/1.1742867; TANAKA M, 1973, J BIOL CHEM, V248, P1141; TANIGUCHI T, 1976, BIOCHEMISTRY-US, V13, P2849; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P9777, DOI 10.1021/bi00451a035; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; TULS J, 1987, J BIOL CHEM, V262, P10020; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	38	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6252	6258						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848852				2022-12-25	WOS:A1991FE37300040
J	DENICHILO, MO; STEWART, AG; VADAS, MA; LOPEZ, AF				DENICHILO, MO; STEWART, AG; VADAS, MA; LOPEZ, AF			GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IS A STIMULANT OF PLATELET-ACTIVATING-FACTOR AND SUPEROXIDE ANION GENERATION BY HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN GRANULOCYTE; HUMAN GM-CSF; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PERITONEAL-MACROPHAGES; PRIMES NEUTROPHILS; ENDOTHELIAL-CELLS; RELEASE; INVITRO; EXPRESSION; MODULATION	Human granulocyte-macrophage colony-stimulating factor (GM-CSF) was studied for its ability to stimulate the synthesis and release of the inflammatory mediator platelet-activating factor (PAF) from human neutrophils as measured by bioassay and incorporation of [H-3]acetate into PAF. GM-CSF stimulated the synthesis but not the release of PAF from neutrophils. PAF synthesis took place in a time- and concentration-dependent manner, was dependent on a pertussis toxin-sensitive G protein and could be inhibited by antibodies to GM-CSF. On the other hand, pre-incubation of neutrophils with GM-CSF followed by stimulation with the bacterial tripeptide formylmethionylleucylphenylalanine caused PAF synthesis and release. The effect of GM-CSF was qualitative and not simply the result of larger amounts of PAF being synthesized since similar amounts were generated in response to the calcium ionophore A23187 but no released PAF could be detected. In functional studies GM-CSF stimulated superoxide anion generation from neutrophils with a time and dose relationship that paralleled PAF synthesis. In addition, the serine protease inhibitor L-1-tosylamide-2-phenylethyl chloromethyl ketone, which inhibits PAF synthesis, reduced PAF accumulation as well as superoxide generation, raising the possibility of a causal relationship between cell-associated PAF and cell activation. These results identify PAF as a direct product of GM-CSF stimulation in neutrophils where it may play a role in signal transduction and demonstrate that PAF is released only after subsequent neutrophil stimulation. The selective release of PAF may play a role in regulating and amplifying the inflammatory response.	INST MED & VET SCI,DIV HUMAN IMMUNOL,FROME RD,ADELAIDE,SA 5000,AUSTRALIA; UNIV MELBOURNE,DEPT PHYSIOL,PARKVILLE,VIC 3052,AUSTRALIA	Institute Medical & Veterinary Science Australia; University of Melbourne			Vadas, Mathew/R-1378-2019; stewart, alastair/A-3590-2010; Lopez, Angel F/E-2260-2011	Lopez, Angel F/0000-0001-7430-0135; stewart, alastair/0000-0002-2271-5942				ATKINSON YH, 1990, IMMUNOLOGY, V70, P82; ATKINSON YH, 1988, IMMUNOLOGY, V64, P519; BEGLEY CG, 1986, BLOOD, V67, P37; BOCOCK GM, 1984, CELL, V39, P301; BRAQUET P, 1989, J LIPID MEDIATOR, V1, P75; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; COREY SJ, 1989, J BIOL CHEM, V264, P14165; DAHINDEN CA, 1988, J EXP MED, V167, P1281, DOI 10.1084/jem.167.4.1281; DEWAR A, 1984, J PATHOL, V144, P24; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; FEARON DT, 1983, J IMMUNOL, V130, P370; GAMBLE JR, 1990, EXP HEMATOL, V18, P897; GAY JC, 1986, BLOOD, V67, P931; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1984, BIOCHEM J, V219, P419, DOI 10.1042/bj2190419; GRABSTEIN KH, 1986, SCIENCE, V232, P506, DOI 10.1126/science.3083507; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; KAPP A, 1988, J INVEST DERMATOL, V91, P49, DOI 10.1111/1523-1747.ep12463288; KAUFMAN SE, 1989, EXP HEMATOL, V17, P800; LOPEZ AF, 1983, J IMMUNOL, V131, P2983; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOPEZ AF, 1988, PROG LEUKOCYTE BIOL, V8, P235; LUDWIG JC, 1984, ARCH BIOCHEM BIOPHYS, V232, P102, DOI 10.1016/0003-9861(84)90525-3; MAYER P, 1987, BLOOD, V70, P206; MCCOLL SR, 1989, BLOOD, V73, P588; METCALF D, 1986, BLOOD, V67, P37; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; NATHAN CF, 1989, BLOOD, V73, P301; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SIEFF CA, 1985, SCIENCE, V236, P1229; SISSON JH, 1987, J IMMUNOL, V138, P3918; STEWART AG, 1989, BRIT J PHARMACOL, V98, P141, DOI 10.1111/j.1476-5381.1989.tb16874.x; STEWART AG, 1989, BRIT J PHARMACOL, V96, P503, DOI 10.1111/j.1476-5381.1989.tb11845.x; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; SULLIVAN R, 1987, J IMMUNOL, V139, P3422; VADAS MA, 1983, J IMMUNOL, V130, P795; WEDMORE CV, 1981, BRIT J PHARMACOL, V74, P916; WEISBART RH, 1987, BLOOD, V69, P18; WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0; WIRTHMUELLER U, 1989, J IMMUNOL, V142, P3213; WONG GG, 1984, SCIENCE, V226, P1339; WORTHEN GS, 1988, J IMMUNOL, V140, P3553; XU WD, 1989, J CLIN INVEST, V83, P876, DOI 10.1172/JCI113971	44	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4896	4902						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848228				2022-12-25	WOS:A1991FC21700036
J	KLARLUND, JK; JASPERS, SR; KHALAF, N; BRADFORD, AP; MILLER, TB; CZECH, MP				KLARLUND, JK; JASPERS, SR; KHALAF, N; BRADFORD, AP; MILLER, TB; CZECH, MP			AN INSULIN-STIMULATED KEMPTIDE KINASE PURIFIED FROM RAT-LIVER IS DEACTIVATED BY PHOSPHATASE-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT SKELETAL-MUSCLE; PROTEIN PHOSPHATASE; S6 KINASE; PHOSPHOTYROSYL-PROTEIN; MOLECULAR-WEIGHT; PURIFICATION; PHOSPHORYLATION; ACTIVATION; TYROSINE; CELLS	Insulin action leads to the rapid stimulation of a cytosolic Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) kinase (KIK) that has been recently purified to near homogeneity (Klarlund, J. K., Bradford, A. P., Milla, M. G., and Czech, M. P. (1990) J. Biol. Chem. 265, 227-234). To examine its activation mechanism, purified KIK was treated with purified protein phosphatases. The catalytic subunit of phosphatase 2A inhibited the activity of control KIK by about 50% and abolished the 5-fold elevation in KIK activity due to insulin action. The catalytic subunit of phosphatase 1 with equivalent activity based on dephosphorylation of P-32-labeled phosphorylase a had no effect on either control or insulin-stimulated KIK activity. The deactivation of insulin-stimulated KIK by phosphatase 2A was time- and concentration-dependent and was blocked by phosphatase inhibitors. The purified native complexes of phosphatase 2A, phosphatase 2A1, and phosphatase 2A2 similarly deactivated KIK. Analysis of control or insulin-stimulated KIK with two antiphosphotyrosine antibodies by immunoblotting and immunoprecipitation failed to detect the presence of phosphotyrosine in the kinase. These results indicate that KIK is activated by phosphorylation as part of a kinase cascade emanating from insulin receptor stimulation.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	KLARLUND, JK (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NHLBI NIH HHS [HL20476] Funding Source: Medline; NIDDK NIH HHS [DK18269, DK39625] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020476, R37HL020476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018269, R01DK039625] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; FOULKES JG, 1980, EUR J BIOCHEM, V105, P195, DOI 10.1111/j.1432-1033.1980.tb04489.x; FOULKES JG, 1983, J BIOL CHEM, V258, P431; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; IMOAKA T, 1983, J BIOL CHEM, V258, P1526; JASPERS SR, 1991, IN PRESS MOL CELL BI; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KLARLUND JK, 1988, BIOCHIM BIOPHYS ACTA, V971, P112, DOI 10.1016/0167-4889(88)90167-X; KLARLUND JK, 1990, J BIOL CHEM, V265, P227; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TAMURA S, 1980, EUR J BIOCHEM, V111, P217; USUI H, 1988, J BIOL CHEM, V263, P3752; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; YU KT, 1987, J BIOL CHEM, V262, P7865; YU KT, 1990, BIOCHEM J, V268, P539, DOI 10.1042/bj2680539	33	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4052	4055						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847913				2022-12-25	WOS:A1991FA69400008
J	ROGEL, A; MELLER, R; HANSKI, E				ROGEL, A; MELLER, R; HANSKI, E			ADENYLATE-CYCLASE TOXIN FROM BORDETELLA-PERTUSSIS - THE RELATIONSHIP BETWEEN INDUCTION OF CAMP AND HEMOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; VIRULENCE FACTORS; MEMBRANE DAMAGE; PROTEIN; BINDING; IDENTIFICATION; PENETRATION; CELL; PURIFICATION; SECRETION	Bordetella pertussis produces a calmodulin-activated adenylate cyclase (AC) that exists in several forms. Only one form of AC, of apparent 200 kDa, is a toxin that penetrates eukaryotic cells and generates uncontrolled levels of intracellular cAMP. Recombination studies in transposon Tn5-insertion mutants of B. pertussis and amino acid sequence homology with alpha-hemolysin of Escherichia coli suggested that AC toxin may also have a hemolytic activity. Here, we demonstrate that only the toxic form of B. pertussis AC possesses hemolytic activity. Immunoblotting of membranes from sheep erythrocytes throughout the process of cell lysis detects the presence and accumulation of only the 200-kDa form of B. pertussis AC. cAMP generation induced by AC toxin in sheep erythrocytes is immediate whereas appearance of hemolysis is delayed by about 1 h and requires a higher level of AC toxin activity. Addition of exogenous calmodulin to sheep erythrocyte incubation medium potentiates the hemolytic activity of AC toxin but blocks cAMP generation. Extracellular Ca2+ at mM concentrations is absolutely required for cAMP generation but not for hemolysis. However, binding of AC toxin to sheep erythrocytes in the absence of exogenous Ca2+ followed by reincubation of cells in a toxin-free buffer containing Ca2+ leads to an immediate rise in intracellular cAMP. Human erythrocytes bind AC toxin and generate cAMP but are resistant to lysis. These results show that binding of AC toxin to erythrocytes can cause both cAMP generation and hemolysis or only one of these depending on conditions applied and cell type used.	WEIZMANN INST SCI, DEPT HORMONE RES, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science			hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628				BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; BHAKDI S, 1983, BIOCHIM BIOPHYS ACTA, V737, P343, DOI 10.1016/0304-4157(83)90006-0; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLIE RM, 1988, MICROB PATHOGENESIS, V4, P335, DOI 10.1016/0882-4010(88)90061-7; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; EBERSPACHER B, 1989, INFECT IMMUN, V57, P983; EHRMANN I, 1990, 1990 AM SOC MICR ANN; FARFEL Z, 1987, BIOCHEM J, V243, P153, DOI 10.1042/bj2430153; FRIEDMAN E, 1987, BIOCHEM J, V243, P145, DOI 10.1042/bj2430145; FRIEDMAN R L, 1988, Clinical Microbiology Reviews, V1, P365; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GILBOARON A, 1989, BIOCHEM J, V262, P25, DOI 10.1042/bj2620025; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HARTLEIN M, 1983, J CELL BIOCHEM, V22, P87, DOI 10.1002/jcb.240220203; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; MACKMAN N, 1985, MOL GEN GENET, V201, P529, DOI 10.1007/BF00331351; MASURE HR, 1989, BIOCHEMISTRY-US, V28, P438, DOI 10.1021/bi00428a005; MASURE HR, 1987, MICROBIOL REV, V51, P60, DOI 10.1128/MMBR.51.1.60-65.1987; MASURE HR, 1988, J BIOL CHEM, V263, P6933; NICAUD JM, 1985, FEBS LETT, V187, P339, DOI 10.1016/0014-5793(85)81272-2; ROGEL A, 1988, J BIOL CHEM, V263, P13310; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHATTUCK RL, 1985, BIOCHEMISTRY-US, V24, P6323, DOI 10.1021/bi00344a001; WAGNER W, 1983, J BACTERIOL, V154, P200, DOI 10.1128/JB.154.1.200-210.1983; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983	39	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3154	3161						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847141				2022-12-25	WOS:A1991EX60000073
J	UNSON, CG; MACDONALD, D; RAY, K; DURRAH, TL; MERRIFIELD, RB				UNSON, CG; MACDONALD, D; RAY, K; DURRAH, TL; MERRIFIELD, RB			POSITION-9 REPLACEMENT ANALOGS OF GLUCAGON UNCOUPLE BIOLOGICAL-ACTIVITY AND RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; CHEMICAL-PROPERTIES; ANTAGONISTS; HEPATOCYTES; ACTIVATION; MEMBRANE; RESIDUES; PEPTIDE; AMIDE	Recent studies on the glucagon antagonist des-His1-[Glu9]glucagon amide have resulted in pure inhibitors of the hormone, suggesting that the inhibitory properties may be centered around position 9. The present study was designed to investigate the chemical characteristics of substitutions in position 9 of glucagon that determine binding affinity and biological activity. Twenty replacement analogs of position 9 of glucagon were synthesized and assessed for their ability to bind to the glucagon receptor in rat hepatocyte membranes and to activate adenylate cyclase. Any substitution of aspartic acid 9 was accompanied by a severely diminished capacity to transmit the biological signal, while retaining receptor binding affinity. These results are an indication of an uncoupling of receptor binding and biological activity at this locus and define a central role of aspartic acid 9 in glucagon activity. Single replacement or deletion of either His1 or Asp9 in glucagon caused a 20- to 50-fold decrease in cyclase activity, whereas these same changes made in tandem caused virtually complete loss of activity, with decreases of 10(4)- to 10(6)-fold. These observations have led us to speculate that, at the molecular level, the region of glucagon required for transduction of the biological response may be distinct from the binding region and is mediated by a coupled interaction between His1 and Asp9 of the hormone and a complementary functional site of the glucagon receptor.			UNSON, CG (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.				NIDDK NIH HHS [DK 24039] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024039] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREU D, 1987, EUR J BIOCHEM, V164, P585, DOI 10.1111/j.1432-1033.1987.tb11167.x; ANDREU D, 1985, PEPTIDES STRUCTURE F, P595; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; BONNEVIENIELSEN V, 1983, J BIOL CHEM, V258, P1313; EPAND RM, 1981, J BIOL CHEM, V256, P1128; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEFFORD MA, 1985, BIOCHEMISTRY-US, V24, P867, DOI 10.1021/bi00325a009; HEFFORD MA, 1989, BIOCHIM BIOPHYS ACTA, V998, P267, DOI 10.1016/0167-4838(89)90283-5; IYENGAR R, 1988, J BIOL CHEM, V263, P15348; KOFOD H, 1988, INT J PEPT PROT RES, V32, P436; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MERRIFIELD RB, 1987, PEPTIDES 1986, P517; POHL SL, 1976, METHODS RECEPTOR R 1, P160; RODBELL M, 1971, J BIOL CHEM, V246, P1872; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SONNE O, 1978, J BIOL CHEM, V253, P3203; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; UNSON CG, 1989, J BIOL CHEM, V264, P789; UNSON CG, 1990, PEPTIDES CHEM STRUCT, P203; WRIGHT DE, 1979, J BIOL CHEM, V254, P268	24	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2763	2766						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847133				2022-12-25	WOS:A1991EX60000017
J	DESIDERI, A; CACCURI, AM; POLIZIO, F; BASTONI, R; FEDERICI, G				DESIDERI, A; CACCURI, AM; POLIZIO, F; BASTONI, R; FEDERICI, G			ELECTRON-PARAMAGNETIC RESONANCE IDENTIFICATION OF A HIGHLY REACTIVE THIOL-GROUP IN THE PROXIMITY OF THE CATALYTIC SITE OF HUMAN PLACENTA GLUTATHIONE TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASES; ACTIVE-SITE; BINDING; PURIFICATION	The reaction of the glutathione transferase from human placenta with a maleimide spin label derivative has been followed by EPR. Incubation of the enzyme at pH 7.0 with 50-fold molar excess of the spin label reagent gives rise to an immobilized nitroxyl EPR spectrum indicative of two reacting thiol groups per dimer of enzyme as evaluated by double integration of the EPR spectrum; the activity is lost in parallel. The same type of spectrum can be obtained simply by adding 2 eq of the spin label reagent to the enzyme. The binding is completed after less than 1 min at pH 8.0; it requires 2 min at pH 7.0 and more than 10 min at pH 6.0. These data indicate that the maleimide derivative reacts, in each subunit, with a thiol group which plays a crucial role for the maintenance of the catalytic activity and is characterized by a low pK. Inactivation of the enzyme at pH 7.0 in the presence of 2 eq of spin label reagent per mol of enzyme requires 15 min, suggesting the occurrence of a structural rearrangement after the binding of the thiol blocking agent. The same binding in the presence of S-methylglutathione or protoporphyrin IX shows a decreased reaction rate with respect to the reaction in the absence of inhibitors, indicating that the thiols are in proximity of both the glutathione and the porphyrin binding sites. For this latter case, this unambiguously demonstrated by the titration of spin-labeled enzyme with hemin, which produces a decrease of the EPR signal amplitude from which an interspin distance of about 10 angstrom can be evaluated.			DESIDERI, A (corresponding author), UNIV ROME TOR VERGATA, DEPT BIOL, VIA ORAZIO RAIMONDO, I-00173 ROME, ITALY.		CACCURI, ANNA MARIA/AFU-2643-2022	CACCURI, ANNA MARIA/0000-0002-3756-4163; desideri, alessandro/0000-0003-1541-4217				BERTINI I, 1986, NMR PARAMAGNETIC MOL; BOOTH J, 1961, BIOCHEM J, V79, P516, DOI 10.1042/bj0790516; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACCURI AM, 1988, BIOCHEM MED METAB B, V40, P123, DOI 10.1016/0885-4505(88)90113-2; CARNE T, 1979, BIOCHEM J, V177, P433, DOI 10.1042/bj1770433; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GORIN G, 1966, ARCH BIOCHEM BIOPHYS, V115, P593, DOI 10.1016/0003-9861(66)90079-8; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; HABIG WH, 1974, J BIOL CHEM, V249, P7130; KANO T, 1987, CANCER RES, V47, P5626; LEIGH JS, 1970, J CHEM PHYS, V52, P2608, DOI 10.1063/1.1673348; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; POLIDORO G, 1981, BIOCHEM MED METAB B, V25, P247, DOI 10.1016/0006-2944(81)90082-X; RICCI G, 1989, J BIOL CHEM, V264, P5462; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; WEBER K, 1969, J BIOL CHEM, V244, P4406	22	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2063	2066						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846610				2022-12-25	WOS:A1991EV51500011
J	FAY, PJ; COUMANS, JV; WALKER, FJ				FAY, PJ; COUMANS, JV; WALKER, FJ			VONWILLEBRAND-FACTOR MEDIATES PROTECTION OF FACTOR-VIII FROM ACTIVATED PROTEIN-C-CATALYZED INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; BLOOD-COAGULATION; BOVINE PLASMA; LIGHT CHAIN; FACTOR-XA; FACTOR-V; THROMBIN; BINDING; ANTIBODIES; COMPLEX	Factor VIII, a cofactor of the intrinsic clotting pathway, is proteolytically inactivated by the vitamin K-dependent serine protease, activated protein C in a reaction requiring Ca2+ and a phospholipid surface. Factor VIII was inactivated 15 times faster than factor VIII in complex with either von Willebrand factor (vWf) or the large homodimeric fragment, SPIII (vWf residues 1-1365). Free factor VIII or factor VIII in complex with a smaller fragment, SPIII-T4 (vWf residues 1-272), were inactivated at the same rate, suggesting that this effect was dependent upon the size of factor VIII-vWf complex rather than changes in factor VIII brought about by occupancy of the vWf-binding site. Thrombin cleavage of the factor VIII light chain to remove the vWf-binding site eliminated the protective effects of vWf. In the absence of phospholipid, high levels of the protease inactivated both free and vWf-bound factor VIII at equivalent rates. Using the same conditions isolated heavy chains and the heavy chains of factor VIII were proteolyzed at similar rates. Taken together, these results suggested that, in the absence of phospholipid, inactivation of factor VIII is independent of factor VIII light chain and further suggest that vWf did not mask susceptible cleavage sites in the cofactor. Solution studies employing fluorescence energy transfer using coumarin-labeled factor VIII (fluorescence donor) and synthetic phospholipid vesicles labeled with octadecyl rhodamine (fluorescence acceptor) indicated saturable binding and equivalent extents of donor fluorescence quenching for factor VIII alone or when complexed with SPIII-T4. However, complexing of factor VIII with either vWf or SPIII eliminated its binding to the phospholipid. Since a phospholipid surface is required for efficient catalysis by the protease, these results suggest that vWf protects factor VIII by inhibiting cofactor-phospholipid interactions.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV CONNECTICUT,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,DEPT LAB MED,FARMINGTON,CT 06032; AMER RED CROSS,BLOOD SERV,FARMINGTON,CT	University of Rochester; University of Rochester; University of Connecticut; University of Connecticut; American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, R01HL040328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38199, HL-40328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169; BLOOM JW, 1987, THROMB RES, V48, P439, DOI 10.1016/0049-3848(87)90401-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1990, J BIOL CHEM, V265, P6197; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FAY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P142, DOI 10.1016/0167-4838(89)90153-2; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FULCHER CA, 1984, BLOOD, V63, P486; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HAMER RJ, 1987, EUR J BIOCHEM, V167, P253, DOI 10.1111/j.1432-1033.1987.tb13331.x; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KANE WH, 1988, BLOOD, V71, P539; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MARLAR RA, 1982, BLOOD, V59, P1067; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; OWEN WG, 1972, THROMB DIATH HAEMOST, V27, P502, DOI 10.1055/s-0038-1649389; RICK ME, 1990, J LAB CLIN MED, V115, P415; Seegers W.H., 1972, THROMB RES, V1, P443; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; STENFLO J, 1976, J BIOL CHEM, V251, P355; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788	39	124	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2172	2177						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846615				2022-12-25	WOS:A1991EV51500027
J	JOSEPHSON, RA; SILVERMAN, HS; LAKATTA, EG; STERN, MD; ZWEIER, JL				JOSEPHSON, RA; SILVERMAN, HS; LAKATTA, EG; STERN, MD; ZWEIER, JL			STUDY OF THE MECHANISMS OF HYDROGEN-PEROXIDE AND HYDROXYL FREE RADICAL-INDUCED CELLULAR INJURY AND CALCIUM OVERLOAD IN CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEART-CELLS; REPERFUSION INJURY; SUPEROXIDE-DISMUTASE; ISCHEMIA REPERFUSION; MYOCARDIAL ISCHEMIA; XANTHINE-OXIDASE; PERFUSED HEART; OXYGEN; REDUCTION; CATALASE	There is evidence that myocardial injury, as would occur on post-ischemic reperfusion, may be caused by the generation of oxygen radicals, as well as by the induction of intracellular calcium overload; however, the relationship between these two mechanisms of injury is not known. To test the hypothesis that oxidants and oxygen radicals can cause cardiac myocyte injury and intracellular calcium overload, isolated adult rat ventricular myocytes were exposed to H2O2 (1-10 mM) and Fe3+-nitrilotriacetate. EPR measurements confirmed the production of the highly reactive .OH radical by this system. The oxygen radical generating system initially caused a transient augmentation of twitch amplitude in single field stimulated myocytes. This was followed by contractile oscillations occurring during the twitch prior to full cell relaxation, and spontaneous mechanical oscillations occurring between electrically stimulated contractions. Eventually, cells became inexcitable and abruptly underwent contracture. In the presence of lower bathing calcium concentrations, these oxidant-induced alterations were prevented or delayed. However, cells exposed to the radical generating system in the absence of extracellular calcium still eventually underwent contracture but stimulated contractions or mechanical oscillations were not seen. Measurements in single myocytes loaded with the fluorescent probe of intracellular calcium, Indo-1, demonstrated a rise in both systolic and diastolic fluorescence ratio, as well as oscillation and widening of the fluorescence transient, suggestive of cellular calcium loading, following exposure to the radical generating system. Injured myocytes did not take up trypan blue dye. Contractile dysfunction and calcium overload were prevented by the calcium channel blocker, nitrendipine. NMR measurements of cellular [ATP] demonstrated that these alterations in cellular calcium preceded the depletion of ATP. Subsequent depletion of ATP was accompanied by the appearance of increased concentrations of sugar phosphates indicative of a block in glycolysis and ATP depletion correlated with cellular rigor. Thus, oxygen free radicals can cause cardiac myocyte injury with contractile abnormalities which occur due to myocyte calcium loading. The mechanism of oxidant-induced calcium loading is not due to nonspecific membrane damage, or energy depletion, but rather due to increased calcium influx through voltage gated calcium channels. This early calcium overload state as well as oxidant induced block of glycolysis result in cellular energy depletion and cell death with the induction of contracture.	JOHNS HOPKINS MED INST,DEPT MED,DIV CARDIOL,ELECTRON PARAMAGNET RESONANCE LABS,BALTIMORE,MD 21224; NIA,GERONTOL RES CTR,CARDIOVASC SCI LAB,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Lakatta, Edward G/AAL-1447-2020	Lakatta, Edward/0000-0002-4772-0035; Stern, Michael/0000-0003-4476-7425	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017655, R01HL038324, R29HL038324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17655-13, HL-07227, HL-38324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AISEN P, 1978, J BIOL CHEM, V253, P1930; ALLSHIRE A, 1987, BIOCHEM J, V244, P381, DOI 10.1042/bj2440381; AMBROSIO G, 1987, CIRCULATION, V75, P282, DOI 10.1161/01.CIR.75.1.282; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; BARRINGTON PL, 1988, J MOL CELL CARDIOL, V20, P1163, DOI 10.1016/0022-2828(88)90596-2; BARRY WH, 1987, CIRC RES, V61, P726, DOI 10.1161/01.RES.61.5.726; BOLLI R, 1987, CIRCULATION, V76, P458, DOI 10.1161/01.CIR.76.2.458; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; CHAMBERS DE, 1985, J MOL CELL CARDIOL, V17, P145, DOI 10.1016/S0022-2828(85)80017-1; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; GOLDHABER JI, 1989, J CLIN INVEST, V83, P1800, DOI 10.1172/JCI114085; HAWORTH RA, 1981, CIRC RES, V49, P1119, DOI 10.1161/01.RES.49.5.1119; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KLEIN HH, 1989, J AM COLL CARDIOL, V13, P1395, DOI 10.1016/0735-1097(89)90317-3; KORT AA, 1985, CIRC RES, V57, P844, DOI 10.1161/01.RES.57.6.844; KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880; MURPHY JG, 1987, CIRCULATION, V75, P15; PONIE M, 1986, SCIENCE, V233, P886; REEVES JP, 1986, J BIOL CHEM, V261, P4948; SHINE KI, 1978, CIRC RES, V43, P712, DOI 10.1161/01.RES.43.5.712; SHLAFER M, 1982, J THORAC CARDIOV SUR, V83, P830; SILVER LH, 1983, AM J PHYSIOL, V245, pH891, DOI 10.1152/ajpheart.1983.245.5.H891; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; STERN MD, 1988, P NATL ACAD SCI USA, V85, P6954, DOI 10.1073/pnas.85.18.6954; STUART J, 1989, Biophysical Journal, V55, p15A; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; WEISS RG, 1990, IN PRESS J CLIN INVE; WERNS SW, 1985, CIRC RES, V56, P895, DOI 10.1161/01.RES.56.6.895; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	36	255	260	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2354	2361						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846625				2022-12-25	WOS:A1991EV51500053
J	KOUZARIDES, T; PACKHAM, G; COOK, A; FARRELL, PJ				KOUZARIDES, T; PACKHAM, G; COOK, A; FARRELL, PJ			THE BZLF1 PROTEIN OF EBV HAS A COILED COIL DIMERIZATION DOMAIN WITHOUT A HEPTAD LEUCINE REPEAT BUT WITH HOMOLOGY TO THE C/EBP LEUCINE ZIPPER	ONCOGENE			English	Article							DNA-BINDING SPECIFICITY; LIVER NUCLEAR-PROTEIN; EPSTEIN-BARR VIRUSES; FOS-JUN INTERACTION; SWITCH GENE BZLF1; DIMERIZATION SPECIFICITY; ZTA TRANSACTIVATOR; MESSENGER-RNAS; EARLY PROMOTER; C-FOS	The EBV transactivator protein BZLF1 can bind many sites in EBV genome, most of which have homology to a consensus AP-1 site, the binding site for the fos/jun family of transcription factors. Here we present evidence that BZLF1 can also recognise the binding site for the CCAAT/enhancer binding protein C/EBP and that a BZLF1 binding site within the BZLF1 promoter is recognised by the C/EBP protein. Analysis of the BZLF1 DNA binding domain suggests that the BZLF1 protein binds to DNA as a dimer using sequences adjacent to a basic DNA binding motif. The BZLF1 dimerisation domain does not have a hepatad repeat of leucine residues common to leucine zipper proteins but does not have characteristics of a coiled coil structure, as judged by site directed mutagenesis. We therefore propose that the dimerisation domain of BZLF1 is structurally related to the coiled coil structure of leucine zippers but lacks the highly conserved leucine repeat. We show that the PZLF1 dimerisation domain has residues in common with the C/EBP leucine zipper and discuss the possible implications of this relationship.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research	KOUZARIDES, T (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PATHOL,DIV VIROL,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.			Kouzarides, Tony/0000-0002-8918-4162; Farrell, Paul/0000-0002-6754-9351				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHAVRIER P, 1989, J VIROL, V63, P607, DOI 10.1128/JVI.63.2.607-614.1989; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COHEN DR, 1990, ONCOGENE, V5, P929; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; COX MA, 1990, J VIROL, V64, P313, DOI 10.1128/JVI.64.1.313-321.1990; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FLEMINGTON E, 1990, J VIROL, V64, P1217, DOI 10.1128/JVI.64.3.1217-1226.1990; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KENNEY S, 1989, J VIROL, V63, P1729, DOI 10.1128/JVI.63.4.1729-1736.1989; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; LIEBERMAN PM, 1989, J VIROL, V63, P3040, DOI 10.1128/JVI.63.7.3040-3050.1989; LIEBERMAN PM, 1990, J VIROL, V64, P2560, DOI 10.1128/JVI.64.6.2560-2568.1990; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MANET E, 1989, EMBO J, V8, P1819, DOI 10.1002/j.1460-2075.1989.tb03576.x; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; PACKHAM G, 1990, J VIROL, V64, P2110, DOI 10.1128/JVI.64.5.2110-2116.1990; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; TAYLOR N, 1989, J VIROL, V63, P1721, DOI 10.1128/JVI.63.4.1721-1728.1989; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	47	96	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					195	204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847997				2022-12-25	WOS:A1991FZ13400003
J	TOURAY, M; RYAN, F; SAURER, S; MARTIN, F; JAGGI, R				TOURAY, M; RYAN, F; SAURER, S; MARTIN, F; JAGGI, R			MOS-INDUCED INHIBITION OF GLUCOCORTICOID RECEPTOR FUNCTION IS MEDIATED BY FOS	ONCOGENE			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; GENE-EXPRESSION; C-FOS; PHORBOL ESTER; RAS ONCOGENE; DEPENDENT TRANSCRIPTION; STEROID-HORMONES; V-MOS	Activation of glucocorticoid hormone-dependent transcription involves the binding of the glucocorticoid hormone to its receptor followed by a specific interaction of the hormone/receptor complex with glucocorticoid responsive elements in the promoter region of hormone-inducible genes. In stably transfected NIH3T3 cells expressing the oncogene product of v-mos or fos, the expression from two glucocorticoid responsive promoters, MMTV LTR and metallothionein IIA (Mt(IIA)), was shown to be impaired and was only transient. Cadmium-dependent Mt(IIA) gene expression was not affected by the expression of v-mos in the cells. In transiently transfected NIH3T3 cells constitutive fos expression also inhibited glucocorticoid hormone-induced expression from the MMTV LTR. However, co-expression of antisense fos (here referred to as sof) inhibited the down-regulatory effect of Fos on glucocorticoid induced gene expression. v-mos expression in NIH3T3 cells induces fos mRNA and functional fos product (Fos) as reflected by its ability to induce expression of a transiently transfected AP-1 dependent reporter plasmid. We show that sof expression inhibits the down-regulatory effect of mos on expression of a transiently transfected pMMTV LTR-CAT. Our findings, thus, strongly suggest that the inhibition of glucocorticoid receptor function in cells expressing the v-mos oncogene is mediated by Fos.	UNIV BERN, DEPT CLIN & EXPTL CANC RES, TIEFENAUSTR 120, CH-3004 BERN, SWITZERLAND; NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND	University of Bern; University College Dublin			Ryan, Fergus/B-8407-2012					ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUETTI E, 1983, EMBO J, V2, P1423, DOI 10.1002/j.1460-2075.1983.tb01601.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HAMILTON BJ, 1989, P NATL ACAD SCI USA, V86, P597, DOI 10.1073/pnas.86.2.597; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAGGI R, 1989, CANCER RES, V49, pS2266; JAGGI R, 1988, J STEROID BIOCHEM, V29, P457, DOI 10.1016/0022-4731(88)90179-3; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; PRATT WB, 1988, J BIOL CHEM, V263, P267; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SALMONS B, 1986, GENE, V45, P215, DOI 10.1016/0378-1119(86)90257-X; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHUSTER WA, 1988, EMBO J, V7, P1721, DOI 10.1002/j.1460-2075.1988.tb03001.x; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; VASSALLI JD, 1976, CELL, V8, P271, DOI 10.1016/0092-8674(76)90011-8; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	59	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1991	6	2					211	217						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847998				2022-12-25	WOS:A1991FZ13400005
J	WIATER, LA; GRINDLEY, NDF				WIATER, LA; GRINDLEY, NDF			GAMMA-DELTA-TRANSPOSASE - PURIFICATION AND ANALYSIS OF ITS INTERACTION WITH A TRANSPOSON END	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL INVERTED REPEATS; BACTERIOPHAGE-MU; GAMMA-DELTA; GEL-ELECTROPHORESIS; CLONING VEHICLES; TN3 TRANSPOSASE; DNA; BINDING; PROTEIN; RECOMBINATION	gamma-delta, a member of the Tn3 family of prokaryotic transposons, encodes a transposase that binds to the 35-base pair (bp) terminal inverted repeats (IRs) which define the transposing DNA segment. The gamma-delta transposase has been overexpressed, identified by molecular weight determination and by immunoblotting, and purified to homogeneity. Production of soluble transposase required the presence of Mg2+ prior to cell lysis. Fractions from a Sephacryl S-300 column contained levels of IR-binding activity that parallel the concentration of transposase, indicating that transposase alone is sufficient for binding to the ends of gamma-delta. Hydroxyl radical footprinting indicated that transposase binds to one face of the DNA helix. The protected region extends across the IR and up to 17 bp into the flanking DNA. Integration host factor (IHF), which binds adjacent to transposase, also protects one face of the DNA helix and is shifted about 70-degrees around the helical axis from the transposase protection. Analysis of transposase-DNA complexes by electrophoresis on nondenaturing gels indicated that three complexes, two within the gel and one trapped at the well, result from specific interactions with the IR. The complex in the well and one complex in the gel were analyzed by methylation interference experiments. The results indicate that transposase interacts with specific base pairs between positions 10 and 37 of the IR, a region encompassing three consecutive major and minor grooves. Methylated bases at the very end of the transposon (positions 1-9) and in the flanking DNA did not inhibit transposase binding. Thus, although transposase seems to be in intimate contact throughout the IR of gamma-delta and 17 bp of flanking DNA, specific base pair recognition needed for binding appears to be determined by the inner three-quarters of the IR.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University					NIGMS NIH HHS [GM28470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028470, R01GM028470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; DERBYSHIRE KM, 1987, P NATL ACAD SCI USA, V84, P8049, DOI 10.1073/pnas.84.22.8049; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DODD IB, 1987, J MOL BIOL, V194, P557, DOI 10.1016/0022-2836(87)90681-4; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; GRINDLEY NDF, 1980, P NATL ACAD SCI-BIOL, V77, P7176, DOI 10.1073/pnas.77.12.7176; HAGERMAN PJ, 1986, NATURE, V321, P449, DOI 10.1038/321449a0; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; ICHIKAWA H, 1987, P NATL ACAD SCI USA, V84, P8220, DOI 10.1073/pnas.84.23.8220; KANS JA, 1989, J BACTERIOL, V171, P1904, DOI 10.1128/jb.171.4.1904-1914.1989; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MILLER HI, 1977, DNA INSERTION ELEMEN, P349; Miller J.H., 1972, EXPT MOL GENETICS; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MORITA M, 1987, J BIOCHEM-TOKYO, V101, P1253, DOI 10.1093/oxfordjournals.jbchem.a121989; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NASH HA, 1981, J BIOL CHEM, V256, P9246; NEW JH, 1988, J MOL BIOL, V201, P589, DOI 10.1016/0022-2836(88)90640-7; REED RR, 1981, P NATL ACAD SCI-BIOL, V78, P3428, DOI 10.1073/pnas.78.6.3428; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; Shapiro JA, 1983, MOBILE GENETIC ELEME, P223; SHERRATT D, 1989, MOBILE DNA, P163; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WIATER LA, 1988, EMBO J, V7, P1907, DOI 10.1002/j.1460-2075.1988.tb03024.x; WIATER LA, 1990, J BACTERIOL, V172, P4959, DOI 10.1128/jb.172.9.4959-4963.1990; Williams JGK, 1977, DNA INSERTION ELEMEN, P357; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	50	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1841	1849						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846366				2022-12-25	WOS:A1991EU49700073
J	BURGISSER, DM; ROTH, BV; GIGER, R; LUTHI, C; WEIGL, S; ZARN, J; HUMBEL, RE				BURGISSER, DM; ROTH, BV; GIGER, R; LUTHI, C; WEIGL, S; ZARN, J; HUMBEL, RE			MUTANTS OF HUMAN INSULIN-LIKE GROWTH FACTOR-II WITH ALTERED AFFINITIES FOR THE TYPE-1 AND TYPE-2 INSULIN-LIKE GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; STRUCTURAL HOMOLOGY; BIOLOGICAL-ACTIVITY; BINDING; EXPRESSION; CLEAVAGE; ANALOGS; SERUM; CHAIN; CELLS	With the aim to produce insulin-like growth factors (IGF) with enhanced specificity for the type 1 or type 2 IGF receptors, three mutants of IGF II have been prepared and expressed in NIH-3T3 cells. IGF II mutated at Tyr27 to Leu and Glu showed a 25- and 54-fold decrease in affinity for the type 1 IGF receptor and a 3.4- and 9.2-fold decrease in affinity for the type 2 IGF receptor. IGF II mutated at Phe48 to Glu showed a 18-fold decrease in affinity for the type 2 IGF receptor and a 2.8-fold decrease in affinity for the type 1 IGF receptor. These affinities were measured in radioreceptor assays using type 1 or 2 IGF receptor overexpressing cells. Data obtained on receptor cross-linking and thymidine incorporation assays confirmed the results of the radioreceptor assays. It is concluded that mutations of Tyr27 preferentially decrease binding to the type 1 IGF receptor and of Phe48 to the type 2 IGF receptor, either by the loss of a residue involved in receptor binding or by preferentially destabilizing the region involved in receptor binding.			BURGISSER, DM (corresponding author), UNIV ZURICH,DEPT BIOCHEM,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Zarn, Juerg/0000-0003-2216-560X				BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BLUNDELL TL, 1980, NATURE, V287, P781, DOI 10.1038/287781a0; BURGISSER DM, 1990, BIOCHEM BIOPH RES CO, V169, P832; CARA JF, 1988, ENDOCRINOLOGY, V122, P2881, DOI 10.1210/endo-122-6-2881; CASCIERI MA, 1988, BIOCHEMISTRY-US, V27, P3229, DOI 10.1021/bi00409a016; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAFGARD E, 1985, J CELL SCI, P53; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAVIS LG, 1986, BASIC METHODS MOL BI, P93; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; IRMINGER JC, 1987, P NATL ACAD SCI USA, V84, P6330, DOI 10.1073/pnas.84.18.6330; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KOBAYASHI M, 1982, BIOCHEM J, V206, P597, DOI 10.1042/bj2060597; KOJIMA I, 1988, BIOCHEM BIOPH RES CO, V154, P9, DOI 10.1016/0006-291X(88)90642-0; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUBLI UK, 1982, FEBS LETT, V149, P109, DOI 10.1016/0014-5793(82)81082-X; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1986, BIOCHEM BIOPH RES CO, V138, P1341, DOI 10.1016/S0006-291X(86)80430-2; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; RINDERKNECHT E, 1976, P NATL ACAD SCI USA, V73, P4379, DOI 10.1073/pnas.73.12.4379; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARVER N, 1982, P NATL ACAD SCI-BIOL, V79, P7147, DOI 10.1073/pnas.79.23.7147; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAGER H, 1980, P NATL ACAD SCI-BIOL, V77, P3181, DOI 10.1073/pnas.77.6.3181; TAGER H, 1979, NATURE, V281, P122, DOI 10.1038/281122a0; TALLY M, 1987, BIOCHEM BIOPH RES CO, V147, P1206, DOI 10.1016/S0006-291X(87)80198-5; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOLLMER A, 1981, H-S Z PHYSIOL CHEM, V362, P581, DOI 10.1515/bchm2.1981.362.1.581; ZUMSTEIN PP, 1985, METHOD ENZYMOL, V109, P782	37	34	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1029	1033						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845984				2022-12-25	WOS:A1991ET17700057
J	LUVISETTO, S; CONTI, E; BUSO, M; AZZONE, GF				LUVISETTO, S; CONTI, E; BUSO, M; AZZONE, GF			FLUX RATIOS AND PUMP STOICHIOMETRIES AT SITE-II AND SITE-3 IN LIVER-MITOCHONDRIA - EFFECT OF SLIPS AND LEAKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGE TRANSLOCATION STOICHIOMETRY; PROTON-ELECTROCHEMICAL GRADIENT; ATPASE H+ PUMPS; OXIDATIVE-PHOSPHORYLATION; LOWER LIMITS; MECHANISTIC STOICHIOMETRY; ELECTRON-TRANSPORT; CYTOCHROME-OXIDASE; RESPIRATION; MEMBRANE	Addition of bovine serum albumin to state 4 mitochondria results in a depression of the proton leak and of the resting respiration of 70 and 25%, respectively. The conductance membrane potential diagram, both in the ohmic and in the non-ohmic region, shows that in the presence of bovine serum albumin the level of ohmic conductance is lowered while that of non-ohmic conductance is increased toward higher DELTA-psi values. The same effect is observed during operation of the different proton pumps. Addition of chloroform affects the conductance membrane potential diagram in the following manner: there is no effect in the ohmic region with all pumps, while there is an effect in the non-ohmic region either at site III or at sites II plus III but not at site II. This suggests a possible effect of chloroform at the level of the cytochrome oxidase proton pump. During titration with oligomycin of the ATPase proton pump the conductance potential diagram shows a region of non-ohmicity only in the presence but not in the absence of an ATP-regenerating system. Protonophoric uncouplers such as carbonyl cyanide p(trifluoromethoxy)phenylhydrazone and intrinsic uncouplers such as chloroform have different effects on the relationship between rates of charge translocation and of oxygen consumption, and thus on the pump stoichiometries, in that the slope of the diagram is modified by the latter but not by the former. The differential effects of protonophores and of intrinsic uncouplers on the stoichiometries have been analyzed by computer simulations and represent an additional criterion to distinguish between extrinsic and intrinsic mechanisms of uncoupling.	UNIV PADUA,INST GEN PATHOL,I-35121 PADUA,ITALY	University of Padua	LUVISETTO, S (corresponding author), UNIV PADUA,CNR,STUDY PHYSIOL MITOCHONDRIA UNIT,I-35121 PADUA,ITALY.		Luvisetto, Siro/AAJ-6985-2021; Luvisetto, Siro/M-9557-2015; Luvisetto, Siro/K-1844-2019	Luvisetto, Siro/0000-0003-1399-2152; Luvisetto, Siro/0000-0003-1399-2152; 				AZZONE GF, 1984, CURR TOP BIOENERG, V13, P1; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P307, DOI 10.1111/j.1432-1033.1986.tb09752.x; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P315, DOI 10.1111/j.1432-1033.1986.tb09753.x; BEAVIS AD, 1987, J BIOL CHEM, V262, P6174; BEAVIS AD, 1987, J BIOL CHEM, V262, P6165; BROWN GC, 1989, J BIOL CHEM, V264, P14704; CHANCE B, 1955, J BIOL CHEM, V217, P395; DUSZYNSKI J, 1985, FEBS LETT, V182, P243, DOI 10.1016/0014-5793(85)80307-0; FINEL M, 1986, BIOCHIM BIOPHYS ACTA, V851, P99, DOI 10.1016/0005-2728(86)90253-7; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; LUVISETTO S, 1989, BIOCHEMISTRY-US, V28, P1109, DOI 10.1021/bi00429a027; LUVISETTO S, 1987, BIOCHEMISTRY-US, V26, P7332, DOI 10.1021/bi00397a021; LUVISETTO S, 1989, BIOCHEMISTRY-US, V28, P1100, DOI 10.1021/bi00429a026; MASSARI S, 1972, J MEMBRANE BIOL, V9, P57, DOI 10.1007/BF01868043; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MURPHY MP, 1988, EUR J BIOCHEM, V173, P637, DOI 10.1111/j.1432-1033.1988.tb14046.x; MURPHY MP, 1988, EUR J BIOCHEM, V173, P645, DOI 10.1111/j.1432-1033.1988.tb14047.x; MURPHY MP, 1989, BIOCHIM BIOPHYS ACTA, V977, P123, DOI 10.1016/S0005-2728(89)80063-5; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; PIETROBON D, 1981, EUR J BIOCHEM, V117, P389, DOI 10.1111/j.1432-1033.1981.tb06350.x; PIETROBON D, 1986, BIOELECTROCH BIOENER, V15, P193, DOI 10.1016/0302-4598(86)80028-9; PIETROBON D, 1986, BIOCHEMISTRY-US, V25, P767, DOI 10.1021/bi00352a005; PIETROBON D, 1985, BIOCHEMISTRY-US, V24, P5764, DOI 10.1021/bi00342a012; PIETROBON D, 1987, BIOCHEMISTRY-US, V26, P7339, DOI 10.1021/bi00397a022; PIETROBON D, 1983, BIOCHIM BIOPHYS ACTA, V723, P317, DOI 10.1016/0005-2728(83)90131-7; SONE N, 1984, BIOCHEMISTRY-US, V23, P6550, DOI 10.1021/bi00321a042; VANDAM K, 1980, BIOCHIM BIOPHYS ACTA, V591, P240, DOI 10.1016/0005-2728(80)90156-5; Westerhoff H., 1987, THERMODYNAMICS CONTR; ZOLKIEWSKA A, 1989, ARCH BIOCHEM BIOPHYS, V275, P580; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZORATTI M, 1982, EUR J BIOCHEM, V126, P443, DOI 10.1111/j.1432-1033.1982.tb06800.x; ZORATTI M, 1984, BIOCHIM BIOPHYS ACTA, V767, P231, DOI 10.1016/0005-2728(84)90192-0	32	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1034	1042						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845985				2022-12-25	WOS:A1991ET17700058
J	RUIZGOMEZ, A; VAELLO, ML; VALDIVIESO, F; MAYOR, F				RUIZGOMEZ, A; VAELLO, ML; VALDIVIESO, F; MAYOR, F			PHOSPHORYLATION OF THE 48-KDA SUBUNIT OF THE GLYCINE RECEPTOR BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; NICOTINIC ACETYLCHOLINE-RECEPTOR; BETA-ADRENERGIC-RECEPTOR; POLYACRYLAMIDE-GEL SYSTEM; RAT SPINAL-CORD; AFFINITY-CHROMATOGRAPHY; AGONIST OCCUPANCY; GABAA-RECEPTOR; STRYCHNINE; BRAIN	The postsynaptic glycine receptor purified from rat spinal cord is rapidly and specifically phosphorylated by protein kinase C. The target for phosphorylation is the strychnine-binding subunit of the receptor (molecular mass of approximately 48 kDa), which is phosphorylated on serine residues to a final stoichiometry of approximately 0.8 mol of phosphate/mol of subunit. The 48-kDa phosphoprotein was analyzed by proteolytic cleavage and peptide mapping in order to localize the site of phosphorylation within the receptor molecule. Examination of the P-32-labeled receptor fragments generated by digestion with N-chlorosuccinimide, cyanogen bromide, and endoproteinase lysine C and of the deduced amino acid sequence of the 48-kDa protein (Grenningloh, G., Rienitz, A., Schmitt, B., Methfessel, C., Zensen, M., Beyreuther, K., Gundelfinger, E. D., and Betz, H. (1987) Nature 328, 215-220) indicates that the phosphorylation site is located in a region corresponding to the major intracellular loop of the predicted structure of the glycine receptor subunit and suggest serine 391 as the phosphorylated residue. In fact, a synthetic peptide corresponding to residues 384-392 of the 48-kDa subunit was specifically phosphorylated by protein kinase C. Moreover, tryptic digests of this phosphopeptide and of the phosphorylated 48-kDa subunit of the glycine receptor migrated to the same position in two-dimensional peptide mapping. Furthermore, antibodies elicited against peptide 384-392 were shown to inhibit the protein kinase C-dependent phosphorylation of the 48-kDa polypeptide. Interestingly, the relative position of the phosphorylated domain is similar to those known or proposed to be phosphorylated in other ligand-gated ion channel receptor subunits, thus suggesting further the existence of a homologous regulatory region in these receptor proteins.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,DEPT BIOL MOLEC,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Ruiz-Gomez, Ana/ABF-3079-2021; Ruiz-Gómez, Ana/H-2092-2015; Mayor, Federico/N-7644-2016	Ruiz-Gómez, Ana/0000-0002-1646-3072; Mayor Menendez, Federico/0000-0003-1434-8449				Aprison MH, 1978, ADV NEUROCHEM, V3, P203; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BORMANN J, 1985, P NATL ACAD SCI USA, V82, P2168, DOI 10.1073/pnas.82.7.2168; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Dohlman H.G., 1987, Biochemistry, V26, P2658; DOWNING JEG, 1987, P NATL ACAD SCI USA, V84, P7739, DOI 10.1073/pnas.84.21.7739; GARCIACALVO M, 1989, BIOCHEMISTRY-US, V28, P6405, DOI 10.1021/bi00441a037; GIULIAN GG, 1985, FED PROC, V44, P686; GRAHAM D, 1983, EUR J BIOCHEM, V131, P519, DOI 10.1111/j.1432-1033.1983.tb07292.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HENSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1987, TRENDS PHARMACOL SCI, V8, P472, DOI 10.1016/0165-6147(87)90041-1; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KRISHTAL OA, 1988, NEUROSCI LETT, V84, P271, DOI 10.1016/0304-3940(88)90519-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM KS, 1980, ANAL BIOCHEM, V108, P220, DOI 10.1016/0003-2697(80)90572-2; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MARVIZON JCG, 1986, MOL PHARMACOL, V30, P590; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MIDDLETON P, 1988, J NEUROSCI, V8, P3405; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PROBST A, 1986, NEUROSCIENCE, V17, P11, DOI 10.1016/0306-4522(86)90222-8; RUIZGOMEZ A, 1989, J NEUROCHEM, V52, P1775, DOI 10.1111/j.1471-4159.1989.tb07256.x; RUIZGOMEZ A, 1990, BIOCHEMISTRY-US, V29, P7033, DOI 10.1021/bi00482a012; RUIZGOMEZ A, 1989, BIOCHEM BIOPH RES CO, V160, P375; RUIZGOMEZ A, 1989, J NEUROCHEM S, V52, P58; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; SOUROUJON MC, 1986, EMBO J, V5, P543, DOI 10.1002/j.1460-2075.1986.tb04244.x; STEINBACH JH, 1987, TRENDS NEUROSCI, V10, P61, DOI 10.1016/0166-2236(87)90024-5; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; VAZQUEZ J, 1988, J BIOL CHEM, V263, P1255; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507; YOUNG AB, 1973, P NATL ACAD SCI USA, V70, P2832, DOI 10.1073/pnas.70.10.2832	56	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					559	566						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845981				2022-12-25	WOS:A1991EQ33900082
J	BLUME, JE; ENNIS, HL				BLUME, JE; ENNIS, HL			A DICTYOSTELIUM-DISCOIDEUM CELLULASE IS A MEMBER OF A SPORE GERMINATION-SPECIFIC GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; MOLECULAR-BIOLOGY; SEQUENCE; DEGRADATION	A member of the 270 spore germination-specific gene family in Dictyostelium discoideum is shown to encode a cellulase (endo-(l, 4)-beta-D-glucanase, EC 3.2.1.4) activity. The 270-6 deduced protein shows 38% identity and 58% similarity to an avocado (Persea americana) cellulase. During spore germination in Dictyostelium extracellular cellulase activity starts to accumulate coincident with the appearance of the 270-6 gene transcript. Amoebae transformed by a vector containing the 270-6 mRNA sequence express an extracellular cellulase during vegetative growth when there would otherwise be no cellulase activity. In addition, the expression of a truncated 270-6 polypeptide lacking the 270 gene family-defining tetrapeptide repeat and the C-terminal region, in suitably transformed amoebae, also produces an extracellular cellulase activity. Several differently sized cellulase activities are shown to accumulate during spore germination, and it is possible that the 270 gene family represents a coordinately expressed family of cellulases.			BLUME, JE (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA.			Blume, John/0000-0003-3026-953X				BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BEGUIN P, 1983, ANAL BIOCHEM, V131, P333, DOI 10.1016/0003-2697(83)90178-1; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; COTTER DA, 1970, DEV BIOL, V22, P112, DOI 10.1016/0012-1606(70)90009-6; COTTER DA, 1968, J BACTERIOL, V96, P86, DOI 10.1128/JB.96.1.86-92.1968; COTTER DA, 1969, J BACTERIOL, V100, P1020, DOI 10.1128/JB.100.2.1020-1026.1969; DASILVA AM, 1990, DEV BIOL, V140, P139, DOI 10.1016/0012-1606(90)90061-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWBENKO DJ, 1980, P NATL ACAD SCI-BIOL, V77, P1791, DOI 10.1073/pnas.77.4.1791; ENNIS HL, 1988, DEV GENET, V9, P303, DOI 10.1002/dvg.1020090412; GIORDA R, 1990, BIOCHEMISTRY-US, V29, P7264, DOI 10.1021/bi00483a015; GIORDA R, 1987, MOL CELL BIOL, V6, P2097; GIRI JG, 1978, DEV BIOL, V67, P189, DOI 10.1016/0012-1606(78)90308-1; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; JOHANSSON G, 1989, FEBS LETT, V243, P389, DOI 10.1016/0014-5793(89)80168-1; JONES THD, 1979, J BACTERIOL, V137, P752, DOI 10.1128/JB.137.2.752-757.1979; KLYOSOV AA, 1990, BIOCHEMISTRY-US, V29, P10577, DOI 10.1021/bi00499a001; KNOWLES J, 1987, TRENDS BIOTECHNOL, V5, P255, DOI 10.1016/0167-7799(87)90102-8; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI, P325; MCKEARIN DM, 1987, J BIOL CHEM, V262, P4939; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PAICE MG, 1979, ADV CHEM SER, V181, P361; TUCKER ML, 1987, PLANT MOL BIOL, V9, P197, DOI 10.1007/BF00166456; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WARRICK HM, 1988, NUCLEIC ACIDS RES, V16, P6617, DOI 10.1093/nar/16.14.6617; Wood T.M., 1988, METHOD ENZYMOL, P160; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	28	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15432	15437						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869562				2022-12-25	WOS:A1991GB09700090
J	HUTCHCROFT, JE; HARRISON, ML; GEAHLEN, RL				HUTCHCROFT, JE; HARRISON, ML; GEAHLEN, RL			LYMPHOCYTE-B ACTIVATION IS ACCOMPANIED BY PHOSPHORYLATION OF A 72-KDA PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STIMULATION; ELECTROPHORESIS; PURIFICATION; PROTEOLYSIS; MOLECULES; RECEPTOR; ANTIGEN; CD4	The cross-linking of membrane IgM on the surface of splenic B lymphocytes or WEHI 231 cells leads to the rapid phosphorylation on tyrosine of a 72-kDa protein as detected in Western blotting experiments using anti-phosphotyrosine antibodies. The 72-kDa phosphoprotein detected in this manner comigrates, in both one- and two-dimensional polyacrylamide gel electrophoresis systems, with PTK72, a 72-kDa protein-tyrosine kinase characterized previously in this laboratory (Zioncheck, T. F., Harrison, M. L., Isaacson, C. C., and Geahlen, R. L. (1988) J. Biol. Chem. 263, 19195-19202). Anti-phosphotyrosine antibodies and anti-PTK72 antibodies immunoprecipitate the same protein-tyrosine kinase from extracts of anti-IgM-activated cells as determined by immune complex kinase assays and one-dimensional phosphopeptide mapping. These results indicate that the tyrosine phosphorylation of a 72-kDa protein-tyrosine kinase is an early event in the activation of B lymphocytes via the antigen receptor.	PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [CA09634, CA37372] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372, T32CA009634] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANOSTARIO M, 1990, ANAL BIOCHEM, V190, P60, DOI 10.1016/0003-2697(90)90133-T; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EARP HS, 1985, J BIOL CHEM, V260, P4351; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRISON ML, 1984, J BIOL CHEM, V259, P9348; JIN YJ, 1990, J IMMUNOL, V144, P647; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; LANE PJL, 1990, J IMMUNOL, V144, P3684; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; SALTZMAN EM, 1990, J BIOL CHEM, V265, P10138; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SEVERSON CD, 1987, IMMUNOL LETT, V15, P291, DOI 10.1016/0165-2478(87)90130-1; SWARUP G, 1983, J BIOL CHEM, V258, P341; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	24	207	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14846	14849						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869521				2022-12-25	WOS:A1991GB09700005
J	MAIMONE, MM				MAIMONE, MM			CORRECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition																		MAIMONE MM, 1990, J BIOL CHEM, V265, P18263	1	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14830	14830						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860877				2022-12-25	WOS:A1991FZ35100108
J	SHAIKH, IM; LAU, BWC; SIEGFRIED, BA; VALDES, R				SHAIKH, IM; LAU, BWC; SIEGFRIED, BA; VALDES, R			ISOLATION OF DIGOXIN-LIKE IMMUNOREACTIVE FACTORS FROM MAMMALIAN ADRENAL-CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA ULTRAFILTRATE; DIGITALIS-LIKE SUBSTANCE; IMMUNOACTIVE FACTORS; BINDING; ATPASE; TISSUE; SERUM; BLOOD; RAT; PIG	Endogenous digoxin-like immunoreactive factors (DLIF) are present in serum and tissues of humans and animals. To date, a tissue source for these factors has not been rigorously defined nor have these factors been isolated to identifiable homogeneity. In this study, we define the distribution of DLIF in mammalian tissues, demonstrate the adrenal cortex to be the principal source of this factor in bovine, and isolate DLIF to chromatographic homogeneity using high performance liquid chromatography (HPLC). DLIF concentrations in tissue extracts from rats measured as follows: adrenal glands, 44.3; serum, 6.3; liver, 5.2; kidney, 1.2; heart, brain, or lungs, < 1.4 ng of digoxin-equivalent per g of protein. Human tissues showed similar results. In dogs, the ratio of the DLIF concentration in lumbar vein serum to that in infrarenal inferior vena cava serum was 3.3 +/- 0.4 (mean +/- S.E., n = 4). Bovine adrenal cortex contained 7 times more DLIF per g of tissue than the adrenal medulla. 70 +/- 4% (n = 7) of the total bovine cortical DLIF activity (6,159 pg of digoxin-equivalent) applied to a reverse phase HPLC column eluted as one definitive fraction. 60% of the digoxin-like immunoreactivity extracted from bovine serum also co-eluted with DLIF from adrenal. None of the 14 steroid molecules or 7 cardiac glycoside congeners co-eluted with the major DLIF activity. Our data indicate that 947 pmol of DLIF is equivalent to 1 pmol of digoxin-equivalent immunoreactivity. Preliminary mass spectral analysis suggests that purified DLIF has a molecular mass of 780 daltons comprised of one 390-dalton aglycone component plus several sugar moieties. This study establishes a definitive link between DLIF in serum and the adrenal cortex as a source tissue. We also demonstrate a method for purifying DLIF to chromatographic homogeneity with an extraction capacity of 1.2 nmol of DLIF per g of adrenal cortex.	UNIV LOUISVILLE,SCH MED,DEPT PATHOL,LOUISVILLE,KY 40292; UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT PATHOL & LAB MED,ST LOUIS,MO 63110	University of Louisville; University of Louisville; Barnes-Jewish Hospital; Washington University (WUSTL)					NHLBI NIH HHS [HL-37074, HL-36172] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037074, R01HL036172] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1977, SCIENCE, V198, P569, DOI 10.1126/science.144320; CASTANEDAHERNANDEZ G, 1984, CLIN SCI, V66, P225, DOI 10.1042/cs0660225; DASGUPTA A, 1988, BIOCHEM BIOPH RES CO, V152, P1435, DOI 10.1016/S0006-291X(88)80446-7; DASGUPTA A, 1987, BIOCHEM BIOPH RES CO, V148, P623, DOI 10.1016/0006-291X(87)90922-3; DECASTRO JCB, 1985, P SOC EXP BIOL MED, V179, P132; DORIS PA, 1989, ENDOCRINOLOGY, V125, P2573, DOI 10.1210/endo-125-5-2573; GAULT MH, 1988, CLIN PHYSIOL BIOCH, V6, P253; GRUBER KA, 1982, HYPERTENSION, V4, P348, DOI 10.1161/01.HYP.4.3.348; GRUBER KA, 1980, NATURE, V287, P743, DOI 10.1038/287743a0; HADDY FJ, 1987, ISI ATLAS-PHARMACOL, V1, P119; HAMLYN JM, 1989, J BIOL CHEM, V264, P7395; KELLY RA, 1986, J BIOL CHEM, V261, P1704; KHATTER JC, 1986, LIFE SCI, V39, P2483, DOI 10.1016/0024-3205(86)90491-1; KRAMER HJ, 1986, KLIN WOCHENSCHR, V64, P760, DOI 10.1007/BF01734344; LAU BWC, 1988, CLIN CHIM ACTA, V175, P67, DOI 10.1016/0009-8981(88)90036-8; NISHIKAWA T, 1984, J STEROID BIOCHEM, V20, P1123, DOI 10.1016/0022-4731(84)90354-6; SCHREIBER V, 1981, ENDOCRINOL EXP, V15, P229; SCHREIBER V, 1981, J MOL CELL CARDIOL, V13, P107, DOI 10.1016/0022-2828(81)90232-7; SHILO L, 1989, LIFE SCI, V44, P1867, DOI 10.1016/0024-3205(89)90304-4; SHILO L, 1987, ISRAEL J MED SCI, V23, P294; SOLDIN SJ, 1984, CLIN BIOCHEM, V17, P317, DOI 10.1016/S0009-9120(84)90637-4; TEMPLETON JF, 1988, CAN J PHYSIOL PHARM, V66, P1420, DOI 10.1139/y88-231; VALDES R, 1985, CLIN CHEM, V31, P1015; VALDES R, 1985, J CLIN ENDOCR METAB, V60, P1135, DOI 10.1210/jcem-60-6-1135; VALDES R, 1985, CLIN CHEM, V31, P1525; VALDES R, 1988, LIFE SCI, V42, P103, DOI 10.1016/0024-3205(88)90629-7; VALDES R, 1985, FED PROC, V44, P2800; Valdes R Jr, 1985, Prog Clin Biol Res, V192, P229	28	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13672	13678						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856201				2022-12-25	WOS:A1991FY02700036
J	WANG, QP; VANDUSEN, WJ; PETROSKI, CJ; GARSKY, VM; STERN, AM; FRIEDMAN, PA				WANG, QP; VANDUSEN, WJ; PETROSKI, CJ; GARSKY, VM; STERN, AM; FRIEDMAN, PA			BOVINE LIVER ASPARTYL BETA-HYDROXYLASE - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-DEPENDENT PROTEINS; FACTOR-LIKE DOMAINS; HYDROXYASPARTIC ACID; PROLYL 4-HYDROXYLASE; CALCIUM-BINDING; FACTOR-IX; IDENTIFICATION; IRON	The alpha-ketoglutarate-dependent dioxygenase, L-Asp (L-Asn)-beta-hydroxylase which posttranslationally hydroxylates specific aspartic acid (asparagine) residues within epidermal growth factor-like domains was purified from bovine liver and characterized. A 52-kDa and a 56-kDa species of this enzyme, which accounted for 60 and 30% of the total enzymatic activity, respectively, were purified to apparent homogeneity. Amino-terminal sequence analyses and immunoblots utilizing antisera raised to the intact 52-kDa species as well as to two complementary fragments of this species demonstrated that the 52- and 56-kDa species differ by a 22-amino acid amino-terminal extension. The remaining 10% of the purified enzymatic activity could be accounted for by the presence of immunologically related higher molecular mass forms (56-90 kDa) Of L-Asp(L-Asn)-beta-hydroxylase. Strong evidence was obtained from the results of immunoextraction studies that L-Asp(L-Asn)-beta-hydroxylase can be identified with the purified proteins. Kinetic and physical studies suggest that L-Asp(L-Asn)-beta-hydroxylase exists as a monomer with a compact catalytic domain and an extended protease-sensitive amino terminus whose function remains to be determined. Since the purified L-Asp(L-Asn)-beta-hydroxylase hydroxylated both L-Asp- and L-Asn-containing substrates, it is possible that a single enzyme is responsible for the hydroxylation of Asp and Asn residues in vivo.	MERCK SHARP & DOHME LTD, W44-204, West Point, PA 19486 USA	Merck & Company				Stern, Andrew/0000-0002-8437-2957				Abbott MT, 1974, MOL MECHANISMS OXYGE, P167; ARLAUD GJ, 1987, FEBS LETT, V222, P129, DOI 10.1016/0014-5793(87)80205-3; CARDINALE GJ, 1974, ADV ENZYMOL RAMB, V41, P245; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FOWLER SA, 1986, J BIOL CHEM, V261, P4371; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; GRONKE RS, 1990, J BIOL CHEM, V265, P8558; HAYAISHI O, 1976, ENZYMES, V12, P119; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1980, ENZYMOLOGY POST TRAN, P53; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MCMULLEN BA, 1983, BIOCHEM BIOPH RES CO, V115, P8, DOI 10.1016/0006-291X(83)90961-0; NIETFELD JJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P349, DOI 10.1016/0005-2744(80)90089-3; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; TUDERMAN L, 1977, EUR J BIOCHEM, V80, P341, DOI 10.1111/j.1432-1033.1977.tb11888.x	24	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14004	14010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856229				2022-12-25	WOS:A1991FY02700086
J	PADRELL, E; CARTY, DJ; MORIARTY, TM; HILDEBRANDT, JD; LANDAU, EM; IYENGAR, R				PADRELL, E; CARTY, DJ; MORIARTY, TM; HILDEBRANDT, JD; LANDAU, EM; IYENGAR, R			2 FORMS OF THE BOVINE BRAIN G0 THAT STIMULATE THE INOSITOL TRISPHOSPHATE-MEDIATED CL- CURRENTS IN XENOPUS-OOCYTES - DISTINCT GUANINE-NUCLEOTIDE BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; PERTUSSIS TOXIN; REGULATORY PROTEINS; MOLECULAR CHARACTERIZATION; ADENYLATE-CYCLASE; ESCHERICHIA-COLI; PHOSPHOLIPASE-C; NERVOUS-SYSTEM; GO-PROTEIN; IDENTIFICATION	Heterotrimeric GTP-binding proteins from bovine brain were resolved by fast protein liquid chromatography chromatography using Mono Q columns. Two distinct forms of the protein G(o) were identified. Both forms had stochiometric amounts of alpha- and beta-gamma-subunits. The alpha-subunits of both forms were recognized by an alpha-o-specific antiserum, but not by any of the alpha-i-specific antisera. The two forms showed distinct migration patterns on 9% sodium dodecyl sulfate-polyacrylamide gels containing 4-8 M urea gradients. Neither form comigrated with the recombinant alpha-o1. Both the recombinant alpha-o1 and the most abundant form of G(o) were recognized by an antiserum, H-660, against a peptide encoding amino acids 3-17 of alpha-i2. H-660 has been shown previously to recognize alpha-o and alpha-i (Mumby, S. M., Pang, I. K., Gilman, A. G., and Sternweis, P. C. (1988) J. Biol. Chem. 263, 2020-2026). This more abundant form is called G(o) A most likely corresponds to the cloned alpha-o1. The less abundant form, G(o) B, was not recognized by H-660. However, both forms of bovine brain G(o) were recognized by GC/2, an antiserum against the N-terminal region of alpha-o1. Hence alpha-o(A) and alpha-o(B) may be different in their N terminus regions. Neither form of bovine brain G(o) was recognized by an antisera made to a peptide encoding the unique regions of the cloned alpha-o2 from HIT cells (Hsu W. H., Rudolph, U., Sanford, J., Bertrand, P., Olate, J., Nelson, C., Moss, L. E., Boyd, A. E., III, Codina, J., and Birnbaumer, L. (1990) J. Biol. Chem. 265, 11220-11226). G(o) A and G(o) B have similar guanine nucleotide binding and release properties. Both release GDP within 1 min in the absence of added Mg2+. Both bind guanosine (GTP-gamma-S) rapidly as well. However G(o) A binds GTP-gamma-S about 2.5-fold faster than G(o) B, in the absence of added Mg2+ ion. Both forms of G(o) as well as the recombinant alpha-o (alpha-o1) can increase muscarinic stimulation of inositol trisphosphate-mediated Cl- current in Xenopus oocytes. These data indicate that we have identified two structurally distinct forms of G(o) that have different guanine nucleotide binding properties and are capable of functioning in the receptor-regulated phospholipase C pathway in Xenopus oocytes.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,BOX 1215,ONE GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT PSYCHIAT,NEW YORK,NY 10029; WORCHESTER FDN EXPTL BIOL,SHREWSBURY,MA 01549; VET ADM MED CTR,DEPT PSYCHIAT,BRONX,NY 10468	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA 44998] Funding Source: Medline; NIDA NIH HHS [DA 07135] Funding Source: Medline; NIDDK NIH HHS [DK 38761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BIRNBAUMER L, 1988, COLD SPRING HARB SYM, V53, P229, DOI 10.1101/SQB.1988.053.01.029; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CODINA J, 1984, J BIOL CHEM, V259, P5871; DESOUSA SM, 1989, J BIOL CHEM, V264, P18544; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HSU WH, 1990, J BIOL CHEM, V265, P11220; INANOBE A, 1990, FEBS LETT, V263, P369, DOI 10.1016/0014-5793(90)81416-L; ITOH H, 1988, J BIOL CHEM, V263, P6656; IYENGAR R, 1987, J BIOL CHEM, V262, P9239; IYENGAR R, 1988, J BIOL CHEM, V263, P15348; IYENGAR R, 1990, G PROTEINS, P1; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KIM S, 1988, P NATL ACAD SCI USA, V85, P4153, DOI 10.1073/pnas.85.12.4153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG J, 1989, EUR J BIOCHEM, V183, P687, DOI 10.1111/j.1432-1033.1989.tb21099.x; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; PREMONT RT, 1989, J BIOL CHEM, V264, P14960; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; THAMBI NC, 1989, J BIOL CHEM, V264, P18552; TOUANT M, 1987, FEBS LETT, V215, P339; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YOON JS, 1989, J BIOL CHEM, V264, P18536	40	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9771	9777						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851756				2022-12-25	WOS:A1991FM45900067
J	ULMER, JB; PALADE, GE				ULMER, JB; PALADE, GE			EFFECTS OF BREFELDIN-A ON THE PROCESSING OF VIRAL ENVELOPE GLYCOPROTEINS IN MURINE ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCUS-FORMING VIRUS; CULTURED RAT HEPATOCYTES; INTRACELLULAR-TRANSPORT; MEMBRANE-GLYCOPROTEINS; LEUKEMIA-VIRUS; ENDOPLASMIC-RETICULUM; PROTEIN ANTIGENS; SURFACE EXPRESSION; SECRETORY PROTEINS; OLIGOSACCHARIDES	This paper documents the effects of brefeldin A (BFA) on the processing and transport of viral envelope glycoproteins in a retrovirus-transformed murine erythroleukemia (MEL) cell line. BFA is a fungal metabolite that disrupts intracellular membrane traffic at the endoplasmic reticulum (ER)-Golgi complex junction. In MEL cells, BFA inhibited the processing of the newly synthesized precursor, gPr90env, of the murine leukemia virus envelope protein, gp70, and curtailed the budding of virions into the culture medium by blocking the transport of this protein out of the ER. The block resulted in the intracellular accumulation of gPr90env and two putative products of its processing (78 and 66 kDa). The results of endoglycosidase (endo) H and D digestion of the viral glycoproteins in the presence and absence of BFA indicated that (i) there was no glycoprotein processing during the first approximately 2 h of the BFA block; (ii) active Golgi enzymes relocated to the ER in approximately 2 h during BFA treatment, resulting in the production of partially endo H-resistant forms of the spleen focus-forming virus glycoprotein, gp55 (in controls, this glycoprotein was generally retained in the ER as an endo H-sensitive entity); and (iii) proteolytic processing of gPr90env to gp70 occurred prior to the acquisition of endo H resistance and at approximately the same time as endo D sensitivity (i.e. in a cis Golgi compartment). In control cells, the spleen focus-forming virus glycoprotein, gp55, underwent turnover with a half-life of approximately 5 h. In contrast, its turnover was considerably slower during BFA treatment (t1/2 = approximately 20 h), suggesting that transport of gp55 out of the ER was required for its degradation or that BFA afforded it protection from proteolysis within the ER.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University					NCI NIH HHS [P01 CA 46128-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FAMULARI NG, 1981, J VIROL, V40, P971, DOI 10.1128/JVI.40.3.971-976.1981; FITTING T, 1982, J BIOL CHEM, V257, P4011; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEYER R, 1984, EUR J BIOCHEM, V143, P531, DOI 10.1111/j.1432-1033.1984.tb08402.x; GLINIAK BC, 1989, J VIROL, V63, P3561, DOI 10.1128/JVI.63.9.3561-3568.1989; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; KATO S, 1989, BIOCHIM BIOPHYS ACTA, V991, P36, DOI 10.1016/0304-4165(89)90025-1; KILPATRICK DR, 1989, J BIOL CHEM, V264, P10732; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACHIDA CA, 1982, J BIOL CHEM, V257, P4018; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MYZOUCHI T, 1984, J BIOCHEM-TOKYO, V95, P1209; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; PERKEL VS, 1988, ENDOCRINOLOGY, V123, P310, DOI 10.1210/endo-123-1-310; POLONOFF E, 1982, J BIOL CHEM, V257, P4023; RUTA M, 1980, J VIROL, V35, P844, DOI 10.1128/JVI.35.3.844-853.1980; SHIELDS A, 1978, CELL, V14, P601, DOI 10.1016/0092-8674(78)90245-3; SRINIVAS RV, 1983, VIROLOGY, V125, P274, DOI 10.1016/0042-6822(83)90201-5; STPIERRE Y, 1990, J IMMUNOL, V145, P812; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; ULMER JB, 1989, J BIOL CHEM, V264, P1084; ULMER JB, 1991, EUR J CELL BIOL, V54, P38; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; WITTE ON, 1979, J VIROL, V29, P735, DOI 10.1128/JVI.29.2.735-743.1979; WOLFF L, 1983, P NATL ACAD SCI-BIOL, V80, P4718, DOI 10.1073/pnas.80.15.4718; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	40	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9173	9179						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851169				2022-12-25	WOS:A1991FM03800078
J	KANAYA, S; KATSUDA, C; KIMURA, S; NAKAI, T; KITAKUNI, E; NAKAMURA, H; KATAYANAGI, K; MORIKAWA, K; IKEHARA, M				KANAYA, S; KATSUDA, C; KIMURA, S; NAKAI, T; KITAKUNI, E; NAKAMURA, H; KATAYANAGI, K; MORIKAWA, K; IKEHARA, M			STABILIZATION OF ESCHERICHIA-COLI RIBONUCLEASE-H BY INTRODUCTION OF AN ARTIFICIAL DISULFIDE BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED PROTEIN THERMOSTABILITY; ENGINEERED DISULFIDE; DNA-REPLICATION; RNASE-H; CONFORMATIONAL STABILITY; DEFECTIVE-MUTANTS; INITIATION; HYDROPHOBICITY; T4-LYSOZYME; MUTATIONS	To examine the effect of the introduction of a disulfide bond on the stability of Escherichia coli ribonuclease H, a disulfide bond was engineered between Cys13, which is present in the wild-type enzyme, and Cys44, which is substituted for Asn44 by site-directed mutagenesis. The disulfide bond was only formed between these residues upon oxidation in vitro with redox buffer. The conformational and thermal stabilities were estimated from the guanidine hydrochloride and thermal denaturation curves, respectively. The oxidized (cross-linked) mutant enzyme showed a T(m) of 62.3-degrees-C, which was 11.8-degrees-C higher than that observed for the wild-type enzyme. The free energy change of unfolding in the absence of denaturant, DELTA-G[H2O], and the mid-point of the denaturation curve, [D]1/2, of the oxidized mutant enzyme were also increased by 2.1-2.8 kcal/mol and 0.36-0.48 M, respectively. Introduction of a disulfide bond thus greatly enhanced both the thermal and conformational stabilities of the enzyme. In addition, kinetic analyses for the enzymatic activities of mutant enzymes suggest that Thr43 and Asn44 are involved in the substrate-binding site of the enzyme.			KANAYA, S (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nakamura, Haruki/O-4028-2014					BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P863; Crouch R. J., 1982, NUCLEASES, P211; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; HORIUCHI T, 1984, MOL GEN GENET, V195, P17, DOI 10.1007/BF00332717; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; JOHNSON RE, 1978, BIOCHEMISTRY-US, V17, P1479, DOI 10.1021/bi00601a019; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANE CM, 1988, BIOCHEMISTRY-US, V27, P3187, DOI 10.1021/bi00409a010; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOGOMA T, 1985, MOL GEN GENET, V200, P103, DOI 10.1007/BF00383320; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1984, BIOCHEMISTRY-US, V23, P5504, DOI 10.1021/bi00318a019; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MILLER HI, 1973, J BIOL CHEM, V248, P2621; Miller J. H., 1972, EXPT MOL GENETICS, P433; MITCHINSON C, 1989, BIOCHEMISTRY-US, V28, P4807, DOI 10.1021/bi00437a043; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; NISHIKAWA S, 1990, PROTEIN ENG, V3, P443, DOI 10.1093/protein/3.5.443; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; OGAWA T, 1984, P NATL ACAD SCI-BIOL, V81, P1040, DOI 10.1073/pnas.81.4.1040; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PACE CN, 1988, J BIOL CHEM, V263, P11820; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SAUER RT, 1986, BIOCHEMISTRY-US, V25, P5992, DOI 10.1021/bi00368a024; TAKAGI H, 1990, J BIOL CHEM, V265, P6874; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VILLAFRANCA JE, 1987, BIOCHEMISTRY-US, V26, P2182, DOI 10.1021/bi00382a017; YANG W, 1990, J BIOL CHEM, V265, P13553; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	46	119	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6038	6044						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848845				2022-12-25	WOS:A1991FE37300009
J	THOMAS, TJ; GUNNIA, UB; THOMAS, T				THOMAS, TJ; GUNNIA, UB; THOMAS, T			POLYAMINE-INDUCED B-DNA TO Z-DNA CONFORMATIONAL TRANSITION OF A PLASMID DNA WITH (DG-DC)N INSERT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-HANDED DNA; LIGHT-SCATTERING; STRUCTURAL SPECIFICITY; SUPERCOILED PLASMIDS; ELECTRON-MICROSCOPY; ESTROGEN-RECEPTOR; CONDENSATION; SEQUENCES; POLYNUCLEOTIDES; BINDING	We investigated the ability of natural polyamines putrescine, spermidine, and spermine to provoke a left-handed Z-DNA conformation in a recombinant plasmid (pDHg16) with a 23-base pair insert of (dG-dC)n.(dG-dC)n sequences. Using a monoclonal anti-Z-DNA antibody (Z22) and an enzyme-linked immunosorbent assay protocol, we found that spermidine and spermine were capable of converting pDHg16 to the Z-DNA form. The concentrations of spermidine and spermine at the midpoint of the B-DNA to Z-DNA transition were 280 and 5-mu-M, respectively, in buffer containing 50 mM NaCl, 1 mM sodium cacodylate, and 0.15 mM EDTA, pH 7.4. A plot of ln[Na+] versus ln [spermine4+], where [Na+] is the bulk NaCl concentration and [spermine4+] is the spermine concentration at the midpoint of the B-DNA to Z-DNA transition, gave a straight line with a slope of 1.2. Structural specificity was clearly evident in the efficacy of three spermidine homologs to induce the Z-DNA conformation in pDHg16. Putrescine and acetylspermidines had no effect on the conformation of the plasmid DNA up to a 3 mM concentration. Control experiments with the parental plasmid (pDPL6) showed no binding of the plasmid DNA with Z22. These results indicate that spermidine and spermine are capable of provoking the left-handed Z-DNA conformation in small blocks of (dG-dC)n sequences embedded in a right-handed B-DNA matrix. Since blocks of (dG-dC)n sequences are found in certain native DNAs, conformational alterations of these regions to the Z-DNA form in the presence of polyamines may have important gene regulatory effects.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MED,NEW BRUNSWICK,NJ 08903; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT COMMUNITY MED,NEW BRUNSWICK,NJ 08903	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	THOMAS, TJ (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CLIN RES CTR,NEW BRUNSWICK,NJ 08903, USA.				NATIONAL CANCER INSTITUTE [R01CA042439, R23CA042439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039020] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42439] Funding Source: Medline; NIAMS NIH HHS [AR 39020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAM AK, 1981, TRENDS BIOCHEM SCI, V6, P106, DOI 10.1016/0968-0004(81)90039-6; ALLISON SA, 1981, BIOPOLYMERS, V20, P469, DOI 10.1002/bip.1981.360200305; ASTELL CR, 1979, CELL, V17, P691, DOI 10.1016/0092-8674(79)90276-9; BASU HS, 1988, J BIOMOL STRUCT DYN, V6, P299, DOI 10.1080/07391102.1988.10507714; BASU HS, 1989, CANCER RES, V49, P5591; BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; CHEN HH, 1984, NUCLEIC ACIDS RES, V12, P2381, DOI 10.1093/nar/12.5.2381; FEUERSTEIN BG, 1986, P NATL ACAD SCI USA, V83, P5948, DOI 10.1073/pnas.83.16.5948; GESSNER RV, 1989, J BIOL CHEM, V264, P7921; GOSULE LC, 1978, J MOL BIOL, V121, P311, DOI 10.1016/0022-2836(78)90366-2; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HAYES TE, 1985, J BIOL CHEM, V260, P8145; ISONO K, 1974, P NATL ACAD SCI USA, V71, P1612, DOI 10.1073/pnas.71.5.1612; IVANOV VI, 1981, NUCLEIC ACIDS RES, V9, P4682; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KMIEC EB, 1985, CELL, V40, P139, DOI 10.1016/0092-8674(85)90317-4; LAFER EM, 1988, J MOL BIOL, V203, P511, DOI 10.1016/0022-2836(88)90017-4; Marton LJ, 1987, INHIB POLYAM METABOL, P79; MORGAN JE, 1987, BIOCHEMISTRY-US, V26, P3643, DOI 10.1021/bi00386a058; NORDHEIM A, 1982, CELL, V31, P309, DOI 10.1016/0092-8674(82)90124-6; NORDHEIM A, 1986, J BIOL CHEM, V261, P468; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; PEGG AE, 1988, CANCER RES, V48, P759; PORTER CW, 1983, SCIENCE, V219, P1083, DOI 10.1126/science.6823570; PULLEYBLANK DE, 1979, MOL BIOL REP, V9, P191; SCHELLMAN JA, 1984, J MOL BIOL, V175, P313, DOI 10.1016/0022-2836(84)90351-6; SEN D, 1986, BIOCHEMISTRY-US, V25, P1495, DOI 10.1021/bi00355a004; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMIRNOV IV, 1988, J BIOMOL STRUCT DYN, V5, P1149, DOI 10.1080/07391102.1988.10506455; SUNKARA PS, 1987, INHIBITION POLYAMINE, P121; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THOMAS T, 1989, CANCER RES, V49, P4734; THOMAS T, 1988, NUCLEIC ACIDS RES, V16, P4705, DOI 10.1093/nar/16.10.4705; THOMAS TJ, 1985, BIOPOLYMERS, V24, P2185, DOI 10.1002/bip.360241203; THOMAS TJ, 1989, NUCLEIC ACIDS RES, V17, P3795, DOI 10.1093/nar/17.10.3795; THOMAS TJ, 1984, BIOPOLYMERS, V23, P1295, DOI 10.1002/bip.360230713; THOMAS TJ, 1988, ANAL BIOCHEM, V168, P358, DOI 10.1016/0003-2697(88)90330-2; THOMAS TJ, 1988, J MOL BIOL, V201, P463, DOI 10.1016/0022-2836(88)90155-6; THOMAS TJ, 1986, NUCLEIC ACIDS RES, V14, P6721, DOI 10.1093/nar/14.16.6721; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILLIAMS LD, 1990, NUCLEIC ACIDS RES, V18, P5533, DOI 10.1093/nar/18.18.5533; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009	47	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6137	6141						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848849				2022-12-25	WOS:A1991FE37300024
J	UMEI, T; BABIOR, BM; CURNUTTE, JT; SMITH, RM				UMEI, T; BABIOR, BM; CURNUTTE, JT; SMITH, RM			IDENTIFICATION OF THE NADPH-BINDING SUBUNIT OF THE RESPIRATORY BURST OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; DEPENDENT ISOCITRATE DEHYDROGENASE; HUMAN-NEUTROPHILS; PIG NEUTROPHILS; COMPONENT; ACTIVATION; MEMBRANE; PROTEIN	The respiratory burst oxidase is a multicomponent membrane-bound enzyme that uses NADPH to reduce oxygen to O2-. When oxidase-containing membranes from activated neutrophils are treated with 0.3 M KCl, the NADPH-binding component of the oxidase elutes from the membranes in an active form. Treatment of this eluate with [P-32]NADPH dialdehyde labels an almost-equal-to 32-kDa protein that is absent from eluates obtained from normal resting membranes or from resting or activated membranes from patients with one form of chronic granulomatous disease. We propose that this almost-equal-to 32-kDa protein is the NADPH-binding component of the oxidase.	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, SAN DIEGO, CA 92103 USA	Scripps Research Institute; University of California System; University of California San Diego					NIAID NIH HHS [AI-30742, AI-24427, AI-24838] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030742, R21AI130742, R01AI024838] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABIOR BM, 1990, SEMIN HEMATOL, V27, P247; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1989, J CLIN INVEST, V83, P1236, DOI 10.1172/JCI114006; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GABIG TG, 1983, J BIOL CHEM, V258, P6352; KING MM, 1983, BIOCHEMISTRY-US, V22, P1656, DOI 10.1021/bi00276a021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARK RH, 1986, J BIOL CHEM, V261, P659; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MAS MT, 1983, J BIOL CHEM, V258, P9332; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; SMITH RM, 1989, J BIOL CHEM, V264, P12243; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TAKASUGI S, 1989, J BIOCHEM-TOKYO, V105, P155, DOI 10.1093/oxfordjournals.jbchem.a122630; UMEI T, 1986, J BIOL CHEM, V261, P5229; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITE BJ, 1987, J BIOL CHEM, V262, P1223	24	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6019	6022						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848844				2022-12-25	WOS:A1991FE37300004
J	CANFIELD, WM; JOHNSON, KF; YE, RD; GREGORY, W; KORNFELD, S				CANFIELD, WM; JOHNSON, KF; YE, RD; GREGORY, W; KORNFELD, S			LOCALIZATION OF THE SIGNAL FOR RAPID INTERNALIZATION OF THE BOVINE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE INSULIN-LIKE GROWTH FACTOR-II RECEPTOR TO AMINO-ACIDS 24-29 OF THE CYTOPLASMIC TAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ASIALOGLYCOPROTEIN RECEPTOR; CELLS; SEQUENCE; PROTEIN; CLONING; BINDING; ENZYME; LIVER; OLIGOSACCHARIDES	The signal for the rapid internalization of the cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor has been previously localized to the inner half of the 163-amino acid cytoplasmic tail, including tyrosine 24 and tyrosine 26 (Lobel, P., Fujimoto, K., Ye, R. D., Griffiths, G., and Kornfeld, S. (1989) Cell 57, 787-796). To define this signal more precisely, we generated a series of truncation and substitution mutants and analyzed them for their ability to mediate the endocytosis of extracellular lysosomal enzymes. Mutant receptors containing cytoplasmic domains of 29 or more amino acids functioned normally in endocytosis whereas a mutant receptor with a 28-amino acid cytoplasmic domain was internalized extremely slowly. Alanine scanning of the region between amino acids 19 and 30 identified tyrosine 26 and valine 29 as the most important residues for rapid receptor internalization. Tyrosine 24 and lysine 28 also contributed to the signal while the other amino acids were not critical. The tyrosine residues could be substituted with phenylalanines with no loss of activity, indicating the requirement for an aromatic residue in these positions rather than tyrosine specifically. Conservative substitutions of arginine or histidine for lysine 28 also preserved the internalization signal. These results indicate that the sequence Tyr-Lys-Tyr-Ser-Lys-Val serves as the internalization signal for the mannose 6-phosphate/insulin-like growth factor-II receptor. The crucial elements of this sequence are present in the cytoplasmic tails of a number of other membrane receptors and proteins known to undergo rapid internalization.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOL CHEM,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline; NHLBI NIH HHS [T32-HL07088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BORDEN LA, 1990, J BIOL CHEM, V265, P8497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DRICKAMER K, 1981, J BIOL CHEM, V256, P5827; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; JIN M, 1989, J BIOL CHEM, V264, P7675; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MESSNER DJ, 1989, J CELL BIOL, V108, P2149, DOI 10.1083/jcb.108.6.2149; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OKA Y, 1986, J BIOL CHEM, V261, P9090; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLEIN MW, 1957, METHOD ENZYMOL, V3, P154, DOI 10.1016/S0076-6879(57)03359-5; SPIESS M, 1985, J BIOL CHEM, V260, P1979; TAIT JF, 1981, J BIOL CHEM, V256, P1086; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILLINGHAM MC, 1981, P NATL ACAD SCI-BIOL, V78, P6967, DOI 10.1073/pnas.78.11.6967; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0	44	168	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5682	5688						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848556				2022-12-25	WOS:A1991FD37000051
J	SALATI, LM; MA, XJ; MCCORMICK, CC; STAPLETON, SR; GOODRIDGE, AG				SALATI, LM; MA, XJ; MCCORMICK, CC; STAPLETON, SR; GOODRIDGE, AG			TRIIODOTHYRONINE STIMULATES AND CYCLIC-AMP INHIBITS TRANSCRIPTION OF THE GENE FOR MALIC ENZYME IN CHICK-EMBRYO HEPATOCYTES IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; NUCLEASE-HYPERSENSITIVE SITES; MESSENGER-RNA PRECURSOR; LIVER-CELLS INVIVO; THYROID-HORMONE; PROTEIN-SYNTHESIS; AVIAN LIVER; NUTRITIONAL REGULATION; CHROMATIN STRUCTURE; LIPOGENIC ENZYMES	In chick embryo hepatocytes in culture, insulin and triiodothyronine (T3) increase malic enzyme activity and the abundance of malic enzyme mRNA by at least 50-fold, and glucagon or cAMP blocks this effect. Steps regulated by these hormones were defined by measuring transcriptional activity with the nuclear run-on assay and multiple fragments of the malic enzyme gene as probes. T3 alone caused a significant increase in transcription within 1 h, with a maximal increase of 30-40-fold occurring by 24 h. When T3 was added with insulin, 80% of the maximum rate was reached in 1 h. Insulin alone had no effect on transcription of the malic enzyme gene; it amplified the response to T3 in the first few hours after adding T3 but did not alter T3's maximal effect. Cyclic AMP for 1 h completely inhibited the increase in transcription caused by T3. The size and speed of the responses of the malic enzyme gene to T3 and cAMP suggest regulation of transcription initiation. T3-stimulated transcription of the malic enzyme gene did not require ongoing protein synthesis despite the fact that inhibitors of protein synthesis inhibited the T3-stimulated accumulation of its mRNA. T3 may directly activate transcription of this gene via its receptor. The pattern of DNase I hypersensitivity of the malic enzyme gene in chick embryo hepatocytes was the same as that in fed chick liver. Insulin, T3, and cAMP had no effect on that pattern. In chick embryo hepatocytes in culture, factors involved in regulation of transcription by insulin, T3, and cAMP may be bound to DNA independently of hormonal treatment.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa					NIDDK NIH HHS [DK 07018, DK25295, DK21594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, T32DK007018, R01DK021594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BACK DW, 1986, J BIOL CHEM, V261, P4190; BACK DW, 1986, J BIOL CHEM, V261, P2555; BIANCO AC, 1988, J BIOL CHEM, V263, P18168; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRITTON HP, 1983, NUCLEIC ACIDS RES, V11, P3467, DOI 10.1093/nar/11.11.3467; FROESCH ER, 1985, DIABETOLOGIA, V28, P485, DOI 10.1007/BF00281982; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GOODRIDGE AG, 1986, ANN NY ACAD SCI, V478, P46, DOI 10.1111/j.1749-6632.1986.tb15520.x; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; IP YT, 1989, MOL CELL BIOL, V9, P1289, DOI 10.1128/MCB.9.3.1289; JACOBY DB, 1987, MOL CELL BIOL, V7, P1352, DOI 10.1128/MCB.7.4.1352; JUMP DB, 1989, J BIOL CHEM, V264, P4698; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MA XJ, 1990, J BIOL CHEM, V265, P18435; MCCORMICK CC, 1991, IN PRESS BIOCH J, V273; MORRIS SM, 1982, J BIOL CHEM, V257, P3225; NARAYAN P, 1984, P NATL ACAD SCI-BIOL, V81, P4687, DOI 10.1073/pnas.81.15.4687; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SANTOS A, 1987, J BIOL CHEM, V262, P16880; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SEAL SN, 1972, BIOCHEM BIOPH RES CO, V46, P1895, DOI 10.1016/0006-291X(72)90067-8; SHUPNIK MA, 1985, ENDOCRINOLOGY, V117, P1940, DOI 10.1210/endo-117-5-1940; SIDDIQUI UA, 1981, J BIOL CHEM, V256, P4544; SIMONET WS, 1988, J BIOL CHEM, V263, P12448; SONG MKH, 1988, J BIOL CHEM, V263, P17970; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; UCKER DS, 1984, J BIOL CHEM, V259, P7416; USALA SJ, 1988, MOL ENDOCRINOL, V2, P619, DOI 10.1210/mend-2-7-619; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WILSON SB, 1986, J BIOL CHEM, V261, P5179; WINBERRY LK, 1983, J BIOL CHEM, V258, P1337; YAFFE BM, 1984, J BIOL CHEM, V259, P6284; YUAN ZY, 1988, P NATL ACAD SCI USA, V85, P6328, DOI 10.1073/pnas.85.17.6328	46	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					4010	4016						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847395				2022-12-25	WOS:A1991EY68200098
J	STEINBERG, RA; GORMAN, KB; OGREID, D; DOSKELAND, SO; WEBER, IT				STEINBERG, RA; GORMAN, KB; OGREID, D; DOSKELAND, SO; WEBER, IT			MUTATIONS THAT ALTER THE CHARGE OF TYPE-I REGULATORY SUBUNIT AND MODIFY ACTIVATION PROPERTIES OF CYCLIC AMP-DEPENDENT PROTEIN-KINASE FROM S49 MOUSE LYMPHOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-BINDING DOMAINS; PREDICTED STRUCTURES; NUCLEOTIDE-BINDING; CYTOSINE RESIDUES; ESCHERICHIA-COLI; GENE-EXPRESSION; MOLECULAR-BASIS; POINT MUTATION; SITE-A; AMPLIFICATION	Mutations in regulatory (R) subunit of cAMP-dependent protein kinase were analyzed from cAMP-resistant mutants of S49 mouse lymphoma cells by direct sequencing of amplified regions of mutant R subunit cDNAs. Eight distinct single base-change lesions were identified in 24 independent mutants that were hemizygous for expression of mutant R subunits with altered protein charge. CG --> TA transitions predominated, but AT --> GC transitions and GC --> TA transversions were also observed. Four of five spontaneous mutants had identical C --> T transitions at CG causing substitution of Trp for Arg-334. Sites mutated in isolates obtained after mutagenesis with ethyl methane-sulfonate or N-methyl-N'-nitrosoguanidine were more varied. Six of the lesions (two in binding site A and four in site B) were at amino acid residues that are highly conserved among cAMP-binding sites of R subunits and the Escherichia coli catabolite activator protein. These mutations all either prevented or strongly hindered binding of cyclic nucleotides to the mutated site. One of the remaining lesions (at Arg-242) also prevented cyclic nucleotide binding to the mutated binding site; the other (at Gly-170) had only minimal effects on binding of cyclic nucleotides but, nevertheless, increased the apparent constant for cAMP-dependent kinase activation. These results are discussed with reference to a model for the cAMP-binding sites of R subunit based on the crystal structure of the E. coli catabolite activator protein.	UNIV BERGEN,INST ANAT,CELL BIOL RES GRP,N-5009 BERGEN,NORWAY; NCI,FREDERICK CANC RES FACIL,CRYSTALLOG LAB,ADV BIOSCI LABS,BASIC RES PROGRAM,FREDERICK,MD 21701	University of Bergen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	STEINBERG, RA (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,POB 26901,OKLAHOMA CITY,OK 73190, USA.			Doskeland, Stein Ove/0000-0002-4009-4756	NIDDK NIH HHS [DK37583] Funding Source: Medline; PHS HHS [N01-C01-74101] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037583, R55DK037583] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUBIS J, 1988, J BIOL CHEM, V263, P9668; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DEJONG PJ, 1988, P NATL ACAD SCI USA, V85, P3499; DOERFLER W, 1981, J GEN VIROL, V57, P1, DOI 10.1099/0022-1317-57-1-1; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FRIEDRICH U, 1977, P NATL ACAD SCI USA, V74, P679, DOI 10.1073/pnas.74.2.679; GORMAN KB, 1989, BIOTECHNIQUES, V7, P326; GRONENBORN AM, 1988, BIOCHEM J, V253, P801, DOI 10.1042/bj2530801; HOUGE G, 1990, J BIOL CHEM, V265, P19507; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KUNO T, 1989, EUR J PHARM-MOLEC PH, V172, P263, DOI 10.1016/0922-4106(89)90056-4; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; Maniatis T., 1982, MOL CLONING; MURPHY CS, 1985, SOMAT CELL MOLEC GEN, V11, P605, DOI 10.1007/BF01534725; OGREID D, 1988, J BIOL CHEM, V263, P17397; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHENDEL PF, 1981, CRIT REV TOXICOL, V9, P311; STEINBERG RA, 1987, SOMAT CELL MOLEC GEN, V13, P645, DOI 10.1007/BF01534485; STEINBERG RA, 1987, J BIOL CHEM, V262, P2664; STEINBERG RA, 1984, MOL CELL BIOL, V4, P1086, DOI 10.1128/MCB.4.6.1086; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; STRUHL K, 1985, Biotechniques, V3, P452; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1982, P NATL ACAD SCI-BIOL, V79, P7679, DOI 10.1073/pnas.79.24.7679; WETTERS TV, 1983, MOL CELL BIOL, V3, P250, DOI 10.1128/MCB.3.2.250; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; YAROSH DB, 1985, MUTAT RES, V145, P1, DOI 10.1016/0167-8817(85)90034-3	39	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3547	3553						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847378				2022-12-25	WOS:A1991EY68200034
J	GILLIES, RJ; MARTINEZZAGUILAN, R				GILLIES, RJ; MARTINEZZAGUILAN, R			REGULATION OF INTRACELLULAR PH IN BALB/C 3T3 CELLS - BICARBONATE RAISES PH VIA NAHCO3/HCL EXCHANGE AND ATTENUATES THE ACTIVATION OF NA+/H+ EXCHANGE BY SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; FIBROBLASTS; FLUORESCENCE; STIMULATION	There is abundant evidence implicating a role for intracellular pH (PHin) in the proliferation response of many cells to mitogenic agents. In mammalian cells, pH(in) is generally regulated by two systems: Na+/H+ exchange and HCO3- transport. Activation of Na+/H+ exchange is one of the earliest responses of mammalian cells to mitogens. In the absence of HCO3-, this activation raises the pH(in). However, in the presence of HCO3-, the effect of mitogens on the pH(in) is unclear. HCO3- regulates pH(in) via mechanisms which can either acidify or alkalinize the cytosol, depending on the cell type and tissue of origin. BALB/c 3T3 mouse embryo cells are employed in the present study because they are used extensively in investigations of mammalian cell proliferation. Since these cells are of indefinite origin, there is no way to predict which HCO3- transporting system is operable in these cells and, hence, what effect HCO3- will have on the pH(in) and the response of pH(in) to mitogens. In the present article, we examine the mechanism and effect of HCO3--based pH(in) regulation. Our results indicate that HCO3--dependent pH(in) regulation in BALB/c 3T3 cells occurs via NaHCO3/HCl exchange which raises pH(in) under physiological conditions. This activity can raise the pH(in) to above the set point of the activated Na+/H+ exchanger, consequently attenuating the mitogen-induced Na+/H+ exchange-mediated increases in pH(in).			GILLIES, RJ (corresponding author), UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT BIOCHEM, TUCSON, AZ 85724 USA.			Gillies, Robert/0000-0002-8888-7747	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043046] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43046] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; BURNS CP, 1983, BIOCHEM BIOPH RES CO, V116, P931; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; CHAMBARD JC, 1986, EXP CELL RES, V164, P282, DOI 10.1016/0014-4827(86)90029-7; GILLIES RJ, 1989, J CELL PHYSIOL, V139, P125, DOI 10.1002/jcp.1041390118; GIULIANO KA, 1987, ANAL BIOCHEM, V167, P362, DOI 10.1016/0003-2697(87)90178-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1988, NA PLUS H PLUS EXCHA; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZZAGUILA.R, 1990, IN PRESS AM J PHYSL; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P7563; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; PLEDGER WJ, 1982, ANN NY ACAD SCI, V397, P1, DOI 10.1111/j.1749-6632.1982.tb43411.x; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SOLTOFF SP, 1988, ANNU REV PHYSIOL, V50, P207; VICENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053, DOI 10.1073/pnas.82.23.8053; WIKEHOOLEY JL, 1985, EUR J CANCER CLIN ON, V21, P785, DOI 10.1016/0277-5379(85)90216-0	23	61	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1551	1556						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846359				2022-12-25	WOS:A1991EU49700032
J	BROYLES, SS; LI, J; MOSS, B				BROYLES, SS; LI, J; MOSS, B			PROMOTER DNA CONTACTS MADE BY THE VACCINIA VIRUS EARLY TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; ESCHERICHIA-COLI; THYMIDINE KINASE; EARLY GENES; PURIFICATION; VIRIONS; SEQUENCES; BINDING; REGION	Vaccinia virus RNA polymerase requires the heterodimeric protein, vaccinia early transcription factor (VETF), for transcription of early gene templates in vitro. We have analyzed the vaccinia growth factor promoter sequences interacting with VETF at the nucleotide level and provide evidence that the factor contacts the DNA at two separate sites. DNase I protection analysis showed that VETF was bound to nucleotides -12 to -29 relative to the transcription initiation site, and also to nucleotides +8 to +10 downstream of the initiation site. The importance of both binding sites for stable complex formation was supported by methylation interference analysis. Using synthetic oligonucleotides encoding different parts of the vaccinia growth factor promoter, it was shown that nucleotides downstream of the transcription initiation site are required for stable complex formation. Competition binding experiments demonstrated that only the upstream binding site contributes significantly to binding specificity. Binding to two separated DNA sequences results in a bend in the promoter DNA as demonstrated by electrophoretic mobility shift analysis of permuted DNA fragments. These findings suggest that VETF activates transcription by sequence specific binding and structural alteration of the promoter DNA helix.	NIAID, VIRAL DIS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	BROYLES, SS (corresponding author), PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA.			Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028432] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01-AI28432-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; COCHRAN MA, 1985, J VIROL, V54, P30, DOI 10.1128/JVI.54.1.30-37.1985; COUPAR BEH, 1987, J GEN VIROL, V68, P2299, DOI 10.1099/0022-1317-68-9-2299; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MOSS B, 1990, POXVIRIDAE THEIR REP, P2079; NEVINS JR, 1977, J BIOL CHEM, V252, P6930; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; ROHRMANN G, 1985, J VIROL, V56, P349, DOI 10.1128/JVI.56.2.349-355.1985; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SHUEY DJ, 1986, NATURE, V323, P459, DOI 10.1038/323459a0; SPENCER E, 1980, J BIOL CHEM, V255, P5388; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VENKATESAN S, 1982, J VIROL, V44, P637, DOI 10.1128/JVI.44.2.637-646.1982; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WEIR JP, 1987, VIROLOGY, V158, P206, DOI 10.1016/0042-6822(87)90254-6; WRIGHT CF, 1989, J VIROL, V63, P4224, DOI 10.1128/JVI.63.10.4224-4233.1989; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069	25	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15539	15544						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869571				2022-12-25	WOS:A1991GB09700106
J	LEIBERSPERGER, H; GSCHWENDT, M; GERNOLD, M; MARKS, F				LEIBERSPERGER, H; GSCHWENDT, M; GERNOLD, M; MARKS, F			IMMUNOLOGICAL DEMONSTRATION OF A CALCIUM-UNRESPONSIVE PROTEIN-KINASE-C OF THE DELTA-TYPE IN DIFFERENT SPECIES AND MURINE TISSUES - PREDOMINANCE IN EPIDERMIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; MOUSE EPIDERMIS; TUMOR PROMOTION; ADDITIONAL MEMBERS; PHOSPHORYLATION; FAMILY; IDENTIFICATION; KERATINOCYTES; PURIFICATION; CULTIVATION	An antiserum raised against a delta-protein kinase C (delta-PKC)-specific peptide recognized the purified calcium-unresponsive 76-kDa protein kinase of porcine spleen in the native and the denatured form. This antiserum was used to demonstrate the delta-PKC-like enzyme in spleen of different species, in various cell types and in murine tissues by immunoblotting of the respective extracts. Due to species differences, delta-PKC-like kinases with slightly different molecular weights were observed. The enzyme was found to be present in primary murine keratinocytes, primary bovine endothelial cells, and many cell lines originating from human, rat, and murine tissues. It was present also in all murine tissues tested, predominantly in epidermis, uterus, placenta, lung, brain, spleen, and kidney. In contrast to the conventional alpha,beta,gamma-PKC, it was located almost exclusively in the particulate fraction. The delta-like PKC could be demonstrated in the epidermis and brain of newborn mice, and in both tissues its concentration increased dramatically between day 7 and 14 after birth. The delta-PKC-like kinase of mouse epidermis (p82-kinase) was down-regulated after topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA) to mouse skin. The amount of the enzyme decreased to less than 20% of the controls within 16 h and recovered almost completely within 72 h after TPA. The existence of the delta-PKC-like kinase in mouse skin, papillomas, and carcinomas could also be demonstrated by immunocytochemical staining of the respective sections. The enzyme was observed predominantly in epithelial layers. A remarkable immunostaining of nuclei in skin sections disappeared after TPA treatment of the animals.	GERMAN CANC RES CTR, INST BIOCHEM, NEUENHEIMER FELD 280, W-6900 HEIDELBERG 1, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg								BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BERTSCH S, 1974, CANCER RES, V34, P3283; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; DURST M, 1987, ONCOGENE, V1, P251; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FURSTENBERGER G, 1986, CARCINOGENESIS, V7, P1745, DOI 10.1093/carcin/7.10.1745; FURSTENBERGER G, 1985, CARCINOGENESIS, V6, P289, DOI 10.1093/carcin/6.2.289; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GSCHWENDT M, 1989, BIOCHEM BIOPH RES CO, V164, P974, DOI 10.1016/0006-291X(89)91765-8; GSCHWENDT M, 1986, BIOCHEM BIOPH RES CO, V137, P766, DOI 10.1016/0006-291X(86)91145-9; GSCHWENDT M, 1989, IMMUNOBIOLOGY, V179, P1; GSCHWENDT M, 1987, CARCINOGENESIS, V8, P203, DOI 10.1093/carcin/8.2.203; GSCHWENDT M, 1989, J CELL BIOCHEM, V40, P295, DOI 10.1002/jcb.240400306; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; HALLE W, 1980, ACTA BIOL MED GER, V39, P1165; HANSEN LA, 1990, CANCER RES, V50, P5740; HORN F, 1985, EUR J BIOCHEM, V148, P533, DOI 10.1111/j.1432-1033.1985.tb08872.x; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; JOO F, 1973, CYTOBIOS, V8, P41; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; OSADA S, 1990, J BIOL CHEM, V265, P22434; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; STRICKLAND JE, 1988, CANCER RES, V48, P165; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	30	104	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14778	14784						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860875				2022-12-25	WOS:A1991FZ35100102
J	ORII, Y; YUMOTO, I; FUKUMORI, Y; YAMANAKA, T				ORII, Y; YUMOTO, I; FUKUMORI, Y; YAMANAKA, T			STOPPED-FLOW AND RAPID-SCAN STUDIES OF THE REDOX BEHAVIOR OF CYTOCHROME ACO FROM FACULTATIVE ALKALOPHILIC BACILLUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER PROTEINS; C OXIDASE; THERMUS-THERMOPHILUS; PURIFICATION; RECONSTITUTION; LIPOSOMES; BACTERIUM; CATALASE; COMPOUND	Cytochrome aco purified from an alkalophilic bacterium grown at pH 10 contains hemes a, b, and c as prosthetic groups, and their redox behavior was examined by using stopped-flow and rapid-scan techniques. Under anaerobic conditions the reduction of both heme a and c moieties with dithionite proceeded exponentially but with different rates, usually the former being reduced about 4 times faster than the latter. The reduction of protoheme was much slower, and a time-difference spectrum for this species was of a high spin type with absorption peaks at 433, 557, and 609 nm. Only the protoheme combined with CO, fulfilling the criteria for cytochrome o. Potentiometric titrations determined a midpoint potential of c heme to be 95 mV at pH 7.0 and 25-degrees-C and suggested the presence of two forms of a heme with midpoint potentials of 250 and 323 mV. Cytochrome aco utilizes ascorbate plus N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) to reduce oxygen relatively rapidly without added cytochrome c (Qureshi, M. H., Yumoto, I., Fujiwara, T., Fukumori, Y., Yamanaka, T. (1990) J. Biochem. 107, 480-485). During the steady state, however, heme a stayed almost fully reduced in contrast to a partial reduction of heme c. Even after exhaustion of the dissolved oxygen the extent of reduction of heme c was 60-70% that attained by the dithionite reduction. When ascorbate plus TMPD-reduced cytochrome aco was exposed to oxygen the reduced heme c was oxidized rapidly whereas the oxidation of reduced a heme was negligibly slow. The full reduction of heme a during the steady state and its extremely slow oxidation rendered participation of heme a in the oxidase reaction less likely. A novel peak appearing transiently around 567 nm during the reaction was tentatively ascribed to an intermediate form of protoheme, or o heme, which was thus supposed to react directly with molecular oxygen. These results suggest strongly that the main electron transfer pathway would be c --> o --> oxygen. A possible role of a in regulating the electron flow through the main pathway and its functional relationship to a heme in the aa3-type cytochrome oxidase were discussed.	TOKYO INST TECHNOL, FAC SCI, DEPT LIFE SCI, MEGURO KU, TOKYO 152, JAPAN	Tokyo Institute of Technology	ORII, Y (corresponding author), KYOTO UNIV, FAC MED, DEPT PUBL HLTH, KYOTO 606, JAPAN.		Yumoto, Isao/N-2053-2018; Fukumori, Yoshihiro/J-2483-2014	Yumoto, Isao/0000-0001-9525-3155; 				ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; Dutton P L, 1978, Methods Enzymol, V54, P411; FROUD SJ, 1984, J GEN MICROBIOL, V130, P2201; HENDERSON RW, 1961, HAEMATIN ENZYMES, P370; HONNAMI K, 1984, BIOCHEMISTRY-US, V23, P454, DOI 10.1021/bi00298a009; HUDIG H, 1984, BIOCHIM BIOPHYS ACTA, V765, P171, DOI 10.1016/0005-2728(84)90011-2; LAMBETH DO, 1973, J BIOL CHEM, V248, P6095; Michaelis L, 1933, J AM CHEM SOC, V55, P1481, DOI 10.1021/ja01331a027; MIKI T, 1986, J BIOCHEM-TOKYO, V100, P735, DOI 10.1093/oxfordjournals.jbchem.a121766; ORII Y, 1989, BIOCHEM BIOPH RES CO, V162, P1272, DOI 10.1016/0006-291X(89)90811-5; ORII Y, 1990, FEBS LETT, V267, P117, DOI 10.1016/0014-5793(90)80303-Z; ORII Y, 1988, CHEM SCRIPTA, V28A, P63; ORII Y, 1984, J BIOL CHEM, V259, P7187; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; POOLE RK, 1983, BIOCHIM BIOPHYS ACTA, V726, P205, DOI 10.1016/0304-4173(83)90006-X; QURESHI MH, 1990, J BIOCHEM-TOKYO, V107, P480, DOI 10.1093/oxfordjournals.jbchem.a123071; SONE N, 1982, BIOCHIM BIOPHYS ACTA, V682, P216, DOI 10.1016/0005-2728(82)90101-3; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; YANG T, 1982, EUR J BIOCHEM, V121, P335, DOI 10.1111/j.1432-1033.1982.tb05791.x; YANG T, 1986, BIOCHIM BIOPHYS ACTA, V848, P342, DOI 10.1016/0005-2728(86)90209-4; YOSHIDA T, 1984, J BIOL CHEM, V259, P112; YUMOTO I, 1990, J BIOCHEM, V108, P583, DOI 10.1093/oxfordjournals.jbchem.a123246	22	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14310	14316						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860840				2022-12-25	WOS:A1991FZ35100033
J	ZHOU, DH; MUNSTER, A; WINCHURCH, RA				ZHOU, DH; MUNSTER, A; WINCHURCH, RA			PATHOLOGICAL CONCENTRATIONS OF INTERLEUKIN-6 INHIBIT T-CELL RESPONSES VIA INDUCTION OF ACTIVATION OF TGF-BETA	FASEB JOURNAL			English	Note						MACROPHAGES; IMMUNOSUPPRESSION; CON-A	GROWTH-FACTOR-BETA; BURN PATIENTS; IL-6; ENDOTOXEMIA; INFECTION; HIV	Interleukin 6 levels are increased in a variety of clinical conditions including bacterial and viral infections, HIV infection, autoimmune diseases, certain neoplasias, and traumatic injury. In general, all these conditions are characterized by suppression of one or more manifestations of the immune response. Concentrations of IL 6 comparable to those found in the sera of immunosuppressed, thermally injured patients selectively inhibit T cell proliferative responses. This suppression is independent of IL 2-mediated responses, is dependent on macrophage activity, and is reversed by antisera specific for transforming growth factor-beta (TGF-beta).	JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE REG BURN CTR,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins University								AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BAUMANN H, 1984, J BIOL CHEM, V259, P7331; BREEN EC, 1990, J IMMUNOL, V144, P480; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; ERTEL W, 1990, J SURG RES, V48, P622, DOI 10.1016/0022-4804(90)90242-T; FONG YM, 1989, J IMMUNOL, V142, P2321; GUO Y, 1990, CLIN IMMUNOL IMMUNOP, V54, P361, DOI 10.1016/0090-1229(90)90050-Z; HELLE M, 1988, EUR J IMMUNOL, V18, P957, DOI 10.1002/eji.1830180619; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HOUSSIAU FA, 1988, CLIN EXP IMMUNOL, V71, P320; LOTZ M, 1990, J IMMUNOL, V144, P4189; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; PETERSON PK, 1991, J IMMUNOL, V146, P81; SHORR RM, 1984, J TRAUMA, V24, P319, DOI 10.1097/00005373-198404000-00006; VANOERS MHJ, 1988, CLIN EXP IMMUNOL, V71, P314; WAHL SM, 1988, J IMMUNOL, V140, P3026; WARDEN GD, 1981, IMMUNE CONSEQUENCES, P1; WEISSENBACH J, 1980, P NATL ACAD SCI-BIOL, V77, P7152, DOI 10.1073/pnas.77.12.7152; WINCHURCH RA, 1987, SURGERY, V102, P808; WINCHURCH RA, 1988, CLIN IMMUNOL IMMUNOP, V49, P215, DOI 10.1016/0090-1229(88)90111-0	20	84	84	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2582	2585		10.1096/fasebj.5.11.1868982	http://dx.doi.org/10.1096/fasebj.5.11.1868982			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868982				2022-12-25	WOS:A1991GB09400012
J	GUNWAR, S; NOELKEN, ME; HUDSON, BG				GUNWAR, S; NOELKEN, ME; HUDSON, BG			PROPERTIES OF THE COLLAGENOUS DOMAIN OF THE ALPHA-3(IV) CHAIN, THE GOODPASTURE ANTIGEN, OF LENS BASEMENT-MEMBRANE COLLAGEN - SELECTIVE CLEAVAGE OF ALPHA-(IV) CHAINS WITH RETENTION OF THEIR TRIPLE HELICAL STRUCTURE AND NONCOLLAGENOUS DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGEN; MOLECULAR ARCHITECTURE; ALPORT SYNDROME; PROTEINS; IDENTIFICATION; ALPHA-1-CHAIN; GENE	A third chain, alpha-3(IV), of basement membrane collagen was recently discovered and was identified as the primary target for the autoantibodies of patients with Goodpasture syndrome (Saus, J., Wieslander, J., Langeveld, J. P. M., Quinones, S., and Hudson, B. G. (1988) J. Biol. Chem. 263, 13374-13380). In the present study, this chain was excised in the form of a truncated protomer by cleavage of basement membrane with Pseudomonas aeruginosa elastase and characterized. The triple helical structure and NCI domain were retained. Elastase selectively cleaved at a site within the triple helical domain of the alpha-3 chain that is distinct from the cleavage site of the alpha-1 and alpha-2 chains. The truncated alpha-3 chain was found to contain 1460 residues, of which 1225 comprise the collagenous domain, and is cross-linked within this domain by disulfide bonds, forming a high M(r) complex (> 300,000). Truncated protomers with a length of 340 nm corresponding to the theoretical length for the truncated alpha-3 chain were observed by electron microscopy as suprastructures in which the triple helical domains of three protomers were intertwined. These protomers were also connected to each other and to the 140-nm protomers that appear to be comprised of the alpha-1 and alpha-2 chains. These results extended the known length of the alpha-3 chain by about 1000 residues and suggested that protomers of this chain self-associate through interactions between their triple helical domains and between their NC1 domains.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66103 USA	University of Kansas; University of Kansas Medical Center				Hudson, Billy/0000-0002-5420-4100	NCRR NIH HHS [1 S10RR05554-01] Funding Source: Medline; NIDDK NIH HHS [DK 18381] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHINGER HP, 1982, J BIOL CHEM, V257, P9796; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BEJARANO PA, 1989, INFECT IMMUN, V57, P3783, DOI 10.1128/IAI.57.12.3783-3787.1989; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1972, J BIOL CHEM, V247, P4229; HUDSON BG, 1991, IN PRESS NEPHROLOGY; HUSZAR G, 1980, ANAL BIOCHEM, V105, P424, DOI 10.1016/0003-2697(80)90481-9; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; NOELKEN ME, 1981, ANAL BIOCHEM, V110, P131, DOI 10.1016/0003-2697(81)90123-8; PECZON BD, 1982, EXP EYE RES, V35, P643, DOI 10.1016/S0014-4835(82)80076-6; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; SAUS J, 1989, J BIOL CHEM, V264, P6318; SAUS J, 1988, J BIOL CHEM, V263, P13374; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOININEN R, 1987, FEBS LETT, V225, P188; TIMONEDA J, 1990, CONNECT TISSUE RES, V24, P169, DOI 10.3109/03008209009152147; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	31	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14088	14094						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856232				2022-12-25	WOS:A1991FY02700097
J	HARVEY, PRC; UPADHYA, GA; STRASBERG, SM				HARVEY, PRC; UPADHYA, GA; STRASBERG, SM			IMMUNOGLOBULINS AS NUCLEATING PROTEINS IN THE GALLBLADDER BILE OF PATIENTS WITH CHOLESTEROL GALLSTONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY COMPONENT; CRYSTAL NUCLEATION; LIQUID-CHROMATOGRAPHY; MONOCLONAL-ANTIBODIES; SUPERSATURATED BILE; PROMOTING ACTIVITY; BILIARY PROTEINS; MODEL SYSTEMS; GALL-BLADDER; IGA	The gallbladder bile of patients with cholesterol gallstones contains pronucleating proteins which accelerate precipitation of cholesterol crystals from bile. In this study we have improved the purification procedure developed earlier for these nucleating proteins and have now identified the nature of these proteins. Gallbladder bile from patients with cholesterol gallstones was applied to concanavalin A affinity columns. The ConA-binding glycoprotein fractions containing the nucleating proteins were then separated by FPLC (fast protein liquid chromatography) using a Superose 12 gel filtration column. Nucleating activity was detected in the high molecular weight (FPLC-1) as well as in the low molecular weight fractions (FPLC-3). Investigation of the high molecular weight fraction by sodium dodecyl sulfate-polyacrylamide get electrophoresis followed by electroelution and amino acid sequencing suggested that these proteins were immunoglobulins. Immunostaining of Western blots with specific monoclonal antibodies identified the presence of immunoglobulin (Ig) M and IgA in the FPLC-1 fraction. These immunoglobulins were further purified by affinity chromatography employing an antibody exchanger (ABx) column which specifically binds immunoglobulins. There was no reduction in the cholesterol nucleating activity in the ABx-bound fraction compared to FPLC-1. Additional studies showed that the FPLC-1 fraction was significantly more potent than the ConA glycoproteins from either rapid and slow nucleating biles. Also the number of crystals formed was significantly greater in the FPLC-1 fraction isolated from cholesterol gallstone biles than from the FPLC-1 fraction from control patient biles. Commercially obtained IgM and IgA had no effect on nucleation, but IgM isolated from the serum of patients with Waldenstrom's macroglobulinemia did accelerate the nucleation of cholesterol. We conclude that the IgM and possibly IgA are pronucleating proteins and may be important in the pathogenesis of cholesterol gallstones in man.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT SURG,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University of Toronto	HARVEY, PRC (corresponding author), MT SINAI HOSP,LUNENFELD RES INST,600 UNIV AVE,SUITE 988,TORONTO M5G 1X5,ONTARIO,CANADA.							BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BROWN WR, 1989, HEPATOLOGY, V9, P763, DOI 10.1002/hep.1840090518; BURNSTEIN MJ, 1983, GASTROENTEROLOGY, V85, P801; BUSCH N, 1989, Gastroenterology, V96, pA581; CAREY MC, 1978, J LIPID RES, V19, P945; CHEN FM, 1988, J CHROMATOGR, V444, P153, DOI 10.1016/S0021-9673(01)94018-X; CHODIRKER WB, 1963, SCIENCE, V142, P1080, DOI 10.1126/science.142.3595.1080; CRANE LJ, 1987, MONOCLONAL ANTIBODY, P139; DELACROIX DL, 1982, J CLIN INVEST, V70, P230, DOI 10.1172/JCI110610; DELACROIX DL, 1983, HEPATOLOGY, V3, P980; FISHER MM, 1979, P NATL ACAD SCI USA, V76, P2008, DOI 10.1073/pnas.76.4.2008; GALLINGER S, 1987, GASTROENTEROLOGY, V92, P867, DOI 10.1016/0016-5085(87)90959-0; GALLINGER S, 1985, GASTROENTEROLOGY, V89, P648, DOI 10.1016/0016-5085(85)90464-0; GOLLISH SH, 1983, GUT, V24, P836, DOI 10.1136/gut.24.9.836; GREEN FHY, 1972, GUT, V13, P379, DOI 10.1136/gut.13.5.379; GROEN AK, 1989, J LIPID RES, V30, P51; GROEN AK, 1990, HEPATOLOGY, V11, P525, DOI 10.1002/hep.1840110402; GROEN AK, 1988, HEPATOLOGY, V8, P347, DOI 10.1002/hep.1840080226; HALPERN Z, 1986, GASTROENTEROLOGY, V90, P875, DOI 10.1016/0016-5085(86)90863-2; HALPERN Z, 1986, J LIPID RES, V27, P295; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HARVEY PRC, 1989, CLIN CHIM ACTA, V183, P147, DOI 10.1016/0009-8981(89)90330-6; HARVEY PRC, 1989, CLIN CHIM ACTA, V185, P185, DOI 10.1016/0009-8981(89)90041-7; HARVEY PRC, 1987, BIOCHIM BIOPHYS ACTA, V921, P198, DOI 10.1016/0005-2760(87)90019-1; HOLAN KR, 1979, GASTROENTEROLOGY, V77, P611; HOLZBACH RT, 1984, J CLIN INVEST, V73, P35, DOI 10.1172/JCI111204; HOPF U, 1978, SCAND J IMMUNOL, V8, P543, DOI 10.1111/j.1365-3083.1978.tb00554.x; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KIBE A, 1985, J LIPID RES, V26, P1102; KIBE A, 1984, SCIENCE, V225, P514, DOI 10.1126/science.6429856; LEE SP, 1987, AM J PHYSIOL, V252, pG374, DOI 10.1152/ajpgi.1987.252.3.G374; LEMAITRECOELHO I, 1977, EUR J IMMUNOL, V8, P588; LEVY PF, 1984, GASTROENTEROLOGY, V87, P270; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORIN R J, 1975, Annals of Clinical and Laboratory Science, V5, P52; MULLOCK BM, 1980, BIOCHEM J, V190, P819, DOI 10.1042/bj1900819; NAGURA H, 1981, J IMMUNOL, V126, P587; NAGURA H, 1983, CLIN EXP IMMUNOL, V54, P671; NAU D R, 1989, Biochromatography, V4, P4; NAU DR, 1987, COMMERCIAL PRODUCTIO, P247; ORLANS E, 1979, J EXP MED, V150, P1577, DOI 10.1084/jem.150.6.1577; PELED Y, 1988, HEPATOLOGY, V8, P914, DOI 10.1002/hep.1840080435; PEPPARD JV, 1983, CLIN EXP IMMUNOL, V53, P623; PLUSKAL MG, 1986, BIOTECHNIQUES, V4, P272; ROSS AH, 1987, J IMMUNOL METHODS, V102, P227, DOI 10.1016/0022-1759(87)90081-0; SOCKEN DJ, 1979, J EXP MED, V50, P1538; STRASBERG SM, 1990, HEPATOLOGY, V12, pS1; TALALAY PAUL, 1960, METHODS BIOCHEM ANAL, V8, P119; TERA H, 1960, ACTA CHIR SCAND    S, V256, P4; TOMASI TB, 1970, ANNU REV MED, V21, P281, DOI 10.1146/annurev.me.21.020170.001433; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; VIGNE JL, 1981, BIOCHIMIE, V63, P735, DOI 10.1016/S0300-9084(81)80033-8; VUITTON DA, 1985, CLIN EXP IMMUNOL, V62, P185; WEISSMANN G, 1974, J CLIN INVEST, V53, P536, DOI 10.1172/JCI107587; 1978, SAS USERS GUIDE	56	119	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13996	14003						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856228				2022-12-25	WOS:A1991FY02700085
J	LATIMER, LJP; LEE, JS				LATIMER, LJP; LEE, JS			ETHIDIUM-BROMIDE DOES NOT FLUORESCE WHEN INTERCALATED ADJACENT TO 7-DEAZAGUANINE IN DUPLEX DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INTERACTIONS; NUCLEIC-ACIDS; BINDING; BASE; SPECIFICITY; LIGANDS; FORM	Several synthetic DNAs were prepared containing the unusual bases 7-deazaadenine (c7A) and 7-deazaguanine (c7G). As judged from changes in melting temperatures these modified DNAs bound ethidium to a similar extent as the parent polymers. However, duplexes such as poly[d(Tc7G)].poly[d(CA)] and poly[d(TC)].poly[d(c7GA)] gave no enhancement of ethidium fluorescence in a standard ethidium fluorescence assay. Fluorescence spectra in the range 400-650 nm showed that ethidium bound to poly[d(TC)].poly[d(Gc7A)] gave 70% of the fluorescence of the parent polymer poly[d(TC)].poly[d(GA)], whereas the fluorescence of poly[d(TC)].poly[d(c7GA)] was essentially 0%. Even the intrinsic fluorescence of ethidium in solution was quenched in the presence of poly[d(TC)].poly[d(c7GA)]. Binding constants were estimated from Scatchard analysis and were 4.8, 3.4, and 2.0 x 10(6) m-1 for poly[d(TC)].poly[d(GA)], poly[d(TC)].poly[d(Gc7A)], and poly[d(TC)]-poly[d(c7GA)], respectively. This reduction in binding constant cannot account for the loss of fluorescence. The UV spectrum of ethidium was measured in the presence of these DNAs, and some significant differences were noted. Presumably the presence of 7-deazaguanine alters the electronic structure of bound ethidium so that it can no longer fluoresce.	UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	University of Saskatchewan								BRESLOFF JL, 1981, BIOCHEMISTRY-US, V20, P3547, DOI 10.1021/bi00515a038; CROTHERS DM, 1968, BIOPOLYMERS, V6, P575, DOI 10.1002/bip.1968.360060411; EVANS DH, 1982, CAN J BIOCHEM CELL B, V60, P131, DOI 10.1139/o82-018; HUDSON B, 1975, BIOPOLYMERS, V14, P1309, DOI 10.1002/bip.1975.360140619; JAIN SC, 1977, J MOL BIOL, V114, P317, DOI 10.1016/0022-2836(77)90253-4; KRUGH TR, 1975, J MOL BIOL, V97, P133, DOI 10.1016/S0022-2836(75)80031-3; LEE JS, 1982, BIOCHEMISTRY-US, V21, P4940, DOI 10.1021/bi00263a017; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3703; LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MOLLER A, 1984, BIOCHEMISTRY-US, V23, P54, DOI 10.1021/bi00296a009; MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P547, DOI 10.1093/nar/7.3.547; MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P571, DOI 10.1093/nar/7.3.571; MULLER W, 1975, EUR J BIOCHEM, V54, P267, DOI 10.1111/j.1432-1033.1975.tb04137.x; OLMSTED J, 1977, BIOCHEMISTRY-US, V16, P3647, DOI 10.1021/bi00635a022; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SEELA F, 1982, BIOCHEMISTRY-US, V21, P4338, DOI 10.1021/bi00261a024; SEELA F, 1982, NUCLEIC ACIDS RES, V10, P1389, DOI 10.1093/nar/10.4.1389; SEELA F, 1985, BIOCHEMISTRY-US, V24, P7556, DOI 10.1021/bi00347a008; SEELA F, 1985, NUCLEIC ACIDS RES, V13, P911, DOI 10.1093/nar/13.3.911; SHARP PA, 1973, BIOCHEMISTRY-US, V12, P3055, DOI 10.1021/bi00740a018; TSAI CC, 1977, J MOL BIOL, V114, P333; WARING MJ, 1965, J MOL BIOL, V13, P269, DOI 10.1016/S0022-2836(65)80096-1	24	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13849	13851						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856218				2022-12-25	WOS:A1991FY02700063
J	DOBASHI, Y; STERN, DF				DOBASHI, Y; STERN, DF			MEMBRANE-ANCHORED FORMS OF EGF STIMULATE FOCUS FORMATION AND INTERCELLULAR COMMUNICATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; STOMATITIS-VIRUS GLYCOPROTEIN; ALTERED CYTOPLASMIC DOMAINS; CELL-SURFACE; FACTOR PRECURSOR; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; SECRETORY PROTEIN; FACTOR-ALPHA; TRANSPORT	Epidermal growth factor (EGF) is the prototype for a small family of soluble proteins that bind to and activate the EGF receptor. These proteins are derived from larger propeptides that are anchored to the plasma membrane. Although the signalling properties of soluble EGF are well-characterized, the signalling potential of the membrane-anchored form had not been determined. We therefore investigated whether membrane-anchored EGF can stimulate the EGF receptor. An EGF mini-gene expression system that we had previously constructed for expression of soluble EGF was modified to encode anchored forms of EGF. In the encoded proteins EGF was fused to the spacer in the EGF propeptide that separates EGF from the transmembrane domain. The spacer was followed by vesicular stomatitis virus G protein transmembrane and cytoplasmic domain sequences. Three forms of EGF/G fusion protein were expressed in rat fibroblasts. The plasmids for expression of anchored EGF induced focus formation in rat fibroblasts, indicating that anchored EGF can cause autocrine transformation. When mixed with indicator HeLa cells, cell lines expressing EGF/G fusion proteins activated the HeLa EGF receptor. This activation was mediated by cell-associated, rather than soluble EGF. The finding that membrane-anchored EGF is capable of activating the EGF receptor on neighboring cells has broad implications for the functions of EGF in the organism.	YALE UNIV,SCH MED,DEPT PATHOL,310 CEDAR ST,POB 3333,NEW HAVEN,CT 06510	Yale University	STERN, DF (corresponding author), YALE UNIV,SCH MED,DEPT PATHOL,310 CEDAR ST,POB 3333,NEW HAVEN,CT 06510, USA.			Dobashi, Yoh/0000-0003-0507-3332	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [CA45708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; DAVIS C G, 1990, New Biologist, V2, P410; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GUAN JL, 1988, MOL CELL BIOL, V8, P2869, DOI 10.1128/MCB.8.7.2869; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; GUAN JL, 1988, J BIOL CHEM, V263, P5306; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	39	24	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1151	1159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861865				2022-12-25	WOS:A1991GV26000009
J	BUECHLER, YJ; TAYLOR, SS				BUECHLER, YJ; TAYLOR, SS			MUTATIONS IN THE AUTOINHIBITOR SITE OF THE REGULATORY SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE-I - REPLACEMENT OF ALA-97 AND SER-99 INTERFERES WITH REASSOCIATION WITH THE CATALYTIC SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; CARDIAC-MUSCLE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE BINDING; MOLECULAR-CLONING; AUTOPHOSPHORYLATION; MECHANISM; DOMAINS; IDENTIFICATION	Each regulatory (R) subunit of cAMP-dependent protein kinase contains an autoinhibitor site that lies approximately 90-100 residues from the amino terminus. In order to study the importance of this autoinhibitor site in the type I R-subunit for interacting with the catalytic (C) subunit, recombinant techniques were used to replace Ala-97 with Gln, His, Lys, and Arg and to replace Ser-99 with Gly and Lys. All of the mutant proteins having a replacement at Ala-97 showed reduced affinity for the C-subunit ranging from 14- to 55-fold. In general, the decrease in affinity of the Ala-97 mutants for the C-subunit correlated with the increase in size of the side chain. In contrast to wild type R-subunit, where MgATP facilitates holoenzyme formation, MgATP inhibits the reassociation in all of the Ala-97 mutants suggesting that the larger side chains sterically interfere with bound MgATP in the active site of the C-subunit. Whereas MgATP slowed holoenzyme formation, AMP actually accelerated the reassociation of the A97K, A97H (pH 6.0), and A97Q mutants with the C-subunit. Therefore, the side chains of Lys-97, His-97, and Gln-97 can interact either electrostatically or by hydrogen bonding with the phosphate of AMP. This interpretation is reinforced by the fact that the stimulatory effect of AMP on the A97H mutant was pH-dependent. The affinities of the S99G and S99K mutants for the C-subunit were reduced 7- and 24-fold, respectively, suggesting that Ser-99 also may contribute to interactions between the R- and C-subunits.	UNIV CALIF SAN DIEGO,DEPT CHEM,DIV BIOCHEM,0654,LA JOLLA,CA 92093	University of California System; University of California San Diego					NIGMS NIH HHS [GM-34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BUBIS J, 1987, J BIOL CHEM, V262, P14961; BUILDER SE, 1980, J BIOL CHEM, V255, P3514; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; FIRST EA, 1988, J BIOL CHEM, V263, P5176; GRANOT J, 1981, BIOCHEMISTRY-US, V20, P602, DOI 10.1021/bi00506a024; HOFFMAN F, 1975, J BIOL CHEM, V250, P7795; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LU XY, 1990, J BIOL CHEM, V265, P3293; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NELSON NC, 1981, J BIOL CHEM, V256, P3743; NELSON NC, 1983, J BIOL CHEM, V258, P981; POTTER RL, 1979, J BIOL CHEM, V254, P9000; PURI RN, 1985, BIOCHEMISTRY-US, V24, P6499, DOI 10.1021/bi00344a029; RANGELALDAO R, 1976, J BIOL CHEM, V251, P7526; REIMANN EM, 1986, BIOCHEMISTRY-US, V25, P119, DOI 10.1021/bi00349a018; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; TAKIO K, 1980, FEBS LETT, V114, P83, DOI 10.1016/0014-5793(80)80865-9; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1982, P NATL ACAD SCI-BIOL, V79, P7679, DOI 10.1073/pnas.79.24.7679; WEBER W, 1979, BIOCHEM BIOPH RES CO, V90, P1073, DOI 10.1016/0006-291X(79)91935-1; WELDON SL, 1985, J BIOL CHEM, V260, P4203; ZOLLER MJ, 1988, J BIOL CHEM, V263, P9142; ZOLLER MJ, 1979, J BIOL CHEM, V254, P2408	42	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3491	3497						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847375				2022-12-25	WOS:A1991EY68200026
J	GRUPPUSO, PA; MIKUMO, R; BRAUTIGAN, DL; BRAUN, L				GRUPPUSO, PA; MIKUMO, R; BRAUTIGAN, DL; BRAUN, L			GROWTH ARREST INDUCED BY TRANSFORMING GROWTH FACTOR-BETA-1 IS ACCOMPANIED BY PROTEIN PHOSPHATASE ACTIVATION IN HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR-REGULATION; KINASE-C; FACTOR-BETA; FAMILY; CELLS; DIFFERENTIATION; TYPE-1; CYCLE	Protein phosphorylation and dephosphorylation are involved in regulation of cell growth. We tested the hypothesis that the growth inhibitory effect of transforming growth factor beta-1 (TGF-beta-1) involves activation of protein phosphatases. Exposure of human keratinocytes in culture to 400 pM TGF-beta-1 for 48 h led to 80% inhibition of DNA synthesis as measured by nuclear labeling. Incubation of cultured keratinocytes with 400 pM TGF-beta-1 rapidly activated (within 30 min) protein serine/threonine phosphatase, measured using phosphorylase as a substrate. Based on several criteria, including neutralization of activity with specific antibodies and inhibitor-2, TGF-beta-1-activated phosphorylase phosphatase was identified as protein phosphatase 1. TGF-beta-1 did not have rapid effects on protein serine/threonine phosphatase activity (type 2A) measured with histone phosphorylated by protein kinase C or on protein tyrosine phosphatase activity. However, protein tyrosine phosphatase was activated at 48 h, coincident with growth arrest. Differentiation, induced by the combination of TGF-beta-1 plus calcium or by serum, was not accompanied by further serine/threonine or tyrosine phosphatase activation. We conclude that induction of growth arrest in keratinocytes by TGF-beta-1 involves acute activation of protein phosphatase 1, while activation of protein tyrosine phosphatases may represent an additional mechanism for maintaining cells in a growth-arrested state.	BROWN UNIV, DEPT PEDIAT, PROVIDENCE, RI 02912 USA; BROWN UNIV, DEPT BIOCHEM, PROVIDENCE, RI 02912 USA; BROWN UNIV, DEPT PATHOL, PROVIDENCE, RI 02912 USA	Brown University; Brown University; Brown University					NCI NIH HHS [CA46617] Funding Source: Medline; NICHD NIH HHS [HD24455] Funding Source: Medline; NIDDK NIH HHS [DK31374] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA046617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031374] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYOUB P, 1963, Oral Surg Oral Med Oral Pathol, V16, P580, DOI 10.1016/0030-4220(63)90148-8; BRAUN L, 1990, CANCER RES, V50, P7324; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; BRAUTIGAN DL, 1986, J BIOL CHEM, V261, P4924; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DRAETTA G, 1988, COLD SPRING HARB SYM, V53, P195, DOI 10.1101/SQB.1988.053.01.025; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FRANK DA, 1986, BIOCHEM BIOPH RES CO, V140, P440, DOI 10.1016/0006-291X(86)91110-1; Freshney RI., 1987, CULTURE ANIMAL CELLS; GRUPPUSO PA, 1985, J BIOL CHEM, V260, P4288; GRUPPUSO PA, 1990, J CLIN INVEST, V85, P1754, DOI 10.1172/JCI114632; GRUPPUSO PA, 1990, PEDIATR RES, V27, P599, DOI 10.1203/00006450-199006000-00014; GRUPPUSO PA, 1991, IN PRESS BIOCH J; HAWLEYNELSON P, 1980, J INVEST DERMATOL, V75, P176, DOI 10.1111/1523-1747.ep12522602; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; JAKES S, 1988, BIOCHIM BIOPHYS ACTA, V967, P11, DOI 10.1016/0304-4165(88)90182-1; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MOSES HL, 1985, CANCER CELL, V3, P65; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAY LB, 1988, J BIOL CHEM, V263, P12721; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; ROBERTS AB, 1988, BIOFACTORS, V1, P89; SHIPLEY GD, 1986, CANCER RES, V46, P2068; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TONKS NK, 1990, J BIOL CHEM, V265, P10674; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WIKNER NE, 1988, J INVEST DERMATOL, V91, P207, DOI 10.1111/1523-1747.ep12464997	35	78	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3444	3448						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847373				2022-12-25	WOS:A1991EY68200019
J	KNOLLER, S; SHPUNGIN, S; PICK, E				KNOLLER, S; SHPUNGIN, S; PICK, E			THE MEMBRANE-ASSOCIATED COMPONENT OF THE AMPHIPHILE-ACTIVATED, CYTOSOL-DEPENDENT SUPEROXIDE-FORMING NADPH OXIDASE OF MACROPHAGES IS IDENTICAL TO CYTOCHROME-B559	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SODIUM DODECYL-SULFATE; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; PARTIAL-PURIFICATION; PHAGOCYTIC-CELLS; POLYMORPHONUCLEAR LEUKOCYTES; FLAVOPROTEIN COMPONENT	The superoxide (O2-) forming NADPH oxidase complex of resting phagocytes can be activated in a cell-free system by certain anionic amphiphiles, such as sodium dodecyl sulfate (SDS). For O2- production to occur, the participation of both membrane-associated and cytosol-derived components is required. The purpose of this investigation was to isolate and characterize the membrane component of NADPH oxidase. For this purpose, guinea pig macrophage membranes were extracted with 1 M NaCl, solubilized by 40 mM octyl glucoside, and subjected to a purification sequence consisting of absorption with DEAE-Sepharose, affinity chromatography on heparin-agarose, and chromatography on hydroxylapatite. At each purification step, fractions were assayed for their ability to support SDS-elicited, cytosol-dependent O2- production, following incorporation in liposomes of phosphatidylcholine. We found that membrane oxidase activity copurified strictly with cytochrome b559. Peak hydroxylapatite fractions exhibited specific O2- -forming activity in the range of 81-115-mu-mol of O2-/mg protein/min and a specific cytochrome b559 content of 7-14 nmol of cytochrome b559/mg protein. SDS-polyacrylamide gel electrophoresis analysis of the peak oxidase activity fractions, derived by hydroxylapatite chromatography, revealed essentially two bands that were identified as the beta(54-60 kDa) and alpha(21/22 kDa) subunits of guinea pig cytochrome b559. The relation of the two polypeptides to cytochrome b559 was established by correlation with a spectral signal characteristic of cytochrome b559, immunoblotting with antibodies against defined human cytochrome b559, beta and alpha-chain peptides, crosslinking studies, and deglycosylation experiments. Hydroxylapatite-purified membrane oxidase preparations did not contain FAD and were free of cytochrome c reductase activity. Purified membrane oxidase preparations were also capable of cooperating with purified cytosolic components in SDS-elicited cell-free O2- production. We conclude that the membrane-associated component of the O2- generating NADPH oxidase is identical to cytochrome b559.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IMMUNOPHARMACOL LAB,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine			Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1990, European Journal of Clinical Investigation, V20, pA37; AMIT N, 1988, BIOCHIM BIOPHYS ACTA, V944, P437, DOI 10.1016/0005-2736(88)90514-7; BABIOR BM, 1984, BLOOD, V64, P959; BELLAVITE P, 1984, BIOCHEM J, V223, P639, DOI 10.1042/bj2230639; BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BERTON G, 1985, BIOCHIM BIOPHYS ACTA, V810, P164, DOI 10.1016/0005-2728(85)90132-X; BJERRUM OW, 1989, EUR J HAEMATOL, V43, P67; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CURNETTE JT, 1988, CLIN RES, V36, P408; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; GABIG TG, 1983, J BIOL CHEM, V258, P6352; GLASS GA, 1986, J BIOL CHEM, V261, P3247; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARLOW E, 1988, ANTIBODIES LABORATOR, P651; HARPER AM, 1985, BIOCHEM J, V227, P783, DOI 10.1042/bj2270783; HARPER AM, 1984, BIOCHEM J, V219, P519, DOI 10.1042/bj2190519; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; KLEINBERG ME, 1989, J IMMUNOL, V143, P4152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE F, 1990, BIOCHEM BIOPH RES CO, V167, P790, DOI 10.1016/0006-291X(90)92095-H; LIGHT DR, 1981, BIOCHEMISTRY-US, V20, P1468, DOI 10.1021/bi00509a010; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; NOZAKI M, 1990, EUR J BIOCHEM, V187, P335, DOI 10.1111/j.1432-1033.1990.tb15310.x; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARKINSON JF, 1988, J BIOENERG BIOMEMBR, V20, P653, DOI 10.1007/BF00762547; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; PEMBER SO, 1984, J BIOL CHEM, V259, P590; PICK E, 1987, J BIOL CHEM, V262, P16476; PICK E, 1989, J IMMUNOL, V143, P4180; PICK E, 1988, J IMMUNOL, V140, P1611; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROTROSEN D, 1989, CLIN RES, V37, P438; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1979, BIOCHEM J, V182, P181, DOI 10.1042/bj1820181; SEGAL AW, 1983, NEW ENGL J MED, V308, P245, DOI 10.1056/NEJM198302033080503; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHAAG D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P405, DOI 10.1016/0167-4838(90)90044-G; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; YAMAGUCHI T, 1989, J BIOL CHEM, V264, P112; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095	57	98	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2795	2804						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847135				2022-12-25	WOS:A1991EX60000023
J	SHINABARGER, D; BERRY, A; MAY, TB; ROTHMEL, R; FIALHO, A; CHAKRABARTY, AM				SHINABARGER, D; BERRY, A; MAY, TB; ROTHMEL, R; FIALHO, A; CHAKRABARTY, AM			PURIFICATION AND CHARACTERIZATION OF PHOSPHOMANNOSE ISOMERASE-GUANOSINE DIPHOSPHO-D-MANNOSE PYROPHOSPHORYLASE - A BIFUNCTIONAL ENZYME IN THE ALGINATE BIOSYNTHETIC-PATHWAY OF PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETASE-CHORISMATE MUTASE; BACILLUS-SUBTILIS 168; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; NUCLEOTIDE-SEQUENCE; MUCOID STRAINS; GENE MANA; CLONING; OVERPRODUCTION; EXPRESSION	We report here the purification and characterization of phosphomannose isomerase-guanosine 5'-diphospho-D-mannose pyrophosphorylase, a bifunctional enzyme (PMI-GMP) which catalyzes both the phosphomannose isomerase (PMI) and guanosine 5'-diphospho-D-mannose pyrophosphorylase (GMP) reactions of the Pseudomonas aeruginosa alginate biosynthetic pathway. The PMI and GMP activities co-eluted in the same protein peak through successive fractionation on hydrophobic interaction, ion exchange, and gel filtration chromatography. The purified enzyme migrated as a 56,000 molecular weight protein on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the native protein migrated as a monomer of 54,000 molecular weight upon gel filtration chromatography. The apparent K(m) for D-mannose 6-phosphate was 3.03 mM, and the V(max) was 830 nmol/min/mg of enzyme. For the GMP forward reaction, apparent K(m) values of 20.5-mu-M and 29.5-mu-M for D-mannose 1-phosphate and GTP, respectively, were obtained from double reciprocal plots. The GMP forward reaction V(max) (5,680 nmol)/min/mg of enzyme) was comparable to the reverse reaction V(max) (5,170 nmol/min/mg of enzyme), and the apparent K(m) for GDP-D-mannose was determined to be 14.2-mu-M. Both reactions required Mg2+ activation, but the PMI reaction rate was 4-fold higher with Co2+ as the activator. PMI (but not GMP) activity was sensitive to dithiothreitol, indicating the involvement of disulfide bonds to form a protein structure capable of PMI activity. DNA sequencing of a cloned mutant algA gene from P. aeruginosa revealed that a point mutation at nucleotide 961 greatly decreased the levels of both PMI and GMP in a crude extract.	UNIV ILLINOIS,COLL MED,DEPT MICROBIOL & IMMUNOL,835 S WOLCOTT AVE,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Fialho, Arsenio/A-6246-2008; AM, Fialho/AAB-5715-2021	Fialho, Arsenio/0000-0002-8066-5787; AM, Fialho/0000-0002-8066-5787	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI007890, R01AI016790, R37AI016790] Funding Source: NIH RePORTER; NIAID NIH HHS [F32AI07890, AI-16790-12] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDRICH TL, 1989, MOL GEN GENET, V218, P266, DOI 10.1007/BF00331277; BAGDASARIAN MM, 1983, GENE, V39, P440; BALTIMORE RS, 1980, J INFECT DIS, V141, P238, DOI 10.1093/infdis/141.2.238; BENSON AA, 1957, METHOD ENZYMOL, V3, P110, DOI 10.1016/S0076-6879(57)03353-4; BRUNS FH, 1958, NATURE, V181, P1467, DOI 10.1038/1811467a0; CREIGHTON TE, 1966, J BIOL CHEM, V241, P4616; DARZINS A, 1984, J BACTERIOL, V159, P9, DOI 10.1128/JB.159.1.9-18.1984; DARZINS A, 1986, GENE, V42, P293, DOI 10.1016/0378-1119(86)90233-7; DARZINS A, 1985, J BACTERIOL, V161, P249, DOI 10.1128/JB.161.1.249-257.1985; DAVIDSON BE, 1972, J BIOL CHEM, V247, P4441; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; EVANS LR, 1973, J BACTERIOL, V116, P915, DOI 10.1128/JB.116.2.915-924.1973; GILL JF, 1986, J BACTERIOL, V167, P611, DOI 10.1128/jb.167.2.611-615.1986; GOLDBERG JB, 1984, J BACTERIOL, V158, P1115, DOI 10.1128/JB.158.3.1115-1121.1984; GOVAN JRW, 1978, J ANTIMICROB CHEMOTH, V4, P233, DOI 10.1093/jac/4.3.233; GOVAN JRW, 1986, MICROBIOL SCI, V3, P302; GOVAN JRW, 1979, J GEN MICROBIOL, V110, P229, DOI 10.1099/00221287-110-1-229; GOVAN JRW, 1975, J MED MICROBIOL, V8, P513, DOI 10.1099/00222615-8-4-513; HOIBY N, 1974, ACTA PATH MICRO IM B, VB 82, P551; HOUGH L, 1954, METHOD BIOCHEM ANAL, V1, P205; HUANG L, 1974, J BIOL CHEM, V249, P4467; HUANG L, 1974, J BIOL CHEM, V249, P4473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARRIE TJ, 1979, J INFECT DIS, V139, P357, DOI 10.1093/infdis/139.3.357; MILES JS, 1984, GENE, V32, P41, DOI 10.1016/0378-1119(84)90030-1; MUNCHPETERSEN A, 1956, ACTA CHEM SCAND, V10, P928, DOI 10.3891/acta.chem.scand.10-0928; NOLTMANN E, 1958, BIOCHEM Z, V330, P514; OLIVER AM, 1983, J CLIN LAB IMMUNOL, V10, P221; PADGETT PJ, 1986, CURR MICROBIOL, V14, P187, DOI 10.1007/BF01568516; PIGGOTT NH, 1981, EUR J APPL MICROBIOL, V13, P179, DOI 10.1007/BF00703050; PREISS J, 1964, J BIOL CHEM, V239, P3119; ROYCHOUDHURY S, 1989, J BIOL CHEM, V264, P9380; SACORREIA I, 1987, J BACTERIOL, V169, P3224, DOI 10.1128/jb.169.7.3224-3231.1987; SCHWARZMANN S, 1971, INFECT IMMUN, V3, P762, DOI 10.1128/IAI.3.6.762-767.1971; SLACK MPE, 1981, LANCET, V1, P270; SLEIN MW, 1955, METHOD ENZYMOL, V1, P299, DOI 10.1016/0076-6879(55)01041-0; SLEIN MW, 1950, J BIOL CHEM, V186, P753; SUTHERLAND IW, 1969, BIOCHEM J, V115, P935, DOI 10.1042/bj1150935; WINBERG G, 1980, NUCLEIC ACIDS RES, V8, P253, DOI 10.1093/nar/8.2.253	39	125	131	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2080	2088						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846611				2022-12-25	WOS:A1991EV51500014
J	IWAMOTO, M; SHIMAZU, A; NAKASHIMA, K; SUZUKI, F; KATO, Y				IWAMOTO, M; SHIMAZU, A; NAKASHIMA, K; SUZUKI, F; KATO, Y			REDUCTION IN BASIC FIBROBLAST GROWTH-FACTOR RECEPTOR IS COUPLED WITH TERMINAL DIFFERENTIATION OF CHONDROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT COSTAL CHONDROCYTES; FACTOR-BETA; PROTEOGLYCAN SYNTHESIS; ALKALINE-PHOSPHATASE; PARATHYROID-HORMONE; CHICK CHONDROCYTES; COLONY FORMATION; MUSCLE-CELLS; SOFT AGAR; CARTILAGE	Basic fibroblast growth factor (bFGF) stimulates proliferation of chondrocytes and their extracellular matrix synthesis but inhibits terminal differentiation to hypertrophic cells (Kato, Y., and Iwamoto, M., (1990) J. Biol. Chem. 265, 5903-5909). In the present study, we examined changes in bFGF binding during chondrocyte cytodifferentiation. In cultures of pelleted growth plate chondrocytes, binding of I-125-bFGF to 140-kDa receptors was observed during the mitotic and matrix-forming stages but decreased to a very low level as chondrocytes became hypertrophic. Scatchard plot analysis showed that the decrease in binding of bFGF was due to a decrease in the number not in the affinity of the receptor. The loss of bFGF receptor was associated with a decrease in biological responses to bFGF. On the other hand, the binding of transforming growth factor-beta and epidermal growth factor was constant throughout all stages of growth plate chondrocytes. A rapid decrease in bFGF binding was not observed with articular chondrocytes or bFGF-exposed growth plate chondrocytes, perhaps because they scarcely underwent terminal differentiation. A decrease in bFGF binding associated with terminal differentiation in situ was also demonstrated by examination of sequential slices of growth plates. These observations suggest that rapid reduction in bFGF receptor is a special event during terminal differentiation.	OSAKA UNIV,FAC DENT,DEPT BIOCHEM,1-8 YAMADAOKA,SUITA,OSAKA 565,JAPAN	Osaka University				Nakashima, Kazuhisa/0000-0003-0491-2149				BEQUINOT F, 1985, J BIOL CHEM, V260, P15892; BESSEY OA, 1946, J BIOL CHEM, V164, P321; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CAPASSO O, 1984, MOL CELL BIOL, V4, P1163, DOI 10.1128/MCB.4.6.1163; COURTY J, 1988, J BIOL CHEM, V263, P11217; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GIBSON GJ, 1982, J CELL BIOL, V93, P767, DOI 10.1083/jcb.93.3.767; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; INOUE H, 1989, J CELL PHYSIOL, V138, P329, DOI 10.1002/jcp.1041380216; IWAMOTO M, 1989, DEV BIOL, V136, P500, DOI 10.1016/0012-1606(89)90275-3; IWAMOTO M, 1989, BIOCHEM BIOPH RES CO, V159, P1006, DOI 10.1016/0006-291X(89)92208-0; JOHNSONWINT B, 1982, ANAL BIOCHEM, V122, P338, DOI 10.1016/0003-2697(82)90292-5; KATO Y, 1990, P NATL ACAD SCI USA, V87, P6522, DOI 10.1073/pnas.87.17.6522; KATO Y, 1987, J CELL PHYSIOL, V133, P491, DOI 10.1002/jcp.1041330309; KATO Y, 1990, ENDOCRINOLOGY, V127, P114, DOI 10.1210/endo-127-1-114; KATO Y, 1988, P NATL ACAD SCI USA, V85, P9552, DOI 10.1073/pnas.85.24.9552; KATO Y, 1983, EUR J BIOCHEM, V129, P685; KATO Y, 1984, J CELL PHYSIOL, V120, P354, DOI 10.1002/jcp.1041200314; KATO Y, 1985, J CELL BIOL, V100, P477, DOI 10.1083/jcb.100.2.477; KATO Y, 1990, J BIOL CHEM, V265, P5903; KATO Y, 1985, J BIOL CHEM, V260, P2364; KAWASHIMA K, 1980, ENDOCRINOL JAPON, V27, P349; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; LOBB R, 1986, J BIOL CHEM, V261, P1924; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MAOR G, 1987, COLLAGEN REL RES, V7, P351; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATTSSON MEK, 1986, J CELL BIOL, V102, P1949, DOI 10.1083/jcb.102.5.1949; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; RINDERKNECHT E, 1976, P NATL ACAD SCI USA, V74, P4173; Robison R, 1923, BIOCHEM J, V17, P286, DOI 10.1042/bj0170286; SCHMID TM, 1982, J BIOL CHEM, V257, P2451; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SILBERMANN M, 1983, CARTILAGE, V2, P327; SUDA S, 1985, CALCIFIED TISSUE INT, V37, P82, DOI 10.1007/BF02557684; SUZUKI F, 1976, FEBS LETT, V70, P155, DOI 10.1016/0014-5793(76)80747-8; TERRACIO L, 1988, J CELL BIOL, V107, P1947, DOI 10.1083/jcb.107.5.1947; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	47	99	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					461	467						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845975				2022-12-25	WOS:A1991EQ33900067
J	DELCOURT, SG; BLAKE, RD				DELCOURT, SG; BLAKE, RD			STACKING ENERGIES IN DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE COMPOSITION; THERMAL-DENATURATION; MELTING PROFILES; COIL TRANSITION; DOUBLE HELICES; FINE-STRUCTURE; NUCLEIC-ACIDS; SEQUENCE; STABILITY; PROTEINS	Variations in base mono- and dipoles result in variations in stacking energies for the 10 unique neighbor pairs in DNA. Stacking energies for pair M on N, expressed as T(MN), were derived by matrix decomposition of a large set of linear algebraic expressions relating the measured T(m) for subtransitions emanating from large polymeric DNAs, and the fractional neighbor frequencies, f(MN), for the domains responsible for the transitions, T(m) = SIGMA-f(MN)T(MN). T(m) were determined for subtransitions that dissociate in approximately all-or-none fashion in high resolution melting profiles of partially deleted and recombinant forms of pBR322 DNA. Three different analytical maneuvers were undertaken to resolve subtransitions: site-specific cleavage of domains; deletion of domains; and addition of domains. Three dozen domains of widely divergent, quasi-random neighbor frequencies were identified and assigned, resulting in a unique set of values for T(MN) with standard deviation, sigma = +/- 0.23-degrees-C. The average difference between calculated and experimental T(m) for domains is only +/- 0.17-degrees-C, indicating that the thermodynamic properties of these domains are not in any way unusual. Assuming DELTA-S to be constant for all pairs, the corresponding DELTA-H(MN) are found to have a precision of +/- 10 calories.mol-1 and an accuracy of +/- 606 calories.mol-1. T(MN) used to calculate melting curves by statistical mechanical analysis of sequences of the different plasmid specimens in this study were in quantitative agreement with observed curves for most sequences. These T(MN) differ significantly from those determined previously and also correlate poorly with values determined by quantum chemical analysis. Stabilities of neighbor pairs, expressed as the difference in free energy between that for a given pair (MN) and that for the average of like pairs (M, N), depend on the relationship of stacked purines and pyrimidines as follows. Delta-DELTA-GBAR(pu-py)(-466 cal) > delta-DELTA-GBAR(pu-pu)(+52 cal) > delta-DELTA-GBAR(py-pu)(+335 cal). Differences between experimental T(m) and T(m) calculated with T(MN) for the isolated neighbor pairs in the B-conformation are useful in the identification of altered structures and unusual modes of dissociation of helixes. A significantly higher T(m) is observed for the highly biased repeated sequence synthetic helixes dA.dT, d(AGC).d(GCT), and d(GAT).d(ATC), reflecting auxiliary sources of stability such as bifurcated hydrogen bonds and/or altered structures for these helixes.			DELCOURT, SG (corresponding author), UNIV MAINE,DEPT BIOCHEM MICROBIOL & MOLEC BIOL,ORONO,ME 04469, USA.				NIGMS NIH HHS [GM22827] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022827] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZBEL MY, 1980, BIOPOLYMERS, V19, P61, DOI 10.1002/bip.1980.360190105; BALDWIN RL, 1971, ACCOUNTS CHEM RES, V4, P265, DOI 10.1021/ar50044a001; BELENKTSEV BN, 1976, MOL BIOL, V10, P764; BLAKE RD, 1985, J BIOCHEM BIOPH METH, V11, P307, DOI 10.1016/0165-022X(85)90023-5; BLAKE RD, 1979, BIOPOLYMERS, V18, P3089, DOI 10.1002/bip.1979.360181214; BLAKE RD, 1990, BIOPOLYMERS, V29, P393, DOI 10.1002/bip.360290211; BLAKE RD, 1987, BIOPOLYMERS, V26, P1063, DOI 10.1002/bip.360260706; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BUCKIN VA, 1989, NATURE, V340, P321, DOI 10.1038/340321a0; CALLADINE CR, 1986, J MOL BIOL, V192, P907, DOI 10.1016/0022-2836(86)90036-7; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; FIXMAN M, 1977, BIOPOLYMERS, V16, P2693, DOI 10.1002/bip.1977.360161209; FRANKKAM.MD, 1971, BIOPOLYMERS, V10, P2623, DOI 10.1002/bip.360101223; GLICKMAN BW, 1986, MECHANISMS DNA DAMAG, P425; GOTOH O, 1983, ADV BIOPHYS, V16, P1; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; GRUENWEDEL DW, 1975, BIOCHIM BIOPHYS ACTA, V395, P246, DOI 10.1016/0005-2787(75)90195-1; HARAN TE, 1987, J BIOMOL STRUCT DYN, V5, P199, DOI 10.1080/07391102.1987.10506390; Hill T.L., 1956, STAT MECH PRINCIPLES; INMAN RB, 1964, J MOL BIOL, V8, P452, DOI 10.1016/S0022-2836(64)80003-6; Ising E, 1925, Z PHYS, V31, P253, DOI 10.1007/BF02980577; JONES M, 1987, GENETICS, V115, P605; KENNARD O, 1989, Q REV BIOPHYS, V22, P327, DOI 10.1017/S0033583500002997; KLUMP H, 1971, BIOPOLYMERS, V10, P513, DOI 10.1002/bip.360100307; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KRAKAUER H, 1968, BIOPOLYMERS, V6, P491, DOI 10.1002/bip.1968.360060406; LANGLET J, 1981, INT J QUANTUM CHEM, V19, P299; LESLIE AGW, 1980, J MOL BIOL, V143, P49, DOI 10.1016/0022-2836(80)90124-2; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; Maniatis T., 1982, MOL CLONING; MCCAMPBELL CR, 1989, BIOPOLYMERS, V28, P1745, DOI 10.1002/bip.360281008; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NORRIS AC, 1981, COMPUTATIONAL CHEM, P101; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; OLSON WK, 1988, UNUSUAL DNA STRUCTUR, P207; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; ORNSTEIN RL, 1983, BIOPOLYMERS, V22, P1979, DOI 10.1002/bip.360220811; POLAND D, 1974, BIOPOLYMERS, V13, P1859, DOI 10.1002/bip.1974.360130916; POLAND D, 1970, THEORY HELIX COIL TR; PRESS WH, 1986, NUMERICAL RECIPES, P31; PRIVALOV PL, 1969, BIOPOLYMERS, V8, P559, DOI 10.1002/bip.1969.360080502; RATLIFF RL, 1973, BIOCHEMISTRY-US, V12, P5005, DOI 10.1021/bi00748a029; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; ROMER R, 1970, EUR J BIOCHEM, V15, P77, DOI 10.1111/j.1432-1033.1970.tb00978.x; SCHEFFLER IE, 1969, J MOL BIOL, V42, P577, DOI 10.1016/0022-2836(69)90244-7; SHAKKED Z, 1986, PROG BIOPHYS MOL BIO, V47, P159, DOI 10.1016/0079-6107(86)90013-1; SHIAO DDF, 1973, BIOPOLYMERS, V12, P1829, DOI 10.1002/bip.1973.360120810; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; TUNG CS, 1986, J BIOL CHEM, V261, P3700; VOVELLE F, 1990, INT J BIOL MACROMOL, V12, P369, DOI 10.1016/0141-8130(90)90045-C; WADA A, 1980, CRC CR REV BIOCH MOL, V9, P87, DOI 10.3109/10409238009105432; WARTELL RM, 1985, PHYS REP, V126, P67, DOI 10.1016/0370-1573(85)90060-2; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WELLS R D, 1970, Journal of Molecular Biology, V54, P465, DOI 10.1016/0022-2836(70)90121-X; WELLS R D, 1974, P41	59	155	157	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15160	15169						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869547				2022-12-25	WOS:A1991GB09700055
J	ISHIGURO, S; SUZUKI, Y; TAMAI, M; MIZUNO, K				ISHIGURO, S; SUZUKI, Y; TAMAI, M; MIZUNO, K			PURIFICATION OF RETINOL DEHYDROGENASE FROM BOVINE RETINAL ROD OUTER SEGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT-EPITHELIUM; BINDING-PROTEIN; BIOCHEMICAL ASPECTS; VISUAL PROCESS; VITAMIN-A; IMMUNOCYTOCHEMICAL LOCALIZATION; SUBCELLULAR-FRACTIONS; TRANSPORT; MEMBRANES; CYCLE	We purified retinol dehydrogenase from bovine rod outer segments using polyethylene glycol precipitation and hydroxylapatite, concanavalin A-Sepharose CL-4B, and Sepharose CL-6B column chromatography in the presence of NADP. We obtained 13-fold purification of retinol dehydrogenase with specific activity of 61.8 nmol/min/mg and 3.8% recovery. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that retinol dehydrogenase had a molecular mass of 37,000 daltons. The K(m) values of purified retinol dehydrogenase for all-trans retinol and all-trans retinal were 6.6 mM and 0.085 mM, respectively. The purified enzyme reacted with the all-trans retinal but not with 13-, 11-, and 9-cis compounds. In addition, we prepared antibody to retinol dehydrogenase using rat. The anti-retinol dehydrogenase antibody precipitated retinol dehydrogenase activity and was confirmed to bind to 37-kDa protein by Western blotting. We also found that anti-retinol dehydrogenase antibody bound to bovine rod outer segments specifically by immunohistochemical technique. The molar ratio of retinol dehydrogenase to opsin in rod outer segments estimated by enzyme-linked immunosorbent assay was 1:140.			ISHIGURO, S (corresponding author), TOHOKU UNIV, SCH MED, DEPT OPHTHALMOL, 1-1 SEIRYO MACHI, SENDAI, MIYAGI 980, JAPAN.							ANDREWS JS, 1964, J BIOL CHEM, V239, P4073; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; BOK D, 1984, INVEST OPHTH VIS SCI, V25, P877; BRIDGES CD, 1987, SCIENCE, V236, P1678, DOI 10.1126/science.3603006; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FUTTERMAN S, 1970, J NEUROCHEM, V17, P149, DOI 10.1111/j.1471-4159.1970.tb02195.x; FUTTERMAN S, 1961, J BIOL CHEM, V236, P1652; ISHIGURO S, 1987, CELL STRUCT FUNCT, V12, P141, DOI 10.1247/csf.12.141; KISSUN RD, 1972, EXP EYE RES, V14, P150, DOI 10.1016/0014-4835(72)90061-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LIN ZS, 1989, VISION RES, V29, P1699, DOI 10.1016/0042-6989(89)90152-1; LIOU GI, 1982, VISION RES, V22, P1457, DOI 10.1016/0042-6989(82)90210-3; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SAARI JC, 1982, J BIOL CHEM, V257, P13329; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; TSUKIDA K, 1977, J NUTR SCI VITAMINOL, V23, P263; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZIMMERMAN WF, 1975, EXP EYE RES, V21, P325, DOI 10.1016/0014-4835(75)90043-3	32	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15520	15524						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869569				2022-12-25	WOS:A1991GB09700103
J	HOYT, DW; GIERASCH, LM				HOYT, DW; GIERASCH, LM			A PEPTIDE CORRESPONDING TO AN EXPORT-DEFECTIVE MUTANT OMPA SIGNAL SEQUENCE WITH ASPARAGINE IN THE HYDROPHOBIC CORE IS UNABLE TO INSERT INTO MODEL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; FLUORESCENCE; BILAYERS; TRANSITIONS; FLUIDITY; PROBES; HELIX	We have examined the comparative membrane interaction properties of synthetic peptides corresponding to the wild-type and an export-defective, mutated signal sequence from the Escherichia coli outer membrane protein, OmpA. As part of a collaborative study of the effects of various alterations on the function of the OmpA signal sequence and the biophysical properties of the corresponding synthetic peptides, we incorporated the small, neutral polar residue, asparagine, into the hydrophobic core in place of Ile-8. This seemingly minor perturbation to the signal sequence caused a complete block of export in vivo (J. Goldstein, S. Lehnhardt, and M. Inouye, following paper). We now explore in detail the difference in the properties of the wild-type and the Ile-8 --> Asn OmpA signal peptides. The fluorescent residue Trp was substituted in both peptides in place of the wild-type Phe at position 15. This mutation is silent phenotypically and provides a superb probe of membrane interaction. We find that the Asn substitution leaves the conformational properties of the signal sequence essentially unchanged, but prevents any significant interaction of the peptide with a lipid bilayer. Asparagines are very underrepresented among known signal sequences. We believe this low frequency to be due to the lowering of mean residue hydrophobicity caused by incorporation of Asn and the consequent reduced ability to bind and insert into membranes.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Hoyt, David/H-6295-2013; Gierasch, Lila M/D-1494-2009	Hoyt, David/0000-0002-2857-719X; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034962] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; BRUCH MD, 1989, BIOCHEMISTRY-US, V28, P8554, DOI 10.1021/bi00447a043; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Fendler JH, 1982, MEMBRANE MIMETIC CHE, P6; FRANKS NP, 1976, J MOL BIOL, V100, P345, DOI 10.1016/S0022-2836(76)80067-8; GOLDSTEIN J, 1991, J BIOL CHEM, V266, P14413; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4529, DOI 10.1021/bi00665a030; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; LONDON E, 1982, MOL CELL BIOCHEM, V45, P181; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; NOGGLE JN, 1985, PROGRAM F CURVE; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RIGELL CW, 1985, BIOCHEMISTRY-US, V24, P5638, DOI 10.1021/bi00341a053; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TANFORD C, 1980, HYDROPHOBIC EFFECT, P190; TENNYSON J, 1986, J BIOL CHEM, V261, P14196; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3	26	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14406	14412						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860847				2022-12-25	WOS:A1991FZ35100047
J	NICE, EC; FABRI, L; WHITEHEAD, RH; JAMES, R; SIMPSON, RJ; BURGESS, AW				NICE, EC; FABRI, L; WHITEHEAD, RH; JAMES, R; SIMPSON, RJ; BURGESS, AW			THE MAJOR COLONIC CELL MITOGEN EXTRACTABLE FROM COLONIC MUCOSA IS AN N-TERMINALLY EXTENDED FORM OF BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; TRANSFORMED-CELLS; LINE LIM1215; EXPRESSION; PROTEIN; BINDING; MOUSE; CHROMATOGRAPHY; POLYPEPTIDES; CODONS	Colonic growth factors (CGFs) were extracted from porcine intestinal epithelium and mucosa. Under acidic conditions, very little mitogenic activity (as assayed using murine 3T3 fibroblasts and a human colonic cell line) was extractable. However, by extracting at neutral or slightly alkaline pH, significant mitogenic activity for both the murine fibroblasts and human colonic carcinoma cell line could be detected. CGFs are Present throughout the intestine and cecum. The epithelial mucosa of the distal colorectal region appeared to contain mitogens which were more potent for the colonic cells than the 3T3 fibroblasts. Purification of CGFs from the colonic mucosa required removal of associated mucin by pH precipitation prior to chromatographic fractionation. It was then possible to develop a complete purification (390,000-fold) scheme for the major CGF, an 18-kDa protein which bound to heparin-Sepharose. N-terminal sequence analysis yielded a single sequence (Q)SPGGAMAAGSITTLPALP, i.e. an N-terminally extended form of basic fibroblast growth factor. Apart from the substitution of Gly in bovine basic fibroblast growth factor by a Ser in porcine CGF, the proteins are identical. A similar extraction procedure using purified human colonic crypt epithelial cells yielded a mitogen for the human colonic cell line with similar chromatographic properties.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,JOINT PROT STRUCT LAB,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute			Nice, Edouard C/B-1026-2011	Simpson, Richard/0000-0002-9834-0796; fabri, louis/0000-0003-4033-3304				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALNAFUSSI AI, 1982, VIRCHOWS ARCH B, V40, P63, DOI 10.1007/BF02932851; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS AW, 1982, P NATL ACAD SCI-BIOL, V79, P5753, DOI 10.1073/pnas.79.19.5753; BURGESS AW, 1990, J GASTROEN HEPATOL, V5, P10, DOI 10.1111/j.1440-1746.1990.tb01778.x; BURGESS AW, 1983, EMBO J, V2, P2065, DOI 10.1002/j.1460-2075.1983.tb01701.x; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARTHIDGE SA, 1990, BRIT J CANCER, V60, P657; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DESCHNER EE, 1990, COLON CANCER CELLS, P15; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GLASS GBJ, 1964, ADV CLIN CHEM, P235; JOHNSON LR, 1980, AM J PHYSIOL, V238, pG45, DOI 10.1152/ajpgi.1980.238.1.G45; KLAGSBRUN M, 1987, P NATL ACAD SCI USA, V84, P1839, DOI 10.1073/pnas.84.7.1839; KOYAMA S, 1989, J CLIN INVEST, V83, P1768, DOI 10.1172/JCI114080; KUROKAWA T, 1987, FEBS LETT, V213, P189, DOI 10.1016/0014-5793(87)81489-8; LEE F, 1985, P NATL ACAD SCI USA, V82, P4360, DOI 10.1073/pnas.82.13.4360; MALO C, 1982, GASTROENTEROLOGY, V83, P28; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; NICE EC, 1989, J PHARMACEUT BIOMED, V7, P1039, DOI 10.1016/0731-7085(89)80043-3; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; SIMPSON RJ, 1987, FEBS LETT, V224, P128, DOI 10.1016/0014-5793(87)80435-0; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P1; Sisson S, 1953, ANATOMY DOMESTIC ANI, V3; SOMMER A, 1989, BIOCHEM BIOPH RES CO, V160, P1267, DOI 10.1016/S0006-291X(89)80140-8; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; WHITEHEAD RH, 1990, INT J CANCER, V46, P858, DOI 10.1002/ijc.2910460518; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; WRIGHT NA, 1990, NATURE, V343, P82, DOI 10.1038/343082a0; WRIGHT NA, 1984, BIOL EPITHELIAL CELL, V2, P842; [No title captured]	39	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14425	14430						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860849				2022-12-25	WOS:A1991FZ35100050
J	YAMAMOTO, D; MATSUMOTO, K; OHISHI, H; ISHIDA, T; INOUE, M; KITAMURA, K; MIZUNO, H				YAMAMOTO, D; MATSUMOTO, K; OHISHI, H; ISHIDA, T; INOUE, M; KITAMURA, K; MIZUNO, H			REFINED X-RAY STRUCTURE OF PAPAIN.E-64-C COMPLEX AT 2.1-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL PROTEASE INHIBITOR; CATHEPSIN-B; CRYSTAL-STRUCTURE; DYSTROPHIC MICE; PAPAIN; E-64; ANALOGS; BINDING; DERIVATIVES; SUBSTRATE	E-64-c, a synthetic cysteine protease inhibitor designed from E-64, binds to papain through a thioether covalent bond. The x-ray diffraction data for 2.1-angstrom resolution were used to determine the three-dimensional structure of this complex and refined it to R = 0.159. In the complex structure, the configurational conversion from S to R took place on the epoxy carbon of E-64-c, implying that the nucleophilic attack of the Cys-25 thiol group occurs at the opposite side of the epoxy oxygen atom. The leucyl and isoamylamide groups of E-64-c were strongly fixed to papain S subsites by specific interactions, including hydrogen bonding to the Gly-66 residue. The carboxyl-terminal anion of E-64-c formed an electrostatic interaction with the protonated His-159 imidazole ring (O-...HN+ = 3.76 angstrom) and consequently prevented the participation of this residue in the hydrolytic charge-relay system. No significant distortion caused by the binding of E-64-c was shown in the secondary structure of papain. It is important to note that inhibitor and substrate have opposite binding modes for the peptide groups. The possible relationship between the binding mode and inhibitory activity is discussed on the basis of the crystal structure of this complex.	OSAKA UNIV PHARMACEUT SCI,2-10-65 KAWAI,MATSUBARA,OSAKA 580,JAPAN; NATL INST AGROBIOL RESOURCES,DEPT MOLEC BIOL,TSUKUBA,IBARAKI 305,JAPAN; TAISHO PHARMACEUT CO LTD,RES CTR,OMIYA,SAITAMA 330,JAPAN	Osaka University of Pharmaceutical Sciences; National Institute of Agrobiological Sciences - Japan; Taisho Pharmaceutical Holdings Co Ltd			Yamamoto, Daisuke/N-3496-2014	Yamamoto, Daisuke/0000-0002-2628-7172				AMAMOTO T, 1984, MICROBIOL IMMUNOL, V28, P85, DOI 10.1111/j.1348-0421.1984.tb02949.x; AMAMOTO T, 1984, JPN J PHARMACOL, V34, P335, DOI 10.1254/jjp.34.335; Arnon R., 1970, PAPAIN METHODS ENZYM, V19, P226, DOI DOI 10.1016/0076-6879(70)19017-3; BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; Drenth J, 1971, Adv Protein Chem, V25, P79, DOI 10.1016/S0065-3233(08)60279-X; GOPALAN P, 1987, CAN J PHYSIOL PHARM, V65, P124, DOI 10.1139/y87-025; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P529, DOI 10.1080/00021369.1978.10863015; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P523, DOI 10.1080/00021369.1978.10863014; HANADA K, 1980, PEPTIDE CHEM 1979; HEINEMANN U, 1982, J MOL BIOL, V161, P591, DOI 10.1016/0022-2836(82)90410-7; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; ISHIDA T, 1988, J CHEM SOC PERK T 2, P851, DOI 10.1039/p29880000851; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KIMMEL JR, 1954, J BIOL CHEM, V207, P515; KOMATSU K, 1986, EXP NEUROL, V91, P23, DOI 10.1016/0014-4886(86)90022-1; KOMATSU K, 1986, EXP NEUROL, V93, P642, DOI 10.1016/0014-4886(86)90183-4; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MAEDA K, 1971, J ANTIBIOT, V24, P402, DOI 10.7164/antibiotics.24.402; MATSUMOTO K, 1989, FEBS LETT, V245, P177, DOI 10.1016/0014-5793(89)80216-9; MELOUN B, 1988, J BIOL CHEM, V263, P9087; Miyahara T, 1985, RINSHO YAKURI, V16, P537, DOI [10.3999/jscpt.16.357, DOI 10.3999/JSCPT.16.357]; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PRIESTLE JP, 1984, ACTA CRYSTALLOGR A, V40, pC17, DOI 10.1107/S010876738409930X; RABBANI N, 1987, BIOCHEM MED METAB B, V37, P282, DOI 10.1016/0885-4505(87)90038-7; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RICH DH, 1986, PROTEINASE INHIBITOR, P153; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SLUYTERMAN LA, 1970, BIOCHIM BIOPHYS ACTA, V200, P593, DOI 10.1016/0005-2795(70)90122-4; STEIGEMANN W, 1985, PROGRAM SYSTEM CRYST; SUDA H, 1972, J ANTIBIOT, V25, P263, DOI 10.7164/antibiotics.25.263; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; TAMAI M, 1981, AGR BIOL CHEM TOKYO, V45, P675, DOI 10.1080/00021369.1981.10864575; TAMAI M, 1981, J BIOCHEM, V90, P255, DOI 10.1093/oxfordjournals.jbchem.a133458; VARUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330, DOI 10.1021/bi00429a058; WILLENBROCK F, 1984, BIOCHEM J, V222, P805, DOI 10.1042/bj2220805; YABE Y, 1988, J AM CHEM SOC, V110, P4043, DOI 10.1021/ja00220a056; YAMAMOTO D, 1990, BIOCHEM BIOPH RES CO, V171, P711, DOI 10.1016/0006-291X(90)91204-6; YAMAMOTO D, 1989, CHEM PHARM BULL, V37, P2577; YAMAMOTO D, 1990, CHEM PHARM BULL, V38, P2339, DOI 10.1248/cpb.38.2339; YAMAMOTO D, 1990, FEBS LETT, V263, P134, DOI 10.1016/0014-5793(90)80722-U	44	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14771	14777						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860874				2022-12-25	WOS:A1991FZ35100101
J	MAHE, Y; MUKAIDA, N; KUNO, K; AKIYAMA, M; IKEDA, N; MATSUSHIMA, K; MURAKAMI, S				MAHE, Y; MUKAIDA, N; KUNO, K; AKIYAMA, M; IKEDA, N; MATSUSHIMA, K; MURAKAMI, S			HEPATITIS-B VIRUS-X PROTEIN TRANSACTIVATES HUMAN INTERLEUKIN-8 GENE THROUGH ACTING ON NUCLEAR FACTOR-KB AND CCAAT ENHANCER-BINDING PROTEIN-LIKE CIS-ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NEUTROPHIL CHEMOTACTIC FACTOR; TUMOR NECROSIS FACTOR; TRANSCRIPTION FACTOR; HEPATOCELLULAR-CARCINOMA; HUMAN-FIBROBLASTS; MAMMALIAN-CELLS; MESSENGER-RNA; EXPRESSION; ACTIVATION	Interleukin-8 (IL-8) is a newly described leukocyte chemotactic and activating cytokine that belongs to the novel family of inflammatory cytokines whose genes locate on human chromosome 4, q12-21 region. The production of IL-8 is usually not constitutive and can be induced rapidly and abundantly in different cell types by a variety of stimuli such as lipopolysaccharide, interleukin-1, tumor necrosis factor-alpha as well as a tumor promotor phorbol myristate acetate. We report here that in addition to these stimuli the IL-8 gene can also be induced by the protein X of the hepatitis B virus (HBV-X) as evidenced by the enhanced IL-8 mRNA expression and IL-8 production observed in HBV-X-transfected cells. Furthermore, using several deletion mutants of the 5'-flanking regulatory region of the human IL-8 gene linked to the chloramphenicol acetyl transferase gene as a reporter, we have established here that both nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements located at -94 to -71 base pairs of IL-8 gene are essential and sufficient for the induction of the IL-8 gene by HBV-X. The same elements have been identified recently by us to be interleukin-l-, tumor necrosis factor-alpha-, and phorbol myristate acetate-responsive elements on the IL-8 gene. This suggests the existence of a common pathway for these inflammatory cytokines and HBV-X to activate the IL-8 gene. These observations might be relevant to the pathogenesis of inflammation in viral hepatitis.	KANAZAWA UNIV,INST CANC RES,DEPT PHARMACOL,13-1 TAKARAMACHI,KANAZAWA,ISHIKAWA 920,JAPAN; JICHI MED SCH,DEPT CLIN PATHOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; KANAZAWA UNIV,INST CANC RES,DEPT BIOPHYS,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Jichi Medical University; Kanazawa University			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851; MAHE, yann Franck/0000-0001-7403-4471				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEASLEY RP, 1981, LANCET, V2, P1129; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; DORN PL, 1988, J VIROL, V62, P3522, DOI 10.1128/JVI.62.9.3522-3526.1988; FAKTOR O, 1990, ONCOGENE, V5, P867; GANEM D, 1982, REV INFECT DIS, V4, P1026; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; KARIN M, 1985, MOL CELL BIOL, V5, P2866, DOI 10.1128/MCB.5.10.2866; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LARSEN CG, 1989, BIOCHEM BIOPH RES CO, V160, P1403, DOI 10.1016/S0006-291X(89)80160-3; LE J, 1987, LAB INVEST, V6, P234; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; Maniatis T., 1982, MOL CLONING LAB MANU, P191; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NIMER SD, 1989, J IMMUNOL, V143, P2374; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROBINSON WS, 1990, J MED VIROL, V31, P18, DOI 10.1002/jmv.1890310106; ROBINSON WS, 1974, J VIROL, V14, P384, DOI 10.1128/JVI.14.2.384-391.1974; SCHROEDER JM, 1987, J IMMUNOL, V130, P3474; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; SICA A, 1990, IMMUNOLOGY, V69, P548; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; THORNTON AJ, 1990, J IMMUNOL, V144, P2609; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; WALTHER Z, 1988, J IMMUNOL, V140, P974; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	50	203	211	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13759	13763						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856209				2022-12-25	WOS:A1991FY02700049
J	SUGISAKI, H; YAMAMOTO, K; TAKANAMI, M				SUGISAKI, H; YAMAMOTO, K; TAKANAMI, M			THE HGAI RESTRICTION-MODIFICATION SYSTEM CONTAINS 2 CYTOSINE METHYLASE GENES RESPONSIBLE FOR MODIFICATION OF DIFFERENT DNA STRANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAEMOPHILUS-GALLINARUM; NUCLEOTIDE-SEQUENCES; METHYLTRANSFERASES; SPECIFICITY; CLONING; DOMAINS; VECTORS; FOKI; ENDONUCLEASES; CLEAVAGE	A DNA fragment of about 3.4 kilobase pairs that expressed the HgaI modification activity was cloned from the chromosomal DNA of Haemophilus gallinarum, and its nucleotide sequence was determined. Two open reading frames (ORF) which could code for structurally similar proteins were identified in the upstream and middle regions and a truncated ORF in the downstream region in the same orientation. When the respective ORFs were separately cloned, the clones carrying the upstream and middle ORFs both expressed the modification activity, indicating that the two genes are involved in modification of the HgaI restriction-modification system. In order to determine the sites of modification precisely, the respective genes were recloned into an expression vector, from which gene products were purified. A short DNA fragment carrying the HgaI recognition site was treated with each of these enzymes, and, after separation of the two strands by duplex formation with M13 viral DNAs carrying the respective strands, the presence or absence of modification was judged from susceptibility to HgaI endonuclease. The results of analysis showed that different strands were modified in an asymmetric way by each gene product. Analysis of the species and positions of modified bases by the Maxam-Gilbert method further demonstrated that the gene products from the upstream and middle ORFs participated in methylation of the internal cytosine residues of the strands carrying 3'-CTGCG-5' and 5'-GACGC-3', respectively. We concluded that the HgaI modification system consisted of two cytosine methylase genes responsible for modification of different strands in the target DNA.			SUGISAKI, H (corresponding author), KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN.							BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BROWN NL, 1977, P NATL ACAD SCI USA, V74, P3213, DOI 10.1073/pnas.74.8.3213; BUTKUS V, 1985, NUCLEIC ACIDS RES, V13, P5727, DOI 10.1093/nar/13.16.5727; KESSLER C, 1990, GENE, V92, P1, DOI 10.1016/0378-1119(90)90486-B; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LAUSTER R, 1989, J MOL BIOL, V206, P313, DOI 10.1016/0022-2836(89)90481-6; LOONEY MC, 1989, GENE, V80, P193, DOI 10.1016/0378-1119(89)90284-9; MANN MB, 1978, GENE, V3, P97, DOI 10.1016/0378-1119(78)90054-9; Maxam A M, 1980, Methods Enzymol, V65, P499; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NWANKWO D, 1987, MOL GEN GENET, V209, P570, DOI 10.1007/BF00331164; OHMORI H, 1978, NUCLEIC ACIDS RES, V5, P1479, DOI 10.1093/nar/5.5.1479; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGISAKI H, 1989, J BIOL CHEM, V264, P5757; SUGISAKI H, 1978, GENE, V3, P17, DOI 10.1016/0378-1119(78)90004-5; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TAKANAMI M, 1973, FEBS LETT, V34, P318, DOI 10.1016/0014-5793(73)80821-X; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; THOMAS CA, 1966, PROCEDURES NUCLEIC A, P535; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	24	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13952	13957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856224				2022-12-25	WOS:A1991FY02700079
J	CHUNG, IK; MULLER, MT				CHUNG, IK; MULLER, MT			AGGREGATES OF OLIGO(DG) BIND AND INHIBIT TOPOISOMERASE-II ACTIVITY AND INDUCE FORMATION OF LARGE NETWORKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; TELOMERIC DNA; EUKARYOTIC TOPOISOMERASE; GEL-ELECTROPHORESIS; REGIONS; SINGLE; YEAST; DIFFERENTIATION; CHROMATIN; COMPONENT	DNA cleavage by eukaryotic type II DNA topoisomerase (EC 5.99.1.3) was strongly inhibited by an oligonucleotide containing 10 dGua residues. Catalytic activities of topoisomerase II, as measured by relaxation and decatenation reactions, were also inhibited by oligo(dG)10. Inhibition was specific to oligo(dG)10; other oligonucleotides, nucleotides, or single-stranded DNAs tested did not influence the activity of topoisomerase II. Oligo(dG)10 did not inhibit other activities such as restriction enzymes. Although the enzyme neither binds nor cleaves oligo(dG)10, inhibition can be explained by the finding that topoisomerase II binds tightly with aggregated oligo(dG) structures (estimated to contain between 20 and 30 molecules of monomeric oligo(dG)10) that form spontaneously prior to addition of enzyme. These aggregated oligo(dG)-topoisomerase complexes are large networks that can be pelleted by a 20-min centrifugation step in a Microfuge. Western blotting with a monoclonal antibody confirmed that topoisomerase II is trapped in these pellets. The ability of the enzyme to form large DNA-protein networks could be a biochemical mechanism by which topoisomerase II might promote or participate in chromosome condensation in vivo prior to mitosis.	OHIO STATE UNIV,DEPT MOLEC GENET,484 W 12TH AVE,COLUMBUS,OH 43210	Ohio State University					NCI NIH HHS [CA09338] Funding Source: Medline; NIAID NIH HHS [AI28362] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P4553, DOI 10.1093/nar/18.15.4553; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2014; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDRICKSON W, 1984, J MOL BIOL, V174, P611; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MILES HT, 1972, BIOCHEM BIOPH RES CO, V49, P199, DOI 10.1016/0006-291X(72)90029-0; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; MULLER MT, 1988, MOL CELL BIOL, V8, P3661, DOI 10.1128/MCB.8.9.3661; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PINNAVAIA TJ, 1975, J AM CHEM SOC, V97, P7198, DOI 10.1021/ja00857a059; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; SPITZLEY T, 1989, RATIO, V2, P63, DOI 10.1111/j.1467-9329.1989.tb00127.x; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SPITZNER JR, 1990, NUCLEIC ACIDS RES, V18, P1, DOI 10.1093/nar/18.1.1; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272	38	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9508	9514						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851749				2022-12-25	WOS:A1991FM45900030
J	JANICOT, M; FLORESRIVEROS, JR; LANE, MD				JANICOT, M; FLORESRIVEROS, JR; LANE, MD			THE INSULIN-LIKE GROWTH FACTOR-I (IGF-1) RECEPTOR IS RESPONSIBLE FOR MEDIATING THE EFFECTS OF INSULIN, IGF-1, AND IGF-2 IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE-ACTIVITY; BETA-SUBUNIT; PROTEIN-KINASE; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; HUMAN-PLACENTA; SOMATOMEDIN-C; PHOSPHORYLATION; PURIFICATION	Competitive hormone binding studies with membrane and partially purified receptors from Xenopus laevis oocytes revealed that the oocyte possesses high affinity (K(D) = 1-3 nM) binding sites for both insulin growth factors 1 and 2 (IGF-1 and IGF-2), but not for insulin. Consistent with these findings, IGF-1 activates hexose uptake by Xenopus oocytes with a K(A) (3 nM) identical with its K(D), while IGF-2 and insulin activate hexose uptake with K(A) values of 50 nM and 200-250 nM, respectively, suggesting activation mediated through an IGF-1 receptor. Both IGF-1 and insulin activate receptor beta-subunit autophosphorylation and, thereby, protein substrate (reduced and carboxyamidomethylated lysozyme, i.e. RCAM-lysozyme) phosphorylation with K(A) values comparable to their respective K(D) values for ligand binding and K(A) values for activation of hexose uptake. The autophosphorylated beta-subunit(s) of the receptor were resolved into two discrete components, beta-1 and beta-2 (108 kDa and 94 kDa, respectively), which were phosphorylated exclusively on tyrosine and which exhibited similar extents of IGF-1-activated autophosphorylation. When added prior to autophosphorylation, RCAM-lysozyme blocks IGF-1-activated autophosphorylation and, thereby, IGF-1-activated protein substrate (RCAM-lysozyme) phosphorylation. Based on these findings, we conclude that IGF-1-stimulated autophosphorylation of its receptor is a prerequisite for catalysis of protein substrate phosphorylation by the receptor's tyrosine-specific protein kinase. The IGF-1 receptor kinase is implicated in signal transmission from the receptor, since anti-tyrosine kinase domain antibody blocks IGF-1-stimulated kinase activity in vitro and, when microinjected into intact oocytes, prevents IGF-1-stimulated hexose uptake.			JANICOT, M (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.				NIDDK NIH HHS [NIDDK-14574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014574, R37DK014574] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; AUGUST GP, 1983, J BIOL CHEM, V258, P9033; AVRUCH J, 1982, J BIOL CHEM, V257, P5162; BALA RM, 1983, INSULIN LIKE GROWTH, P491; BAXTER RC, 1983, BIOCHEM BIOPH RES CO, V116, P62, DOI 10.1016/0006-291X(83)90380-7; BEQUINOT F, 1985, J BIOL CHEM, V260, P15892; BHAUMICK B, 1981, P NATL ACAD SCI-BIOL, V78, P4279, DOI 10.1073/pnas.78.7.4279; BLONDEAU JP, 1985, J BIOL CHEM, V260, P3617; CLOT JP, 1990, MOL CELL ENDOCRINOL, V72, P175, DOI 10.1016/0303-7207(90)90142-U; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELETR M, 1979, SCIENCE, V205, P1397, DOI 10.1126/science.472755; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FROESCH ER, 1985, DIABETOLOGIA, V28, P485, DOI 10.1007/BF00281982; GAROFALO RS, 1989, MOL CELL BIOL, V9, P2806, DOI 10.1128/MCB.9.7.2806; JACOBS S, 1981, ENDOCR REV, V2, P251, DOI 10.1210/edrv-2-3-251; JACOBS S, 1983, J BIOL CHEM, V258, P9581; JACOBS S, 1985, MOL BASIS INSULIN AC, P31; JANICOT M, 1989, P NATL ACAD SCI USA, V86, P2642, DOI 10.1073/pnas.86.8.2642; JONAS HA, 1985, J BIOL CHEM, V260, P2288; KAHN CR, 1985, ANNU REV MED, V36, P429; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KIESS W, 1988, J BIOL CHEM, V263, P9339; KOHANSKI RA, 1986, J BIOL CHEM, V261, P2272; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; KOHANSKI RA, 1985, J BIOL CHEM, V260, P5014; KULL FC, 1983, J BIOL CHEM, V258, P6561; LANE MD, 1986, P EK FERNTRON S MECH, P59; LANE MD, 1985, INSULIN ITS RECEPTOR, P237; LEGOASCOGNE C, 1987, DEV BIOL, V119, P511; LEIS JF, 1982, P NATL ACAD SCI-BIOL, V79, P6507, DOI 10.1073/pnas.79.21.6507; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P5560, DOI 10.1021/bi00367a032; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; NISSLEY SP, 1984, CLIN ENDOCRINOL META, V13, P43; OLSON TS, 1988, J BIOL CHEM, V263, P7342; OTA A, 1988, EUR J BIOCHEM, V174, P521, DOI 10.1111/j.1432-1033.1988.tb14130.x; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; RUBIN JB, 1983, NATURE, V305, P438, DOI 10.1038/305438a0; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SAKANOUE Y, 1988, BIOCHEM BIOPH RES CO, V150, P1176, DOI 10.1016/0006-291X(88)90753-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH AA, 1987, FASEB J, V1, P380, DOI 10.1096/fasebj.1.5.2824269; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEFANOVIC D, 1986, EMBO J, V5, P157, DOI 10.1002/j.1460-2075.1986.tb04190.x; STITH BJ, 1984, DEV BIOL, V102, P79, DOI 10.1016/0012-1606(84)90176-3; SWARUP G, 1982, J BIOL CHEM, V257, P7298; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Van Wyk JJ, 1984, HORMONAL PROTEINS PE, V12, P81; VERA JC, 1990, MOL CELL BIOL, V10, P743, DOI 10.1128/MCB.10.2.743; VERA JC, 1973, MOL CELL BIOL, V4187, P89; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YEE D, 1989, J BIOL CHEM, V264, P21439; YU KT, 1986, J BIOL CHEM, V261, P1341; ZICK Y, 1984, BIOCHEM BIOPH RES CO, V119, P6, DOI 10.1016/0006-291X(84)91610-3	65	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9382	9391						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851744				2022-12-25	WOS:A1991FM45900010
J	OGRADY, P; KUO, MD; BALDASSARE, JJ; HUANG, SS; HUANG, JS				OGRADY, P; KUO, MD; BALDASSARE, JJ; HUANG, SS; HUANG, JS			PURIFICATION OF A NEW TYPE HIGH-MOLECULAR-WEIGHT RECEPTOR (TYPE-V RECEPTOR) OF TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) FROM BOVINE LIVER - IDENTIFICATION OF THE TYPE-V TGF-BETA RECEPTOR IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEOGLYCAN; DOMAIN-STRUCTURE; HUMAN-PLATELETS; BINDING; INVIVO	A 400-kDa transforming growth factor-beta (TGF-beta) receptor was purified from plasma membranes of bovine liver using Triton X-100 extraction, wheat germ lectin-Sepharose 4B affinity chromatography, DEAE-cellulose anion exchange chromatography, and Sepharose CL-4B gel filtration chromatography. This procedure yielded approximately 20-mu-g of the receptor from 1 kg of bovine liver. During purification, the 400-kDa TGF-beta receptor was detected by a cross-linking assay in which the TGF-beta receptor-I-125-TGF-beta complex was cross-linked by disuccinimidyl suberate, a bifunctional reagent, and analyzed by 5.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by autoradiography. This novel 400-kDa TGF-beta receptor was also identified on cultured cells including cells reported to lack the type III receptor. The 400-kDa TGF-beta receptor, a nonproteoglycan glycoprotein, appears to be distinct from TGF-beta receptors (types I, II, III, and IV) previously identified on cultured cells and is designated as the type V receptor. The 400-kDa TGF-beta receptor as well as type I, II, and III receptors underwent internalization upon I-125-TGF-beta binding in mink lung epithelial cells.	ST LOUIS UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, ST LOUIS, MO 63104 USA; ST LOUIS UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63104 USA	Saint Louis University; Saint Louis University					NCI NIH HHS [CA 38808] Funding Source: Medline; NHLBI NIH HHS [HL 41782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GRUPPUSO PA, 1990, CANCER RES, V50, P1464; KUO MD, 1990, J BIOL CHEM, V265, P16455; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P7059; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1990, ANN NY ACAD SCI, V593, P73, DOI 10.1111/j.1749-6632.1990.tb16101.x; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SPORN MB, 1983, SCIENCE, V219, P1329, DOI 10.1126/science.6572416; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	24	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8583	8589						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850748				2022-12-25	WOS:A1991FK44100093
J	STEINRUCKE, P; GERHUS, E; LUDWIG, B				STEINRUCKE, P; GERHUS, E; LUDWIG, B			PARACOCCUS-DENITRIFICANS MUTANTS DELETED IN THE GENE FOR SUBUNIT-II OF CYTOCHROME-C-OXIDASE ALSO LACK SUBUNIT-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO INSERTIONAL MUTAGENESIS; DNA FRAGMENTS; SEQUENCE; PROTEIN; ENZYME	As a prerequisite to site-directed mutagenesis on cytochrome c oxidase, two different mutants are constructed by inactivating the cta gene locus encoding subunits II and III (ctaC and ctaE) of the Paracoccus denitrificans oxidase. Either a short fragment encoding part of the putative copper binding site near the C terminus of subunit II, or a substantial fragment, comprising parts of the coding region for both subunits and all of the intervening three open readingframes, are removed and replaced by the kanamycin resistance gene. Each construct, ligated into a suicide vector, is mated into Paracoccus, and mutants originating from double homologous recombination events are selected. We observe complete loss of a-type heme and of oxidase subunits, as well as a substantial decrease in the cytochrome c oxidase activity. Upon complementation with the ctaC gene (plus various lengths of downstream sequence extending into the operon), subunit II gets expressed in all cases. Wild-type phenotype, however, is only restored with the whole operon. Using smaller fragments for complementation gives interesting clues on roles of the open reading frames for the assembly process of the oxidase complex: two of the open reading frame genes most likely code for two independent assembly factors. Since homologous genes have been described not only for other bacterial oxidases, but their gene products shown to participate also in the assembly of the yeast enzyme, they seem to constitute a group of evolutionary conserved proteins.	MED UNIV LUBECK, INST BIOCHEM, W-2400 LUBECK, GERMANY	University of Lubeck								AZZI A, 1990, ARCH BIOCHEM BIOPHYS, V280, P242, DOI 10.1016/0003-9861(90)90326-T; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BOLGIANO B, 1988, BIOCHIM BIOPHYS ACTA, V933, P341, DOI 10.1016/0005-2728(88)90041-2; BUSE G, 1987, CYTOCHROME SYSTEMS M, P261; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; DEVRIES GE, 1989, ARCH MICROBIOL, V152, P52, DOI 10.1007/BF00447011; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GERHUS E, 1990, J BACTERIOL, V172, P2392, DOI 10.1128/jb.172.5.2392-2400.1990; HALTIA T, 1988, EUR J BIOCHEM, V172, P543, DOI 10.1111/j.1432-1033.1988.tb13923.x; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KING MT, 1976, EUR J BIOCHEM, V68, P5, DOI 10.1111/j.1432-1033.1976.tb10759.x; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MUELLER JP, 1989, J BACTERIOL, V171, P4967, DOI 10.1128/jb.171.9.4967-4978.1989; MULLER M, 1988, P NATL ACAD SCI USA, V85, P6647, DOI 10.1073/pnas.85.18.6647; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PANSKUS G, 1988, ANN NY ACAD SCI, V550, P308, DOI 10.1111/j.1749-6632.1988.tb35345.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; RAITIO M, 1990, FEBS LETT, V261, P431, DOI 10.1016/0014-5793(90)80609-M; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SIMON R, 1983, MOL GENETICS BACTERI, P100; SOLIOZ M, 1982, J BIOL CHEM, V257, P1579; STEINRUCKE P, 1987, EUR J BIOCHEM, V167, P431, DOI 10.1111/j.1432-1033.1987.tb13356.x; STEINRUCKE P, 1991, J BIOENERG BIOMEMBR, V23, P227, DOI 10.1007/BF00762219; STOUTHAMER AH, 1980, TRENDS BIOCHEM SCI, V5, P164, DOI 10.1016/0968-0004(80)90015-8; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; VANSPANNING RJM, 1990, J BACTERIOL, V172, P986, DOI 10.1128/jb.172.2.986-996.1990; VANVERSEVELD HW, 1978, ARCH MICROBIOL, V118, P13, DOI 10.1007/BF00406068; Wikstrom M., 1981, CYTOCHROME OXIDASE S	43	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7676	7681						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850416				2022-12-25	WOS:A1991FJ34200057
J	THOMPSON, AK; FISHER, SK				THOMPSON, AK; FISHER, SK			PREFERENTIAL COUPLING OF CELL-SURFACE MUSCARINIC RECEPTORS TO PHOSPHOINOSITIDE HYDROLYSIS IN HUMAN NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; CHOLINERGIC RECEPTORS; INOSITOL TRISPHOSPHATE; TERM REGULATION; DESENSITIZATION; AGONIST; REQUIREMENTS; QUATERNARY; LIGANDS; BRAIN	The ability of muscarinic receptors, present in either the cell surface or sequestered compartments of intact human SK-N-SH neuroblastoma cells, to stimulate phosphoinositide hydrolysis has been examined. When cells were first exposed to carbachol for 1 h at 37-degrees-C, approximately 50% of the cell surface receptors became sequestered, and this was accompanied by a comparable reduction in the subsequent ability of muscarinic agonists to stimulate phosphoinositide turnover, as monitored by the release of labeled inositol phosphates at 10-degrees-C. At this temperature, muscarinic receptor cycling between the two cell compartments is prevented. Upon warming the carbachol-pretreated cells to 37-degrees-C, receptor cycling is reinitiated and stimulated phosphoinositide turnover is fully restored within 5-8 min. When measured at 10-degrees-C, the reduction of stimulated phosphoinositide turnover observed following carbachol pretreatment was similar in magnitude for both hydrophilic (carbachol, oxotremorine-M) and lipophilic (arecoline, oxotremorine-2, and L-670,548) agonists. The loss of response for both groups of agonists could be prevented if the incubation temperature was maintained at 37-degrees-C, rather than at 10-degrees-C. At the latter temperature carbachol pretreatment of SK-N-SH cells reduced the maximum release of inositol phosphates elicited by either carbachol or L-670,548 but not the agonist concentrations required for half-maximal stimulation. Radioligand binding studies, carried out at 10-degrees-C, indicate that following receptor sequestration, significantly higher concentrations of carbachol were required to occupy the available muscarinic receptor sites. In contrast the lipophilic full agonist L-670,548 recognized receptors present in control and carbachol-pretreated cells with comparable affinities. Analysis of the inositol lipids present after carbachol pretreatment indicate that only a minimal depletion of the substrates necessary for phospholipase C activation had occurred. The results indicate that the agonist-induced sequestration of muscarinic receptors from the cell surface results in a loss of stimulated phosphoinositide hydrolysis when measured under conditions in which the return of the sequestered receptors to the cell surface is prevented. Thus, only those receptors present at the cell surface are linked to phospholipase C activation.	UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan	THOMPSON, AK (corresponding author), UNIV MICHIGAN,NEUROSCI LAB,ANN ARBOR,MI 48104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH042652] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32 GM07767-10] Funding Source: Medline; NIMH NIH HHS [MH42652] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAUMGOLD J, 1989, NEUROPHARMACOLOGY, V28, P1253, DOI 10.1016/0028-3908(89)90219-0; BROWN JH, 1986, J PHARMACOL EXP THER, V238, P580; CIOFFI CL, 1989, BIOCHEM PHARMACOL, V38, P1827, DOI 10.1016/0006-2952(89)90418-8; FEIGENBAUM P, 1985, J PHARMACOL EXP THER, V233, P134; FISHER SK, 1989, MOL PHARMACOL, V35, P195; FISHER SK, 1990, MOL PHARMACOL, V38, P54; FISHER SK, 1987, MOL PHARMACOL, V32, P81; FISHER SK, 1985, J NEUROCHEM, V45, P1085, DOI 10.1111/j.1471-4159.1985.tb05527.x; FISHER SK, 1988, J NEUROCHEM, V50, P984, DOI 10.1111/j.1471-4159.1988.tb03008.x; FISHER SK, 1988, MOL PHARMACOL, V33, P414; GEIGER PJ, 1972, ANAL BIOCHEM, V49, P467, DOI 10.1016/0003-2697(72)90450-2; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEACOCK AM, 1990, J NEUROCHEM, V54, P1405, DOI 10.1111/j.1471-4159.1990.tb01976.x; HONEGGER P, 1976, BRAIN RES, V109, P334; MASTERS SB, 1985, MOL PHARMACOL, V27, P325; MCMILLIAN MK, 1987, BIOCHEM BIOPH RES CO, V148, P1017, DOI 10.1016/S0006-291X(87)80233-4; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; SAUNDERS J, 1989, TRENDS PHARM SCI S, V4, P70; SIMAN RG, 1979, P NATL ACAD SCI USA, V76, P4141, DOI 10.1073/pnas.76.8.4141; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; XU J, 1987, J PHARMACOL EXP THER, V242, P238	23	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5004	5010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848233				2022-12-25	WOS:A1991FC21700051
J	YOSHIDA, A; NISHIKAWA, T; TAMURA, Y; YOSHIDA, S				YOSHIDA, A; NISHIKAWA, T; TAMURA, Y; YOSHIDA, S			ACTH-INDUCED INHIBITION OF THE ACTION OF ANGIOTENSIN-II IN BOVINE ZONA GLOMERULOSA CELLS - A MODULATORY EFFECT OF CYCLIC-AMP ON THE ANGIOTENSIN-II RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL PHOSPHATE ACCUMULATION; BETA-ADRENERGIC-RECEPTOR; ADRENAL-CELLS; FREE CALCIUM; ALDOSTERONE PRODUCTION; CYTOSOLIC CALCIUM; ADENYLATE-CYCLASE; PHOSPHORYLATION; ACTIVATION	Both angiotensin II and adrenocorticotropic hormone (ACTH) are well known to play a crucial role on the regulation of aldosterone production in adrenal glomerulosa cells. Recent observations suggest that the steroidogenic action of ACTH is mediated via the cAMP messenger system, whereas angiotensin II acts mainly through the phosphoinositide pathway. However, there have been no reports concerning the interaction between the cAMP messenger system activated by ACTH and the Ca2+ messenger system induced by angiotensin II. Both ACTH and angiotensin II simultaneously act on adrenal cells for regulating steroidogenesis under physiological conditions. Thus the present experiments were performed to examine the effect of ACTH on the action of angiotensin II by measuring angiotensin II receptor activity, cytosolic Ca2+ movement, and aldosterone production. The major findings of the present study are that short-term exposure to a high dose of ACTH (10(-7) M) inhibited I-125-angiotensin II binding to bovine adrenal glomerulosa cells, decreased the initial spike phase of [Ca2+]i induced by angiotensin II, and inhibition of angiotensin II-induced aldosterone production. Low dose of ACTH (10(-10) M), which did not increase cAMP formation, did not affect angiotensin II receptor activity. These studies have shown that angiotensin II receptors of bovine adrenal glomerulosa cells can be down-regulated by 1 mM dibutyryl cyclic AMP, as well as by effectors which are able to activate cAMP formation (10(-7) M ACTH and 10(-5) M forskolin). The rapid decrease in angiotensin II receptors induced by 10(-7) M ACTH was associated with a decreased steroidogenic responsiveness and a decreased rise in the [Ca2+]i response induced by angiotensin II. These studies show that the cAMP-dependent processes activated by ACTH have the capacity to interfere with signal transduction mechanisms initiated by receptors for angiotensin II.	CHIBA UNIV,SCH MED,DEPT INTERNAL MED 2,1-8-1 INOHANA,CHIBA 280,JAPAN	Chiba University								ANDOKA G, 1984, BIOCHEM BIOPH RES CO, V121, P441, DOI 10.1016/0006-291X(84)90202-X; APFELDORF WJ, 1988, CELL CALCIUM, V9, P71, DOI 10.1016/0143-4160(88)90026-7; BALLA T, 1989, ARCH BIOCHEM BIOPHYS, V270, P398, DOI 10.1016/0003-9861(89)90043-X; BARRETT PQ, 1986, BIOCHEM J, V238, P893, DOI 10.1042/bj2380893; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; CAPPONI AM, 1984, J RECEPTOR RES, V4, P283, DOI 10.3109/10799898409042555; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; FUJITA K, 1979, J BIOL CHEM, V254, P8567; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLON G, 1988, BIOCHEM J, V253, P765, DOI 10.1042/bj2530765; HAUSDORFF WP, 1988, ENDOCRINOLOGY, V123, P2818, DOI 10.1210/endo-123-6-2818; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JOHANSSON H, 1989, CELL CALCIUM, V10, P205, DOI 10.1016/0143-4160(89)90003-1; KOJIMA I, 1984, J BIOL CHEM, V259, P4448; KOJIMA I, 1986, J BIOL CHEM, V261, P9832; LANG U, 1987, J BIOL CHEM, V262, P8047; LAU K, 1989, J BIOL CHEM, V264, P4028; NISHIKAWA T, 1990, HORM METAB RES, V22, P29, DOI 10.1055/s-2007-1004842; PENHOAT A, 1988, EUR J BIOCHEM, V172, P247, DOI 10.1111/j.1432-1033.1988.tb13880.x; QUINN SJ, 1988, ANNU REV PHYSIOL, V50, P409, DOI 10.1146/annurev.ph.50.030188.002205; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; RASMUSSEN H, 1987, HYPERTENSION S1, V10, P23; SAEZ JM, 1981, ADV CYCL NUCL RES<D>, V14, P563; SEYA A, 1988, PROSTAG LEUKOTR ESS, V34, P47, DOI 10.1016/0952-3278(88)90024-5; SIBLEY DR, 1985, J BIOL CHEM, V260, P3883; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TAIT JF, 1980, J ENDOCRINOL, V87, P11, DOI 10.1677/joe.0.0870011; WOODCOCK EA, 1989, MOL CELL ENDOCRINOL, V63, P247, DOI 10.1016/0303-7207(89)90101-9	30	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4288	4294						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847918				2022-12-25	WOS:A1991FA69400044
J	BURSTEIN, ES; LINKOSTENTZ, K; LU, ZJ; MACARA, IG				BURSTEIN, ES; LINKOSTENTZ, K; LU, ZJ; MACARA, IG			REGULATION OF THE GTPASE ACTIVITY OF THE RAS-LIKE PROTEIN-P25RAB3A - EVIDENCE FOR A RAB3A-SPECIFIC GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING PROTEIN; BOVINE BRAIN; ACTIVATING PROTEIN; PURIFICATION; TISSUE; P21; EXPRESSION; SMG-P25A	The rab3A gene product is a 25-kilodalton guanine nucleotide-binding, expressed at high levels in neural tissue, which has about 30% homology to ras. Recombinant rab3A protein and p25rab3A purified from bovine brain membranes have been used as substrates to look for factors that regulate its biochemical activity. A detergent-soluble factor associated with rat brain membranes exists that accelerates the GTPase activity of both mammalian and recombinant p25rab3A. The activity was thermolabile, sensitive to trypsin, and behaved like an integral membrane protein. GTPase-activating protein (GAP) activity toward p25rab3A was also detected in the cytosolic fraction. This activity was observed in all other tissues examined, in addition to brain. Based upon dose-response data, the rab3A-GAP activity from rat brain was approximately equally distributed between cytosolic and membrane fractions; no activity was found in the nuclear fraction. Recombinant ras-specific GAP had no effect upon the GTPase activity of p24rab3A. By gel filtration chromatography, the factor in rat brain cytosol has a molecular size of 400,000 daltons.			BURSTEIN, ES (corresponding author), UNIV ROCHESTER,MED CTR,CTR ENVIRONM HLTH SCI,DEPT BIOPHYS,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.				NCI NIH HHS [CA-43551] Funding Source: Medline; NIEHS NIH HHS [ES-01247] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; ERLICH HA, 1989, PCR TECHNOLOGY, P7; FISHER G, 1990, P NATL ACAD SCI USA, V87, P1988; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; MACARA IG, 1989, TRENDS ENDOCRIN MET, V1, P26, DOI 10.1016/1043-2760(89)90026-X; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	31	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2689	2692						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847129				2022-12-25	WOS:A1991EX60000003
J	HART, D; NORD, EP				HART, D; NORD, EP			POLARIZED DISTRIBUTION OF NA+/H+ ANTIPORT AND NA+/HCO3- COTRANSPORT IN PRIMARY CULTURES OF RENAL INNER MEDULLARY COLLECTING DUCT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY EPITHELIAL-CELLS; PROXIMAL CONVOLUTED TUBULE; GLOMERULAR MESANGIAL CELLS; INTRACELLULAR PH; BASOLATERAL MEMBRANE; CYTOPLASMIC-PH; H+ SECRETION; RAT; EXCHANGE; MECHANISMS	Primary cultures of rat renal inner medullary collecting duct cells were grown to confluence on glass coverslips and treated permeant supports, and the pH-sensitive fluorescent probe 2,7-biscarboxyethyl-5,6-carboxyfluorescein was employed to delineate the nature of the transport pathways that allowed for recovery from an imposed acid load in a HCO3-/CO2-buffered solution. The H+ efflux rate of acid-loaded cells was 13.44 +/- 0.94 mM/min. Addition of amiloride, 10(-4) M, to the recovery solution reduced the H+ efflux rate to 4.06 +/- 0.63 mM/min. The amiloride-resistant pH(i) recovery mechanism displayed an absolute requirement for Na+ but was Cl- independent. Studies performed on permeable supports demonstrated that the latter pathway was located primarily on the basolateral-equivalent (BE) cell surface and was inhibited by 50-mu-M 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS). In a Na+-replete solution containing DIDS (50-mu-M) and amiloride (10(-4)M), acid-loaded cells failed to return to basal pH(i). To delineate further the amiloride-inhibitable component of pH(i) recovery, monolayers were studied in the nominal absence of HCO3-/CO2. In 70% of monolayers studied, Na+-dependent, amiloride-inhibitable H+ efflux was the sole mechanism whereby acid-loaded cells returned to basal pH(i). A Na+-independent pathway was observed in 30% of monolayers examined and represented only a minor component of the pH(i) recovery process. In studies performed on permeable supports, the Na+-dependent amiloride-inhibitable pathway was found to be confined exclusively to the BE cell surface. In summary, confluent monolayers of rat renal inner medullary collecting duct cells in primary culture possess two major mechanisms that contribute toward recovery from an imposed acid load, namely, Na+/H+ antiport and Na+/HCO3- cotransport. Na+-independent pH(i) recovery mechanisms represent a minor component of the pH(i) recovery process in the cultured cell. Both the Na+/H+ antiporter and Na+/HCO3- cotransporter are located primarily on the BE cell surface.	SUNY STONY BROOK,SCH MED,DEPT MED,DIV NEPHROL,HSC T-15,RM 020,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIDDK NIH HHS [DK-41585] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041585] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RJ, 1985, J GEN PHYSIOL, V86, P613, DOI 10.1085/jgp.86.5.613; BIAGI BA, 1985, J MEMBRANE BIOL, V88, P25, DOI 10.1007/BF01871210; BIERMAN AJ, 1988, J BIOL CHEM, V263, P15253; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BRION LP, 1989, AM J PHYSIOL, V257, pF486, DOI 10.1152/ajprenal.1989.257.3.F486; CANTIELLO HF, 1986, J BIOL CHEM, V261, P3252; FINEMAN I, 1990, AM J PHYSIOL, V258, pF883, DOI 10.1152/ajprenal.1990.258.4.F883; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRABER ML, 1981, AM J PHYSIOL, V241, pF659, DOI 10.1152/ajprenal.1981.241.6.F659; HENDERSON RM, 1988, PFLUG ARCH EUR J PHY, V412, P334, DOI 10.1007/BF00582518; JENTSCH TJ, 1986, J BIOL CHEM, V261, P673; JENTSCH TJ, 1986, AM J PHYSIOL, V251, pF954, DOI 10.1152/ajprenal.1986.251.6.F954; KLEINMAN JG, 1987, J CLIN INVEST, V80, P1660, DOI 10.1172/JCI113255; KRAUT JA, 1988, KIDNEY INT, V33, P403; LALLEMAIN G, 1985, J BIOL CHEM, V260, P4877; NORD EP, 1988, J BIOL CHEM, V263, P5599; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SANDS JM, 1985, AM J PHYSIOL, V248, pF762, DOI 10.1152/ajprenal.1985.248.6.F762; SASAKI S, 1984, AM J PHYSIOL, V246, pF889, DOI 10.1152/ajprenal.1984.246.6.F889; SELVAGGIO AM, 1988, AM J PHYSIOL, V254, pF391, DOI 10.1152/ajprenal.1988.254.3.F391; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; STANTON BA, 1989, AM J PHYSIOL, V256, pF862, DOI 10.1152/ajprenal.1989.256.5.F862; TAUB M, 1980, J CELL PHYSIOL, V105, P369, DOI 10.1002/jcp.1041050220; ULLRICH KJ, 1981, PFLUG ARCH EUR J PHY, V389, P271, DOI 10.1007/BF00584789; WALL SM, 1987, AM J PHYSIOL, V253, pF889, DOI 10.1152/ajprenal.1987.253.5.F889	27	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2374	2382						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846627				2022-12-25	WOS:A1991EV51500056
J	HILL, BC				HILL, BC			THE REACTION OF THE ELECTROSTATIC CYTOCHROME-C-CYTOCHROME OXIDASE COMPLEX WITH OXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX CENTERS; FLOW-FLASH; SUBUNIT-II; COPPER-A; IDENTIFICATION; TEMPERATURE; PATHWAYS; SITE; HEME; CUA	The reaction of the electrostatic cytochrome c-cytochrome oxidase complex with oxygen is measured by transient absorption spectroscopy. The oxygen reaction is initiated by photolytic removal of CO from cytochrome oxidase, using a flash-pumped dye laser. The subsequent reaction of the cytochrome c-cytochrome oxidase complex with oxygen is reported at 550, 605, 744, and 830 nm at different cytochrome c:cytochrome oxidase ratios and different oxygen concentrations. In the absence of cytochrome c the time course of the reaction of the oxidase is well described by a triple exponential process at any of the measured wavelengths. The three processes are well resolved at high O2 levels (i.e. > 200-mu-M), where they reach first-order rate limits of 2.4 x 10(4), 7.5 x 10(3), and 650 s-1. When cytochrome c is added the oxidation of cytochrome a and one of the redox active copper centers (Cu(A)) are interrupted. The maximal effect of cytochrome c on the oxidation of the oxidase occurs at a c:aa3 ratio of 1. Cytochrome c reacts in a biphasic process with rates of up to 7 x 10(3) and 550 s-1 at high oxygen. The fast phase takes up 60% of the process, and this is independent of the cytochrome c:cytochrome oxidase ratio. The results are discussed in the context of a model in which electron entry into cytochrome oxidase from cytochrome c is via Cu(A), and cytochrome a functions to mediate electron transfer from Cu(A) to the oxygen binding site. The role of Cu(A) as initial electron acceptor in cytochrome c oxidase is related to its physical proximity to cytochrome c in the cytochrome c-cytochrome oxidase complex.	CONCORDIA UNIV, DEPT CHEM & BIOCHEM, MONTREAL H3G 1M8, QUEBEC, CANADA	Concordia University - Canada								ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; BABCOCK GT, 1985, J INORG BIOCHEM, V23, P243, DOI 10.1016/0162-0134(85)85031-5; BISSON R, 1982, FEBS LETT, V150, P49, DOI 10.1016/0014-5793(82)81302-1; BISSON R, 1982, FEBS LETT, V144, P359, DOI 10.1016/0014-5793(82)80672-8; BLASIE JK, 1982, BIOCHIM BIOPHYS ACTA, V679, P188, DOI 10.1016/0005-2728(82)90290-0; BRUDVIG GW, 1984, J BIOL CHEM, V259, P1001; BRUDVIG GW, 1981, BIOCHEMISTRY-US, V20, P3912, DOI 10.1021/bi00516a039; BRZEZINSKI P, 1987, BIOCHIM BIOPHYS ACTA, V894, P29, DOI 10.1016/0005-2728(87)90209-X; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CLORE GM, 1980, BIOCHEM J, V185, P139, DOI 10.1042/bj1850139; DOCKTER ME, 1978, J BIOL CHEM, V253, P311; GELLES J, 1985, BIOCHEMISTRY-US, V24, P3963, DOI 10.1021/bi00336a025; GOODMAN G, 1985, BIOCHEMISTRY-US, V24, P2310, DOI 10.1021/bi00330a028; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; GREENWOOD C, 1976, BIOCHEM J, V157, P591, DOI 10.1042/bj1570591; HALL J, 1988, J BIOL CHEM, V263, P8142; HAN S, 1990, P NATL ACAD SCI USA, V87, P2491, DOI 10.1073/pnas.87.7.2491; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; HILL BC, 1980, BIOCHEM J, V187, P809, DOI 10.1042/bj1870809; HILL BC, 1984, FEBS LETT, V166, P362, DOI 10.1016/0014-5793(84)80113-1; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V853, P91, DOI 10.1016/0304-4173(86)90006-6; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; KUBOYAMA M, 1972, J BIOL CHEM, V247, P6375; MICHEL B, 1984, J BIOL CHEM, V259, P85; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; NILSSON T, 1990, FEBS LETT, V260, P45, DOI 10.1016/0014-5793(90)80062-N; OHNISHI T, 1982, J BIOL CHEM, V257, P4821; SARASTE M, 1988, ANN NY ACAD SCI, V550, P314, DOI 10.1111/j.1749-6632.1988.tb35346.x; STEFFENS GJ, 1979, H-S Z PHYSIOL CHEM, V360, P613; WEINTRAUB ST, 1981, J BIOL CHEM, V256, P1669; YONETANI T, 1966, BIOCHEM PREP, V11, P14	34	163	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2219	2226						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846619				2022-12-25	WOS:A1991EV51500033
J	BERNARD, DW; RODRIGUEZ, A; ROTHBLAT, GH; GLICK, JM				BERNARD, DW; RODRIGUEZ, A; ROTHBLAT, GH; GLICK, JM			CAMP STIMULATES CHOLESTERYL ESTER CLEARANCE TO HIGH-DENSITY-LIPOPROTEINS IN J774 MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; LEYDIG TUMOR-CELLS; FAT-FED RABBITS; CYCLIC-AMP; HEPATOMA-CELLS; PHYSICAL STATE; FOAM CELLS; ATHEROSCLEROSIS; PROSTAGLANDINS	The regulation by cAMP of cholesteryl ester hydrolysis and net depletion of cellular cholesteryl ester (cholesteryl ester clearance) in J774 murine macrophages was explored. Using Sandoz 58035 to selectively inhibit acyl CoA:cholesterol acyltransferase, we showed that the absolute rate of cholesteryl ester hydrolysis was stimulated 2-fold in J774 cells by the cAMP analogues 8-(4-chlorophenylthio)adenosine 3':5'-cyclic monophosphate and dibutyryl-cAMP. The rate of hydrolysis was also stimulated by prostaglandin E1, by cholera toxin, and by a mixture of forskolin and isobutylmethylxanthine, but was not affected by epinephrine or dibutyryl-cGMP. These data demonstrate that cholesteryl ester hydrolysis in J774 cells can be stimulated by cAMP-dependent protein kinase. Cholesteryl ester clearance from J774 cells was achieved upon incubation with high density lipoproteins (HDL) plus CPT-cAMP but not with HDL alone. HDL-mediated cholesteryl ester clearance was dependent on the concentration of both HDL and CPT-cAMP. The data suggest that the defect responsible for the lack of HDL-mediated cholesteryl ester clearance in J774 cells involves a failure to modulate cAMP levels.	MED COLL PENN, DEPT PHYSIOL & BIOCHEM, PHILADELPHIA, PA 19129 USA	Drexel University					NHLBI NIH HHS [HL22633, HL07443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN SJ, 1984, J BIOL CHEM, V259, P3844; AVIRAM M, 1989, J LIPID RES, V30, P65; BAMBERGER M, 1983, J LIPID RES, V24, P869; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V149, P545, DOI 10.1016/0006-291X(87)90402-5; BERNARD DW, 1990, ARTERIOSCLEROSIS, V10, P135, DOI 10.1161/01.ATV.10.1.135; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONTA IL, 1982, INT J IMMUNOPHARMACO, V4, P103, DOI 10.1016/0192-0561(82)90057-1; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHAMBAUTGUERIN AM, 1987, EUR J BIOCHEM, V170, P381, DOI 10.1111/j.1432-1033.1987.tb13711.x; ETINGIN OR, 1990, CIRC RES, V66, P185, DOI 10.1161/01.RES.66.1.185; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; FREEMAN DA, 1987, EUR J BIOCHEM, V164, P351, DOI 10.1111/j.1432-1033.1987.tb11065.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLICK JM, 1987, ATHEROSCLEROSIS, V64, P223, DOI 10.1016/0021-9150(87)90250-4; GLICK JM, 1983, J BIOL CHEM, V258, P3425; GLICK JM, 1990, ADV CHOLESTEROL RES, P167; GOLDBERG DI, 1990, BIOCHIM BIOPHYS ACTA, V1042, P132, DOI 10.1016/0005-2760(90)90067-8; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1985, BIOCHEM PHARMACOL, V34, P295, DOI 10.1016/0006-2952(85)90034-6; HAJJAR DP, 1986, ARCH BIOCHEM BIOPHYS, V247, P49, DOI 10.1016/0003-9861(86)90531-X; Hatch F T, 1968, Adv Lipid Res, V6, P1; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; JEROME WG, 1987, AM J PATHOL, V128, P253; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KHOO JC, 1981, J BIOL CHEM, V256, P2659; KRAEMER FB, 1990, ARTERIOSCLEROSIS, V10, P8, DOI 10.1161/01.ATV.10.1.8; LEWIS JC, 1988, EXP MOL PATHOL, V48, P103, DOI 10.1016/0014-4800(88)90049-4; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; NUMANO F, 1976, ANN NY ACAD SCI, V275, P311, DOI 10.1111/j.1749-6632.1976.tb43363.x; OLASHAW NE, 1988, ADV SEC MESS PHOSPH, V22, P139; OPPENHEIMER MJ, 1988, J BIOL CHEM, V263, P19318; PITAS RE, 1983, ARTERIOSCLEROSIS, V3, P2, DOI 10.1161/01.ATV.3.1.2; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P9, DOI 10.1161/01.ATV.7.1.9; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P24, DOI 10.1161/01.ATV.7.1.24; RUNYON RP, 1985, FUNDAMENTALS STATIST, P170; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; SMALL CA, 1989, FEBS LETT, V247, P205, DOI 10.1016/0014-5793(89)81335-3; SOKOLOFF L, 1972, BIOCHIM BIOPHYS ACTA, V280, P172, DOI 10.1016/0005-2760(72)90222-6; SUCKLING KE, 1983, BIOCHIM BIOPHYS ACTA, V753, P422, DOI 10.1016/0005-2760(83)90066-8; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; TERTOV VV, 1987, BIOMED BIOCHIM ACTA, V46, P727; THOMAS DB, 1975, CELL, V5, P37, DOI 10.1016/0092-8674(75)90089-6	45	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					710	716						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845991				2022-12-25	WOS:A1991ET17700008
J	BOWLUS, CL; MCQUILLAN, JJ; DEAN, DC				BOWLUS, CL; MCQUILLAN, JJ; DEAN, DC			CHARACTERIZATION OF 3 DIFFERENT ELEMENTS IN THE 5'-FLANKING REGION OF THE FIBRONECTIN GENE WHICH MEDIATE A TRANSCRIPTIONAL RESPONSE TO CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; SEQUENCE-SPECIFIC INTERACTIONS; POLYOMA-VIRUS ENHANCER; NUCLEAR FACTOR CREB; ALPHA-SUBUNIT GENE; HA-RAS ONCOGENE; CYCLIC-AMP; DNA-BINDING; SOMATOSTATIN GENE; PROTEIN	A cAMP regulatory element (CRE) at nucleotide position -170 of the fibronectin gene was characterized previously (Dean, D. C., Blakeley, M. S., Newby, R. F., Ghazal, P., Hennighausen, L., and Bourgeois, S. (1989) Mol. Cell. Biol. 9, 1498-1506). Here we identify two additional low affinity CREs at nucleotide positions -260 and -415 which differ in sequence by 1 base pair. Interestingly, these CREs did not compete for binding of nuclear proteins in gel retardation assays, and partial tryptic digestion of protein-DNA complexes produced a different pattern with each CRE, indicating that they bind different proteins. CRE (-170) competed for binding of proteins to both CREs, suggesting that it may represent a composite of the two elements. CRE (-415) competed effectively for binding of nuclear proteins to the somatostatin gene CRE, suggesting that, like the somatostatin CRE, it binds the nuclear protein CREB. On the other hand, CRE (-260) appears to bind the nuclear protein PEA-2, which also binds a site in the polyoma virus enhancer. In summary, disruption of dyad symmetry in the 3' region of the CRE, as occurs with CRE (-260) and CRE (-415), results in a lower affinity site and may also change the specificity for different nuclear proteins.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV RESP & CRIT CARE,BOX 8052,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Bowlus, Christopher/N-9276-2016	Bowlus, Christopher/0000-0002-3906-6811	NCI NIH HHS [CA-49438] Funding Source: Medline; NIGMS NIH HHS [GM 35751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOKAR JA, 1988, J BIOL CHEM, V263, P19740; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HERBOMEL P, 1984, CELL, V39, P657; HOD Y, 1984, J BIOL CHEM, V259, P5609; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SATAKE M, 1988, ONCOGENE, V3, P69; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; VELDMAN GM, 1985, MOL CELL BIOL, V5, P649, DOI 10.1128/MCB.5.4.649; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	39	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1122	1127						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845987				2022-12-25	WOS:A1991ET17700070
J	GOLDFARB, M; DEED, R; MACALLAN, D; WALTHER, W; DICKSON, C; PETERS, G				GOLDFARB, M; DEED, R; MACALLAN, D; WALTHER, W; DICKSON, C; PETERS, G			CELL-TRANSFORMATION BY INT-2 - A MEMBER OF THE FIBROBLAST GROWTH-FACTOR FAMILY	ONCOGENE			English	Article							PROTO-ONCOGENE INT-2; NUCLEOTIDE-SEQUENCE; SARCOMA DNA; FACTOR CDNA; 3T3 CELLS; MOUSE; GENE; EXPRESSION; FGF; HST	The sequence similarities between Int-2 and members of the fibroblast growth factor (FGF) family have prompted functional as well as structural comparisons with other FGFs. Here we examine the ability of int-2 sequences to induced morphological transformation of NIH3T3 cells, a characteristic property of the secreted FGFs, such as FGF-5 and Hst1/kFGF. Despite encoding a short signal sequence, which directs the product to the secretory pathway, mouse int-2 DNA is incapable of inducing foci of transformation in the standard transfection assay. However, when transfected cells are enriched by coselection with the neomycin resistance gene, a proportion of the int-2-expressing cells display a transformed phenotype, including the ability to grow as colonies in soft agar and in defined medium. Analyses of int-2 RNA and protein in these cells suggest that transformation by int-2 may require a threshold level of expression, and that the subsequent phenotype is dependent on the level of int-2 protein present in the cells.	ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND LABS,DOMINION HOUSE,59 BARTHOLOMEW CLOSE,LONDON EC1A 7BE,ENGLAND; COLUMBIA UNIV,DEPT BIOCHEM,NEW YORK,NY 10032; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; Columbia University; Cancer Research UK								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1974, P NATL ACAD SCI USA, V71, P4648, DOI 10.1073/pnas.71.12.4648; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LOBB RL, 1989, ANAL BIOCHEM, V154, P1; MARICS I, 1989, ONCOGENE, V4, P335; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; PATERNO GD, 1989, DEVELOPMENT, V106, P79; Peters G, 1987, CELLULAR MOL BIOL MA, P307; QUARTO N, 1989, ONCOGENE RES, V5, P101; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; THOMAS KA, 1988, TRENDS BIOCHEM SCI, V13, P327, DOI 10.1016/0968-0004(88)90098-9; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	48	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					65	71						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846956				2022-12-25	WOS:A1991EY03900009
J	ANDRESEN, K; TOM, TD; STRAND, M				ANDRESEN, K; TOM, TD; STRAND, M			CHARACTERIZATION OF CDNA CLONES ENCODING A NOVEL CALCIUM-ACTIVATED NEUTRAL PROTEINASE FROM SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL TROPONIN-C; SYNTHETIC PEPTIDE ANALOGS; AMINO-ACID SEQUENCE; BINDING SITE; ESCHERICHIA-COLI; DEPENDENT PROTEASE; LARGE SUBUNIT; MOLECULAR-CLONING; SURFACE-ANTIGEN; MESSENGER-RNA	To identify and characterize Schistosoma mansoni proteins that are recognized by infected hosts, we have used a pool of sera from infected humans to screen cDNA libraries constructed from poly(A)+ mRNA of adult S. mansoni. The deduced amino acid sequences of the three isolated clones showed a high degree of similarity to the large subunit of calcium-activated neutral proteinase (CANP) from humans and chicken. These overlapping clones, which include a nearly full-length clone with an open reading frame of 758 amino acid residues, together encode the entire large subunit of CANP. The deduced sequence of this S. mansoni protein can be divided into four domains (I-IV) that include the two domains characteristic of other large subunits of CANP: a thiol-protease domain (II) and a calcium-binding domain (IV) containing EF hand motifs. However, the schistosome protein is unique in having only three EF hand motifs in the calcium-binding domain and in having an additional EF hand motif that is shared between domains II and III. We have shown that these EF hand motifs are capable of binding Ca-45(2+). Furthermore, the large subunit in S. mansoni contains an NH2-terminal sequence of 28 residues that is absent from the mammalian CANPs and has a high degree of similarity to the presumed receptor binding sequence of colicin Ia and Ib.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, 725 N WOLFE ST, BALTIMORE, MD 21205 USA	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI019217, R37AI019217] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19217] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CORDINGLEY JS, 1983, GENE, V26, P25, DOI 10.1016/0378-1119(83)90033-1; CORDINGLEY JS, 1986, MOL BIOCHEM PARASIT, V18, P73, DOI 10.1016/0166-6851(86)90052-6; DALTON JP, 1987, P NATL ACAD SCI USA, V84, P4268, DOI 10.1073/pnas.84.12.4268; DAVIS AH, 1986, P NATL ACAD SCI USA, V83, P5534, DOI 10.1073/pnas.83.15.5534; ELSHERBEINI M, 1990, EXP PARASITOL, V70, P72, DOI 10.1016/0014-4894(90)90087-S; EMORI Y, 1986, J BIOL CHEM, V261, P9465; GOUDOTCROZEL V, 1989, J EXP MED, V170, P2065, DOI 10.1084/jem.170.6.2065; HAN X, 1989, EXP PARASITOL, V69, P373, DOI 10.1016/0014-4894(89)90087-8; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; JOHNSON KS, 1989, MOL BIOCHEM PARASIT, V36, P19, DOI 10.1016/0166-6851(89)90196-5; KANELLIS P, 1983, ARCH BIOCHEM BIOPHYS, V220, P530, DOI 10.1016/0003-9861(83)90444-7; KLINKERT MQ, 1987, MOL BIOCHEM PARASIT, V25, P247, DOI 10.1016/0166-6851(87)90088-0; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAR DE, 1985, MOL BIOCHEM PARASIT, V17, P45, DOI 10.1016/0166-6851(85)90127-6; MACMANUS JP, 1990, J BIOL CHEM, V265, P10358; MALIK NA, 1987, BIOCHIM BIOPHYS ACTA, V911, P221, DOI 10.1016/0167-4838(87)90011-2; MANKOVICH JA, 1986, J BACTERIOL, V168, P228, DOI 10.1128/jb.168.1.228-236.1986; MARSDEN BJ, 1988, BIOCHEMISTRY-US, V27, P4198, DOI 10.1021/bi00411a043; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; OLIVIER L, 1952, J PARASITOL, V38, P19, DOI 10.2307/3274166; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; REID RE, 1990, J BIOL CHEM, V265, P5971; REID RE, 1980, J BIOL CHEM, V255, P3642; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; STEIN LD, 1986, MOL BIOCHEM PARASIT, V20, P253, DOI 10.1016/0166-6851(86)90106-4; STEIN LD, 1990, J BIOL CHEM, V265, P6582; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; WRIGHT MD, 1990, J IMMUNOL, V144, P3195; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	43	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15085	15090						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869543				2022-12-25	WOS:A1991GB09700046
J	BENOVIC, JL; ONORATO, JJ; ARRIZA, JL; STONE, WC; LOHSE, M; JENKINS, NA; GILBERT, DJ; COPELAND, NG; CARON, MG; LEFKOWITZ, RJ				BENOVIC, JL; ONORATO, JJ; ARRIZA, JL; STONE, WC; LOHSE, M; JENKINS, NA; GILBERT, DJ; COPELAND, NG; CARON, MG; LEFKOWITZ, RJ			CLONING, EXPRESSION, AND CHROMOSOMAL LOCALIZATION OF BETA-ADRENERGIC-RECEPTOR KINASE-2 - A NEW MEMBER OF THE RECEPTOR KINASE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; PROTEIN-KINASE; ADENYLATE-CYCLASE; RHODOPSIN KINASE; CHICK HEART; HOMOLOGOUS DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR; DICTYOSTELIUM-DISCOIDEUM; CHEMOTACTIC RECEPTOR; S49-LYMPHOMA CELLS	The beta-adrenergic receptor kinase (beta-ARK) specifically phosphorylates the agonist-occupied form of the beta-adrenergic and related G protein-coupled receptors. Structural features of this enzyme have been elucidated recently by the isolation of a cDNA that encodes bovine-beta-ARK. Utilizing a catalytic domain fragment of the beta-ARK cDNA to screen a bovine brain cDNA library we have isolated a clone encoding a beta-ARK-related enzyme which we have termed beta-ARK2. Overall, this enzyme has 85% amino acid identity with beta-ARK, with the protein kinase catalytic domain having 95% identity. The ability of beta-ARK2 to phosphorylate various substrates was studied after expression in COS 7 cells. Although beta-ARK2 is essentially equiactive with beta-ARK in phosphorylating an acid-rich synthetic model peptide it was only approximately 50% as active when the substrate was the agonist-occupied beta-2-adrenergic receptor and only approximately 20% as active toward light-bleached rhodopsin. As with beta-ARK, phosphorylation of the receptor substrates by beta-ARK2 was completely stimulus dependent. RNA blot analysis with selected bovine tissues reveals an mRNA of 8 kilobases with a distribution similar to that of beta-ARK. More detailed RNA analysis using a ribonuclease protection assay in various rat tissues suggests that the beta-ARK2 message is present at much lower levels (typically 10-20%) than the beta-ARK message. In the rat the beta-ARK2 mRNA is localized predominantly in neuronal tissues although low levels are also observed in various peripheral tissues. The beta-ARK2 gene has been localized to a region of mouse chromosome 5 whereas the beta-ARK gene is localized on mouse chromosome 19. These data suggest the existence of a ''family'' of receptor kinases which may serve broadly to regulate receptor function.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; TEMPLE UNIV,HLTH SCI CTR,SCH MED,INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Duke University; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Lohse, Martin J/A-7160-2012; Lefkowitz, Robert/AAW-2649-2021	Lohse, Martin J/0000-0002-0599-3510; 	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLANSON JE, 1987, AM J MED GENET, V29, P517; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1991, FEBS LETT, V283, P122, DOI 10.1016/0014-5793(91)80568-N; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1986, NATURE, V322, P867; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P1718; Green EL, 1981, GENETICS PROBABILITY, P77; HECHT BK, 1989, CYTOGENET CELL GENET, V51, P1012; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; Hoffmann BB, 1990, PHARMACOL BASIS THER, P187; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KLEIN C, 1985, J CELL BIOL, V100, P715, DOI 10.1083/jcb.100.3.715; KLEIN P, 1987, J BIOL CHEM, V262, P358; KUHN H, 1973, BIOCHEMISTRY-US, V12, P2495; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAU NR, 1984, P NATL ACAD SCI-BIOL, V81, P5836, DOI 10.1073/pnas.81.18.5836; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOPETA MA, 1984, NUCLEIC ACIDS RES, V12, P5707; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MEIER K, 1988, P NATL ACAD SCI USA, V85, P2181, DOI 10.1073/pnas.85.7.2181; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NGUYEN C, 1988, ONCOGENE, V3, P703; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SOMERS RL, 1984, SCIENCE, V226, P182, DOI 10.1126/science.6091271; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; TABAS JA, 1991, GENOMICS, V9, P283, DOI 10.1016/0888-7543(91)90254-C; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; VILLEMUR R, 1987, MOL CELL BIOL, V7, P512, DOI 10.1128/MCB.7.1.512; WARTELL RM, 1980, GENE, V9, P307, DOI 10.1016/0378-1119(90)90329-P; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	58	215	220	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14939	14946						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869533				2022-12-25	WOS:A1991GB09700024
J	MCANDREW, SJ; CHEN, NY; KELDER, B; CIOFFI, JA; KOPCHICK, JJ				MCANDREW, SJ; CHEN, NY; KELDER, B; CIOFFI, JA; KOPCHICK, JJ			EFFECTS OF A LEUCINE ANALOG ON GROWTH-HORMONE PROCESSING AND SECRETION BY CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; SIGNAL PEPTIDE; BOVINE; TRANSLOCATION; EXPRESSION; MEMBRANES; SEQUENCE; GENE	Bovine and rat growth hormones (bGH and rGH, respectively) possess signal peptides that direct the hormone to the secretory pathway and are proteolytically cleaved prior to secretion. Previous in vitro translation studies indicated that incorporation of the polar leucine analog beta-hydroxyleucine into de novo synthesized polypeptides inhibits signal peptide function. To test the effects of this analog on GH secretion by cultured animal cells, transfections of mouse L-cells with a bGH expression plasmid or metabolic labeling of endogenous rGH in anterior pituitary cells was performed in the absence or presence of beta-hydroxyleucine. Transient expression of bGH in mouse L-cells or endogenous expression of rGH in anterior pituitary cells resulted in an accumulation of GH in the culture medium. Treatment with beta-hydroxyleucine resulted in a block in secretion as evidenced by an accumulation of GHs within these cells. Amino-terminal sequencing of the intracellular form of the analog-substituted GHs demonstrated accurate signal peptide cleavage. In contrast, in vitro translations of bGH RNA performed in the presence of beta-hydroxyleucine and microsomal membranes resulted in the inhibition of signal peptide cleavage. The results suggest that beta-hydroxyleucine can uncouple signal peptide processing and protein secretion in cultured cells.	OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,ATHENS,OH 45701	University System of Ohio; Ohio University	MCANDREW, SJ (corresponding author), OHIO UNIV,DEPT ZOOL,MOLEC & CELLULAR BIOL PROGRAM,ATHENS,OH 45701, USA.							BIRD P, 1990, J BIOL CHEM, V265, P8420; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHEN CH, 1977, BIOCHEMISTRY-US, V16, P2110, DOI 10.1021/bi00629a010; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CIOFFI JA, 1989, J BIOL CHEM, V264, P15052; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; HORTIN G, 1980, P NATL ACAD SCI-BIOL, V77, P1356, DOI 10.1073/pnas.77.3.1356; KOPCHICK JJ, 1985, DNA-J MOLEC CELL BIO, V4, P23, DOI 10.1089/dna.1985.4.23; KOPCHICK JJ, 1979, J VIROL, V30, P610, DOI 10.1128/JVI.30.2.610-623.1979; KOZAK M, 1983, CELL, V34, P971, DOI 10.1016/0092-8674(83)90554-8; KOZAK M, 1983, MICROBIOL REV, V47, P1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEUNG FC, 1986, ENDOCRINOLOGY, V119, P1489, DOI 10.1210/endo-119-4-1489; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LORENSON MG, 1975, ENDOCRINOLOGY, V96, P833, DOI 10.1210/endo-96-4-833; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; RYAN JP, 1986, J BIOL CHEM, V261, P3389; SCHECHTER I, 1973, P NATL ACAD SCI USA, V70, P2256, DOI 10.1073/pnas.70.8.2256; SILHAVY TJ, 1983, MICROBIOL REV, V47, P313, DOI 10.1128/MMBR.47.3.313-344.1983; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545	27	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15016	15020						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869539				2022-12-25	WOS:A1991GB09700035
J	JIN, DJ; GROSS, CA				JIN, DJ; GROSS, CA			RPOB8, A RIFAMPICIN-RESISTANT TERMINATION-PROFICIENT RNA-POLYMERASE, HAS AN INCREASED KM FOR PURINE NUCLEOTIDES DURING TRANSCRIPTION ELONGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN OPERON ATTENUATOR; RIBONUCLEIC-ACID POLYMERASE; LAMBDA-PR PROMOTER; ESCHERICHIA-COLI; FUNCTIONAL TOPOGRAPHY; TERNARY COMPLEXES; CHAIN ELONGATION; LEADER REGION; BETA-SUBUNIT; INVITRO	The rpoB8 allele of Escherichia coli maps to the beta-subunit of RNA polymerase and confers rifampicin resistance as well as increased termination at both intrinsic and rho-dependent terminators in vivo. This phenotype suggests that the mutant is defective in an enzymatic property of RNA polymerase important for all termination events. We analyzed the in vitro transcription properties of this enzyme to determine the nature of the defect. As compared with the wild-type enzyme, RpoB8 exhibits enhanced pausing and a significant reduction in rate of elongation on natural templates. In addition, RpoB8 RNA polymerase has a 3-5-fold higher K(m) for purine nucleotides during elongation on synthetic templates. In contrast, both the mutant and wild-type enzyme have the same initiation K(m) for ATP. Kinetic analysis indicates that RpoB8 is likely to be defective in nucleotide binding during elongation, suggesting that the mutational alteration affects the binding site. We show that our data are consistent with the idea that the altered K(m) underlies the altered pausing and elongation properties of the enzyme, and we discuss the implication of these results for the termination proficiency of the mutant strain.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019635] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19635] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERTRANDBURGGRAF E, 1984, NUCLEIC ACIDS RES, V12, P1697, DOI 10.1093/nar/12.3.1697; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CHRISTIE GE, 1981, P NATL ACAD SCI-BIOL, V78, P4180, DOI 10.1073/pnas.78.7.4180; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; FISHER RF, 1983, J BIOL CHEM, V258, P8146; FOX CF, 1964, J BIOL CHEM, V239, P175; FURTH JJ, 1962, J BIOL CHEM, V237, P2611; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GUARENTE LP, 1978, P NATL ACAD SCI USA, V75, P294, DOI 10.1073/pnas.75.1.294; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; JENSEN KF, 1986, J BACTERIOL, V166, P857, DOI 10.1128/jb.166.3.857-865.1986; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN DJ, 1988, J MOL BIOL, V204, P247, DOI 10.1016/0022-2836(88)90573-6; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; LANDICK R, 1984, J BIOL CHEM, V259, P1550; LAU LF, 1983, J BIOL CHEM, V258, P9391; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LISITSYN NA, 1985, BIOORG KHIM+, V11, P132; Maniatis T., 1982, MOL CLONING; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; NEFF NF, 1980, BIOCHEMISTRY-US, V19, P3005, DOI 10.1021/bi00554a027; RHODES G, 1974, J BIOL CHEM, V249, P6675; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; SOMERS DG, 1975, J BIOL CHEM, V250, P4825; STROYNOWSKI I, 1983, P NATL ACAD SCI-BIOL, V80, P2206, DOI 10.1073/pnas.80.8.2206; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; YANOFSKY C, 1981, J BACTERIOL, V145, P1334, DOI 10.1128/JB.145.3.1334-1341.1981; YARBROUGH LR, 1979, J BIOL CHEM, V254, P2069	39	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14478	14485						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860856				2022-12-25	WOS:A1991FZ35100059
J	SAKAI, LY; KEENE, DR; GLANVILLE, RW; BACHINGER, HP				SAKAI, LY; KEENE, DR; GLANVILLE, RW; BACHINGER, HP			PURIFICATION AND PARTIAL CHARACTERIZATION OF FIBRILLIN, A CYSTEINE-RICH STRUCTURAL COMPONENT OF CONNECTIVE-TISSUE MICROFIBRILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARFAN-SYNDROME; VII COLLAGEN; FIBRONECTIN; PROCOLLAGEN; PROTEINS; LOCATION; SYSTEM; GENE	Fibrillin, a connective tissue macromolecule (M(r) = 350,000) which is normally insoluble in its tissue form, has been purified from the medium of human skin fibroblast and ligament cells in culture. Analysis of the amino acid composition indicates that fibrillin contains approximately 14% cysteine, of which one-third appears to be in the free reactive sulfhydryl form. Electron microscopic images of fibrillin reveal an extended, flexible molecule approximately 148 nm long and 2.2 nm wide. These length measurements are consistent with shape calculations based upon velocity sedimentation data. It is likely that the material we have purified from cell culture medium represents monomeric fibrillin consisting of a single polypeptide chain. Additional ultrastructural immunohistochemical data presented here suggest a model for the parallel, head-to-tail alignment of fibrillin molecules in microfibrils.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University	SAKAI, LY (corresponding author), SHRINERS HOSP CRIPPLED CHILDREN, 3101 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.							BIRK DE, 1986, J CELL BIOL, V103, P231, DOI 10.1083/jcb.103.1.231; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; BURGESON RE, 1976, P NATL ACAD SCI USA, V73, P2579, DOI 10.1073/pnas.73.8.2579; CLEARY EG, 1981, CONNECT TISSUE RES, V8, P161, DOI 10.3109/03008208109152367; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; FLEISCHMAJER R, 1991, J HISTOCHEM CYTOCHEM, V39, P51, DOI 10.1177/39.1.1983873; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; INOUE S, 1986, AM J ANAT, V176, P121, DOI 10.1002/aja.1001760203; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KAPOOR R, 1988, J CELL BIOL, V107, P721, DOI 10.1083/jcb.107.2.721; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LOW FN, 1962, ANAT REC, V142, P131, DOI 10.1002/ar.1091420205; LOW FN, 1961, ANAT RECORD, V139, P105, DOI 10.1002/ar.1091390203; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MAGENIS RE, 1991, IN PRESS GENOMICS; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PROCKOP DJ, 1990, ADV HUM GENET, V19, P105; ROSS R, 1969, J CELL BIOL, V40, P366, DOI 10.1083/jcb.40.2.366; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SAKAI LY, 1982, AM J PATHOL, V108, P310; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAKAI LY, 1990, ELASTIN CHEM BIOL AS, P213; STREETEN BW, 1983, INVEST OPHTH VIS SCI, V24, P667; WRIGHT DW, 1988, J ULTRA MOL STRUCT R, V100, P224, DOI 10.1016/0889-1605(88)90039-0	30	241	247	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14763	14770						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860873				2022-12-25	WOS:A1991FZ35100100
J	LEBEAU, J; LECHALONY, C; PROSPERI, MT; GOUBIN, G				LEBEAU, J; LECHALONY, C; PROSPERI, MT; GOUBIN, G			CONSTITUTIVE OVEREXPRESSION OF A 89 KDA HEAT-SHOCK PROTEIN GENE IN THE HBL100 HUMAN MAMMARY CELL-LINE CONVERTED TO A TUMORIGENIC PHENOTYPE BY THE EJ/T24 HARVEY-RAS ONCOGENE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; MOLECULAR-CLONING; PLATELET PROTEIN; TRANSCRIPTION; EXPRESSION; DNA; FIBROBLASTS; ACTIVATION	The non tumorigenic human mammary cell line HBL100 has been transformed by the EJ/T24 human bladder carcinoma Harvey(Ha)-ras oncogene. Six cell lines were established from transformed colonies. They all expressed a high level of the ras oncogene and were tumorigenic in athymic nude mice. During an in vivo passage in animals, tumour cells presenting a growth advantage were selected, and some of the tumours revealed an amplification of the transfected ras sequences. Using this model of human cell transformation, we have isolated a cDNA clone corresponding to a heat shock protein gene (hsp89-alpha). This gene, normally transcribed at a higher rate in response to serum stimulation, was found to be constitutively overexpressed in ras-transformed HBL100 cells. In contrast, a closely related hsp gene (hsp89-beta), remained sensitive to serum stimulation, in both untransformed and ras-transformed HBL100 cells. Thus, the regulation of the expression of the hsp89 genes, upon serum stimulation, involves ras-dependent and ras-independent pathways. Constitutive overexpression of the murine homolog of the hsp89-alpha was observed in NIH3T3 cells transformed by the three ras oncogenes, but not with some other oncogenes. Therefore, alteration of the hsp89-alpha gene expression is not a general characteristic of transformed cells, but seems to be linked to ras transformation.	INST CURIE,ONCOGENESE MOLEC LAB,26 RUE ULM,F-75005 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	GOUBIN, G (corresponding author), INST CURIE,ONCOGENESE MOLEC LAB,26 RUE ULM,F-75005 PARIS,FRANCE.							BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BARNIER JV, 1987, EXP CELL RES, V170, P186, DOI 10.1016/0014-4827(87)90128-5; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHRISTIAN BJ, 1990, CANCER RES, V50, P4779; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGAG N, 1990, ONCOGENE, V5, P1481; HAIRE RN, 1988, J CELL BIOL, V106, P883, DOI 10.1083/jcb.106.3.883; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HICKEY E, 1986, GENE, V43, P147, DOI 10.1016/0378-1119(86)90018-1; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANKS KW, 1979, BIOCHIM BIOPHYS ACTA, V578, P1, DOI 10.1016/0005-2795(79)90106-5; LEGAGNEUX V, 1989, DIFFERENTIATION, V41, P42, DOI 10.1111/j.1432-0436.1989.tb00730.x; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; Maniatis T., 1982, MOL CLONING LAB MANU; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MOORE SK, 1989, J BIOL CHEM, V264, P5343; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OSHIMURA M, 1988, CANCER RES, V48, P1623; PROSPERI MT, 1987, ONCOGENE RES, V1, P121; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOW ND, 1976, J GEN VIROL, V33, P447, DOI 10.1099/0022-1317-33-3-447; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; YAMAZAKI M, 1989, NUCLEIC ACIDS RES, V17, P7108, DOI 10.1093/nar/17.17.7108; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	47	50	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1125	1132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861862				2022-12-25	WOS:A1991GV26000005
J	JOURNOT, L; PANTALONI, C; BOCKAERT, J; AUDIGIER, Y				JOURNOT, L; PANTALONI, C; BOCKAERT, J; AUDIGIER, Y			DELETION WITHIN THE AMINO-TERMINAL REGION OF GS-ALPHA IMPAIRS ITS ABILITY TO INTERACT WITH BETA-GAMMA-SUBUNITS AND TO ACTIVATE ADENYLATE-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; GTP-BINDING PROTEIN; ADP-RIBOSYLATION; PERTUSSIS TOXIN; S49 LYMPHOMA; LIMITED PROTEOLYSIS; ESCHERICHIA-COLI; BOVINE BRAIN; 2 FORMS; TRANSDUCIN	Proteolytic experiments performed on transducin and G(o)alpha subunit strongly suggest that the amino-terminal residues of the alpha-chain are involved in the interaction with beta-gamma-subunits. To test the possibility that the same region in G(s) may fulfill a similar function, we introduced a deletion in the amino-terminal domain of G(s)alpha. The properties of the wild type and the deleted alpha-chains were characterized on in vitro translated proteins or after reconstitution of cyc- membranes by in vitro-translated alpha-subunits. The mutant (DELTA-2-29) G(s)alpha could still bind guanosine 5'-3-O-(thio)triphosphate, as revealed by its resistance to trypsin proteolysis and was still able to interact with the membrane. However, (DELTA-2-29) G(s)alpha was not ADP-ribosylated by cholera toxin. In contrast to G(s)alpha, addition of beta-gamma-subunits did not increase the rate of sedimentation of (DELTA-2-29) G(s)alpha in sucrose gradients. Binding experiments on reconstituted membranes showed that the coupling to beta-adrenergic receptors was very low with (DELTA-2-29) G(s)alpha. Finally, the mutant did not restore activation of adenylate cyclase of cyc- membranes. We propose that the primary functional defect is the loss of interaction with beta-gamma-subunits, which secondarily impairs beta-gamma-dependent properties such as receptor coupling and cholera toxin-catalyzed ADP-ribosylation. However, it remains to be established that the lack of adenylate cyclase activation also results from this impaired interaction with beta-gamma-subunits.	CNRS, INSERM PHARMACOL & ENDOCRINOL, RUE CARDONILLE, F-34094 MONTPELLIER 5, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Journot, Laurent/T-9652-2018	Journot, Laurent/0000-0003-3499-8887				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BOCKAERT J, 1985, EMBO J, V4, P1413, DOI 10.1002/j.1460-2075.1985.tb03795.x; BOURNE HR, 1988, COLD SPRING HARB SYM, V53, P221, DOI 10.1101/SQB.1988.053.01.028; CHEE WW, 1989, J BIOL CHEM, V264, P5687; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; ISHIKAWA Y, 1990, J BIOL CHEM, V265, P8458; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JONES DT, 1987, J BIOL CHEM, V262, P14241; JOURNOT L, 1989, FEBS LETT, V251, P230, DOI 10.1016/0014-5793(89)81460-7; KAHN RA, 1984, J BIOL CHEM, V259, P6235; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MANNING DR, 1983, J BIOL CHEM, V258, P7059; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OLATE J, 1988, J BIOL CHEM, V263, P10394; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SALOMON MR, 1981, MOL PHARMACOL, V19, P109; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; VANDOP C, 1984, J BIOL CHEM, V259, P23; VANDOP C, 1984, J BIOL CHEM, V259, P696; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571	43	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9009	9015						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851161				2022-12-25	WOS:A1991FM03800055
J	LU, XP; LEFFERT, HL				LU, XP; LEFFERT, HL			INDUCTION OF SODIUM-PUMP BETA-1-SUBUNIT MESSENGER-RNA EXPRESSION DURING HEPATOCELLULAR GROWTH TRANSITIONS INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT HEPATOCYTES; DEOXYRIBONUCLEIC-ACID SYNTHESIS; TISSUE-SPECIFIC EXPRESSION; PRIMARY MONOLAYER-CULTURE; NA+-K+-ATPASE; BETA-SUBUNIT; ALPHA-SUBUNIT; LIVER-REGENERATION; MOLECULAR-CLONING; RIBONUCLEIC-ACID	Previous suggestions (Hubert, J. J., Schenk, D. B., Skelly, H., and Leffert, H. L. (1986) Biochemistry 25, 4156-4163) of tissue-specific isoforms or nonexistence of hepatic Na,K-ATPase beta-1-subunits were reevaluated by quantifying beta-1-subunit mRNA levels in quiescent and proliferating liver. RNA was extracted from caudate liver lobes of sham or 67% hepatectomized adult rats and from primary cultures of adult rat hepatocytes that simulate developmental and regenerating growth transitions. Northern blot analysis with a P-32-labeled full-length Na,K-ATPase beta-1-cDNA probe (Mercer, R. W., Schneider, J. W., Savitz, A., Emmanuel, J., Benz, T. J., and Levenson, R. (1986) Mol. Cell. Biol. 6, 3884-3890) revealed four (almost-equal-to 2.7, 2.4, 1.7-1.8, and 1.5 kilobases) low abundance mRNA species in quiescent tissue, freshly isolated hepatocytes, and cultured hepatocytes derived from lag or late stationary phase (1-2 days or 11-12 days postplating, respectively). In contrast, proliferating liver from 4 h post-67% hepatectomized rats or cultured hepatocytes in logarithmic growth phase contained levels of beta-1-subunit mRNA which exceeded quiescent levels by 4-35-fold. Membrane Na,K-ATPase activity also increased 2-3-fold during liver regeneration 12-24 h after partial hepatectomy. When proliferation in vitro was augmented by transforming growth factor-alpha, a hepatocyte mitogen, or reinitiated in late stationary phase by a change to fresh culture medium containing rat serum, beta-1-subunit mRNA expression was restimulated 4-20-fold. Parallel measurements of alpha-tubulin mRNA induction showed relatively nonsynchronous or invariant changes during hepatocyte proliferative transitions; similar results were obtained after Northern blots with a sodium pump alpha-I-subunit cDNA probe. No detectable hybridization signals were observed when either rat kidney or hepatocyte RNAs from freshly isolated and cultured cells or regenerating tissues were probed for the sodium pump 3.4-kilobase mRNA beta-2-isoform. These observations suggest that enhanced hepatic beta-1-subunit gene expression is linked specifically to growth-associated increases in Na,K-ATPase activity, hepatocyte proliferation, and mitogen activation.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NIDDK NIH HHS [DK28215] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028215] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRENNER DA, 1989, DNA-J MOLEC CELL BIO, V8, P279, DOI 10.1089/dna.1.1989.8.279; BROWN JW, 1983, DIFFERENTIATION, V25, P176; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOJKIER M, 1989, J BIOL CHEM, V264, P9583; DEHEMPTINNE B, 1983, ENDOCRINOLOGY, V112, P1224, DOI 10.1210/endo-112-4-1224; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; EMMANUEL JR, 1987, P NATL ACAD SCI USA, V84, P9030; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; FAUSTO N, 1984, MOL CELL BIOCHEM, V59, P131; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GICK GG, 1988, J BIOL CHEM, V263, P16610; GICK GG, 1988, NAPLUS KPLUS PUMP B, P277; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GLYNN IM, 1989, J ROY COLL PHYS LOND, V23, P39; HERRERA VLM, 1987, J CELL BIOL, V105, P1855, DOI 10.1083/jcb.105.4.1855; HIATT A, 1984, J BIOL CHEM, V259, P2629; HUBERT JJ, 1986, BIOCHEMISTRY-US, V25, P4156, DOI 10.1021/bi00362a025; KAPLAN JG, 1978, ANNU REV PHYSIOL, V40, P19, DOI 10.1146/annurev.ph.40.030178.000315; KENT RB, 1987, P NATL ACAD SCI USA, V84, P5369, DOI 10.1073/pnas.84.15.5369; KOCH KS, 1979, NATURE, V279, P104, DOI 10.1038/279104a0; KOCH KS, 1979, CELL, V18, P153, DOI 10.1016/0092-8674(79)90364-7; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAD PJ, 1982, ALCOHOL CLIN EXP RES, V6, P72, DOI 10.1111/j.1530-0277.1982.tb05383.x; LEFFERT H, 1975, P NATL ACAD SCI USA, V72, P4033, DOI 10.1073/pnas.72.10.4033; LEFFERT H, 1978, P NATL ACAD SCI USA, V75, P1834, DOI 10.1073/pnas.75.4.1834; Leffert H L, 1979, Methods Enzymol, V58, P536; Leffert H.L., 1987, CIRRHOSIS LIVER METH, P121; LEFFERT HL, 1976, J CELL BIOL, V70, P20, DOI 10.1083/jcb.70.1.20; LEFFERT HL, 1977, NATURE, V267, P58, DOI 10.1038/267058a0; LEFFERT HL, 1980, ANN NY ACAD SCI, V339, P1; LEFFERT HL, 1988, LIVER BIOL PATHOBIOL, P833; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; OMORI K, 1988, NA PLUS K PLUS PUMP, P127; PRESSLEY TA, 1988, AM J PHYSIOL, V255, pC252, DOI 10.1152/ajpcell.1988.255.2.C252; ROSS M H, 1969, Journal of Nutrition, V97, P563; Sambrook J, 1989, MOL CLONING LABORATO; SCHENK DB, 1984, J BIOL CHEM, V259, P14941; SCHWARTZ A, 1969, J PHARMACOL EXP THER, V168, P31; SELL S, 1982, HEPATOLOGY, V2, P77; SHAFRITZ DA, 1988, SEMIN LIVER DIS, V18, P285; SHORT J, 1972, J BIOL CHEM, V247, P1757; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAORMINO JP, 1990, J BIOL CHEM, V265, P4116; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	56	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9276	9284						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851173				2022-12-25	WOS:A1991FM03800092
J	GUAN, RJ; KHATRA, BS; COHLBERG, JA				GUAN, RJ; KHATRA, BS; COHLBERG, JA			PHOSPHORYLATION OF BOVINE NEUROFILAMENT PROTEINS BY PROTEIN-KINASE FA (GLYCOGEN-SYNTHASE KINASE-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ATP-CITRATE LYASE; INSULIN INDUCES ACTIVATION; AMINO-ACID-SEQUENCE; SUBUNIT NF-H; PHOSPHOPROTEIN PHOSPHATASE; MULTISITE PHOSPHORYLATION; MULTIPLE PHOSPHORYLATION; MAMMALIAN NEUROFILAMENTS; DYE BINDING	A highly purified preparation of protein kinase F(A) (where F(A) is the activating factor for phosphatase 1)/glycogen synthase kinase 3 from rabbit muscle readily phosphorylated bovine neurofilaments. All three neurofilament proteins, the high, middle, and low molecular proteins (NF-H, NF-M, and NF-L), were phosphorylated when intact filaments were incubated with the kinase. Experiments with individual proteins showed that NF-M was the best substrate. At protein concentrations of 0.13 mg/ml, the initial rate of NF-M phosphorylation was 30% of that observed for glycogen synthase. K(m) values were 0.24 mg/ml (7 X 10(-7) M tetramer) for glycogen synthase and 0.10 mg/ml (5 X 10(-7) M dimer) for NF-M. V(max) values were 0.36-mu-mol/min/mg for glycogen synthase and 0.035-mu-mol/min/mg for NF-M. Dephosphorylated NF-M was phosphorylated only half as much as native NF-M; this is consistent with the known substrate specificity of the kinase. The possible involvement of F(A)/GSK-3 in the phosphorylation of neurofilaments in vivo is discussed.	CALIF STATE UNIV LONG BEACH,DEPT CHEM & BIOCHEM,LONG BEACH,CA 90840; CALIF STATE UNIV LONG BEACH,DEPT ANAT & PHYSIOL,LONG BEACH,CA 90840	California State University System; California State University Long Beach; California State University System; California State University Long Beach					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026334] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26334] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P288, DOI 10.1016/0167-4838(84)90034-7; BALLOU LM, 1985, CURR TOP CELL REGUL, V27, P183; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEN KC, 1988, FEBS LETT, V241, P213, DOI 10.1016/0014-5793(88)81064-0; BROSTROM CO, 1971, J BIOL CHEM, V246, P1961; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CHIN TK, 1989, BIOCHEM J, V264, P53, DOI 10.1042/bj2640053; COHEN P, 1982, EUR J BIOCHEM, V124, P21, DOI 10.1111/j.1432-1033.1982.tb05902.x; COHLBERG JA, 1987, J BIOL CHEM, V262, P17009; DAHL D, 1988, J COMP NEUROL, V271, P445, DOI 10.1002/cne.902710311; DAHL D, 1989, BRAIN RES BULL, V22, P225, DOI 10.1016/0361-9230(89)90047-6; DAUTIGNY A, 1988, BIOCHEM BIOPH RES CO, V154, P1099, DOI 10.1016/0006-291X(88)90254-9; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; GEISLER N, 1985, EMBO J, V4, P57, DOI 10.1002/j.1460-2075.1985.tb02317.x; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; GEORGES E, 1987, NEUROSCIENCE, V22, P753, DOI 10.1016/0306-4522(87)90370-8; GEORGES E, 1986, J NEUROCHEM, V47, P477; GOLD BG, 1988, J NEUROPATH EXP NEUR, V47, P145, DOI 10.1097/00005072-198803000-00007; GORIS J, 1979, FEBS LETT, V99, P279, DOI 10.1016/0014-5793(79)80972-2; GUAN R, 1990, Journal of Cell Biology, V111, p433A; GUAN R, 1989, Journal of Cell Biology, V109, p71A; HEGAZY MG, 1987, ARCH BIOCHEM BIOPHYS, V258, P470, DOI 10.1016/0003-9861(87)90368-7; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HISANAGA S, 1989, J NEUROSCI, V9, P959; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P223, DOI 10.1083/jcb.108.2.223; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; JULIEN JP, 1983, BIOCHIM BIOPHYS ACTA, V755, P25, DOI 10.1016/0304-4165(83)90268-4; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; KHATRA B S, 1988, Journal of Cell Biology, V107, p281A; KHATRA BS, 1986, J BIOL CHEM, V261, P8944; KHATRA BS, 1989, FASEB J, V3, pA1289; KREBS EG, 1958, J BIOL CHEM, V231, P73; KSIEZAKREDING H, 1987, J NEUROSCI, V7, P3554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; MACK K, 1988, J NEUROSCI RES, V20, P129, DOI 10.1002/jnr.490200118; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MERLEVEDE W, 1984, CURR TOP CELL REGUL, V23, P177; METZUALS J, 1985, ELECTRON MICROSCOPY; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; PUCCI DL, 1983, J BIOL CHEM, V258, P2907; RAMAKRISHNA S, 1983, J BIOL CHEM, V258, P4950; RUNGE MS, 1981, BIOCHEMISTRY-US, V20, P175, DOI 10.1021/bi00504a029; SCHMIDT ML, 1987, LAB INVEST, V56, P282; SHECKET G, 1982, J BIOL CHEM, V257, P4788; SHEORAIN VS, 1985, J BIOL CHEM, V260, P2287; SHNEIDMAN PS, 1988, MOL BRAIN RES, V4, P217, DOI 10.1016/0169-328X(88)90028-9; SIHAG RK, 1989, J BIOL CHEM, V264, P457; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SODERLING TR, 1970, J BIOL CHEM, V245, P6317; TANIUCHI M, 1986, J BIOL CHEM, V261, P3342; TORUDELBAUFFE D, 1986, BIOCHEM J, V235, P283, DOI 10.1042/bj2350283; TORUDELBAUFFE D, 1983, FEBS LETT, V162, P230, DOI 10.1016/0014-5793(83)80761-3; TRONCOSO JC, 1986, BRAIN RES, V364, P295, DOI 10.1016/0006-8993(86)90842-5; TUNG HYL, 1989, J BIOL CHEM, V264, P2985; VANDENHEEDE JR, 1980, J BIOL CHEM, V255, P17768; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; YANG SD, 1987, BIOCHEM BIOPH RES CO, V142, P38, DOI 10.1016/0006-291X(87)90448-7; YANG SD, 1990, BIOCHEM BIOPH RES CO, V166, P267, DOI 10.1016/0006-291X(90)91940-T; YANG SD, 1988, BIOCHEM BIOPH RES CO, V151, P61, DOI 10.1016/0006-291X(88)90559-1; YANG SD, 1989, BIOCHEM BIOPH RES CO, V158, P762, DOI 10.1016/0006-291X(89)92787-3; YANG SD, 1989, J BIOL CHEM, V264, P5407; YANG SD, 1986, J BIOL CHEM, V261, P1786; YANG SD, 1985, J BIOL CHEM, V260, P3464; YANG SD, 1980, J BIOL CHEM, V255, P1759	86	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8262	8267						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850742				2022-12-25	WOS:A1991FK44100050
J	MADDUX, BA; GOLDFINE, ID				MADDUX, BA; GOLDFINE, ID			EVIDENCE THAT INSULIN PLUS ATP MAY INDUCE A CONFORMATIONAL CHANGE IN THE BETA-SUBUNIT OF THE INSULIN-RECEPTOR WITHOUT INDUCING RECEPTOR AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RAT HEPATOMA-CELLS; MONOCLONAL-ANTIBODIES; TYROSINE KINASE; BINDING SITE; PROTEIN; REPLACEMENT; HORMONE; FAMILY; PHOSPHORYLATION	The effect of insulin and ATP on insulin receptor-beta subunit conformation was studied in vitro with radio-iodinated monoclonal antibodies directed at several regions of the receptor-beta subunit. Insulin plus ATP inhibited their binding to the receptor. The greatest inhibitory effect of insulin and ATP was seen with antibody 17A3 which recognizes a domain of the beta-subunit that is near the major tyrosine autophosphorylation sites at residues 1158, 1162, and 1163. ATP alone inhibited 17A3 binding with a one-half maximal ATP inhibitory concentration of 186 +/- 7-mu-M. Insulin at concentrations as low as 100 pM potentiated the effect of ATP; at 100 nM where insulin had its maximal effect, insulin lowered the one-half maximal inhibitory concentration of ATP to 16 +/- 6-mu-M. At 1 mM CTP, GTP, ITP, TTP, and AMP were without effect in either the presence or absence of insulin; in contrast, ADP was inhibitory in the presence of insulin. Of major interest was adenyl-5'-yl imidodiphosphate (AMP-PNP). This nonhydrolyzable analog of ATP inhibited 17A3 binding, and the effect of AMP-PNP (like ATP) was potentiated by insulin. Two insulin receptor-beta subunit mutants then were studied. Mutant receptor F3, where the major tyrosine autophosphorylation sites at residues 1158, 1162, and 1163 were changed to phenylalanines, bound to 17A3; antibody binding was inhibited by insulin and ATP in a manner similar to normal receptors. In contrast, mutant receptor M1030, where the lysine in the ATP binding site at residue 1030 was changed to methionine, bound 17A3, but unlike either normal receptors or F3 receptors, the binding of 17A3 was not inhibited by insulin and ATP. Therefore, these studies raise the possibility that, in vivo, ATP binding in the presence of insulin may induce a conformational change in the insulin receptor-beta subunit which in turn signals some of the biological effects of insulin.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	MADDUX, BA (corresponding author), UNIV CALIF SAN FRANCISCO,MT ZION MED CTR,DIV DIABET & ENDOCRINE RES,SAN FRANCISCO,CA 94143, USA.							BIRNBAUMER L, 1987, KIDNEY INT, V32, pS24; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARESE RV, 1986, J BIOL CHEM, V261, P8598; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HOUSLAY MD, 1984, BIOCHEM SOC T, V12, P766, DOI 10.1042/bst0120766; IWAMOTO Y, 1981, ENDOCRINOLOGY, V108, P44, DOI 10.1210/endo-108-1-44; JACOBS S, 1981, ENDOCR REV, V2, P251, DOI 10.1210/edrv-2-3-251; JARETT L, 1984, VITAM HORM, V41, P51; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KAHN CR, 1985, ANNU REV MED, V36, P429; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PEZZINO V, 1989, AM J PHYSIOL, V257, pE451, DOI 10.1152/ajpendo.1989.257.3.E451; RAFAELOFF R, 1990, DIABETES, V39, pA11; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SALTIEL AR, 1990, TEM              JAN, P158; SBRACCIA P, 1990, J BIOL CHEM, V265, P4902; SEINO S, 1990, DIABETES, V39, P123, DOI 10.2337/diabetes.39.1.123; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	41	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6731	6736						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849890				2022-12-25	WOS:A1991FG72700016
J	SAKAUE, M; HOFFMAN, BB				SAKAUE, M; HOFFMAN, BB			CAMP REGULATES TRANSCRIPTION OF THE ALPHA-2A ADRENERGIC-RECEPTOR GENE IN HT-29 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; MESSENGER-RNA STABILITY; CYCLIC-AMP REGULATION; ALPHA-2-ADRENERGIC RECEPTOR; DOWN-REGULATION; EXPRESSION; SUBUNIT; DESENSITIZATION; PHOSPHORYLATION	Since cAMP has a number of important effects regulating activity of adrenergic receptor pathways, we wondered if expression of the alpha-2A adrenergic receptor gene is regulated by this second messenger. We have examined the effects of a cAMP analog (Bt2cAMP) on the expression of alpha-2A adrenergic receptors in HT-29 cells. Bt2cAMP induced a 5.3 +/- 0.8-fold increase in alpha-2A receptor mRNA abundance as did forskolin and vasoactive intestinal polypeptide which both increase cAMP accumulation in these cells. Bt2cAMP increased alpha-2A receptor number up to 2.4 +/- 0.3-fold. The rate of alpha-2A receptor gene transcription increased 7.8 +/- 3.2-fold in cells treated with Bt2cAMP for 2 h; after 24 h, the transcription rate was 3.7 +/- 1.7-fold higher than in controls. The increased rate of transcription occurred in the presence of the protein synthesis inhibitor cycloheximide. The half life of the alpha-2A receptor mRNA in cells incubated with Bt2cAMP for 2 h increased by 1.5-fold but returned to the original value after exposure to Bt2cAMP for 24 h. The increased expression of alpha-2A receptors was associated with an increased efficacy of inhibition of cAMP accumulation mediated by the alpha-2 adrenergic agonist UK14304. Using a chloramphenicol acetyltransferase (CAT) reporter plasmid containing 5'-flanking sequences of the alpha-2A receptor gene, we found that co-transfection of JEG-3 cells with expression vectors containing cAMP-dependent protein kinase regulatory subunit cDNA with mutations at both cAMP binding sites inhibited basal and Bt2cAMP-stimulated expression of CAT activity. These results demonstrate that an alpha-2A adrenergic receptor gene is regulated by the second messenger cAMP via cAMP-dependent protein kinase, mainly by controlling the rate of transcription, which leads to an increased expression of these receptors.	VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN 182B,3801 MIRANDA AVE,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41315] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battey, 1986, BASIC METHODS MOL BI; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; DRUBIN DG, 1984, J CELL BIOL, V98, P1090, DOI 10.1083/jcb.98.3.1090; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GAY DA, 1987, CELL, V50, P671, DOI 10.1016/0092-8674(87)90325-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1988, CURRENT PROTOCOLS MO; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HACCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HOD Y, 1988, J BIOL CHEM, V263, P7747; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V170, P46, DOI 10.1016/0006-291X(90)91238-N; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LABURTHE M, 1980, CANCER RES, V40, P2529; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIMBIRD LE, 1987, FASEB J, V1, P119; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MILSTED A, 1987, DNA-J MOLEC CELL BIO, V6, P213, DOI 10.1089/dna.1987.6.213; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; PARIS H, 1987, MOL PHARMACOL, V32, P646; PARIS H, 1985, FEBS LETT, V184, P82, DOI 10.1016/0014-5793(85)80658-X; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUGG EL, 1978, MOL PHARMACOL, V14, P996; Sambrook J, 1989, MOL CLONING LABORATO; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SMITH JD, 1988, EMBO J, V7, P3711, DOI 10.1002/j.1460-2075.1988.tb03254.x; THOMAS JM, 1987, TRENDS PHARMACOL SCI, V8, P308, DOI 10.1016/0165-6147(87)90124-6; THOMAS JM, 1986, ENDOCRINOLOGY, V119, P1305, DOI 10.1210/endo-119-3-1305; THOMAS JM, 1989, MOL PHARMACOL, V34, P116; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; UHLER MD, 1987, J BIOL CHEM, V262, P15202; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	47	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5743	5749						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848558				2022-12-25	WOS:A1991FD37000060
J	CHAKRABORTY, T; BRENNAN, T; OLSON, E				CHAKRABORTY, T; BRENNAN, T; OLSON, E			DIFFERENTIAL TRANSACTIVATION OF A MUSCLE-SPECIFIC ENHANCER BY MYOGENIC HELIX-LOOP-HELIX PROTEINS IS SEPARABLE FROM DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE GENE; MYC HOMOLOGY; MYOD1; EXPRESSION; FIBROBLASTS; UPSTREAM; ELEMENTS; REGION; IDENTIFICATION; MYOBLASTS	The muscle creatine kinase (MCK) enhancer was used as a target to study the specificity of DNA binding and trans-activation by members of the helix-loop-helix (HLH) family of myogenic regulatory factors, MyoD1, myogenin, myf-5, and MRF-4. Whereas all four myogenic factors bound with similar affinities to the MCK enhancer in the presence of the widely expressed HLH protein E12, only MyoD1, myogenin, and myf-5 efficiently trans-activated the enhancer in transiently transfected 10T1/2 and 3T3 cells. That MRF4 binds the MCK enhancer without activating transcription suggests that domains in addition to those required for DNA binding are important for transcriptional activation and supports the notion that the different members of the HLH family of myogenic regulatory factors may selectively regulate unique sets of muscle-specific genes.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	29	81	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2878	2882						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847137				2022-12-25	WOS:A1991EX60000035
J	WEISS, BA; INSEL, PA				WEISS, BA; INSEL, PA			INTRACELLULAR CA2+ AND PROTEIN-KINASE-C INTERACT TO REGULATE-ALPHA-1-ADRENERGIC-STIMULATED AND BRADYKININ RECEPTOR-STIMULATED PHOSPHOLIPASE-A2 ACTIVATION IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PROSTAGLANDIN SYNTHESIS; PHOSPHOINOSITIDE HYDROLYSIS; HUMAN-PLATELETS; PHORBOL ESTER; PHOSPHATIDYLCHOLINE HYDROLYSIS; DIACYLGLYCEROL METABOLISM; DIGLYCERIDE LIPASE; HUMAN-NEUTROPHILS; MUSCLE-CELLS	alpha-1-Adrenergic receptors and bradykinin receptors are two distinct membrane receptors that stimulate phospholipid breakdown and arachidonic acid and arachidonic acid metabolite release. In the current studies, we have examined several mechanisms to assess their possible contribution to arachidonic acid release in the Madin-Darby canine kidney cell line by agonist stimulation of these receptors: 1) activation of phospholipase A2 (PLA2); 2) sequential activation of phospholipase C, diacylglycerol lipase, and monoacylglycerol lipase; and 3) inhibition of the sequential action of fatty acyl-CoA synthetase and lysophosphatide acyltransferase. Experiments were conducted to measure the stimulation of lysophospholipid production by epinephrine and bradykinin, the rate of incorporation of [H-3]arachidonic acid into stimulated and unstimulated cells, and the effect on [H-3]arachidonic acid release of treating cells with exogenous phospholipase C. The data indicate that stimulation of PLA2 activity is regulated by alpha-1-adrenergic and bradykinin receptors and that this stimulation is mediated, at least in part, by the activation of protein kinase C. We find that the role of diacylglycerol in arachidonic acid release is as an activator of protein kinase C and not as a substrate for a lipase. Moreover, the hormonal agonists do not appear to inhibit fatty acid reacylation. Experiments using the Ca2+-sensitive dye fura-2 and the intracellular Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid suggest that bradykinin activates PLA2 by a transient elevation of intracellular Ca2+. This action appears to be less important for activation of PLA2 by epinephrine. Taken together, these data are consistent with the following conclusions. 1) Hormone-stimulated arachidonic acid release in Madin-Darby canine kidney-D1 cells occurs as a consequence of PLA2 activation. 2) The ability of an agonist both to mobilize Ca2+ and to activate protein kinase C contributes to its efficacy as a stimulator of PLA2-mediated arachidonic acid release.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,M-036,LA JOLLA,CA 92093	University of California System; University of California San Diego					NHLBI NIH HHS [HL0761] Funding Source: Medline; NIGMS NIH HHS [GM35847, GM31987] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031987, R01GM035847] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER SK, 1988, J BIOL CHEM, V263, P1952; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONVENTRE JV, 1988, J CLIN INVEST, V82, P168, DOI 10.1172/JCI113566; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BYRON KL, 1989, J BIOL CHEM, V264, P18234; CANONICO PL, 1989, GYNECOL ENDOCRINOL, V3, P165, DOI 10.3109/09513598909152464; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; CCHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CHASE HS, 1988, AM J PHYSIOL, V254, pF374, DOI 10.1152/ajprenal.1988.254.3.F374; CHAU LY, 1983, BIOCHEM BIOPH RES CO, V113, P241, DOI 10.1016/0006-291X(83)90457-6; COTECCHIA S, 1985, LIFE SCI, V37, P2389, DOI 10.1016/0024-3205(85)90106-7; DANIEL LW, 1981, J BIOL CHEM, V256, P2830; DIXON JF, 1984, J BIOL CHEM, V259, P4418; ERBLAND JF, 1965, BIOCHIM BIOPHYS ACTA, V106, P128, DOI 10.1016/0005-2760(65)90101-3; ERBLAND JF, 1965, BIOCHIM BIOPHYS ACTA, V106, P139, DOI 10.1016/0005-2760(65)90102-5; EXTON JH, 1990, J BIOL CHEM, V265, P1; FAROOQUI AA, 1990, BIOCHEM BIOPH RES CO, V166, P1001, DOI 10.1016/0006-291X(90)90910-F; FRANCEL P, 1988, BIOCHEM BIOPH RES CO, V152, P724, DOI 10.1016/S0006-291X(88)80098-6; FUSE I, 1989, J BIOL CHEM, V264, P3890; GODSON C, 1990, J BIOL CHEM, V265, P8369; GONZALES RA, 1987, J PHARMACOL EXP THER, V242, P764; GOPPELT M, 1984, ANAL BIOCHEM, V140, P152, DOI 10.1016/0003-2697(84)90146-5; GOPPELTSTRUBE M, 1987, BIOCHEM J, V247, P773, DOI 10.1042/bj2470773; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSOVSKY F, 1990, J PHARMACOL EXP THER, V252, P466; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HANSCH GM, 1985, J IMMUNOL, V135, P1320; HO AK, 1987, J BIOL CHEM, V262, P11764; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; HUNTER SA, 1984, BIOCHIM BIOPHYS ACTA, V793, P202, DOI 10.1016/0005-2760(84)90322-9; JEREMY JY, 1987, EUR J PHARMACOL, V136, P311, DOI 10.1016/0014-2999(87)90303-7; KAYA H, 1989, J BIOL CHEM, V264, P4972; KRONER EE, 1981, J BIOL CHEM, V256, P3690; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P6566, DOI 10.1073/pnas.82.19.6566; MAJERUS PW, 1984, TRENDS BIOCHEM SCI, V12, P176; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MEIER KE, 1983, J CELL BIOL, V97, P405, DOI 10.1083/jcb.97.2.405; NAKASHIMA S, 1989, BIOCHEM J, V259, P139, DOI 10.1042/bj2590139; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; OZAKI Y, 1989, BIOCHIM BIOPHYS ACTA, V1012, P87, DOI 10.1016/0167-4889(89)90015-3; PARKER J, 1987, J BIOL CHEM, V262, P5385; PAULMICHL M, 1990, KIDNEY INT, V37, P377; PETITOU M, 1978, ANAL BIOCHEM, V91, P350, DOI 10.1016/0003-2697(78)90849-7; PFANNKUCHE HJ, 1986, BIOCHEM BIOPH RES CO, V139, P604, DOI 10.1016/S0006-291X(86)80033-X; PIDIKITI N, 1985, BIOCHEM BIOPH RES CO, V130, P807, DOI 10.1016/0006-291X(85)90488-7; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; PREISS J, 1986, J BIOL CHEM, V261, P8597; RESCH K, 1972, EUR J BIOCHEM, V27, P153, DOI 10.1111/j.1432-1033.1972.tb01821.x; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; TAMOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; WEISS BA, 1989, MOL PHARMACOL, V36, P317; WEISS BA, 1990, J CELL BIOCH B, V14, P370; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	67	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2126	2133						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846614				2022-12-25	WOS:A1991EV51500021
J	DUNTEN, P; KOSHLAND, DE				DUNTEN, P; KOSHLAND, DE			TUNING THE RESPONSIVENESS OF A SENSORY RECEPTOR VIA COVALENT MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DIRECTED CROSS-LINKING; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; PHOSPHODIESTERASE ACTIVATION; CHEMORECEPTOR PROTEINS; SIGNAL TRANSDUCTION; ASPARTATE RECEPTOR; RHODOPSIN KINASE; PHOSPHORYLATION	Down-regulation or adaptation of receptors is an essential part of the chemotaxis mechanism to sense gradients. Using localized mutagenesis it is shown that the covalent modification of the receptors makes a slight change in the binding constant (factor of 2) which is far too small to explain the adaptation. The modification does, however, alter the signaling dramatically, an increasing tumbling signal being correlated with increased covalent modification. Responses in the two extreme cases, namely, completely unmodified and completely modified receptor, occur at attractant concentrations separated by 2 orders of magnitude. Amidation of the regulatory glutamate residues causes essentially the same signaling change as methylation. Thus, adaptation in chemotaxis is due to modulation of the receptor's signaling properties, not its affinity for the chemoeffector.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BLUM P, 1989, J BACTERIOL, V171, P538, DOI 10.1128/jb.171.1.538-546.1989; CLARKE S, 1979, J BIOL CHEM, V254, P9695; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FOSTER DL, 1985, J BIOL CHEM, V260, P1706; GOLDBETER A, 1982, J MOL BIOL, V161, P395, DOI 10.1016/0022-2836(82)90246-7; HAZELBAUER GL, 1989, P NATL ACAD SCI USA, V86, P1448, DOI 10.1073/pnas.86.5.1448; HUGANIR RL, 1989, CRIT REV BIOCHEM MOL, V24, P183, DOI 10.3109/10409238909082553; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; KEHRY MR, 1985, J BACTERIOL, V161, P105, DOI 10.1128/JB.161.1.105-112.1985; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KNOX BE, 1986, P NATL ACAD SCI USA, V83, P2345, DOI 10.1073/pnas.83.8.2345; KOSHLAND DE, 1979, PHYSIOL REV, V59, P811, DOI 10.1152/physrev.1979.59.4.811; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIEBMAN PA, 1984, ADV CYCLIC NUCL PROT, V17, P215; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SAGER BM, 1988, ANAL BIOCHEM, V173, P271, DOI 10.1016/0003-2697(88)90189-3; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANDERS DA, 1988, P NATL ACAD SCI USA, V85, P8425, DOI 10.1073/pnas.85.22.8425; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEL LA, 1986, J THEOR BIOL, V120, P151, DOI 10.1016/S0022-5193(86)80171-0; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P5460, DOI 10.1021/bi00367a017; SLOCUM MK, 1983, J BACTERIOL, V155, P565, DOI 10.1128/JB.155.2.565-577.1983; SPRINGER MS, 1984, P NATL ACAD SCI-BIOL, V81, P5061, DOI 10.1073/pnas.81.16.5061; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STOCK J, 1985, CELL, V42, P683, DOI 10.1016/0092-8674(85)90125-4; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; WEIS RM, 1988, P NATL ACAD SCI USA, V85, P83, DOI 10.1073/pnas.85.1.83	41	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1491	1496						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846357				2022-12-25	WOS:A1991EU49700024
J	BASTIAN, NR; KAY, CJ; BARBER, MJ; RAJAGOPALAN, KV				BASTIAN, NR; KAY, CJ; BARBER, MJ; RAJAGOPALAN, KV			SPECTROSCOPIC STUDIES OF THE MOLYBDENUM-CONTAINING DIMETHYL-SULFOXIDE REDUCTASE FROM RHODOBACTER-SPHAEROIDES F-SP DENITRIFICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; TRIMETHYLAMINE-N-OXIDE; IRON-SULFUR CENTERS; NITRATE REDUCTASE; SULFITE OXIDASE; XANTHINE-OXIDASE; ESCHERICHIA-COLI; RHODOPSEUDOMONAS-SPHAEROIDES; METHANOBACTERIUM-FORMICICUM; FORMATE DEHYDROGENASE	Absorption and EPR spectroscopic properties of purified dimethyl sulfoxide (Me2SO) reductase from Rhodobacter sphaeroides f. sp. denitrificans have been examined. The absence of prosthetic groups other than the molybdenum center in the enzyme has made it possible to study its absorption properties. The enzyme displays multiple absorbance peaks in both the oxidized and the dithionite-reduced forms. The oxidized enzyme has absorbance peaks at 280, 350, 470, 550, and 720 nm while the dithionite-reduced enzyme has peaks at 280, 374, and 645 nm with a shoulder at 430 nm. A comparison of the absorbance spectrum of oxidized Me2SO reductase with that of the molybdenum fragment of rat liver sulfite oxidase shows that the 350 and 470 peaks are common to both proteins. EPR studies of the Mo(V) form of Me2SO reductase show a rhombic signal with g1 = 1.988, g2 = 1.977, g3 = 1.961, and g(ave) = 1.975. The signal shows evidence of coupling to an exchangeable proton with A1 = 1.05, A2 = 1.13, A3 = 0.98, and A(ave) = 1.05 millitesla. These parameters are similar to those of other Mo enzymes, however, the epr signal of this enzyme differs from those of other Mo hydroxylases in showing only a slight sensitivity to pH and no detectable anion effect. EPR potentiometric titrations of Me2So reductase gave midpoint potentials of +144 mV for the Mo(VI)/Mo(V) couple and +160 mV for the Mo(V)/Mo(IV) couple at room temperature and +141 mV for the Mo(VI)/Mo(V) couple and +200 mV for the Mo(V)/Mo(IV) couple at 173 K.	UNIV S FLORIDA,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612	State University System of Florida; University of South Florida	BASTIAN, NR (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07031] Funding Source: Medline; NIGMS NIH HHS [GM32696, GM00091] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN EA, 1963, J CHEM SOC, P4649, DOI 10.1039/jr9630004649; ANDREAE MO, 1980, LIMNOL OCEANOGR, V25, P1054, DOI 10.4319/lo.1980.25.6.1054; BARBER MJ, 1983, BIOCHEMISTRY-US, V22, P618, DOI 10.1021/bi00272a014; BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P3561, DOI 10.1021/bi00258a006; BARBER MJ, 1986, BIOCHEMISTRY-US, V25, P8150, DOI 10.1021/bi00373a004; BARBER MJ, 1983, J BIOL CHEM, V258, P839; BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P1638, DOI 10.1021/bi00536a026; BARBER MJ, 1989, J CELL BIOL, V107, pA843; BARBER MJ, 1980, MOLYBDENUM MOLYBDENU, P543; BASTIAN N R, 1988, Journal of Cell Biology, V107, p845A; BEINERT H, 1962, MAGNETIC RESONANCE B, P221; BERG JM, 1985, J AM CHEM SOC, V107, P917, DOI 10.1021/ja00290a029; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; BOYD IW, 1982, INORG CHEM, V21, P1602, DOI 10.1021/ic00134a066; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN MD, 1962, J CHEM SOC, P3044, DOI 10.1039/jr9620003044; CRAIG JA, 1989, J AM CHEM SOC, V111, P2111, DOI 10.1021/ja00188a026; CRAMER SP, 1983, ADV INORG BIOINORG M, V2, P259; DANIELS L, 1984, ANAL BIOCHEM, V141, P232, DOI 10.1016/0003-2697(84)90450-0; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GUTTERIDGE S, 1980, BIOCHEM J, V191, P285, DOI 10.1042/bj1910285; GUTTERIDGE S, 1978, BIOCHEM J, V173, P879; Johnson J. L., 1980, MOLYBDENUM MOLYBDENU, P345; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1988, METHOD ENZYMOL, V158, P371, DOI 10.1016/0076-6879(88)58069-2; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KAY CJ, 1990, ANAL BIOCHEM, V183, P11; KIKUCHI T, 1982, INORG CHIM A-BIOINOR, V66, pL5, DOI 10.1016/S0020-1693(00)85758-8; KRAMER S, 1984, ARCH BIOCHEM BIOPHYS, V233, P821, DOI 10.1016/0003-9861(84)90511-3; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; LAMY MT, 1980, BIOCHEM J, V185, P397, DOI 10.1042/bj1850397; LOVELOCK JE, 1972, NATURE, V237, P452, DOI 10.1038/237452a0; MCEWAN AG, 1983, ARCH MICROBIOL, V136, P300, DOI 10.1007/BF00425221; MCEWAN AG, 1987, ARCH MICROBIOL, V147, P340, DOI 10.1007/BF00406130; Orme-Johnson N R, 1978, Methods Enzymol, V52, P252; SATOH T, 1987, J BIOCHEM-TOKYO, V102, P191, DOI 10.1093/oxfordjournals.jbchem.a122032; SATOH T, 1976, ARCH MICROBIOL, V108, P265, DOI 10.1007/BF00454851; SPENCER ME, 1973, J BACTERIOL, V114, P563, DOI 10.1128/JB.114.2.563-570.1973; STEIFEL EI, 1966, J AM CHEM SOC, V88, P2956; STYRVOLD OB, 1984, ARCH MICROBIOL, V140, P74, DOI 10.1007/BF00409774; TOPICH J, 1983, INORG CHIM A-BIOINOR, V80, pL41, DOI 10.1016/S0020-1693(00)91242-8; VINCENT SP, 1978, BIOCHEM J, V171, P639, DOI 10.1042/bj1710639; WAHL RC, 1982, J BIOL CHEM, V257, P1354; WEINER JH, 1988, J BACTERIOL, V170, P1505, DOI 10.1128/jb.170.4.1505-1510.1988; WILLIAMSSMITH DL, 1977, BIOCHEM J, V167, P593, DOI 10.1042/bj1670593	49	101	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					45	51						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845974				2022-12-25	WOS:A1991EQ33900009
J	KIM, MY; LINARDIC, C; OBEID, L; HANNUN, Y				KIM, MY; LINARDIC, C; OBEID, L; HANNUN, Y			IDENTIFICATION OF SPHINGOMYELIN TURNOVER AS AN EFFECTOR MECHANISM FOR THE ACTION OF TUMOR-NECROSIS-FACTOR-ALPHA AND GAMMA-INTERFERON - SPECIFIC ROLE IN CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROMYELOCYTIC LEUKEMIA-CELLS; HL-60 CELLS; LINE; EXPRESSION; SPHINGOLIPIDS; TRANSCRIPTION; SPHINGOSINE; MODULATION; PLATELETS	The biochemical signaling mechanisms involved in transducting the effects of tumor necrosis factor-alpha (TNF-alpha) and gamma-interferon (gamma-IFN) on leukemia cell differentiation are poorly defined. Recent studies established the existence of a sphingomyelin cycle that operates in response to the action of vitamin D3 on HL-60 cells and that may transduce the effects of vitamin D3 on cell differentiation (Okazaki, T., Bell, R., and Hannun, Y. (1989) J. Biol. Chem. 264, 19076-19080). The effects of TNF-alpha and gamma-IFN on sphingomyelin turnover were determined, and the specificity and role of sphingomyelin hydrolysis in HL-60 human promyelocytic leukemia cells with 20% hydrolysis of sphingomyelin at 15 min, 40% hydrolysis at 30-60 min, and return to base line at 2 h. The hydrolyzed sphingomyelin (18 pmol/nmol total phospholipid) was accompanied by the concomitant generation of ceramide (11.2 pmol/nmol total phospholipid). Gamma-IFN also caused reversible hydrolysis of sphingomyelin with onset at 1 h and peak effect at 2 h. This sphingomyelin cycle appeared to be specific to the monocytic pathway of HL-60 differentiation, since it was not activated by retinoic acid or dibutyryl cAMP, inducers of granulocytic differentiation, nor with phorbol myristate acetate, an inducer of macrophage-like differentiation. Addition of synthetic ceramide or bacterial sphingomyelinase induced monocytic differentiation of HL-60 cells. Cell-permeable ceramide also caused prompt down-regulation of mRNa for the c-myc protooncogene. The time course of c-myc down-regulation was consistent with the action of ceramide as the mediator of TNF-alpha action. These results suggest that sphingomyelin turnover may be an important signaling mechanism transducing the actions of TNF-alpha, and gamma-IFN with specific function in cell differentiation.	DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University				obeid, lina/0000-0002-0734-0847	NIEHS NIH HHS [ES-00155] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K11ES000155] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALL ED, 1984, J CLIN INVEST, V73, P1072, DOI 10.1172/JCI111292; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1987, BLOOD, V70, P1233; FERRERO D, 1983, BLOOD, V61, P171; GRAZIANO RF, 1983, BLOOD, V61, P1215; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KISS Z, 1988, ARCH BIOCHEM BIOPHYS, V265, P38, DOI 10.1016/0003-9861(88)90368-2; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KRONKE M, 1987, P NATL ACAD SCI USA, V84, P469, DOI 10.1073/pnas.84.2.469; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; Maniatis T., 1982, MOL CLONING; MCCACHREN SS, 1988, BIOCHEM BIOPH RES CO, V151, P574, DOI 10.1016/0006-291X(88)90633-X; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MURAO S, 1983, CANCER RES, V43, P4989; NEWBURGER PE, 1981, CANCER RES, V41, P1861; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SUREWICZ WK, 1989, BIOCHEM BIOPH RES CO, V160, P126, DOI 10.1016/0006-291X(89)91630-6; TRINCHIERI G, 1986, J EXP MED, V164, P1206, DOI 10.1084/jem.164.4.1206; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	31	649	661	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					484	489						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845977				2022-12-25	WOS:A1991EQ33900071
J	DENSTMAN, S; HROMCHAK, R; GUAN, XP; BLOCH, A				DENSTMAN, S; HROMCHAK, R; GUAN, XP; BLOCH, A			IDENTIFICATION OF TRANSFERRIN AS A PROGRESSION FACTOR FOR ML-1 HUMAN MYELOBLASTIC-LEUKEMIA CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN KINASE-C; RECEPTOR EXPRESSION; PHORBOL DIESTERS; TRANSCRIPTIONAL REGULATION; SURFACE GLYCOPROTEIN; DIFERRIC TRANSFERRIN; NA+/H+ ANTIPORT; HL-60 CELLS; GROWTH; PROLIFERATION	We have previously demonstrated (Guan X.-P., Hromchak, R. A., and Bloch, A. (1989) Cancer Commun. 1, 111-115) that ML-1 human myeloblastic leukemia cells differentiate to monocyte/macrophage-like cells by the sequential action of competence and progression factors. Tumor necrosis factor-alpha, transforming growth factor-beta, and the phorbol ester tetradecanoylphorbol acetate were found to induce competence, whereas a 77-kDa glycoprotein (DF77) isolated from mitogen-stimulated human leukocyte-conditioned medium initiated progression. In this communication we show DF77 to be an isoform of human transferrin. Hemin or soluble iron complexes did not induce differentiation progression, suggesting that the participation of transferrin in ML-1 cell differentiation may not be related to its iron-carrying capacity.	ROSWELL PK CANC INST, GRACE CANC DRUG CTR,DEPT EXPTL THERAPEUT,RM 273, CARLTON & ELM STS, BUFFALO, NY 14263 USA	Roswell Park Cancer Institute					NCI NIH HHS [CA-09072, CA-36241] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036241] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ALCANTARA O, 1986, J CELL PHYSIOL, V129, P329, DOI 10.1002/jcp.1041290310; ALCANTARA O, 1989, J IMMUNOL, V142, P1719; CANA RS, 1976, STRUCTURE FUNCTION P, P53; CARCOLA M, 1990, BLOOD, V75, P1903; CHITAMBAR CR, 1983, J CLIN INVEST, V72, P1314, DOI 10.1172/JCI111087; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DILLNERCENTERLIND ML, 1979, EUR J IMMUNOL, V9, P942, DOI 10.1002/eji.1830091207; DORLAND L, 1977, FEBS LETT, V77, P15, DOI 10.1016/0014-5793(77)80183-X; ENNS CA, 1988, EXP CELL RES, V174, P89, DOI 10.1016/0014-4827(88)90144-9; FUJII Y, 1990, LEUKEMIA RES, V14, P941, DOI 10.1016/0145-2126(90)90105-I; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; Guan X P, 1989, Cancer Commun, V1, P111; GUAN XP, 1991, CANCER COMMUN-US, V3, P11; HASS R, 1989, EUR J CELL BIOL, V48, P282; HO PTC, 1989, CANCER RES, V49, P1989; HO PTC, 1986, BIOCHEM BIOPH RES CO, V138, P995, DOI 10.1016/S0006-291X(86)80594-0; HOFFBRAND AV, 1976, BRIT J HAEMATOL, V33, P517, DOI 10.1111/j.1365-2141.1976.tb03570.x; HONMA Y, 1986, CANCER RES, V46, P6311; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; ISHIKURA H, 1989, BLOOD, V73, P419; KENTON P, 1989, BIOCHIM BIOPHYS ACTA, V1014, P271, DOI 10.1016/0167-4889(89)90223-1; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL CB, 1947, ACTA CHEM SCAND, V1, P770, DOI 10.3891/acta.chem.scand.01-0770; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAY WS, 1987, J BIOL CHEM, V262, P16710; MAY WS, 1985, J MEMBRANE BIOL, V88, P205, DOI 10.1007/BF01871086; MULFORD CA, 1988, J BIOL CHEM, V263, P5455; NECKERS LM, 1986, CANCER INVEST, V4, P461, DOI 10.3109/07357908609017524; NECKERS LM, 1986, EXP CELL RES, V166, P151, DOI 10.1016/0014-4827(86)90515-X; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PHILLIPS JL, 1987, J CELL PHYSIOL, V132, P349, DOI 10.1002/jcp.1041320222; Putnam F. W., 1975, PLASMA PROTEINS STRU, V1, P265; PUTNAM FW, 1984, PLASMA PROTEINS, V9, P6; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; RUDLAND PS, 1977, BIOCHEM BIOPH RES CO, V75, P556, DOI 10.1016/0006-291X(77)91508-X; SUN IL, 1987, BIOCHEM BIOPH RES CO, V145, P467, DOI 10.1016/0006-291X(87)91344-1; SUN IL, 1988, BIOCHIM BIOPHYS ACTA, V938, P17, DOI 10.1016/0005-2736(88)90117-4; SUTHERLAND R, 1981, P NATL ACAD SCI-BIOL, V78, P4515, DOI 10.1073/pnas.78.7.4515; TAETLE R, 1987, BLOOD, V70, P852; TAETLE R, 1990, EXP HEMATOL, V18, P360; TAETLE R, 1985, J CLIN INVEST, V75, P1061, DOI 10.1172/JCI111768; TAKEDA K, 1983, CELL IMMUNOL, V79, P288, DOI 10.1016/0008-8749(83)90071-0; TEI I, 1982, BIOCHEM BIOPH RES CO, V107, P1419, DOI 10.1016/S0006-291X(82)80157-5; Testa U, 1985, Curr Top Hematol, V5, P127; TRAYNER ID, 1990, CANCER RES, V50, P7221; TROWBRIDGE IS, 1984, BIOCHEM PHARMACOL, V33, P925, DOI 10.1016/0006-2952(84)90447-7; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1986, BIOCHEM SOC SYMP, P117; YEH CJG, 1982, EXP CELL RES, V138, P429, DOI 10.1016/0014-4827(82)90192-6	52	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14873	14876						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869525				2022-12-25	WOS:A1991GB09700012
J	GUNWAR, S; BALLESTER, F; KALLURI, R; TIMONEDA, J; CHONKO, AM; EDWARDS, SJ; NOELKEN, ME; HUDSON, BG				GUNWAR, S; BALLESTER, F; KALLURI, R; TIMONEDA, J; CHONKO, AM; EDWARDS, SJ; NOELKEN, ME; HUDSON, BG			GLOMERULAR-BASEMENT-MEMBRANE - IDENTIFICATION OF DIMERIC SUBUNITS OF THE NONCOLLAGENOUS DOMAIN (HEXAMER) OF COLLAGEN-IV AND THE GOODPASTURE ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR ARCHITECTURE; GLOBULAR DOMAIN; ALPORT SYNDROME; PROTEINS; CHAIN; ELECTROPHORESIS; NEPHRITIS; LOCALIZATION; SEQUENCE	The noncollagenous (NC1) domain hexamer of glomerular basement membrane (GBM) collagen is composed of a multiplicity of monomeric and dimeric subunits, and specific subunits are the targets for anti-GBM autoantibodies of patients with Goodpasture (GP) syndrome. The identity of GBM monomers has been established and the alpha-3(IV)NC1 monomer identified as the one that binds GP antibodies (Gunwar, S., Saus, J., Noelken, M. E., and Hudson, B. G. (1990) J. Biol. Chem. 265, 5466-5469). In the present study, the chain origin of 25 dimeric components and the identity of those that bound the anti-GBM antibodies from two GP patients were determined. This was accomplished by NH2-terminal sequence analysis and immunoblotting analysis of dimeric components that were resolved by two-dimensional electrophoresis in combination with high pressure liquid chromatography. The results revealed that (alpha) the components are mainly homodimers of the NC1 domains of alpha-1, alpha-2, alpha-3, alpha-4, and probably alpha-5 chains of collagen IV, reflecting a specificity of protomer-protomer association and (b) each homodimer had several size and charge isoforms. The GP antibodies bound exclusively to both alpha-3(IV)NC1 monomers and dimers and not to other basement membrane constituents. These findings provided new insights about the structure of GBM collagen and together with our previous findings firmly established the alpha-3(IV) chain as the target for the anti-GBM antibodies that mediate glomerulonephritis and pulmonary hemorrhage in patients with Goodpasture syndrome.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66103 USA; UNIV KANSAS, MED CTR, DEPT MED, KANSAS CITY, KS 66103 USA; UNIV VALENCIA, DEPT BIOCHEM, E-46010 VALENCIA, SPAIN	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Valencia			Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Hudson, Billy/0000-0002-5420-4100	NCRR NIH HHS [1 S10RR0554-01] Funding Source: Medline; NIDDK NIH HHS [DK 18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, R37DK018381] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENJAMIN T, 1989, ELECTROPHORESIS, V10, P447, DOI 10.1002/elps.1150100702; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1990, J LAB CLIN MED, V115, P365; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; FREYTAG JW, 1976, BIOCHEM BIOPH RES CO, V72, P796; GLASSOCK RJ, 1986, KIDNEY, V3, P1014; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HARALSON MA, 1985, BIOCHEMISTRY-US, V24, P5972; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1991, IN PRESS NEPHROLOGY; KASHTAN CE, 1990, J LAB CLIN MED, V116, P508; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LUNSTRUM GP, 1988, J BIOL CHEM, V263, P18318; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISON KE, 1991, J BIOL CHEM, V266, P34; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; SAUS J, 1988, J BIOL CHEM, V263, P13374; SAVAGE COS, 1989, LAB INVEST, V60, P613; SEGELMARK M, 1990, IN PRESS NEPHROL DIA; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; TIMONEDA J, 1990, CONNECT TISSUE RES, V24, P169, DOI 10.3109/03008209009152147; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VANDERHEUVEL LPWJ, 1989, PEDIATR NEPHROL, V3, P406; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P3838, DOI 10.1073/pnas.81.12.3838; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; [No title captured]	34	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15318	15324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869555				2022-12-25	WOS:A1991GB09700074
J	BLOUNT, P; MERLIE, JP				BLOUNT, P; MERLIE, JP			CHARACTERIZATION OF AN ADULT MUSCLE ACETYLCHOLINE-RECEPTOR SUBUNIT BY EXPRESSION IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; TORPEDO-MARMORATA; EPSILON-SUBUNIT; DELTA-SUBUNIT; BINDING-SITE; ASSEMBLY INTERMEDIATE; NUCLEOTIDE-SEQUENCE; MESSENGER-RNAS; IMAGE-ANALYSIS; CDNA SEQUENCE	To study the functional and structural roles of the epsilon-subunit in adult muscle acetylcholine receptor (AChR), we have co-expressed the alpha and epsilon-subunits of the mouse receptor in transfected fibroblasts. Ligand binding studies suggest that association of epsilon with alpha-subunit results in a lower association rate constant for I-125-labeled alpha-bungarotoxin binding than that of the unassembled alpha-subunit, approaching that for toxin binding to the AChR. Furthermore, alpha-epsilon-complexes contain high affinity binding sites for competitive antagonists and agonists not present in the unassembled alpha-subunit, but similar to one of the two nonequivalent binding sites in the adult AChR. Structural analysis of alpha-epsilon-complexes by sucrose gradient velocity centrifugation suggests that some of the complexes formed are trimers or tetramers of alpha and epsilon-subunits. Comparison of these data with those previously obtained for alpha-gamma-complexes suggests that gamma and epsilon have homologous functional roles and identical structural positions in the fetal and adult AChRs, respectively.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)					NIGMS NIH HHS [2 T32 GM 07805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, IN PRESS CURR TOP ME, V39; BON F, 1984, J MOL BIOL, V176, P205, DOI 10.1016/0022-2836(84)90421-2; BOULTER J, 1985, J NEUROSCI, V5, P2545; BOULTER J, 1977, BIOCHEMISTRY-US, V16, P4900, DOI 10.1021/bi00641a025; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CONROY WG, 1990, J BIOL CHEM, V265, P21642; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DREYER F, 1976, PFLUG ARCH EUR J PHY, V367, P115, DOI 10.1007/BF00585146; GARDNER PD, 1990, NUCLEIC ACIDS RES, V18, P6714, DOI 10.1093/nar/18.22.6714; GU Y, 1988, J BIOL CHEM, V263, P12878; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; HAGGERTY JG, 1981, J BIOL CHEM, V256, P8294; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; KARLIN A, 1983, J BIOL CHEM, V258, P6678; Karlin A., 1980, CELL SURFACE NEURONA, P191; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KISTLER J, 1982, BIOPHYS J, V37, P371, DOI 10.1016/S0006-3495(82)84685-7; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; KUBO T, 1985, EUR J BIOCHEM, V149, P5, DOI 10.1111/j.1432-1033.1985.tb08885.x; KUROSAKI T, 1987, FEBS LETT, V214, P253, DOI 10.1016/0014-5793(87)80065-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGENBUCHCACHAT J, 1988, BIOCHEMISTRY-US, V27, P2337, DOI 10.1021/bi00407a015; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MERLIE JP, 1981, J BIOL CHEM, V256, P3605; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NEHER E, 1976, J PHYSIOL-LONDON, V258, P705, DOI 10.1113/jphysiol.1976.sp011442; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0; SINE SM, 1980, J BIOL CHEM, V255, P144; SINE SM, 1981, J BIOL CHEM, V256, P6692; TAKAI T, 1985, NATURE, V315, P761, DOI 10.1038/315761a0; WISE DS, 1981, J BIOL CHEM, V256, P2624; WITZEMANN V, 1987, FEBS LETT, V223, P104, DOI 10.1016/0014-5793(87)80518-5; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539; ZINGSHEIM HP, 1982, NATURE, V299, P81, DOI 10.1038/299081a0	52	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14692	14696						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860868				2022-12-25	WOS:A1991FZ35100089
J	HROMAS, R; COLLINS, SJ; HICKSTEIN, D; RASKIND, W; DEAVEN, LL; OHARA, P; HAGEN, FS; KAUSHANSKY, K				HROMAS, R; COLLINS, SJ; HICKSTEIN, D; RASKIND, W; DEAVEN, LL; OHARA, P; HAGEN, FS; KAUSHANSKY, K			A RETINOIC ACID-RESPONSIVE HUMAN ZINC FINGER GENE, MZF-1, PREFERENTIALLY EXPRESSED IN MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; SECONDARY-STRUCTURE; HUMAN-CHROMOSOMES; MULTIGENE FAMILY; BINDING DOMAINS; KRUPPEL FAMILY; PROTEIN; MOUSE; LOCALIZATION; SEQUENCE	Zinc finger genes encode metal-binding proteins that can act as transcriptional regulators of other genes. In an effort to identify activators of the genetic cascade in hemopoietic differentiation, we used degenerate synthetic oligonucleotides to the conserved zinc finger histidine-cysteine link to probe a human myeloid lambda-gt11 cDNA library. One of the cDNA clones obtained hybridized preferentially to mRNA from myeloid cells. This cDNA was used to isolate clones encompassing the coding region for this gene. Sequence analysis found 13 zinc finger regions and a glycine-proline-rich region between the fourth and fifth zinc finger domain. The gene was localized to chromosome 19q13.2-4, a chromosome that has a large cluster of zinc finger genes. The gene was preferentially expressed in myeloid leukemia cell lines with the highest mRNA levels noted in HL-60 cells induced to differentiate with retinoic acid. Thus, this new zinc finger gene (designated MZF-1) may be one regulator of transcriptional events during hemopoietic development.	FRED HUTCHINSON CANC RES CTR,DEPT MOLEC MED,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV CALIF LOS ALAMOS SCI LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; ZYMOGENET,SEATTLE,WA 98105	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; United States Department of Energy (DOE); Los Alamos National Laboratory; Zymogenet Inc.	HROMAS, R (corresponding author), INDIANA UNIV,MED CTR,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46202, USA.				NATIONAL CANCER INSTITUTE [R37CA016448, R01CA031615, R01CA016448] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16448, CA 31615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOWDHURY K, 1988, NUCLEIC ACIDS RES, V16, P9995, DOI 10.1093/nar/16.21.9995; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COLLINS SJ, 1987, BLOOD, V70, P1233; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DEAVEN LL, 1986, COLD SPRING HARB SYM, V51, P159, DOI 10.1101/SQB.1986.051.01.019; DRESSLER GR, 1988, TRENDS GENET, V4, P214, DOI 10.1016/S0168-9525(88)80003-9; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; HAGEN FS, 1988, BIOTECHNIQUES, V6, P340; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRANZ DM, 1985, SCIENCE, V227, P941, DOI 10.1126/science.3918347; LANIA L, 1990, GENOMICS, V6, P333, DOI 10.1016/0888-7543(90)90574-E; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; MAVILIO F, 1988, DIFFERENTIATION, V37, P773; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; OLIVER G, 1988, CELL, V55, P1017, DOI 10.1016/0092-8674(88)90246-2; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5465; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SCHWEIZER D, 1980, CYTOGENET CELL GENET, V27, P190, DOI 10.1159/000131482; THIESEN H-J, 1990, New Biologist, V2, P363; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879	44	176	179	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14183	14187						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860835				2022-12-25	WOS:A1991FZ35100012
J	WINTER, ML; LIEHR, JG				WINTER, ML; LIEHR, JG			FREE RADICAL-INDUCED CARBONYL CONTENT IN PROTEIN OF ESTROGEN-TREATED HAMSTERS ASSAYED BY SODIUM BORO[H-3]HYDRIDE REDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE SYRIAN-HAMSTERS; MICROSOMAL CYTOCHROME-P-450 SYSTEM; GLUTAMINE-SYNTHETASE; INACTIVATION; ESTRADIOL; ENZYMES	Oxidative damage to proteins is known to occur via conversion of side chain amino groups to corresponding carbonyl derivatives. Such damage to enzymes and purified proteins has been quantified previously by reduction with sodium boro[H-3]hydride and subsequent measurement of the incorporation of H-3 into amino acid fractions. In this study, the (NaBH4)-H-3 reduction assay was modified to permit the quantitation of free radical-mediated oxidative damage to proteins obtained from animals. Modifications included additional extractions of protein isolates with organic solvents to remove lipids and with nitric acid to remove metal ions. The modified assay has first been validated in vitro by measuring changes in levels of oxidative damage to bovine serum albumin exposed to xanthine plus xanthine oxidase (2-fold increase), to hydrogen peroxide and iron(II) sulfate (5-fold increase), or to gamma-radiation (30-fold increase over controls, respectively). Gamma-radiation of isolated hamster kidney protein also raised the carbonyl content in a dose-dependent manner. The modified assay has then been validated in vivo by measuring the changes in oxidative damage to lung tissue in animals exposed to approximately 85% oxygen (2-fold increase) or to different doses of paraquat (5-fold increase with the high dose over controls, respectively). The assay was then used to examine free radical-mediated oxidation introduced by acute or chronic treatment of hamsters with estrogens, since both synthetic and natural estrogens induce kidney tumors in this species. Priming of hamsters for 3 days with 20 mg/kg/day diethylstilbestrol and treatment with 100 mg/kg of this drug on the 4th day resulted in a 160% increase in free radical modification of renal proteins. Oxidative damage to kidney proteins was also assayed in hamsters treated with estradiol implants for up to 7 months, a regimen known to induce kidney tumors. Significant increases in covalent oxidative modification to renal proteins over values in age-matched controls were detected after 1, 2, and 7 months of continuous estradiol exposure. It is concluded that the modification of the (NaBH4)-H-3 reduction assay is a useful postlabeling method for monitoring free radical action in vivo. Furthermore, it is postulated that free radical damage in estrogen-treated hamster kidney plays a role in estrogen-induced car cinogenesis.	UNIV TEXAS, MED BRANCH, DEPT PHARMACOL & TOXICOL, GALVESTON, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston					NATIONAL CANCER INSTITUTE [R01CA043233, R37CA043233] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN SR, 1986, LANCET, V1, P11; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINGHAM KL, 1986, CHEST, V89, P859; DIZDAROGLU M, 1986, ANAL BIOCHEM, V156, P182, DOI 10.1016/0003-2697(86)90171-5; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; KALYANARAMAN B, 1985, ENVIRON HEALTH PERSP, V64, P185, DOI 10.2307/3430009; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASPER DL, 1986, NEW ENGL J MED, V314, P302, DOI 10.1056/NEJM198601303140508; KIM K, 1985, J BIOL CHEM, V260, P5394; KIRKMAN HADLEY, 1959, NAIL CANCER INST MONOGR, V1, P1; LEVINE RL, 1984, METHOD ENZYMOL, V107, P370; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LIEHR JG, 1986, J BIOL CHEM, V261, P6865; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; LIEHR JG, 1983, CANCER RES, V43, P4638; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; NAKAMURA K, 1985, ARCH BIOCHEM BIOPHYS, V240, P319, DOI 10.1016/0003-9861(85)90037-2; NANDI A, 1987, J BIOSCIENCE, V11, P435, DOI 10.1007/BF02704692; Oliver C.N., 1985, MODIFICATION PROTEIN, P39; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; ROY D, 1988, CANCER RES, V48, P5726; ROY D, 1988, J BIOL CHEM, V263, P3646; ROY D, 1989, CANCER RES, V49, P1475; SMITH P, 1976, CRC CR REV TOXICOL, V4, P411, DOI 10.1080/10408447609164020; STADTMAN ER, 1985, ARCH BIOCHEM BIOPHYS, V239, P379, DOI 10.1016/0003-9861(85)90703-9	29	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14446	14450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860852				2022-12-25	WOS:A1991FZ35100054
J	HUANG, S; AXELROD, DE				HUANG, S; AXELROD, DE			ALTERED POSTTRANSLATIONAL PROCESSING OF P21RAS ONCOPROTEIN IN A TRANSFORMATION-SUPPRESSED CELL-LINE	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; RAS PROTO-ONCOGENE; SACCHAROMYCES-CEREVISIAE; FATTY ACYLATION; GENE FAMILY; H-RAS; PROTEINS; HARVEY; IDENTIFICATION; MUTANT	We have isolated a transformation-suppressed cell line, R35, which is altered in the maturation of p21ras. It was obtained from the transformed cell line NIH3T3(ras(EJ)) as a revertant with flat morphology and anchorage dependent growth. Immunoprecipitation of steady state labeled ras proteins reveals that the revertant produces p21ras, and in addition, accumulates a protein that migrates as 23 kD. Fusion of revertant cells with non-transformed rat2 cells yields cell hybrids which are retransformed and do not accumulate p23, suggesting that accumulation of p23 and suppression of transformation may be related. The accumulated p23 appears to be a precursor to p21 because (1) pulse labeling and cell fractionation of revertant cells shows that label chases from cytoplasmic p23 to membrane-associated p21, although at a slower rate, and (2) the p23 of revertant cells is indistinguishable from the p23 precursor of p21 in parent cells by partial V8 protease digestion and two dimensional electrophoresis. R35 cells are slower than their transformed parent in palmitylation and polyisoprenylation, but not in methylation of ras proteins. These results suggest that the transformation-suppressed cell line R35 is defective in the rate at which it post-translationally processes ras proteins, possibly because it is slower in polyisoprenylation of the cytoplasmic p23 precursor protein.	RUTGERS STATE UNIV,WAKSMAN INST,POB 759,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick	AXELROD, DE (corresponding author), RUTGERS STATE UNIV,WAKSMAN INST,POB 759,PISCATAWAY,NJ 08855, USA.				NATIONAL CANCER INSTITUTE [R01CA042795] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Aswad DW, 1989, CURR OPIN CELL BIOL, V1, P1182, DOI 10.1016/S0955-0674(89)80069-9; BARBACID H, 1987, ANN REV BIOCH, V56, P779; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COLBY WW, 1986, MOL CELL BIOL, V6, P730, DOI 10.1128/MCB.6.2.730; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEE J, 1989, UNPUB; LEE J, 1985, J CELL BIOL, V101, pA116; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; POLONIS VR, 1987, ARCH BIOCHEM BIOPHYS, V254, P541, DOI 10.1016/0003-9861(87)90135-4; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	34	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1211	1218						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861867				2022-12-25	WOS:A1991GV26000017
J	LUCCHESI, PA; SWEADNER, KJ				LUCCHESI, PA; SWEADNER, KJ			POSTNATAL CHANGES IN NA,K-ATPASE ISOFORM EXPRESSION IN RAT CARDIAC VENTRICLE - CONSERVATION OF BIPHASIC OUABAIN AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; SPONTANEOUSLY HYPERTENSIVE RATS; BINDING-SITES; CATALYTIC SUBUNIT; NA+,K+-ATPASE ACTIVITY; DEVELOPMENTAL-CHANGES; NA+/K+-ATPASE; HEART-MUSCLE; ISOZYME; MYOCYTES	The cardiac glycoside sensitivity of the rat heart changes during postnatal maturation and in response to certain pathological conditions. The Na,K-ATPase is thought to be the receptor for cardiac glycosides, and there are three isozymes of its catalytic (alpha) subunit with different cardiac glycoside affinities: alpha-1 (low affinity) and alpha-2 and alpha-3 (high affinity). We examined the developmental expression of the alpha-subunit isozymes in rat ventricular membrane preparations by immunoblotting with isozyme-specific antibodies. The alpha-1 isozyme was present throughout all stages of maturation. A developmental switch from alpha-3 to alpha-2 occurred between 14 and 21 days after birth. Measurements of [H-3]ouabain binding and inhibition of Na,K-ATPase activity indicated that alpha-2 and alpha-3 should make equivalent contributions to ion pump capacity; in both neonatal and adult preparations, ouabain interacted with a single class of high-affinity binding sites (K(D) = 15 or 40 nM, respectively; B(max) = 4-5 pmol/mg protein), and at low concentrations produced a similar degree of Na,K-ATPase inhibition (25%). The results indicate that the developmental difference in cardiac glycoside sensitivity cannot be explained by quantitative differences in the proportion of high-affinity isozymes of the Na,K-ATPase. The switch from alpha-3 to alpha-2 coincides with other major changes in cardiac electrophysiology and calcium metabolism.	MASSACHUSETTS GEN HOSP, WELLMAN 4, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Lucchesi, Pamela A/E-3558-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008110, R01HL036271] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36271, HL08110] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1982, NATURE, V296, P167, DOI 10.1038/296167a0; AKERA T, 1986, EUR J PHARMACOL, V132, P137; BERREBIBERTRAND I, 1990, BIOCHIM BIOPHYS ACTA, V1021, P148, DOI 10.1016/0005-2736(90)90027-L; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRODSKY JL, 1990, AM J PHYSIOL, V258, pC803, DOI 10.1152/ajpcell.1990.258.5.C803; CHARLEMAGNE D, 1987, J BIOL CHEM, V262, P8941; CHARLEMAGNE D, 1986, J BIOL CHEM, V261, P185; COHEN NM, 1988, J PHYSIOL-LONDON, V406, P115, DOI 10.1113/jphysiol.1988.sp017372; DAVIDDUFILHO M, 1984, J CARDIOVASC PHARM, V6, P273, DOI 10.1097/00005344-198403000-00011; ERDMANN E, 1980, BIOCHEM PHARMACOL, V29, P3219, DOI 10.1016/0006-2952(80)90295-6; ERDMANN E, 1984, BASIC RES CARDIOL S, V79, P5; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FINET M, 1983, BRIT J PHARMACOL, V80, P751, DOI 10.1111/j.1476-5381.1983.tb10067.x; GRUPP I, 1985, J PHYSIOL-LONDON, V360, P149, DOI 10.1113/jphysiol.1985.sp015609; GRUPP IL, 1981, LIFE SCI, V29, P2789, DOI 10.1016/0024-3205(81)90539-7; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; Hickerson T W, 1988, Prog Clin Biol Res, V258, P223; HIRAKOW R, 1975, DEV PHYSL CORRELATES, P37; HOROWITZ B, 1990, J BIOL CHEM, V265, P14308; HSU YM, 1989, BIOCHEMISTRY-US, V28, P569, DOI 10.1021/bi00428a023; Jorgensen P L, 1974, Methods Enzymol, V32, P277; KAZAZOGLOU T, 1983, FEBS LETT, V164, P75, DOI 10.1016/0014-5793(83)80022-2; LANGER GA, 1975, CIRC RES, V36, P744, DOI 10.1161/01.RES.36.6.744; LEE SW, 1983, HYPERTENSION, V5, P682, DOI 10.1161/01.HYP.5.5.682; LELIEVRE LG, 1986, BIOCHEM PHARMACOL, V35, P3449, DOI 10.1016/0006-2952(86)90611-8; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCCHESI PA, 1990, J GEN PHYSIOL, V96, pA64; LYTTON J, 1985, J BIOL CHEM, V260, P75; MATSUDA T, 1984, J BIOL CHEM, V259, P3858; MCDONOUGH AA, 1987, AM J PHYSIOL, V253, pC862, DOI 10.1152/ajpcell.1987.253.6.C862; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NG YC, 1987, AM J PHYSIOL, V252, pH1016; NOEL F, 1984, BIOCHEM PHARMACOL, V33, P47, DOI 10.1016/0006-2952(84)90369-1; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; PAGE E, 1974, CIRC RES, V35, P12; SMITH T W, 1988, New England Journal of Medicine, V318, P358; SWEADNER KJ, 1987, P NATL ACAD SCI USA, V84, P8404, DOI 10.1073/pnas.84.23.8404; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; VORNANEN M, 1987, BASIC RES CARDIOL, V82, P82, DOI 10.1007/BF01907056; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; WATANABE T, 1988, ANAL BIOCHEM, V175, P284, DOI 10.1016/0003-2697(88)90390-9; WERDAN K, 1984, BIOCHEM PHARMACOL, V33, P1873, DOI 10.1016/0006-2952(84)90542-2	51	141	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9327	9331						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851176				2022-12-25	WOS:A1991FM03800100
J	MASUCCI, MT; PEDERSEN, N; BLASI, F				MASUCCI, MT; PEDERSEN, N; BLASI, F			A SOLUBLE, LIGAND-BINDING MUTANT OF THE HUMAN UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXTRACELLULAR-MATRIX DESTRUCTION; FIBROBLAST PROTEINASE-INHIBITOR; CELL-SURFACE UROKINASE; PROTEASE NEXIN-I; BOUND UROKINASE; MEDIATED INTERNALIZATION; MAMMALIAN-CELLS; U937 MONOCYTES; SARCOMA-CELLS; PRO-UROKINASE	A truncated version of the human urokinase plasminogen activator receptor has been obtained by in vitro mutagenesis by insertion of a premature nonsense codon in the urokinase plasminogen activator receptor cDNA. This results in a protein truncated immediately upstream of the region which appears to be required for membrane attachment of the receptor via a glycolipid anchor. The modified receptor cDNA inserted into an expression vector has been transfected into mouse LB6 cells. Transfectants produce a urokinase plasminogen activator (u-PA)-binding protein that is secreted into the medium. It can be cross-linked to iodinated ATF (amino-terminal fragment of u-PA) and can also inhibit binding of iodinated ATF to mouse LB6 cells that express the wild type human receptor. The soluble u-PA receptor will be used in a variety of experiments aimed at identifying the role and mechanism of u-PA in physiological and pathological invasive processes, as well as in therapeutical attempts to block or decrease cancer cell invasion and in general u-PA-mediated tissue destruction.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK	University of Copenhagen				MASUCCI, Maria Teresa/0000-0001-5213-6557; Blasi, Francesco/0000-0001-9406-1784				APPELLA E, 1987, J BIOL CHEM, V262, P4437; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAJPAI A, 1985, BIOCHEM BIOPH RES CO, V133, P994, DOI 10.1016/0006-291X(85)91234-3; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BERGMAN BL, 1986, P NATL ACAD SCI USA, V83, P996, DOI 10.1073/pnas.83.4.996; Blasi F, 1990, Semin Cancer Biol, V1, P117; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; CORSARO CM, 1981, SOMAT CELL GENET, V7, P603, DOI 10.1007/BF01549662; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEARING VJ, 1988, CANCER RES, V48, P1270; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; JAENICKE F, 1990, Fibrinolysis, V4, P69; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; REICH R, 1988, CANCER RES, V48, P3307; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86	38	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8655	8658						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851152				2022-12-25	WOS:A1991FM03800003
J	YEH, YC; CHANG, DY; MASIN, J; LU, AL				YEH, YC; CHANG, DY; MASIN, J; LU, AL			2 NICKING ENZYME-SYSTEMS SPECIFIC FOR MISMATCH-CONTAINING DNA IN NUCLEAR EXTRACTS FROM HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; BASE-PAIR; NUCLEOTIDE-SEQUENCE; MUTY GENE; STREPTOCOCCUS-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; EXCISION REPAIR; INVITRO; ENDONUCLEASE	We have identified two novel enzyme systems in human HeLa nuclear extracts that can nick at specific sites of DNA molecules with base mismatches, in addition to the T/G mismatch-specific nicking enzyme system (Wiebauer, K., and Jiricny, J. (1989) Nature 339, 234-236). One enzyme (called all-type) can nick all eight base mismatches with different efficiencies. The other (A/G-specific) nicks only DNA containing an A/G mismatch. The all-type enzyme can be separated from the T/G-specific and A/G-specific nicking enzymes by Bio-Rex 70 chromatography. Further purification on a DEAE-5PW column separated the A/G-specific nicking enzyme from the T/G-specific nicking enzyme. Therefore, at least three different enzyme systems are able to cleave mismatched DNA in HeLa nuclear extracts. The all-type and A/G-specific enzymes work at different optimal salt concentrations and cleave at different sites within the mismatched DNA. The all-type enzyme can only cleave at the first phosphodiester bond 5' to the mispaired bases. This enzyme shows nick disparity to only one DNA strand and may be involved in genetic recombination. The A/G-specific enzyme simultaneously makes incisions at the first phosphodiester bond both 5' and 3' to the mispaired adenine but not the guanine base. This enzyme may be involved in an A/G mismatch-specific repair similar to the Escherichia coli mutY (or micA)-dependent pathway.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOLEC & CELL BIOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NIGMS NIH HHS [GM 35132] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; DICKIE P, 1987, J BIOL CHEM, V262, P14826; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; FINCHAM JRS, 1970, MOL GEN GENET, V109, P309, DOI 10.1007/BF00267701; FUJII H, 1989, J BIOL CHEM, V264, P10057; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HOLLIDAY R, 1974, GENETICS, V78, P273; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; JENSCH F, 1989, EMBO J, V8, P4325, DOI 10.1002/j.1460-2075.1989.tb08619.x; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JONES M, 1987, CELL, V50, P621, DOI 10.1016/0092-8674(87)90035-3; KEMPER B, 1981, EUR J BIOCHEM, V115, P123; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LIEB M, 1986, GENETICS, V114, P1041; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; LU AL, 1990, J BACTERIOL, V172, P1232, DOI 10.1128/jb.172.3.1232-1240.1990; LU AL, 1988, GENETICS, V118, P593; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; Maniatis T., 1982, MOL CLONING; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; Maxam A M, 1980, Methods Enzymol, V65, P499; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PRUDHOMME M, 1989, J BACTERIOL, V171, P5332, DOI 10.1128/jb.171.10.5332-5338.1989; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; RADMAN M, 1986, ANNU REV GENET, V20, P523, DOI 10.1146/annurev.ge.20.120186.002515; RAPOSA S, 1987, GENETICS, V117, P381; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; SU SS, 1988, J BIOL CHEM, V263, P6829; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; WALDMAN AS, 1988, NUCLEIC ACIDS RES, V16, P10249, DOI 10.1093/nar/16.21.10249; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	43	73	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6480	6484						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848856				2022-12-25	WOS:A1991FE37300072
J	LIND, SE; SMITH, CJ				LIND, SE; SMITH, CJ			ACTIN IS A NONCOMPETITIVE PLASMIN INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-BINDING-PROTEIN; AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE ACTIN; FIBRIN CLOTS; STRUCTURAL PROTEINS; NATIVE PLASMINOGEN; LYSINE RESIDUES; GELSOLIN LEVELS; LUNG INJURY; ACTIVATOR	Actin, one of the most abundant cellular proteins, circulates at micromolar concentrations in peripheral blood. Because actin released from dying cells may be trapped in fibrin clots that form at sites of tissue injury, we examined the effects of actin upon lysis of fibrin clots in vitro. Incorporation of native rabbit skeletal muscle actin into fibrin clots slowed their rates of lysis for periods of up to 24 h, an effect not seen when comparable concentrations of human IgG or bovine serum albumin were added instead. Actins isolated from a variety of sources inhibited plasmin's hydrolysis of the synthetic substrate S-2251 in a noncompetitive manner, with a K(i) of a 0.6-3.1-mu-M. Inhibition was rapid, but covalent actin-plasmin complexes were not formed. Both epsilon-aminocaproic acid and tranexamic acid prevented actin's inhibition of plasmin, suggesting that accessible lysine residues of actin interact with the kringle (lysine-binding) regions of plasmin. Neither of the high-affinity actin-binding proteins of plasma (plasma gelsolin and vitamin D-binding protein) prevented actin from inhibiting plasmin. These findings suggest that actin released into the extracellular space following cell death may modulate plasmin action, and hence a number of plasmin-dependent biological responses, at sites of inflammation and tissue injury.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	LIND, SE (corresponding author), MASSACHUSETTS GEN HOSP,HEMATOL UNIT,COX BLDG,6TH FLOOR,BOSTON,MA 02114, USA.				NHLBI NIH HHS [HL 42457] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAKURA S, 1961, ARCH BIOCHEM BIOPHYS, V92, P140, DOI 10.1016/0003-9861(61)90228-4; BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CARRELL N, 1983, BLOOD, V62, P439; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; COLLEN D, 1976, EUR J BIOCHEM, V69, P209, DOI 10.1111/j.1432-1033.1976.tb10875.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; GOLDSCHMIDTCLERMONT PJ, 1988, GASTROENTEROLOGY, V94, P1454, DOI 10.1016/0016-5085(88)90686-5; GOLDSCHMIDTCLERMONT PJ, 1988, J CLIN INVEST, V81, P1519, DOI 10.1172/JCI113484; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HARPER KD, 1987, J CLIN INVEST, V79, P1365, DOI 10.1172/JCI112963; JANMEY PA, 1985, BIOCHIM BIOPHYS ACTA, V841, P151, DOI 10.1016/0304-4165(85)90016-9; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KAHN DR, 1981, BIOCHIM BIOPHYS ACTA, V668, P490, DOI 10.1016/0005-2795(81)90184-7; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KWAAN HC, 1958, CLIN SCI, V17, P361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKI K, 1974, BIOCHIM BIOPHYS ACTA, V371, P519, DOI 10.1016/0005-2795(74)90048-8; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEE WM, 1989, CIRC SHOCK, V28, P249; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; LIND SE, 1988, AM REV RESPIR DIS, V138, P429, DOI 10.1164/ajrccm/138.2.429; LU RC, 1981, BIOCHEMISTRY-US, V20, P5914, DOI 10.1021/bi00523a040; MARKUS G, 1978, J BIOL CHEM, V253, P727; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MEJEAN C, 1987, J IMMUNOL METHODS, V99, P129; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; MOROI M, 1976, J BIOL CHEM, V251, P5956; MOSHER DF, 1973, J BIOL CHEM, V248, P6896; MUI PTK, 1977, AM J PHYSIOL, V233, pH346, DOI 10.1152/ajpheart.1977.233.3.H346; MULLERTZ S, 1976, BIOCHEM J, V159, P545; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; RADCLIFFE R, 1983, BIOCHIM BIOPHYS ACTA, V743, P422, DOI 10.1016/0167-4838(83)90401-6; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SMITH DB, 1988, BLOOD, V72, P214; SMITH DB, 1988, AM J PATHOL, V130, P261; SMITH DB, 1987, J LAB CLIN MED, V110, P189; SOTTRUPJENSEN L, 1975, P NATL ACAD SCI USA, V72, P2577, DOI 10.1073/pnas.72.7.2577; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; VALI Z, 1982, J BIOL CHEM, V257, P2104; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x	52	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5273	5278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848244				2022-12-25	WOS:A1991FC21700086
J	CRUTE, JJ; LEHMAN, IR				CRUTE, JJ; LEHMAN, IR			HERPES-SIMPLEX VIRUS-1 HELICASE-PRIMASE - PHYSICAL AND CATALYTIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; DNA-BINDING PROTEIN; GENETIC-ANALYSIS; TYPE-1; POLYMERASE; REPLICATION; ORIGIN; IDENTIFICATION; COMPLEMENTATION; PURIFICATION	Herpes simplex virus type 1 (HSV-1) encodes a helicase-primase that consists of the products of the UL5, UL8, and UL52 genes (Crute, J. J., Tsurumi, T., Zhu, L., Weller, S. K., Olivo, P. D., Challberg, M. D., Mocarski, E. S. and Lehman, I. R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2186-2189). Further characterization of the three-subunit enzyme isolated from HSV-1-infected CV-1 cells shows it to be a heterotrimer, consisting of one polypeptide encoded by each of the UL5, UL8, and UL52 genes. Analysis of the primase and helicase components of the HSV-1 helicase-primase has shown that the primase component synthesizes oligoribonucleotide primers 8-12 nucleotides in length. The helicase component unwinds duplex DNA substrates at the rate of about two nucleotides/s, but only in the presence of the HSV-1-encoded single-stranded DNA binding protein. Thus, the HSV-1 helicase-primase contains the requisite enzymatic activities that permit it to function at the viral replication fork.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					NIAID NIH HHS [AI 26538] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APOSHIAN HV, 1962, J BIOL CHEM, V237, P519; BENPORAT T, 1977, J VIROL, V22, P734, DOI 10.1128/JVI.22.3.734-741.1977; BROOKS M, 1989, J BIOL CHEM, V264, P3602; CONAWAY RC, 1982, P NATL ACAD SCI USA, V79, P4584; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; EISENBERG S, 1975, J MOL BIOL, V99, P107, DOI 10.1016/S0022-2836(75)80162-8; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Kornberg A., 1980, DNA REPLICATION; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCHETTI ME, 1988, J VIROL, V62, P715, DOI 10.1128/JVI.62.3.715-721.1988; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; OSTERLUND M, 1982, GENE, V20, P121, DOI 10.1016/0378-1119(82)90093-2; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PURIFOY DJM, 1977, NATURE, V269, P621, DOI 10.1038/269621a0; RICHARDSON CC, 1987, UCLA S MOL CELL BIOL, V47, P151; ROIZMAN B, 1990, VIROLOGY 1990, P1795; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFER PA, 1973, VIROLOGY, V52, P57, DOI 10.1016/0042-6822(73)90398-X; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SPAETE RR, 1982, CELL, V30, P295, DOI 10.1016/0092-8674(82)90035-6; STOW ND, 1982, EMBO J, V1, P863, DOI 10.1002/j.1460-2075.1982.tb01261.x; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; WELLER SK, 1983, VIROLOGY, V130, P290, DOI 10.1016/0042-6822(83)90084-3; WELLER SK, 1983, J VIROL, V45, P354, DOI 10.1128/JVI.45.1.354-366.1983; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	34	83	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4484	4488						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847923				2022-12-25	WOS:A1991FA69400072
J	RADI, R; BECKMAN, JS; BUSH, KM; FREEMAN, BA				RADI, R; BECKMAN, JS; BUSH, KM; FREEMAN, BA			PEROXYNITRITE OXIDATION OF SULFHYDRYLS - THE CYTOTOXIC POTENTIAL OF SUPEROXIDE AND NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; NITROGEN-DIOXIDE; TISSUE-INJURY; FREE-RADICALS; L-ARGININE; MITOCHONDRIA; OXIDANTS; ANION; LUNG; ACID	Peroxynitrite anion (ONOO-) is a potent oxidant that mediates oxidation of both nonprotein and protein sulfhydryls. Endothelial cells, macrophages, and neutrophils can generate superoxide as well as nitric oxide, leading to the production of peroxynitrite anion in vivo. Apparent second order rate constants were 5,900 M-1.S-1 and 2,600-2,800 M-1.S-1 for the reaction of peroxynitrite anion with free cysteine and the single thiol of albumin, respectively, at pH 7.4 and 37-degrees-C. These rate constants are 3 orders of magnitude greater than the corresponding rate constants for the reaction of hydrogen peroxide with sulfhydryls at pH 7.4. Unlike hydrogen peroxide, which oxidizes thiolate anion, peroxynitrite anion reacts preferentially with the undissociated form of the thiol group. Peroxynitrite oxidizes cysteine to cystine and the bovine serum albumin thiol group to an arsenite nonreducible product, suggesting oxidation beyond sulfenic acid. Peroxynitrous acid was a less effective thiol-oxidizing agent than its anion, with oxidation presumably mediated by the decomposition products, hydroxyl radical and nitrogen dioxide. The reactive peroxynitrite anion may exert cytotoxic effects in part by oxidizing tissue sulfhydryls.	UNIV ALABAMA,DEPT ANESTHESIOL,619 19TH ST S,BIRMINGHAM,AL 35233; UNIV REPUBL MONTEVIDEO,SCH MED,DEPT BIOCHEM,MONTEVIDEO,URUGUAY; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35233	University of Alabama System; University of Alabama Birmingham; Universidad de la Republica, Uruguay; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Freeman, Bruce A/H-9342-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024388, R01NS024275] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40458] Funding Source: Medline; NINDS NIH HHS [NS24388, NS24275] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG DA, 1978, PHOTOCHEM PHOTOBIOL, V28, P743, DOI 10.1111/j.1751-1097.1978.tb07011.x; BABBS CF, 1989, FREE RADICAL BIO MED, V6, P493, DOI 10.1016/0891-5849(89)90042-7; BARTON JP, 1973, J CHEM SOC PERK T 2, P1547, DOI 10.1039/p29730001547; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BLOUGH NV, 1985, INORG CHEM, V24, P3504; BROWN WD, 1960, BIOCHIM BIOPHYS ACTA, V44, P365; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; ELLIOT AJ, 1989, CAN J CHEM, V62, P1831; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEMAN BA, 1983, J BIOL CHEM, V258, P2534; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; FREEMAN BA, 1982, LAB INVEST, V47, P412; FRIDOVICH I, 1986, ANNU REV PHYSIOL, V48, P693; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; ISLES TE, 1963, BIOCHEM J, V88, P84, DOI 10.1042/bj0880084; IYER KS, 1973, J BIOL CHEM, V248, P707; KING TP, 1960, J AM CHEM SOC, V82, P3355, DOI 10.1021/ja01498a031; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Mason RP, 1982, FREE RADICALS BIOL, V5, P161; MATSUBARA T, 1986, J CELL PHYSIOL, V127, P207, DOI 10.1002/jcp.1041270203; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MONCADA S, 1988, HYPERTENSION, V12, P365, DOI 10.1161/01.HYP.12.4.365; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PATEL JM, 1986, AM REV RESPIR DIS, V134, P1196; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; RADI R, 1991, IN PRESS ARCH BIOCH, V286; REED JW, 1974, J AM CHEM SOC, V96, P1248, DOI 10.1021/ja00811a062; ROSEN GM, 1984, P NATL ACAD SCI-BIOL, V81, P7269, DOI 10.1073/pnas.81.23.7269; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOLOVSKY M, 1969, BIOCHEMISTRY-US, V8, P4740, DOI 10.1021/bi00840a013; TORCHINSKY YM, 1981, SULFUR PROTEINS, P48; TORCHINSKY YM, 1981, SULFUR PROTEINS, P145; TORCHINSKY YM, 1981, SULFUR PROTEINS, P3; WEISS SJ, 1982, LAB INVEST, V47, P5	44	2397	2442	2	86	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4244	4250						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847917				2022-12-25	WOS:A1991FA69400037
J	SAMIEI, M; DAYAMAKIN, M; CLARKLEWIS, I; PELECH, SL				SAMIEI, M; DAYAMAKIN, M; CLARKLEWIS, I; PELECH, SL			PLATELET-ACTIVATING FACTOR-INDUCED AND THROMBIN-INDUCED STIMULATION OF P34CDC2-CYCLIN HISTONE H1-KINASE ACTIVITY IN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN KINASE-C; CELL-CYCLE; M-PHASE; POLYPHOSPHOINOSITIDE HYDROLYSIS; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; RABBIT PLATELETS; TRANSLOCATION; COMPONENT	Numerous studies of cell cycle control in dividing cells have pointed to the central role of a 34-kDa histone H1 kinase (p34cdc2) complexed with regulatory subunits known as cyclins. We now report that p34cdc2-cyclin may also participate in signal transduction in nonproliferating, terminally differentiated cells, in this instance during sheep platelet activation. Immunological evidence for the presence of a p34cdc2 cognant in sheep platelet cytosol was obtained with antipeptide antibodies raised against peptide sequences in the conserved PSTAIRE and C-terminus regions of murine cdc2. The immunoreactive 32-kDa protein was adsorbed onto p13suc1-Sepharose, which selectively binds p34cdc2. A 58-kDa protein that also bound to p13suc1-Sepharose was identified as cyclin A on the basis of its size and immunoreactivity with two different anticyclin peptide antibodies. The p34cdc12-cyclin A complex was regulated during platelet activation. Its histone H-1 phosphorylating activity was stimulated 2-fold in p13suc1-Sepharose extracts from platelets that had been exposed to platelet-activating factor or thrombin for 1 min prior to harvesting. Our findings imply that the p34cdc2-cyclin complex may serve alternative functions besides control of cell division.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HALL FL, 1991, IN PRESS CURR OPIN C; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PELECH SL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P100, DOI 10.1016/0167-4889(90)90179-H; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; SALARI H, 1990, BIOCHEM J, V267, P689, DOI 10.1042/bj2670689; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U	24	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14889	14892						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869529				2022-12-25	WOS:A1991GB09700016
J	GOLDSTEIN, J; LEHNHARDT, S; INOUYE, M				GOLDSTEIN, J; LEHNHARDT, S; INOUYE, M			INVIVO EFFECT OF ASPARAGINE IN THE HYDROPHOBIC REGION OF THE SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI; PEPTIDE; SECRETION; MEMBRANE; EXPORT; MUTATIONS; CONFORMATIONS; PRECURSOR; MUTANTS	On the basis of the biophysical studies on the synthetic mutant (Ile-8 --> Asn) OmpA signal peptide in the preceding paper (Hoyt, D. C., and Gierasch, L. M. (1991) J. Biol. Chem. 266, 14406-14412), the in vivo effects of the same mutation were examined by fusing the mutant OmpA signal sequence to Staphylococcus aureus nuclease or TEM beta-lactamase. The mutation in which the isoleucine residue at position 8 of the OmpA signal sequence of Escherichia coli was replaced with a neutral polar residue, asparagine, resulted in a defective signal peptide. The mutant signal sequence was unable to be processed, and the precursor molecule accumulated in the cytoplasmic as well as in the membrane fractions, indicating that the Ile-8 --> Asn OmpA signal sequence is not competent for translocating nuclease A or beta-lactamase across the membrane. This result is consistent with the in vitro studies on the Ile-8 --> Asn OmpA signal peptide, which indicated that the mutant signal peptide was unable to penetrate into the hydrophobic core of the lipid bilayer. Other asparagine or glutamine substitution mutations in the hydrophobic region of the OmpA signal sequence were also examined. Interestingly, the OmpA signal sequence with either Ile-8 --> Gln, Val-10 --> Asn, or Leu-12 --> Asn mutation was completely defective as the Ile-8 --> Asn OmpA signal sequence, while the Ile-6 --> Asn and Ala-9 --> Asn OmpA nucleases were able to be processed to secrete nuclease, although the processing occurred at a much slower rate than the wild-type OmpA nuclease. These results indicate that the defects depend on the position of the lesion in the hydrophobic core of the OmpA signal sequence.	RUTGERS STATE UNIV,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LN,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								BANKAITIS VA, 1984, CELL, V37, P243, DOI 10.1016/0092-8674(84)90320-9; BATENBURG AM, 1988, J BIOL CHEM, V263, P4202; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CORNELL DG, 1989, BIOCHEMISTRY-US, V28, P2789, DOI 10.1021/bi00433a008; DUFFAUD GD, 1985, CURR TOP MEMBR TRANS, V24, P65; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; FRENDL R, 1988, J BIOL CHEM, V263, P344; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GOLDSTEIN J, 1990, J BACTERIOL, V172, P1225, DOI 10.1128/jb.172.3.1225-1231.1990; HOYT DW, 1991, J BIOL CHEM, V266, P14406; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; INOUYE S, 1986, DNA RNA SYNTHESIS, P181; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAHNHARDT S, 1988, J BIOL CHEM, V263, P10300; LEHNHARDT S, 1987, J BIOL CHEM, V262, P1716; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; NAKAMURA K, 1982, J MOL APPL GENET, V1, P284; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; STADER J, 1986, J BIOL CHEM, V261, P5075; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; TANIGUCHI T, 1980, NATURE, V285, P547, DOI 10.1038/285547a0; TANJI Y, 1991, J BACTERIOL, V173, P1997, DOI 10.1128/jb.173.6.1997-2005.1991; VLASUK GP, 1983, J BIOL CHEM, V258, P7141	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14413	14417						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860848				2022-12-25	WOS:A1991FZ35100048
J	NAGAMATSU, S; NISHI, M; STEINER, DF				NAGAMATSU, S; NISHI, M; STEINER, DF			BIOSYNTHESIS OF ISLET AMYLOID POLYPEPTIDE - ELEVATED EXPRESSION IN MOUSE BETA-TC3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; INSULIN GENE; B-CELLS; HUMAN PROINSULIN; MESSENGER-RNA; RAT ISLETS; GLUCOSE; SECRETION; HORMONE; PREPROINSULIN	Islet amyloid polypeptide (IAPP) messenger RNA levels, biosynthesis, processing, and secretion were studied in cultured mouse beta-TC3 insulinoma cells. Northern blot analysis revealed that the size of IAPP mRNA (0.9 kb) in beta-TC3 cells was the same as that in normal mouse islets; IAPP mRNA was approximately 60% of the level of insulin mRNA in beta-TC3 cells. However, the ratio of synthesis of insulin to IAPP was approximately 6:1, suggesting that IAPP mRNA is not translated efficiently in these cells. Metabolic labeling of beta-TC3 cells with [H-3]leucine revealed the synthesis of both a precursor form of IAPP (pro-IAPP) of apparent M(r) 7400 and a mature form (IAPP)) of apparent M(r) 3900. In pulse-chase experiments, pro-IAPP could be shown to be processed to IAPP in a manner similar to proinsulin. The t1/2 for conversion of pro-IAPP to IAPP was about 25 min, faster than the t1/2 for proinsulin to insulin of 70 min. A significant proportion of newly synthesized IAPP and insulin precursors were secreted via a constitutive pathway from beta-TC3 cells. Possible effects of dexamethasone and forskolin on IAPP mRNA levels and biosynthesis were examined but no effects were observed. In conclusion, the IAPP gene is strongly expressed in beta-TC3 cells leading to the biosynthesis, proteolytic processing, and secretion of IAPP, a putative islet hormone.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago	NAGAMATSU, S (corresponding author), UNIV CHICAGO,DEPT BIOCHEM,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK-20595, DK-13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK013914, R37DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI M, 1987, SCIENCE, V235, P467, DOI 10.1126/science.3798121; BETSHOLTZ C, 1989, EXP CELL RES, V183, P473; BREIMER LH, 1988, BIOCHEM J, V255, P377, DOI 10.1042/bj2550377; BRETHERTONWATT D, 1989, DIABETOLOGIA, V32, P881, DOI 10.1007/BF00297454; BRUNSTEDT J, 1982, ACTA BIOL MED GER, V41, P1151; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK A, 1986, DIABETOLOGIA, V29, pA528; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FEHMANN HC, 1990, FEBS LETT, V262, P279, DOI 10.1016/0014-5793(90)80210-A; GIDDINGS SJ, 1985, DIABETES, V34, P235, DOI 10.2337/diabetes.34.3.235; GOLD G, 1982, J CLIN INVEST, V69, P554, DOI 10.1172/JCI110481; GOLD G, 1988, DIABETES, V37, P160, DOI 10.2337/diabetes.37.2.160; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; JOHNSON KH, 1988, AM J PATHOL, V310, P1; KAHN SE, 1990, DIABETES, V39, P634, DOI 10.2337/diabetes.39.5.634; KANATSUKA A, 1989, FEBS LETT, V259, P199, DOI 10.1016/0014-5793(89)81527-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFERT JD, 1989, P NATL ACAD SCI USA, V86, P3127; LERNMARK A, 1976, J CELL BIOL, V71, P606, DOI 10.1083/jcb.71.2.606; LUKINIUS A, 1989, DIABETOLOGIA, V32, P240, DOI 10.1007/BF00285291; MADSEN OD, 1991, MOL ENDOCRINOL, V5, P143, DOI 10.1210/mend-5-1-143; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NAGAMATSU S, 1990, DIABETES, V39, P871, DOI 10.2337/diabetes.39.7.871; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; NISHI M, 1990, J BIOL CHEM, V265, P4173; NISHI M, 1989, P NATL ACAD SCI USA, V86, P5738, DOI 10.1073/pnas.86.15.5738; SANKE T, 1988, J BIOL CHEM, V263, P17243; WELSH M, 1988, BIOMED BIOCHIM ACTA, V47, P299; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; WESTERMARK P, 1978, DIABETOLOGIA, V15, P417, DOI 10.1007/BF01219652; WESTERMARK P, 1977, LAB INVEST, V37, P212; WESTERMARK P, 1987, DIABETOLOGIA, V30, P887	35	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13737	13741						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856207				2022-12-25	WOS:A1991FY02700045
J	VOSS, H; WIRKNER, U; JAKOBI, R; HEWITT, NA; SCHWAGER, C; ZIMMERMANN, J; ANSORGE, W; PYERIN, W				VOSS, H; WIRKNER, U; JAKOBI, R; HEWITT, NA; SCHWAGER, C; ZIMMERMANN, J; ANSORGE, W; PYERIN, W			STRUCTURE OF THE GENE ENCODING HUMAN CASEIN KINASE-II SUBUNIT-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; SERINE THREONINE KINASES; DNA-BINDING PROTEINS; LARGE T-ANTIGEN; CATALYTIC SUBUNIT; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT; MOLECULAR-CLONING	Casein kinase II (CKII) is a ubiquitous serine/threonine protein kinase with numerous key functions in cell metabolism and growth. The human CKII has a tetrameric structure; two catalytic subunits (alpha and alpha') form the holoenzyme together with two presumably regulatory subunits (beta). The gene encoding CKII subunit-beta was isolated from human genomic DNA and analyzed for its primary structure using exclusively nonradioactive procedures. The gene was found to span 4.2 kilobase pairs and to be composed of seven exons. Exon sizes range from 76 (exon 5) to 329 base pairs (bp) (exon 1), intron sizes from 145 (intron V) to 965 bp (intron 11). All exon-intron junctional sequences conform to the canonical GT-AG rule. Primer extension analysis determined three transcription initiation sites, at 951, 919, and (minor) 840 bp upstream of the translation start site. The translation start is located early in the second exon; exon 1 is untranslated. The 3'-cleavage/polyadenylation signal sequence (AATAAA) is in the last exon at position 4173 bp relative to the first transcription initiation site. The coding sequence for CKII-beta comprises 648 nucleotides identical to the published CKII-beta-cDNA sequence (Jakobi, R., Voss, H., and Pyerin, W. (1989) Eur. J. Biochem. 183, 227-233). The upstream promoter region of the CKII-beta-gene contains multiple potential gene regulatory sequence elements, noticeable DNA structures, and the characteristics of a housekeeping gene (more than one transcription initiation site, lack of a TATA-box, presence of a CpG island, occurrence of multiple GC boxes and of nonstandard positioned CCAAT boxes). The CKII-beta-gene promotor shares common features with that of mammalian protein kinases and is closely related to the regulatory subunit gene promoter of cAMP-dependent protein kinase.	GERMAN CANC RES CTR, INST EXPTL PATHOL, W-6900 HEIDELBERG 1, GERMANY; EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL)			Ansorge, Wilhelm/AAN-8780-2020					ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; ANSORGE W, 1987, NUCLEIC ACIDS RES, V15, P4593, DOI 10.1093/nar/15.11.4593; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; COCHET C, 1983, J BIOL CHEM, V258, P1403; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; FEIGE JJ, 1983, BIOCHEMISTRY-US, V22, P1452, DOI 10.1021/bi00275a020; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRZLAFF J M, 1989, New Biologist, V1, P44; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HALEY J, 1987, ONCOGENE RES, V1, P375; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HU ED, 1990, J BIOL CHEM, V265, P5072; HUNTER T, 1988, COLD SPRING HARB SYM, V53, P131, DOI 10.1101/SQB.1988.053.01.019; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; JAKOBI R, 1988, ANAL BIOCHEM, V175, P196, DOI 10.1016/0003-2697(88)90378-8; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOPATZ I, 1990, NUCLEIC ACIDS RES, V18, P3639, DOI 10.1093/nar/18.12.3639; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LEEGWATER PAJ, 1986, EMBO J, V5, P381, DOI 10.1002/j.1460-2075.1986.tb04223.x; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LU XY, 1990, J BIOL CHEM, V265, P3293; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; Maniatis T, 1989, MOL CLONING; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLUMB MA, 1986, NUCLEIC ACIDS RES, V14, P7675, DOI 10.1093/nar/14.19.7675; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; PYERIN W, 1990, Journal of Cell Biology, V111, p342A; PYERIN W, 1988, BIOL CHEM H-S, V369, P896; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; VOSS H, 1990, NUCLEIC ACIDS RES, V18, P5314, DOI 10.1093/nar/18.17.5314; VOSS H, 1990, METHODS MOL CELL BIO, V1, P155; ZIMMERMANN J, 1990, NUCLEIC ACIDS RES, V18, P1067, DOI 10.1093/nar/18.4.1067	69	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13706	13711						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856204				2022-12-25	WOS:A1991FY02700040
J	KUSTERS, R; DOWHAN, W; DEKRUIJFF, B				KUSTERS, R; DOWHAN, W; DEKRUIJFF, B			NEGATIVELY CHARGED PHOSPHOLIPIDS RESTORE PREPHOE TRANSLOCATION ACROSS PHOSPHATIDYLGLYCEROL-DEPLETED ESCHERICHIA-COLI INNER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MALTOSE-BINDING PROTEIN; MODEL MEMBRANES; SIGNAL PEPTIDE; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; PLASMA-MEMBRANE; LEADER PEPTIDE; SECB PROTEIN; PHOE PROTEIN; EXPORT	Translocation of outer membrane precursor proteins across the Escherichia coli inner membrane is severely hampered in lipid biosynthetic mutants with strongly reduced phosphatidylglycerol (PG) levels (De Vrije, T., De Swart, R. L., Dowhan, W., Tommassen, J., and De Kruiiff, B. (1988) Nature 334, 173-175; Lill, R., Dowhan, W., and Wickner, W. (1990) Cell 60, 271-280). Two independent methods were used to demonstrate that anionic lipids by virtue of their negative headgroup charge are involved in membrane translocation of the precursor of the pore protein PhoE. Using a lipid transfer protein-based method we show that introduction from lipid vesicles of PG and other acidic phospholipids but not of phosphatidylcholine restores efficient translocation across the membrane of PG-depleted inner membrane vesicles. Moreover, translocation was found to be proportional to the PG content in vesicles isolated from strain HDL11 in which the PG content was altered by varying the synthesis of the PG-phosphate synthase.	STATE UNIV UTRECHT, INST MOLEC BIOL & MED BIOTECHNOL, 3584 CH UTRECHT, NETHERLANDS; UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77225 USA	Utrecht University; University of Texas System	KUSTERS, R (corresponding author), STATE UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, PADUALAAN 8, 3584 CH UTRECHT, NETHERLANDS.				NIGMS NIH HHS [GM 20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; ASAI Y, 1989, J BACTERIOL, V171, P6867, DOI 10.1128/jb.171.12.6867-6869.1989; BACALLAO R, 1986, J BIOL CHEM, V261, P2907; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; FANDL JP, 1987, P NATL ACAD SCI USA, V84, P7448, DOI 10.1073/pnas.84.21.7448; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GANNON PM, 1989, J BACTERIOL, V171, P813, DOI 10.1128/jb.171.2.813-818.1989; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LOPES J, 1972, J BACTERIOL, V109, P520, DOI 10.1128/JB.109.2.520-525.1972; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MIYAZAKI C, 1985, P NATL ACAD SCI USA, V82, P7530, DOI 10.1073/pnas.82.22.7530; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; POORTHUIS BJHM, 1983, METHOD ENZYMOL, V98, P592; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SATRE M, 1978, J BIOL CHEM, V253, P479; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SHIBUYA I, 1985, J BACTERIOL, V161, P1086, DOI 10.1128/JB.161.3.1086-1092.1985; VANDEENEN LLM, 1964, ADV LIPID RES, V2, P167; YEM DW, 1978, J BACTERIOL, V133, P1419, DOI 10.1128/JB.133.3.1419-1426.1978	42	124	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8659	8662						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851153				2022-12-25	WOS:A1991FM03800004
J	MINAMI, Y; STAFFORD, FJ; LIPPINCOTTSCHWARTZ, J; YUAN, LC; KLAUSNER, RD				MINAMI, Y; STAFFORD, FJ; LIPPINCOTTSCHWARTZ, J; YUAN, LC; KLAUSNER, RD			NOVEL REDISTRIBUTION OF AN INTRACELLULAR POOL OF CD45 ACCOMPANIES T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASES; LEUKOCYTE-COMMON ANTIGEN; INTEGRAL MEMBRANE-PROTEINS; RECEPTOR COMPLEX; MONOCLONAL-ANTIBODY; SIGNAL TRANSDUCTION; HUMAN-PLACENTA; ZETA-CHAIN; PHOSPHORYLATION; IDENTIFICATION	The major tyrosine phosphatase activity against angiotensin detected in membranes of the antigen-specific T cell hybridoma 2B4 is contained in the cytoplasmic tail of the CD45 molecule. When these cells are stimulated with either an antibody directed against the T cell antigen receptor or an activating anti-Thy-1 antibody, there is a rapid redistribution of CD45 in the cells. The redistribution can be observed in two ways: morphology and subcellular fractionation. Morphologic examination of resting cells reveals intense CD45 staining of the Golgi as well as surface staining. Upon activation the Golgi is rapidly cleared of CD45. This redistribution is specific for CD45 and is not observed for an intrinsic Golgi protein, mannosidase II, or a protein traversing the secretory pathway, the T cell receptor. In activated cells, in contrast to resting cells, approximately 30% of the total cellular CD45 is precipitated either at 280 x g or at 200,000 x g through a 2.2 M sucrose cushion after cell homogenization. This fraction is not accessible to cell surface labeling. CD45 redistribution does not require hydrolysis of phosphatidylinositides and cannot be reproduced by the addition of phorbol ester and calcium ionophore. It does require the presence of an intact functional T cell receptor on the cell surface. These studies suggest that the residence time of CD45 within an intracellular organelle can be acutely regulated by a signal mediated via the T cell receptor. This regulation may control access of this phosphatase to critical substrates.			MINAMI, Y (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; GARDNER P, 1989, J BIOL CHEM, V264, P1068; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HELLSTROM I, 1979, INT J CANCER, V23, P555, DOI 10.1002/ijc.2910230418; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1986, ENZYMES, V17, P191; JONES SW, 1989, J BIOL CHEM, V264, P7747; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUPFER A, 1984, J IMMUNOL, V133, P2762; LACAL P, 1988, J BIOL CHEM, V263, P9946; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LEE JK, 1988, CELL, V55, P807, DOI 10.1016/0092-8674(88)90136-5; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIMTUNG HT, 1987, ANAL BIOCHEM, V161, P412; MASON DL, 1985, BIOCHIM BIOPHYS ACTA, V829, P221, DOI 10.1016/0167-4838(85)90191-8; MERCEP M, 1988, SCIENCE, V242, P571, DOI 10.1126/science.2845582; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1746; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1987, J IMMUNOL, V139, P2708; SAMELSON LE, 1985, P NATL ACAD SCI USA, V82, P1969, DOI 10.1073/pnas.82.7.1969; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SAMELSON LE, 1983, P NATL ACAD SCI USA, V80, P6971; SHRINER CL, 1984, J BIOL CHEM, V259, P1383; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	46	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9222	9230						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851171				2022-12-25	WOS:A1991FM03800085
J	STEVERDING, D; KADENBACH, B				STEVERDING, D; KADENBACH, B			INFLUENCE OF N-ETHOXYCARBONYL-2-ETHOXY-1,2-DIHYDROQUINOLINE MODIFICATION ON PROTON TRANSLOCATION AND MEMBRANE-POTENTIAL OF RECONSTITUTED CYTOCHROME-C-OXIDASE SUPPORT PROTON SLIPPAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SUBUNIT-III; CHARGE TRANSLOCATION; INNER MEMBRANE; MOTIVE FORCE; H+-PUMPS; DICYCLOHEXYLCARBODIIMIDE; STOICHIOMETRY; CONDUCTANCE; LIPOSOMES	Bovine heart cytochrome-c oxidase was reconstituted in liposomes and modified with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). EEDQ reacted mainly with subunits II and III and to a lower extent with subunit I, as shown by difference labeling with [C-14]dicyclohexylcarbodiimide. EEDQ treatment of cytochrome-c oxidase vesicles influenced ferrocytochrome c-induced proton pumping by reducing maximally the H+/e- stoichiometry from 0.84 (control) to 0.24, but had only small effects on respiration, respiratory control ratio, and proton conductivity of the proteoliposomes. By titrating the reaction rate of the control and the modified cytochrome-c oxidase vesicles versus the membrane potential, as measured with a Ph3MeP+ electrode, saturation curves are obtained, which in both cases approach 225 mV. The ratios of electron transport rates of the two proton pumps at various membrane potentials decrease between 160 and 225 mV from about 2.2 to 1, indicating that the nonlinear flow/force relationship of these proton pumps is at least partly due to "slippage" of proton pumping.			STEVERDING, D (corresponding author), UNIV MARBURG,FACHBEREICH CHEM,HANS MEERWEIN STR,W-3550 MARBURG,GERMANY.		Steverding, Dietmar/A-6947-2010; Steverding, Dietmar/ABD-9452-2021	Steverding, Dietmar/0000-0002-0050-7771				Brautigan D L, 1978, Methods Enzymol, V53, P128; BROWN GC, 1989, J BIOL CHEM, V264, P14704; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; BROWN GC, 1986, BIOCHEM J, V234, P75, DOI 10.1042/bj2340075; CASEY RP, 1980, J BIOL CHEM, V255, P3994; CASEY RP, 1979, BIOCHEM BIOPH RES CO, V87, P1044, DOI 10.1016/S0006-291X(79)80013-3; CASEY RP, 1982, EUR J BIOCHEM, V122, P313, DOI 10.1111/j.1432-1033.1982.tb05882.x; Errede B, 1978, Methods Enzymol, V53, P40; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; MURPHY MP, 1988, EUR J BIOCHEM, V173, P637, DOI 10.1111/j.1432-1033.1988.tb14046.x; MURPHY MP, 1988, EUR J BIOCHEM, V173, P645, DOI 10.1111/j.1432-1033.1988.tb14047.x; MURPHY MP, 1987, NATURE, V329, P170, DOI 10.1038/329170a0; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; OKU N, 1982, BIOCHIM BIOPHYS ACTA, V691, P332, DOI 10.1016/0005-2736(82)90422-9; OSHEA PS, 1984, BIOCHEM J, V219, P719, DOI 10.1042/bj2190719; Papa S, 1979, Methods Enzymol, V55, P614; PIETROBON D, 1981, EUR J BIOCHEM, V117, P389, DOI 10.1111/j.1432-1033.1981.tb06350.x; PIETROBON D, 1983, BIOCHIM BIOPHYS ACTA, V723, P317, DOI 10.1016/0005-2728(83)90131-7; POUGEOIS R, 1978, BIOCHEMISTRY-US, V17, P3018, DOI 10.1021/bi00608a013; PROCHASKA LJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P360, DOI 10.1016/0005-2728(81)90175-4; PROCHASKA LJ, 1987, J BIOENERG BIOMEMBR, V19, P143, DOI 10.1007/BF00762722; PUETTNER I, 1985, J BIOL CHEM, V260, P3719; SARTI P, 1985, P NATL ACAD SCI USA, V82, P4876, DOI 10.1073/pnas.82.15.4876; SKULACHEV VP, 1988, MEMBRANE BIOENERGETI, P254; SORGATO C, 1979, BIOCHEMISTRY-US, V18, P5737; SUNDARAM PV, 1974, BIOCHEM BIOPH RES CO, V61, P717, DOI 10.1016/0006-291X(74)91016-X; WESTERHOFF HV, 1981, BIOCHEM J, V200, P193, DOI 10.1042/bj2000193; WILLIAMSON JR, 1981, J BIOL CHEM, V256, P7287; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004	30	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8097	8101						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850736				2022-12-25	WOS:A1991FK44100025
J	BLASCO, MA; BERNAD, A; BLANCO, L; SALAS, M				BLASCO, MA; BERNAD, A; BLANCO, L; SALAS, M			CHARACTERIZATION AND MAPPING OF THE PYROPHOSPHOROLYTIC ACTIVITY OF THE PHAGE-PHI-29 DNA-POLYMERASE - INVOLVEMENT OF AMINO-ACID MOTIFS HIGHLY CONSERVED IN ALPHA-LIKE DNA-POLYMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE PHI-29 DNA; I REACTION PATHWAY; ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; TERMINAL PROTEIN; REPLICATION; MECHANISM; INVITRO; INITIATION; FRAGMENT	The phi-29 DNA polymerase, an alpha-like DNA polymerase, shows an inorganic pyrophosphate-dependent degradative activity with similar requirements to the corresponding one of Escherichia coli DNA polymerase I: (a) it requires a high concentration of inorganic pyrophosphate and is reversed by polymerization; (b) like DNA polymerization, it needs a duplex DNA with protruding 5' single-strand; (c) it acts in the 3' to 5' direction releasing free dNTPs, thus, it can be considered as the reversal of polymerization; (d) although a correctly base-paired 3' primer terminus is the preferred substrate, the pyrophosphorolytic activity is able to remove mismatched 3' ends. In agreement with the structural and functional model previously proposed for the phi-29 DNA polymerase, the analysis of point mutations has revealed that the pyrophosphorolytic activity, like the polymerization activity, is located at the C-terminal portion of the molecule, involving the amino acid motif YCDTD, highly conserved in alpha-like DNA polymerases. Furthermore, the analysis of phi-29 DNA polymerase mutants indicates that pyrophosphorolysis, like DNA polymerization, also requires an efficient translocation of the enzyme along the template.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Blanco, Luis/I-1848-2015; Salas, Margarita/J-9873-2014; Bernad, Antonio/P-8573-2017; Blasco, Maria A./M-1694-2014	Salas, Margarita/0000-0001-5939-3441; Blasco, Maria A./0000-0002-4211-233X; Bernad, Antonio/0000-0003-0620-9668	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01-GM27242-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1985, NUCLEIC ACIDS RES, V13, P1239, DOI 10.1093/nar/13.4.1239; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1991, IN PRESS GENE AMST; BLASCO MA, 1990, NUCLEIC ACIDS RES, V18, P4763; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CHANG LMS, 1973, J BIOL CHEM, V248, P3398; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DEUTSCHER MP, 1969, J BIOL CHEM, V244, P3019; INCIARTE MR, 1976, EUR J BIOCHEM, V71, P77, DOI 10.1111/j.1432-1033.1976.tb11091.x; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; MIZRAHI V, 1986, P NATL ACAD SCI USA, V83, P231, DOI 10.1073/pnas.83.2.231; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; MIZRAHI V, 1986, P NATL ACAD SCI USA, V83, P5769, DOI 10.1073/pnas.83.16.5769; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; SALAS M, 1988, CURR TOP MICROBIOL, V136, P72; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TABOR S, 1990, J BIOL CHEM, V265, P8322; TABOR S, 1989, J BIOL CHEM, V264, P6447; WATABE K, 1984, P NATL ACAD SCI-BIOL, V81, P5374, DOI 10.1073/pnas.81.17.5374; YEE D, 1979, BIOCHEMISTRY-US, V18, P4116, DOI 10.1021/bi00586a009	29	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7904	7909						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850426				2022-12-25	WOS:A1991FJ34200091
J	FRAPPIER, L; ODONNELL, M				FRAPPIER, L; ODONNELL, M			OVERPRODUCTION, PURIFICATION, AND CHARACTERIZATION OF EBNA1, THE ORIGIN BINDING-PROTEIN OF EPSTEIN-BARR-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-ANTIGEN; DNA-BINDING; EXPRESSION VECTORS; HUMAN-CELLS; ESCHERICHIA-COLI; SV40 DNA; REPLICATION; SITES; PHOSPHORYLATION; SEQUENCE	The baculovirus expression system was used to overproduce the Epstein-Barr virus nuclear antigen, EBNA1, in insect cells. EBNA1 overproduced via baculovirus expression (baculoEBNA1) was followed during purification to homogeneity using its ability to specifically retain the family of repeats of the latent origin of replication, oriP, onto nitrocellulose filters. A two-column procedure was developed which yields more than 1 mg of homogeneous baculoEBNA1 from 9 x 10(8) insect cells (1.5 liters). Pure baculoEBNA1 had no detectable ATPase or helicase activity. BaculoEBNA1 was labeled with [P-32]orthophosphate in vivo, and analysis showed detectable levels of phosphoserine; no phosphothreonine or phosphotyrosine could be detected. The baculoEBNA1 appeared dimeric in solution, and a stoichiometry of 56 baculoEBNA1 monomers per 24 EBNA1 binding sites in oriP suggests baculoEBNA1 binds its consensus site as a dimer. The binding of baculoEBNA1 to the dyad symmetry element of oriP (K(d) approximately 2 nM) required more baculoEBNA1 and appeared less stable than the binding of baculoEBNA1 to the family of repeats in oriP (K(d) approximately 0.2 nM).	CORNELL UNIV,MED CTR,COLL MED,HEARST MICROBIOL DEPT,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA531-01] Funding Source: Medline; NCRR NIH HHS [S07 RR05396] Funding Source: Medline; NIGMS NIH HHS [R0I-GM38839] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHITTENDEN T, 1989, J VIROL, V63, P3016, DOI 10.1128/JVI.63.7.3016-3025.1989; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DONALDSON RW, 1987, P NATL ACAD SCI USA, V84, P759, DOI 10.1073/pnas.84.3.759; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAUSEN HZ, 1981, DNA TUMOR VIRUSES, P747; HEARING JC, 1985, VIROLOGY, V145, P105; JONES CH, 1989, J VIROL, V63, P101, DOI 10.1128/JVI.63.1.101-110.1989; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KLAUSING K, 1988, J VIROL, V62, P1258, DOI 10.1128/JVI.62.4.1258-1265.1988; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINDAHL T, 1976, J MOL BIOL, V102, P511, DOI 10.1016/0022-2836(76)90331-4; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATSON SW, 1986, J BIOL CHEM, V261, P169; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SHAW SB, 1981, VIROLOGY, V115, P88, DOI 10.1016/0042-6822(81)90091-X; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555, P27; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1988, CANCER CELL, V6, P197	38	136	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7819	7826						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850421				2022-12-25	WOS:A1991FJ34200079
J	ITO, M; IKEGAMI, Y; YAMAGATA, T				ITO, M; IKEGAMI, Y; YAMAGATA, T			ACTIVATOR PROTEINS FOR GLYCOSPHINGOLIPID HYDROLYSIS BY ENDOGLYCOCERAMIDASES - ELUCIDATION OF BIOLOGICAL FUNCTIONS OF CELL-SURFACE GLYCOSPHINGOLIPIDS INSITU BY ENDOGLYCOCERAMIDASES MADE POSSIBLE USING THESE ACTIVATOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDES; OLIGOSACCHARIDES; RECEPTOR; DIFFERENTIATION; GLYCOLIPIDS; CERAMIDE; BINDING; ACID; GM3	Endoglycoceramidase (EGCase) cleaves the linkage between oligosaccharides and ceramides of various glycosphingolipids (Ito, M., and Yamagata, T. (1986) J. Biol. Chem. 261, 14278-14282). Recently, by extensive purification, it was separated from cell-lytic factor (hemolysin) and found to consist of three molecular species each with its own specificity (EGCases I, II, and III) (Ito, M., and Yamagata, T. (1989) J. Biol. Chem. 264, 9510-9519). A detergent was required for EGCases to express full activity, possibly due to their hydrophobic nature, and thus EGCases cannot be used for research on live cells. This paper presents findings on activator proteins in the culture supernatant of Rhodococcus sp. M-777 regarding the stimulation of EGCase activity in the absence of detergents. The activator protein, exhaustively purified and designated as activator II in this study, showed a single protein band on sodium dodecyl sulfate-, native-, and isoelectrofocussing-polyacrylamide slab gel electrophoresis after being stained with Coomassie Brilliant Blue. Its molecular weight and pI were 69,200 and 4.0, respectively. The activator protein enhanced the hydrolysis of glycosphingolipids in vitro and on the cell-surface by EGCase II in the absence of detergents in a concentration-dependent manner. Interestingly, activator II stimulated the activity of EGCase II much more than that of EGCase I on using asialo-G(M1) as the substrate. This activator protein was found nonspecific to substrates susceptible to hydrolysis with EGCase II. Besides activator II, strain M-777 produced a second minor molecular species of activator protein designated as activator I which appeared specific for stimulating the activity of EGCase I in contrast to activator II. Following the addition of activator II, EGCase II hydrolyzed cell-surface glycosphingolipids quite efficiently at neutral pH at which hydrolysis hardly occurred at all in its absence. When using activator II in place of Triton X-100 for stimulating EGCase II activity, it was also noted to cause no damage to intact cells. It is thus possible by activator proteins to elucidate the biological functions of endogenous glycosphingolipids in situ by EGCases.			ITO, M (corresponding author), MITSUBISHI KASEI INST LIFE SCI,GLYCOCONJUGATE RES LAB,MACHIDA,TOKYO 194,JAPAN.			ito, Makoto/0000-0003-3159-7818				BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHERISH DA, 1986, J CELL BIOL, V102, P1898; FEIZI T, 1985, TRENDS BIOCHEM SCI, V10, P24, DOI 10.1016/0968-0004(85)90012-X; FISHMAN PH, 1982, J MEMBRANE BIOL, V69, P85, DOI 10.1007/BF01872268; FUKAYA N, 1989, BIOCHIM BIOPHYS ACTA, V1004, P108, DOI 10.1016/0005-2760(89)90220-8; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; HIGASHI H, 1987, J BIOCHEM-TOKYO, V102, P291, DOI 10.1093/oxfordjournals.jbchem.a122053; HIGASHI H, 1990, ANAL BIOCHEM, V186, P355, DOI 10.1016/0003-2697(90)90094-P; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; ITO M, 1990, METHOD ENZYMOL, V179, P488; ITO M, 1990, 15TH P INT CARB S YO, P241; ITO M, 1989, 10TH P INT S GLYC IS, P281; ITO M, 1990, P INT C BIOL FUNCTIO, P57; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P417, DOI 10.1093/nar/12.1Part1.417; KARLSSON KA, 1986, CHEM PHYS LIPIDS, V42, P153, DOI 10.1016/0009-3084(86)90050-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LI SC, 1981, J BIOL CHEM, V256, P6234; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LI YT, 1982, ADV CARBOHYDR CHEM B, V40, P281; Makita A., 1985, GLYCOLIPIDS, P1; MARCUS DM, 1984, MOL IMMUNOL, V21, P1083, DOI 10.1016/0161-5890(84)90118-4; Mehl E, 1964, Hoppe Seylers Z Physiol Chem, V339, P260, DOI 10.1515/bchm2.1964.339.1.260; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PARK JT, 1949, J BIOL CHEM, V181, P149; RASILO ML, 1989, BIOCHEM BIOPH RES CO, V162, P1093, DOI 10.1016/0006-291X(89)90785-7; SCHRODER M, 1989, FEBS LETT, V251, P197, DOI 10.1016/0014-5793(89)81454-1; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUZUKI Y, 1985, J BIOL CHEM, V260, P1362; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TSUJI S, 1985, J BIOCHEM-TOKYO, V97, P969, DOI 10.1093/oxfordjournals.jbchem.a135140; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; ZHOU B, 1989, J BIOL CHEM, V264, P12272	42	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7919	7926						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850427				2022-12-25	WOS:A1991FJ34200093
J	LIAO, K; HOFFMAN, RD; LANE, MD				LIAO, K; HOFFMAN, RD; LANE, MD			PHOSPHOTYROSYL TURNOVER IN INSULIN SIGNALING - CHARACTERIZATION OF 2 MEMBRANE-BOUND PP15 PROTEIN TYROSINE PHOSPHATASES FROM 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING PROTEIN; GROWTH FACTOR-I; CYTOSOLIC PROTEIN; GLUCOSE-TRANSPORT; KINASE-ACTIVITY; MESSENGER-RNAS; HUMAN-PLACENTA; RECEPTOR; PHOSPHORYLATION; PURIFICATION	It was shown previously that 422 (aP2) protein, a 15-kDa fatty acid binding protein, is phosphorylated on Tyr19 both in vitro by the insulin receptor tyrosine kinase and in intact 3T3-L1 adipocytes treated with insulin and phenylarsine oxide (PAO). Phospho-422(aP2) protein (pp15) accumulates in cells treated with insulin and PAO because the arsenical blocks turnover of the phosphoryl group of pp15. These findings suggest that a PAO-sensitive enzyme mediates turnover of the pp15 tyrosine phosphoryl group. We have purified and characterized two membrane protein tyrosine phosphatases (PTPases) from 3T3-L1 adipocytes that catalyze hydrolysis of phospho-Tyr19 of authentic pp15. These enzymes, designated PTPases HA1 and HA2, were purified approximately 20,000-fold and approximately 15,000-fold, respectively, and shown to differ markedly in their sensitivity to both vanadate and phosphotyrosine. Both enzymes are inhibited by PAO and accordingly can be labeled with 4-[I-125]iodo-PAO. By this method, it was demonstrated that PTPases HA1 and HA2 have molecular masses of approximately 60 kDa and approximately 38 kDa, respectively. Both enzymes exhibit substrate preference for pp15 when compared with other phosphotyrosine-containing protein substrates. Proteins containing phosphoserine and phosphothreonine do not serve as substrates for the enzymes. The pp15 PTPase HA2 is expressed both in 3T3-L1 preadipocytes and adipocytes, whereas pp15 PTPase HA1 is expressed only in 3T3-L1 adipocytes.			LIAO, K (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA.				NIDDK NIH HHS [NIDDK-14574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014574, R01DK014574] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; BEGUINOT F, 1987, DIABETES S1, V36, pA78; BERNIER M, 1988, J BIOL CHEM, V263, P13626; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHENG HF, 1989, BIOCHIM BIOPHYS ACTA, V998, P271, DOI 10.1016/0167-4838(89)90284-7; CHINANDER LL, 1989, J BIOL CHEM, V264, P19564; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DRAETTA G, 1989, J CELL SCI, P21; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FROST SC, 1985, J BIOL CHEM, V260, P2646; FROST SC, 1987, J BIOL CHEM, V262, P9872; GAMMELTOFT S, 1986, BIOCHEM J, V235, P1; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GUAN K, SCIENCE, V249, P553; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HRESKO RC, 1990, J BIOL CHEM, V265, P21075; HRESKO RC, 1988, P NATL ACAD SCI USA, V85, P8835, DOI 10.1073/pnas.85.23.8835; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; INGEBRITSEN TS, 1989, J BIOL CHEM, V264, P7754; JONES SW, 1989, J BIOL CHEM, V264, P7747; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAHN CR, 1985, MOL BASIS INSULIN AC, P67; KOHANSKI RA, 1986, J BIOL CHEM, V261, P2272; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; PERROTTI N, 1986, DIABETES, V35, pA9; RAIZISS GW, 1923, ACS MONOGR SER, V15, P130; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; REED BC, 1981, J BIOL CHEM, V256, P3917; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHRINER CL, 1984, J BIOL CHEM, V259, P1383; SIBLEY E, 1989, P NATL ACAD SCI USA, V86, P9732, DOI 10.1073/pnas.86.24.9732; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SWARUP G, 1989, J BIOL CHEM, V264, P7801; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	58	100	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6544	6553						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848858				2022-12-25	WOS:A1991FE37300081
J	KOCHEL, T; MUSHINSKI, JF; RICE, NR				KOCHEL, T; MUSHINSKI, JF; RICE, NR			THE V-REL AND C-REL PROTEINS EXIST IN HIGH-MOLECULAR-WEIGHT COMPLEXES IN AVIAN AND MURINE CELLS	ONCOGENE			English	Article							NF-KAPPA-B; VIRUS-STRAIN-T; TRANSFORMED LYMPHOID-CELLS; DNA-BINDING SUBUNIT; BONE-MARROW CELLS; RETICULOENDOTHELIOSIS VIRUS; ONCOGENE PRODUCT; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS	We reported previously that the v-rel protein (p59v-rel) exists in a high molecular weight complex with at least four other proteins in the cytoplasm of v-rel-transformed chicken pre-B lymphoid cells (Simek, S. & Rice, N.R., J. Virol., 62, 4730-4736, 1989). One of these proteins is the chicken c-rel protein, but the identities of the others (of about 36 kDa, 115kDa, and 124 kDa) are unknown. In this report we extend that observation to additional v-rel-transformed cell lines of both pre-B and B cell phenotypes. We also introduced and expressed v-rel in several other avian cell lines (a chicken T cell line, chick embryo fibroblasts, and quail fibroblasts) and found that in these cells p59v-rel was complexed with the same proteins as observed in the v-rel-transformed cells. Thus, the associated proteins are not limited to pre-B cells, but occur and complex with p59v-rel in B cells, T cells, and fibroblasts. We next examined five uninfected avian cells and tissues and found that, with only one exception, p75c-rel was complexed with p36, p115, and p124. Thus, in most cases complex formation is not limited to or dependent on the presence of the transforming v-rel protein, but also occurs with the normal c-rel protein. To determine whether a mammalian c-rel protein is similarly associated with other proteins, we screened murine cell lines for the presence of c-rel mRNA. In agreement with our earlier findings, we found the highest expression in mature B cells, although several pre-B and myeloid cell lines were also strongly positive. Using one of the B cell lines, we detected the murine c-rel protein. We found that, like its avian counterpart, it is a protein of about 75 kDa and is associated with proteins of 36 kDa and 115 kDa. Sephacryl S-400 chromatography revealed that both the avian and murine complexes are of high molecular weight, with an average size of about 400 kDa.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,FREDERICK,MD 21701; NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; CHEN L, 1988, P NATL ACAD SCI USA, V85, P549, DOI 10.1073/pnas.85.2.549; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DORN PL, 1988, J VIROL, V62, P3522, DOI 10.1128/JVI.62.9.3522-3526.1988; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; Maniatis T., 1982, MOL CLONING; MOORE BE, 1989, ONCOGENE, V4, P845; MORRISON LE, 1989, ONCOGENE, V4, P677; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSHINSKI JF, 1987, CANCER INVEST, V5, P345; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7; ZABELU, 1990, CELL, V61, P255	51	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					615	626						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851550				2022-12-25	WOS:A1991FR93900017
J	NAUSEEF, WM; VOLPP, BD; MCCORMICK, S; LEIDAL, KG; CLARK, RA				NAUSEEF, WM; VOLPP, BD; MCCORMICK, S; LEIDAL, KG; CLARK, RA			ASSEMBLY OF THE NEUTROPHIL RESPIRATORY BURST OXIDASE - PROTEIN-KINASE-C PROMOTES CYTOSKELETAL AND MEMBRANE ASSOCIATION OF CYTOSOLIC OXIDASE COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; NADPH-OXIDASE; PHOSPHOLIPASE-C; SUBCELLULAR-LOCALIZATION; MICROBICIDAL OXIDASE; PHAGOCYTIC-CELLS; HEAVY-CHAIN; 2 FORMS; ACTIVATION; PHOSPHORYLATION	Activated human polymorphonuclear neutrophils (PMNs) convert molecular oxygen into superoxide anion, a process known as the respiratory burst, through the activity of a latent multicomponent NADPH-dependent oxidase. Components of this respiratory burst oxidase include the membrane-bound cytochrome b558 and the cytosolic factors p47-phox and p67-phox. We initiated these studies based on three observations: 1) that stimulation of PMN oxidase activity is associated with translocation of the cytosolic oxidase components to the plasma membrane; 2) that p47-phox is phosphorylated during PMN activation and that there is a sequential relationship between phosphorylation of p47-phox in the cytosol and appearance of the phosphoprotein in the membrane; and 3) that the predicted amino acid sequences of p47-phox and of p67-phox contain regions of homology to the SH3 or A domain of the src family of tyrosine kinases, a region found in a variety of proteins which interact with the cytoskeleton or the subplasmalemmal cytoskeleton. Thus the purpose of our studies was to examine the role of protein kinase C (PKC)-dependent phosphorylation in the stimulus-induced association of p47-phox and p67-phox with the plasma membrane and the cytoskeleton. Using the PKC activator phorbol myristate acetate (PMA) as the agonist, we found that activation of the respiratory burst oxidase was associated with translocation of cytosolic p47-phox and p67-phox to the plasma membrane as well as redistribution of p47-phox to the Triton-insoluble cytoskeleton. Furthermore, the PKC inhibitor staurosporine inhibited phosphorylation of p47-phox, interrupted the redistribution of cytosolic oxidase factors, and blocked PMA-induced generation of superoxide anion. Taken together these results indicate that PKC-dependent phosphorylation of p47-phox correlates with association of p47-phox with the cytoskeleton and with translocation of p47-phox and p67-phox to the plasma membrane, with the ensuing assembly of an active superoxide-generating NADPH-dependent oxidase.	DEPT VET AFFAIRS,DEPT MED,IOWA CITY,IA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	NAUSEEF, WM (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,SW54,GH,IOWA CITY,IA 52242, USA.		Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619; Nauseef, William/0000-0003-4032-757X	NHLBI NIH HHS [HL-34327] Funding Source: Medline; NIAID NIH HHS [AI-28412, R01 AI020866, AI-20866, R37 AI020866] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412, R01AI020866, R37AI020866] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)		AMREIN PC, 1980, BLOOD, V56, P442; BABIOR BM, 1988, HEMATOL ONCOL CLIN N, V2, P201, DOI 10.1016/S0889-8588(18)30615-4; BADWEY JA, 1989, BIOCHEM BIOPH RES CO, V158, P1029, DOI 10.1016/0006-291X(89)92825-8; BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; Bennett V, 1990, CURR OPIN CELL BIOL, V2, P51, DOI 10.1016/S0955-0674(05)80030-4; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HEYWORTH PG, 1986, BIOCHEM J, V239, P723, DOI 10.1042/bj2390723; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; JUNCO M, 1990, FEBS LETT, V263, P169, DOI 10.1016/0014-5793(90)80731-W; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; MARTIN MA, 1988, J IMMUNOL, V140, P3928; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; NAUSEEF WM, 1983, BLOOD, V62, P635; NAUSEEF WM, 1990, BLOOD, V76, P2622; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PAWSON T, 1988, ONCOGENE, V3, P491; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; PONTREMOLI S, 1990, P NATL ACAD SCI USA, V87, P3705, DOI 10.1073/pnas.87.10.3705; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SATO T, 1988, CANCER RES, V48, P4646; SCHNEIDER C, 1981, FEBS LETT, V127, P4, DOI 10.1016/0014-5793(81)80327-4; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEVENSON KB, 1989, BLOOD, V74, P2136; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAUBER AI, 1987, BLOOD, V69, P711; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TEAHAN CG, 1990, BIOCHEM J, V267, P485, DOI 10.1042/bj2670485; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79	64	320	323	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5911	5917						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848559				2022-12-25	WOS:A1991FD37000086
J	SZEBENYI, G; ROTWEIN, P				SZEBENYI, G; ROTWEIN, P			DIFFERENTIAL REGULATION OF MANNOSE 6-PHOSPHATE RECEPTORS AND THEIR LIGANDS DURING THE MYOGENIC DEVELOPMENT OF C2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; AMINO-ACID SEQUENCES; BINDING-PROTEIN; IGF-I; LYSOSOMAL-ENZYMES; MESSENGER-RNA; INSULIN; EXPRESSION; CLONING; MUSCLE	The mammalian insulin-like growth factor II/cation-independent mannose 6-phosphate receptor (IGF-II/CIMPR) mediates both targeting and endocytosis of mannose 6-phosphate-containing proteins and binds insulin-like growth factor II (IGF-II). The cation-dependent mannose 6-phosphate receptor (CDMPR) lacks an IGF-II-binding site and participates only in the intracellular trafficking of lysosomal enzymes. During terminal differentiation of the myogenic C2 cell line, there is an increase in cell surface expression of the IGF-II/CIMPR in parallel with a rise in secretion of IGF-II (Tollefsen, S. E., Sadow, J. L., and Rotwein, P. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1543-1547). In this study we show that IGF-II/CIMPR mRNA increases by more than 10-fold during the initial 48 h of C2 muscle differentiation with kinetics similar to the rise in IGF-II mRNA. Comparable levels of both mRNAs are expressed in C2 myotubes and in primary cultures of fetal muscle. By contrast, no change is observed in CDMPR transcript abundance during differentiation, and only a small, transient increase is seen in the enzymatic activities and mRNA levels of several lysosomal enzymes. The differential regulation of the two mannose 6-phosphate receptors during muscle differentiation suggests that they may serve distinct functions in development.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV BIOL & BIOMED SCI,BOX 8127,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579, P60DK020579, R01DK042748] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20579, R01 DK042748] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDRIDES T, 1989, ENDOCRINOLOGY, V124, P1064, DOI 10.1210/endo-124-2-1064; BAPAT B, 1988, FEBS LETT, V237, P191, DOI 10.1016/0014-5793(88)80199-6; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; BROWN AL, 1986, J BIOL CHEM, V261, P3144; BRUALKE T, 1990, J BIOL CHEM, V265, P6650; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GAMMELTOFT S, 1985, EMBO J, V4, P3407, DOI 10.1002/j.1460-2075.1985.tb04097.x; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OBRIEN DA, 1989, ENDOCRINOLOGY, V125, P2973, DOI 10.1210/endo-125-6-2973; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; ROGERS SA, 1989, J BIOL CHEM, V264, P4273; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SHIMIZU M, 1986, AM J PHYSIOL, V251, pE611, DOI 10.1152/ajpendo.1986.251.5.E611; SKLAR MM, 1989, J BIOL CHEM, V264, P16733; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; WARREN L, 1989, J BIOL CHEM, V264, P8835; Woo S L, 1979, Methods Enzymol, V68, P389; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	43	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5534	5539						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848553				2022-12-25	WOS:A1991FD37000029
J	BRODER, CC; LOTTENBERG, R; VONMERING, GO; JOHNSTON, KH; BOYLE, MDP				BRODER, CC; LOTTENBERG, R; VONMERING, GO; JOHNSTON, KH; BOYLE, MDP			ISOLATION OF A PROKARYOTIC PLASMIN RECEPTOR - RELATIONSHIP TO A PLASMINOGEN-ACTIVATOR PRODUCED BY THE SAME MICROORGANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; UROKINASE RECEPTORS; POLYACRYLAMIDE GELS; FC-RECEPTORS; PROTEINS; CELLS; ANTIBODIES; METASTASIS; MEMBRANE; BINDING	Plasminogen receptors have been identified on the surface of a number of prokaryotic and eukaryotic cells. A receptor demonstrating high affinity for plasmin with minimal reactivity with the native zymogen Glu-plasminogen has been identified on the surface of certain group A streptococci. In this study the group A streptococcal plasmin receptor has been solubilized and purified to homogeneity. The isolated protein was an M(r) approximately 41,000 molecule which retained its ability to bind plasmin following solubilization and affinity purification on a column of enzymatically inactivated human plasmin. The isolated plasmin receptor was compared functionally, antigenically, and physiochemically to the secreted plasminogen activator, streptokinase, produced by the same organism. The M(r) approximately 41,000 surface plasmin receptor was shown to be functionally and antigenically distinct from the M(r) approximately 48,000 streptokinase molecule produced by the same strain and lacked any plasminogen activator activity. The streptokinase molecule produced by this strain was shown to be closely related to the plasminogen activator protein secreted by other group A and C streptococci. This study represents the first report of the isolation of a plasmin receptor, either prokaryotic or eukaryotic, with functional activity.	UNIV FLORIDA,COLL MED,DEPT IMMUNOL & MED MICROBIOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT MED,GAINESVILLE,FL 32610; LOUISIANA STATE UNIV,MED CTR,DEPT MICROBIOL IMMUNOL & PARASITOL,NEW ORLEANS,LA 70112; MED COLL OHIO,DEPT MICROBIOL,TOLEDO,OH 43699	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Louisiana State University System			Broder, Christopher/E-1169-2013		NHLBI NIH HHS [HL 41898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN B, 1988, BLOOD, V72, P1530; BAUER PI, 1984, BIOCHEM J, V218, P119, DOI 10.1042/bj2180119; BRODER CC, 1989, INFECT IMMUN, V57, P2597, DOI 10.1128/IAI.57.9.2597-2605.1989; BROESEKER TA, 1988, MICROB PATHOGENESIS, V5, P19, DOI 10.1016/0882-4010(88)90077-0; BURTIN P, 1988, J NATL CANCER I, V80, P762, DOI 10.1093/jnci/80.10.762; CHILES TC, 1987, ANAL BIOCHEM, V163, P136, DOI 10.1016/0003-2697(87)90103-5; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DESJARDIN LE, 1989, THROMB RES, V55, P187, DOI 10.1016/0049-3848(89)90435-0; DILLON HC, 1965, J EXP MED, V121, P351, DOI 10.1084/jem.121.3.351; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FISCHETTI VA, 1976, J EXP MED, V144, P32, DOI 10.1084/jem.144.1.32; FRANCIS CW, 1986, ANNU REV MED, V37, P197; GONIAS SL, 1989, BLOOD, V74, P729; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HUANG TT, 1989, INFECT IMMUN, V57, P502, DOI 10.1128/IAI.57.2.502-506.1989; JOHNSTON KH, 1986, J EXP MED, V163, P697, DOI 10.1084/jem.163.3.697; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KULISEK ES, 1989, ANAL BIOCHEM, V177, P78, DOI 10.1016/0003-2697(89)90017-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lancefield RC, 1928, J EXP MED, V47, P91, DOI 10.1084/jem.47.1.91; LIOTTA LA, 1981, THROMB RES, V21, P663, DOI 10.1016/0049-3848(81)90268-1; LIOTTA LA, 1981, CANCER RES, V41, P4629; LIU TY, 1965, J BIOL CHEM, V240, P1138; LOTTENBERG R, 1987, INFECT IMMUN, V55, P1914, DOI 10.1128/IAI.55.8.1914-1918.1987; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1988, BLOOD, V72, P628; NEILSEN LS, 1988, J BIOL CHEM, V263, P2358; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; REIS KJ, 1988, J IMMUNOL METHODS, V107, P273, DOI 10.1016/0022-1759(88)90228-1; REIS KJ, 1984, J IMMUNOL, V132, P3091; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SIEGALJL, 1981, INFECT IMMUN, V31, P303; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLBERG M, 1990, INFECT IMMUN, V58, P21, DOI 10.1128/IAI.58.1.21-25.1990; ULLBERG M, 1989, APMIS, V97, P996, DOI 10.1111/j.1699-0463.1989.tb00508.x; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WEINSTEIN L, 1953, P SOC EXP BIOL MED, V83, P689, DOI 10.3181/00379727-83-20460; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; YARNALL M, 1986, MOL CELL BIOCHEM, V70, P57	47	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4922	4928						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848229				2022-12-25	WOS:A1991FC21700040
J	MATHER, MW; SPRINGER, P; FEE, JA				MATHER, MW; SPRINGER, P; FEE, JA			CYTOCHROME-OXIDASE GENES FROM THERMUS-THERMOPHILUS - NUCLEOTIDE-SEQUENCE AND ANALYSIS OF THE DEDUCED PRIMARY STRUCTURE OF SUBUNIT-IIC OF CYTOCHROME-CAA3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; C-OXIDASE; PARACOCCUS-DENITRIFICANS; MITOCHONDRIAL GENOME; EXTREME THERMOPHILE; MEMBRANE-PROTEINS; DNA-SEQUENCE; LEISHMANIA-TARENTOLAE; RESPIRATORY PROTEINS; PSEUDOMONAS-STUTZERI	Cytochrome caa3, a cytochrome c oxidase from Thermus thermophilus, is a two-subunit enzyme containing the four canonical metal centers of cytochrome c oxidases (cytochromes a and a3; copper centers Cu(A) and Cu(B)) and an additional cytochrome c. The smaller subunit contains heme C and was termed the C-protein. We have cloned the genes encoding the subunits of the oxidase and determined the nucleotide sequence of the C-protein gene. The gene and deduced primary amino acid sequences establish that both the gene and the protein are fusions with a typical subunit II sequence and a characteristic cytochrome c sequence; we now call this subunit IIc. The protein thus appears to represent a covalent joining of substrate (cytochrome c) to its enzyme (cytochrome c oxidase). In common with other subunits II, subunit IIc contains two hydrophobic segments of amino acids near the amino terminus that probably for transmembrane helices. Variability analysis of the Thermus and other subunit II sequences suggests that the two putative transmembrane helices in subunit II may be located on the surface of the hydrophobic portion of the intact cytochrome oxidase protein complex. Also in common with other subunits II is a relatively hydrophilic intermembrane domain containing a set of conserved amino acids (2 cysteines and 2 histidines) which have previously been proposed by others to serve as ligands to the Cu(A) center. We compared the subunit IIc sequence with that of related proteins. N2O reductase of Pseudomonas stutzeri, a multi-copper protein that appears to contain a Cu(A) site (Scott, R. A., Zumft, W. G., Coyle, C. L., and Dooley, D. M. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 4082-4086), contains a 59-residue sequence element that is homologous to the "Cu(A) sequence motif" found in cytochrome oxidase subunits II, including all four putative copper ligands. By contrast, subunit II of the Escherichia coli quinol oxidase, cytochrome bo, also contains a region homologous to the Cu(A) motif, but it lacks the proposed metal binding histidine and cysteine residues; this is consistent with the apparent absence of Cu(A) from cytochrome bo.	UNIV CALIF LOS ALAMOS SCI LAB, STABLE ISOTOPE RESOURCE ISOTOPE & STRUCT CHEM GRP, LOS ALAMOS, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	MATHER, MW (corresponding author), UNIV CALIF LOS ALAMOS SCI LAB, BIOCHEM SECT, LOS ALAMOS, NM 87545 USA.			Mather, Michael/0000-0002-1062-0137	NIGMS NIH HHS [GM35342] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035342] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; AZZI A, 1990, ARCH BIOCHEM BIOPHYS, V280, P242, DOI 10.1016/0003-9861(90)90326-T; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BISSON R, 1982, J BIOL CHEM, V257, P6716; BISSON R, 1982, FEBS LETT, V144, P359, DOI 10.1016/0014-5793(82)80672-8; BOMBELKA E, 1986, BIOCHEM BIOPH RES CO, V140, P1007, DOI 10.1016/0006-291X(86)90735-7; BONEN L, 1984, EMBO J, V3, P2531, DOI 10.1002/j.1460-2075.1984.tb02168.x; BOWEN D, 1988, BIOCHEM J, V254, P509, DOI 10.1042/bj2540509; BROWN GG, 1982, P NATL ACAD SCI-BIOL, V79, P3246, DOI 10.1073/pnas.79.10.3246; BROWN NL, 1984, METHOD MICROBIOL, V17, P301; BURTON FH, 1988, GENE, V67, P159, DOI 10.1016/0378-1119(88)90393-9; BUSE G, 1989, EUR J BIOCHEM, V181, P261, DOI 10.1111/j.1432-1033.1989.tb14720.x; CANTATORE P, 1989, J BIOL CHEM, V264, P10965; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Clary D O, 1983, Nucleic Acids Res, V11, P4211, DOI 10.1093/nar/11.12.4211; CORUZZI G, 1979, J BIOL CHEM, V254, P9324; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CROFT JE, 1987, MOL GEN GENET, V210, P490, DOI 10.1007/BF00327202; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEBRUIJN MHL, 1983, NATURE, V304, P234, DOI 10.1038/304234a0; DELACRUZ VF, 1984, J BIOL CHEM, V259, P5136; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; ESPOSTI MD, 1989, ITAL J BIOCHEM, V38, P1; FEE JA, 1988, ANN NY ACAD SCI, V550, P33, DOI 10.1111/j.1749-6632.1988.tb35319.x; FEE JA, 1980, P NATL ACAD SCI-BIOL, V77, P147, DOI 10.1073/pnas.77.1.147; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENWOOD C, 1988, ANN NY ACAD SCI, V550, P47, DOI 10.1111/j.1749-6632.1988.tb35321.x; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HARTMANN RK, 1987, BIOCHIMIE, V69, P1097, DOI 10.1016/0300-9084(87)90009-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENSGENS LAM, 1984, NUCLEIC ACIDS RES, V12, P7327, DOI 10.1093/nar/12.19.7327; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; HONNAMI K, 1984, BIOCHEMISTRY-US, V23, P454, DOI 10.1021/bi00298a009; HORNE DS, 1988, BIOPOLYMERS, V27, P451, DOI 10.1002/bip.360270308; JACOBS HT, 1988, J MOL BIOL, V202, P185, DOI 10.1016/0022-2836(88)90452-4; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KLEIN P, 1986, BIOPOLYMERS, V25, P1659, DOI 10.1002/bip.360250909; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWSON JE, 1985, CURR GENET, V9, P351, DOI 10.1007/BF00421605; MACINO G, 1983, J BIOL CHEM, V258, P3230; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MARTIN CT, 1988, J BIOL CHEM, V263, P8420; MARTIN R, 1987, FOCUS, V9, P8; MATHER MW, 1988, BIOTECHNIQUES, V6, P444; MATHER MW, 1990, IN PRESS 41ST P MOSB; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MULLER M, 1988, BIOCHEMISTRY-US, V27, P7546; MULLER M, 1988, P NATL ACAD SCI USA, V85, P6647, DOI 10.1073/pnas.85.18.6647; NUNN DN, 1988, BIOCHEM J, V256, P673, DOI 10.1042/bj2560673; OBLAD M, 1989, BIOCHIM BIOPHYS ACTA, V975, P267, DOI 10.1016/S0005-2728(89)80257-9; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; PALMER G, 1987, PURE APPL CHEM, V59, P749, DOI 10.1351/pac198759060749; PHEIFFER BH, 1983, NUCLEIC ACIDS RES, V11, P7853, DOI 10.1093/nar/11.22.7853; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; RAMHARACK R, 1987, J BIOL CHEM, V262, P14014; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROE BA, 1985, J BIOL CHEM, V260, P9759; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1988, BIOCHIM BIOPHYS ACTA, V950, P303, DOI 10.1016/0167-4781(88)90126-1; SCOTT RA, 1989, P NATL ACAD SCI USA, V86, P4082, DOI 10.1073/pnas.86.11.4082; SEIDLER L, 1987, NUCLEIC ACIDS RES, V15, P9263, DOI 10.1093/nar/15.22.9263; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; SHERIDAN RP, 1985, BIOPOLYMERS, V24, P1995, DOI 10.1002/bip.360241011; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SONE N, 1983, FEBS LETT, V155, P150, DOI 10.1016/0014-5793(83)80228-2; SONE N, 1988, J BIOCHEM-TOKYO, V103, P606, DOI 10.1093/oxfordjournals.jbchem.a122314; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; STEINRUCKE P, 1987, EUR J BIOCHEM, V167, P431, DOI 10.1111/j.1432-1033.1987.tb13356.x; TITANI K, 1985, BIOCHEM BIOPH RES CO, V128, P781, DOI 10.1016/0006-291X(85)90115-9; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; VANDERSPEK H, 1990, EMBO J, V9, P257, DOI 10.1002/j.1460-2075.1990.tb08103.x; VANDERSPEK H, 1989, NUCLEIC ACIDS RES, V17, P4876, DOI 10.1093/nar/17.12.4876; VIEBROCK A, 1988, J BACTERIOL, V170, P4658, DOI 10.1128/jb.170.10.4658-4668.1988; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wikstrom M, 1985, ENZYMES BIOL MEMBR, V4, P111; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438; YOSHIDA T, 1984, J BIOL CHEM, V259, P1031; YOSHIDA T, 1984, J BIOL CHEM, V259, P112; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; ZIMMERMANN BH, 1988, P NATL ACAD SCI USA, V85, P5779, DOI 10.1073/pnas.85.16.5779	106	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5025	5035						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848234				2022-12-25	WOS:A1991FC21700054
J	STETTER, G; BRAUN, MA; MONTENARH, M				STETTER, G; BRAUN, MA; MONTENARH, M			A NEW DNA-BINDING ASSAY TO STUDY SUBCLASSES OF SV40 LARGE T-ANTIGEN BINDING TO INDIVIDUAL BINDING-SITES ON THE SV40 DNA	ONCOGENE			English	Article							LARGE-TUMOR-ANTIGEN; SIMIAN-VIRUS 40; PRODUCTIVELY INFECTED-CELLS; ORIGIN DNA; SV40-TRANSFORMED CELLS; TRANSCRIPTION INVITRO; REPLICATION INVITRO; MUTATIONAL ANALYSIS; REGULATORY MUTANTS; CONTROL REGION	SV40 large T antigen interacts specifically with three different sequences, termed sites I, II or III, within the control region of the SV40 DNA to regulate transcription as well as the initiation and progress of SV40 DNA replication. We have biotinylated three different DNAs containing either site I, II or III and immobilized these constructs on a streptavidin agarose matrix. All three immobilized DNAs were shown to bind T antigen from a total cell extract of SV40 infected monkey cells although with different affinities. Pulse chase experiments revealed that newly synthesized T antigen bound efficiently to all three binding sites whereas mature T antigen bound only to site I and site III DNA. The analysis of non-binding and DNA-bound T antigen on sucrose density gradients showed that only low molecular weight forms of T antigen were bound to all three immobilized DNAs. However, incubation of T antigen in the total cell extract with site I DNA resulted in high molecular weight forms of T antigen, indicating that the presence of site I DNA influences the quaternary structure of T antigen which might result in a detachment from the DNA.	UNIV ULM,DEPT BIOCHEM,W-7900 ULM,GERMANY	Ulm University			Montenarh, Mathias/AAB-6689-2020					ARTHUR AK, 1988, J VIROL, V62, P1999, DOI 10.1128/JVI.62.6.1999-2006.1988; BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, P99; DIMAIO D, 1980, J MOL BIOL, V140, P129, DOI 10.1016/0022-2836(80)90359-9; DIMAIO D, 1982, J MOL BIOL, V156, P531, DOI 10.1016/0022-2836(82)90265-0; DORN A, 1982, EUR J BIOCHEM, V128, P53; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; FANNING E, 1982, EMBO J, V1, P1023, DOI 10.1002/j.1460-2075.1982.tb01290.x; FIELDS BN, 1985, VIROLOGY; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIDONI D, 1982, J VIROL, V42, P456, DOI 10.1128/JVI.42.2.456-466.1982; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; JONES KA, 1984, EMBO J, V3, P3247, DOI 10.1002/j.1460-2075.1984.tb02286.x; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KLAUSING K, 1988, J VIROL, V62, P1258, DOI 10.1128/JVI.62.4.1258-1265.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEBLONDFRANCILLARD M, 1987, EUR J BIOCHEM, V166, P351, DOI 10.1111/j.1432-1033.1987.tb13522.x; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARGOLSKEE R, 1984, J VIROL, V49, P385; MASTRANGELO IA, 1985, P NATL ACAD SCI USA, V82, P3626, DOI 10.1073/pnas.82.11.3626; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MONTENARH M, 1983, J VIROL, V45, P531, DOI 10.1128/JVI.45.2.531-538.1983; MONTENARH M, 1986, FEBS LETT, V204, P51, DOI 10.1016/0014-5793(86)81386-2; MONTENARH M, 1980, FEBS LETT, V114, P107, DOI 10.1016/0014-5793(80)80870-2; MULLER D, 1987, VIROLOGY, V161, P81, DOI 10.1016/0042-6822(87)90173-5; Rigby P. W. J., 1983, ADV VIRAL ONCOL, V3, P31; RIO D, 1980, P NATL ACAD SCI-BIOL, V77, P5706, DOI 10.1073/pnas.77.10.5706; RUNZLER R, 1987, J VIROL, V61, P2076, DOI 10.1128/JVI.61.7.2076-2083.1987; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHELLER A, 1982, CELL, V29, P375, DOI 10.1016/0092-8674(82)90154-4; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SCHURMANN C, 1985, VIROLOGY, V146, P1, DOI 10.1016/0042-6822(85)90047-9; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SHORTLE DR, 1979, P NATL ACAD SCI USA, V76, P6128, DOI 10.1073/pnas.76.12.6128; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STETTER G, 1988, VIROLOGY, V164, P309, DOI 10.1016/0042-6822(88)90543-0; STETTER G, 1989, ONCOGENE, V4, P1353; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; TENEN DG, 1982, J MOL BIOL, V157, P473, DOI 10.1016/0022-2836(82)90472-7; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; VOGT B, 1986, J VIROL, V58, P765, DOI 10.1128/JVI.58.3.765-772.1986; WACHTER M, 1985, J VIROL, V56, P520, DOI 10.1128/JVI.56.2.520-526.1985; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643	58	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					389	396						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849245				2022-12-25	WOS:A1991FT34400006
J	AMBRUS, JL; CHESKY, L; CHUSED, T; YOUNG, KR; MCFARLAND, P; AUGUST, A; BROWN, EJ				AMBRUS, JL; CHESKY, L; CHUSED, T; YOUNG, KR; MCFARLAND, P; AUGUST, A; BROWN, EJ			INTRACELLULAR SIGNALING EVENTS ASSOCIATED WITH THE INDUCTION OF PROLIFERATION OF NORMAL HUMAN LYMPHOCYTES-B BY 2 DIFFERENT ANTIGENICALLY RELATED HUMAN B-CELL GROWTH-FACTORS (HIGH-MOLECULAR-WEIGHT B-CELL GROWTH-FACTOR (HMW-BCGF) AND THE COMPLEMENT FACTOR-BB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NECROSIS FACTOR-ALPHA; DIACYLGLYCEROL PRODUCTION; INTERLEUKIN-2 RECEPTORS; MONOCLONAL-ANTIBODY; ACTIVATION; HYDROLYSIS; CALCIUM; EXPRESSION; LINE	High molecular weight B cell growth factor (HMW-BCGF) and the complement component, Factor B, are antigenically related. HMW-BCGF and the physiologic Factor B activation fragment Bb, are both mitogenic for B lymphocytes and compete for binding to the B cell plasma membrane (Peters, M., Ambrus, J. L., Jr., Fauci, A., and Brown, E. (1988) J. Exp. Med. 168, 1225-1235). To understand which second messengers that occur after ligand-receptor interaction are associated with mitogenesis, we have examined the early signaling events after stimulation of activated B cells with these related growth factors. HMW-BCGF but not Bb increased [cAMP]i with a maximum between 45 and 60 min after stimulation. The increase in [cAMP]i was inhibited by indomethacin, suggesting that prostaglandin synthesis is involved in this response. Increase in [cAMP]i induced by HMW-BCGF, cholera toxin, or dibutyryl cAMP was associated with increased expression of the HMW-BCGF receptor, but there was no increase in proliferation of activated B cells when they were stimulated with cAMP agonists other than HMW-BCGF. These data suggest that cAMP is associated with regulation of receptor expression but is neither necessary nor sufficient for induction of proliferation. Both HMW-BCGF and Bb increased cellular levels of diacylglycerol and a water-soluble molecule which could be labeled with both [H-3]myoinositol and [C-14] glucosamine. However, only HMW-BCGF induced increases in intracellular calcium. Thus, two antigenically related B cell growth factors, HMW-BCGF and Bb, produce overlapping but distinct sets of second messengers after incubation with Sac-activated B cells. Since both induced increases in diacylglycerol and water-soluble inositol, one or both of these molecules may be involved in the proliferative signal generated by the related growth factors. In contrast, the increase in [cAMP]i caused by HMW-BCGF but not Bb is involved in the signal to increase HMW-BCGF receptor expression, but is unrelated to proliferation.	MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA; UNIV ALABAMA, DIV PULM & CRIT CARE MED, BIRMINGHAM, AL 35294 USA; WASHINGTON UNIV, ST LOUIS CHILDRENS HOSP, DIV NEWBORN MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MED, DIV INFECT DIS, ST LOUIS, MO 63130 USA	Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Alabama System; University of Alabama Birmingham; St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL)	AMBRUS, JL (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DEPT MED, DIV RHEUMATOL,660 S EUCLID, CAMPUS BOX 8045, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024674, R01AI024674] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24674] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBRUS JL, 1988, J IMMUNOL, V141, P861; AMBRUS JL, 1985, J CLIN INVEST, V75, P732, DOI 10.1172/JCI111754; AMBRUS JL, 1985, J EXP MED, V162, P1319, DOI 10.1084/jem.162.4.1319; AMBRUS JL, 1988, LYMPHOCYTE ACTIVATIO, P73; AMBRUS JL, 1987, MECHANISMS LYMPHOCYT, P163; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOWEN DL, 1986, J IMMUNOL, V136, P2158; BUTLER JL, 1983, J EXP MED, V157, P60, DOI 10.1084/jem.157.1.60; CAMPBELL RD, 1983, P NATL ACAD SCI-BIOL, V80, P4464, DOI 10.1073/pnas.80.14.4464; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHESKY L, 1989, FASEB J, V3, P1091; CHUSED TM, 1987, CYTOMETRY, V8, P396, DOI 10.1002/cyto.990080409; COLLE JH, 1990, CRIT REV IMMUNOL, V10, P259; DEFRANCE T, 1986, J IMMUNOL, V137, P3861; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DELFRAISSY JF, 1986, EUR J IMMUNOL, V16, P1251, DOI 10.1002/eji.1830161011; DUTTON RW, 1975, TRANSPLANT REV, V23, P66; FALKOFF RM, 1982, J IMMUNOL METHODS, V50, P39, DOI 10.1016/0022-1759(82)90302-7; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GORDON J, 1988, IMMUNOLOGY, V65, P493; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARADA H, 1983, J IMMUNOL, V131, P238; HAYNES BF, 1981, J IMMUNOL, V126, P1409; IRVINE RF, 1985, BIOCHEM J, V229, P505, DOI 10.1042/bj2290505; JELINEK DF, 1987, J IMMUNOL, V139, P2970; JELINEK DF, 1987, ADV IMMUNOL, V40, P1, DOI 10.1016/S0065-2776(08)60237-0; KACICH RL, 1988, MOL ENDOCRINOL, V2, P73, DOI 10.1210/mend-2-1-73; KEHRL JH, 1984, IMMUNOL REV, V78, P75, DOI 10.1111/j.1600-065X.1984.tb00477.x; KEHRL JH, 1987, J EXP MED, V166, P786, DOI 10.1084/jem.166.3.786; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; MEHTA SR, 1985, J IMMUNOL, V135, P3298; MURAGUCHI A, 1982, J IMMUNOL, V129, P1104; MURAGUCHI A, 1984, J IMMUNOL, V133, P1283; MURAGUCHI A, 1985, J EXP MED, V161, P181, DOI 10.1084/jem.161.1.181; NAKAGAWA T, 1988, J IMMUNOL, V140, P465; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PARKER DC, 1979, J IMMUNOL, V123, P931; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PETERS MG, 1988, J EXP MED, V168, P1225, DOI 10.1084/jem.168.4.1225; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANSOM JT, 1988, J IMMUNOL, V140, P3150; RANSOM JT, 1986, J IMMUNOL, V136, P66; ROMERO G, 1990, P NATL ACAD SCI USA, V87, P1476, DOI 10.1073/pnas.87.4.1476; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SHEARER WT, 1988, J IMMUNOL, V141, P1678; SPIEGEL A, 1988, RECENT PROG HORM RES, V44, P337; UCKUN FM, 1989, J CLIN INVEST, V84, P1595, DOI 10.1172/JCI114337; VAZQUEZ A, 1987, J IMMUNOL, V139, P2344; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; YAMASHITA T, 1987, J BIOL CHEM, V262, P5536	53	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3702	3708						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847385				2022-12-25	WOS:A1991EY68200055
J	IKEDASAITO, M; SHELLEY, DA; LU, L; BOOTH, KS; CAUGHEY, WS; KIMURA, S				IKEDASAITO, M; SHELLEY, DA; LU, L; BOOTH, KS; CAUGHEY, WS; KIMURA, S			SALICYLHYDROXAMIC ACID INHIBITS MYELOPEROXIDASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLEEN GREEN HEMEPROTEIN; INTESTINAL PEROXIDASE; LIGAND-BINDING; LACTOPEROXIDASE; SPECTROSCOPY; CHLORIDE; DIFFERENCE; COMPLEXES; SITE	Salicylhydroxamic and benzohydroxamic acids were found to bind to the resting state of myeloperoxidase and inhibit ligand binding to the heme iron. An ionizable group on the enzyme with pK(a) = 4 affects salicylhydroxamic acid binding; binding occurs when this group is not protonated. The binding of the heme iron ligands (e.g. cyanide, nitrite, and chloride) is probably controlled by the same ionizable group. The equilibrium dissociation constant of the salicylhydroxamic acid-myeloperoxidase complex is about 2 x 10(-6) M, and the association rate constant is 7.4 x 10(6) M-1.S-1. Salicylhydroxamic acid serves as a donor to the higher oxidation state of myeloperoxidase and thereby inhibits guaiacol oxidation. Salicylhydroxamic acid was also found to bind to intestinal peroxidase and lactoperoxidase. Salicylhydroxamic acid binding to all three mammalian peroxidases was about 3 orders of magnitude stronger than benzohydroxamic acid binding. We conclude that the salicylhydroxamic and benzohydroxamic acids bind in the distal heme cavity of these peroxidases and interact with the heme ligand binding site.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523; NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892	Colorado State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	IKEDASAITO, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.		Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015		NHLBI NIH HHS [HL15890] Funding Source: Medline; NIGMS NIH HHS [GM 29492] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; BOOTH KS, 1989, BIOCHEM BIOPH RES CO, V160, P897, DOI 10.1016/0006-291X(89)92519-9; DAVIES B, 1989, BIOCHEM J, V258, P801, DOI 10.1042/bj2580801; DUGAD DB, 1990, J BIOL CHEM, V265, P7137; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HORI H, 1990, BIOCHEMISTRY-US, V29, P7106, DOI 10.1021/bi00482a023; HUMPHREYS JM, 1989, J GEN MICROBIOL, V135, P1187; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; IKEDASAITO M, 1989, J BIOL CHEM, V264, P4559; IKEDASAITO M, 1985, J BIOL CHEM, V260, P8301; IKEDASAITO M, 1987, BIOCHEMISTRY-US, V26, P4344, DOI 10.1021/bi00388a024; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; KIMURA S, 1978, ARCH BIOCHEM BIOPHYS, V189, P14, DOI 10.1016/0003-9861(78)90108-X; KIMURA S, 1979, ARCH BIOCHEM BIOPHYS, V198, P580, DOI 10.1016/0003-9861(79)90534-4; KITAGAWA T, 1983, BIOCHEMISTRY-US, V22, P2788, DOI 10.1021/bi00281a003; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; LUKAT GS, 1987, BIOCHEMISTRY-US, V26, P6927, DOI 10.1021/bi00396a011; MODI S, 1989, BIOCHIM BIOPHYS ACTA, V996, P214, DOI 10.1016/0167-4838(89)90250-1; PAUL KG, 1978, ACTA CHEM SCAND B, V32, P395, DOI 10.3891/acta.chem.scand.32b-0395; SAUNDERS BC, 1964, PEROXIDASE; SCHONBAUM GR, 1973, J BIOL CHEM, V248, P502; SONO M, 1986, BIOCHIM BIOPHYS ACTA, V873, P62, DOI 10.1016/0167-4838(86)90190-1; TAYLOR KL, 1990, J BIOL CHEM, V265, P15938; THANABAL V, 1987, J AM CHEM SOC, V109, P7519	25	58	58	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3611	3616						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847381				2022-12-25	WOS:A1991EY68200042
J	SIPE, DM; JESURUM, A; MURPHY, RF				SIPE, DM; JESURUM, A; MURPHY, RF			ABSENCE OF NA+,K+-ATPASE REGULATION OF ENDOSOMAL ACIDIFICATION IN K562 ERYTHROLEUKEMIA-CELLS - ANALYSIS VIA INHIBITION OF TRANSFERRIN RECYCLING BY LOW-TEMPERATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MULTIVESICULAR BODIES; IRON UPTAKE; RAT-LIVER; KINETICS; PH; ENDOCYTOSIS; RECEPTOR; LINE; IDENTIFICATION; DISSOCIATION	Transferrin (Tf) acidification has been shown to be limited to pH 6 in murine Balb/c 3T3 fibroblasts, human A549 epidermoid carcinoma cells, and Chinese hamster ovary cells and is followed by alkalinization during recycling. In contrast, Tf acidification in the human erythroleukemic cell line K562 proceeds to below pH 5.5, and alkalinization of internal Tf during recycling is not observed. To explore the regulation of endosomal pH in K562 cells, we determined whether the existence of an early endosome of pH 6 could be demonstrated in K562 cells. The kinetics of Tf internalization, acidification, and recycling were determined at temperatures which block recycling of Tf in 3T3 cells. As in 3T3, Tf recycling in K562 was inhibited at 24-degrees-C and below. At these temperatures, Tf internalization and acidification were delayed relative to 37-degrees-C, yet the minimum pH achieved was below 5.5. Temperatures at or below 19-degrees-C resulted in a complete block in recycling (at least over 40 min), which was rapidly reversible by incubation at 37-degrees-C. Ouabain (a specific inhibitor of the Na+,K+-ATPase) had no effect on K562 Tf acidification, indicating that K562 endosomal pH is probably not regulated by the Na+,K+-ATPase. The results suggest that differentiation of the early endocytic pathway in erythroid cells involves changes such that the pH of Tf-containing compartments is not limited to 6 by the Na+,K+-ATPase.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,4400 5TH AVE,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,CTR FLUORESCENCE RES BIOMED SCI,PITTSBURGH,PA 15213	Carnegie Mellon University; Carnegie Mellon University					NIGMS NIH HHS [GM08067, GM32508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; HARDING CV, 1990, EUR J IMMUNOL, V20, P323, DOI 10.1002/eji.1830200214; HUEBERS HA, 1987, PHYSIOL REV, V67, P521; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; IACOPETTA BJ, 1983, J BIOL CHEM, V258, P9108; JANDL JH, 1963, J CLIN INVEST, V42, P314, DOI 10.1172/JCI104718; KIELIAN MC, 1986, EMBO J, V5, P3103, DOI 10.1002/j.1460-2075.1986.tb04616.x; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MORGAN EH, 1981, MOL ASPECTS MED, P1; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; MURPHY RF, 1988, ADV CELL BIOL, V2, P159; OKA JA, 1983, J BIOL CHEM, V258, P253; PATERSON S, 1984, J CELL PHYSIOL, V120, P225, DOI 10.1002/jcp.1041200217; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROEDERER M, 1990, EUR J CELL BIOL, V51, P229; ROEDERER M, 1986, CYTOMETRY, V7, P558, DOI 10.1002/cyto.990070610; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SIPE D M, 1987, Journal of Cell Biology, V105, p248A; SIPE D M, 1988, Journal of Cell Biology, V107, p119A; SIPE DM, 1987, P NATL ACAD SCI USA, V84, P7119, DOI 10.1073/pnas.84.20.7119; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; VANDYKE RW, 1985, J BIOL CHEM, V260, P1021; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; WAGNER M, 1990, CYTOMETRY S, V4, pA459; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713	32	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3469	3474						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847374				2022-12-25	WOS:A1991EY68200023
J	BRUCKNER, RC; CRUTE, JJ; DODSON, MS; LEHMAN, IR				BRUCKNER, RC; CRUTE, JJ; DODSON, MS; LEHMAN, IR			THE HERPES-SIMPLEX VIRUS-1 ORIGIN BINDING-PROTEIN - A DNA HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; NONSTRUCTURAL PROTEINS; GENETIC-ANALYSIS; UNIQUE REGION; TYPE-1 ORIGIN; SV40 ORIGIN; T-ANTIGEN; REPLICATION; POLYMERASE; IDENTIFICATION	A recombinant herpes simplex 1 origin binding protein, the product of the herpes UL9 gene, has been overexpressed in mammalian cells and purified to near homogeneity. The origin binding protein shows DNA-dependent nucleoside 5'-triphosphatase and DNA helicase activities in addition to its origin binding activity. The ability to hydrolyze nucleoside 5'-triphosphates is influenced strongly by the structure and sequence of the DNA cofactor. The properties of the recombinant origin binding protein are identical to those of the protein synthesized in herpes simplex 1-infected mammalian cells.			BRUCKNER, RC (corresponding author), STANFORD UNIV, BECKMAN CTR, DEPT BIOCHEM, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012092] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26538] Funding Source: Medline; NIGMS NIH HHS [1FO 32 GM12092] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDTJOVIN DJ, 1975, EUR J BIOCHEM, V54, P411, DOI 10.1111/j.1432-1033.1975.tb04151.x; BAYLISS GJ, 1975, VIROLOGY, V68, P124, DOI 10.1016/0042-6822(75)90154-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CRUTE JJ, 1990, UCLA SYM BI, V127, P327; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEAN P, 1988, TRENDS BIOTECHNOL, V6, P113, DOI 10.1016/0167-7799(88)90099-6; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DODSON MS, 1989, J BIOL CHEM, V264, P20835; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; GALLO ML, 1988, J VIROL, V62, P2874, DOI 10.1128/JVI.62.8.2874-2883.1988; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRAY CP, 1984, J GEN VIROL, V65, P2109, DOI 10.1099/0022-1317-65-12-2109; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KOFF A, 1988, J VIROL, V62, P4096, DOI 10.1128/JVI.62.11.4096-4103.1988; Kornberg A., 1980, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LOCKSHON D, 1986, J VIROL, V58, P513, DOI 10.1128/JVI.58.2.513-521.1986; Maniatis T., 1982, MOL CLONING; MANOS MM, 1988, VIRAL VECTORS; MARCHETTI ME, 1988, J VIROL, V62, P715, DOI 10.1128/JVI.62.3.715-721.1988; MARSDEN HS, 1987, J VIROL, V61, P2428, DOI 10.1128/JVI.61.8.2428-2437.1987; MARSHALL T, 1984, ANAL BIOCHEM, V136, P340, DOI 10.1016/0003-2697(84)90227-6; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGEOCH DJ, 1985, J MOL BIOL, V181, P1, DOI 10.1016/0022-2836(85)90320-1; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; ODONNELL ME, 1987, J BIOL CHEM, V262, P4252; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; PARRIS DS, 1988, J VIROL, V62, P818, DOI 10.1128/JVI.62.3.818-825.1988; POWELL KL, 1977, J VIROL, V24, P618, DOI 10.1128/JVI.24.2.618-626.1977; POWELL KL, 1981, J VIROL, V39, P894, DOI 10.1128/JVI.39.3.894-902.1981; Roizman B., 1985, VIROLOGY, P497; SCHAFFER PA, 1973, VIROLOGY, V52, P57, DOI 10.1016/0042-6822(73)90398-X; SPAETE RR, 1985, P NATL ACAD SCI USA, V82, P694, DOI 10.1073/pnas.82.3.694; SPAETE RR, 1982, CELL, V30, P295, DOI 10.1016/0092-8674(82)90035-6; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STOW ND, 1982, EMBO J, V1, P863, DOI 10.1002/j.1460-2075.1982.tb01261.x; STOW ND, 1983, VIROLOGY, V130, P427, DOI 10.1016/0042-6822(83)90097-1; VLAZNY DA, 1981, P NATL ACAD SCI-BIOL, V78, P742, DOI 10.1073/pnas.78.2.742; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; WELLER SK, 1983, VIROLOGY, V130, P290, DOI 10.1016/0042-6822(83)90084-3; WELLER SK, 1983, J VIROL, V45, P354, DOI 10.1128/JVI.45.1.354-366.1983; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	54	130	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2669	2674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846632				2022-12-25	WOS:A1991EV51500098
J	MORRIS, GM; HADCOCK, JR; MALBON, CC				MORRIS, GM; HADCOCK, JR; MALBON, CC			CROSS-REGULATION BETWEEN G-PROTEIN-COUPLED RECEPTORS - ACTIVATION OF BETA-2-ADRENERGIC RECEPTORS INCREASES ALPHA-1-ADRENERGIC RECEPTOR MESSENGER-RNA LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; MUSCLE-CELL-LINE; VASCULAR SMOOTH-MUSCLE; STEADY-STATE LEVELS; ALPHA-1-ADRENERGIC RECEPTOR; PHYSIOLOGICAL REGULATION; A431 CELLS; KINASE-C; AGONIST; DESENSITIZATION	Stimulation of DDT1 MF-2 vas deferens cells with epinephrine resulted in a time- and dose-dependent loss of alpha-1-adrenergic receptor-specific ligand binding. Regulation of alpha-1-adrenergic receptor mRNA was characterized. In monolayer culture, cells displayed 0.7 +/- 0.05 amol of alpha-1-adrenergic receptor mRNA/mu-g of total cellular RNA. Epinephrine, which acts at both alpha-1- and beta-2-adrenergic receptors of DDT1 MF-2 cells, induced a short term (2-8 h) increase (50-70%) in the abundance of alpha-1-adrenergic receptor mRNA. Propranolol, a beta-2-adrenergic receptor antagonist, attenuated the epinephrine-mediated increase in alpha-1-adrenergic receptor mRNA but did not affect the decrease in alpha-1-adrenergic receptor-specific ligand binding. Phentolamine, an alpha-1-adrenergic receptor antagonist, did not attenuate the epinephrine-mediated increase in alpha-1-adrenergic receptor mRNA at 4 h but did block the decrease in alpha-1-adrenergic receptor-specific ligand binding. The half-life of the alpha-1-adrenergic receptor mRNA was approximately 7 h in untreated cells as well as in cells challenged with epinephrine. The epinephrine-promoted increase in alpha-1-adrenergic receptor mRNA was found to result from cross-regulation via beta-2-adrenergic receptors. Cholera toxin, forskolin, as well as the cyclic AMP analog CPT cAMP (8-(4-chlorophenylthio)adenosine 3':5'-cyclic monophosphate) increased the alpha-1-adrenergic receptor mRNA at 4 h, as did epinephrine in the presence of alpha-1-antagonists but not in the presence of a beta-adrenergic antagonist. This is the first report of heterologous upregulation of mRNA levels of adrenergic receptors. Cross-regulation between alpha-1- and beta-2-adrenergic receptor-mediated pathways at 4 h occurs at the level of mRNA whereas later down-regulation of alpha-1-receptor mRNA and binding proceed via agonist activation of alpha-1-adrenergic receptors.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410, T32DK007521, R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32DK07521, DK30111, DK25410] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BOBIK A, 1984, BIOCHEM PHARMACOL, V33, P1143, DOI 10.1016/0006-2952(84)90527-6; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; CORNETT LE, 1982, J BIOL CHEM, V257, P694; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COWLEN MS, 1988, MOL PHARMACOL, V34, P340; EXTON JH, 1985, AM J PHYSIOL, V248, pE633, DOI 10.1152/ajpendo.1985.248.6.E633; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1989, AM J PHYSIOL, V256, pC457, DOI 10.1152/ajpcell.1989.256.3.C457; HUGHES RJ, 1986, MOL PHARMACOL, V29, P521; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LURIE KG, 1985, J PHARMACOL EXP THER, V234, P147; MALBON CC, 1988, BIOCHEM BIOPH RES CO, V154, P676, DOI 10.1016/0006-291X(88)90192-1; Maniatis T., 1982, MOL CLONING; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; STILES GL, 1984, PHYSIOL REV, V64, P661, DOI 10.1152/physrev.1984.64.2.661; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; Wang H Y, 1990, Receptor, V1, P13; WANG HY, 1989, BIOCHEM J, V263, P519, DOI 10.1042/bj2630519; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; WILLIAMS DL, 1986, METHOD ENZYMOL, V128, P671	37	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2233	2238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846620				2022-12-25	WOS:A1991EV51500035
J	ROSS, TS; MAJERUS, PW				ROSS, TS; MAJERUS, PW			INOSITOL-1,2-CYCLIC-PHOSPHATE 2-INOSITOLPHOSPHOHYDROLASE - SUBSTRATE-SPECIFICITY AND REGULATION OF ACTIVITY BY PHOSPHOLIPIDS, METAL-ION CHELATORS, AND INOSITOL 2-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-2-CYCLIC PHOSPHATE 2-PHOSPHOHYDROLASE; MOUSE PANCREATIC MINILOBULES; 1,2-CYCLIC 4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; BINDING-PROTEINS; STIMULATION; PHOSPHATIDYLINOSITOL; METABOLISM; CALCIUM; CELLS	Glycerophosphoinositol (GroPIns) is a major inositol phosphate in many cell types. In this study we have determined the optimal conditions (pH 8.0 and 0.5 mM MnCl2) for the metabolism of this molecule in an extract from human placenta, and we show that the major product is inositol (1)-phosphate (Ins(1)P). The enzyme activity that catalyzes this reaction is contained in the same protein designated previously as inositol-(1,2)-cyclic-phosphate 2-inositolphosphohydrolase (cyclic hydrolase), a phosphodiesterase that catalyzes the conversion of inositol-(1,2)-cyclic phosphate (cIns(1,2)P) to Ins(1)P. In addition, the enzyme also catalyzes the production of Ins(1)P from inositol (1)-methylphosphate. All of these substrates, (cIns(1,2)P, GroPIns, and inositol (1)-methylphosphate), contain a phosphodiester bond at the 1-position of the inositol ring. Additional phosphate groups on the 4- or 5-positions of the inositol ring prevent hydrolysis by cyclic hydrolase. The K(m) of the enzyme for GroPIns is 0.67 mM, and the V(m) is 5-mu-mol/min/mg of protein. GroPIns competitively inhibits cIns(1,2)P hydrolysis with a K(i) equal to its K(m) as a substrate. Hydrolysis of GroPIns and cIns(1,2)P is stimulated by MnCl2, phosphatidylserine, and [ethylenebis(oxyethylenenitrilo)]tetraacetic acid (EGTA). However, whereas cIns(1,2)P hydrolysis is increased 5-8-fold by phosphatidylserine and EGTA only a 2-fold increase of GroPIns hydrolysis occurs under the same conditions. Hydrolysis of both GroPIns and cIns(1,2)P is inhibited by Ins(2)P; the ID50 values are 12 and 1-mu-M, respectively. There are significant quantities of GroPIns and Ins(2)P in 3T3 cells, indicating that these compounds that alter cIns(1,2)P hydrolase activity may modulate intracellular levels of cIns(1,2)P. Finally, we present evidence suggesting that the substrate specificity of this enzyme is altered during cell transformation.			ROSS, TS (corresponding author), WASHINGTON UNIV,SCH MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110, USA.			Ross, Theodora/0000-0002-9166-1802	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL016634, R01HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLBI 16634, HLBI 14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BINDER H, 1985, ANAL BIOCHEM, V148, P220, DOI 10.1016/0003-2697(85)90649-9; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAWSON RMC, 1973, BIOCHEM J, V134, P59, DOI 10.1042/bj1340059; DAWSON RMC, 1977, BIOCHEM J, V162, P241, DOI 10.1042/bj1620241; DAWSON RMC, 1972, BIOCHEM J, V127, P113, DOI 10.1042/bj1270113; DIXON JF, 1987, BIOCHEM BIOPH RES CO, V149, P1208, DOI 10.1016/0006-291X(87)90536-5; DIXON JF, 1985, J BIOL CHEM, V260, P6068; DIXON JF, 1987, J BIOL CHEM, V262, P13892; EISENBER.F, 1967, J BIOL CHEM, V242, P1375; GRAHAM RA, 1987, J BIOL CHEM, V262, P35; HAIGLER HT, 1989, TRENDS BIOCHEM SCI, V14, P48, DOI 10.1016/0968-0004(89)90041-8; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; ISHII H, 1986, P NATL ACAD SCI USA, V83, P6397, DOI 10.1073/pnas.83.17.6397; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; KOCH MA, 1974, BIOCHEM BIOPH RES CO, V58, P361, DOI 10.1016/0006-291X(74)90373-8; LAND L, 1983, NATURE, V304, P397; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SEKAR MC, 1987, J BIOL CHEM, V262, P340; SHAYMAN JA, 1986, ARCH BIOCHEM BIOPHYS, V886, P171; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; WILSON DB, 1985, J BIOL CHEM, V260, P3496	32	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					851	856						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845995				2022-12-25	WOS:A1991ET17700030
J	WILLEMS, L; KETTMANN, R; BURNY, A				WILLEMS, L; KETTMANN, R; BURNY, A			THE AMINO-ACID (157-197) PEPTIDE SEGMENT OF BOVINE LEUKEMIA-VIRUS P34TAX ENCOMPASS A LEUCINE-RICH GLOBALLY NEUTRAL ACTIVATION DOMAIN	ONCOGENE			English	Note							TRANSCRIPTIONAL ACTIVATOR; MAMMALIAN-CELLS; FUNCTIONAL DISSECTION; GENE-EXPRESSION; TRANS-ACTIVATOR; GAL4; PROTEINS; YEAST; ELEMENTS; ESTROGEN	The specific DNA-binding Ga14 amino-terminal portion (amino acids 1 to 147) was fused to protein segments of BLV transactivator p34tax and tested for its capacity to activate CAT-gene expression in mammalian cells. The p34tax peptide segment 157 to 197 encompasses an activating region. The segment is approximately located in the middle of p34tax and is globally neutral (net charge zero). The tax (157-197) domain contains 24% of leucine residues, possibly involved in heterologous protein interactions.	UNIV BRUSSELS,DEPT MOLEC BIOL,B-1640 RHODE ST GENESE,BELGIUM; FAC AGRON GEMBLOUX,DEPT MOLEC BIOL,B-5030 GEMBLOUX,BELGIUM	University of Liege	WILLEMS, L (corresponding author), FAC AGRON GEMBLOUX,DEPT MOLEC BIOL,B-5800 GEMBLOUX,BELGIUM.			Willems, Luc/0000-0002-0563-2213				BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BURNY A, 1987, CANCER SURV, V6, P139; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1988, J VIROL, V62, P1115, DOI 10.1128/JVI.62.4.1115-1119.1988; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KETTMANN R, 1982, P NATL ACAD SCI-BIOL, V79, P2465, DOI 10.1073/pnas.79.8.2465; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER JM, 1969, JNCI-J NATL CANCER I, V43, P1297; PORTETELLE D, 1978, ANN RECH VET, V9, P667; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLEMS L, 1987, EMBO J, V6, P3385, DOI 10.1002/j.1460-2075.1987.tb02661.x; WILLEMS L, 1987, VIROLOGY, V160, P55, DOI 10.1016/0042-6822(87)90043-2; WILLEMS L, 1989, VIROLOGY, V171, P615, DOI 10.1016/0042-6822(89)90633-8; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	31	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					159	163						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846955				2022-12-25	WOS:A1991EY03900023
J	CHAVEZ, RA; HALL, ZW				CHAVEZ, RA; HALL, ZW			THE TRANSMEMBRANE TOPOLOGY OF THE AMINO TERMINUS OF THE ALPHA-SUBUNIT OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; SUBSTRATE RECOGNITION; DIRECTED MUTAGENESIS; INVITRO SYNTHESIS; GLYCINE RECEPTOR; STOP TRANSFER; SITE; GLYCOSYLATION; MEMBRANES	We have investigated the transmembrane topology of the amino-terminal domain of the alpha-subunit of the mouse muscle nicotinic acetylcholine receptor synthesized in vitro and in vivo. Using oligonucleotide-directed mutagenesis we introduced new glycosylation consensus sequences at alpha-154 and at alpha-200. For each novel site, additional constructs were made in which the original site at alpha-N141 was eliminated. Glycosylation at the new sites, as exhibited in a rabbit reticulocyte cell-free translation system supplemented with canine pancreatic microsomes and in a transient transfection system with COS cells, was taken as evidence of the transmembrane translocation of the new site. Each of the new sites was glycosylated in both systems. In separate experiments we found that an alpha-subunit fragment terminating at alpha-M207 could be extracted from microsomal membranes with sodium carbonate after in vitro translation, indicating that this fragment is not an integral membrane protein. Our results, taken together with previous experiments, indicate that the amino terminus of the alpha-subunit up to at least residue alpha-207 is translocated across the membrane of the endoplasmic reticulum. This topology probably represents the orientation of the amino terminus of the alpha-subunit in the assembled receptor.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BOULTER J, 1985, J NEUROSCI, V5, P2545; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BURKE DT, 1986, DNA-J MOLEC CELL BIO, V5, P325, DOI 10.1089/dna.1986.5.325; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CRIADO M, 1985, P NATL ACAD SCI USA, V82, P2004, DOI 10.1073/pnas.82.7.2004; DAS MK, 1989, BIOCHEM BIOPH RES CO, V165, P865, DOI 10.1016/S0006-291X(89)80046-4; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GHOSH PK, 1981, P NATL ACAD SCI-BIOL, V78, P100, DOI 10.1073/pnas.78.1.100; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KAO PN, 1986, J BIOL CHEM, V261, P8085; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LAU JTY, 1983, J BIOL CHEM, V258, P5255; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MERLIE JP, 1981, J BIOL CHEM, V256, P6995; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; NEUMANN D, 1989, P NATL ACAD SCI USA, V86, P7255, DOI 10.1073/pnas.86.18.7255; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; NUMA S, 1983, COLD SPRING HARB SYM, V48, P57, DOI 10.1101/SQB.1983.048.01.008; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YOST CS, 1983, CELL, V34, P759	43	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15532	15538						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869570				2022-12-25	WOS:A1991GB09700105
J	QIN, S; NAKAJIMA, B; NOMURA, M; ARFIN, SM				QIN, S; NAKAJIMA, B; NOMURA, M; ARFIN, SM			CLONING AND CHARACTERIZATION OF A SACCHAROMYCES-CEREVISIAE GENE ENCODING A NEW MEMBER OF THE UBIQUITIN-CONJUGATING PROTEIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SEQUENCE ANALYSIS; YEAST-CELL CYCLE; N-END RULE; CARRIER PROTEIN; ACTIVATING ENZYME; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; BINDING-SITES; RAD6 PROTEIN; WHEAT-GERM	Ubiquitin-conjugating enzymes (E2s), which participate in the post-translational conjugation of ubiquitin to proteins, are encoded by a multigene family in the yeast Saccharomyces cerevisiae. E2s function in a variety of cellular activities including intracellular proteolysis, DNA repair, sporulation, and cell cycle traverse. Here, we report the cloning and characterization of a new member of the yeast UBC gene family, UBC8. UBC8 encodes a 206-amino acid protein containing a highly acidic carboxyl terminus. The primary structure of the protein is similar to that of all other known E2s, with the highest homology being to the E2 (23 kDa) of wheat germ. Haploid strains in which the UBC8 gene is disrupted are viable, and the disruption does not produce any obvious phenotype. The UBC8 protein, produced in Escherichia coli, forms thiol ester adducts with ubiquitin and, apparently, diubiquitin, but does not transfer abiquitin to histones.	UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIGMS NIH HHS [R37GM35949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAMEZAI S, 1989, BIOCHEM BIOPH RES CO, V162, P89, DOI 10.1016/0006-291X(89)91966-9; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BASSON ME, 1987, GENETICS, V117, P645; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1990, New Biologist, V2, P227; COX BS, 1968, MUTAT RES, V6, P37, DOI 10.1016/0027-5107(68)90101-2; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER A, 1989, J BIOL CHEM, V264, P2060; MONTELONE BA, 1981, MOL GEN GENET, V184, P410, DOI 10.1007/BF00352514; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1988, J BIOL CHEM, V263, P15076; PRAKASH L, 1974, GENETICS, V78, P1101; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SCHWINDINGER WF, 1984, NUCLEIC ACIDS RES, V12, P601, DOI 10.1093/nar/12.1Part2.601; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sherman F., 1982, METHODS YEAST GENETI; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SULLIVAN ML, 1989, P NATL ACAD SCI USA, V86, P9861, DOI 10.1073/pnas.86.24.9861; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367	52	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15549	15554						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869573				2022-12-25	WOS:A1991GB09700108
J	ARVAN, P; KULIAWAT, R; PRABAKARAN, D; ZAVACKI, AM; ELAHI, D; WANG, S; PILKEY, D				ARVAN, P; KULIAWAT, R; PRABAKARAN, D; ZAVACKI, AM; ELAHI, D; WANG, S; PILKEY, D			PROTEIN DISCHARGE FROM IMMATURE SECRETORY GRANULES DISPLAYS BOTH REGULATED AND CONSTITUTIVE CHARACTERISTICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEWLY SYNTHESIZED PROINSULIN; RAT ISLETS; INTRACELLULAR STORAGE; EXOCRINE PANCREAS; STORED INSULIN; PATHWAY; RELEASE; CELLS; COMPARTMENT; LANGERHANS	At physiological glucose concentrations, isolated pancreatic islets release a minor portion of their newly synthesized insulin and precursors in a phase of secretion which is largely complete by 4 h of chase. Discharge during this period can be amplified by secretagogues, yet is not abolished by conditions which fully suppress regulated release from dense core secretory granules. The ability to stimulate the secretion and the biochemical profile of released proinsulin-related peptides indicate that secretion during this period originates from immature granules. The stoichiometry of release of labeled C-peptide:insulin during this phase is 1:1 at high glucose concentrations. However, at physiologic or low concentrations, C-peptide is released in molar excess of insulin as if the exocytotic vesicles carrying this secretion were budding from a post-Golgi compartment in which the lumen was composed of condensing insulin and soluble C-peptide. These findings can be explained by a model for regulated secretory protein traffic in which direct exocytosis of young granules is stimulated by higher glucose concentrations and vesicle budding from immature granules occurs at lower concentrations. Thus, insulin targeting from immature granules exhibits both regulated and constitutive-like characteristics.	BETH ISRAEL HOSP,DIV GERONTOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,CELL & DEV BIOL PROGRAM,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	ARVAN, P (corresponding author), BETH ISRAEL HOSP,DIV ENDOCRINOL,BOSTON,MA 02215, USA.			Kuliawat, Regina/0000-0001-8386-2279	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040344, R01DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVAN P, 1987, J BIOL CHEM, V262, P3886; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; Blundell T L, 1971, Recent Prog Horm Res, V27, P1; BOLAFFI JL, 1986, DIABETES, V35, P370, DOI 10.2337/diabetes.35.3.370; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DUDEK RW, 1984, P SOC EXP BIOL MED, V176, P1; GOLD G, 1982, J CLIN INVEST, V69, P554, DOI 10.1172/JCI110481; GROSS DJ, 1989, P NATL ACAD SCI USA, V86, P4107, DOI 10.1073/pnas.86.11.4107; GRUPPUSO PA, 1984, NEW ENGL J MED, V311, P629, DOI 10.1056/NEJM198409063111003; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; HOWELL SL, 1967, BIOCHEM J, V102, P922, DOI 10.1042/bj1020922; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; MALAISSELAGAE F, 1979, J CLIN INVEST, V63, P1284, DOI 10.1172/JCI109423; MENEILLY GS, 1987, J GERONTOL, V42, P196, DOI 10.1093/geronj/42.2.196; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; ORCI L, 1974, DIABETOLOGIA, V10, P163, DOI 10.1007/BF00423031; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; SANDO H, 1972, J CLIN INVEST, V51, P1476, DOI 10.1172/JCI106944; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35	30	113	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14171	14174						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860833				2022-12-25	WOS:A1991FZ35100009
J	VERCESI, AE; BERNARDES, CF; HOFFMANN, ME; GADELHA, FR; DOCAMPO, R				VERCESI, AE; BERNARDES, CF; HOFFMANN, ME; GADELHA, FR; DOCAMPO, R			DIGITONIN PERMEABILIZATION DOES NOT AFFECT MITOCHONDRIAL-FUNCTION AND ALLOWS THE DETERMINATION OF THE MITOCHONDRIAL-MEMBRANE POTENTIAL OF TRYPANOSOMA-CRUZI INSITU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ASCITES TUMOR-CELLS; CA-2+ TRANSPORT; CRYSTAL VIOLET; ACCUMULATION; RESPIRATION; SAFRANINE; BRUCEI	Digitonin can be used to permeabilize selectively the plasma membrane of Trypanosoma cruzi epimastigotes without significantly affecting the functional integrity of mitochondria. Addition of digitonin at concentrations close to 64-mu-M caused decrease in the rate of basal respiration of epimastigotes similar to that caused by oligomycin. A further addition of carbonyl cyanide p-trifluorophenylhydrazone (FCCP) brought respiration to the same rate observed prior to the inclusion of digitonin or oligomycin. This suggests that like oligomycin, digitonin is shifting respiration to a nonphosphorylating state probably by depleting the cells from adenine nucleotides due to permeabilization of the plasma membrane. The use of low concentrations of digitonin allowed the quantitative determination of the mitochondrial membrane potential of these cells in situ using safranine O. The response of epimastigotes mitochondrial membrane potential to phosphate, FCCP, valinomycin, nigericin, ADP, and Ca2+ indicates that these mitochondria behave similarly to vertebrate mitochondria regarding the properties of their electrochemical proton gradient. In addition, T. cruzi mitochondria are able to build up and retain a membrane potential of a value comparable to that of mammalian mitochondria. The trypanocidal drug crystal violet, as well as other cationic drugs such as dequalinium, induced a rapid dose-related collapse of the inner mitochondrial membrane potential.	UNIV ILLINOIS,DEPT VET PATHOBIOL,2001 S LINCOLN AVE,URBANA,IL 61801; UNIV ESTADUAL CAMPINAS,DEPT BIOQUIM,BR-13081 CAMPINAS,SP,BRAZIL	University of Illinois System; University of Illinois Urbana-Champaign; Universidade Estadual de Campinas			Vercesi, Aníbal E/C-8767-2012	Vercesi, Anibal Eugenio/0000-0001-6671-7125	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFFRANCHINO JL, 1985, MOL BIOCHEM PARASIT, V16, P289, DOI 10.1016/0166-6851(85)90071-4; AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; AKERMAN KEO, 1979, BIOCHIM BIOPHYS ACTA, V546, P341, DOI 10.1016/0005-2728(79)90051-3; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; DAVIS S, 1985, J BIOL CHEM, V260, P3844; DOCAMPO R, 1989, J BIOL CHEM, V264, P108; DOCAMPO R, 1989, ARCH BIOCHEM BIOPHYS, V272, P122, DOI 10.1016/0003-9861(89)90202-6; GADELHA FR, 1989, MOL BIOCHEM PARASIT, V34, P117, DOI 10.1016/0166-6851(89)90003-0; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HILL GC, 1976, BIOCHIM BIOPHYS ACTA, V456, P149, DOI 10.1016/0304-4173(76)90011-2; KIM YV, 1985, EUR J BIOCHEM, V153, P503, DOI 10.1111/j.1432-1033.1985.tb09330.x; MORENO SNJ, 1988, J BIOL CHEM, V263, P12493; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; Nussenzweig V., 1953, Hospital Rio de Janeiro, V44, P731; OLAVARRIA JS, 1988, BIOCHIM BIOPHYS ACTA, V935, P322, DOI 10.1016/0005-2728(88)90227-7; PHILOSOPH H, 1989, J BIOL CHEM, V264, P10420; TURRENS JF, 1989, BIOCHEM J, V259, P363, DOI 10.1042/bj2590363; VERCESI AE, 1990, MOL BIOCHEM PARASIT, V42, P119, DOI 10.1016/0166-6851(90)90119-7; WEISS MJ, 1987, P NATL ACAD SCI USA, V84, P5444, DOI 10.1073/pnas.84.15.5444	21	152	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14431	14434						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860850				2022-12-25	WOS:A1991FZ35100051
J	KODADEK, T				KODADEK, T			INHIBITION OF PROTEIN-MEDIATED HOMOLOGOUS PAIRING BY A DNA HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; BACTERIOPHAGE-T4 UVSX; RECA PROTEIN; SACCHAROMYCES-CEREVISIAE; RECOMBINATION PROTEIN; GENETIC-RECOMBINATION; GENE-32 PROTEINS; PURIFICATION; REPLICATION	Protein-mediated exchange of homologous DNA strands is a central reaction in general genetic recombination and the mechanism by which proteins mediate this process in vivo is a topic of keen interest. The dda protein of the bacteriophage T4 is a DNA helicase that has been shown to accelerate branch migration catalyzed by the phage uvsX and gene 32 proteins in vitro (Kodadek, T., and Alberts, B. M. (1987) Nature 326, 312-314). This study did not address the potential role of the helicase in protein-mediated homologous pairing, the first phase of the overall strand-exchange reaction. It is shown here that the dda protein inhibits uvsX protein-mediated pairing between homologous single and double-stranded DNAs. Experiments using deproteinized heteroduplex joints demonstrate that the dda helicase is capable of unwinding these structures to some extent and suggests that this activity may be responsible for the observed inhibition of pairing. It is found that the helicase also reduces the level of uvsX protein-mediated, single-stranded DNA-dependent ATP hydrolysis in the strand-exchange reactions, suggesting that the helicase may also act to destabilize the uvsX protein-DNA filaments that are important intermediates in the pairing reaction. Three other helicases are found to have no effect on the uvsX protein-mediated pairing reaction. A model rationalizing the ability of the dda protein to both inhibit homologous pairing and stimulate branch migration is presented and possible in vivo roles for this interesting activity are discussed.	UNIV TEXAS,CLAYTON FDN BIOCHEM INST,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	KODADEK, T (corresponding author), UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712, USA.							BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; BEHME MT, 1975, J VIROL, V15, P50, DOI 10.1128/JVI.15.1.50-54.1975; BITTNER M, 1979, J BIOL CHEM, V254, P9565; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1988, ANN REV BIOCH, V56, P226; EGNER C, 1987, J BACTERIOL, V169, P3422, DOI 10.1128/jb.169.8.3422-3428.1987; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HEYER WD, 1989, BIOCHEMISTRY-US, V28, P2856, DOI 10.1021/bi00433a017; HINTON DM, 1986, J BIOL CHEM, V261, P5663; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KAHN R, 1984, J BIOL CHEM, V259, P7495; KMIEC EB, 1984, CELL, V36, P593, DOI 10.1016/0092-8674(84)90338-6; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KODADEK T, 1988, J BIOL CHEM, V263, P9427; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MATSON SW, 1986, J BIOL CHEM, V261, P169; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOSIG G, 1983, BACTERIOPHAGE T4, P120; OFARRELL P, 1981, FOCUS, V3, P1; Radding C.M., 1988, GENETIC RECOMBINATIO, P193; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; SCOTT JF, 1978, J BIOL CHEM, V253, P3292; SINGER BS, 1982, CELL, V31, P25, DOI 10.1016/0092-8674(82)90401-9; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; WU R, 1972, VIROLOGY, V47, P147, DOI 10.1016/0042-6822(72)90248-6; YONESAKI T, 1985, EUR J BIOCHEM, V148, P127, DOI 10.1111/j.1432-1033.1985.tb08816.x; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	34	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9712	9718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851754				2022-12-25	WOS:A1991FM45900059
J	PARADIS, H; GAUDREAU, P; MASSIE, B; LAMARCHE, N; GUILBAULT, C; GRAVEL, S; LANGELIER, Y				PARADIS, H; GAUDREAU, P; MASSIE, B; LAMARCHE, N; GUILBAULT, C; GRAVEL, S; LANGELIER, Y			AFFINITY PURIFICATION OF ACTIVE SUBUNIT-1 OF HERPES-SIMPLEX VIRUS TYPE-1 RIBONUCLEOTIDE REDUCTASE EXHIBITING A PROTEIN-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; INHIBITION; CELLS; ACYCLOVIR; SEQUENCE; PROTEOLYSIS; DELETION; TERMINUS	Herpes simplex virus (HSV) ribonucleotide reductase is formed by the association of two distinct dimeric subunits, R1 and R2. Attempts to purify either the HSV holoenzyme or its R1 subunit in their active form have been unsuccessful until now. The C terminus of the R2 protein being involved in the association with R1, the synthetic nonapeptide corresponding to this terminus, impedes the formation of the holoenzyme by competing with R2 for a critical site on R1. Based upon these observations, we developed an affinity chromatographic procedure to purify the R1 protein from HSV-1-infected baby hamster kidney cells. Specific binding of R1 to an affinity column made by linking the peptide HSV R2-(326-337) to Affi-Gel 10, followed by specific elution with an excess of an analogous peptide exhibiting a higher affinity for R1 yielded, in a single step, highly purified R1 protein. The purified R1 preparations contained approximately 95% of intact R1, the remaining 5% consisting of two R1 copurifying proteolytic breakdown products. The purified R1 protein exhibited a high reductase specific activity when mixed with an excess of the R2 subunit. Moreover, in vitro kinase assays revealed that the purified R1 protein of HSV-1 possesses an autophosphorylating activity also able to phosphorylate alpha-casein and histone II-S. The intrinsic protein kinase activity of HSV R1 is associated with its unique N-terminal domain which is absent from all other reductase subunits 1 and contains consensus motifs found in Ser/Thr protein kinases. A preliminary characterization of the kinase activity of the R1 protein of HSV-1 ribonucleotide reductase is presented.	INST CANC MONTREAL, 1560 SHERBROOKE EST, MONTREAL H2L 4M1, QUEBEC, CANADA; NOTRE DAME HOSP, RES CTR, NEUROENDOCRINOL LAB, MONTREAL H2L 4M1, QUEBEC, CANADA; INST RECH BIOTECHNOL, MONTREAL H4P 2R2, QUEBEC, CANADA; BIO MEGA INC, LAVAL H7S 2G5, QUEBEC, CANADA	Universite de Montreal; Universite de Montreal								BACCHETTI S, 1984, J VIROL, V49, P591, DOI 10.1128/JVI.49.2.591-593.1984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAS IW, 1985, J BIOL CHEM, V260, P7015; CHUNG TD, 1989, J VIROL, V63, P3389, DOI 10.1128/JVI.63.8.3389-3398.1989; COCKING JM, 1987, SOMAT CELL MOLEC GEN, V13, P221, DOI 10.1007/BF01535204; COEN DM, 1989, ANTIMICROB AGENTS CH, V33, P1395, DOI 10.1128/AAC.33.8.1395; COHEN EA, 1985, J GEN VIROL, V66, P733, DOI 10.1099/0022-1317-66-4-733; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; COHEN EA, 1986, J VIROL, V60, P1130, DOI 10.1128/JVI.60.3.1130-1133.1986; COHEN EA, 1987, J VIROL, V51, P2046; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ERLKSSON S, 1977, J BIOL CHEM, V252, P6132; GAUDREAU P, 1987, J BIOL CHEM, V262, P12413; GAUDREAU P, 1990, J MED CHEM, V33, P723, DOI 10.1021/jm00164a040; GIBSON T, 1984, NUCLEIC ACIDS RES, V12, P5087, DOI 10.1093/nar/12.12.5087; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; INGEMARSON R, 1987, VIROLOGY, V156, P417, DOI 10.1016/0042-6822(87)90422-3; KARLSSON A, 1988, ANTIMICROB AGENTS CH, V32, P1100, DOI 10.1128/AAC.32.7.1100; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCHE N, 1990, J GEN VIROL, V71, P1785, DOI 10.1099/0022-1317-71-8-1785; LANKINEN H, 1989, J GEN VIROL, V70, P3159, DOI 10.1099/0022-1317-70-12-3159; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCCLEMENTS W, 1988, VIROLOGY, V162, P270, DOI 10.1016/0042-6822(88)90421-7; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NIKAS I, 1986, Proteins Structure Function and Genetics, V1, P376, DOI 10.1002/prot.340010411; NILSSON O, 1988, BIOCHEM SOC T, V16, P91, DOI 10.1042/bst0160091; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PARADIS H, 1988, J BIOL CHEM, V263, P16045; PARADIS N, 1991, INT J PEPT PROT RES, V37, P72; PRESTON VG, 1988, VIROLOGY, V167, P458, DOI 10.1016/S0042-6822(88)90108-0; SPECTOR T, 1989, P NATL ACAD SCI USA, V86, P1051, DOI 10.1073/pnas.86.3.1051; SPECTOR T, 1989, INT ENCY PHARM THERA, V128, P235; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SWAIN MA, 1986, J VIROL, V57, P802, DOI 10.1128/JVI.57.3.802-808.1986; TELFORD E, 1990, J GEN VIROL, V71, P1373, DOI 10.1099/0022-1317-71-6-1373; TENGELSEN LA, 1988, VIROLOGY, V164, P121, DOI 10.1016/0042-6822(88)90627-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAGLE K, 1990, MOL CELL BIOL, V10, P5553, DOI 10.1128/MCB.10.10.5553	41	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9647	9651						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851753				2022-12-25	WOS:A1991FM45900049
J	HUANG, FL; HUANG, KP				HUANG, FL; HUANG, KP			INTERACTION OF PROTEIN-KINASE-C ISOZYMES WITH PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER-BINDING; RAT-BRAIN; MIXED MICELLES; CALCIUM INTERDEPENDENCIES; MECHANISTIC IMPLICATIONS; 2ND MESSENGERS; ACTIVATION; DIACYLGLYCEROL; EXPRESSION; SUBSTRATE	Interaction of protein kinase C (PKC) isozymes with phosphatidylinositol 4,5-bisphosphate (PIP2) was investigated by monitoring the changes in the intrinsic fluorescence of the enzyme, the kinase activity, and phorbol ester binding. Incubation of PKC I, II, and III with PIP2 resulted in different rates of quenching of PKC fluorescence and different degrees of inactivation of these enzymes. Other inositol-containing phospholipids such as phosphatidylinositol and phosphatidylinositol 4-phosphate also caused differential rates of quenching of the intrinsic fluorescence of these enzymes. These latter two phospholipids were, however, less potent in the inactivation of PKCs than PIP2. The IC50 of PIP2 were 2, 4, and 11-mu-M for PKC I, II, and III, respectively. Inactivation of PKCs by PIP2 cannot be reversed by extensive dilution of PIP2 with Nonidet P-40 nor by digestion of PIP2 with phospholipase C. Interaction of PIP2 with the various PKC isozymes was greatly facilitated in the presence of Mg2+ or Ca2+ as evidenced by the accelerated quenching of the PKC fluorescence, however, these divalent metal ions protected PKC from the PIP2-induced inactivation. Binding of PIP2 to PKC in the absence of divalent metal ion also caused a reduction of [H-3]phorbol 12,13-dibutyrate binding as a result of reducing the affinity of the enzyme for phorbol ester. Based on gel filtration chromatography, it was estimated that one molecule of PKC interacted with one PIP2 micelle with an aggregation number of 80-90. The PIP2-bound PKC could further interact with phosphatidylserine in the presence of Ca2+ to form a larger complex. Binding of PKC to both PIP2 and phosphatidylserine in the presence of Ca2+ was also evident by changes in the intrinsic fluorescence of PKC. As the interaction of PKC with PIP2, but not with phosphatidylserine, could be enhanced by millimolar concentrations of Mg2+, we propose that PIP2 may be a component of the membrane anchor for PKC under basal physiological conditions when [Ca2+]i is low and Mg2+ is plentiful. Under the in vitro assay conditions, PIP2 could stimulate PKC activity to a level approximately 10-20% of that by diacylglycerol. The stimulatory effect of PIP2 on PKC apparently is not due to binding to the same site recognized by diacylglycerol or phorbol ester, because PIP2 cannot effectively compete with phorbol 12,13-dibutyrate in the binding assay.			HUANG, FL (corresponding author), NICHHD,ENDOCRINOL & REPROD RES BRANCH,METAB REGULAT SECT,BLDG 10,RM B1-L400,BETHESDA,MD 20892, USA.							ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUHAN A, 1989, BIOCHEMISTRY-US, V28, P4952, DOI 10.1021/bi00438a007; CHAUHAN VPS, 1988, BIOCHEM BIOPH RES CO, V155, P18, DOI 10.1016/S0006-291X(88)81043-X; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEGRAAN PNE, 1989, J NEUROCHEM, V52, P17; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HAWTHORNE JN, 1964, ADV LIPID RES, V2, P127; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HUANG FL, 1987, BIOCHEM BIOPH RES CO, V149, P946, DOI 10.1016/0006-291X(87)90500-6; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; HUANG KP, 1990, J BIOL CHEM, V265, P738; HUANG KP, 1988, J BIOL CHEM, V263, P14839; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KIKKAWA U, 1987, FEBS LETT, V217, P227, DOI 10.1016/0014-5793(87)80668-3; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBRIAN CA, 1987, FEBS LETT, V214, P339, DOI 10.1016/0014-5793(87)80083-2; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PIKE MC, 1990, J BIOL CHEM, V265, P1866; SAMSONOFF C, 1986, J COLLOID INTERF SCI, V109, P325, DOI 10.1016/0021-9797(86)90310-3; SMITH CD, 1989, J BIOL CHEM, V264, P3206; STUBBS EB, 1988, BIOCHIM BIOPHYS ACTA, V958, P247, DOI 10.1016/0005-2760(88)90183-X; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; URUMOW T, 1990, FEBS LETT, V263, P15, DOI 10.1016/0014-5793(90)80694-E; VANDONGEN CJ, 1985, ANAL BIOCHEM, V144, P104, DOI 10.1016/0003-2697(85)90090-9; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	48	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8727	8733						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851155				2022-12-25	WOS:A1991FM03800017
J	WEI, L; ALHENCGELAS, F; CORVOL, P; CLAUSER, E				WEI, L; ALHENCGELAS, F; CORVOL, P; CLAUSER, E			THE 2 HOMOLOGOUS DOMAINS OF HUMAN ANGIOTENSIN-I-CONVERTING ENZYME ARE BOTH CATALYTICALLY ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; C-TERMINAL HALF; DIPEPTIDYL CARBOXYPEPTIDASE; MOLECULAR-CLONING; RABBIT LUNG; BINDING; INHIBITORS; CHLORIDE; THERMOLYSIN; BRADYKININ	Molecular cloning of human endothelial angiotensin I-converting enzyme (kininase II; EC 3.4.15.1) (ACE) has recently shown that the enzyme contains two large homologous domains (called here the N and C domains), each bearing a putative active site, identified by sequence comparisons with the active sites of other zinc metallopeptidases. However, the previous experiments with zinc or competitive ACE inhibitors suggested a single active site in ACE. To establish whether both domains of ACE are enzymatically active, a series of ACE mutants, each containing only one intact domain, were constructed by deletion or point mutations of putative critical residues of the other domain, and expressed in heterologous Chinese hamster ovary cells. Both domains are enzymatically active and cleave the C-terminal dipeptide of hippuryl-His-Leu or angiotensin I. Moreover, both domains have an absolute zinc requirement for activity, are activated by chloride and are sensitive to competitive ACE inhibitors, and appear to function independently. However, the two domains display different catalytic constants and different patterns of chloride activation. At high chloride concentrations, the C domain hydrolyzes the two substrates tested faster than does the N domain. His-361,365 and His-959,963 are established as essential residues in the N and C domains, respectively, most likely involved in zinc binding, and Glu-362 in the N domain and Glu-960 in the C domain are essential catalytic residues. These observations provide strong evidence that ACE possesses two independent catalytic domains and suggest that they may have different functions.			WEI, L (corresponding author), COLL FRANCE,INSERM,U36,3 RUE ULM,F-75231 PARIS 05,FRANCE.		Alhenc-Gelas, Francois/F-9511-2017					BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BRUNEVAL P, 1986, HISTOCHEMISTRY, V85, P73, DOI 10.1007/BF00508656; BULL HG, 1985, J BIOL CHEM, V260, P2952; BUNNING P, 1983, BIOCHEMISTRY-US, V22, P110, DOI 10.1021/bi00270a016; BUNNING P, 1985, J INORG BIOCHEM, V24, P183, DOI 10.1016/0162-0134(85)85002-9; CHEUNG HS, 1980, J BIOL CHEM, V255, P401; CUMIN F, 1989, BIOCHEM BIOPH RES CO, V163, P718, DOI 10.1016/0006-291X(89)92282-1; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DAS M, 1975, J BIOL CHEM, V250, P6762; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; DORER FE, 1974, CIRC RES, V34, P824, DOI 10.1161/01.RES.34.6.824; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; EHLERS MRW, 1988, BIOCHEMISTRY-US, V27, P5538, DOI 10.1021/bi00415a023; ELDORRY HA, 1982, P NATL ACAD SCI-BIOL, V79, P4295, DOI 10.1073/pnas.79.14.4295; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERDOS EG, 1987, LAB INVEST, V56, P345; IWATA K, 1983, ARCH BIOCHEM BIOPHYS, V227, P188, DOI 10.1016/0003-9861(83)90362-4; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P5315, DOI 10.1021/bi00292a010; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STRITTMATTER SM, 1986, MOL PHARMACOL, V29, P142; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WEI L, 1991, J BIOL CHEM, V266, P5540; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	34	347	362	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9002	9008						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851160				2022-12-25	WOS:A1991FM03800054
J	ZHENG, W; PERRY, DF; NELSON, DL; APOSHIAN, HV				ZHENG, W; PERRY, DF; NELSON, DL; APOSHIAN, HV			CHOROID-PLEXUS PROTECTS CEREBROSPINAL-FLUID AGAINST TOXIC METALS	FASEB JOURNAL			English	Article						CHOROID PLEXUS; HEAVY METALS; CENTRAL NERVOUS SYSTEM; NEUROTOXICITY; BLOOD-CSF BARRIER	LIQUID-CHROMATOGRAPHY; BRAIN; TRANSPORT; CADMIUM; BARRIER; ACID; LEAD	Although heavy metal ions are known to be toxic to the central nervous system (CNS), the mechanisms by which the CNS may protect itself from initial challenges of such toxic ions is unknown. The choroid plexus is the principal site of formation of the cerebrospinal fluid (CSF) which bathes the brain. We have determined in rats and rabbits that after intraperitoneal administration of lead, cadmium, mercury, and arsenic compounds, these toxic metal ions accumulated in the lateral choroid plexus at concentrations of Pb, Hg, and As that were 70-, 95-, and 40-fold higher, respectively, than those found in the CSF. Cd was not detected in the CSF. In addition, concentrations of these heavy metal ions were found to be many fold greater in the choroid plexus than in the brain or blood. The accumulation of Pb in the choroid plexus was dose-dependent and time-related. When the choroid plexus was preincubated, in vitro, with ouabain (1.5 mM), the uptake of Cd from the CSF side of the choroid plexus was inhibited 57%. Cadmium metallothionein was not found in the choroid plexus. Whereas the concentration of reduced glutathione in the choroid plexus was less than that in the brain cortex, the concentration of cystine was fourfold greater. The lateral choroid plexus sequesters Pb, Cd, As, and Hg. It appears to be one of the important mechanisms that protects the CSF and the brain from the fluxes of toxic heavy metals in the blood.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,BIOSCI W,ROOM 308,TUCSON,AZ 85721; UNIV ARIZONA,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT VET SCI,TUCSON,AZ 85721	University of Arizona; University of Arizona; University of Arizona					NATIONAL CANCER INSTITUTE [R01CA049252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004940, R01ES003356] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49252] Funding Source: Medline; NIEHS NIH HHS [ES-03356, ES-04940] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON ME, 1989, FASEB J, V3, P1632, DOI 10.1096/fasebj.3.5.2920877; ANDERSON ME, 1989, FASEB J, V3, P2527, DOI 10.1096/fasebj.3.13.2572501; BERLIN M, 1963, ARCH ENVIRON HEALTH, V6, P589, DOI 10.1080/00039896.1963.10663447; Bradbury M W, 1988, Ann N Y Acad Sci, V529, P1, DOI 10.1111/j.1749-6632.1988.tb51414.x; Clarkson T.W., 1988, BIOL MONITORING TOXI; DAVSON H, 1963, J PHYSIOL-LONDON, V167, P239, DOI 10.1113/jphysiol.1963.sp007144; DEANE R, 1990, J NEUROCHEM, V54, P905, DOI 10.1111/j.1471-4159.1990.tb02337.x; DIBENEDETTO FE, 1986, J NEUROCHEM, V46, P1725; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FRIEDHEIM E, 1983, LANCET, V1, P981; HERSHEY CO, 1987, TRACE ELEM MED, V4, P21; HIDALGO J, 1990, J NEUROCHEM, V55, P651, DOI 10.1111/j.1471-4159.1990.tb04182.x; JACOBSON KB, 1980, TOXICOLOGY, V16, P1, DOI 10.1016/0300-483X(80)90107-9; Kagi J.H.R., 1979, METALLOTHIONEIN; KRYNITSKY AJ, 1987, ANAL CHEM, V59, P1884, DOI 10.1021/ac00141a034; LEHMAN LD, 1986, ANAL BIOCHEM, V153, P305, DOI 10.1016/0003-2697(86)90097-7; LINDVALL M, 1978, SCIENCE, V201, P176, DOI 10.1126/science.663649; MAIORINO RM, 1986, J CHROMATOGR, V374, P297, DOI 10.1016/S0378-4347(00)83285-5; MANTON WI, 1984, LANCET, V2, P351; MIHORAT TH, 1976, INT REV CYTOL, V47, P225; NOHJOH T, 1989, J PHARMACOL EXP THER, V250, P324; OTUAMA LA, 1976, TOXICOL APPL PHARM, V36, P1, DOI 10.1016/0041-008X(76)90021-1; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SIGNHAL RK, 1987, FASEB J, V1, P220; SPECTOR R, 1989, J NEUROCHEM, V53, P1667, DOI 10.1111/j.1471-4159.1989.tb09229.x; SPECTOR R, 1974, J PHARMACOL EXP THER, V188, P55; VALOIS AA, 1989, TOXICOLOGY, V55, P193, DOI 10.1016/0300-483X(89)90186-8; 1977, MED BIOL EFFECTS ENV	28	87	96	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1991	5	8					2188	2193		10.1096/fasebj.5.8.1850706	http://dx.doi.org/10.1096/fasebj.5.8.1850706			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1850706				2022-12-25	WOS:A1991FK11100011
J	YU, XP; MOCHARLA, H; HUSTMYER, FG; MANOLAGAS, SC				YU, XP; MOCHARLA, H; HUSTMYER, FG; MANOLAGAS, SC			VITAMIN-D RECEPTOR EXPRESSION IN HUMAN-LYMPHOCYTES - SIGNAL REQUIREMENTS AND CHARACTERIZATION BY WESTERN BLOTS AND DNA SEQUENCING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,25-DIHYDROXYVITAMIN-D3 RECEPTORS; RAT THYMUS; T-CELLS; ACTIVATION; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; PHYTOHEMAGGLUTININ; CLONING	The signals controlling the expression of the receptor protein for 1-alpha,25-dihydroxyvitamin D3 in normal human lymphocytes and the relationship of this protein to the classical vitamin D receptor were examined. Lymphocytes activated with the OKT3 antibody to the T-cell antigen receptor expressed fewer binding sites as compared to lymphocytes that were activated by the polyclonal activator phytohemagglutinin (PHA). However, combination of OKT3 and phorbol myristate acetate produced a concentration of binding sites similar to the PHA-activated cells. The receptor from OKT3 and OKT3 + phorbol myristate acetate-activated lymphocytes exhibited decreased binding to DNA-cellulose compared to PHA-activated lymphocytes. In lymphocytes activated either by PHA or OKT3 (but not in resting cells), a 50-kDa species cross-reacting with a monoclonal antibody against the intestinal vitamin D receptor was detected. Finally, RNA from activated lymphocytes was amplified by polymerase chain reaction using oligonucleotide primers flanking the 196 base pair long region encoding the DNA-binding domain of the human intestinal receptor. The amplified product showed an identical nucleotide sequence to the DNA-binding domain of the human intestinal receptor. These findings suggest that expression of the 1,25-(OH)2D3 receptor in lymphocytes is triggered by distinct and contingent signals, and that the protein and the mRNA encoding it are identical to the classical vitamin D receptor.	RICHARD L ROUDEBUSH VET ADM MED CTR,ENDOCRINOL & METAB SECT,148 W 10TH ST 111E,INDIANAPOLIS,IN 46202; INDIANA UNIV,DEPT MED,INDIANAPOLIS,IN 46202	US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021761] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21761] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN TA, 1990, J BIOL CHEM, V265, P10025; CHEN TL, 1981, J BIOL CHEM, V256, P5561; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; KELSEY SM, 1989, BRIT J HAEMATOL, V71, P173, DOI 10.1111/j.1365-2141.1989.tb04250.x; KRISHNAN AV, 1990, J BONE MINE RES S2, V5, pS209; LECA G, 1986, SCAND J IMMUNOL, V23, P535, DOI 10.1111/j.1365-3083.1986.tb01985.x; MANOLAGAS SC, 1980, J BIOL CHEM, V255, P4414; MANOLAGAS SC, 1986, J LAB CLIN MED, V108, P596; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; MANOLAGAS SC, 1987, ANTICANCER RES, V7, P625; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NUNN JD, 1986, IMMUNOLOGY, V59, P479; OFLYNN K, 1985, NATURE, V313, P686, DOI 10.1038/313686a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIKE JW, 1984, J BIOL CHEM, V259, P1167; PROVVEDINI DM, 1987, J BONE MINER RES, V2, P239; PROVVEDINI DM, 1986, J IMMUNOL, V136, P2734; PROVVEDINI DM, 1984, BIOCHEM BIOPH RES CO, V121, P277, DOI 10.1016/0006-291X(84)90719-8; PROVVEDINI DM, 1989, J CLIN ENDOCR METAB, V68, P774, DOI 10.1210/jcem-68-4-774; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; PROVVEDINI DM, 1989, ENDOCRINOLOGY, V124, P1532, DOI 10.1210/endo-124-3-1532; RAVID A, 1984, BIOCHEM BIOPH RES CO, V123, P163, DOI 10.1016/0006-291X(84)90394-2; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; ROSSI JF, 1988, CANCER RES, V48, P1213; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	35	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7588	7595						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850412				2022-12-25	WOS:A1991FJ34200044
J	FUJIKI, M; VERNER, K				FUJIKI, M; VERNER, K			COUPLING OF PROTEIN-SYNTHESIS AND MITOCHONDRIAL IMPORT IN A HOMOLOGOUS YEAST INVITRO SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND CYTOPLASMIC POLYSOMES; TRANSLATION SYSTEM; PRECURSOR; TRANSLOCATION; MEMBRANES; OUTER; CELLS; MICROSOMES; INSERTION; TRANSPORT	We made use of a homologous cell-free mitochondrial protein import system derived from the yeast Saccharomyces cerevisiae to investigate the coupling of protein synthesis and import. Mitochondrial precursor proteins were synthesized in a yeast lysate either in the presence or absence of isolated yeast mitochondria. We were, therefore, able to analyze protein import into mitochondria either in a strictly posttranslational reaction (when isolated mitochondria were added only after protein synthesis has been arrested by the addition of cycloheximide) or in a reaction in which synthesis and import were permitted to occur simultaneously. We found that the import of a precursor protein consisting of the amino-terminal mitochondrial targeting sequence of cytochrome oxidase subunit IV fused to mouse dihydrofolate reductase is very inefficient in a strictly posttranslational reaction, whereas efficient import is observed if precursor synthesis and import are coupled. The same result was obtained when we analyzed the import of bulk endogenous yeast mitochondrial proteins in this system. Finally, we found that the insertion of the yeast outer membrane protein porin is also several times more efficient when synthesis and insertion are coupled.			FUJIKI, M (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA.							ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; ADES IZ, 1980, J BIOL CHEM, V255, P9918; ARGAN C, 1985, BIOCHEM BIOPH RES CO, V131, P289, DOI 10.1016/0006-291X(85)91801-7; Battey, 1986, BASIC METHODS MOL BI; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; FIRGAIRA FA, 1984, SCIENCE, V226, P1319, DOI 10.1126/science.6209799; GASSER SM, 1982, J BIOL CHEM, V257, P3034; HALLERMAYER G, 1977, EUR J BIOCHEM, V81, P523, DOI 10.1111/j.1432-1033.1977.tb11978.x; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; OHTA S, 1984, EMBO J, V3, P651, DOI 10.1002/j.1460-2075.1984.tb01862.x; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; RANDALL SK, 1989, FEBS LETT, V250, P561, DOI 10.1016/0014-5793(89)80796-3; REID GA, 1982, J BIOL CHEM, V257, P3056; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; SUISSA M, 1982, J BIOL CHEM, V257, P3048; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VERNER K, 1989, J BIOL CHEM, V264, P3877; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; ZHAUNG ZP, 1989, J BIOL CHEM, V264, P14594; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	35	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6841	6847						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849892				2022-12-25	WOS:A1991FG72700033
J	SAKANE, F; YAMADA, K; IMAI, S; KANOH, H				SAKANE, F; YAMADA, K; IMAI, S; KANOH, H			PORCINE 80-KDA DIACYLGLYCEROL KINASE IS A CALCIUM-BINDING AND CALCIUM PHOSPHOLIPID-DEPENDENT ENZYME AND UNDERGOES CALCIUM-DEPENDENT TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHORBOL ESTER; PIG BRAIN; SN-1,2-DIACYLGLYCEROL KINASE; NITROCELLULOSE MEMBRANE; 80 KDA; CYTOSOL; CELLS; PHOSPHORYLATION; ACTIVATION	We attempted to assess the regulatory role of EF-hand motifs recently detected in the primary structure of porcine 80-kDa diacylglycerol kinase (DGK) (Sakane, F., Yamada, K., Kanoh, H., Yokoyama, C., and Tanabe, T. (1990) Nature 344, 345-348). By using 80-kDa DGK purified from porcine thymus cytosol, we found that this isozyme indeed bound 2 mol Ca2+ per mol enzyme with high affinity (apparent dissociation constant, K(d) = 0.3-mu-M). The Ca2+ binding was cooperative with a Hill coefficient of 1.4. We next studied the effect of 1 X 10(-5) M Ca2+ on the kinetic properties of DGK employing a beta-octyl glucoside mixed micellar assay system. In the absence of Ca2+, phosphatidylserine, so far used as an enzyme activator in various assay systems, was rather inhibitory, and Ca2+ alone activated enzyme to a limited extent. However, phosphatidylserine plus Ca2+ markedly activated the enzyme, giving approximately 4-fold higher V(max) and 10-fold less K(m) values for ATP. In contrast, the apparent K(m) values for diacylglycerol were not significantly affected (approximately 3 mol %). Furthermore, by immunoblotting using anti-80 kDa DGK antibodies we found that the soluble DGK in the homogenate of porcine thymocytes was translocated to membranes in a Ca2+-dependent manner. Indeed we noted the presence of a 33-residue amphipathic alpha-helix in the DGK sequence, which may account for the protein-lipid interaction. The results demonstrate that Ca2+ plays a key role in the regulation of DGK action by controlling enzyme interaction with membrane phospholipids.	SAPPORO MED COLL,DEPT BIOCHEM,W 17,S 1,SAPPORO,HOKKAIDO 060,JAPAN	Sapporo Medical University			Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DIEZ E, 1990, J BIOL CHEM, V265, P14654; EXTON JH, 1990, J BIOL CHEM, V265, P1; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KANOH H, 1986, J BIOL CHEM, V261, P5597; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1989, BIOCHEM J, V258, P455, DOI 10.1042/bj2580455; KATO M, 1990, J BIOL CHEM, V265, P794; KAWASAKI H, 1985, ANAL BIOCHEM, V148, P297, DOI 10.1016/0003-2697(85)90232-5; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; Kretsinger R H, 1979, Adv Cyclic Nucleotide Res, V11, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MELLONI E, 1985, P NATL ACAD SCI USA, V82, P6435, DOI 10.1073/pnas.82.19.6435; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SOLING HD, 1989, J BIOL CHEM, V264, P10643; TANAKA T, 1980, J BIOL CHEM, V255, P1078; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1986, J BIOL CHEM, V261, P6239; YADA Y, 1990, J BIOL CHEM, V265, P19237; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; YAMADA K, 1988, BIOCHEM J, V255, P601; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	44	122	123	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7096	7100						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849900				2022-12-25	WOS:A1991FG72700071
J	HONKANEN, RE; ZWILLER, J; DAILY, SL; KHATRA, BS; DUKELOW, M; BOYNTON, AL				HONKANEN, RE; ZWILLER, J; DAILY, SL; KHATRA, BS; DUKELOW, M; BOYNTON, AL			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF A NOVEL SERINE THREONINE PROTEIN PHOSPHATASE FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; TYPE-2 CATALYTIC SUBUNITS; CELLULAR-REGULATION; MONOCLONAL IMMUNOGLOBULINS; INOSITOL TRISPHOSPHATE; PHOSPHORYLASE-KINASE; MAMMALIAN-TISSUES; BIND INHIBITOR-2; TETRAKISPHOSPHATE; DISTINGUISH	A novel serine/threonine protein, phosphatase is identified, and the catalytic subunit, obtained from a detergent extraction of the pellet generated by a 100,000 x g centrifugation of a whole bovine brain homogenate, is purified and characterized. The protein phosphatase, designated as PP3, has a M(r) of 36,000, does not require divalent cations for activity, is stimulated rather than inhibited by inhibitor 2, is inhibited by both okadaic acid and microcystin-LR with an intermediate IC50 compared to type 1 and type 2A protein phosphatases, and preferentially dephosphorylates the beta-subunit of phosphorylase kinase. Substrate specificity, immunoblotting with type-specific antisera, and the amino acid sequences of peptides derived from PP3 indicate that PP3 is not an isoform of any known serine/threonine protein phosphatase.	UNIV HAWAII, CANC RES CTR HAWAII, MOLEC ONCOL PROGRAM, HONOLULU, HI 96813 USA; CNRS, CTR NEUROCHIM, F-67084 STRASBOURG, FRANCE; CALIF STATE UNIV LONG BEACH, DEPT ANAT & PHYSIOL, LONG BEACH, CA 90840 USA	Cancer Research Center of Hawaii; University of Hawaii System; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; California State University System; California State University Long Beach					NCI NIH HHS [CA39745] Funding Source: Medline; NCRR NIH HHS [RR08125] Funding Source: Medline; NIDDK NIH HHS [DK26334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039745] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S06RR008125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER DR, 1988, BIOCHEM J, V256, P885, DOI 10.1042/bj2560885; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; BRAUTIGAN DL, 1986, J BIOL CHEM, V261, P4924; CODD GA, 1982, FEMS MICROBIOL LETT, V13, P409, DOI 10.1111/j.1574-6968.1982.tb08296.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1989, J BIOL CHEM, V264, P21435; DOMBRADI V, 1989, FEBS LETT, V247, P391, DOI 10.1016/0014-5793(89)81377-8; GERGELY P, 1984, FEBS LETT, V169, P45, DOI 10.1016/0014-5793(84)80286-0; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; KILLILEA SD, 1978, ARCH BIOCHEM BIOPHYS, V191, P638, DOI 10.1016/0003-9861(78)90402-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MEISLER MH, 1969, J BIOL CHEM, V244, P4961; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; SILVA OBDE, 1988, FEBS LETT, V242, P106, DOI 10.1016/0014-5793(88)80995-5; WHITAKER M, 1990, DEVELOPMENT, V108, P525; YOSHIZAWA S, 1990, J CANCER RES CLIN, V116, P609, DOI 10.1007/BF01637082; ZWILLER J, 1990, EXP CELL RES, V187, P193, DOI 10.1016/0014-4827(90)90081-K; ZWILLER J, 1988, BIOCHEM BIOPH RES CO, V155, P767, DOI 10.1016/S0006-291X(88)80561-8	28	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6614	6619						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848859				2022-12-25	WOS:A1991FE37300090
J	REMBOLD, CM; WEAVER, BA; LINDEN, J				REMBOLD, CM; WEAVER, BA; LINDEN, J			ADENOSINE-TRIPHOSPHATE INDUCES A LOW [CA2+]I SENSITIVITY OF PHOSPHORYLATION AND AN UNUSUAL FORM OF RECEPTOR DESENSITIZATION IN SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN PHOSPHORYLATION; PROTEIN KINASE-C; MYOSIN PHOSPHORYLATION; INTRACELLULAR CA-2+; PURINERGIC TRANSMISSION; PLASMA-MEMBRANE; FREE-CALCIUM; CONTRACTION; ACTIVATION; CELLS	The contractile sensitivity of smooth muscle to changes in myoplasmic [Ca2+] is dependent on the form of stimulation. Both myosin phosphorylation and force are less sensitive to increases in [Ca2+]i derived from Ca2+ entry through L-type Ca2+ channels than to increases in [Ca2+] induced by agents which release internal Ca2+ stores. We hypothesized that activation of receptor-operated channels should produce a [Ca2+]i sensitivity similar to that induced by opening L channels. Aequorin-estimated myoplasmic [Ca2+] and myosin light chain phosphorylation were measured in swine carotid media tissues stimulated with ATP, an activator of the only known receptor-operated cation channel in smooth muscle. ATP, via activation of a P2x purinergic receptor, induced large, transient increases in [Ca2+]i, yet only small transient elevations in phosphorylation or force. Rapid desensitization to ATP was partially, but not completely, caused by hydrolysis of ATP into adenosine since 1) alpha-beta-methylene ATP (a poorly hydrolyzable analog of ATP) produced larger, yet still transient increases in [Ca2+]i, phosphorylation, and force; 2) BW A1433U, a P1 (adenosine) receptor antagonist, enhanced ATP-induced contractions; and 3) ATP, but not alpha-beta-methylene ATP increased bath [adenosine]. The [Ca2+]i sensitivity of phosphorylation during P2x receptor activation was similar to that observed with KCl-depolarization-induced opening of L channels, supporting the hypothesis that transplasmalemmal Ca2+ influx produces less phosphorylation and force than mobilization of intracellular Ca2+ stores. Cumulative additions of higher alpha-beta-methylene ATP concentrations induced repeated transient contractions, indicative of an unusual form of receptor desensitization which could be explained if the affinity of the P2x receptor for ATP, but not the receptor number were rapidly reduced.	UNIV VIRGINIA, SCH MED, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia	REMBOLD, CM (corresponding author), UNIV VIRGINIA, HLTH SCI CTR,SCH MED,DEPT INTERNAL MED,DIV CARDIOL, BOX 146, CHARLOTTESVILLE, VA 22908 USA.		Rembold, Christopher/K-8359-2013	Rembold, Christopher/0000-0003-0819-7488	NHLBI NIH HHS [R01-HL38918] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038918] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKSOY MO, 1983, AM J PHYSIOL, V245, pC255, DOI 10.1152/ajpcell.1983.245.3.C255; ALLEN DG, 1979, DETECTION MEASUREMEN, P159; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BOLTON TB, 1979, PHYSIOL REV, V59, P606, DOI 10.1152/physrev.1979.59.3.606; BOZLER E, 1969, AM J PHYSIOL, V216, P671, DOI 10.1152/ajplegacy.1969.216.3.671; BREDEHORST R, 1983, ANAL BIOCHEM, V135, P156, DOI 10.1016/0003-2697(83)90745-5; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; BURNSTOCK G, 1990, PURINES IN CELLULAR SIGNALLING, P241; BURNSTOCK G, 1988, TRENDS PHARMACOL SCI, V9, P116, DOI 10.1016/0165-6147(88)90185-X; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CLEMO HF, 1987, J PHARMACOL EXP THER, V242, P478; DELANEROLLE P, 1984, SCIENCE, V223, P1415, DOI 10.1126/science.6322302; DENHERTOG A, 1990, PROG CLIN BIOL RES, V327, P183; DETH R, 1977, J MEMBRANE BIOL, V30, P363; DRISKA SP, 1981, AM J PHYSIOL, V240, pC222, DOI 10.1152/ajpcell.1981.240.5.C222; FORDER J, 1985, J PHARMACOL EXP THER, V235, P267; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GUNST SJ, 1989, AM J PHYSIOL, V257, pC355, DOI 10.1152/ajpcell.1989.257.2.C355; GUNST SJ, 1989, AM J PHYSIOL, V256, pC807, DOI 10.1152/ajpcell.1989.256.4.C807; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; HIMPENS B, 1988, J GEN PHYSIOL, V92, P713, DOI 10.1085/jgp.92.6.713; HONORE E, 1989, AM J PHYSIOL, V257, pC297, DOI 10.1152/ajpcell.1989.257.2.C297; Kamm K E, 1989, Prog Clin Biol Res, V315, P265; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; LINDEN J, 1988, J MED CHEM, V31, P745, DOI 10.1021/jm00399a010; MCDANIEL NL, 1991, IN PRESS J PHYSL LON; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MOODY CJ, 1984, EUR J PHARMACOL, V97, P47, DOI 10.1016/0014-2999(84)90511-9; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; MORGAN JP, 1982, PFLUG ARCH EUR J PHY, V395, P75, DOI 10.1007/BF00584972; MURAMATSU I, 1989, J PHYSIOL-LONDON, V411, P227, DOI 10.1113/jphysiol.1989.sp017570; MURPHY RA, 1989, ANNU REV PHYSIOL, V51, P275, DOI 10.1146/annurev.ph.51.030189.001423; NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; RATZ PH, 1987, CIRC RES, V60, P410, DOI 10.1161/01.RES.60.3.410; REMBOLD CM, 1990, J PHYSIOL-LONDON, V429, P77, DOI 10.1113/jphysiol.1990.sp018245; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; REMBOLD CM, 1989, AM J PHYSIOL, V257, pC122, DOI 10.1152/ajpcell.1989.257.1.C122; REMBOLD CM, 1989, J PHYSIOL-LONDON, V416, P273, DOI 10.1113/jphysiol.1989.sp017760; REMBOLD CM, 1986, CIRC RES, V58, P803, DOI 10.1161/01.RES.58.6.803; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; STULL JT, 1990, J BIOL CHEM, V265, P16683; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; VANBREEMEN C, 1986, J CARDIOVASC PHARM, V8, pS111, DOI 10.1097/00005344-198600088-00023	50	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5407	5411						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848549				2022-12-25	WOS:A1991FD37000011
J	BENKE, D; MERTENS, S; TRZECIAK, A; GILLESSEN, D; MOHLER, H				BENKE, D; MERTENS, S; TRZECIAK, A; GILLESSEN, D; MOHLER, H			GABA-A RECEPTORS DISPLAY ASSOCIATION OF GAMMA-2-SUBUNIT WITH ALPHA-1-SUBUNIT AND BETA-2/3-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZODIAZEPINE RECEPTORS; MONOCLONAL-ANTIBODIES; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; BRAIN-AREAS; ION CHANNEL; SEQUENCE; RAT; HETEROGENEITY	Recombinant GABA(A) (gamma-aminobutyrate-Type A) receptors that are sensitive to benzodiazepine receptor ligands can be generated by coexpression of alpha-, beta-, and gamma-2-subunit cDNAs (Pritchett, D. B., Sontheimer, H., Shivers, B. D., Ymer, S., Kettenmann, H., Schofield, P. R., and Seeburg, P. H. (1989) Nature 338, 582-585; Pritchett, D. B., Luddens, H., and Seeburg, P. H. (1989) Science 245, 1389-1392; Malherbe, P., Sigel, E., Baur, R., Perssohn, E., Richards, J. G., and Mohler, H. (1990) J. Neurosci. 10, 2330-2337). However, in brain tissue, only alpha- and beta-subunit proteins have so far been detected. To identify the size and distribution of the gamma-2-subunit protein in brain tissue, polyclonal antibodies were prepared against two synthetic peptides corresponding to amino acids 1-15 and 336-350 of the cDNA-derived rat gamma-2-subunit sequence. On Western blots, both anti-gamma-2-subunit antisera selectively labeled a 43-kDa protein. Gamma-2-Subunit immunoreactivity was detected immunohistochemically in various brain regions, e.g. in the olfactory bulb, cerebral cortex, islands of Calleja, hippocampus, substantia nigra, and cerebellum. Immunoprecipitation with both antisera identified the gamma-2-subunit immunoreactivity in 40 and 50% of the native GABA(A) receptors purified from bovine and rat brains, respectively. Monoclonal antibody bd24 selectively recognizes the alpha-1-subunit, whereas bd17 recognizes both the beta-2- and beta-3-subunits (Ewert, M., Shivers, B. D., Luddens, H., Mohler, H., and Seeburg, P. H. (1990) J. Cell Biol. 110, 2043-2048). Since either of these monoclonal antibodies (bd17 and bd24) precipitated approximately 90% of the GABA(A) receptors, the gamma-2-subunit is frequently associated with the alpha-1-subunit and the beta-2- and/or beta-3-subunit in vivo.	F HOFFMANN LA ROCHE & CO LTD,PHARMA RES DEPT,CH-4002 BASEL,SWITZERLAND	Roche Holding	BENKE, D (corresponding author), UNIV ZURICH,INST PHARMACOL,CH-8006 ZURICH,SWITZERLAND.							Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; BRANDT E, 1986, IMMUNOBIOLOGY, V172, P33, DOI 10.1016/S0171-2985(86)80051-1; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; DUGGAN MJ, 1989, J NEUROCHEM, V53, P132, DOI 10.1111/j.1471-4159.1989.tb07304.x; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; GARRETT KM, 1988, BIOCHEM BIOPH RES CO, V156, P1039, DOI 10.1016/S0006-291X(88)80949-5; HAEFELY WE, 1989, ALLOSTERIC MODULATIO, P47; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; KATO K, 1990, J MOL BIOL, V214, P619, DOI 10.1016/0022-2836(90)90276-R; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LEVITAN ES, 1988, NEURON, V1, P779; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MAHERBE P, 1990, FEBS LETT, V260, P261; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RICHARDS JG, 1987, J NEUROSCI, V7, P1866; SCHOCH P, 1985, NATURE, V314, P168, DOI 10.1038/314168a0; SCHOCH P, 1983, EUR J PHARMACOL, V95, P323, DOI 10.1016/0014-2999(83)90656-8; SCHOFIELD PR, 1989, FEBS LETT, V244, P361, DOI 10.1016/0014-5793(89)80563-0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEQUIER JM, 1988, P NATL ACAD SCI USA, V85, P7815, DOI 10.1073/pnas.85.20.7815; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIGEL E, 1983, J BIOL CHEM, V258, P6965; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOMOGYI P, 1989, J NEUROSCI, V9, P2197; STEPHENSON FA, 1988, BIOCHEM J, V249, P21, DOI 10.1042/bj2490021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; YMER S, 1989, FEBS LETT, V258, P119, DOI 10.1016/0014-5793(89)81630-8	41	232	233	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4478	4483						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847922				2022-12-25	WOS:A1991FA69400071
J	MOND, JJ; FEUERSTEIN, N; JUNE, CH; BALAPURE, AK; GLAZER, RI; WITHERSPOON, K; BRUNSWICK, M				MOND, JJ; FEUERSTEIN, N; JUNE, CH; BALAPURE, AK; GLAZER, RI; WITHERSPOON, K; BRUNSWICK, M			BIMODAL EFFECT OF PHORBOL ESTER ON B-CELL ACTIVATION - IMPLICATION FOR THE ROLE OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYRISTATE ACETATE; MEMBRANE IMMUNOGLOBULIN; RESPIRATORY BURST; ANTI-IMMUNOGLOBULIN; PLASMA-MEMBRANE; LYMPHOMA CELLS; LYMPHOCYTES-B; TRANSLOCATION; PHOSPHORYLATION; PROLIFERATION	The role of protein kinase C PKC in B cell activation is controversial. These studies were undertaken to determine whether protein kinase C has a stimulatory or inhibitory role in B cell activation. We found that treatment of B cells for a short period of time (30 min) with the PKC activator phorbol 12,13-dibutyrate (PDBU) primed the cells for enhanced proliferative responses to anti-immunoglobulin (anti-Ig) antibody whereas treatment for a longer period of time (3 h or more) resulted in suppression of proliferation. The enhanced proliferative response to treatment of B cells with PDBU for short periods of time was associated with inhibition of anti-Ig-stimulated increases in phosphatidyl 4,5-bisphosphate (PIP2) hydrolysis and inhibition of increases in [Ca2+]i, indicating that activation of PKC per se might be sufficient for enhancing B cell activation. The time-dependent effect of phorbol esters on the inhibition of B cell proliferation was found to be closely correlated with the kinetics of disappearance of PKC as measured by Western blot and by enzymatic activity but not with inhibition of [Ca2+]i and PIP2. These data demonstrate a bimodal time-dependent effect of PDBU on B cell activation and suggest that (a) the inhibitory effect of phorbol ester on anti-Ig-induced proliferation may be due to the disappearance of PKC rather than to the inhibition of PIP2 and Ca2+; and (b) the early activation of PKC is a stimulatory rather than an inhibitory signal in the induction of B lymphocyte proliferation by anti-Ig.	USN,MED RES INST,MED COMMAND,BETHESDA,MD 20814; GEORGETOWN UNIV,ROCKVILLE,MD 20850	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Georgetown University	MOND, JJ (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814, USA.			BALAPURE, ANIL/0000-0003-1213-4586	NCI NIH HHS [CA48667-03] Funding Source: Medline; NIAID NIH HHS [R01 AI27465, R01 AI24273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024273, R01AI027465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AQUINO A, 1988, CANCER RES, V48, P3324; BASS DA, 1988, J BIOL CHEM, V263, P19610; BASS DA, 1987, J BIOL CHEM, V262, P6643; BIANCA V D, 1986, Biochemical and Biophysical Research Communications, V135, P556, DOI 10.1016/0006-291X(86)90030-6; BRUNSWICK M, 1988, J IMMUNOL, V140, P3364; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CHEN ZZ, 1986, J IMMUNOL, V136, P2300; CLEVERS HC, 1985, J IMMUNOL, V135, P3827; COGGESHALL KM, 1984, J IMMUNOL, V133, P3382; DENNIS G, 1987, J IMMUNOL, V139, P2516; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GUY GR, 1985, BIOCHEM BIOPH RES CO, V131, P484, DOI 10.1016/0006-291X(85)91828-5; HAWRYLOWICZ CM, 1984, IMMUNOLOGY, V51, P327; HORNBECK P, 1986, J BIOL CHEM, V261, P4817; ITO T, 1988, J CELL BIOL, V107, P929, DOI 10.1083/jcb.107.3.929; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; KOLESNICK RN, 1990, J BIOL CHEM, V265, P10900; LANIER LL, 1982, HYBRIDOMA, V1, P125, DOI 10.1089/hyb.1.1982.1.125; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LINDSTEN T, 1984, J IMMUNOL, V132, P235; MCCALL CE, 1979, J INFECT DIS, V140, P577; MCPHAIL LC, 1984, J BIOL CHEM, V259, P5768; MILLS GB, 1989, J IMMUNOL, V142, P1995; MIZUGUCHI J, 1987, J IMMUNOL, V139, P1054; MIZUGUCHI J, 1986, P NATL ACAD SCI USA, V83, P4474, DOI 10.1073/pnas.83.12.4474; MOND JJ, 1987, P NATL ACAD SCI USA, V84, P8588, DOI 10.1073/pnas.84.23.8588; MONROE JG, 1984, J IMMUNOL, V132, P1472; MONROE JG, 1988, J IMMUNOL, V140, P1454; NAKA M, 1983, NATURE, V306, P490, DOI 10.1038/306490a0; NEL AE, 1986, BIOCHEM J, V233, P145, DOI 10.1042/bj2330145; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAGE DM, 1988, J IMMUNOL, V140, P3717; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; ROTHSTEIN TL, 1986, J CELL PHYSIOL, V129, P347, DOI 10.1002/jcp.1041290313; ROTHSTEIN TL, 1988, J IMMUNOL, V140, P2880; ROTHSTEIN TL, 1986, CELL IMMUNOL, V102, P364, DOI 10.1016/0008-8749(86)90430-2; SNOW EC, 1986, J EXP MED, V164, P944, DOI 10.1084/jem.164.3.944; SUZUKI T, 1985, J IMMUNOL, V134, P2470; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; ZITRON IM, 1980, J EXP MED, V152, P1135, DOI 10.1084/jem.152.5.1135	42	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4458	4463						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847921				2022-12-25	WOS:A1991FA69400068
J	ZWERLING, SJ; COHEN, SA; BARCHI, RL				ZWERLING, SJ; COHEN, SA; BARCHI, RL			ANALYSIS OF PROTEASE-SENSITIVE REGIONS IN THE SKELETAL-MUSCLE SODIUM-CHANNEL INVITRO AND IMPLICATIONS FOR CHANNEL TERTIARY STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROPHORUS-ELECTRICUS; RAT-BRAIN; PHOSPHORYLATION SITES; MONOCLONAL-ANTIBODIES; CDNA SEQUENCE; NA+ CHANNEL; INACTIVATION; IDENTIFICATION; LOCALIZATION; PEPTIDE	The tertiary structure of the rat skeletal muscle sodium channel was probed in vitro by determining regions of sensitivity to V-8 protease, trypsin, and chymotrypsin. Resultant channel fragments were identified with antibodies to defined sequences distributed along the primary structure. The temporal pattern of proteolysis was followed with channel protein in either detergent-phospholipid micelles or membrane fragments as well as with channel exposed to sodium dodecyl sulfate. Proteolysis in micelles and membranes occurred in discrete, reproducible steps that were similar in both systems. Although the size of intermediates varied slightly, their sequence of appearance was similar for all enzymes, suggesting that the observed pattern was determined by the relative accessibility of selected sites in the tertiary structure. No major change in channel organization appeared to occur after solubilization of membranes in nonionic detergents. Highly accessible sites in the native structure included the carboxyl terminus and the region linking the second and third internal repeat domains, while the amino terminus and the repeat domains themselves were relatively resistant to proteolysis unless the protein was denatured. Kinetically, interdomain II-III was the most readily cleaved; interdomains I-II and especially III-IV were less easily accessible. While domains I and IV appeared to remain intact throughout our experiments, limit fragments for epitopes associated with domains II and III suggest that cleavage eventually occurs at sites between the putative S5 and S6 helices in these domains.	UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	ZWERLING, SJ (corresponding author), UNIV PENN,SCH MED,DAVID MAHONEY INST NEUROL SCI,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018013] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07502] Funding Source: Medline; NINDS NIH HHS [NS-18013] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; CASADEI JM, 1987, J NEUROCHEM, V48, P773, DOI 10.1111/j.1471-4159.1987.tb05584.x; CASADEI JM, 1984, P NATL ACAD SCI-BIOL, V81, P6227, DOI 10.1073/pnas.81.19.6227; ELMER LW, 1985, BIOCHEMISTRY-US, V24, P8128, DOI 10.1021/bi00348a044; EMERICK MC, 1989, BIOCHEMISTRY-US, V28, P8367, DOI 10.1021/bi00447a016; GORDON RD, 1988, J NEUROSCI, V8, P3742; GORDON RD, 1987, P NATL ACAD SCI USA, V84, P308, DOI 10.1073/pnas.84.1.308; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KRANER S, 1989, J BIOL CHEM, V264, P13273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; ROBERTS RH, 1987, J BIOL CHEM, V262, P2298; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; SALKOFF L, 1987, SCIENCE, V237, P744, DOI 10.1126/science.2441469; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANAKA JC, 1983, J BIOL CHEM, V258, P7519; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WEIGELE JB, 1982, P NATL ACAD SCI-BIOL, V79, P3651, DOI 10.1073/pnas.79.11.3651; YANG J, 1990, J NEUROCHEM, V54, P954, DOI 10.1111/j.1471-4159.1990.tb02343.x	30	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4574	4580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847924				2022-12-25	WOS:A1991FA69400085
J	MCLANE, KE; WU, XD; SCHOEPFER, R; LINDSTROM, JM; CONTITRONCONI, BM				MCLANE, KE; WU, XD; SCHOEPFER, R; LINDSTROM, JM; CONTITRONCONI, BM			IDENTIFICATION OF SEQUENCE SEGMENTS FORMING THE ALPHA-BUNGAROTOXIN BINDING-SITES ON 2 NICOTINIC ACETYLCHOLINE-RECEPTOR ALPHA-SUBUNITS FROM THE AVIAN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SODIUM DODECYL-SULFATE; CHICK OPTIC LOBE; TORPEDO-CALIFORNICA; LIGAND-BINDING; MONOCLONAL-ANTIBODIES; RAT-BRAIN; KAPPA-BUNGAROTOXIN; SYNTHETIC PEPTIDES; GENE FAMILY	The relationship between neuronal alpha-bungarotoxin binding proteins (alpha-BGTBPs) and nicotinic acetylcholine receptor function in the brain of higher vertebrates has remained controversial for over a decade. Recently, the cDNAs for two homologous putative ligand binding subunits, designated alpha-BGTBP alpha-1 and alpha-BGTBP alpha-2, have been isolated on the basis of their homology to the N terminus of an alpha-BGTBP purified from chick brain. In the present study, a panel of overlapping synthetic peptides corresponding to the complete chick brain alpha-BGTBP alpha-1 subunit and residues 166-215 of the alpha-BGTBP alpha-2 subunits were tested for their ability to bind I-125-alpha-BGT. The sequence segments corresponding to alpha-BGTBP alpha-1-(181-200) and alpha-BGTBP alpha-2-(181-200) were found to consistently and specifically bind I-125-alpha-BGT. The ability of these peptides to bind alpha-BGT was significantly decreased by reduction and alkylation of the Cys residues at positions 190/191, whereas oxidation had little effect on alpha-BGT binding activity. The relative affinities for alpha-BGT of the peptide sequences alpha-BGTBP alpha-1-(181-200) and alpha-BGTBP alpha-2-(181-200) were compared with those of peptides corresponding to the sequence segments Torpedo alpha-1-(181-200) and chick muscle alpha-1-(179-198). In competition assays, the IC50 for alpha-BGTBP alpha-1-(181-200) was 20-fold higher than that obtained for the other peptides (approximately 2 versus 40-mu-M). These results indicate that alpha-BGTBP alpha-1 and alpha-BGTBP alpha-2 are ligand binding subunits able to bind alpha-BGT at sites homologous with nAChR-alpha-subunits and that these subunits may confer differential ligand binding properties on the two alpha-BGTBP subtypes of which they are components.	UNIV MINNESOTA,COLL BIOL SCI,DEPT BIOCHEM,ST PAUL,MN 55108; UNIV PENN,SCH MED,INST NEUROL SCI,PHILADELPHIA,PA 19104; UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG 1,GERMANY	University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania; Ruprecht Karls University Heidelberg					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA005695] Funding Source: NIH RePORTER; NIDA NIH HHS [5P01-DA05695] Funding Source: Medline; NIGMS NIH HHS [5-T32-GMO7323] Funding Source: Medline; NINDS NIH HHS [NS11323] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONHEIM A, 1988, J BIOL CHEM, V263, P9933; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BARKAS T, 1987, SCIENCE, V235, P77, DOI 10.1126/science.2432658; BASUS VJ, 1988, BIOCHEMISTRY-US, V27, P2763, DOI 10.1021/bi00408a016; BETZ H, 1984, J NEUROSCI, V4, P2095; BLACKLOW SC, 1990, BIOCHEMISTRY-US, V29, P4099, DOI 10.1021/bi00469a012; BLANCHARD SG, 1979, BIOCHEMISTRY-US, V18, P1875, DOI 10.1021/bi00577a005; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOSSY B, 1988, EMBO J, V7, P611, DOI 10.1002/j.1460-2075.1988.tb02854.x; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BOYD RT, 1988, NEURON, V1, P495; BURDEN SJ, 1975, P NATL ACAD SCI USA, V72, P3245, DOI 10.1073/pnas.72.8.3245; BURSZTAJN S, 1977, J PHYSIOL-LONDON, V269, P17, DOI 10.1113/jphysiol.1977.sp011890; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CARBONETTO ST, 1978, P NATL ACAD SCI USA, V75, P1016, DOI 10.1073/pnas.75.2.1016; CHIAPPINELLI VA, 1983, BRAIN RES, V277, P9, DOI 10.1016/0006-8993(83)90902-2; CHIAPPINELLI VA, 1985, PHARMACOL THERAPEUT, V31, P1, DOI 10.1016/0163-7258(85)90035-X; CLARK DG, 1972, BIOCHEMISTRY-US, V11, P1663, DOI 10.1021/bi00759a020; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; CONROY WG, 1990, J BIOL CHEM, V265, P21642; CONTITRONCONI BM, 1982, SCIENCE, V218, P1227, DOI 10.1126/science.7146904; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; CONTITRONCONI BM, 1985, P NATL ACAD SCI USA, V82, P5208, DOI 10.1073/pnas.82.15.5208; CONTITRONCONI BM, 1991, BIOCHEMISTRY-US, V30, P2575, DOI 10.1021/bi00224a003; CONTITRONCONI BM, 1988, NATO ASI SER H, V25, P119; CONTITRONCONI BM, 1989, NATO ASI H, V32, P291; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DELAGARZA R, 1989, NEUROSCI LETT, V99, P95, DOI 10.1016/0304-3940(89)90271-1; DELAGARZA R, 1987, NEUROSCIENCE, V23, P887, DOI 10.1016/0306-4522(87)90165-5; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DINGER B, 1985, BRAIN RES, V339, P295, DOI 10.1016/0006-8993(85)90095-2; DUFTON MJ, 1983, CRC CR REV BIOCH MOL, V14, P113, DOI 10.3109/10409238309102792; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; ELLIOTT J, 1980, BIOCHEM J, V185, P667, DOI 10.1042/bj1850667; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GARCIABORRON JC, 1987, BIOCHEMISTRY-US, V26, P4295, DOI 10.1021/bi00388a017; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; GOTTI C, 1987, NEUROSCI LETT, V82, P113, DOI 10.1016/0304-3940(87)90180-7; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRIESMANN GE, 1990, J NEUROCHEM, V54, P1541, DOI 10.1111/j.1471-4159.1990.tb01202.x; HAGGERTY JG, 1981, J BIOL CHEM, V256, P8294; HALVORSEN SW, 1986, J NEUROSCI, V6, P3405; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; INAGAKI F, 1982, EUR J BIOCHEM, V123, P99, DOI 10.1111/j.1432-1033.1982.tb06504.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; KELLARIS KV, 1989, BIOCHEMISTRY-US, V28, P3469, DOI 10.1021/bi00434a048; KEMP G, 1987, MOL PHARMACOL, V32, P356; KEMP G, 1985, BRAIN RES, V347, P274, DOI 10.1016/0006-8993(85)90187-8; KOSEN PA, 1988, BIOCHEMISTRY-US, V27, P2775, DOI 10.1021/bi00408a018; KUROSAKI T, 1987, FEBS LETT, V214, P253, DOI 10.1016/0014-5793(87)80065-0; Lindstrom J, 1981, Methods Enzymol, V74 Pt C, P432; LINDSTROM J, 1987, MOL NEUROBIOL, V1, P281, DOI 10.1007/BF02935740; LIPTON SA, 1987, PFLUG ARCH EUR J PHY, V410, P37, DOI 10.1007/BF00581893; LORING RH, 1984, NEUROSCIENCE, V11, P989, DOI 10.1016/0306-4522(84)90209-4; LORING RH, 1988, TRENDS NEUROSCI, V11, P73, DOI 10.1016/0166-2236(88)90168-3; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1979, HDB EXPT PHARMACOLOG, V52, P213; LUETJE CW, 1990, J NEUROCHEM, V55, P632, DOI 10.1111/j.1471-4159.1990.tb04180.x; LUETJE CW, 1990, FASEB J, V4, P2753, DOI 10.1096/fasebj.4.10.2197155; LUKAS RJ, 1986, J NEUROCHEM, V47, P1768, DOI 10.1111/j.1471-4159.1986.tb13087.x; LUKAS RJ, 1986, P NATL ACAD SCI USA, V83, P5741, DOI 10.1073/pnas.83.15.5741; LUKAS RJ, 1984, BIOCHEMISTRY-US, V23, P1160, DOI 10.1021/bi00301a020; MARKS MJ, 1986, MOL PHARMACOL, V30, P427; MCLANE KE, 1990, J BIOL CHEM, V265, P9816; MCLANE KE, 1991, BIOCHEMISTRY-US, V30, P4925, DOI 10.1021/bi00234a013; MCLANE KE, 1990, J BIOL CHEM, V265, P1537; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MEEKER RB, 1986, J NEUROSCI, V6, P1866; MEHRABAN F, 1984, EUR J BIOCHEM, V138, P53, DOI 10.1111/j.1432-1033.1984.tb07880.x; MIHOVILOVIC M, 1981, J BIOL CHEM, V29, P427; MOLINOFF PB, 1981, LIFE SCI, V29, P427, DOI 10.1016/0024-3205(81)90208-3; MOSCKOVITZ R, 1988, J BIOL CHEM, V263, P1017; MULLE C, 1990, J NEUROSCI, V10, P169; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P3008, DOI 10.1073/pnas.83.9.3008; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9250, DOI 10.1073/pnas.83.23.9250; NEUMANN D, 1989, P NATL ACAD SCI USA, V86, P7255, DOI 10.1073/pnas.86.18.7255; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; NORMAN RI, 1982, P NATL ACAD SCI-BIOL, V79, P1321, DOI 10.1073/pnas.79.4.1321; OHANA B, 1990, BIOCHEMISTRY-US, V29, P6409, DOI 10.1021/bi00479a011; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; PATRICK J, 1977, J BIOL CHEM, V252, P8629; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; QUIK M, 1988, CAN J PHYSIOL PHARM, V66, P971, DOI 10.1139/y88-160; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; RAINES RT, 1986, BIOCHEMISTRY-US, V25, P7142, DOI 10.1021/bi00370a057; RALSTON S, 1987, BIOCHEMISTRY-US, V26, P3261, DOI 10.1021/bi00386a004; Rodbard D, 1975, Methods Enzymol, V37, P3; RUSAK B, 1990, ANNU REV NEUROSCI, V13, P387, DOI 10.1146/annurev.ne.13.030190.002131; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SAWRUK E, 1990, EMBO J, V9, P2671, DOI 10.1002/j.1460-2075.1990.tb07452.x; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SCHOEPFER R, 1988, NEURON, V1, P241, DOI 10.1016/0896-6273(88)90145-6; SCHULZ DW, 1989, NEUROSCI LETT, V98, P310, DOI 10.1016/0304-3940(89)90420-5; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; VIDAL C, 1989, NEUROSCIENCE, V29, P261, DOI 10.1016/0306-4522(89)90056-0; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WATTERS D, 1983, BIOCHEMISTRY-US, V22, P1811, DOI 10.1021/bi00277a011; WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595; WHITING PJ, 1986, BIOCHEMISTRY-US, V25, P2082, DOI 10.1021/bi00356a037; WHITING PJ, 1987, NATURE, V327, P515, DOI 10.1038/327515a0; WILSON PT, 1988, BIOCHEMISTRY-US, V27, P6667, DOI 10.1021/bi00418a004; WILSON PT, 1988, MOL PHARMACOL, V34, P643; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; WILSON PT, 1984, P NATL ACAD SCI-BIOL, V81, P2553, DOI 10.1073/pnas.81.8.2553; WONG LA, 1989, NATURE, V341, P439, DOI 10.1038/341439a0; WONNACOTT S, 1986, J NEUROCHEM, V47, P1706, DOI 10.1111/j.1471-4159.1986.tb13078.x; ZATZ M, 1981, BRAIN RES, V213, P438, DOI 10.1016/0006-8993(81)90250-X; [No title captured]	120	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15230	15239						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869552				2022-12-25	WOS:A1991GB09700063
J	NESS, GC; KELLER, RK; PENDLETON, LC				NESS, GC; KELLER, RK; PENDLETON, LC			FEEDBACK-REGULATION OF HEPATIC 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE-ACTIVITY BY DIETARY-CHOLESTEROL IS NOT DUE TO ALTERED MESSENGER-RNA LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; CRYSTALLOID ENDOPLASMIC-RETICULUM; FARNESYL PYROPHOSPHATE SYNTHETASE; TRANSCRIPTION INITIATION SITES; MEVALONATE-DERIVED PRODUCT; RAT-LIVER; NUCLEOTIDE-SEQUENCE; UT-1 CELLS; 7-ALPHA-HYDROXYLASE	Feeding rats diets containing 2% cholesterol markedly reduced hepatic 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase activity but had little effect on mRNA levels. Addition of mevalonolactone to the diet further decreased reductase activity independent of a change in mRNA levels. In contrast, farnesyl pyrophosphate synthetase mRNA levels and enzyme activity were decreased to similar degrees in response to dietary cholesterol. Addition of mevalonolactone to the diet did not further decrease farnesyl pyrophosphate synthetase activity. Dietary cholesterol and mevalonolactone had no effect on mRNA levels for ''cellular nucleic acid-binding protein'' which has been demonstrated to bind the sterol regulatory elements in the HMG-CoA reductase and farnesyl pyrophosphate synthetase promoters. Dietary cholesterol increased cholesterol 7-alpha-hydroxylase mRNA levels as expected. These results suggest that cholesterol-mediated feedback regulation of hepatic HMG-CoA reductase gene expression does not occur at the level of transcription.			NESS, GC (corresponding author), UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,12901 BRUCE B DOWNS BLVD,TAMPA,FL 33612, USA.				NHLBI NIH HHS [HL 43111, HL 18094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043111, R01HL018094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1983, J CELL SCI, V63, P1; AREBALO RE, 1982, P NATL ACAD SCI-BIOL, V79, P51, DOI 10.1073/pnas.79.1.51; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DUGAN RE, 1982, EUR J BIOCHEM, V125, P497, DOI 10.1111/j.1432-1033.1982.tb06710.x; GIL G, 1986, J BIOL CHEM, V261, P3710; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD RG, 1951, AM J MED, V11, P209, DOI 10.1016/0002-9343(51)90107-6; GOULD RG, 1950, FED PROC, V9, P179; GREGG RG, 1983, 3 HYDROXY 3 METHYLGL, P245; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JENKE HS, 1981, J BIOL CHEM, V256, P9622; KANDUTSCH AA, 1970, ARCH BIOCHEM BIOPHYS, V140, P122, DOI 10.1016/0003-9861(70)90016-0; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; LANGDON RG, 1953, J BIOL CHEM, V202, P77; LEE YP, 1965, J BIOL CHEM, V240, P1427; LI YC, 1990, J BIOL CHEM, V265, P12012; LIMI TC, 1967, J BIOL CHEM, V242, P990; LISCUM L, 1983, J BIOL CHEM, V258, P8450; LUSKEY KL, 1987, MOL CELL BIOL, V7, P1881, DOI 10.1128/MCB.7.5.1881; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NESS GC, 1985, J BIOL CHEM, V260, P2391; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; NESS GC, 1987, LIPIDS, V22, P409, DOI 10.1007/BF02537269; NESS GC, 1985, J BIOL CHEM, V260, P6395; NESS GC, 1983, MOL CELL BIOCHEM, V53-4, P299; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; RILLING HC, 1985, METHOD ENZYMOL, V110, P145; Rodwell V W, 1976, Adv Lipid Res, V14, P1; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SHAPIRO DJ, 1971, J BIOL CHEM, V246, P60; SIMONET WS, 1987, BIOCHEM BIOPH RES CO, V146, P1033, DOI 10.1016/0006-291X(87)90751-0; SINENSKY M, 1982, J BIOL CHEM, V257, P7284; SINGER II, 1984, P NATL ACAD SCI-BIOL, V81, P5556, DOI 10.1073/pnas.81.17.5556; SIPERSTEIN MD, 1966, J BIOL CHEM, V241, P602; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; TOMKINS GM, 1953, J BIOL CHEM, V201, P137; WHITE LW, 1970, BIOCHEMISTRY-US, V9, P2725, DOI 10.1021/bi00815a021	49	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14854	14857						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869523				2022-12-25	WOS:A1991GB09700007
J	LEVY, S; NGUYEN, VQ; ANDRIA, ML; TAKAHASHI, S				LEVY, S; NGUYEN, VQ; ANDRIA, ML; TAKAHASHI, S			STRUCTURE AND MEMBRANE TOPOLOGY OF TAPA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE SURFACE-ANTIGEN; TUMOR-ASSOCIATED ANTIGEN; T-CELL AGGREGATION; ANTIPROLIFERATIVE ANTIBODY; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; PROTEIN; TRANSLOCATION; TARGET	TAPA-1 (the target of an antiproliferative antibody) is a 26-kDa cell surface protein expressed on most human cell lines. TAPA-1 is a member of an evolutionarily related family of cell surface proteins all of which contain four transmembrane domains. A model is proposed for the topology of TAPA-1 based on proteolysis studies of the in vitro translated protein embedded into microsomal membranes. This analysis predicts that the amino and the carboxyl termini of the molecule are cytoplasmic and that the two hydrophilic regions of the molecule are extracellular. The antigenic epitope of the human TAPA-1 is contained within a subregion of the second extracellular domain of the protein. This is the only region in the protein that has not been tightly conserved in mammalian evolution.			LEVY, S (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT MED, DIV ONCOL, STANFORD, CA 94305 USA.				NCI NIH HHS [CA34233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIOT M, 1990, J IMMUNOL, V145, P4322; ANGELISOVA P, 1990, IMMUNOGENETICS, V32, P281, DOI 10.1007/BF00187099; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY L, 1991, FASEB J, V5, pA611; CHEN YX, 1984, J IMMUNOL, V133, P2496; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLASSON BJ, 1990, J EXP MED, V172, P1007, DOI 10.1084/jem.172.3.1007; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HOTTA H, 1988, CANCER RES, V48, P2955; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIEN TW, 1985, MOL IMMUNOL, V22, P1185; LEVY S, 1987, GENE, V54, P167, DOI 10.1016/0378-1119(87)90484-7; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1982, J BIOL CHEM, V257, P1860; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PUMAROLASUNE T, 1986, J IMMUNOL, V137, P826; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V952, P92, DOI 10.1016/0167-4838(88)90105-7; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TEDDER TF, 1989, J IMMUNOL, V143, P712; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VAICKUS L, 1985, J IMMUNOL, V135, P1987; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WRIGHT MD, 1990, J IMMUNOL, V144, P3195; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZELENETZ AD, 1990, GENE, V89, P123, DOI 10.1016/0378-1119(90)90214-C	34	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14597	14602						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860863				2022-12-25	WOS:A1991FZ35100076
J	WU, GY; WILSON, JM; SHALABY, F; GROSSMAN, M; SHAFRITZ, DA; WU, CH				WU, GY; WILSON, JM; SHALABY, F; GROSSMAN, M; SHAFRITZ, DA; WU, CH			RECEPTOR-MEDIATED GENE DELIVERY INVIVO - PARTIAL CORRECTION OF GENETIC ANALBUMINEMIA IN NAGASE RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY ELEMENTS; ALBUMIN; DNA; RNA; HEPATOCYTES; EXPRESSION; EXTRACTION; SEQUENCES; ANTIBODY; PROTEINS	A plasmid (palb3) was constructed containing the structural gene for human serum albumin driven by mouse albumin enhancer-rat albumin promoter elements. Using an asialoglycoprotein-polycation conjugate consisting of asialoorosomucoid coupled to poly-L-lysine, a soluble DNA complex was formed that was capable of targeting specifically to hepatocytes via asialoglycoprotein receptors present on these cells. Groups of Nagase analbuminemic rats were injected with complexed DNA or controls, followed by two-thirds partial hepatectomy to stimulate hepatocyte replication. Using a cDNA probe for the human albumin structural gene, hybridizable sequences were detected in analbuminemic rats treated with complex as determined by Southern blot analysis. Two weeks post-injection, the targeted DNA was found to exist primarily in plasmid form with an average copy number of 1000/diploid cell. Human albumin mRNA was detected by dot-blot hybridization with a specific oligonucleotide cDNA probe and confirmed by RNase protection assay using a vector-specific probe. Circulating human albumin was detected in the serum of palb3-treated Nagase analbuminemic rats by Western blots using an antibody specific for human serum albumin. A time course demonstrated that circulating human albumin was not detectable 24 h after injection, but became measurable at a level of 0.05-mu-g/ml within 48 h and increased in concentration to a maximum of 34-mu-g/ml by 2 weeks post-injection. This level of expression remained stable through 4 weeks after injection and partial hepatectomy.	UNIV MICHIGAN,SCH MED,DEPT MED,HOWARD HUGHES MED RES LABS,ANN ARBOR,MI 48109; YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,DEPT MED,BRONX,NY 10461	University of Michigan System; University of Michigan; Yeshiva University; Albert Einstein College of Medicine	WU, GY (corresponding author), UNIV CONNECTICUT,SCH MED,DEPT MED,DIV GASTROENTEROL HEPATOL,FARMINGTON,CT 06030, USA.				NCI NIH HHS [CA46801] Funding Source: Medline; NIDDK NIH HHS [DK42182, DK42193] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042182, R01DK042193] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GORIN MB, 1981, J BIOL CHEM, V256, P1954; JUNG G, 1981, BIOCHEM BIOPH RES CO, V101, P599, DOI 10.1016/0006-291X(81)91301-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1982, MOL CLONING LABORATO, P150; MCKEE PA, 1983, METABOLIC BASIS INHE, P1531; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; PFARR DS, 1985, DNA-J MOLEC CELL BIO, V4, P461, DOI 10.1089/dna.1985.4.461; PINCKERT CA, 1987, GENE DEV, V1, P268; Sambrook J, 1989, MOL CLONING LABORATO; SHALABY F, 1990, P NATL ACAD SCI USA, V87, P2652, DOI 10.1073/pnas.87.7.2652; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; URANO Y, 1986, J BIOL CHEM, V261, P3244; VANBEVEREN C, 1985, RNA TUMOR VIRUSES, P766; WAYNFORTH HB, 1980, EXPT SURGICAL TECHNI; WHITEHEAD PH, 1966, BIOCHIM BIOPHYS ACTA, V124, P209, DOI 10.1016/0304-4165(66)90336-9; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621	27	333	384	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14338	14342						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860843				2022-12-25	WOS:A1991FZ35100037
J	KOBAYASHI, T; TAO, T; GRABAREK, Z; GERGELY, J; COLLINS, JH				KOBAYASHI, T; TAO, T; GRABAREK, Z; GERGELY, J; COLLINS, JH			CROSS-LINKING OF RESIDUE-57 IN THE REGULATORY DOMAIN OF A MUTANT RABBIT SKELETAL-MUSCLE TROPONIN-C TO THE INHIBITORY REGION OF TROPONIN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CALCIUM-BINDING PROTEIN; BIOLOGICAL-ACTIVITY; PROTEOLYTIC FRAGMENTS; CALMODULIN; SUBUNITS; 4-MALEIMIDOBENZOPHENONE; FLUORESCENCE; CONTRACTION; CYSTEINE-98	Interactions between troponin C (TnC) and troponin I (TnI) play an important role in the Ca2+-dependent regulation of vertebrate striated muscle contraction. In the present study, we investigated the sites of interaction between the N-terminal regulatory domain of TnC and the inhibitory region (residues 96-116) of TnI, using a mutant rabbit skeletal TnC (designated as TnC57) that contains a single Cys at residue 57 in the C-helix. TnC57 was modified with the photoreactive cross-linker 4-maleimidobenzophenone (BP-Mal), and, after formation of a binary complex with TnI, cross-linking between the proteins was induced by photolysis. The resulting product was cleaved with CNBr and several proteases, and peptides containing cross-links were purified and subjected to amino acid sequencing. The results show that Cys-57 of TnC57 is cross-linked to the segment of TnI spanning residues 113-121. Previously, we showed that Cys-98 of TnC can be cross-linked via BP-Mal to TnI residues 103-110 (Leszyk, J., Collins, J. H., Leavis, P. C., and Tao, T. (1987) Biochemistry 26, 7042-7047). Taken together, these results demonstrate that both the C- and the N-terminal domains of TnC interact with the inhibitory region of TnI and are consistent with the hypothesis that, in a complex with TnI, TnC adopts a more compact conformation than in the crystal structure.	UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA; UNIV MARYLAND, CTR MED BIOTECHNOL, INST BIOTECHNOL, BALTIMORE, MD 21201 USA; BOSTON BIOMED RES INST, DEPT MUSCLE RES, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, NEUROL SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Boston Biomedical Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Grabarek, Zenon/0000-0002-3636-5701	NHLBI NIH HHS [R-37-HL-05949] Funding Source: Medline; NIAMS NIH HHS [AR-21673] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL005949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021673, R37AR021673] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; Campbell A P, 1989, Adv Exp Med Biol, V255, P195; CHEUNG H C, 1989, Biophysical Journal, V55, p122A; COLLINS JH, 1980, PREP BIOCHEM, V10, P77, DOI 10.1080/00327488008061721; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COLLINS JH, 1973, FEBS LETT, V36, P268, DOI 10.1016/0014-5793(73)80388-6; COLLINS JH, 1988, J BIOL CHEM, V263, P15378; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KOBAYASHI T, 1988, EUR J BIOCHEM, V174, P579, DOI 10.1111/j.1432-1033.1988.tb14137.x; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; NOZAKI S, 1980, CHEM LETT, P345, DOI 10.1246/cl.1980.345; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHAR S5, V12, P1; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; WANG CLA, 1987, J BIOL CHEM, V262, P9636; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WILKINSON JM, 1975, BIOCHEM J, V149, P493, DOI 10.1042/bj1490493; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	38	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13746	13751						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856208				2022-12-25	WOS:A1991FY02700047
J	WANG, CLA; CHALOVICH, JM; GRACEFFA, P; LU, RC; MABUCHI, K; STAFFORD, WF				WANG, CLA; CHALOVICH, JM; GRACEFFA, P; LU, RC; MABUCHI, K; STAFFORD, WF			A LONG HELIX FROM THE CENTRAL REGION OF SMOOTH-MUSCLE CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD CALDESMON; CALMODULIN-BINDING FRAGMENT; AMINO-ACID-SEQUENCE; MOLECULAR-WEIGHT; SECONDARY-STRUCTURE; ATPASE ACTIVITY; TROPONIN-C; ANALYTICAL ULTRACENTRIFUGATION; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE	The central region of smooth muscle caldesmon is predicted to form alpha-helices on the basis of its primary structure. We have isolated a fragment (CT54) that contains this region. The hydrodynamic properties and the electron microscopic images suggest that CT54 is an elongated (35 nm), monomeric molecule. The circular dichroic spectrum yields an overall alpha-helical content of 55-58%. These results are consistent with the model that the middle portion of CT54 forms a long stretch of single-stranded alpha-helix. Such a structure, if it in fact exists, is thought to be stabilized by numerous salt bridges between charged residues at positions i and i + 4. The structural characteristics of this fragment not only represent an unusual protein configuration but also provide information about the functional role of caldesmon in smooth muscle contraction.	HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; E CAROLINA UNIV, SCH MED, DEPT BIOCHEM, GREENVILLE, NC 27858 USA	Harvard University; Harvard Medical School; University of North Carolina; East Carolina University	WANG, CLA (corresponding author), BOSTON BIOMED RES INST, DEPT MUSCLE RES, 20 STANIFORD ST, BOSTON, MA 02114 USA.		Stafford, Walter/ABC-6553-2020	Chalovich, Joseph/0000-0002-1243-4055	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035216] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41411] Funding Source: Medline; NIAMS NIH HHS [R01 AR035216, AR35216, AR30917] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAILEY JE, 1966, THESIS LONDON U; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRYAN J, 1990, J MUSCLE RES CELL M, V11, P434; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; FUJII T, 1987, J BIOL CHEM, V262, P2757; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GRACEFFA P, 1990, BIOPHYS J, V57, pA161; GRACEFFA P, 1990, J MUSCLE RES CELL M, V11, P440; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1989, BIOCHEMISTRY-US, V28, P1282, DOI 10.1021/bi00429a050; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KATAYAMA E, 1989, BIOCHEM BIOPH RES CO, V160, P1316, DOI 10.1016/S0006-291X(89)80147-0; KING L, 1989, BIOCHEMISTRY-US, V28, P3498, DOI 10.1021/bi00434a052; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LASH JA, 1986, J BIOL CHEM, V261, P6155; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; LYNCH W, 1986, METHOD ENZYMOL, V134, P37; MABUCHI K, 1990, J STRUCT BIOL, V103, P249, DOI 10.1016/1047-8477(90)90043-C; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARQUSEE S, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P85; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1984, BIOCHEM SOC T, V12, P945, DOI 10.1042/bst0120945; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MAXFIELD FR, 1975, MACROMOLECULES, V8, P491, DOI 10.1021/ma60046a022; NGAI PK, 1984, J BIOL CHEM, V259, P3656; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PRITCHARD K, 1986, CELL CALCIUM, V7, P309, DOI 10.1016/0143-4160(86)90035-7; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; STAFFORD WF, 1990, ARCH BIOCHEM BIOPHYS, V281, P66, DOI 10.1016/0003-9861(90)90413-S; STAFFORD WF, 1985, BIOCHEMISTRY-US, V24, P3314, DOI 10.1021/bi00334a036; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SUNDARALINGAM M, 1985, P NATL ACAD SCI USA, V82, P7944, DOI 10.1073/pnas.82.23.7944; SUNDARALINGAM M, 1987, PROTEINS, V2, P64, DOI 10.1002/prot.340020108; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAGI T, 1989, J BIOCHEM-TOKYO, V106, P778, DOI 10.1093/oxfordjournals.jbchem.a122930; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WANG CLA, 1990, BIOPHYS J, V57, pA162; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	58	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13958	13963						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856225				2022-12-25	WOS:A1991FY02700080
J	BIRCHENALLROBERTS, MC; FALK, LA; KASPER, J; KELLER, J; FALTYNEK, CR; RUSCETTI, FW				BIRCHENALLROBERTS, MC; FALK, LA; KASPER, J; KELLER, J; FALTYNEK, CR; RUSCETTI, FW			DIFFERENTIAL EXPRESSION OF TRANSFORMING GROWTH FACTOR-BETA-1 (TGF-BETA-1) RECEPTORS IN MURINE MYELOID CELL-LINES TRANSFORMED WITH ONCOGENES - CORRELATION WITH DIFFERENTIAL GROWTH-INHIBITION BY TGF-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; FACTOR-BETA; MONOCYTIC DIFFERENTIATION; MEMBRANE-RECEPTOR; PROLIFERATION; MODULATION; BINDING	Transforming growth factor-beta-1 (TGF-beta-1) is a pleiotropic polypeptide hormone known to play an important role as a modulator of hematopoietic processes in human and murine cells. One of the characteristics of TGF-beta-1 is the ability to inhibit the growth of several cell types, including cells of the myeloid lineage. To study the mechanism by which TGF-beta-1 inhibits the growth of myeloid cells, we have used three murine myeloid cell lines, the parental interleukin-3-dependent 32D-123 cell line and two retrovirally infected interleukin-3-independent cell lines (32D-abl, 32D-src), all of which are growth inhibited by TGF-beta-1. Each of these oncogene-transfected cells expresses a greater number of TGF-beta-1 receptors than the parental cell line and responds to TGF-beta-1 with increased sensitivity; 32D and 32D-src cells are 2- and 58-fold more sensitive to TGF-beta-1 inhibition than the parental cell line (ED50 = 35 pM). Both 32D-abl- and 32D-src-transformed cell lines expressed higher levels of the 65- and 85-kDa TGF-beta-1 receptor species than did the parental cells. We observed a correlation between the greater sensitivity of 32D-src cells to TGF-beta-1 and the more rapid down-modulation and reappearance of cell surface TGF-beta-1 receptors on 32D-src cells. Thus, the level of TGF-beta-1 receptor expression and rate of reexpression both have a crucial regulatory effect on the functional activity of the TGF-beta-1 ligand.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; STERLING DRUG INC,STERLING RES GRP,MALVERN,PA 19355	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BIRCHENALLROBERTS, MC (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,BIOL CARCINOGENESIS DEV PROGRAM,POB B,FREDERICK,MD 21702, USA.		Keller, Jonathan R./O-6677-2018		OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1982, CANCER RES, V42, P4776; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; COFFEY RJ, 1988, CANCER RES, V48, P1596; CUATRECASAS P, 1985, MECHANISMS RECEPTOR, P207; DEBENEDETTI F, 1990, BLOOD, V75, P626; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; ELLINGSWORTH L, 1989, J CELL BIOCHEM, V39, P489, DOI 10.1002/jcb.240390414; FAUSTO N, 1987, S FUNDAM CANCER RES, V39, P69; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GREENBERGER JS, 1984, LEUKEMIA RES, V8, P363, DOI 10.1016/0145-2126(84)90076-6; HEBERT CD, 1989, CANCER RES, V49, P3196; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HOLLEY RW, 1983, CELL BIOL INT REP, V7, P141, DOI 10.1016/0309-1651(83)90027-9; HOOSEIN NM, 1987, CANCER RES, V47, P2950; IGNATZ RA, 1985, P NATL ACAD SCI USA, V82, P8530; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JACOBSEN SEW, 1991, IN PRESS BLOOD; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KELLER JR, 1990, BLOOD, V75, P596; KELLER JR, 1990, ONCOGENE, V5, P549; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MOSES HL, 1985, CANCER CELL, V3, P65; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; RANCHALIS JE, 1987, BIOCHEM BIOPH RES CO, V148, P783, DOI 10.1016/0006-291X(87)90944-2; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SING GK, 1988, BLOOD, V72, P1504; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965	39	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9617	9621						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851752				2022-12-25	WOS:A1991FM45900045
J	HARRIS, RZ; WARIISHI, H; GOLD, MH; DEMONTELLANO, PRO				HARRIS, RZ; WARIISHI, H; GOLD, MH; DEMONTELLANO, PRO			THE CATALYTIC SITE OF MANGANESE PEROXIDASE - REGIOSPECIFIC ADDITION OF SODIUM-AZIDE AND ALKYLHYDRAZINES TO THE HEME GROUP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; LIGNIN-DEGRADING BASIDIOMYCETE; NUCLEAR MAGNETIC-RESONANCE; N-PHENYLPROTOPORPHYRIN-IX; WHITE ROT BASIDIOMYCETE; HORSERADISH-PEROXIDASE; PROSTHETIC HEME; EXTRACELLULAR PEROXIDASES; SPECTRAL CHARACTERIZATION; DIARYLPROPANE OXYGENASE	Manganese peroxidase (MnP), which normally oxidizes Mn2+ to Mn3+, is rapidly and completely inactivated in an H2O2-dependent reaction by 2 equivalents of sodium azide. The inactivation is paralleled by formation of the azidyl radical and high yield conversion of the prosthetic heme into a meso-azido adduct. The meso-azido enzyme is oxidized by H2O2 to a Compound II-like species with the Soret band red-shifted 2 nm relative to that of native Compound II. The time-dependent decrease in this Compound II-like spectrum (t1/2 = 2.3 h) indicates that the delta-meso azido heme is more rapidly degraded by H2O2 than the prosthetic heme of control enzyme (t1/2 = 4.8 h). MnP is also inactivated by phenyl-, methyl-, and ethylhydrazine. The phenylhydrazine reaction is too rapid for kinetic analysis, but K(I) = 402-mu-M and k(inact) = 0.22/min for the slower inactivation by methylhydrazine. Reaction with phenylhydrazine at pH 4.5 does not yield iron-phenyl, N-phenyl, or meso-phenyl heme adducts. Ethylhydrazine inactivates the enzyme both at pH 4.5 and 7.0, but only detectably produces delta-meso-ethylheme at pH 7.0. Reconstitution of apo-MnP with hemin or delta-meso-ethylheme yields enzyme with, respectively, 50 and 5% of the native activity. The delta-meso-alkyl group thus suppresses most of the catalytic activity of the enzyme even though a Compound II-like species is still formed with H2O2. Finally, Co2+ inhibits the enzyme competitively with respect to Mn2+ but does not inhibit its inactivation by azide or the alkylhydrazines. The results argue that substrates interact with the heme edge in the vicinity of the delta-meso-carbon. They also suggest that Mn2+ and Co2+ bind to a common site close to the delta-meso-carbon without blocking the approach of small molecules to the heme edge. An active site model is proposed that accommodates these results.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM & BIOL SCI,BEAVERTON,OR 97006	University of California System; University of California San Francisco					NIGMS NIH HHS [GM-32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN MD, 1990, ARCH BIOCHEM BIOPHYS, V276, P405, DOI 10.1016/0003-9861(90)90739-L; ALIC M, 1987, APPL ENVIRON MICROB, V53, P1464, DOI 10.1128/AEM.53.7.1464-1469.1987; ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1989, J BIOL CHEM, V264, P9250; ATOR MA, 1987, J BIOL CHEM, V262, P1542; AUGUSTO O, 1982, J BIOL CHEM, V257, P6231; BUSHWELL JA, 1987, CRC CRIT R BIOTECH, V6, P1; CHOE YS, 1991, J BIOL CHEM, V266, P8523; Crawford R.L., 1981, LIGNIN BIODEGRADATIO; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P558; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1988, BIOCHEMISTRY-US, V27, P5470, DOI 10.1021/bi00415a013; DEPILLIS GD, 1989, BIOCHEMISTRY-US, V28, P7947, DOI 10.1021/bi00445a059; DEPILLIS GD, 1990, ARCH BIOCHEM BIOPHYS, V280, P217, DOI 10.1016/0003-9861(90)90539-B; FOINZEL BC, 1987, J BIOL CHEM, V259, P13027; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1984, ARCH BIOCHEM BIOPHYS, V234, P353, DOI 10.1016/0003-9861(84)90280-7; GOLD MH, 1989, ACS SYM SER, V389, P127; HINMAN RL, 1958, J ORG CHEM, V23, P1587, DOI 10.1021/jo01104a629; HUANG PKC, 1968, J AM CHEM SOC, V90, P2354, DOI 10.1021/ja01011a027; KALYANARAMAN B, 1985, J BIOL CHEM, V260, P4003; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; LAMAR GN, 1989, J AM CHEM SOC, V111, P485, DOI 10.1021/ja00184a014; LAMAR GN, 1980, J AM CHEM SOC, V102, P4833, DOI 10.1021/ja00534a046; LEISOLA MSA, 1987, J BIOL CHEM, V262, P419; LEVY MJ, 1985, J BIOL CHEM, V260, P3694; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINO Y, 1988, J BIOL CHEM, V263, P7029; PASCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750; PEASE EA, 1989, J BIOL CHEM, V264, P13531; POCHAPSKY TC, 1990, J AM CHEM SOC, V112, P5258, DOI 10.1021/ja00169a038; POULOS TL, 1980, J BIOL CHEM, V255, P8199; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RENGANATHAN V, 1985, ARCH BIOCHEM BIOPHYS, V241, P304, DOI 10.1016/0003-9861(85)90387-X; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; SAITO S, 1981, P NATL ACAD SCI-BIOL, V78, P5508, DOI 10.1073/pnas.78.9.5508; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SARKANEN KV, 1971, LIGNINS; Tien M, 1987, NATURE, V326, P520, DOI 10.1038/326520a0; TIEN M, 1984, P NATL ACAD SCI-BIOL, V81, P2280, DOI 10.1073/pnas.81.8.2280; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WELINDER KG, 1976, FEBS LETT, V72, P19, DOI 10.1016/0014-5793(76)80804-6	48	58	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8751	8758						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851156				2022-12-25	WOS:A1991FM03800021
J	SHIBASAKI, F; HOMMA, Y; TAKENAWA, T				SHIBASAKI, F; HOMMA, Y; TAKENAWA, T			2 TYPES OF PHOSPHATIDYLINOSITOL 3-KINASE FROM BOVINE THYMUS - MONOMER AND HETERODIMER FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SIGNAL TRANSDUCTION; CELLULAR-REGULATION; MIDDLE-T; BRAIN; POLYPHOSPHOINOSITIDES; PHOSPHORYLATION; TRANSFORMATION; FIBROBLASTS; PP60C-SRC	Two types of phosphatidylinositol (PI) 3-kinase (PI3K) have been purified 6250-fold (PI3KI) and 1250-fold (PI3KII) from the cytosol fraction of bovine thymus. Purified PI3KI and PI3KII were found to have apparent molecular masses of 110 and 190 kDa, respectively, by gel filtration. On the other hand, on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, while the molecular mass of PI3KI was again estimated as 110 kDa, PI3KII showed two bands with apparent molecular masses of 110 and 85 kDa, suggesting a heterodimer form. Peptide mapping analysis demonstrated that the 110-kDa protein in PI3KII was the same protein as PI3KI. The specific activity of PI3KI was calculated as 250 nmol/min/mg of protein, while that of PI3KII was 50 nmol/min/mg of protein. The product of PI phosphorylation by PI3KI and PI3KII were confirmed as phosphatidylinositol 3-phosphate by PartiSphere Sax column chromatography. The results show that there are two types of PI 3-kinase in bovine thymus. One exists as a monomer and the other as a heterodimer form. Furthermore, the biochemical properties of these two PI 3-kinases are markedly different. These two types of PI 3-kinase may be regulated differently under physiological conditions.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN									AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KATO M, 1987, J BIOL CHEM, V262, P5696; LIPS DL, 1989, J BIOL CHEM, V264, P8759; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; VANDAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAKAWA A, 1988, J BIOL CHEM, V263, P17555	22	154	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8108	8114						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850737				2022-12-25	WOS:A1991FK44100027
J	CHU, A; STEFANI, E				CHU, A; STEFANI, E			PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE-INDUCED CA2+ RELEASE FROM SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM TERMINAL CISTERNAL MEMBRANES - CA2+ FLUX AND SINGLE CHANNEL STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; RABBIT SKELETAL; CA-2+ RELEASE; FIBERS; PHOSPHATES	We report here that the inositol 1,4,5-trisphosphate (IP3) precursor, L-alpha-phosphatidylinositol 4,5-bisphosphate (PIP2) is a potent molecule (1-mu-M) which activates the ryanodine-sensitive Ca2+ release channel from rabbit skeletal muscle terminal cisternae incorporated into a phospholipid bilayer. It also stimulates Ca2+ release from these membrane vesicles. Therefore, it may play a modulating role in excitation-contraction coupling. In the bilayer, PIP2 added on the cytoplasmic side increased the mean channel opening probability 2-12-fold in the presence and absence of physiological Mg2+ and ATP. From flux studies, PIP2-induced Ca2+ release, occurring through the ryanodine-sensitive Ca2+ release channel, displayed saturation kinetics. The rate of Ca2+ release induced by PIP2 was approximately > 50% slower than the rates induced by other agents (e.g. caffeine, Ca2+, ATP). PIP2, and not IP3, effectively elicited Ca2+ release from terminal cisternae. On the contrary, IP3, and not PIP2, specifically mediated Ca2+ release from dog brain cerebellum microsomes, where IP3 receptors are known to be found. The PIP2-induced Ca2+ release from muscle membranes was not dependent on medium [Ca2+] (from < 10(-9) to approximately 10(-4) M). However, IP3 could activate the terminal cisternae Ca2+ channel in the bilayer when there was low Ca2+ (< 10(-7) M). The data suggest that the ionic microenvironment around the Ca2+ channel may be different for observing the two phosphoinositide actions.	BAYLOR UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; METHODIST HOSP, HOUSTON, TX 77030 USA	Baylor University; The Methodist Hospital System; The Methodist Hospital - Houston	CHU, A (corresponding author), BAYLOR UNIV, DEPT MED, CARDIOVASC SCI SECT, HOUSTON, TX 77030 USA.				NHLBI NIH HHS [R01HL13870] Funding Source: Medline; NIAMS NIH HHS [R01AR38970] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038970] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALDERSON BH, 1989, ARCH BIOCHEM BIOPHYS, V272, P162, DOI 10.1016/0003-9861(89)90207-5; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEST PM, 1986, AM J PHYSIOL, V250, pC245, DOI 10.1152/ajpcell.1986.250.2.C245; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; CHU A, 1988, METHOD ENZYMOL, V157, P36; DONALDSON SK, 1989, MED SCI SPORT EXER, V21, P411; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HIDALGO C, 1989, J BIOENERG BIOMEMBR, V21, P267, DOI 10.1007/BF00812072; KOBAYASHI M, 1989, BIOCHEM BIOPH RES CO, V163, P1487, DOI 10.1016/0006-291X(89)91147-9; LUI QY, 1989, BIOPHYS J, V55, pA85; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; NAKAMURA Y, 1987, ENDOCRINOLOGY, V120, P2302, DOI 10.1210/endo-120-6-2302; OGAWA Y, 1989, J BIOCHEM-TOKYO, V106, P864, DOI 10.1093/oxfordjournals.jbchem.a122943; PAPE PC, 1988, FEBS LETT, V235, P57, DOI 10.1016/0014-5793(88)81233-X; Peachey LD, 1983, HDB PHYSL, V10, P73; ROJAS C, 1990, BIOPHYS J, V57, pA342; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SUAREZISLA BA, 1988, BIOPHYS J, V54, P737, DOI 10.1016/S0006-3495(88)83009-1; VALDIVIA C, 1990, BIOPHYS J, V57, P1233, DOI 10.1016/S0006-3495(90)82642-4; VARSANYI M, 1986, BIOCHEM BIOPH RES CO, V138, P1395, DOI 10.1016/S0006-291X(86)80438-7; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; VERGARA J, 1987, CELL CALCIUM CONTROL, P131; VOLPE P, 1985, NATURE, V316, P347, DOI 10.1038/316347a0; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; ZHAO H, 1990, J BIOL CHEM, V265, P21419	30	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7699	7705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850418				2022-12-25	WOS:A1991FJ34200061
J	RAMSEIER, TM; WINTELER, HV; HENNECKE, H				RAMSEIER, TM; WINTELER, HV; HENNECKE, H			DISCOVERY AND SEQUENCE-ANALYSIS OF BACTERIAL GENES INVOLVED IN THE BIOGENESIS OF C-TYPE CYTOCHROMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE ISOMERASE; DEPENDENT TRANSPORT-SYSTEMS; MICROBIAL HEME SYNTHESIS; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; RHIZOBIUM-JAPONICUM; BRADYRHIZOBIUM-JAPONICUM; NUCLEOTIDE-SEQUENCE; LATE STEP; PARACOCCUS-DENITRIFICANS	We report the DNA sequence and mutational analysis of a novel cluster of six Bradyrhizobium japonicum genes of which at least three (designated cycV, cycW, and cycX) are essential for the formation of all cellular c-type cytochromes. Mutants having insertions in these genes were completely devoid of any soluble (periplasmic) or membrane-bound c-type cytochromes; even the apo form of cytochrome c1 was not detectable, neither in the membrane nor in the soluble fraction. As a consequence, the mutants had pleiotropic phenotypes such as defects in nitrate respiration, H-2 oxidation, electron transport to cytochrome aa3, and microaerobic respiration during symbiosis. A fourth open reading frame (ORF132) encoded a protein that might also be concerned with cytochrome c formation, but perhaps only indirectly. The other two open reading frames did not appear to function in this process. The predicted amino acid sequences of the cycW and cycX gene products suggested that these proteins were membrane-bound. The cycV gene product showed extensive similarity to the ATP-binding subunit of a superfamily of membrane-associated transport systems. The predicted ORF132 product was strikingly similar to bacterial thioredoxins and eukaryotic protein disulfide isomerase. Based on these findings it is possible that these proteins are members of a complex transport system involved in the biogenesis of all cytochromes c.	SWISS FED INST TECHNOL, INST MIKROBIOL, SCHMELZBERGSTR 7, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								APPLEBY CA, 1969, BIOCHIM BIOPHYS ACTA, V172, P88, DOI 10.1016/0005-2728(69)90094-2; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; BASILE G, 1980, J BIOL CHEM, V255, P7181; BERG DE, 1980, J BACTERIOL, V142, P439, DOI 10.1128/JB.142.2.439-446.1980; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BIEL SW, 1990, J BACTERIOL, V172, P1321, DOI 10.1128/jb.172.3.1321-1326.1990; BOTT M, 1990, MOL MICROBIOL, V4, P2147, DOI 10.1111/j.1365-2958.1990.tb00576.x; COLE MA, 1973, ANTIMICROB AGENTS CH, V4, P248, DOI 10.1128/AAC.4.3.248; DALDAL F, 1986, P NATL ACAD SCI USA, V83, P2012, DOI 10.1073/pnas.83.7.2012; DANIEL RM, 1972, BIOCHIM BIOPHYS ACTA, V275, P347, DOI 10.1016/0005-2728(72)90215-0; DAVIDSON E, 1987, BIOCHIM BIOPHYS ACTA, V890, P292, DOI 10.1016/0005-2728(87)90156-3; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FRANCIS RT, 1984, ANAL BIOCHEM, V136, P509, DOI 10.1016/0003-2697(84)90253-7; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FRIEDRICH MJ, 1986, J BACTERIOL, V167, P928, DOI 10.1128/jb.167.3.928-934.1986; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GRAY L, 1989, J CELL SCI, P45; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; HAHN M, 1984, MOL GEN GENET, V193, P46, DOI 10.1007/BF00327412; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENNECKE H, 1982, GENE, V19, P231, DOI 10.1016/0378-1119(82)90011-7; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HIGGINS CF, 1990, PHILOS T R SOC B, V326, P353, DOI 10.1098/rstb.1990.0017; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JACOBS NJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P540, DOI 10.1016/0304-4165(78)90328-8; JACOBS NJ, 1976, BIOCHIM BIOPHYS ACTA, V449, P1, DOI 10.1016/0005-2728(76)90002-5; JACOBS NJ, 1977, BIOCHIM BIOPHYS ACTA, V459, P141, DOI 10.1016/0005-2728(77)90017-2; JURTSHUK P JR, 1975, Critical Reviews in Microbiology, V3, P399, DOI 10.3109/10408417509108757; KEITHLY JH, 1983, J BACTERIOL, V154, P838, DOI 10.1128/JB.154.2.838-845.1983; KRANZ RG, 1989, J BACTERIOL, V171, P456, DOI 10.1128/jb.171.1.456-464.1989; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIM CJ, 1987, J BIOL CHEM, V262, P12114; LIM CJ, 1985, J BACTERIOL, V163, P311, DOI 10.1128/JB.163.1.311-316.1985; LIM CJ, 1986, J BACTERIOL, V168, P1258, DOI 10.1128/jb.168.3.1258-1264.1986; MAIER RJ, 1986, CRC CR REV BIOTECHN, V3, P17; Maniatis T., 1982, MOL CLONING; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OBRIAN MR, 1987, J BACTERIOL, V169, P1089, DOI 10.1128/jb.169.3.1089-1094.1987; OBRIAN MR, 1987, P NATL ACAD SCI USA, V84, P8390, DOI 10.1073/pnas.84.23.8390; PAGE MD, 1990, MOL MICROBIOL, V4, P1181, DOI 10.1111/j.1365-2958.1990.tb00693.x; PAGE MD, 1989, MOL MICROBIOL, V3, P653, DOI 10.1111/j.1365-2958.1989.tb00213.x; PETTIGREW GW, 1987, CYTOCHROMES C, P160; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; PILLE S, 1990, J BACTERIOL, V172, P1556, DOI 10.1128/jb.172.3.1556-1561.1990; POULSON R, 1975, J BIOL CHEM, V250, P1269; RAMSEIER TM, 1989, ARCH MICROBIOL, V151, P203, DOI 10.1007/BF00413131; RANAWEERA SS, 1985, BIOCHEM INT, V10, P415; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REGENSBURGER B, 1984, FEMS MICROBIOL LETT, V21, P77, DOI 10.1111/j.1574-6968.1984.tb00189.x; REGENSBURGER B, 1986, ARCH MICROBIOL, V144, P355, DOI 10.1007/BF00409885; REGENSBURGER B, 1983, ARCH MICROBIOL, V135, P103, DOI 10.1007/BF00408017; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; Simon R., 1983, MOL GENETICS BACTERI, V1st ed., P98; Smibert RM, 1981, MANUAL METHODS GEN B, P409; STOLTZFUS A, 1988, GENETICS, V120, P345; TANIUCHI H, 1983, J BIOL CHEM, V258, P963; THONY B, 1987, NUCLEIC ACIDS RES, V15, P8479, DOI 10.1093/nar/15.20.8479; THONYMEYER L, 1989, CELL, V57, P683, DOI 10.1016/0092-8674(89)90137-2; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUN NJ, 1989, J CELL SCI, P13; VANBERKUM P, 1985, APPL ENVIRON MICROB, V49, P772, DOI 10.1128/AEM.49.4.772-777.1985; VANVERSEVELD HW, 1981, BIOCHIM BIOPHYS ACTA, V635, P525, DOI 10.1016/0005-2728(81)90111-0; VELOSO D, 1981, J BIOL CHEM, V256, P8646; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOOD PM, 1983, FEBS LETT, V164, P223, DOI 10.1016/0014-5793(83)80289-0; YANOFSKY C, 1987, ESCHERICHIA COLI SAL, P1453	83	142	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7793	7803						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850420				2022-12-25	WOS:A1991FJ34200076
J	ODONNELL, M; GARIPPA, RJ; ONEILL, NC; BOLIN, DR; COTTRELL, JM				ODONNELL, M; GARIPPA, RJ; ONEILL, NC; BOLIN, DR; COTTRELL, JM			STRUCTURE-ACTIVITY STUDIES OF VASOACTIVE INTESTINAL POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN AIRWAYS; PEPTIDE; VIP; ASTHMA; NEUROPEPTIDES; SECRETIN; LUNG	This report explores the potential side-chain functional groups required for interaction of the bronchodilator neuropeptide, vasoactive intestinal peptide (VIP), with its receptor. The binding affinity and biological activity of native VIP have been found to be sensitive to the removal of amino- and carboxyl-terminal residues. This data suggests that elements within the entire primary sequence of the VIP molecule appear to be necessary for recognition by VIP receptors. The introduction of alanine residues substituted into the VIP molecule is utilized to probe for side-chain functional groups that are crucial for eliciting high receptor binding affinity in vitro and high biological potency in vivo. The VIP pharmacophore appears to be identical in guinea pig lung and human lung and consists of multiple binding sites most likely involving positions Asp3, Phe6, Thr7, Tyr10, Tyr22, and Leu23. These findings could be exploited to enhance the biological potency of VIP by increasing the binding energy at these positions.	HOFFMANN LA ROCHE INC,DEPT PEPTIDE RES,NUTLEY,NJ 07110	Roche Holding	ODONNELL, M (corresponding author), HOFFMANN LA ROCHE INC,DEPT PHARMACOL,NUTLEY,NJ 07110, USA.							ALTIERE RJ, 1983, PHARMACOLOGIST, V25, pA123; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BARNES PJ, 1984, AM REV RESPIR DIS, V130, P162; BARNES PJ, 1987, TRENDS PHARMACOL SCI, V8, P24, DOI 10.1016/0165-6147(87)90029-0; BOLIN DR, 1989, PEPTIDES CHEM BIOL, P208; BUNDGAARD A, 1983, EUR J RESPIR DIS, V64, P427; CAMERON AR, 1983, Q J EXP PHYSIOL CMS, V68, P413, DOI 10.1113/expphysiol.1983.sp002735; CHRISTOPHE J, 1981, PEPTIDES, V2, P253, DOI 10.1016/0196-9781(81)90040-1; COLES SJ, 1981, AM REV RESPIR DIS, V124, P531; DEY RD, 1981, CELL TISSUE RES, V220, P231; FRY DC, 1989, BIOCHEMISTRY-US, V28, P2399, DOI 10.1021/bi00432a010; LAITINEN A, 1985, HISTOCHEMISTRY, V82, P213; MOJARAD M, 1985, American Review of Respiratory Disease, V131, pA281; NUTT RF, 1988, PEPTIDES CHEM BIOL, P444; OLLERENSHAW S, 1989, NEW ENGL J MED, V320, P1244, DOI 10.1056/NEJM198905113201904; PALMER JBD, 1986, AM REV RESPIR DIS, V133, pA239; PALMER JBD, 1986, J APPL PHYSIOL, V61, P1322, DOI 10.1152/jappl.1986.61.4.1322; POLAK JM, 1982, EXP LUNG RES, V3, P313, DOI 10.3109/01902148209069660; SAGA T, 1984, T ASSOC AM PHYSICIAN, V97, P304; SAID SI, 1972, EUR J BIOCHEM, V28, P199, DOI 10.1111/j.1432-1033.1972.tb01903.x	20	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6389	6392						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848854				2022-12-25	WOS:A1991FE37300059
J	CHEN, JM; AIMES, RT; WARD, GR; YOUNGLEIB, GL; QUIGLEY, JP				CHEN, JM; AIMES, RT; WARD, GR; YOUNGLEIB, GL; QUIGLEY, JP			ISOLATION AND CHARACTERIZATION OF A 70-KDA METALLOPROTEASE (GELATINASE) THAT IS ELEVATED IN ROUS-SARCOMA VIRUS-TRANSFORMED CHICKEN-EMBRYO FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; DEPENDENT DNA POLYMERASE; SEQUENCE IDENTIFICATION; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; SYNOVIAL FIBROBLASTS; TISSUE INHIBITOR; GENE-PRODUCT; IV COLLAGEN; CELLS	Chicken embryo fibroblasts (CEF) transformed by Rous sarcoma virus (RSVCEF) secrete a 70-kDa metallo-gelatinase at elevated levels over that of normal CEF. The 70-kDa enzyme has been purified from RSVCEF conditioned medium and represents 1-3% of the total protein in the RSVCEF conditioned medium. A 22-kDa protein, which appears to be the avian form of the tissue inhibitor of metalloproteases (TIMP), is co-isolated in association with the 70-kDa enzyme and can be separated from the enzyme by gel filtration carried out under denaturing conditions. The isolated 70-kDa species is in the zymogen form. It can be activated by treatment with the organomercurial, p-aminophenylmercuric acetate (APMA), yielding a 62-kDA active species derived by an apparent autoproteolytic cleavage from the 70-kDa proenzyme as determined by both substrate gel analysis and immunoblots using a monospecific antibody to the 70-kDa proenzyme. The proenzyme is poorly activated by trypsin and not activated by plasmin. The APMA-activated enzyme rapidly degrades denatured collagens but under identical conditions is unable to degrade native collagens, including basement membrane type IV collagen. Only at very high enzyme to substrate ratios (1:2) will native type IV collagen be hydrolyzed. Partial N-terminal amino acid sequencing of both the 70-kDa proenzyme and the 62-kDa active enzyme indicates that the avian enzyme is a member of the matrix metalloprotease family (MMP-2). When CEF cultures, infected with a temperature sensitive mutant of RSV, conditional for the expression of the transforming src oncogene, were incubated at the permissive and nonpermissive temperatures, differential levels of the 70-kDa enzyme were produced in direct proportion to the functioning of the src oncogene.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PATHOL, STONY BROOK, NY 11794 USA; THOMAS JEFFERSON UNIV, DEPT ANAT, PHILADELPHIA, PA 19107 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Jefferson University					NCI NIH HHS [CA16740] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLIN M, 1988, BIOCHEM BIOPH RES CO, V158, P228; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FAIRBAIRN S, 1985, J CELL BIOL, V101, P1790, DOI 10.1083/jcb.101.5.1790; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; GARBISA S, 1987, CANCER RES, V47, P1523; GARBISA S, 1986, J BIOL CHEM, V261, P2369; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HARRIS ED, 1984, COLLAGEN REL RES, V4, P493; HATANAKA M, 1970, VIROLOGY, V41, P647, DOI 10.1016/0042-6822(70)90429-0; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HICKS NJ, 1984, INT J CANCER, V33, P835, DOI 10.1002/ijc.2910330620; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KLEINMAN HK, 1981, J CELL BIOL, V88, P473, DOI 10.1083/jcb.88.3.473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1981, BIOCHEMISTRY-US, V20, P100, DOI 10.1021/bi00504a017; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V831, P49, DOI 10.1016/0167-4838(85)90148-7; MURPHY G, 1989, INT J CANCER, V44, P757, DOI 10.1002/ijc.2910440434; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; NAKAJIMA M, 1987, CANCER RES, V47, P4869; OKADA Y, 1986, J BIOL CHEM, V261, P14245; Quigley J. P, 1979, SURFACES NORMAL MALI, P247; REICH R, 1988, CANCER RES, V48, P3307; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALO T, 1983, J BIOL CHEM, V258, P3058; SAUS J, 1988, J BIOL CHEM, V263, P6742; SPINUCCI C, 1988, JNCI-J NATL CANCER I, V80, P1416, DOI 10.1093/jnci/80.17.1416; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V101, P1790; UNKELESS JC, 1973, J EXP MED, V137, P85, DOI 10.1084/jem.137.1.85; VAHERI A, 1974, INT J CANCER, V13, P579, DOI 10.1002/ijc.2910130502; WEBER MJ, 1973, J BIOL CHEM, V248, P2978; WEBER MJ, 1984, ADV VIRAL ONCOL, P249; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725	59	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5113	5121						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848240				2022-12-25	WOS:A1991FC21700065
J	HJELMSTAD, RH; BELL, RM				HJELMSTAD, RH; BELL, RM			SN-1,2-DIACYLGLYCEROL CHOLINEAMINEPHOSPHOTRANSFERASE AND ETHANOLAMINEPHOSPHOTRANSFERASE IN SACCHAROMYCES-CEREVISIAE - MIXED MICELLAR ANALYSIS OF THE CPT1 AND EPT1 GENE-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DIACYLGLYCEROL ETHANOLAMINEPHOSPHOTRANSFERASE; RAT-BRAIN; YEAST; CHOLINEPHOSPHOTRANSFERASE; MUTANTS; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLCHOLINE; SOLUBILIZATION; BIOSYNTHESIS	The Saccharomyces cerevisiae CPT1 and EPT1 genes are structural genes encoding distinct sn-1,2-diacylglycerol choline- and ethanolaminephosphotransferases. A haploid cpt1 ept1 double null mutant lacked detectable choline- and ethanolaminephosphotransferase activity but was viable for growth, establishing that these enzymes are nonessential. The activities of the CPT1 and EPT1 gene products were independently studied in membranes prepared from strains mutant in the cognate locus using mixed micellar assays. Both enzymes absolutely required phospholipid cofactors; half-maximal activation was observed at low mole fractions, suggesting that a small number of phospholipid molecules are required. The activities of the CPT1 and EPT1 gene products were compared with respect to dioleoylglycerol dependence, CDP-aminoalcohol specificity, phospholipid activation, and inhibition by CMP. The EPT1 gene product utilized CDP-ethanolamine, -monomethylethanolamine, -dimethylethanolamine, and -choline to significant extents, while the CPT1 gene product manifested relative specificity for CDP-choline and -dimethylethanolamine. The CPT1 and EPT1 gene products exhibited differing properties with respect to phospholipid activation, but this difference was dependent on the CDP-aminoalcohol substrate. In contrast, the two enzymes could be distinguished on the basis of their dioleoylglycerol dependencies, activation by Mg2+, and CMP inhibition profiles regardless of the CDP-aminoalcohol substrate employed. These studies provide the first definitive kinetic properties of individual choline- and ethanolaminephosphotransferases.			HJELMSTAD, RH (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.				NIGMS NIH HHS [GM20015] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANSELL GB, 1966, BIOCHEM J, V98, P303, DOI 10.1042/bj0980303; ANSELL GB, 1971, J NEUROCHEM, V18, P647, DOI 10.1111/j.1471-4159.1971.tb11995.x; ANWER MK, 1980, SYNTHESIS-STUTTGART, P929; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CHOJNACKI T, 1967, J NEUROCHEM, V14, P413, DOI 10.1111/j.1471-4159.1967.tb09539.x; CHRISTIANSEN K, 1979, BIOCHIM BIOPHYS ACTA, V574, P448, DOI 10.1016/0005-2760(79)90241-8; COLEMAN R, 1977, J BIOL CHEM, V252, P3050; CORNELL R, 1985, BIOCHIM BIOPHYS ACTA, V821, P97, DOI 10.1016/0005-2736(85)90159-2; GREEN TW, 1981, PROTECTIVE GROUPS OR; GROSS A, 1983, J AM CHEM SOC, V105, P7428, DOI 10.1021/ja00363a037; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Helenius A, 1979, Methods Enzymol, V56, P734; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOLUB BJ, 1978, J BIOL CHEM, V253, P691; HOMANN MJ, 1983, ANAL BIOCHEM, V135, P447, DOI 10.1016/0003-2697(83)90710-8; HUNTER K, 1972, YEASTS, V2, P211; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; KANOH H, 1976, EUR J BIOCHEM, V66, P201, DOI 10.1111/j.1432-1033.1976.tb10440.x; KANOH H, 1975, BIOCHIM BIOPHYS ACTA, V380, P199; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KHWAJA TA, 1970, J CHEM SOC C, P2092, DOI 10.1039/j39700002092; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KOVAC L, 1980, EUR J BIOCHEM, V111, P491, DOI 10.1111/j.1432-1033.1980.tb04965.x; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; MCELHANEY RN, 1982, CURR TOP MEMBR TRANS, V17, P317; MOFFATT JG, 1961, J AM CHEM SOC, V83, P649, DOI 10.1021/ja01464a034; MORIMOTO K, 1978, J BIOL CHEM, V2256, P5056; PERCY AK, 1984, ARCH BIOCHEM BIOPHYS, V230, P69, DOI 10.1016/0003-9861(84)90087-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLOKOFF MA, 1981, J BIOL CHEM, V256, P7687; RADOMINSKAPYREK A, 1978, BIOCHEM BIOPH RES CO, V85, P1074, DOI 10.1016/0006-291X(78)90652-6; RAETZ CRH, 1975, P NATL ACAD SCI USA, V72, P2274, DOI 10.1073/pnas.72.6.2274; RAETZ CRH, 1983, ENZYMES, V16, P207; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANDERMANN H, 1978, BIOCHIM BIOPHYS ACTA, V515, P209, DOI 10.1016/0304-4157(78)90015-1; SANDERMANN H, 1986, PROGR PROTEIN LIPID, V2, P197; TANAKA TERUO, 1965, YAKUGAKU ZASSHI, V85, P863; UKITA T, 1961, CHEM PHARM BULL, V9, P369; VECCHINI A, 1987, BIOCHIM BIOPHYS ACTA, V918, P40, DOI 10.1016/0005-2760(87)90007-5; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1; WAECHTER CJ, 1971, J BACTERIOL, V105, P837, DOI 10.1128/JB.105.3.837-843.1971; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1986, J BIOL CHEM, V261, P6239	48	56	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4357	4365						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847919				2022-12-25	WOS:A1991FA69400054
J	GONZALEZHALPHEN, D; VAZQUEZACEVEDO, M; GARCIAPONCE, B				GONZALEZHALPHEN, D; VAZQUEZACEVEDO, M; GARCIAPONCE, B			ON THE INTERACTION OF MITOCHONDRIAL COMPLEX-III WITH THE RIESKE IRON-SULFUR PROTEIN (SUBUNIT-V)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; AMINO-ACID-SEQUENCE; INTEGRAL MEMBRANE-PROTEINS; BEEF-HEART; BC1 COMPLEX; ELECTRON-TRANSFER; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; RESPIRATORY-CHAIN; UBIQUINOL	Limited proteolysis of solubilized beef heart mitochondrial complex III with trypsin yields a product previously identified as fragment V" (Gonzalez-Halphen, D., Lindorfer, M. A., and Capaldi, R. A. (1988) Biochemistry 27, 7021-7031). In this work, fragment V" was generated by trypsin treatment of both the intact complex III and the purified Rieske iron-sulfur protein. Thus, in its bound or isolated form, the same sites of subunit V are sensitive to protease action. Fragment V" was a soluble protein that retained its iron-sulfur moiety. It was purified by exclusion from a hydrophobic phenyl-Sepharose CL-4B column followed by gel filtration. In contrast to the pure, intact subunit V, fragment V" did not reconstitute oxidoreductase activity when combined with complex III devoid of subunit V. However, a 20-amino acid synthetic peptide carrying the sequence between amino acids Lys33 and Lys52 of the Rieske iron-sulfur protein competed with intact subunit V in reconstitution assays. The results obtained suggest that the iron-sulfur protein binds to complex III by hydrophobic protein-protein interactions, and that a nontransmembrane 18-amino acid amphipathic stretch accounts for the association of this subunit to the rest of the complex.			GONZALEZHALPHEN, D (corresponding author), NATL AUTONOMOUS UNIV MEXICO,INST FISIOL CELULAR,DEPT BIOENERGET,APARTADO POSTAL 70243,MEXICO CITY 04510,DF,MEXICO.			Gonzalez-Halphen, Diego/0000-0003-0654-655X; Garcia-Ponce, Berenice/0000-0002-7312-0754				BALL MB, 1977, FEBS LETT, V83, P99, DOI 10.1016/0014-5793(77)80650-9; BALLESTER F, 1987, THESIS U BOLOGNA ITA; BAUM H, 1967, J BIOL CHEM, V242, P4876; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BECKMANN JD, 1989, J BIOL CHEM, V264, P3716; BELL RL, 1979, P NATL ACAD SCI USA, V76, P741, DOI 10.1073/pnas.76.2.741; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brumby P.E., 1967, METHOD ENZYMOL, V10, P463, DOI DOI 10.1016/0076-6879(67)10078-5; CAPALDI RA, 1986, FEBS LETT, V207, P11, DOI 10.1016/0014-5793(86)80004-7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; DSOUZA MP, 1982, J BIOL CHEM, V257, P1760; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELLEFSON WL, 1979, ARCH BIOCHEM BIOPHYS, V194, P593, DOI 10.1016/0003-9861(79)90654-4; ENGEL WD, 1983, EUR J BIOCHEM, V132, P395, DOI 10.1111/j.1432-1033.1983.tb07376.x; ESPOSTI MD, 1989, EUR J BIOCHEM, V182, P27; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; ESPOSTI MD, 1990, IN PRESS ARCH BIOCH, V283; GATTI DL, 1989, J MOL BIOL, V205, P421, DOI 10.1016/0022-2836(89)90352-5; GELLERFORS P, 1977, EUR J BIOCHEM, V80, P275, DOI 10.1111/j.1432-1033.1977.tb11880.x; GONZALEZHALPHEN D, 1990, HIGHLIGHTS IN UBIQUINONE RESEARCH, P158; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GUTWENIGER H, 1981, J BIOL CHEM, V256, P1132; HALL DO, 1972, BIOCHEM BIOPH RES CO, V47, P798, DOI 10.1016/0006-291X(72)90562-1; HARNISCH U, 1985, EUR J BIOCHEM, V149, P95, DOI 10.1111/j.1432-1033.1985.tb08898.x; HARNISCH U, 1986, 5TH EBEC COLL WAL RE, P184; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; JAPA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P716, DOI 10.1016/0003-9861(89)90340-8; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; LI Y, 1981, FEBS LETT, V135, P277, DOI 10.1016/0014-5793(81)80800-9; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; LORUSSO M, 1989, EUR J BIOCHEM, V179, P535, DOI 10.1111/j.1432-1033.1989.tb14580.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NISHIKIMI M, 1989, BIOCHEM BIOPH RES CO, V159, P19, DOI 10.1016/0006-291X(89)92398-X; OHNISHI T, 1989, J BIOL CHEM, V264, P735; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; PAYNE WE, 1987, FEBS LETT, V213, P107, DOI 10.1016/0014-5793(87)81473-4; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REECK GR, 1987, CELL, V50, P667, DOI 10.1016/0092-8674(87)90322-9; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; RIESKE JS, 1976, BIOCHIM BIOPHYS ACTA, V456, P195, DOI 10.1016/0304-4173(76)90012-4; RIESKE JS, 1964, BIOCHEM BIOPH RES CO, V15, P338, DOI 10.1016/0006-291X(64)90171-8; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SHIMOMURA Y, 1984, J BIOL CHEM, V259, P4059; SHIMOMURA Y, 1985, J BIOL CHEM, V260, P5075; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TRUMPOWER BL, 1981, J BIOENERG BIOMEMBR, V13, P1, DOI 10.1007/BF00744743; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; ZHANG YZ, 1984, BIOCHEMISTRY-US, V23, P5616, DOI 10.1021/bi00318a036	60	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3870	3876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847390				2022-12-25	WOS:A1991EY68200078
J	KUMAR, RS; THEKKUMKARA, TJ; SEN, GC				KUMAR, RS; THEKKUMKARA, TJ; SEN, GC			THE MESSENGER-RNAS ENCODING THE 2 ANGIOTENSIN-CONVERTING ISOZYMES ARE TRANSCRIBED FROM THE SAME GENE BY A TISSUE-SPECIFIC CHOICE OF ALTERNATIVE TRANSCRIPTION INITIATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL CARBOXYPEPTIDASE; MOLECULAR-CLONING; YEAST INVERTASE; ENZYME; RABBIT; TESTIS; SEQUENCES; DIFFER	The two tissue-specific isozymes of angiotensin-converting enzyme are encoded by two mRNAs. The 5-kilobase pulmonary mRNA (mRNA(P)) and the 2.5-kilobase testicular mRNA (mRNA(T)) have identical sequences near their 3'-ends, whereas each has a unique sequence toward its 5'-end. Here we report that the two mRNAs originate from the same gene by initiation of transcription at two alternative sites. We have isolated a rabbit genomic clone which encodes these mRNAs. The sequence organization of the genome is such that the unique sequence of mRNA(P) precedes that of mRNA(T), which in turn precedes the sequence common to both species. For generation of mRNA(P), the mRNA(T)-specific sequence is eliminated as an intron from the primary transcript by splicing. Transcription of mRNA(T), on the other hand, initiates within this intron at the middle of the gene. The exact initiation sites of mRNA(T) and mRNA(P) have been determined by DNA sequencing; DNA, oligonucleotide, and antisense RNA protection assays; and primer extension assays. Analyses of the sequence upstream of the transcription initiation sites revealed the presence of putative binding sites of several known transcription factors including SP-1, AP-2, and IID.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035667] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35667] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BERG T, 1986, J HISTOCHEM CYTOCHEM, V34, P753, DOI 10.1177/34.6.3009604; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ELDORRY HA, 1983, BIOCHEM BIOPH RES CO, V115, P1096, DOI 10.1016/S0006-291X(83)80048-5; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; HAGENBUCHLE O, 1981, NATURE, V289, P643, DOI 10.1038/289643a0; IWATA K, 1982, BIOCHEM BIOPH RES CO, V107, P1097, DOI 10.1016/0006-291X(82)90634-9; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; Maniatis T., 1982, MOL CLONING; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; PERLMAN D, 1981, CELL, V25, P525, DOI 10.1016/0092-8674(81)90071-4; PERLMAN D, 1982, P NATL ACAD SCI-BIOL, V79, P781, DOI 10.1073/pnas.79.3.781; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SEN GC, 1990, CARDIOVASC PHARM, V16, pS14; SHAI SY, 1990, BIOCHEM BIOPH RES CO, V167, P1128, DOI 10.1016/0006-291X(90)90640-9; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; THEKKUMKARA TJ, 1990, FASEB J, V4, pA2091; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9	29	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3854	3862						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847388				2022-12-25	WOS:A1991EY68200076
J	REECE, RJ; MAXWELL, A				REECE, RJ; MAXWELL, A			PROBING THE LIMITS OF THE DNA BREAKAGE-REUNION DOMAIN OF THE ESCHERICHIA-COLI DNA GYRASE-A PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT MUTATIONS; GYRB GENE; TOPOISOMERASES; ACID; PURIFICATION; SEQUENCE; COMPLEX; CLONING	In a previous report (Reece, R. J., and Maxwell, A. (1989) J. Biol. Chem. 264, 19648-19653) we showed that treatment of the Escherichia coli DNA gyrase A protein with trypsin generates two stable fragments. The N-terminal 64-kDa fragment supports DNA supercoiling, while the C-terminal 33-kDa fragment shows no enzymic activity. We proposed that the 64-kDa fragment represents the DNA breakage-reunion domain of the A protein. We have now engineered the gyrA gene such that the 64-kDa protein is generated as a gene product. The properties of this protein confirm the findings of the experiments with the 64-kDa tryptic fragment. We have also generated a series of deletions of the gyrA gene such that C-terminal and N-terminal truncated versions of the A protein are produced. The smallest of the N-terminal fragments found to be able to carry out the DNA breakage-reunion reaction is GyrA(1-523). The cleavage reaction mediated by this protein occurs with equal efficacy as that performed by the intact GyrA protein. Deletion of the N-terminal 6 amino acids from either the A protein or these deletion derivatives has no effect on enzymic activity, while deletion of the N-terminal 69 amino acids completely abolishes the DNA breakage-reunion reaction. Therefore the smallest GyrA protein we have found that will perform DNA breakage and reunion is GyrA(7-523). A model is proposed for the domain organization of the gyrase A protein.			REECE, RJ (corresponding author), UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, ENGLAND.			Maxwell, Anthony/0000-0002-5756-6430				ADACHI T, 1987, NUCLEIC ACIDS RES, V15, P771, DOI 10.1093/nar/15.2.771; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; Grunstein M, 1979, Methods Enzymol, V68, P379; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; Perbal B., 1988, PRACTICAL GUIDE MOL; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; REECE RJ, 1990, J MOL BIOL, V215, P493, DOI 10.1016/S0022-2836(05)80162-7; REECE RJ, 1989, J BIOL CHEM, V264, P19648; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SWANBERG SL, 1987, J MOL BIOL, V197, P729, DOI 10.1016/0022-2836(87)90479-7; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WILKINSON AJ, 1990, STRUCTURE FUNCTION N; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012; YOSHIDA H, 1988, MOL GEN GENET, V211, P1, DOI 10.1007/BF00338386	28	75	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3540	3546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847377				2022-12-25	WOS:A1991EY68200033
J	JEFFERSON, AB; TRAVIS, SM; SCHULMAN, H				JEFFERSON, AB; TRAVIS, SM; SCHULMAN, H			ACTIVATION OF MULTIFUNCTIONAL CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE IN GH3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; CLONAL PITUITARY-CELLS; CYTOSOLIC FREE CA-2+; CALCIUM-CALMODULIN; MOLECULAR-CLONING; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; CYTOPLASMIC CALCIUM; AUTONOMOUS ENZYME; BRAIN	We report that the rat pituitary cell line GH3 contains a Ca2+- and calmodulin-dependent protein kinase with properties characteristic of multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase) from rat brain. The GH3 kinase exhibits the hallmark of authentic CaM kinase: conversion from Ca2+-dependent to Ca2+-independent activity following a brief initial phosphorylation in vitro. This phosphorylation occurs at a site which is similar or identical to that of the "autonomy" site of the rat brain enzyme and thus may be an autophosphorylation event. GH3 CaM kinase is phosphorylated and becomes Ca2+-independent in situ. Depolarization of intact cells with K+ opens calcium channels and leads to the phosphorylation of CaM kinase at the autonomy site, and the kinase becomes significantly and persistently Ca2+-independent. Treatment of cells with thyrotropin-releasing hormone (TRH), which activates the phosphatidylinositol signaling pathway, also generates a Ca2+-independent CaM kinase in situ. The primary effect of TRH on CaM kinase activity is transient and correlates with the spike of Ca2+ released from intracellular stores and the rapid phase of prolactin release from GH3 cells. This study demonstrates that CaM kinase is able to detect and respond to both calcium that enters the cell through voltage-sensitive Ca2+ channels and calcium released from internal stores via the phosphatidylinositol pathway. We find that TRH, a hormone that causes release of prolactin and was previously believed to activate primarily protein kinase C, also significantly activates CaM kinase in intact cells.			JEFFERSON, AB (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030179, R01GM040600, R01GM030179] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40600, GM30179] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA T, 1985, ENDOCRINOLOGY, V116, P909, DOI 10.1210/endo-116-3-909; ALBERT PR, 1984, J BIOL CHEM, V259, P5827; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; DRUST DS, 1985, BIOCHEM BIOPH RES CO, V128, P531, DOI 10.1016/0006-291X(85)90079-8; FEARON CW, 1985, J BIOL CHEM, V260, P8366; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GERSHENGORN MC, 1983, ENDOCRINOLOGY, V113, P1522, DOI 10.1210/endo-113-4-1522; GORELICK FS, 1988, J BIOL CHEM, V263, P17209; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HATADA Y, 1983, J NEUROCHEM, V40, P1082, DOI 10.1111/j.1471-4159.1983.tb08096.x; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; KOLESNICK RN, 1986, ENDOCRINOLOGY, V119, P2461, DOI 10.1210/endo-119-6-2461; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOU LL, 1989, J NEUROSCI, V9, P2020; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHLEGEL W, 1984, J CELL BIOL, V99, P83, DOI 10.1083/jcb.99.1.83; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; SCHULMAN H, 1984, MOL CELL BIOL, V4, P1175, DOI 10.1128/MCB.4.6.1175; SCHULMAN H, 1978, P NATL ACAD SCI USA, V75, P5432, DOI 10.1073/pnas.75.11.5432; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1985, ARCH BIOCHEM BIOPHYS, V242, P137, DOI 10.1016/0003-9861(85)90487-4; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; TAN KN, 1984, J BIOL CHEM, V259, P418; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; UEDA T, 1977, J BIOL CHEM, V252, P5155	41	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1484	1490						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846356				2022-12-25	WOS:A1991EU49700023
J	KIM, JM; KLEIN, PG; MULLET, JE				KIM, JM; KLEIN, PG; MULLET, JE			RIBOSOMES PAUSE AT SPECIFIC SITES DURING SYNTHESIS OF MEMBRANE-BOUND CHLOROPLAST REACTION CENTER PROTEIN-D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; RHODOBACTER-SPHAEROIDES R-26; ILLUMINATED BARLEY SEEDLINGS; PHOTOSYSTEM-II; TRANSLATION INITIATION; BINDING PROTEIN; MESSENGER-RNA; RHODOPSEUDOMONAS-VIRIDIS; THYLAKOID MEMBRANE; ESCHERICHIA-COLI	Photosynthetic reaction center protein D1 contains five membrane-spanning alpha-helices which form binding sites for pheophytin, chlorophyll, carotenoids, quinone, Fe2+, and probably Mn2+. D1 translation intermediates of 15 to 28 kD were detected when isolated chloroplasts were pulse-labeled with [S-35]methionine. The D1 translation intermediates were associated with membrane polysomes and can be chased into full length D1. The sites of translation pausing were determined by mapping the distribution of ribosomes on D1 mRNA using toeprint analysis. Clusters of toeprint signals were generated by D1 mRNA associated with membranes but not by D1 mRNA in nonpolysomal fractions of the soluble phase or phenol-extracted mRNA. The distribution of ribosomes on D1 mRNA determined by toeprint analysis was consistent with D1 translation intermediates observed with pulse-labeling. Ribosome pausing may facilitate co-translational binding of cofactors such as chlorophyll to D1 and aid the integration of D1 into thylakoid membranes	TEXAS A&M UNIV SYST, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station				Kim, Jungmook/0000-0003-1735-5564	NIGMS NIH HHS [GM 37987] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE S, 1985, PLANT CELL PHYSIOL, V26, P1499; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; ALTUVIA S, 1989, J MOL BIOL, V210, P265, DOI 10.1016/0022-2836(89)90329-X; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOYER SK, 1988, NUCLEIC ACIDS RES, V16, P8184, DOI 10.1093/nar/16.16.8184; CHARNEY WG, 1979, ARCH BIOCHEM BIOPHYS, V194, P283; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; GAMBLE PE, 1989, J BIOL CHEM, V264, P7236; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRUISSEM W, 1985, EMBO J, V4, P3375, DOI 10.1002/j.1460-2075.1985.tb04093.x; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KLEIN RR, 1988, PLANT PHYSIOL, V88, P1246, DOI 10.1104/pp.88.4.1246; KLEIN RR, 1986, J BIOL CHEM, V261, P1138; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LIPP J, 1987, J BIOL CHEM, V262, P1680; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MASON HS, 1988, PLANT MOL BIOL, V11, P845, DOI 10.1007/BF00019524; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MINAMI E, 1988, PLANT CELL PHYSIOL, V29, P1303; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1985, PLANT MOL BIOL, V4, P39, DOI 10.1007/BF02498714; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; MULLET JE, 1986, EUR J BIOCHEM, V155, P331, DOI 10.1111/j.1432-1033.1986.tb09495.x; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RUTHERFORD AW, 1989, TRENDS BIOCHEM SCI, V14, P227, DOI 10.1016/0968-0004(89)90032-7; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; TREBST A, 1986, Z NATURFORSCH C, V41, P240; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; VARENNE S, 1982, J MOL BIOL, V159, P57, DOI 10.1016/0022-2836(82)90031-6; VERMAAS WFJ, 1988, PHOTOSYNTH RES, V17, P97, DOI 10.1007/BF00047683; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	47	140	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14931	14938						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869532				2022-12-25	WOS:A1991GB09700023
J	FISHER, LW; HEEGAARD, AM; VETTER, U; VOGEL, W; JUST, W; TERMINE, JD; YOUNG, MF				FISHER, LW; HEEGAARD, AM; VETTER, U; VOGEL, W; JUST, W; TERMINE, JD; YOUNG, MF			HUMAN BIGLYCAN GENE - PUTATIVE PROMOTER, INTRON-EXON JUNCTIONS, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEOGLYCAN-I; AMINO-ACID-SEQUENCE; OSTEOINDUCTIVE FACTOR; CORE PROTEIN; BONE; DECORIN; LEUCINE; YEAST; PURIFICATION; DROSOPHILA	Biglycan (PG-I, DS-PG1, PG-S1) is a small cellular or pericellular matrix proteoglycan that is closely related in structure to two other small proteoglycans, decorin (PG-II, PG-S2, DS-PG2, or PG-40) and fibromodulin. The core protein is made up predominantly of a series of 11 tandem repeats that appear to have been used throughout evolution for protein-protein, protein-cell, or cell-cell interactions. The function of biglycan is unclear at this time, but it has been shown to bind transforming growth factor-beta in vitro. We have cloned and partially sequenced the approximately 8-kilobase pair human biglycan gene. The gene consists of eight exons including one in the sequence that encodes the 5'-untranslated region of the mRNA. The first and seventh introns are approximately 1 kilobase pair, while the remainder are shorter. With the exception of the first two introns, all of the introns are spread throughout the hydrophobic repeat domain. The 500-base pair 5' to the start of transcription contains several elements that strongly suggest that it contains a significant amount of the gene promoter. The elements include one AP2 and five SP1 consensus sequences. Like in many other genes, the biglycan gene promoter lacks both a CAAT and TATA box but is rich in GC content. Using H-3-labeled cDNA and in situ hybridization and autoradiography of human chromosomes, the human gene was localized to the end of the long arm of the X chromosome (Xq27-ter). The relationship of biglycan to a number of other proteins containing the leucine-rich repeats is discussed with respect to homologies of cysteine regions immediately adjacent to the repeat sequences.	UNIV ULM,KLIN GENET ABT,W-7900 ULM,GERMANY	Ulm University	FISHER, LW (corresponding author), NIDR,BONE RES BRANCH,RM 106,BLDG 30,BETHESDA,MD 20892, USA.			Young, Marian F/0000-0003-0929-8854; Heegaard, Anne-Marie/0000-0003-2754-0800				ADOLPH S, 1987, CYTOGENET CELL GENET, V44, P65, DOI 10.1159/000132345; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BENTZ H, 1990, J BIOL CHEM, V265, P5024; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DREHER KL, 1990, EUR J CELL BIOL, V53, P296; EPPLEN JT, 1975, CYTOGENET CELL GENET, V15, P177, DOI 10.1159/000130516; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FISHER LW, 1985, CHEM BIOL MINERALIZE, P188; GILMAN M, 1989, CURRENT PROTOCOLS MO, V1; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KUKITA A, 1990, P NATL ACAD SCI USA, V87, P3023, DOI 10.1073/pnas.87.8.3023; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MCBRIDE OW, 1990, GENOMICS, V6, P219, DOI 10.1016/0888-7543(90)90560-H; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMILEY BL, 1990, J BONE MINER RES, V5, P1189; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693	36	126	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14371	14377						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860845				2022-12-25	WOS:A1991FZ35100042
J	BECHET, DM; FERRARA, MJ; MORDIER, SB; ROUX, MP; DEVAL, CD; OBLED, A				BECHET, DM; FERRARA, MJ; MORDIER, SB; ROUX, MP; DEVAL, CD; OBLED, A			EXPRESSION OF LYSOSOMAL CATHEPSIN-B DURING CALF MYOBLAST-MYOTUBE DIFFERENTIATION - CHARACTERIZATION OF A CDNA-ENCODING BOVINE CATHEPSIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TRANSFORMED MOUSE FIBROBLASTS; MAJOR EXCRETED PROTEIN; MESSENGER-RNA LEVELS; BREAST-CANCER-CELLS; CYSTEINE PROTEINASES; SKELETAL-MUSCLE; PORCINE SPLEEN; SPECIES VARIATIONS; GENE STRUCTURE	Expression of lysosomal cysteine proteinases was studied during fetal calf myoblast-myotube differentiation. Activities of cathepsin B and L, but not cathepsin H, increase during bovine myogenic differentiation. In fetal muscle, cathepsin B and L activities are 2-4-fold orders of magnitude lower than in cultured myoblasts. Active-site titrations of cathepsin B with E-64 nevertheless reveal similar concentrations of active cathepsin B in myoblasts and myotubes, but 5-6-fold lower concentrations in fetal muscle. To specify whether concentrations of cathepsin B are related to levels of cathepsin B transcript, a cDNA clone encoding bovine cathepsin B was isolated and liquid hybridizations were performed with P-32-riboprobes complementary to the mRNA. In agreement with active-site titrations, there is no difference in cathepsin B mRNA levels between cultured myoblasts and myotubes, but lower levels of mRNA are found in fetal muscle. Concentrations of active cathepsin B therefore reflect levels of cathepsin B mRNA. Kinetic studies revealed that the catalytic efficiency (k(cat)/K(m)) of cathepsin B is 2-3-fold higher in myotubes than in myoblasts. The increase in cathepsin B activity during calf myoblast-myotube differentiation is thus due to modifications of enzymatic properties, and not of enzyme concentrations. The different catalytic efficiency of cathepsin B in myotubes and myoblasts was related neither to modifications of mRNA size, as revealed by Northern blot analysis, nor to a different M(r) of the active enzyme, as revealed by affinity labeling with benzyloxycarbonyl-Tyr(-I-125)-Ala-CHN2, but to limited differences in cathepsin B isozymes.			BECHET, DM (corresponding author), SRV THEIX, INST NATL RECH AGRON, UNITE RECH EXPRESS PROTEASES, F-63122 CEYRAT, FRANCE.			Bechet, Daniel/0000-0002-3812-8099				BANDO Y, 1986, J BIOCHEM-TOKYO, V100, P35, DOI 10.1093/oxfordjournals.jbchem.a121703; BARICOS WH, 1988, BIOCHEM J, V252, P301, DOI 10.1042/bj2520301; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BECHET D, 1986, BIOSCIENCE REP, V6, P991, DOI 10.1007/BF01114976; BECHET DM, 1990, AM J PHYSIOL, V259, pE822, DOI 10.1152/ajpendo.1990.259.6.E822; BIGE L, 1985, BIOCHIM BIOPHYS ACTA, V843, P269, DOI 10.1016/0304-4165(85)90148-5; BIRD JWC, 1981, J HISTOCHEM CYTOCHEM, V29, P431, DOI 10.1177/29.3.431; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMME D, 1989, BIOCHEM J, V264, P475; BUCKINGHAM ME, 1976, J MOL BIOL, V103, P611, DOI 10.1016/0022-2836(76)90220-5; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; COLELLA R, 1986, BIOMED BIOCHIM ACTA, V45, P1413; CONNER GE, 1987, LYSOSOMES THEIR ROLE, P151; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DAUBAS P, 1981, DEV BIOL, V84, P133, DOI 10.1016/0012-1606(81)90377-8; DEVAL C, 1990, BIOCHEM CELL BIOL, V68, P822, DOI 10.1139/o90-121; DOHERTY PJ, 1985, MOL CELL BIOL, V5, P466, DOI 10.1128/MCB.5.3.466; DONG JM, 1989, J BIOL CHEM, V264, P7377; DUFOUR E, 1987, BIOCHEMISTRY-US, V26, P5689, DOI 10.1021/bi00392a017; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FERRARA M, 1990, FEBS LETT, V273, P195, DOI 10.1016/0014-5793(90)81083-Z; FIRESTEIN GS, 1987, ANAL BIOCHEM, V167, P381, DOI 10.1016/0003-2697(87)90180-1; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GAL S, 1986, BIOCHEM BIOPH RES CO, V139, P156, DOI 10.1016/S0006-291X(86)80093-6; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GOSPODAROWICZ D, 1976, J CELL BIOL, V70, P395, DOI 10.1083/jcb.70.2.395; HARPER JMM, 1987, J ENDOCRINOL, V112, P87, DOI 10.1677/joe.0.1120087; HASHIDA S, 1980, J BIOCHEM-TOKYO, V88, P1805, DOI 10.1093/oxfordjournals.jbchem.a133155; ISHIDOH K, 1987, FEBS LETT, V226, P33, DOI 10.1016/0014-5793(87)80545-8; ISHIDOH K, 1989, FEBS LETT, V259, P71, DOI 10.1016/0014-5793(89)81497-8; KATUNUMA N, 1989, INTRACELLULAR PROTEO, P3; KIRSCHKE H, 1981, BIOCHEM BIOPH RES CO, V101, P454, DOI 10.1016/0006-291X(81)91281-X; KIRSCHKE H, 1983, BIOCHEM J, V214, P871, DOI 10.1042/bj2140871; KIRSCHKE H, 1984, FEBS LETT, V174, P123, DOI 10.1016/0014-5793(84)81089-3; KIRSCHKE H, 1986, BIOCHEM J, V240, P455, DOI 10.1042/bj2400455; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KOMINAMI E, 1985, J BIOCHEM-TOKYO, V98, P87, DOI 10.1093/oxfordjournals.jbchem.a135277; Maniatis T., 1982, MOL CLONING; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MELOUN B, 1988, J BIOL CHEM, V263, P9087; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V261, P64, DOI 10.1016/0003-9861(88)90104-X; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V262, P159, DOI 10.1016/0003-9861(88)90178-6; OBLED A, 1984, BIOCHIMIE, V66, P609, DOI 10.1016/0300-9084(84)90114-7; Ouali A., 1986, CYSTEINE PROTEINASES, P545; PONTREMOLI S, 1983, P NATL ACAD SCI-BIOL, V80, P1261, DOI 10.1073/pnas.80.5.1261; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANSEGUNDO B, 1986, FEBS LETT, V201, P251; SEGUNDO BS, 1985, P NATL ACAD SCI USA, V82, P2320, DOI 10.1073/pnas.82.8.2320; SHEWALE JG, 1984, P NATL ACAD SCI-BIOL, V81, P3703, DOI 10.1073/pnas.81.12.3703; SLOANE BF, 1987, EXP CELL BIOL, V55, P209; SMITH SM, 1989, BIOCHEM J, V262, P931, DOI 10.1042/bj2620931; STAUBER W, 1985, HISTOCHEM J, V17, P787, DOI 10.1007/BF01003314; STAUBER WT, 1981, J HISTOCHEM CYTOCHEM, V29, P866, DOI 10.1177/29.7.7264276; TAKAHASHI T, 1986, J BIOL CHEM, V261, P9368; TAKAHASHI T, 1984, J BIOL CHEM, V259, P6059; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; TAYLOR MAJ, 1987, HISTOCHEMISTRY, V86, P379, DOI 10.1007/BF00494997; TOWATARI T, 1988, FEBS LETT, V236, P57, DOI 10.1016/0014-5793(88)80285-0; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	68	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14104	14112						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856234				2022-12-25	WOS:A1991FY02700099
J	MATHESON, NR; VANHALBEEK, H; TRAVIS, J				MATHESON, NR; VANHALBEEK, H; TRAVIS, J			EVIDENCE FOR A TETRAHEDRAL INTERMEDIATE COMPLEX DURING SERPIN-PROTEINASE INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN ALPHA-1-PROTEINASE INHIBITOR; PANCREATIC TRYPSIN-INHIBITOR; NUCLEAR MAGNETIC-RESONANCE; REACTIVE SITE; ALPHA-1-ANTITRYPSIN; BINDING	Proteinase inhibitors in the serpin family form complexes with serine proteinases by interactions between the gamma-OH group at serine 195 of the enzyme and a specific peptide bond within the reactive site loop of the inhibitor. However, the type of complex formed (i.e. Michaelis, acyl, or tetrahedral) is unknown. Until now, C-13 NMR spectroscopy studies have only been useful in examining complexes formed with either peptide-related or small protein inhibitors, where C-13-labeled amino acids can be inserted semi-synthetically. Recombinant DNA technology has, however, made it possible to specifically enrich larger proteins with C-13. In the case of serpins we have examined the structure of the complex formed between human alpha-1-proteinase inhibitor uniformally labeled with [C-13]methionine and porcine pancreatic elastase. C-13 NMR spectroscopic studies revealed a large upfield chemical shift of the carbonyl signal of Met-358 upon complex formation suggesting for the first time that a tetrahedral adduct is formed between a serpin inhibitor and a serine proteinase.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia								BAILLARGEON MW, 1980, BIOCHEMISTRY-US, V19, P5703, DOI 10.1021/bi00566a006; BEATTY K, 1980, J BIOL CHEM, V255, P3931; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; HUNKAPILLER MW, 1979, BIOCHEM BIOPH RES CO, V87, P25, DOI 10.1016/0006-291X(79)91642-5; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; RICH DH, 1982, J AM CHEM SOC, V104, P3535, DOI 10.1021/ja00376a062; RICHARZ R, 1980, BIOCHEMISTRY-US, V19, P5711, DOI 10.1021/bi00566a007; ROSENBERG S, 1984, NATURE, V312, P77, DOI 10.1038/312077a0; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; TRAVIS J, 1985, J BIOL CHEM, V260, P4384; TRAVIS J, 1974, PROTEINASE INHIBITOR, P31	15	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13489	13491						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856187				2022-12-25	WOS:A1991FY02700006
J	THORNE, BA; VIVEROS, OH; THOMAS, G				THORNE, BA; VIVEROS, OH; THOMAS, G			EXPRESSION AND PROCESSING OF MOUSE PROOPIOMELANOCORTIN IN BOVINE ADRENAL CHROMAFFIN CELLS - A MODEL SYSTEM TO STUDY TISSUE-SPECIFIC PROHORMONE PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-TUMOR CELLS; CHROMOGRANIN-A; PRO-OPIOMELANOCORTIN; SECRETION; CLEAVAGE; PRECURSOR; SITE; PROENKEPHALIN; ENKEPHALINS; PROINSULIN	Many neuroendocrine precursor proteins, such as proopiomelanocortin (POMC), are cleaved in a tissue specific manner at distinct pairs of basic amino acids. Elucidating the specificity of the prohormone endoprotease(s) is essential to understanding cleavage specificity. However, isolation of these enzymes has been difficult, due to the inability to distinguish authentic maturation enzyme from the many other trypsin-like activities present in tissue homogenates. Recently, a "signature" of the insulin cell endoprotease(s) was defined in vivo by assessing the processing of a series of mutant cleavage sites in a model prohormone, mouse POMC (mPOMC) (Thorne, B. A., and Thomas, G. (1990) J. Biol. Chem. 265, 8436-8443. To investigate mechanisms of tissue-specific processing, we sought to identify the endoprotease signature of a cell having a processing phenotype distinct from insulinoma cells. In this report, the cleavage site specificity of the endoprotease(s) expressed in bovine adrenal chromaffin cells is examined. High levels of mPOMC (1.6 pmol/10(6) cells) were expressed in these cells using a vaccinia virus vector, and the precursor was targeted to the regulated secretory pathway. Analysis of POMC-derived peptides revealed that chromaffin cells processed the prohormone to a set of peptides highly similar to anterior pituitary corticotrophs, including adrenocorticotropin hormone (ACTH) and beta-lipotropin, gamma-lipotropin, and beta-endorphin1-31. This processing contrasted with the pattern of cleavage site utilization in Rin m5F insulinoma cells, which more closely resembled that of the intermediate pituitary melanotrophs. However, the processing preference for the sequences of pairs of basic amino acids (as tested using the entire series of mutant cleavage sites; -LysArg- (native), -ArgArg-, -ArgLys-, -LysLys-, -HisArg-, -MetArg- at the ACTH/beta-lipotropin junction and -LysLys- (native), -LysArg-, -ArgArg-, -ArgLys- in beta-endorphin) was the same in both insulinoma and adrenal chromaffin cells, suggesting recognition and cleavage by similar enzymes in both cell types. The cell-specific processing of mPOMC may thus result from expression of a common core set of processing enzymes and factors unique to each cell type affecting the enzyme accessibility to precursor cleavage sites.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; BURROUGHS WELLCOME CO, DIV PHARMACOL, RES TRIANGLE PK, NC 27709 USA	Oregon Health & Science University; Burroughs Wellcome Fund					NIDDK NIH HHS [DK 37274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDO Y, 1981, FEBS LETT, V131, P286, DOI 10.1016/0014-5793(81)80386-9; BOKSA P, 1984, J NEUROCHEM, V42, P607, DOI 10.1111/j.1471-4159.1984.tb02726.x; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CROMLISH JA, 1986, J BIOL CHEM, V261, P850; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; FISCHERCOLBRIE R, 1987, ANN NY ACAD SCI, V493, P120, DOI 10.1111/j.1749-6632.1987.tb27189.x; FISHER JM, 1988, J BIOL CHEM, V263, P16515; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GLUSCHANKOF P, 1988, FEBS LETT, V234, P149, DOI 10.1016/0014-5793(88)81322-X; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HELDMAN E, 1989, J BIOL CHEM, V264, P7914; HILLARP NA, 1953, ACTA PHYSIOL SCAND, V30, P55; HUTTON JC, 1987, BIOCHEM J, V244, P449, DOI 10.1042/bj2440449; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LEMAIRE S, 1984, CAN J PHYSIOL PHARM, V62, P484, DOI 10.1139/y84-078; LINDBERG I, 1990, ENDOCRINOLOGY, V126, P480, DOI 10.1210/endo-126-1-480; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LIVETT BG, 1982, NEUROSCIENCE, V7, P1323, DOI 10.1016/0306-4522(82)91138-1; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; LOH YP, 1986, J BIOL CHEM, V261, P1949; NOE BD, 1984, J CELL BIOL, V99, P578, DOI 10.1083/jcb.99.2.578; PHILLIPS MA, 1981, BIOCHEMISTRY-US, V20, P1666, DOI 10.1021/bi00509a040; RHODES CJ, 1989, BIOCHEM J, V258, P305, DOI 10.1042/bj2580305; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGER MA, 1986, J STEROID BIOCHEM, V25, P703, DOI 10.1016/0022-4731(86)90298-0; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; SPRUCE BA, 1988, J BIOL CHEM, V263, P19788; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1989, J BIOL CHEM, V264, P3545; THORNE BA, 1990, J BIOL CHEM, V265, P8436; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; UNSWORTH CD, 1987, STIMULUS SECRETION C, P87; VIVEROS OH, 1987, ANN NY ACAD SCI, V493, P324, DOI 10.1111/j.1749-6632.1987.tb27216.x; VIVEROS OH, 1979, MOL PHARMACOL, V16, P1101; WILSON SP, 1981, EXP CELL RES, V133, P159, DOI 10.1016/0014-4827(81)90366-9; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WOHLFARTER T, 1988, FEBS LETT, V231, P67, DOI 10.1016/0014-5793(88)80704-X	43	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13607	13615						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856197				2022-12-25	WOS:A1991FY02700027
J	LAIHO, M; WEIS, FMB; BOYD, FT; IGNOTZ, RA; MASSAGUE, J				LAIHO, M; WEIS, FMB; BOYD, FT; IGNOTZ, RA; MASSAGUE, J			RESPONSIVENESS TO TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) RESTORED BY GENETIC COMPLEMENTATION BETWEEN CELLS DEFECTIVE IN TGF-BETA RECEPTOR-I AND RECEPTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITION; PROLIFERATION; PROTEOGLYCAN; EXPRESSION; RESISTANT; BINDING; FORMS	Selection of mutant Mv1Lu mink lung epithelial cells resistant to growth inhibition by transforming growth factor-beta (TGF-beta) has led to the isolation of cell clones with distinct alterations in type I and II TGF-beta receptors. Certain mutant clones present a decreased number or complete loss of detectable type I receptor. Other clones show a loss and/or altered electrophoretic mobility of the type II receptor, with concomitant loss of the type I receptor. Using somatic cell hybridization analysis we demonstrate the recessive nature of these mutants with respect to the wild-type phenotype and define various mutant complementation groups. Among these, hybrids between cells that express only type II receptor (R mutants) and cells that express neither receptor type (DRa mutants) rescue wild-type expression of type I receptors. Moreover, these hybrids regain full responsiveness to TGF-beta-1, as measured by inhibition of DNA synthesis as well as stimulation of fibronectin and plasminogen activator inhibitor-1 production. These results provide evidence for an interaction between TGF-beta receptor components I and II and show that, in Mv1Lu cells, expression of both receptor types is required for mediation of biological responses to TGF-beta-1.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,BOX 116,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHINKERS M, 1987, J CELL PHYSIOL, V130, P1, DOI 10.1002/jcp.1041300102; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8347; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SHIPLEY GD, 1986, CANCER RES, V46, P2068; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	22	249	255	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9108	9112						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851167				2022-12-25	WOS:A1991FM03800069
J	SHENKER, A; GOLDSMITH, P; UNSON, CG; SPIEGEL, AM				SHENKER, A; GOLDSMITH, P; UNSON, CG; SPIEGEL, AM			THE G-PROTEIN COUPLED TO THE THROMBOXANE-A2 RECEPTOR IN HUMAN PLATELETS IS A MEMBER OF THE NOVEL GQ FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; CARBOXYL-TERMINAL DECAPEPTIDE; HIGH-AFFINITY GTPASE; REGULATORY PROTEINS; PERTUSSIS-TOXIN; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; ANTIBODIES; MEMBRANES	The thromboxane A2 (TXA2) receptor in human platelets is coupled to a pertussis toxin-insensitive G protein whose identity has remained unknown. Candidates for this role include the atypical G protein known as G(z) and members of a recently discovered G protein family known as G(q). Because of the proven utility of antibodies directed against the C terminus of G protein alpha-subunits as functional probes, we prepared an antibody against a synthetic decapeptide corresponding to the C-terminal sequence shared by alpha-11 and alpha-q, two members of the new family. This antibody (QL) does not recognize known alpha-subunits but selectively binds to a 42-kDa protein in a variety of tissues, including human platelet membranes. QL and two other C-terminal antibodies, QN and AS, known to recognize alpha-z and alpha-i2, respectively, were tested for their ability to block agonist-stimulated GTPase activity in human platelet membranes. Pretreatment of platelet membranes with AS has previously been shown to interfere with alpha-2 adrenergic receptor-mediated inhibition of adenylylcyclase. As expected, only AS antibody produced inhibition of alpha-2 receptor-stimulated GTPase. Pretreatment of membranes with QL, but not QN or AS, caused marked inhibition of TXA2 receptor-stimulated GTPase. This identifies the G protein coupled to human platelet TXA2 receptors as a member of the novel G(q) family.	ROCKEFELLER UNIV,DEPT BIOCHEM,NEW YORK,NY 10021	Rockefeller University	SHENKER, A (corresponding author), NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BLDG 10,RM 8D17,BETHESDA,MD 20892, USA.							AKTORIES K, 1983, N-S ARCH PHARMACOL, V324, P196, DOI 10.1007/BF00503894; AKTORIES K, 1981, FEBS LETT, V130, P235, DOI 10.1016/0014-5793(81)81128-3; AVDONIN PV, 1985, THROMB RES, V40, P101, DOI 10.1016/0049-3848(85)90354-8; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; BRASS LF, 1989, BLOOD CELLS ARTERIES, P59; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; COCKCROFT S, 1988, PHILOS T ROY SOC B, V320, P247, DOI 10.1098/rstb.1988.0075; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GIERSCHIK P, 1989, EUR J PHARM-MOLEC PH, V172, P481, DOI 10.1016/0922-4106(89)90031-X; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HALUSHKA PV, 1988, CELLULAR MOL ASPECTS, P335; HEDBERG A, 1988, J PHARMACOL EXP THER, V245, P786; HOFFMAN BB, 1982, ENDOCRINOLOGY, V110, P926, DOI 10.1210/endo-110-3-926; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; KUCERA GL, 1988, BIOCHEM BIOPH RES CO, V153, P417, DOI 10.1016/S0006-291X(88)81240-3; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCCLUE SJ, 1990, FEBS LETT, V269, P430, DOI 10.1016/0014-5793(90)81209-7; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MORINELLI TA, 1989, J PHARMACOL EXP THER, V251, P557; OGLETREE ML, 1987, FED PROC, V46, P133; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARKER EM, 1991, J BIOL CHEM, V266, P519; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIESS W, 1985, BLOOD, V65, P1141; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; UEDA H, 1988, P NATL ACAD SCI USA, V85, P7013, DOI 10.1073/pnas.85.18.7013; WILLIAMS AG, 1990, BLOOD, V76, P721	40	365	368	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9309	9313						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851174				2022-12-25	WOS:A1991FM03800097
J	GOODMAN, RB; FORSTROM, JW; OSBORN, SG; CHI, EY; MARTIN, TR				GOODMAN, RB; FORSTROM, JW; OSBORN, SG; CHI, EY; MARTIN, TR			IDENTIFICATION OF 2 NEUTROPHIL CHEMOTACTIC PEPTIDES PRODUCED BY PORCINE ALVEOLAR MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET BASIC-PROTEIN; TUMOR NECROSIS FACTOR; BETA-THROMBOGLOBULIN; ACTIVATING PEPTIDE; GENE-EXPRESSION; POLYMORPHONUCLEAR LEUKOCYTES; MESSENGER-RNA; HUMAN-BLOOD; HUMAN-LUNG; PURIFICATION	We have purified to homogeneity two distinct 10-kDa proteins with potent chemotactic activity for neutrophils from porcine alveolar macrophages incubated for 24 h with Escherichia coli endotoxin (lipopolysaccharide (LPS), 10-mu-g/ml). Neutrophil chemotactic activity in alveolar macrophage supernatants was concentrated by adsorption to SP-Sephadex, and purified by cation exchange and reversed phase high performance liquid chromatography. The first peptide, alveolar macrophage chemotactic factor (AMCF)-I, had chemotactic activity for both porcine and human neutrophils. The chemotactic activity for porcine neutrophils was detectable at 3 x 10(-10) M, peaked at 3 x 10(-8) M, and was comparable to that of zymosan-activated porcine serum. Segmental instillation of AMCF-I into porcine lungs caused marked neutrophil accumulation at 4 h in both bronchoalveolar lavage fluid and in lung tissue. The second peptide, AMCF-II, was active at 1.4 x 10(-9) M for porcine neutrophils, but it was less active for human polymorphonuclear neutrophils than was AMCF-I. Oligonucleotide probes to regions of the N-terminal sequences of AMCF-I and AMCF-II hybridized to mRNA recovered from LPS-stimulated alveolar macrophages. The N-terminal sequences and amino acid compositions indicate that AMCF-I and AMCF-II are distinct proteins, but that both have homologies with a family of peptide chemoattractants produced by human blood monocytes and platelets. Thus, alveolar macrophages stimulated with LPS produce two distince 10-kDa cytokines with potent chemotactic activity for neutrophils. This indicates that there are two different peptide pathways by which alveolar macrophages can recruit neutrophils into the lung.	ZYMOGENET INC,SEATTLE,WA 98108	Zymogenet Inc.	GOODMAN, RB (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE VET ADM CTR,DEPT MED,DEPT PATHOL,DIV PULM & CRIT CARE MED,SEATTLE,WA 98108, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033247, P50HL030542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029103] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33247, HL 30542] Funding Source: Medline; NIAID NIH HHS [AI 29103] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; CHERNIAK RM, 1990, AM REV RESPIR DIS, V141, pS169; CIAGLOWSKI RE, 1986, ARCH BIOCHEM BIOPHYS, V250, P249, DOI 10.1016/0003-9861(86)90723-X; DEUEL TF, 1981, P NATL ACAD SCI-BIOL, V78, P4584, DOI 10.1073/pnas.78.7.4584; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DOI T, 1987, MOL CELL BIOL, V7, P898, DOI 10.1128/MCB.7.2.898; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; HUNNINGHAKE GW, 1980, J CLIN INVEST, V66, P473, DOI 10.1172/JCI109878; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338; MARTIN TR, 1987, J CLIN INVEST, V80, P1114, DOI 10.1172/JCI113168; MARTIN TR, 1984, AM REV RESPIR DIS, V129, P106; MATHISON JC, 1990, J CLIN INVEST, V85, P1108, DOI 10.1172/JCI114542; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MERRILL WW, 1980, J CLIN INVEST, V65, P268, DOI 10.1172/JCI109668; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; PILLEMER L, 1956, J EXP MED, V103, P1, DOI 10.1084/jem.103.1.1; RANKIN JA, 1990, J CLIN INVEST, V86, P1556, DOI 10.1172/JCI114875; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SCHRODER JM, 1988, BIOCHEM BIOPH RES CO, V152, P277, DOI 10.1016/S0006-291X(88)80711-3; STRIETER RM, 1990, AM J RESP CELL MOL, V2, P321, DOI 10.1165/ajrcmb/2.4.321; STRIETER RM, 1988, BIOCHEM BIOPH RES CO, V156, P1340, DOI 10.1016/S0006-291X(88)80779-4; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUZUKI K, 1989, J EXP MED, V169, P1895, DOI 10.1084/jem.169.6.1895; SYLVESTER I, 1990, AM REV RESPIR DIS, V141, P683, DOI 10.1164/ajrccm/141.3.683; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; WALZ A, 1989, BIOCHEM BIOPH RES CO, V159, P969, DOI 10.1016/0006-291X(89)92203-1; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	45	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8455	8463						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850745				2022-12-25	WOS:A1991FK44100075
J	PETROVICH, RM; RUZICKA, FJ; REED, GH; FREY, PA				PETROVICH, RM; RUZICKA, FJ; REED, GH; FREY, PA			METAL COFACTORS OF LYSINE-2,3-AMINOMUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE 2,3-AMINOMUTASE; S-ADENOSYLMETHIONINE; ENZYME; BOND	Lysine-2,3-aminomutase from Clostridium SB4 contains iron and sulfide in equimolar amounts, as well as cobalt, zinc, and copper. The iron and sulfide apparently constitute an Fe-S cluster that is required as a cofactor of the enzyme. Although no B12 derivative can be detected, enzyme-bound cobalt is a cofactor; however, the zinc and copper bound to the enzyme do not appear to play a role in its catalytic activity. These conclusions are supported by the followingfacts reported in this paper. Purification of the enzyme under anaerobic conditions increases the iron and sulfide content. Lysine-2,3-aminomutase purified from cells grown in media supplemented with added CoCl2 contains higher levels of cobalt and correspondingly lower levels of zinc and copper relative to enzyme from cells grown in media not supplemented with cobalt. The specific activity of the purified enzyme increases with increasing iron and sulfide content, and it also increases with increasing cobalt and with decreasing zinc and copper content. The zinc and copper appear to occupy cobalt sites under conditions of insufficient cobalt in the growth medium, and they do not support the activity of the enzyme. The best preparations of lysine-2,3-aminomutase obtained to date exhibit a specific activity of approximately 23 units/mg of protein and contain about 12 g atoms of iron and of sulfide per mol of hexameric enzyme. These preparations also contain 3.5 g atoms of cobalt per mol, but even the best preparations contain small amounts of zinc and copper. The sum of cobalt, zinc, and copper in all preparations analyzed to date corresponds to 5.22 +/- 0.75 g atoms per mol of enzyme. An EPR spectrum of the enzyme as isolated reveals a signal corresponding to high spin Co(II) at temperatures below 20 K. The signal appears as a partially resolved Co-59 octet centered at an apparent g value of 7. The Co-59 hyperfine splitting (approximately 35 G) is prominent at 4.2 K. These findings show that lysine-2,3-aminomutase requires Fe-S clusters and cobalt as cofactors, in addition to the known requirement for pyridoxal 5'-phosphate and S-adenosylmethionine.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	PETROVICH, RM (corresponding author), UNIV WISCONSIN, GRAD SCH, INST ENZYME RES, MADISON, WI 53705 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028607, R01DK028607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM035752, R01GM035752] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28607] Funding Source: Medline; NIGMS NIH HHS [GM35752] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1976, ACCOUNTS CHEM RES, V9, P114, DOI 10.1021/ar50099a006; BARANIAK J, 1989, J BIOL CHEM, V264, P1357; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; FREY PA, 1990, ANN NY ACAD SCI, V585, P368, DOI 10.1111/j.1749-6632.1990.tb28069.x; GOLDING BH, 1982, B12, V2, P574; Goodman BA, 1970, ADV INORG CHEM RAD, V13, P135, DOI DOI 10.1016/S0065-2792(08)60336-2; HAN O, 1990, J AM CHEM SOC, V112, P8982, DOI 10.1021/ja00180a054; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; KIM SH, 1988, J AM CHEM SOC, V110, P3120, DOI 10.1021/ja00218a021; MOSS M, 1987, J BIOL CHEM, V262, P14859; MOSS ML, 1990, J BIOL CHEM, V265, P18112; SONG KB, 1991, J BIOL CHEM, V266, P7651; STADTMAN TC, 1973, ADV ENZYMOL RAMB, V38, P413	14	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7656	7660						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850415				2022-12-25	WOS:A1991FJ34200054
J	WEEGAERSSENS, E; WU, WS; YE, RW; TIEDJE, JM; CHANG, CK				WEEGAERSSENS, E; WU, WS; YE, RW; TIEDJE, JM; CHANG, CK			PURIFICATION OF CYTOCHROME CD1 NITRITE REDUCTASE FROM PSEUDOMONAS-STUTZERI JM300 AND RECONSTITUTION WITH NATIVE AND SYNTHETIC HEME-D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTHETIC GROUP; THIOBACILLUS-DENITRIFICANS; PARACOCCUS-DENITRIFICANS; OXIDASE; AERUGINOSA; PROTEIN; MECHANISM	Cytochrome cd1 nitrite reductase has been purified from Pseudomonas stutzeri strain JM 300. This enzyme appears to be a dimer with a subunit molecular mass of 54 kDa and its isoelectric point is determined to be 5.4. The N terminus of amino acid sequence has strong homology with that of nitrite reductase from P. aeruginosa. The apoprotein of this enzyme has been reconstituted with native and synthetic heme d1. The nitrite reductase activity measured by NO and N2O gas evolution can be restored to 82% of the activity of the original enzyme when the protein was reconstituted with the native heme d1 and to 77% of the activity when reconstituted with the synthetic heme d1. The absorption spectra of both reconstituted enzymes are essentially identical to that of the original nitrite reductase. These results further substantiate the novel dione structure of heme d1 as proposed. The loss of NO2- reducing activity in the absence of heme d1 and its restoration by addition of heme d1 provides further evidence that heme d1 plays a key role in the conversion of NO2- to NO and N2O.	MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT CROP & SOIL SCI, E LANSING, MI 48824 USA	Michigan State University; Michigan State University	WEEGAERSSENS, E (corresponding author), MICHIGAN STATE UNIV, DEPT MICROBIOL & PUBL HLTH, E LANSING, MI 48824 USA.		Chang, Chi K./B-1675-2010	Chang, Chi K./0000-0002-4113-1950	NIGMS NIH HHS [GM36520] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036520] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER D, 1976, BIOCHEM J, V157, P431, DOI 10.1042/bj1570431; CARLSON CA, 1983, APPL ENVIRON MICROB, V45, P1247, DOI 10.1128/AEM.45.4.1247-1253.1983; CHANG CK, 1986, BIOCHEMISTRY-US, V25, P8447, DOI 10.1021/bi00374a019; CHANG CK, 1986, J BIOL CHEM, V261, P8593; CHANG CK, 1985, J BIOL CHEM, V260, P9520; CHANG CK, 1980, INORG SYNTH, V20, P147; COYNE MS, 1990, FEMS SYMP, P21; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HILL KE, 1978, J BIOL CHEM, V253, P489; HOCHSTEIN LI, 1988, ANNU REV MICROBIOL, V42, P231, DOI 10.1146/annurev.mi.42.100188.001311; HORIO T, 1961, J BIOL CHEM, V236, P944; KASPAR HF, 1980, J CHROMATOGR, V193, P142, DOI 10.1016/S0021-9673(00)81455-7; KODAMA T, 1970, PLANT CELL PHYSIOL, V11, P231, DOI 10.1093/oxfordjournals.pcp.a074504; LAM Y, 1969, BIOCHIM BIOPHYS ACTA, V180, P459, DOI 10.1016/0005-2728(69)90025-5; LEGALL J, 1979, BIOCHEM BIOPH RES CO, V87, P355, DOI 10.1016/0006-291X(79)91804-7; MANCINELLI RL, 1986, ARCH MICROBIOL, V145, P202, DOI 10.1007/BF00446781; MOKHELE K, 1987, J BACTERIOL, V169, P5721, DOI 10.1128/jb.169.12.5721-5726.1987; NEWTON N, 1969, BIOCHIM BIOPHYS ACTA, V185, P316, DOI 10.1016/0005-2744(69)90425-2; PARR SR, 1976, BIOCHEM J, V157, P423, DOI 10.1042/bj1570423; RADCLIFFHBC, 1968, BIOCHIM BIOPHYS ACTA, V153, P545, DOI 10.1016/0005-2728(68)90184-9; SAWHNEY V, 1978, J GEN MICROBIOL, V106, P119, DOI 10.1099/00221287-106-1-119; SHEARER G, 1988, J BIOL CHEM, V263, P13231; SILVESTRINI MC, 1989, FEBS LETT, V254, P33, DOI 10.1016/0014-5793(89)81004-X; SILVESTRINI MC, 1983, ANAL BIOCHEM, V129, P318, DOI 10.1016/0003-2697(83)90556-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TIMKOVICH R, 1982, ARCH BIOCHEM BIOPHYS, V215, P47, DOI 10.1016/0003-9861(82)90277-6; WALSH TA, 1981, J INORG BIOCHEM, V14, P15, DOI 10.1016/S0162-0134(00)80011-2; WEBER K, 1969, METHOD ENZYMOL, V26, P3; WEEGAERSSENS E, 1988, J AM CHEM SOC, V110, P6851, DOI 10.1021/ja00228a039; WU WS, 1987, J AM CHEM SOC, V109, P3149, DOI 10.1021/ja00244a050; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P407; YAMANAKA T, 1963, BIOCHEM Z, V338, P62; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P379; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P394; ZUMFT WG, 1982, BIOCHIM BIOPHYS ACTA, V681, P459, DOI 10.1016/0005-2728(82)90188-8	35	50	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7496	7502						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850410				2022-12-25	WOS:A1991FJ34200030
J	JALUKAR, V; KELLEY, PM; NJUS, D				JALUKAR, V; KELLEY, PM; NJUS, D			REACTION OF ASCORBIC-ACID WITH CYTOCHROME-B561 - CONCERTED ELECTRON AND PROTON-TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN-GRANULE MEMBRANE; GHOSTS; MECHANISM; REDUCTION; OXIDATION; VESICLES	Rate constants for reduction of cytochrome b561 by internal ascorbate (k0A) and oxidation by external ferricyanide (k1F) were determined as a function of pH from rates of steady-state electron transfer across chromaffin-vesicle membranes. The pH dependence of electron transfer from cytochrome b561 to ferricyanide (k1F) may be attributed to the pH dependence of the membrane surface potential. The rate constant for reduction by internal ascorbate (k0A), like the previously measured rate constant for reduction by external ascorbate (k-1A), is not very pH-dependent and is not consistent with reduction of cytochrome b561 by the ascorbate dianion. The rate at which ascorbate reduces cytochrome b561 is orders of magnitude faster than the rate at which it reduces cytochrome c, despite the fact that midpoint reduction potentials favor reduction of cytochrome c. Moreover, the rate constant for oxidation of cytochrome b561 by ferricyanide (k1F) is smaller than the previously measured rate constant for oxidation by semidehydroascorbate, despite the fact that ferricyanide has a higher midpoint reduction potential. These results may be reconciled by a mechanism in which electron transfer between cytochrome b561 and ascorbate/semidehydroascorbate is accelerated by concerted transfer of a proton. This may be a general property of biologically significant electron transfer reactions of ascorbic acid.			JALUKAR, V (corresponding author), WAYNE STATE UNIV,DEPT BIOL SCI,DETROIT,MI 48202, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033849, R01GM030500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33849, GM-30500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1987, J BIOL CHEM, V262, P1485; ALAYASH AI, 1979, BIOCHEM J, V177, P641, DOI 10.1042/bj1770641; APPS DK, 1984, BIOCHIM BIOPHYS ACTA, V764, P8, DOI 10.1016/0005-2728(84)90134-8; BIELSKI BHJ, 1981, J AM CHEM SOC, V103, P3516, DOI 10.1021/ja00402a042; BUTLER J, 1981, J INORG BIOCHEM, V15, P41, DOI 10.1016/S0162-0134(00)80134-8; CREUTZ C, 1981, INORG CHEM, V20, P4449, DOI 10.1021/ic50226a088; DUONG LT, 1984, J BIOL CHEM, V259, P4885; FLATMARK T, 1971, BIOCHIM BIOPHYS ACTA, V253, P487, DOI 10.1016/0005-2728(71)90052-1; GROUSELLE M, 1982, BIOCHEM J, V202, P759, DOI 10.1042/bj2020759; IYANAGI T, 1985, BIOCHIM BIOPHYS ACTA, V806, P255, DOI 10.1016/0005-2728(85)90103-3; KELLEY PM, 1988, J BIOL CHEM, V263, P3799; KELLEY PM, 1986, J BIOL CHEM, V261, P6429; KELLEY PM, 1990, J BIOL CHEM, V265, P19409; KHAN MMT, 1969, J AM CHEM SOC, V91, P4668, DOI 10.1021/ja01045a011; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; LAROFF GP, 1972, J AM CHEM SOC, V94, P9062, DOI 10.1021/ja00781a013; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARGALIT R, 1973, EUR J BIOCHEM, V32, P492, DOI 10.1111/j.1432-1033.1973.tb02633.x; MATTHEWS EK, 1972, BIOCHEM J, V130, P825, DOI 10.1042/bj1300825; MCLAUGHLIN S, 1976, BIOCHEMISTRY-US, V15, P1941, DOI 10.1021/bi00654a023; NJUS D, 1983, J BIOL CHEM, V258, P27; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; NJUS D, 1979, BIOCHEM J, V180, P579, DOI 10.1042/bj1800579; WILLIAMS NH, 1982, AUST J CHEM, V35, P1133, DOI 10.1071/CH9821133; YAMAZAKI I, 1962, J BIOL CHEM, V237, P224	25	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6878	6882						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849895				2022-12-25	WOS:A1991FG72700039
J	HAMMERLE, T; HELLEN, CUT; WIMMER, E				HAMMERLE, T; HELLEN, CUT; WIMMER, E			SITE-DIRECTED MUTAGENESIS OF THE PUTATIVE CATALYTIC TRIAD OF POLIOVIRUS 3C PROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASES; GENE ORGANIZATION; SERINE PROTEASES; ESCHERICHIA-COLI; EXPRESSION; CLEAVAGE; INVITRO; RNA; PICORNAVIRUSES; FAMILIES	Based on predictions of the structure of proteinase 3C of poliovirus, mutations have been made at residues that are supposed to constitute the catalytic triad. Wild-type and mutant 3C were expressed in Escherichia coli, purified to homogeneity, and characterized by the ability to cleave a synthetic peptide substrate or an in vitro translated polypeptide consisting of part of the polyprotein of poliovirus. Additionally, the ability of autocatalytic processing of a precursor harboring wild-type or mutant 3C sequences was tested. Single substitutions of the residues His-40, Glu-71, and Cys-147 by Tyr, Gln, and Ser, respectively, resulted in an inactive enzyme. Replacement of Asp-85 by Asn resulted in an enzyme that was as active as wild-type enzyme in trans cleavage assays but whose autoprocessing ability was impaired. Our results are consistent with the proposal that residues His-40, Glu-71, and Cys-147 constitute the catalytic triad of poliovirus 3C proteinase. Furthermore, residue Asp-85 is not required for proper proteolytic activity despite being highly conserved between different picornaviruses. This indicates that Asp-85 might be involved in a different function of 3C.			HAMMERLE, T (corresponding author), SUNY STONY BROOK, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA.				NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-15122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015122, R37AI015122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; CHEAH KC, 1990, J BIOL CHEM, V265, P7180; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3; HANECAK R, 1982, P NATL ACAD SCI-BIOL, V79, P3973, DOI 10.1073/pnas.79.13.3973; HANECAK R, 1984, CELL, V37, P1063, DOI 10.1016/0092-8674(84)90441-0; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; IVANOFF LA, 1986, P NATL ACAD SCI USA, V83, P5392, DOI 10.1073/pnas.83.15.5392; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KAY J, 1990, BIOCHIM BIOPHYS ACTA, V1048, P1, DOI 10.1016/0167-4781(90)90015-T; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWSON MA, 1990, CURR TOP MICROBIOL, V161, P49; MCGRATH ME, 1989, BIOCHEMISTRY-US, V28, P9264, DOI 10.1021/bi00450a005; NICKLIN MJH, 1987, P NATL ACAD SCI USA, V84, P4002, DOI 10.1073/pnas.84.12.4002; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; RUECKERT RR, 1984, J VIROL, V50, P957, DOI 10.1128/JVI.50.3.957-959.1984; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; TOYODA H, 1984, J MOL BIOL, V174, P561, DOI 10.1016/0022-2836(84)90084-6; WANG LM, 1989, BIOTECHNIQUES, V7, P1000; WERNER G, 1986, J VIROL, V57, P1084, DOI 10.1128/JVI.57.3.1084-1093.1986	33	87	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5412	5416						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848550				2022-12-25	WOS:A1991FD37000012
J	DIXON, JL; FURUKAWA, S; GINSBERG, HN				DIXON, JL; FURUKAWA, S; GINSBERG, HN			OLEATE STIMULATES SECRETION OF APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS FROM HEP G2 CELLS BY INHIBITING EARLY INTRACELLULAR DEGRADATION OF APOLIPOPROTEIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; FATTY-ACID UPTAKE; MESSENGER-RNA; APOPROTEIN-B; OLEIC-ACID; ENDOPLASMIC-RETICULUM; METABOLISM; INSULIN; LINE; HYPERCHOLESTEROLEMIA	Studies were conducted to explore the effects of oleate addition on the secretion of apolipoprotein B (apoB)-containing lipoproteins from Hep G2 cells. Whether oleate was added simultaneously with [H-3]-leucine or added to prelabeled cells, the rate of secretion of apoB was stimulated more than 100% within 40 min. When oleate was withdrawn from the cells, the rate of secretion returned to the prestimulated rate within 40 min. These observations suggested that oleate affects apoB secretion early in the secretory pathway. When the effects of oleate on apoB secretion were studied in pulse-chase experiments, it was observed that although apoB synthesis was not affected, apoB intracellular degradation was significant inhibited by oleate. In the absence of oleate, 58% of apoB synthesized during the labeling period was degraded within 20 min, before secretion of apoB into the media had begun, whereas only 29% of labeled apoB was degraded intracellularly during this same time period when oleate was present. Thus, it appears that oleate rapidly stimulates the secretion of apoB by protecting nascent apoB from degradation early in the secretory pathway. Furthermore, stimulation of apoB secretion was observed over a range that includes physiological concentrations of oleate, from 0.1 mM (oleate:bovine serum albumin ratio = 0.45) to 0.8 mM (oleate:ratio = 3.6), suggesting that exogenous oleate could be a physiological modulator of apoB secretion.			DIXON, JL (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.				NHLBI NIH HHS [HL-21006, HL-36000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ARAD Y, 1990, J LIPID RES, V31, P567; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CHAMBAZ J, 1986, BIOCHIM BIOPHYS ACTA, V878, P310, DOI 10.1016/0005-2760(86)90238-9; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; DASHTI N, 1989, J LIPID RES, V30, P1365; DASHTI N, 1987, J LIPID RES, V28, P423; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; ELLSWORTH JL, 1986, J LIPID RES, V27, P858; ERICKSON SK, 1986, J LIPID RES, V27, P875; GIBBONS GF, 1990, BIOCHEM J, V268, P1; GIBSON JC, 1983, J LIPID RES, V24, P886; GINSBERG HN, 1985, J CLIN INVEST, V75, P614, DOI 10.1172/JCI111739; GRUNDY SM, 1985, J LIPID RES, V26, P1464; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MELISH J, 1980, AM J PHYSIOL, V239, pE354, DOI 10.1152/ajpendo.1980.239.5.E354; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RASH JM, 1981, BIOCHIM BIOPHYS ACTA, V666, P294, DOI 10.1016/0005-2760(81)90120-X; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SATO R, 1990, J BIOL CHEM, V265, P11880; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; STREMMEL W, 1989, BIOCHIM BIOPHYS ACTA, V1013, P218, DOI 10.1016/0167-4889(89)90138-9; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TURNER JD, 1981, AM J PHYSIOL, V241, pE57, DOI 10.1152/ajpendo.1981.241.1.E57; WONG S, 1987, ATHEROSCLEROSIS, V64, P139, DOI 10.1016/0021-9150(87)90239-5; WONG SH, 1989, ARTERIOSCLEROSIS, V9, P836, DOI 10.1161/01.ATV.9.6.836	40	393	395	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5080	5086						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848237				2022-12-25	WOS:A1991FC21700061
J	LUND, LR; RONNE, E; ROLDAN, AL; BEHRENDT, N; ROMER, J; BLASI, F; DANO, K				LUND, LR; RONNE, E; ROLDAN, AL; BEHRENDT, N; ROMER, J; BLASI, F; DANO, K			UROKINASE RECEPTOR MESSENGER-RNA LEVEL AND GENE-TRANSCRIPTION ARE STRONGLY AND RAPIDLY INCREASED BY PHORBOL-MYRISTATE ACETATE IN HUMAN MONOCYTE-LIKE U937 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR-INHIBITOR; CELLULAR-BINDING SITE; GROWTH FACTOR-BETA; PROTEIN KINASE-C; ENDOTHELIAL-CELLS; TUMOR PROMOTERS; SARCOMA-CELLS; PRO-UROKINASE; TYPE-1; SEQUENCE	We have studied the effect of the tumor promotor phorbol myristate acetate (PMA) on the level of mRNA for the receptor for urokinase-type plasminogen activator (u-PAR) in the human monocyte-like cell line U937. PMA causes an early increase in the u-PAR mRNA level which reaches a maximal 50-fold enhancement after 24 h of treatment. Half-maximal stimulation occurs at almost-equal-to 5 nM PMA. The effect is observed only with phorbol esters that also act as tumor promotors. The protein synthesis inhibitor cycloheximide (10-mu-g/ml) also increases the level of u-PAR mRNA. Nuclear run-on experiments show a time-dependent increase in the u-PAR gene transcription rate after exposure of the cells to PMA. The PMA-induced increase in u-PAR mRNA is paralleled by a time-dependent increase in u-PAR protein as detected by cross-linking studies with radiolabeled ligand. We conclude that PMA stimulates transcription of the u-PAR gene in U937 cells, and this is responsible at least in part for the accumulation of the u-PAR mRNA and for the subsequent increase in urokinase-binding capacity.	UNIV COPENHAGEN, INST MICROBIOL, DK-1553 COPENHAGEN, DENMARK	University of Copenhagen	LUND, LR (corresponding author), RIGSHOSP, FINSEN LAB, STRANDBLVD 49, DK-2100 COPENHAGEN, DENMARK.			Blasi, Francesco/0000-0001-9406-1784; Behrendt, Niels/0000-0003-1833-3922				ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BAJPAI A, 1985, BIOCHEM BIOPH RES CO, V133, P475, DOI 10.1016/0006-291X(85)90931-3; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BLASI F, 1990, NATO ADV SCI I A-LIF, V191, P21; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOYD D, 1988, CANCER RES, V48, P3112; CASTAGNA M, 1987, BIOL CELL, V59, P3, DOI 10.1111/j.1768-322X.1987.tb00513.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DANO K, 1988, DEV FUNCTION REPRODU, V2, P259; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GREENBERG ME, 1984, NATURE, V311, P432; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; LAIHO M, 1989, CANCER RES, V49, P2533; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; MAKELA TP, 1987, MOL CELL BIOL, V7, P3656; MAYER M, 1988, J BIOL CHEM, V263, P15688; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHLEEF RR, 1988, HAEMOSTASIS, V18, P328; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRENGERS ED, 1987, BLOOD, V69, P381; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	55	108	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5177	5181						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848242				2022-12-25	WOS:A1991FC21700074
J	EITINGER, T; FRIEDRICH, B				EITINGER, T; FRIEDRICH, B			CLONING, NUCLEOTIDE-SEQUENCE, AND HETEROLOGOUS EXPRESSION OF A HIGH-AFFINITY NICKEL TRANSPORT GENE FROM ALCALIGENES-EUTROPHUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; MEMBRANE; PROTEIN; SYSTEM; MOBILIZATION; MUTAGENESIS; GENERATION	High-affinity nickel transport in Alcaligenes eutrophus H16 is mediated by a function designated hoxN. hoxN lies within the hydrogenase gene cluster of megaplasmid pHG1. An insertional mutation at the hoxN locus led to an increased nickel requirement. In this mutant (strain HF260) both autotrophic growth on hydrogen and wild-type level of urease, a nickel-containing enzyme, were dependent on high concentration of nickel in the medium. Studies with a heterologous in vivo expression system revealed that the hoxN locus encodes two proteins with M(r) = 30,000 and 28,000. Only the larger polypeptide was essential for nickel transport. The hoxN locus was cloned on a 2.2-kilobase pair fragment. Nucleotide sequence analysis of the hoxN locus revealed an open reading frame with a coding capacity for a protein of 33.1 kDa. The insertion leading to the Nic- phenotype of strain HF260 maps within this open reading frame indicating that it does in fact have coding function. The deduced amino acid sequence of the hoxN gene has several features typical of a hydrophobic integral membrane protein. Alkaline phosphatase fusion proteins produced by insertion of the transposon TnphoA into hoxN gave significant levels of alkaline phosphatase activity indicating that protein HoxN contains periplasmic domains. Taken together, our results suggest that gene hoxN encodes the high-affinity nickel transporter of A. eutrophus.	FREE UNIV BERLIN,INST PFLANZENPHYSIOL & MIKROBIOL,KONIGIN LUISE STR 12-16,W-1000 BERLIN 33,GERMANY	Free University of Berlin			Eitinger, Thomas/C-3926-2019	Eitinger, Thomas/0000-0003-1449-6433				APPLEYARD RK, 1954, GENETICS, V39, P440; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; DEBRUIJN FJ, 1984, GENE, V27, P131, DOI 10.1016/0378-1119(84)90135-5; DRAKE HL, 1988, BIOINORGANIC CHEM NI, P111; EBERZ G, 1989, J BACTERIOL, V171, P1340, DOI 10.1128/jb.171.3.1340-1345.1989; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; HAUSINGER RP, 1987, MICROBIOL REV, V51, P22, DOI 10.1128/MMBR.51.1.22-42.1987; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOHMEYER M, 1987, ARCH MICROBIOL, V149, P130, DOI 10.1007/BF00425078; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Silver S., 1987, ION TRANSPORT PROKAR, P165; SIMON R, 1989, GENE, V80, P161, DOI 10.1016/0378-1119(89)90262-X; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WU LF, 1989, MOL MICROBIOL, V3, P1709, DOI 10.1111/j.1365-2958.1989.tb00156.x	22	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3222	3227						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847142				2022-12-25	WOS:A1991EX60000083
J	KALVAKOLANU, DVR; BANDYOPADHYAY, SK; TIWARI, RK; SEN, GC				KALVAKOLANU, DVR; BANDYOPADHYAY, SK; TIWARI, RK; SEN, GC			ENHANCEMENT OF EXPRESSION OF EXOGENOUS GENES BY 2-AMINOPURINE - REGULATION AT THE POSTTRANSCRIPTIONAL LEVEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INITIATION FACTOR-II; ADENOVIRUS VAI RNA; MESSENGER-RNA; PROTEIN-SYNTHESIS; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSLATIONAL CONTROL; SYNTHETASE GENE; NUCLEAR FACTORS; FACTOR EIF-2	In human and mouse cell lines, expression of exogenous genes was enhanced by treatment with 2-aminopurine (2-AP). Chloramphenicol acetyltransferase (CAT) and neomycin phosphotransferase activities were increased by up to 50-fold upon 2-AP treatment of cells permanently transfected with genes encoding these enzymes. Neomycin phosphotransferase activity was also increased by this treatment in cells infected with a retroviral vector carrying the neomycin phosphotransferase gene. 2-AP-mediated increase in CAT activity was observed in various cell lines which had been permanently transfected with chimeric CAT genes containing transcriptional regulatory elements of the interferon-inducible genes 6-16 and 561, SV40 early genes, mouse mammary tumor viral gene, or metallothionein II gene. The increase in the cellular CAT enzymatic activity was due to an elevated level of CAT protein. The 2-AP-mediated enhancement of CAT expression was operative at the translational level; the rate of transcription of CAT mRNA or its steady-state level was affected only marginally. The translational up-regulation by 2-AP was restricted to the genes introduced from outside; there was no gross change in the rate of synthesis of other cellular proteins.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022510] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22510] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DEBENEDETTI A, 1983, J BIOL CHEM, V258, P4556; DEBENEDETTI A, 1984, NATURE, V311, P79, DOI 10.1038/311079a0; FREGIEN N, 1985, ANAL BIOCHEM, V148, P101, DOI 10.1016/0003-2697(85)90633-5; GIANTINI M, 1989, J VIROL, V63, P2415, DOI 10.1128/JVI.63.6.2415-2421.1989; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HUISMANS H, 1976, VIROLOGY, V70, P411, DOI 10.1016/0042-6822(76)90282-8; KAEMPFER R, 1978, P NATL ACAD SCI USA, V75, P209, DOI 10.1073/pnas.75.1.209; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KUMAR R, 1989, VIRUS RES, V13, P295, DOI 10.1016/0168-1702(89)90075-0; KUSARI J, 1986, MOL CELL BIOL, V6, P2062, DOI 10.1128/MCB.6.6.2062; KUSARI J, 1987, MOL CELL BIOL, V7, P528, DOI 10.1128/MCB.7.1.528; LEGON S, 1974, BIOCHEM BIOPH RES CO, V56, P745, DOI 10.1016/0006-291X(74)90668-8; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MYERS RM, 1988, SCIENCE, V230, P276; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; PINE R, 1988, NUCLEIC ACIDS RES, V16, P1371, DOI 10.1093/nar/16.4.1371; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; RAJ NBK, 1989, J BIOL CHEM, V264, P16658; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SAMUEL CE, 1990, VIROLOGY, V176, P106, DOI 10.1016/0042-6822(90)90235-J; SCHNEIDER RJ, 1985, P NATL ACAD SCI USA, V82, P4321, DOI 10.1073/pnas.82.13.4321; SIEKIERKA J, 1985, P NATL ACAD SCI USA, V82, P1959, DOI 10.1073/pnas.82.7.1959; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SVENSSON C, 1984, MOL CELL BIOL, V4, P736, DOI 10.1128/MCB.4.4.736; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	41	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					873	879						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845996				2022-12-25	WOS:A1991ET17700033
J	BROWN, NF; ESSER, V; GONZALEZ, AD; EVANS, CT; SLAUGHTER, CA; FOSTER, DW; MCGARRY, JD				BROWN, NF; ESSER, V; GONZALEZ, AD; EVANS, CT; SLAUGHTER, CA; FOSTER, DW; MCGARRY, JD			MITOCHONDRIAL IMPORT AND PROCESSING OF RAT-LIVER CARNITINE PALMITOYLTRANSFERASE-II DEFINES THE AMINO TERMINUS OF THE MATURE PROTEIN - POSSIBILITY OF DIFFERENTIAL MODIFICATION OF THE RAT AND HUMAN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SYSTEM; EXPRESSION; PRECURSOR; SEQUENCE; COA	[S-35]Methionine-labeled porcine heart citrate synthase (used here as a positive control) and rat liver carnitine palmitoyltransferase II (CPT II) were generated by in vitro transcription and translation of their cDNA constructs in appropriate Bluescript plasmids. Each product was imported into rat liver mitochondria in an energy-dependent manner to yield an immunoprecipitable protein of smaller size that comigrated with the corresponding purified enzyme. The size shift occurring with citrate synthase was consistent with the removal of the postulated 27-amino acid leader peptide. To determine the amino terminus of mature CPT II, [S-35]methionine- or [H-3]leucine-labeled material (after import and processing) was subjected to Edman degradation, followed by counting of the radioactivity released on each cycle. The results established that the precursor targeting peptide was cleaved between leucine 25 and serine 26 in the previously deduced amino acid sequence. Taken in conjunction with the recent report of Finocchiaro et al. (Finocchiaro, G., Taroni, F., Rocchi, M., Martin, A. L., Colombo, I., Tarelli, G. T., and DiDonato, S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 661-665), the present results establish three key points concerning the rat and human forms of CPT II. First, it appears that in both species the initial translation product contains 658 amino acids and, upon mitochondrial import, is reduced in length by 25 residues through cleavage at an identical site. Second, the difference in electrophoretic mobility between the two mature proteins (documented earlier) presumably reflects either anomalous behavior of one of them on polyacrylamide gels or differential covalent modification. Finally, the recent suggestion by Brady et al. (Brady, P. S., Liu, J. S., Park, E. A., Hanson, R. W., and Brady, L. J. (1991) FASEB J. 5, A817) that our CPT II cDNA construct is incomplete in the 5'-coding region is refuted.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CTR DIABET RES,DALLAS,TX 75235; DEPT VET AFFAIRS MED CTR,DALLAS,TX 75216	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK11313, DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R01DK011313, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADY PS, 1988, J NUTR, V118, P1128, DOI 10.1093/jn/118.9.1128; BRADY PS, 1991, FASEB J, V5, pA817; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; EVANS CT, 1988, BIOCHEMISTRY-US, V27, P4680, DOI 10.1021/bi00413a015; FENTON WA, 1984, J BIOL CHEM, V259, P6616; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; KOLANSKY DM, 1982, J BIOL CHEM, V257, P8467; KRAUS JP, 1983, J BIOL CHEM, V258, P7245; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714	17	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15446	15449						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869564				2022-12-25	WOS:A1991GB09700092
J	HAZEN, SL; GROSS, RW				HAZEN, SL; GROSS, RW			ATP-DEPENDENT REGULATION OF RABBIT MYOCARDIAL CYTOSOLIC CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; GTP-BINDING PROTEINS; CELL-LINE; MEMBRANE FLUIDITY; FATTY-ACIDS; K+-CHANNEL; KINASE-C; PURIFICATION; ISCHEMIA; ACTIVATION	We report here that rabbit myocardial cytosolic calcium-independent phospholipase A2 exists as a high molecular weight complex comprised of catalytic and regulatory polypeptides whose activity and stability are influenced by specific interactions with ATP. Multiple lines of evidence document the functional significance of interactions between the catalytic complex and ATP including: 1) adenine nucleotide triphosphates attenuate the rate of thermal denaturation of native cytosolic phospholipase A2; 2) ATP augments the initial rate of phospholipid hydrolysis in a manner independent of the concentration, interfacial properties, and physical state of aggregated substrate; 3) adenine nucleotide triphosphates attenuate the reactivity of an essential thiol residue to covalent modification by 5,5'-dithiobis(2-nitrobenzoic acid); and 4) the catalytic complex specifically and reversibly binds to ATP affinity matrices, although the purified 40-kDa catalytic subunit neither binds to ATP affinity matrices nor is subject to ATP-dependent activation and stabilization. The catalytic and regulatory elements were functionally resolved by differential thermal inactivation and the ATP-regulatable phospholipase A2 catalytic complex was reassembled by reconstitution of highly purified catalytic and partially purified regulatory proteins. Thus, alterations in ATP concentration influence the activity and longevity of the myocardial cytosolic calcium-independent phospholipase A2 catalytic complex, thereby potentially modulating the release of lipidic second messengers and facilitating adaptive alterations in membrane physical properties.	WASHINGTON UNIV,SCH MED,MOLEC & CELLULAR CARDIOVASC BIOCHEM SECT,660 S EUCLID AVE,BOX 8020,ST LOUIS,MO 63110	Washington University (WUSTL)			Hazen, Stanley L/ABD-5845-2021		NHLBI NIH HHS [HL34839] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034839] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYANOGLU E, 1984, J AM CHEM SOC, V106, P5246, DOI 10.1021/ja00330a035; BILLS TK, 1977, J CLIN INVEST, V60, P1, DOI 10.1172/JCI108745; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOEYNAEMS JM, 1989, BIOCHEM PHARMACOL, V38, P3261, DOI 10.1016/0006-2952(89)90623-0; BOIME I, 1970, ARCH BIOCHEM BIOPHYS, V139, P425, DOI 10.1016/0003-9861(70)90496-0; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CHIEN KR, 1981, CIRC RES, V48, P711, DOI 10.1161/01.RES.48.5.711; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CREER MH, 1985, J CHROMATOGR, V338, P61, DOI 10.1016/0378-4347(85)80070-0; DAS DK, 1986, AM J PHYSIOL, V251, pH71, DOI 10.1152/ajpheart.1986.251.1.H71; Dennis EA, 1983, ENZYMES, P307; ECKSTEIN F, 1983, ANGEW CHEM INT EDIT, V22, P423, DOI 10.1002/anie.198304233; EDEMAN AM, 1987, ANNU REV BIOCHEM, V56, P567; EDGAR AD, 1982, J NEUROCHEM, V39, P1111, DOI 10.1111/j.1471-4159.1982.tb11503.x; FELDER CC, 1990, P NATL ACAD SCI USA, V87, P2187, DOI 10.1073/pnas.87.6.2187; FORD DA, 1989, CIRC RES, V64, P173, DOI 10.1161/01.RES.64.1.173; FRIEDLANDER G, 1990, BIOCHIM BIOPHYS ACTA, V1022, P1, DOI 10.1016/0005-2736(90)90393-3; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GASSER KW, 1990, BIOCHEMISTRY-US, V29, P7282, DOI 10.1021/bi00483a018; GEISBUHLER T, 1984, CIRC RES, V54, P536, DOI 10.1161/01.RES.54.5.536; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HERMONILEVINE M, 1990, BIOCHEMISTRY-US, V29, P4940, DOI 10.1021/bi00472a026; HUSEBYE ES, 1987, BIOCHIM BIOPHYS ACTA, V920, P120, DOI 10.1016/0005-2760(87)90251-7; JELSEMA CL, 1987, J BIOL CHEM, V262, P163; JESSE RL, 1976, BIOCHEM J, V158, P283, DOI 10.1042/bj1580283; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LOEB LA, 1986, J BIOL CHEM, V261, P467; LOHNER K, 1984, CHEM PHYS LIPIDS, V34, P163, DOI 10.1016/0009-3084(84)90041-0; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NGUYEN VD, 1988, J CLIN INVEST, V82, P1098, DOI 10.1172/JCI113666; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OPIE LH, 1976, CIRC RES, V38, P52; OTARMIRI T, 1988, AGENTS ACTIONS, V25, P378; PARKER J, 1987, J BIOL CHEM, V262, P5385; PIERIK AJ, 1988, BIOCHIM BIOPHYS ACTA, V962, P345, DOI 10.1016/0005-2760(88)90264-0; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SAWYER DB, 1989, BIOCHIM BIOPHYS ACTA, V987, P129, DOI 10.1016/0005-2736(89)90464-1; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; VANBILSEN M, 1989, CIRC RES, V64, P304, DOI 10.1161/01.RES.64.2.304; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WOLF RA, 1985, J LIPID RES, V26, P629; WOLF RA, 1985, J BIOL CHEM, V260, P7295	55	93	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14526	14534						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860859				2022-12-25	WOS:A1991FZ35100066
J	MOORES, SL; SCHABER, MD; MOSSER, SD; RANDS, E; OHARA, MB; GARSKY, VM; MARSHALL, MS; POMPLIANO, DL; GIBBS, JB				MOORES, SL; SCHABER, MD; MOSSER, SD; RANDS, E; OHARA, MB; GARSKY, VM; MARSHALL, MS; POMPLIANO, DL; GIBBS, JB			SEQUENCE DEPENDENCE OF PROTEIN ISOPRENYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; GTP-BINDING; CARBOXYL-METHYLATION; TERMINAL CYSTEINE; RAS PROTEINS; P21RAS; YEAST; IDENTIFICATION; MEMBRANE; FARNESYL	Several proteins have been shown to be post-translationally modified on a specific C-terminal cysteine residue by either of two isoprenoid biosynthetic pathway metabolites, farnesyl diphosphate or geranylgeranyl diphosphate. Three enzymes responsible for protein isoprenylation were resolved chromatographically from the cytosolic fraction of bovine brain: a farnesyl-protein transferase (FTase), which modified the cell-transforming Ras protein, and two geranylgeranyl-protein transferases, one (GGTase-I) which modified a chimeric Ras having the C-terminal amino acid sequence of the gamma-6 subunit of heterotrimeric GTP-binding proteins, and the other (GGTase-II) which modified the Saccharomyces cerevisiae secretory GTPase protein YPT1. In a S. cerevisiae strain lacking FTase activity (ram1), both GGTases were detected at wild-type levels. In a ram2 S. cerevisiae strain devoid of FTase activity, GGTase-I activity was reduced by 67%, suggesting that GGTase-I and FTase activities derive from different enzymes but may share a common genetic feature. For the FTase and the GGTase-I activities, the C-terminal amino acid sequence of the protein substrate, the CAAX box, appeared to contain all the critical determinants for interaction with the transferase. In fact, tetrapeptides with amino acid sequences identical to the C-terminal sequences of the protein substrates for FTase or GGTase-I competed for protein isoprenylation by acting as alternative substrates. Changes in the CAAX amino acid sequence of protein substrates markedly altered their ability to serve as substrates for both FTase and GGTase-I. In addition, it appeared that FTase and GGTase-I had complementary affinities for CAAX protein substrates; that is, CAAX proteins that were good substrates for FTase were, in general, poor substrates for GGTase-I, and vice versa. In particular, a leucine residue at the C terminus influenced whether a CAAX protein was either farnesylated or geranylgeranylated preferentially. The YPT1 C terminus peptide, TGGGCC, did not compete or serve as a substrate for GGTase-II, indicating that the interaction between GGTase-II and YPT1 appeared to depend on more than the 6 C-terminal residues of the protein substrate sequence. These results identify three different isoprenyl-protein transferases that are each selective for their isoprenoid and protein substrates.	MERCK SHARP & DOHME LTD, DEPT CANC RES, West Point, PA 19486 USA; MERCK SHARP & DOHME LTD, DEPT MED CHEM, West Point, PA 19486 USA	Merck & Company; Merck & Company								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER JM, 1974, EXPT TECHNIQUES BIOC, P1; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; RINE J, 1990, New Biologist, V2, P219; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHABERMD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	36	573	605	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14603	14610						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860864				2022-12-25	WOS:A1991FZ35100077
J	PETTIT, SC; SIMSIC, J; LOEB, DD; EVERITT, L; HUTCHISON, CA; SWANSTROM, R				PETTIT, SC; SIMSIC, J; LOEB, DD; EVERITT, L; HUTCHISON, CA; SWANSTROM, R			ANALYSIS OF RETROVIRAL PROTEASE CLEAVAGE SITES REVEALS 2 TYPES OF CLEAVAGE SITES AND THE STRUCTURAL REQUIREMENTS OF THE P1 AMINO-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; SYNTHETIC HIV-1 PROTEASE; MAMMARY-TUMOR VIRUS; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE; GENE-PRODUCTS; GAG GENE; ASPARTIC PROTEINASES; MUTATIONAL ANALYSIS	Retroviruses encode a protease which cleaves the viral Gag and Gag/Pol protein precursors into mature products. To understand the target sequence specificity of the viral protease, the amino acid sequences from 46 known processing sites from 10 diverse retroviruses were compared. Sequence preference was evident in positions P4 through P3' when compared to flanking sequences. Approximately 80% of all cleavage site sequences could be grouped into two classes based on the sequence composition flanking the scissile bond. The sequences at the amino-terminal cleavage site of the major capsid protein of Gag is always a member of one of the two classes while the carboxyl-terminal cleavage site is of the other class, suggesting a biological role for the two classes. Known processing site sequences proved useful in a motif searching strategy to identify processing sites in retroviral protein sequences, particularly in Gag. In all known cleavage sites, the P1 amino acid is hydrophobic and unbranched at the beta-carbon. The sequence requirements of the P1 position were tested by site-directed mutagenesis of the P1 Phe codon in an HIV-1 Pol cleavage site. Mutations were tested for protease-mediated cleavage of the Pol precursor expressed in Escherichia coli.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Pettit, Steve/J-4536-2013	Pettit, Steve/0000-0002-1967-1491	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008998, U01AI025697, R01AI025321, R01AI008998, R21AI008998] Funding Source: NIH RePORTER; NIAID NIH HHS [VO1-AI25697, AI-08998, R0I-AI25321] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHOWN AS, 1980, J BIOL CHEM, V265, P6962; BILLICH S, 1988, J BIOL CHEM, V263, P17905; COPELAND TD, 1985, VIROLOGY, V143, P676, DOI 10.1016/0042-6822(85)90411-8; COPELAND TD, 1983, FEBS LETT, V156, P37, DOI 10.1016/0014-5793(83)80243-9; CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DEVARE SG, 1985, VIROLOGY, V42, P206; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOWDA SD, 1989, J BIOL CHEM, V264, P8459; HENDERSON LE, 1985, J VIROL, V55, P778, DOI 10.1128/JVI.55.3.778-787.1985; HENDERSON LE, 1984, J VIROL, V52, P492, DOI 10.1128/JVI.52.2.492-500.1984; HENDERSON LE, 1987, J VIROL, V61, P1116, DOI 10.1128/JVI.61.4.1116-1124.1987; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; HIPPENMEYER PJ, 1984, VIROLOGY, V137, P358, DOI 10.1016/0042-6822(84)90228-9; HIZI A, 1989, J VIROL, V63, P2543, DOI 10.1128/JVI.63.6.2543-2549.1989; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; HUNTER E, 1983, J VIROL, V45, P885, DOI 10.1128/JVI.45.2.885-888.1983; KATOH I, 1989, J VIROL, V63, P2226, DOI 10.1128/JVI.63.5.2226-2232.1989; KATOH I, 1985, VIROLOGY, V145, P280, DOI 10.1016/0042-6822(85)90161-8; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KOTLER M, 1989, J BIOL CHEM, V264, P3428; KOTLER M, 1988, P NATL ACAD SCI USA, V85, P4185, DOI 10.1073/pnas.85.12.4185; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPATTO P, 1989, NATURE, V342, P299; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MISANO KS, 1980, FED P EXP BIOL ABS, V60, P1611; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; MYERS G, 1990, HUMAN RETROOVIRUSES; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; OROSZLAN S, 1979, P NATL ACAD SCI USA, V76, P2996, DOI 10.1073/pnas.76.6.2996; OROSZLAN S, 1978, P NATL ACAD SCI USA, V75, P1404, DOI 10.1073/pnas.75.3.1404; OROSZLAN S, 1985, CURR TOP MICROBIOL, V115, P221; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PARTIN K, 1990, J VIROL, V64, P3938, DOI 10.1128/JVI.64.8.3938-3947.1990; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PEARL LH, 1987, NATURE, V328, P482, DOI 10.1038/328482b0; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER RT, 1981, BIOCHEMISTRY-US, V20, P3784, DOI 10.1021/bi00516a018; STADEN R, 1988, COMPUT APPL BIOSCI, V4, P53; STADEN R, 1985, GENETIC ENG PRINCIPL, V7, P67; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; SWANSTROM R, 1990, SEMIN VIROL, V1, P175; TOH H, 1985, NATURE, V315, P361; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGT VM, 1985, J VIROL, V56, P31, DOI 10.1128/JVI.56.1.31-39.1985; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YOSHINAKA Y, 1980, J GEN VIROL, V48, P329, DOI 10.1099/0022-1317-48-2-329; YOSHINAKA Y, 1978, J GEN VIROL, V40, P151, DOI 10.1099/0022-1317-40-1-151; YOSHINAKA Y, 1986, J VIROL, V57, P826, DOI 10.1128/JVI.57.3.826-832.1986; YOSHINAKA Y, 1977, P NATL ACAD SCI USA, V74, P3446, DOI 10.1073/pnas.74.8.3446; [No title captured]	71	128	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14539	14547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860860				2022-12-25	WOS:A1991FZ35100068
J	WANG, E; NORRED, WP; BACON, CW; RILEY, RT; MERRILL, AH				WANG, E; NORRED, WP; BACON, CW; RILEY, RT; MERRILL, AH			INHIBITION OF SPHINGOLIPID BIOSYNTHESIS BY FUMONISINS - IMPLICATIONS FOR DISEASES ASSOCIATED WITH FUSARIUM-MONILIFORME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PROTEIN-KINASE-C; SERINE PALMITOYLTRANSFERASE; CULTURE MATERIAL; FREE SPHINGOSINE; LIVER; CANCER; RATS; LEUKOENCEPHALOMALACIA; HEPATOTOXICITY	Culture materials and grains contaminated with certain isolates of Fusarium moniliforme cause equine leucoencephalomalacia, porcine pulmonary edema syndrome, and liver cancer in rats. The causative agents are thought to be a family of compounds called fumonisins, which bear considerable structural similarity to the long-chain (sphingoid) base backbones of sphingolipids. Incubation of rat hepatocytes with fumonisins inhibited incorporation of [C-14]serine into the sphingosine moiety of cellular sphingolipids with an IC50 of 0.1-mu-M for fumonisin B1. In contrast, fumonisin B, increased the amount of the biosynthetic intermediate sphinganine, which suggests that fumonisins inhibit the conversion of [C-14]sphinganine to N-acyl-[C-14] sphinganines, a step that is thought to precede introduction of the 4,5-trans double bond of sphingosine (Merrill, A. H., Jr. and Wang, E. (1986) J. Biol. Chem. 261, 3764-3769). In agreement with this mechanism, fumonisin B1 inhibited the activity of sphingosine N-acyltransferase (ceramide synthase) in rat liver microsomes with 50% inhibition at approximately 0.1-mu-M and reduced the conversion of [H-3]sphingosine to [H-3] ceramide by intact hepatocytes. As far as we are aware, this is the first discovery of a naturally occurring inhibitor of this step of sphingolipid metabolism. These findings suggest that disruption of the de novo pathway of sphingolipid biosynthesis may be a critical event in the diseases that have been associated with consumption of fumonisins.	EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322; USDA ARS,TOXICOL & MYCOTINS RES UNIT,ATHENS,GA 30613	Emory University; United States Department of Agriculture (USDA)				Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM33369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033369] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEZUIDENHOUT CS, 1988, J CHEM SOC CHEM COMM, P743; BOTTINI AT, 1981, TETRAHEDRON LETT, V22, P2723, DOI 10.1016/S0040-4039(01)90535-0; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GELDERBLOM WCA, 1988, APPL ENVIRON MICROB, V54, P1806, DOI 10.1128/AEM.54.7.1806-1811.1988; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Harrison L R, 1990, J Vet Diagn Invest, V2, P217; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JASKIEWICZ K, 1987, JNCI-J NATL CANCER I, V78, P321; KELLERMAN T S, 1972, Onderstepoort Journal of Veterinary Research, V39, P205; KRIENK NPJ, 1981, ONDERSTEPOORT J VET, V55, P129; LIN M, 1980, GENETIC ENV FACTORS, P139; Marasas W. F. O., 1982, CANCER ESOPHAGUS, V1, P29; MARASAS WFO, 1984, INT J CANCER, V34, P383, DOI 10.1002/ijc.2910340315; MARASAS WFO, 1988, ONDERSTEPOORT J VET, V55, P197; MARASAS WFO, 1984, TOXIGENIC FUSARIUM S; MEDLOCK KA, 1988, BIOCHEM BIOPH RES CO, V157, P232, DOI 10.1016/S0006-291X(88)80037-8; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P4360; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; MORRELL P, 1970, J BIOL CHEM, V245, P342; OISHI K, 1990, J BIOL CHEM, V265, P70; ROSS PF, 1991, MYCOPATHOLOGIA, V114, P129, DOI 10.1007/BF00437200; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; Sweely CC, 1985, BIOCH LIPIDS MEMBRAN, P361; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P285, DOI 10.1021/jf00091a064; VOSS KA, 1990, MYCOPATHOLOGIA, V112, P81, DOI 10.1007/BF00436503; VOSS KA, 1989, FOOD CHEM TOXICOL, V27, P89, DOI 10.1016/0278-6915(89)90002-1; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; YANG CS, 1980, CANCER RES, V40, P2633; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZHANG H, 1990, J BIOL CHEM, V265, P76	40	986	1019	2	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14486	14490						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860857				2022-12-25	WOS:A1991FZ35100060
J	SENEAR, DF; BRENOWITZ, M				SENEAR, DF; BRENOWITZ, M			DETERMINATION OF BINDING CONSTANTS FOR COOPERATIVE SITE-SPECIFIC PROTEIN-DNA INTERACTIONS USING THE GEL MOBILITY-SHIFT ASSAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-PHAGE REPRESSOR; FOOTPRINT TITRATION; GENE-REGULATION; LAC REPRESSOR; ELECTROPHORESIS; COMPLEXES; SEQUENCE	We have investigated the question of whether the gel mobility-shift assay can provide data that are useful to the demonstration of cooperativity in the site-specific binding of proteins to DNA. Three common patterns of protein-DNA interaction were considered: (i) the cooperative binding of a protein to two sites (illustrated by the Escherichia coli Gal repressor); (ii) the cooperative binding of a bidentate protein to two sites (illustrated by the E. coli Lac repressor); and (iii) the cooperative binding of a protein to three sites (illustrated by the lambda-cI repressor). A simple, rigorous, and easily extendable statistical mechanical approach to the derivation of the binding equations for the different patterns is presented. Both simulated and experimental data for each case are analyzed. The mobility-shift assay provides estimates of the macroscopic binding constants for each step of ligation based on its separation of liganded species by the number of ligands bound. Resolution of the binding constants depends on the precision with which the equilibrium distribution of liganded species is determined over the entire range of titration of each of the sites. However, the evaluation of cooperativity from the macroscopic binding constants is meaningful only for data that are also accurate. Some criteria that are useful in evaluating accuracy are introduced and illustrated. Resolution of cooperative effects is robust only for the simplest case, in which there are two identical protein binding sites. In this case, cooperative effects of up to 1,000-fold are precisely determined. For heterogeneous sites, cooperative effects of greater than 1,000-fold are resolvable, but weak cooperativity is masked by the heterogeneity. For three-site systems, only averaged pair-wise cooperative effects are resolvable.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	SENEAR, DF (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.				NIGMS NIH HHS [GM39929, GM41465] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041465, R01GM039929, R29GM039929] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; ADHYA S, 1989, ANNU REV GENET, V23, P207; BOSSINGER J, 1979, J BIOL CHEM, V254, P7986; BOX GEP, 1960, ANN NY ACAD SCI, V86, P792, DOI 10.1111/j.1749-6632.1960.tb42843.x; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENOWITZ M, 1991, IN PRESS BIOCHEMISTR, V30; BRENOWITZ M, 1989, CURRENT PROTOCOLS S7, V2; CANN JR, 1989, J BIOL CHEM, V264, P17032; CANN JR, 1991, J MOL BIOL, V216, P1067; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CODISH LA, 1989, CURRENT PROTOCOLS S7, V2; DANDANELL G, 1987, NATURE, V325, P823, DOI 10.1038/325823a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRALLA JD, 1989, CELL, V57, P193, DOI 10.1016/0092-8674(89)90955-0; HABER R, 1988, P NATL ACAD SCI USA, V85, P9683, DOI 10.1073/pnas.85.24.9683; Hildebrand F. B., 1974, INTRO NUMERICAL ANAL; HILL TL, 1960, INTRO STATISTICAL ME; HUDSON JM, 1990, J BIOL CHEM, V265, P3219; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; JOHNSON AD, 1980, THESIS HARVARD U CAM; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; MAJUMDAR A, 1987, J BIOL CHEM, V262, P2326; Maniatis T., 1982, MOL CLONING; REINER P, 1991, IN PRESS CABIOS; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; SAUER RT, 1979, THESIS HARVARD U CAM; SENEAR DF, 1990, BIOCHEMISTRY-US, V29, P6568, DOI 10.1021/bi00480a004; SENEAR DF, 1986, BIOCHEMISTRY-US, V25, P7344, DOI 10.1021/bi00371a016; SENEAR DF, 1991, IN PRESS BIOCHEMISTR, V30; SENEAR DF, 1991, IN PRESS METHODS ENZ; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; TJIAN R, 1989, SCIENCE, V245, P371; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	43	105	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13661	13671						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856200				2022-12-25	WOS:A1991FY02700035
J	MACKAY, K; DANIELPOUR, D				MACKAY, K; DANIELPOUR, D			NOVEL 150-KDA AND 180-KDA GLYCOPROTEINS THAT BIND TRANSFORMING GROWTH-FACTOR (TGF)-BETA-1 BUT NOT TGF-BETA-2 ARE PRESENT IN SEVERAL CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; GLYCOSAMINOGLYCAN CHAINS; MEMBRANE-RECEPTOR; LIGAND-BINDING; PROTEINS; PROTEOGLYCAN; FIBROBLASTS; EXPRESSION; CULTURE	We identified transforming growth factor-beta (TGF-beta)-binding proteins which are distinct from previously described TGF-beta receptors or TGF-beta-binding proteins. These TGF-beta-binding proteins migrate as 150- and 180-kDa I-125-TGF-beta-1 affinity-labeled complexes which are consistently co-expressed in A549, Mv 1Lu, MG-63, and BS-C-1 cells. They differ from the types I, II, and III TGF-beta-receptors in their electrophoretic mobilities, their lack of binding to TGF-beta-2, and their failure to undergo the marked down-regulation seen with types I,II, and III receptors following a 16-h incubation with TGF-beta-1. The 150- and 180-kDa TGF-beta-binding proteins also are distinct from the recently described disulfide-linked TGF-beta-1-binding proteins which are present in rat glomeruli. In contrast to the glomerular TGF-beta-1-binding proteins the electrophoretic mobilities of the 150- and 180-kDa binding proteins are unchanged following reduction. In addition, the 150- and 180-kDa TGF-beta-binding proteins are present in the detergent-rich phase during Triton X-114 phase separation, whereas the glomerular TGF-beta-binding proteins partition exclusively into the detergent-poor phase.	NCI, CHEMOPREVENT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MACKAY, K (corresponding author), NIDDKD, METAB DIS BRANCH,KIDNEY DIS SECT,BLDG 10,RM 3N106, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CABRAL F, 1978, ANAL BIOCHEM, V91, P548, DOI 10.1016/0003-2697(78)90542-0; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; CONTI FG, 1988, AM J PHYSIOL, V255, pF1214, DOI 10.1152/ajprenal.1988.255.6.F1214; FROLIK CA, 1984, J BIOL CHEM, V259, P995; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKAY K, 1989, J CLIN INVEST, V83, P1160, DOI 10.1172/JCI113996; MACKAY K, 1990, J BIOL CHEM, V265, P9351; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P958, DOI 10.1073/pnas.82.4.958; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MASSAGUE J, 1987, J CELL PHYSIOL, P43; MASSAGUE J, 1986, J CELL PHYSIOL, V128, P216, DOI 10.1002/jcp.1041280212; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; STOW JL, 1989, AM J PATHOL, V135, P637; Thompson L H, 1973, Methods Cell Biol, V6, P209, DOI 10.1016/S0091-679X(08)60052-7; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965	25	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9907	9911						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851759				2022-12-25	WOS:A1991FM45900084
J	TARTARE, S; BALLOTTI, R; LAMMERS, R; ALENGRIN, F; DULL, T; SCHLESSINGER, J; ULLRICH, A; VANOBBERGHEN, E				TARTARE, S; BALLOTTI, R; LAMMERS, R; ALENGRIN, F; DULL, T; SCHLESSINGER, J; ULLRICH, A; VANOBBERGHEN, E			INSULIN-EGF RECEPTOR CHIMERAE MEDIATE TYROSINE TRANSPHOSPHORYLATION AND SERINE THREONINE PHOSPHORYLATION OF KINASE-DEFICIENT EGF RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ALTERED AUTOPHOSPHORYLATION SITES; ATP-BINDING-SITE; SIGNAL TRANSDUCTION; LIGAND-BINDING; PROTEIN-KINASE; POINT MUTATION; CELLS; MUTANTS; ACTIVATION	To study cross-talk between unoccupied epidermal growth factor (EGF) receptors and activated EGF receptor kinases, we have used double-transfected cells, IHE2 cells, expressing both an enzymatically active insulin-EGF chimeric receptor and an inactive kinase EGF receptor mutant. Using immunoaffinity-purified receptors, we show that insulin increased phosphorylation of the insulin-EGF chimeric beta-subunit and of the kinase-deficient EGF receptor. Stimulation of intact IHE2 cells with insulin leads to a rapid tyrosine autophosphorylation of the insulin-EGF chimeric beta-subunit and to tyrosine phosphorylation of the unoccupied kinase-deficient EGF receptor. Insulin-stimulated transphosphorylation of the kinase-deficient EGF receptor yields the same pattern of tryptic phosphopeptides as those in EGF-induced autophosphorylation of the wild-type human EGF receptor. We conclude that insulin, through activation of the insulin-EGF chimeric receptor, mediates transphosphorylation of the kinase-deficient EGF receptor, further confirming that EGF receptor autophosphorylation may proceed by an intermolecular mechanism. In addition to receptor tyrosine phosphorylation, we find that exposure of cells to insulin results in enhanced phosphorylation on serine and threonine residues of the unoccupied kinase-deficient EGF receptor. These results suggest that insulin-EGF chimeric receptor activation stimulates at least one serine/threonine kinase, which in turn phosphorylates the kinase-deficient EGF receptor. Finally, we show that transphosphorylation and coexpression of an active kinase cause a decrease in the number of cell surface kinase-deficient EGF receptors without increasing their degradation rate.	FAC MED NICE,INSERM,U145,F-06034 NICE,FRANCE; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; NYU,DEPT PHARMACOL,NEW YORK,NY 10016	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Max Planck Society; New York University			BALLOTTI, Robert/F-8825-2013; TARTARE-DECKERT, Sophie/P-6057-2015	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; BALLOTTI, Robert/0000-0002-7322-4908				BALLOTTI R, 1989, CELL SIGNAL, V1, P195, DOI 10.1016/0898-6568(89)90010-7; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; KADOWAKI T, 1987, BIOCHEM BIOPH RES CO, V144, P699, DOI 10.1016/S0006-291X(87)80021-9; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRUPP M, 1981, J BIOL CHEM, V256, P1689; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SCIMECA JC, 1989, J BIOL CHEM, V264, P6831; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	39	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9900	9906						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851758				2022-12-25	WOS:A1991FM45900083
J	ANDERSEN, AH; SORENSEN, BS; CHRISTIANSEN, K; SVEJSTRUP, JQ; LUND, K; WESTERGAARD, O				ANDERSEN, AH; SORENSEN, BS; CHRISTIANSEN, K; SVEJSTRUP, JQ; LUND, K; WESTERGAARD, O			STUDIES OF THE TOPOISOMERASE-II-MEDIATED CLEAVAGE AND RELIGATION REACTIONS BY USE OF A SUICIDAL DOUBLE-STRANDED DNA SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; DROSOPHILA-MELANOGASTER; HUMAN-LYMPHOCYTES; ANTITUMOR DRUGS; RIBOSOMAL-RNA; SINGLE; CHROMATIN; INVITRO; ENZYME; YEAST	The cleavage and religation reactions of eukaryotic topoisomerase II were studied by use of a 5'-recessed DNA substrate containing a strong recognition sequence for the enzyme. Cleavage of the DNA substrate was suicidal, that is the enzyme was unable to religate the cleaved DNA due to a release of DNA 5' to the cleavage position. With this substrate cleavage products accumulated with time in the absence of protein-denaturing agents, and the cleavage reaction was not reversible with salt. The suicide cleavage complexes contained a kinetically competent topoisomerase II enzyme as determined by the enzyme's ability to perform intermolecular ligation of the cleaved DNA to a free 3'-hydroxyl end on another DNA strand. The efficiency of the religation reaction depended on the ability of the religation substrate to base pair to the DNA in the cleaved enzyme-DNA complex. Higher levels of religation were obtained with dinucleotides than with long DNA substrates. Mononucleotides also were efficiently religated, indicating an ability of the enzyme to mediate religation without making contacts to a long stretch of nucleotides 5' to the cleavage position.			ANDERSEN, AH (corresponding author), AARHUS UNIV,DEPT MOLEC BIOL & PLANT PHYSIOL,DK-8000 AARHUS,DENMARK.		Andersen, Anni/O-1162-2017	Svejstrup, Jesper/0000-0003-4964-6147; Andersen, Anni/0000-0001-7194-3258; Sorensen, Boe/0000-0002-9472-8099				ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; ANDERSSON HC, 1989, CARCINOGENESIS, V10, P123, DOI 10.1093/carcin/10.1.123; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BODLEY AL, 1988, BIO-TECHNOL, V6, P1315, DOI 10.1038/nbt1188-1315; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GLIKIN GC, 1986, EMBO J, V5, P151, DOI 10.1002/j.1460-2075.1986.tb04189.x; GLISSON BS, 1987, PHARMACOL THERAPEUT, V32, P89, DOI 10.1016/0163-7258(87)90054-4; GOCKE E, 1983, NUCLEIC ACIDS RES, V11, P7661, DOI 10.1093/nar/11.22.7661; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HWANG JL, 1989, CANCER RES, V49, P958; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KREUZER KN, 1984, J BIOL CHEM, V259, P5347; LEE MP, 1989, J BIOL CHEM, V264, P13510; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LONN U, 1989, CANCER RES, V49, P6202; LUND K, 1990, J BIOL CHEM, V265, P13856; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; NELSON WG, 1986, NATURE, V322, P187, DOI 10.1038/322187a0; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; POMMIER Y, 1985, CANCER RES, V45, P3143; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROWE TC, 1986, MOL CELL BIOL, V6, P985, DOI 10.1128/MCB.6.4.985; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHOMBURG U, 1986, EUR J BIOCHEM, V160, P451, DOI 10.1111/j.1432-1033.1986.tb10061.x; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; TSEDINH YC, 1986, J BIOL CHEM, V261, P931; UDVARDY A, 1985, CELL, V40, P933, DOI 10.1016/0092-8674(85)90353-8; UDVARDY A, 1986, J MOL BIOL, V191, P231, DOI 10.1016/0022-2836(86)90260-3; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YANG L, 1985, CELL, V41, P127, DOI 10.1016/0092-8674(85)90067-4; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	47	47	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9203	9210						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851170				2022-12-25	WOS:A1991FM03800082
J	ZHOU, XM; FISHMAN, PH				ZHOU, XM; FISHMAN, PH			DESENSITIZATION OF THE HUMAN BETA-1-ADRENERGIC RECEPTOR - INVOLVEMENT OF THE CYCLIC AMP-DEPENDENT BUT NOT A RECEPTOR-SPECIFIC PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; COUPLED ADENYLATE-CYCLASE; HETEROLOGOUS DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR; LYMPHOMA-CELLS; WILD-TYPE; TRANSLOCATION; AGONIST; PHOSPHORYLATION; ACTIVATION	Human SK-N-MC neurotumor cells express beta-1- but not beta-2-adrenergic receptors. Following exposure of the cells to isoproterenol, there was no reduction in the maximum response of adenylyl cyclase to the agonist but a 3-fold shift to less sensitivity in the concentration response. This desensitization was very rapid and dose dependent; half-maximal effects occurred at 10 nM isoproterenol. A similar shift was observed when membranes from control cells were incubated with ATP and the catalytic subunit of cyclic AMP-dependent protein kinase (PKA). No shift, however, was observed in intact cells exposed to either dibutyryl cyclic AMP or dopamine, which stimulates adenylyl cyclase in these cells through D1 dopamine receptors. To pursue the role of protein kinases in the desensitization process, cells were made permeable, loaded with a PKA inhibitor or with heparin, an inhibitor of the beta-adrenergic receptor kinase (beta-ARK), and exposed to isoproterenol. The PKA inhibitor but not heparin blocked the agonist-mediated desensitization. In contrast, desensitized human tumor cells (HeLa and A431), which express beta-2-adrenergic receptors, exhibited both a shift in concentration response and a reduction in maximum response; the former was blocked by the PKA inhibitor and the latter by heparin. Our results indicated that whereas both human beta-1- and beta-2-adrenergic receptors are susceptible to PKA, only the beta-2 receptors are susceptible to beta-ARK. These differences in desensitization may be due to differences in receptor structure as the human beta-1 receptor has fewer potential phosphorylation sites for beta-ARK in the carboxyl terminus than the human beta-2 receptor.	NINCDS,MOLEC & CELLULAR NEUROBIOL LAB,MEMBRANE BIOCHEM SECT,PK BLDG,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FISHMAN PH, 1991, J NEUROCHEM, V56, P596, DOI 10.1111/j.1471-4159.1991.tb08191.x; FISHMAN PH, 1987, J NEUROCHEM, V49, P282, DOI 10.1111/j.1471-4159.1987.tb03427.x; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOMBURGER V, 1981, MOL PHARMACOL, V20, P463; IYENGAR R, 1982, P NATL ACAD SCI-BIOL, V79, P5179, DOI 10.1073/pnas.79.17.5179; KASSIS S, 1984, P NATL ACAD SCI-BIOL, V81, P6686, DOI 10.1073/pnas.81.21.6686; KASSIS S, 1982, J BIOL CHEM, V257, P5312; KASSIS S, 1986, J BIOL CHEM, V261, P2233; KASSIS S, 1988, J RECEPTOR RES, V8, P627, DOI 10.3109/10799898809049016; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KUNKEL MW, 1989, FASEB J, V3, P2067, DOI 10.1096/fasebj.3.9.2545497; LAI E, 1982, J BIOL CHEM, V257, P6691; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MAYOR F, 1987, J BIOL CHEM, V262, P6468; PAZOS A, 1985, BRAIN RES, V358, P324, DOI 10.1016/0006-8993(85)90977-1; PERKINS JP, 1984, ADV CYCLIC NUCL PROT, V17, P37; SIDHU A, 1990, BIOCHEM BIOPH RES CO, V166, P574, DOI 10.1016/0006-291X(90)90847-G; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; STRASSER RH, 1984, ENDOCRINOLOGY, V115, P1392, DOI 10.1210/endo-115-4-1392; SU YF, 1980, J BIOL CHEM, V255, P7410; WALDO GL, 1983, J BIOL CHEM, V258, P3900; ZAREMBA TG, 1984, MOL PHARMACOL, V26, P206	34	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7462	7468						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850409				2022-12-25	WOS:A1991FJ34200025
J	DAGNINO, L; BENNETT, LL; PATERSON, ARP				DAGNINO, L; BENNETT, LL; PATERSON, ARP			SUBSTRATE-SPECIFICITY, KINETICS, AND STOICHIOMETRY OF SODIUM-DEPENDENT ADENOSINE TRANSPORT IN L1210/AM MOUSE LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; PLASMA-MEMBRANE VESICLES; NUCLEOSIDE TRANSPORT; BRUSH-BORDER; COTRANSPORT SYSTEMS; URIDINE UPTAKE; MECHANISM; MODELS	Two equilibrative (facilitated diffusion) nucleoside transport processes and a concentrative Na+-dependent co-transport process contribute to zero-trans inward fluxes of nucleosides in L1210 mouse leukemia cells. Na+-linked inward adenosine fluxes in L1210/AM cells (a clone deficient in adenosine, deoxyadenosine, and deoxycytidine kinase activities) were measured as initial rates of [H-3]adenosine influx in medium containing Na+ salts and 10-mu-M dipyridamole. The Na+-linked transporter distinguished between the D- and L-enantiomers of adenosine, the latter being a virtual nonpermeant in the initial-rate assay. Adenine arabinoside, inosine, 2'-deoxyadenosine and 2'-deoxyadenosine derivatives with halogen atoms at the purine C-2 position were recognized as substrates of the Na+-linked system because of their inhibition of adenosine (10-mu-M) fluxes under the condition of Na+-dependence with IC50 values ranging between 25 and 183-mu-M; uridine, deoxycytidine, and cytosine arabinoside (each at 400-mu-M) inhibited adenosine fluxes by 10-40%. Inward Na+-linked adenosine fluxes were saturable with respect to extracellular adenosine and Na+ concentrations ([Na+]omicron); K(m) and V(max) values for adenosine influx were 9.4 +/- 2.6-mu-M and 1.67 +/- 0.2 pmol/mu-l cell water/s when [Na+]omicron was 100 mM. The stoichiometry of Na+: adenosine co-transport, determined by Hill analysis of the dependence of adenosine fluxes on [Na+]omicron, was 1:1. The thiol-reactive agents, N-ethylmaleimide (NEM), showdomycin and p-chloromercuriphenylsulphonate (pCMPS), inhibited Na+-linked adenosine fluxes with IC50 values of 40, 10, and 2-mu-M, respectively. This inhibition was partially reversed by the presence of adenosine in incubation media containing pCMPS, but not NEM. Thiol groups accessible to pCMPS may be involved in substrate recognition by the transporter and in the permeation step.	UNIV ALBERTA, CANC RES GRP, MCEACHERN LAB, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, DEPT PHARMACOL, EDMONTON T6G 2H7, ALBERTA, CANADA; SO RES INST, BIRMINGHAM, AL 35255 USA	University of Alberta; University of Alberta				Dagnino, Lina/0000-0003-1483-5159				ASAI M, 1967, CHEM PHARM BULL, V15, P1863; BELT JA, 1983, MOL PHARMACOL, V24, P479; BENNETT LL, 1982, P AM ASSOC CANC RES, V23, P6; Crane R K, 1980, Ann N Y Acad Sci, V339, P46, DOI 10.1111/j.1749-6632.1980.tb15967.x; DAGNINO L, 1991, J BIOL CHEM, V266, P6308; DAGNINO L, 1990, CANCER RES, V50, P6549; DAGNINO L, 1988, THESIS U ALBERTA EDM; DARNOWSKI JW, 1986, CANCER RES, V46, P3490; DARNOWSKI JW, 1987, CANCER RES, V47, P2614; GATI WP, 1989, BIOCHEM J, V263, P957, DOI 10.1042/bj2630957; GATI WP, 1989, RED BLOOD CELL MEMBR, P635; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; JAKOBS ES, 1986, BIOCHEM BIOPH RES CO, V140, P1028, DOI 10.1016/0006-291X(86)90738-2; JAKOBS ES, 1990, J BIOL CHEM, V265, P22210; JARVIS SM, 1988, ADENOSINE RECEPTORS, P113; KINNE R, 1975, J MEMBRANE BIOL, V21, P375, DOI 10.1007/BF01941077; LEHIR M, 1985, PFLUG ARCH EUR J PHY, V404, P238, DOI 10.1007/BF00581245; PATERSON ARP, 1979, MOL PHARMACOL, V16, P900; PATERSON ARP, 1986, MEMBRANE TRANSPORT A, P309; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; SANDERS D, 1984, J MEMBRANE BIOL, V77, P123; SCHWENK M, 1984, BIOCHIM BIOPHYS ACTA, V805, P370, DOI 10.1016/0167-4889(84)90020-X; SPECTOR R, 1984, J NEUROCHEM, V42, P1048, DOI 10.1111/j.1471-4159.1984.tb12709.x; STEIN WD, 1989, METHOD ENZYMOL, V171, P23; TURNER RJ, 1981, BIOCHIM BIOPHYS ACTA, V649, P269, DOI 10.1016/0005-2736(81)90415-6; TURNER RJ, 1985, ANN NY ACAD SCI, V456, P10, DOI 10.1111/j.1749-6632.1985.tb14839.x; UEHARA Y, 1980, BIOCHEM PHARMACOL, V29, P2199; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WEAST RC, 1966, HDB CHEM PHYSICS, pF124; WILLIAMS TC, 1989, BIOCHEM J, V264, P223, DOI 10.1042/bj2640223	30	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6312	6317						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848853				2022-12-25	WOS:A1991FE37300048
J	DEAN, FB; HURWITZ, J				DEAN, FB; HURWITZ, J			SIMIAN VIRUS-40 LARGE T-ANTIGEN UNTWISTS DNA AT THE ORIGIN OF DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-TUMOR-ANTIGEN; COLI RNA-POLYMERASE; SV40 ORIGIN; RECA PROTEIN; ESCHERICHIA-COLI; UNWINDING ACTIVITY; INVITRO REPLICATION; ELECTRON-MICROSCOPY; HELICASE ACTIVITY; MULTIPLE STAGES	Simian virus 40 large tumor antigen (SV40 T antigen) untwists DNA at the SV40 replication origin. In the presence of ATP, T antigen shifted the average linking number of an SV40 origin-containing plasmid topoisomer distribution. The loss of up to two helical turns was detected. The reaction required the presence of the 64-base pair core origin of replication containing T antigen DNA binding site II; binding site I had no effect on the untwisting reaction. The presence of human single-stranded DNA binding protein (SSB) slightly reduced the degree of untwisting in the presence of ATP. ATP hydrolysis was not required since untwisting occurred in the presence of nonhydrolyzable analogs of ATP. However, in the presence of a nonhydrolyzable analog of ATP, the requirement for the SV40 origin sequence was lost. The origin requirement for DNA untwisting was also lost in the absence of dithiothreitol. The origin-specific untwisting activity of T antigen is distinct from its DNA helicase activity, since helicase activity does not require the SV40 origin but does require ATP hydrolysis. The lack of a requirement for SSB or ATP hydrolysis and the reduction in the pitch of the DNA helix by just a few turns at the replication origin distinguishes this reaction from the T antigen-mediated DNA unwinding reaction, which results in the formation of a highly underwound DNA molecule. Untwisting occurred without a lag after the start of the reaction, whereas unwound DNA was first detected after a lag of 10 min. It is proposed that the formation of a multimeric T antigen complex containing untwisted DNA at the SV40 origin is a prerequisite for the initiation of DNA unwinding and replication.			DEAN, FB (corresponding author), SLOAN KETTERING MEM CANC CTR, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.			Dean, Frank/0000-0002-9416-4449	NIGMS NIH HHS [5R01 GM34559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034559] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; CRICK FHC, 1976, P NATL ACAD SCI USA, V73, P2639, DOI 10.1073/pnas.73.8.2639; DEAN FB, 1990, UCLA SYM BI, V127, P315; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GIACHERIO D, 1980, J BIOL CHEM, V255, P8963; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM R, 1982, COLD SPRING HARB SYM, V47, P451, DOI 10.1101/SQB.1983.047.01.053; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KING K, 1989, J BIOL CHEM, V264, P11807; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; MYERS RM, 1981, J BIOL CHEM, V256, P156; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; ROBERTS JM, 1989, P NATL ACAD SCI USA, V86, P3939, DOI 10.1073/pnas.86.11.3939; RYDER K, 1985, CELL, V42, P539, DOI 10.1016/0092-8674(85)90111-4; SAUCIER JM, 1972, NATURE-NEW BIOL, V239, P167, DOI 10.1038/newbio239167a0; SCHEFFNER M, 1989, NUCLEIC ACIDS RES, V17, P93, DOI 10.1093/nar/17.1.93; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SEIF R, 1982, MOL CELL BIOL, V2, P1463, DOI 10.1128/MCB.2.12.1463; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WANG JC, 1977, NUCLEIC ACIDS RES, V4, P1225, DOI 10.1093/nar/4.5.1225; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	63	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5062	5071						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848235				2022-12-25	WOS:A1991FC21700059
J	HORIUCHI, T; CHAMPIGNY, C; RABBANI, SA; HENDY, GN; GOLTZMAN, D				HORIUCHI, T; CHAMPIGNY, C; RABBANI, SA; HENDY, GN; GOLTZMAN, D			EXPRESSION OF ADENYLATE CYCLASE-COUPLED OSSEOUS PARATHYROID-HORMONE AND PARATHYROID HORMONE-LIKE PEPTIDE RECEPTORS IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RIBONUCLEIC-ACID; HUMORAL HYPERCALCEMIA; PROTEIN; GENE; CELLS; MALIGNANCY; BINDING; CDNA; MEMBRANE	Functional parathyroid hormone (PTH) and PTH-like peptide receptors were expressed in Xenopus laevis oocytes after injection of poly(A)+ RNA isolated from the rat osteogenic sarcoma cell line, UMR 106. Increases in cAMP were seen in individual oocytes in response to added bovine (b) PTH-(1-34) (10(-6) M), human (h) PLP-(1-34) (hPLP-(1-34), 10(-6) M), isoproterenol (10(-4) M), and forskolin (10(-4) M). Although both intracellular and extracellular cAMP levels were stimulated approximately 1.5-2-fold by these agonists, intracellular concentrations. Peak increases with bPTH-(1-34) occurred after a 30-min incubation with the hormone 48 h after oocyte injection. bPTH-(1-34) caused a concentration-dependent augmentation of cAMP in injected oocytes, and the in vitro antagonist hPLP-(3-34) produced dose-dependent inhibition of both bPTH-(1-34)- and hPLP-(1-34)-stimulated cAMP accumulation. Specific binding of PTH to oocyte membranes was also demonstrated 48 h after oocyte injection with UMR 106 cell mRNA. Following size fractionation of isolated UMR 106 poly(A)+ RNA by sucrose density gradients, mRNA directing the expression of both PTH- and PLP-stimulated cAMP in oocytes appeared in the 3.5-4.9-kilobase fraction. These results demonstrate that adenylate cyclase-coupled osseous PTH and PLP receptors can be expressed after injection of naturally occurring mRNA into Xenopus oocytes, that PTH- and PLP-stimulated increases in cAMP concentrations can be detected in individual oocytes injected with bone cell-derived mRNA, that PTH and PLP appear to cross-react at a common receptor after injection of UMR 106 cell mRNA into oocytes, and that size selection of mRNA encoding the PTH and PLP receptors can be achieved by density gradient centrifugation. These studies, therefore, indicate the potential usefulness of the Xenopus oocyte system in expression cloning of PTH and PLP receptor cDNAs and illustrate the feasibility of employing this system to examine the biology of PTH and PLP receptors.	ROYAL VICTORIA HOSP,CALCIUM RES LAB,RM H467,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3A 2T5,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University				rabbani, shafaat/0000-0001-5594-3899				BARNARD EA, 1982, PROC R SOC SER B-BIO, V215, P241, DOI 10.1098/rspb.1982.0040; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN A, 1984, TRANSCRIPTION TRANSL, P271; DEMAY M, 1985, AM J PHYSIOL, V249, pE437, DOI 10.1152/ajpendo.1985.249.5.E437; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; GUNDERSEN CB, 1984, J PHYSIOL-LONDON, V353, P231, DOI 10.1113/jphysiol.1984.sp015333; HENDERSON J, 1990, ENDOCRINOLOGY, V127, P1310, DOI 10.1210/endo-127-3-1310; HRUSKA KA, 1987, J CLIN INVEST, V79, P230, DOI 10.1172/JCI112788; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KREMER R, 1982, J BIOL CHEM, V257, P4048; KUSHNER L, 1988, P NATL ACAD SCI USA, V85, P3250, DOI 10.1073/pnas.85.9.3250; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MARCI Y, 1987, NATURE, V329, P836; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MCINTOSH RP, 1987, P NATL ACAD SCI USA, V84, P9045, DOI 10.1073/pnas.84.24.9045; MEYUHAS O, 1979, CELL, V16, P139, DOI 10.1016/0092-8674(79)90195-8; MITCHELL J, 1990, ENDOCRINOLOGY, V126, P2327, DOI 10.1210/endo-126-5-2327; MITCHELL J, 1990, ENDOCRINOLOGY, V126, P2650, DOI 10.1210/endo-126-5-2650; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; ORLOFF JJ, 1989, J BIOL CHEM, V264, P6097; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; SEALFON SC, 1990, MOL ENDOCRINOL, V4, P119, DOI 10.1210/mend-4-1-119; SMITH AA, 1987, FASEB J, V1, P380, DOI 10.1096/fasebj.1.5.2824269; SNUTCH TP, 1988, TRENDS NEUROSCI, V11, P250, DOI 10.1016/0166-2236(88)90102-6; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; WHITE MM, 1990, P NATL ACAD SCI USA, V87, P133, DOI 10.1073/pnas.87.1.133; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; YASUDA T, 1989, J BIOL CHEM, V264, P7720; YASUDA T, 1989, MOL ENDOCRINOL, V3, P518, DOI 10.1210/mend-3-3-518	39	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4700	4705						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848224				2022-12-25	WOS:A1991FC21700008
J	GROPPER, R; BRANDT, RA; ELIAS, S; BEARER, CF; MAYER, A; SCHWARTZ, AL; CIECHANOVER, A				GROPPER, R; BRANDT, RA; ELIAS, S; BEARER, CF; MAYER, A; SCHWARTZ, AL; CIECHANOVER, A			THE UBIQUITIN-ACTIVATING ENZYME, E1, IS REQUIRED FOR STRESS-INDUCED LYSOSOMAL DEGRADATION OF CELLULAR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE MUTANT TS85; MAMMALIAN-CELLS; HEAT-SHOCK; SYSTEM; BREAKDOWN; IDENTIFICATION; PURIFICATION; FIBROBLASTS; INTACT	ts85, a cell line that harbors a mutant thermolabile ubiquitin-activating enzyme, E1, fails to degrade short lived proteins at the restrictive temperature (Ciechanover, A., Finley, D., and Varshavsky, A. (1984) Cell 37, 57-66). However, the involvement of the ubiquitin system in the degradation of long lived proteins (most cellular proteins fall in this category) has not been addressed. In the present study we show that upon shifting the mutant cells to the restrictive temperature, there is no change in the rate of degradation of long lived proteins. In contrast, shifting the wild-type cells (FM3A) to the high temperature is accompanied by a 2-fold increase in the rate of proteolysis of this group of proteins. This heat-induced accelerated degradation can be inhibited completely by NH4Cl and chloroquine. Similarly, exposure of the cells to starvation, a stimulus that activates the autophagic-lysosomal pathway, has no effect on the degradation of long lived proteins in the mutant cells after inactivation of E1. Under the same conditions, the degradation rate in the wild-type cells increases almost 4-fold. Analogous results were obtained using a different cell line that also harbors a thermolabile E1 (ts20 (Kulka, R. G., Raboy, B., Schuster, R., Parag, H. A., Diamond, G., Ciechanover, A., and Marcus, M. (1988) J. Biol. Chem. 263, 15726-15731)). Cycloheximide and 3-methyladenine, known inhibitors of formation of autophagic vacuoles, inhibit the heat-induced accelerated degradation of long lived proteins in wild-type cells. Taken together, the results suggest that 1) heat stress induces enhanced degradation of intracellular proteins; 2) the process occurs most probably in autophagic vacuoles; and 3) activation of ubiquitin is required for the formation of these vacuoles. As there is no change in the basal rate of degradation of intracellular proteins in the mutant cells at the restrictive temperature, it appears that the ubiquitin system is not involved in their breakdown.	TECHNION ISRAEL INST TECHNOL, FAC MED, RAPPAPORT INST RES MED SCI, IL-31096 HAIFA, ISRAEL; WASHINGTON UNIV, SCH MED, EDWARD MALLINCRODT DEPT PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, EDWARD MALLINCRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CHILDRENS HOSP, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CHILDRENS HOSP, DIV NEWBORN MED, ST LOUIS, MO 63110 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	GROPPER, R (corresponding author), TECHNION ISRAEL INST TECHNOL, FAC MED, DEPT BIOCHEM, IL-31096 HAIFA, ISRAEL.		Ciechanover, Aaron J/C-9166-2017	Bearer, Cynthia/0000-0003-4809-2250				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DICE JF, 1986, J BIOL CHEM, V261, P6853; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Finley D., 1988, UBIQUITIN, P39; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MAYER A, 1989, J BIOL CHEM, V264, P2060; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; MORTIMORE GE, 1987, LYSOSOMES THEIR ROLE, P415; NEFF NT, 1981, J CELL BIOL, V91, P184, DOI 10.1083/jcb.91.1.184; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; RECHSTEINER M, 1988, UBIQUITIN, P1; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; SCHNEIDER DL, 1981, J BIOL CHEM, V256, P3858; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; SCHWORER CM, 1981, J BIOL CHEM, V256, P7652; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028	40	106	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3602	3610						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847380				2022-12-25	WOS:A1991EY68200041
J	RALEYSUSMAN, KM; CRAGOE, EJ; SAPOLSKY, RM; KOPITO, RR				RALEYSUSMAN, KM; CRAGOE, EJ; SAPOLSKY, RM; KOPITO, RR			REGULATION OF INTRACELLULAR PH IN CULTURED HIPPOCAMPAL-NEURONS BY AN AMILORIDE-INSENSITIVE NA+/H+ EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVILLUS MEMBRANE-VESICLES; BRUSH-BORDER-MEMBRANE; SQUID GIANT-AXONS; RAT-BRAIN; H+ EXCHANGER; HYDROGEN-IONS; BINDING-SITES; CELLS; SODIUM; BICARBONATE	Regulation of intracellular pH (pH(i)) in single cultured rat hippocampal neurons was investigated using the fluorescent pH(i) indicator dye bis-carboxyethylcarboxyfluorescein. Resting pH(i) was dependent on the presence of bicarbonate and external Na+ but was not altered significantly by removal of Cl- or treatment with the anion exchange inhibitor diisothiocyanatostilbene-2,2'-disulfonate. Recovery of pH(i) from acute acid loading was due, in large part, to a pharmacologically distinct variant of the Na+/H+ antiporter. In nominally HCO3- free solutions, this recovery exhibited a saturable dose dependence on extracellular Na+ (K(m) = 23-26 mM) or Li+. The antiporter was activated by decreasing pH(i) and was unaffected by collapse of the membrane potential with valinomycin. Like the Na+/H+ antiporter described in other cell systems, the hippocampal activity was inhibited by harmaline, but in sharp contrast, neither amiloride nor its more potent 5-amino-substituted analogues were able to prevent the recovery from an acid load. These data indicate that Na+-dependent mechanisms dominate pH(i) regulation in hippocampal neurons and suggests a role for a novel variant of the Na+/H+ antiporter.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NIA NIH HHS [AG06633] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NIGMS NIH HHS [GM8543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006633] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMED Z, 1980, J GEN PHYSIOL, V75, P403, DOI 10.1085/jgp.75.4.403; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1980, AM J PHYSIOL, V238, pF210, DOI 10.1152/ajprenal.1980.238.3.F210; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BALKOVETZ DF, 1986, AM J PHYSIOL, V251, pC852, DOI 10.1152/ajpcell.1986.251.6.C852; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARMAN TE, 1969, ENZYME HDB, V1, P6; BORON WF, 1981, AM J PHYSIOL, V240, pC80, DOI 10.1152/ajpcell.1981.240.1.C80; BORON WF, 1988, NATURE, V332, P262, DOI 10.1038/332262a0; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1983, J GEN PHYSIOL, V81, P373, DOI 10.1085/jgp.81.3.373; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BOYARSKY G, 1989, NEUR ABST, V15, P15; BURNHAM C, 1982, BIOCHIM BIOPHYS ACTA, V685, P260, DOI 10.1016/0005-2736(82)90066-9; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P795, DOI 10.1085/jgp.86.6.795; CHESLER M, 1985, BRAIN RES, V325, P313, DOI 10.1016/0006-8993(85)90330-0; CHESLER M, 1987, AM J PHYSIOL, V253, pR666, DOI 10.1152/ajpregu.1987.253.4.R666; CONNOR JA, 1984, J PHYSIOL-LONDON, V354, P163, DOI 10.1113/jphysiol.1984.sp015369; CSIBA L, 1983, BRAIN RES, V289, P334, DOI 10.1016/0006-8993(83)90037-9; DIETMER JW, 1987, J PHYSIOL-LONDON, V388, P261; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P585, DOI 10.1085/jgp.84.4.585; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRUOL DL, 1980, BRAIN RES, V183, P247, DOI 10.1016/0006-8993(80)90138-9; GURICH RW, 1986, AM J PHYSIOL, V251, pF702, DOI 10.1152/ajprenal.1986.251.4.F702; HAGGERTY JG, 1985, BIOCHEM BIOPH RES CO, V127, P759, DOI 10.1016/S0006-291X(85)80008-5; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HAGGERTY JG, 1988, AM J PHYSIOL, V255, pC495, DOI 10.1152/ajpcell.1988.255.4.C495; HORNER HC, 1990, IN PRESS NEUROENDOCR; JAROLIMEK W, 1989, BRAIN RES, V505, P225, DOI 10.1016/0006-8993(89)91447-9; JEAN T, 1985, J BIOL CHEM, V260, P9678; KAILA K, 1987, NATURE, V330, P163, DOI 10.1038/330163a0; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; LALLEMAIN G, 1985, J BIOL CHEM, V260, P4877; LAMANNA JC, 1984, ANAL BIOCHEM, V142, P117, DOI 10.1016/0003-2697(84)90525-6; LOMBARDINI JB, 1985, NEUROCHEM RES, V10, P77, DOI 10.1007/BF00964773; MADSHUS IH, 1987, J BIOL CHEM, V262, P7486; MONTROSE MH, 1988, NA H EXCHANGE, P57; MOOLENAAR WH, 1981, J BIOL CHEM, V256, P2883; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; PARADISO AM, 1987, NATURE, V325, P447, DOI 10.1038/325447a0; PARKER JC, 1988, NA PLUS H PLUS EXCHA, P179; POUYSSEGUR J, 1987, KIDNEY INT, V32, pS144; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; PUTNAM RW, 1988, NAPLUS HPLUS EXCHANG, P139; PYLOVA SI, 1989, BRAIN RES, V490, P170, DOI 10.1016/0006-8993(89)90446-0; ROOS A, 1971, AM J PHYSIOL, V221, P176, DOI 10.1152/ajplegacy.1971.221.1.176; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; RUSSELL JM, 1976, NATURE, V264, P730; SAPOLSKY RM, 1988, BRAIN RES, V453, P367, DOI 10.1016/0006-8993(88)90180-1; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SAUVAIGO S, 1984, BRAIN RES, V301, P371, DOI 10.1016/0006-8993(84)91106-5; SCHLUE WR, 1985, J PHYSIOL-LONDON, V364, P327, DOI 10.1113/jphysiol.1985.sp015748; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SIMCHOWITZ L, 1986, MOL PHARMACOL, V30, P112; SPYROPOULOS AC, 1984, BRAIN RES, V322, P189, DOI 10.1016/0006-8993(84)91204-6; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THOMAS RC, 1977, J PHYSIOL-LONDON, V273, P317, DOI 10.1113/jphysiol.1977.sp012096; TOLKOVSKY AM, 1987, NEUROSCIENCE, V22, P1093, DOI 10.1016/0306-4522(87)92984-8; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P111, DOI 10.1113/jphysiol.1979.sp012957; VIGNE P, 1982, J BIOL CHEM, V257, P9394; WALLERT MA, 1989, AM J PHYSIOL, V257, pC207, DOI 10.1152/ajpcell.1989.257.2.C207; [No title captured]	67	154	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2739	2745						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847131				2022-12-25	WOS:A1991EX60000013
J	CROWL, RM; STOLLER, TJ; CONROY, RR; STONER, CR				CROWL, RM; STOLLER, TJ; CONROY, RR; STONER, CR			INDUCTION OF PHOSPHOLIPASE-A2 GENE-EXPRESSION IN HUMAN HEPATOMA-CELLS BY MEDIATORS OF THE ACUTE PHASE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; ARTHRITIC SYNOVIAL-FLUID; STIMULATORY FACTOR-II; LINE YT-CELLS; RHEUMATOID-ARTHRITIS; EXTRACELLULAR PHOSPHOLIPASE-A2; PLASMA-PROTEINS; INTERLEUKIN-6; PURIFICATION; RECEPTOR	Serum levels of phospholipase A2 (PLA2) activity have been shown to be elevated in cases of septic shock and rheumatoid arthritis. The cellular origin of serum PLA2, however, is not known. In this report, we demonstrate that human group II PLA2 expression and secretion are induced in hepatoma cells (HepG2) following treatment with interleukin-6 (IL-6), tumor necrosis factor (TNF), and interleukin-1 (IL-1). Of the three cytokines, IL-6 is the most potent. Significant synergy is observed between IL-6 and IL-1 and between IL-6 and TNF, but not between IL-1 and TNF. PLA2 induction does not occur in human YT cells, which are known to have receptors for both IL-1 and IL-6, indicating that the regulatory mechanism involved is cell type-specific. The results of RNA blot analysis indicate that the PLA2 gene is regulated in HepG2 cells at the pretranslational level. Induction of PLA2 synthesis in HepG2 cells in response to these cytokines resembles the induction of the acute phase plasma proteins which are synthesized in cultured hepatocytes and hepatoma cells following exposure to the same cytokines and in liver in response to inflammation and infection. In addition, a putative IL-6-responsive element, which is homologous to a similar element found in several acute phase genes, is present in the 5'-promoter-proximal region of the PLA2 gene. These results suggest that serum PLA2 is synthesized in and secreted from liver cells in response to inflammatory stimuli, mediated primarily by IL-6, and therefore should be classified as an acute phase protein.			CROWL, RM (corresponding author), HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT MOLEC GENET, NUTLEY, NJ 07110 USA.							ANDUS T, 1988, EUR J BIOCHEM, V173, P287, DOI 10.1111/j.1432-1033.1988.tb13997.x; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BAUMANN H, 1987, J IMMUNOL, V139, P4122; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWL R, 1990, ADV EXP MED BIOL, V279, P173; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DENNIS EA, 1987, DRUG DEVELOP RES, V10, P205, DOI 10.1002/ddr.430100404; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; FEY GH, 1989, ANN NY ACAD SCI, V557, P317; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GOLDMAN ND, 1987, J BIOL CHEM, V262, P2363; GOREVIC PD, 1982, ANN NY ACAD SCI, V389, P380, DOI 10.1111/j.1749-6632.1982.tb22151.x; GOTSCHLICH EC, 1989, ANN NY ACAD SCI, V557, P9; GRAY PW, 1989, J BIOL CHEM, V264, P9505; GRAYSON DR, 1989, ANN NY ACAD SCI, V557, P243; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; HACK CE, 1989, BLOOD, V74, P1704; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HOUSSIAU FA, 1988, ARTHRITIS RHEUM, V31, P784, DOI 10.1002/art.1780310614; HUBER P, 1990, J BIOL CHEM, V265, P5695; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; KAPLAN MH, 1982, ANN NY ACAD SCI, V389, P419, DOI 10.1111/j.1749-6632.1982.tb22154.x; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; LOTZ M, 1989, ANN NY ACAD SCI, V557, P509; LYONSGIORDANO B, 1989, BIOCHEM BIOPH RES CO, V164, P488, DOI 10.1016/0006-291X(89)91746-4; MORRONE G, 1988, J BIOL CHEM, V263, P12554; OKAZAKI T, 1981, BIOL REPROD, V25, P103, DOI 10.1095/biolreprod25.1.103; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; PROWSE KR, 1989, J LEUKOCYTE BIOL, V45, P55, DOI 10.1002/jlb.45.1.55; PRUZANSKI W, 1985, J RHEUMATOL, V12, P211; PRUZANSKI W, 1988, J RHEUMATOL, V15, P1351; ROCK CO, 1985, J BIOL CHEM, V260, P2720; ROMERO R, 1990, J CLIN INVEST, V85, P1392, DOI 10.1172/JCI114583; SEILHAMER JJ, 1989, J BIOCHEM, V106, P38, DOI 10.1093/oxfordjournals.jbchem.a122815; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHIRAKAWA F, 1986, J IMMUNOL, V137, P551; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X; VADAS P, 1983, CAN J PHYSIOL PHARM, V61, P561, DOI 10.1139/y83-086; VADAS P, 1988, AGENTS ACTIONS, V24, P320, DOI 10.1007/BF02028289; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; WAAGE A, 1989, CLIN IMMUNOL IMMUNOP, V50, P394, DOI 10.1016/0090-1229(89)90146-3; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YODOI J, 1985, J IMMUNOL, V134, P1623	58	423	431	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2647	2651						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846631				2022-12-25	WOS:A1991EV51500095
J	PAN, LP; LI, ZY; LARSEN, R; CHAN, SI				PAN, LP; LI, ZY; LARSEN, R; CHAN, SI			THE NATURE OF CUX IN CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUBUNIT-III; COPPER; ZINC; HEME; SITE; BEEF	We report here extensive and accurate analyses of the copper, iron, zinc, and magnesium contents in bovine heart cytochrome c oxidase by direct current plasma atomic emission spectrometry. The precision of an individual measurement is within +/- 5%. The analyses confirm a stoichiometry of 5Cu/4Fe/2Zn/2Mg per dimer. Seven enzyme preparations treated by various methods are also analyzed to investigate the nature of Cu(x). It is shown that Cu(x) is removable by either monomerization of the enzyme or subunit III depletion. This result suggests that Cu(x) is associated with subunit III and that it plays a structural role in enzyme dimerization. EPR measurements indicate that Cu(x) is heterogeneous and mostly reduced. In addition, we find Cu(x) has no effect on the spectroscopic properties and electron transfer activity of the enzyme.	CALTECH,ARTHUR AMOS NOYES LAB CHEM PHYS,PASADENA,CA 91125	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022432, R01GM022432] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22432] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOMBELKA E, 1986, BIOCHEM BIOPH RES CO, V140, P1007, DOI 10.1016/0006-291X(86)90735-7; EINARSDOTTIR O, 1984, BIOCHEM BIOPH RES CO, V124, P836, DOI 10.1016/0006-291X(84)91033-7; EINARSDOTTIR O, 1985, BIOCHEM BIOPH RES CO, V129, P840, DOI 10.1016/0006-291X(85)91968-0; FINEL M, 1986, BIOCHIM BIOPHYS ACTA, V851, P99, DOI 10.1016/0005-2728(86)90253-7; FINEL M, 1988, EUR J BIOCHEM, V176, P125, DOI 10.1111/j.1432-1033.1988.tb14259.x; GEORGEVICH G, 1983, BIOCHEMISTRY-US, V22, P1317, DOI 10.1021/bi00275a001; HALL J, 1988, J BIOL CHEM, V263, P8142; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; LI PM, 1988, BIOCHEMISTRY-US, V27, P7538, DOI 10.1021/bi00419a054; LUDWIG B, 1980, BIOCHIM BIOPHYS ACTA, V594, P177, DOI 10.1016/0304-4173(80)90008-7; MARTIN CT, 1988, J BIOL CHEM, V263, P8420; NAQUI A, 1988, J BIOL CHEM, V263, P12342; NILSSON T, 1988, BIOCHEMISTRY-US, V27, P296, DOI 10.1021/bi00401a045; NILSSON T, 1988, BIOCHEMISTRY-US, V27, P8254, DOI 10.1021/bi00421a040; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; WIKSTROM M, 1981, CYTOCHROME OXIDASE S, P2; WINTER DB, 1980, J BIOL CHEM, V255, P1408; YEWEY GL, 1987, BIOCHEM BIOPH RES CO, V148, P1520, DOI 10.1016/S0006-291X(87)80304-2; YEWEY GL, 1988, ANN NY ACAD SCI, V550, P23; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354	21	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1367	1370						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846351				2022-12-25	WOS:A1991EU49700004
J	KOMORIYA, A; GREEN, LJ; MERVIC, M; YAMADA, SS; YAMADA, KM; HUMPHRIES, MJ				KOMORIYA, A; GREEN, LJ; MERVIC, M; YAMADA, SS; YAMADA, KM; HUMPHRIES, MJ			THE MINIMAL ESSENTIAL SEQUENCE FOR A MAJOR CELL TYPE-SPECIFIC ADHESION SITE (CS1) WITHIN THE ALTERNATIVELY SPLICED TYPE-III CONNECTING SEGMENT DOMAIN OF FIBRONECTIN IS LEUCINE-ASPARTIC ACID-VALINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; SURFACE RECEPTORS; IDENTIFICATION; ATTACHMENT; FRAGMENTS; INTEGRINS; REGION	Fibronectin contains at least two major domains that support cell adhesion. One is the central cell-binding domain that is recognized by a variety of cell types via the integrin-alpha-5-beta-1. The second, originally identified by its ability to support melanoma cell adhesion, is located in the alternatively spliced type III connecting segment (IIICS). A dominant cell type-specific adhesion site within the IIICS has been localized to a peptide designated as CS1 comprising its amino-terminal 25 residues. The receptor for CS1 is the integrin-alpha-4-beta-1. We have synthesized a variety of peptides with overlapping sequences in order to identify the minimum active amino acid sequence of this major cell adhesion site. A peptide comprising the carboxyl-terminal 8 amino acids of CS1, EILDVPST, was found to support melanoma cell spreading, while all peptides without this sequence had little or no activity. Two smaller overlapping pentapeptides, EILDV and LDVPS, were also active, whereas EILEV, containing a conservative substitution of Glu for Asp, was inactive. These data suggested that the minimum sequence for cell adhesion activity is Leu-Asp-Val, the tripeptide sequence common to both active peptides. This prediction was confirmed by the observed ability of the Leu-Asp-Val peptide itself to block spreading on fibronectin, whereas Leu-Glu-Val was inactive. Interspecies amino acid sequence comparison also supports the importance of the LDV sequence, since it is completely conserved in the IIICS regions of human, rat, bovine, and avian fibronectins.	UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND; RORER GRP INC,KING OF PRUSSIA,PA 19406; NCI,MOLEC BIOL LAB,MEMBRANE BIOCHEM SECT,BETHESDA,MD 20892	University of Manchester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KOMORIYA, A (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,CELL BIOL LAB,8000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Humphries, Martin/0000-0002-4331-6967; Yamada, Kenneth/0000-0003-1512-6805	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	20	329	368	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15075	15079						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869542				2022-12-25	WOS:A1991GB09700044
J	CARR, DW; STOFKOHAHN, RE; FRASER, IDC; BISHOP, SM; ACOTT, TS; BRENNAN, RG; SCOTT, JD				CARR, DW; STOFKOHAHN, RE; FRASER, IDC; BISHOP, SM; ACOTT, TS; BRENNAN, RG; SCOTT, JD			INTERACTION OF THE REGULATORY SUBUNIT (RII) OF CAMP-DEPENDENT PROTEIN-KINASE WITH RII-ANCHORING PROTEINS OCCURS THROUGH AN AMPHIPATHIC HELIX BINDING MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; SKELETAL-MUSCLE; LOCALIZATION; CALMODULIN; IDENTIFICATION; MEMBRANE; CLONING; DOMAIN; MODEL; BETA	The type II cAMP-dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit (RII) dimer to RII-anchoring proteins. Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices. The potential amphipathic helix region of Ht 31 (Leu-Ile-Glu-Glu-Ala-Ala-Ser-Arg-Ile-Val-Asp-Ala-Val-Ile) lies between residues 494 and 507. A bacterially expressed 318-amino acid fragment, Ht 31 (418-736), containing the amphipathic helix region, was able to bind RII-alpha. Site-directed mutagenesis designed to disrupt the secondary structure in the putative binding helix reduced binding dramatically. Specifically, substitution of proline for Ala-498 significantly diminished RII-alpha-binding, and similar mutation of Ile-502 or Ile-507 abolished interaction. Mutation of Ala-522 to proline, which is located outside the predicted amphipathic helix region, had no effect on RII-alpha-binding. These data suggest that anchoring proteins interact with RII-alpha via an amphipathic helix binding motif.	VOLLUM INST ADV BIOMED RES,L474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT OPHTHALMOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907; Brennan, Richard/0000-0001-7647-485X	NATIONAL EYE INSTITUTE [R01EY003279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044427] Funding Source: NIH RePORTER; NEI NIH HHS [EY 03279] Funding Source: Medline; NIGMS NIH HHS [GM 44427] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMAN DB, 1989, J BIOL CHEM, V264, P4648; CORBIN JD, 1975, J BIOL CHEM, V250, P218; CORBIN JD, 1977, J BIOL CHEM, V252, P3845; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ERICKSONVIITANE.S, 1987, PROTEIN ENG, P201; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HARPER JF, 1985, VITAM HORM, V42, P197; HATHAWAY DR, 1981, J BIOL CHEM, V256, P8183; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; JOACHIM S, 1990, EUR J CELL BIOL, V51, P76; KOSTREWA D, 1991, NATURE, V349, P178, DOI 10.1038/349178a0; KREBS EG, 1987, ANN REV BIOCH, V56, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUDVIG N, 1990, BRAIN RES, V520, P90, DOI 10.1016/0006-8993(90)91694-C; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SALVATORI S, 1990, BIOCHEM J, V267, P679, DOI 10.1042/bj2670679; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SCOTT JD, 1991, IN PRESS PHARM THER; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHARMA RK, 1983, METHOD ENZYMOL, V102, P210; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THREURKAUF W, 1982, J BIOL CHEM, V257, P3284; WIEMANN S, 1991, J BIOL CHEM, V266, P5140	35	378	443	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14188	14192						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860836				2022-12-25	WOS:A1991FZ35100013
J	REPPE, S; GABRIELSEN, OS; OLSTAD, OK; MORRISON, N; SAETHER, O; BLINGSMO, OR; GAUTVIK, VT; GORDELADZE, J; HAFLAN, AK; VOELKEL, EF; OYEN, TB; TASHJIAN, AH; GAUTVIK, KM				REPPE, S; GABRIELSEN, OS; OLSTAD, OK; MORRISON, N; SAETHER, O; BLINGSMO, OR; GAUTVIK, VT; GORDELADZE, J; HAFLAN, AK; VOELKEL, EF; OYEN, TB; TASHJIAN, AH; GAUTVIK, KM			CHARACTERIZATION OF A K26Q SITE-DIRECTED MUTANT OF HUMAN PARATHYROID-HORMONE EXPRESSED IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PREPRO-ALPHA-FACTOR; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PREPROPARATHYROID HORMONE; POLYACRYLAMIDE GELS; BONE-RESORPTION; SECRETION; PROTEINS; GENE	Human parathyroid hormone (hPTH) is susceptible to proteolytical cleavage both in humans and when expressed as a secretory product in Escherichia coli (Hogseth, A., Blingsmo, 0. R., Saether, O., Gautvik, V. T., Holmgren, E., Hartmanis, M., Josephson, S., Gabrielsen, 0. S., Gordeladze, J. O., Alestrom, P., and Gautvik, K. M. (1990) J. Biol. Chem. 265,7338-7344) and Saccharomyces cerevisiae (Gabrielsen, 0. S., Reppe, S., Saether, O., Blingsmo, 0. R., Sletten, K., Gordeladze, J. O., Hogset, A., Gautvik, V. T., Alestrom, P., Oyen, T. B., and Gautvik, K. M. (1990) Gene (Amst.) 90, 255-262). In the latter system, one major site of cleavage was identified (Arg25-Lys26 down Lys27). To produce hPTH resistant to this proteolytic processing, a point mutation changing Lys26 to Gln was introduced, and the modified gene expressed in S. cerevisiae as a fusion protein with the alpha-factor leader sequence. The resulting major form of hPTH secreted to the growth medium was of full length showing that the mutation had eliminated internal processing. Consequently, the yield of the mutant hormone was significantly higher than obtained with the natural peptide. Using improved purification procedures, a significantly higher purity was also obtained. The secreted mutant hPTH-(1-84,Q26) had the correct size, full immunological reactivity with two different hPTH antisera, correct amino acid composition and N-terminal sequence, and correct mass as determined by mass spectrometry. Furthermore, the introduced mutation did not reduce the biological activity of the hormone as judged from its action in three biological assay systems: 1) a hormone-sensitive osteoblast adenylate cyclase assay; 2) an in vivo calcium mobilizing assay in rats; and 3) an in vitro bone resorption assay.	UNIV OSLO,NATL HOSP,INST SURG RES,N-0027 OSLO 1,NORWAY; CTR IND RES,N-0314 OSLO 3,NORWAY; HARVARD UNIV,SCH PUBL HLTH,TOXICOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	University of Oslo; National Hospital Norway; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	REPPE, S (corresponding author), UNIV OSLO,DEPT BIOCHEM,POB 1041 BLINDERN,N-0316 OSLO 3,NORWAY.				NIDDK NIH HHS [DK 10206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK010206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORN W, 1987, MOL ENDOCRINOL, V1, P5, DOI 10.1210/mend-1-1-5; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; BURK RR, 1983, METHOD ENZYMOL, V91, P247; CARTER BLA, 1987, DNA CLONING PRACTICA, V3, P141; COHN DV, 1983, RECENT PROG HORM RES, V39, P181; FOSTER DC, 1990, BIOCHEMISTRY-US, V29, P347, DOI 10.1021/bi00454a007; GABRIELSEN OS, 1990, GENE, V90, P255, DOI 10.1016/0378-1119(90)90188-W; GARDELLA TJ, 1990, J BIOL CHEM, V265, P15854; GAUTVIK K M, 1984, European Surgical Research, V16, P41, DOI 10.1159/000128621; GAUTVIK KM, 1979, SCAND J CLIN LAB INV, V39, P469, DOI 10.3109/00365517909106133; GAUTVIK KM, 1983, J BIOL CHEM, V258, P304; GAUTVIK KM, 1983, SCAND J CLIN LAB INV, V43, P553; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HEINRICH G, 1984, J BIOL CHEM, V259, P3320; HOGSET A, 1990, J BIOL CHEM, V265, P7338; INNIS MA, 1985, SCIENCE, V228, P21, DOI 10.1126/science.228.4695.21; IVEY JL, 1976, J CLIN INVEST, V58, P1327, DOI 10.1172/JCI108588; JACOBSON MA, 1989, GENE, V85, P511, DOI 10.1016/0378-1119(89)90445-9; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KEMPER B, 1976, BIOCHEMISTRY-US, V15, P20, DOI 10.1021/bi00646a004; KEUTMANN HT, 1978, BIOCHEMISTRY-US, V17, P5723, DOI 10.1021/bi00619a019; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOISON G, 1988, BIO-TECHNOL, V6, P72, DOI 10.1038/nbt0188-72; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOODY AJ, 1987, FEBS LETT, V212, P302, DOI 10.1016/0014-5793(87)81365-0; MOREL F, 1983, RECENT PROG HORM RES, V39, P271; MULLENBACH GT, 1986, J BIOL CHEM, V261, P719; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; POTTS JT, 1982, ADV PROTEIN CHEM, V35, P323, DOI 10.1016/S0065-3233(08)60471-4; RABBANI SA, 1988, J BIOL CHEM, V263, P1307; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; ROBINSON DR, 1975, J CLIN INVEST, V56, P1181, DOI 10.1172/JCI108195; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER RT, 1974, BIOCHEMISTRY-US, V13, P1994, DOI 10.1021/bi00706a033; SLATOPOLSKY E, 1982, J LAB CLIN MED, V90, P309; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASICEK TJ, 1983, P NATL ACAD SCI-BIOL, V80, P2127, DOI 10.1073/pnas.80.8.2127; VLASUK GP, 1986, J BIOL CHEM, V261, P4789; WINGENDER E, 1989, J BIOL CHEM, V264, P4367; ZSEBO KM, 1986, J BIOL CHEM, V261, P5858	43	14	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14198	14201						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860837				2022-12-25	WOS:A1991FZ35100015
J	BRONDYK, WH; BOECKMAN, FA; FAHL, WE				BRONDYK, WH; BOECKMAN, FA; FAHL, WE			N-MYC ONCOGENE ENHANCES MITOGENIC RESPONSIVENESS OF DIPLOID HUMAN FIBROBLASTS TO GROWTH-FACTORS BUT FAILS TO IMMORTALIZE	ONCOGENE			English	Article							MALIGNANT TRANSFORMATION; HUMAN NEUROBLASTOMAS; PROTO-ONCOGENE; NEOPLASTIC TRANSFORMATION; ANCHORAGE-INDEPENDENCE; EMBRYO FIBROBLASTS; SIMIAN VIRUS-40; MAMMALIAN-CELLS; NEURO-BLASTOMA; GENE FAMILY	The N-myc gene is amplified in several types of human tumors. To assess the role of the N-myc gene in the transformation of normal human cells, we transfected an N-myc expression vector into diploid human fibroblasts. Transfected clones were isolated and found to express the N-myc gene at levels similar to those seen in a tumor cell line (neuroblastoma LA-N-1) which contains an amplified N-myc gene. The level of N-myc expression decreased as the N-myc clones senesced. Clones expressing N-myc had an increased saturation density and an altered morphology but did not have an extended lifespan. Under low serum conditions, neither the clones expressing N-myc nor the control cells showed anchorage-independent growth. Clones expressing N-myc were compared to control cells to determine if different growth factors would affect the ability of cells to grow in soft agarose. Clones expressing N-myc and the control cells did not grow in soft agarose supplemented with epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha). However, compared to control cells, clones expressing N-myc grew in agarose 2.8- to 18-fold higher in response to basic fibroblast growth factor (bFGF) and 5.5- to 55-fold higher in response to platelet-derived growth factor B-chain homodimer (PDGF-BB).	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	FAHL, WE (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706, USA.				NATIONAL CANCER INSTITUTE [P30CA007175, R37CA042024] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA07175, R37-CA42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERNARD O, 1989, J NEUROSCI RES, V24, P9, DOI 10.1002/jnr.490240104; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CURATOLO L, 1984, IN VITRO CELL DEV B, V20, P597; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GARSON JA, 1986, LANCET, V1, P1496; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; HURLIN PJ, 1987, CANCER RES, V47, P5752; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MACIEIRACOELHO A, 1980, GERONTOLOGY, V26, P276, DOI 10.1159/000212428; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MATLASHEWSKI G, 1988, INT J CANCER, V42, P232, DOI 10.1002/ijc.2910420215; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NORWOOD TH, 1985, HDB BIOL AGING, P291; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PALMER H, 1988, J CELL PHYSIOL, V137, P588, DOI 10.1002/jcp.1041370328; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH JR, 1980, SCIENCE, V207, P82; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; STEVENS CW, 1989, J CANCER RES CLIN, V115, P118, DOI 10.1007/BF00397911; STINSKI MF, 1985, J VIROL, V55, P431, DOI 10.1128/JVI.55.2.431-441.1985; STRAUSS M, 1990, ONCOGENE, V5, P1223; TUBO RA, 1987, ONCOGENE RES, V1, P407; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	59	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1269	1276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861869				2022-12-25	WOS:A1991GV26000024
J	KUNZE, N; YANG, G; DOLBERG, M; SUNDARP, R; KNIPPERS, R; RICHTER, A				KUNZE, N; YANG, G; DOLBERG, M; SUNDARP, R; KNIPPERS, R; RICHTER, A			STRUCTURE OF THE HUMAN TYPE-I DNA TOPOISOMERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SYSTEMIC-SCLEROSIS; TRANSCRIPTION; EXPRESSION; SITES; RECOMBINATION; CAMPTOTHECIN; REPLICATION; INHIBITORS; SEQUENCE	We describe the molecular organization of the human gene coding for type I DNA topoisomerase. The coding sequence is split into 21 exons distributed over at least 85 kilobase pairs (kb) of human genomic DNA. The sizes of the 20 introns vary widely between 0.2 and at least 30 kb and all contain the sequence elements known to be required for pre-mRNA splicing. Several of the intron sequences separate exons encoding parts of the enzyme that are highly conserved between human and yeast suggesting that at least some of the exons may code for individual, structurally, or functionally important domains of the enzyme. We also describe the promoter sequence of the human topoisomerase I gene and show that it is composed of distinct functional elements.			KUNZE, N (corresponding author), UNIV CONSTANCE,DIV BIOL,W-7750 CONSTANCE,GERMANY.							AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DIBB NJ, 1989, EMBO J, V8, P2015, DOI 10.1002/j.1460-2075.1989.tb03609.x; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; Go M., 1985, Advances in Biophysics, V19, P91; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GRUSS C, 1988, VIROLOGY, V167, P349, DOI 10.1016/S0042-6822(88)90095-5; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; HWONG CL, 1989, J BIOL CHEM, V264, P14923; JUAN CC, 1988, P NATL ACAD SCI USA, V85, P8910, DOI 10.1073/pnas.85.23.8910; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KUNZE N, 1990, EUR J BIOCHEM, V194, P323, DOI 10.1111/j.1432-1033.1990.tb15620.x; KUNZE N, 1989, HUM GENET, V84, P6, DOI 10.1007/BF00210661; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MACGREGOR GR, 1989, METHODS MOL BIOL, V7; Maniatis T., 1982, MOL CLONING; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MATTERN MR, 1987, CANCER RES, V47, P1793; MAUL GG, 1989, P NATL ACAD SCI USA, V86, P8492, DOI 10.1073/pnas.86.21.8492; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; ODDOU P, 1988, EUR J BIOCHEM, V177, P523, DOI 10.1111/j.1432-1033.1988.tb14404.x; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RICHTER A, 1989, LIFE SCI ADV, V8, P125; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROMIG H, 1990, BIOCHIM BIOPHYS ACTA, V1048, P274, DOI 10.1016/0167-4781(90)90067-C; ROMIG H, 1990, NUCLEIC ACIDS RES, V18, P801, DOI 10.1093/nar/18.4.801; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; SAAVEDRA RA, 1990, BIOESSAYS, V12, P125, DOI 10.1002/bies.950120306; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schreiber E., 1989, TISSUE SPECIFIC GENE, P33; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; SOBCZAK J, 1989, EUR J BIOCHEM, V180, P49, DOI 10.1111/j.1432-1033.1989.tb14613.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART AF, 1990, CELL, V60, P141; STOUT JT, 1985, ANNU REV GENET, V19, P127, DOI 10.1146/annurev.genet.19.1.127; TAN KB, 1989, J NATL CANCER I, V81, P1732, DOI 10.1093/jnci/81.22.1732; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; UEMURA T, 1987, NUCLEIC ACIDS RES, V15, P9727, DOI 10.1093/nar/15.23.9727; VERHEIJEN R, 1990, CLIN EXP IMMUNOL, V80, P38; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; YANG GC, 1990, GENE, V91, P247, DOI 10.1016/0378-1119(90)90095-9; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23; ZHOU BS, 1989, CANCER RES, V49, P3922	64	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9610	9616						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851751				2022-12-25	WOS:A1991FM45900044
J	CAIRNS, MT; MCDONALD, TP; HORNE, P; HENDERSON, PJF; BALDWIN, SA				CAIRNS, MT; MCDONALD, TP; HORNE, P; HENDERSON, PJF; BALDWIN, SA			CYTOCHALASIN-B AS A PROBE OF PROTEIN-STRUCTURE AND SUBSTRATE RECOGNITION BY THE GALACTOSE/H+ TRANSPORTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; INSULIN-RESPONSIVE TISSUES; MOLECULAR-CLONING; SKELETAL-MUSCLE; PROTON SYMPORT; MESSENGER-RNA; DNA-SEQUENCE; BINDING; SYSTEM; GENE	Cytochalasin B is a potent inhibitor of mammalian passive glucose transporters. The recent demonstration of sequence similarities between these proteins and several bacterial proton-linked sugar transporters suggested that cytochalasin B might be a useful tool for investigation of the galactose/H+ symport protein (GalP) of Escherichia coli. Equilibrium binding studies using membranes from a GalP-constitutive (GalP(c)) strain of E. coli revealed a single set of high affinity binding sites for cytochalasin B with a K(d) of 0.8-2.2-mu-M. Binding was inhibited by D-glucose, but not by L-glucose. UV irradiation of the membranes in the presence of [4-H-3]cytochalasin B photolabeled principally a protein of apparent M(r) 38,000, corresponding to the GalP protein. Labeling was inhibited by > 80% in the presence of 500 mM D-glucose or D-galactose, the major substrates of the GalP system. The extent of inhibition of photolabeling by different sugars and sugar analogues showed that the substrate specificity of GalP closely resembles that of the mammalian passive glucose transporters. Structural similarity to the latter was revealed by tryptic digestion of [4-H-3]cytochalasin B-photolabeled GalP, which yielded a radiolabeled fragment of apparent M(r) 17,000-19,000, similar to that previously reported for the human erythrocyte glucose transporter.	UNIV LONDON, ROYAL FREE HOSP, SCH MED, DEPT PROT & MOLEC BIOL, LONDON NW3 2PF, ENGLAND; UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Cambridge	CAIRNS, MT (corresponding author), UNIV LONDON, ROYAL FREE HOSP, SCH MED, DEPT BIOCHEM & CHEM, ROWLAND HILL ST, LONDON NW3 2PF, ENGLAND.		Cairns, Michael T/C-6821-2008; Henderson, Peter JF/Q-1907-2018	Cairns, Michael T/0000-0003-3455-184X; Henderson, Peter/0000-0002-9187-0938	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLOCH R, 1973, BIOCHEMISTRY-US, V12, P4799, DOI 10.1021/bi00747a036; BOOS W, 1969, EUR J BIOCHEM, V10, P66; BUTTIN G, 1968, ADV ENZYMOL RAMB, V30, P81; BUTTIN G, 1963, J MOL BIOL, V7, P164, DOI 10.1016/S0022-2836(63)80044-3; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; CARTERSU C, 1982, J BIOL CHEM, V257, P5419; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHANG YD, 1988, J BIOL CHEM, V263, P16696; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CIARALDI TP, 1986, BIOCHEM J, V240, P115, DOI 10.1042/bj2400115; Cleland W W, 1979, Methods Enzymol, V63, P103; CORNISHBOWDEN A, 1978, BIOCHIM BIOPHYS ACTA, V523, P268, DOI 10.1016/0005-2744(78)90030-X; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DARUWALLA KR, 1981, BIOCHEM J, V200, P611, DOI 10.1042/bj2000611; DAVIS EO, 1987, J BIOL CHEM, V262, P13928; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; DEZIEL M, 1984, BIOCHIM BIOPHYS ACTA, V772, P403, DOI 10.1016/0005-2736(84)90157-3; Fersht A., 1985, ENZYME STRUCTURE MEC; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; FUTAI M, 1978, BACTERIAL TRANSPORT, P7; GOODMAN D, 1971, ANAL BIOCHEM, V42, P481, DOI 10.1016/0003-2697(71)90062-5; GRIFFIN JF, 1982, P NATL ACAD SCI-BIOL, V79, P3759, DOI 10.1073/pnas.79.12.3759; HARAYAMA S, 1983, J BACTERIOL, V153, P408, DOI 10.1128/JB.153.1.408-415.1983; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; HENDERSON PJF, 1977, BIOCHEM J, V168, P15, DOI 10.1042/bj1680015; HORNE P, 1983, BIOCHEM J, V210, P699, DOI 10.1042/bj2100699; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KARIM AR, 1987, BIOCHIM BIOPHYS ACTA, V902, P402, DOI 10.1016/0005-2736(87)90208-2; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENHARD GE, 1984, BIOCHIM BIOPHYS ACTA, V769, P404, DOI 10.1016/0005-2736(84)90324-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACPHERSON AJS, 1983, J BIOL CHEM, V258, P4390; MACPHERSON AJS, 1981, BIOCHEM J, V196, P269, DOI 10.1042/bj1960269; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; POSTMA PW, 1977, J BACTERIOL, V129, P630, DOI 10.1128/JB.129.2.630-639.1977; REES WD, 1981, BIOCHIM BIOPHYS ACTA, V646, P251, DOI 10.1016/0005-2736(81)90331-X; ROTMAN B, 1968, J MOL BIOL, V36, P247, DOI 10.1016/0022-2836(68)90379-3; SAUER N, 1989, FEBS LETT, V259, P43, DOI 10.1016/0014-5793(89)81489-9; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHANAHAN MF, 1982, J BIOL CHEM, V257, P7290; SILHAVY TJ, 1978, BACTERIAL TRANSPORT, P127; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TAVERNA RD, 1973, BIOCHIM BIOPHYS ACTA, V323, P207, DOI 10.1016/0005-2736(73)90145-4; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; VYAS NK, 1983, P NATL ACAD SCI-BIOL, V80, P1792, DOI 10.1073/pnas.80.7.1792; WILSON DB, 1974, J BIOL CHEM, V249, P553; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; YAO B, 1989, GENE, V79, P189, DOI 10.1016/0378-1119(89)90201-1; ZHANG CC, 1989, MOL MICROBIOL, V3, P1221, DOI 10.1111/j.1365-2958.1989.tb00272.x; ZOCCOLI MA, 1978, J BIOL CHEM, V253, P6923	65	31	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8176	8183						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850739				2022-12-25	WOS:A1991FK44100037
J	WENDLAND, M; VONFIGURA, K; POHLMANN, R				WENDLAND, M; VONFIGURA, K; POHLMANN, R			MUTATIONAL ANALYSIS OF DISULFIDE BRIDGES IN THE MR 46,000 MANNOSE 6-PHOSPHATE RECEPTOR - LOCALIZATION AND ROLE FOR LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; PROTEINS; CLONING; BIOSYNTHESIS; FIBROBLASTS; CLEAVAGE	Formation of intramolecular disulfide bonds is a key step in the early maturation of newly synthesized M(r) 46,000 mannose 6-phosphate receptors to acquire ligand-binding activity (Hille, A., Waheed, A., and von Figura, K. (1990) J. Cell Biol. 110, 963-972). The luminal domain of the receptor, which carries the ligand-binding site, contains 6 cysteine residues. We have analyzed the function of individual cysteine residues for the ligand-binding conformation by exchanging cysteine for glycine. In each case, the replacement of cysteine resulted in a complete loss of binding activity, indicating that all 6 luminal cysteine residues are required for the ligand-binding conformation. The cysteine mutants displayed a greatly reduced immunoreactivity, decreased stability, and a blocked or delayed transport to the trans Golgi. The glycosylation pattern allowed the distinguishing of three phenotypes, each of which was represented by one pair of cysteine mutants. Based on the assumption that replacement of either of the 2 cysteine residues forming a disulfide bond results in an identical phenotype, we postulate that disulfide bonds are formed between Cys-32 and Cys-78 and between Cys-132 and Cys-167, as well as between Cys-145 and Cys-179. This assumption was supported by the observation that the simultaneous exchange of the 2 cysteine residues of a putative pair resulted in the same phenotypes as the single exchange of either of the 2 cysteine residues.	UNIV GOTTINGEN, BIOCHEM 2 ABT, GOSSLERSTR 12D, W-3400 GOTTINGEN, GERMANY	University of Gottingen								BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; GARTUNG C, 1985, EMBO J, V4, P1725, DOI 10.1002/j.1460-2075.1985.tb03842.x; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HILLE A, 1989, J BIOL CHEM, V264, P13460; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NOLAN CM, 1987, J CELL BIOCHEM, V35, P137, DOI 10.1002/jcb.240350207; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WENDLAND M, 1991, J BIOL CHEM, V266, P4598	26	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7132	7136						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849901				2022-12-25	WOS:A1991FG72700076
J	WEINHOLD, PA; CHARLES, L; ROUNSIFER, ME; FELDMAN, DA				WEINHOLD, PA; CHARLES, L; ROUNSIFER, ME; FELDMAN, DA			CONTROL OF PHOSPHATIDYLCHOLINE SYNTHESIS IN HEP G2 CELLS - EFFECT OF FATTY-ACIDS ON THE ACTIVITY AND IMMUNOREACTIVE CONTENT OF CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; RAT LUNG; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; APOLIPOPROTEIN-B; II PNEUMOCYTES; OLEIC-ACID; BIOSYNTHESIS; CTP; LINE; STIMULATION	We examined the effect of fatty acids on phosphatidylcholine synthesis and cytidylyltransferase activity in Hep G2 cells. Treatment of Hep G2 cells with oleic acid caused an increase in the incorporation of [methyl-C-14]choline into phosphatidylcholine and a corresponding decrease in radioactivity in choline phosphate using a pulse-chase procedure. This result is consistent with a fatty acid-induced increase in the cytidylyltransferase step in the choline pathway. We measured cytidylyltransferase activity in membrane fractions and in cytosol (100,000 X g supernatant or soluble enzyme released by digitonin). The activity increased in both membrane and cytosol. Thus, an increase in total activity occurred. Cytidylyltransferase protein determined by Western blot immunoassay increased after oleic acid treatment. Immunotitration of cytidylyltransferase protein also indicated that an increase in enzyme protein resulted from oleic acid treatment. Cycloheximide did not prevent the oleic acid-induced increase in cytidylyltransferase activity. The increase in enzyme activity was apparent when we measured the activity in the presence or absence of lipid activators. Separation of cytosolic cytidylyltransferase into H- and L-forms showed that the increase in cytosolic activity was due to an increase in H-form. The amount of L-form did not change. We interpret these results to suggest that fatty acid treatment of Hep G2 cells promoted the formation of active cytidylyltransferase (H-form) from a preexisting inactive form. The increased activity was distributed between membranes and the lipoprotein form in cytosol (H-form).	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	WEINHOLD, PA (corresponding author), VET ADM MED CTR,ANN ARBOR,MI 48105, USA.				NICHD NIH HHS [HD 02871, HD 21992] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD002871, R01HD021992] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AEBERHARD EE, 1986, BIOCHIM BIOPHYS ACTA, V875, P6, DOI 10.1016/0005-2760(86)90004-4; BLANK ML, 1988, J BIOL CHEM, V263, P5656; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BURKHARDT R, 1988, BIOCHEM J, V254, P495, DOI 10.1042/bj2540495; CHANDER A, 1988, BIOCHIM BIOPHYS ACTA, V958, P343, DOI 10.1016/0005-2760(88)90219-6; CHU AJ, 1985, BIOCHIM BIOPHYS ACTA, V834, P346, DOI 10.1016/0005-2760(85)90008-6; DASHTI N, 1989, J LIPID RES, V30, P1365; DASHTI N, 1987, BIOCHEMISTRY-US, V26, P4837, DOI 10.1021/bi00389a035; DASHTI N, 1987, J LIPID RES, V28, P423; ELLSWORTH JL, 1986, J LIPID RES, V27, P858; EXTON JH, 1990, J BIOL CHEM, V265, P1; FELDMAN DA, 1990, BIOCHIM BIOPHYS ACTA, V1045, P49, DOI 10.1016/0005-2760(90)90202-9; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P238; GORDON JI, 1984, J BIOL CHEM, V259, P468; HUNT AN, 1990, BIOCHIM BIOPHYS ACTA, V1043, P19, DOI 10.1016/0005-2760(90)90105-7; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOLESNICK RN, 1987, J BIOL CHEM, V262, P14525; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIM PH, 1983, BIOCHIM BIOPHYS ACTA, V753, P74, DOI 10.1016/0005-2760(83)90100-5; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; MAEDA M, 1985, J BIOL CHEM, V260, P5925; MCCALL MR, 1988, J LIPID RES, V29, P1127; MILLER JC, 1981, J BIOL CHEM, V256, P2662; MOCK T, 1986, BIOCHEM CELL BIOL, V64, P413, DOI 10.1139/o86-058; MORRIS KM, 1982, SCIENCE, V215, P399, DOI 10.1126/science.7199205; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P447, DOI 10.1016/0005-2760(84)90171-1; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; POST M, 1987, BIOCHEM J, V241, P291, DOI 10.1042/bj2410291; PRITCHARD PH, 1982, J BIOL CHEM, V257, P6362; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RASH JM, 1981, BIOCHIM BIOPHYS ACTA, V666, P294, DOI 10.1016/0005-2760(81)90120-X; ROONEY SA, 1990, BIOCHIM BIOPHYS ACTA, V1044, P385, DOI 10.1016/0005-2760(90)90085-C; ROONEY SA, 1986, BIOCHIM BIOPHYS ACTA, V888, P208, DOI 10.1016/0167-4889(86)90023-6; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THRIFT RN, 1986, J LIPID RES, V27, P236; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; VANHARKEN DR, 1969, J BIOL CHEM, V244, P2278; WALKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1981, BIOCHIM BIOPHYS ACTA, V665, P134, DOI 10.1016/0005-2760(81)90241-1; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; WHITLON DS, 1985, BIOCHIM BIOPHYS ACTA, V835, P369, DOI 10.1016/0005-2760(85)90293-0; YAO ZM, 1990, J BIOL CHEM, V265, P4326; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P7089, DOI 10.1021/bi00528a006	51	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6093	6100						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848848				2022-12-25	WOS:A1991FE37300017
J	COWELL, JK; WADEY, RB; HABER, DA; CALL, KM; HOUSMAN, DE; PRITCHARD, J				COWELL, JK; WADEY, RB; HABER, DA; CALL, KM; HOUSMAN, DE; PRITCHARD, J			STRUCTURAL REARRANGEMENTS OF THE WT1 GENE IN WILMS-TUMOR CELLS	ONCOGENE			English	Article							HUMAN RETINOBLASTOMA GENE; PHYSICAL MAP; HUMAN CHROMOSOME-11; WAGR COMPLEX; BAND 11P13; SHORT ARM; ANIRIDIA; HETEROZYGOSITY; DELETIONS; MUTATIONS	We have analysed 55 Wilms' tumour DNAs using the cDNA from the candidate Wilms' predisposition gene, WT1. One tumour, GOS 129, shows a partial homozygous deletion involving only the 3'-most exon of the gene. An adjacent 3' DNA sequence, J7-18, which lies on the same NotI fragment as WT1, is present in GOS 129. Thus, this partial deletion does not extend to the adjacent unmethylated 3' HTF island. These data support the candidature of WT1 as a Wilms' predisposition gene. Tumour GOS 129 has become homozygous as a result of a mitotic recombination event proximal to WT1. Three other tumours showed abnormally sized bands on Southern blot analysis which appear to reflect internal heterozygous rearrangements involving the 5' end of the gene. One of these tumours was from a bilaterally-affected patient and the other 3 were from stage III or IV tumours.	MIT,CTR CANC RES,CAMBRIDGE,MA 02193	Massachusetts Institute of Technology (MIT)	COWELL, JK (corresponding author), INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,LONDON WC1,ENGLAND.							BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; COUILLIN P, 1989, HUM GENET, V82, P171, DOI 10.1007/BF00284053; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GESSLER M, 1989, GENOMICS, V5, P43, DOI 10.1016/0888-7543(89)90084-0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P375; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HIGGINS MJ, 1989, MOL CELL BIOL, V9, P1; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MITCHELL CD, 1989, ONCOGENE, V4, P253; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; WADEY RB, 1990, ONCOGENE, V5, P901; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	35	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					595	599						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851548				2022-12-25	WOS:A1991FR93900014
J	DOSAKAAKITA, H; ROSENBERG, RK; MINNA, JD; BIRRER, MJ				DOSAKAAKITA, H; ROSENBERG, RK; MINNA, JD; BIRRER, MJ			A COMPLEX PATTERN OF TRANSLATIONAL INITIATION AND PHOSPHORYLATION IN L-MYC PROTEINS	ONCOGENE			English	Article							CELL LUNG-CANCER; FIBROBLAST GROWTH-FACTOR; CASEIN KINASE-II; NON-AUG CODONS; C-MYC; MESSENGER-RNAS; EMBRYO FIBROBLASTS; GENE FAMILY; LINES; TRANSFORMATION	Molecular analysis of the human proto-oncogene L-myc revealed a complex pattern of gene expression including alternative splicing and polyadenylation site selection of mRNA, giving rise to at least four mRNAs. These mRNAs in turn can code for several proteins. In this report, we characterize and define the origins of the major L-myc proteins. In vitro translation revealed that (i) two L-myc proteins (p59 and p65) were derived through alternative translational initiation at a non-AUG (CUG) site in intron 1 and at an AUC site in exon 2 of L-myc, and that (ii) extensive post-translational phosphorylation of these proteins yielded three additional proteins (p60, p66, and p68). Transfection experiments in rat embryo cells revealed the in vivo existence of this unusual CUG-initiated protein and demonstrated that it possessed transforming activity. Further, immuno-precipitation using high titered anti-L-myc peptide antisera, of two L-myc expressing small-cell lung cancer cell lines revealed three major L-myc proteins (p60, p66 and p68) all of which were derived from extensive phosphorylation of a p59 protein.	NCI,USN,MED ONCOL BRANCH,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA								BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BISTER K, 1987, ONCOGENE, V1, P97; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CARNEY DN, 1985, CANCER RES, V45, P2913; CLEAVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RAMSAY G, 1982, EMBO J, V9, P1111; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SAKSELA K, 1989, INT J CANCER, V44, P182, DOI 10.1002/ijc.2910440132; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849244				2022-12-25	WOS:A1991FT34400004
J	SZABO, I; ZORATTI, M				SZABO, I; ZORATTI, M			THE GIANT CHANNEL OF THE INNER MITOCHONDRIAL-MEMBRANE IS INHIBITED BY CYCLOSPORINE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OXIDATIVE STRESS; PERMEABILITY TRANSITION; CA-2+-DEPENDENT PORE; INORGANIC-PHOSPHATE; LIVER-MITOCHONDRIA; HEART-MITOCHONDRIA; CYCLOPHILIN; TRANSPORT; CA2+; K+	In patch-clamp experiments on rat liver mitoplasts, cyclosporin A inhibited the activity of the recently described (Petronilli, V., Szabo, I., and Zoratti, M. (1989) FEBS Lett. 259, 137-143) 1.3-nanosiemens channel of the inner mitochondrial membrane at concentrations in the 10(-8)-10(-7) M range. The inhibitor acts when present on the matrix side of membrane. The Ca2+-dependent "permeability transition channel" of mitochondria is inhibited by cyclosporin A in the same concentration range. The results suggest therefore that the same pore is responsible for the permeabilization of the inner mitochondrial membrane and for the conduction of the high currents observed in electrophysiological experiments.			ZORATTI, M (corresponding author), CNR, CTR STUDI FISIOL MITOCONDRI, IST PATOL GEN, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Padova, Ildiko/K-5344-2016; Szabo, Ildiko/AAW-5972-2021	Szabo, Ildiko/0000-0002-3637-3947				BERNARDI P, 1990, EUR J BIOCHEM, V188, P91, DOI 10.1111/j.1432-1033.1990.tb15375.x; BERNARDI P, 1989, J BIOL CHEM, V264, P18902; BOREL JF, 1986, CYCLOSPORIN; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; DIWAN JJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P155, DOI 10.1016/S0304-4173(87)80001-0; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HARDING MW, 1988, TRANSPLANTATION, V46, pS29; IGBAVBOA U, 1989, BIOCHEM BIOPH RES CO, V161, P619, DOI 10.1016/0006-291X(89)92644-2; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; MASON J, 1989, PHARMACOL REV, V41, P423; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; MORAN O, 1990, J BIOL CHEM, V265, P908; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; RYFFEL B, 1989, PHARMACOL REV, V41, P407; SILIPRANDI D, 1979, BIOCHEM BIOPH RES CO, V88, P388, DOI 10.1016/0006-291X(79)92060-6; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; ZORATTI M, 1991, IN PRESS TRENDS BIOM	29	334	337	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3376	3379						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847371				2022-12-25	WOS:A1991EY68200006
J	TANTI, JF; GREMEAUX, T; VANOBBERGHEN, E; LEMARCHANDBRUSTEL, Y				TANTI, JF; GREMEAUX, T; VANOBBERGHEN, E; LEMARCHANDBRUSTEL, Y			EFFECTS OF OKADAIC ACID, AN INHIBITOR OF PROTEIN PHOSPHATASES-1 AND PHOSPHATASES-2A, ON GLUCOSE-TRANSPORT AND METABOLISM IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE; INSULIN-RECEPTOR; RAT ADIPOCYTES; SOLEUS MUSCLE; OBESE MICE; PHOSPHORYLATION; KINASE; ACTIVATION	The effect of okadaic acid, an inhibitor of protein phosphatases-1 and -2A, was studied on glucose transport and metabolism in soleus muscles isolated from lean and insulin-resistant obese mice. In muscles from lean mice, the uptake of 2-deoxyglucose, an index of glucose transport and phosphorylation, was increased by okadaic acid in a concentration-dependent manner. At 5-mu-M, okadaic acid was as efficient as a maximally effective insulin concentration. Glucose metabolism (glycolysis and glycogen synthesis) was also measured. Whereas glycolysis was stimulated by okadaic acid, glycogen synthesis was unchanged. When okadaic acid and insulin were added together in the incubation medium, the rates of glucose transport, glycolysis, and glycogen synthesis were similar to those obtained with insulin alone, whether maximal or submaximal insulin concentrations were used. Furthermore, okadaic acid did not activate the kinase activity of the insulin receptor studied in an acellular system or in intact muscles. These results indicate that a step in the insulin-induced stimulation of muscle glucose transport involves a serine/threonine phosphorylation event that is regulated by protein phosphatases-1 and/or -2A. In muscles of insulin-resistant obese mice, the absolute values of deoxyglucose uptake stimulated by okadaic acid were lower than in muscles from lean mice. However, the okadaic acid effect, expressed as a fold stimulation, was normal. These observations suggest that in the insulin-resistant state linked to obesity, the serine/threonine phosphorylation event is likely occurring normally, but a defect at the level of the glucose transporter itself would prevent a normal response to insulin or okadaic acid.			TANTI, JF (corresponding author), FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06034 NICE,FRANCE.			Tanti, Jean-Francois/0000-0003-1782-1318				BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GAMMELTOFT S, 1986, BIOCHEM J, V235, P1; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; JAMES DE, 1989, P NATL ACAD SCI USA, V86, P8368, DOI 10.1073/pnas.86.21.8368; JOOST HG, 1989, DIABETOLOGIA, V32, P831, DOI 10.1007/BF00297447; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KLUMPP S, 1990, EMBO J, V9, P685, DOI 10.1002/j.1460-2075.1990.tb08160.x; KORANYI L, 1990, J CLIN INVEST, V85, P962, DOI 10.1172/JCI114526; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LEMARCHANDBRUST.Y, 1990, IN PRESS ENDOCRINOLO, V127; LEMARCHANDBRUSTEL Y, 1978, AM J PHYSIOL, V234, pE348, DOI 10.1152/ajpendo.1978.234.4.E348; LEMARCHANDBRUSTEL Y, 1981, BIOCHIM BIOPHYS ACTA, V677, P13; LEMARCHANDBRUSTEL Y, 1985, NATURE, V315, P676, DOI 10.1038/315676a0; ORON Y, 1980, MOL CELL BIOCHEM, V32, P153; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; TANTI JF, 1989, BIOCHEM J, V258, P141, DOI 10.1042/bj2580141; ZANINETTI D, 1989, DIABETOLOGIA, V32, P56	27	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2099	2103						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846612				2022-12-25	WOS:A1991EV51500016
J	MONNOT, M; MAUFFRET, O; SIMON, V; LESCOT, E; PSAUME, B; SAUCIER, JM; CHARRA, M; BELEHRADEK, J; FERMANDJIAN, S				MONNOT, M; MAUFFRET, O; SIMON, V; LESCOT, E; PSAUME, B; SAUCIER, JM; CHARRA, M; BELEHRADEK, J; FERMANDJIAN, S			DNA-DRUG RECOGNITION AND EFFECTS ON TOPOISOMERASE-II-MEDIATED CYTOTOXICITY - A 3-MODE BINDING MODEL FOR ELLIPTICINE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTROSCOPY; NUCLEIC-ACID INTERACTIONS; P388 LEUKEMIA-CELLS; DEOXYRIBONUCLEIC-ACID; INTERCALATING DRUGS; ACRIDINE-ORANGE; BREAST-CANCER; STRAND BREAKS; CYTO-TOXICITY; L1210 CELLS	Cytotoxic effects and topoisomerase II-mediated DNA breaks induced in vitro by ellipticine derivatives were examined in connection with H-1 NMR and circular dichroism (CD) studies on molecular structures and interactions of drugs with DNA. The compounds included four 9-hydroxyellipticine and two 7-hydroxyisoellipticine derivatives. Structure-activity relationships indicated that a change in nitrogen atom position in the pyridinic ring greatly affected drug effects both on topoisomerase II action and cytotoxicity to L1210 cells. The four 9-hydroxyellipticine derivatives yielded bell-shaped curves in in vitro topoisomerase II-mediated DNA break assays, whereas the two 7-hydroxyisoellipticine derivatives demonstrated an almost linear increase at the same concentration (0-10-mu-M). In both cases, the intensity of cleavage was modulated by the position and the degree of methylation on the pyridinic ring, and results were correlated with cytotoxic activity expressed as the in vitro ID50 values for L1210 leukemia cells. H-1 NMR experiments performed on free drug molecules in solution revealed that the two protons (alpha and beta) contiguous to the biologically important hydroxy group were sensitive to changes in electron distribution produced by the distant chemical modifications and methylations of the pyridinic ring. A linear relationship was observed between the differences in chemical shifts of alpha and beta protons (DELTA-delta-alpha-beta) versus ID50 values. CD experiments indicated that, at weak ionic strength I = 0.02 and at pH 7, drugs interact with the poly[d(A-T)] duplex according to a "three-mode binding model" which is governed by the drug structure and the drug to DNA ratio. The intercalation mode was related to the induction of topoisomerase II-mediated DNA cleavage, while the external binding mode consecutive to intercalation was related to cleavage suppression. These two modes concerned the good intercalators 9-hydroxyellipticines. The third was found for the weak intercalators 7-hydroxyisoellipticines and was characterized by self-stacked molecules bound "outside" DNA, presumably in the minor groove. Ligands either could be intercalated partially or linked at the edge of bases with a small number of molecules filling intercalation sites, for the second alternative. In addition to having different binding modes, 9-hydroxyellipticines were better inducers of DNA distortions than 7-hydroxyisoellipticines. The incidence of the drug binding modes on DNA-topicomerase II recognition was discussed in connection with the in vitro cytotoxic activity exhibited by the drugs.	INST GUSTAVE ROUSSY,BIOCHIM ENZYMOL LAB,CNRS,URA 147,INSERM,U140,PR II,F-94800 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy								AHOND A, 1981, J NAT PROD, V44, P193, DOI 10.1021/np50014a009; ARNOTT S, 1980, NATURE, V287, P561, DOI 10.1038/287561a0; ASSAMUNT N, 1984, BIOCHEMISTRY-US, V23, P791, DOI 10.1021/bi00300a001; AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V259, P1, DOI 10.1016/0003-9861(87)90463-2; AUCLAIR C, 1987, CANCER RES, V47, P6254; BALDWIN RL, 1971, ACCOUNTS CHEM RES, V4, P265, DOI 10.1021/ar50044a001; BERNADOU J, 1983, J MED CHEM, V26, P574, DOI 10.1021/jm00358a022; BESTERMAN JM, 1989, J BIOL CHEM, V264, P2324; BODLEY A, 1989, CANCER RES, V49, P5969; Cantor C.R., 1980, BIOPHYS CHEM; CAPRANICO G, 1986, CANCER RES, V46, P5499; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CAPRANICO G, 1987, CANCER RES, V47, P3752; CARVLIN MJ, 1982, BIOCHEM BIOPH RES CO, V108, P66, DOI 10.1016/0006-291X(82)91832-0; CARVLIN MJ, 1983, NUCLEIC ACIDS RES, V11, P6121, DOI 10.1093/nar/11.17.6121; CHOW KC, 1988, MOL PHARMACOL, V34, P467; DALTON LK, 1967, AUST J CHEM, V20, P2715, DOI 10.1071/CH9672715; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DENNY WA, 1986, CANCER RES, V46, P1717; DENNY WA, 1989, ANTI-CANCER DRUG DES, V4, P241; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; FESTY B, 1971, FEBS LETT, V17, P321, DOI 10.1016/0014-5793(71)80176-X; FIEL RJ, 1989, J BIOMOL STRUCT DYN, V6, P1259, DOI 10.1080/07391102.1989.10506549; FORNASIERO D, 1981, J PHYS CHEM-US, V85, P613, DOI 10.1021/j150605a032; FOSSE P, 1990, BIOCHEM PHARMACOL, V39, P669, DOI 10.1016/0006-2952(90)90144-A; FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016; FREDERICQ E, 1972, BIOPOLYMERS, V11, P2281, DOI 10.1002/bip.1972.360111108; GABBAY EJ, 1976, BIOCHEMISTRY-US, V15, P2062, DOI 10.1021/bi00655a006; GOODWIN S, 1959, J AM CHEM SOC, V81, P1903, DOI 10.1021/ja01517a031; GOUYETTE A, 1980, EUR J MED CHEM, V15, P503; GUTHRIE RW, 1975, J MED CHEM, V18, P755, DOI 10.1021/jm00241a023; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HURLEY LH, 1989, J MED CHEM, V32, P2027, DOI 10.1021/jm00129a001; JACKSON K, 1971, T FARADAY SOC, V67, P966, DOI 10.1039/tf9716700966; JURET P, 1978, EUR J CANCER, V14, P205, DOI 10.1016/0014-2964(78)90180-9; JURET P, 1982, CANCER TREAT REP, V66, P1909; KAMIYA M, 1979, BIOCHIM BIOPHYS ACTA, V562, P70, DOI 10.1016/0005-2787(79)90127-8; LEPECQ JB, 1974, P NATL ACAD SCI USA, V71, P5078, DOI 10.1073/pnas.71.12.5078; LI HJ, 1969, BIOPOLYMERS, V8, P217, DOI 10.1002/bip.1969.360080208; LIU LF, 1983, CRC CR REV BIOCH MOL, V15, P1, DOI 10.3109/10409238309102799; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LODER JW, 1966, AUST J CHEM, V19, P1947, DOI 10.1071/CH9661947; LYNG R, 1987, BIOPOLYMERS, V26, P1327, DOI 10.1002/bip.360260809; MAFTOUH M, 1985, J MED CHEM, V28, P708, DOI 10.1021/jm00383a004; Maniatis T., 1982, MOL CLONING; MARKOVITS J, 1986, CANCER RES, V46, P5821; MILLER KG, 1981, J BIOL CHEM, V256, P9334; NEIDLE S, 1978, TOPICS ANTIBIOTIC CH, P241; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; NORDEN B, 1982, BIOPOLYMERS, V21, P1713, DOI 10.1002/bip.360210904; NUSS ME, 1980, BIOCHIM BIOPHYS ACTA, V609, P136, DOI 10.1016/0005-2787(80)90207-5; PATEL DJ, 1981, P NATL ACAD SCI-BIOL, V78, P3333, DOI 10.1073/pnas.78.6.3333; PHILLIPS DR, 1980, BIOCHEMISTRY-US, V19, P4795, DOI 10.1021/bi00562a013; PHILLIPS DR, 1990, BIOCHEMISTRY-US, V29, P4812, DOI 10.1021/bi00472a010; PIERSON V, 1989, BIOCHEM PHARMACOL, V38, P1395, DOI 10.1016/0006-2952(89)90178-0; PIERSON V, 1988, CANCER RES, V48, P1404; POMMIER Y, 1987, BIOCHEM PHARMACOL, V36, P3477, DOI 10.1016/0006-2952(87)90329-7; POMMIER Y, 1987, NUCLEIC ACIDS RES, V15, P6713, DOI 10.1093/nar/15.16.6713; PORUMB H, 1978, PROG BIOPHYS MOL BIO, V34, P175; RIOU JF, 1987, NATL CANCER I MONOGR, V4, P41; ROUESSE JG, 1985, CANCER TREAT REP, V69, P707; ROWE T, 1985, BIOCHEM PHARMACOL, V34, P2483, DOI 10.1016/0006-2952(85)90530-1; ROWE TC, 1986, CANCER RES, V46, P2021; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHWALLER MA, 1988, J BIOMOL STRUCT DYN, V6, P443, DOI 10.1080/07391102.1988.10506499; SIZUN P, 1988, BIOPOLYMERS, V27, P1085, DOI 10.1002/bip.360270704; SUZUKI E, 1986, BIOCHEMISTRY-US, V25, P6854, DOI 10.1021/bi00370a019; TAKESADA H, 1970, B CHEM SOC JPN, V43, P181, DOI 10.1246/bcsj.43.181; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; Tinoco I Jr, 1970, Methods Biochem Anal, V18, P81, DOI 10.1002/9780470110362.ch3; WANG AHJ, 1987, BIOCHEMISTRY-US, V26, P1152, DOI 10.1021/bi00378a025; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WARING MJ, 1976, EUR J CANCER, V12, P995, DOI 10.1016/0014-2964(76)90066-9; WILSON WD, 1981, ADV PHARMACOL CHEMOT, V18, P177, DOI 10.1016/S1054-3589(08)60255-0; WILSON WD, 1985, BIOCHEMISTRY-US, V24, P3991, DOI 10.1021/bi00336a029; WILSON WR, 1981, MOL PHARMACOL, V20, P404; ZEGAR I, 1989, CHEM-BIOL INTERACT, V72, P277, DOI 10.1016/0009-2797(89)90004-5; ZWELLING LA, 1981, BIOCHEMISTRY-US, V20, P6553, DOI 10.1021/bi00526a006	80	115	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1820	1829						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846365				2022-12-25	WOS:A1991EU49700071
J	FAN, JG; VITOLS, KS; HUENNEKENS, FM				FAN, JG; VITOLS, KS; HUENNEKENS, FM			BIOTIN DERIVATIVES OF METHOTREXATE AND FOLATE - SYNTHESIS AND UTILIZATION FOR AFFINITY PURIFICATION OF 2 MEMBRANE-ASSOCIATED FOLATE TRANSPORTERS FROM L1210 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE-C; SEQUENCE; PLACENTA; CARRIER; CLONING; CDNA	Biotin derivatives of methotrexate and folate (2-(biotinamido) ethyl-1,3'-dithiopropionyldiaminopentyl methotrexate and/or folate), in which carboxyl groups of the functional components are joined by a disulfide-containing spacer, have been synthesized, purified by DEAE-Trisacryl chromatography, and characterized by high pressure liquid chromatography and mass spectrometry. These bifunctional, dissociable probes were utilized for the single-step purification to homogeneity of two folate transport proteins (43 and 39 kDa) from L1210 cells. Treatment of the 39-kDa protein with peptide N-glycosidase F produced a smaller component (32 kDa); the 43-kDa protein, conversely, was unchanged by this procedure. When the 39-kDa transporter in intact cells was labeled with a fluorescein derivative of folate and then treated with phosphoinositol-specific phospholipase C, complete loss of fluorescence was observed. Alternatively, there was no change in fluorescence when the 43-kDa transporter was labeled with a fluorescein derivative of methotrexate and treated with the enzyme. These results indicate that the 43-kDa transporter is a nonglycosylated, integral membrane protein, whereas the 39kDa counterpart is heavily glycosylated and anchored exofacially to the membrane by a glycosylphosphatidylinositol component.	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CANCER INSTITUTE [R35CA039836] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39836] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGER J, 1988, J BIOL CHEM, V263, P10016; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FAN J, 1990, ADV ENZYME REGUL, V30, P3; FAN JG, 1991, BIOCHEMISTRY-US, V30, P4573, DOI 10.1021/bi00232a030; HENDERSON GB, 1978, CANCER RES, V38, P859; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1986, FOLATES PTERINS, V3, P208; JANSEN G, 1989, CANCER RES, V49, P1959; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LEVESQUE JP, 1985, EXP CELL RES, V156, P558, DOI 10.1016/0014-4827(85)90563-4; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MATHERLY LH, 1990, P AM ASSOC CANC RES, V31, P340; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; TAGUCHI R, 1980, BIOCHIM BIOPHYS ACTA, V619, P48; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; YANG CH, 1988, J BIOL CHEM, V263, P9703	21	36	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14862	14865						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869524				2022-12-25	WOS:A1991GB09700009
J	ZAMIR, LO; DEVOR, KA; SAURIOL, F				ZAMIR, LO; DEVOR, KA; SAURIOL, F			BIOSYNTHESIS OF THE TRICHOTHECENE 3-ACETYLDEOXYNIVALENOL - IDENTIFICATION OF THE OXYGENATION STEPS AFTER ISOTRICHODERMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-ROSEUM ATCC-28114; TRICHODIENE BIOSYNTHESIS; NEROLIDYL PYROPHOSPHATE; ENZYMATIC CYCLIZATION; MINOR METABOLITES; CULMORUM	Upon feeding an excess of the substrate isotrichodermin, five tricyclic metabolites accumulated in Fusarium culmorum cultures. These compounds were also identified as transient intermediates of trichothecene biosynthesis by kinetic pulse labeling. Their structures were characterized by spectroscopic techniques (H-1 NMR, C-13 NMR, H-2 NMR, and nuclear Overhauser effect difference experiments) as: 1, 15-deacylcalonectrin; 2, calonectrin; 3, 7-hydroxyisotrichodermin; 4, 8-hydroxyisotrichodermin; and 5, 7, hydroxycalonectrin. Four of these metabolites (1-4) were rigorously proven to be biosynthetic precursors to 3-acetyldeoxynivalenol. Indeed, their deuteriated derivatives were shown to be incorporated very efficiently into 3-acetyldeoxynivalenol by H-2-NMR. In addition, our experimental data suggests that the first oxygenation step after isotrichodermin is at C-15, producing 15-deacylcalonectrin.	MCGUILL UNIV,DEPT CHEM,MONTREAL H9N 4Z3,QUEBEC,CANADA	McGill University	ZAMIR, LO (corresponding author), UNIV QUEBEC,INST ARMAND FRAPPIER,CTR MICROBIOL APPL,531 BLVD PRAIRIES,C P 100,LAVAL H7V 1B7,QUEBEC,CANADA.							CANE DE, 1986, J AM CHEM SOC, V108, P3097, DOI 10.1021/ja00271a046; CANE DE, 1988, J AM CHEM SOC, V110, P6865, DOI 10.1021/ja00228a041; GARDNER D, 1972, J CHEM SOC PERK T 1, P2576, DOI 10.1039/p19720002576; GREENHALGH R, 1986, J AGR FOOD CHEM, V34, P115, DOI 10.1021/jf00067a032; GREENHALGH R, 1984, J AGR FOOD CHEM, V32, P945, DOI 10.1021/jf00124a060; GREENHALGH R, 1984, J AGR FOOD CHEM, V32, P1261, DOI 10.1021/jf00126a013; GREENHALGH R, 1986, J AGR FOOD CHEM, V34, P98, DOI 10.1021/jf00067a027; GROVE JF, 1988, NAT PROD REP, V5, P187, DOI 10.1039/np9880500187; HESKETH AR, 1990, J CHEM SOC CHEM COMM, P1184, DOI 10.1039/c39900001184; LAUREN DR, 1987, J AGR FOOD CHEM, V35, P884, DOI 10.1021/jf00078a008; MARASAAS WFD, 1984, TOXIGENIC FUSARIUMS, P147; SAVARD ME, 1987, CAN J CHEM, V65, P2254, DOI 10.1139/v87-376; ZAMIR LO, 1987, J CHEM SOC CHEM COMM, P127, DOI 10.1039/c39870000127; ZAMIR LO, 1987, J BIOL CHEM, V262, P15354; ZAMIR LO, 1989, J CHEM SOC CHEM COMM, P598, DOI 10.1039/c39890000598; ZAMIR LO, 1989, TETRAHEDRON, V45, P2277, DOI 10.1016/S0040-4020(01)83432-3; ZAMIR LO, 1990, J BIOL CHEM, V265, P6713; ZAMIR LO, 1987, J BIOL CHEM, V262, P15348	18	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14992	15000						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869536				2022-12-25	WOS:A1991GB09700032
J	HUI, KY; MANETTA, JV; GYGI, T; BOWDON, BJ; KEITH, KA; SHANNON, WM; LAI, MHT				HUI, KY; MANETTA, JV; GYGI, T; BOWDON, BJ; KEITH, KA; SHANNON, WM; LAI, MHT			A RATIONAL APPROACH IN THE SEARCH FOR POTENT INHIBITORS AGAINST HIV PROTEINASE	FASEB JOURNAL			English	Note						HIV PROTEASE; INHIBITORS; ANTIVIRAL	CONCENTRATION FLUORESCENCE IMMUNOASSAY; IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOTIDE-SEQUENCE; 3-DIMENSIONAL STRUCTURE; RETROVIRAL PROTEASES; ANTIVIRAL ACTIVITY; ANALOG INHIBITORS; RENIN INHIBITORS; AIDS VIRUS; PEPSTATIN	Synthetic peptides described as dog renin inhibitors were found to effectively inhibit the aspartyl protease of human immunodeficiency virus (HIV). The selection of oligopeptides for the HIV protease inhibition study was based on 1) the current strategy of inhibiting aspartyl proteases with transition state analogs, and 2) our previous observations regarding optimal structural differentiation at the P2 position among human, dog, and rat renin inhibitors. In an in vitro assay system consisting of recombinant HIV protease and a synthetic decapeptide substrate (at pH 5.5), results show that HIV protease was unaffected by statine-containing analogs carrying histidine at the P2 position whereas analogs containing valine at the same position yielded anti-protease IC50 values ranging from 50 to 500 nm. As anticipated, some analogs were also shown to inhibit processing of recombinant polyprotein substrate by HIV protease in vitro. The antiviral activity of three inhibitors was studied in HIV-infected CEM and MT-2 cells. Results showed that one compound, Ac-Naphthylalanyl-Pro-Phe-Val-Statine-Leu-Phe-NH2 (antiprotease IC50 value = 0.4-mu-M), protected the infected cells effectively with IC50 values (0.73-mu-M for CEM cells and 0.88-mu-M for MT-2 cells). This antiviral effect is comparable to those obtained with AZT and ddC in parallel studies of MT-2 cells.	SO RES INST,BIRMINGHAM,AL 35255		HUI, KY (corresponding author), ELI LILLY & CO,LILLY RES LAB,LILLY CORP CTR,INDIANAPOLIS,IN 46285, USA.							BILLICH S, 1988, J BIOL CHEM, V263, P17905; BOGER J, 1983, NATURE, V303, P81, DOI 10.1038/303081a0; BOGER J, 1985, J MED CHEM, V28, P1779, DOI 10.1021/jm00150a007; BOTT R, 1982, BIOCHEMISTRY-US, V21, P6956, DOI 10.1021/bi00269a052; DREYER GB, 1989, P NATL ACAD SCI USA, V86, P9752, DOI 10.1073/pnas.86.24.9752; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GRINDE B, 1990, ARCH VIROL, V114, P167, DOI 10.1007/BF01310746; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HUI KY, 1987, J MED CHEM, V30, P1287, DOI 10.1021/jm00391a005; HUI KY, 1988, J MED CHEM, V31, P1679, DOI 10.1021/jm00117a003; HUI KY, 1990, PEPTIDES CHEM STRUCT, P399; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JAMES MNG, 1982, P NATL ACAD SCI-BIOL, V79, P6137, DOI 10.1073/pnas.79.20.6137; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KATOH I, 1987, NATURE, V329, P654, DOI 10.1038/329654a0; KAY J, 1985, ASPARTIC PROTEINASES, P401; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAI MT, 1990, RETROVIRAL PROTEASES, P63; LAPATTO P, 1989, NATURE, V342, P299; MACCRINDLE C, 1985, CLIN CHEM, V31, P1487; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088; MARGOLIN N, 1990, BIOCHEM BIOPH RES CO, V167, P554, DOI 10.1016/0006-291X(90)92060-D; MARSHALL GR, 1976, FED PROC, V35, P2494; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Stewart JM, 1984, SOLID PHASE PEPTIDE; SZELKE M, 1982, NATURE, V299, P555, DOI 10.1038/299555a0; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	46	18	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2606	2610		10.1096/fasebj.5.11.1868985	http://dx.doi.org/10.1096/fasebj.5.11.1868985			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868985				2022-12-25	WOS:A1991GB09400016
J	BUSH, GL; TASSIN, AM; FRIDEN, H; MEYER, DI				BUSH, GL; TASSIN, AM; FRIDEN, H; MEYER, DI			SECRETION IN YEAST - PURIFICATION AND INVITRO TRANSLOCATION OF CHEMICAL AMOUNTS OF PREPRO-ALPHA-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-TRANSLATIONAL TRANSLOCATION; ESCHERICHIA-COLI; AFFINITY-CHROMATOGRAPHY; PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; MEMBRANE; RECONSTITUTION; GLYCOSYLATION	The Saccharomyces cerevisiae mating pheromone precursor, prepro-alpha-factor, can be translocated across yeast endoplasmic reticulum membranes post-translationally in an in vitro system. This characteristic makes prepro-alpha-factor potentially useful as a probe in the biochemical dissection of the mechanism of this basic cellular process. Efforts have been limited by the inability to isolate sufficient quantities of such secretory protein precursors in a translocation-competent form. We report here the one-step purification of chemical amounts of translocation-competent prepro-alpha-factor using nickel ion affinity chromatography on nitrilotriacetate resin. An oligonucleotide encoding 6 histidine residues was inserted into a genomic clone encoding prepro-alpha-factor 5' of the naturally occurring translational stop codon by site-directed mutagenesis. The construct was expressed at high levels in a Sec Y- strain of Escherichia coli. The produced preprotein was solubilized in 6 m guanidine hydrochloride and bound to nitrilotriacetate resin. Prepro-alpha-factor was recovered at a purity in excess of 95% by elution with 0.25 M imidazole, 8 m urea, which competitively displaced the histidine affinity tag from the nickel column. The chemical amounts of prepro-alpha-factor obtained in this way were determined to be competent for translocation across yeast microsomal membranes and for subsequent modifications such as signal sequence cleavage and N-linked glycosylation.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM07185, GM38538] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038538, T32GM007185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; COPPENHAVER DH, 1986, METHOD ENZYMOL, V119, P199; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GENTZ R, 1988, EMBO J, V7, P225, DOI 10.1002/j.1460-2075.1988.tb02803.x; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HOCHST H, 1988, J VAC SCI TECHNOL B, V6, P1320, DOI 10.1116/1.584257; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; LECKER S, 1989, J BIOL CHEM, V264, P1882; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SANZ P, 1988, EMBO J, V7, P3553, DOI 10.1002/j.1460-2075.1988.tb03232.x; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SMITH MC, 1988, J BIOL CHEM, V263, P7211; STUBER D, 1991, IMMUNOLOGICAL METHOD, V4; STUDIER FW, 1986, J MOL BIOL, V189, P112; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	22	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13811	13814						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856213				2022-12-25	WOS:A1991FY02700057
J	HWANG, SR; TABITA, FR				HWANG, SR; TABITA, FR			ACYL CARRIER PROTEIN-DERIVED SEQUENCE ENCODED BY THE CHLOROPLAST GENOME IN THE MARINE DIATOM CYLINDROTHECA SP STRAIN N1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FATTY-ACID SYNTHETASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; INVERTED REPEAT; CDNA CLONE; ACP; GENES; PURIFICATION; EXPRESSION; SUBUNITS	The chloroplast genome of chromophytic and rhodophytic algae differs from the plastid genome of plants and green algae in that it encodes the gene for the small subunit (rbcS) of ribulose 1,5-bisphosphate carboxylase/oxygenase. Hybridization studies indicated that there was a second region of chloroplast DNA from the marine diatom Cylindrotheca sp. strain Nl that strongly hybridized to a previously isolated Cylindrotheca fragment that contained the rbcS gene and flanking sequences. Subsequent determination of the oligonucleotide sequence of this second chloroplast DNA fragment, however, indicated that hybridization was due to identical sequences 3' to the previously cloned Cylindrotheca chloroplast rbcL rbcS genes. Sequences derived from the 5' end of the second chloroplast DNA fragment contained a short open reading frame of 80 amino acids which was found to be highly homologous to bacterial acyl carrier protein and nuclear-encoded acyl carrier protein from plants. Amino acid residues in the environment of Ser-36 of the Escherichia coli protein, which is bound to a 4'-phosphopantetheine moiety, are virtually identical in the Cylindrotheca deduced sequence and all other sources of this protein. Unlike plant acyl carrier-deduced amino acid sequences, there was no leader peptide sequence found for the presumptive Cylindrotheca protein, consistent with the location of this DNA fragment on the chloroplast genome of this organism. DNA encoding the putative acyl carrier protein gene and rbcS thus represent two genes that are chloroplast-encoded in the chromophytic marine diatom Cylindrotheca, a significant departure from the organization of such genes in plants.	OHIO STATE UNIV,DEPT MICROBIOL,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	Ohio State University; Ohio State University					NIGMS NIH HHS [GM24497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEREMAND PD, 1987, ARCH BIOCHEM BIOPHYS, V256, P90, DOI 10.1016/0003-9861(87)90428-0; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; COOPER CL, 1987, BIOCHEMISTRY-US, V26, P2740, DOI 10.1021/bi00384a013; DOUGLAS SE, 1991, NATURE, V350, P148, DOI 10.1038/350148a0; DOUGLAS SE, 1989, PLANT MOL BIOL, V13, P13, DOI 10.1007/BF00027331; GATENBY AA, 1985, EUR J BIOCHEM, V153, P355, DOI 10.1111/j.1432-1033.1985.tb09310.x; HALE RS, 1987, FEBS LETT, V224, P133, DOI 10.1016/0014-5793(87)80436-2; HANSEN L, 1987, CARLSBERG RES COMMUN, V52, P381, DOI 10.1007/BF02907526; HOJ PB, 1983, CARLSBERG RES COMMUN, V48, P285, DOI 10.1007/BF02911912; HOLAK TA, 1986, BIOCHEMISTRY-US, V25, P5766, DOI 10.1021/bi00367a063; HWANG SR, 1991, J BIOL CHEM, V266, P6271; HWANG SR, 1989, PLANT MOL BIOL, V13, P69, DOI 10.1007/BF00027336; KARLINNEUMANN GA, 1986, EMBO J, V5, P9, DOI 10.1002/j.1460-2075.1986.tb04170.x; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; NEWMAN SM, 1989, PLANT MOL BIOL, V11, P821; OHLROGGE JB, 1979, P NATL ACAD SCI USA, V76, P1194, DOI 10.1073/pnas.76.3.1194; OHLROGGE JB, 1978, ARCH BIOCHEM BIOPHYS, V189, P382, DOI 10.1016/0003-9861(78)90225-4; OHLROGGE JB, 1982, TRENDS BIOCHEM SCI, V7, P386, DOI 10.1016/0968-0004(82)90176-1; PALMER JD, 1982, CELL, V29, P537, DOI 10.1016/0092-8674(82)90170-2; PLATT MW, 1990, J BACTERIOL, V172, P5440, DOI 10.1128/jb.172.9.5440-5444.1990; POSTBEITTENMILLER MA, 1989, NUCLEIC ACIDS RES, V17, P1777, DOI 10.1093/nar/17.4.1777; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; REITH M, 1986, P NATL ACAD SCI USA, V83, P8599, DOI 10.1073/pnas.83.22.8599; ROSE RE, 1987, NUCLEIC ACIDS RES, V15, P7197, DOI 10.1093/nar/15.17.7197; SAFFORD R, 1988, EUR J BIOCHEM, V174, P287, DOI 10.1111/j.1432-1033.1988.tb14096.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER DE, 1987, PLANT MOL BIOL, V9, P127, DOI 10.1007/BF00015645; SCHWEIZER E, 1980, MULTIFUNCTIONAL PROT, P197; SIMONI RD, 1967, J BIOL CHEM, V242, P573; THOMPSON GA, 1981, REGULATION MEMBRANE, P20; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; VALENTIN K, 1989, CURR GENET, V16, P203, DOI 10.1007/BF00391478; VANAMAN TC, 1968, J BIOL CHEM, V243, P6420; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541	34	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13492	13494						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856188				2022-12-25	WOS:A1991FY02700007
J	JOHNSON, AW; KOLODNER, RD				JOHNSON, AW; KOLODNER, RD			STRAND EXCHANGE PROTEIN-1 FROM SACCHAROMYCES-CEREVISIAE - A NOVEL MULTIFUNCTIONAL PROTEIN THAT CONTAINS DNA STRAND EXCHANGE AND EXONUCLEASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; GENETIC-RECOMBINATION; ESCHERICHIA-COLI; MEIOTIC CELLS; PURIFICATION; HYDROLYSIS; SITE; ATP; EXORIBONUCLEASE; BINDING	Strand exchange protein 1 (Sep1) from Saccharomyces cerevisiae catalyzes the formation of heteroduplex DNA molecules from single-stranded circles and homologous linear duplex DNA in vitro. Previously, Sep1 was purified as a 132,000-Da species; however, DNA sequence analysis indicates that the SEP1 gene is capable of encoding a 175,000-Da protein (Tishkoff, D. X., Johnson, A. W., and Kolodner, R. D. (1991) Mol. Cell. Biol. 11, 2593-2608). The SEP1 gene was cloned into a GAL1O expression vector and expressed in a protease-deficient yeast strain. Intact Sepl, which migrated as a M(r)-160,000 polypeptide during sodium dodecyl sulfate-polyacrylamide gel electrophoresis, was purified to apparent homogeneity and shown to have activities similar to those of the originally purified M(r) = 132,000 fragment. We report here that, in addition to strand exchange activity, Sep1 contains an intrinsic exonuclease that is active on single- and double-stranded DNA with a severalfold preference for single-stranded DNA. The nuclease was induced in crude extracts upon induction with galactose, it co-purified with the strand exchange activity of Sep1, and the nuclease and strand exchange activities of Sep1 showed the same kinetics of heat inactivation. Sep1 nuclease, which requires Mg2+, can be functionally separated from the strand exchange activity by the substitution of Ca2+ for Mg2+. Under these conditions, the nuclease is inactive, and strand exchange activity is dependent on prior resection of the DNA ends by an exogenous exonuclease. Thus, the nuclease is necessary for synapsis but not strand exchange. Electron microscopic analysis revealed that true strand exchange products, alpha-molecules and nicked double-stranded circular molecules, were formed. In addition, strand transfer proceeded to similar extents on 5'-resected and 3'-resected DNA. This result suggests that the polarity of strand transfer by Sep1 is determined by the polarity of its intrinsic nuclease.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Johnson, Arlen/0000-0002-4742-085X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013594, R01GM029383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29383, GM13594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; BAUER GA, 1988, J BIOL CHEM, V263, P917; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERS PMJ, 1988, J BIOL CHEM, V263, P8099; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; CLEMENTS JE, 1978, J BIOL CHEM, V253, P2990; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; Kornberg A., 1980, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LOWENHAUPT K, 1989, J BIOL CHEM, V264, P20568; Maniatis T., 1982, MOL CLONING; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; Rogers S G, 1980, Methods Enzymol, V65, P201; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOLTIS DA, 1983, J BIOL CHEM, V258, P4073; STEVENS A, 1980, J BIOL CHEM, V255, P3080; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; VILLADSEN IS, 1982, J BIOL CHEM, V257, P8177; WEST SC, 1980, P NATL ACAD SCI-BIOL, V77, P2569, DOI 10.1073/pnas.77.5.2569; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	44	109	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14046	14054						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856231				2022-12-25	WOS:A1991FY02700092
J	OSBORNE, TF				OSBORNE, TF			SINGLE NUCLEOTIDE RESOLUTION OF STEROL REGULATORY REGION IN PROMOTER FOR 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; RECEPTOR GENE; ELEMENT; SEQUENCE; DNA; REPRESSION; BINDING	Sterol-dependent regulation of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase promoter was previously localized to a 42-base pair region containing an octamer sequene, referred to as the sterol regulatory element (SRE-1). A similar motif is found in the region of DNA that is required for sterol-dependent regulation of the HMG-CoA synthase and low density lipoprotein receptor genes. Single nucleotide substitution analyses of the low density lipoprotein receptor and HMG-CoA synthase promoters confirmed that the SRE-1 is an important sterol regulatory motif. In the current studies, a series of single nucleotide mutations were introduced into the HMG-COA reductase regulatory region and transfected into Chinese hamster ovary cells. RNA produced by each mutant promoter was then measured in the presence or absence of sterols. Thirty-seven independent mutations were analyzed, and two separate domains were identified as being critical. One essential region was spread over 10 bases and contained half of the SRE-1; however, the other half of the SRE-1 was not important for sterol regulation. The second essential region spanned four contiguous bases. These two critical elements are separated from each other by three nonessential bases. The results are interpreted to suggest that regulation of HMG-CoA reductase gene transcription by sterols requires additional or possibly separate factors from those required for sterol regulation of the low density lipoprotein receptor and HMG-CoA synthase promoters.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GIL G, 1988, J BIOL CHEM, V263, P19009; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; Stadtman E.R., 1970, ENZYMES, V1, P397; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	18	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13947	13951						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856223				2022-12-25	WOS:A1991FY02700078
J	SAFRAN, M; FARWELL, AP; LEONARD, JL				SAFRAN, M; FARWELL, AP; LEONARD, JL			EVIDENCE THAT TYPE-II 5'-DEIODINASE IS NOT A SELENOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IODOTHYRONINE 5'-DEIODINASE; GLUTATHIONE-PEROXIDASE; EPITHELIAL-CELLS; RAT-KIDNEY; SELENIUM; ASTROCYTES; CULTURE; GROWTH; LIVER	Brain type II 5'-iodothyronine deiodinase and liver type I 5'-iodothyronine deiodinase activities are decreased in rats fed a Se2+-deficient diet suggesting that both enzymes are Se2+-dependent proteins. Since serum thyroxine (T4) concentrations are twice normal in the Se2+ -deficient animals, it is unclear whether the Se2+ deficiency or the increased circulating T4 account for the decrease in the brain enzyme. In order to separate these two possibilities, the effects of Se2+ on 5'-deiodinase in glial cells (type II) and LLC-PK1 cells (type I) were examined. LLC-PK1 and glial cells were grown in serum-free defined medium containing 0, 1 pm, 10 nm, and 40 nm Se2+ for 3-5 days or in medium containing (Se2+)-Se-75 for 24 h. Deiodinase isozymes were determined by measuring catalytic activity and by quantification of the BrAc[I-125]T4 affinity-labeled substrate binding subunits. Se2+ deficiency was confirmed by measuring the activity of the selenoprotein, glutathione peroxidase. Se2+ caused a concentration-dependent increase in glutathione peroxidase activity in both cell types, as well as in the type I enzyme, but had no effect on the type II enzyme. LLC-PK1 cells contained multiple (Se2+)-Se-75-labeled proteins including the 27-kDa substrate binding subunit of the type I 5'-deiodinase. Glial cells contained seven (Se2+)-Se-75-labeled proteins ranging in size from 12 to 62 kDa, none of which corresponded to the type II substrate binding subunit. These data show that, unlike the type I enzyme, the type II enzyme does not contain a selenocysteine or selenomethionine, further emphasizing the differences between these two isozymes.			SAFRAN, M (corresponding author), UNIV MASSACHUSETTS,SCH MED,DIV ENDOCRINOL,MOLEC ENDOCRINOL LAB,55 LAKE AVE N,WORCESTER,MA 01655, USA.			Farwell, Alan/0000-0001-7716-2719	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038772, P30DK032520, K08DK002005] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38772, DK32520, DK02005] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTHUR JR, 1990, BIOCHEM J, V272, P537, DOI 10.1042/bj2720537; ARTHUR JR, 1988, RES VET SCI, V45, P122, DOI 10.1016/S0034-5288(18)30906-8; BECKETT GJ, 1989, BIOCHEM J, V259, P887, DOI 10.1042/bj2590887; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; CHADA S, 1989, BLOOD, V74, P2535; CHUMAN L, 1982, J CELL BIOL, V94, P506, DOI 10.1083/jcb.94.3.506; COURTIN F, 1986, MOL CELL ENDOCRINOL, V48, P167, DOI 10.1016/0303-7207(86)90039-0; DANIELSON KG, 1986, CANCER RES, V46, P4582; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; Kaplan MM, 1986, THYROID HORMONE META, P231; KOEHRLE J, 1990, Journal of Biological Chemistry, V265, P6155; KOEHRLE J, 1990, J BIOL CHEM, V265, P6146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD JL, 1991, J BIOL CHEM, V266, P11262; LEONARD JL, 1980, ENDOCRINOLOGY, V106, P444, DOI 10.1210/endo-106-2-444; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; LEONARD JL, 1980, ENDOCRINOLOGY, V107, P1376, DOI 10.1210/endo-107-5-1376; LEONARD JL, 1984, BIOCHIM BIOPHYS ACTA, V787, P122, DOI 10.1016/0167-4838(84)90070-0; Leonard JL, 1986, THYROID HORMONE META, P189; MORRISON RS, 1981, P NATL ACAD SCI-BIOL, V78, P7205, DOI 10.1073/pnas.78.11.7205; RFARWELL AP, 1989, J BIOL CHEM, V264, P20561; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; VISSER TJ, 1983, MOL CELL ENDOCRINOL, V33, P321, DOI 10.1016/0303-7207(83)90177-6; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; VISSER TJ, 1983, J CLIN INVEST, V71, P991; Wendel A, 1989, SELENIUM BIOL MED	27	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13477	13480						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856186				2022-12-25	WOS:A1991FY02700003
J	STRANDBERG, L; LAWRENCE, DA; JOHANSSON, LBA; NY, T				STRANDBERG, L; LAWRENCE, DA; JOHANSSON, LBA; NY, T			THE OXIDATIVE INACTIVATION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 RESULTS FROM A CONFORMATIONAL CHANGE IN THE MOLECULE AND DOES NOT REQUIRE THE INVOLVEMENT OF THE P1' METHIONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; BOVINE ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; BINDING-PROTEIN; HUMAN ALPHA-2-ANTIPLASMIN; REACTIVE SITE; PURIFICATION; PLASMA; DNA; NEUTROPHILS	Plasminogen activator inhibitor 1 (PAI-1) is sensitive to oxidative inactivation, and it has been suggested that specific oxidation of a methionine residue, Met347, situated in the P1' position of the reactive center may be the cause of the inactivation. To test this hypothesis we have purified and biochemically characterized mutant proteins of PAI-1 in which Met347 and either of two other methionines, Met266 or Met354, has been replaced with oxidation-resistant valine residues. The mutant proteins were found to be equally sensitive to oxidation as wild-type PAI-1, suggesting that a specific oxidation of the P1' Met347 is not responsible for the inactivation. When PAI-1 was oxidized, circular dichroism analysis revealed a rapid conformational change that correlated to the loss of inhibitory activity. The oxidation sensitivity of PAI-1 was enhanced dramatically in the presence of 0.001% sodium dodecyl sulfate, and the circular dichroism spectrum was significantly different from that of untreated PAI-1, suggesting that the increased sensitivity to oxidation may be caused by a conformational change in the inhibitor molecule. Taken together, our data suggest that the oxidative inactivation of PAI-1 is not caused by the specific oxidation of the P1' methionine but results from a conformational change in the protein structure.	UMEA UNIV, DEPT APPL CELL & MOLEC BIOL, S-90187 UMEA, SWEDEN; UMEA UNIV, DEPT PHYS CHEM, S-90187 UMEA, SWEDEN	Umea University; Umea University				Lawrence, Daniel/0000-0003-3126-1935				ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOSTROM S, 1990, THROMB RES, V59, P851, DOI 10.1016/0049-3848(90)90398-V; BOSWELL DR, 1988, BIOESSAYS, V8, P83, DOI 10.1002/bies.950080209; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BRODIN P, 1986, BIOCHEMISTRY-US, V25, P5371, DOI 10.1021/bi00367a004; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; GLOOR S, 1986, CELL, V47, P687; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HALLIWELL B, 1989, FREE RADICAL BIO MED, P15; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEEB MJ, 1987, J BIOL CHEM, V262, P15813; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOLMBERG L, 1978, BIOCHIM BIOPHYS ACTA, V544, P128, DOI 10.1016/0304-4165(78)90216-7; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HSUEH AJW, 1988, MEIOTIC INHIBITION M, P227; JIRGENSONS B, 1981, MAKROMOL CHEM-RAPID, V2, P213; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1986, BIOCHEMISTRY-US, V25, P6351, DOI 10.1021/bi00369a001; LEVIN EG, 1987, BLOOD, V70, P1090; Lindman B, 1980, Top Curr Chem, V87, P1; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PERLMUTTER DH, 1989, AM J P HYSL, V257, pL142; RIJKEN DC, 1988, PHYSL CLIN ASPECTS, V1, P101; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; SHINGLER V, 1989, J GEN MICROBIOL, V135, P1083; STIEF TW, 1988, THROMB RES, V50, P559, DOI 10.1016/0049-3848(88)90204-6; STIEF TW, 1988, THROMB RES, V49, P581, DOI 10.1016/0049-3848(88)90255-1; STUMP DC, 1986, J BIOL CHEM, V261, P2759; TRAVIS J, 1985, J BIOL CHEM, V260, P4384; TRISLER P, 1984, J BACTERIOL, V160, P184, DOI 10.1128/JB.160.1.184-191.1984; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WEISS SJ, 1984, J CLIN INVEST, V73, P1297, DOI 10.1172/JCI111332; WIMAN B, 1988, THROMB HAEMOSTASIS, V59, P392	64	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13852	13858						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856219				2022-12-25	WOS:A1991FY02700064
J	ZAVITZ, KH; DIGATE, RJ; MARIANS, KJ				ZAVITZ, KH; DIGATE, RJ; MARIANS, KJ			THE PRIB AND PRIC REPLICATION PROTEINS OF ESCHERICHIA-COLI - GENES, DNA-SEQUENCE, OVEREXPRESSION, AND PURIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PBR322 DNA; FACTOR-Y; PRIMOSOME; DIRECTION; HELICASE; CLONING; MAP; N'	The Escherichia coli DNA replication proteins n and n" function in vitro in the assembly of the primosome, a mobile multiprotein replication priming complex thought to operate on the lagging-strand template at the E. coli DNA replication fork. Both proteins have been purified from E. coli HMS83 cells based on their requirement for the reconstitution of bacteriophage phi-X174 complementary strand DNA synthesis in vitro with purified proteins. As a step toward understanding the role of these proteins in vivo, the genes for primosomal proteins n and n", designated priB and priC, respectively, have been cloned molecularly. priB encodes a 104-amino acid 11.4-kDa polypeptide and corresponds to a previously identified open reading frame between rpsF and rpsR within a ribosomal protein operon at 95.5 min on the E. coli chromosome. priC encodes a 175-amino acid 20.3-kDa polypeptide. These two gene products were overexpressed at least 1000-fold in E. coli using a bacteriophage T7 transient expression system. Both proteins have been purified to apparent homogeneity from extracts prepared from these overproducing strains.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University	ZAVITZ, KH (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAZUA P, 1984, J BIOL CHEM, V259, P14286; Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; CAMPBELL JL, 1972, P NATL ACAD SCI USA, V69, P2090, DOI 10.1073/pnas.69.8.2090; GREENBAUM JH, 1984, J BIOL CHEM, V259, P2595; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KONIGSBERG W, 1983, P NATL ACAD SCI-BIOL, V80, P687, DOI 10.1073/pnas.80.3.687; Kornberg A., 1980, DNA REPLICATION; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARK CA, 1978, J BACTERIOL, V136, P1008, DOI 10.1128/JB.136.3.1008-1017.1978; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE MS, 1989, J BIOL CHEM, V264, P14531; LOW RL, 1982, J BIOL CHEM, V257, P6242; Maniatis T., 1982, MOL CLONING; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MASAI H, 1986, P NATL ACAD SCI USA, V83, P1256, DOI 10.1073/pnas.83.5.1256; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; SCHNIER J, 1986, MOL GEN GENET, V204, P126, DOI 10.1007/BF00330199; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SMILEY BL, 1982, P NATL ACAD SCI-BIOL, V79, P4550, DOI 10.1073/pnas.79.15.4550; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C	31	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13988	13995						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856227				2022-12-25	WOS:A1991FY02700084
J	BAIRD, P; WADEY, R; COWELL, J				BAIRD, P; WADEY, R; COWELL, J			LOSS OF HETEROZYGOSITY FOR CHROMOSOME REGION 11P15 IN WILMS-TUMORS IS NOT RELATED TO HRAS GENE TRANSFORMING MUTATIONS	ONCOGENE			English	Note							BECKWITH-WIEDEMANN SYNDROME; TUMORS; EXPRESSION; CARCINOMA; DELETION; ANIRIDIA; ALLELES; ASSOCIATION; ONCOGENE; LOCUS	Although a candidate Wilms' tumour gene-WT1-has been identified in chromosome region 11p13, there is strong evidence from loss of heterozygosity studies suggesting that a second relevant gene is present in region 11p15. The Harvey-Ras proto-oncogene also lies in this region. In other types of tumours mutations in RAS genes have been associated with the development and/or progression of a number of tumour types. We therefore analysed the sequence of the Ras oncogene for possible mutations in six Wilms' tumours showing loss of heterozygosity for chromosome region 11p15. No tumour analysed showed HRAS sequence mutations. We conclude that loss of heterozygosity at 11p15 does not implicate HRAS mutations in the molecular pathogenesis of Wilms' tumour.			BAIRD, P (corresponding author), INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,LONDON WC1N 1EH,ENGLAND.			Cowell, John/0000-0002-2079-5950; Baird, Paul/0000-0002-1305-3502				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1990, ONCOGENE, V5, P893; Beckwith JB, 1963, W SOC PEDIAT RES; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; Maniatis T., 1982, MOL CLONING; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MATSUNAGA E, 1981, HUM GENET, V57, P231; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; TURLEAU C, 1984, HUM GENET, V67, P219, DOI 10.1007/BF00273006; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WADEY RB, 1990, ONCOGENE, V5, P901; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WIEDEMANN H. R., 1964, J GENET HUM, V13, P223; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	29	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1147	1149						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861864				2022-12-25	WOS:A1991GV26000008
J	BALZARINI, J; DECLERCQ, E				BALZARINI, J; DECLERCQ, E			5-PHOSPHORIBOSYL 1-PYROPHOSPHATE SYNTHETASE CONVERTS THE ACYCLIC NUCLEOSIDE PHOSPHONATES 9-(3-HYDROXY-2-PHOSPHONYLMETHOXYPROPYL)ADENINE AND 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE DIRECTLY TO THEIR ANTIVIRALLY ACTIVE DIPHOSPHATE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ERYTHROCYTE PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE; MURINE SARCOMA-VIRUS; ANTIRETROVIRUS ACTIVITY; SUBUNIT ASSOCIATION; INVITRO; INVIVO; REPLICATION; POTENT; AGENT; INHIBITION	The acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) are potent inhibitors of DNA viruses and retroviruses, respectively. Unlike nucleoside triphosphates, the metabolically active (diphosphorylated) forms of HPMPA and PMEA (designated HPMPApp and PMEApp) are synthesized in a reversible reaction in which the pyrophosphate group of 5-phosphoribosyl 1-pyrophosphate (PRPP) is directly transferred to HPMPA and PMEA by purified PRPP synthetase. In this respect, PRPP synthetase does not act stereospecifically in that it recognizes both the S-enantiomer and the R-enantiomer of HPMPA as substrate. PRPP synthetase also recognizes other acyclic adenine and 2,6-diaminopurine riboside phosphonates as a substrate. It is now imperative to evaluate the potential role of PRPP synthetase, as activating enzyme, in the antiviral action of this type of molecules in intact cells.			BALZARINI, J (corresponding author), CATHOLIC UNIV LEUVEN, REGA INST MED RES, B-3000 LOUVAIN, BELGIUM.			De Clercq, Erik/0000-0002-2985-8890				BABA M, 1987, EUR J CLIN MICROBIOL, V6, P158, DOI 10.1007/BF02018198; BABA M, 1987, ANTIMICROB AGENTS CH, V31, P337, DOI 10.1128/AAC.31.2.337; BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332; BALZARINI J, 1990, INT J CANCER, V46, P337, DOI 10.1002/ijc.2910460233; BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P1499, DOI 10.1073/pnas.88.4.1499; BALZARINI J, 1991, AIDS, V5, P21, DOI 10.1097/00002030-199101000-00003; BALZARINI J, 1990, INT J CANCER, V45, P486, DOI 10.1002/ijc.2910450319; BALZARINI J, 1991, IN PRESS P NATL ACAD; BECKER MA, 1977, J BIOL CHEM, V252, P3911; DECLERCQ E, 1987, ANTIVIR RES, V8, P261; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; EGBERINK H, 1990, P NATL ACAD SCI USA, V87, P3087, DOI 10.1073/pnas.87.8.3087; ELLIS DB, 1965, CAN J BIOCHEM CELL B, V43, P617, DOI 10.1139/o65-071; FOX IH, 1972, J BIOL CHEM, V247, P2126; GANGEMI JD, 1989, ANTIMICROB AGENTS CH, V33, P1864, DOI 10.1128/AAC.33.11.1864; KELLEY WN, 1970, CLIN RES, V18, P457; LIN JC, 1987, ANTIMICROB AGENTS CH, V31, P1431, DOI 10.1128/AAC.31.9.1431; MEYER LJ, 1977, J BIOL CHEM, V252, P3919; NAESENS L, 1989, EUR J CLIN MICROBIOL, V8, P1043, DOI 10.1007/BF01975167; NORD LD, 1989, BIOCHEM PHARMACOL, V38, P3543; PALELLA TD, 1990, METABOLIC BASIS INHE, V1, P965; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; SABINA RL, 1984, SCIENCE, V223, P1193, DOI 10.1126/science.6199843; SNOECK R, 1988, ANTIMICROB AGENTS CH, V32, P1839, DOI 10.1128/AAC.32.12.1839; SWITZER RL, 1971, J BIOL CHEM, V246, P2447; TYRSTED G, 1968, BIOCHIM BIOPHYS ACTA, V155, P619, DOI 10.1016/0005-2787(68)90209-8; WILLIS RC, 1989, ADV ENZYME REGUL, V28, P167; YEN RCK, 1981, J BIOL CHEM, V256, P1839; YOKOTA T, 1991, ANTIMICROB AGENTS CH, V35, P394, DOI 10.1128/AAC.35.2.394; YOKOTA T, 1990, ANTIMICROB AGENTS CH, V34, P1326, DOI 10.1128/AAC.34.7.1326	30	72	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8686	8689						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851154				2022-12-25	WOS:A1991FM03800011
J	CHOUDHURY, GG; WANG, LM; PIERCE, J; HARVEY, SA; SAKAGUCHI, AY				CHOUDHURY, GG; WANG, LM; PIERCE, J; HARVEY, SA; SAKAGUCHI, AY			A MUTATIONAL ANALYSIS OF PHOSPHATIDYLINOSITOL-3-KINASE ACTIVATION BY HUMAN COLONY-STIMULATING FACTOR-I RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR-I RECEPTOR; HEMATOPOIETIC GROWTH-FACTORS; TYROSINE KINASE-ACTIVITY; PDGF RECEPTOR; SIGNAL TRANSDUCTION; FACTOR CSF-1; PROTEIN; CELLS; PHOSPHORYLATION	Colony-stimulating factor-1 (CSF1) is a cell lineage-specific hemopoietin required for the growth, differentiation, and survival of macrophages and their precursors. The human CSF1 receptor (CSF1R) is a 150-kDa transmembrane glycoprotein whose cytoplasmic tyrosine kinase domain is split by a kinase insert (KI) region of approximately 70 amino acids. We tested the ability of CSF1R KI domain deletion mutants to stimulate phosphatidylinositol-3-kinase (PtdIns-3-kinase), an enzyme whose activity is augmented by tyrosine kinase oncogenes and receptor tyrosine kinases, and to support mitogenesis in transfected cells. Receptor immunoprecipitates from CSF1-stimulated cells contained > 5-fold more PtdIns-3-kinase activity compared to nonstimulated cells. High performance liquid chromatography analysis of the PtdIns-3-kinase product scraped from thin layer chromatography plates indicated that PtdIns-3-P was produced. CSF1R KI domain deletion mutants retained tyrosine kinase activity in vitro. Receptor immunoprecipitates of two partially overlapping 28 and 30 amino acid KI deletion mutants of CSF1R retained some PtdIns-3-kinase activity, in contrast to immunoprecipitates of CSF1R lacking 67 amino acids of the KI domain. Each deletion mutant stimulated CSF1-dependent DNA synthesis in transfected cells at much reduced levels compared to wild-type receptor expressing cells. These data suggest a role for the CSF1R KI domain in PtdIns-3-kinase association and for CSF1-induced thymidine incorporation into DNA.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL INSTITUTE ON AGING [P01AG006872] Funding Source: NIH RePORTER; NIA NIH HHS [P01-AG06872] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOUDHURY GG, 1990, BIOCHEM BIOPH RES CO, V172, P154, DOI 10.1016/S0006-291X(05)80186-X; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hartmann T, 1990, GROWTH FACTORS, V2, P289; HUHN RD, 1989, J CELL BIOCHEM, V39, P129, DOI 10.1002/jcb.240390205; Jubinsky P T, 1988, Adv Exp Med Biol, V234, P75; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MORGAN CJ, 1984, BIOCHEM BIOPH RES CO, V119, P35, DOI 10.1016/0006-291X(84)91614-0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; SUGIMOTO Y, 1985, MOL CELL BIOL, V5, P3194, DOI 10.1128/MCB.5.11.3194; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WANG LM, 1989, BIOTECHNIQUES, V7, P1000; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268	47	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8068	8072						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850734				2022-12-25	WOS:A1991FK44100020
J	TAKAHASHI, SI; CONTI, M; PROKOP, C; VANWYK, JJ; EARP, HS				TAKAHASHI, SI; CONTI, M; PROKOP, C; VANWYK, JJ; EARP, HS			THYROTROPIN AND INSULIN-LIKE GROWTH FACTOR-I REGULATION OF TYROSINE PHOSPHORYLATION IN FRTL-5 CELLS - INTERACTION BETWEEN CAMP-DEPENDENT AND GROWTH FACTOR-DEPENDENT SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID FOLLICULAR CELL; KINASE-ACTIVITY; PROTEIN-KINASE; EPITHELIAL-CELLS; RECEPTOR; STIMULATION; CULTURE; ADENOSINE-3',5'-MONOPHOSPHATE; PHOSPHOTYROSINE; GLYCOPROTEIN	Pretreatment of rat FRTL-5 thyroid cells with thyrotropin (TSH) markedly potentiated the mitogenic response to insulin-like growth factor I (IGF-I) (Tramontano, D., Moses, A. C., Veneziani, B. M., and Ingbar, S. H. (1988) Endocrinology 122, 127-132; Takahashi, S.-I., Conti, M., and Van Wyk, J. J. (1990) Endocrinology 126, 736-745). The present study was undertaken to determine whether this synergism between TSH and IGF-I in FRTL-5 cells was correlated with changes in tyrosine phosphorylation of intracellular proteins. Tyrosine phosphorylation in intact cells was determined by gel electrophoresis and immunoblotting using monospecific anti-phosphotyrosine antibodies. Cells were preincubated for up to 24 h with TSH, dibutyryl cAMP, forskolin, or cholera toxin and then incubated for an additional 1 min in the absence or presence of IGF-I. As reported by others, IGF-I rapidly increased tyrosine phosphorylation of a 175-kDa protein as well as a less intense band of 90-100 kDa. Pretreatment for 6-12 h with either TSH or other agents that elevate intracellularcAMP potentiated the IGF-I-dependent tyrosine phosphorylation of the 175-kDa substrate by 3-5-fold. Since TSH did not increase IGF receptor number or kinase activity, the effect of TSH is assumed to be exerted at a step distal to IGF receptor tyrosine kinase. Surprisingly, IGF-I-independent tyrosine phosphorylation was also increased by pretreatment with TSH. When intact cells were analyzed TSH produced a time- and concentration-dependent increase in tyrosine phosphorylation of a prominent 120-125-kDa substrate and less prominent 100- and 80-kDa substrates. Assays using Triton X-100-soluble extracts incubated with MgCl2, ATP, and orthovanadate demonstrated that TSH pretreatment increased tyrosine phosphorylation over that observed in untreated cells. In this cell-free assay, TSH pretreatment enhanced the phosphorylation of multiple substrates. These studies suggest that a cAMP stimulus that initiates a trophic effect can be propagated indirectly through multiple pathways including enhancement of tyrosine phosphorylation.	UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,REPROD BIOL LABS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	VANWYK, JJ (corresponding author), UNIV N CAROLINA,DEPT PEDIAT,CB 7220,CHAPEL HILL,NC 27599, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031683] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 20788] Funding Source: Medline; NIDDK NIH HHS [DK 1022-33, DK31683] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BEGUINOT F, 1989, ENDOCRINOLOGY, V125, P1599, DOI 10.1210/endo-125-3-1599; BEGUINOT F, 1987, DIABETES, V36, P312; BRENNERGATI L, 1989, ENDOCRINOLOGY, V125, P1315, DOI 10.1210/endo-125-3-1315; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CONDORELLI G, 1989, J BIOL CHEM, V264, P12633; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FURLANETTO RW, 1977, J CLIN INVEST, V60, P648, DOI 10.1172/JCI108816; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P237, DOI 10.1113/jphysiol.1967.sp008298; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; ISOZAKI O, 1987, MOL ENDOCRINOL, V1, P839, DOI 10.1210/mend-1-11-839; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; TRAMONTANO D, 1987, ENDOCRINOLOGY, V120, P785; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WHARTON W, 1982, J CELL PHYSIOL, V111, P201, DOI 10.1002/jcp.1041110212; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7834	7841						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850422				2022-12-25	WOS:A1991FJ34200081
J	CHEN, WY; BAHL, OP				CHEN, WY; BAHL, OP			RECOMBINANT CARBOHYDRATE VARIANT OF HUMAN CHORIOGONADOTROPIN BETA-SUBUNIT (HCG-BETA) DESCARBOXYL TERMINUS (115-145) - EXPRESSION AND CHARACTERIZATION OF CARBOXYL-TERMINAL DELETION MUTANT OF HCG-BETA IN THE BACULOVIRUS SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; ALPHA-SUBUNIT; PURIFICATION; UNITS; DNA; LOCATION	A recombinant analog of human choriogonadotropin beta-subunit descarboxyl-terminal peptide (115-145 residues, delhCG-beta) was obtained by the expression of corresponding beta-cDNA in the baculovirus expression system. The efficiency of expression and secretion was high. The recombinant delhCG-beta was purified by immunoaffinity using a specific monoclonal antibody against hCG-beta and reverse phase high performance liquid chromatography. The hCG-beta analog lacked the carboxyl-terminal 31-residue peptide as well as the four O-linked carbohydrates. Also, the N-linked "complex" type carbohydrates in the deletion mutant were modified to the high mannose type. The apparent molecular weights of delhCG-beta in sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing and nonreducing conditions were found to be 19,000 and 27,500 respectively. delhCG-beta on hydrolysis with endo N-acetylglucosaminidase F or H yielded a 17,500 protein band whereas treatment with N-glycanase gave a protein band with a molecular weight of 16,000. The carbohydrate analysis of delhCG-beta, calculated on the basis of 4 residues of N-acetylglucosamine, showed 3 or 4 fucose, 0.6 N-acetylgalactosamine, and 11.4 mannose residues, indicating the high mannose type structures of the two N-linked carbohydrate chains. Despite the carbohydrate modification of the N-linked carbohydrates and the carboxyl-terminal deletion, the delhCG-beta had about 87% of the immunological activity of the native hCG-beta, indicating no significant conformational alteration induced by the mutation. The delhCG-beta combined readily with native hCG-alpha, and the reconstituted hCG-alpha-del-beta required 0.031 pmol to achieve 50% inhibition of binding of the tracer with rat lutropin/choriogonadotropin receptor compared with 0.039 pmol by native hCG. Like native hCG, hCG-alpha-del-beta also had most comparable ability to stimulate cAMP accumulation and progesterone production in rat Leydig cells. Thus it is clear from the data that the carboxyl-terminal deletion and thereby the deletion of four O-linked carbohydrates had no effect on its in vitro immunological and biological properties.			CHEN, WY (corresponding author), SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; BURAND JP, 1980, VIROLOGY, V101, P286, DOI 10.1016/0042-6822(80)90505-X; CARSTENS EB, 1980, VIROLOGY, V101, P311, DOI 10.1016/0042-6822(80)90511-5; CHEN WY, 1991, J BIOL CHEM, V266, P4081; COLE LA, 1987, MOL CELL ENDOCRINOL, V50, P45, DOI 10.1016/0303-7207(87)90076-1; ELDEIRY S, 1989, MOL ENDOCRINOL, V3, P1523, DOI 10.1210/mend-3-10-1523; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; KESSLER MJ, 1979, J BIOL CHEM, V254, P7909; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6345; PARSONS TF, 1983, J BIOL CHEM, V258, P240; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAIRAM MR, 1985, SCIENCE, V229, P65, DOI 10.1126/science.2990039; SHEN QX, 1990, MOL CELL ENDOCRINOL, V72, P167, DOI 10.1016/0303-7207(90)90141-T; SOJAR HT, 1989, J BIOL CHEM, V264, P2552	18	32	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6246	6251						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848851				2022-12-25	WOS:A1991FE37300039
J	COOK, RJ; LLOYD, RS; WAGNER, C				COOK, RJ; LLOYD, RS; WAGNER, C			ISOLATION AND CHARACTERIZATION OF CDNA CLONES FOR RAT-LIVER 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE-BINDING-PROTEIN; GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; MITOCHONDRIAL ALDEHYDE DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; C1-TETRAHYDROFOLATE SYNTHASE; CYTOPLASMIC ISOENZYME; TRIFUNCTIONAL ENZYME; HORSE LIVER; CYTOSOL-I	We have isolated and characterized cDNA clones encoding rat liver cytosol 10-formyltetrahydrofolate dehydrogenase (EC 1.5.1.6). An open reading frame of 2706 base pairs encodes for 902 amino acids of M(r) 99,015. The deduced amino acid sequence contains exact matches to the NH2-terminal sequence (28 residues) and the sequences of five peptides derived from cyanogen bromide cleavage of the purified protein. The amino acid sequence of 10-formyltetrahydrofolate dehydrogenase has three putative domains. The NH2-terminal sequence (residues 1-203) is 24-30% identical to phosphoribosylglycinamide formyltransferase (EC 2.1.2.2) from Bacillus subtilis (30%), Escherichia coli (24%), Drosophila melanogaster (24%), and human hepatoma HepG2 (27%). Residues 204-416 show no extensive homology to any known protein sequence. Sequence 417-900 is 46% (mean) identical to the sequences of a series of aldehyde dehydrogenase (NADP+) (EC 1.2.1.3). Intact 10-formyltetrahydrofolate dehydrogenase exhibits NADP-dependent aldehyde dehydrogenase activity. The sequence identity to phosphoribosylglycinamide formyltransferase is discussed, and a binding region for 10-formyltetrahydrofolate is proposed.	VANDERBILT UNIV, CTR MOLEC TOXICOL, SCH MED, NASHVILLE, TN 37232 USA; VET ADM MED CTR, NASHVILLE, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	COOK, RJ (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.			Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015289, R37DK015289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 15289] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARLOWE C K, 1988, Biofactors, V1, P171; CASE GL, 1988, J BIOL CHEM, V263, P10204; CHABNER B A, 1986, P945; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOK RJ, 1986, METHOD ENZYMOL, V122, P251; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; COOK RJ, 1984, J BIOL CHEM, V259, P2475; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; HEMPEL J, 1985, EUR J BIOCHEM, V153, P13, DOI 10.1111/j.1432-1033.1985.tb09260.x; HEMPEL J, 1984, EUR J BIOCHEM, V141, P21, DOI 10.1111/j.1432-1033.1984.tb08150.x; HENIKOFF S, 1983, NUCLEIC ACIDS RES, V11, P789, DOI 10.1093/nar/11.3.789; HENIKOFF S, 1983, CELL, V34, P405, DOI 10.1016/0092-8674(83)90374-4; HSU LC, 1985, P NATL ACAD SCI USA, V82, P3771, DOI 10.1073/pnas.82.11.3771; Hsu LC, 1988, GENOMICS, V2, P57, DOI 10.1016/0888-7543(88)90109-7; HUM DW, 1988, J BIOL CHEM, V263, P15946; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P6678, DOI 10.1021/bi00480a018; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P1436, DOI 10.1021/bi00458a014; JOHANSSON J, 1988, EUR J BIOCHEM, V172, P527, DOI 10.1111/j.1432-1033.1988.tb13920.x; JOHLIN FC, 1989, MOL PHARMACOL, V35, P745; JONES DE, 1988, P NATL ACAD SCI USA, V85, P1782, DOI 10.1073/pnas.85.6.1782; KOK M, 1989, J BIOL CHEM, V264, P5442; KREBS HA, 1976, BIOCHEM J, V158, P341, DOI 10.1042/bj1580341; KRZYWICKI KA, 1984, MOL CELL BIOL, V4, P2837, DOI 10.1128/MCB.4.12.2837; KUTZBACH C, 1968, BIOCHEM BIOPH RES CO, V30, P111, DOI 10.1016/0006-291X(68)90456-7; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LINDAHL R, 1984, BIOCHEM PHARMACOL, V33, P3383, DOI 10.1016/0006-2952(84)90109-6; LOVELL CR, 1990, BIOCHEMISTRY-US, V29, P5687, DOI 10.1021/bi00476a007; Maniatis T., 1982, MOL CLONING; MCMARTIN KE, 1977, J PHARMACOL EXP THER, V201, P564; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; NEEDLEMAN S, 1979, J MOL BIOL, V48, P444; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; Pietruszko R, 1981, Methods Enzymol, V71 Pt C, P772; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P4034, DOI 10.1021/bi00517a013; SMITH JM, 1987, J BIOL CHEM, V262, P10565; STABEN C, 1986, J BIOL CHEM, V261, P4629; STURA EA, 1989, J BIOL CHEM, V264, P9703; THIGPEN AE, 1990, J BIOL CHEM, V265, P7907; VONBAHRLINDSTROM H, 1984, EUR J BIOCHEM, V141, P37; WAGNER C, 1989, FASEB J, V3, pA1059; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; WHITEHEAD TR, 1988, J BACTERIOL, V170, P3255, DOI 10.1128/jb.170.7.3255-3261.1988; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258	52	99	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4965	4973						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848231				2022-12-25	WOS:A1991FC21700046
J	BAULDRY, SA; BASS, DA; COUSART, SL; MCCALL, CE				BAULDRY, SA; BASS, DA; COUSART, SL; MCCALL, CE			TUMOR-NECROSIS-FACTOR-ALPHA PRIMING OF PHOSPHOLIPASE-D IN HUMAN NEUTROPHILS - CORRELATION BETWEEN PHOSPHATIDIC-ACID PRODUCTION AND SUPEROXIDE GENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; PROTEIN KINASE-C; STIMULATED HUMAN-NEUTROPHILS; RESPIRATORY BURST; HUMAN-GRANULOCYTES; POLYMORPHONUCLEAR LEUKOCYTES; ANION PRODUCTION; NADPH OXIDASE; LEU-PHE; DIACYLGLYCEROL	Tumor necrosis factor-alpha (TNF) primes human neutrophils (PMN) for enhanced superoxide (O2-) production if cells are subsequently stimulated with the chemotactic peptide, n-formyl-Met-Leu-Phe (fMLP). fMLP activates phospholipase D to form phosphatidic acid (PA), and a correlation may exist between PA production and O2- generation in PMN. Therefore, we assessed the ability of TNF to prime phospholipase D activation in PMN stimulated with fMLP. TNF (100 units/ml) pretreatment primed enhanced PA production in PMN challenged with 1-mu-M fMLP, in the absence of cytochalasin B, as demonstrated by increased production of tritiated PA from PMN label with 1-O-[9', 10'-H-3]hexadecyl-2-lyso-sn-glycero-3-phosphocholine ([H-3]LPAF) and by increased PA mass. PA was formed via activation of phospholipase D and occurred with minimal production of diglycerides. Production of O2- was also enhanced in identically treated cells, and we demonstrated a direct correlation between enhanced PA formation and O2- production. Conversely, ethanol inhibition of PA formation led to a comparable reduction in O2- generation. This report of priming of phospholipase D by physiological agonists is the only natural system where enhanced PA formation has been dissociated from diglyceride formation. Our results suggest a link between PA production and NADPH oxidase activation in human PMN.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,INFECT DIS SECT,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	BAULDRY, SA (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,PULM CRIT CARE SECT,WINSTON SALEM,NC 27103, USA.				NIAID NIH HHS [AI 09169, AI 14929, AI 10732] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI009169, R01AI014929, R01AI009169, R01AI010732] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AGWU DE, 1989, J BIOL CHEM, V264, P1405; AVIRAM I, 1989, BIOCHEM BIOPH RES CO, V161, P712, DOI 10.1016/0006-291X(89)92658-2; BASS DA, 1988, J BIOL CHEM, V263, P19610; BASS DA, 1987, J BIOL CHEM, V262, P6643; BAULDRY SA, 1990, CLIN RES, V38, pA395; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BEUTLER B, 1990, HOSP PRACT, V25, P45; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; COX CC, 1986, J IMMUNOL, V136, P4611; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; EXTON JH, 1990, J BIOL CHEM, V265, P1; GAY JC, 1986, BLOOD, V67, P931; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GRZESKOWIAK M, 1986, BIOCHEM BIOPH RES CO, V135, P785, DOI 10.1016/0006-291X(86)90997-6; HONEYCUTT PJ, 1986, J BIOL CHEM, V261, P5900; JESAITIS AJ, 1985, J CELL BIOCHEM, V27, P241, DOI 10.1002/jcb.240270306; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KONIARIS LG, 1990, CLIN RES, V38, pA478; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; LARRICK JW, 1987, BLOOD, V69, P640; LAUDANNA C, 1990, BIOCHEM BIOPH RES CO, V166, P308, DOI 10.1016/0006-291X(90)91946-P; MCCALL CE, 1973, J INFECT DIS, V127, P26, DOI 10.1093/infdis/127.1.26; MCCALL CE, 1979, J INFECT DIS, V140, P277, DOI 10.1093/infdis/140.3.277; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; RIDER LG, 1987, J BIOL CHEM, V262, P5603; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SHALABY MR, 1985, J IMMUNOL, V135, P2069; STEADMAN R, 1990, J IMMUNOL, V144, P2712; STEINBECK MJ, 1989, REV INFECT DIS, V11, P549; SURLES JR, 1985, J MED CHEM, V28, P73, DOI 10.1021/jm00379a015; TENNENBERG SD, 1990, J LEUKOCYTE BIOL, V47, P217, DOI 10.1002/jlb.47.3.217; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; VERCELLOTTI GM, 1988, BLOOD, V71, P1100; WYRICK SD, 1985, J LABELLED COMPD RAD, V22, P1169, DOI 10.1002/jlcr.2580221110; YUO A, 1989, J IMMUNOL, V142, P1678	41	145	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4173	4179						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847915				2022-12-25	WOS:A1991FA69400027
J	DECLERCK, YA; YEAN, TD; LU, HS; TING, J; LANGLEY, KE				DECLERCK, YA; YEAN, TD; LU, HS; TING, J; LANGLEY, KE			INHIBITION OF AUTOPROTEOLYTIC ACTIVATION OF INTERSTITIAL PROCOLLAGENASE BY RECOMBINANT METALLOPROTEINASE INHIBITOR MI TIMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; RABBIT SYNOVIAL FIBROBLASTS; NUCLEOTIDE-SEQUENCE; POLYACRYLAMIDE GELS; MAMMALIAN-CELLS; IV COLLAGENASE; PURIFICATION; EXPRESSION; STROMELYSIN; PROTEINS	The purification and cloning of a novel metalloproteinase inhibitor (MI or TIMP-2) related to tissue inhibitor of metalloproteinases (TIMP) has been recently described by our laboratory (DeClerck, Y. A., Yean, T. D., Ratzkin, B. J., Lu, H. S., and Langley, K. E. (1989) J. Biol. Chem. 264, 17445-17453; Boone, T. C., Johnson, M. J., DeClerck, Y. A., and Langley, K. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2800-2804). We have transfected Chinese hamster ovary cells with a vector containing human MI/TIMP-2 cDNA and purified recombinant-derived MI/TIMP-2 (rMI/rTIMP-2) from the conditioned medium of such cells. We have investigated the inhibitory activity of rMI/rTIMP-2 toward rabbit fibroblast interstitial collagenase. The inhibition of activated collagenase by rMI/rTIMP-2 is stoichiometric and consistent with the formation of a 1:1 molar ratio complex. In addition to blocking the activated enzyme, rMI/rTIMP-2 inhibits the conversion of 52-kDa procollagenase to the 42-kDa active enzyme initiated by organomercurials. When plasmin is used as activator, rMI/rTIMP-2 does not inhibit the plasmin-mediated conversion of the 52-kDa proenzyme to the 46-kDa inactive intermediate but blocks further conversion of the 46-kDa intermediate to the 42-kDa active enzyme. The data indicate that rMI/rTIMP-2 blocks the autoproteolytic activation of procollagenase. Also, rMI/rTIMP-2 forms complexes with the 52-kDa procollagenase, the 46-kDa intermediate, and with the 42-kDa activated enzyme which are stable to sodium dodecyl sulfate (SDS), such that the complexes can be visualized by SDS-polyacrylamide gel electrophoresis. It appears that the formation of a SDS-stable complex with procollagenase requires an initial conformational change of the procollagenase brought about by organomercurials or by plasmin cleavage. The data suggest that MI/TIMP-2 may be able to control the extracellular action of certain metalloproteinases not only at the level of the activated enzyme but also at the level of proenzyme activation.	AMGEN INC,THOUSAND OAKS,CA 91320; UNIV SO CALIF,LOS ANGELES,CA 90027	Amgen; University of Southern California	DECLERCK, YA (corresponding author), CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,4650 SUNSET BLVD,LOS ANGELES,CA 90027, USA.			DeClerck, Yves/0000-0002-3688-0113	NATIONAL CANCER INSTITUTE [R01CA042919] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINCKERHOFF CE, 1987, J CLIN INVEST, V79, P542, DOI 10.1172/JCI112845; BURNETTE WN, 1988, BIO-TECHNOL, V6, P699, DOI 10.1038/nbt0688-699; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DECLERCK YA, 1988, ARCH BIOCHEM BIOPHYS, V265, P28, DOI 10.1016/0003-9861(88)90367-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GASSER CS, 1982, P NATL ACAD SCI-BIOL, V79, P6522, DOI 10.1073/pnas.79.21.6522; GOODWIN RG, 1983, NUCLEIC ACIDS RES, V11, P6873, DOI 10.1093/nar/11.19.6873; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSONWINT B, 1980, ANAL BIOCHEM, V104, P175, DOI 10.1016/0003-2697(80)90295-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1981, BIOCHEM J, V195, P167, DOI 10.1042/bj1950167; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; REICH R, 1988, CANCER RES, V48, P3307; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267	38	153	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3893	3899						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847392				2022-12-25	WOS:A1991EY68200082
J	FOX, BG; LIU, Y; DEGE, JE; LIPSCOMB, JD				FOX, BG; LIU, Y; DEGE, JE; LIPSCOMB, JD			COMPLEX-FORMATION BETWEEN THE PROTEIN-COMPONENTS OF METHANE MONOOXYGENASE FROM METHYLOSINUS-TRICHOSPORIUM OB3B - IDENTIFICATION OF SITES OF COMPONENT INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS-BATH; ELECTRON-PARAMAGNETIC RESONANCE; BINUCLEAR IRON CENTER; HYDROXYLASE COMPONENT; MONO-OXYGENASE; II METHANOTROPH; PURIFICATION; MOSSBAUER; ORGANISMS; EPR	Kinetic, spectroscopic, and chemical evidence for the formation of specific catalytically essential complexes between the three protein components of the soluble form of methane monooxygenase from Methylosinus trichosporium OB3b is reported. The effects of the concentrations of the reductase and component B on the hydroxylation activity of the reconstituted enzyme system has been numerically simulated based on a kinetic model which assumes formation of multiple high affinity complexes with the hydroxylase component during catalysis. The formation of several of these complexes has been directly demonstrated. By using EPR spectroscopy, the binding of approximately 2 mol of component B/mol of hydroxylase (subunit structure (alpha-beta-gamma)2) is shown to significantly change the electronic environment of the mu-(H/R)-oxo-bridged binuclear iron cluster of the hydroxylase in both the mixed valent (Fe(II).Fe(III)) and fully reduced (Fe(II).Fe(II) states. Protein-protein complexes between the reductase and component B as well as between the reductase and hydroxylase between shown to form by monitoring quenching of the tryptophan fluorescence spectrum of either the component B (K(D) almost-equal-to 0.4-mu-M) or hydroxylase (two binding sites, K(Da) almost-equal-to 10 nM, K(Db) almost-equal-to 8-mu-M). The observed K(D) values are in agreement with the best fit values from the kinetic simulation. Through the use of the covalent zero length cross-linking reagent 1-ethyl-3-(-dimethylaminopropyl)-carbodiimide (EDC), the binding sites of the component B and reductase were shown to be on the hydroxylase alpha and beta-subunits, respectively. The alpha and beta-subunits of the hydroxylase are cross-linked by EDC suggesting that they are juxtaposed. EDC also caused the rapid loss of the ability of the monomeric component B to stimulate the hydroxylation reaction suggesting that cross-linking of reactive groups on the protein surface had occuurred. This effect was inhibited by the presence of hydroxylase and was accompanied by a loss of the ability of the component B to bind to the hydroxylase. Thus, formation of a component B-hydroxylase complex is apparently required for effective catalysis linked to NADH oxidation. When present in concentrations greater than required to saturate the initial hydroxylase complex, component B inhibited both the rate of the enzymic reaction and the cross-linking of the reductase to the hydroxylase. This suggests that a second complex involving component B can form that negatively regulates catalysis by preventing formation of the reductase-hydroxylase complex.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,4-225 MILLARD HALL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities				Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [GM40466, R01 GM040466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Abragam A., 1970, ELECT PARAMAGNETIC R; Anthony C., 1982, BIOCH METHYLOTROPHS; BERTRAND P, 1986, ARCH BIOCHEM BIOPHYS, V245, P305, DOI 10.1016/0003-9861(86)90220-1; BURROWS KJ, 1984, J GEN MICROBIOL, V130, P3327; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; Fox B. G., 1990, BIOL OXIDATION SYSTE, V1, P367; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FOX BG, 1988, BIOCHEM BIOPH RES CO, V154, P165, DOI 10.1016/0006-291X(88)90665-1; GREEN J, 1985, J BIOL CHEM, V260, P5795; GREEN J, 1989, BIOCHEM J, V259, P167, DOI 10.1042/bj2590167; Gunsalus I. C., 1973, OXIDASES RELATED RED, P583; Hanson R. S., 1980, ADV APPL MICROBIOL, V26, P3; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; Lipscomb J. D., 1983, Computer Enhanced Spectroscopy, V1, P11; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; PATEL RN, 1987, J BACTERIOL, V169, P2313, DOI 10.1128/jb.169.5.2313-2317.1987; PEARCE LL, 1987, J AM CHEM SOC, V109, P7286, DOI 10.1021/ja00258a007; PEDERSON TC, 1977, MICROSOMES DRUG OXID, P275; PRINCE RC, 1988, BIOCHIM BIOPHYS ACTA, V952, P220, DOI 10.1016/0167-4838(88)90119-7; PYRZ JW, 1986, J BIOL CHEM, V261, P1015; RUTTER R, 1984, BIOCHEMISTRY-US, V23, P6809, DOI 10.1021/bi00321a082; RUZICKA F, 1990, BIOCHEMISTRY-US, V29, P1696, DOI 10.1021/bi00459a005; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; STANLEY SH, 1983, BIOTECHNOL LETT, V5, P487, DOI 10.1007/BF00132233; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; TSIEN HC, 1989, APPL ENVIRON MICROB, V55, P3155, DOI 10.1128/AEM.55.12.3155-3161.1989; WILLING AH, 1989, J BIOL CHEM, V264, P8499; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6	36	165	170	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					540	550						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845980				2022-12-25	WOS:A1991EQ33900080
J	POTTER, JJ; CHENEVAL, D; DANG, CV; RESAR, LMS; MEZEY, E; YANG, VW				POTTER, JJ; CHENEVAL, D; DANG, CV; RESAR, LMS; MEZEY, E; YANG, VW			THE UPSTREAM STIMULATORY FACTOR BINDS TO AND ACTIVATES THE PROMOTER OF THE RAT CLASS-I ALCOHOL-DEHYDROGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR USF; NUCLEOTIDE-SEQUENCE ANALYSIS; PRIMARY HEPATOCYTE CULTURE; GAMMA-FIBRINOGEN PROMOTER; LOOP-HELIX PROTEIN; DNA-BINDING; IMMUNOGLOBULIN ENHANCER; GROWTH-HORMONE; KINASE GENE	The gene encoding rat class I alcohol dehydrogenase (ADH) is expressed primarily in the liver. Recent studies in our laboratories indicate that multiple cellular factors present in the rat liver interact with various regions of the promoter of this gene. One of the regions contains the sequence 5'-CACATG-3' that has an ''E box'' homology to which a number of transcription factors containing the basic helix-loop-helix motif bind. We now demonstrate that the human transcription factor, upstream stimulatory factor (USF), a basic helix-loop-helix-containing protein, binds to and activates the promoter of the rat class I ADH gene. Electrophoretic mobility shift assays of labeled oligonucleotide containing the 5'-CACATG-3' sequence within the ADH promoter revealed the formation of multiple DNA-protein complexes when nuclear extracts obtained from adult rat liver were used. The binding of proteins to the DNA could be competed away with an oligonucleotide specifying a sequence within the adenovirus major late promoter (MLP) that had previously been shown to bind USF. Similar complexes were observed when electrophoretic mobility shift assays of labeled MLP oligonucleotide were performed with rat liver nuclear extracts. Conversely, nuclear extracts isolated from HeLa cells, cells known to have abundant USF, contain factors that interact with the sequence present in the ADH promoter. This interaction could be competed efficiently by the MLP oligonucleotide. USF synthesized in an in vitro transcription and translation system also binds to the ADH promoter as well as to the MLP. In addition, antiserum directed against USF recognizes factors present in the rat liver nuclear extracts that interact with the ADH promoter. Furthermore, transcription directed from both the ADH and the adenovirus major late promoters was inhibited by an oligonucleotide representing the USF-binding site within the ADH promoter in a cell-free in vitro transcription system. Lastly, an ADH promoter-reporter gene construct was transactivated by an eukaryotic expression vector containing USF in HepG2 cells co-transfected with the two constructs. These experiments demonstrate that USF is present in the rat liver and that it binds to and activates the promoter of the rat class I ADH gene in a sequence-specific manner.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ANAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	POTTER, JJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205, USA.		Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NATIONAL CANCER INSTITUTE [R01CA051497, R37CA051497, R29CA051497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA000626] Funding Source: NIH RePORTER; NCI NIH HHS [CA51497] Funding Source: Medline; NIAAA NIH HHS [AA000626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BILANCHONE V, 1986, NUCLEIC ACIDS RES, V14, P3911, DOI 10.1093/nar/14.9.3911; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARR LG, 1989, GENE, V78, P277, DOI 10.1016/0378-1119(89)90230-8; CARR LG, 1990, J BIOL CHEM, V265, P1658; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CECI JD, 1986, GENE, V41, P217, DOI 10.1016/0378-1119(86)90101-0; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CRABB DW, 1989, GENOMICS, V5, P906, DOI 10.1016/0888-7543(89)90133-X; DONG Y, 1988, P NATL ACAD SCI USA, V85, P767, DOI 10.1073/pnas.85.3.767; DUESTER G, 1986, J BIOL CHEM, V261, P2027; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KUGLER W, 1990, NUCLEIC ACIDS RES, V18, P6943, DOI 10.1093/nar/18.23.6943; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEMAIGRE FP, 1989, J STEROID BIOCHEM, V34, P79, DOI 10.1016/0022-4731(89)90068-X; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LENNARD AC, 1987, EMBO J, V6, P3027, DOI 10.1002/j.1460-2075.1987.tb02608.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; MEISTER A, 1989, J BIOL CHEM, V264, P20744; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MEZEY E, 1986, HEPATOLOGY, V6, P1386, DOI 10.1002/hep.1840060627; MEZEY E, 1990, ARCH BIOCHEM BIOPHYS, V280, P390, DOI 10.1016/0003-9861(90)90347-2; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8779, DOI 10.1093/nar/12.23.8779; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; POTTER JJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P246, DOI 10.1016/0003-9861(91)90356-N; POTTER JJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P548, DOI 10.1016/0003-9861(89)90469-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STEWART MJ, 1990, MOL CELL BIOL, V10, P5007, DOI 10.1128/MCB.10.9.5007; STEWART MJ, 1990, GENE, V90, P271, DOI 10.1016/0378-1119(90)90190-3; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WINTER LA, 1990, GENE, V91, P233, DOI 10.1016/0378-1119(90)90093-7; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAMADA K, 1990, J BIOL CHEM, V265, P19885; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9	61	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15457	15463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869565				2022-12-25	WOS:A1991GB09700094
J	SZARO, BG; PANT, HC; WAY, J; BATTEY, J				SZARO, BG; PANT, HC; WAY, J; BATTEY, J			SQUID LOW-MOLECULAR-WEIGHT NEUROFILAMENT PROTEINS ARE A NOVEL CLASS OF NEUROFILAMENT PROTEIN - A NUCLEAR LAMIN-LIKE CORE AND MULTIPLE DISTINCT PROTEINS FORMED BY ALTERNATIVE RNA PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; AMINO-ACID SEQUENCE; STELLATE GANGLION; XENOPUS-LAEVIS; MONOCLONAL-ANTIBODY; SINGLE GENE; SPINAL-CORD; OPTIC-NERVE; GIANT-AXON; EXPRESSION	The primary structure of the major 60-kDa squid low molecular mass neurofilament protein (NF60) and a related 70-kDa neurofilament protein have been determined from cDNA clones isolated from a squid brain cDNA library. Structural analysis suggests that the squid NF60 and NF70 neurofilament genes and proteins are remarkably distinct from vertebrate neuronal intermediate filaments characterized previously. Both proteins are encoded on mRNAs generated by alternative RNA processing of the primary transcript of a single gene. Among the known intermediate filament proteins, NF60 and NF70 neurofilament proteins show highest similarity to an epithelial intermediate filament protein from Helix pomatia, a gastropod mollusk, and are less similar to vertebrate neurofilaments. The length of the alpha-helical rod domain in the NF60 and NF70 proteins was reminiscent of the vertebrate nuclear lamins, 6 heptads longer than is found in all known vertebrate cytoplasmic intermediate filaments, in particular the vertebrate neurofilaments. These distinct structural properties suggest that the vertebrate and invertebrate low molecular weight neurofilaments evolved independently from primordial intermediate filament proteins.	NINCDS, NEUROCHEM LAB, BLDG 36, RM 4D-20, BETHESDA, MD 20892 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Marine Biological Laboratory - Woods Hole								AUTILIOGAMBETTI L, 1986, J NEUROCHEM, V46, P366, DOI 10.1111/j.1471-4159.1986.tb12977.x; Battey, 1986, BASIC METHODS MOL BI; Bodian D, 1936, ANAT REC, V65, P89, DOI 10.1002/ar.1090650110; CHIU FC, 1989, NEURON, V2, P1435, DOI 10.1016/0896-6273(89)90189-X; COHEN RS, 1987, J NEUROSCI, V7, P2056; DEVEREAUX J, 1984, NUCLEIC ACIDS RES, V11, P524; EAGLES PAM, 1990, CELLULAR MOL BIOL IN, P37; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLANT PE, 1986, J NEUROCHEM, V46, P1573, DOI 10.1111/j.1471-4159.1986.tb01779.x; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GRUENBAUM Y, 1988, J CELL BIOL, V106, P585, DOI 10.1083/jcb.106.3.585; HOFFMANN W, 1988, FEBS LETT, V237, P178, DOI 10.1016/0014-5793(88)80196-0; Humason G.L., 1962, ANIMAL TISSUE TECHNI; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; LASEK RJ, 1985, ANN NY ACAD SCI, V455, P462, DOI 10.1111/j.1749-6632.1985.tb50429.x; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; LEWIS SA, 1985, J CELL BIOL, V100, P843, DOI 10.1083/jcb.100.3.843; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; MAIZEL JV, 1981, P NATL ACAD SCI-BIOL, V78, P7665, DOI 10.1073/pnas.78.12.7665; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PANT HC, 1978, J CELL BIOL, V78, pR23, DOI 10.1083/jcb.78.2.R23; PARYSEK LM, 1988, NEURON, V1, P395, DOI 10.1016/0896-6273(88)90189-4; PHILLIPS LL, 1983, BRAIN RES, V278, P219, DOI 10.1016/0006-8993(83)90240-8; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; PRUSS RM, 1985, J NEUROIMMUNOL, V8, P293, DOI 10.1016/S0165-5728(85)80068-0; QUITSCHKE W, 1986, J NEUROCHEM, V46, P545, DOI 10.1111/j.1471-4159.1986.tb13002.x; QUITSCHKE W, 1985, J NEUROCHEM, V44, P1465, DOI 10.1111/j.1471-4159.1985.tb08784.x; SHARPE CR, 1989, DEVELOPMENT, V107, P701; SHNEIDMAN PS, 1988, MOL BRAIN RES, V4, P217, DOI 10.1016/0169-328X(88)90028-9; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SZARO BG, 1988, J COMP NEUROL, V273, P344, DOI 10.1002/cne.902730306; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYTELL M, 1988, CELL MOTIL CYTOSKEL, V9, P349, DOI 10.1002/cm.970090407; TYTELL M, 1990, J NEUROSCI RES, V25, P153, DOI 10.1002/jnr.490250202; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WEBER K, 1989, EMBO J, V8, P3221, DOI 10.1002/j.1460-2075.1989.tb08481.x; WEBER K, 1988, EMBO J, V7, P2995, DOI 10.1002/j.1460-2075.1988.tb03162.x; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; ZACKROFF RV, 1980, SCIENCE, V208, P1152, DOI 10.1126/science.7189605; ZACKROFF RV, 1986, METHOD ENZYMOL, V134, P371	52	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15035	15041						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869540				2022-12-25	WOS:A1991GB09700038
J	LOUGHEED, M; ZHANG, HF; STEINBRECHER, UP				LOUGHEED, M; ZHANG, HF; STEINBRECHER, UP			OXIDIZED LOW-DENSITY-LIPOPROTEIN IS RESISTANT TO CATHEPSINS AND ACCUMULATES WITHIN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTE-MACROPHAGES; OXIDATIVELY MODIFIED LDL; APOLIPOPROTEIN-B; SCAVENGER RECEPTOR; CHOLESTEROL; DEGRADATION; DERIVATIZATION; PEROXIDATION; PRODUCTS; BINDING	The rate of uptake of oxidized low density lipoprotein (LDL) by mouse peritoneal macrophages is similar to that of acetyl LDL; but only approximately 50% of the internalized oxidized LDL is ultimately degraded, in contrast to the near-complete degradation seen with acetyl LDL. The objectives of this study were to determine if this was due to increased surface binding of oxidized LDL, different uptake pathways for oxidized LDL and acetyl LDL, lysosomal dysfunction caused by oxidized LDL, or resistance of oxidized LDL to hydrolysis by lysosomal proteinases. LDL binding studies at 4-degrees-C showed that the increased cell association with oxidized LDL could not be explained by differences in cell-surface binding. Immunofluorescence microscopy confirmed intracellular accumulation of apoB-immunoreactive material in macrophages incubated with oxidized LDL, but not with acetyl LDL. The scavenger receptor ligand polyinosinic acid inhibited both the cell association and degradation of oxidized LDL in macrophages by > 75%, suggesting a common uptake pathway for degraded LDL and nondegraded LDL. Studies in THP-1 cells also did not reveal more than one specific uptake pathway for oxidized LDL. LDL derivatized by incubation with oxidized arachidonic acid (under conditions that prevented oxidation of the LDL itself) showed inefficient degradation, similar to oxidized LDL. When macrophages were incubated with oxidized LDL together with acetyl I-125-LDL, the acetyl LDL was degraded normally, excluding lysosomal dysfunction as the explanation for the accumulation of oxidized LDL. Generation of trichloroacetic acid-soluble products from oxidized I-125-LDL by exposure to cathepsins B and D was less than that observed with native LDL. LDL modified by exposure to reactive products derived from oxidized arachidonic acid was also degraded more slowly than native I-125-LDL by cathepsins. In contrast, acetyl I-125-LDL was degraded more rapidly by cathepsins than native I-125-LDL, and aggregated LDL and malondialdehyde-modified LDL were degraded at the same rate as native I-125-LDL. It is concluded that the intracellular accumulation of oxidized LDL in macrophages can be explained at least in part by the resistance of oxidatively modified apolipoprotein B to cathepsins. This resistance to cathepsins does not appear to be due to aggregation of oxidized LDL, but may be a consequence of modification of apolipoprotein B by lipid peroxidation products.			LOUGHEED, M (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED,2211 WESBROOK MALL,VANCOUVER V6T 1W5,BC,CANADA.							ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BARRETT AJ, 1978, PROTEIN TURNOVER LYS, P295; BGIANTURCO SH, 1989, ARTERIOSCLEROSIS, V9, P699; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FONG LG, 1987, J LIPID RES, V28, P1466; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KODAMA T, 1990, NATURE, V343, P532; LEPAGE G, 1988, J LIPID RES, V29, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; RANKIN SM, 1989, ATHEROSCLEROSIS, V79, P71, DOI 10.1016/0021-9150(89)90035-X; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, J LIPID RES, V25, P1109; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; VANLENTEN BJ, 1990, J LIPID RES, V31, P1455; VIA DP, 1985, J BIOL CHEM, V260, P7379; VIA DP, 1989, J LIPID RES, V30, P1515; ZHANG HF, 1990, J LIPID RES, V31, P1361	33	132	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14519	14525						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860858				2022-12-25	WOS:A1991FZ35100065
J	WONG, KR; BUCKLEY, JT				WONG, KR; BUCKLEY, JT			SITE-DIRECTED MUTAGENESIS OF A SINGLE TRYPTOPHAN NEAR THE MIDDLE OF THE CHANNEL-FORMING TOXIN AEROLYSIN INHIBITS ITS TRANSFER ACROSS THE OUTER-MEMBRANE OF AEROMONAS-SALMONICIDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC EXPORT MUTANTS; GRAM-NEGATIVE BACTERIUM; ESCHERICHIA-COLI; EXTRACELLULAR SECRETION; SALMONELLA-TYPHIMURIUM; CLONED AEROLYSIN; VIBRIO-CHOLERAE; HYDROPHILA; PROTEINS; GENE	The channel-forming protein aerolysin must cross both the inner and outer bacterial membranes during its secretion from Aeromonas hydrophila or from Aeromonas salmonicida containing the cloned structural gene. We examined the fate of three mutant proteins in which Trp-227, near the middle of the amino acid chain, was replaced with glycine, leucine, or phenylalanine by site-directed mutagenesis. All three proteins crossed the inner membrane and entered the periplasm in the same way as wild-type, and in each case the signal sequence was removed correctly. Little or none of the proaerolysin substituted with glycine or leucine was released into the culture supernatant. Instead, significant amounts became associated with the outer membrane. The Phe-227 protoxin was secreted by the bacteria but at a reduced rate. The leucine and phenylalanine mutant proteins were purified and compared with native proaerolysin. They were processed correctly to the mature forms by treatment with trypsin, and, like native aerolysin, both were resistant to further proteolysis. In each case, processing was followed by the formation of oligomers similar to those produced by native toxin. The hemolytic activity of the processed Phe-227 mutant was one-quarter that of wild-type toxin whereas Leu-227 aerolysin had less than one-hundredth the wild-type activity. These results are further evidence that aerolysin is secreted in at least two steps. As well, they show that the last step, crossing the outer membrane, can be blocked by an apparently small change in the structure of the protein.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA	University of Victoria								BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; BUCKLEY JT, 1991, IN PRESS EXPERIENTIA; CHAKRABORTI AS, 1986, J BACTERIOL, V168, P1422, DOI 10.1128/jb.168.3.1422-1429.1986; DEKRUIJFF B, 1990, BIOSCIENCE REP, V10, P127; FEMLEE T, 1985, J BACTERIOL, V163, P88; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; HOWARD SP, 1983, J BACTERIOL, V154, P413, DOI 10.1128/JB.154.1.413-418.1983; HOWARD SP, 1985, J BACTERIOL, V161, P1118, DOI 10.1128/JB.161.3.1118-1124.1985; HOWARD SP, 1987, J BACTERIOL, V169, P2869, DOI 10.1128/jb.169.6.2869-2871.1987; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; JIANG B, 1991, J BACTERIOL, V173, P1241, DOI 10.1128/jb.173.3.1241-1249.1991; KLOSE M, 1988, J BIOL CHEM, V263, P13291; MACINTYRE S, 1980, CAN J BIOCHEM CELL B, V58, P1018, DOI 10.1139/o80-138; MANIATIS T, 1982, MOL CLONING LABORATO, P63; Miller J. H., 1972, EXPT MOL GENETICS, P431; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; REYSS I, 1990, MOL GEN GENET, V222, P176, DOI 10.1007/BF00633815; SANDKVIST M, 1990, J BIOL CHEM, V265, P15239; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHIEBEL E, 1989, J BIOL CHEM, V264, P16311; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIS RC, 1974, ARCH BIOCHEM BIOPHYS, V161, P64, DOI 10.1016/0003-9861(74)90235-5; WONG KR, 1989, SCIENCE, V246, P654, DOI 10.1126/science.2814486; WONG KR, 1989, J BACTERIOL, V171, P2523, DOI 10.1128/jb.171.5.2523-2527.1989; WONG KR, 1990, J BACTERIOL, V172, P372, DOI 10.1128/JB.172.1.372-376.1990; YOUNG DB, 1982, INFECT IMMUN, V37, P875, DOI 10.1128/IAI.37.3.875-883.1982	34	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14451	14456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860853				2022-12-25	WOS:A1991FZ35100055
J	HASLER, P; BROT, N; WEISSBACH, H; PARNASSA, AP; ELKON, KB				HASLER, P; BROT, N; WEISSBACH, H; PARNASSA, AP; ELKON, KB			RIBOSOMAL PROTEIN-P0, PROTEIN-P1, AND PROTEIN-P2 ARE PHOSPHORYLATED BY CASEIN KINASE-II AT THEIR CONSERVED CARBOXYL TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ACIDIC PROTEINS; ARTEMIA-SALINA; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; EUKARYOTIC RIBOSOMES; ELONGATION-FACTORS; GROWTH-FACTOR; SUBUNIT; INVITRO	A potential casein kinase II (CK II) recognition site is located within the conserved carboxyl (COOH) terminus of the ribosomal P (phospho) proteins P0, P1, and P2. To determine whether the COOH termini of the P proteins are physiological substrates for CK II, we studied the phosphorylation of the P proteins in vitro and in intact cells. The results show that the addition of exogenous purified CK II and ATP to intact ribosomes in vitro resulted in the relatively selective phosphorylation of all three P proteins. A synthetic peptide corresponding to the COOH-terminal 22 amino acids of P2 (C-22) was also phosphorylated by CK II with a K(m) of 13.4-mu-m. An endogenous ribosome-associated, CK II-like enzyme also phosphorylated the P proteins relatively selectively in the presence of 10 mm Mg2+ and ATP. The endogenous kinase was inhibited by heparin, utilized either ATP or GTP as a phosphate donor, and phosphorylated casein. A CK II-specific peptide (Arg-Arg-Arg-Glu-Glu-Glu-Thr-Glu-Glu-Glu) and the C-22 peptide inhibited the phosphorylation of the P proteins by the endogenous kinase, providing further evidence for its CK II-like properties and for localization of the CK II phosphorylation site to the COOH termini of the P proteins. Tryptic phosphopeptide maps of P1 and P2 phosphorylated by exogenous CK II and the endogenous ribosome-bound kinase were virtually identical. These phosphopeptides comigrated with the tryptic digest of C-22 and with the tryptic phosphopeptides derived from Pl and P2 isolated from intact cells metabolically labeled with [P-32]orthophosphate in vivo. These studies demonstrate that exogenous CK Il and a ribosome-bound, CK II-like enzyme phosphorylate the ribosomal P proteins in vitro and localize the target site for phosphorylation to the COOH terminus. The incorporation of phosphate into the same target site in intact cells indicates that the P proteins are in vivo substrates of CK II.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110		HASLER, P (corresponding author), CORNELL UNIV,HOSP SPECIAL SURG,COLL MED,535 E 70TH ST,NEW YORK,NY 10021, USA.				NIAMS NIH HHS [AR-38915] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038915] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMONS R, 1982, FEBS LETT, V146, P143, DOI 10.1016/0014-5793(82)80722-9; BINI P, 1990, J CLIN INVEST, V85, P325, DOI 10.1172/JCI114441; BONFA E, 1987, NEW ENGL J MED, V317, P265, DOI 10.1056/NEJM198707303170503; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CENATIEMPO Y, 1983, P NATL ACAD SCI-BIOL, V80, P3223, DOI 10.1073/pnas.80.11.3223; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; ELKON KB, 1985, J EXP MED, V162, P459, DOI 10.1084/jem.162.2.459; ELKON KB, 1984, J IMMUNOL, V132, P2350; FAIRHURST E, 1971, BIOCHEM J, V123, P865, DOI 10.1042/bj1230865; FRANCOEUR AM, 1985, J IMMUNOL, V135, P2378; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MAGSAAM J, 1989, CLIN EXP IMMUNOL, V76, P165; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MATHESON AT, 1980, RIBOSOMES STRUCTURE, P297; MOLLER W, 1975, P NATL ACAD SCI USA, V72, P4744, DOI 10.1073/pnas.72.12.4744; MOLLER W, 1985, STRUCTURE FUNCTION G; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; REMACHA M, 1988, J BIOL CHEM, V263, P9094; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; RICHTER D, 1973, J BIOL CHEM, V248, P2853; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STACEY DW, 1988, ARCH BIOCHEM BIOPHYS, V267, P398; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TRAUGH JA, 1976, BIOCHEMISTRY-US, V15, P610, DOI 10.1021/bi00648a025; TSURUGI K, 1978, J BIOL CHEM, V253, P946; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; VIDALES FJ, 1984, BIOCHEMISTRY-US, V23, P390, DOI 10.1021/bi00297a032	45	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13815	13820						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856214				2022-12-25	WOS:A1991FY02700058
J	ROSSI, F; GRZESKOWIAK, M; DELLABIANCA, V; SBARBATI, A				ROSSI, F; GRZESKOWIAK, M; DELLABIANCA, V; SBARBATI, A			DENOVO SYNTHESIS OF DIACYLGLYCEROL FROM GLUCOSE - A NEW PATHWAY OF SIGNAL TRANSDUCTION IN HUMAN NEUTROPHILS STIMULATED DURING PHAGOCYTOSIS OF BETA-GLUCAN PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR TYPE 3; PHOSPHOLIPASE-D; PANCREATIC-ISLETS; PHOSPHATIDATE PHOSPHOHYDROLASE; CHEMOTACTIC PEPTIDE; HL-60 GRANULOCYTES; ACTIVATION; DIGLYCERIDE; ACID	The phagocytosis of beta-glucan particles by human neutrophils and the associated activation of NADPH O2- forming oxidase were accompanied by an increased hydrolysis of phosphoinositides by phospholipase C, hydrolysis of phosphatidylcholine by phospholipase D, accumulation of diglyceride (DG) mass, and [Ca2+]i rise. The reaction of phospholipid hydrolysis played a minor role in the formation of DG, which was mainly formed by de novo synthesis from glucose. The activation of this pathway was shown by the stimulation of the incorporation of [U-C-14]glucose into DG, which occurred very rapidly after the challenge of neutrophils with beta-glucan particles. This DG derived from glucose was found almost completely as 1-acyl-2-acyl-glycerol (DAG). On the basis of the finding that phosphatidic acid was the precursor of DAG, an increase in the incorporation of [U-C-14]acetate into DAG did not occur, and the [C-14]radioactivity was in the glycerol backbone, the synthesis of DAG from [U-C-14]glucose occurred very likely via dihydroxyacetone phosphate and glycerol 3-phosphate, stepwise acylation to phosphatidic acid, and dephosphorylation by phosphatidate phosphatase.	UNIV VERONA,INST HUMAN ANAT & HISTOL,I-37134 VERONA,ITALY	University of Verona	ROSSI, F (corresponding author), UNIV VERONA,INST GEN PATHOL,STRADA LE GRAZIE,I-37134 VERONA,ITALY.							AGWU DE, 1989, J BIOL CHEM, V264, P1405; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CAIN JA, 1987, COMPLEMENT INFLAMMAT, V4, P75, DOI 10.1159/000463011; CHIARUGI V, 1989, BIOCHEM BIOPH RES CO, V164, P816, DOI 10.1016/0006-291X(89)91532-5; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; DUNLOP ME, 1985, BIOCHEM BIOPH RES CO, V132, P467, DOI 10.1016/0006-291X(85)91157-X; FARESE RV, 1987, SCIENCE, V236, P586, DOI 10.1126/science.3107122; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KOUL O, 1987, ARCH BIOCHEM BIOPHYS, V253, P453, DOI 10.1016/0003-9861(87)90199-8; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PAJ JK, 1988, J BIOL CHEM, V263, P12472; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PREISS J, 1986, J BIOL CHEM, V261, P8597; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; ROSS GD, 1987, COMPLEMENT INFLAMMAT, V4, P61, DOI 10.1159/000463010; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROSSI F, 1966, BIOCHIM BIOPHYS ACTA, V121, P110, DOI 10.1016/0304-4165(66)90353-9; ROSSI F, 1989, J IMMUNOL, V142, P1652; SBARBATI A, 1990, AM J ANAT, V188, P199, DOI 10.1002/aja.1001880209; SBARRA AJ, 1959, J BIOL CHEM, V234, P1355; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; STJERNHOLM R L, 1970, RES Journal of the Reticuloendothelial Society, V8, P550; TRUETT AP, 1989, BIOCHEM J, V260, P909, DOI 10.1042/bj2600909; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; WILLIAMS JD, 1986, IMMUNOLOGY, V58, P117	33	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8034	8038						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850733				2022-12-25	WOS:A1991FK44100014
J	LACOMBE, C; CHRETIEN, S; LEMARCHANDEL, V; MAYEUX, P; ROMEO, PH; GISSELBRECHT, S; CARTRON, JP				LACOMBE, C; CHRETIEN, S; LEMARCHANDEL, V; MAYEUX, P; ROMEO, PH; GISSELBRECHT, S; CARTRON, JP			SPLEEN FOCUS-FORMING VIRUS LONG TERMINAL REPEAT INSERTIONAL ACTIVATION OF THE MURINE ERYTHROPOIETIN RECEPTOR GENE IN THE T3CL-2 FRIEND-LEUKEMIA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE GENE; ERYTHROLEUKEMIA-CELLS; RETROVIRAL INSERTION; PROMOTER INSERTION; EXPRESSION; IDENTIFICATION; ONCOGENE; PROTEIN	We have characterized the structure of the erythropoietin receptor gene promoter in normal murine erythroid tissues and in Friend-induced tumor cells. Using primer extension analysis, we identified two distinct transcriptional start sites, which were located 2 base pairs apart in anemic spleens, fetal liver, Friend-induced tumoral spleens, and mouse erythroleukemia cells. In contrast, transcription was initiated 37 base pairs upstream of the normal cap sites in T3Cl-2, a Friend virus-induced murine erythroleukemia cell line. Also, the erythropoietin receptor mRNA in T3Cl-2 was overexpressed when compared with other erythroleukemia cell lines. We found that abnormal transcription occurring in T3Cl-2 cells resulted from an erythropoietin receptor gene alteration. Indeed, one erythropoietin allele was rearranged by insertion of a spleen focus-forming virus long terminal repeat within the noncoding region of the first exon, 45 bases upstream of the ATG initiation codon and in the same 5' --> 3' orientation. The transcription of the rearranged allele was shown to be directed from the long terminal repeat promoter, leading to a long terminal repeat-erythropoietin receptor fusion transcript, whereas the normal erythropoietin receptor allele was weakly transcribed. Such altered receptor gene activation may provide a positive pressure in the development of tumorigenic erythroleukemia.	INST NATL TRANSFUS SANGUINE, F-75015 PARIS, FRANCE; INSERM, U76, F-75015 PARIS, FRANCE; HOP HENRI MONDOR, INSERM, U91, F-94010 CRETEIL, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	LACOMBE, C (corresponding author), INSERM, U152, INST COCHIN GENET MOLEC, 27 RUE FAUBOURG ST JACQUES, F-75014 PARIS, FRANCE.		Romeo, Paul-Henri/L-5989-2017; Chretien, Stany/M-5166-2018	Romeo, Paul-Henri/0000-0002-8294-0367; 				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; BROUDY VC, 1988, P NATL ACAD SCI USA, V85, P6513, DOI 10.1073/pnas.85.17.6513; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; CUYPERS HT, 1984, CELL, V37, P141; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; IKAWA Y, 1976, GANN, V67, P767; JELKMAN W, 1986, REV PHYSL BIOCH PHAR, V36, P139; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KOCH W, 1984, J VIROL, V49, P828, DOI 10.1128/JVI.49.3.828-840.1984; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LACOMBE C, 1987, MOL CELLULAR ASPEC H, V8, P61; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYEUX P, 1987, FEBS LETT, V211, P229, DOI 10.1016/0014-5793(87)81442-4; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; RUSCETTI S, 1984, CURR TOP MICROBIOL, V112, P21; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SPIRO C, 1988, VIROLOGY, V164, P350, DOI 10.1016/0042-6822(88)90548-X; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODOKORO K, 1988, BIOCHIM BIOPHYS ACTA, V943, P326, DOI 10.1016/0005-2736(88)90564-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WOLFF L, 1988, J VIROL, V62, P2158, DOI 10.1128/JVI.62.6.2158-2163.1988; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	37	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6952	6956						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849897				2022-12-25	WOS:A1991FG72700051
J	BERTELOOT, A; VIDAL, H; VANDEWERVE, G				BERTELOOT, A; VIDAL, H; VANDEWERVE, G			RAPID KINETICS OF LIVER MICROSOMAL GLUCOSE-6-PHOSPHATASE - EVIDENCE FOR TIGHT-COUPLING BETWEEN GLUCOSE-6-PHOSPHATE TRANSPORT AND PHOSPHOHYDROLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE DISEASE; RAT-LIVER; GLUCOSE 6-PHOSPHATASE; MEMBRANE INTEGRITY; SYSTEM; PERMEABILITY; POLYPEPTIDE; COMPONENT	Rapid kinetics of both glucose-6-P uptake and hydrolysis in fasted rat liver microsomes were investigated with a recently developed fast-sampling, rapid-filtration apparatus. Experiments were confronted with both the substrate transport and conformational models currently proposed for the glucose-6-phosphatase system. Accumulation in microsomes of C-14 products from [U-C-14]glucose-6-P followed biexponential kinetics. From the inside to outside product concentrations, it could be inferred that mostly glucose should accumulate inside the vesicles. While biexponential kinetics are compatible with the mathematical predictions of a simplified substrate transport model, the latter fails in explaining the "burst" in total glucose production over a similar time scale to that used for the uptake measurements. Since the initial rate of the burst phase in untreated microsomes exactly matched the steady-state rate of glucose production in detergent-treated vesicles, it can be definitely concluded that the substrate transport model does not describe adequately our results. While the conformational model accounts for both the burst of glucose production and the kinetics of glucose accumulation into the vesicles, it cannot explain the burst in 32Pi production from [P-32]glucose-6-P measured under the same conditions. Since the amplitude of the observed bursts is not compatible with a presteady state in enzyme activity, we propose that a hysteretic transition best explains our results in both untreated and permeabilized microsomes, thus providing a new rationale to understand the molecular mechanism of the glucose-6-phosphatase system.	UNIV MONTREAL,DEPT NUTR,ENDOCRINOL METAB LAB,CP 6128,SUCCURSALE A,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,RECH TRANSPORT MEMBRANAIRE GRP,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,DEPT PHYSIOL,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal			Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317				ARION WJ, 1982, J BIOL CHEM, V257, P1217; ARION WJ, 1975, MOL CELL BIOCHEM, V6, P75, DOI 10.1007/BF01732001; ARION WJ, 1976, J BIOL CHEM, V251, P4901; ARION WJ, 1980, J BIOL CHEM, V255, P387; BALLAS LM, 1977, J BIOL CHEM, V252, P8512; BERTELOOT A, 1991, IN PRESS J MEMBR BIO; BURCHELL A, 1989, J INHERIT METAB DIS, V12, P315, DOI 10.1007/BF03335409; BURCHELL A, 1982, BIOCHEM J, V205, P267; CANFIELD WK, 1988, J BIOL CHEM, V263, P7458; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; DIXON M, 1979, ENZYMES, P182; IGARASHI Y, 1984, BIOCHEM BIOPH RES CO, V119, P593, DOI 10.1016/S0006-291X(84)80290-9; Neet K E, 1980, Methods Enzymol, V64, P192; NESS GC, 1989, J BIOL CHEM, V264, P7111; NILSSON R, 1973, J CELL BIOL, V56, P762, DOI 10.1083/jcb.56.3.762; NORDLIE RC, 1964, J BIOL CHEM, V239, P1680; NORDLIE RC, 1982, METHOD ENZYMOL, V87, P319; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; PEARS J, 1989, BIOCHIM BIOPHYS ACTA, V993, P224, DOI 10.1016/0304-4165(89)90168-2; PULLMAN ME, 1967, METHOD ENZYMOL, V10, P59; SCHULZE HU, 1986, J BIOL CHEM, V261, P6571; STETTEN MR, 1967, BIOCHIM BIOPHYS ACTA, V139, P138, DOI 10.1016/0005-2744(67)90120-9; TRAXINGER RR, 1990, BIOCHEM CELL BIOL, V68, P454, DOI 10.1139/o90-064; VANDEWERVE G, 1989, J BIOL CHEM, V264, P6033; VANSTAPEL F, 1988, J CLIN INVEST, V82, P1113, DOI 10.1172/JCI113668; WADDELL ID, 1987, BIOCHEM SOC T, V15, P1126, DOI 10.1042/bst0151126; WALLIN BK, 1973, J BIOL CHEM, V248, P2380; WIERZBICKI W, 1990, J MEMBRANE BIOL, V117, P11, DOI 10.1007/BF01871562; WOHLHUETER RM, 1980, INT REV CYTOL, V64, P171, DOI 10.1016/S0074-7696(08)60238-7; ZAKIM D, 1982, J BIOL CHEM, V257, P1145; ZAKIM D, 1990, J BIOL CHEM, V265, P201; ZOCCOLI MA, 1982, J BIOL CHEM, V257, P3919	32	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5497	5507						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848552				2022-12-25	WOS:A1991FD37000024
J	HJELMSTAD, RH; BELL, RM				HJELMSTAD, RH; BELL, RM			SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASES AND ETHANOLAMINEPHOSPHOTRANSFERASES IN SACCHAROMYCES-CEREVISIAE - NUCLEOTIDE-SEQUENCE OF THE EPT1 GENE AND COMPARISON OF THE CPT1 AND EPT1 GENE-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; UPSTREAM ACTIVATION SITES; PHOSPHATIDYLSERINE SYNTHASE; TRANSCRIPTION TERMINATION; PHOSPHOGLYCERATE KINASE; SECONDARY-STRUCTURE; BINDING-SITE; YEAST; DNA; PROTEINS	The complete nucleotide sequence of the Saccharomyces cerevisiae EPT1 gene, a structural gene encoding an sn-1,2-diacylglycerol ethanolamine- and cholinephosphotransferase (Hjelmstad, R. H., and Bell, R. M. (1988) J. Biol. Chem. 263, 19748-19757), was determined. The 2123-nucleotide extent of DNA sequenced contained an open reading frame encoding 391 amino acids interrupted by an intron near its 5' end. Northern hybridization analysis detected a single 1.4-kilobase transcript. The inferred 44,525-dalton EPT1 gene product exhibited 54% amino acid sequence homology to the cholinephosphotransferase product of the yeast CPT1 gene. Predictive structural analysis of the EPT1 gene product revealed close structural similarity to the CPT1 gene product with respect to membrane topography, features of secondary structure, and transmembrane asymmetry. Regional protein homologies were identified between the EPT1 gene product and several enzymes as well as the nicotinic acetylcholine receptor. Comparative analysis of this set of protein homologies and the related set of protein homologies to the CPT1 gene product permitted identification of a presumptive active site region which contains highly conserved and divergent subregions and a common mononucleotide binding site.			HJELMSTAD, RH (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020015] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20015] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alwine J C, 1979, Methods Enzymol, V68, P220; ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ARDNT KT, 1987, SCIENCE, V237, P874; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BALLAS LM, 1980, BIOCHIM BIOPHYS ACTA, V602, P578, DOI 10.1016/0005-2736(80)90336-3; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BELL RM, 1981, J LIPID RES, V22, P391; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLAKE CCF, 1974, J MOL BIOL, V84, P585, DOI 10.1016/0022-2836(74)90118-1; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CORNELL R, 1985, BIOCHIM BIOPHYS ACTA, V821, P97, DOI 10.1016/0005-2736(85)90159-2; DADDONA PE, 1984, J BIOL CHEM, V259, P2101; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEGEUS P, 1984, EMBO J, V3, P1799, DOI 10.1002/j.1460-2075.1984.tb02048.x; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HALPERT J, 1975, J BIOL CHEM, V250, P6990; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HENRY SA, 1984, ANNU REV GENET, V18, P207; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HINNEBUSCH AG, 1983, J BIOL CHEM, V258, P5238; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOLLAND JP, 1980, J BIOL CHEM, V255, P2596; HONZATKO RB, 1982, J MOL BIOL, V160, P265, DOI 10.1016/0022-2836(82)90176-0; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KANOH H, 1976, EUR J BIOCHEM, V66, P201, DOI 10.1111/j.1432-1033.1976.tb10440.x; KIYONO K, 1987, J BIOCHEM-TOKYO, V102, P1089, DOI 10.1093/oxfordjournals.jbchem.a122147; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KREIL G, 1981, ANNU REV BIOCHEM, V50, P317, DOI 10.1146/annurev.bi.50.070181.001533; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Maniatis T., 1982, MOL CLONING; Miller J.H., 1972, EXPT MOL GENETICS; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKAWA J, 1981, BIOCHIM BIOPHYS ACTA, V665, P420, DOI 10.1016/0005-2760(81)90254-X; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; PERCY AK, 1984, ARCH BIOCHEM BIOPHYS, V230, P69, DOI 10.1016/0003-9861(84)90087-0; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RADOMINSKAPYREK A, 1978, BIOCHEM BIOPH RES CO, V85, P1074, DOI 10.1016/0006-291X(78)90652-6; RAETZ CRH, 1983, ENZYMES, V16, P207; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SEGREST JP, 1977, BIOPOLYMERS, V16, P2053, DOI 10.1002/bip.1977.360160916; SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; STRUHL K, 1986, MAXIMIZING GENE EXPR, P35; TAYLOR GR, 1987, J BIOL CHEM, V262, P5298; TUMER NE, 1983, NATURE, V306, P337, DOI 10.1038/306337a0; VECCHINI A, 1987, BIOCHIM BIOPHYS ACTA, V918, P40, DOI 10.1016/0005-2760(87)90007-5; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAO Y, 1984, J BIOCHEM-TOKYO, V95, P1513, DOI 10.1093/oxfordjournals.jbchem.a134759; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	70	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5094	5103						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848238				2022-12-25	WOS:A1991FC21700063
J	HUANG, CL; TAKENAWA, T; IVES, HE				HUANG, CL; TAKENAWA, T; IVES, HE			PLATELET-DERIVED GROWTH FACTOR-MEDIATED CA2+ ENTRY IS BLOCKED BY ANTIBODIES TO PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE BUT DOES NOT INVOLVE HEPARIN-SENSITIVE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE CELLS; CALCIUM RELEASE; NA+/H+ EXCHANGER; PERTUSSIS TOXIN; TRISPHOSPHATE; BINDING; CA-2+; EXPRESSION; ACTIVATION; CHANNELS	Elevation of intracellular Ca2+ by platelet-derived growth factor (PDGF) and other growth factors involves both release of Ca2+ from intracellular Ca2+ stores and Ca2+ entry from the extracellular medium. Release from intracellular stores is believed to be mediated by inositol 1,4,5-trisphosphate (IP3) and the heparin-sensitive IP3 receptor. We studied the mechanism by which entry of extracellular Ca2+ is induced by PDGF. Intracellular free Ca2+ (Ca2+i) was measured in single cultured rat vascular smooth muscle cells using fura 2 microspectrofluorometry. In nominally Ca2+-free medium, PDGF (recombinant BB, 10 ng/ml) raised intracellular Ca2+ transiently (< 5 min); addition of 2 mM Ca2+ to the bathing medium after 5 min caused a second, prolonged increase in intracellular Ca2+. Repeated changes in extracellular Ca2+ from 0 to 2 mM over 90 min caused rapid, parallel changes in Ca2+i of approximately 200 nM. This change in Ca2+i in response to changes in extracellular Ca2+ was virtually undetectable in control or thrombin-treated cells. The intracellular response to changes in medium Ca2+ after PDGF was completely blocked by 10 mM CoCl2, but not by 10(-7) M nicardipine. Microinjection of monoclonal antibodies to phosphatidylinositol 4,5-bisphosphate (PIP2) (kt 10, 2 mg/ml) totally abolished both mobilization of intracellular Ca2+ stores and entry of extracellular Ca2+. Consistent with this finding, maintenance of Ca2+ entry required ongoing receptor occupancy, since displacement of PDGF from its receptor with suramin (1 mM) eradicated extracellular Ca2+ entry in < 5 min. To determine whether extracellular Ca2+ entry involves the heparin-sensitive IP3 receptor, cells were microinjected with heparin (4 mg/ml) prior to addition of PDGF. Heparin, but not chondroitin sulfate, prevented mobilization of intracellular Ca2+ stores but did not affect extracellular Ca2+ entry. We conclude that entry of extracellular Ca2+ induced by PDGF requires ongoing receptor occupancy and involves PIP2 or PIP2 metabolism. However, the signal which mediates PDGF-induced Ca2+ entry does not require the heparin-sensitive IP3 receptor.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,TOKYO 173,JAPAN	Tokyo Metropolitan Institute of Gerontology	HUANG, CL (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DIV NEPHROL,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL-41210] Funding Source: Medline; NIDDK NIH HHS [DK34127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Graessmann A, 1980, Methods Enzymol, V65, P816; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1989, MOL PHARMACOL, V35, P339; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; HUANG CL, 1989, J BIOL CHEM, V264, P4391; HUANG CL, 1987, J BIOL CHEM, V262, P14134; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MATSUOKA K, 1988, SCIENCE, V239, P640; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MITSUHASHI T, 1988, J BIOL CHEM, V263, P8790; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; THEIBERT AB, 1987, BIOCHEM BIOPH RES CO, V148, P1283, DOI 10.1016/S0006-291X(87)80272-3; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	29	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4045	4048						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847912				2022-12-25	WOS:A1991FA69400006
J	KATO, K; NAKANISHI, M; KANEDA, Y; UCHIDA, T; OKADA, Y				KATO, K; NAKANISHI, M; KANEDA, Y; UCHIDA, T; OKADA, Y			EXPRESSION OF HEPATITIS-B VIRUS SURFACE-ANTIGEN IN ADULT-RAT LIVER - CO-INTRODUCTION OF DNA AND NUCLEAR-PROTEIN BY A SIMPLIFIED LIPOSOME METHOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HVJ SENDAI VIRUS; GENE; CELLS; MACROMOLECULES; SEQUENCE	We established a simple and efficient method for gene transfer in vitro (to cultured cells) and in vivo (to an adult organ) using liposomes. Plasmid DNA and proteins were efficiently co-encapsulated in liposomes by agitation and sonication, and were co-introduced into cells by hemagglutinating virus of Japan (HVJ)-mediated membrane fusion. Introduction of the Escherichia coli beta-galactosidase gene with non-histone chromosomal protein high mobility group 1 (HMG1) into LLCMK2 cells resulted in about 3 times higher beta-galactosidase activity than that on introduction of the gene alone. Two days after injection of HVJ-liposomes containing the beta-galactosidase gene and HMG1 under the perisplanchnic membrane of adult rat liver, hepatic cells near the injection site were found by 5-bromo-4-chloro-3-indolyl beta-D-galactoside staining to have beta-galactosidase activity. After similar injection of HVJ-liposomes containing the hepatitis B virus surface antigen (HBsAg) gene and HMG1, HBsAg was detected in the serum for 9 days with a maximum of 25-45 ng/ml on day 2 after the injection.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADAOKA,SUITA,OSAKA 565,JAPAN	Osaka University								BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; BENVENISTY N, 1986, P NATL ACAD SCI USA, V83, P9551, DOI 10.1073/pnas.83.24.9551; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GOODWIN GH, 1975, BIOCHIM BIOPHYS ACTA, V405, P280, DOI 10.1016/0005-2795(75)90094-X; GOODWIN GH, 1983, BIOCHIM BIOPHYS ACTA, V100, P293; HARLOW E, 1988, ANTIBODIES LABORATOR, P408; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANEDA Y, 1987, EXP CELL RES, V173, P56, DOI 10.1016/0014-4827(87)90331-4; KANEDA Y, 1989, J BIOL CHEM, V264, P12126; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malone, 1989, FOCUS, V11, P61; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; NAKANISHI M, 1985, EXP CELL RES, V159, P399, DOI 10.1016/S0014-4827(85)80013-6; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; SALK JE, 1944, J IMMUNOL, V69, P87; SEEGER C, 1984, P NATL ACAD SCI-BIOL, V81, P5849, DOI 10.1073/pnas.81.18.5849; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; UCHIDA T, 1988, EXP CELL RES, V178, P1, DOI 10.1016/0014-4827(88)90372-2; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WU CH, 1989, J BIOL CHEM, V264, P16985	25	149	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3361	3364						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847370				2022-12-25	WOS:A1991EY68200002
J	LEVINE, BA; CLACK, B; ELLIS, L				LEVINE, BA; CLACK, B; ELLIS, L			A SOLUBLE INSULIN-RECEPTOR KINASE CATALYZES ORDERED PHOSPHORYLATION AT MULTIPLE TYROSINES OF DODECAPEPTIDE SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CYTOPLASMIC DOMAIN; BACULOVIRUS VECTOR; INSECT CELLS; BETA-SUBUNIT; AUTOPHOSPHORYLATION; RESIDUES; SITES; IDENTIFICATION; EXPRESSION	At present, the requirements for efficient phosphorylation of exogenous substrates by protein-tyrosine kinases are largely unknown. The proton resonances of each of the 3 tyrosines of the dodecapeptide substrate RRDIYETDYYRK are well resolved in the aromatic region of the H-1 NMR spectra: thus, it is feasible to directly monitor phosphorylation at each site. A soluble approximately 48-kDa derivative of the human insulin receptor cytoplasmic protein-tyrosine kinase domain phosphorylates this peptide at all 3 tyrosine sites and does so in a highly ordered and progressive manner (Y9, then Y10 and finally Y5), proceeding to full stoichiometry at each site before phosphorylating the next. This experimental system now provides an approach by which to follow the stereochemical requirements and dynamics of substrate phosphorylation by a protein-tyrosine kinase in solution in real time.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV OXFORD, INORGAN CHEM LAB, OXFORD OX1 3QR, ENGLAND	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Oxford								COBB MH, 1989, J BIOL CHEM, V264, P18701; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GRIFFEY RH, 1987, Q REV BIOPHYS, V19, P51, DOI 10.1017/S0033583500004029; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; OH BH, 1988, SCIENCE, V240, P908, DOI 10.1126/science.3129784; ROSEN OM, 1988, FEBS LETT, V231, P397, DOI 10.1016/0014-5793(88)80858-5; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; STADTMAUER L, 1986, J BIOL CHEM, V261; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WESTLER WM, 1988, J AM CHEM SOC, V110, P6256, DOI 10.1021/ja00226a057; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITTAKER J, 1988, J BIOL CHEM, V263, P3063; Wuthrich K., 1986, NMR PROTEINS NUCL AC	25	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3565	3570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847379				2022-12-25	WOS:A1991EY68200036
J	TYAGI, SR; OLSON, SC; BURNHAM, DN; LAMBETH, JD				TYAGI, SR; OLSON, SC; BURNHAM, DN; LAMBETH, JD			CYCLIC AMP-ELEVATING AGENTS BLOCK CHEMOATTRACTANT ACTIVATION OF DIRADYLGLYCEROL GENERATION BY INHIBITING PHOSPHOLIPASE-D ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; FMET-LEU-PHE; NUCLEOTIDE REGULATORY PROTEIN; STIMULATED HUMAN-NEUTROPHILS; SUPEROXIDE ANION PRODUCTION; S49 LYMPHOMA-CELLS; ADENYLATE-CYCLASE; DIACYLGLYCEROL GENERATION; PHORBOL-ESTER	Agents which elevate cellular cAMP (prostaglandin E2, theophylline, and forskolin) or mimic cAMP action (dibutyryl cAMP) are known to inhibit human neutrophil activation (superoxide generation and secretion) by receptor-linked agonists such as formyl-methionyl-leucyl-phenylalanine (fMLP). Herein, we show that these agents also markedly inhibit fMLP-stimulated diradylglycerol generation (assayed by mass methods). The magnitude of inhibition correlated with the ability of a given agent or combination of agents to elevate cAMP. Both 1,2-diacylglycerol and 1-O-alkyl,2-acyl glycerol generation were affected. Effects on the latter species, as well as a lack of effect on fMLP-stimulated inositol phosphate release, implied that cAMP affected diradylglycerol generation from a source other than phospholipase C-dependent phosphoinositide hydrolysis, since phosphatidylinositols do not contain appreciable quantities of the 1-O-alkyl linkage. In cells in which the phosphatidylcholine pool was prelabeled using 1-O-[H-3]octadecyl-2-lyso-sn-glycero-3-phosphocholine, prostaglandin E2 plus theophylline inhibited the fMLP-activated rapid generation of [H-3]phosphatidic acid and its subsequent conversion to [H-3]diradylglycerol, implying an effect at the level of phospholipase D. In the presence of ethanol, the fMLP-activated transphosphatidylation of [H-3]phosphatidylcholine to generate [H-3]phosphatidylethanol (a phospholipase D-dependent reaction) was also markedly inhibited. In contrast, when phorbol 12-myristate 13-acetate was used to activate cells, cAMP-related agents had no effect on phospholipase D activity, diradylglycerol generation, or superoxide generation. The data indicate an inhibitory effect of cyclic AMP on receptor-mediated phospholipase D activation at a site proximal to phospholipase D (e.g., the receptor or G protein). These studies provide a new example of "cross-talk" among signal transduction systems.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NCI NIH HHS [CA46508] Funding Source: Medline; NIDDK NIH HHS [T32 DK07298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGWU DE, 1989, J BIOL CHEM, V264, P1405; BABIOR BM, 1984, BLOOD, V64, P959; BADWEY JA, 1989, J BIOL CHEM, V264, P20676; BELL JD, 1986, J BIOL CHEM, V261, P2036; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BJORNSON AB, 1989, J IMMUNOL, V143, P2609; BLANK ML, 1975, BIOCHIM BIOPHYS ACTA, V380, P208, DOI 10.1016/0005-2760(75)90007-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOSNER RW, 1989, BIOCHEM J, V264, P617; BROMBERG Y, 1983, CELL IMMUNOL, V79, P240, DOI 10.1016/0008-8749(83)90067-9; BURNHAM DN, 1989, ARCH BIOCHEM BIOPHYS, V269, P345, DOI 10.1016/0003-9861(89)90116-1; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; COURCELLES DC, 1985, J BIOL CHEM, V260, P15762; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DETOGNI P, 1984, BIOCHEM J, V224, P629, DOI 10.1042/bj2240629; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HONEYCUTT PJ, 1986, J BIOL CHEM, V261, P5900; IGNARRO LJ, 1974, J EXP MED, V139, P1395, DOI 10.1084/jem.139.6.1395; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JOHNSON JA, 1986, J CYCLIC NUCL PROT, V11, P199; KIKUCHI A, 1987, J BIOL CHEM, V262, P6766; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LAPETINA EG, 1979, BIOCHIM BIOPHYS ACTA, V573, P394, DOI 10.1016/0005-2760(79)90072-9; LAPETINA EG, 1986, FEBS LETT, V195, P111, DOI 10.1016/0014-5793(86)80141-7; LEHMEYER JE, 1978, CLIN IMMUNOL IMMUNOP, V9, P482, DOI 10.1016/0090-1229(78)90144-7; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MARIDONNEAUPARINI I, 1986, J IMMUNOL, V137, P2925; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MUELLER HW, 1982, LIPIDS, V17, P72, DOI 10.1007/BF02535178; MUFSON RA, 1981, CARCINOGENESIS, V2, P1095; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PEMBER SO, 1983, BLOOD, V61, P1105; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PREISS J, 1986, J BIOL CHEM, V261, P8597; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIDER LG, 1987, J BIOL CHEM, V262, P5603; RIDER LG, 1988, J IMMUNOL, V140, P200; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIMCHOWITZ L, 1980, J IMMUNOL, V124, P1482; SMITH CD, 1987, J BIOL CHEM, V262, P6121; SMOLEN JE, 1980, J CLIN INVEST, V65, P1077, DOI 10.1172/JCI109760; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V672, P197, DOI 10.1016/0304-4165(81)90393-7; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; TAUBER AI, 1987, BLOOD, V69, P711; TENCE M, 1985, THROMB RES, V38, P207, DOI 10.1016/0049-3848(85)90148-3; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; TYAGI SR, 1989, FEBS LETT, V257, P188, DOI 10.1016/0014-5793(89)81817-4; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; VERGHESE MW, 1985, J BIOL CHEM, V260, P6769; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	69	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3498	3504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847376				2022-12-25	WOS:A1991EY68200027
J	ATREYA, PL; ANANTHANARAYANAN, VS				ATREYA, PL; ANANTHANARAYANAN, VS			INTERACTION OF PROLYL 4-HYDROXYLASE WITH SYNTHETIC PEPTIDE-SUBSTRATES - A CONFORMATIONAL MODEL FOR COLLAGEN PROLINE HYDROXYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-OXOGLUTARATE BINDING-SITE; PROTEIN DISULFIDE ISOMERASE; CONTAINING BETA-TURNS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; HYDROXYPROLINE; PROCOLLAGEN; SUBUNIT; IDENTIFICATION; SEQUENCE	With the aim of understanding the structural basis for the substrate specificity of collagen prolyl 4-hydroxylase, we have studied the conformational features of synthetic oligopeptide substrates and their interaction with the enzyme purified from chicken embryo. Circular dichroism and infrared spectral data, taken in conjunction with relevant crystal structure data, indicated an equilibrium mixture of the polyproline-II (PP-II) helix, the beta-turn, and the random coil conformations in aqueous and trifluoroethanol solutions of the "collagen-related" peptides: t-Boc-Pro-Pro-Gly-Pro-OH, t-Boc-Pro-Pro-Gly-Pro-NHCH3, t-Pro-Pro-Gly-Pro-Pro-OH, T-Boc-Pro-Pro-Ala-Pro-OH, and t-Boc-Pro-Pro-Gln-Pro-OCH3, where t-Boc is tert-butoxycarbonyl. In another set of peptides related to elastin, t-Boc-Val-Pro-Gly-Val-OH and t-Boc-Gly-Val-Pro-Gly-Val-OH, the data indicated the beta-structure, rather than the PP-II helix, was in equilibrium with the beta-turn. Kinetic parameters for the enzymatic hydroxylation of the peptides showed that as a group, the first (proline-rich) set of peptides has higher K(m) values and lower V(max) and K(cat)/K(m) values than the valine-rich peptides. Data on the inhibition of hydroxylation of the standard assay substrate (Pro-Pro-Gly)10 by the oligopeptides pointed to common binding sites for the peptides. Hydroxyproline-containing peptides had no effect on the hydroxylation of the standard substrate, showing the absence of product inhibition. Based on these and earlier data, we propose that in collagen and related peptides, a supersecondary structure consisting of the PP-II helix followed by the beta-turn is the minimal structural requirement for proline hydroxylation. The PP-II structure would aid effective interaction at the substrate binding subsites, while the beta-turn would be essential at the catalytic site of the enzyme. In elastin and related peptides, the beta-strand structure may be interchangeable with the PP-II structure. This conformational model for proline hydroxylation resolves the discrepancies in earlier proposals on the substrate specificity of prolyl 4-hydroxylase. It is also consistent with the available information on the active site geometry of the enzyme.	MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University								ADZHUBEI AA, 1987, BIOCHEM BIOPH RES CO, V146, P934, DOI 10.1016/0006-291X(87)90736-4; ANANTHANARAYANA.VS, 1983, CONFORMATION BIOL, P99; ANANTHANARAYANA.VS, 1985, 1LTH P FEBS C A, P23; ANANTHANARAYANAN VS, 1988, INT J PEPT PROT RES, V31, P399; ANANTHANARAYANAN VS, 1987, J MOL BIOL, V198, P705, DOI 10.1016/0022-2836(87)90211-7; ATREYA PL, 1988, THESIS MEMORIAL U NE; BANSAL M, 1988, BIOPOLYMERS, V27, P299, DOI 10.1002/bip.360270209; BENEDETTI E, 1977, MACROMOLECULES, V10, P1350, DOI 10.1021/ma60060a035; BENNICK A, 1975, BIOCHEM J, V145, P557, DOI 10.1042/bj1450557; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; BRAHMACHARI SK, 1979, P NATL ACAD SCI USA, V76, P5119, DOI 10.1073/pnas.76.10.5119; BRAHMACHARI SK, 1981, J AM CHEM SOC, V103, P1703, DOI 10.1021/ja00397a020; BRAHMACHARI SK, 1982, BIOPOLYMERS, V21, P1107, DOI 10.1002/bip.360210608; CHOPRA RK, 1982, P NATL ACAD SCI-BIOL, V79, P7180, DOI 10.1073/pnas.79.23.7180; CHOPRA RK, 1983, BIOCHEM INT, V7, P415; CORNISHBOWDEN A, 1981, FUNDAMENTALS ENZYME, P75; DEWAAL A, 1985, BIOCHEMISTRY-US, V24, P6493, DOI 10.1021/bi00344a028; DEWAAL A, 1988, BIOCHEMISTRY-US, V27, P150, DOI 10.1021/bi00401a023; DEWAAL A, 1987, BIOCHIM BIOPHYS ACTA, V912, P151, DOI 10.1016/0167-4838(87)90260-3; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; FERSHT A, 1985, ENZYME STRUCTURE MEC, P85; GUNZLER V, 1988, BIOCHEM J, V251, P365, DOI 10.1042/bj2510365; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; HAWGOOD S, 1989, FERNS FOUND SERIES, V12, P57; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HOLLOSI M, 1985, BIOPOLYMERS, V24, P211, DOI 10.1002/bip.360240117; HOYHTYA M, 1984, EUR J BIOCHEM, V141, P477, DOI 10.1111/j.1432-1033.1984.tb08217.x; JENNESS DD, 1976, BIOPOLYMERS, V15, P513, DOI 10.1002/bip.1976.360150308; KEDERSHA NL, 1981, COLLAGEN REL RES, V1, P345; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KOIVU J, 1987, J BIOL CHEM, V262, P6159; LEE E, 1984, BIOPOLYMERS, V23, P1193, DOI 10.1002/bip.360230705; MAJAMAA K, 1984, EUR J BIOCHEM, V138, P239, DOI 10.1111/j.1432-1033.1984.tb07907.x; MATSUZAKI T, 1979, ACTA CRYSTALLOGR B, V30, P1029; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Prockop D.J., 1976, BIOCH COLLAGENS, P163; RAPAKA RS, 1978, BIOCHEMISTRY-US, V17, P2892, DOI 10.1021/bi00607a030; REID KBM, 1972, BIOCHEM J, V130, P749, DOI 10.1042/bj1300749; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3550, DOI 10.1021/bi00635a008; SUBRAMANIAN E, 1983, BIOPOLYMERS, V22, P833, DOI 10.1002/bip.360220306; TANAKA I, 1977, ACTA CRYSTALLOGR B, V33, P116, DOI 10.1107/S0567740877002714; TANAKA I, 1979, ACTA CRYSTALLOGR B, V35, P110, DOI 10.1107/S056774087900265X; TINKER DA, 1988, J BIOL CHEM, V263, P5024; URRY DW, 1974, BIOCHEMISTRY-US, V13, P609, DOI 10.1021/bi00700a032; WOODY RW, 1974, PEPTIDES POLYPEPTIDE, P339; YAGI Y, 1983, J AM CHEM SOC, V105, P1242, DOI 10.1021/ja00343a027; ZIJENAH LS, 1986, SYNTHESIS CONFORMATI	50	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2852	2858						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847136				2022-12-25	WOS:A1991EX60000031
J	WENDLAND, M; WAHEED, A; VONFIGURA, K; POHLMANN, R				WENDLAND, M; WAHEED, A; VONFIGURA, K; POHLMANN, R			MR 46,000 MANNOSE 6-PHOSPHATE RECEPTOR - THE ROLE OF HISTIDINE AND ARGININE RESIDUES FOR BINDING OF LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHOXYFORMIC ANHYDRIDE; LYSOSOMAL-ENZYMES; PROTEINS; CELLS; BIOSYNTHESIS; CLEAVAGE; GENE	The chemical modification of histidine and arginine residues results in a loss of binding of the M(r) 46,000 mannose 6-phosphate receptor (MPR 46) to a phosphomannan affinity matrix (Stein, M., Meyer, J. E., Hasilik, A., and von Figura, K. (1987) Biol. Chem. Hoppe-Seyler 368, 927-936). Reversal of the modification or presence of mannose 6-phosphate during the modification partially restores or protects the binding activity, indicating that histidine and arginine residues contribute to the mannose 6-phosphate binding site. The 5 histidine and 8 arginine residues within the luminal domain of MPR 46, which contains the ligand binding site, were exchanged by site-directed mutagenesis. Only the conservative replacement of His-131 and Arg-137 by serine and lysine, respectively, results in a loss of binding activity without affecting other properties of the receptor such as the presence of intramolecular disulfide bonds, immunoreactivity, processing of N-linked oligosaccharides, formation of dimers, intracellular distribution, and surface expression. Conservative replacement of other histidine and arginine residues did not effect the binding activity. Nonconservative replacement of several arginine residues reduced binding activity and immunoreactivity, indicating that the loss of a positive charge at these positions alters the folding of MPR 46. We conclude from these results that His-131 and Arg-137 are essential for binding of ligands by MPR 46.			WENDLAND, M (corresponding author), UNIV GOTTINGEN, BIOCHEM ABT 2, GOSSLERSTR 12D, W-3400 GOTTINGEN, GERMANY.							ANDERSEN TT, 1979, J BIOL CHEM, V254, P995; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HILLE A, 1989, J BIOL CHEM, V264, P13460; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PARKER KC, 1983, BIOCHEMISTRY-US, V22, P1145, DOI 10.1021/bi00274a024; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	24	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2917	2923						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847138				2022-12-25	WOS:A1991EX60000041
J	BROCKMAN, JL; ANDERSON, RA				BROCKMAN, JL; ANDERSON, RA			CASEIN KINASE-I IS REGULATED BY PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE IN NATIVE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE PROTEIN-KINASE; 2ND MESSENGERS; PHOSPHORYLATION; POLYPHOSPHOINOSITIDES; SPECTRIN; ANKYRIN; PURIFICATION; ASSOCIATION; AFFINITY; TURNOVER	Casein kinase I activity is present in cells as a cytosolic and a membrane-bound enzyme. Previously, the erythroid membrane-bound casein kinase I was shown to associate with purified integral membrane proteins; this association and protein kinase activity was regulated by phosphatidylinositol 4,5-bisphosphate (PIP2) (Bazenet, C. E., Brockman, J. L., Lewis, D., Chan, C., and Anderson, R. A. (1990) J. Biol. Chem. 265, 7369-7376). Here we show that both the membrane-bound and the cytosolic casein kinase interact with native membranes content of PIP2. On native membranes, casein kinase I activity is potently inhibited by small increases (10-20%) in the membrane content of either exogenously added or intrinsic PIP2. However, the majority of the intrinsic content of PIP2 is isolated membranes does not inhibit casein kinase suggesting that this PIP2 is not accessible. Regulation of the casein kinases on membranes is sensitive to detergents and to chymotrypsin treatment of membranes.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,1300 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,CELL & MOLEC BIOL PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Anderson, Richard/0000-0001-6265-8359	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038906, R01GM038906] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38906] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; ANDERSON RA, 1989, RED BLOOD CELL MEMBR, P187; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BAZENET CE, 1990, J BIOL CHEM, V265, P7369; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOIVIN P, 1988, BIOCHEM J, V256, P689, DOI 10.1042/bj2560689; CHAUHAN A, 1989, BIOCHEMISTRY-US, V28, P4952, DOI 10.1021/bi00438a007; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDER PS, 1986, BIOCHEMISTRY-US, V25, P1764, DOI 10.1021/bi00355a047; ERUSALIMSKY JD, 1983, BIOCHIM BIOPHYS ACTA, V756, P171, DOI 10.1016/0304-4165(83)90089-2; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; GASCARD P, 1989, BIOCHEM J, V264, P547, DOI 10.1042/bj2640547; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LU PW, 1985, J BIOL CHEM, V260, P4958; MISCHE SM, 1988, PROTOPLASMA, V145, P167, DOI 10.1007/BF01349355; MULLER E, 1986, BIOCHEM J, V235, P775; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; SCHACHT J, 1978, J LIPID RES, V19, P1063; SIMKOWSKI KW, 1980, J BIOL CHEM, V255, P6456; SINGH TJ, 1985, FEBS LETT, V190, P84, DOI 10.1016/0014-5793(85)80433-6; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TAO M, 1980, J BIOL CHEM, V255, P2563; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	33	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2508	2512						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846628				2022-12-25	WOS:A1991EV51500075
J	TAKUWA, N; IWAMOTO, A; KUMADA, M; YAMASHITA, K; TAKUWA, Y				TAKUWA, N; IWAMOTO, A; KUMADA, M; YAMASHITA, K; TAKUWA, Y			ROLE OF CA2+ INFLUX IN BOMBESIN-INDUCED MITOGENESIS IN SWISS 3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-CYCLE PROGRESSION; GROWTH-FACTOR; PHOSPHOLIPASE-C; SMOOTH-MUSCLE; CA-2+ INFLUX; 12-O-TETRADECANOYLPHORBOL 13-ACETATE; INOSITOL 1,4,5-TRISPHOSPHATE; PLASMA-MEMBRANE; TUMOR PROMOTER	In Swiss 3T3'fibroblasts a peptide mitogen bombesin, which acts through the phospholipase C-protein kinase C signaling pathway, stimulates DNA synthesis in a manner strictly dependent on the medium calcium concentration: [H-3]thymidine incorporation into DNA in the presence of a saturating concentration of bombesin (10(-8) M) is 4-fold greater at 3.0 mM extracellular calcium. In the present study we attempted to identify the site and the mechanism of action of Ca2+ influx along the bombesin-induced mitogenic signaling pathway, by comparing bombesin effects at 0.03 and 3.0 mM of medium calcium. Bombesin induces the same extent of increases in [H-3]inositol phosphates after 1 min, and comparable sustained increases in the cellular content of 1,2-diacylglycerol for up to 4 h, at either 0.03 or 3.0 mM calcium. Bombesin induces the same extent of phosphorylation of MARCKS protein, the major cellular substrate for protein kinase C, irrespective of the medium calcium concentration for at least 4 h. Moreover, diverse cellular responses elicited by bombesin, including c-fos expression, activation of microtubule-associated protein 2 kinase and S6 kinase, glucose uptake, and protein synthesis but not the release of arachidonic acid and its metabolites, are induced similarly at either 0.03 or 3.0 mM calcium. Down-regulation of cellular protein kinase C nearly completely abolishes bombesin effects on c-fos expression, S6 kinase activation, glucose uptake, and DNA synthesis. These results suggest that the target of Ca2+ influx in bombesin-induced mitogenic signaling pathway is not located along the phospholipase C-protein kinase C signal transduction system including cellular events in early G1 phase that exist downstream to protein kinase C action.	UNIV TOKYO,FAC MED,DEPT BACTERIOL,TOKYO 113,JAPAN; UNIV TSUKUBA,INST CLIN MED,DEPT INTERNAL MED,SAKURA,IBARAKI 305,JAPAN	University of Tokyo; University of Tsukuba	TAKUWA, N (corresponding author), UNIV TOKYO,FAC MED,DEPT PHYSIOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.			TAKUWA, Noriko/0000-0002-4278-2704				ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; BALK SD, 1973, P NATL ACAD SCI USA, V70, P675, DOI 10.1073/pnas.70.3.675; BARRETT PQ, 1986, BIOCHEM J, V238, P893, DOI 10.1042/bj2380893; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; BIERMAN AJ, 1990, J CELL PHYSIOL, V142, P441, DOI 10.1002/jcp.1041420302; Borle A B, 1986, Methods Enzymol, V124, P90; BOYNTON AL, 1988, MINER ELECTROL METAB, V14, P86; BOYNTON AL, 1976, IN VITRO CELL DEV B, V12, P120; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; BROSTROM CO, 1986, MOL PHARMACOL, V29, P104; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; BURCH RM, 1986, J BIOL CHEM, V261, P1236; CHAFOULEAS JG, 1981, P NATL ACAD SCI-BIOL, V78, P996, DOI 10.1073/pnas.78.2.996; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHIN KV, 1987, J BIOL CHEM, V262, P16509; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DICICCOBLOOM E, 1989, BRAIN RES, V491, P403, DOI 10.1016/0006-8993(89)90080-2; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISCHER JB, 1988, J BIOL CHEM, V263, P2808; HAMMOND RA, 1988, BIOCHIM BIOPHYS ACTA, V951, P315, DOI 10.1016/0167-4781(88)90101-7; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HO AK, 1988, J BIOL CHEM, V263, P9292; HOSHI M, 1988, J BIOL CHEM, V263, P5396; ISHIJIMA S, 1989, AM J PHYSIOL, V257, pC1113; KENDALL DA, 1985, EUR J PHARMACOL, V115, P31, DOI 10.1016/0014-2999(85)90580-1; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LICHTMAN AH, 1983, BLOOD, V61, P413; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MAUGER JP, 1984, BIOCHEM J, V221, P121, DOI 10.1042/bj2210121; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NAKAKI T, 1989, BIOCHEM BIOPH RES CO, V158, P880, DOI 10.1016/0006-291X(89)92804-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLSEN R, 1989, BIOCHEM BIOPH RES CO, V162, P448, DOI 10.1016/0006-291X(89)92018-4; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; PREISS J, 1986, J BIOL CHEM, V261, P8597; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; RASMUSSEN H, 1986, P109; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; RASMUSSEN H, 1988, CELLULAR MECHANISMS, P3; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1987, J CELL PHYSIOL, V131, P218, DOI 10.1002/jcp.1041310211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TAKUWA N, 1987, BIOCHEM J, V243, P647, DOI 10.1042/bj2430647; TAKUWA N, 1988, J BIOL CHEM, V263, P9738; TAKUWA N, 1989, AM J PHYSIOL, V257, pF431, DOI 10.1152/ajprenal.1989.257.3.F431; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TAKUWA Y, 1989, AM J PHYSIOL, V257, pE797, DOI 10.1152/ajpendo.1989.257.6.E797; TAKUWA Y, 1988, MOL CELL ENDOCRINOL, V60, P71, DOI 10.1016/0303-7207(88)90121-9; TAKUWA Y, 1990, J CLIN INVEST, V85, P653, DOI 10.1172/JCI114488; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; WANDOSELL F, 1986, J BIOL CHEM, V261, P332; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211	69	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1403	1409						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846353				2022-12-25	WOS:A1991EU49700011
J	HANNA, PM; CHEN, Y; CHASTEEN, ND				HANNA, PM; CHEN, Y; CHASTEEN, ND			INITIAL IRON OXIDATION IN HORSE SPLEEN APOFERRITIN - CHARACTERIZATION OF A MIXED-VALENCE IRON(II)-IRON(III) COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; X-RAY ABSORPTION; FERRITIN H-CHAIN; CHEMICAL MODIFICATION; MUTATIONAL ANALYSIS; MAMMALIAN FERRITIN; LOOP SEQUENCES; MECHANISM; UTEROFERRIN; DEPOSITION	In ferritin, iron is stored by oxidative deposition of the ferrous ion to form a hydrous ferric oxide mineral core. Two intermediates, formed during the initial stages of iron accumulation in apoferritin, have been observed previously in our laboratory and have been identified as a mononuclear Fe3+-protein complex and a mixed-valence Fe2+-Fe3+-protein complex. The physical characteristics of the mixed-valence Fe2+-Fe3+ complex and its relationship to the mononuclear Fe3+ complex in horse spleen apoferritin samples to which 0-240 iron atoms were added was examined by EPR spectroscopy. The results indicate that the mononuclear complex is not a precursor to the formation of the mixed-valence complex. Competitive binding studies with Cd2+, Zn2+, Tb3+, and UO2(2+) suggest that the mixed-valence complex is formed on the interior of the protein in the vicinity of the 2-fold axis of the subunit dimer. The mixed-valence complex could be generated by the partial oxidation of Fe2+ in apoferritin containing 120 Fe2+ or by the addition of up to 120 Fe2+ to ferritin already containing 18 Fe3+/protein molecule. The fact that the complex is generated during early Fe2+ oxidation suggests that it may be a key intermediate during the initial oxidative deposition of iron in the protein. The unusual EPR powder lineshape at 9.3 GHz of the mixed-valence complex was simulated with a rhombic g-tensor (g(x) = 1.95, g(y) = 1.88, g(z) = 1.77) and large linewidths and g-strain parameters. The presence of significant g-strain in the complex probably accounts for the failure to observe an EPR signal at 35 GHz and likely reflect considerable flexibility in the structure of the metal site. The temperature dependence of the EPR intensity in the range 8-38 K was modeled successfully by an effective spin Hamiltonian including exchange coupling (-2JS1 triple-over-dot.S2 triple-over-dot) and zero-field terms, from which an antiferromagnetic coupling of J = -4.0 +/- 0.5 cm-1 was obtained. This low value for J may reflect the presence of a mu-oxo bridge(s) in the dimer.	UNIV NEW HAMPSHIRE, DEPT CHEM, DURHAM, NH 03824 USA	University System Of New Hampshire; University of New Hampshire					NIGMS NIH HHS [GM20194] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020194, R01GM020194] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANTANAITIS BC, 1983, J BIOL CHEM, V258, P3166; AROSIO P, 1978, J BIOL CHEM, V253, P4451; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BAUMINGER ER, 1989, BIOCHEMISTRY-US, V28, P5486, DOI 10.1021/bi00439a025; BELFORD RL, 1979, 21ST COMP SIM POWD S; BIELIG HJ, 1955, NATURWISSENSCHAFTEN, V42, P125, DOI 10.1007/BF00589402; BRYCE CFA, 1973, BIOCHEM J, V133, P301, DOI 10.1042/bj1330301; CHASTEEN ND, 1985, J BIOL CHEM, V260, P2926; CHASTEEN ND, 1982, J BIOL CHEM, V257, P7672; CHEN Y, 1989, THESIS U NEW HAMPSHI; CLEGG GA, 1980, NATURE, V288, P298, DOI 10.1038/288298a0; CLEGG GA, 1980, PROG BIOPHYS MOL BIO, V36, P53; CRICHTON RR, 1978, J MOL CATAL, V4, P75; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DAY EP, 1988, J BIOL CHEM, V263, P15561; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GAYDA JP, 1981, BIOCHIMIE, V63, P847; GIBSON JF, 1966, P NATL ACAD SCI USA, V56, P987, DOI 10.1073/pnas.56.3.987; GRADY JK, 1989, J BIOL CHEM, V264, P20224; Granick S, 1944, J BIOL CHEM, V155, P661; HARRISON PM, 1985, PROTEINS IRON STORAG, P67; HARRISON PM, 1986, FRONTIERS BIOINORGAN, P268; HENDRICH MP, 1989, BIOPHYS J, V56, P489, DOI 10.1016/S0006-3495(89)82696-7; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; JACOBS D, 1989, BIOCHEMISTRY-US, V28, P9216, DOI 10.1021/bi00449a038; LAUFFER RB, 1983, J BIOL CHEM, V258, P4212; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; MARONEY MJ, 1984, J AM CHEM SOC, V106, P6445, DOI 10.1021/ja00333a070; Maurice AM, 1980, THESIS U ILLINOIS UR; Nilges M. J., 1979, THESIS U ILLINOIS UR; PAQUES EP, 1979, J MOL CATAL, V5, P363, DOI 10.1016/0304-5102(79)80012-7; RICE DW, 1983, ADV INORG BIOCHEM, V5, P39; ROSENBERG LP, 1982, BIOCH PHYSL IRON, P405; SAYERS DE, 1983, J BIOL CHEM, V258, P4076; THEIL EC, 1989, ADV ENZYMOL RELAT AR, V63, P421; TOWE KM, 1967, J COLLOID INTERF SCI, V24, P384, DOI 10.1016/0021-9797(67)90266-4; TOWE KM, 1981, J BIOL CHEM, V256, P9377; TREFFRY A, 1989, FEBS LETT, V247, P268, DOI 10.1016/0014-5793(89)81350-X; Treffry A., 1977, PROTEINS IRON METABO, P3; WATT GD, 1985, P NATL ACAD SCI USA, V82, P3640, DOI 10.1073/pnas.82.11.3640; WETZ K, 1976, EUR J BIOCHEM, V61, P545, DOI 10.1111/j.1432-1033.1976.tb10049.x; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023; ZIMMERMANN R, 1974, CHEM PHYS, V4, P133, DOI 10.1016/0301-0104(74)80053-4	49	41	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					886	893						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845997				2022-12-25	WOS:A1991ET17700035
J	BECK, I; RAMIREZ, S; WEINMANN, R; CARO, J				BECK, I; RAMIREZ, S; WEINMANN, R; CARO, J			ENHANCER ELEMENT AT THE 3'-FLANKING REGION CONTROLS TRANSCRIPTIONAL RESPONSE TO HYPOXIA IN THE HUMAN ERYTHROPOIETIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAMMALIAN-CELLS; EXPRESSION; CLONING; LIVER	Erythropoietin gene expression is greatly stimulated under conditions of hypoxia. The activation of the erythropoietin gene appears regulated primarily at the level of gene transcription. To study cis-acting elements involved in the response to hypoxia a mini-gene was constructed by an internal deletion from exon II to V of the human erythropoietin gene and used in transient transfection assays in the erythropoietin producing Hep 3B cell line. It was initially found that hypoxia responsiveness was present in an erythropoietin fragment containing 400 base pairs (bp) of 5'-flanking and 600 bp of 3'-flanking regions. Deletion analysis showed no significant effect on the response to hypoxia when highly conserved regions of 5'-flanking sequence, exon and intron 1, and exon V were removed from the mini-gene construct. However, removal of a fragment containing the 3' end of the gene and 3'-flanking sequences completely eliminated hypoxia responsiveness. Reinsertion of the above fragment upstream of the 5' end of the mini-gene restored the response to hypoxia. Further analysis using hybrid erythropoietin-chloramphenicolacetyltransferase constructs allowed the localization of enhancer-like element(s) in the 3'-flanking region, approximately 120 bp downstream of the polyadenylation site of the human erythropoietin gene. Activation by these sequences were position- and orientation-independent and stimulated 15-fold transcription of the erythropoietin gene in response to hypoxia.	THOMAS JEFFERSON UNIV, CARDEZA FDN HEMATOL RES, PHILADELPHIA, PA 19107 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	Jefferson University; The Wistar Institute					NCI NIH HHS [CA10815] Funding Source: Medline; NHLBI NIH HHS [HL40791] Funding Source: Medline; NIDDK NIH HHS [DK34642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERU N, 1990, J BIOL CHEM, V265, P14100; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COSTAGIOMI P, 1990, J BIOL CHEM, V265, P10185; ERSLEV AJ, 1987, J LAB CLIN MED, V109, P429; FRIED W, 1972, BLOOD-J HEMATOL, V40, P671, DOI 10.1182/blood.V40.5.671.671; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035; IMAGAWA S, 1991, BLOOD, V77, P278; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Sambrook J, 1989, MOL CLONING LABORATO; SCHUSTER SJ, 1989, BLOOD, V73, P13; SCHUSTER SJ, 1987, BLOOD, V70, P316; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SEMENZA GL, 1990, AM J HUM GENET, V47, pA117; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	21	193	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15563	15566						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874713				2022-12-25	WOS:A1991GB97700003
J	DEQUARDCHABLAT, M; RIVA, M; CARLES, C; SENTENAC, A				DEQUARDCHABLAT, M; RIVA, M; CARLES, C; SENTENAC, A			RPC19, THE GENE FOR A SUBUNIT COMMON TO YEAST RNA-POLYMERASES A-(I) AND C-(III)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; RIBOSOMAL-PROTEIN GENES; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PHOSPHORYLATED SUBUNITS; OLIGONUCLEOTIDE PROBES; SUBSTRATE-SPECIFICITY; SYNTHETIC PEPTIDES; ANTIBODY PROBES	Yeast RNA polymerases A (I) and C (III) share a subunit called AC 19. The gene encoding AC 19 has been isolated from yeast genomic DNA using oligonucleotide probes deduced from peptide sequences of the isolated subunit. This gene (RPC19) contains an intron-free open reading frame of 143 amino acid residues. RPC19 is a single copy gene that maps on chromosome II and is essential for cell viability. The amino acid sequence contains a sequence motif common to the Escherichia coli RNA polymerase-alpha-subunit, the Saccharomyces cerevisiae AC40 and B44.5 subunits, the human hRPB33 product, and the CnjC conjugation-specific gene product of Tetrahymena. The 5'-upstream region contains a sequence element, the PAC box, that has been conserved in at least 10 genes encoding subunits of RNA polymerases A and C.	CENS,DEPT BIOL CELLULAIRE & MOLEC,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE; CENS,INGN PROT LAB,F-91191 GIF SUR YVETTE,FRANCE	CEA; CEA								Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BELL GI, 1977, J BIOL CHEM, V252, P3082; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BONNEAUD N, 1991, IN PRESS YEAST; BREANT B, 1983, EUR J BIOCHEM, V130, P247; BREANT B, 1983, J BIOL CHEM, V258, P1968; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; BUHLER JM, 1980, J BIOL CHEM, V255, P9949; BUHLER JM, 1976, FEBS LETT, V71, P37, DOI 10.1016/0014-5793(76)80893-9; BUHLER JM, 1974, P NATL ACAD SCI USA, V249, P5963; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; Davis R.W., 1980, ADV BACTERIAL GENET, P254; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DELLASETA F, 1990, J BIOL CHEM, V265, P15168; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GUDENUS R, 1988, GENETICS, V119, P517; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HEALY AM, 1987, MOL CELL BIOL, V7, P3785, DOI 10.1128/MCB.7.10.3785; HIMMELFARB HJ, 1987, MOL CELL BIOL, V7, P2155, DOI 10.1128/MCB.7.6.2155; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUET J, 1982, J BIOL CHEM, V257, P2613; HUET J, 1985, J BIOL CHEM, V260, P5304; HUET J, 1982, EMBO J, V1, P1193, DOI 10.1002/j.1460-2075.1982.tb00012.x; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; INGLES CJ, 1984, P NATL ACAD SCI-BIOL, V81, P2157, DOI 10.1073/pnas.81.7.2157; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES P, 1991, J BIOL CHEM, V266, P5616; KAWAKAMI K, 1980, BIOCHEMISTRY-US, V19, P3491, DOI 10.1021/bi00556a013; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEER RJ, 1985, CURR GENET, V9, P273, DOI 10.1007/BF00419955; MANIATIS T, 1982, MOL CLONING LABORATO, P269; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; MEMET S, 1988, J BIOL CHEM, V263, P2830; MICOUIN JY, 1988, THESIS U PARIS 11 OR; MORROW BE, 1989, J BIOL CHEM, V264, P9061; MOSRIN C, 1990, CURR GENET, V17, P367, DOI 10.1007/BF00334516; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; MOSRIN C, 1990, THESIS U PARIS 11 OR; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; Parent S A, 1985, Yeast, V1, P83, DOI 10.1002/yea.320010202; PATI UK, 1990, J BIOL CHEM, V265, P8400; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIFTINA F, 1990, BIOCHEMISTRY-US, V29, P4440, DOI 10.1021/bi00470a026; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; RIVA M, 1987, J BIOL CHEM, V262, P14377; RIVA M, 1986, P NATL ACAD SCI USA, V83, P1554, DOI 10.1073/pnas.83.6.1554; RIVA M, 1982, J BIOL CHEM, V257, P4570; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SHERMAN F, 1986, METHODS YEAST GENETI, P164; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WITTEKIND M, 1988, MOL CELL BIOL, V8, P3997, DOI 10.1128/MCB.8.10.3997; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	78	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15300	15307						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869554				2022-12-25	WOS:A1991GB09700072
J	JACOBS, AL; CARSON, DD				JACOBS, AL; CARSON, DD			PROTEOGLYCAN SYNTHESIS AND METABOLISM BY MOUSE UTERINE STROMA CULTURED INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; HEPARIN HEPARAN-SULFATE; EXTRACELLULAR-MATRIX; SURFACE PROTEOGLYCAN; MESSENGER-RNA; D-XYLOSIDES; LAMININ; LOCALIZATION; PREGNANCY; UTERUS	Chondroitin sulfate proteoglycans (CSPGs) and hyaluronate have been identified as the predominant glycoconjugates synthesized and secreted by mouse uterine stromal cells (USC) cultured in vitro. CSPGs in both the cell-associated and secreted fractions have identical characteristics with regard to anion exchange chromatographic behavior, sensitivity of the intact molecules and constituent glycosaminoglycans to a variety of chemical and enzymatic digestions, lack of interaction with hydrophobic affinity resins, and density (> 1.46 g/ml). Chase labeling studies indicated a metabolic half-life of cell-associated, [S-35]sulfate-labeled macromolecules of 5-6 h. Once secreted, CSPGs did not appear to be degraded or endocytosed to a significant extent. In contrast, a large fraction (50%) of the cell-associated CSPGs were degraded to low M(r) (< 3000) products via a chloroquine-sensitive pathway. Studies of the kinetics of intracellular transport indicated that approximately 30 min were required for CSPG core proteins to move from the rough endoplasmic reticulum to the Golgi apparatus and 15-20 min to move from the Golgi to the cell surface, i.e. protease-accessible compartment. There was no significant lag period between the time CSPGs first arrived at the cell surface and the time at which they were first detectable in the medium. Examination of CSPG expression during USC differentiation in utero or in vitro demonstrated that these molecules were produced with similar efficiency by USC under both conditions. Collectively, these studies provide the first comprehensive description of proteoglycan production and metabolism in USC, a uterine cell type intimately involved with embryo implantation processes. Potential functions for CSPGs and hyaluronate as modulators of embryo invasive processes and uterine expansion are proposed.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007207, R37HD025235, R01HD025235] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 07207, HD 25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARSON DD, 1987, DEV BIOL, V120, P228, DOI 10.1016/0012-1606(87)90120-5; CARSON DD, 1988, J CELL BIOL, V107, P2425, DOI 10.1083/jcb.107.6.2425; CHEN LH, 1987, J BIOL CHEM, V262, P17247; CIDADAO AJ, 1990, EUR J CELL BIOL, V52, P105; DUTT A, 1990, J BIOL CHEM, V265, P430; DUTT A, 1986, ENDOCRINOLOGY, V118, P661, DOI 10.1210/endo-118-2-661; ENDERS AC, 1981, CELLULAR MOL ASPECTS, P365; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FINN CA, 1986, BIOL REV, V61, P313, DOI 10.1111/j.1469-185X.1986.tb00657.x; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; GLASSER SR, 1986, BIOL REPROD, V35, P463, DOI 10.1095/biolreprod35.2.463; GRINNELL F, 1982, J CELL BIOL, V94, P597, DOI 10.1083/jcb.94.3.597; HASCALL VC, 1985, CELL BIOL EXTRACELLU, P39; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; JACOBS AL, 1990, J CELL BIOL, V111, P1472; KARKAVELAS G, 1988, J ULTRA MOL STRUCT R, V100, P137, DOI 10.1016/0889-1605(88)90021-3; KISALUS LL, 1987, ANAT RECORD, V218, P402, DOI 10.1002/ar.1092180408; LEIVO I, 1980, DEV BIOL, V76, P100, DOI 10.1016/0012-1606(80)90365-6; LEPI TJ, 1982, J HISTOCHEM CYTOCHEM, V30, P413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OSBORN M, 1982, CELL, V31, P303, DOI 10.1016/0092-8674(82)90122-2; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAITO H, 1968, J BIOL CHEM, V243, P1536; SCHLAFKE S, 1975, BIOL REPROD, V12, P41, DOI 10.1095/biolreprod12.1.41; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SENIOR PV, 1988, DEVELOPMENT, V104, P431; TANG JP, 1987, J BIOL CHEM, V262, P12832; TOOLE BP, 1979, P NATL ACAD SCI USA, V76, P6299, DOI 10.1073/pnas.76.12.6299; WEWER UM, 1986, DIFFERENTIATION, V32, P49, DOI 10.1111/j.1432-0436.1986.tb00555.x; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; WOODS A, 1985, J BIOL CHEM, V260, P872; WU TC, 1983, DEV BIOL, V100, P496, DOI 10.1016/0012-1606(83)90242-7; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260; YULEE LY, 1988, MOL ENDOCRINOL, V2, P431, DOI 10.1210/mend-2-5-431; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15464	15473						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869566				2022-12-25	WOS:A1991GB09700095
J	LIVI, GP; LILLQUIST, JS; MILES, LM; FERRARA, A; SATHE, GM; SIMON, PL; MEYERS, CA; GORMAN, JA; YOUNG, PR				LIVI, GP; LILLQUIST, JS; MILES, LM; FERRARA, A; SATHE, GM; SIMON, PL; MEYERS, CA; GORMAN, JA; YOUNG, PR			SECRETION OF N-GLYCOSYLATED INTERLEUKIN-1-BETA IN SACCHAROMYCES-CEREVISIAE USING A LEADER PEPTIDE FROM CANDIDA-ALBICANS - EFFECT OF N-LINKED GLYCOSYLATION ON BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY STRUCTURAL REQUIREMENTS; HUMAN RECOMBINANT INTERLEUKIN-1-BETA; RECEPTOR-BINDING AFFINITY; SITE-SPECIFIC MUTAGENESIS; 2.0 A-RESOLUTION; CELL-FREE SYSTEM; ESCHERICHIA-COLI; PROTEIN GLYCOSYLATION; CRYSTALLOGRAPHIC REFINEMENT; ENDOPLASMIC-RETICULUM	Human interleukin-1-beta (IL-1-beta) is expressed in activated monocytes as a 31-kDa precursor protein which is processed and secreted as a mature, unglycosylated 17-kDa carboxyl-terminal fragment, despite the fact that it contains a potential N-linked glycosylation site near the NH2 terminus (-Asn7-Cys8-Thr9-). cDNA coding for authentic mature IL-1-beta was fused to the signal sequence from the Candida albicans glucoamylase gene, two amino acids downstream from the signal processing site. Upon expression in Saccharomyces cerevisiae, approximately equimolar amounts of N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1-beta protein were secreted. The N-glycosylated yeast recombinant IL-1-beta exhibited a 5-7-fold lower specific activity compared to the unglycosylated species. The mechanism responsible for inefficient glycosylation was also studied. We found no differences in secretion kinetics or processing between the two extracellular forms of IL-1-beta. The 17-kDa protein, which was found to lack core sugars, does not result from deglycosylation of the 22-kDa protein in vivo and does not result from saturation of the glycosylation enzymatic machinery through overexpression. Alteration of the uncommon Cys8 residue in the -Asn-X-Ser/Thr-glycosylation site to Ser also had no effect. However, increasing the distance between Asn7 and the signal processing site increased the extent of core N-linked glycosylation, suggesting a reduction in glycosylation efficiency near the NH2 terminus.	SMITHKLINE BEECHAM PHARMACEUT, DEPT GENE EXPRESS SCI, L48, POB 1539, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MOLEC GENET, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT IMMUNOL, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								AURON PE, 1987, J IMMUNOL, V138, P1447; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; BALDARI C, 1987, PROTEIN ENG, V1, P433, DOI 10.1093/protein/1.5.433; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BEUSCHER HU, 1990, J IMMUNOL, V144, P2179; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CARSON DD, 1981, J BIOL CHEM, V256, P1552; CASAGLI MC, 1989, BIOCHEM BIOPH RES CO, V162, P357, DOI 10.1016/0006-291X(89)92004-4; DESHAIES RJ, 1989, TRENDS GENET, V5, P87, DOI 10.1016/0168-9525(89)90032-2; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ERNST JF, 1988, DNA-J MOLEC CELL BIO, V7, P355, DOI 10.1089/dna.1.1988.7.355; ESMON B, 1984, J BIOL CHEM, V259, P322; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FURUTANI Y, 1985, NUCLEIC ACIDS RES, V13, P5869, DOI 10.1093/nar/13.16.5869; GAIT MJ, OLIGONUCLEOTIDE SYNT; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GIRI JG, 1985, J IMMUNOL, V134, P343; GORMAN JA, 1986, GENE, V48, P13, DOI 10.1016/0378-1119(86)90347-1; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GRAY PW, 1986, J IMMUNOL, V137, P3644; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HART GW, 1979, J BIOL CHEM, V254, P9747; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; HICKS JB, 1976, GENETICS, V83, P245; HUANG JJ, 1987, FEBS LETT, V223, P294, DOI 10.1016/0014-5793(87)80307-1; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KAMOGASHIRA T, 1988, J BIOCHEM-TOKYO, V104, P837, DOI 10.1093/oxfordjournals.jbchem.a122559; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1984, BIOCHIM BIOPHYS ACTA, V799, P246, DOI 10.1016/0304-4165(84)90267-8; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LILLQUIST JS, 1988, J IMMUNOL, V141, P1975; LIVI GP, 1990, GENE, V88, P297, DOI 10.1016/0378-1119(90)90048-V; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MACDONALD HR, 1986, FEBS LETT, V209, P295, DOI 10.1016/0014-5793(86)81130-9; Maniatis T., 1982, MOL CLONING; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Marshall R D, 1974, Biochem Soc Symp, P17; MASUI Y, 1989, THERAPEUTIC PEPTIDES, P167; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCUNE JM, 1981, P NATL ACAD SCI-BIOL, V78, P5127, DOI 10.1073/pnas.78.8.5127; MEYERS CA, 1987, J BIOL CHEM, V262, P11176; MIERENDORF RC, 1983, J BIOL CHEM, V258, P5878; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; ODATAMAI S, 1985, J BIOL CHEM, V260, P57; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RANBY M, 1982, FEBS LETT, V146, P289, DOI 10.1016/0014-5793(82)80936-8; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; Rothstein R., 1985, DNA CLONING, VII, P45; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHATZMAN AR, 1986, ANN NY ACAD SCI, V478, P233, DOI 10.1111/j.1749-6632.1986.tb15534.x; SIMON PL, 1985, J IMMUNOL METHODS, V84, P85, DOI 10.1016/0022-1759(85)90417-X; STRUCK DK, 1978, J BIOL CHEM, V253, P5786; SUTTLES J, 1990, J IMMUNOL, V144, P175; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; WALTER P, 1984, CELL, V45, P397; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WINGFIELD P, 1987, FEBS LETT, V215, P160, DOI 10.1016/0014-5793(87)80133-3; YEM AW, 1988, LYMPHOKINE RES, V7, P85; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447	75	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15348	15355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869556				2022-12-25	WOS:A1991GB09700078
J	WOLF, DL; SINHA, U; HANCOCK, TE; LIN, PH; MESSIER, TL; ESMON, CT; CHURCH, WR				WOLF, DL; SINHA, U; HANCOCK, TE; LIN, PH; MESSIER, TL; ESMON, CT; CHURCH, WR			DESIGN OF CONSTRUCTS FOR THE EXPRESSION OF BIOLOGICALLY-ACTIVE RECOMBINANT HUMAN FACTOR-X AND FACTOR-XA - KINETIC-ANALYSIS OF THE EXPRESSED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PROTHROMBIN; MAMMALIAN-CELLS; STUART FACTOR; FACTOR-VA; COAGULATION; ACTIVATION; PROTEASE; MECHANISM; EFFICIENT; INHIBITION	Activation of vitamin K-dependent plasma proteases occurs by specific interaction with components of the blood coagulation cascade. In this report, we describe the direct expression and enzymatic characterization of the human coagulation zymogen factor X and its activated form, factor Xa, from transformed Chinese hamster ovary fibroblast cell lines. Expression was achieved using either a full-length factor X cDNA or a unique mutant factor Xa cDNA. The functional factor Xa precursor contained a novel tripeptide bridge in place of the native 52-amino acid activation peptide. This mutation allowed for intracellular processing and secretion of the activated form of factor X. Secreted recombinant factors X (rX) and Xa (rXa) were purified by sequential anion-exchange and immunoaffinity chromatography. The enzymatic activities of factors rX and rXa were compared with those of plasma factors X and Xa in three independent assay systems. In comparison to human plasma factor X, the amidolytic, prothrombinase complex, and plasma clotting activities of factor rX were 50, 85, and 43%, respectively. The corresponding comparative activities for factor rXa were 32, 64, and 48%, respectively. The ability to directly express mutant forms of biologically active human factor X will facilitate the structure/function analysis of this important blood coagulation protein and may lead to the development of novel coagulation inhibitors.	UNIV OKLAHOMA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT PATHOL,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,OKLAHOMA CITY,OK 73190; OKLAHOMA MED RES FDN,CARDIOVASC BIOL SECT,OKLAHOMA CITY,OK 73104; UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405	Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Vermont	WOLF, DL (corresponding author), COR THERAPEUT INC,256 E GRAND AVE,SUITE 80,S SAN FRANCISCO,CA 94080, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL044782, R01HL029807, P50HL035058, R43HL044782] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29807-10, HL44782-01, HL35058] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BROZE GJ, 1988, BLOOD, V71, P335; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHURCH WR, 1985, THROMB RES, V38, P417, DOI 10.1016/0049-3848(85)90140-9; CREIGHTON T, 1984, PROTEINS STRUCTURE M, P427; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; EHRLICH HJ, 1989, J BIOL CHEM, V264, P14298; FAIR DS, 1984, BLOOD, V64, P194; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FURIE B, 1990, BLOOD, V75, P1753; GIRARD TJ, 1990, SCIENCE, V248, P1421, DOI 10.1126/science.1972598; GRINNELL BW, 1990, BLOOD, V76, P2546; HARLOW E, 1988, ANTIBODIES LABORATOR; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; Maniatis T., 1982, MOL CLONING; MANN KG, 1990, BLOOD, V76, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MESSIER TL, 1991, IN PRESS GENE AMST; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; RAPAPORT SI, 1989, BLOOD, V73, P359; SALVESEN G, 1984, PROTEOLYTIC ENZYMES; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Steinberg M, 1987, HEMOSTASIS THROMBOSI, P112; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1990, J BIOL CHEM, V265, P10821; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	34	22	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13726	13730						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856206				2022-12-25	WOS:A1991FY02700043
J	THEVENIN, C; KIM, SJ; KEHRL, JH				THEVENIN, C; KIM, SJ; KEHRL, JH			INHIBITION OF PROTEIN PHOSPHATASES BY OKADAIC ACID INDUCES AP1 IN HUMAN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-EXPRESSION; TUMOR PROMOTER; JUN PROTEINS; FOS; ONCOGENE; PRODUCT; PHOSPHORYLATION; ACTIVATION; ENCODES; MEMBER	To examine the role of protein phosphatases in T cell activation,Jurkat cells were treated with okadaic acid, an inhibitor of type 1 and 2A phosphatases, and nuclear extracts were examined for the presence of AP1 as a measure of early T cell activation. Okadaic acid was found to be a potent inducer of AP1. In contrast to phorbol esters such as phorbol myristate acetate (PMA), the induction of AP1 by okadaic acid occurs predominantly by transcriptional activation of the jun and fos family of proto-oncogenes. Surprisingly, while the addition of phytohemagglutinin further enhanced the induction of AP1, the addition of PMA inhibited it. Okadaic acid treatment was found to dramatically increase mRNA transcripts of the jun family of proto-oncogenes including c-jun, junD, and junB and to a lesser extent the fos family including c-fos and fra-1. By comparison, PMA is a very inefficient inducer of the jun gene family in Jurkat cells. Similar to its effect on the induction of AP1 by okadaic acid, PMA inhibits the induction of c-jun mRNA by okadaic acid. Transfection of c-jun promoter constructs confirmed the marked difference between PMA and okadaic acid in inducing c-jun transcription. The induction of AP1 by okadaic acid suggests that protein phosphatases 1 and 2A (PP1 and PP2A) may be involved in T cell activation as important negative regulators of the transcription factor AP1.	NIAID,IMMUNOREGULAT LAB,BLDG 10,RM 11B-13,BETHESDA,MD 20892; NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DORSETT DL, 1983, J VIROL, V48, P218, DOI 10.1128/JVI.48.1.218-228.1983; ERDODI F, 1988, BIOCHEM BIOPH RES CO, V153, P156, DOI 10.1016/S0006-291X(88)81202-6; FRANZA B, 1988, SCIENCE, V243, P1695; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KOURAZIDES T, 1989, NATURE, V340, P568; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; WILKINSON, 1988, NUCLEIC ACIDS RES, V16; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	27	113	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9363	9366						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851743				2022-12-25	WOS:A1991FM45900007
J	BESSMAN, MJ; BULLIONS, LC; BHATNAGAR, SK; BRADEN, BC; LOVE, WE				BESSMAN, MJ; BULLIONS, LC; BHATNAGAR, SK; BRADEN, BC; LOVE, WE			CRYSTALLIZATION AND PRELIMINARY-X-RAY DIFFRACTION STUDIES ON THE MUTT NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MUTATOR GENE	The mutT nucleoside triphosphatase, which prevents AT-->CG transversions during DNA replication, has been crystallized from ammonium sulfate utilizing a novel technique involving vapor diffusion in capillaries. X-ray diffraction analysis has revealed that the crystals are monoclinic, space group P2(1), with cell constants a = 34.14, b = 72.54, c = 56.38, and beta = 98.90. The V(m) value of 2.31 angstrom3/Da is consistent with two molecules of enzyme per asymmetric unit. The crystals are reasonably stable in the x-ray beam, and a data set to 2.5 angstrom resolution has been collected for native protein. There is evidence that the crystals diffract to at least 2.1 angstrom.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,THOMAS C JENKINS DEPT BIOPHYS,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University	BESSMAN, MJ (corresponding author), JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218, USA.				NICHD NIH HHS [HD 07103] Funding Source: Medline; NIGMS NIH HHS [GM-18649] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007103] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; BHATNAGAR SK, 1990, J BACTERIOL, V172, P2802, DOI 10.1128/jb.172.5.2802-2803.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; MATHEWS BW, 1968, J MOL BIOL, V33, P1491; MATHEWS BW, 1974, J MOL BIOL, V82, P513; SCHAAPER RM, 1987, J BIOL CHEM, V262, P16267; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; ZEPPEZAUER M, 1986, ARCH BIOCHEM BIOPHYS, V126, P564	11	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9055	9056						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851163				2022-12-25	WOS:A1991FM03800062
J	WATSON, F; ROBINSON, J; EDWARDS, SW				WATSON, F; ROBINSON, J; EDWARDS, SW			PROTEIN KINASE-C-DEPENDENT AND C-INDEPENDENT ACTIVATION OF THE NADPH OXIDASE OF HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING SYSTEM; RESPIRATORY BURST; CHEMI-LUMINESCENCE; POLYMORPHONUCLEAR LEUKOCYTES; SUBCELLULAR-LOCALIZATION; STAPHYLOCOCCUS-AUREUS; STAUROSPORINE; INHIBITOR	The protein kinase C inhibitor, staurosporine, inhibited NADPH oxidase activity of human neutrophils activated by phorbol myristate acetate. However, this inhibitor had no effect on either the initiation or the maximal rate of O2- secretion activated by the chemotactic peptide, fMet-Leu-Phe, but resulted in a more rapid termination of oxidant production. Similarly, staurosporine had no effect on the rapid (1 min) increase in luminol-dependent chemiluminescence activated by fMet-Leu-Phe, but the second (intracellular) phase of oxidant production was inhibited. The initial burst of oxidant production during phagocytosis was similarly protein kinase C-independent, but again the later phases of oxidase activity were staurosporine-sensitive. Neutrophils loaded with Quin-2 at concentrations sufficient to act as a Ca2+ buffer could not secrete O2- in response to fMet-Leu-Phe; although the initial (protein kinase C-independent) burst of luminol chemiluminescence was not observed in fMet-Leu-Phe-stimulated Ca2+-buffered cells, the second phase of (protein kinase C-dependent) oxidant production was largely unaffected. Hence, the initial burst of oxidant production activated by fMet-Leu-Phe, opsonized zymosan, and latex beads is independent of the activity of protein kinase C-dependent intracellular activation processes, but the activity of this kinase is required to extend or sustain the duration of oxidant production.	UNIV LIVERPOOL,DEPT BIOCHEM,POB 147,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool				Edwards, Steven/0000-0002-7074-0552	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKARD LP, 1988, BLOOD, V72, P322; ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1984, BLOOD, V64, P959; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BENDER JG, 1983, INFECT IMMUN, V41, P1062, DOI 10.1128/IAI.41.3.1062-1070.1983; BENDER JG, 1986, INFLAMMATION, V10, P443, DOI 10.1007/BF00915828; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRIHEIM G, 1984, INFECT IMMUN, V45, P1; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BROWN KA, 1988, BRIT J RHEUMATOL, V27, P150; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; CURNUTTE JT, 1988, PHAGOCYTIC DEFECTS 1; DAHLGREN C, 1985, INFECT IMMUN, V47, P326, DOI 10.1128/IAI.47.1.326-328.1985; DAHLGREN C, 1987, BIOCHIM BIOPHYS ACTA, V930, P33, DOI 10.1016/0167-4889(87)90152-2; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; EDWARDS SW, 1990, FREE RADICAL RES COM, V10, P333, DOI 10.3109/10715769009149902; EDWARDS SW, 1989, FEBS LETT, V256, P62, DOI 10.1016/0014-5793(89)81718-1; EDWARDS SW, 1988, J GEN MICROBIOL, V134, P37; EDWARDS SW, 1986, BIOCHEM J, V237, P601, DOI 10.1042/bj2370601; EDWARDS SW, 1987, J GEN MICROBIOL, V133, P3591; EDWARDS SW, 1987, J CLIN LAB IMMUNOL, V22, P35; GARCIA RC, 1984, BIOCHEM J, V219, P233, DOI 10.1042/bj2190233; GARCIA RC, 1988, BIOCHEM J, V252, P901, DOI 10.1042/bj2520901; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; HALLETT MB, 1983, BIOCHEM J, V216, P459, DOI 10.1042/bj2160459; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; KOENDERMAN L, 1989, FEBS LETT, V243, P399, DOI 10.1016/0014-5793(89)80170-X; LACKIE JM, 1987, BIOCHEM PHARMACOL, V36, P1941, DOI 10.1016/0006-2952(87)90492-8; LACKIE JM, 1988, J CELL SCI, V89, P449; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARIDONNEAUPARINI I, 1986, J IMMUNOL, V137, P2925; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MCPHAIL LC, 1985, J CLIN INVEST, V751, P735; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; NURCOMBE HL, 1989, ANN RHEUM DIS, V48, P56, DOI 10.1136/ard.48.1.56; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SADLER KL, 1988, PHAGOCYTIC DEFECTS, V2, P185; SAKO T, 1988, CANCER RES, V48, P4646; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAUBER AI, 1987, BLOOD, V69, P711; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WEISBART RH, 1989, ANN INTERN MED, V110, P297, DOI 10.7326/0003-4819-110-4-297; WOLF M, 1988, BIOCHEM BIOPH RES CO, V154, P1273, DOI 10.1016/0006-291X(88)90277-X	59	115	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7432	7439						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850407				2022-12-25	WOS:A1991FJ34200021
J	HUNZICKERDUNN, M; CUTLER, RE; MAIZELS, ET; DEMANNO, DA; LAMM, MLG; ERLICHMAN, J; SANWAL, BD; LABARBERA, AR				HUNZICKERDUNN, M; CUTLER, RE; MAIZELS, ET; DEMANNO, DA; LAMM, MLG; ERLICHMAN, J; SANWAL, BD; LABARBERA, AR			ISOZYMES OF CAMP-DEPENDENT PROTEIN-KINASE PRESENT IN THE RAT CORPUS-LUTEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; II REGULATORY SUBUNIT; AMP RECEPTOR PROTEINS; NEURO-BLASTOMA CELLS; AMINO-ACID-SEQUENCE; CYCLIC-AMP; BINDING-PROTEINS; SKELETAL-MUSCLE; MOLECULAR CHARACTERIZATION; CATALYTIC SUBUNIT	Regulatory (R) subunits and their association with catalytic subunits to form cAMP-dependent protein kinase holoenzymes were investigated in corpora lutea of pregnant rats. Following separation by DEAE-cellulose chromatography, R subunits were identified by labeling with 8-N3[P-32]cAMP and autophosphorylation on one and two-dimensional gel electrophoresis and by reactivity with antisera. DEAE-cellulose elution of R subunits with catalytic subunits as holoenzymes or without catalytic subunits was determined by sedimentation characteristics on sucrose density gradient centrifugation and by cAMP-stimulated kinase activation characteristics on Eadie-Scatchard analysis. We identified the presence of a type I holoenzyme containing RI-alpha (M(r) 47,000) subunits, a prominent type II holoenzyme containing RII-beta (M(r) 52,000) subunits, and a second more acidic type II holoenzyme peak containing both RII-beta and RII-alpha (M(r) 54,000) subunits. However, the majority of total R subunit activity was associated with a catalytic subunit-free peak of RI-alpha protein which on elution from DEAE-cellulose was associated with cAMP. This report establishes the more basic elution position from DEAE-cellulose of the prominent rat luteal RII-beta holoenzyme in very close proximity to free RI-alpha and presents one of the few reports of a normal tissue containing a large percentage of catalytic subunit-free RI-alpha.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA; UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 5C1, ONTARIO, CANADA; UNIV CINCINNATI, COLL MED, DEPT OBSTET & GYNECOL, CINCINNATI, OH 45267 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Western University (University of Western Ontario); University System of Ohio; University of Cincinnati	HUNZICKERDUNN, M (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011356] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11356] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAVO JA, 1982, HDB EXPT PHARM, V58, P363; BEER DG, 1984, ARCH BIOCHEM BIOPHYS, V228, P207, DOI 10.1016/0003-9861(84)90062-6; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTLEY MS, 1984, J BIOL CHEM, V259, P6001; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COBB CE, 1987, J BIOL CHEM, V262, P16566; CORBIN JD, 1975, J BIOL CHEM, V250, P218; ERLICHMA.J, 1973, J BIOL CHEM, V248, P7607; ERLICHMAN J, 1984, J BIOL CHEM, V259, P289; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; GIBORI G, 1988, RECENT PROG HORM RES, V44, P377; HARTL FT, 1983, J BIOL CHEM, V258, P3950; HATHAWAY DR, 1981, J BIOL CHEM, V256, P8183; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HOROWITZ JA, 1988, J BIOL CHEM, V263, P2098; HUNZICKERDUNN M, 1984, ENDOCRINOLOGY, V115, P302, DOI 10.1210/endo-115-1-302; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; HUNZICKERDUNN M, 1985, J BIOL CHEM, V260, P3360; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JAHNSEN T, 1986, J BIOL CHEM, V261, P6637; JAHNSEN T, 1985, J BIOL CHEM, V260, P5980; KAPOOR CL, 1979, J BIOL CHEM, V254, P2427; KERLAVAGE AR, 1980, J BIOL CHEM, V255, P8483; KURTEN RC, 1988, ENDOCRINOLOGY, V123, P2408, DOI 10.1210/endo-123-5-2408; LABARBERA AR, 1982, ENDOCRINOLOGY, V111, P1897, DOI 10.1210/endo-111-6-1897; LABARBERA AR, 1983, AM J PHYSIOL, V244, pE435, DOI 10.1152/ajpendo.1983.244.5.E435; LEISER M, 1986, J BIOL CHEM, V261, P1904; LIU AYC, 1980, J BIOL CHEM, V255, P4421; LIU AYC, 1981, CANCER RES, V41, P4579; LIU AYC, 1987, BIOCHEM BIOPH RES CO, V148, P350, DOI 10.1016/0006-291X(87)91117-X; LORIMER IAJ, 1987, J BIOL CHEM, V262, P17200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKINSON AM, 1981, CANCER RES, V41, P1334; MALKINSON AM, 1983, BIOCHEM BIOPH RES CO, V112, P214, DOI 10.1016/0006-291X(83)91818-1; MUMBY M, 1981, PROTEIN PHOSPHORYLAT, P105; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; PANTER SS, 1981, J NEUROCHEM, V36, P2080, DOI 10.1111/j.1471-4159.1981.tb10837.x; POTTER RL, 1980, J BIOL CHEM, V255, P9706; PRASHAD N, 1979, BIOCHEMISTRY-US, V18, P2717, DOI 10.1021/bi00580a005; RANGELALDAO R, 1979, J BIOL CHEM, V254, P2499; RICHARDS JS, 1980, J BIOL CHEM, V260, P10991; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; Rudolph S A, 1979, Adv Cyclic Nucleotide Res, V10, P107; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SINGH TJ, 1981, J BIOL CHEM, V256, P926; STEIN JC, 1985, J BIOL CHEM, V260, P991; SUDGEN PH, 1976, BIOCHEM J, V159, P423; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALTER U, 1977, J BIOL CHEM, V252, P6494; WALTER U, 1979, P NATL ACAD SCI USA, V76, P3251, DOI 10.1073/pnas.76.7.3251; WELDON SL, 1985, J BIOL CHEM, V260, P6440; ZOLLER MJ, 1979, J BIOL CHEM, V254, P2408	64	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7166	7175						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849902				2022-12-25	WOS:A1991FG72700081
J	MONTPIED, P; GINNS, EI; MARTIN, BM; ROCA, D; FARB, DH; PAUL, SM				MONTPIED, P; GINNS, EI; MARTIN, BM; ROCA, D; FARB, DH; PAUL, SM			GAMMA-AMINOBUTYRIC-ACID (GABA) INDUCES A RECEPTOR-MEDIATED REDUCTION IN GABA-A RECEPTOR ALPHA SUBUNIT MESSENGER-RNAS IN EMBRYONIC CHICK NEURONS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GATED CHLORIDE CURRENTS; RAT-BRAIN; BENZODIAZEPINE RECEPTORS; DOWN-REGULATION; EXPRESSION; COMPLEX; CHANNEL; FAMILY; MUSCLE; SHOWS	Gamma-Aminobutyric acid (GABA), the major inhibitory neurotransmitter in brain, is known to interact with a subclass of receptors that activate a ligand-gated chloride ion channel. Exposure of cultured embryonic chick neurons to physiological concentrations of GABA results in a time-dependent down-regulation of these GABA(A) receptors. To delineate the cellular mechanism(s) responsible for agonist-induced down-regulation of GABA(A) receptors we quantified the levels of GABA(A) receptor alpha-subunit messenger RNAs, which encode the subunit(s) containing agonist recognition site(s), and observed a marked reduction in alpha-subunit mRNAs following exposure of embryonic chick neurons to GABA. Both the down-regulation of GABA(A) receptors and the reduction in alpha-subunit mRNAs induced by GABA were completely antagonized by the specific GABA(A) receptor antagonist SR-95531. These data demonstrate the presence of an agonist-induced receptor-mediated mechanism for regulating the expression of receptor subunit-encoding mRNAs that may be involved in the development of tolerance to the pharmacological actions of drugs known to act via GABA(A) receptors.	NIMH,CLIN NEUROSCI BRANCH,MOLEC PHARMACOL SECT,BLDG 10,RM 4N224,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,MOLEC NEUROGENET SECT,BETHESDA,MD 20892; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			Paul, Steve/ABE-5400-2020; Farb, david H/C-7089-2014	Farb, david H/0000-0002-9050-6480				AKAIKE N, 1985, J PHYSIOL-LONDON, V360, P367, DOI 10.1113/jphysiol.1985.sp015622; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BATESON AN, 1991, IN PRESS MOL BRAIN R; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; CASH DJ, 1987, BIOCHEMISTRY-US, V26, P7557; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI DW, 1977, NATURE, V269, P342, DOI 10.1038/269342a0; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COSTA E, 1987, LIFE SCI, V41, P799, DOI 10.1016/0024-3205(87)90166-4; GYENES M, 1988, MOL PHARMACOL, V34, P719; HABLITZ JJ, 1989, BRAIN RES, V501, P332, DOI 10.1016/0006-8993(89)90650-1; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HANSEN GH, 1987, NEUROTROPHIC ACTIVIT, P109; HEAULME M, 1987, J NEUROCHEM, V48, P1677, DOI 10.1111/j.1471-4159.1987.tb05723.x; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MADTES P, 1983, LIFE SCI, V33, P979, DOI 10.1016/0024-3205(83)90754-3; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MALOTEAUX JM, 1987, EUR J PHARMACOL, V144, P173, DOI 10.1016/0014-2999(87)90517-6; MAMALAKI C, 1987, EMBO J, V6, P561, DOI 10.1002/j.1460-2075.1987.tb04791.x; MONTPIED P, 1988, J NEUROCHEM, V51, P1651, DOI 10.1111/j.1471-4159.1988.tb01137.x; MONTPIED P, 1989, FEBS LETT, V258, P94, DOI 10.1016/0014-5793(89)81623-0; MONTPIED P, 1991, IN PRESS MOL PHARM; MORROW AL, 1990, MOL PHARMACOL, V37, P263; OFFORD J, 1989, NEURON, V2, P1447, DOI 10.1016/0896-6273(89)90190-6; OLSEN RW, 1981, J NEUROCHEM, V37, P1, DOI 10.1111/j.1471-4159.1981.tb05284.x; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; RASBAND W, 1989, IMAGE 1 15; ROCA DJ, 1990, MOL PHARMACOL, V37, P37; SCHOCH P, 1985, NATURE, V314, P168, DOI 10.1038/314168a0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHWARTZ RD, 1986, MOL PHARMACOL, V30, P419; SHIEH BH, 1988, NEUROSCIENCE, V24, P175, DOI 10.1016/0306-4522(88)90321-1; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SKOLNICK P, 1988, ISI ATLAS-PHARMACOL, V2, P19; TEHRANI MHJ, 1988, NEUROSCI LETT, V87, P288, DOI 10.1016/0304-3940(88)90463-6	37	101	102	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6011	6014						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848843				2022-12-25	WOS:A1991FE37300002
J	LIGGETT, SB; CARON, MG; LEFKOWITZ, RJ; HNATOWICH, M				LIGGETT, SB; CARON, MG; LEFKOWITZ, RJ; HNATOWICH, M			COUPLING OF A MUTATED FORM OF THE HUMAN BETA-2-ADRENERGIC RECEPTOR TO GI AND GS - REQUIREMENT FOR MULTIPLE CYTOPLASMIC DOMAINS IN THE COUPLING PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-ADRENERGIC RECEPTOR; BINDING; PROTEIN; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; AFFINITY; CLONING; REGION; SITES	We constructed five genes encoding mutant human beta-2-adrenergic receptor sequence (beta-2AR) which contained 12-22 amino acid substitutions with corresponding sequence from the human alpha-2A(AR) in order to assess the receptor domains involved in G(s) versus G(i) recognition and coupling. Mutant beta-2AR with substitutions in the N (S1)- and C-terminal (S2) portions of the third intracellular loop, the proximal cytoplasmic tail (S3), and two combinations thereof (S2,3 and S1,2,3), were stably expressed in Chinese hamster fibroblasts (CHW-1102), as were the human beta-2AR and alpha-2A(AR) at comparable receptor levels. All mutant receptors with S2 substitutions (i.e. S2, S2,3, S1,2,3) were significantly (approximately 85%) uncoupled from G(s). Upon exposure to pertussis toxin, which uncouples receptors from G(i), S1,2,3 exhibited a 526 +/- 99% increase in agonist-stimulated adenylylcyclase activity compared with a 59 +/- 13% increase with the wild type receptor. This enhanced ability of S1,2,3 to interact with G(s) following pertussis toxin treatment indicates that, in the absence of toxin exposure, substantial coupling occurs between the mutant receptor and G(i). Mutant beta-2AR bearing only one or two alpha-2A(AR)-substituted sequences showed no such enhancement. Forskolin-stimulated enzyme activities were increased by pertussis toxin treatment to similar degrees in all clones examined, indicating that the observed effects are confined to the receptor-mediated pathway. In the absence of GTP, competition binding experiments with S1,2,3, beta-2AR and alpha-2A(AR) revealed that approximately 40-50% of the receptors formed a high affinity binding state for agonist. Pertussis toxin treatment markedly reduced this to approximately 19% with S1,2,3, while having no effect on beta-2AR and completely eliminating high affinity agonist binding to alpha-2A(AR). These results suggest that S1,2,3 interacts with G(i) as well as G(s), and that receptor:G protein coupling requires the concerted participation of multiple cytoplasmic receptor domains.	DUKE UNIV,MED CTR,DEPT MED,BOX 3821,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021; liggett, stephen b/E-7453-2012		NHLBI NIH HHS [HL02386, HL16037, HL45967] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045967, R37HL045967, R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CAMPBELL PT, 1991, IN PRESS MOL PHARM; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WONG SKF, 1990, J BIOL CHEM, V265, P6219	23	127	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4816	4821						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848226				2022-12-25	WOS:A1991FC21700025
J	WENDLAND, M; WAHEED, A; SCHMIDT, B; HILLE, A; NAGEL, G; VONFIGURA, K; POHLMANN, R				WENDLAND, M; WAHEED, A; SCHMIDT, B; HILLE, A; NAGEL, G; VONFIGURA, K; POHLMANN, R			GLYCOSYLATION OF THE MR 46,000 MANNOSE 6-PHOSPHATE RECEPTOR - EFFECT ON LIGAND-BINDING, STABILITY, AND CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; BIOSYNTHESIS; ACQUISITION; CELLS; PURIFICATION; EXPRESSION; CLEAVAGE; PROTEINS; GENE	Using site-directed mutagenesis the N-glycosylation sites of the M(r) 46,000 mannose 6-phosphate receptor (MPR 46) were identified as asparagine residues 57, 83, 107, and 113. The two outer asparagines carry high mannose-type and the two inner asparagines carry complex-type oligosaccharides. The glycosylation mutants were analyzed for stability, binding activity, and subcellular distribution. Replacing asparagine 57, 83, or 107 by threonine decreased only the stability of the receptor. Replacing asparagine 113 by threonine decreased the stability and binding activity. Deletion of three or all four N-glycosylation sites led in addition to an accumulation of the mutant receptors in endoplasmic reticulum-like structures. Nonglycosylated MPR 46 synthesized in the presence of tunicamycin, thus preserving the asparagine residues, had a normal stability and high affinity binding. The decreased stability and binding activity of the receptor mutants is therefore due to the exchange of asparagine residues rather than to the loss of N-linked oligosaccharides. The nonglycosylated receptor, however, displayed a decreased conformational stability after solubilization as a single cycle of freezing and thawing reduced the binding activity to one-third of the control. Simultaneously, the receptor lost its quaternary structure. It is concluded from these results that the N-glycosylation of the receptor is required for the stability of a high affinity conformation, but not for the binding itself or the intracellular stability.	UNIV GOTTINGEN, BIOCHEM ABT 2, GOSSLERSTR 12D, W-3400 GOTTINGEN, GERMANY	University of Gottingen								BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BREITFELD PP, 1984, J BIOL CHEM, V259, P414; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HILLE A, 1989, J BIOL CHEM, V264, P13460; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HUNT RC, 1989, J BIOL CHEM, V264, P9643; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OLSON TS, 1987, J BIOL CHEM, V262, P6816; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; RANDS E, 1990, J BIOL CHEM, V265, P10759; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	29	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4598	4604						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847926				2022-12-25	WOS:A1991FA69400089
J	DUNTEN, RL; COHEN, RE; GREGORI, L; CHAU, V				DUNTEN, RL; COHEN, RE; GREGORI, L; CHAU, V			SPECIFIC DISULFIDE CLEAVAGE IS REQUIRED FOR UBIQUITIN CONJUGATION AND DEGRADATION OF LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE SYSTEM; SHORT-LIVED PROTEIN; HEN EGG LYSOZYME; RIBONUCLEASE-A; ACID; PURIFICATION; PROTEOLYSIS; ATP; POLYPEPTIDE; BREAKDOWN	Both ubiquitin conjugation and ubiquitin-dependent degradation of chicken egg white lysozyme in a reticulocyte lysate depend on the presence of a reducing agent. We present evidence that the reduction of a specific disulfide bond, namely that at Cys6-Cys127, facilitates ubiquitination and is a prerequisite to the formation of a multiubiquitin chain on one of at least four chain initiation sites on lysozyme. The Cys6-Cys127 disulfide bond in lysozyme can be specifically reduced, and the modified protein can be isolated after carboxymethylation of the 2 resulting cysteines. This modified lysozyme no longer requires the presence of a reducing agent for ubiquitin conjugation and degradation. Inhibition of ubiquitination by the dipeptide Lys-Ala revealed that this modified lysozyme, like the unmodified protein, is recognized via the binding of the ubiquitin protein ligase, E3, to the substrate's N-terminal lysyl residue. Both the rate and the extent of ubiquitin-lysozyme conjugation, however, are significantly higher with this modified substrate. Likewise, ubiquitin-dependent degradation of 6,127-reduced/carboxymethylated lysozyme was 2-4 fold faster than degradation of the unmodified counterpart. These results are consistent with an interpretation that the modified lysozyme mimics an intermediate formed at the rate-limiting step of the degradation of lysozyme in the reticulocyte lysate. Reduction of the Cys6-Cys127 disulfide bond is expected to unhinge the N-terminal region of lysozyme, and we propose that the recognition of this otherwise stable protein by the ubiquitin pathway is due to facilitated binding of E3 that results from such a conformational transition.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Wayne State University					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035803, R01GM037666] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR04921] Funding Source: Medline; NIGMS NIH HHS [GM37666, GM35803] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA AS, 1980, INT J PEPT PROT RES, V15, P503; ACHARYA AS, 1978, BIOCHEMISTRY-US, V17, P3064, DOI 10.1021/bi00608a019; AUNE KC, 1969, BIOCHEMISTRY-US, V8, P4579, DOI 10.1021/bi00839a052; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; CANFIELD RE, 1965, J BIOL CHEM, V240, P1997; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAZRA AK, 1984, ANAL BIOCHEM, V137, P437, DOI 10.1016/0003-2697(84)90110-6; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HOUGH R, 1986, J BIOL CHEM, V261, P2391; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOLLES J, 1979, BIOCHEMISTRY-US, V18, P2744, DOI 10.1021/bi00580a009; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685	32	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3260	3267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847143				2022-12-25	WOS:A1991EX60000089
J	RAYNOR, RL; BIN, Z; KUO, JF				RAYNOR, RL; BIN, Z; KUO, JF			MEMBRANE INTERACTIONS OF AMPHIPHILIC POLYPEPTIDES MASTOPARAN, MELITTIN, POLYMYXIN-B, AND CARDIOTOXIN - DIFFERENTIAL INHIBITION OF PROTEIN-KINASE-C, CA2+ - CALMODULIN-DEPENDENT PROTEIN KINASE-II AND SYNAPTOSOMAL MEMBRANE NA,K-ATPASE AND NA+ PUMP AND DIFFERENTIATION OF HL60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; ADENOSINE-TRIPHOSPHATASE; DEGRANULATING PEPTIDES; ISOZYMIC FORMS; WASP VENOM; TROPONIN-C; PHOSPHORYLATION; BINDING; SODIUM; BRAIN	Interactions of certain naturally occurring, amphiphilic polypeptides with membranes were investigated. Mastoparan (wasp venom toxin), melittin (bee venom toxin), cardiotoxin (cobra venom toxin), and polymyxin B (antibacterial antibiotic) inhibited protein kinase C stimulated by phosphatidylserine bilayer or arachidonate monomer and blocked binding of [H-3] phorbol 12,13-dibutyrate to protein kinase C in the presence of phosphatidylserine bilayer, with IC50 values (concentrations causing 50% inhibition) of 1-8-mu-M. Mastoparan and polymyxin B were much less inhibitory (IC50, 10-20-mu-M), whereas melittin and cardiotoxin were similarly inhibitory (IC50, 1-4-mu-M), when protein kinase C was activated instead by synaptosomal membrane. Kinetic analysis indicate that mastoparan inhibited protein kinase C, assayed using phosphatidylserine or synaptosomal membrane as the phospholipid cofactor, competitively with the phospholipid cofactor, in a mixed manner with CaCl2 or diacylglycerol, noncompetitively with histone, and uncompetitively with ATP, with apparent K(i) values of 1.6-18.7-mu-M. Inhibition of Na,K-ATPase in the membrane by these polypeptides had relative potencies different from those for their inhibition of protein kinase C activated by the same membrane preparation; mastoparan and melittin inhibited the two activities with comparable potencies, but polymyxin B and cardiotoxin were far less effective in inhibiting Na,K-ATPase. The same relative inhibitory potencies of the polypeptides (melittin > mastoparan > polymyxin B) for inhibition of Na,K-ATPase were also noted for their inhibition of Ca2+/calmodulin-dependent protein kinase II, Rb-86 uptake (Na+ pump) by HL60 cells and the phorbol ester-induced differentiation of the leukemia cells. These findings were consistent with discrete interactions of the polypeptides with functionally distinct sites on the membrane, leading to differential inhibition of biological activities associated with the membrane. Actions of certain polypeptides appeared to be more specific compared to those of lipid second messengers such as lyso-phosphatidylcholine and sphingosine, and the antineoplastic ether lipid analogs such as 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine.			RAYNOR, RL (corresponding author), EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322, USA.				NATIONAL CANCER INSTITUTE [R01CA036777] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015696, R37HL015696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017608] Funding Source: NIH RePORTER; NCI NIH HHS [CA-36777] Funding Source: Medline; NHLBI NIH HHS [HL-15696] Funding Source: Medline; NINDS NIH HHS [NS-17608] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; ARGIOLAS A, 1985, J BIOL CHEM, V260, P1437; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CHARP PA, 1988, BIOCHEM PHARMACOL, V37, P951, DOI 10.1016/0006-2952(88)90187-6; FUJISAWA H, 1984, CALCIUM CELL FUNCTIO, V25, P67; GIRARD PR, 1986, J BIOL CHEM, V261, P370; HELFMAN DM, 1983, CANCER RES, V43, P2955; HIRAI Y, 1980, BIOMED RES-TOKYO, V1, P185, DOI 10.2220/biomedres.1.185; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KATOH N, 1982, BIOCHEM J, V202, P217, DOI 10.1042/bj2020217; KELLY RA, 1985, J BIOL CHEM, V260, P1396; KISS Z, 1987, BIOCHEM BIOPH RES CO, V142, P661, DOI 10.1016/0006-291X(87)91465-3; KUO JF, 1983, FEBS LETT, V153, P183, DOI 10.1016/0014-5793(83)80144-6; LEUNG WW, 1976, ARCH EXP PHARM, V292, P193; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MATSUDA T, 1983, BIOCHEMISTRY-US, V22, P2209, DOI 10.1021/bi00278a023; MAZZEI GJ, 1982, BIOCHEM BIOPH RES CO, V109, P1129, DOI 10.1016/0006-291X(82)91894-0; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MIYAMOTO E, 1969, J BIOL CHEM, V244, P6395; NESTLER EJ, 1984, PROTEIN PHOSPHORYLAT, P50; OISHI K, 1988, J BIOL CHEM, V263, P6865; OISHI K, 1990, J BIOL CHEM, V265, P70; OKANO Y, 1985, FEBS LETT, V188, P363, DOI 10.1016/0014-5793(85)80403-8; PERIYASAMY SM, 1983, COMP BIOCHEM PHYS B, V76, P449, DOI 10.1016/0305-0491(83)90274-2; Post RL, 1967, METHOD ENZYMOL, V10, P773; SHOJI M, 1988, CANCER RES, V48, P6669; VANEYK JE, 1987, BIOCHEM CELL BIOL, V65, P982; WALLACE MA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P311, DOI 10.1016/0005-2760(89)90018-0; ZHENG B, 1990, CANCER RES, V50, P3025; ZHOU QZ, 1988, BIOCHEMISTRY-US, V27, P7361, DOI 10.1021/bi00419a028	35	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2753	2758						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847132				2022-12-25	WOS:A1991EX60000015
J	KUO, TH; WANG, KKW; CARLOCK, L; DIGLIO, C; TSANG, W				KUO, TH; WANG, KKW; CARLOCK, L; DIGLIO, C; TSANG, W			PHORBOL ESTER INDUCES BOTH GENE-EXPRESSION AND PHOSPHORYLATION OF THE PLASMA-MEMBRANE CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CA-2+ PUMP; CA-2+-TRANSPORTING ATPASE; MOLECULAR-CLONING; MESSENGER-RNA; SMOOTH-MUSCLE; CALCIUM-PUMP; CELLS; PROTEOLYSIS; LYMPHOCYTES	Regulation of the plasma membrane Ca2+ pump in the cell is of critical importance in maintaining calcium homeostasis. Since protein kinase C is known to regulate functions of cellular proteins by direct phosphorylation or by inducing their gene expression, we investigated the possible involvement of protein kinase C in the regulation of the plasma membrane Ca2+ pump. The Ca2+ pump was isolated by immunoprecipitation from [P-32]orthophosphate-labeled cultured rat aortic endothelial cells grown in the absence or presence of phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C. PMA treatment of cells led to a rapid increase in the phosphorylation level (1.3-fold) within 5 min and a further increase to 2.9-fold after 3 h. Prolonged PMA treatment also induced the accumulation of the Ca2+ pump mRNA, followed by increased levels of the pump protein. The peak level of the pump mRNA induction occurred at 4 h and was 8-20-fold higher than the control culture without PMA. The rate of the Ca2+ pump protein accumulation was slower, reaching a maximum of 3.5-fold after 6 h. Induction of the pump mRNA was suppressed by the protein kinase C inhibitor 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine and by down-regulation of protein kinase C. Inactive phorbol ester 4-alpha-phorbol didecanoate also failed to mimic the PMA effect. These results suggest that the induction of Ca2+ pump expression is mediated by a protein kinase C-dependent mechanism. Furthermore, since the induction of the Ca2+ pump mRNA was blocked when cycloheximide and PMA were added together, this suggests that newly synthesized protein factor is needed to produce the mRNA induction. Our results suggest that protein kinase C is involved in the regulation of the Ca2+ pump in endothelial cells. At the protein level, it modifies the Ca2+ pump by phosphorylation, and at the gene level, it stimulates the expression of its mRNA and thereby increases the amount of the pump protein.	WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL,DETROIT,MI 48201	Wayne State University	KUO, TH (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PATHOL,540 E CANFIELD,DETROIT,MI 48201, USA.			Wang, Kevin/0000-0002-9343-6473	NHLBI NIH HHS [HL-39481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKON DL, 1988, SCIENCE, V239, P998; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARRERA AC, 1989, J BIOL CHEM, V264, P15650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGLIO CA, 1989, LAB INVEST, V60, P523; DU Y, 1990, FASEB J, V4, pA935; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; GREEB J, 1989, J BIOL CHEM, V264, P18569; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KIMURA E, 1990, J BIOL CHEM, V265, P3518; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1989, J BIOL CHEM, V264, P16030; MORGAN J, 1990, J CELL BIOCHEM, V14, P11; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHATZMANN HJ, 1986, J CARDIOVASC PHARM, V8, P533; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; WANG KW, 1990, 7TH INT S CALC BIND, P11	33	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2520	2525						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846629				2022-12-25	WOS:A1991EV51500077
J	KOVACS, KL; TIGYI, G; THANH, LT; LAKATOS, S; KISS, Z; BAGYINKA, C				KOVACS, KL; TIGYI, G; THANH, LT; LAKATOS, S; KISS, Z; BAGYINKA, C			STRUCTURAL REARRANGEMENTS IN ACTIVE AND INACTIVE FORMS OF HYDROGENASE FROM THIOCAPSA-ROSEOPERSICINA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; GEL-ELECTROPHORESIS; CHROMATIUM-VINOSUM; NICKEL	The electrophoretic behavior of Thiocapsa roseopersicina hydrogenase on sodium dodecyl sulfate gels demonstrates that the protein exists in two active forms, A1 and A2, which may be interconverted. Each of these forms has a characteristic electrophoretic mobility and differs in its sensitivity to O2. Form A1 is O2-labile and converts to A2 under O2. Form A2 is less sensitive to O2 and may be converted into A1 under H2 atmosphere. Both active forms are present in aerobically isolated samples. Because the proteins are still active on 15% sodium dodecyl sulfate gels, they are not completely denatured, and the apparent molecular masses do not necessarily represent the true molecular masses of the enzymes. A1 has an R(f) = 0.19, corresponding to an apparent molecular mass of 90 kDa, and A2 has an R(f) = 0.35, corresponding to an apparent molecular mass of 49 kDa. A sedimentation equilibrium centrifugation study of the active enzyme shows that the holoenzyme has a molecular mass of 98 kDa. Form A2 may be separated into two subunits of molecular mass of 64 kDa and 34 kDa, respectively. Thus, form A2 represents the holoenzyme with a true molecular mass of 98 kDa. Amino acid compositions and N-terminal amino acid sequences of the A2 protein and these subunits are consistent with a heterodimeric holoenzyme. The relationship between the conformational changes detected in this study and a three-state scheme proposed on the basis of EPR spectroscopic studies of the metal-containing cofactors present in the enzyme is also discussed.	HUNGARIAN ACAD SCI,CTR BIOL RES,INST ENZYMOL,H-6701 SZEGED,HUNGARY; HUNGARIAN ACAD SCI,CTR BIOL RES,INST BIOCHEM,H-6701 SZEGED,HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Hungarian Academy of Sciences; Hungarian Biological Research Center	KOVACS, KL (corresponding author), HUNGARIAN ACAD SCI,CTR BIOL RES,INST BIOPHYS,H-6701 SZEGED,HUNGARY.		Lakatos, Susan/I-9498-2019; Bagyinka, Csaba/D-1600-2012; Kovacs, Kornel L./C-3265-2012					ACKRELL BAC, 1966, J BACTERIOL, V92, P828, DOI 10.1128/JB.92.4.828-838.1966; ADAMS MWW, 1981, BIOCHIM BIOPHYS ACTA, V594, P105; ALBRACHT SPJ, 1985, BIOCHIM BIOPHYS ACTA, V832, P89, DOI 10.1016/0167-4838(85)90177-3; ALBRACHT SPJ, 1982, BIOCHIM BIOPHYS ACTA, V681, P330, DOI 10.1016/0005-2728(82)90041-X; BAGYINKA C, 1984, ANAL BIOCHEM, V142, P7, DOI 10.1016/0003-2697(84)90509-8; BAGYINKA C, 1981, ACTA BIOL ACAD SCI H, V32, P311; CAMMACK R, 1986, BIOCHIMIE, V68, P85, DOI 10.1016/S0300-9084(86)81072-0; CAMMACK R, 1989, EUR J BIOCHEM, V182, P357, DOI 10.1111/j.1432-1033.1989.tb14838.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DER A, 1985, ANAL BIOCHEM, V150, P481, DOI 10.1016/0003-2697(85)90538-X; GOGOTOV IN, 1978, BIOCHIM BIOPHYS ACTA, V523, P335, DOI 10.1016/0005-2744(78)90036-0; KLIBANOV AM, 1983, PROCESS BIOCHEM, V8, P13; KOVACS KL, 1985, PREP BIOCHEM, V15, P321, DOI 10.1080/00327488508062449; KOVACS KL, 1983, CURR MICROBIOL, V9, P215, DOI 10.1007/BF01567584; MAYHEW SG, 1982, TRENDS BIOCHEM SCI, V7, P18, DOI 10.1016/0968-0004(82)90057-3; MOORE S, 1963, J BIOL CHEM, V238, P235; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSHIRI F, 1988, J BIOL CHEM, V263, P17809; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; SEEFELDT LC, 1987, J BIOL CHEM, V262, P16816; TEIXEIRA M, 1983, EUR J BIOCHEM, V130, P481, DOI 10.1111/j.1432-1033.1983.tb07175.x; TIGYI G, 1986, BIOCHIMIE, V68, P69, DOI 10.1016/S0300-9084(86)81070-7; TIGYI GJ, 1984, CURR MICROBIOL, V11, P329, DOI 10.1007/BF01567701; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; YAMAMOTO I, 1978, J BIOCHEM-TOKYO, V84, P673, DOI 10.1093/oxfordjournals.jbchem.a132172; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	26	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					947	951						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845998				2022-12-25	WOS:A1991ET17700044
J	RYALS, PE; PAK, Y; THOMPSON, GA				RYALS, PE; PAK, Y; THOMPSON, GA			PHOSPHATIDYLINOSITOL-LINKED GLYCANS AND PHOSPHATIDYLINOSITOL-ANCHORED PROTEINS OF TETRAHYMENA-MIMBRES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; LEISHMANIA-DONOVANI LIPOPHOSPHOGLYCAN; PHOSPHOLIPID MEMBRANE ANCHOR; ERYTHROCYTE ACETYLCHOLINESTERASE; RAT-BRAIN; BIOSYNTHESIS; GLYCOLIPIDS; MOIETY; ACID	The insoluble residue from Tetrahymena mimbres cells that had been preincubated in vivo for 2 h with [H-3]myristic acid and then exhaustively delipidated with organic solvents retained radioactivity, principally in material which migrated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with an apparent molecular mass of 10-14 kDa. This material was extractable from the delipidated cell residue with organic solvents known to solubilize phosphatidylinositol glycans (PI glycans). The same material could also be labeled with [H-3]inositol, [C-14]glucosamine, and [H-3] ethanolamine. When the delipidated residue of cells labeled for 2 h with [H-3]myristate was treated with phosphatidylinositol-specific phospholipase C or nitrous acid, much of the associated radioactivity was released. A similar release was obtained using the putative PI glycan fraction extracted from the cell residue. After further purification by thin layer chromatography, this latter material was hydrolyzed with HCl and shown to contain fatty acids, alkylglyceryl ethers, phosphate, inositol, glucosamine, mannose, and ethanolamine. The findings indicate that T. mimbres contains PI glycans resembling in structure those recently characterized in trypanosomes and mammalian cells. As the time of incubation with the radiotracers enumerated above was increased to 6-24 h, increasing amounts of radioactivity appeared in the 22-27-kDa region of sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. This higher molecular weight material is shown in the companion paper (Pak, Y., Ryals, P. E., and Thompson, G. A., Jr. (1991) J. Biol. Chem. 266, 15054-15059) to be released by in vivo phosphatidylinositol-specific phospholipase C treatment. Thus T. mimbres contains a pool of free PI glycans and at least one phosphatidylinositol-anchored protein.	UNIV TEXAS, DEPT BOT, AUSTIN, TX 78713 USA	University of Texas System; University of Texas Austin				Pak, Yunbae/0000-0002-8594-5673				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ELLIOTT A M, 1973, P508; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; JOLLES J, 1979, FEBS LETT, V105, P110, DOI 10.1016/0014-5793(79)80897-2; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MARINETTI GV, 1962, J LIPID RES, V3, P1; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MEYER EB, 1987, ISOZYMES-CURR T BIOL, V13, P61; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PAK Y, 1991, J BIOL CHEM, V266, P15054; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, BIOCHEM BIOPH RES CO, V150, P271, DOI 10.1016/0006-291X(88)90516-5; RYALS PE, 1988, ARCH BIOCHEM BIOPHYS, V266, P408, DOI 10.1016/0003-9861(88)90272-X; RYALS PE, 1987, BIOCHIM BIOPHYS ACTA, V919, P122, DOI 10.1016/0005-2760(87)90198-6; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THOMPSON GA, 1967, BIOCHEMISTRY-US, V6, P2015, DOI 10.1021/bi00859a020; THOMPSON GA, 1969, METHOD ENZYMOL, V14, P668; TURCO SJ, 1989, J BIOL CHEM, V264, P6711	30	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15048	15053						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869541				2022-12-25	WOS:A1991GB09700040
J	STEINER, B; PARISE, LV; LEUNG, B; PHILLIPS, DR				STEINER, B; PARISE, LV; LEUNG, B; PHILLIPS, DR			CA2+-DEPENDENT STRUCTURAL TRANSITIONS OF THE PLATELET GLYCOPROTEIN-IIB-IIIA COMPLEX - PREPARATION OF STABLE GLYCOPROTEIN-IIB AND GLYCOPROTEIN-IIIA MONOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOGEN BINDING; PLASMA-MEMBRANES; CATION REGULATION; DIVALENT-CATIONS; CALCIUM; SURFACE; RECEPTOR; IDENTIFICATION; CONFORMATION; DISSOCIATION	The platelet membrane glycoprotein (GP) IIb-IIIa complex is the receptor for adhesive proteins on activated platelets that mediates platelet aggregation. In the present study, factors affecting the structural stability of the purified GP IIb-IIIa complex and the dissociated subunits were investigated. Purified GP IIb-IIIa was incubated in various Ca2+ concentrations, and the percentage of dissociated subunits was quantitated by sucrose gradient sedimentation. Two Ca2+-dependent transitions were observed, one at about 60-mu-M Ca2+, where half of the complexes became dissociated, and the other at 0.1-mu-M Ca2+, where half of the dissociated subunits became incapable of reforming heterodimer complexes when higher Ca2+-concentrations were readded. This loss in ability to reform heterodimer complexes was caused primarily by a Ca2+-dependent transition in GP IIIa, leading to an apparent unfolding of this subunit, followed by the formation of high molecular weight aggregates. The formation of these aggregates was time- and temperature-dependent and could not be reversed by added Ca2+. Although Mg2+ prevented dissociation of GP IIb-IIIa, it failed to promote reassociation of the dissociated subunits. Based on these findings, conditions were developed for the preparation of dissociated GP IIb and GP IIIa such that 70% of the subunits remained functional in that they retained the ability to reform heterodimer complexes.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE FDN LABS CARDIOVASC DIS,SAN FRANCISCO,CA 94140	University of California System; University of California San Francisco; The J David Gladstone Institutes					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038405, R37HL028947, R01HL032254, R01HL028947] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28947, HL-32254, HL-38405] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BRASS LF, 1985, J BIOL CHEM, V260, P7875; BRASS LF, 1984, J CLIN INVEST, V73, P626, DOI 10.1172/JCI111252; BRASS LF, 1982, J BIOL CHEM, V257, P4000; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GOGSTAD GO, 1982, BIOCHIM BIOPHYS ACTA, V689, P21, DOI 10.1016/0005-2736(82)90184-5; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KUNICKI TJ, 1981, BLOOD, V58, P268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; PARISE LV, 1985, J BIOL CHEM, V260, P698; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PARISE LV, 1985, BLOOD, V66, pA310; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; PHILLIPS DR, 1988, BLOOD, V71, P831; PHILLIPS DR, IN PRESS METHODS ENZ; PLOW EF, 1980, J BIOL CHEM, V255, P971; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; SHATTIL SJ, 1985, BLOOD, V66, P92; STEINER B, 1989, J BIOL CHEM, V264, P13102; STEINER B, 1985, BIOCHIM BIOPHYS ACTA, V818, P299, DOI 10.1016/0005-2736(85)90003-3; ZUCKER MB, 1978, BLOOD, V52, P505	29	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14986	14991						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869535				2022-12-25	WOS:A1991GB09700031
J	VANCOMPERNOLLE, K; VANDEKERCKHOVE, J; BUBB, MR; KORN, ED				VANCOMPERNOLLE, K; VANDEKERCKHOVE, J; BUBB, MR; KORN, ED			THE INTERFACES OF ACTIN AND ACANTHAMOEBA ACTOBINDIN - IDENTIFICATION OF A NEW ACTIN-BINDING MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MYOSIN SUBFRAGMENT-1; CROSS-LINKING; ALPHA-ACTININ; HEAVY-CHAIN; PROTEINS; TROPOMYOSIN; COMPLEX; PLASTIN; DOMAINS	Actobindin is an 88-amino acid polypeptide, containing two almost identical repeated domains of 33 and 34 residues. Depending on the molar ratios in which they are mixed, actobindin binds either one or two actin molecules. We cross-linked actobindin and actin in the 1:1 complex, using the zero-length cross-linker 1-ethyl-3(3-dimethylaminopropyl)carbodiimide. The cross-linked peptides were purified after consecutive CNBr cleavage and trypsin and Staphylococcus protease V8 digestions, and the cross-linked side chains were identified by amino acid sequencing. Isopeptide linkages were formed between residues Glu-100 of actin and Lys-16 of actobindin. In addition, we found a connection between one or more of the acidic residues 1, 2, or 3 of actin and Lys- 16 and Lys- 52 of actobindin. The cross-linked regions in actobindin contain Leu-Lys-His-Ala-Glu-Thr motifs, similar to sequences observed in several other actin-binding proteins.	NHLBI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	VANCOMPERNOLLE, K (corresponding author), STATE UNIV GHENT, PHYSIOL CHEM LAB, KL LEDEGANCKSTR 35, B-9000 GHENT, BELGIUM.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				AUDEMARD E, 1988, J MUSCLE RES CELL M, V9, P197, DOI 10.1007/BF01773891; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1988, J PROTEIN CHEM, V7, P194; BERTRAND R, 1988, BIOCHEMISTRY-US, V27, P5728, DOI 10.1021/bi00415a050; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BUBB MR, 1991, J BIOL CHEM, V266, P3820; BUBB MR, 1991, METHOD ENZYMOL, V196, P119; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; ELZINGA M, 1987, METHODS PROTEIN SEQU, P615; ELZINGA M, 1976, CONTRACTILE SYSTEMS, P29; GORDON DJ, 1976, J BIOL CHEM, V251, P4778; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; LAMBOOY PK, 1988, J BIOL CHEM, V263, P12836; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; LANAR DE, 1986, SCIENCE, V234, P593, DOI 10.1126/science.3094144; LEWIS WG, 1983, FEBS LETT, V156, P269, DOI 10.1016/0014-5793(83)80511-0; LIN CS, 1988, MOL CELL BIOL, V8, P4659, DOI 10.1128/MCB.8.11.4659; MEANS GE, 1968, BIOCHEMISTRY-US, V7, P2192, DOI 10.1021/bi00846a023; MIMURA N, 1987, J BIOL CHEM, V262, P4717; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SCHROEDER WA, 1969, ARCH BIOCHEM BIOPHYS, V130, P551, DOI 10.1016/0003-9861(69)90069-1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; VANDEKERCKHOVE J, 1990, J BIOL CHEM, V265, P12801; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; YAMAMOTO K, 1989, BIOCHEMISTRY-US, V28, P5573, DOI 10.1021/bi00439a035	30	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15427	15431						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869561				2022-12-25	WOS:A1991GB09700089
J	NAYAK, BR; SPIRO, RG				NAYAK, BR; SPIRO, RG			LOCALIZATION AND STRUCTURE OF THE ASPARAGINE-LINKED OLIGOSACCHARIDES OF TYPE-IV COLLAGEN FROM GLOMERULAR-BASEMENT-MEMBRANE AND LENS CAPSULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; PERFORMANCE LIQUID-CHROMATOGRAPHY; COMPLEX CARBOHYDRATE UNITS; AMINO-ACID SEQUENCE; AFFINITY-CHROMATOGRAPHY; PROTEINS; CHAIN; COMPONENTS; DOMAIN; BINDING	Analysis of the Sephacryl S-200 fractionated type IV collagen domains from bovine and human glomerular basement membranes (GBM) and calf anterior lens capsule (ALC) indicated that Asn-linked oligosaccharides are primarily or exclusively localized in the 7 S region, whereas the hydroxylysine-linked Glc-alpha-1 --> 2Gal disaccharides (Glc-Gal-Hyl) are present in all the major segments of the molecule (7 S, NC 1, and helical domain); no Ser/Thr-linked saccharide were detected. The Asn-linked carbohydrate units observed in the 7 S domain (M(r) approximately 300,000) occurred in a number equal to the 12 polypeptide chains constituting this cross-linked region, and this was consistent with lectin blots of the reduced electrophoretically resolved 7 S components. Fractionation of the N-glycanase and endo-beta-N-acetylglucosaminidase-released oligosaccharides by concanavalin A affinity and high performance liquid chromatography indicated that the Asn-linked carbohydrate occurred predominantly in the form of complex tri- and biantennary units, although submolar amounts of polymannose variants (Man5-7GlcNAC2) were also present in calf ALC and bovine GBM. Structural studies of the complex N-linked oligosaccharides employing hydrazine/nitrous acid fragmentation and glycosidase digestions indicated a pattern in which there was complete fucosylation of the innermost GlcNAc residue of the Man3GlcNAc2 core but only sparse substitution with capping groups of the nonrepeating N-acetyllactosamine branches. Whether tri- or biantennary, the oligosaccharides from bovine GBM contained only one capping residue, in the form of either NeuAc or alpha-D-Gal, whereas those from ALC had only a single alpha-D-Gal and no NeuAc; human GBM oligosaccharides were devoid of both NeuAc and alpha-D-Gal. The absence of terminal alpha-D-Gal in the human 7 S domain was reflected in its lack of reactivity with Bandeiraea simplicifolia I and from its failure to yield Gal-alpha-1 --> 3Gal-beta-1 --> 4[H-3]anhydromannitol after hydrazine/nitrous acid/NaB3H4 treatment. Application of the latter procedure to the collagen domains yielded, in addition to fragments from the N-linked oligosaccharides, a disaccharide (Glc-alpha-1 --> 2[H-3]galactitol) derived from the Glc-Gal-Hyl units. The localization of Asn-linked carbohydrate units in the evolutionarily conserved 7 S domain of type IV collagens suggests that these oligosaccharides may play a role in the assembly of the collagen network of basement membranes.	JOSLIN DIABET CTR,ELLIOTT P JOSLIN RES LAB,1 JOSLIN PL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 17325] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017325] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; ECKHARDT AE, 1983, BIOCHEMISTRY-US, V22, P5290, DOI 10.1021/bi00292a007; EDGE ASB, 1985, ARCH BIOCHEM BIOPHYS, V240, P560, DOI 10.1016/0003-9861(85)90063-3; EDGE ASB, 1985, J BIOL CHEM, V260, P5332; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; EDGE ASB, 1987, J BIOL CHEM, V262, P6893; FUKUSHI S, 1969, J BIOL CHEM, V244, P2041; GALILI U, 1988, J BIOL CHEM, V263, P17755; GLANVILLE RW, 1985, EUR J BIOCHEM, V152, P213, DOI 10.1111/j.1432-1033.1985.tb09186.x; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GREEN ED, 1986, ANAL BIOCHEM, V158, P42, DOI 10.1016/0003-2697(86)90585-3; HAYES CE, 1974, J BIOL CHEM, V249, P1904; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HUDSON BG, 1972, J BIOL CHEM, V247, P4239; KRESS BC, 1986, ENDOCRINOLOGY, V118, P974, DOI 10.1210/endo-118-3-974; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1991, J BIOL CHEM, V266, P2622; LEVINE MJ, 1979, J BIOL CHEM, V254, P8121; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MOHAN PS, 1986, J BIOL CHEM, V261, P4328; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; NATOWICZ M, 1980, ANAL BIOCHEM, V105, P159, DOI 10.1016/0003-2697(80)90439-X; PARTHASARATHY N, 1984, J BIOL CHEM, V259, P2749; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; RISTELI J, 1980, EUR J BIOCHEM, V108, P239, DOI 10.1111/j.1432-1033.1980.tb04717.x; ROBEY PG, 1981, COLLAGEN REL RES, V1, P27; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; SATO T, 1976, J BIOL CHEM, V251, P4062; SAUS J, 1989, J BIOL CHEM, V264, P6318; SHIMOMURA H, 1987, DIABETES, V36, P374, DOI 10.2337/diabetes.36.3.374; SPIRO MJ, 1985, J BIOL CHEM, V260, P5805; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; SPIRO RG, 1967, J BIOL CHEM, V242, P4813; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; SPIRO RG, 1969, J BIOL CHEM, V244, P2049; SPIRO RG, 1967, J BIOL CHEM, V242, P1915; SPIRO RG, 1972, GLYCOPROTEINS, P964; SPIRO RG, 1982, PHILOS T R SOC LON B, V30, P117; TANG PW, 1984, ANAL BIOCHEM, V142, P37, DOI 10.1016/0003-2697(84)90513-X; TIMPL R, 1978, EUR J BIOCHEM, V84, P43, DOI 10.1111/j.1432-1033.1978.tb12139.x; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEB B, 1982, J BIOL CHEM, V257, P5239; TURCO SJ, 1981, ANAL BIOCHEM, V118, P278, DOI 10.1016/0003-2697(81)90582-0; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	53	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13978	13987						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856226				2022-12-25	WOS:A1991FY02700083
J	STILES, MK; CRAIG, ME; GUNNELL, SLN; PFEIFFER, DR; TAYLOR, RW				STILES, MK; CRAIG, ME; GUNNELL, SLN; PFEIFFER, DR; TAYLOR, RW			THE FORMATION-CONSTANTS OF IONOMYCIN WITH DIVALENT-CATIONS IN 80-PERCENT METHANOL WATER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES ANALYSIS; IONOPHORE A23187; MOLECULAR-STRUCTURE; LINEAR RELATIONSHIPS; CALCIUM IONOPHORES; METAL-COMPLEXES; ION COMPLEX; TRANSPORT; CA-2+; LIPOSOMES	The protonation constants and complex formation constants of ionomycin have been determined in 80% methanol/water (w/w) at 25.0-degrees-C and mu = 0.050 (tetraethylammonium perchlorate). Potentiometric and spectrometric titration techniques give the following values for the mixed-mode protonation constants of ionomycin: log K(H1) = 11.94 +/- 0.02 and log K(H2) = 6.80 +/- 0.03. Comparison of these values with those for model compounds indicates that K(H1) and K(H2) refer to equilibria involving the beta-diketone and carboxylic acid moieties, respectively. Titrations of ionomycin with metal ion at fixed values of pH* produced changes in the UV-visual absorbance spectra which were analyzed to give conditional complex formation constants, K'MI. The pH* dependence of the values of K'MI indicated that 1:1 divalent metal ion-ionomycin (MI) complexes and protonated MHI+ complexes were formed in the pH* range studied. The values of log K(MI) ranged from 5.30 +/- 0.11 for Sr2+ to 10.25 +/- 0.03 for Ni2+. The selectivity pattern and relative affinities (in parentheses) for the formation of the species MI are as follows: Ni2+ (2000) > Zn2+ (600) > Co2+ (440) > Mn2+ (47) > Mg2+ (1.00) > Ca2+ (0.21) > Sr2+ (0.022). Logarithmic values of K(MHI), for the reaction MI + H+ arrow pointing right over arrow pointing left MHI+, range from 5.9 (Ni2+) to 8.4 (Sr2+). Calculations using the values of the equilibrium constants determined indicate that an appreciable fraction of the complexed ionophore exists as the protonated complex, MHI+, in the pH* range of 6.5-8.5.	UNIV OKLAHOMA,DEPT CHEM,NORMAN,OK 73019; UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	University of Oklahoma System; University of Oklahoma - Norman; University of Minnesota System					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL008214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024701] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 08214] Funding Source: Medline; NIGMS NIH HHS [GM 24701] Funding Source: Medline; PHS HHS [2-S07-R07078-15] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akerlof G, 1930, J AM CHEM SOC, V52, P2353, DOI 10.1021/ja01369a023; ALBRECHTGARY AM, 1989, J AM CHEM SOC, V111, P8598, DOI 10.1021/ja00205a007; ALLEAUME M, 1985, CAN J CHEM, V63, P3482, DOI 10.1139/v85-571; ANTEUNIS MJO, 1981, B SOC CHIM BELG, V90, P1153; ARTALEJO AR, 1988, BIOCHIM BIOPHYS ACTA, V941, P48, DOI 10.1016/0005-2736(88)90212-X; BACARELLA AL, 1955, J ORG CHEM, V20, P747, DOI 10.1021/jo01124a007; BAKER E, 1984, J AM CHEM SOC, V106, P2860, DOI 10.1021/ja00322a020; BEELER TJ, 1979, J BIOL CHEM, V254, P6229; BENNETT JP, 1980, NATURE, V282, P851; BLAU L, 1988, BIOCHEMISTRY-US, V27, P5661, DOI 10.1021/bi00415a040; BOLTE J, 1982, CAN J CHEM, V60, P981, DOI 10.1139/v82-147; BOLTE J, 1985, CAN J CHEM, V63, P3478, DOI 10.1139/v85-570; CHANEY MO, 1974, J AM CHEM SOC, V96, P1932, DOI 10.1021/ja00813a047; CHAPMAN CJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P44, DOI 10.1016/0003-9861(90)90411-Q; CHAPMAN CJ, 1987, BIOCHEMISTRY-US, V26, P5009, DOI 10.1021/bi00390a019; CHRISTIAN SD, 1982, AM LAB, V14, P36; CHRISTIAN SD, 1982, AM LAB, V14, P31; COX BG, 1985, J AM CHEM SOC, V107, P4297, DOI 10.1021/ja00300a037; DEBER CM, 1985, ANAL BIOCHEM, V146, P349, DOI 10.1016/0003-2697(85)90550-0; DEBER CM, 1986, BIOCHEM BIOPH RES CO, V134, P731, DOI 10.1016/S0006-291X(86)80481-8; DEGANI H, 1974, BIOCHEMISTRY-US, V13, P5022, DOI 10.1021/bi00721a025; DELEERS M, 1981, CELL CALCIUM, V2, P159, DOI 10.1016/0143-4160(81)90032-4; DELIGNY CL, 1960, RECL TRAV CHIM PAY B, V79, P699; DELIGNY CL, 1960, RECL TRAV CHIM PAY B, V79, P713; DIVIRGILIO F, 1983, FEBS LETT, V163, P315, DOI 10.1016/0014-5793(83)80843-6; EVANS DA, 1986, TETRAHEDRON LETT, V27, P1007, DOI 10.1016/S0040-4039(86)80034-X; FASOLATO C, 1989, J BIOL CHEM, V264, P19630; GACHON P, 1975, J CHEM SOC PERK T 2, P907, DOI 10.1039/p29750000907; GELSEMA WJ, 1967, RECL TRAV CHIM PAY-B, V86, P852; GELSEMA WJ, 1966, RECL TRAV CHIM PAY B, V84, P647; GOMPERTS BD, 1981, EUR J BIOCHEM, V117, P559; GRELL E, 1984, PROGR BIOORGANIC CHE, P239; HANESSIAN S, 1986, CAN J CHEM, V64, P2231; HILGENFELD R, 1982, TOP CURR CHEM, V101, P1; HOOGERHEIDE JG, 1979, J SOLUTION CHEM, V8, P83, DOI 10.1007/BF00646810; IRVING H, 1953, J CHEM SOC, V156, P3192; IVES HE, 1987, P NATL ACAD SCI USA, V84, P1950, DOI 10.1073/pnas.84.7.1950; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; KAUFFMAN RF, 1982, BIOCHEMISTRY-US, V21, P2426, DOI 10.1021/bi00539a023; KAWAGUCHI S, 1986, COORDIN CHEM REV, V70, P51, DOI 10.1016/0010-8545(86)80035-2; KOSKIKALLIO J, 1957, SUOMEN KEM         B, V30, P111; KRAUSE G, 1983, PHYSICAL CHEM TRANSM, P255; Lehn JM., 1973, STRUCT BONDING BERLI, V16, P1, DOI DOI 10.1017/BFB0004364; LIU CM, 1978, J BIOL CHEM, V253, P5892; LIU WC, 1978, J ANTIBIOT, V31, P815, DOI 10.7164/antibiotics.31.815; Martell A.E., 1974, CRITICAL STABILITY C, V1, P204; MARTELL AE, 1982, CRITICAL STABILITY C, V5, P357; MARTELL AE, 1977, CRITICAL STABILITY C, V3, P244; OFLAHERTY JT, 1981, BIOCHIM BIOPHYS ACTA, V640, P223, DOI 10.1016/0005-2736(81)90547-2; OIWA IT, 1956, J PHYS CHEM-US, V60, P754, DOI 10.1021/j150540a011; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POINTUD Y, 1983, J SOLUTION CHEM, V12, P473, DOI 10.1007/BF00651699; RINK TJ, 1983, BIOCHIM BIOPHYS ACTA, V762, P593, DOI 10.1016/0167-4889(83)90064-2; RORABACH.DB, 1971, ANAL CHEM, V43, P561, DOI 10.1021/ac60299a014; SCANLON M, 1987, J BIOL CHEM, V262, P6308; SERHAN C, 1981, J BIOL CHEM, V256, P2736; SHEDLOVSKY T, 1956, J PHYS CHEM-US, V60, P151, DOI 10.1021/j150536a003; SHELLY KP, 1988, CAN J CHEM, V66, P1359, DOI 10.1139/v88-220; SMITH GD, 1976, J AM CHEM SOC, V98, P1578, DOI 10.1021/ja00422a050; SPINO C, 1987, TETRAHEDRON LETT, V28, P731, DOI 10.1016/S0040-4039(01)80974-6; SUZUKI K, 1988, ANAL CHEM, V60, P1714, DOI 10.1021/ac00168a016; SUZUKI K, 1987, J CHEM SOC CHEM COMM, P932, DOI 10.1039/c39870000932; TAYLOR RW, 1985, BIOCHEMISTRY-US, V24, P4852, DOI 10.1021/bi00339a019; TAYLOR RW, 1982, POLYETHER ANTIBIOTIC, V1, P103; THOMAS TP, 1987, J AM CHEM SOC, V109, P6670, DOI 10.1021/ja00256a020; TOEPLITZ BK, 1979, J AM CHEM SOC, V101, P3344, DOI 10.1021/ja00506a035; VALLEE BL, 1964, COMPR BIOCHEM, V12, P165; VOGEL AI, 1961, QUANTITATIVE INORGAN, P415; WARD DL, 1978, ACTA CRYSTALLOGR B, V34, P110, DOI 10.1107/S056774087800240X; WUTS PGM, 1984, J ORG CHEM, V49, P2582, DOI 10.1021/jo00188a014	70	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8336	8342						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850743				2022-12-25	WOS:A1991FK44100059
J	MARTI, T; OTTO, H; MOGI, T; ROSSELET, SJ; HEYN, MP; KHORANA, HG				MARTI, T; OTTO, H; MOGI, T; ROSSELET, SJ; HEYN, MP; KHORANA, HG			BACTERIORHODOPSIN MUTANTS CONTAINING SINGLE SUBSTITUTIONS OF SERINE OR THREONINE RESIDUES ARE ALL ACTIVE IN PROTON TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC ACID-96; TRANSMEMBRANE PROTEINS; NEUTRON-DIFFRACTION; ESCHERICHIA-COLI; PURPLE MEMBRANE; BACTERIO-OPSIN; SCHIFF-BASE; CHROMOPHORE; PUMP; GENE	To study their role in proton translocation by bacteriorhodopsin, 22 serine and threonine residues presumed to be located within and near the border of the transmembrane segments have been individuallyreplaced by alanine or valine, respectively. Thr-89 was substituted by alanine, valine, and aspartic acid, and Ser-141 by alanine and cysteine. Most of the mutants showed essentially wild-type phenotype with regard to chromophore regeneration and absorption spectrum. However, replacement of Thr-89 by Val and of Ser-141 by Cys caused striking blue shifts of the chromophore by 100 and 80 nm, respectively. All substitutions of Thr-89 regenerated the chromophore at least 10-fold faster with 13-cis retinal than with all-trans retinal. The substitutions at positions 89, 90, and 141 also showed abnormal dark-light adaptation, suggesting interactions between these residues and the retinylidene chromophore. Proton pumping measurements revealed 60-75% activity for mutants of Thr-46, -89, -90, -205, and Ser-226, and about 20% for Ser-141 --> Cys, whereas the remaining mutants showed normal pumping. Kinetic studies of the photocycle and of proton release and uptake for mutants in which proton pumping was reduced revealed generally little alterations. The reduced activity in several of these mutants is most likely due to a lower percentage of all-trans retinal in the light-adapted state. In the mutants Thr-46 --> Val and Ser-226 --> Ala the decay of the photointermediate M was significantly accelerated, indicating an interaction between these residues and Asp-96 which reprotonates the Schiff base. Our results show that no single serine or threonine residue is obligatory for proton pumping.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; FREE UNIV BERLIN, BIOPHYS GRP, W-1000 BERLIN 33, GERMANY	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Free University of Berlin					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028289, R37GM028289] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11479] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; BLANCK A, 1989, EMBO J, V8, P3963, DOI 10.1002/j.1460-2075.1989.tb08579.x; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; DUNACH M, 1990, J BIOL CHEM, V265, P16978; EIGEN M, 1958, PROC R SOC LON SER-A, V247, P505, DOI 10.1098/rspa.1958.0208; FANG JM, 1983, J AM CHEM SOC, V105, P5162, DOI 10.1021/ja00353a068; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; GARTNER W, 1983, BIOCHEMISTRY-US, V22, P2637, DOI 10.1021/bi00280a007; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; HACKETT NR, 1987, J BIOL CHEM, V262, P9277; HAUSS T, 1990, BIOCHEMISTRY-US, V29, P4904, DOI 10.1021/bi00472a022; HEYN MP, 1988, P NATL ACAD SCI USA, V85, P2146, DOI 10.1073/pnas.85.7.2146; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; KOUYAMA T, 1988, BIOCHEMISTRY-US, V27, P5855, DOI 10.1021/bi00416a006; LANYI JK, 1990, J BIOL CHEM, V265, P1253; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LONDON E, 1982, J BIOL CHEM, V257, P7003; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; MARINETTI T, 1989, P NATL ACAD SCI USA, V86, P529, DOI 10.1073/pnas.86.2.529; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOGI T, 1987, P NATL ACAD SCI USA, V84, P5595, DOI 10.1073/pnas.84.16.5595; MOGI T, 1989, J BIOL CHEM, V264, P14192; MOGI T, 1989, J BIOL CHEM, V264, P14197; NAGLE JF, 1983, J MEMBRANE BIOL, V74, P1, DOI 10.1007/BF01870590; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NASSAL M, 1987, J BIOL CHEM, V262, P9264; OESTERHELT D, 1974, FEBS LETT, V44, P262, DOI 10.1016/0014-5793(74)81153-1; Onsagar L., 1967, NEUROSCIENCES, P75; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; REHOREK M, 1979, BIOCHEMISTRY-US, V18, P4977, DOI 10.1021/bi00589a027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; SCHRECKENBACH T, 1977, FED PROC, V36, P1810; SEIFF F, 1986, P NATL ACAD SCI USA, V83, P7746, DOI 10.1073/pnas.83.20.7746; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STERN LJ, 1989, BIOCHEMISTRY-US, V28, P10035, DOI 10.1021/bi00452a023; STERN LJ, 1989, J BIOL CHEM, V264, P14202; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; SUGIYAMA Y, 1989, J BIOL CHEM, V264, P20859; TITTOR J, 1989, EMBO J, V8, P3477, DOI 10.1002/j.1460-2075.1989.tb08512.x; YUN RH, 1991, IN PRESS PROTEINS ST	51	102	102	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6919	6927						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849896				2022-12-25	WOS:A1991FG72700046
J	TRIEU, VN; ZIONCHECK, TF; LAWN, RM; MCCONATHY, WJ				TRIEU, VN; ZIONCHECK, TF; LAWN, RM; MCCONATHY, WJ			INTERACTION OF APOLIPOPROTEIN(A) WITH APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; HUMAN-PLASMINOGEN; AFFINITY CHROMATOGRAPHY; MYOCARDIAL-INFARCTION; LP(A) LIPOPROTEIN; BINDING-SITES; PROTEIN; KRINGLE-4; POLYMORPHISM; PURIFICATION	Recombinant DNA-derived apolipoprotein(a) was used to demonstrate that the apo(a) moiety of lipoprotein(a) (Lp(a)) is responsible for the binding of Lp(a) to other apolipoprotein B-containing lipoproteins (apoB-Lp) including LDL2, a subclass of low density lipoproteins (d = 1.030-1.063 g/ml). The r-apo(a).LDL2 complexes exhibited the same binding constant as Lp(a).LDL2 (10(-8) M). Treatment of either recombinant apo(a) or Lp(a) with a reducing agent destroyed binding activity. A synthetic polypeptide corresponding to a portion of apo(a)'s kringle-4 inhibited the binding (K(I) 1.9 X 10(-4) M) of LDL2 to Lp(a). Therefore, we concluded that binding to apoB-Lp was mediated by the kringle-4-like domains on apo(a). Using ligand chromatography which can detect complexes having a K(D) as low as 10(-2) M, we demonstrated the binding of plasminogen to apoB-Lp. Like Lp(a), binding of plasminogen to apoB-Lp was mediated by the kringle domain(s). The differences in binding affinity may be due to amino acid substitutions in the kringle-4-like domain. In most of the kringle-4-like domains of apo(a), the aspartic residue critical for binding to lysine was substituted by valine. Consistent with this substitution, we found that L-proline and hydroxyproline, but not L-lysine, inhibited the binding of LDL2 to apo(a). Inhibition by L-proline could be reversed in the binding studies by increasing the amount of apo(a); and L-proline-Sepharose bound plasma Lp(a), suggesting that L-proline acted as a ligand for the kringle-4-like domain(s) of apo(a) involved in the binding of apoB-Lp. The binding of apo(a) to proline and hydroxyproline could be responsible for the binding of apo(a) to the subendothelial extracellular matrix, i.e. domains of proteins rich in proline or hydroxyproline (e.g. collagen and elastin).	OKLAHOMA MED RES FDN,LIPOPROT ATHEROSCLEROSIS RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Oklahoma Medical Research Foundation; Roche Holding; Genentech					NHLBI NIH HHS [P01-HL23181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL023181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1977, J LIPID RES, V18, P331; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKWAY WJ, 1972, ARCH BIOCHEM BIOPHYS, V151, P194, DOI 10.1016/0003-9861(72)90488-2; CAMPOS E, 1986, ARCH BIOCHEM BIOPHYS, V249, P455, DOI 10.1016/0003-9861(86)90022-6; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DURRINGTON PN, 1988, LANCET, V1, P1070; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; FLESS GM, 1984, J BIOL CHEM, V259, P1470; FLESS GM, 1985, J LIPID RES, V26, P1224; GONIAS SL, 1989, BLOOD, V74, P729; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; HOCHSCHWENDER SM, 1983, ARCH BIOCHEM BIOPHYS, V223, P58, DOI 10.1016/0003-9861(83)90571-4; HOCHSCHWENDER SM, 1981, J BIOL CHEM, V256, P1172; HOFFMANN SL, 1990, J CLIN INVEST, V85, P1542; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KOSCHINSKY ML, 1991, IN PRESS BIOCHEMISTR; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KOWAL R, 1980, ANAL BIOCHEM, V102, P72, DOI 10.1016/0003-2697(80)90319-X; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V2, P47; MCCONATHY WJ, 1989, FEBS LETT, V251, P250, DOI 10.1016/0014-5793(89)81464-4; MCCONATHY WJ, 1986, METHOD ENZYMOL, V128, P297; MCCONATHY WJ, 1985, J CHROMATOGR, V342, P47, DOI 10.1016/S0378-4347(00)84488-6; MCCONATHY WJ, 1985, CLIN RES, V33, pA210; MCCONATHY WJ, 1990, FASEB J, V4, pA1019; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1988, J BIOL CHEM, V263, P11928; OLOFSSON SO, 1978, BIOCHEMISTRY-US, V17, P1032, DOI 10.1021/bi00599a014; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; RAPACZ J, 1989, COMP BIOCHEM PHYS B, V93, P325; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SKODA U, 1986, VOX SANG, V51, P244, DOI 10.1111/j.1423-0410.1986.tb01963.x; SWINN ES, 1980, EUR J BIOCHEM, V104, P579; TREXLER M, 1982, J BIOL CHEM, V257, P7401; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; YE SQ, 1988, J BIOL CHEM, V263, P6337; ZIONCHECK TF, 1990, IN PRESS J CLIN INVE	47	87	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5480	5485						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848551				2022-12-25	WOS:A1991FD37000022
J	RIJNBOUTT, S; AERTS, HMFG; GEUZE, HJ; TAGER, JM; STROUS, GJ				RIJNBOUTT, S; AERTS, HMFG; GEUZE, HJ; TAGER, JM; STROUS, GJ			MANNOSE 6-PHOSPHATE-INDEPENDENT MEMBRANE ASSOCIATION OF CATHEPSIN-D, GLUCOCEREBROSIDASE, AND SPHINGOLIPID-ACTIVATING PROTEIN IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; CULTURED HUMAN-FIBROBLASTS; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; BIOSYNTHESIS; ENZYMES; OLIGOSACCHARIDES; PERMEABILIZATION; RECEPTORS; SURFACE	The membrane association of the lysosomal enzymes cathepsin D and glucocerebrosidase and its naturally occurring sphingolipid activating protein was studied in HepG2 cells. We differentially permeabilized cells with low concentrations of saponin, at which secretory proteins rinsed out completely, whereas integral membrane proteins were not released. All relevant intracellular compartments were shown to be permeabilized by saponin. Metabolic labeling showed that early precursors of cathepsin D, sphingolipid activating protein, and glucocerebrosidase were completely released from the cells, whereas more than 80% of the high molecular mass intermediates were retained by the cells. Treatment of permeabilized cells with 10 mM mannose 6-phosphate released only 50% of the cell-associated cathepsin D. Glucocerebrosidase remained membrane-associated, but cathepsin D and sphingolipid activating protein were released from the cells after proteolytic processing. Sphingolipid activating proteins and cathepsin D behaved similarly during biosynthesis and showed similar sensitivity to mannose 6-phosphate. The membrane association of the intermediate form of cathepsin D was independent of the presence of N-linked oligosaccharides. Subcellular fractionation on sucrose gradients showed that the lysosomal proteins became membrane-associated probably in the Golgi complex, and that both mannose 6-phosphate-dependent and mannose 6-phosphate-independent membrane association occur in the same compartments. We conclude that, in HepG2 cells, cathepsin D, sphingolipid activating protein, and glucocerebrosidase exhibit MPR-independent membrane association which is acquired in the same compartments beyond the rough endoplasmic reticulum.	UNIV AMSTERDAM, ACAD MED CTR, EC SLATER INST BIOCHEM RES, 1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	RIJNBOUTT, S (corresponding author), STATE UNIV UTRECHT, SCH MED, CELL BIOL LAB, UTRECHT, NETHERLANDS.		Aerts, Johannes/A-1028-2009	Aerts, Johannes/0000-0001-8168-2565				AERTS JMFG, 1986, ANAL BIOCHEM, V154, P655, DOI 10.1016/0003-2697(86)90043-6; AERTS JMFG, 1988, BIOCHIM BIOPHYS ACTA, V964, P303, DOI 10.1016/0304-4165(88)90030-X; BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0; Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CASTLE JD, 1978, J CELL BIOL, V76, P323, DOI 10.1083/jcb.76.2.323; CREEK KE, 1984, LYSOSOM BIOL PATHOL, P63; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DIMENT S, 1988, J BIOL CHEM, V263, P6901; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; ERICKSON AH, 1981, J BIOL CHEM, V256, P1224; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; GALJAARD H, 1980, GENETIC METABOLIC DI, P790; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; HASILIK A, 1981, EUR J BIOCHEM, V121, P125, DOI 10.1111/j.1432-1033.1981.tb06440.x; Hasilik A, 1984, LYSOSOM BIOL PATHOL, P3; JONSSON LMV, 1987, EUR J BIOCHEM, V164, P171, DOI 10.1111/j.1432-1033.1987.tb11008.x; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Neufeld EF, 1983, METABOLIC BASIS INHE, P778; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; SCHLOSSER E, 1969, Z NATURFORSCH PT B, VB 24, P1284; STROUS GJ, 1989, BIOCHEM J, V257, P159, DOI 10.1042/bj2570159; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; VANWEELY S, 1990, IN PRESS EUR J BIOCH; VARKI A, 1983, J BIOL CHEM, V258, P2808; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WASSLER M, 1987, BIOCHEM J, V247, P407, DOI 10.1042/bj2470407	35	146	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4862	4868						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848227				2022-12-25	WOS:A1991FC21700031
J	KUMJIAN, DA; BARNSTEIN, A; RHEE, SG; DANIEL, TO				KUMJIAN, DA; BARNSTEIN, A; RHEE, SG; DANIEL, TO			PHOSPHOLIPASE-C-GAMMA COMPLEXES WITH LIGAND-ACTIVATED PLATELET-DERIVED GROWTH-FACTOR RECEPTORS - AN INTERMEDIATE IMPLICATED IN PHOSPHOLIPASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE FORMATION; PROTEIN-TYROSINE KINASES; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; PDGF RECEPTOR; C-GAMMA; CALCIUM MOBILIZATION; PHOSPHORYLATION; PHOSPHOTYROSINE; SIMILARITY	Several steps implicated in platelet-derived growth factor (PDGF) receptor-coupled signaling are activated by PDGF exposure at 0-4-degrees-C. These include receptor self-phosphorylation, physical association with and phosphorylation of phospholipase C-gamma (PLC-gamma). Reduced temperature blocks PDGF internalization, making it possible to dissociate bound PDGF after PLC-gamma tyrosine phosphorylation. We addressed the functional consequences of PDGF dissociation from intact cell PDGF receptors. PDGF exposure at 0-4-degrees-C for 15 min stimulated self-phosphorylation of a subpopulation of BALB/c 3T3 cell PDGF beta-type receptors (35%) and initiated subsequent inositol phosphate production. A small fraction of cellular PLC-gamma (1-3%) coprecipitated with ligand-activated PDGF receptors; 3-5% of cellular PLC-gamma acquired phosphotyrosine. The PLC-gamma coprecipitating with PDGF receptors did not contain detectable phosphotyrosine. Phosphotyrosine antibody recovered similar amounts of PLC-gamma from soluble and particulate fractions of PDGF-stimulated cells. Acid dissociation of bound PDGF from receptor caused rapid dephosphorylation of PDGF receptors and PLC-gamma, and interrupted PLC-gamma-PDGF receptor coprecipitation. Orthovanadate blocked tyrosine dephosphorylation of both PDGF receptors and PLC-gamma and stabilized coprecipitation. Orthovanadate reversed the acid wash effect to abrogate PDGF-stimulated inositol phosphate production. PDGF receptor remains competent to coprecipitate with PLC-gamma and stimulate PLC-mediated inositol phosphate production if PDGF-induced receptor phosphorylation is maintained. Formation of a coprecipitable PDGF receptor-PLC-gamma complex appears required for PDGF-stimulated inositol phosphate production.	VANDERBILT UNIV,DEPT MED,DIV NEPHROL,MCN S3223,NASHVILLE,TN 37232; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Vanderbilt University					NIDDK NIH HHS [DK38517] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038517] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BISHAYEE S, 1986, P NATL ACAD SCI USA, V83, P6756, DOI 10.1073/pnas.83.18.6756; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DANIEL TO, 1985, P NATL ACAD SCI USA, V82, P2684, DOI 10.1073/pnas.82.9.2684; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; HARRINGTON MA, 1987, METHOD ENZYMOL, V147, P400; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KIM JW, 1990, J BIOL CHEM, V265, P3940; KIM UH, 1989, J BIOL CHEM, V264, P20167; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PAWSON T, 1988, ONCOGENE, V3, P491; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STURANI E, 1988, FEBS LETT, V233, P371, DOI 10.1016/0014-5793(88)80463-0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	41	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3973	3980						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847394				2022-12-25	WOS:A1991EY68200093
J	FALCHETTO, R; VORHERR, T; BRUNNER, J; CARAFOLI, E				FALCHETTO, R; VORHERR, T; BRUNNER, J; CARAFOLI, E			THE PLASMA-MEMBRANE CA2+ PUMP CONTAINS A SITE THAT INTERACTS WITH ITS CALMODULIN-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; PURIFIED ERYTHROCYTE CA-2+-ATPASE; CA-2+ PUMP; ESCHERICHIA-COLI; PART; IDENTIFICATION; PHENYLALANINE; PROTEOLYSIS; ACTIVATION; PROTEINS	A synthetic, 28-residue peptide derived from the calmodulin-binding sequence of the plasma membrane Ca2+ pump (C28W) inhibits the ATPase activity of a calpain-produced, truncated fragment of the enzyme. The fragment, which has lost the calmodulin-binding domain, has a molecular mass of 124 kDa and is fully active in the absence of calmodulin. Replacement of Trp-8 in the peptide by an Ala decreases the overall inhibitory activity, while replacement with a Tyr increases it. However, at very low peptide concentrations the effect of Tyr replacement disappears. The synthetic peptide has been made photoactivatable by replacing Phe in position 9 with a synthetic phenylalanine analogue containing a diazirine group and was radioactively labeled by coupling a [H-3]acetyl function to its N terminus. After cross-linking with the derivatized peptide, the 124-kDa fragment has been proteolyzed with either Lys-C, Asp-N, or V8 proteases, and the fragment(s) have been separated. Partial sequencing of the cross-linked, radioactive peptides has identified a site of the pump located C terminally to the phosphoenzyme-forming aspartic acid, spanning residues 537-544 of the hPMCA4 isoform of the enzyme. It is concluded that this sequence is part of a site which binds the calmodulin-binding domain of the pump.	SWISS FED INST TECHNOL,BIOCHEM LAB,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; Bayley H, 1983, PHOTOGENERATED REAGE; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; Bornstein P, 1977, Methods Enzymol, V47, P132; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; GUERINI D, 1984, J BIOL CHEM, V259, P5172; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KLEE CB, 1980, PROTEIN PHOSPHORYLAT, P61; KOSKKOSICKA D, 1989, J BIOL CHEM, V264, P19495; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; Markwell M A, 1981, Methods Enzymol, V72, P296; NASSAL M, 1984, J AM CHEM SOC, V106, P7540, DOI 10.1021/ja00336a038; NIGGLI V, 1981, J BIOL CHEM, V256, P395; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1989, J BIOL CHEM, V264, P28569; Smith RM, 1974, CRITICAL STABILITY C, V1-6; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1991, J BIOL CHEM, V266, P22; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; ZURINI M, 1984, J BIOL CHEM, V259, P618	34	181	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2930	2936						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847139				2022-12-25	WOS:A1991EX60000043
J	CIFUENTES, ME; ESPINET, C; LANGE, AJ; PILKIS, SJ; HOD, Y				CIFUENTES, ME; ESPINET, C; LANGE, AJ; PILKIS, SJ; HOD, Y			HORMONAL-CONTROL OF 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE GENE-EXPRESSION IN RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; 2-KINASE FRUCTOSE 2,6-BISPHOSPHATASE; PYRUVATE-KINASE GENE; AMINO-ACID-SEQUENCE; MESSENGER-RNA; GLUCOKINASE GENE; CDNA CLONE; INSULIN; LIVER; TRANSCRIPTION	The hormonal control of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase gene expression was studied in the rat hepatoma cells, FTO-2B. In contrast to another hepatoma cell line (HTC), the enzyme in FTO-2B cells displays both kinase and bisphosphatase activities. As in rat liver, the mRNA in FTO-2B cells is 2.2-kilobases in length. However, the 5' region of the mRNA differs from the mRNA in the liver in that it contains sequences unique to 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase mRNA from skeletal muscle. These results suggest that the mRNA in FTO-2B cells may represent an additional alternative splicing product of the 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase gene. Exposure of FTO-2B cells to media containing either insulin (10(-7) M) or dexamethasone (10(-6) M) induced about a 10-fold increases in the level of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase mRNA within 6-10 h of hormone treatment. The concentrations of insulin or dexamethasone giving half-maximal stimulation were 10(-9) M and 2 x 10(-8) M, respectively, and dibutyryl cyclic AMP (5 x 10(-7) M) completely prevented the increases in enzyme mRNA induced by these hormones. Exposure of cells to glucose-free medium abolished the insulin-mediated enhancement in 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase mRNA, but not that induced by dexamethasone. No alteration in the degradation rate of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase mRNA was noted when cells were treated with insulin. Run-on transcription assays with isolated nuclei showed an increase in the relative transcription rate of the gene in cells treated with either insulin or dexamethasone. The time course of transcription activation preceded the increase in the level of the mRNA, indicating that the main mechanism for the induction of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase expression by insulin and dexamethasone is mediated by stimulation of gene transcription.			CIFUENTES, ME (corresponding author), SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.		Espinet, Carme/A-7950-2010	EspinetMestre, Carme/0000-0001-7172-3407; Cifuentes-Pagano, Eugenia/0000-0002-2482-080X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU DTW, 1988, J BIOL CHEM, V263, P13007; CLAUS TH, 1984, BIOCHEM BIOPH RES CO, V125, P655, DOI 10.1016/0006-291X(84)90589-8; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P51; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1982, BIOCHEM BIOPH RES CO, V106, P794, DOI 10.1016/0006-291X(82)91780-6; ELMAGHRABI MR, 1990, FRUCTOSE 2 6 BISPHOS, P87; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GEHNRICH SC, 1988, J BIOL CHEM, V263, P11755; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; HOD Y, 1984, J BIOL CHEM, V259, P5603; HOD Y, 1988, J BIOL CHEM, V263, P7747; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KILLARY AM, 1984, BIOCHEM GENET, V22, P201, DOI 10.1007/BF00484224; KUMMEL L, 1990, BIOCHEM BIOPH RES CO, V169, P406, DOI 10.1016/0006-291X(90)90346-O; LANGE AJ, 1989, BIOCHEM BIOPH RES CO, V162, P753, DOI 10.1016/0006-291X(89)92374-7; LIVELY MO, 1988, J BIOL CHEM, V263, P839; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MARKER AJ, 1989, J BIOL CHEM, V264, P7000; MESSINA JL, 1985, J BIOL CHEM, V260, P6418; MIRA E, 1989, J BIOL CHEM, V264, P18209; MURRAY KJ, 1984, J BIOL CHEM, V259, P7673; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1990, DIABETES CARE, V13, P582, DOI 10.2337/diacare.13.6.582; PILKIS SJ, 1987, ENZYMES, V18, P3; PILKIS SJ, 1970, BIOCHIM BIOPHYS ACTA, V216, P461; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SASAKI K, 1988, P NATL ACAD SCI USA, V85, P2954, DOI 10.1073/pnas.85.9.2954; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAUB R, 1987, J BIOL CHEM, V262, P10893; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VAULONT S, 1986, J BIOL CHEM, V261, P7621; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YAMASHITA S, 1986, J CLIN INVEST, V78, P1008, DOI 10.1172/JCI112654; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	56	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1557	1563						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846360				2022-12-25	WOS:A1991EU49700033
J	FUNG, LS; NEIL, G; LEIBOWITZ, J; COLE, EH; CHUNG, S; CROW, A; LEVY, GA				FUNG, LS; NEIL, G; LEIBOWITZ, J; COLE, EH; CHUNG, S; CROW, A; LEVY, GA			MONOCLONAL-ANTIBODY ANALYSIS OF A UNIQUE MACROPHAGE PROCOAGULANT ACTIVITY INDUCED BY MURINE HEPATITIS-VIRUS STRAIN-3 INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION PROTEASE CASCADE; TISSUE FACTOR; BACTERIAL LIPOPOLYSACCHARIDE; PLASMINOGEN-ACTIVATOR; CELLULAR RECEPTOR; HUMAN-MONOCYTES; EXPRESSION; INDUCTION; MICE; SUSCEPTIBILITY	A panel of 24 IgG2ak monoclonal antibodies was produced against murine hepatitis virus strain 3 (MHV-3)-induced procoagulant activity (PCA) from murine macrophages. The antibodies were specific and did not react in an enzyme-linked immunosorbent assay with purified MHV-3; lipopolysaccharide-induced PCA; crude mouse, human, or rabbit tissue factor, or unstimulated murine macrophages. Sixteen of 24 monoclonal antibodies inhibited functional PCA expression in a one-stage clotting assay. More detailed studies on one monoclonal antibody, 3D4.3, demonstrated that it inhibited prothrombin cleavage at concentrations of greater-than-or-equal-to 0.1 mu-g/ml, and by Western blot this antibody reacted with proteins of a molecular mass of 140, 74, and 70 kDa on nonreduced gels and 74 and 70 kDa on reduced gels distinct from tissue factor known to have a molecular mass of 47 kDa. Induction of PCA was dependent on both host RNA and protein synthesis. Immunofluorescence studies showed specific binding to MHV-3-stimulated PCA-positive macrophage membranes. Both numbers of positive macrophages and intensity of staining correlated with multiplicity of infection. These monoclonal antibodies will be useful in isolation and characterization of the unique viral-induced PCA as well as in determining its biologic role in MHV infection and other diseases in which the prothrombinase has been implicated.	UNIV TORONTO,DEPT MED,MSB 7302,1 KINGS COLL CIR,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV IOWA,DEPT MED,IOWA CITY,IA 52242; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Toronto; University of Iowa; University of Texas System; University of Texas Health Science Center Houston				Crow, Andrew R/0000-0001-6978-4999				BROZE GJ, 1985, J BIOL CHEM, V260, P917; COLE EH, 1985, J CLIN INVEST, V75, P861, DOI 10.1172/JCI111784; COLE EH, 1985, TRANSPLANTATION, V40, P363, DOI 10.1097/00007890-198510000-00005; COLVIN RB, 1973, J EXP MED, V138, P686, DOI 10.1084/jem.138.3.686; DINDZANS VJ, 1986, J IMMUNOL, V137, P2355; DINDZANS VJ, 1985, J IMMUNOL, V135, P4189; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DRAKE TA, 1989, AM J PATHOL, V134, P1087; EDGINGTON TS, 1974, MONONUCLEAR PHAGOCYT, V18, P508; EDWARDS RL, 1980, J IMMUNOL, V125, P606; EDWARDS RL, 1984, PROG HEMOST THROMB, V7, P183; GITLIN D, 1957, AM J PATHOL, V33, P55; HOGG N, 1983, CLIN EXP IMMUNOL, V53, P725; HOGG N, 1983, J EXP MED, V157, P473, DOI 10.1084/jem.157.2.473; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOWITZ JL, 1983, J VIROL METHODS, V3, P255; LEVY GA, 1981, J IMMUNOL, V127, P357; LEVY GA, 1981, J EXP MED, V154, P1150, DOI 10.1084/jem.154.4.1150; LEVY GA, 1980, J EXP MED, V151, P1232, DOI 10.1084/jem.151.5.1232; LEVY GA, 1983, HEPATOLOGY, V3, P964; LEVY GA, 1982, GASTROENTEROLOGY, V82, P1140; LEVY GA, 1989, REV INFECT DIS, V11, P712; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MACPHEE PJ, 1988, MICROVASC RES, V36, P140, DOI 10.1016/0026-2862(88)90014-3; MACPHEE PJ, 1985, HEPATOLOGY, V5, P649, DOI 10.1002/hep.1840050422; MAIER RV, 1981, J IMMUNOL, V127, P1596; MORICE LM, 1985, J IMMUNOL METHODS, V85, P421; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MUHLFELDER TW, 1979, J CLIN INVEST, V63, P147, DOI 10.1172/JCI109269; NEMERSON Y, 1982, PROG HEMOST THROMB, V6, P237; OTTAWAY CA, 1984, J CLIN IMMUNOL, V4, P348, DOI 10.1007/BF00917137; ROSENTHAL GA, 1988, SURG FORUM, V24, P103; ROTHBERGER H, 1978, J CLIN INVEST, V62, P649, DOI 10.1172/JCI109172; ROTHBERGER H, 1977, J CLIN INVEST, V59, P549, DOI 10.1172/JCI108670; SCHWARTZ BS, 1982, J EXP MED, V155, P1464, DOI 10.1084/jem.155.5.1464; SINCLAIR SB, 1990, INFECT IMMUN, V58, P1821, DOI 10.1128/IAI.58.6.1821-1827.1990	38	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1789	1795						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846363				2022-12-25	WOS:A1991EU49700067
J	YAMAMOTO, K; KAWANISHI, S				YAMAMOTO, K; KAWANISHI, S			SITE-SPECIFIC DNA DAMAGE INDUCED BY HYDRAZINE IN THE PRESENCE OF MANGANESE AND COPPER IONS - THE ROLE OF HYDROXYL RADICAL AND HYDROGEN-ATOM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; COBALT(II) ION; SINGLET OXYGEN; PEROXIDE; DERIVATIVES; SUPEROXIDE; CELLS; MUTAGENICITY; ACTIVATION; HISTIDINE	The mechanism of DNA damage by hydrazine in the presence of metal ions was investigated by DNA sequencing technique and ESR-spin trapping method. Hydrazine caused DNA damage in the presence of Mn(III), Mn(II), Cu(II), Co(II), and Fe(III). The order of inducing effect on hydrazine-dependent DNA damage (Mn(II) > Mn(II) approximately Cu(II) >> Co(II) approximately Fe(II I)) was related to that of the accelerating effect on the O2 consumption rate of hydrazine autoxidation. DNA damage by hydrazine plus Mn(II) or Mn(III) was inhibited by hydroxyl radical scavengers and superoxide dismutase, but not by catalase. On the other hand, bathocuproine and catalase completely inhibited DNA damage by hydrazine plus Cu(II), whereas hydroxyl radical scavengers and superoxide dismutase did not. Hydrazine plus Mn(II) or Mn(III) caused cleavage at every nucleotide with a little weaker cleavage at adenine residues, whereas hydrazine plus Cu(II) induced piperidine-labile sites frequently at thymine residues, especially of the GTC sequence. ESR-spin trapping experiments showed that hydroxyl radical is generated during the Mn(III)-catalyzed autoxidation of hydrazine, whereas hydrogen atom adducts of spin trapping reagents are generated during Cu(II)-catalyzed autoxidation. The results suggest that hydrazine plus Mn(II) or Mn(III) generate hydroxyl free radical not via H2O2 and that this hydroxyl free radical causes DNA damage. A possibility that the hydrogen atom releasing compound participates in hydrazine plus Cu(II)-induced DNA damage is discussed.	KYOTO UNIV,FAC MED,DEPT PUBL HLTH,KYOTO 606,JAPAN	Kyoto University								ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452, DOI 10.1016/0003-9861(82)90049-2; BACK RA, 1984, REV CHEM INTERMED, V5, P293, DOI 10.1007/BF03155648; BIANCIFIORI C, 1962, NATURE, V194, P488, DOI 10.1038/194488a0; BROWN DM, 1966, BIOCHEM BIOPH RES CO, V24, P967, DOI 10.1016/0006-291X(66)90345-7; BRYAN SE, 1981, NUCLEIC ACIDS RES, V9, P5811, DOI 10.1093/nar/9.21.5811; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; CABELLI DE, 1984, J PHYS CHEM-US, V88, P6291, DOI 10.1021/j150669a047; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHU BCF, 1973, MUTAT RES, V20, P265, DOI 10.1016/0027-5107(73)90196-6; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GEORGE A M, 1987, British Journal of Cancer, V55, P141; HENNER WD, 1982, J BIOL CHEM, V257, P1750; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; INOUE S, 1989, BIOCHEM BIOPH RES CO, V159, P445, DOI 10.1016/0006-291X(89)90012-0; INOUE S, 1987, CANCER RES, V47, P6522; INOUE S, 1990, CHEM RES TOXICOL, V3, P144, DOI 10.1021/tx00014a010; KAWANISHI S, 1986, J BIOL CHEM, V261, P6090; KAWANISHI S, 1986, J BIOL CHEM, V261, P5952; KAWANISHI S, 1989, BIOCHEM PHARMACOL, V38, P3491, DOI 10.1016/0006-2952(89)90119-6; KIMBALL RF, 1977, MUTAT RES, V39, P111, DOI 10.1016/0165-1110(77)90018-5; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LIM PK, 1989, J AM CHEM SOC, V111, P8404, DOI 10.1021/ja00204a012; MAKINO K, 1983, J PHYS CHEM-US, V87, P1369, DOI 10.1021/j100231a020; Maxam A M, 1980, Methods Enzymol, V65, P499; NASSICALO L, 1989, CARCINOGENESIS, V10, P1055, DOI 10.1093/carcin/10.6.1055; PARODI S, 1981, CANCER RES, V41, P1469; ROE FJC, 1967, NATURE, V216, P375, DOI 10.1038/216375a0; SAKURAI H, 1985, BIOCHIM BIOPHYS ACTA, V841, P208; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SEVERI L, 1968, JNCI-J NATL CANCER I, V41, P331; SINHA BK, 1987, BIOCHIM BIOPHYS ACTA, V924, P261, DOI 10.1016/0304-4165(87)90021-3; Sissoeff I, 1976, Prog Biophys Mol Biol, V31, P165; Thiele J, 1892, LIEBIGS ANN CHEM, V271, P127; TOSK J, 1979, MUTAT RES, V66, P247, DOI 10.1016/0165-1218(79)90085-5; TOTH B, 1975, CANCER RES, V35, P3693; WHITING RF, 1979, MUTAT RES, V62, P505, DOI 10.1016/0027-5107(79)90046-0; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; YAMAMOTO K, 1989, CHEM RES TOXICOL, V2, P234, DOI 10.1021/tx00010a004; YIM MB, 1990, P NATL ACAD SCI USA, V87, P394, DOI 10.1073/pnas.87.1.394	39	130	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1509	1515						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846358				2022-12-25	WOS:A1991EU49700027
J	ACCILI, D; MOSTHAF, L; ULLRICH, A; TAYLOR, SI				ACCILI, D; MOSTHAF, L; ULLRICH, A; TAYLOR, SI			A MUTATION IN THE EXTRACELLULAR DOMAIN OF THE INSULIN-RECEPTOR IMPAIRS THE ABILITY OF INSULIN TO STIMULATE RECEPTOR AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FMS PROTO-ONCOGENE; GROWTH-FACTOR; 3T3-L1 ADIPOCYTES; TYROSINE KINASE; PLASMA-MEMBRANE; INTACT-CELLS; PHOSPHORYLATION; SUBUNITS; IDENTIFICATION; GLYCOSYLATION	Mutations of the insulin receptor gene have been shown to cause insulin-resistant diabetes in patients with genetic forms of insulin resistance. We have previously reported that a mutation substituting valine for Phe382 in the alpha-subunit of the insulin receptor is associated with impaired transport of the mutant receptor to the plasma membrane (Accili, D., Frapier, C., Mosthaf, L., McKeon, C., Elbein, S. C., Permutt, M. A., Ramos, E., Lander, E. S., Ullrich, A., and Taylor, S. I. (1989) EMBO J. 8, 2509-2517). In this study, we demonstrate that the Val382 mutation impairs the ability of insulin to activate receptor autophosphorylation. Furthermore, the Val382 receptor has reduced activity to phosphorylate other peptide substrates in the presence of insulin. Nevertheless, when the Val382 mutant and wild-type receptor, thereby activating the tyrosine kinase activity of the mutant receptor. Thus, the conformational change used by the Val382 mutation compromises the ability of the receptor to transmit a signal across the plasma membrane. Furthermore, our observations suggest that receptor phosphorylation by an intermolecular mechanism (i.e. transphosphorylation) may play a role in mediating the action of insulin upon the target cell.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,W-8033 MARTINSRIED,GERMANY	Max Planck Society	ACCILI, D (corresponding author), NIDDKD,DIABET BRANCH,BIOCHEM & MOLEC PATHOPHYSIOL SECT,BETHESDA,MD 20892, USA.							ACCILI D, 1986, ENDOCRINOLOGY, V119, P1274, DOI 10.1210/endo-119-3-1274; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; ACCILI D, 1990, DIABETES S1, V39, pA113; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BARNES ND, 1974, DIABETOLOGIA, V10, P285; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GAROFALO RS, 1989, MOL CELL BIOL, V9, P2806, DOI 10.1128/MCB.9.7.2806; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; HEDO JA, 1983, J BIOL CHEM, V258, P20; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P1228, DOI 10.1073/pnas.80.5.1228; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KONO T, 1971, J BIOL CHEM, V246, P6210; LEWIS RE, 1990, J BIOL CHEM, V265, P947; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RONNETT GV, 1983, J BIOL CHEM, V258, P283; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; STADTMAUER L, 1986, J BIOL CHEM, V261; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAYLOR SI, 1990, TRENDS ENDOCRINOL ME, V2, P134; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1983, J BIOL CHEM, V258, P75	35	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					434	439						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845971				2022-12-25	WOS:A1991EQ33900063
J	LU, HM; YAMADA, H; MIZUSHIMA, S				LU, HM; YAMADA, H; MIZUSHIMA, S			A PROLINE RESIDUE NEAR THE AMINO TERMINUS OF THE MATURE DOMAIN OF SECRETORY PROTEINS LOWERS THE LEVEL OF THE PROTON MOTIVE FORCE REQUIRED FOR TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MEMBRANE-VESICLES; SEQUENCE CLEAVAGE SITES; ESCHERICHIA-COLI; INVITRO TRANSLOCATION; NUCLEOTIDE-SEQUENCE; SIGNAL-SEQUENCE; SECA PROTEIN; GENE; PEPTIDE; OMPA	A large variety of proOmpF-Lpps, hybrid secretory proteins composed of the signal region of proOmpF and the mature part of the major lipoprotein, either possessing or not possessing a proline residue near the amino terminus of their mature domains, were constructed at a DNA level, and the rates of their in vitro translocation were determined in the presence and absence of the proton motive force (DELTA-mu-H+ approximately). A proline residue at the signal peptide cleavage site (position +1) blocked the cleavage reaction but not the translocation reaction. All the proOmpF-Lpps examined exhibited approximately the same translocation rate in the presence of DELTA-mu-H+ approximately irrespective of the presence or absence of a proline residue near the amino terminus. In the absence of DELTA-mu-H+ approximately, which was achieved by either depletion of the respiratory substrate or the use of urea-treated membrane vesicles permeable to protons, proOmpF-Lpps possessing a proline residue near the amino terminus of the mature domain were translocated whereas those possessing no proline residue in this region were not translocated at all or only very weakly. The position of the proline residue was then moved stepwise away from the amino terminus of the mature domain. The further the position was moved away, the slower was the rate of translocation in the absence of DELTA-mu-H+ approximately. The removal of the proline residue at position +2 of the mature domain of proOmpA also made the DELTA-mu-H+ approximately-independent translocation appreciably slower. It is suggested that the conformational flexibility endowed by the proline residue on the junction region between the signal peptide and the mature domain allows the translocation in the absence of DELTA-mu-H+ approximately and that this junction region must take on a particular conformation for initiation of the translocation reaction.	UNIV TOKYO,APPL MICROBIOL LAB,BUNKYO KU,TOKYO 113,JAPAN; NAGOYA UNIV,MICROBIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	University of Tokyo; Nagoya University								CHANG CN, 1986, GENE, V44, P121; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALLAS WS, 1980, NATURE, V288, P499, DOI 10.1038/288499a0; DIERSTEIN R, 1986, EMBO J, V5, P427, DOI 10.1002/j.1460-2075.1986.tb04228.x; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; DUFFAUD GD, 1985, CURR TOP MEMBR TRANS, V24, P65; GELLER BL, 1989, J BIOL CHEM, V264, P16465; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1986, J BIOL CHEM, V261, P970; JAURIN B, 1981, P NATL ACAD SCI-BIOL, V78, P4897, DOI 10.1073/pnas.78.8.4897; LEE C, 1971, BIOCHEMISTRY-US, V10, P4375, DOI 10.1021/bi00800a004; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LU HM, 1990, MECHANISM PROTEIN SE, P14; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; MOVVA NR, 1980, J MOL BIOL, V143, P317, DOI 10.1016/0022-2836(80)90193-X; PATEL L, 1975, P NATL ACAD SCI USA, V72, P3387, DOI 10.1073/pnas.72.9.3387; POLLITT S, 1986, J BIOL CHEM, V261, P1835; Richardson J. T., 1989, PREDICTION PROTEIN S, P49; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1980, BIOCHIM BIOPHYS ACTA, V599, P150, DOI 10.1016/0005-2736(80)90064-4; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YAMANE K, 1988, J BIOL CHEM, V263, P5368	36	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9977	9982						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851761				2022-12-25	WOS:A1991FM45900095
J	NINFA, EG; STOCK, A; MOWBRAY, S; STOCK, J				NINFA, EG; STOCK, A; MOWBRAY, S; STOCK, J			RECONSTITUTION OF THE BACTERIAL CHEMOTAXIS SIGNAL TRANSDUCTION SYSTEM FROM PURIFIED COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SENSORY TRANSDUCTION; SALMONELLA-TYPHIMURIUM; CHEB METHYLESTERASE; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; SITE; PHOSPHOTRANSFER	In bacterial chemotaxis, transmembrane receptor proteins detect attractants and repellents in the medium and send intracellular signals that control motility. The cytoplasmic proteins that transduce information from the receptors to the flagellar motor have previously been purified and many of their enzymatic activities have been identified. Here we report the reconstitution of the complete signal transduction system from purified components. The protein kinase, CheA, plays a central role in both the initial excitation response to stimuli as well as subsequent events associated with adapatation. This kinase provides phosphoryl groups to two acceptor proteins, CheY, which interacts with the flagellar motor, and CheB, which demethylates the receptors. The purified aspartate receptor, Tar, reconstituted into phospholipid vesicles, acts in conjunction with an auxiliary protein, CheW, to stimulate the rate of kinase autophosphorylation greater than 10-fold. This stimulation is inhibited by aspartate. The activity of the kinase is increased by increased levels of receptor methylation. This effect provides a mechanism that explains how changes in receptor methylation mediate adaptive responses to attractant and repellant stimuli.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201; SWEDISH UNIV AGR SCI,DEPT MOLEC BIOL,S-75124 UPPSALA,SWEDEN	Princeton University; Princeton University; Wayne State University; Swedish University of Agricultural Sciences			Mowbray, Sherry L/D-2141-2013	Gottlin, Elizabeth/0000-0003-0886-0024	NIAID NIH HHS [AI 20980] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; FOSTER DL, 1985, J BIOL CHEM, V260, P1706; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MACNAB RM, 1987, CELLULAR MOL BIOL, P732; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; RAVID S, 1986, P NATL ACAD SCI USA, V83, P7157, DOI 10.1073/pnas.83.19.7157; SANDERS DA, 1989, J BACTERIOL, V171, P6271, DOI 10.1128/jb.171.11.6271-6278.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SMITH JM, 1988, J BACTERIOL, V170, P2698, DOI 10.1128/jb.170.6.2698-2704.1988; SPRINGER MS, 1984, P NATL ACAD SCI-BIOL, V81, P5061, DOI 10.1073/pnas.81.16.5061; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STEWART RC, 1988, COLD SPRING HARB SYM, V53, P27, DOI 10.1101/SQB.1988.053.01.007; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK A, 1987, J BIOL CHEM, V262, P535; STOCK AM, 1987, J BACTERIOL, V169, P3301, DOI 10.1128/jb.169.7.3301-3311.1987; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; STOCK J, 1987, TRENDS BIOCHEM SCI, V12, P371, DOI 10.1016/0968-0004(87)90172-1; STOCK J, 1990, PROTEIN METHYLATION; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STOCK JB, 1981, J BIOL CHEM, V256, P826; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986	39	199	201	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9764	9770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851755				2022-12-25	WOS:A1991FM45900066
J	LIGHTOWLERS, R; CHRZANOWSKALIGHTOWLERS, Z; MARUSICH, M; CAPALDI, RA				LIGHTOWLERS, R; CHRZANOWSKALIGHTOWLERS, Z; MARUSICH, M; CAPALDI, RA			SUBUNIT FUNCTION IN EUKARYOTE CYTOCHROME-C-OXIDASE - A MUTATION IN THE NUCLEAR-CODED SUBUNIT-IV ALLOWS ASSEMBLY BUT ALTERS THE FUNCTION AND STABILITY OF YEAST CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SEQUENCE; KINETICS; BINDING; HEART; GENE; PURIFICATION; CEREVISIAE; ISOZYMES; PROTEINS	Strains of the yeast Saccharomyces cerevisiae disrupted in YCOX4, the nuclear gene encoding cytochrome c oxidase subunit IV, do not assemble a functional or spectrally visible oxidase. We report the characterization of a yeast strain, RM1, expressing a mutated YCOX4 gene which is temperature sensitive for respiration at 37-degrees-C, but incorporates cytochrome aa3 over all growth temperatures. The mutant enzyme is less stable than the wild type, with subunit IV readily proteolyzed without gross denaturation of the complex but with a concomitant loss of oxidase activity. When grown fermentatively at 37-degrees-C, cytochrome c oxidase from the mutant strain had a turnover number of less than 3% of the normal complex, while K(m) values and subunit levels were comparable to normal. Thus alterations in subunit IV can perturb the enzyme structure and alter its catalytic rate, implying a role for this subunit in cytochrome c oxidase function as distinct from assembly.			LIGHTOWLERS, R (corresponding author), UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA.		Marusich, Michael/AAQ-3447-2020	Chrzanowska-Lightowlers, Zofia/0000-0002-0045-3152	NHLBI NIH HHS [HL 22050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1990, J BIOL CHEM, V265, P16389; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BIBUS CR, 1988, J BIOL CHEM, V263, P13097; BISSON R, 1985, BIOCHEMISTRY-US, V24, P7845, DOI 10.1021/bi00347a051; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DAUM G, 1982, J BIOL CHEM, V257, P3028; DETHMERS JK, 1979, J BIOL CHEM, V254, P1973; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1986, METHOD ENZYMOL, V126, P32; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KOLODKIN AL, 1986, CELL, V46, P733, DOI 10.1016/0092-8674(86)90349-1; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LUSTIG A, 1982, BIOCHEMISTRY-US, V21, P309, DOI 10.1021/bi00531a017; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MARUSICH MF, 1988, J IMMUNOL METHODS, V114, P155, DOI 10.1016/0022-1759(88)90167-6; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; NAQUI A, 1988, J BIOL CHEM, V263, P12342; NILSSON T, 1988, BIOCHEMISTRY-US, V27, P296, DOI 10.1021/bi00401a045; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; POWER SD, 1984, J BIOL CHEM, V259, P6564; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; PROCHASKA LJ, 1987, J BIOENERG BIOMEMBR, V19, P143, DOI 10.1007/BF00762722; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; REIK LM, 1987, J IMMUNOL METHODS, V100, P123, DOI 10.1016/0022-1759(87)90180-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1981, EUR J BIOCHEM, V115, P261, DOI 10.1111/j.1432-1033.1981.tb05232.x; Sherman F., 1986, METHODS YEAST GENETI; SONE N, 1988, J BIOCHEM-TOKYO, V103, P606, DOI 10.1093/oxfordjournals.jbchem.a122314; THORNSTROM PE, 1988, BIOCHIM BIOPHYS ACTA, V935, P103, DOI 10.1016/0005-2728(88)90206-X; TRIVEDI A, 1986, BIOCHEM CELL BIOL, V64, P1195, DOI 10.1139/o86-157; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V118, P47; Weiss H, 1978, Methods Enzymol, V53, P66; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG YZ, 1988, BIOCHEMISTRY-US, V27, P1389, DOI 10.1021/bi00404a045	41	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7688	7693						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850417				2022-12-25	WOS:A1991FJ34200059
J	BALTZ, JM; BIGGERS, JD; LECHENE, C				BALTZ, JM; BIGGERS, JD; LECHENE, C			2-CELL STAGE MOUSE EMBRYOS APPEAR TO LACK MECHANISMS FOR ALLEVIATING INTRACELLULAR ACID LOADS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC PH; SNAIL NEURONS; WEAK ACIDS; CELL-LINE; CHLORIDE; ANTIPORT; SODIUM; BICARBONATE; MEMBRANE; RECOVERY	Mouse embryos at the two-cell stage, like other cells, can recover from an intracellular acid-load. Our previous work has shown, surprisingly, that there is no contribution to this recovery by Na+/H+ antiport activity. Here we show that the recovery similarly is not affected by inhibition of other known intracellular pH (pH(i)) regulatory mechanisms. Specifically, the recovery is unaffected by lack of external Na+, inhibition of anion exchange, or lack of bicarbonate, which eliminates the Na+-dependent HCO3-/Cl- exchanger as a possible mechanism. These conditions also eliminate any possible Na+,HCO3- cotransporter operating to relieve acid-loading. Recovery is unaffected similarly by nonspecific inhibitors of H+-ATPase activity. These observations lead to the conclusion that recovery from acid-load is a passive process in the two-cell mouse embryo. Similarly, the mean base-line pH(i) (6.84) is not dependent on known pH(i) regulatory mechanisms. The embryos exhibit a marked intracellular alkalinization when exposed to Cl--free medium in the presence of bicarbonate. This response is eliminated by an inhibitor of anion exchange and by lack of bicarbonate, but is independent of Na+. These results indicate that there is probably a Na+-independent HCO3-/Cl- exchanger active in these cells, presumably functioning to alleviate alkaline loads.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, NATL ELECTRON PROBE RESOURCE ANAL CELLS, CELLULAR PHYSIOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	BALTZ, JM (corresponding author), HARVARD UNIV, SCH MED, HUMAN REPROD & REPROD BIOL LAB, 45 SHATTUCK ST, BOSTON, MA 02115 USA.			Baltz, Jay/0000-0002-9749-2480	NCRR NIH HHS [5P441RR02064] Funding Source: Medline; NICHD NIH HHS [HD21581, HD21988] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021581, U01HD021988] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AICKIN CC, 1988, CIBA F SYMP, V139, P3; ALPER SL, 1988, J BIOL CHEM, V263, P17092; BALTZ JM, 1990, DEV BIOL, V138, P421, DOI 10.1016/0012-1606(90)90208-Z; BARBEHENN EK, 1974, P NATL ACAD SCI USA, V71, P1056, DOI 10.1073/pnas.71.4.1056; BIDANI A, 1989, AM J PHYSIOL, V257, pC65, DOI 10.1152/ajpcell.1989.257.1.C65; BORON WF, 1983, J MEMBRANE BIOL, V72, P1, DOI 10.1007/BF01870311; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; DEHEMPTINNE A, 1983, AM J PHYSIOL, V245, pC178, DOI 10.1152/ajpcell.1983.245.3.C178; FRELIN C, 1985, HORMONES CELL REGULA, V9, P259; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; GILLESPIE JI, 1988, J PHYSIOL-LONDON, V405, P385, DOI 10.1113/jphysiol.1988.sp017338; GRINSTEIN S, 1988, NAPLUS HPLUS EXCHANG; HOGAN B, 1986, MANIPULATING MOUSE E; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; LEESE HJ, 1984, ANAL BIOCHEM, V140, P443, DOI 10.1016/0003-2697(84)90191-X; LIN PY, 1990, AM J PHYSIOL, V258, pC132, DOI 10.1152/ajpcell.1990.258.1.C132; LUBMAN RL, 1989, AM J PHYSIOL, V257, pL438, DOI 10.1152/ajplung.1989.257.6.L438; MANEJWALA FM, 1989, DEV BIOL, V133, P210, DOI 10.1016/0012-1606(89)90312-6; MILLS RM, 1967, EXP CELL RES, V47, P337, DOI 10.1016/0014-4827(67)90236-4; MOOLENAAR WH, 1986, TRENDS BIOCHEM SCI, V11, P141, DOI 10.1016/0968-0004(86)90069-1; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; OLSNES S, 1986, J CELL BIOL, V102, P967, DOI 10.1083/jcb.102.3.967; REINERTSEN KV, 1988, J BIOL CHEM, V263, P11117; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF354, DOI 10.1152/ajprenal.1989.256.2.F354; SZATKOWSKI MS, 1989, J PHYSIOL-LONDON, V409, P103, DOI 10.1113/jphysiol.1989.sp017487; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THOMAS RC, 1977, J PHYSIOL-LONDON, V273, P317, DOI 10.1113/jphysiol.1977.sp012096; THOMAS RC, 1984, J PHYSIOL-LONDON, V354, pP3; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7	32	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6052	6057						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848847				2022-12-25	WOS:A1991FE37300011
J	YAMAGUCHI, A; ADACHI, K; AKASAKA, T; ONO, N; SAWAI, T				YAMAGUCHI, A; ADACHI, K; AKASAKA, T; ONO, N; SAWAI, T			METAL-TETRACYCLINE H+ ANTIPORTER OF ESCHERICHIA-COLI ENCODED BY A TRANSPOSON TN10 - HISTIDINE-257 PLAYS AN ESSENTIAL ROLE IN H+ TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC PERMEASE; RESISTANCE DETERMINANTS; NUCLEOTIDE-SEQUENCE; MEMBRANE-VESICLES; PROTEIN; REPLACEMENT; MUTAGENESIS; RESIDUES; SYMPORT; MUTANTS	The transposon Tn10-encoded tetA gene product is a metal-tetracycline/proton antiporter (Yamaguchi, A., Udagawa, T., and Sawai, T. (1990) J. Biol. Chem. 265, 4809-4813). Its tetracycline transport activity was inhibited by a histidine-specific reagent, diethyl pyrocarbonate. Among five histidine residues in this antiporter, only His257 is located in the putative transmembrane helices. Thus, His257 was replaced by Glu or Asp. Inverted vesicles containing the Glu257 and Asp257 mutant proteins showed only 20 and 10% of the tetracycline uptake of wild-type vesicles, respectively. In contrast to wild-type vesicles, the mutant vesicles showed no tetracycline-dependent proton translocation, indicating that the mutant proteins had lost the tetracycline/H+ antiport activity. The significant Co-60(2+) uptake without proton translocation by the mutant vesicles also confirmed that the mutant carriers act as uniporters of a metal-tetracycline complex. The metal-tetracycline uniport by the mutant proteins was not inhibited by diethyl pyrocarbonate, indicating that His257 is the only histidine residue essential for proton translocation. These mutant proteins conferred about half-level resistance to tetracycline, probably due to their catalyzing downhill efflux of a metal-tetracycline complex out of the cells.			YAMAGUCHI, A (corresponding author), CHIBA UNIV,FAC PHARMACEUT SCI,DIV MICROBIAL CHEM,CHIBA 260,JAPAN.							ARGAST M, 1985, ARCH MICROBIOL, V141, P260, DOI 10.1007/BF00408069; ARGAST M, 1984, ANTIMICROB AGENTS CH, V26, P263, DOI 10.1128/AAC.26.2.263; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CHOPRA I, 1986, J ANTIMICROB CHEMOTH, V18, P51, DOI 10.1093/jac/18.Supplement_C.51; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; ECKERT B, 1989, J BIOL CHEM, V264, P11663; HARAYAMA S, 1984, MOL GEN GENET, V194, P444, DOI 10.1007/BF00425556; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KING SC, 1989, J BIOL CHEM, V264, P7390; KOBAYASHI H, 1978, J BIOL CHEM, V253, P2085; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MENDEZ B, 1980, PLASMID, V3, P99, DOI 10.1016/0147-619X(80)90101-8; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; PADAN E, 1985, P NATL ACAD SCI USA, V82, P6765, DOI 10.1073/pnas.82.20.6765; PADAN E, 1979, P NATL ACAD SCI USA, V76, P6221, DOI 10.1073/pnas.76.12.6221; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; PUTTNER IB, 1988, P NATL ACAD SCI USA, V85, P1467, DOI 10.1073/pnas.85.5.1467; PUTTNER IB, 1989, BIOCHEMISTRY-US, V28, P2525, DOI 10.1021/bi00432a027; RUBIN RA, 1990, J BACTERIOL, V172, P2303, DOI 10.1128/jb.172.5.2303-2312.1990; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; SAWAI T, 1982, ANTIMICROB AGENTS CH, V22, P585, DOI 10.1128/AAC.22.4.585; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981	35	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6045	6051						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848846				2022-12-25	WOS:A1991FE37300010
J	BIZUB, D; WEBER, IT; CAMERON, CE; LEIS, JP; SKALKA, AM				BIZUB, D; WEBER, IT; CAMERON, CE; LEIS, JP; SKALKA, AM			A RANGE OF CATALYTIC EFFICIENCIES WITH AVIAN RETROVIRAL PROTEASE SUBUNITS GENETICALLY LINKED TO FORM SINGLE POLYPEPTIDE-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HIV-1 PROTEASE; GENE-PRODUCTS; MUTAGENESIS; PROTEINS; DNA	Molecular modeling based on the crystal structure of the Rous sarcoma virus (RSV) protease dimer has been used to link the two identical subunits of this enzyme into a functional, single polypeptide chain resembling the nonviral aspartic proteases. Six different linkages were selected to test the importance of different interactions between the amino acids at the amino and carboxyl termini of the two subunits. These linkages were introduced into molecular clones of fused protease genes and the linked protease dimers were expressed in Escherichia coli and purified. Catalytically active proteins were obtained from the inclusion body fraction after renaturation. The linked protease dimers exhibited a 10-20-fold range in catalytic efficiencies (V(max)/K(m)) on peptide substrates. Both flexibility and ionic interactions in the linkage region affect catalytic efficiency. Some of the linked protease dimers were 2-3-fold more active than the nonlinked enzyme purified from bacteria, although substrate specificities were unchanged. Similar relative efficiencies were observed using a polyprotein precursor as substrate. Mutation of one catalytic Asp in the most active linked protease dimer inactivated the enzyme, demonstrating that these proteins function as single polypeptide chains rather than as multimers.	FOX CHASE CANC INST,INST CANC RES,7701 BURKHOLME AVE,PHILADELPHIA,PA 19111; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21701; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Case Western Reserve University					NATIONAL CANCER INSTITUTE [R01CA048703, R01CA049042] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49042, CA-48703] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BIANCHI M, 1990, BIOCHEM BIOPH RES CO, V167, P339, DOI 10.1016/0006-291X(90)91770-S; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; DECHIARA TM, 1986, METHOD ENZYMOL, V119, P403; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HARLOW E, 1988, ANTIBODIES LAB MANUA, P632; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOTLER M, 1989, J BIOL CHEM, V264, P3428; KOTLER M, 1988, J VIROL, V62, P2696, DOI 10.1128/JVI.62.8.2696-2700.1988; KOTLER M, 1988, P NATL ACAD SCI USA, V85, P4185, DOI 10.1073/pnas.85.12.4185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIS J, 1989, CURRENT COMMUNICATIO, P235; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; WEBER IT, 1990, PROTEINS, V7, P172, DOI 10.1002/prot.340070206; WEBER IT, 1990, J BIOL CHEM, V265, P10492	27	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4951	4958						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848230				2022-12-25	WOS:A1991FC21700044
J	LOTZ, M; GUERNE, PA				LOTZ, M; GUERNE, PA			INTERLEUKIN-6 INDUCES THE SYNTHESIS OF TISSUE INHIBITOR OF METALLOPROTEINASES-1/ERYTHROID POTENTIATING ACTIVITY (TIMP-1/EPA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR-BETA; HEPATOCYTE-STIMULATING FACTOR; SKIN FIBROBLAST COLLAGENASE; IV COLLAGENASE; EXPRESSION; CELLS; PROGELATINASE; BIOSYNTHESIS; MACROPHAGES; MONOCYTES	The study examines the role of interleukin-6 (IL-6) in connective tissue metabolism. Effects of different preparations of IL-6 on production of collagenase and tissue inhibitor of metalloproteinases-1/erythroid potentiating activity production are studied in human fibroblasts, synoviocytes, and articular chondrocytes. In contrast to interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNF-alpha), IL-6 does not stimulate the production of collagenase, nor does it modulate the stimulatory effects of IL-1-beta and TNF-alpha on the production of this proteinase. Furthermore, IL-6 has no detectable effect on prostaglandin E2 production, and additional proinflammatory response induced by IL-1-beta and TNF-alpha. IL-6, however, is identified as a potent inducer of de novo synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity in all types of connective tissue cells examined. These results define new biological activities of IL-6 and provide further insight into the regulation of connective tissues by cytokines.	HOP CANTONAL GENEVA, DIV RHUMATOL, CH-1211 GENEVA, SWITZERLAND	University of Geneva	LOTZ, M (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, SO45, LA JOLLA, CA 92093 USA.				NIA NIH HHS [AG07996] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG007996] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FONG YM, 1989, J IMMUNOL, V142, P2321; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GASSON JC, 1985, STEM CELL PHYSL, P95; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GUERNE PA, 1990, J IMMUNOL, V144, P499; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; ITO A, 1988, FEBS LETT, V234, P326, DOI 10.1016/0014-5793(88)80109-1; JIRIK FR, 1989, J IMMUNOL, V142, P144; JOHNSONWINT B, 1980, ANAL BIOCHEM, V104, P175, DOI 10.1016/0003-2697(80)90295-X; JOHNSTON RB, 1988, NEW ENGL J MED, V318, P747, DOI 10.1056/NEJM198803243181205; KHOKHA R, 1989, INVAS METAST, V9, P391; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; MAY LT, 1988, J BIOL CHEM, V263, P7760; MIZEL SB, 1981, P NATL ACAD SCI-BIOL, V78, P2474, DOI 10.1073/pnas.78.4.2474; MURPHY G, 1985, J BIOL CHEM, V260, P3079; OVERALL CM, 1989, CONNECT TISSUE RES, V20, P289, DOI 10.3109/03008208909023899; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; SODEK J, 1988, BIOL MECHANISMS TOOT, P303; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YOSHIOKA H, 1987, ANAL BIOCHEM, V166, P172, DOI 10.1016/0003-2697(87)90559-8; ZURAW BL, 1990, J BIOL CHEM, V265, P12664	34	275	281	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2017	2020						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846608				2022-12-25	WOS:A1991EV51500004
J	TEMSAMANI, J; AGRAWAL, S; PEDERSON, T				TEMSAMANI, J; AGRAWAL, S; PEDERSON, T			BIOTINYLATED ANTISENSE METHYLPHOSPHONATE OLIGODEOXYNUCLEOTIDES - INHIBITION OF SPLICEOSOME ASSEMBLY AND AFFINITY SELECTION OF U1 AND U2 SMALL NUCLEAR RNPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; RNA SPLICING INVITRO; MESSENGER-RNA; 2'-OME RNA; RIBONUCLEOPROTEIN-PARTICLES; OLIGONUCLEOTIDES; ANALOGS; PRECURSORS; SNRNP; DNA	Methylphosphonate (PC) backbone oligodeoxynucleotides complementary to the 5'-terminal nucleotides of U1 and U2 small nuclear (sn) RNAs do not elicit RNase H action under conditions in which natural (phosphodiester) oligodeoxynucleotides yield extensive Rnase H cleavage. We show here that antisense PC oligonucleotides can mask sites in U1 and U2 snRNPs that are required for spliceosome formation. We further report that biotinylated derivates of antisense PC oligos can be used for affinity selection of U1 and U2 snRNPs.	WORCESTER FDN EXPTL BIOL INC,CELL BIOL GRP,SHREWSBURY,MA 01545	Worcester Foundation for Biomedical Research					NIGMS NIH HHS [GM-21595-16] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL S, 1989, TETRAHEDRON LETT, V30, P7025, DOI 10.1016/S0040-4039(01)93414-8; AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AGRAWAL S, 1986, NUCLEIC ACIDS RES, V14, P6227, DOI 10.1093/nar/14.15.6227; AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; AGRAWAL S, 1987, TETRAHEDRON LETT, V28, P3539, DOI 10.1016/S0040-4039(00)95529-1; AGRAWAL S, 1990, TETRAHEDRON LETT, V31, P1543, DOI 10.1016/0040-4039(90)80011-A; Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BERGET SM, 1986, CELL, V46, P691, DOI 10.1016/0092-8674(86)90344-2; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CALVET JP, 1982, SCIENCE, V217, P456, DOI 10.1126/science.6178162; CALVET JP, 1981, CELL, V26, P363, DOI 10.1016/0092-8674(81)90205-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNLAP BE, 1971, BIOCHEMISTRY-US, V10, P2581; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; FROEHLER B, 1988, NUCLEIC ACIDS RES, V16, P4831, DOI 10.1093/nar/16.11.4831; FROEHLER BC, 1986, TETRAHEDRON LETT, V27, P5575, DOI 10.1016/S0040-4039(00)85269-7; FROEHLER BC, 1986, NUCLEIC ACIDS RES, V14, P5399, DOI 10.1093/nar/14.13.5399; FURDON PJ, 1989, NUCLEIC ACIDS RES, V17, P9193, DOI 10.1093/nar/17.22.9193; GAREGG PJ, 1985, CHEM SCRIPTA, V25, P280; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; MILLER PS, 1979, BIOCHEMISTRY-US, V18, P5134, DOI 10.1021/bi00590a017; MURAKAMI A, 1985, BIOCHEMISTRY-US, V24, P4041, DOI 10.1021/bi00336a036; QUARTIN RS, 1989, BIOCHEMISTRY-US, V28, P1040, DOI 10.1021/bi00429a018; SARIN PS, 1988, P NATL ACAD SCI USA, V85, P7448, DOI 10.1073/pnas.85.20.7448; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	39	14	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					468	472						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845976				2022-12-25	WOS:A1991EQ33900068
J	LAX, I; MITRA, AK; RAVERA, C; HURWITZ, DR; RUBINSTEIN, M; ULLRICH, A; STROUD, RM; SCHLESSINGER, J				LAX, I; MITRA, AK; RAVERA, C; HURWITZ, DR; RUBINSTEIN, M; ULLRICH, A; STROUD, RM; SCHLESSINGER, J			EPIDERMAL GROWTH-FACTOR (EGF) INDUCES OLIGOMERIZATION OF SOLUBLE, EXTRACELLULAR, LIGAND-BINDING DOMAIN OF EGF RECEPTOR - A LOW RESOLUTION PROJECTION STRUCTURE OF THE LIGAND-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; SELF-PHOSPHORYLATION; ELECTRON-MICROSCOPY; POINT MUTATION; CROSS-LINKING; LIVING CELLS; AUTOPHOSPHORYLATION; ACTIVATION; SITE	Ligand-induced oligomerization is a universal phenomenon among growth factor receptors. Although the mechanism involved is yet to be defined, much evidence indicates that receptor oligomerization plays a crucial role in receptor activation and signal transduction. Here we show that epidermal growth factor (EGF) is able to stimulate the oligomerization of a recombinant, soluble, extracellular ligand-binding domain of EGF receptor. Covalent cross-linking experiments, analysis by sodium dodecyl sulfate-gel electrophoresis, size exclusion chromatography, and electron microscopy demonstrate that receptor dimers, trimers and larger multimers are formed in response to EGF. This establishes that receptor oligomerization is an intrinsic property of the extracellular ligand-binding domain of EGF receptor. Ligand-induced conformational change in the extracellular domain will stimulate receptor-receptor interactions. This may bring about the allosteric change involved in signal transduction from the extracellular domain across the plasma membrane, resulting in the activation of the cytoplasmic kinase domain. Electron microscopic images of individual extracellular ligand-binding domains appear as clusters of four similarly-sized stain-excluding areas arranged around a central, relatively less stain-excluded area. This suggests that the extracellular ligand-binding domain is structurally composed of four separate domains.	RORER CENT RES INC,KING OF PRUSSIA,PA 19406; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Max Planck Society; University of California System; University of California San Francisco	LAX, I (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Boggara, Mohan/D-1184-2009; Mitra, Alok/P-7800-2016	Mitra, Alok/0000-0003-0891-5697	NIGMS NIH HHS [GM24485] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024485, R01GM024485] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN H, 1990, HDB BIOL CONFOCAL MI, P141; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COCHET C, 1988, J BIOL CHEM, V263, P3290; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P6414, DOI 10.1021/bi00369a011; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1985, NEW METHODOLOGIES ST, P36; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LIVNEH E, 1987, EMBO J, V6, P2669, DOI 10.1002/j.1460-2075.1987.tb02558.x; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UNWIN PNT, 1975, J MOL BIOL, V98, P235, DOI 10.1016/S0022-2836(75)80111-2; UNWIN PNT, 1974, J MOL BIOL, V87, P641, DOI 10.1016/0022-2836(74)90075-8; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; WEBER W, 1984, J BIOL CHEM, V259, P4631; WILLIAMS RC, 1981, J MOL BIOL, V150, P399, DOI 10.1016/0022-2836(81)90555-6; YARDEN Y, 1985, J BIOL CHEM, V260, P315; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YARDEN Y, 1985, GROWTH FACTORS BIOL, P23; ZIDOVETZKI R, 1981, P NATL ACAD SCI-BIOL, V78, P6981, DOI 10.1073/pnas.78.11.6981	43	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13828	13833						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856216				2022-12-25	WOS:A1991FY02700060
J	SUGUMARAN, G; SILBERT, JE				SUGUMARAN, G; SILBERT, JE			SUBFRACTIONATION OF CHICK-EMBRYO EPIPHYSEAL CARTILAGE GOLGI - LOCALIZATION OF ENZYMES INVOLVED IN THE SYNTHESIS OF THE POLYSACCHARIDE PORTION OF PROTEOCHONDROITIN SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; MOUSE MASTOCYTOMA-CELLS; CHONDROITIN SULFATE; RAT-LIVER; PROTEOGLYCAN BIOSYNTHESIS; SUBCELLULAR ORGANIZATION; LINKED OLIGOSACCHARIDES; MICROSOMAL PREPARATIONS; TERMINAL GLYCOSYLATION; MEDIAL CISTERNAE	Membranes from chick embryo epiphyseal cartilage were fractionated by equilibrium sucrose density gradient centrifugation and assayed for galactosyl xylose transferase, chondroitin polymerization and sulfation as well as the marker enzymes glucose-6-phosphatase, NADH cytochrome c reductase, galactosyl ovalbumin transferase, and sialyltransferase. The order of distribution of chondroitin sulfate synthesis from dense to light membranes correlated with the established sequence of events for its synthesis. The linkage region enzyme, viz. galactosyl xylose transferase, distributed with NADH cytochrome c reductase in an earlier and heavier cis compartment. Chondroitin polymerization and sulfation had a dual distribution similar to the galactosyl ovalbumin transferase and sialyltransferase in separate later and lighter medial and trans compartments, or in an extended medial or trans compartment. The galactosyl xylose transferase had a distribution distinctly different from that of the galactosyl ovalbumin transferase indicating that there distinct enzymes showed no cross-reactivity with their respective acceptor substrates. The dual distribution of chondroitin sulfate synthesis was consistent with our previous demonstration of the two nascent proteochondroitin populations produced by microsomal preparations from the same source. The results indicated separate subcellular locations for synthesis of the two forms.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	SUGUMARAN, G (corresponding author), DEPT VET AFFAIRS, OUTPATIENT CLIN, CONNECT TISSUE RES LAB, BLDG 70, 200 SPRINGS RD, BEDFORD, MA 01730 USA.				NIAMS NIH HHS [AR-36984] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036984] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CRANE FL, 1976, FEBS LETT, V68, P153, DOI 10.1016/0014-5793(76)80425-5; DELUCA S, 1973, BIOCHEMISTRY-US, V12, P3911, DOI 10.1021/bi00744a019; DEUTSCHER SL, 1983, P NATL ACAD SCI-BIOL, V80, P3938, DOI 10.1073/pnas.80.13.3938; DORFMAN A, 1981, CELL BIOL EXTRACELLU, P115; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FALTYNEK CR, 1981, J BIOL CHEM, V256, P7202; FALTYNEK CR, 1982, J BIOL CHEM, V257, P5490; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FREILICH LS, 1975, BIOCHEM J, V146, P741, DOI 10.1042/bj1460741; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GONATAS JO, 1989, J BIOL CHEM, V264, P646; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; HORWITZ AL, 1968, J CELL BIOL, V38, P358, DOI 10.1083/jcb.38.2.358; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEWIS RG, 1973, BIOCHEM J, V134, P465, DOI 10.1042/bj1340465; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRE DJ, 1983, EUR J CELL BIOL, V31, P263; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; PERLMAN RL, 1964, J BIOL CHEM, V239, P3623; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RATCLIFFE A, 1985, J CELL BIOL, V101, P2355, DOI 10.1083/jcb.101.6.2355; RICHMOND ME, 1973, BIOCHEMISTRY-US, V12, P3904, DOI 10.1021/bi00744a018; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1986, J BIOL CHEM, V261, P14307; SILBERT JE, 1964, J BIOL CHEM, V239, P1310; SILBERT JE, 1980, BIOCHEM J, V190, P307, DOI 10.1042/bj1900307; SILBERT JE, 1969, J BIOL CHEM, V244, P876; SUGUMARAN G, 1986, CARBOHYD RES, V151, P185, DOI 10.1016/S0008-6215(00)90339-2; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; SUGUMARAN G, 1991, IN PRESS BIOCH J; SUGUMARAN G, 1989, METHOD ENZYMOL, V179, P422; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	41	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9565	9569						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851750				2022-12-25	WOS:A1991FM45900037
J	KRUEGER, KM; MENDEMUELLER, LM; BARBIERI, JT				KRUEGER, KM; MENDEMUELLER, LM; BARBIERI, JT			PROTEASE TREATMENT OF PERTUSSIS TOXIN IDENTIFIES THE PREFERENTIAL CLEAVAGE OF THE S1-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; ADENINE-NUCLEOTIDES; ADP-RIBOSYLTRANSFERASE; S-1 SUBUNIT; GENE	Trypsin digestion of pertussis toxin (PT) preferentially cleaved the S1 subunit at Arg-218 without detectable degradation of the B oligomer. The fragment produced, termed the tryptic S1 fragment, appears to remain associated with the B oligomer. Chymotrypsin digestion of PT also preferentially cleaved the S1 subunit without detectable degradation of the B oligomer. The chymotryptic S1 fragment possessed a slightly lower apparent molecular weight than the tryptic S1 fragment and was more accessible to the respective protease. Trypsin- and chymotrypsin-treated PT and PT required the presence of dithiothreitol and ATP for optimal enzymatic activity. Trypsin-treated PT showed approximately a 2-4-fold higher level of expression of ADP-ribosyltransferase and NAD-glycohydrolase activities than PT. Chymotrypsin-treated PT also exhibited approximately a 2-fold greater level of ADP-ribosyltransferase activity than PT. The observed increase in activity of protease-treated PT was due primarily to a shorter time for activation in PT mediated ADP-ribosylation of transducin. In addition, trypsin-digested PT possessed the same cytotoxic potential for Chinese hamster ovary cell clustering as PT. One possible role for the generation of a proteolytic fragment of the S1 subunit of PT would be to produce a catalytic fragment with increased efficiency for ADP-ribosylation of G proteins in vivo.	MED COLL WISCONSIN,DEPT MICROBIOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226; MED COLL WISCONSIN,SHARED RES FACIL,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162, R29AI025079] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30162, AI25079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBIERI JT, 1990, INFECT IMMUN, V58, P999, DOI 10.1128/IAI.58.4.999-1003.1990; BARBIERI JT, 1988, INFECT IMMUN, V56, P1934, DOI 10.1128/IAI.56.8.1934-1941.1988; BARBIERI JT, 1989, J BACTERIOL, V171, P4362, DOI 10.1128/JB.171.8.4362-4369.1989; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS DL, 1987, J BIOL CHEM, V262, P17677; BURNS DL, 1986, J BIOL CHEM, V261, P4324; CORTINA G, 1991, J BIOL CHEM, V266, P3022; Decker L.A., 1977, WORTHINGTON ENZYME M, P215; HEWLETT EL, 1983, INFECT IMMUN, V40, P198; KATADA T, 1982, J BIOL CHEM, V257, P3739; LIM LK, 1985, J BIOL CHEM, V260, P2585; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MOSS J, 1986, BIOCHEMISTRY-US, V25, P2720, DOI 10.1021/bi00357a066; Moss J, 1990, ADP RIBOSYLATING TOX; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021	17	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8122	8128						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850738				2022-12-25	WOS:A1991FK44100029
J	APOSTOL, BL; WESTAWAY, SK; ABELSON, J; GREER, CL				APOSTOL, BL; WESTAWAY, SK; ABELSON, J; GREER, CL			DELETION ANALYSIS OF A MULTIFUNCTIONAL YEAST TRANSFER-RNA LIGASE POLYPEPTIDE - IDENTIFICATION OF ESSENTIAL AND DISPENSABLE FUNCTIONAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; COLI DIHYDROFOLATE-REDUCTASE; T4 POLYNUCLEOTIDE KINASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; ADENYLYLATION SITE; GENE; PROTEIN; BINDING	Splicing of tRNA precursors in extracts of Saccharomyces cerevisiae requires the action of two enzymes: a site specific endonuclease and a tRNA ligase. The tRNA ligase contains three distinct enzymatic activities: a polynucleotide kinase, a cyclic phosphodiesterase, and an RNA ligase. The polypeptide also has a high affinity pre-tRNA binding site based on its ability to form stable complexes with pre-tRNA substrates. To investigate the organization of functional enzymatic and binding elements within the polypeptide a series of defined tRNA ligase gene deletions were constructed and corresponding proteins were expressed in Escherichia coli as fusions with bacterial dihydrofolate reductase (DHFR). The DHFR/ligase derivative proteins were then efficiently purified by affinity chromatography. The complete ligase fusion protein retained enzymatic and binding activities which were unaffected by the presence of the DHFR segment. Examination of tRNA ligase deletion derivatives revealed that the amino-terminal region was required for adenylylation, while the carboxyl-terminal region was sufficient for cyclic phosphodiesterase activity. Deletions within the central region affected kinase activity. Pre-tRNA binding activity was not strictly correlated with a distinct enzymatic domain. A DHFR/ligase-derived protein lacking kinase activity efficiently joined tRNA halves. We postulate that this variant utilizes a novel RNA ligation mechanism.	UNIV CALIF IRVINE, CALIF COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of California System; University of California Irvine; California Institute of Technology					NIGMS NIH HHS [GM-32637] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032637, R01GM032637] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; BACCANARI DP, 1981, J BIOL CHEM, V256, P1738; BACCANARI DP, 1977, BIOCHEMISTRY-US, V16, P3566, DOI 10.1021/bi00635a010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHALL JJ, 1965, MOL PHARMACOL, V1, P126; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CHIN DT, 1988, J BIOL CHEM, V263, P11718; DAYHOFF MO, 1988, ATLAS PROTEIN SEQ S3, V5; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGELKE DR, 1985, J BIOL CHEM, V260, P1271; FILIPOWICZ W, 1984, TRENDS BIOCHEM SCI, V9, P68, DOI 10.1016/0968-0004(84)90186-5; FISCHHOFF DA, 1984, GENE, V27, P239, DOI 10.1016/0378-1119(84)90069-6; GREER CL, 1986, MOL CELL BIOL, V6, P635, DOI 10.1128/MCB.6.2.635; GREER CL, 1987, MOL CELL BIOL, V7, P76, DOI 10.1128/MCB.7.1.76; GREER CL, 1983, CELL, V33, P899, DOI 10.1016/0092-8674(83)90032-6; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; HOSTOMSKY Z, 1989, BIOCHEM BIOPH RES CO, V161, P1056, DOI 10.1016/0006-291X(89)91350-8; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; KOONIN EV, 1990, FEBS LETT, V268, P231, DOI 10.1016/0014-5793(90)81015-G; KUBY SA, 1984, BIOCHEMISTRY-US, V23, P2393, DOI 10.1021/bi00306a012; KURIHARA T, 1987, J BIOL CHEM, V262, P3256; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MIDGLEY CA, 1985, EMBO J, V4, P2695, DOI 10.1002/j.1460-2075.1985.tb03989.x; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6694; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; UHLENBECK OC, 1983, TRENDS BIOCHEM SCI, V8, P94, DOI 10.1016/0968-0004(83)90258-X; UHLENBECK OC, 1981, ENZYMES, V15; VOLCKAERT G, 1976, ANAL BIOCHEM, V72, P433, DOI 10.1016/0003-2697(76)90551-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALLACE RB, 1980, SCIENCE, V209, P1396, DOI 10.1126/science.6997991; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XU Q, 1990, METHOD ENZYMOL, V181, P463; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	52	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7445	7455						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850408				2022-12-25	WOS:A1991FJ34200023
J	RAMPERSAUD, A; UTSUMI, R; DELGADO, J; FORST, SA; INOUYE, M				RAMPERSAUD, A; UTSUMI, R; DELGADO, J; FORST, SA; INOUYE, M			CA2+-ENHANCED PHOSPHORYLATION OF A CHIMERIC PROTEIN-KINASE INVOLVED WITH BACTERIAL SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PORIN GENE-EXPRESSION; OUTER-MEMBRANE; OMPC GENES; ENVZ; OSMOLARITY; OSMOREGULATION; ACTIVATION	The Tar-EnvZ hybrid molecule (Taz1) is an inner membrane transducer that activates OmpR, a transcriptional activator for porin gene expression (ompC), in response to an aspartic acid signal. Signal transduction by Taz1 most likely involves a phosphorylated Taz1 intermediate that donates its phosphate to OmpR. Phosphorylated OmpR has already been implicated in transcriptional activation of porin genes. Using a cell-free system containing Taz1-enriched membrane fractions,we have examined the phosphorylation properties of Taz1 and the stimulatory effects of divalent and monovalent ions. Highest activation of Taz1 phosphorylation was observed with CaCl2, and its stimulation could be observed with as low as 60-mu-M of CaCl2. Phosphorylated Taz1 could readily donate its phosphate group to OmpR in the presence of calcium. CaCl2 was also able to enhance phosphorylation of intact membrane-bound EnvZ and a cytoplasmic fragment of EnvZ lacking the receptor and transmembrane domains. These results indicate that the site for CaCl2 stimulation is within the cytoplasmic region of EnvZ and probably involves an enhanced rate of EnvZ phosphorylation.			RAMPERSAUD, A (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.				NIGMS NIH HHS [GM19043, GM12350] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, F32GM012350, R01GM019043] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BUKAU B, 1985, J BACTERIOL, V163, P61, DOI 10.1128/JB.163.1.61-68.1985; COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; FORST S, 1987, J BIOL CHEM, V262, P16433; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST S, 1988, ANNU REV CELL BIOL, V4, P21, DOI 10.1146/annurev.cb.04.110188.000321; FORST SA, 1989, J BACTERIOL, V171, P2949, DOI 10.1128/jb.171.6.2949-2955.1989; GANGOLA P, 1988, CELLULAR CALCIUM PHO, P215; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; IGO M M, 1990, New Biologist, V2, P5; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; KAWAJI H, 1979, J BACTERIOL, V140, P843, DOI 10.1128/JB.140.3.843-847.1979; LOEB JA, 1988, J BIOL CHEM, V263, P9752; Lynn A.R., 1987, ION TRANSPORT PROKAR, P181; MAEDA S, 1990, J BACTERIOL, V172, P501, DOI 10.1128/JB.172.1.501-503.1990; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NORIOKA S, 1986, J BIOL CHEM, V261, P7113; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TSUNG K, 1990, P NATL ACAD SCI USA, V87, P5940, DOI 10.1073/pnas.87.15.5940; TSUNG K, 1989, J BIOL CHEM, V264, P10104; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; VANALPHEN W, 1977, J BACTERIOL, V131, P623	29	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7633	7637						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850414				2022-12-25	WOS:A1991FJ34200050
J	PAPADOPOULOS, V; NOWZARI, FB; KRUEGER, KE				PAPADOPOULOS, V; NOWZARI, FB; KRUEGER, KE			HORMONE-STIMULATED STEROIDOGENESIS IS COUPLED TO MITOCHONDRIAL BENZODIAZEPINE RECEPTORS - TROPIC HORMONE ACTION ON STEROID-BIOSYNTHESIS IS INHIBITED BY FLUNITRAZEPAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; DIAZEPAM BINDING INHIBITOR; RAT ADRENAL MITOCHONDRIA; ADRENOCORTICOTROPIC HORMONE; CHOLESTEROL SULFATE; RECOGNITION SITE; SPIN STATES; CELLS; CYTOCHROME-P-450; EXPRESSION	The mitochondrial (peripheral-type) benzodiazepine receptor (MBR) is a drug binding site associated with outer mitochondrial membranes which is coupled to intramitochondrial cholesterol transport, the rate-determining step of steroid biosynthesis. To examine the relationship between MBR function and steroid synthesis regulated by polypeptide hormones, the Y-1 adrenocortical and MA-10 Leydig cell lines were used as model systems responsive to adrenocorticotropin and human choriogonadotropin, respectively. Flunitrazepam, a benzodiazepine which binds to MBR with high nanomolar affinity, inhibited the steroidogenic activity of these hormones, or the activation by 1 mM dibutyryl cAMP, in both cell lines by 30-60% with an IC50 of 500-1000 nM. Scatchard analysis in both cell lines revealed one class of specific binding sites for [H-3] flunitrazepam verified as being MBR by displacement studies with a series of MBR ligands. The potencies of these ligands to compete against the antagonism of hormone-stimulated steroidogenesis by flunitrazepam correlated significantly with their abilities to compete against [H-3]flunitrazepam binding to MBR (r = 0.99). An inhibition in pregnenolone formation was also observed in isolated mitochondrial preparations characterized as a reduction of cholesterol transport to inner mitochondrial membranes. These observations provide unequivocal evidence that the antagonistic action of flunitrazepam is mediated through its interaction with MBR demonstrating that these drug recognition sites are coupled to steroid biosynthesis activated by tropic hormones.	GEORGETOWN UNIV,FIDIA GEORGETOWN INST NEUROSCI,WASHINGTON,DC 20007	Georgetown University	PAPADOPOULOS, V (corresponding author), GEORGETOWN UNIV,SCH MED,DEPT ANAT & CELL BIOL,3900 RESERVOIR RD,WASHINGTON,DC 20007, USA.		Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH044284] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-05360] Funding Source: Medline; NIMH NIH HHS [MH44284] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALHO H, 1988, P NATL ACAD SCI USA, V85, P7018, DOI 10.1073/pnas.85.18.7018; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ANTKIEWICZMICHALUK L, 1988, MOL PHARMACOL, V34, P272; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BOVOLIN P, 1990, REGUL PEPTIDES, V29, P267, DOI 10.1016/0167-0115(90)90089-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; DUBROEUCQ MC, 1986, EUR J PHARMACOL, V128, P269, DOI 10.1016/0014-2999(86)90776-4; GAMBLE W, 1978, J LIPID RES, V19, P1068; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; GRAY PW, 1986, P NATL ACAD SCI USA, V83, P7547, DOI 10.1073/pnas.83.19.7547; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; GUIDOTTI A, 1988, IMIDAZOPYRIDINES SLE, P25; Hall P F, 1985, Recent Prog Horm Res, V41, P1; HALL PF, 1984, INT REV CYTOL, V86, P53, DOI 10.1016/S0074-7696(08)60177-1; HALL PF, 1979, J BIOL CHEM, V254, P9080; HIRSCH JD, 1989, MOL PHARMACOL, V35, P164; IIDA S, 1989, ENDOCRINOLOGY, V124, P2619, DOI 10.1210/endo-124-5-2619; JEFCOATE CR, 1974, EUR J BIOCHEM, V42, P539, DOI 10.1111/j.1432-1033.1974.tb03369.x; JEFCOATE CR, 1975, J BIOL CHEM, V250, P4671; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; JEFCOATE CR, 1975, J BIOL CHEM, V250, P4663; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; LAMBETH JD, 1987, J BIOL CHEM, V262, P9181; Langer SZ, 1988, IMIDAZOPYRIDINES SLE, P55; LEFUR G, 1983, LIFE SCI, V32, P1839, DOI 10.1016/0024-3205(83)90062-0; MCNAMARA BC, 1989, ARCH BIOCHEM BIOPHYS, V275, P53, DOI 10.1016/0003-9861(89)90349-4; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; NAKAMURA M, 1980, J ENDOCRINOL, V84, P179, DOI 10.1677/joe.0.0840179; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; SALA GB, 1979, J BIOL CHEM, V254, P3861; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1978, J BIOL CHEM, V253, P3135; SLOBODYANSKY E, 1989, J NEUROCHEM, V53, P1276, DOI 10.1111/j.1471-4159.1989.tb07425.x; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; SOLVEYRA CG, 1988, LIFE SCI, V42, P393, DOI 10.1016/0024-3205(88)90077-X; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; STEVENS VL, 1985, ARCH BIOCHEM BIOPHYS, V242, P324, DOI 10.1016/0003-9861(85)90508-9; STEVENS VL, 1984, J BIOL CHEM, V259, P1174; THOMAS JW, 1981, J BIOL CHEM, V256, P9838; TRZECIAK WH, 1973, EUR J BIOCHEM, V37, P327, DOI 10.1111/j.1432-1033.1973.tb02991.x; XU XX, 1989, J BIOL CHEM, V264, P7222; XU XX, 1989, J BIOL CHEM, V264, P17674; YANAGIBASHI K, 1989, J BIOCHEM, V106, P1026, DOI 10.1093/oxfordjournals.jbchem.a122958; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075	46	106	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3682	3687						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847384				2022-12-25	WOS:A1991EY68200052
J	ELWOOD, PC; DEUTSCH, JC; KOLHOUSE, JF				ELWOOD, PC; DEUTSCH, JC; KOLHOUSE, JF			THE CONVERSION OF THE HUMAN MEMBRANE-ASSOCIATED FOLATE BINDING-PROTEIN (FOLATE RECEPTOR) TO THE SOLUBLE FOLATE BINDING-PROTEIN BY A MEMBRANE-ASSOCIATED METALLOPROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KB-CELLS; AMINO-ACID-SEQUENCE; MYELOGENOUS LEUKEMIA-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; HUMAN-PLACENTA; FOLIC-ACID; COWS MILK; PURIFICATION; TRANSPORT; IDENTIFICATION	The membrane-associated (M-FBP) and soluble (S-FBP) forms of human folate binding proteins (FBP) have been well characterized. Although related in a precursor-product manner, the mechanism of conversion and the basis for differences between M-FBP and S-FBP are not known. The conversion of M-FBP to S-FBP in crude human nasopharyngeal carcinoma (KB) cell preparations is demonstrated based on characteristic gel filtration elution profiles of M-FBP and S-FBP (V(e)/V(o) = 1.3 and 1.7, respectively) in Triton X-100. M-FBP is stoichiometrically converted to S-FBP in a time- and temperature-dependent reaction by a metalloprotease which is: heat-labile; particulate; contained in human KB cell and placental membranes, and rat kidney homogenates; inhibited by EDTA, 1,10-phenanthroline, and parahydroxymercuribenzoate; requires divalent cations; is maximally active at neutral pH; and is active in the presence or absence of detergent. The purified soluble FBP product appears to be identical to S-FBP. Conversion of purified endogenously [H-3]leucine-labeled M-FBP yields a soluble FBP characterized by a 45% decrease in specific activity (moles of H-3/mol folate bound) relative to M-FBP and a non-folate binding fragment which contains 45% of the [H-3]eucine from M-FBP, requires detergent and/or urea to remain soluble, and migrates aberrantly on gel filtration in 1% (v/v) Triton X-100 and 8 M urea. Based on changes in the specific activity and the gel filtration elution profiles of purified labeled M-FBP associated with conversion to S-FBP, the endoproteolytic cleavage site is predicted between residues 226 and 229 of the cDNA predicted human FBP amino acid sequence. These results suggest that the cDNA predicted hydrophobic carboxyl terminus (residues 227-257) remains intact on the fully processed, membrane-anchored M-FBP, contains the Triton binding domain, and is involved in the formation of the membrane anchor of M-FBP.	UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV HEMATOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ELWOOD, PC (corresponding author), NCI, DIV CANC TREATMENT,MED BRANCH,BLDG 10,RM 12N226, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM122610] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM07709-01] Funding Source: Medline; NIGMS NIH HHS [GM122610-01] Funding Source: Medline; PHS HHS [26486] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANTONY AC, 1987, J CLIN INVEST, V80, P711, DOI 10.1172/JCI113126; ANTONY AC, 1985, J BIOL CHEM, V260, P4911; ANTONY AC, 1982, J BIOL CHEM, V257, P81; ANTONY AC, 1987, J CLIN INVEST, V80, P1618, DOI 10.1172/JCI113249; ANTONY AC, 1989, J BIOL CHEM, V264, P1911; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; ASHMUN RA, 1990, BLOOD, V75, P462; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; CHITAMBAR CR, 1989, BLOOD, V74, P602; DACOSTA M, 1988, BIOCHIM BIOPHYS ACTA, V939, P533, DOI 10.1016/0005-2736(88)90100-9; DACOSTA M, 1981, J LAB CLIN MED, V98, P956; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DEUTSCH JC, 1989, BLOOD, V74, P675; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FISCHER CD, 1975, BLOOD, V46, P855; FREISHEIM JH, 1989, ADV ENZYME REGUL, V29, P13, DOI 10.1016/0065-2571(89)90091-5; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1986, J BIOL CHEM, V261, P44; KANE MA, 1986, J BIOL CHEM, V261, P5625; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; KNIGHT CB, 1988, BLOOD, V72, P274; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LESLIE GI, 1972, BIOCHEMISTRY-US, V11, P1696, DOI 10.1021/bi00759a026; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; LUHRS CA, 1987, P NATL ACAD SCI USA, V84, P6546, DOI 10.1073/pnas.84.18.6546; MASON JB, 1988, AM J CLIN NUTR, V48, P620, DOI 10.1093/ajcn/48.3.620; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; MOSTOV KE, 1980, P NATL ACAD SCI-BIOL, V77, P7257, DOI 10.1073/pnas.77.12.7257; PETERS DG, 1974, CHEM SEPARATIONS MEA, P172; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1987, BIOCHIM BIOPHYS ACTA, V925, P36, DOI 10.1016/0304-4165(87)90145-0; SALTER DN, 1988, BRIT J NUTR, V59, P497, DOI 10.1079/BJN19880059; SELHUB J, 1984, J BIOL CHEM, V259, P6601; SULEIMAN SA, 1981, ARCH BIOCHEM BIOPHYS, V208, P87, DOI 10.1016/0003-9861(81)90126-0; SVENDSEN IB, 1984, CARLSBERG RES COMMUN, V49, P123, DOI 10.1007/BF02913971; VISWANADHAN VN, 1990, J BIOMOL STRUCT DYN, V7, P985, DOI 10.1080/07391102.1990.10508537; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WAXMAN S, 1975, BIOCHEMISTRY-US, V14, P5422, DOI 10.1021/bi00696a007; WAXMAN S, 1975, BRIT J HAEMATOL, V29, P23, DOI 10.1111/j.1365-2141.1975.tb01796.x; WAXMAN S, 1973, BLOOD, V42, P291, DOI 10.1182/blood.V42.2.291.291	49	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2346	2353						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846624				2022-12-25	WOS:A1991EV51500052
J	ZHANG, CS; HOLLOCHER, TC; KOLODZIEJ, AF; ORMEJOHNSON, WH				ZHANG, CS; HOLLOCHER, TC; KOLODZIEJ, AF; ORMEJOHNSON, WH			ELECTRON-PARAMAGNETIC RESONANCE OBSERVATIONS ON THE CYTOCHROME-C-CONTAINING NITROUS-OXIDE REDUCTASE FROM WOLINELLA-SUCCINOGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-STUTZERI; DENITRIFYING BACTERIA; MULTICOPPER ENZYME; PURIFICATION; PERFECTOMARINA; DENITRIFICANS; PROTEIN; SITES	Nitrous oxide reductase from Wolinella succinogenes, an enzyme containing one heme c and four Cu atoms/subunit of M(r) = 88,000, was studied by electron paramagnetic resonance (EPR) at 9.2 GHz from 6 to 80 K. In the oxidized state, low spin ferric cytochrome c was observed with g(z) = 3.10 and an axial Cu resonance was observed with g parallel-to = 2.17 and g perpendicular-to = 2.035. No signals were detected at g values greater than 3.10. For the Cu resonance, six hyperfine lines each were observed in the g parallel-to and g perpendicular-to regions with average separations of 45.2 and 26.2 gauss, respectively. The hyperfine components are attributed to Cu(I)-Cu(II) S = 1/2 (half-met) centers. Reduction of the enzyme with dithionite caused signals attributable to heme c and Cu to disappear; exposure of that sample of N2O for a few min caused the reappearance of the g = 3.10 component and a new Cu signal with g parallel-to 2.17 and g perpendicular-to = 2.055 that lacked the simple hyperfine components attributed to a single species of half-met center. The enzyme lost no activity as the result of this cycle of reduction and reoxidation. EPR provided no evidence for a Cu-heme interaction. The EPR detectable Cu in the oxidized and reoxidized forms of the enzyme comprised about 23 and 20% of the total Cu, respectively, or about one spin/subunit. The enzyme offers the first example of a nitrous oxide reductase which can have two states of high activity that present very different EPR spectra of Cu. These two states may represent enzyme in two different stages of the catalytic cycle.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Brandeis University; Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM31574-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031574] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beinert H, 1978, Methods Enzymol, V54, P111; COYLE CL, 1985, EUR J BIOCHEM, V153, P459, DOI 10.1111/j.1432-1033.1985.tb09324.x; DOOLEY DM, 1987, J AM CHEM SOC, V109, P6730, DOI 10.1021/ja00256a029; HORI H, 1970, BIOCHIM BIOPHYS ACTA, V200, P581, DOI 10.1016/0005-2795(70)90118-2; HULSE CL, 1990, BIOCHEM BIOPH RES CO, V166, P729, DOI 10.1016/0006-291X(90)90870-S; INGRAM DJE, 1949, P PHYS SOC LOND A, V62, P664, DOI 10.1088/0370-1298/62/10/110; JIN HY, 1989, J AM CHEM SOC, V111, P4262, DOI 10.1021/ja00194a017; KORNECK PMH, 1988, FEBS LETT, V242, P70; KRISTJANSSON JK, 1980, J BIOL CHEM, V255, P704; MCEWAN AG, 1985, J BACTERIOL, V164, P823, DOI 10.1128/JB.164.2.823-830.1985; MICHALSKI WP, 1986, BIOCHIM BIOPHYS ACTA, V872, P50, DOI 10.1016/0167-4838(86)90146-9; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; SCOTT RA, 1989, P NATL ACAD SCI USA, V86, P4082, DOI 10.1073/pnas.86.11.4082; SIGWART C, 1968, INORG CHEM, V7, P2545, DOI 10.1021/ic50070a015; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER SW, 1984, BIOCHEM BIOPH RES CO, V119, P588, DOI 10.1016/S0006-291X(84)80289-2; SNYDER SW, 1987, J BIOL CHEM, V262, P6515; Solomon E.I., 1983, STRUCT BONDING BERLI, V53, P1; SOLOMON EI, 1981, COPPER PROTEINS, P41; SOOHOO CK, 1991, J BIOL CHEM, V266, P2203; SOOHOO CK, 1991, J BIOL CHEM, V266, P2210; TANNER ACR, 1984, BERGEYS MANUAL SYSTE, P646; TERAGUCHI S, 1989, J BIOL CHEM, V264, P1972; WOLIN MJ, 1961, J BACTERIOL, V81, P911, DOI 10.1128/JB.81.6.911-917.1961; YOSHINARI T, 1980, APPL ENVIRON MICROB, V39, P81, DOI 10.1128/AEM.39.1.81-84.1980	25	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2199	2202						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846617				2022-12-25	WOS:A1991EV51500030
J	GARDNER, PR; FRIDOVICH, I				GARDNER, PR; FRIDOVICH, I			SUPEROXIDE SENSITIVITY OF THE ESCHERICHIA-COLI 6-PHOSPHOGLUCONATE DEHYDRATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; PULSE RADIOLYSIS; DISMUTASE; BINDING; CLUSTER; ENZYME; ACONITASE; MUTANTS	The activity of 6-phosphogluconate dehydratase was significantly lower in extracts of aerobically grown Escherichia coli deficient in superoxide dismutase (sodAsodB) and in mutants lacking the inducible manganese-containing superoxide dismutase (sodA), exposed to the redox-cycling agent paraquat, than in the parental strain. Growth of these strains on a gluconate minimal medium was also impaired under these conditions. The enzyme was most susceptible to dioxygen in superoxide dismutase (SOD)-free extracts, and exogenous SOD afforded a concentration-dependent protection against inactivation. The amount of SOD necessary for full protection was comparable to the amount normally present in extracts of aerobic E. coli (7-36 units/mg protein), and the rate of reaction of O2- with the dehydratase was estimated to be approximately 2.0 x 10(8) M-1 S-1. The dehydratase was much less sensitive to O2 or H2O2 than to O2-. The virtual substrate, alpha-glycerophosphate, provided partial protection. Iron chelators, thiol-reactive reagents, and oxidants, including nitrite and diamide, inactivated the enzyme. Fluoride ions stabilized the dehydratase and blocked the effect of oxidants. The O2BAR-sensitive target site is proposed to be an iron-sulfur cluster which is readily destroyed by oxidation.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University				Gardner, Paul/0000-0001-8189-0903				BEERS RF, 1952, J BIOL CHEM, V195, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; DIXON M, 1979, ENZYMES, P934; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; FEE JA, 1982, TRENDS BIOCHEM SCI, V7, P84, DOI 10.1016/0968-0004(82)90151-7; FLINT D H, 1990, P285; FLINT DH, 1988, J BIOL CHEM, V263, P3558; FORMAN HJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P396, DOI 10.1016/0003-9861(73)90636-X; FRAENKEL DG, 1964, J BIOL CHEM, V239, P2765; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; FRIDOVICH I, 1985, HARVEY LECT, V79, P51; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KANAMORI M, 1963, J BIOL CHEM, V238, P998; KLUG D, 1972, J BIOL CHEM, V247, P4839; KOVACHEVICH R, 1955, J BIOL CHEM, V213, P745; KUO CF, 1987, J BIOL CHEM, V262, P4724; LOEWEN PC, 1984, J BACTERIOL, V157, P622, DOI 10.1128/JB.157.2.622-626.1984; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; MELOCHE HP, 1964, J BIOL CHEM, V239, P3505; MYERS JW, 1961, J BIOL CHEM, V236, P1414; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; OBRIEN RW, 1970, FEBS LETT, V10, P343, DOI 10.1016/0014-5793(70)80468-9; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SCOPES RK, 1984, ANAL BIOCHEM, V136, P530, DOI 10.1016/0003-2697(84)90257-4; Sevag MG, 1934, J EXP MED, V60, P95, DOI 10.1084/jem.60.1.95; TELSER J, 1986, J BIOL CHEM, V261, P4840; Wax R, 1970, J BACTERIOL, V101, P1092, DOI 10.1128/JB.101.3.1092-1093.1970; ZABLOTNY R, 1967, J BACTERIOL, V93, P1579, DOI 10.1128/JB.93.5.1579-1581.1967	34	217	221	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1478	1483						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846355				2022-12-25	WOS:A1991EU49700022
J	BRASS, LF; MANNING, DR; WILLIAMS, AG; WOOLKALIS, MJ; PONCZ, M				BRASS, LF; MANNING, DR; WILLIAMS, AG; WOOLKALIS, MJ; PONCZ, M			RECEPTOR AND G-PROTEIN-MEDIATED RESPONSES TO THROMBIN IN HEL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET ADENYLATE-CYCLASE; PERMEABILIZED HUMAN-PLATELETS; HUMAN ERYTHROLEUKEMIA-CELLS; ISLET-ACTIVATING PROTEIN; ARACHIDONIC-ACID RELEASE; HUMAN-ENDOTHELIAL CELLS; PERTUSSIS TOXIN; PHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPASE-C; PROTEOLYTIC ACTIVATION	Thrombin is believed to activate platelets via cell surface receptors coupled to G proteins. In order to better understand this process, we have examined the interaction of thrombin with HEL cells, a leukemic cell line that has served as a useful model for studies of platelet structure and function. In HEL cells, as in platelets, thrombin stimulated inositol trisphosphate (IP3) formation and suppressed cAMP synthesis. Both events were inhibited by pertussis toxin with 50% inhibition occurring at a toxin concentration that ADP-ribosylated 50% of the G(i-alpha) subunits present in HEL cells. IP3 formation was also stimulated by a second serine protease, trypsin. The trypsin response was identical to the thrombin response in time course, magnitude, and pertussis toxin sensitivity, suggesting that a similar mechanism is involved. Agonist-induced changes in the cytosolic-free Ca2+ concentration were used to test this hypothesis. Both proteases caused a transient increase in intracellular calcium [Ca2+]i that could be inhibited with D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone thrombin. Exposure to either protease desensitized HEL cells against subsequent increases in [Ca2+]i and IP3 caused by the other, although responses to other agonists were retained. This loss of responsiveness persisted despite repeated washing of the cells and the addition of hirudin. Complete recovery occurred after 20 h and could be prevented with cycloheximide. These observations suggest that 1) HEL cell thrombin receptors, like those on platelets, are coupled to phospholipase C and adenylyl-cyclase by pertussis toxin-sensitive G proteins, 2) the G proteins involved are equally accessible to pertussis toxin in situ, 3) when access is limited to the outside of the cell the response mechanisms for thrombin and trypsin are similar, if not identical, despite the broader substrate specificity of trypsin, 4) both proteases cause persistent changes that may involve proteolysis of their receptors or associated proteins, and 5) desensitization of the thrombin response occurs at a step no later than the activation of phospholipase C and requires protein synthesis for recovery.	UNIV PENN, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	BRASS, LF (corresponding author), UNIV PENN, DEPT MED, HEMATOL ONCOL SECT, SILVERSTEIN 7, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA.				NCI NIH HHS [CA39712] Funding Source: Medline; NHLBI NIH HHS [HL40387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1983, N-S ARCH PHARMACOL, V324, P196, DOI 10.1007/BF00503894; AKTORIES K, 1984, EUR J BIOCHEM, V145, P333, DOI 10.1111/j.1432-1033.1984.tb08558.x; ANDERSON WB, 1978, J BIOL CHEM, V253, P2921; BABICH M, 1990, ENDOCRINOLOGY, V126, P948, DOI 10.1210/endo-126-2-948; BAGDY O, 1976, METHOD ENZYMOL, V45, P669; BANGA HS, 1988, BIOCHEM J, V252, P297, DOI 10.1042/bj2520297; BANGA HS, 1987, J BIOL CHEM, V262, P14871; BIENZ D, 1986, BLOOD, V68, P720; BRASS LF, 1989, METHOD ENZYMOL, V169, P355; BRASS LF, 1988, J BIOL CHEM, V263, P5210; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BRASS LF, 1986, J BIOL CHEM, V261, P6838; BRASS LF, 1988, ISI ATLAS-BIOCHEM, V1, P343; BRASS LF, 1991, IN PRESS TRENDS CARD; BROCK TA, 1989, AM REV RESPIR DIS, V140, P1121, DOI 10.1164/ajrccm/140.4.1121; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHIEN WW, 1990, J CLIN INVEST, V85, P1436, DOI 10.1172/JCI114588; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HARMON JT, 1985, BIOCHEMISTRY-US, V24, P58, DOI 10.1021/bi00322a010; HUANG CL, 1989, J BIOL CHEM, V264, P4391; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; HUGHES RJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P202, DOI 10.1016/0304-4165(80)90422-5; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JAKOBS KH, 1988, BIOCHEM J, V249, P639, DOI 10.1042/bj2490639; JAKOBS KH, 1988, EUR J BIOCHEM, V172, P255, DOI 10.1111/j.1432-1033.1988.tb13881.x; JONES LG, 1989, MOL PHARMACOL, V36, P142; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1986, BIOCHIM BIOPHYS ACTA, V884, P219, DOI 10.1016/0304-4165(86)90166-2; LAZAROWSKI ER, 1990, ARCH BIOCHEM BIOPHYS, V276, P265, DOI 10.1016/0003-9861(90)90037-Y; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MOTULSKY HJ, 1988, AM J PHYSIOL, V255, pE880, DOI 10.1152/ajpendo.1988.255.6.E880; MURAYAMA T, 1985, J BIOL CHEM, V260, P7226; NAKASHIMA S, 1987, BIOCHEM BIOPH RES CO, V148, P971, DOI 10.1016/S0006-291X(87)80227-9; OROURKE F, 1987, FEBS LETT, V214, P176, DOI 10.1016/0014-5793(87)80037-6; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PARIS S, 1988, J BIOL CHEM, V263, P11250; POBINER BF, 1985, J BIOL CHEM, V260, P6200; PONCZ M, 1987, BLOOD, V69, P219; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RABEN DM, 1987, BIOCHEMISTRY-US, V26, P2759, DOI 10.1021/bi00384a016; RUGGIERO M, 1985, BIOCHEM BIOPH RES CO, V131, P1198, DOI 10.1016/0006-291X(85)90218-9; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STILES GL, 1982, J BIOL CHEM, V257, P6287; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TAM SW, 1979, J BIOL CHEM, V254, P8723; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; WILLIAMS AG, 1990, BLOOD, V76, P721; WOOLKALIS M J, 1990, Journal of Cell Biology, V111, p215A; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478	57	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					958	965						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845999				2022-12-25	WOS:A1991ET17700046
J	NAKAYAMA, H; SHIBATA, M; WOHLENBERG, C; ROONEY, JF; NOTKINS, AL				NAKAYAMA, H; SHIBATA, M; WOHLENBERG, C; ROONEY, JF; NOTKINS, AL			TRANSPLANTATION OF SYNGENEIC TRANSFECTED CELLS TO PROBE THE INVIVO IMMUNE-RESPONSE TO VIRAL-PROTEINS	FASEB JOURNAL			English	Note						CYTOTOXIC T-CELLS; INVIVO IMMUNE RESPONSE; TRANSPLANTATION; TRANSFECTED CELLS; VIRAL PROTEINS; HERPES SIMPLEX VIRUS; GLYCOPROTEIN-D	SIMPLEX VIRUS TYPE-1; GLYCOPROTEIN-D; INFECTED-CELLS; HERPES; GD; TRANSFORMATION; LINES; MICE; GENE; DNA	BALB/3T3 cells were transfected with the glycoprotein D(gD) gene of herpes simplex virus (HSV) and a cell line expressing gD on the cell surface was isolated. In vitro, Cr-51 release tests showed that the transfected cells were destroyed by anti-HSV antibody in the presence of complement. To investigate in vivo immune response, the gD-transfected cells were transplanted into the footpads of syngeneic HSV-immunized or unimmunized BALB/c mice. In unimmunized mice, transfected cells remained intact for 7 days or longer, and the site of injection showed only slight lymphocyte infiltration. In contrast, in immunized mice, transfected cells elicited massive lymphocyte infiltration and were mostly destroyed by day 4. Analysis of infiltrating cells revealed that they were mainly Thy1+ and CD8+ lymphoyctes along with small numbers of CD5+, CD4+, and B lymphocytes. These studies show that transfected murine cells expressing gD can be used to study the in vivo immune response to single viral proteins and they argue that the immune response contributes to the pathogenesis of HSV infection.	NIDR,ORAL MED LAB,BLDG 30,ROOM 121,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BARBACID M, 1981, J VIROL, V37, P518, DOI 10.1128/JVI.37.1.518-523.1981; BLACKLAWS BA, 1987, J GEN VIROL, V68, P1103, DOI 10.1099/0022-1317-68-4-1103; COHEN GH, 1980, J VIROL, V36, P429, DOI 10.1128/JVI.36.2.429-439.1980; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; CREMER KJ, 1985, SCIENCE, V228, P737, DOI 10.1126/science.2986288; FLEXNER C, 1988, NATURE, V335, P259, DOI 10.1038/335259a0; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JOHNSON DC, 1985, J VIROL, V54, P682, DOI 10.1128/JVI.54.3.682-689.1985; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN S, 1987, J VIROL, V61, P726, DOI 10.1128/JVI.61.3.726-734.1987; ROONEY JF, 1988, J VIROL, V62, P1530, DOI 10.1128/JVI.62.5.1530-1534.1988; ROSENTHAL KL, 1987, J VIROL, V61, P2438, DOI 10.1128/JVI.61.8.2438-2447.1987; SHIBATA M, 1989, DIABETOLOGIA, V32, P709, DOI 10.1007/BF00274529; SHOWALTER SD, 1981, INFECT IMMUN, V34, P684, DOI 10.1128/IAI.34.3.684-692.1981; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPEAR PG, 1976, J VIROL, V17, P991, DOI 10.1128/JVI.17.3.991-1008.1976; SPEAR PG, 1985, HERPESVIRUSES, V3, P315; UCHIGATA Y, 1987, J EXP MED, V165, P124, DOI 10.1084/jem.165.1.124; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	21	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					104	108		10.1096/fasebj.5.1.1846831	http://dx.doi.org/10.1096/fasebj.5.1.1846831			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1846831				2022-12-25	WOS:A1991ET60900022
J	VOLZ, K; MATSUMURA, P				VOLZ, K; MATSUMURA, P			CRYSTAL-STRUCTURE OF ESCHERICHIA-COLI CHEY REFINED AT 1.7-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; PROTEIN-PHOSPHORYLATION; MACROMOLECULAR STRUCTURES; FOLDED CONFORMATION; RESPONSE REGULATOR; CHAIN; PHOSPHOTRANSFER; TRANSDUCTION	The three-dimensional structure of wild-type CheY from Escherichia coli has been refined by stereochemically restrained least squares minimization to a crystallographic R-factor of 15.1% at 1.7-angstrom resolution. The structure contains 1165 atoms, including all atoms of the protein, 147 water molecules, and three sulfate ions. The final model has root mean square deviations of 0.018 and 0.049 angstrom from idealized bond lengths and angle distances, respectively. Seven amino acid side chains have been modeled in dual conformations. CheY folds as a compact (beta/alpha)5, globular protein, with the phosphorylation region contained in a cavity on one face of the molecule. This active site area is bordered by the carboxyl termini of the three central beta-strands, by alpha-1, and by the loop connecting beta-5 to alpha-5. The Lys-109 side chain of this loop extends into the active site by virtue of its cis peptide bond conformation preceding Pro-110. The epsilon-amino group of Lys-109 is in close bonding contact with the carboxyl group of Asp-57, the residue that is phosphorylated in the activation process of CheY. The details of the hydrogen bonding network in the phosphorylation region indicate that structural rearrangements must accompany the phosphorylation of Asp-57.			VOLZ, K (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL & IMMUNOL,835 S WOLCOTT AVE,CHICAGO,IL 60612, USA.				NIAID NIH HHS [AI18985] Funding Source: Medline; NIGMS NIH HHS [GM39919] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039919] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BALASUBRAMANIAN R, 1977, NATURE, V266, P856, DOI 10.1038/266856a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOURRET R, 1991, IN PRESS ANN REV BIO; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HALL SR, 1988, XTAL24 USERS MANUAL; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, COLD SPRING HARB SYM, V53, P41, DOI 10.1101/SQB.1988.053.01.008; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JAMES MNG, 1983, J MOL BIOL, V163, P299, DOI 10.1016/0022-2836(83)90008-6; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MATSUMURA P, 1990, BIOL CHEMOTACTIC RES, P135; MATTHEWS BW, 1972, MACROMOLECULES, V5, P818, DOI 10.1021/ma60030a031; MILNERWHITE EJ, 1988, J MOL BIOL, V204, P777, DOI 10.1016/0022-2836(88)90368-3; MOOTONEN JM, 1989, THESIS MIT BOSTON; NEMETHY G, 1972, MACROMOLECULES, V5, P755, DOI 10.1021/ma60030a017; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; PARKINSON JS, 1988, CELL, V53, P1, DOI 10.1016/0092-8674(88)90478-3; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REID LS, 1989, PROTEINS, V5, P170, DOI 10.1002/prot.340050212; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1976, P NATL ACAD SCI USA, V73, P2619, DOI 10.1073/pnas.73.8.2619; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1980, ACTA CRYSTALLOGR B, V36, P819, DOI 10.1107/S056774088000461X; RYDEL JJ, 1983, PURIFICATION BIOCH C; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; VOLZ K, 1986, J BIOL CHEM, V261, P4723; WATENPAUGH KD, 1979, J MOL BIOL, V131, P509, DOI 10.1016/0022-2836(79)90005-6; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	43	278	286	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15511	15519						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869568				2022-12-25	WOS:A1991GB09700102
J	ALAKOKKO, L; HYLAND, J; SMITH, C; KIVIRIKKO, KI; JIMENEZ, SA; PROCKOP, DJ				ALAKOKKO, L; HYLAND, J; SMITH, C; KIVIRIKKO, KI; JIMENEZ, SA; PROCKOP, DJ			EXPRESSION OF A HUMAN CARTILAGE PROCOLLAGEN GENE (COL2A1) IN MOUSE 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							II COLLAGEN GENE; 1ST INTRON; SPONDYLOEPIPHYSEAL DYSPLASIA; TRANSCRIPTIONAL CONTROL; MILD CHONDRODYSPLASIA; NUCLEOTIDE-SEQUENCES; REGULATORY ELEMENTS; LINKAGE; CHAIN; DNA	Expression in a recombinant system has been difficult to obtain for any of the major fibrillar collagens that require processing by eight or more post-translational enzymes. Here, two DNA constructs were designed so that the promoter region of the gene for the pro-alpha-1(I) chain of human type I procollagen drove expression of the human type II procollagen gene in mouse NIH 3T3 cells, a culture line that normally synthesizes type I procollagen but not any cartilage-specific protein such as type II procollagen. Both constructs were expressed as both mRNA and protein. In clones expressing the construct at high levels, the steady-state levels of mRNA and the production of type II procollagen were comparable to the mRNA levels and production of type I procollagen from the endogenous mouse genes. Comparison of clones containing the two constructs demonstrated that sequences extending 80 base pairs beyond the major polyadenylation signal of the gene are not in themselves sufficient for correct termination and 3' processing of RNA transcripts. The results strongly suggest that specific sequences present in a downstream 3.5-kilobase SphI/SphI fragment determine the termination of the transcription. Of special importance is that the system will make it possible to examine the consequences of mutations in the human type II procollagen gene on the processing of RNA transcripts and on the functional properties of the protein simply by using the genomic DNA from leukocytes or other non-cartilaginous sources.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT MED, PHILADELPHIA, PA 19107 USA; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND; UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND	Jefferson University; Jefferson University; University of Oulu; University of Oulu				Jimenez, Sergio/0000-0001-5213-1203	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, P01AR038188] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39740, AR38188] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHMAD NN, 1990, IN PRESS P NATL ACAD; ALAKOKKO L, 1990, MATRIX, V10, P279, DOI 10.1016/S0934-8832(11)80182-4; ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; ALAKOKKO L, 1990, GENOMICS, V8, P454, DOI 10.1016/0888-7543(90)90031-O; ANDERSON IJ, 1990, AM J HUM GENET, V46, P896; AULTHOUSE AL, 1989, IN VITRO CELL DEV B, V25, P659; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1988, MOL CELL BIOL, V8, P4851, DOI 10.1128/MCB.8.11.4851; CHEAH KSE, 1985, P NATL ACAD SCI USA, V82, P2555, DOI 10.1073/pnas.82.9.2555; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1991, IN PRESS EXTRACELLUL; DALESSIO M, 1988, GENE, V67, P105, DOI 10.1016/0378-1119(88)90013-3; ELIMA K, 1987, NUCLEIC ACIDS RES, V15, P9499, DOI 10.1093/nar/15.22.9499; ELIMA K, 1989, FEBS LETT, V258, P195, DOI 10.1016/0014-5793(89)81651-5; FRANCOMANO C A, 1987, Genomics, V1, P293, DOI 10.1016/0888-7543(87)90027-9; GREENSPAN DS, 1989, J BIOL CHEM, V264, P20683; KNOWLTON RG, 1989, AM J HUM GENET, V45, P681; KNOWLTON RG, 1990, NEW ENGL J MED, V322, P526, DOI 10.1056/NEJM199002223220807; LAW MF, 1983, MOL CELL BIOL, V3, P2110, DOI 10.1128/MCB.3.11.2110; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PALOTIE A, 1989, LANCET, V1, P924; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Sambrook J, 1989, MOL CLONING LABORATO; SANGIORGI FO, 1985, NUCLEIC ACIDS RES, V13, P2207, DOI 10.1093/nar/13.7.2207; SCHNIEKE A, 1987, P NATL ACAD SCI USA, V84, P764, DOI 10.1073/pnas.84.3.764; STROM CM, 1984, NUCLEIC ACIDS RES, V12, P1025, DOI 10.1093/nar/12.2.1025; SU MW, 1989, GENOMICS, V4, P438, DOI 10.1016/0888-7543(89)90353-4; TILLER GE, 1990, P NATL ACAD SCI USA, V87, P3889, DOI 10.1073/pnas.87.10.3889; VIKKULA M, 1989, FEBS LETT, V50, P171; VISSING H, 1989, J BIOL CHEM, V264, P18265	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14175	14178						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860834				2022-12-25	WOS:A1991FZ35100010
J	KURZBAN, GP; BAYER, EA; WILCHEK, M; HOROWITZ, PM				KURZBAN, GP; BAYER, EA; WILCHEK, M; HOROWITZ, PM			THE QUATERNARY STRUCTURE OF STREPTAVIDIN IN UREA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN RESIDUES; BIOTIN-BINDING; GUANIDINE-HYDROCHLORIDE; CORE STREPTAVIDIN; PROTEINS; AVIDIN; PURIFICATION; GENE	We report on the interactions of urea and guanidinium salts with streptavidin. Gel filtration chromatography in 0, 4, 6, and 7 m urea indicates that the streptavidin tetramer remains intact in urea. Biotin alters the electrophoretic mobility of streptavidin whether or not 6 M urea is present. The intrinsic fluorescence of streptavidin is increased and blue-shifted in 6 m urea. The fluorescence changes indicate the absence of unfolding. A conformational response to urea is possible, but much of the fluorescence change is due to urea binding as a weak biotin analog (K(a) almost-equal-to 1.3 m-1). The resistance to structural perturbation by urea reflects the structural stability of streptavidin's antiparallel beta-barrel motif. Unfolding is sluggish in 6 M guanidinium hydrochloride (half-time, almost-equal-to 50 days). After guanidinium thiocyanate unfolding, streptavidin can be refolded, but the unfolding and refolding transitions are centered at different concentrations of perturbant. Slow unfolding, with a 15th power dependence on guanidinium thiocyanate concentration, may be partially responsible for the noncoincidence of the unfolding and refolding processes. Nonequilibrium behavior is also seen in 6 M urea, as native streptavidin does not unfold and guanidinium thiocyanate unfolded streptavidin does not refold. Refolding does occur at lower concentrations of urea. Guanidinium thiocyanate only slowly unfolds the biotin-streptavidin complex. In the presence of biotin, unfolded streptavidin does not refold in 6 M guanidinium thiocyanate or in 6 M urea.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284; WEIZMANN INST SCI,DEPT BIOPHYS,IL-76100 REHOVOT,ISRAEL	University of Texas System; University of Texas Health San Antonio; Weizmann Institute of Science					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGARANA CE, 1986, NUCLEIC ACIDS RES, V14, P1871, DOI 10.1093/nar/14.4.1871; BAYER EA, 1986, J BIOCHEM BIOPH METH, V13, P103, DOI 10.1016/0165-022X(86)90022-9; BAYER EA, 1989, BIOCHEM J, V259, P369, DOI 10.1042/bj2590369; BAYER EA, 1990, METHOD ENZYMOL, V184, P80; BELEW M, 1978, J CHROMATOGR, V147, P205, DOI 10.1016/S0021-9673(00)85132-8; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; CHAIET L, 1964, 3RD P INT C ANT AG C, P28; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DITTMER J, 1989, ELECTROPHORESIS, V10, P762, DOI 10.1002/elps.1150101106; FISH WW, 1970, J BIOL CHEM, V245, P5166; GITLIN G, 1988, BIOCHEM J, V256, P279, DOI 10.1042/bj2560279; GREEN N. M., 1970, Methods in Enzymology, V18A, P418, DOI 10.1016/0076-6879(71)18342-5; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1963, BIOCHEM J, V89, P599, DOI 10.1042/bj0890599; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; GREENE RF, 1974, J BIOL CHEM, V249, P5388; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; KHYM JX, 1976, ANAL BIOCHEM, V71, P231, DOI 10.1016/0003-2697(76)90032-4; KURZBAN GP, 1989, BIOCHEMISTRY-US, V28, P8537, DOI 10.1021/bi00447a040; KURZBAN GP, 1990, J PROTEIN CHEM, V9, P673, DOI 10.1007/BF01024762; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P162; PAHLER A, 1987, J BIOL CHEM, V262, P13933; SANO T, 1990, J BIOL CHEM, V265, P3369; SANO T, 1990, P NATL ACAD SCI USA, V87, P142, DOI 10.1073/pnas.87.1.142; SIMPSON RB, 1953, J AM CHEM SOC, V75, P5139, DOI 10.1021/ja01117a001; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; SUTER M, 1988, J IMMUNOL METHODS, V113, P83, DOI 10.1016/0022-1759(88)90384-5; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; VONHIPPEL PH, 1964, SCIENCE, V145, P577, DOI 10.1126/science.145.3632.577; WASHABAUGH MW, 1986, J BIOL CHEM, V261, P2477; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WILCHEK M, 1989, TRENDS BIOCHEM SCI, V14, P408, DOI 10.1016/0968-0004(89)90289-2; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; 1982, GEL FILTRATION THEOR	39	64	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14470	14477						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860855				2022-12-25	WOS:A1991FZ35100058
J	AMEGADZIE, BY; AHN, BY; MOSS, B				AMEGADZIE, BY; AHN, BY; MOSS, B			IDENTIFICATION, SEQUENCE, AND EXPRESSION OF THE GENE ENCODING A MR 35,000 SUBUNIT OF THE VACCINIA VIRUS DNA-DEPENDENT RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE MESSENGER-RNAS; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION; GENOME; INITIATION; PROMOTERS; LEADER; ENDS	The gene rpo35, encoding a subunit of the vaccinia virus DNA-dependent RNA polymerase, was identified, and its RNA and protein products were characterized. An M(r) 35,000 polypeptide, which bound antibody to the purified RNA polymerase, was synthesized in reticulocyte lysates programmed with viral mRNA that hybridized to a 2,300-base pair segment of the viral genome. Determination of the sequence of the DNA segment revealed four potential protein coding regions, none of which had evident similarity to any described RNA polymerase subunit of prokaryotes or eukaryotes. One open reading frame that could encode a 35,400-Da protein was identified as rpo35 on the basis of mRNA hybridization, cell-free translation, and immunoprecipitation. The identification was confirmed by sequencing tryptic peptides of the authentic M(r) 35,000 RNA polymerase subunit. Antiserum to the purified recombinant protein, expressed in bacteria, reacted specifically with a M(r) 35,000 polypeptide that was detected starting 2 h after virus infection and that co-sedimented with RNA polymerase purified from virions. RNA analyses indicated that the 5'-end of an early transcript started 25 nucleotides upstream of rpo35, which is consistent with the location of an early promoter consensus sequence.			AMEGADZIE, BY (corresponding author), NIAID,VIRAL DIS LAB,BETHESDA,MD 20892, USA.			Moss, Bernard/0000-0002-2154-8564				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AHN BY, 1989, J VIROL, V63, P226, DOI 10.1128/JVI.63.1.226-232.1989; AHN BY, 1990, J VIROL, V64, P3019, DOI 10.1128/JVI.64.6.3019-3024.1990; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AMEGADZIE BY, 1991, VIROLOGY, V180, P88, DOI 10.1016/0042-6822(91)90012-Z; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BERTHOLET C, 1987, CELL, V50, P153, DOI 10.1016/0092-8674(87)90211-X; BOONE RF, 1979, J VIROL, V30, P365, DOI 10.1128/JVI.30.1.365-374.1979; BROYLES SS, 1990, J VIROL, V64, P5376, DOI 10.1128/JVI.64.11.5376-5382.1990; BROYLES SS, 1986, P NATL ACAD SCI USA, V83, P3141, DOI 10.1073/pnas.83.10.3141; COLBY C, 1971, J VIROL, V7, P71, DOI 10.1128/JVI.7.1.71-76.1971; COOPER JA, 1979, VIROLOGY, V96, P368, DOI 10.1016/0042-6822(79)90095-3; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; GERSHON PD, 1989, J VIROL, V63, P4703, DOI 10.1128/JVI.63.11.4703-4708.1989; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HANGGI M, 1986, EMBO J, V5, P1071, DOI 10.1002/j.1460-2075.1986.tb04324.x; JONES EV, 1987, J VIROL, V61, P1765, DOI 10.1128/JVI.61.6.1765-1771.1987; Maniatis T., 1982, MOL CLONING LABORATO, P86; MOSS B, 1991, J BIOL CHEM, V266, P1355; NEVINS JR, 1977, J BIOL CHEM, V252, P6930; PATEL DD, 1989, J VIROL, V63, P1076, DOI 10.1128/JVI.63.3.1076-1086.1989; PATEL DD, 1987, EMBO J, V6, P3787, DOI 10.1002/j.1460-2075.1987.tb02714.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUICK SD, 1990, VIROLOGY, V178, P603, DOI 10.1016/0042-6822(90)90362-U; RODRIGUEZ JF, 1987, J VIROL, V61, P3550, DOI 10.1128/JVI.61.11.3550-3554.1987; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWER B, 1987, CELL, V50, P163, DOI 10.1016/0092-8674(87)90212-1; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; 1987, TECHNICAL B, V8, P1	34	41	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13712	13718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856205				2022-12-25	WOS:A1991FY02700041
J	ERLANDSSON, R; BOLDOG, F; PERSSON, B; ZABAROVSKY, ER; ALLIKMETS, RL; SUMEGI, J; KLEIN, G; JORNVALL, H				ERLANDSSON, R; BOLDOG, F; PERSSON, B; ZABAROVSKY, ER; ALLIKMETS, RL; SUMEGI, J; KLEIN, G; JORNVALL, H			THE GENE FROM THE SHORT ARM OF CHROMOSOME-3, AT D3F15S2, FREQUENTLY DELETED IN RENAL-CELL CARCINOMA, ENCODES ACYLPEPTIDE HYDROLASE	ONCOGENE			English	Note							ACYL-PEPTIDE HYDROLASE; ACID-RELEASING ENZYME; RAT-LIVER; SEQUENCE-ANALYSIS; LUNG-CANCER; PURIFICATION; ALPHA; DNF15S2; CLONING; LOCI	Loss or inactivation of a gene on the short arm of chromosome 3 may contribute to the genesis of renal cell carcinoma. A gene that corresponds to the most frequently lost RFLP site (D3F15S2) is expressed in a variety of human tissues, and at a particularly high level in the kidney. Its expression is markedly reduced in renal cell carcinoma. A database search showed that the gene product is closely related to or identical with acylpeptide hydrolase. The nucleotide identity between the rat acylpeptide hydrolase and the human gene at D3F15S2 is 88%, compatible with normal species differences. It is therefore likely that the human gene product is acylpeptide hydrolase. The renal cell carcinoma is then associated with a decrease of acylpeptide hydrolase activity. The gene may represent a tumor suppressor gene, whose loss contributes to the development of renal cell carcinoma. It might be speculated that it could act e.g. by affecting the activity of a small acetylated growth factor. Alternatively, its decreased expression may merely reflect the impairment of differentiation in RCC, compared to normal kidney. Loss of a linked but irrelevant gene by the 3p deletion is another possibility.	KAROLINSKA INST,DEPT CHEM 1,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet	ERLANDSSON, R (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Zabarovsky, Eugene R/A-6645-2010; Allikmets, Rando/ABD-4533-2021		NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA14054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BODENMULLER H, 1981, NATURE, V293, P579, DOI 10.1038/293579a0; BOLDOG F, 1989, CANCER GENET CYTOGEN, V42, P295, DOI 10.1016/0165-4608(89)90098-8; BOLDOG F, IN PRESS GENES CHROM; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; GADE W, 1978, J BIOL CHEM, V253, P5012; HARRIS JI, 1959, BIOCHEM J, V71, P451, DOI 10.1042/bj0710451; JONES WM, 1985, BIOCHEM BIOPH RES CO, V126, P933, DOI 10.1016/0006-291X(85)90275-X; JONES WM, 1986, BIOCHEM BIOPH RES CO, V139, P244, DOI 10.1016/S0006-291X(86)80105-X; KAISER R, 1989, BIOCHEMISTRY-US, V28, P8432, DOI 10.1021/bi00447a024; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MARKS N, 1983, J NEUROCHEM, V41, P201, DOI 10.1111/j.1471-4159.1983.tb13670.x; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; VANDERHOUT AH, 1988, CANCER GENET CYTOGEN, V32, P281, DOI 10.1016/0165-4608(88)90292-0; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; YOUNG LJS, 1988, HUM GENET, V79, P137, DOI 10.1007/BF00280552; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	50	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1293	1295						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861871				2022-12-25	WOS:A1991GV26000028
J	FISHER, RP; LISOWSKY, T; BREEN, GAM; CLAYTON, DA				FISHER, RP; LISOWSKY, T; BREEN, GAM; CLAYTON, DA			A RAPID, EFFICIENT METHOD FOR PURIFYING DNA-BINDING PROTEINS - DENATURATION-RENATURATION CHROMATOGRAPHY OF HUMAN AND YEAST MITOCHONDRIAL EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; TRANSCRIPTION FACTOR-I; RNA-POLYMERASE; PROMOTER RECOGNITION; ORIENTATION; SEQUENCES; STRAND; NUMBER	We describe a novel method for the purification of DNA-binding proteins. Isolated mitochondria were lysed in boiling sodium dodecyl sulfate-containing buffer, the extracts were chromatographed on hydroxylapatite in the presence of sodium dodecyl sulfate, and DNA-binding activities were identified after adding a large excess of nonionic detergent (Triton X-100) and assaying fractions by a gel retardation procedure. Fractions containing DNA-binding activity were bulk renatured and chromatographed on phosphocellulose in the presence of Triton X-100. When applied to human mitochondria, the technique resulted in the purification to homogeneity of fully functional mitochondrial transcription factor 1 (mtTF1), the major activator of mammalian mitochondrial transcription. Moreover, the yield of mtTF1 purified by this method was at least 25 times higher than that obtained by conventional nondenaturing chromatographies. When yeast mitochondria were subjected to the same protein isolation scheme, a 19-kilodalton putative yeast homologue of mtTF1 was purified to homogeneity. These results suggest that the denaturation-renaturation approach may be a valuable general method for the identification and high yield purification of DNA-binding proteins.	UNIV TEXAS, CELL BIOL PROGRAM, RICHARDSON, TX 75083 USA; UNIV TEXAS, MOLEC PROGRAM, RICHARDSON, TX 75083 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	FISHER, RP (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM41738, GM33088-20, GM07365-14] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365, R37GM033088, R01GM033088, R01GM041738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; DEZAMAROCZY M, 1984, GENE, V32, P439, DOI 10.1016/0378-1119(84)90019-2; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FILSON AJ, 1985, J BIOL CHEM, V260, P3164; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSS B, 1972, J BIOL CHEM, V247, P5194; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	16	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9153	9160						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851168				2022-12-25	WOS:A1991FM03800075
J	FERNANDEZ, MD; LAMPPA, GK				FERNANDEZ, MD; LAMPPA, GK			ACYL CARRIER PROTEIN IMPORT INTO CHLOROPLASTS - BOTH THE PRECURSOR AND MATURE FORMS ARE SUBSTRATES FOR PHOSPHOPANTETHEINE ATTACHMENT BY A SOLUBLE CHLOROPLAST HOLO-ACYL CARRIER PROTEIN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOROTHIOATE-MODIFIED DNA; SPINACH; MITOCHONDRIA; FERREDOXIN; ENZYME; PLANTS; SEED; HEME	Recently a chloroplast holo-acyl carrier protein (holoACP) synthase activity was identified which attached the phosphopantetheine prosthetic group to acyl carrier protein, producing holoACP (Fernandez and Lamppa (1990) Plant Cell 2, 195-206). Here we show that the mature form of ACP (apoACP), after entry into the chloroplast and removal of the transit peptide, is a substrate for modification by the holoACP synthase. Modification occurs optimally at 37-degrees-C and is inhibited by 5 mM 3',5'-ADP and 2 mM EDTA. An ACP construct (matACP) lacking the transit peptide was also converted to the holoACP form in an organelle-free assay, independent of precursor cleavage. The matACP construct was used to monitor the chromatographic separation of the holoACP synthase from the transit peptidase. Superose 12 gel filtration analysis indicates that the holoACP synthase has an apparent M(r) of approximately 50,000. Using fractions enriched for the holoACP synthase it was demonstrated that the precursor of ACP is also modified in the presence of CoA and subsequently can be proteolytically processed directly to holoACP. Kinetic analysis, however, indicates that removal of the transit peptide is a much faster reaction than phosphopantetheine addition, suggesting that apoACP is the primary substrate for the chloroplast holoACP synthase in vivo.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago								ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CARRILLO N, 1985, EUR J BIOCHEM, V150, P469, DOI 10.1111/j.1432-1033.1985.tb09045.x; ELHUSSEIN SA, 1988, BIOCHEM J, V252, P39, DOI 10.1042/bj2520039; ELOVSON J, 1968, J BIOL CHEM, V243, P3603; FERNANDEZ MD, 1990, PLANT CELL, V2, P195, DOI 10.1105/tpc.2.3.195; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; HANNAPEL DJ, 1988, PLANT PHYSIOL, V86, P1174, DOI 10.1104/pp.86.4.1174; HOJ PB, 1984, CARLSBERG RES COMMUN, V49, P483, DOI 10.1007/BF02904401; KUO TM, 1984, ARCH BIOCHEM BIOPHYS, V234, P290, DOI 10.1016/0003-9861(84)90351-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OHLROGGE JB, 1979, P NATL ACAD SCI USA, V76, P1194, DOI 10.1073/pnas.76.3.1194; OHLROGGE JB, 1985, J BIOL CHEM, V260, P8032; PICCIONI R, 1982, METHODS CHLOROPLAST, P985; POSTBEITTENMILLER MA, 1989, PLANT CELL, V1, P889, DOI 10.1105/tpc.1.9.889; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SAFFORD R, 1988, EUR J BIOCHEM, V174, P287, DOI 10.1111/j.1432-1033.1988.tb14096.x; SCHERER DE, 1987, PLANT MOL BIOL, V9, P127, DOI 10.1007/BF00015645; Stumpf P. K., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P177; TAKAHASHI Y, 1986, P NATL ACAD SCI USA, V83, P2434, DOI 10.1073/pnas.83.8.2434; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765	26	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7220	7226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849904				2022-12-25	WOS:A1991FG72700089
J	DENIS, D; FALGUEYRET, JP; RIENDEAU, D; ABRAMOVITZ, M				DENIS, D; FALGUEYRET, JP; RIENDEAU, D; ABRAMOVITZ, M			CHARACTERIZATION OF THE ACTIVITY OF PURIFIED RECOMBINANT HUMAN 5-LIPOXYGENASE IN THE ABSENCE AND PRESENCE OF LEUKOCYTE FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONATE 5-LIPOXYGENASE; LEUKOTRIENE-A4 SYNTHASE; PORCINE LEUKOCYTES; SINGLE PROTEIN; PURIFICATION; CELLS; BIOSYNTHESIS; STIMULATION; EXPRESSION; CLONING	Purified recombinant human 5-lipoxygenase was used to investigate the catalytic properties of the protein in the presence and absence of leukocyte stimulatory factors. Recombinant human 5-lipoxygenase was purified to apparent homogeneity (95-99%) from a high expression baculovirus system by chromatography on ATP-agarose with a yield of 0.6 mg of protein per 100 ml of culture (2 X 10(8) cells) and a specific activity of 3-6-mu-mol of 5-hydroperoxyeicosatetraenoic acid (5-HPETE) per mg of protein in the presence of ATP, Ca2+, and phosphatidylcholine as the only factors. In the absence of leukocyte factors, the reaction catalyzed by the purified recombinant enzyme showed a half-time of maximal 5-HPETE formation of 0.5-0.7 min and was sensitive to the selective 5-lipoxygenase inhibitors BW755C (IC50 = 13-mu-M) and L-656,224 (IC50 = 0.8-mu-M). The reaction products of arachidonic acid oxidation were 5-HPETE and 6-trans- and 12-epi-6-trans-leukotriene B4, the nonenzymatic hydrolysis products of leukotriene A4 (LTA4), indicating that the purified protein expressed both the 5-oxygenase and leukotriene A4 synthase activities (ratio 6:1). The microsomal fraction and the 60-90% ammonium sulfate precipitate fraction from sonicated human leukocytes did not increase product formation by the isolated enzyme when assayed in the presence of ATP, Ca2+, and phosphatidylcholine. These factors were found to stabilize 5-lipoxygenase during preincubation of the enzyme at 37-degrees-C with the assay mixture but they failed to stimulate enzymatic activity when added at the end of the preincubation period. The results demonstrate that human 5-lipoxygenase can be isolated in a catalytically active form and that protein factors from leukocytes protect against enzyme inactivation but are not essential for enzyme activity.	MERCK FROSST CTR THERAPEUT RES, DEPT BIOCHEM, POINTE CLAIRE H9R 4P8, QUEBEC, CANADA; MERCK FROSST CTR THERAPEUT RES, DEPT MOLEC BIOL, POINTE CLAIRE H9R 4P8, QUEBEC, CANADA	Merck & Company; Merck & Company								BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BELANGER P, 1987, CAN J PHYSIOL PHARM, V65, P2441, DOI 10.1139/y87-387; BORGEAT P, 1985, ADV LIPID RES, V21, P47; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIN SD, 1990, PHARMACOL THERAPEUT, V46, P57, DOI 10.1016/0163-7258(90)90035-Z; CRAWFORD AM, 1988, J VIROL, V62, P2773, DOI 10.1128/JVI.62.8.2773-2781.1988; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FITZSIMMONS BJ, 1989, LEUKOTRIENES LIPOXYG, V2, P427; FORDHUTCHINSON AW, 1989, LEUKOTRIENES LIPOXYG, V2, P405; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2592, DOI 10.1073/pnas.86.8.2592; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P343, DOI 10.1016/0003-2697(87)90234-X; GOETZE AM, 1985, PROSTAGLANDINS, V29, P689, DOI 10.1016/0090-6980(85)90130-3; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HOGABOOM GK, 1986, MOL PHARMACOL, V30, P510; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NAKAMURA M, 1990, GENE, V89, P231, DOI 10.1016/0378-1119(90)90010-O; NOGUCHI M, 1989, FEBS LETT, V249, P267, DOI 10.1016/0014-5793(89)80638-6; PUUSTINEN T, 1988, BIOCHIM BIOPHYS ACTA, V960, P261, DOI 10.1016/0005-2760(88)90033-1; RIENDEAU D, 1989, BIOCHEM PHARMACOL, V38, P2313, DOI 10.1016/0006-2952(89)90471-1; RIENDEAU D, 1989, BIOCHEM J, V263, P565, DOI 10.1042/bj2630565; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1988, J BIOL CHEM, V263, P10135; ROUZER CA, 1988, ANN NY ACAD SCI, V524, P1; ROUZER CA, 1990, METHOD ENZYMOL, V187, P312; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA N, 1986, J BIOL CHEM, V261, P7982; UEDA N, 1988, J BIOL CHEM, V263, P1937; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WISEMAN JS, 1989, BIOCHEMISTRY-US, V28, P2106, DOI 10.1021/bi00431a021; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; YAMAMOTO S, 1989, PROSTAG LEUKOTR ESS, V35, P219, DOI 10.1016/0952-3278(89)90005-7	42	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5072	5079						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848236				2022-12-25	WOS:A1991FC21700060
J	WATERLAND, RA; BASU, A; CHANCE, B; POYTON, RO				WATERLAND, RA; BASU, A; CHANCE, B; POYTON, RO			THE ISOFORMS OF YEAST CYTOCHROME-C-OXIDASE SUBUNIT-V ALTER THE INVIVO KINETIC-PROPERTIES OF THE HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; OXYGEN; LIVER; HEART; GENES; IDENTIFICATION; POLYPEPTIDES; EVOLUTION; ENZYME; FORMS	One of the nuclear-coded subunits of yeast cytochrome c oxidase is specified by a gene family composed of two genes, COX5a and COX5b. These genes are regulated differentially by oxygen and encode isoforms of subunit V, designated Va and Vb, which have only 66% primary sequence identity. Yeast cells require one or the other isoform for a functional cytochrome c oxidase (Trueblood, C. E., and Poyton, R. O. (1987) Mol. Cell Biol. 7, 3520-3526). To determine if these isoforms of subunit V alter the catalytic properties of holocytochrome c oxidase, we have analyzed various aspects of cytochrome c oxidase function in intact yeast cells that produce only one type of isoform. From measurements of room temperature turnover numbers and low temperature rates of ligand binding, single turnover cytochrome c oxidation, and internal electron transfer (heme a oxidation), we have found that isozymes which incorporate the Vb isoform have both higher turnover rates and higher rates of heme a oxidation than isozymes which incorporate Va. These findings support the conclusion that the isoforms of subunit V modulate cytochrome c oxidase activity in vivo and suggest that they do so by altering the rates of one or more intramolecular electron transfer reactions.	UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Colorado System; University of Colorado Boulder; University of Pennsylvania					NIGMS NIH HHS [GMHL31909] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNORI M, 1987, EUR J BIOCHEM, V169, P1, DOI 10.1111/j.1432-1033.1987.tb13572.x; BRUNORI M, 1979, J BIOL CHEM, V254, P769; BRZEZINSKI P, 1986, FEBS LETT, V194, P1, DOI 10.1016/0014-5793(86)80040-0; BUGE U, 1986, EUR J BIOCHEM, V161, P383, DOI 10.1111/j.1432-1033.1986.tb10457.x; BUSE G, 1987, CYTOCHROME SYSTEMS M, P261; CAPALDI RA, 1987, CURR TOP BIOENERG, V15, P91; CAPALDI RA, 1983, BIOCHIM BIOPHYS ACTA, V726, P135, DOI 10.1016/0304-4173(83)90003-4; CHANCE B, 1975, J BIOL CHEM, V250, P9226; CHANCE B, 1975, P NATL ACAD SCI USA, V72, P1635, DOI 10.1073/pnas.72.4.1635; CLORE GM, 1980, BIOCHEM J, V185, P139, DOI 10.1042/bj1850139; CUMSKY MG, 1985, P NATL ACAD SCI USA, V82, P2235, DOI 10.1073/pnas.82.8.2235; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; HODGE MR, 1989, MOL CELL BIOL, V9, P1958, DOI 10.1128/MCB.9.5.1958; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; KADENBACH B, 1984, FEBS LETT, V173, P374, DOI 10.1016/0014-5793(84)80808-X; KADENBACH B, 1986, J BIOENERG BIOMEMBR, V18, P39, DOI 10.1007/BF00743611; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADENBACH B, 1983, ANGEW CHEM INT EDIT, V22, P275, DOI 10.1002/anie.198302751; KADENBACH B, 1983, TRENDS BIOCHEM SCI, V8, P398, DOI 10.1016/0968-0004(83)90302-X; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MERLE P, 1982, EUR J BIOCHEM, V125, P239, DOI 10.1111/j.1432-1033.1982.tb06674.x; MYERS D, 1988, ANN NY ACAD SCI, V550, P85, DOI 10.1111/j.1749-6632.1988.tb35325.x; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; PATTERSON TE, 1988, CYTOCHROME SYSTEMS M, P253; POOLE RK, 1979, BIOCHEM J, V184, P555, DOI 10.1042/bj1840555; POOLE RK, 1983, BIOCHIM BIOPHYS ACTA, V726, P205, DOI 10.1016/0304-4173(83)90006-X; POWER SD, 1984, J BIOL CHEM, V259, P6564; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; SARTI P, 1988, ANN NY ACAD SCI, V550, P161, DOI 10.1111/j.1749-6632.1988.tb35332.x; SEKUZU I, 1967, J BIOCHEM, V62, P710, DOI 10.1093/oxfordjournals.jbchem.a128727; SINJORGO KMC, 1987, BIOCHIM BIOPHYS ACTA, V893, P251, DOI 10.1016/0005-2728(87)90046-6; TRUEBLOOD CE, 1988, GENETICS, V120, P671; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WRIGHT RM, 1987, CYTOCHROME SYSTEMS M, P49	37	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4180	4186						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847916				2022-12-25	WOS:A1991FA69400028
J	CHANG, SF; NG, D; BAIRD, L; GEORGOPOULOS, C				CHANG, SF; NG, D; BAIRD, L; GEORGOPOULOS, C			ANALYSIS OF AN ESCHERICHIA-COLI DNAB TEMPERATURE-SENSITIVE INSERTION MUTATION AND ITS COLD-SENSITIVE EXTRAGENIC SUPPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; BACTERIOPHAGE-LAMBDA; ATP HYDROLYSIS; PROTEIN ACTION; STRANDED DNA; P-PROTEIN; REPLICATION; IDENTIFICATION; INITIATION; GROWTH	An Escherichia coli mutant, ts121, was isolated following random insertional mutagenesis using phage-lambda-Mu transposition. The mutant phenotype includes inability to form colonies at temperatures above 38-degrees-C and inability to propagate phage-lambda at all temperatures. A lambda-i434cI- (ts121)+ transducing phage was isolated on the basis of its ability to form plaques on ts121 mutant bacteria. Using this transducing phage, it was shown through complementation and protein analyses, that the ts121 mutation is located in the dnaB gene. The exact insertion event was identified by polymerase chain reaction amplification of the DNA sequences containing the insertion junction. The mutational insertion event in ts121 was mapped precisely between base pairs 1514 and 1515 of the dnaB gene. This result predicts that the mutant dnaB protein has lost its six terminal amino acids. The reading frame shifts into Mu-specific DNA sequences resulting in an additional 20 amino acid residues. The E. coli wild type dnaB protein participates in host replication and interacts with lambda-P protein to initiate phage-lambda DNA replication. Our results demonstrate that the extreme carboxyl end of the dnaB protein is required for productive interaction with the lambda-P replication protein at all temperatures, and is important for dnaB function at temperatures above 38-degrees-C. Cold-sensitive extragenic suppressors of the ts121 mutation were isolated on the basis of their ability to restore colony formation at 42-degrees-C. One of these extragenic suppressors was mapped at 54 min on the E. coli genetic map and localized to the suhB gene, whose product may affect the expression of a number of genes at the translational level.	UNIV UTAH,SCH MED,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah								ANG D, 1986, J BACTERIOL, V167, P25, DOI 10.1128/jb.167.1.25-29.1986; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAIRD L, 1990, J BACTERIOL, V172, P1587, DOI 10.1128/jb.172.3.1587-1594.1990; BREMER E, 1985, J BACTERIOL, V162, P1092, DOI 10.1128/JB.162.3.1092-1099.1985; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GEORGOPOULOS CP, 1978, P NATL ACAD SCI USA, V75, P131, DOI 10.1073/pnas.75.1.131; GROISMAN EA, 1986, J BACTERIOL, V168, P357, DOI 10.1128/jb.168.1.357-364.1986; KLEIN A, 1980, EUR J BIOCHEM, V105, P1, DOI 10.1111/j.1432-1033.1980.tb04467.x; KLINKERT J, 1979, MOL GEN GENET, V171, P219, DOI 10.1007/BF00270008; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBERG A, 1980, DNA REPLICATION, P386; LANKA E, 1978, P NATL ACAD SCI USA, V75, P799, DOI 10.1073/pnas.75.2.799; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; Miller JH, 1972, EXPT MOL GENETICS, P201; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFER A, 1983, MICROBIOLOGY+, P96; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; WRISCHNIK LA, 1987, NUCLEIC ACIDS RES, V15, P529, DOI 10.1093/nar/15.2.529; YANO R, 1990, J BACTERIOL, V172, P2124, DOI 10.1128/jb.172.4.2124-2130.1990; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYSKIND JW, 1977, J BACTERIOL, V129, P1476, DOI 10.1128/JB.129.3.1476-1486.1977	35	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3654	3660						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847383				2022-12-25	WOS:A1991EY68200048
J	HEAD, SC; KARMALI, MA; LINGWOOD, CA				HEAD, SC; KARMALI, MA; LINGWOOD, CA			PREPARATION OF VT1 AND VT2 HYBRID TOXINS FROM THEIR PURIFIED DISSOCIATED SUBUNITS - EVIDENCE FOR B-SUBUNIT MODULATION OF A SUBUNIT FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIGA-LIKE TOXINS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; INVITRO FORMATION; PROTEIN-SYNTHESIS; CYTO-TOXIN; VEROTOXIN; CELLS; VEROCYTOTOXIN-2; PURIFICATION	Verocytotoxins comprise a family of closely related subunit proteins. Two members of this group, VT1 and the immunologically distinct VT2, have been found to share similar physical properties, and yet several differences in their biological activities have been noted. The subunits of these toxins were separated using urea and isolated by high performance liquid chromatography gel filtration. Reconstituted VT1 and VT2 as well as VT1-A:VT2-B and VT2-A:VT1-B hybrid toxins were then prepared. The B subunit was found to determine cell culture specificity, cytotoxic titer, and antibody neutralizability as determined on Vero and MRC-5 cells. Cross-linking isolated B chains revealed 5 species upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis for both VT1-B and VT2-B. Using an in vitro translation system, both toxin A subunits inhibited protein synthesis at concentrations as low as 4 pM. In glycolipid binding assays, VT1 and VT1-B subunits competed equally on a molar basis with I-125-VT1 for the receptor, globotriaosylceramide, however, a 1000-fold excess of VT2 was required. Ligand analysis of direct VT1 and VT2 receptor binding assays revealed a difference in binding affinity constants (K(d) of VT1 = 4.6 x 10(-8) M; VT2 = 3.7 x 10(-7) M).	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT MICROBIOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MICROBIOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto				Karmali, Mohamed/0000-0001-7308-6085				BOEDTKER H, 1976, BIOCHEMISTRY-US, V15, P4765, DOI 10.1021/bi00667a003; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEGRANDIS S, 1987, J BACTERIOL, V169, P4313, DOI 10.1128/jb.169.9.4313-4319.1987; DONOHUEROLFE A, 1989, MOL MICROBIOL, V3, P1231, DOI 10.1111/j.1365-2958.1989.tb00273.x; EIKLID K, 1980, J RECEPTOR RES, V1, P199, DOI 10.3109/10799898009044098; HEAD SC, 1988, FEMS MICROBIOL LETT, V51, P211, DOI 10.1111/j.1574-6968.1988.tb02999.x; HUANG A, 1986, J BACTERIOL, V166, P375, DOI 10.1128/jb.166.2.375-379.1986; ITO H, 1988, MICROB PATHOGENESIS, V5, P189, DOI 10.1016/0882-4010(88)90021-6; JACEWICZ M, 1989, J INFECT DIS, V159, P881, DOI 10.1093/infdis/159.5.881; JACKSON MP, 1987, MICROB PATHOGENESIS, V2, P147, DOI 10.1016/0882-4010(87)90106-9; JIMENEZ A, 1985, ANNU REV MICROBIOL, V39, P649, DOI 10.1146/annurev.mi.39.100185.003245; KARMALI MA, 1985, J CLIN MICROBIOL, V22, P614, DOI 10.1128/JCM.22.4.614-619.1985; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1986, LANCET, V1, P164; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; LUDWIG DS, 1986, P NATL ACAD SCI USA, V83, P8585, DOI 10.1073/pnas.83.22.8585; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; OBRIEN AD, 1982, J INFECT DIS, V146, P763, DOI 10.1093/infdis/146.6.763; OBRIG TG, 1987, BIOCHEM J, V244, P287, DOI 10.1042/bj2440287; PETRIC M, 1987, FEMS MICROBIOL LETT, V41, P63; RAMOTAR K, 1990, BIOCHEM J, V272, P805, DOI 10.1042/bj2720805; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTLAND SM, 1985, LANCET, V2, P885; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; TAKEDA Y, 1981, INFECT IMMUN, V34, P341, DOI 10.1128/IAI.34.2.341-346.1981; WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3; WEINSTEIN DL, 1989, INFECT IMMUN, V57, P3743, DOI 10.1128/IAI.57.12.3743-3750.1989	29	122	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3617	3621						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847382				2022-12-25	WOS:A1991EY68200043
J	ELMAGHRABI, MR; LANGE, AJ; KUMMEL, L; PILKIS, SJ				ELMAGHRABI, MR; LANGE, AJ; KUMMEL, L; PILKIS, SJ			THE RAT FRUCTOSE-1,6-BISPHOSPHATASE GENE - STRUCTURE AND REGULATION OF EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; PHOSPHOENOLPYRUVATE CARBOXYKINASE; FRUCTOSE 1,6-BISPHOSPHATASE; SEQUENCE-ANALYSIS; MAMMALIAN-CELLS; MESSENGER-RNA; TRANSCRIPTION; LIVER; 1,25-DIHYDROXYVITAMIN-D3; 2,6-BISPHOSPHATE	The gene encoding rat fructose-1,6-bisphosphatase was isolated from a rat genomic Charon 4A library by screening with a cDNA to the rat liver enzyme. Southern blotting of rat genomic DNA showed that there is a single copy of the fructose-1,6-bisphosphatase gene. It extends over 23 kilobases and is composed of seven exons and six introns that range in size from 93 to 267 base pairs and from 1,400 to 11,300 base pairs, respectively. The intron/exon boundary sequences conform to consensus acceptor (GTn) and donor (nAG) sequences, and the exons in the gene appear to code for functional protein domains. The transcription start site, determined by 5'-extension sequencing of mRNA, was assigned to a guanine 119 bases 5' to the translation initiation AUG. The sequence of the gene upstream to the cap site contains characteristic RNA polymerase II promoter-binding sites: a putative TATA box at position -29 and a Sp1 binding site (GGGGCGGAGA) at position -48. A 1,300-base pair fragment of 5'-flanking sequence containing these elements, ligated upstream from a firefly luciferase reporter gene and transfected into cultured normal rat kidney cells, demonstrated strong promoter activity. The accumulation of fructose-1,6-bisphosphatase mRNA in hepatocytes incubated with cAMP suggests that the gene may be cAMP-responsive, which is consistent with the presence of three consensus cAMP regulatory elements at positions -169, -282, and -698 in the 5'-flanking region of the gene. Expression of the fructose-1,6-bisphosphatase promoter-driven luciferaes gene was 2-3-fold activated by the cyclic nucleotide, suggesting that one or more of these elements may be functional. On the other hand, insulin decreased the expression of the endogenous gene in hepatocytes. Thus, expression of the fructose-1,6-bisphosphatase gene is regulated independently by both cAMP and insulin.			ELMAGHRABI, MR (corresponding author), SUNY STONY BROOK, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURMESTER JK, 1988, P NATL ACAD SCI USA, V85, P9499, DOI 10.1073/pnas.85.24.9499; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELMAGHRABI MR, 1988, P NATL ACAD SCI USA, V85, P8430, DOI 10.1073/pnas.85.22.8430; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HOD Y, 1988, J BIOL CHEM, V263, P7747; HORECKER BL, 1975, ADV ENZYMOL RAMB, V42, P193; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KITAJIMA S, 1983, J BIOL CHEM, V258, P7352; KUMMEL L, 1990, BIOCHEM BIOPH RES CO, V169, P406, DOI 10.1016/0006-291X(90)90346-O; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Maniatis T., 1982, MOL CLONING; MAZZOTTA MY, 1980, BIOCHIM BIOPHYS ACTA, V611, P156, DOI 10.1016/0005-2744(80)90051-0; PILKIS SJ, 1975, J BIOL CHEM, V250, P6328; PILKIS SJ, 1988, ADV SEC MESS PHOSPH, V22, P175; PILKIS SJ, 1981, J BIOL CHEM, V256, P1489; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1980, J BIOL CHEM, V255, P2770; PILKIS SJ, 1974, BIOCHIM BIOPHYS ACTA, V343, P250, DOI 10.1016/0304-4165(74)90258-X; RITTENHOUSE J, 1983, J BIOL CHEM, V258, P7648; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SOLOMON DH, 1988, P NATL ACAD SCI USA, V85, P6904, DOI 10.1073/pnas.85.18.6904; TASHIMA Y, 1984, J BIOCHEM-TOKYO, V96, P805, DOI 10.1093/oxfordjournals.jbchem.a134898; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WEBER G, 1965, P NATL ACAD SCI USA, V53, P96, DOI 10.1073/pnas.53.1.96	38	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2115	2120						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846613				2022-12-25	WOS:A1991EV51500019
J	HENDERSON, GB; STRAUSS, BP				HENDERSON, GB; STRAUSS, BP			EVIDENCE FOR CAMP AND CHOLATE EXTRUSION IN C6 RAT GLIOMA-CELLS BY A COMMON ANION EFFLUX PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT VESICLES; CYCLIC-AMP; P-GLYCOPROTEIN; L1210 CELLS; GLUTATHIONE TRANSPORT; MULTIDRUG-RESISTANCE; PIGEON ERYTHROCYTES; IDENTIFICATION; METHOTREXATE; INHIBITION	C6 rat giloma cells were investigated for a shared unidirectional efflux, system for cAMP and cholate. [H-3]Cholate was accumulated (at pH 7.3) by scraped C6 cell monolayers via a process which was rapid initially and then slowed to a steady state after 10 min at 37-degrees-C. Release of the accumulated label was also rapid (t1/2 = 2 min), was essentially complete within 15 min, and exhibited energy dependence since it could be blocked by antimycin A. Half-maximal inhibition by antimycin A occurred at 0.87 mu-m, and maximal inhibition exceeded 90%. Various other compounds also inhibited [H-3]cholate efflux. The most effective was prostaglandin A1, which reduced efflux half-maximally at a concentration of 0.14-mu-M. Other inhibitors, prostaglandin B1, verapamil, probenecid, and bromo-sulfophthalein, produced half-maximal inhibition at 5.3, 42, 78, and 110-mu-M, respectively. Cholate efflux was also blocked by 40-mu-M vincristine. Initial influx of [H-3]cholate was not affected by antimycin A, prostaglandin A1, or vincristine and hence was attributed to a process separate from efflux. C6 rat glioma cells also have the ability to produce high intracellular levels of cAMP in response to isoproterenol and to release cAMP into the medium via a carrier-mediated efflux system. When measured under the same conditions employed for cholate efflux, the efflux of cAMP was found to be sensitive to each of the inhibitors of cholate efflux. Moreover, plots of cAMP efflux versus varying concentrations of prostaglandin A1, antimycin A, prostaglandin B1, verapamil, and probenecid showed similar response curves and comparable values for half-maximal inhibition when compared with the efflux of cholate. These results indicate that C6 rat glioma cells contain a unidirectional efflux pump for cholate and that this same system also appears to mediate the unidirectional efflux of cAMP. These findings support the hypothesis that various cells contain efflux pumps which exhibit a broad specificity for large organic anions of diverse structure and that the function of these efflux pumps resides primarily in cellular anion detoxification. Analogous efflux pumps for hydrophobic drugs are overproduced in tumor cells exhibiting multidrug resistance.			HENDERSON, GB (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA23970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA023970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BRUNTON LL, 1979, J BIOL CHEM, V254, P9714; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; DOORE BJ, 1975, J BIOL CHEM, V250, P4371; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HEASLEY LE, 1985, J BIOL CHEM, V260, P1520; HEASLEY LE, 1985, J BIOL CHEM, V260, P1514; HEASLEY LE, 1985, MOL PHARMACOL, V27, P60; HENDERSON GB, 1988, CANCER RES, V48, P5995; HENDERSON GB, 1989, ADV ENZYME REGUL, V29, P61, DOI 10.1016/0065-2571(89)90094-0; HENDERSON GB, 1990, BIOCHIM BIOPHYS ACTA, V1051, P60, DOI 10.1016/0167-4889(90)90174-C; HENDERSON GB, 1987, J BIOL CHEM, V262, P13571; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KING CD, 1974, MOL PHARMACOL, V10, P941; KONDO T, 1980, P NATL ACAD SCI-BIOL, V77, P6359, DOI 10.1073/pnas.77.11.6359; KONDO T, 1981, BIOCHIM BIOPHYS ACTA, V645, P132, DOI 10.1016/0005-2736(81)90520-4; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; PENIT J, 1974, FEBS LETT, V41, P156, DOI 10.1016/0014-5793(74)80977-4; PLAGEMANN PGW, 1977, J BIOL CHEM, V252, P2010; RINDLER MJ, 1978, J BIOL CHEM, V253, P5431; RIORDAN JR, 1989, SCIENCE, V245, P1066; SPECTOR R, 1974, J PHARMACOL EXP THER, V188, P55; SPECTOR R, 1985, SCIENCE, V228, P325, DOI 10.1126/science.3983632; STEINBERG TH, 1987, J CELL BIOL, V105, P2695, DOI 10.1083/jcb.105.6.2695; TISA LS, 1990, J BIOL CHEM, V265, P190; ZUMSTEIN P, 1974, FEBS LETT, V49, P65, DOI 10.1016/0014-5793(74)80633-2	30	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1641	1645						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846362				2022-12-25	WOS:A1991EU49700045
J	COCHET, C; FILHOL, O; PAYRASTRE, B; HUNTER, T; GILL, GN				COCHET, C; FILHOL, O; PAYRASTRE, B; HUNTER, T; GILL, GN			INTERACTION BETWEEN THE EPIDERMAL GROWTH-FACTOR RECEPTOR AND PHOSPHOINOSITIDE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE KINASE; PHOSPHOLIPASE C-II; PHOSPHATIDYLINOSITOL KINASE; EGF RECEPTOR; SIGNAL TRANSDUCTION; PDGF RECEPTOR; A431 CELLS; CELLULAR-REGULATION; A-431 CELLS; PHOSPHORYLATION	Ligand-activated epidermal growth factor (EGF) receptors are coupled to the phosphatidylinositol (PtdIns) pathways to simulate formation of two second messengers, inositol trisphosphate and diacylglycerol. Investigation of the interaction between EGF receptors and phosphoinositide kinases identified PtdINs and PtdIns(4)P kinase activities in extensively washed EGF receptor immunoprecipitates. Studies using COOH-terminal truncation mutant EGF receptors and immunoisolation by and EGF receptor peptide antiserum in the presence of peptide (residues 644-666) indicated that the phosphoinositide kinase were associated with the region located between the inner membrane boundary and the kinase domain of the EGF receptor. In vivo cross-linking identified four tyrosine phosphorylated proteins of approximately 135, 62, 55, and 47 kDa associated with the EGF receptor. After EGF stimulation, PtdIns and PtdIns(4)P kinase activities were markedly increased among proteins isolated by monoclonal antiphosphotyrosine antibodies. The activities associated with the EGF receptor and with tyrosine-phosphorylated proteins were identified as PtdIns4- and PtdIns(4)P 5-kinase. Tyrosine dephosphorylation did not alter the activity of the prominent PtdIns(4)P 5-kinase activity. These results indicate that the phosphoinositide kinases are associated with and tyrosine phosphorylated by the EGF receptor as part of the mechanism coordinating responses between signal transduction pathways but do not demonstrate that tyrosine phosphorylation of PtdIns(4)P 5-kinase is sufficient to activate the enzyme.	CEN,INSERM,U244,85X,F-38041 GRENOBLE,FRANCE; HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego; Salk Institute; University of California System; University of California San Diego			Filhol-Cochet, Odile/I-3962-2016	, Bernard/0000-0002-8693-0190; Cochet, Claude/0000-0002-1772-4270; Filhol, Odile/0000-0003-1964-7958				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLOU LM, 1986, ENZYMES, V17, P311; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HESIERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM JW, 1990, J BIOL CHEM, V265, P3940; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LING LE, 1989, J BIOL CHEM, V264, P5080; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; SAWYER ST, 1981, BIOCHEMISTRY-US, V20, P6280, DOI 10.1021/bi00524a057; TAYLOR MV, 1984, NATURE, V312, P462, DOI 10.1038/312462a0; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDONGEN CJ, 1984, BIOCHEM J, V223, P197, DOI 10.1042/bj2230197; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	48	136	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					637	644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845983				2022-12-25	WOS:A1991EQ33900092
J	HSU, CYJ; HURWITZ, DR; MERVIC, M; ZILBERSTEIN, A				HSU, CYJ; HURWITZ, DR; MERVIC, M; ZILBERSTEIN, A			AUTOPHOSPHORYLATION OF THE INTRACELLULAR DOMAIN OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR RESULTS IN DIFFERENT EFFECTS ON ITS TYROSINE KINASE-ACTIVITY WITH VARIOUS PEPTIDE-SUBSTRATES - PHOSPHORYLATION OF PEPTIDES REPRESENTING TYR(P) SITES OF PHOSPHOLIPASE C-GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; PROTEIN-KINASE; ACTIVATION; CONFORMATION; INVITRO; CELLS	The effect of autophosphorylation on the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) is not well understood. We previously demonstrated that phospholipase C-gamma physically associates with the EGF-activated EGFR, but not with a kinase-negative mutant of the EGFR, and, moreover, that only the tyrosine-phosphorylated EGFR is able to associate with phospholipase C-gamma. We have now investigated the effect of autophosphorylation on the tyrosine kinase activity of the EGFR by employing the purified kinase-active intracellular domain of the EGFR (EGFR-IC) produced by a baculovirus expression system. Synthetic peptides, including ones which contain the individual major tyrosine phosphorylation sites of phospholipase C-gamma, were used as substrates. We found that the extensively prephosphorylated EGFR-IC exhibited similar reaction kinetics to the unphosphorylated EGFR-IC when angiotensin II was used as a nonspecific substrate. In contrast there was a clear stimulation of kinase activity due to autophosphorylation of the EGFR-IC when peptides representing either the major autophosphorylation site of the EGFR or the EGFR phosphorylation sites of phospholipase C-gamma were used as substrates. However, the modes of stimulation for these peptides differed. The binding affinity (K(m)) for the unphosphorylated EGFR-IC for tHE PEPTide containing Tyr-771 of phospholipase C-gamma was was relatively poor compared with other peptides, but improved 5- 6-fold when tHE EGFR-IC was prephosphorylated. On the other hand, autophosphorylation improved the reaction velocitY (V(M)) of the phosphorylation of other peptides by 2-3-fold, with little or no increase in affinity. These results suggest that autophosphorylation of the EGFR may induce a conformational change of its kinase domain which enhances its kinase activity with exogenous substrates and may induce association with phospholipase C-gamma by increasing its affinity to a domain containing Tyr-771.			HSU, CYJ (corresponding author), RHONE POULENC RORER CENT RES,KING OF PRUSSIA,PA 19406, USA.							BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KIM JW, 1990, J BIOL CHEM, V265, P3940; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P4715	28	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					603	608						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845982				2022-12-25	WOS:A1991EQ33900087
J	PUTKEY, JA; LIU, W; SWEENEY, HL				PUTKEY, JA; LIU, W; SWEENEY, HL			FUNCTION OF THE N-TERMINAL CALCIUM-BINDING SITES IN CARDIAC SLOW TROPONIN-C ASSESSED IN FAST SKELETAL-MUSCLE FIBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID SEQUENCE; BIOLOGICAL-ACTIVITY; CROSS-LINKING; RABBIT; CALMODULIN; CONTRACTION; SUBUNITS; SPECTROSCOPY; MYOFIBRILS; EXCHANGE	Fast skeletal troponin C (sTnC) has two low affinity Ca2+-binding sites (sites I and II), whereas in cardiac troponin C (cTnC) site I is inactive. By modifying the Ca2+ binding properties of sites I and II in cTnC it was demonstrated that binding of Ca2+ to an activated site I alone is not sufficient for triggering contraction in slow skeletal muscle fibers (Sweeney, H. L., Brito, R. M. M., Rosevear, P. R., and Putkey, J. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9538-9542). However, a similar study using sTnC showed that Ca2+ binding to site I alone could partially activate force production in fast skeletal muscle fibers (Sheng, Z., Strauss, W. L., Francois, J. M., and Potter, J. D. (1990) J. Biol. Chem. 265, 21554-21560). The purpose of the current study was to examine the functional characteristics of modified cTnC derivatives in fast skeletal muscle fibers to assess whether or not either low affinity site can mediate force production when coupled to fast skeletal isoforms of troponin (Tn) I and TnT. Normal cTnC and sTnC were compared with engineered derivatives of cTnC having either both sites I and II active, or only site I active. In contrast to what is seen in slow muscle, binding of Ca2+ to site I alone recovered about 15-20% of the normal calcium-activated force and ATPase activity in skinned fast skeletal muscle fibers and myofibrils, respectively. This is most likely due to structural differences between TnI and/or TnT isoforms that allow for partial recognition and translation of the signal represented by binding Ca2+ to site I of TnC when associated with fast skeletal but not slow skeletal muscle.	UNIV PENN, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	PUTKEY, JA (corresponding author), UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, POB 20708, 6431 FANNIN ST, HOUSTON, TX 77225 USA.		Sweeney, H Lee/F-1862-2010		NIAMS NIH HHS [AR-39210] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU A, 1989, FEBS LETT, V251, P177, DOI 10.1016/0014-5793(89)81450-4; BABU A, 1987, J BIOL CHEM, V262, P5815; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BYERS DM, 1982, FEBS LETT, V148, P12, DOI 10.1016/0014-5793(82)81232-5; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COX JA, 1981, BIOCHEM J, V195, P205, DOI 10.1042/bj1950205; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; EASTWOOD AB, 1979, TISSUE CELL, V11, P553, DOI 10.1016/0040-8166(79)90062-4; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fiske CH, 1925, J BIOL CHEM, V66, P375; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GULATI J, 1989, FEBS LETT, V248, P5, DOI 10.1016/0014-5793(89)80420-X; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HITCHCOCK SE, 1981, J MOL BIOL, V147, P153, DOI 10.1016/0022-2836(81)90083-8; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; SUTOH K, 1980, BIOCHEMISTRY-US, V19, P3878, DOI 10.1021/bi00557a037; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P9538, DOI 10.1073/pnas.87.24.9538; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; WANG CLA, 1986, EUR J BIOCHEM, V154, P225, DOI 10.1111/j.1432-1033.1986.tb09383.x	32	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14881	14884						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869527				2022-12-25	WOS:A1991GB09700014
J	SHARP, JD; WHITE, DL; CHIOU, XG; GOODSON, T; GAMBOA, GC; MCCLURE, D; BURGETT, S; HOSKINS, J; SKATRUD, PL; SPORTSMAN, JR; BECKER, GW; KANG, LH; ROBERTS, EF; KRAMER, RM				SHARP, JD; WHITE, DL; CHIOU, XG; GOODSON, T; GAMBOA, GC; MCCLURE, D; BURGETT, S; HOSKINS, J; SKATRUD, PL; SPORTSMAN, JR; BECKER, GW; KANG, LH; ROBERTS, EF; KRAMER, RM			MOLECULAR-CLONING AND EXPRESSION OF HUMAN CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; MACROPHAGE CELL-LINE; MESANGIAL CELLS; PURIFICATION; ACID; ACTIVATION; MEMBRANE; CHANNELS; RELEASE	Phospholipases A2 (PLA2s) play a key role in inflammatory processes through production of precursors of eicosanoids and platelet-activating factor. Recently, we described the purification of a novel approximately 100-kDa cytosolic PLA2 (cPLA2) from human monoblast U937 cells that is activated by physiological (intracellular) concentrations of Ca2+ (Kramer, R. M., Roberts, E. F., Manetta, J., and Putnam, J. E. (1991) J. Biol. Chem. 266, 5268-5272). Here we report the isolation of the complementary DNA encoding human cPLA2 and confirm its identity by expression in bacteria and in hamster cells. The predicted 749-amino acid cPLA2 protein has no similarity to the well known secretory PLA2s, but contains a structural element homologous to the C2 region of protein kinase C. The molecular cloning of cPLA2 will allow further studies defining the structure, function, and regulation of this novel PLA2.	ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285	Eli Lilly								[Anonymous], 1987, PHOSPHOLIPASES; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BONVENTRE JV, 1988, J CLIN INVEST, V82, P168, DOI 10.1172/JCI113566; BURCH RM, 1989, MOL NEUROBIOL, V3, P155, DOI 10.1007/BF02935629; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEZ E, 1990, J BIOL CHEM, V265, P14654; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; HALLING SM, 1982, CELL, V28, P155, DOI 10.1016/0092-8674(82)90385-3; HWANG TC, 1990, P NATL ACAD SCI USA, V87, P5706, DOI 10.1073/pnas.87.15.5706; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P267; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARSEN GL, 1983, ANNU REV IMMUNOL, V1, P335, DOI 10.1146/annurev.iy.01.040183.002003; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PARKER J, 1987, J BIOL CHEM, V262, P5385; PIOMELLI D, 1990, TRENDS PHARMACOL SCI, V11, P367, DOI 10.1016/0165-6147(90)90182-8; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON SM, 1987, BIO-TECHNOL, V5, P1207, DOI 10.1038/nbt1187-1207; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNYDER F, 1989, P SOC EXP BIOL MED, V190, P125; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3	33	469	485	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14850	14853						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869522				2022-12-25	WOS:A1991GB09700006
J	WU, JT; GONG, QH; CHOU, RH; WIELAND, SJ				WU, JT; GONG, QH; CHOU, RH; WIELAND, SJ			CA2+-INSENSITIVE MODULATION OF A K+ CONDUCTANCE BY INOSITOL POLYPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POTASSIUM CHANNELS; CHROMAFFIN CELLS; SMOOTH-MUSCLE; PATCH-CLAMP; 1,3,4,5-TETRAKISPHOSPHATE; CURRENTS; NEURONS; INWARD; CSF-1; LINE	Macrophages derived from phorbol ester-induced human leukemic (HL-60) cells exhibit a voltage-activated inward rectifying potassium conductance which was modulated by macrophage colony-stimulating factor (Wieland, S. J., Chou, R. H., and Gong, Q. H. (1990) J. Cell. Physiol. 142, 643-651). Roles of intracellular messengers in this regulatory mechanism were investigated. Intracellular dialysis with inositol 1,3,4,5-tetrakisphosphate (IP4) or inositol 1,4,5-trisphosphate during tight-seal whole cell recording produced a rapid increase in the inward rectifying conductance. Changes in intracellular Ca2+ levels alone did not reproduce the stimulatory effect of these modulators. Intracellular dialysis with guanosine 5'-O-(thiotriphosphate) (GTP-gamma-S) resulted in profound inhibition of this conductance. These data suggest a novel cellular function for inositol polyphosphates, particularly IP4, and show antagonistic modulation with GTP-gamma-S on a human macrophage inward rectifier.	HAHNEMANN UNIV,SCH MED,DEPT ANAT,MAIL STOP 408,BROAD & VINE ST,PHILADELPHIA,PA 19102	Drexel University								BELARDETTI F, 1987, NATURE, V325, P153, DOI 10.1038/325153a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BROWN DA, 1990, ANNU REV PHYSIOL, V52, P215; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GALLIN EK, 1985, J PHYSIOL-LONDON, V369, P475, DOI 10.1113/jphysiol.1985.sp015911; GONG QH, 1989, TOXICON, V27, P1339, DOI 10.1016/0041-0101(89)90066-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIGASHIDA H, 1986, FEBS LETT, V208, P283, DOI 10.1016/0014-5793(86)81033-X; KAKEI M, 1984, J PHYSIOL-LONDON, V352, P265, DOI 10.1113/jphysiol.1984.sp015290; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; MCCANN JD, 1986, J PHYSIOL-LONDON, V372, P113, DOI 10.1113/jphysiol.1986.sp016000; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; RANDRIAMAMPITA C, 1987, J CELL BIOL, V105, P761, DOI 10.1083/jcb.105.2.761; SAWADA M, 1990, BRAIN RES, V512, P333, DOI 10.1016/0006-8993(90)90644-Q; SIMS SM, 1988, SCIENCE, V239, P190, DOI 10.1126/science.2827305; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; WIELAND SJ, 1990, J CELL PHYSIOL, V142, P643, DOI 10.1002/jcp.1041420326	19	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14893	14895						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869530				2022-12-25	WOS:A1991GB09700017
J	GOLDSTEIN, S; PHILLIPS, LS				GOLDSTEIN, S; PHILLIPS, LS			EXTRACTION AND NUTRITIONAL HORMONAL-REGULATION OF TISSUE INSULIN-LIKE GROWTH FACTOR-I ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; FACTOR-I; BINDING-PROTEIN; RAT-LIVER; SOMATOMEDIN ACTIVITY; DIABETIC RATS; ADULT-RAT; SERUM; INHIBITORS; INVIVO	Studies of insulin-like growth factor 1 (IGF-1) mRNA translation products suggest synthesis as a high M(r) precursor, larger than circulating forms. To search for a precursor, we characterized IGF-1 immunoreactivity and IGF bioactivity in extracts from the liver and other body tissues. Sequential extraction with neutral followed by acid buffer was superior to extraction with acid/ethanol or acid alone in yield of immunoreactivity and specific activity. Extracts of normal rat liver exhibited both immuno- and bioactivity parallel to that of recombinant IGF-1 and serum IGFs over a 25-fold concentration range. Based on immunoreactivity, the liver of a 134-g rat appears to contain 1.2-mu-g of IGF-1 equivalents, 50% of the 2.45-mu-g in the circulation. Diaphragm, spleen, and kidney contained no significant IGF bioactivity and 8, 17, and 32% of the IGF-1 immunoreactivity of normal liver, respectively. Although serum IGFs were found at 7.5 kDa after size exclusion chromatography at pH 3, hepatic extracts contained a predominant peak of immuno- and bioactivity of apparent molecular mass of 30-35 kDa; both sizes were present in liver perfusates. Both immunoaffinity chromatography followed by Western blotting and IGF-binding protein affinity chromatography followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed two predominant species, at 18-19 and 12 kDa. The 18-19-kDa species is consistent with the apparent size of the glycosylated propeptide encoded by IGF-1A mRNA, while the 12-kDa species may be nonglycosylated propeptide. Extract activity was pituitary-dependent; the livers of hypophysectomized rats contained 15.4 and 48.8% of normal immuno- and bioactivity, respectively. During fasting and refeeding of rats, fluctuations in hepatic extract IGF-1 immunoreactivity generally paralleled changes in serum IGF-1 (r = 0.93, p < 0.001). These studies demonstrate that the liver contains a pituitary- and nutrition-dependent, high M(r) form of IGF-1 with immunological and biological properties similar to circulating IGF-1. Processing of this 18-19-kDa molecule through a 12-kDa intermediate may contribute IGF-1 to the circulation.	EMORY UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL,69 BUTLER ST SE,ATLANTA,GA 30322	Emory University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034785, R01DK033475] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-34785, DK-33475] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH MA, 1990, MOL ENDOCRINOL, V4, P899, DOI 10.1210/mend-4-6-899; DAUGHADAY WH, 1976, ENDOCRINOLOGY, V98, P1214, DOI 10.1210/endo-98-5-1214; DAUGHADAY WH, 1980, J CLIN ENDOCR METAB, V51, P781, DOI 10.1210/jcem-51-4-781; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAUGHADAY WH, 1987, J LAB CLIN MED, V109, P355; DAVOREN JB, 1986, ENDOCRINOLOGY, V118, P888, DOI 10.1210/endo-118-2-888; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DROP SLS, 1984, J CLIN ENDOCR METAB, V59, P899, DOI 10.1210/jcem-59-5-899; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GLASER EW, 1987, DIABETES, V36, P1152, DOI 10.2337/diabetes.36.10.1152; GOLDSTEIN S, 1988, MOL ENDOCRINOL, V2, P1093, DOI 10.1210/mend-2-11-1093; GOLDSTEIN S, 1985, J CHROMATOGR, V339, P388, DOI 10.1016/S0378-4347(00)84668-X; GRIFFEN SC, 1987, P NATL ACAD SCI USA, V84, P7300, DOI 10.1073/pnas.84.20.7300; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; HALL K, 1979, HORM METAB RES, V1, P235; HARP JB, 1989, CLIN RES, V37, P36; KING GL, 1980, J CLIN INVEST, V66, P130, DOI 10.1172/JCI109826; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MCCONAGHEY P, 1970, NATURE, V225, P1249, DOI 10.1038/2251249b0; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; OGASAWARA M, 1989, BIOCHEMISTRY-US, V28, P2710, DOI 10.1021/bi00432a052; PHILLIPS LS, 1982, DIABETES, V31, P97, DOI 10.2337/diabetes.31.2.97; PHILLIPS LS, 1983, DIABETES, V32, P1117, DOI 10.2337/diabetes.32.12.1117; PHILLIPS LS, 1979, ENDOCRINOLOGY, V104, P1513, DOI 10.1210/endo-104-5-1513; PHILLIPS LS, 1978, ENDOCRINOLOGY, V103, P121, DOI 10.1210/endo-103-1-121; PHILLIPS LS, 1979, ENDOCRINOLOGY, V104, P1519, DOI 10.1210/endo-104-5-1519; PHILLIPS LS, 1976, ENDOCRINOLOGY, V99, P304, DOI 10.1210/endo-99-1-304; PHILLIPS LS, 1980, NEW ENGL J MED, V302, P438, DOI 10.1056/NEJM198002213020805; PHILLIPS LS, 1980, NEW ENGL J MED, V302, P371, DOI 10.1056/NEJM198002143020704; PHILLIPS LS, 1989, METABOLISM, V38, P745; ROBERTS CT, 1987, MOL ENDOCRINOL, V1, P243, DOI 10.1210/mend-1-3-243; ROMANUS JA, 1988, ENDOCRINOLOGY, V122, P709, DOI 10.1210/endo-122-2-709; ROTWEIN P, 1987, J BIOL CHEM, V262, P11807; SARA VR, 1986, P NATL ACAD SCI USA, V83, P4904, DOI 10.1073/pnas.83.13.4904; SCHWANDER JC, 1983, ENDOCRINOLOGY, V113, P297, DOI 10.1210/endo-113-1-297; SCOTT CD, 1985, ENDOCRINOLOGY, V116, P1102, DOI 10.1210/endo-116-3-1102; SCOTT CD, 1986, ENDOCRINOLOGY, V119, P2346, DOI 10.1210/endo-119-5-2346; SCOTT CD, 1985, ENDOCRINOLOGY, V116, P1094, DOI 10.1210/endo-116-3-1094; SMITH EP, 1987, DEVELOPMENT, V101, P73; SMITH GL, 1984, MOL CELL ENDOCRINOL, V34, P83, DOI 10.1016/0303-7207(84)90058-3; VASSILOPOULOUSELLIN R, 1982, ENDOCRINOLOGY, V110, P582, DOI 10.1210/endo-110-2-582; VASSILOPOULOUSELLIN R, 1984, ENDOCRINOLOGY, V114, P576, DOI 10.1210/endo-114-2-576; YANG YWH, 1985, J BIOL CHEM, V260, P2570; ZAPF J, 1986, J CLIN INVEST, V77, P1768, DOI 10.1172/JCI112500	45	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14725	14731						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860871				2022-12-25	WOS:A1991FZ35100095
J	POORMAN, RA; TOMASSELLI, AG; HEINRIKSON, RL; KEZDY, FJ				POORMAN, RA; TOMASSELLI, AG; HEINRIKSON, RL; KEZDY, FJ			A CUMULATIVE SPECIFICITY MODEL FOR PROTEASES FROM HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2, INFERRED FROM STATISTICAL-ANALYSIS OF AN EXTENDED SUBSTRATE DATA-BASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 PROTEASE; PSEUDOMONAS EXOTOXIN; MUTATIONAL ANALYSIS; PROTEINS; IDENTIFICATION; POLYPROTEINS; CLEAVAGE; GAG	Statistical analysis of an expanded data base of regions in viral polyproteins and in non-viral proteins that are sensitive to hydrolysis by the protease from human immunodeficiency virus (HIV) type 1 has generated a model which characterizes the substrate specificity of this retroviral enzyme. The model leads to an algorithm for predicting protease-susceptible sites from primary structure. Amino acids in each of the sites from P4 to P4' are tabulated for 40 protein substrates, and the frequency of occurrence for each residue is compared to the natural abundance of that amino acid in a selected data set of globular proteins. The results suggest that the highest stringency for particular amino acid residues is at the P2, P1, and P2' positions of the substrate. The broad specificity of the HIV-1 protease appears to be a consequence of its being able to bind productively substrates in which interactions with only a few P(i) or P(i') side-chains need be optimized. The analysis, extended to 22 protein segments cleaved by the HIV-2 protease, delineates marked differences in specificity from that of the HIV-1 enzyme.			POORMAN, RA (corresponding author), UPJOHN CO,BIOCHEM UNIT,KALAMAZOO,MI 49001, USA.							ARGOS P, 1982, EUR J BIOCHEM, V128, P65; CHAUDHARY VK, 1990, J BIOL CHEM, V265, P16306; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; HEINRIKSON RL, 1990, HYPERTENSION PATHOPH, P1179; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; HUI J, 1990, 4TH PROT SOC S SAN D; HUI JO, 1990, J BIOL CHEM, V265, P21386; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; PARTIN K, 1990, J VIROL, V64, P3938, DOI 10.1128/JVI.64.8.3938-3947.1990; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; TANG J, 1963, NATURE, V199, P1094, DOI 10.1038/1991094a0; TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P408; TOMASSELLI AG, 1991, PROTEINS, V10, P1, DOI 10.1002/prot.340100102	28	176	179	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14554	14561						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology	FZ351	1860861				2022-12-25	WOS:A1991FZ35100070
J	CHEUNG, WF; STRAIGHT, DL; SMITH, KJ; LIN, SW; ROBERTS, HR; STAFFORD, DW				CHEUNG, WF; STRAIGHT, DL; SMITH, KJ; LIN, SW; ROBERTS, HR; STAFFORD, DW			THE ROLE OF THE EPIDERMAL GROWTH FACTOR-I AND HYDROPHOBIC STACK DOMAINS OF HUMAN FACTOR-IX IN BINDING TO ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY CALCIUM-BINDING; FACTOR-X; ACTIVATION; EXPRESSION; PROTEINS; SYSTEMS; SITE; DNA; INHIBITORS; SURFACE	To determine the function and specificity in factor IX of the first epidermal growth factor (EGF)-like domain and the eight-amino acid hydrophobic stack encoded by exon C (residues 39-46), these domains were replaced by the corresponding polypeptide regions of factor X and chimeric proteins were produced in human embryo kidney cells. Both chimeras were activated by factor XIa at a rate similar to plasma factor IX and exhibited calcium-dependent fluorescence quenching similar to plasma factor IX. Both chimeras competed equally for binding to the endothelial cell receptor. Our findings make it unlikely that the first EGF-like domain or the hydrophobic stack of factor IX are responsible for the specific binding of factor IX to its endothelial cell receptor.	UNIV N CAROLINA,DEPT BIOL,442 WILSON HALL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DIV HEMATOL,CHAPEL HILL,NC 27599; UNIV NEW MEXICO,SCH MED,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNITED BLOOD SERV,ALBUQUERQUE,NM 87131; NATL TAIWAN UNIV HOSP,COLL MED,GRAD INST MED TECHNOL,TAIPEI 100,TAIWAN	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of New Mexico; University of New Mexico; National Taiwan University; National Taiwan University Hospital				LIN, SHU-WHA/0000-0001-6748-5581	NHLBI NIH HHS [R01 HL38973-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038973] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BRAUNSTEIN KM, 1981, J CLIN INVEST, V68, P1420, DOI 10.1172/JCI110393; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HARLOS K, 1987, NATURE, V330, P82, DOI 10.1038/330082a0; HEIMARK RL, 1983, BIOCHEM BIOPH RES CO, V111, P723, DOI 10.1016/0006-291X(83)90365-0; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; LIN SW, 1990, J BIOL CHEM, V265, P144; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RIMON S, 1987, J BIOL CHEM, V262, P6023; RYAN J, 1989, J BIOL CHEM, V264, P20283; RYAN J, 1989, FASEB J, V3, pA1050; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH KJ, 1987, AM J CLIN PATHOL, V87, P370, DOI 10.1093/ajcp/87.3.370; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; STERN DM, 1983, P NATL ACAD SCI-BIOL, V80, P4119, DOI 10.1073/pnas.80.13.4119; STERN DM, 1984, P NATL ACAD SCI-BIOL, V81, P913, DOI 10.1073/pnas.81.3.913; STERN DM, 1985, J BIOL CHEM, V260, P6717	28	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8797	8800						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851159				2022-12-25	WOS:A1991FM03800028
J	SOKOLIK, CW; COHEN, RE				SOKOLIK, CW; COHEN, RE			THE STRUCTURES OF UBIQUITIN CONJUGATES OF YEAST ISO-2-CYTOCHROME-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DEGRADATIVE PATHWAY; PROTEIN LIGASE SYSTEM; SHORT-LIVED PROTEIN; CYTOCHROMES-C; DICTYOSTELIUM-DISCOIDEUM; SACCHAROMYCES-CEREVISIAE; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; CARRIER PROTEINS; BINDING-SITES	Ubiquitin (Ub) conjugates to Saccharomyces cerevisiae iso-2-cytochrome c were formed in vitro in a rabbit reticulocyte extract (Fraction II). In the presence of ubiquitin-aldehyde, used to inhibit ubiquitin-protein isopeptidases in Fraction II, mono-, di-, and triubiquitinated cytochrome c conjugates accumulated in a 1.2:1.0:0.2 molar ratio. CNBr digestions showed that, in all three conjugates, Ub attachment was within the first 73 amino acids of the cytochrome c. For the two most abundant conjugates, this region was further narrowed to the first 30 residues by peptide mapping with Staphylococcus aureus V8 protease. N-terminal protein sequencing identified Lys-13 as the major ubiquitination site in each conjugate. For di- and triubiquitinated iso-2-cytochrome c, this suggested that Ub2 and Ub3 multiubiquitin chains extend from Lys-13. This conclusion was supported by a variation of protein sequencing in which polypeptides recovered after Edman degradation were analyzed to determine at which cycle(s) radiolabeled Ub or Ub(n) was cleaved from the conjugate. Because of the sensitivity afforded by the use of I-125-Ub in this "stutter-step" sequencing method, minor ubiquitination at Lys-8 also was detected. Thus, Ub2-iso-2-cytochrome c conjugates contain mostly Ub2 at Lys-13 with a small fraction of conjugates having single Ubs on 2 residues, Lys-8 and Lys-13. Similarly, Ub3-iso-2-cytochrome c predominantly has a Ub3 chain on Lys-13, although minor species with combinations of Ub1 and Ub2 distributed on Lys-8 and Lys-13 also may be present. This specificity is discussed in the context of iso-2-cytochrome c structure.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666, T32GM007185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07185, GM37666] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BUSCH H, 1981, MOL CELL BIOCHEM, V40, P173; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; FUSAUCHI Y, 1985, J BIOCHEM-TOKYO, V97, P1467, DOI 10.1093/oxfordjournals.jbchem.a135201; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; GREGORI L, 1987, J BIOL CHEM, V262, P2562; GREGORI L, 1985, J BIOL CHEM, V260, P5232; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KLEMPERER NS, 1989, BIOCHEMISTRY-US, V28, P6035, DOI 10.1021/bi00440a047; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MATNER RR, 1982, J BIOL CHEM, V257, P9811; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MOERSCHELL RP, 1988, P NATL ACAD SCI USA, V85, P524, DOI 10.1073/pnas.85.2.524; MONTGOMERY DL, 1980, P NATL ACAD SCI-BIOL, V77, P541, DOI 10.1073/pnas.77.1.541; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P964, DOI 10.1021/bi00429a007; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1988, J BIOL CHEM, V263, P15076; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Rechsteiner M., 1988, UBIQUITIN; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; STEWART JW, 1966, FED PROC, V25, P647; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; THORNE AW, 1987, EMBO J, V6, P1005, DOI 10.1002/j.1460-2075.1987.tb04852.x; WRIGHT CF, 1984, MOL CELL BIOL, V4, P2023, DOI 10.1128/MCB.4.10.2023; ZIEGENHAGEN R, 1990, FEBS LETT, V271, P71, DOI 10.1016/0014-5793(90)80374-R	50	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9100	9107						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851166				2022-12-25	WOS:A1991FM03800068
J	BOYAJIAN, CL; GARRITSEN, A; COOPER, DMF				BOYAJIAN, CL; GARRITSEN, A; COOPER, DMF			BRADYKININ STIMULATES CA2+ MOBILIZATION IN NCB-20 CELLS LEADING TO DIRECT INHIBITION OF ADENYLYLCYCLASE - A NOVEL MECHANISM FOR INHIBITION OF CAMP PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; CYCLIC-AMP; BIMODAL REGULATION; PHORBOL ESTERS; CALCIUM; BRAIN; PROTEIN; HORMONE; GTP; ACTIVATION	The modulation of neuronal adenylylcyclase by Ca2+, acting via calmodulin, is a long-established example of a positive interaction between the Ca2+ -mobilizing and cAMP-generating systems. In the present study, concentrations of Ca2+ that stimulate brain adenylylcyclase inhibit the adenylylcyclase of NCB-20 plasma membranes. These inhibitory effects of Ca2+ have been characterized and seem to be exerted at the catalytic unit of the enzyme; they are independent of calmodulin, G(i), and phosphodiesterase. To determine whether this inhibition of adenylylcyclase by Ca2+ could occur in the intact cell, cAMP accumulation was measured in response to bradykinin. Bradykinin, which mobilizes Ca2+ in NCB-20 cells, as a consequence of stimulating inositol phosphate production, causes a transient inhibition of prostaglandin E1 stimulation of cAMP accumulation. The inhibitory action of bradykinin is attenuated significantly by treatment of cells with the cell-permeant Ca2+ chelator, 1,2-bis-(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid. It seems likely that the inhibition of adenylylcyclase by low concentrations of Ca2+ represents a novel means for a negative interaction between Ca2+ -mobilizing and cAMP-generating systems.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,C236,4200 E 9TH AVE,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM 32488] Funding Source: Medline; NINDS NIH HHS [NS 28389] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028389] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADNOT S, 1982, J CYCLIC NUCL PROT, V8, P103; AHLIJANIAN MK, 1987, J PHARMACOL EXP THER, V241, P407; BELL JD, 1986, J BIOL CHEM, V261, P2036; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERRIDGE MJ, 1982, HDB EXP PHARMAKOL, V58, P227; BERRYKRAVIS E, 1984, J NEUROCHEM, V43, P413, DOI 10.1111/j.1471-4159.1984.tb00917.x; BIRNBAUMER L, 1973, BIOCHIM BIOPHYS ACTA, V300, P129, DOI 10.1016/0304-4157(73)90002-6; BOYAJIAN CL, 1990, CELL CALCIUM, V11, P299, DOI 10.1016/0143-4160(90)90007-H; BROSTROM CO, 1975, P NATL ACAD SCI USA, V72, P64, DOI 10.1073/pnas.72.1.64; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; CHEUNG WY, 1975, BIOCHEM BIOPH RES CO, V66, P1055, DOI 10.1016/0006-291X(75)90747-0; CHUANG DM, 1988, J NEUROCHEM, V51, P505, DOI 10.1111/j.1471-4159.1988.tb01067.x; COOPER DMF, 1979, J BIOL CHEM, V254, P8927; COOPER DMF, 1982, FEBS LETT, V138, P157, DOI 10.1016/0014-5793(82)80431-6; COOPER DMF, 1988, J CELL BIOCHEM, V36, P417, DOI 10.1002/jcb.240360410; DUFY B, 1987, ENDOCRINOLOGY, V121, P793, DOI 10.1210/endo-121-2-793; GARBARG M, 1988, MOL PHARMACOL, V33, P38; GIANNATTASIO G, 1987, ENDOCRINOLOGY, V120, P2611, DOI 10.1210/endo-120-6-2611; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1985, ADV CYCLIC NUCLEOTID, V19, P27; HARRISON JK, 1989, J BIOL CHEM, V264, P15880; HOLLINGSWORTH EB, 1987, BIOCHIM BIOPHYS ACTA, V930, P272, DOI 10.1016/0167-4889(87)90040-1; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LEW VL, 1982, NATURE, V298, P478, DOI 10.1038/298478a0; LIMBIRD LE, 1981, BIOCHEM J, V195, P1; LONDOS C, 1977, J BIOL CHEM, V252, P5951; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTELL AE, 1975, CRITICAL STABILITY C, V2, P269; MELDOLESI J, 1987, EXP CELL RES, V171, P271, DOI 10.1016/0014-4827(87)90161-3; MORK A, 1990, EUR J PHARMACOL, V175, P237, DOI 10.1016/0014-2999(90)90560-S; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; NORONHABLOB L, 1986, MOL PHARMACOL, V30, P526; NORSTEDT C, 1987, FEBS LETT, V220, P57; PEREIRA ME, 1988, ENDOCRINOLOGY, V122, P2232, DOI 10.1210/endo-122-5-2232; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; Rasmussen H, 1980, Ann N Y Acad Sci, V356, P346, DOI 10.1111/j.1749-6632.1980.tb29622.x; REED RR, 1990, J CELL BIOCHEM     S, V14, P127; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; STEER ML, 1975, J BIOL CHEM, V250, P2080; TOMLINSON S, 1985, CLIN ENDOCRINOL, V23, P595, DOI 10.1111/j.1365-2265.1985.tb01120.x	40	102	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4995	5003						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848232				2022-12-25	WOS:A1991FC21700050
J	RAKE, JB; QUINONES, MA; FALLER, DV				RAKE, JB; QUINONES, MA; FALLER, DV			INHIBITION OF PLATELET-DERIVED GROWTH FACTOR-MEDIATED SIGNAL TRANSDUCTION BY TRANSFORMING RAS - SUPPRESSION OF RECEPTOR AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; ONCOGENE; PHOSPHOTYROSINE; PURIFICATION; ACTIVATION; ANTIBODY; BINDING; FAMILY	The function of ras protein and its relationship to growth-factor mediated signal transduction remain unclear. The demonstration that the expression of transforming ras (v-ras) can block the stimulation of growth-related gene expression and cell division mediated by the platelet-derived growth factor (PDGF) may provide a model for the functional interation of ras with growth factor receptors. In the current studies, we have demonstrated that this blockade by v-ras of PDGF-BB signal transduction occurs very early in signal transduction, at the level of PDGF receptor autophosphorylation. Although the expression of PDGF receptor as detected by Western blot with anti-PDGF receptor antibody was not diminished in v-ras-transformed murine Balb/c 3T3 fibroblasts, the autophosphorylation of PDGF receptor in response to ligand (recombinant PDGF-BB homodimer) stimulation was profoundly suppressed. This same phenomenon of v-ras-mediated PDGF receptor autophosphorylation inhibition was also demonstrated in normal rat kidney fibroblasts. Further, factor(s) present in v-ras-expressing fibroblasts found in the membrane fractions of these cells can dominantly inhibit the autophosphorylation of the PDGF receptor obtained from normal fibroblasts. These findings suggest a role for ras in one of the earliest steps of the signal transduction pathway.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,44 BINNEY ST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COHEN S, 1980, J BIOL CHEM, V255, P4834; DANIEL TO, 1985, P NATL ACAD SCI USA, V82, P2684, DOI 10.1073/pnas.82.9.2684; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUHN RD, 1987, P NATL ACAD SCI USA, V84, P4408, DOI 10.1073/pnas.84.13.4408; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PRICE BD, 1989, BIOCHEM J, V260, P157, DOI 10.1042/bj2600157; SIEFERT RA, 1989, J BIOL CHEM, V264, P8771; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	26	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5348	5352						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848245				2022-12-25	WOS:A1991FC21700097
J	SCHOENFELD, HJ; POESCHL, B; FREY, JR; LOETSCHER, H; HUNZIKER, W; LUSTIG, A; ZULAUF, M				SCHOENFELD, HJ; POESCHL, B; FREY, JR; LOETSCHER, H; HUNZIKER, W; LUSTIG, A; ZULAUF, M			EFFICIENT PURIFICATION OF RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-BETA FROM ESCHERICHIA-COLI YIELDS BIOLOGICALLY-ACTIVE PROTEIN WITH A TRIMERIC STRUCTURE THAT BINDS TO BOTH TUMOR-NECROSIS-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-PERMEATION CHROMATOGRAPHY; LYMPHOBLASTOID CELL-LINE; HUMAN LYMPHOTOXIN; FACTOR-ALPHA; FACTOR-BETA; CHROMOSOMAL LOCALIZATION; MOLECULAR-WEIGHT; COMPACT TRIMER; EXPRESSION; SCATTERING	A fast and efficient method for medium scale purification of recombinant human tumor necrosis factor-beta (rTNF-beta) from Escherichia coli cells is described. The purified rTNF-beta displayed biological activity similar to rTNF-alpha in a WEHI 164 cell cytotoxicity assay. The titration curve of rTNF-beta and elution profiles of rTNF-beta in gel filtration experiments were different from those of rTNF-alpha. However, light scattering and ultracentrifugation studies showed that both cytokines have trimeric structures in solution at 0.5 mg/ml, with minor differences in the distribution of nontrimeric species. rTNF-beta bound to purified 55- and 75-kDa TNF receptors with high affinity. The binding of rTNF-beta to either receptor was analyzed on Scatchard plots and compared with that of rTNF-alpha.	UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	University of Basel	SCHOENFELD, HJ (corresponding author), F HOFFMANN LA ROCHE & CO LTD,CTR CENT RES,CH-4002 BASEL,SWITZERLAND.							AGGARWAL BB, 1984, J BIOL CHEM, V259, P686; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2334; AGGARWAL BB, 1987, CIBA F SYMP, V131, P39; ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BRINGMAN TS, 1987, HYBRIDOMA, V6, P489, DOI 10.1089/hyb.1987.6.489; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROWNING J, 1989, J IMMUNOL, V143, P1859; CHERNYAK VY, 1982, ANAL BIOCHEM, V123, P110, DOI 10.1016/0003-2697(82)90630-3; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P1322, DOI 10.1021/bi00379a018; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HAINS JM, 1989, ARCH BIOCHEM BIOPHYS, V274, P417, DOI 10.1016/0003-9861(89)90454-2; HAKOSHIMA T, 1988, J MOL BIOL, V201, P455, DOI 10.1016/0022-2836(88)90153-2; HASS PE, 1985, J BIOL CHEM, V260, P2214; HIRANO K, 1989, J BIOCHEM-TOKYO, V105, P120, DOI 10.1093/oxfordjournals.jbchem.a122605; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHM KS, 1988, J BIOL RESP MODIF, V7, P267; LEWITBENTLEY A, 1988, J MOL BIOL, V199, P389, DOI 10.1016/0022-2836(88)90323-3; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOETSCHER H, 1991, IN PRESS TUMOR NECRO; NARHI LO, 1987, BIOCHEM BIOPH RES CO, V147, P740, DOI 10.1016/0006-291X(87)90992-2; NEDWIN GE, 1985, J CELL BIOCHEM, V29, P171, DOI 10.1002/jcb.240290302; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; PECK R, 1989, CELL IMMUNOL, V122, P1, DOI 10.1016/0008-8749(89)90143-3; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PETERSEN CM, 1989, EUR J IMMUNOL, V19, P1887, DOI 10.1002/eji.1830191020; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SREEKRISHNA K, 1989, BIOCHEMISTRY-US, V28, P4117, DOI 10.1021/bi00435a074; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; STUEBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TAVERNIER J, 1989, FEBS LETT, V257, P315, DOI 10.1016/0014-5793(89)81560-1; WAKABAYASHI T, 1990, J BIOL CHEM, V265, P7604; WINGFIELD P, 1987, FEBS LETT, V211, P179, DOI 10.1016/0014-5793(87)81432-1; YOSHIMURA T, 1988, BIOCHEM INT, V17, P1157	43	79	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3863	3869						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847389				2022-12-25	WOS:A1991EY68200077
J	GRABAU, C; SCHATT, E; JOUANNEAU, Y; VIGNAIS, PM				GRABAU, C; SCHATT, E; JOUANNEAU, Y; VIGNAIS, PM			A NEW [FE2-S2] FERREDOXIN FROM RHODOBACTER-CAPSULATUS - COEXPRESSION WITH A 2[FE4-S4] FERREDOXIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RHODOPSEUDOMONAS-CAPSULATA; NITROGEN-FIXATION; CLOSTRIDIUM-PASTEURIANUM; GENES; PROTEIN; PURIFICATION; EXPRESSION; CLONING; COMPLEX	A 285-base pair open reading frame was found immediately upstream of the fdxN gene (encoding ferredoxin I) of Rhodobacter capsulatus and coded for a 95-amino acid protein with a predicted molecular weight of 10,156. The deduced amino acid sequence contained 5 cysteines, 4 of which exhibited spacing characteristic of [2Fe-2S] plant and cyanobacterial ferredoxins. The amino acids sequence was found to share approximately 25% amino acids similarity with plant-type ferredoxins. The gene was named fdxC. Expression of the fdxC and fdxN genes together in Escherichia coli was accomplished by subcloning the genes in the vector pUC18 downstream of the lac promoter. Cells containing this plasmid produced a red and a brown protein corresponding to the fdxC and fdxN gene products, respectively. EPR and UV-visible absorption spectroscopy confirmed that the fdxC protein contained a [2Fe-2S] cluster and the FdxN protein contained two [4Fe-4S] clusters and that the centers were correctly assembled and inserted in the ferredoxins expressed in E. coli. Transcription (Northern blot) analysis showed that the genes were transcribed only under nitrogen-limiting (nif-derepressing) growth conditions.	CEN,DEPT BIOL MOLEC SCI,LBIO,BIOCHIM MICROBIENNE LAB,85X,F-38041 GRENOBLE,FRANCE									AVTGES P, 1985, MOL GEN GENET, V201, P363, DOI 10.1007/BF00331324; BOHME H, 1989, PLANT MOL BIOL, V12, P667, DOI 10.1007/BF00044157; BRILL WJ, 1974, ANAL BIOCHEM, V60, P237, DOI 10.1016/0003-2697(74)90149-3; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; BUCHANAN BB, 1970, ADV ENZYMOL REL S BI, V33, P119; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; DUPORT C, 1990, NUCLEIC ACIDS RES, V18, P4618, DOI 10.1093/nar/18.15.4618; HALLENBECK PC, 1982, BIOCHIM BIOPHYS ACTA, V681, P168, DOI 10.1016/0005-2728(82)90020-2; HASE T, 1977, FEBS LETT, V77, P308, DOI 10.1016/0014-5793(77)80257-3; HASE T, 1977, J BIOCHEM-TOKYO, V82, P267, DOI 10.1093/oxfordjournals.jbchem.a131679; HASE T, 1983, BIOCHIM BIOPHYS ACTA, V744, P46, DOI 10.1016/0167-4838(83)90338-2; HOWARD JB, 1983, J BIOL CHEM, V258, P508; JOUANNEAU Y, 1990, BIOCHEM BIOPH RES CO, V171, P273, DOI 10.1016/0006-291X(90)91388-9; JOUANNEAU Y, 1990, IN PRESS NITROGEN FI; KLIPP W, 1988, J BACTERIOL, V170, P693, DOI 10.1128/jb.170.2.693-699.1988; LUDDEN PW, 1978, BIOCHEM J, V175, P251, DOI 10.1042/bj1750251; MARRS B, 1974, P NATL ACAD SCI USA, V71, P971, DOI 10.1073/pnas.71.3.971; MATSUBARA H, 1980, UCLA FORUM MED SCI, V21, P245; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MEYER J, 1986, BIOCHEMISTRY-US, V25, P6054, DOI 10.1021/bi00368a033; MORENOVIVIAN C, 1989, J BACTERIOL, V171, P2591, DOI 10.1128/jb.171.5.2591-2598.1989; MORENOVIVIAN C, 1989, MOL GEN GENET, V216, P353, DOI 10.1007/BF00334376; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MOULIS JM, 1982, BIOCHEMISTRY-US, V21, P4762, DOI 10.1021/bi00262a037; ORMEJOHNSON WH, 1973, IRON SULFUR PROTEINS, V2, P195; SAEKI K, 1990, NUCLEIC ACIDS RES, V18, P1060, DOI 10.1093/nar/18.4.1060; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHATT E, 1989, J BACTERIOL, V171, P6218, DOI 10.1128/jb.171.11.6218-6226.1989; SCHATT E, 1989, THESIS GRENOBLE U 1; TAGAWA K, 1968, BIOCHIM BIOPHYS ACTA, V153, P602, DOI 10.1016/0005-2728(68)90188-6; YAKUNIN AF, 1983, BIOCHIM BIOPHYS ACTA, V725, P298, DOI 10.1016/0005-2728(83)90203-7; YAMANAKA T, 1967, BIOCHIM BIOPHYS ACTA, V131, P317, DOI 10.1016/0005-2728(67)90145-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUVAN DC, 1984, P NATL ACAD SCI-BIOL, V81, P189, DOI 10.1073/pnas.81.1.189	37	46	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3294	3299						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847145				2022-12-25	WOS:A1991EX60000093
J	DESIR, GV; CRAGOE, EJ; ARONSON, PS				DESIR, GV; CRAGOE, EJ; ARONSON, PS			HIGH-AFFINITY BINDING OF AMILORIDE ANALOGS AT AN INTERNAL SITE IN RENAL MICROVILLUS MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; BRUSH-BORDER; ANTIPORTER; TRANSPORT; INHIBITION; NUMBER; SYSTEM; CELL; LI+	Amiloride analogs with hydrophobic substitutions on the 5-amino nitrogen atom are relatively high affinity inhibitors of the plasma membrane Na+-H+ exchanger. We demonstrated that a high affinity-binding site for [H-3]5-(N-methyl-N-isobutyl)amiloride ([H-3]MIA) (K(d) = 6.3 nM, B(max) = 1.2 pmol/mg of protein) is present in microvillus membrane vesicles but not in basolateral membrane vesicles isolated from rabbit renal cortex, in accord with the known membrane localization of the Na+-H+ exchanger in this tissue. The rank order potency for inhibition of microvillus membrane [H-3]MIA binding by amiloride analogs was: MIA (I50 approximately 10 nM) > amiloride (I50 approximately 200 nM) > benzamil (I50 approximately 1200 nM). This correlated with a qualitatively similar rank order potency for inhibition of Na+-H+ exchange: MIA (I50 approximately 4-mu-M) > amiloride (I50 approximately 15-mu-M) > benzamil (I50 approximately 100-mu-M), but did not correlate with the rank order potency for inhibition of the organic cation-H+ exchanger in microvillus membrane vesicles: MIA almost-equal-to benzamil (I50 approximately 0.5-mu-M) > amiloride (I50 approximately 10-mu-M). However, tetraphenylammonium, an inhibitor of organic cation-H+ exchange, inhibited the rate of [H-3]MIA binding without an effect on equilibrium [H-3]MIA binding; the dissociation of bound [H-3]MIA was inhibited by preloading the membrane vesicles with tetraphenylammonium. These findings indicated that high affinity [H-3]MIA binding to renal microvillus membrane vesicles takes place at an internal site to which access is rate-limited by the tetraphenylammonium-sensitive organic cation transporter. Equilibrium [H-3]MIA binding was inhibited by H+ but was unaffected by concentrations of Na+ or Li+ that saturate the external transport site of the Na+-H+ exchanger. Binding of MIA to its high affinity binding site had no effect on the rate of Na+-H+ exchange. This study suggests that the renal Na+-H+ exchanger has a high affinity internal binding site for amiloride analogs that is distinct from the external amiloride inhibitory site.	YALE UNIV,SCH MED,DEPT MED,NEPHROL SECT,333 CEDAR ST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Yale University; Yale University					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM033793] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-33793] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1983, J BIOL CHEM, V258, P6767; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; CASSEL D, 1987, J BIOL CHEM, V262, P4587; DESIR GV, 1988, KIDNEY INT, V33, P399; DIXON SJ, 1987, J BIOL CHEM, V262, P3626; FRELIN C, 1987, KIDNEY INT, V32, P785, DOI 10.1038/ki.1987.277; GRASSL SM, 1986, J BIOL CHEM, V261, P8778; HARRIS RC, 1986, KIDNEY INT, V27, P310; IVES HE, 1983, J BIOL CHEM, V258, P9710; IVES HE, 1983, J BIOL CHEM, V258, P3513; KINSELLA JL, 1980, AM J PHYSIOL, V238, pF461, DOI 10.1152/ajprenal.1980.238.6.F461; KINSELLA JL, 1981, AM J PHYSIOL, V241, pC220, DOI 10.1152/ajpcell.1981.241.5.C220; KINSELLA JL, 1981, AM J PHYSIOL, V241, pF374, DOI 10.1152/ajprenal.1981.241.4.F374; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; TALOR Z, 1989, LIFE SCI, V45, P517, DOI 10.1016/0024-3205(89)90102-1; VIGNE P, 1984, EMBO J, V3, P2647, DOI 10.1002/j.1460-2075.1984.tb02188.x; VIGNE P, 1985, J BIOL CHEM, V260, P4120; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; WRIGHT SH, 1989, AM J PHYSIOL, V256, pF462, DOI 10.1152/ajprenal.1989.256.3.F462	22	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2267	2271						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846621				2022-12-25	WOS:A1991EV51500040
J	HURST, JK; LOEHR, TM; CURNUTTE, JT; ROSEN, H				HURST, JK; LOEHR, TM; CURNUTTE, JT; ROSEN, H			RESONANCE RAMAN AND ELECTRON-PARAMAGNETIC RESONANCE STRUCTURAL INVESTIGATIONS OF NEUTROPHIL CYTOCHROME-B558	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-TYPE CYTOCHROME; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST; NADPH OXIDASE; MICROBICIDAL OXIDASE; PARTIAL-PURIFICATION; REDOX POTENTIALS; PLASMA-MEMBRANE; CELL-LINE	The resonance Raman spectra of neutrophil cytochrome b558 obtained upon Soret excitation indicate that the heme is low spin six-coordinate in both ferric and ferrous oxidation states; comparison with the spectra of bis-imidazole hemin suggests imidazole or imidazolate axial ligation. Minor bands attributable to vibrational motions of ring-conjugated vinyl substituents were also observed, consistent with a heme assignment of protoporphyrin IX. The spectra of deoxycholate-solubilized cytochrome b558 were indistinguishable from neutrophil plasma membranes or specific granules, as were spectra from unstimulated and phorbol myristate acetate-stimulated cells, indicating that the hemes are structurally identical in various subcellular environments and cellular physiological states. However, structural complexity was suggested by biphasic ferric-ferrous photoreduction under 413-nm illumination and the absence of an EPR spectrum for the ferric heme under conditions where simple bis-imidazole heme-containing cytochromes are expected to give detectable signals. Midpoint reduction potentials and resonance Raman spectra of the soluble cytochrome b558 from an individual with cytochrome b558 positive (type IA.2) chronic granulomatous disease were nearly identical to normal oxidase, with the exception that the deficient oxidase did not undergo heme photoreduction. Possible structural models are discussed in relation to other physical properties (ligand binding, thermodynamic potentials) exhibited by the cytochrome.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SWEDISH MED CTR, DEPT MED, SEATTLE, WA 98104 USA	Scripps Research Institute; Swedish Medical Center	HURST, JK (corresponding author), OREGON GRAD INST SCI & TECHNOL, DEPT CHEM & BIOL SCI, 19600 NW VON NEUMANN DR, BEAVERTON, OR 97006 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838, R01AI025606, R01AI015834, R37AI025606] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15834, AI-24838, AI-25606] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON CW, 1979, ANAL BIOCHEM, V93, P366, DOI 10.1016/S0003-2697(79)80164-5; ANZENBACHER P, 1989, INORG CHEM, V28, P4491, DOI 10.1021/ic00324a013; BABCOCK GT, 1985, BIOCHIM BIOPHYS ACTA, V828, P58, DOI 10.1016/0167-4838(85)90009-3; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; BORREGAARD N, 1982, INFECT IMMUN, V38, P1301, DOI 10.1128/IAI.38.3.1301-1303.1982; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BUTLER J, 1982, J BIOL CHEM, V257, P747; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; CHOI SH, 1983, J AM CHEM SOC, V105, P3683, DOI 10.1021/ja00349a056; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CROSS AR, 1984, BIOCHEM J, V223, P337, DOI 10.1042/bj2230337; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DESBOIS A, 1989, BIOCHEMISTRY-US, V28, P8011, DOI 10.1021/bi00446a007; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; DOUSSIERE J, 1985, BIOCHEMISTRY-US, V24, P7231, DOI 10.1021/bi00346a032; Dutton P L, 1978, Methods Enzymol, V54, P411; EDWARDS SW, 1988, FEBS LETT, V227, P39, DOI 10.1016/0014-5793(88)81409-1; GABIG TG, 1985, J BIOL CHEM, V260, P3991; GARCIA RC, 1986, BIOCHEM J, V239, P647, DOI 10.1042/bj2390647; GAYDA JP, 1988, EUR J BIOCHEM, V177, P199, DOI 10.1111/j.1432-1033.1988.tb14362.x; HATATANAKA A, 1987, FEBS LETT, V214, P279, DOI 10.1016/0014-5793(87)80070-4; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; IKEDASAITO M, 1985, J BIOL CHEM, V260, P8301; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; KADISH KM, 1986, PROG INORG CHEM, V34, P435, DOI 10.1002/9780470166352.ch5; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KOBAYASHI S, 1990, BLOOD, V75, P458; KUILA D, 1985, BIOCHEMISTRY-US, V24, P3394, DOI 10.1021/bi00335a002; Lemberg R., 1973, CYTOCHROMES; LOEHR TM, 1979, ANAL BIOCHEM, V96, P456, DOI 10.1016/0003-2697(79)90606-7; LUTTER R, 1985, J BIOL CHEM, V260, P2237; MANTHEY JA, 1986, J BIOL CHEM, V261, P6734; MINO Y, 1988, J BIOL CHEM, V263, P7029; MOREL F, 1984, BIOCHIM BIOPHYS ACTA, V764, P213, DOI 10.1016/0005-2728(84)90030-6; NEWBURGER PE, 1984, J BIOL CHEM, V259, P3771; NUGENT JHA, 1989, BIOCHEM J, V264, P921, DOI 10.1042/bj2640921; OHLSSON PI, 1982, DEV BIOCHEM, V23, P805; OZAKI Y, 1978, BIOCHEMISTRY-US, V17, P5826, DOI 10.1021/bi00619a033; PALMER G, 1979, PORPHYRINS, V4; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1984, J BIOL CHEM, V259, P590; ROBERTS PJ, 1982, J CELL BIOL, V95, P720, DOI 10.1083/jcb.95.3.720; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SCHULTZ J, 1980, RETICULOENDOTHELIAL, V2; SEE EG, 1986, OXIDATION METALS ASS, P185; SEGAL AW, 1979, BIOCHEM J, V182, P181, DOI 10.1042/bj1820181; SEGAL AW, 1979, BIOCHEM BIOPH RES CO, V88, P130, DOI 10.1016/0006-291X(79)91706-6; SEGAL AW, 1981, BIOCHEM J, V196, P363, DOI 10.1042/bj1960363; SIBBETT SS, 1984, BIOCHEMISTRY-US, V23, P3007, DOI 10.1021/bi00308a025; SPIRO TG, 1983, IRON PORPHYRINS, V2, P91; TERAOKA J, 1981, J BIOL CHEM, V256, P3969; VARADARAJAN R, 1989, SCIENCE, V243, P69, DOI 10.1126/science.2563171; WEST BC, 1974, AM J PATHOL, V77, P41; WEVER R, 1980, BIOCHIM BIOPHYS ACTA, V612, P178, DOI 10.1016/0005-2744(80)90291-0; YAMADA H, 1975, ARCH BIOCHEM BIOPHYS, V169, P344, DOI 10.1016/0003-9861(75)90350-1; YAMAGUCHI T, 1989, J BIOL CHEM, V264, P112	64	89	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1627	1634						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846361				2022-12-25	WOS:A1991EU49700043
J	CHU, S; CAVAIGNAC, S; FEUTRIER, J; PHIPPS, BM; KOSTRZYNSKA, M; KAY, WW; TRUST, TJ				CHU, S; CAVAIGNAC, S; FEUTRIER, J; PHIPPS, BM; KOSTRZYNSKA, M; KAY, WW; TRUST, TJ			STRUCTURE OF THE TETRAGONAL SURFACE VIRULENCE ARRAY PROTEIN AND GENE OF AEROMONAS-SALMONICIDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; S-LAYER; CAMPYLOBACTER-FETUS; SECONDARY-STRUCTURE; CODON-CHOICE; A-LAYER; HYDROPHILA; EXPRESSION	The paracrystalline surface protein array of the pathogenic bacterium Aeromonas salmonicida is a primary virulence factor with novel binding capabilities. The species-specific structural gene (vapA) for this array protein (A-protein) was cloned into lambda-gt11 but was unstable when expressed in Escherichia coli, undergoing an 816-base pair deletion due to a 21-base pair direct repeat within the gene. However, the gene was stable in cosmid pLA2917 as long as expression was poor. A-protein was located in the cytoplasmic, inner membrane and periplasmic fractions in E. coli. The DNA sequence revealed a 1,506-base pair open reading frame encoding a protein consisting of a 21-amino acid signal peptide, and a 481-residue 50,778 molecular weight protein containing considerable secondary structure. When assembled into a paracrystalline protein array on Aeromonas the cell surface A-protein was totally refractile to cleavage by trypsin, but became trypsin sensitive when disassembled. Trypsin cleavage of the isolated protein provided evidence that both the NH2- and COOH-terminal regions form distinct structural domains, consistent with three-dimensional ultrastructural evidence. The NH2-terminal 274-residue domain remained refractile to trypsin activity. This segment connects by a trypsin and CNBr-sensitive 78-residue linker region to a COOH-terminal 129-residue fragment which could apparently refold into a partially trypsin-resistant structure after cleavage at residue 323.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA; UNIV VICTORIA,CANADIAN BACTERIAL DIS NETWORK,VICTORIA V8W 3P6,BC,CANADA	University of Victoria; University of Victoria			Phipps, Barry M/F-2388-2013					AIZAWA SI, 1990, J MOL BIOL, V211, P673, DOI 10.1016/0022-2836(90)90064-S; ALLEN LN, 1985, J BACTERIOL, V161, P955, DOI 10.1128/JB.161.3.955-962.1985; AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; BARRANTES FJ, 1975, BIOCHEM BIOPH RES CO, V62, P407, DOI 10.1016/S0006-291X(75)80153-7; BELLAND RJ, 1985, J BACTERIOL, V163, P877, DOI 10.1128/JB.163.3.877-881.1985; BELLAND RJ, 1987, J BACTERIOL, V169, P4086, DOI 10.1128/jb.169.9.4086-4091.1987; BELLAND RJ, 1988, J GEN MICROBIOL, V170, P499; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLASER MJ, 1990, J BIOL CHEM, V265, P14529; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BURNS DM, 1986, NUCLEIC ACIDS RES, V14, P4352; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DOOLEY JSG, 1989, J BACTERIOL, V171, P190, DOI 10.1128/jb.171.1.190-197.1989; DUBREUIL JD, 1990, J BACTERIOL, V172, P5035, DOI 10.1128/jb.172.9.5035-5043.1990; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOBIUS KS, 1988, J BACTERIOL, V170, P1325, DOI 10.1128/jb.170.3.1325-1332.1988; Gros E., 1967, METHOD ENZYMOL, V11, P238; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOWARD SP, 1987, J BACTERIOL, V169, P2869, DOI 10.1128/jb.169.6.2869-2871.1987; IKEMURA T, 1982, COLD SPRING HARB SYM, V47, P1087, DOI 10.1101/SQB.1983.047.01.123; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; ISHIGURO EE, 1981, J BACTERIOL, V148, P333, DOI 10.1128/JB.148.1.333-340.1981; ISHIGURO EE, 1986, APPL ENVIRON MICROB, V51, P668, DOI 10.1128/AEM.51.3.668-670.1986; KAY WW, 1981, J BACTERIOL, V147, P1077, DOI 10.1128/JB.147.3.1077-1084.1981; KAY WW, 1984, CAN J BIOCHEM CELL B, V62, P1064, DOI 10.1139/o84-137; KAY WW, 1985, J BACTERIOL, V164, P1332, DOI 10.1128/JB.164.3.1332-1336.1985; KORN LJ, 1977, P NATL ACAD SCI USA, V74, P4401, DOI 10.1073/pnas.74.10.4401; KOVAL SF, 1988, CAN J MICROBIOL, V34, P407, DOI 10.1139/m88-072; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER J, 1987, J BIOL CHEM, V262, P9724; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; McCarthy D. H., 1980, Advances in Aquatic Microbiology, V2, P293; MUNN CB, 1982, INFECT IMMUN, V36, P1069, DOI 10.1128/IAI.36.3.1069-1075.1982; MURRAY RGE, 1988, J BACTERIOL, V170, P2625, DOI 10.1128/jb.170.6.2625-2630.1988; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERS J, 1989, J BACTERIOL, V171, P6307, DOI 10.1128/jb.171.11.6307-6315.1989; PETERS J, 1986, J BACTERIOL, V167, P1048, DOI 10.1128/jb.167.3.1048-1054.1986; PHIPPS BM, 1983, BIOCHEMISTRY-US, V22, P2934, DOI 10.1021/bi00281a023; PHIPPS BM, 1988, J BIOL CHEM, V263, P9298; PRIEFER U, 1984, ADV MOL GENETICS, P190; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saxton W O, 1986, J Mol Biol, V187, P251, DOI 10.1016/0022-2836(86)90232-9; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SLEYTR UB, 1988, J BACTERIOL, V170, P2891, DOI 10.1128/jb.170.7.2891-2897.1988; SLEYTR UB, 1986, SYST APPL MICROBIOL, V7, P310; STEWART M, 1986, J BACTERIOL, V166, P120, DOI 10.1128/jb.166.1.120-127.1986; THORNTON J, 1988, BIOCHIM BIOPHYS ACTA, V959, P153, DOI 10.1016/0005-2760(88)90026-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUST TJ, 1983, CURR MICROBIOL, V9, P315, DOI 10.1007/BF01588826; TRUST TJ, 1986, ANNU REV MICROBIOL, V40, P479, DOI 10.1146/annurev.mi.40.100186.002403; TSUBOI A, 1986, J BACTERIOL, V168, P365, DOI 10.1128/jb.168.1.365-373.1986; UDEY LR, 1978, MAR FISH REV, V40, P12; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONDERVISZT F, 1990, J MOL BIOL, V214, P97, DOI 10.1016/0022-2836(90)90149-G; VONDERVISZT F, 1989, J MOL BIOL, V209, P127, DOI 10.1016/0022-2836(89)90176-9; WILLIS RC, 1974, ARCH BIOCHEM BIOPHYS, V161, P64, DOI 10.1016/0003-9861(74)90235-5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUDERIAN P, 1982, CELL, V30, P843, DOI 10.1016/0092-8674(82)90289-6; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	65	104	108	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15258	15265						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869553				2022-12-25	WOS:A1991GB09700067
J	RUNDLE, SJ; ZIELINSKI, RE				RUNDLE, SJ; ZIELINSKI, RE			ALTERATIONS IN BARLEY RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE ACTIVASE GENE-EXPRESSION DURING DEVELOPMENT AND IN RESPONSE TO ILLUMINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORDEUM-VULGARE-L; RUBISCO ACTIVASE; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; CIRCADIAN-RHYTHM; LIGHT; PURIFICATION; PROTEINS; NUCLEAR; CALMODULIN	Two genes encode Rbu-P2-carboxylase activase in barley (RcaA and RcaB): RcaA encodes polypeptides of 46 and 42 kDa, which are generated by the alternatively spliced RcaA1 and RcaA2 mRNAs, respectively; RcaB encodes a 42-kDa polypeptide (Rundle, S. J., and Zielinski, R. E. (1991) J. Biol. Chem. 266, 4677-4685). In the cellular differentiation gradient of the first leaf of barley, the three Rca mRNAs accumulate differentially. RcaA1 and A2 mRNAs accumulate predominantly in the mature, most photosynthetically active regions of the leaf in a pattern that parallels accumulation of total Rbu-P2-carboxylase activase protein. However, the kinetics of accumulation of RcaA1 and RcaA2 mRNA differ slightly, indicating that either changes in RcaA pre-mRNA splicing or mRNA turnover occur during development. RcaB mRNA, in contrast, accumulates in the youngest and oldest cell populations at the base and tip of the leaf, respectively. In the mid-region of the leaf, the difference in accumulation between RcaA and RcaB mRNAs is largely attributable to differences in the rates of transcription of the two Rca genes. In this region of the leaf, the three Rca mRNAs accumulate differentially throughout the course of the diurnal cycle. Steady state levels of the three Rca mRNA species increase in parallel in response to increasing irradiance; these changes were accompanied by increased Rbu-P2-carboxylase activase protein accumulation.	UNIV ILLINOIS,DEPT PLANT BIOL,289 MORRILL HALL,505 S GOODWIN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign				Zielinski, Ray/0000-0003-0324-7407				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BROGLIE R, 1983, BIO-TECHNOL, V1, P55, DOI 10.1038/nbt0383-55; CASHMORE AR, 1982, METHODS CHLOROPLAST, P387; CHITNIS PR, 1988, PLANT MOL BIOL, V11, P95, DOI 10.1007/BF00015663; GIULIANO G, 1988, EMBO J, V7, P3635, DOI 10.1002/j.1460-2075.1988.tb03244.x; GOLDSBROUGH PB, 1981, NUCLEIC ACIDS RES, V9, P1301, DOI 10.1093/nar/9.6.1301; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KLOPPSTECH K, 1985, PLANTA, V165, P502, DOI 10.1007/BF00398095; KOBZA J, 1989, PLANT PHYSIOL, V89, P918, DOI 10.1104/pp.89.3.918; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING V, 1989, PLANT PHYSIOL, V90, P714, DOI 10.1104/pp.90.2.714; MCINTOSH L, 1980, NATURE, V288, P556, DOI 10.1038/288556a0; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; PERCHOROWICZ JT, 1981, P NATL ACAD SCI-BIOL, V78, P2985, DOI 10.1073/pnas.78.5.2985; PIECHULLA B, 1987, EMBO J, V6, P3593, DOI 10.1002/j.1460-2075.1987.tb02690.x; PORTIS AR, 1990, BIOCHIM BIOPHYS ACTA, V1015, P15, DOI 10.1016/0005-2728(90)90211-L; REDINBAUGH MG, 1990, P NATL ACAD SCI USA, V87, P6853, DOI 10.1073/pnas.87.17.6853; ROBINSON SP, 1988, PLANT PHYSIOL, V88, P1008, DOI 10.1104/pp.88.4.1008; RUNDLE SJ, 1991, J BIOL CHEM, V266, P4677; SALVUCCI ME, 1987, PLANT PHYSIOL, V84, P930, DOI 10.1104/pp.84.3.930; STAYTON MM, 1989, PLANT PHYSIOL, V89, P776, DOI 10.1104/pp.89.3.776; TAYLOR WC, 1989, PLANT CELL, V1, P259, DOI 10.1105/tpc.1.2.259; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLING L, 1986, P NATL ACAD SCI USA, V83, P2123, DOI 10.1073/pnas.83.7.2123; WEBBER AN, 1986, PLANT CELL ENVIRON, V9, P203, DOI 10.1111/1365-3040.ep11611647; ZIELINSKI RE, 1987, PLANT PHYSIOL, V84, P937, DOI 10.1104/pp.84.3.937; ZIELINSKI RE, 1989, PLANT PHYSIOL, V90, P516, DOI 10.1104/pp.90.2.516	28	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14802	14807						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860876				2022-12-25	WOS:A1991FZ35100104
J	TAKUWA, N; KUMADA, M; YAMASHITA, K; TAKUWA, Y				TAKUWA, N; KUMADA, M; YAMASHITA, K; TAKUWA, Y			MECHANISMS OF BOMBESIN-INDUCED ARACHIDONATE MOBILIZATION IN SWISS 3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; CANINE KIDNEY-CELLS; GTP-BINDING PROTEINS; PHOSPHOLIPASE-C; ACID RELEASE; PHORBOL ESTER; PROSTAGLANDIN SYNTHESIS; ENDOTHELIAL-CELLS; GROWTH-FACTOR; POLYPHOSPHOINOSITIDE HYDROLYSIS	A peptide mitogen bombesin, which activates the phospholipase C-protein kinase C signaling pathway, induces a mepacrine-sensitive, dose-dependent increase in the release of [H-3]arachidonic acid and its metabolites ([H-3]AA) from prelabeled Swiss 3T3 fibroblasts. The effect is temporally composed of two phases, i.e. an initial transient burst that is essentially independent of extracellular Ca2+, and a following sustained phase that is absolutely dependent on the extracellular Ca2+. The initial transient [H-3]AA liberation occurs concomitantly with bombesin-induced Ca-45 efflux from prelabeled cells: both responses being substantially attenuated by loading cells with a Ca2+ chelator quin2. However, bombesin-induced intracellular Ca2+ mobilization by itself is not sufficient as a signal for the initial transient [H-3]AA liberation, since A23187 potently stimulates Ca-45 efflux to an extent comparable to bombesin but fails to induce [H-3]AA release in the absence of extracellular Ca2+. The second sustained phase of the bombesin-induced [H-3]AA release is abolished by reducing extracellular Ca2+ to 0.03 mM, although bombesin effects on phospholipase C and protein kinase C activation are barely affected by the same procedure. A protein kinase C activator phorbol 12,13-dibutyrate induces an extracellular Ca2+-dependent, slowly developing sustained increase in [H-3]AA release, and markedly potentiates both phases of bombesin-induced [H-3]AA release. Downregulation of cellular protein kinase C completely abolishes all of the effects of phorbol dibutyrate, and partially inhibits the second but not the first phase of bombesin-induced [H-3]AA release. These results indicate that bombesin-induced receptor-mediated activation of phospholipase A2 involves multiple mechanisms, including intracellular Ca2+ mobilization for the first phase, protein kinase C activation plus Ca2+ influx for the second phase, and as yet unknown mechanism(s) independent of intracellular Ca2+ mobilization or protein kinase C for both of the phases.	UNIV TSUKUBA,INST CLIN MED,DEPT INTERNAL MED,SAKURA,IBARAKI 305,JAPAN	University of Tsukuba	TAKUWA, N (corresponding author), UNIV TOKYO,FAC MED,DEPT PHYSIOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.			TAKUWA, Noriko/0000-0002-4278-2704				ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; AUSIELLO DA, 1984, BIOCHEM J, V220, P139, DOI 10.1042/bj2200139; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BONVENTRE JV, 1988, J CLIN INVEST, V82, P168, DOI 10.1172/JCI113566; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; BURCH RM, 1988, J BIOL CHEM, V263, P4764; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHARDONNENS D, 1990, J BIOL CHEM, V265, P10451; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; COYNE DW, 1989, BIOCHEM BIOPH RES CO, V161, P1333, DOI 10.1016/0006-291X(89)91389-2; DARTOIS E, 1986, BIOCHEM BIOPH RES CO, V138, P323, DOI 10.1016/0006-291X(86)90283-4; DEGEORGE JJ, 1987, J BIOL CHEM, V262, P8077; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; FELDER CC, 1990, P NATL ACAD SCI USA, V87, P2187, DOI 10.1073/pnas.87.6.2187; FISCHER JB, 1988, J BIOL CHEM, V263, P2808; FORST S, 1986, BIOCHEMISTRY-US, V25, P8381, DOI 10.1021/bi00374a008; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GODSON C, 1990, J BIOL CHEM, V265, P8369; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V104, P767, DOI 10.1093/oxfordjournals.jbchem.a122547; HO AK, 1987, J BIOL CHEM, V262, P11764; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; KAYA H, 1989, J BIOL CHEM, V264, P4972; KHANNA NC, 1986, BIOCHEM BIOPH RES CO, V141, P574; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; LAPETINA EG, 1982, TRENDS PHARMACOL SCI, V3, P115, DOI 10.1016/0165-6147(82)91046-X; MOBLEY A, 1985, BIOCHEM BIOPH RES CO, V130, P717, DOI 10.1016/0006-291X(85)90475-9; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; MURAYAMA T, 1985, J BIOL CHEM, V260, P7226; ONO T, 1988, J BIOL CHEM, V263, P5732; PARKER J, 1987, J BIOL CHEM, V262, P5385; RESINK TJ, 1987, BIOCHEM BIOPH RES CO, V144, P443; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; TAKUWA N, 1988, J BIOL CHEM, V263, P9738; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TOJO H, 1988, J BIOL CHEM, V263, P5724; VOLPI M, 1985, BIOCHEM BIOPH RES CO, V128, P594, DOI 10.1016/0006-291X(85)90087-7; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1	53	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14237	14243						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860838				2022-12-25	WOS:A1991FZ35100021
J	HOMMA, T; HARRIS, RC				HOMMA, T; HARRIS, RC			TIME-DEPENDENT BIPHASIC REGULATION OF NA+/K+/CL- COTRANSPORT IN RAT GLOMERULAR MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 BUMETANIDE BINDING; K-CL COTRANSPORT; CO-TRANSPORT SYSTEM; POTASSIUM FLUX PATHWAYS; KIDNEY OUTER MEDULLA; NA/K/2CL COTRANSPORT; ENDOTHELIAL-CELLS; ACTIVATION; MEMBRANES; SITE	Time-dependent regulation of loop diuretic-sensitive Na+/K+/Cl- cotransport and [H-3]bumetanide binding was investigated in cultured rat glomerular mesangial cells. Angiotensin 11 or epidermal growth factor induced stimulation of Na+/K+/Cl-cotransport within 5 min, with a return to the control values by 30 min. Treatment of cells with phorbol 12-myristate 13-acetate (0.1-mu-m) (PMA), the calcium ionophore A23187 (1-mu-M), or the combination of 5 mm NaF and 10-mu-m AlCl3 produced a transient stimulation of Na+/K+/Cl- cotransport in 5-10 min to 148, 135, and 163% of control, respectively, which was followed by a progressive decrease to 34, 64, and 20% of the base-line activity, respectively, by 60 min. Exposure to cyclic 8-bromo-AMP (0.1 mM) or to forskolin (1-mu-m) and isobutylmethylxanthine (0.1 mm) caused a maximal inhibition of the cotransport in 5 min to 79 and 60% of control, respectively, with a subsequent gradual increase to 137 and 164% of the base-line activity, respectively, by 60 min. The effects of PMA, forskolin, and cyclic 8-bromo-AMP were concentration-dependent. In order to characterize further the alterations in the cotransport activity, binding of [H-3]bumetanide was determined. Saturation binding analyses showed that the late inhibition of the cotransport by PMA and stimulation by forskolin were associated with a significant decrease and increase, respectively, in B(max), with no significant changes in binding affinity. Correlations between changes in the cotransport activity and [H-3]bumetanide binding were also observed in cells treated with cyclic 8-bromo-AMP or with NaF and AlCl3. Incubation of cells in Cl- or Na+ free solution greater-than-or-equal-to 60 min resulted in an increase in both the cotransport activity and [H-3]bumetanide binding. These observations indicate that, in glomerular mesangial cells, persistent stimulation of second messengers that regulate the cotransporter induces a time-dependent, biphasic regulation of Na+/K+/Cl- cotransport and that the regulation occurring after greater-than-or-equal-to 60 min of treatment is primarily due to changes in the number of the active cotransport sites. Because long term removal of the transported ions also increases the number of active cotransport sites, these results suggest that alterations in intracellular ionic homeostasis may also mediate cotransport activity.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV NEPHROL,MED CTR N S-3223,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT PEDIAT,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, P01DK038226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38226, DK39261] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHIPPERFIELD AR, 1986, CLIN SCI, V71, P465, DOI 10.1042/cs0710465; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1, DOI 10.1152/ajprenal.1987.252.1.F1; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; FRANKLIN CC, 1989, J BIOL CHEM, V264, P6667; GIESENCROUSE EM, 1987, J BIOL CHEM, V262, P17393; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HAAS M, 1983, AM J PHYSIOL, V245, pC235, DOI 10.1152/ajpcell.1983.245.3.C235; HANNAFIN J, 1983, J MEMBRANE BIOL, V75, P73, DOI 10.1007/BF01870801; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HOFFMANN EK, 1986, AM J PHYSIOL, V250, pC688, DOI 10.1152/ajpcell.1986.250.5.C688; HOMMA T, 1990, J BIOL CHEM, V265, P17613; HOMMA T, 1990, AM J PHYSIOL, V258, pC862, DOI 10.1152/ajpcell.1990.258.5.C862; HOMMA T, 1990, J AM SOC NEPHROL, V1, P472; KLEIN JD, 1990, J BIOL CHEM, V265, P22238; KLEIN JD, 1990, J AM SOC NEPHROL, V1, P722; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ODONNELL ME, 1988, AM J PHYSIOL, V255, pC169, DOI 10.1152/ajpcell.1988.255.2.C169; ODONNELL ME, 1989, J BIOL CHEM, V264, P20326; ODONNELL ME, 1989, AM J PHYSIOL, V257, pC36, DOI 10.1152/ajpcell.1989.257.1.C36; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OGRADY SM, 1987, J MEMBRANE BIOL, V96, P11, DOI 10.1007/BF01869330; PARIS S, 1987, J BIOL CHEM, V262, P1977; PARIS S, 1986, J BIOL CHEM, V261, P6177; PEWITT EB, 1990, J BIOL CHEM, V265, P14364; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; TURNER RJ, 1988, J MEMBRANE BIOL, V102, P71, DOI 10.1007/BF01875354; TURNER RJ, 1990, J MEMBRANE BIOL, V113, P2203; WIENER H, 1989, J MEMBRANE BIOL, V110, P163, DOI 10.1007/BF01869471	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13553	13559						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856192				2022-12-25	WOS:A1991FY02700018
J	MEDH, JD; WEIGEL, PH				MEDH, JD; WEIGEL, PH			RECONSTITUTION OF GALACTOSYL RECEPTOR INACTIVATION IN PERMEABILIZED RAT HEPATOCYTES IS ATP-DEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID-PHASE ENDOCYTOSIS; ASIALOGLYCOPROTEIN RECEPTOR; MEDIATED ENDOCYTOSIS; LIGAND DISSOCIATION; REVERSIBLE INACTIVATION; ALVEOLAR MACROPHAGES; ASIALO-GLYCOPROTEINS; INSULIN-RECEPTOR; HEPATOMA-CELLS; BINDING	A subpopulation of galactosyl receptors (GalRs) on isolated rat hepatocytes undergo a reversible inactivation and reactivation process during constitutive recycling (McAbee, D. D., and Weigel, P. H. (1988) Biochemistry 27, 2061-2069). Here, we report the reconsitution of this GalR inactivation in digitonin-permeabilized rat hepatocytes. Permeabilization of freshly isolated cells at 4-degrees-C with 0.002% (w/v) digitonin releases cytosol containing 35-40% of the total cellular protein, 10-15% of a lysosomal marker, and 5-10% of an early endosomal marker. Incubation of permeabilized cells with cytosol at 37-degrees-C results in a time-dependent reduction of total I-125-asialoorosomucoid binding activity, which proceeds with first order kinetics (t 1/2 = 11.3 min). Only half of the total cellular GalRs are affected; maximal GalR activity loss, obtained by 30 min, is 50.5 +/- 9.5% (n = 21) of the control (4-degrees-C) value. Increasing the digitonin concentration up to 0.055% does not increase the extent of inactivation. Permeabilized cells with reduced GalR activity were assessed for GalR protein content by Western blot analysis and by binding of anti-GalR antibody. The results show that the reduced I-125-asialoorosomucoid binding is due to GalR inactivation rather than receptor protein degradation. GalR inactivation does not occur in the absence of cytosol or in the presence of dialyzed cytosol. The cytosol also loses its GalR inactivating ability in the presence of an ATP-depleting system. GalR inactivation in the absence of cytosol is achieved by incubating permeabilized washed cells at 37-degrees-C with ATP but not with ADP, AMP, or other NTPs. The rate and extent of inactivation are dependent on the ATP concentration. Half-maximal and maximal GalR inactivation are obtained at 0.3 and 3.0 mM ATP, respectively. In the presence of cytosol, permeabilized hepatocytes could replenish cytosolic ATP by oxidative phosphorylation. As a result, similar levels of GalR inactivation were obtained with 500-fold lower ATP concentrations. We conclude that ATP is the only cytosolic component necessary for GalR inactivation in permeabilized rat hepatocytes.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT HUMAN BIOL CHEM & GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030218] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30218] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURICCHIO F, 1986, J STEROID BIOCHEM, V24, P39, DOI 10.1016/0022-4731(86)90029-4; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BERG T, 1983, EXP CELL RES, V148, P319, DOI 10.1016/0014-4827(83)90156-8; BOLDT DH, 1987, J CELL PHYSIOL, V132, P331, DOI 10.1002/jcp.1041320219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CLARKE BL, 1985, J BIOL CHEM, V260, P128; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DIAZ R, 1989, BIOCHEM J, V260, P127, DOI 10.1042/bj2600127; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, METHOD CELL BIOL, V31, P25; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; DRISCOLL WJ, 1990, J BIOL CHEM, V265, P12306; FIETE D, 1983, J BIOL CHEM, V258, P817; FISHMAN JB, 1986, J BIOL CHEM, V261, P5810; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GUDAS JM, 1986, J CELL PHYSIOL, V128, P449, DOI 10.1002/jcp.1041280314; Hall C W, 1978, Methods Enzymol, V50, P439; HARFORD J, 1983, J CELL BIOL, V96, P1824, DOI 10.1083/jcb.96.6.1824; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; KAPLAN J, 1981, CELL, V24, P925, DOI 10.1016/0092-8674(81)90118-5; KAPLAN J, 1981, SCIENCE, V212, P14, DOI 10.1126/science.6259730; KATZ J, 1985, J CELL BIOCHEM, V28, P207, DOI 10.1002/jcb.240280304; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; LABARCA C, 1980, ANAL CHEM, V133, P437; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; MCABEE DD, 1989, BIOCHEM BIOPH RES CO, V161, P261, DOI 10.1016/0006-291X(89)91589-1; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MCABEE DD, 1990, J BIOL CHEM, V265, P629; MICK GJ, 1988, J BIOL CHEM, V263, P10667; MOONEY RA, 1983, EUR J BIOCHEM, V136, P603, DOI 10.1111/j.1432-1033.1983.tb07783.x; MOONEY RA, 1988, METHOD ENZYMOL, V159, P193; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MOONEY RA, 1989, BIOCHEM BIOPH RES CO, V162, P1200, DOI 10.1016/0006-291X(89)90801-2; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; OKA JA, 1989, J BIOL CHEM, V264, P12016; OKA JA, 1983, J BIOL CHEM, V258, P253; OKA JA, 1988, J CELL BIOCHEM, V36, P169, DOI 10.1002/jcb.240360208; OKA JA, 1987, J CELL PHYSIOL, V133, P243, DOI 10.1002/jcp.1041330207; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; SCARMATO P, 1986, BIOL CELL, V56, P255, DOI 10.1111/j.1768-322X.1986.tb00457.x; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SHEPHERD VL, 1990, J IMMUNOL, V145, P1530; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; TIETZE C, 1980, BIOCHEM BIOPH RES CO, V93, P1, DOI 10.1016/S0006-291X(80)80237-3; TOLLESHAUG H, 1979, BIOCHEM PHARMACOL, V28, P2919, DOI 10.1016/0006-2952(79)90586-0; TOLLESHAUG H, 1985, BIOCHEM PHARMACOL, V34, P1639, DOI 10.1016/0006-2952(85)90628-8; TUURENDONK PF, 1974, BIOCH BIOPHY ACTA, V333, P393; VENTURA MA, 1987, EXP CELL RES, V170, P290, DOI 10.1016/0014-4827(87)90307-7; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; WEIGEL PH, 1975, J BIOL CHEM, V250, P8536; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1986, BIOCHEM BIOPH RES CO, V140, P43, DOI 10.1016/0006-291X(86)91055-7; WEIGEL PH, 1987, VERTEBRATE LECTINS, P65; WILEMAN T, 1985, J BIOL CHEM, V260, P7387; ZIJDERHANDBLEEKEMOLEN JE, 1987, J CELL BIOL, V104, P1647, DOI 10.1083/jcb.104.6.1647	62	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8771	8778						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851157				2022-12-25	WOS:A1991FM03800024
J	CHOE, YS; DEMONTELLANO, PRO				CHOE, YS; DEMONTELLANO, PRO			DIFFERENTIAL ADDITIONS TO THE MYOGLOBIN PROSTHETIC HEME GROUP - OXIDATIVE GAMMA-MESO SUBSTITUTION BY ALKYLHYDRAZINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-PHENYLPROTOPORPHYRIN-IX; HORSERADISH-PEROXIDASE; ARYL-IRON; CATALYTIC MECHANISM; SUBSTRATE OXIDATION; PROTEIN ADDUCTS; SODIUM-AZIDE; INACTIVATION; CYTOCHROME-P-450; HEMOGLOBIN	The oxidative reaction of equine myoglobin with alkylhydrazines results primarily in introduction of the alkyl group at the sterically hindered gamma-meso position. The gamma-meso adducts formed with ethyl- and n-butylhydrazine have been isolated and unambiguously identified. With high pressure liquid chromatography, evidence for the formation of similar adducts with methyl- and n-propylhydrazine but not tert-butyl-, 2,2,2-trifluoroethyl-, or 2-phenylethylhydrazine has also been obtained. The gamma-regiospecificity of the reaction of myoglobin with alkylhydrazines contrasts with the delta-meso regiospecificity in the alkylation of peroxidases. Addition to the porphyrin vinyl groups is not detected, but N-alkylheme adducts appear to be formed in very low yield. Cofactor studies establish that H2O2 is absolutely required for meso heme alkylation and EPR/spin trapping studies show that alkyl free radicals are the probable alkylating species. In contrast, the reductive reaction of sperm whale myoglobin with CBrCl3 results in addition of the CCl3. radical to the 2-vinyl moiety of the heme group (Osawa, Y., Highet, R. J., Murphy, C. M., Cotter, R. J., and Pohl, L. R. (1989) J. Am. Chem. Soc. 111, 4462-4467). Carbon radicals thus apparently add to different sites of the myoglobin prosthetic group under reductive and oxidative conditions, presumably because of differences in the oxidation state of the heme and/or the intrinsic reactivities of alkyl and polyhaloalkyl radicals.			CHOE, YS (corresponding author), UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDDK NIH HHS [DK 30297] Funding Source: Medline; NIGMS NIH HHS [GM 32488] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1989, J BIOL CHEM, V264, P9250; ATOR MA, 1987, J BIOL CHEM, V262, P1542; AUGUSTO O, 1982, J BIOL CHEM, V257, P1288; AUGUSTO O, 1982, J BIOL CHEM, V257, P6231; BONDOC LL, 1989, J BIOL CHEM, V264, P6134; BORNHEIM LM, 1987, MOL PHARMACOL, V32, P299; CATALANO CE, 1987, BIOCHEMISTRY-US, V26, P8373, DOI 10.1021/bi00399a052; CHU KC, 1980, BASIS MED CHEM BUR 1; CORREIA MA, 1989, DRUG METAB REV, V20, P615, DOI 10.3109/03602538909103565; DAVIES HW, 1986, ARCH BIOCHEM BIOPHYS, V244, P387, DOI 10.1016/0003-9861(86)90128-1; DAVIES HW, 1986, CHEM-BIOL INTERACT, V58, P345, DOI 10.1016/S0009-2797(86)80108-9; DELAFORGE M, 1986, CHEM-BIOL INTERACT, V60, P101, DOI 10.1016/0009-2797(86)90020-7; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P558; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1988, BIOCHEMISTRY-US, V27, P5470, DOI 10.1021/bi00415a013; DEMONTELLANO PRO, 1990, PHARMACOL THERAPEUT, V48, P95, DOI 10.1016/0163-7258(90)90020-3; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P8623; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P45; DEMONTELLANO PRO, 1985, BIOCHEMISTRY-US, V24, P1147, DOI 10.1021/bi00326a013; DEPILLIS GD, 1989, BIOCHEMISTRY-US, V28, P7947, DOI 10.1021/bi00445a059; DOYLE MP, 1987, INORG CHEM, V26, P3387, DOI 10.1021/ic00267a035; EVANS SV, 1988, J BIOL CHEM, V263, P4263; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P800; GALARIS D, 1989, ARCH BIOCHEM BIOPHYS, V273, P497, DOI 10.1016/0003-9861(89)90509-2; GRILLER D, 1989, PURE APPL CHEM, V61, P717, DOI 10.1351/pac198961040717; GUENGERICH FP, 1986, BIOCHEM BIOPH RES CO, V138, P193, DOI 10.1016/0006-291X(86)90265-2; HEBBEL RP, 1989, SEMIN HEMATOL, V26, P136; HUANG PKC, 1968, J AM CHEM SOC, V90, P2367, DOI 10.1021/ja01011a029; KING NK, 1963, J BIOL CHEM, V238, P1520; KOSOWER EM, 1971, ACCOUNTS CHEM RES, V4, P193, DOI 10.1021/ar50042a001; KUNZE KL, 1983, J AM CHEM SOC, V105, P1380, DOI 10.1021/ja00343a057; LEE JS, 1988, BIOCHEMISTRY-US, V27, P7703, DOI 10.1021/bi00420a020; MIEYAL JJ, 1985, REV BIOCHEM TOXICOL, V7, P66; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; OSAWA Y, 1989, J AM CHEM SOC, V111, P4462, DOI 10.1021/ja00194a048; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; SAITO S, 1981, P NATL ACAD SCI-BIOL, V78, P5508, DOI 10.1073/pnas.78.9.5508; YONETANI T, 1967, J BIOL CHEM, V242, P1974	40	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8523	8530						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1850746				2022-12-25	WOS:A1991FK44100085
J	BEHRENDT, N; PLOUG, M; PATTHY, L; HOUEN, G; BLASI, F; DANO, K				BEHRENDT, N; PLOUG, M; PATTHY, L; HOUEN, G; BLASI, F; DANO, K			THE LIGAND-BINDING DOMAIN OF THE CELL-SURFACE RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; CDNA CHARACTERIZATION; U937 MONOCYTES; TUMOR-CELLS; PROTEINS; MEMBRANE; SEQUENCES; COMPONENTS; SEPARATION; CANCER	The purified urokinase plasminogen activator receptor (u-PAR) was cleaved into two fragments by mild chymotrypsin treatment. The smaller fragment (apparent M(r) 16,000) possessed the ligand-binding capability, as shown by chemical cross-linking analysis. This fragment constituted the NH2-terminal part of the intact receptor, probably including the whole sequence 1-87, and contained N-linked carbohydrate. After detergent phase separation in the Triton X-114 system, the fragment was present in the water phase where its binding activity could be demonstrated in the absence of the rest of the protein. An analysis of internal homology in the amino acid sequence of u-PAR revealed the presence of three repeats of approximately 90 residues each. The ligand-binding fragment corresponds to the first repeat, supporting that this unit is a structurally autonomous domain. Domains homologous with the internal repeats of u-PAR constitute the extracellular part of Ly-6 antigens and of the squid glycoprotein Sgp-2. Like u-PAR, these proteins are attached to the membrane by a glycosyl-phosphatidylinositol anchor. The hydrophilic, ligand-binding u-PAR domain identified in the present study has potential applications in interfering with cell-surface plasmin-mediated proteolysis.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST ENZYMOL,H-1502 BUDAPEST,HUNGARY; UNIV COPENHAGEN,INST BIOCHEM GENET,DK-1353 COPENHAGEN,DENMARK; UNIV COPENHAGEN,INST MICROBIOL,DK-1353 COPENHAGEN,DENMARK	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; University of Copenhagen; University of Copenhagen	BEHRENDT, N (corresponding author), RIGSHOSP,FINSEN LAB,STRANDBOULEVARDEN 49,DK-2100 COPENHAGEN,DENMARK.		Patthy, Laszlo/Q-6058-2019; Patthy, Laszlo/A-2353-2013	Ploug, Michael/0000-0003-2215-4265; Blasi, Francesco/0000-0001-9406-1784; Houen, Gunnar/0000-0002-5948-4156; Behrendt, Niels/0000-0003-1833-3922				APPELLA E, 1987, J BIOL CHEM, V262, P4437; BAJPAI A, 1985, BIOCHEM BIOPH RES CO, V133, P475, DOI 10.1016/0006-291X(85)90931-3; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOYD D, 1988, CANCER RES, V48, P3112; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DANO K, 1988, TISSUE TYPE PLASMINO, P19; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; HAMMELBURGER JW, 1987, BIOCHEM BIOPH RES CO, V148, P1304, DOI 10.1016/S0006-291X(87)80275-9; HEARING VJ, 1988, CANCER RES, V48, P1270; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECLAIR KP, 1986, EMBO J, V5, P3227, DOI 10.1002/j.1460-2075.1986.tb04633.x; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; NEEDHAM GK, 1987, BRIT J CANCER, V55, P13, DOI 10.1038/bjc.1987.3; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PALFREE RGE, 1988, J IMMUNOL, V140, P305; PALFREE RGE, 1987, IMMUNOGENETICS, V26, P389, DOI 10.1007/BF00343712; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; REISER H, 1988, P NATL ACAD SCI USA, V85, P2255, DOI 10.1073/pnas.85.7.2255; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121	36	248	257	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7842	7847						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850423				2022-12-25	WOS:A1991FJ34200082
J	LI, CH; MOULE, ML; YIP, CC				LI, CH; MOULE, ML; YIP, CC			INSULIN-RECEPTORS PREPARED WITH IODOACETAMIDE SHOW ENHANCED AUTOPHOSPHORYLATION AND RECEPTOR KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-SPECIFIC PHOSPHORYLATION; PROTEIN-KINASE; GROWTH-FACTOR; HUMAN-PLACENTA; BINDING; STIMULATION; THIOL; DITHIOTHREITOL; ASSOCIATION; MEMBRANE	In this study, we found that adding iodoacetamide to the homogenization buffer used in the preparation of mouse or rat liver plasma membranes resulted in an increase of insulin receptor autophosphorylation by 4-5-fold and receptor kinase activity by about 2-fold. Similar effects were obtained with iodoacetate and p-chloromercuriphenyl sulfonate. The effect of iodoacetamide was minimal when it was added to membranes prepared without the thiol reagent. The enhancing effect of iodoacetamide on insulin receptor autophosphorylation was the result of a more than 2-fold decrease in the K(m) and a more than 3-fold increase in V(max) for ATP. The presence of iodoacetamide in the preparation of plasma membranes also greatly increased the solubilization of the insulin receptor from the plasma membrane by Triton X-100. We propose that iodoacetamide acts to alkylate some unknown thiols released during tissue homogenization and that in its absence these thiols form mixed disulfides with the insulin receptor, thus adversely affecting the process of receptor activation by insulin.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto								BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COHEN S, 1980, J BIOL CHEM, V255, P4834; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; FINN FM, 1990, P NATL ACAD SCI USA, V87, P419, DOI 10.1073/pnas.87.1.419; FUJITAYAMAGUCHI Y, 1985, P NATL ACAD SCI USA, V82, P6095, DOI 10.1073/pnas.82.18.6095; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HAYNES FJ, 1986, BIOCHEM J, V239, P127, DOI 10.1042/bj2390127; HELMERHORST E, 1986, BIOCHEMISTRY-US, V25, P2060, DOI 10.1021/bi00356a034; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMARCHANDBRUSTEL Y, 1989, J BIOL CHEM, V264, P21316; LEREA KM, 1986, BIOCHEM J, V236, P535, DOI 10.1042/bj2360535; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; PIKE LJ, 1984, J BIOL CHEM, V259, P9913; RIDGE KD, 1988, P NATL ACAD SCI USA, V85, P9489, DOI 10.1073/pnas.85.24.9489; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUBIN JB, 1983, NATURE, V305, P438, DOI 10.1038/305438a0; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SWEET LJ, 1986, BIOCHEMISTRY-US, V25, P7068, DOI 10.1021/bi00370a047; TAMURA S, 1983, J BIOL CHEM, V258, P4749; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TREADWAY JL, 1990, BIOCHEM J, V271, P99, DOI 10.1042/bj2710099; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1989, ENDOCRINOLOGY, V124, P971, DOI 10.1210/endo-124-2-971; WILDEN PA, 1987, BIOCHEM J, V245, P325, DOI 10.1042/bj2450325; YIP CC, 1984, METHODS DIABETES RES, V1, P3	34	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7051	7057						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849899				2022-12-25	WOS:A1991FG72700064
J	CHOU, JY; RUPPERT, S; SHELLY, LL; PAN, CJ				CHOU, JY; RUPPERT, S; SHELLY, LL; PAN, CJ			ISOLATION AND CHARACTERIZATION OF MOUSE HEPATOCYTE LINES CARRYING A LETHAL ALBINO DELETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER DIFFERENTIATION INVITRO; PHOSPHOENOLPYRUVATE CARBOXYKINASE; MESSENGER-RNA; GENE; CHROMOSOME-7; LOCUS; METALLOTHIONEIN; ESTABLISHMENT; TYROSINASE; EXPRESSION	Mice homozygous for chromosomal deletions at or around the albino locus on chromosome 7 express reduced levels of a group of liver genes, including tyrosine aminotransferase (TAT) and phosphoenolpyruvate carboxykinase (PEPCK), and generally die perinatally. Sequences within the deleted region are thought to encode a regulatory factor(s) that affects expression of these genes in trans. To facilitate study of the putative factors, we immortalized hepatocytes derived from newborn c(ch) wild-type and c14CoS deletion homozygous mice as well as c(ch)/c14CoS heterozygous mice using a SV40 temperature-sensitive A255 mutant virus. Three c14CoS deletion homozygous hepatocyte lines were characterized and compared with the homozygous wild-type and heterozygous lines. The SV40 tsA255 mutant-transformed hepatocyte lines were temperature-sensitive for maintenance of transformation and expressed many liver-specific genes. In agreement with in vivo studies, hepatocyte lines derived from mice homozygous for the deletion expressed reduced mRNA levels of a number of liver genes including TAT, PEPCK, X1, X2, and X7 in comparison with heterozygous and wild-type cell lines. Similar mRNA levels of transferrin and albumin, genes whose expression is unaffected by the mutation in vivo, were observed in all cell lines. The expression of two genes, X5 and metallothionein, reported to be reduced in newborn mutant mice, did not differ appreciably among cell lines. TAT and PEPCK have been shown to respond poorly to glucocorticoids and cAMP in newborn mutant mice. Interestingly, all affected liver genes tested were responsive to glucocorticoids and dibutyryl cAMP in deletion homozygous cell lines as well as in wild-type and heterozygote-derived cell lines. This may suggest that effects of the deletion on expression of liver-specific genes do not cause loss of responsiveness to glucocorticoids and cAMP. These immortalized hepatocyte lines, which express most, if not all, liver-specific genes, should provide a useful means for further investigation of the effects of the albino lethal deletion.	GERMAN CANC RES CTR,INST CELL & TUMOR BIOL,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	CHOU, JY (corresponding author), NICHHD,HUMAN GENET BRANCH,BLDG 10,RM 9S242,BETHESDA,MD 20892, USA.							CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JY, 1981, J CELL BIOL, V89, P216, DOI 10.1083/jcb.89.2.216; CHOU JY, 1985, METHOD ENZYMOL, V109, P385; CHOU JY, 1988, ARCH BIOCHEM BIOPHYS, V263, P378, DOI 10.1016/0003-9861(88)90649-2; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CHOU JY, 1989, MOL ENDOCRINOL, V10, P1511; CORI CF, 1981, P NATL ACAD SCI-BIOL, V78, P479, DOI 10.1073/pnas.78.1.479; DAVIS LG, 1986, BASIC METHODS MOL BI, P62; DEFRANCO D, 1988, P NATL ACAD SCI USA, V85, P1161, DOI 10.1073/pnas.85.4.1161; DISTECHE CM, 1984, SOMAT CELL MOLEC GEN, V10, P211, DOI 10.1007/BF01535243; GLUECKSOHNWAELSCH S, 1979, CELL, V16, P225, DOI 10.1016/0092-8674(79)90001-1; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; JEFFERSON DM, 1984, MOL CELL BIOL, V4, P1929, DOI 10.1128/MCB.4.9.1929; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOOSE DS, 1986, P NATL ACAD SCI USA, V83, P5184, DOI 10.1073/pnas.83.14.5184; MARTIN RG, 1975, J VIROL, V15, P599, DOI 10.1128/JVI.15.3.599-612.1975; NAWA K, 1986, J BIOL CHEM, V261, P6883; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SALATREPAT JM, 1985, P NATL ACAD SCI USA, V82, P2442, DOI 10.1073/pnas.82.8.2442; SCHMID W, 1985, P NATL ACAD SCI USA, V82, P2866, DOI 10.1073/pnas.82.9.2866; SUSSMUTH W, 1984, EUR J BIOCHEM, V143, P607, DOI 10.1111/j.1432-1033.1984.tb08413.x; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	28	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5716	5722						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1848557				2022-12-25	WOS:A1991FD37000056
J	ENGELHARDT, JF; STEEL, G; VALLE, D				ENGELHARDT, JF; STEEL, G; VALLE, D			TRANSCRIPTIONAL ANALYSIS OF THE HUMAN ORNITHINE AMINOTRANSFERASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT-HEPATOCYTES; MESSENGER-RNA LEVELS; CYCLIC-AMP; CULTURED-HEPATOCYTES; THYROID-HORMONE; GENE; INDUCTION; ESTROGEN; KIDNEY; LIVER	The regulation of ornithine delta-aminotransferase (OAT) expression is poorly characterized in humans, but in rat there are tissue-specific responses to nutritional and hormonal stimuli. We analyzed 1.3 kilobases of 5'-flanking sequence and part of intron 1 of the human OAT gene and found several candidate regulatory sequences including four copies of a motif also present in the promoters of three other urea cycle-related enzymes (urea cycle element). We transfected a series of promoter deletion constructs into HepG2 (human heptoma), H4 (rat hepatoma), and HEK (human embryonic kidney) cells and obtained maximal expression with 134 base pairs (bp) of 5'-flanking DNA. One of the urea cycle elements and the 3' end of exon 1 had positive effects on expression in all cell lines. However, mutations in a 22-bp element which overlaps the transcriptional start site decreased activity 4-fold in H4 cells only. cAMP increased endogenous OAT mRNA 4-fold in HepG2 cells and the expression of constructs containing as little as -85 bp of 5' -flanking DNA 2-5-fold in HepG2 and H4 cells. DNase I protection analysis of the first 134 bp of 5'-flanking sequence with nuclear extracts from rat liver, rat kidney, HEK, and HepG2 cells showed two patterns of protection over one of the urea cycle elements. These studies provide the foundation for the understanding of tissue-specific regulation of OAT.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,GENET LAB,PCTB 802,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,PREDOCTORAL TRAINING PROGRAM HUMAN GENET,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Engelhardt, John/0000-0003-2389-9277	NATIONAL EYE INSTITUTE [R01EY002948] Funding Source: NIH RePORTER; NEI NIH HHS [EY02948] Funding Source: Medline; NIGMS NIH HHS [GM07814] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HATA A, 1988, J BIOCHEM-TOKYO, V103, P302, DOI 10.1093/oxfordjournals.jbchem.a122265; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JINNO Y, 1985, J BIOCHEM-TOKYO, V98, P1395, DOI 10.1093/oxfordjournals.jbchem.a135407; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; LYONS RT, 1976, ARCH BIOCHEM BIOPHYS, V174, P262, DOI 10.1016/0003-9861(76)90345-3; Maniatis T., 1982, MOL CLONING; MERRILL MJ, 1985, ARCH BIOCHEM BIOPHYS, V237, P373, DOI 10.1016/0003-9861(85)90289-9; MERRILL MJ, 1985, J BIOL CHEM, V260, P1248; MERRILL MJ, 1987, ARCH BIOCHEM BIOPHYS, V259, P250, DOI 10.1016/0003-9861(87)90493-0; Miller JH., 1972, EXPT MOL GENETICS; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MUECKLER MM, 1983, J BIOL CHEM, V258, P1781; MUECKLER MM, 1984, J BIOL CHEM, V259, P2302; MUECKLER MM, 1983, J BIOL CHEM, V258, P6109; OHTAKE A, 1988, J BIOL CHEM, V263, P2245; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spence J T, 1980, Ann N Y Acad Sci, V349, P99, DOI 10.1111/j.1749-6632.1980.tb29519.x; TAKIGUCHI M, 1987, P NATL ACAD SCI USA, V84, P6136, DOI 10.1073/pnas.84.17.6136; TAKIGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P12662; VALLE D, 1989, METABOLIC BASIS INHE, P599; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WU C, 1978, BIOCHEM BIOPH RES CO, V82, P782, DOI 10.1016/0006-291X(78)90850-1	29	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					752	758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845993				2022-12-25	WOS:A1991ET17700015
J	TAHARA, K; GROLLMAN, EF; SAJI, M; KOHN, LD				TAHARA, K; GROLLMAN, EF; SAJI, M; KOHN, LD			REGULATION OF PROSTAGLANDIN SYNTHESIS BY THYROTROPIN, INSULIN OR INSULIN-LIKE GROWTH FACTOR-I, AND SERUM IN FRTL-5 RAT-THYROID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; MESSENGER-RNA LEVELS; ENDOPEROXIDE SYNTHASE; ALPHA-1-ADRENERGIC STIMULATION; FORMING CYCLOOXYGENASE; COMPLEMENTARY-DNA; GENE-EXPRESSION; 3T3 FIBROBLASTS; G/H SYNTHASE; PURIFICATION	The present report shows that thyrotropin (TSH) regulates all three steps involved in prostaglandin synthesis in FRTL-5 rat thyroid cells, i.e. arachidonic acid release from membrane phospholipids, cyclooxygenase (prostaglandin H synthase) action, and individual prostaglandin formation; however, its action at specific steps may require the presence of, or can be duplicated by, insulin, insulin-like growth factor-I (IGF-I), and/or a serum factor. Thus, TSH releases free arachidonic acid from rat FRTL-5 thyroid cells whose phospholipid fraction is radiolabeled with [H-3]arachidonic acid; this action involves a pertussis toxin-sensitive G protein, is not cAMP mediated, and does not require insulin or 5% serum. To quantitate TSH effects on cyclooxygenase activity and on individual prostaglandin formation, a homogenate system and a rapid reversed-phase high pressure liquid chromatography procedure have been developed to measure cyclooxygenase metabolites. TSH increased cyclooxygenase activity in homogenates only if the cells were also exposed to insulin, IGF-I, and/or 5% calf serum; TSH alone had no apparent effect on the activity. Maximal activation, 4-fold over basal/mu-g of DNA, took 36 h to achieve and reflected, at least in part, an increase in cyclooxygenase gene expression. Like cyclooxygenase activity, induction of prostaglandin E2 production required 2 or more factors, i.e. TSH plus insulin/IGF-I or TSH plus insulin/IGF-I plus serum. Increased production of prostaglandin D2, could, however, be detected if cells were treated with TSH alone and the TSH activity could be duplicated by insulin, IGF-I, or calf serum alone.			TAHARA, K (corresponding author), NIDDKD,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892, USA.		Saji, Motoyasu/E-4007-2011					Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BAILEY JM, 1988, BIOCHEM BIOPH RES CO, V157, P1159, DOI 10.1016/S0006-291X(88)80995-1; BAILEY JM, 1983, J LIPID RES, V24, P1419; BOEYNAEMS JM, 1979, ENDOCRINOLOGY, V105, P988, DOI 10.1210/endo-105-4-988; BURCH RM, 1986, J BIOL CHEM, V261, P1236; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CASEY ML, 1988, J BIOL CHEM, V263, P7846; CHACOS N, 1982, BIOCHEM BIOPH RES CO, V104, P916, DOI 10.1016/0006-291X(82)91336-5; CHRISTHAZELHOF E, 1976, BIOCHIM BIOPHYS ACTA, V450, P450, DOI 10.1016/0005-2760(76)90018-7; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; CORDA D, 1986, BIOCHEM BIOPH RES CO, V141, P1000, DOI 10.1016/S0006-291X(86)80143-7; CORDA D, 1989, HORIZONS ENDOCRINOLO, P169; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1981, J BIOL CHEM, V256, P375; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIELD J, 1971, ANN NY ACAD SCI, V180, P278, DOI 10.1111/j.1749-6632.1971.tb53197.x; GOERIG M, 1988, J BIOL CHEM, V263, P19384; HAYE B, 1974, FEBS LETT, V41, P89, DOI 10.1016/0014-5793(74)80961-0; HAYE B, 1973, FEBS LETT, V30, P253, DOI 10.1016/0014-5793(73)80664-7; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HONG Y, 1989, J BIOL CHEM, V264, P13793; IGARASHI Y, 1981, BIOCHEM BIOPH RES CO, V99, P1045, DOI 10.1016/0006-291X(81)90724-5; ISOZAKI O, 1989, MOL ENDOCRINOL, V3, P1681, DOI 10.1210/mend-3-11-1681; ISOZAKI O, 1987, MOL ENDOCRINOL, V1, P839, DOI 10.1210/mend-1-11-839; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; KOHN LD, 1986, ANN NY ACAD SCI, V475, P157, DOI 10.1111/j.1749-6632.1986.tb20865.x; KOHN LD, 1975, J BIOL CHEM, V250, P6503; KOHN LD, 1986, Patent No. 4609622; KURODA H, 1988, Folia Endocrinologica Japonica, V64, P138; LANDS WEM, 1979, ANNU REV PHYSIOL, V41, P633, DOI 10.1146/annurev.ph.41.030179.003221; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAK W, 1986, FRONTIERS THYROIDOLO, P353; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIYAMOTO T, 1974, P NATL ACAD SCI USA, V71, P3645, DOI 10.1073/pnas.71.9.3645; MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P547, DOI 10.1093/nar/7.3.547; NARUMIYA S, 1981, J BIOL CHEM, V256, P9583; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NOLAN RD, 1988, MOL PHARMACOL, V33, P650; Nugteren D H, 1980, Adv Prostaglandin Thromboxane Res, V6, P129; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; POWELL WS, 1980, PROSTAGLANDINS, V20, P947, DOI 10.1016/0090-6980(80)90144-6; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; ROTELLA CM, 1989, MOL CELL ENDOCRINOL, V65, P63, DOI 10.1016/0303-7207(89)90166-4; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SHIER WT, 1982, J CELL PHYSIOL, V112, P171, DOI 10.1002/jcp.1041120204; SHIMIZU T, 1979, J BIOL CHEM, V254, P5222; SIEGEL MI, 1980, BIOCHEM BIOPH RES CO, V92, P688, DOI 10.1016/0006-291X(80)90388-5; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAKASU N, 1981, FEBS LETT, V136, P153, DOI 10.1016/0014-5793(81)81236-7; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VANDEROUDERAA FJG, 1982, METHOD ENZYMOL, V86, P60; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WINAND RJ, 1970, J BIOL CHEM, V245, P967; WU KK, 1988, J BIOL CHEM, V263, P19043; YOKOTA K, 1986, J BIOL CHEM, V261, P5410; YU SC, 1972, J CLIN INVEST, V51, P1038, DOI 10.1172/JCI106864	67	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					440	448						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845972				2022-12-25	WOS:A1991EQ33900064
J	BROYLES, SS				BROYLES, SS			A ROLE FOR ATP HYDROLYSIS IN VACCINIA VIRUS EARLY GENE-TRANSCRIPTION - DISSOCIATION OF THE EARLY TRANSCRIPTION FACTOR-PROMOTER COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; INITIATION; VIRIONS; PURIFICATION; TEMPLATE; INVITRO; REQUIREMENT; REPLICATION; SUBUNITS; BINDING	Vaccinia virus RNA polymerase requires the vaccinia early transcription factor, VETF, for the in vitro initiation of transcription at early gene promoters in a reaction requiring ATP hydrolysis. VETF binds specifically to early gene promoters and has an associated DNA-dependent ATPase activity. The effect of ATP on the interaction of VETF with the promoter for the vaccinia growth factor gene promoter has been examined. ATP had no marked effect on the steady-state level of promoter binding but dramatically affected the kinetics of dissociation of VETF from the promoter. The half-life of the VETF-promoter complex was greatly reduced in the presence of ATP. The destabilization of the complex was specific for ATP and dATP, consistent with the substrate specificity of the VETF-associated ATPase. ADP or the non-hydrolyzable ATP analog adenylyl-imidodiphosphate did not destabilize the complex suggesting that ATP hydrolysis is obligatory for dissociation. These findings provide a link between the promoter binding and ATPase activities associated with VETF and suggest that the ATP-dependent dissociation of the VETF-promoter complex is an important event in the transcription of vaccinia virus early genes.			BROYLES, SS (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.				NIAID NIH HHS [AI28432-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028432] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; GERSHOWITZ A, 1978, J VIROL, V27, P399, DOI 10.1128/JVI.27.2.399-408.1978; JONES EV, 1987, J VIROL, V61, P1765, DOI 10.1128/JVI.61.6.1765-1771.1987; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSE DS, 1987, J BIOL CHEM, V262, P289; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; MOSS B, 1990, POXVIRIDAE THEIR REP, P2079; NEVINS JR, 1977, J BIOL CHEM, V252, P6930; PUCKETT C, 1983, CELL, V35, P441, DOI 10.1016/0092-8674(83)90177-0; ROHRMANN G, 1985, J VIROL, V56, P349, DOI 10.1128/JVI.56.2.349-355.1985; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SPENCER E, 1980, J BIOL CHEM, V255, P5388; WATANABE Y, 1974, FEBS LETT, V41, P331, DOI 10.1016/0014-5793(74)81241-X; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069	23	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15545	15548						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869572				2022-12-25	WOS:A1991GB09700107
J	HIDE, M; BEAVEN, MA				HIDE, M; BEAVEN, MA			CALCIUM INFLUX IN A RAT MAST-CELL (RBL-2H3) LINE - USE OF MULTIVALENT METAL-IONS TO DEFINE ITS CHARACTERISTICS AND ROLE IN EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; PROTEIN-KINASE-C; ANAPHYLACTIC HISTAMINE SECRETION; CROMOLYN BINDING-PROTEIN; INOSITOL 1,4,5-TRISPHOSPHATE; SYNERGISTIC SIGNALS; 2H3 CELLS; IMMUNOLOGICAL STIMULUS; MEDIATOR RELEASE; IMMUNOGLOBULIN-E	An increase in concentration of cytosolic Ca2+ ([Ca2+]i) is associated with an accelerated influx of Ca-45(2+) when cultured RBL-2H3 cells are stimulated with either antigen or analogs of adenosine although these agents act via different receptors and coupling proteins (Ali, H., Cunha-Melo, J. R., Saul, W. F., and Beaven, M. A. (1990) J. Biol. Chem. 265, 745-753). The same mechanism probably operates for basal Ca2+ influx in unstimulated cells and for the accelerated influx in stimulated cells. This influx had the following characteristics. 1) It was decreased when cells were depolarized with high external K+; 2) it was blocked by other cations (La3+ > Zn2+ > Cd2+ > Mn2 = Co2+ > Ba2+ > Ni2+ > Sr2+) either by competing with Ca2+ at external sites (e.g. La3+ or Zn2+) or by co-passage into the cell (e.g. Mn2+ or Sr2+); and 3) the inhibition of influx by K+ and the metal ions had exactly the same characteristics whether cells were stimulated or unstimulated even though influx rates were different. The dependence of various cellular responses on influx of Ca2+ was demonstrated as follows. The stimulated influx of Ca2+, rise in [Ca2+]i, and secretion, could be blocked in a concentration-dependent manner by increasing the concentration of La3+, but concentrations of La3+ (> 20-mu-M) that suppressed influx to below basal rates of influx markedly suppressed the hydrolysis of inositol phospholipids (levels of inositol 1,4,5-trisphosphate were unaffected). Some metal ions, e.g. Mn2+ and Sr2+, however, supported the stimulated hydrolysis of inositol phospholipid and some secretion in the absence of Ca2+. Thus a basal rate of influx of Ca2+ was required for the full activation of inositol phospholipid hydrolysis, but in addition an accelerated influx was necessary for exocytosis.	NHLBI,CHEM PHARMACOL LAB,BLDG 10,8N114,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Hide, Michihiro/H-2519-2019	Hide, Michihiro/0000-0002-1569-6034				ALI H, 1989, J IMMUNOL, V143, P2626; ALI H, 1990, J BIOL CHEM, V265, P745; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P88, DOI 10.1016/0167-4889(89)90188-2; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; COLLADOESCOBAR D, 1990, J IMMUNOL, V144, P3449; CORCIA A, 1988, BIOCHEMISTRY-US, V27, P7499, DOI 10.1021/bi00419a048; CORCIA A, 1986, EMBO J, V5, P8849; CREWS FT, 1981, ARCH BIOCHEM BIOPHYS, V212, P561, DOI 10.1016/0003-9861(81)90399-4; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; FEWTRELL C, 1987, BIOCHEMISTRY-US, V26, P6995, DOI 10.1021/bi00396a021; FOREMAN JC, 1979, J IMMUNOL, V123, P153; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P193, DOI 10.1113/jphysiol.1977.sp011996; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P233, DOI 10.1113/jphysiol.1977.sp011998; FOREMAN JC, 1973, BRIT J PHARMACOL, V48, P527, DOI 10.1111/j.1476-5381.1973.tb08359.x; FOREMAN JC, 1972, J PHYSIOL-LONDON, V224, P753, DOI 10.1113/jphysiol.1972.sp009921; FOREMAN JC, 1973, J PHYSIOL-LONDON, V230, P493, DOI 10.1113/jphysiol.1973.sp010200; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GOMPERTS BD, 1986, TRENDS BIOCHEM SCI, V11, P290, DOI 10.1016/0968-0004(86)90032-0; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; HEMMERICH S, 1988, BIOCHEMISTRY-US, V27, P7488, DOI 10.1021/bi00419a047; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; ISHIZAKA T, 1987, INT ARCH ALLER A IMM, V82, P327, DOI 10.1159/000234218; KANNER BI, 1984, J BIOL CHEM, V259, P188; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KUNO M, 1989, AM J PHYSIOL, V256, pC560, DOI 10.1152/ajpcell.1989.256.3.C560; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MARCOTTE GV, 1990, J CELL PHYSIOL, V142, P78, DOI 10.1002/jcp.1041420111; MARONE G, 1981, J PHARMACOL EXP THER, V217, P292; MAZUREK N, 1982, EMBO J, V1, P585, DOI 10.1002/j.1460-2075.1982.tb01212.x; MAZUREK N, 1983, P NATL ACAD SCI-BIOL, V80, P6014, DOI 10.1073/pnas.80.19.6014; MAZUREK N, 1984, P NATL ACAD SCI-BIOL, V81, P6841, DOI 10.1073/pnas.81.21.6841; MELDOLESI J, 1987, EXP CELL RES, V171, P271, DOI 10.1016/0014-4827(87)90161-3; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIDDLETON E, 1981, BIOCHEM PHARMACOL, V30, P2867, DOI 10.1016/0006-2952(81)90428-7; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOHR FC, 1987, J BIOL CHEM, V262, P10638; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; PEARCE FL, 1982, PROGR MED CHEM, V19, P59, DOI 10.1016/S0079-6468(08)70328-X; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; RITCHIE DM, 1984, J PHARMACOL EXP THER, V229, P690; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SAGIEISENBERG R, 1985, NATURE, V313, P59, DOI 10.1038/313059a0; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; STUMP RF, 1987, J IMMUNOL, V139, P881; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WHITE JR, 1984, P NATL ACAD SCI-BIOL, V81, P3978, DOI 10.1073/pnas.81.13.3978; WHITE KN, 1988, J IMMUNOL, V141, P942	54	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15221	15229						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869551				2022-12-25	WOS:A1991GB09700062
J	LI, XX; LIAO, WSL				LI, XX; LIAO, WSL			EXPRESSION OF RAT SERUM AMYLOID-A1 GENE INVOLVES BOTH C/EBP-LIKE AND NFKB-LIKE TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; TISSUE-SPECIFIC EXPRESSION; ACUTE-PHASE RESPONSE; HEPATOMA-CELLS; NUCLEAR PROTEINS; ALBUMIN GENE; ELEMENT; INTERLEUKIN-1; FAMILY; VIRUS	Serum amyloid A (SAA) is a major acute-phase protein synthesized and secreted mainly by the liver. During inflammation, its expression is increased by 1000-fold as the result of greatly increased gene transcription. In this study, we analyzed the cis-acting regulatory elements and trans-acting factors important for the expression of the rat SAA1 gene. A DNA fragment containing 304 base pairs (bp) of 5'-flanking sequences of the SAA1 gene was fused to a reporter gene, chloramphenicol acetyltransferase (CAT), and the resulting construct, pSAA1/CAT (-304), was used to assess the function of the 5'-flanking sequences by transient transfection assay. pSAA1/CAT (-304) was not expressed or expressed at very low levels in both the liver- and nonliver-derived cells. However, when stimulated with conditioned medium prepared from mixed lymphocyte cultures, recombinant interleukin 1, or 12-O-tetradecanoylphorbol-13-acetate, expression of the pSAA1/CAT (-304) hybrid gene was induced 15-20-fold, but only in liver-derived cells. Further functional analysis demonstrated that a 66-bp DNA fragment conferred cytokine responsiveness onto a heterologous thymidine kinase promoter both in liver and nonliver cells. Footprint analysis with the Hep3B nuclear proteins revealed four protected regions in the 5'-flanking region of the SAA1 gene. The pattern of protection was identical with nuclear extracts prepared from either unstimulated or conditioned medium-treated Hep3B cells. Two of these footprint regions were identified as binding sites for C/EBP or C/EBP-related proteins, with the distal region having about 10-fold higher binding affinity than the proximal region. One additional cis-element formed a specific protein-DNA complex only with the nuclear proteins from TPA- or conditioned medium-treated Hep3B cells. This cis-element shares sequence identity with nuclear factor NF-kappa-B binding sites. The finding of a NF-kappa-B binding site within the 66-bp cytokine-responsive fragment further suggests its functional importance in the regulation of SAA1 gene expression. Our results suggest that C/EBP- and NF-kappa-B-related proteins may be important regulatory factors that contribute both to tissue specificity and to the high rate of SAA transcription in response to inflammatory mediators.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038858, R29AR038858] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38858] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BENSON MD, 1979, J IMMUNOL, V122, P2077; BENSON MD, 1980, J IMMUNOL, V124, P495; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EDBROOK MR, 1989, MOL CELL BIOL, V6, P3173; FEY GH, 1987, MOL BIOL MED, V4, P323; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; GOREVIC PD, 1981, ANNU REV MED, V32, P261, DOI 10.1146/annurev.me.32.020181.001401; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAYSON DR, 1988, SCIENCE, V239, P786, DOI 10.1126/science.3257586; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEONARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825; LEONARDO MJ, 1989, CELL, V57, P287; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; LIAO WSL, 1908, MOL CELL BIOL, V9, P2779; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2231; MAIZEL AL, 1981, J IMMUNOL, V127, P1058; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MEEK RL, 1989, P NATL ACAD SCI USA, V86, P1890, DOI 10.1073/pnas.86.6.1890; MICHELL PJ, 1989, SCIENCE, V245, P371; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RAMADORI G, 1985, J EXP MED, V162, P930, DOI 10.1084/jem.162.3.930; RIENHOFF HY, 1990, MOL BIOL MED, V7, P287; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; ROSENTHAL CJ, 1976, J IMMUNOL, V116, P1415; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Shibuya H, 1989, INT IMMUNOL, V1, P43, DOI 10.1093/intimm/1.1.43; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WOO P, 1987, J BIOL CHEM, V262, P15790	62	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15192	15201						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869549				2022-12-25	WOS:A1991GB09700059
J	LI, Y; MOCZYDLOWSKI, E				LI, Y; MOCZYDLOWSKI, E			PURIFICATION AND PARTIAL SEQUENCING OF SAXIPHILIN, A SAXITOXIN-BINDING PROTEIN FROM THE BULLFROG, REVEALS HOMOLOGY TO TRANSFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; SODIUM-CHANNELS; SITES; TETRODOTOXIN; LACTOFERRIN; EXPRESSION; RECEPTORS; TISSUE; ACID	Plasma from the bullfrog, Rana catesbeiana, contains a soluble component of unknown function that specifically binds the neurotoxin, [H-3]saxitoxin, with a K(d) of approximately 0.2 nM. Saxiphilin, the protein responsible for this activity, was purified approximately 440-fold from bullfrog plasma by column chromatography on heparin-Sepharose followed by chromatofocusing. The purified saxiphilin preparation exhibits a binding capacity of 9.6 nmol/mg protein and a K(d) of 0.32 nM for [H-3]saxitoxin. Analysis of the preparation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis shows a predominant band migrating with an apparent M(r) of approximately 89,000 which is similar to the expected size of saxiphilin previously estimated by nondenaturing size exclusion chromatography. Amino-terminal sequencing of the approximately 89-kDa protein and sequencing of four different tryptic peptide fragments revealed that each of the partial saxiphilin sequences can be aligned by homology with members of the transferrin protein family with sequence identity as high as 69%. The available sequence corresponding to conserved residues that comprise part of the two Fe3+ binding sites in lactotransferrin show several substitutions in saxiphilin, suggesting that saxiphilin is not an Fe3+-binding protein. Saxiphilin appears to be a monomeric approximately 89-kDa protein that is evolutionarily related to transferrin but which binds saxitoxin instead of Fe3+.	YALE UNIV, SCH MED, DEPT PHARMACOL, 333 CEDAR ST, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038796] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38156] Funding Source: Medline; NIAMS NIH HHS [AR38796] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BOWMAN BH, 1988, ADV GENET, V25, P1; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; DIEZEL W, 1972, ANAL BIOCHEM, V48, P617, DOI 10.1016/0003-2697(72)90117-0; DOYLE DD, 1982, SCIENCE, V215, P1117, DOI 10.1126/science.6278588; HALL S, 1990, ACS SYM SER, V418, P29; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P3723, DOI 10.1073/pnas.83.11.3723; JELTSCH JM, 1982, EUR J BIOCHEM, V122, P291, DOI 10.1111/j.1432-1033.1982.tb05879.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHAR J, 1991, TOXICON, V29, P53, DOI 10.1016/0041-0101(91)90039-T; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MOCZYDLOWSKI E, 1988, MOL PHARMACOL, V33, P202; MOOS M, 1988, J BIOL CHEM, V263, P6005; MOSKAITIS JE, 1990, NUCLEIC ACIDS RES, V18, P6135, DOI 10.1093/nar/18.20.6135; PALMOUR RM, 1971, BIOCHEMISTRY-US, V10, P4026, DOI 10.1021/bi00798a003; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; QUIOCHO FA, 1987, COLD SPRING HARB SYM, V52, P453, DOI 10.1101/SQB.1987.052.01.052; RITCHIE JM, 1977, REV PHYSIOL BIOCH P, V79, P1, DOI 10.1007/BFb0037088; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANAKA JC, 1984, BIOCHIM BIOPHYS ACTA, V775, P203, DOI 10.1016/0005-2736(84)90172-X; THORSTENSEN K, 1990, BIOCHEM J, V271, P1; VALAITIS AP, 1984, J BIOL CHEM, V259, P779; WARD JH, 1987, INVEST RADIOL, V22, P74, DOI 10.1097/00004424-198701000-00017; YANG FM, 1984, P NATL ACAD SCI-BIOL, V81, P2752, DOI 10.1073/pnas.81.9.2752	29	31	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15481	15487						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869567				2022-12-25	WOS:A1991GB09700097
J	MCINTYRE, GF; ERICKSON, AH				MCINTYRE, GF; ERICKSON, AH			PROCATHEPSIN-L AND PROCATHEPSIN-D ARE MEMBRANE-BOUND IN ACIDIC MICROSOMAL VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; UDP-N-ACETYLGLUCOSAMINE; LYSOSOMAL-ENZYME; CATHEPSIN-D; RAT-LIVER; DICTYOSTELIUM-DISCOIDEUM; NH2-TERMINAL SEQUENCES; MACROPHAGE ENDOSOMES; PARTIAL-PURIFICATION; CYSTEINE PROTEINASE	Procathepsins L and D, the proenzyme forms of two lysosomal proteases, are shown to bind to mouse fibroblast microsomal membranes at acidic pH. The propeptide of procathepsin L is necessary for membrane association because the mature forms of this lysosomal protein did not bind to the membranes. Both proenzymes were eluted from the membranes by increasing either the pH or the ionic strength of the buffer, so they are peripheral proteins that interact ionically with the membranes. The proenzymes were not eluted from the membranes with 50 mM mannose or 10 mM mannose 6-phosphate, which suggests that carbohydrate does not mediate membrane binding. Membrane binding is probably a specific, protein-mediated interaction since treatment of the microsomes with trypsin reduced by half the amount of procathepsin L which bound to the membranes, and binding of procathepsin L to the membranes was saturable. One or more ''lysosomal proenzyme receptors'' capable of binding to lysosomal proenzymes at acidic pH could complement the mannose 6-phosphate receptor system in prelysosomes and sort certain lysosomal proenzymes to lysosomes.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM38321] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AERTS JMFG, 1988, BIOCHIM BIOPHYS ACTA, V964, P303, DOI 10.1016/0304-4165(88)90030-X; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DOERING TL, 1990, J BIOL CHEM, V265, P611; DONG JM, 1990, J BIOL CHEM, V265, P4210; ERICKSON AH, 1981, J BIOL CHEM, V256, P1224; ERICKSON AH, 1988, INTRACELLULAR PROTEI, P74; FISCHER HD, 1980, J BIOL CHEM, V255, P9608; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURST W, 1988, BIOL CHEM HOPPESEYLE, V369, P337; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HARA K, 1988, FEBS LETT, V231, P229, DOI 10.1016/0014-5793(88)80737-3; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; JIANG LW, 1990, J BIOL CHEM, V265, P4775; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LENNARTZ MR, 1989, J BIOL CHEM, V264, P2385; LI H, 1990, J BIOL CHEM, V265, P14732; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; MULLOCK BM, 1989, J CELL BIOL, V108, P2093, DOI 10.1083/jcb.108.6.2093; NISHIMURA Y, 1987, BIOCHEM BIOPH RES CO, V148, P335, DOI 10.1016/0006-291X(87)91115-6; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V260, P712, DOI 10.1016/0003-9861(88)90500-0; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RADIN NS, 1984, MOL BASIS LYSOSOMAL, P93; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; ROME LH, 1979, P NATL ACAD SCI USA, V76, P2333; ROZHIN J, 1987, CANCER RES, V47, P6620; ROZHIN J, 1989, BIOCHEM BIOPH RES CO, V164, P556, DOI 10.1016/0006-291X(89)91755-5; SALMINEN A, 1990, BIOCHEM J, V272, P39, DOI 10.1042/bj2720039; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SCOTT GK, 1987, COMP BIOCHEM PHYS B, V87, P1, DOI 10.1016/0305-0491(87)90462-7; SEEMAN P, 1967, J CELL BIOL, V32, P55, DOI 10.1083/jcb.32.1.55; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VARKI A, 1981, J BIOL CHEM, V256, P9937; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003	65	83	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15438	15445						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869563				2022-12-25	WOS:A1991GB09700091
J	MURAKAMI, H; LAM, Z; FURIE, BC; REINHOLD, VN; ASANO, T; FURIE, B				MURAKAMI, H; LAM, Z; FURIE, BC; REINHOLD, VN; ASANO, T; FURIE, B			SULFATED GLYCOLIPIDS ARE THE PLATELET AUTOANTIGENS FOR HUMAN PLATELET-BINDING MONOCLONAL ANTI-DNA AUTOANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-HUMAN HYBRIDOMAS; LUPUS AUTOANTIBODIES; AUTO-ANTIGEN; ANTIBODIES; GANGLIOSIDES; GLYCOSPHINGOLIPIDS; THROMBOCYTOPENIA; IDENTIFICATION; AUTOIMMUNE; PROTEINS	The human monoclonal autoantibody HF2-1/17, produced by a human-human hybridoma derived from lymphocytes of a lupus patient with thrombocytopenia, reacts with single stranded DNA and platelets. To determine the chemical nature of the autoantigen against which this antibody is directed on platelets, this platelet antigen was purified by the lipid extraction of sonicated platelets, DEAE-Sephadex chromatography, and high performance liquid chromatography. The purified glycolipids, a trace component in platelets, demonstrated high reactivity with the HF2-1/17 antibody using a competition enzyme-linked immunosorbent assay system or immunostaining of thin layer chromatograms. The purified glycolipids co-migrated with bovine sulfatides by thin layer chromatography. The purified glycolipids contain sulfate and galactose but not sialic acid or phosphate. Fast atom bombardment-mass spectrometry revealed these sulfatides to be sulfated monohexyl ceramides. The dominant species has a molecular weight of 794 while a minor form has a molecular weight of 812 due to an extra hydroxyl group and loss of a double bond. These results indicate that the platelet autoantigen against which the human monoclonal anti-DNA antibody is directed represents a family of novel monogalactosyl sulfatides.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Tufts University; Tufts University; Harvard University; Harvard T.H. Chan School of Public Health	MURAKAMI, H (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019794] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42442] Funding Source: Medline; NIAID NIH HHS [AI19794] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRESCHWARTZ J, 1984, CLIN IMMUNOL IMMUNOP, V31, P261, DOI 10.1016/0090-1229(84)90246-0; ASANO T, 1985, BLOOD, V66, P1254; ASANO T, 1986, CLIN RES, V34, pA654; ATKINSON PM, 1985, J CLIN INVEST, V75, P1138, DOI 10.1172/JCI111808; BEARDSLEY DS, 1989, BLUT, V59, P47, DOI 10.1007/BF00320248; BEARDSLEY DS, 1984, J CLIN INVEST, V74, P1701, DOI 10.1172/JCI111587; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DERSIMONIAN H, 1987, J IMMUNOL, V139, P2496; DEVINE DV, 1984, BLOOD, V64, P1240; ENDO T, 1984, J IMMUNOL, V132, P1793; GAZZOTTI G, 1985, J CHROMATOGR, V348, P371, DOI 10.1016/S0021-9673(01)92475-6; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HIRANO T, 1980, J CLIN INVEST, V66, P1437, DOI 10.1172/JCI109999; ILYAS AA, 1985, P NATL ACAD SCI USA, V82, P6697, DOI 10.1073/pnas.82.19.6697; JACOB L, 1984, P NATL ACAD SCI-BIOL, V81, P3843, DOI 10.1073/pnas.81.12.3843; KEAN EL, 1968, J LIPID RES, V9, P319; KOERNER TAW, 1989, BLOOD, V74, P274; KUNICKI TJ, 1978, J CLIN INVEST, V61, P1225, DOI 10.1172/JCI109038; LAFER EM, 1981, J EXP MED, V153, P897, DOI 10.1084/jem.153.4.897; LAMPMAN GW, 1989, BLOOD, V74, P262; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MAGNANI JL, 1987, METHOD ENZYMOL, V138, P195; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MARCUS AJ, 1972, J CLIN INVEST, V51, P2602, DOI 10.1172/JCI107078; NUGENT DJ, 1989, BLUT, V59, P52, DOI 10.1007/BF00320249; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; RUBIN RL, 1984, J EXP MED, V159, P1429, DOI 10.1084/jem.159.5.1429; SHOENFELD Y, 1983, NEW ENGL J MED, V308, P414, DOI 10.1056/NEJM198302243080802; SHOENFELD Y, 1982, J CLIN INVEST, V70, P205, DOI 10.1172/JCI110595; SHOENFELD Y, 1983, J EXP MED, V158, P718, DOI 10.1084/jem.158.3.718; Stahl E, 1969, THIN LAYER CHROMATOG, P807; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TAO RVP, 1973, J LIPID RES, V14, P16; VANLEEUWEN EF, 1982, BLOOD, V59, P23; VANNLIET HHD, 1987, BRIT J HAEMATOL, V67, P103; WARREN L, 1959, J BIOL CHEM, V234, P1971; WOODS VL, 1984, BLOOD, V63, P368; WOODS VL, 1984, BLOOD, V64, P156	40	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15414	15419						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869560				2022-12-25	WOS:A1991GB09700087
J	FU, JC; DING, L; CLARKE, S				FU, JC; DING, L; CLARKE, S			PURIFICATION, GENE CLONING, AND SEQUENCE-ANALYSIS OF AN L-ISOASPARTYL PROTEIN CARBOXYL METHYLTRANSFERASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC METHYL ESTERIFICATION; ASPARTYL RESIDUES; HUMAN-ERYTHROCYTES; SUCCINIMIDE FORMATION; S-ADENOSYLMETHIONINE; ASPARAGINYL RESIDUES; NUCLEOTIDE-SEQUENCE; RAPID ANALYSIS; BOVINE BRAIN; PEPTIDES	Mammalian tissues contain protein carboxyl methyltransferases that catalyze the transfer of methyl groups from S-adenosylmethionine to the free carboxyl groups of D-aspartyl or L-isoaspartyl residues (EC 2.1.1.77). These enzymes have been postulated to play a role in the repair and/or degradation of spontaneously damaged proteins. We have now characterized a similar activity from Escherichia coli that recognizes L-isoaspartyl-containing peptides as well as protein substrates such as ovalbumin. The enzyme was purified by DEAE-cellulose, hydroxylapatite, Sephadex G-100, polyaspartate, and reversed-phase chromatography and was shown to consist of a single 24-kDa polypeptide chain. The sequence determined for the N-terminal 39 residues was used to design an oligonucleotide probe that allowed the precise localization of its structural gene (pcm) on the physical map of the E. coli chromosome at 59 min. Transformation of E. coli cells with a plasmid containing DNA from this region results in a 3-4-fold overproduction of enzyme activity. The nucleotide sequence determined for the pcm gene and its flanking regions was used to deduce a mature amino acid sequence of 207 residues with a calculated molecular weight of 23,128. This sequence shows 30.8% sequence identity with the human L-isoaspartyl/D-aspartyl methyltransferase and suggests that this enzyme catalyzes a fundamental reaction in both procaryotic and eucaryotic cells.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05554] Funding Source: Medline; NIGMS NIH HHS [GM-26020] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPERT AJ, 1983, J CHROMATOGR, V266, P23, DOI 10.1016/S0021-9673(01)90876-3; ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1983, J NEUROCHEM, V40, P1718, DOI 10.1111/j.1471-4159.1983.tb08147.x; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BARBER JR, 1984, J BIOL CHEM, V259, P7115; BARTEN DM, 1990, LIFE SCI, V47, P181, DOI 10.1016/0024-3205(90)90319-M; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENDEL V, 1986, J BIOMOL STRUCT DYN, V3, P705, DOI 10.1080/07391102.1986.10508457; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4414; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1980, J SUPRAMOL STR CELL, V13, P315, DOI 10.1002/jss.400130305; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DING L, 1990, THESIS U CALIFORNIA; DOOLITTLE RF, 1986, COLD SPRING HARB SYM, V51, P447, DOI 10.1101/SQB.1986.051.01.054; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P99; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GILBERT JM, 1988, BIOCHEMISTRY-US, V27, P5227, DOI 10.1021/bi00414a042; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOOPES BC, 1987, ESCHERICHIA COLI SAL, V2, P1231; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; JACQUES N, 1990, MOL MICROBIOL, V4, P1063, DOI 10.1111/j.1365-2958.1990.tb00679.x; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; KIM S, 1977, J BACTERIOL, V130, P839, DOI 10.1128/JB.130.2.839-845.1977; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRAWIEC S, 1990, MICROBIOL REV, V54, P502, DOI 10.1128/MMBR.54.4.502-539.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSON J, 1988, BLOOD CELLS, V14, P103; LOWENSON JD, 1990, J BIOL CHEM, V265, P3106; MATEUCCI MD, 1981, J AM CHEM SOC, V103, P3185; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MEDIGUE C, 1990, MOL MICROBIOL, V4, P169, DOI 10.1111/j.1365-2958.1990.tb00585.x; MOMAND J, 1987, BIOCHEMISTRY-US, V26, P7798, DOI 10.1021/bi00398a040; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; MURRAY ED, 1984, J BIOL CHEM, V259, P722; MURRAY ED, 1986, J BIOL CHEM, V261, P306; MUTOH N, 1986, J BACTERIOL, V165, P161, DOI 10.1128/jb.165.1.161-166.1986; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; OCONNOR CM, 1984, P NATL ACAD SCI-BIOL, V81, P7757, DOI 10.1073/pnas.81.24.7757; OGAWA H, 1987, EUR J BIOCHEM, V18, P141; OTA IM, 1988, BIOCHEM BIOPH RES CO, V151, P1136, DOI 10.1016/S0006-291X(88)80484-4; OTA IM, 1989, J BIOL CHEM, V264, P54; OTA IM, 1987, J BIOL CHEM, V262, P8522; OTA IM, 1990, PROTEIN METHYLATION, P179; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RASMUSSEN JL, 1986, J BACTERIOL, V168, P523, DOI 10.1128/jb.168.2.523-533.1986; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1989, BIOCHEM BIOPH RES CO, V161, P342, DOI 10.1016/0006-291X(89)91602-1; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIEBERT PD, 1986, J BIOL CHEM, V261, P2433; Silhavy TJ, 1984, EXPT GENE FUSIONS, P137; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; Smith H O, 1980, Methods Enzymol, V65, P371; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TABOR S, 1989, J BIOL CHEM, V264, P6447; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; THOMPSON JA, 1983, METHOD ENZYMOL, V100, P368; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	76	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14562	14572						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860862				2022-12-25	WOS:A1991FZ35100071
J	PASTERNACK, MS; BLEIER, KJ; MCINERNEY, TN				PASTERNACK, MS; BLEIER, KJ; MCINERNEY, TN			GRANZYME-A BINDING TO TARGET-CELL PROTEINS - GRANZYME-A BINDS TO AND CLEAVES NUCLEOLIN INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYTIC LYMPHOCYTES-T; SERINE ESTERASE; EFFECTOR-CELLS; CYTOPLASMIC GRANULES; LYTIC GRANULES; PROTEASE; LOCALIZATION; SEQUENCE; INVIVO; CDNA	The physiologic substrates of cytotoxic T lymphocyte granule-associated serine esterases (referred to hereafter as proteases or "granzymes"), and the role of these enzymes in cell-mediated activity remain unclear. We have developed an assay for possible ligands of the trypsin-like dimeric serine protease granzyme A based on Western immunoblotting techniques. This protein-binding assay demonstrates the selective binding of granzyme A to several proteins present in the target cell P815. The binding specificity is preserved when enzyme binding is performed in the presence of excess competing proteins, including such cationic species as lysozyme and RNase. Enzyme binding is inhibited, however, by heat or detergent inactivation of granzyme A. Subcellular fractionation of target cells shows that the nuclear fraction contains most granzyme A binding reactivity, which is recovered in the nuclear salt wash fraction. A protein with M(r) = 100,000 and two closely migrating proteins with M(r) = 35,000 and 38,000 are the predominant reactive moieties, and the N-terminal sequence of the 100-kDa protein confirmed that this protein was murine nucleolin. Incubation of granzyme A with nucleolin generates a discrete proteolytic cleavage product of M(r) = 88,000. Since nucleolin is known to shuttle between nucleus and cytoplasm, the interaction of granzyme A and nucleolin may be important in the process of apoptosis which accompanies cytotoxic T lymphocyte-mediated lysis of target cells.	MASSACHUSETTS GEN HOSP,CHILDRENS SERV,INFECT DIS UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,INFECT DIS UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA045658] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA 45658] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARBALLO M, 1983, EMBO J, V2, P1759; BERKE G, 1988, J IMMUNOL, V141, P1429; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; DENNERT G, 1987, P NATL ACAD SCI USA, V84, P5004, DOI 10.1073/pnas.84.14.5004; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FERGUSON WS, 1988, J EXP MED, V167, P528, DOI 10.1084/jem.167.2.528; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HENKART PA, 1987, J IMMUNOL, V139, P2398; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; LAEMMLI VK, 1975, NATURE, V227, P680; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; MASSON D, 1985, J BIOL CHEM, V260, P9069; MASSON D, 1986, EMBO J, V5, P1595, DOI 10.1002/j.1460-2075.1986.tb04401.x; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MUNGER WE, 1988, IMMUNOL REV, V103, P99, DOI 10.1111/j.1600-065X.1988.tb00752.x; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PASTERNACK MS, 1983, J IMMUNOL, V131, P2477; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; RUSSELL JH, 1982, J IMMUNOL, V128, P2087; RUSSELL JH, 1978, P NATL ACAD SCI USA, V75, P441, DOI 10.1073/pnas.75.1.441; SCHMID J, 1987, J IMMUNOL, V139, P250; SIMON MM, 1986, EUR J IMMUNOL, V16, P1559, DOI 10.1002/eji.1830161215; SIMON MM, 1986, EMBO J, V5, P3267, DOI 10.1002/j.1460-2075.1986.tb04638.x; SIMON MM, 1987, IMMUNOLOGY, V60, P219; TAKAYAMA H, 1987, J IMMUNOL, V138, P566; Tata J R, 1974, Methods Enzymol, V31, P253; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOUNG JDE, 1986, CELL, V47, P183, DOI 10.1016/0092-8674(86)90441-1; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	42	86	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14703	14708						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860869				2022-12-25	WOS:A1991FZ35100091
J	KORNACKER, MG; FAUCHER, D; PUGSLEY, AP				KORNACKER, MG; FAUCHER, D; PUGSLEY, AP			OUTER-MEMBRANE TRANSLOCATION OF THE EXTRACELLULAR ENZYME PULLULANASE IN ESCHERICHIA-COLI K12 DOES NOT REQUIRE A FATTY ACYLATED N-TERMINAL CYSTEINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMONIAE STRAIN K21; KLEBSIELLA-PNEUMONIAE; LIPOPROTEIN PULLULANASE; SECRETION; GENE; AEROGENES; LOCALIZATION; EXPRESSION; SEQUENCE; CLONING	Site-directed mutagenesis was used to construct three mutant derivatives of the extracellular, cell surface lipoprotein pullulanase (PulA) in which the normally fatty acylated cysteine of the signal peptide-bearing precursor was replaced by other amino acids. When produced in Escherichia coli expressing all genes required for pullulanase secretion, approximately 90% of the PulA derivatives persisted as cell-associated precursors, indicating inefficient signal peptide processing. Processed (intermediate-sized) forms of the two derivatives that were studied in detail were found to result from proteolytic cleavage at different sites within the signal peptide. Both were further processed to smaller polypeptides by cleavage at an undetermined site that is presumably close to their C termini. The intermediate-sized pullulanase derived from prepullulanase in which Cys+1 had been replaced by Leu and Gly-1 by Glu (PuIA:CIL/G-1E) appeared rapidly, was apparently entirely extracellular, and accounted for approximately 10% of synthesized PulA. Prolonged incubation did not result in further conversion of the precursor to the intermediate form, and the precursor remained anchored to the cytoplasmic membrane. The smaller processed form was also found extracellularly. The active form of the extracellular enzyme was monomeric, which is again in contrast to the fatty acylated, wild-type enzyme. Taken together, these results indicate that replacement of Cys+1 of prePulA eliminates processing by lipoprotein signal peptidase and does not permit processing by leader peptidase, but allows inefficient, aberrant processing by an unknown peptidase and immediate secretion of the resulting polypeptide, which retains most of its signal peptide. Processing and secretion only occur when the pullulanase secretion functions are expressed.	INST PASTEUR,CNRS,UA 1149,UNITE GENET MOLEC,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE; RHONE POULENC SANTE,DEPT BIOTECHNOL,F-94403 VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Sanofi-Aventis								DENFERT C, 1987, MOL MICROBIOL, V1, P107, DOI 10.1111/j.1365-2958.1987.tb00534.x; DENFERT C, 1987, EMBO J, V6, P3531, DOI 10.1002/j.1460-2075.1987.tb02679.x; KATSURAGI N, 1987, J BACTERIOL, V169, P2301, DOI 10.1128/jb.169.5.2301-2306.1987; KORNACKER MG, 1989, J GEN MICROBIOL, V135, P397; KORNACKER MG, 1989, MOL MICROBIOL, V3, P497, DOI 10.1111/j.1365-2958.1989.tb00196.x; KORNACKER MG, 1990, MOL MICROBIOL, V4, P73, DOI 10.1111/j.1365-2958.1990.tb02016.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHAELIS S, 1985, J BACTERIOL, V164, P633, DOI 10.1128/JB.164.2.633-638.1985; Miller J. H., 1972, EXPT MOL GENETICS, P431; MUROOKA Y, 1989, J BIOL CHEM, V264, P17524; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; Perbal B., 1988, PRACTICAL GUIDE MOL; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P59, DOI 10.1111/j.1365-2958.1990.tb02015.x; PUGSLEY AP, 1990, ANNU REV GENET, V24, P67; PUGSLEY AP, 1986, J BACTERIOL, V166, P1083, DOI 10.1128/jb.166.3.1083-1088.1986; PUGSLEY AP, 1991, MOL MICROBIOL, V5, P343, DOI 10.1111/j.1365-2958.1991.tb02115.x; PUGSLEY AP, 1991, IN PRESS MOL MICROBI, V5; PUGSLEY AP, 1989, PROTEIN TARGETING, P90; PUGSLEY AP, 1987, PLASMIDS PRACTICAL A, P106; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TAKIZAWA N, 1985, APPL ENVIRON MICROB, V49, P294, DOI 10.1128/AEM.49.2.294-298.1985; WU HC, 1986, CURR TOP MICROBIOL, V125, P127; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6	23	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13842	13848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856217				2022-12-25	WOS:A1991FY02700062
J	KAISER, S; CURTHOYS, NP				KAISER, S; CURTHOYS, NP			EFFECT OF PH AND BICARBONATE ON PHOSPHOENOLPYRUVATE CARBOXYKINASE AND GLUTAMINASE MESSENGER-RNA LEVELS IN CULTURED RENAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BASE-BALANCE; RAT-KIDNEY; CYCLIC-AMP; METABOLIC-ACIDOSIS; GENE-TRANSCRIPTION; GTP; ELEMENTS; INSULIN; GLUCOCORTICOIDS; HYBRIDIZATION	A gluconeogenic strain of renal epithelial cells (LLC-PK1-F+) was used to characterize the effect of pH and bicarbonate concentration on the levels of phosphoenolpyruvate carboxykinase (PCK) and glutaminase (GA) mRNAs. The levels of both mRNAs are markedly dependent upon medium glucose concentration. The level of PCK mRNA is increased with increasing glucose concentration from 0 to 40 mM, whereas the level of GA mRNA is maximal between 3 and 5 mM glucose. When LLC-PK1-F+ cells are grown with 5 mM glucose and then subjected to an acute decrease in pH (from 7.4 to 6.9) and bicarbonate concentration (from 25 to 10 mM), the level of PCK mRNA exhibits a biphasic response. The PCK mRNA is initially increased 4-fold within 3 h, then decreases slightly and subsequently increases between 10 and 20 h to a level that is 17-fold greater than normal. Only the initial increase parallels the changes observed in vivo. In contrast, after onset of acidosis, the level of GA mRNA initially remains unchanged, is then increased 8-fold between 10 and 16 h, and then decreases slightly. This response closely mimics the results obtained in vivo. A decrease in media pH at constant bicarbonate causes a marked increase in both mRNAs. However, the levels of the two mRNAs are also elevated by decreasing bicarbonate at a constant pH. Thus, both parameters independently affect the level of the two mRNAs. The use of actinomycin D to measure the half-lives of PCK and GA mRNAs at pH 7.4 and 6.9 indicates that stabilization may fully account for the induction of GA mRNA and contributes to the inductive effects of decreased pH and/or bicarbonate on PCK mRNA. Following recovery from acidic conditions, the two mRNAs exhibit a rapid and coordinate decrease (t1/2 approximately 20 min). Dexamethasone had no effect on the level of either mRNA, whereas cAMP increased only PCK mRNA. The latter effect was additive with the increase caused by decreased pH and/or bicarbonate and was reversed by incubating in alkalotic media. Thus, the induction of PCK and GA mRNAs during acidosis is initiated in direct response to a decrease in extracellular pH and/or bicarbonate.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523	Colorado State University					NIDDK NIH HHS [DK-37124] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BANNER C, 1988, MOL BRAIN RES, V3, P247, DOI 10.1016/0169-328X(88)90047-2; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BURCH HB, 1978, AM J PHYSIOL, V235, pF246, DOI 10.1152/ajprenal.1978.235.3.F246; CAVALIERI RL, 1977, P NATL ACAD SCI USA, V74, P4415, DOI 10.1073/pnas.74.10.4415; CHEN TC, 1989, IN VITRO CELL DEV B, V25, P714, DOI 10.1007/BF02623724; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; GSTRAUNTHALER G, 1985, AM J PHYSIOL, V252, pC232; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HOD Y, 1988, J BIOL CHEM, V263, P7747; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; IMAI E, 1990, J CELL BIOCH B, V14, P234; IYNEDJIAN PB, 1977, J BIOL CHEM, V252, P8398; IYNEDJIAN PB, 1975, J BIOL CHEM, V250, P5596; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; KLEMM DJ, 1990, MOL CELL BIOL, V10, P480, DOI 10.1128/MCB.10.2.480; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MURPHY W, 1973, P NATL ACAD SCI USA, V70, P115, DOI 10.1073/pnas.70.1.115; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; POLLOCK AS, 1989, AM J PHYSIOL, V257, pF145, DOI 10.1152/ajprenal.1989.257.1.F145; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI K, 1988, P NATL ACAD SCI USA, V85, P2954, DOI 10.1073/pnas.85.9.2954; SCHROCK H, 1980, BIOCHEM J, V188, P557, DOI 10.1042/bj1880557; THAYER MJ, 1990, MOL CELL BIOL, V10, P2660, DOI 10.1128/MCB.10.6.2660; TONG J, 1987, BIOCHEMISTRY-US, V26, P2773, DOI 10.1021/bi00384a018; TONG J, 1986, BIOCHEM J, V233, P139, DOI 10.1042/bj2330139; TULLY DB, 1989, BIOCHEMISTRY-US, V28, P1968, DOI 10.1021/bi00431a003; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YOOWARREN H, 1981, J BIOL CHEM, V256, P224; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	33	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9397	9402						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851745				2022-12-25	WOS:A1991FM45900012
J	KANE, MA; AGUAYO, SM; PORTANOVA, LB; ROSS, SE; HOLLEY, M; KELLEY, K; MILLER, YE				KANE, MA; AGUAYO, SM; PORTANOVA, LB; ROSS, SE; HOLLEY, M; KELLEY, K; MILLER, YE			ISOLATION OF THE BOMBESIN GASTRIN-RELEASING PEPTIDE RECEPTOR FROM HUMAN SMALL-CELL LUNG-CARCINOMA NCI-H345 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; STRUCTURALLY RELATED PEPTIDES; HIGH-AFFINITY RECEPTORS; RAT-BRAIN MEMBRANES; CROSS-LINKING; SUBSTANCE-P; GASTROINTESTINAL-TRACT; LIGAND-BINDING; PROTEIN; CANCER	Purification of the gastrin-releasing peptide (GRP) or bombesin receptor has proved elusive in part due to technical difficulties. In the present studies, the problem of oxidized radioligand was avoided by the use of I-125-GRP, which was verified to be not oxidized by high performance liquid chromatography. Specific I-125-GRP binding (at 0-degrees-C) to intact human small cell lung carcinoma NCI-H345 cells which had been subjected to a dilute acid wash was 6 fmol/10(6) cells. Inhibition of GRP degradation by human H345 cell membranes through the use of phenanthroline or phosphoramidon permitted the development of binding assays for the GRP receptor in detergent-solubilized crude membrane preparations. The solubilized GRP receptor exhibited saturable, high affinity (K(D) = 1.3 nM), temperature-dependent specific binding averaging 402 +/- 65 fmol/mg protein (mean +/- S.E. for eight separate membrane preparations with I-125-GRP concentration = 3 nM), with a B(max) = 434 fmol/mg protein using a gel filtration binding assay. That the GRP receptor had been solubilized was demonstrated by its failure to pellet when centrifuged at 1000,000 x g for 60 min, its passage through a 0.22-mu-m filter without loss of binding activity, and its elution in the void volume of a Sephadex G-50 gel filtration column, but within the inclusion volume of a Sephacryl S-200 column (V(e)/V0 = 1.1). Isolation of the GRP receptor from human H345 cell-solubilized membranes was achieved by ligand affinity chromatography. A unique 70-kDa band on silver-stained reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis was reproducibly eluted from GRP14-27 affinity columns by an acidic high salt buffer, but binding activity was denatured by these conditions. The protein nature of the GRP receptor was demonstrated by its sensitivity to proteases after isolation. In addition, two unique bands of 65 and 70 kDa were eluted from the GRP14-27 affinity column with GRP14-27 in neutral buffer, and this eluate possessed specific I-125-GRP binding with a stoichiometry of approximately 1:1. Thus, reported here is the isolation of a functional membrane-associated, saturable, high affinity GRP receptor with temperature-dependent binding from the solubilized membranes of human H345 cells.	UNIV COLORADO, VET AFFAIRS MED CTR, CTR CANC, PULM MED SECT, DENVER, CO 80220 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80220 USA	University of Colorado System; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	KANE, MA (corresponding author), UNIV COLORADO, VET AFFAIRS MED CTR, CTR CANC, MED ONCOL SECT, 1055 CLERMONT ST, DENVER, CO 80220 USA.				NCI NIH HHS [R29-CA44763-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL29891] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044763] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUAYO SM, 1988, CLIN RES, V36, pA502; BECK LK, 1988, SEMIN ONCOL, V15, P300; BUNNETT NW, 1988, GASTROENTEROLOGY, V95, P952, DOI 10.1016/0016-5085(88)90168-0; CARNEY DN, 1981, P NATL ACAD SCI-BIOL, V78, P3185, DOI 10.1073/pnas.78.5.3185; CIRILLO DM, 1986, MOL CELL BIOL, V6, P4641, DOI 10.1128/MCB.6.12.4641; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; COWAN A, 1988, TRENDS PHARMACOL SCI, V9, P1, DOI 10.1016/0165-6147(88)90227-1; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; HELKE CJ, 1980, PEPTIDES, V1, P1, DOI 10.1016/0196-9781(80)90027-3; HOLLINGSWORTH EB, 1989, MOL PHARMACOL, V35, P689; HOOK VYH, 1984, NEUROPEPTIDES, V4, P117, DOI 10.1016/0143-4179(84)90122-7; INAOKA Y, 1987, BIOCHIM BIOPHYS ACTA, V925, P27, DOI 10.1016/0304-4165(87)90144-9; JENSEN RT, 1978, P NATL ACAD SCI USA, V75, P6139, DOI 10.1073/pnas.75.12.6139; KANE MA, 1987, CANCER RES, V47, P6444; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KRIS RM, 1987, J BIOL CHEM, V262, P11215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MICHELETTI R, 1988, REGUL PEPTIDES, V21, P219, DOI 10.1016/0167-0115(88)90004-3; MINNA JD, 1987, ONCOGENES CANCER, P109; MOODY TW, 1983, PEPTIDES, V4, P683, DOI 10.1016/0196-9781(83)90018-9; MOODY TW, 1985, LIFE SCI, V37, P105, DOI 10.1016/0024-3205(85)90413-8; MOODY TW, 1978, P NATL ACAD SCI USA, V75, P5372, DOI 10.1073/pnas.75.11.5372; MOODY TW, 1983, LIFE SCI, V32, P487, DOI 10.1016/0024-3205(83)90142-X; MOODY TW, 1981, PEPTIDES, V2, P75, DOI 10.1016/S0196-9781(81)80014-9; MOODY TW, 1989, METHOD ENZYMOL, V168, P481; MORAN TH, 1988, PEPTIDES, V9, P643, DOI 10.1016/0196-9781(88)90177-5; MULSHINE JL, 1989, CHEST S, V96, P315; NALDINI L, 1990, BIOCHEMISTRY-US, V29, P5153, DOI 10.1021/bi00473a022; OBLIN A, 1988, NEUROSCI LETT, V84, P91, DOI 10.1016/0304-3940(88)90343-6; SCEMAMA JL, 1986, REGUL PEPTIDES, V13, P125, DOI 10.1016/0167-0115(86)90220-X; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SWOPE SL, 1987, BIOCHEM J, V247, P731, DOI 10.1042/bj2470731; TSUGITA A, 1980, METHODS PEPTIDE PROT, P359; VIGNA SR, 1988, PEPTIDES, V9, P923, DOI 10.1016/0196-9781(88)90142-8; VIGNA SR, 1987, GASTROENTEROLOGY, V93, P1287, DOI 10.1016/0016-5085(87)90257-5; WESTENDORF JM, 1983, J BIOL CHEM, V258, P7527; WOLF SS, 1985, PEPTIDES, V6, P111, DOI 10.1016/0196-9781(85)90018-X; YOUNES M, 1989, AM J PHYSIOL, V256, pG291, DOI 10.1152/ajpgi.1989.256.2.G291; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	48	25	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9486	9493						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1851748				2022-12-25	WOS:A1991FM45900027
J	BHATNAGAR, SK; BULLIONS, LC; BESSMAN, MJ				BHATNAGAR, SK; BULLIONS, LC; BESSMAN, MJ			CHARACTERIZATION OF THE MUTT NUCLEOSIDE TRIPHOSPHATASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; MUTATOR GENE; MOLECULAR-CLONING; DNA; BASE; TRIPHOSPHOHYDROLASE; PURIFICATION; SUBSTITUTION; INVITRO	The mutT protein, which prevents A:T --> C:G transversions during DNA replication, has the following enzymatic properties. Although it prefers dGTP as a substrate, it hydrolyzes all of the canonical nucleoside triphosphates to some extent. It has no activity in the absence of divalent cations, is maximally activated by magnesium ions, and has a pH optimum of 9.0. Nucleoside triphosphates are hydrolyzed according to the following equation. dGTP --> dGMP + PPi Studies with nucleotide analogues suggest that the enzyme may prefer the syn rather than the anti conformation of the nucleoside triphosphates, which might explain the role it plays in preventing mutations.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University	BHATNAGAR, SK (corresponding author), JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA.				NICHD NIH HHS [HD 07103] Funding Source: Medline; NIGMS NIH HHS [GM-18649] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007103] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AMES BN, 1960, J BIOL CHEM, V235, P769; BERTANI LE, 1961, J BIOL CHEM, V236, pPC67; BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; BESSMAN MJ, 1958, P NATL ACAD SCI USA, V44, P633, DOI 10.1073/pnas.44.7.633; BHATNAGAR SK, 1990, J BACTERIOL, V172, P2802, DOI 10.1128/jb.172.5.2802-2803.1990; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; COX EC, 1973, GENETICS, V73, P67; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; Fiske CH, 1925, J BIOL CHEM, V66, P375; GIROIR IE, 1987, J BIOL CHEM, V262, P130; GUSCHLBAUER W, 1972, JERUSALEM S QUANT CH, V4, P297; LIAO XB, 1990, GENE, V88, P107, DOI 10.1016/0378-1119(90)90066-Z; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MARKHAM R, 1952, BIOCHEM J, V52, P552, DOI 10.1042/bj0520552; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; PLESS RC, 1981, BIOCHEMISTRY-US, V20, P6235, DOI 10.1021/bi00524a051; QUIRK S, 1990, GENE, V89, P13, DOI 10.1016/0378-1119(90)90200-B; ROSCOE DH, 1969, VIROLOGY, V38, P520, DOI 10.1016/0042-6822(69)90172-X; Saenger W., 1984, PRINCIPLES NUCLEIC A, P76; SCHAAPER RM, 1987, J BIOL CHEM, V262, P16267; SCHLOMAI J, 1978, J BIOL CHEM, V253, P3305; SETO D, 1988, J BIOL CHEM, V263, P1494; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; TAVALE SS, 1970, J MOL BIOL, V48, P109, DOI 10.1016/0022-2836(70)90222-6; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; ZIMMERMAN S, 1961, J BIOL CHEM, V236, P1480	29	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9050	9054						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851162				2022-12-25	WOS:A1991FM03800061
J	MACDONALD, H; JONES, AM; KING, PJ				MACDONALD, H; JONES, AM; KING, PJ			PHOTOAFFINITY-LABELING OF SOLUBLE AUXIN-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZEA-MAYS-L; MUNG BEAN SEEDLINGS; ACID-BINDING; IMMUNOLOGICAL METHODS; MOLECULAR-CLONING; PURIFICATION; MAIZE; SITES; BETA-1,3-GLUCANASE; COLEOPTILES	The photoaffinity labeling agent azido-IAA (5-N3-[7-H-3]indole-3-acetic acid), a biologically active analogue of the endogenous auxin indole-3-acetic acid, was used to search for auxin-binding proteins in the soluble fraction of Hyoscyamus muticus cells. Azido-IAA became covalently attached to three polypeptides with a high specific activity. The labeling was specific for IAA and not due to random tagging. Two polypeptides with molecular masses of 31 and 24 kDa in the 0-30% ammonium sulfate fraction were labeled after UV photolysis at 0-degrees-C but not at -196-degrees-C, and appeared to have a high affinity indole-binding site(s) for which active, non-indole auxins were not good ligands. A third polypeptide with a molecular mass of 25 kDa present in the 50-60% ammonium sulfate fraction labeled exclusively at -196-degrees-C and had a significant affinity for active auxins but not for inactive indoles. The azido-IAA labeling pattern, pI, competition results, and immunoprecipitation all indicate that the 31- and 24-kDa polypeptides are related to the basic form of endo-1,3-beta-glucanase (EC 3.2.1.39). Azido-IAA labeling polypeptides equivalent to the 31- and 24-kDa species were apparently also present in the cell wall. The low pH optimum for binding of azido-IAA to the 25-kDa polypeptide suggests the location of active protein in a compartment such as the vacuole or a transport vesicle rather than in the cytosol.	FRIEDRICH MIESCHER INST, POSTFACH 2543, CH-4002 BASEL, SWITZERLAND; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	Friedrich Miescher Institute for Biomedical Research; University of North Carolina; University of North Carolina Chapel Hill								BARRIERBRYGOO H, 1989, P NATL ACAD SCI USA, V86, P891, DOI 10.1073/pnas.86.3.891; Cleland R. E., 1987, Plant hormones and their role in plant growth and development., P132; DOHRMANN U, 1978, PLANTA, V140, P97, DOI 10.1007/BF00384907; FELIX G, 1985, PLANTA, V164, P423, DOI 10.1007/BF00402956; FELIX G, 1986, PLANTA, V167, P206, DOI 10.1007/BF00391416; GEBHARDT C, 1983, PLANTA, V159, P18, DOI 10.1007/BF00998809; Hagen G., 1987, Plant hormones and their role in plant growth and development., P149; HESSE T, 1989, EMBO J, V8, P2453, DOI 10.1002/j.1460-2075.1989.tb08380.x; HICKS GR, 1989, SCIENCE, V245, P52, DOI 10.1126/science.245.4913.52; HICKS GR, 1989, P NATL ACAD SCI USA, V86, P4948, DOI 10.1073/pnas.86.13.4948; HUBER DJ, 1981, PLANTA, V151, P206, DOI 10.1007/BF00395171; IHL M, 1976, PLANTA, V131, P223, DOI 10.1007/BF00385419; INOHARA N, 1989, P NATL ACAD SCI USA, V86, P3564, DOI 10.1073/pnas.86.10.3564; JACOBS M, 1988, SCIENCE, V241, P346, DOI 10.1126/science.241.4863.346; JACOBSEN HJ, 1982, PHYSIOL PLANTARUM, V56, P161, DOI 10.1111/j.1399-3054.1982.tb00319.x; JONES AM, 1989, P NATL ACAD SCI USA, V86, P6153, DOI 10.1073/pnas.86.16.6153; KEEFE D, 1990, PLANTA, V182, P43, DOI 10.1007/BF00239982; KIKUCHI M, 1989, PLANT CELL PHYSIOL, V30, P765; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBENGA KR, 1987, MOL BIOL PLANT GROWT, P229; LOBARZEWSKI J, 1983, PHYTOCHEMISTRY, V22, P2427, DOI 10.1016/0031-9422(83)80133-2; LOBLER M, 1985, J BIOL CHEM, V260, P9848; MELHADO LL, 1984, PLANT PHYSIOL, V74, P289, DOI 10.1104/pp.74.2.289; MURPHY GJP, 1979, PLANT SCI LETT, V15, P183, DOI 10.1016/0304-4211(79)90072-5; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; Rubery P. H., 1987, Plant hormones and their role in plant growth and development., P341; SAKAI S, 1985, PLANT CELL PHYSIOL, V26, P185; SAKAI S, 1983, PLANT CELL PHYSIOL, V24, P685, DOI 10.1093/oxfordjournals.pcp.a076565; SHIMOMURA S, 1986, J BIOCHEM-TOKYO, V99, P1513, DOI 10.1093/oxfordjournals.jbchem.a135621; TANIMOTO E, 1968, PHYSIOL PLANTARUM, V21, P820, DOI 10.1111/j.1399-3054.1968.tb07306.x; TILLMANN U, 1989, EMBO J, V8, P2463, DOI 10.1002/j.1460-2075.1989.tb08381.x; VENIS MA, 1987, MOL BIOL PLANT GROWT, P219; WONG YS, 1980, PLANT PHYSIOL, V65, P222, DOI 10.1104/pp.65.2.222	34	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7393	7399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850406				2022-12-25	WOS:A1991FJ34200016
J	IMLAY, JA; FRIDOVICH, I				IMLAY, JA; FRIDOVICH, I			ASSAY OF METABOLIC SUPEROXIDE PRODUCTION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; OXYGEN; DISMUTASE; MUTAGENESIS; GENERATION; MANGANESE; MUTANTS; COMPLEX; LIFE	Superoxide production has been measured in subcellular fractions of SOD-deficient Escherichia coli provided with physiological reductants. Although cytosolic enzyme(s) do generate O2-, the larger portion is produced by autoxidation of components of the respiratory electron-transport chain. At 37-degrees-C and with pO2, NADH, and NAD+ levels matching those in vivo, respiring membrane vesicles generate 3 O2-./10,000 electrons transferred. This corresponds to intracellular O2-. production, in glucose-fed cells, of 5-mu-M/s. The high SOD content of normal cells restricts O2-. accumulation to 2.10(-10) M, with a moderate gradient from the membrane to the center of the cell. SOD-deficient mutants achieve a much higher steady-state content of O2-.. Rates of superoxide-mediated inactivation of certain enzymes are sufficiently rapid that even 10(-10) M O2-. imposes a significant oxidative stress.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University								ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P25; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN OR, 1983, FUND APPL TOXICOL, V3, P209, DOI 10.1016/S0272-0590(83)80127-4; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; COOPER S, 1989, J BACTERIOL, V171, P5239, DOI 10.1128/jb.171.10.5239-5243.1989; FARMER KJ, 1989, FREE RADICAL BIO MED, V7, P23, DOI 10.1016/0891-5849(89)90096-8; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FLINT D H, 1990, P285; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Fridovich I., 1985, HDB METHODS OXYGEN R, P51; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KARP MT, 1983, ANAL BIOCHEM, V128, P175, DOI 10.1016/0003-2697(83)90359-7; KITA K, 1984, J BIOL CHEM, V259, P3375; KUO CF, 1987, J BIOL CHEM, V262, P4724; LEDER I G, 1972, Journal of Bacteriology, V111, P211; LUNDQUIST R, 1971, J BIOL CHEM, V246, P1107; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Miller J. H., 1972, EXPT MOL GENETICS, P431; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V1, P4; PHILLIPS JP, 1989, P NATL ACAD SCI USA, V86, P2761, DOI 10.1073/pnas.86.8.2761; PUGH SYR, 1984, J BACTERIOL, V160, P137, DOI 10.1128/JB.160.1.137-142.1984; ROSEN BP, 1974, P NATL ACAD SCI USA, V71, P5042, DOI 10.1073/pnas.71.12.5042; SCHELLHORN HE, 1989, ARCH BIOCHEM BIOPHYS, V271, P323, DOI 10.1016/0003-9861(89)90282-8; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WEFERS H, 1983, EUR J BIOCHEM, V137, P29, DOI 10.1111/j.1432-1033.1983.tb07791.x; YOUNG IG, 1976, BIOCHIM BIOPHYS ACTA, V449, P376, DOI 10.1016/0005-2728(76)90149-3	36	345	363	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6957	6965						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1849898				2022-12-25	WOS:A1991FG72700052
J	SOOHOO, CK; HOLLOCHER, TC; KOLODZIEJ, AF; ORMEJOHNSON, WH; BUNKER, G				SOOHOO, CK; HOLLOCHER, TC; KOLODZIEJ, AF; ORMEJOHNSON, WH; BUNKER, G			EXTENDED X-RAY ABSORPTION FINE-STRUCTURE AND ELECTRON-PARAMAGNETIC RESONANCE OF NITROUS-OXIDE REDUCTASE FROM PSEUDOMONAS-AERUGINOSA STRAIN-P2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICOPPER ENZYME; SITE; PURIFICATION; COPPER; STUTZERI; EXAFS; DENITRIFICANS; STELLACYANIN; CONTAINS; STATE	The copper centers of nitrous oxide reductase from Pseudomonas aeruginosa strain P2 were studied by x-ray and electron paramagnetic resonance (EPR) spectroscopy. The enzyme is dimeric and contains four Cu atoms and about seven cysteine residues/subunit of M(r) = 73,000. The extended x-ray absorption fine structure (EX-AFS) spectrum was analyzed for enzyme as isolated (oxidized or slightly reduced), enzyme exposed briefly to air, reduced enzyme, and enzyme at pH 7 after having been activated by standing at pH 10. The average Cu ligand environment in the first shell was best modeled for all forms of the enzyme by a combination of N/O and S atoms at a total coordination number between 3 and 4 and bond distances ranging from 1.96-2.03 angstrom for Cu-N/O and 2.20-2.25 angstrom for Cu-S. The data could be fit without using Cu-Cu interactions. Overall the results are similar to those reported for the enzyme for Pseudomonas stutzeri (Scott, R. A., Zumft, W. G., Coyle, C. L., and Dooley, D. M. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 4082-4086). The first derivative EPR spectra of the Cu(II) centers at 15 and 45 K were qualitatively similar among enzyme as isolated and enzyme exposed to N2O or air. These three nominally oxidized samples showed an axial signal with g perpendicular-to = 2.03 and g parallel-to 2.15-2.16. Hyperfine structure was observed in both the g parallel-to and g perpendicular-to regions with splitting of 43 and 25 gauss, respectively. These hyperfine components are attributed to exchange coupled Cu(I)-Cu(II) S = 1/2 (half-met) centers. In the enzyme as isolated and after exposure to N2O, about 3/4 of the Cu was EPR silent, whereas after exposure to air the signal integrated to about halathe Cu concentration. The EPR spectrum of enzyme activated at pH 10 but frozen at pH 7 was a composite of spectra from activated and inactive species. The activated species presented a complex set of narrow hyperfine components which may arise from contributions from more than one species of half-met center.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BIOSTRUCT INST,PHILADELPHIA,PA 19104; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Brandeis University; Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM-39612, GM31574-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031574, R29GM039612] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONAMICO M, 1965, ACTA CRYSTALLOGR, V19, P886, DOI 10.1107/S0365110X65004619; BUNKER G, 1987, BIOCHEMISTRY-US, V26, P4708, DOI 10.1021/bi00389a017; CHAPMAN SK, 1986, J CHEM SOC DALTON, P2063, DOI 10.1039/dt9860002063; COYLE CL, 1985, EUR J BIOCHEM, V153, P459, DOI 10.1111/j.1432-1033.1985.tb09324.x; DELEON JM, 1988, XAFS, V5, P709; FEITERS MC, 1988, BIOCHIM BIOPHYS ACTA, V955, P250, DOI 10.1016/0167-4838(88)90200-2; FLEISCHER EB, 1964, J AM CHEM SOC, V86, P2342, DOI 10.1021/ja01066a009; GROENEVELD CM, 1986, BIOCHIM BIOPHYS ACTA, V873, P214, DOI 10.1016/0167-4838(86)90048-8; HOLT SD, 1990, FEBS LETT, V269, P117, DOI 10.1016/0014-5793(90)81133-9; HULSE CL, 1990, BIOCHEM BIOPH RES CO, V166, P729, DOI 10.1016/0006-291X(90)90870-S; INGRAM DJE, 1949, P PHYS SOC LOND A, V62, P664, DOI 10.1088/0370-1298/62/10/110; JIN HY, 1989, J AM CHEM SOC, V111, P4262, DOI 10.1021/ja00194a017; Koningsberger D.C., 1988, XRAY ABSORPTION PRIN; KRONECK PMH, 1988, FEBS LETT, V242, P70, DOI 10.1016/0014-5793(88)80987-6; LEE PA, 1981, REV MOD PHYS, V53, P769, DOI 10.1103/RevModPhys.53.769; MALKIN R, 1970, ADV ENZYMOL REL S BI, V33, P177; MCEWAN AG, 1985, J BACTERIOL, V164, P823, DOI 10.1128/JB.164.2.823-830.1985; MICHALSKI WP, 1986, BIOCHIM BIOPHYS ACTA, V872, P50, DOI 10.1016/0167-4838(86)90146-9; PEISACH J, 1982, BIOPHYS J, V38, P277, DOI 10.1016/S0006-3495(82)84559-1; PEISACH J, 1967, J BIOL CHEM, V242, P2847; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SCOTT RA, 1989, P NATL ACAD SCI USA, V86, P4082, DOI 10.1073/pnas.86.11.4082; SCOTT RA, 1982, J AM CHEM SOC, V104, P3364; SNYDER SW, 1987, J BIOL CHEM, V262, P6515; Solomon E.I., 1983, STRUCT BONDING BERLI, V53, P1; SOOHOO CK, 1990, J BIOL CHEM, V266, P2203; STERN EA, 1979, REV SCI INSTRUM, V50, P1579, DOI 10.1063/1.1135763; TERAGUCHI S, 1989, J BIOL CHEM, V264, P1972; TULLIUS TD, 1979, THESIS STANFORD U; VIEBROCK A, 1988, J BACTERIOL, V170, P4658, DOI 10.1128/jb.170.10.4658-4668.1988; Wertz J. E., 1972, ELECT SPIN RESONANCE; ZHANG CS, 1990, J BIOL CHEM, V266, P2199; ZHANG K, 1988, BIOCHEMISTRY-US, V27, P7470, DOI 10.1021/bi00419a045	34	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2210	2218						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846618				2022-12-25	WOS:A1991EV51500032
J	DIAZLAVIADA, I; LARRODERA, P; NIETO, JL; CORNET, ME; DIAZMECO, MT; SANCHEZ, MJ; GUDDAL, PH; JOHANSEN, T; HARO, A; MOSCAT, J				DIAZLAVIADA, I; LARRODERA, P; NIETO, JL; CORNET, ME; DIAZMECO, MT; SANCHEZ, MJ; GUDDAL, PH; JOHANSEN, T; HARO, A; MOSCAT, J			MECHANISM OF INHIBITION OF ADENYLATE-CYCLASE BY PHOSPHOLIPASE C-CATALYZED HYDROLYSIS OF PHOSPHATIDYLCHOLINE - INVOLVEMENT OF A PERTUSSIS TOXIN-SENSITIVE G-PROTEIN AND PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; CYCLIC-AMP; INOSITOL TRISPHOSPHATE; ADP-RIBOSYLATION; PHORBOL-ESTER; GROWTH-FACTOR; RECEPTOR; CELLS; DIACYLGLYCEROL; FIBROBLASTS	The phospholipase C-mediated hydrolysis of phosphatidylcholine has been shown recently to be activated by a number of agonists. Muscarinic receptors, which trigger various signal transduction mechanisms including inhibition of adenylate cyclase through G(i), have been shown to be potent stimulants of this novel phospholipid degradative pathway. We demonstrate here, by exogenous addition of Bacillus cereus phosphatidylcholine-hydrolyzing phospholipase C, that phosphatidylcholine breakdown mimics the ability of carbachol to inhibit adenylate cyclase. This effect is sensitive to pertussis toxin and is entirely dependent on the presence of protein kinase C. This kinase is also required for the inhibition by carbachol of adenylate cyclase. These results suggest that the activation of phosphatidylcholine breakdown by phospholipase C may play an important role linking or favoring the coupling of muscarinic receptors to G(i). Results presented here also show that phospholipase C-mediated hydrolysis of phosphoinositides by exogenous addition of Bacillus thuringiensis phosphoinositide-hydrolyzing phospholipase C does not affect adenylate cyclase, despite the fact that protein kinase C is translocated to an extent similar to that produced by the hydrolysis of phosphatidylcholine. According to the results shown here, both phospholipases also differ in their ability to down-regulate protein kinase C as well as to phosphorylate p80 and to transmodulate the binding of epidermal growth factor, two well established effects of protein kinase C in Swiss 3T3 fibroblasts. This emphasizes the complexity, from a functional point of view, of protein kinase C activation "in vivo."	HOSP GEN GREGORIO MARANON,DR ESQUERDO 46,E-28007 MADRID,SPAIN; UNIV COMPLUTENSE MADRID,DEPT BIOQUIM & BIOL MOLEC,E-28049 MADRID,SPAIN; UNIV TROMSO,INST MED BIOL,N-9001 TROMSO,NORWAY	General University Gregorio Maranon Hospital; Complutense University of Madrid; UiT The Arctic University of Tromso			Johansen, Terje/N-2971-2015; Moscat, Jorge/A-7011-2009; Diaz-Laviada, Ines/I-2838-2015	Johansen, Terje/0000-0003-1451-9578; Diaz-Laviada, Ines/0000-0001-9704-4373; Diaz-Meco, Maria/0000-0003-0147-0998				ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; CORVEN EJ, 1989, CELL, V59, P45; DIAZMECO MT, 1989, BIOCHEM J, V263, P115, DOI 10.1042/bj2630115; EXTON JH, 1990, J BIOL CHEM, V265, P1; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HEPLER JR, 1987, BIOCHEM J, V247, P793, DOI 10.1042/bj2470793; ITO T, 1988, J CELL BIOL, V107, P929, DOI 10.1083/jcb.107.3.929; JAKOBS KH, 1985, EUR J BIOCHEM, V151, P425, DOI 10.1111/j.1432-1033.1985.tb09119.x; JOHANSEN T, 1988, GENE, V65, P293, DOI 10.1016/0378-1119(88)90466-0; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LITTLE C, 1988, BIOCHEM SOC T, V17, P271; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MAGNALDO I, 1986, J BIOL CHEM, V261, P6916; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MOSCAT J, 1989, J BIOL CHEM, V264, P11228; MOSCAT J, 1989, BIOCHEM SOC T, V17, P988, DOI 10.1042/bst0170988; MYRNES BJ, 1980, ACTA CHEM SCAND B, V32, P375; NAMBI P, 1985, J BIOL CHEM, V260, P2165; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QIAN Z, 1989, J BIOL CHEM, V264, P21720; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; ROZENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282, DOI 10.1073/pnas.84.8.2282; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SUGDEN D, 1985, NATURE, V314, P359, DOI 10.1038/314359a0; TRIMBLE ER, 1987, P NATL ACAD SCI USA, V84, P3146, DOI 10.1073/pnas.84.10.3146; WIENER E, 1989, J BIOL CHEM, V264, P4324; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; YAVIN E, 1976, J BIOL CHEM, V251, P1392; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	40	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1170	1176						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845988				2022-12-25	WOS:A1991ET17700077
J	MAEDA, N; KAWASAKI, T; NAKADE, S; YOKOTA, N; TAGUCHI, T; KASAI, M; MIKOSHIBA, K				MAEDA, N; KAWASAKI, T; NAKADE, S; YOKOTA, N; TAGUCHI, T; KASAI, M; MIKOSHIBA, K			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR CHANNEL FROM MOUSE CEREBELLUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; RYANODINE RECEPTOR; SKELETAL-MUSCLE; PURKINJE-CELLS; P-400 PROTEIN; CA-2+ RELEASE; TRISPHOSPHATE RECEPTOR; RAT CEREBELLUM; MUTANT MICE	The cerebellar inositol 1,4,5-trisphosphate (InsP3) receptor is a high molecular weight glycoprotein abundantly expressed in Purkinje cells. The subunit structure of the InsP3 receptor protein was examined by cross-linking experiments. Agarose-polyacrylamide gel electrophoresis of the cross-linked materials demonstrated that the cerebellar InsP3 receptor protein is composed of four noncovalently bound identical subunits each with a M(r) of 320,000 in both purified and microsome-bound states. Chromatography of the purified receptor on a calmodulin-Sepharose column demonstrated a Ca2+-dependent interaction of the InsP3 receptor with calmodulin. Photoaffinity labeling of the cerebellar microsomal fraction with [alpha-P-32]8-azidoadenosine 5'-triphosphate revealed the presence of ATP-binding site in the InsP3 receptor. Scatchard analysis of the purified InsP3 receptor revealed the B(max) and K(d) values for ATP binding of 2.3 pmol/mu-g and 17-mu-M, respectively. Reconstitution of the purified InsP3 receptor into the planar lipid bilayer indicated channel activity in the purified receptor. It exhibited a calcium conductance (26 pS in 53-mM Ca2+) and sodium conductance (21 pS in 100-500 mM asymmetric Na+ solutions) with permeability ratios of PCa/PTris = 6.3 and PNa/PCl = 5.4. The purified channel was activated with submillimolar ATP in the presence of InsP3 and modified to reach a large conductance state.	OSAKA UNIV, INST PROT RES, DIV REGULAT MACROMOLEC FUNCT, 3-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, FAC ENGN SCI, DEPT BIOPHYS ENGN, TOYONAKA, OSAKA 560, JAPAN; NATL INST BASIC BIOL, OKAZAKI, AICHI 444, JAPAN	Osaka University; Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)			Mikoshiba, Katsuhiko/N-7943-2015					ANDERSON K, 1989, J BIOL CHEM, V264, P1329; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1990, FEBS LETT, V267, P85, DOI 10.1016/0014-5793(90)80294-S; HILL TD, 1988, J BIOL CHEM, V263, P16479; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; KAPRIELIAN Z, 1989, MOL BRAIN RES, V6, P55, DOI 10.1016/0169-328X(89)90028-4; KAWASAKI T, 1989, J BIOCHEM-TOKYO, V106, P401, DOI 10.1093/oxfordjournals.jbchem.a122865; KIEHM DJ, 1977, J BIOL CHEM, V252, P8524; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MALLET J, 1976, BRAIN RES, V103, P291, DOI 10.1016/0006-8993(76)90800-3; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1979, DEV NEUROSCI-BASEL, V2, P254, DOI 10.1159/000112489; MIKOSHIBA K, 1985, DEV NEUROSCI-BASEL, V7, P179, DOI 10.1159/000112286; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PALADE P, 1989, MOL PHARMACOL, V36, P673; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SMITH JB, 1985, J BIOL CHEM, V260, P4413; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SUEMATSU E, 1985, COMP BIOCHEM PHYS A, V82, P645; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WILLCOCKS AL, 1987, BIOCHEM BIOPH RES CO, V146, P1071, DOI 10.1016/0006-291X(87)90756-X; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x	38	290	294	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1109	1116						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845986				2022-12-25	WOS:A1991ET17700068
J	WANG, H; SEGALOFF, DL; ASCOLI, M				WANG, H; SEGALOFF, DL; ASCOLI, M			LUTROPIN CHORIOGONADOTROPIN DOWN-REGULATES ITS RECEPTOR BY BOTH RECEPTOR-MEDIATED ENDOCYTOSIS AND A CAMP-DEPENDENT REDUCTION IN RECEPTOR MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; HUMAN CHORIO-GONADOTROPIN; EPIDERMAL GROWTH-FACTOR; BETA-ADRENERGIC RECEPTORS; BETA-2-ADRENERGIC RECEPTOR; LUTEINIZING-HORMONE; ADENYLATE-CYCLASE; AGONIST; DESENSITIZATION; GENE	Using MA-10 Leydig tumor cells as a model system we have examined the possibility that the lutropin/choriogonadotropin (LH/CG)-induced down-regulation of the LH/CG receptor is accompanied by changes in LH/CG receptor mRNA. We show that LH or CG are indeed capable of the reducing the levels of LH/CG receptor mRNA, but that the time course and magnitude of the reduction in receptor mRNA are such that this phenomenon cannot account entirely for the downregulation of the receptor. In fact, we estimate that LH/CG can reduce the number of LH/CG receptors by at least 80% with little or no change in the levels of LH/CG receptor mRNA. These data are consistent with our previous hypothesis that the LH/CG-induced down-regulation of the LH/CG receptor is primarily due to an increase in the rate of degradation of the receptor that occurs as a result of the receptor-mediated endocytosis of LH/CG. Our studies also show that the LH/CG-induced down-regulation of the LH/CG receptor mRNA is mediated by cAMP. Thus, addition of 8-bromo-cAMP to MA-10 cells leads to a similar reduction in the levels of LH/CG receptor and receptor mRNA; while deglycosylated human CG, a hormone derivative that binds to the LH/CG receptor but has a reduced ability to stimulate cAMP synthesis, does not reduce the levels of LH/CG receptor mRNA. Last, human CG or 8-bromo-cAMP are unable to reduce LH/CG receptor mRNA in a mutant MA-10 cell line that express a cAMP-resistant phenotype.	POPULAT COUNCIL, NEW YORK, NY 10021 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	Population Council; University of Iowa; University of Iowa					NCI NIH HHS [CA-40629] Funding Source: Medline; NICHD NIH HHS [HD-22196] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD022196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA040629] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; ASCOLI M, 1989, ANN NY ACAD SCI, V564, P99, DOI 10.1111/j.1749-6632.1989.tb25891.x; ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; ASCOLI M, 1987, ENDOCRINOLOGY, V120, P1161, DOI 10.1210/endo-120-3-1161; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; ASCOLI M, 1989, ENDOCR REV, V10, P27, DOI 10.1210/edrv-10-1-27; ASCOLI M, 1981, J BIOL CHEM, V256, P179; ASCOLI M, 1985, RECEPTORS, V2, P368; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; FREEMAN DA, 1981, P NATL ACAD SCI-BIOL, V78, P6309, DOI 10.1073/pnas.78.10.6309; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P3723, DOI 10.1073/pnas.83.11.3723; LEUNG K, 1987, MOL ENDOCRINOL, V1, P724, DOI 10.1210/mend-1-10-724; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MANJUNATH P, 1982, J BIOL CHEM, V257, P7109; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; REBOIS RV, 1983, J BIOL CHEM, V258, P2775; REBOIS RV, 1984, J BIOL CHEM, V259, P3096; REBOIS RV, 1985, J BIOL CHEM, V260, P8026; SAIRAM MR, 1989, FASEB J, V3, P1915, DOI 10.1096/fasebj.3.8.2542111; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Segaloff D L, 1990, Recent Prog Horm Res, V46, P261; WANG HY, 1990, MOL ENDOCRINOL, V4, P80, DOI 10.1210/mend-4-1-80; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533	32	108	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					780	785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845994				2022-12-25	WOS:A1991ET17700019
J	KANAKURA, Y; DRUKER, B; DICARLO, J; CANNISTRA, SA; GRIFFIN, JD				KANAKURA, Y; DRUKER, B; DICARLO, J; CANNISTRA, SA; GRIFFIN, JD			PHORBOL 12-MYRISTATE 13-ACETATE INHIBITS GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR-INDUCED PROTEIN TYROSINE PHOSPHORYLATION IN A HUMAN FACTOR-DEPENDENT HEMATOPOIETIC-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; INSULIN-RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; INDEPENDENT MECHANISMS; GROWTH-FACTORS; BETA-SUBUNIT; INTERLEUKIN-3; DIFFERENTIATION; EXPRESSION; CD45	The human myeloid cell line MO7 requires either granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin 3 (IL-3) for proliferation. We have previously shown that both GM-CSF and IL-3 transiently induce tyrosine phosphorylation of a number of proteins, including two cytosolic proteins, p93 and p70, which are maximally phosphorylated 5-15 min after addition of growth factor to factor-deprived cells. GM-CSF-induced proliferation of MO7 cells was found to be inhibited by two activators of protein kinase C, phorbol 12-myristate 13-acetate (PMA) and bryostatin-1. PMA did not affect surface expression or affinity of the GM-CSF receptor put significantly inhibited GM-CSF-induced tyrosine phosphorylation of another protein, p42. Pretreatment of cells with sodium orthovanadate to inhibit protein tyrosine phosphatases (PTPase) partially reversed the inhibitory effects of PMA. These results suggest that one aspect of GM-CSF and IL-3 signal transduction, protein tyrosine phosphorylation, can be inhibited by a mechanism which does not involve receptor down-regulation, and may involve either inhibition of a receptor-activated tyrosine kinase, activation of a protein tyrosine phosphatase, or both. This mechanism could be important in exerting control of proliferation of some types of hematopoietic cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [R37CA036167, R01CA036167, P01CA034183, R01CA047843] Funding Source: NIH RePORTER; NCI NIH HHS [CA34183, CA36167, CA47843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CANNISTRA SA, 1988, SEMIN HEMATOL, V25, P173; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; FERRIS DK, 1988, BIOCHEM BIOPH RES CO, V154, P991, DOI 10.1016/0006-291X(88)90237-9; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KANAKURA Y, 1991, IN PRESS BLOOD; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MAY WS, 1987, P NATL ACAD SCI USA, V84, P8483, DOI 10.1073/pnas.84.23.8483; MELLONI E, 1989, J BIOL CHEM, V264, P18414; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OMARY MB, 1980, J EXP MED, V152, P842, DOI 10.1084/jem.152.4.842; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARK LS, 1986, J EXP MED, V164, P251, DOI 10.1084/jem.164.1.251; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIEFF CA, 1987, J CLIN INVEST, V79, P1549, DOI 10.1172/JCI112988; SORENSEN PHB, 1989, BLOOD, V73, P406; SPIVAK JL, 1989, J CLIN INVEST, V83, P100, DOI 10.1172/JCI113844; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1989, J BIOL CHEM, V264, P7801; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VILA J, 1988, J CELL PHYSIOL, V135, P285, DOI 10.1002/jcp.1041350216; WHITE MF, 1988, J BIOL CHEM, V263, P2969; ZYLBERKATZ E, 1985, CANCER RES, V45, P5159	53	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					490	495						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845978				2022-12-25	WOS:A1991EQ33900072
J	FROMMHERZ, KJ; FALLER, B; BIETH, JG				FROMMHERZ, KJ; FALLER, B; BIETH, JG			HEPARIN STRONGLY DECREASES THE RATE OF INHIBITION OF NEUTROPHIL ELASTASE BY ALPHA-1-PROTEINASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; PORCINE PANCREATIC ELASTASE; CATHEPSIN-G; POLYMORPHONUCLEAR LEUKOCYTES; PROTEINASE-INHIBITORS; BRONCHIAL INHIBITOR; ALPHA-1-ANTITRYPSIN; THROMBIN; BINDING; PLASMA	Heparin depresses the second-order rate constant k(a) for the inhibition of neutrophil elastase by alpha-1-proteinase inhibitor. High molecular mass heparin decreases k(a) from 1.3 x 10(7) M-1 s-1 to a limit of 4.6 x 10(4) M-1 s-1. Low molecular mass heparin is about 7-fold less effective. Dermatan sulfate and chondroitin sulfate are less efficient. Heparin preparations used in clinical care also strongly depress k(a) when tested at concentrations corresponding to their clinical efficacy. Heparin also decreases the k(a) for the elastase/eglin c and the cathepsin G/alpha-1-proteinase inhibitor systems but not that for the alpha-1-proteinase inhibitor/pancreatic elastase or trypsin pairs. These results, together with Sepharose-heparin binding studies, indicate that the k(a)-depressing effect of the polymer is related to its ability to form a tight complex with elastase but not with alpha-1-proteinase inhibitor. One mol of high molecular mass heparin binds 3 mol of neutrophil elastase with a K(d) of 3.3 nM. Low molecular mass heparin binds elastase with a 1:1 stoichiometry and a K(d) of 89 nM. For both heparins k(a) is lowest when elastase is fully saturated with heparin. From this we conclude that heparin decreases k(a), because the heparin-elastase complex is able to slowly react with alpha-1-proteinase inhibitor and not because the inhibitor slowly dissociates the heparin-elastase complex. These findings may have important pathophysiological bearing.			FROMMHERZ, KJ (corresponding author), UNIV LOUIS PASTEUR STRASBOURG, ENZYMOL LAB, INSERM, U237, F-67400 ILLKIRCH GRAFFENSTADEN, FRANCE.							BAICI A, 1980, BIOCHEM PHARMACOL, V29, P1723, DOI 10.1016/0006-2952(80)90131-8; BAICI A, 1984, CHEM-BIOL INTERACT, V51, P1, DOI 10.1016/0009-2797(84)90015-2; BAICI A, 1981, BIOCHEM PHARMACOL, V30, P703, DOI 10.1016/0006-2952(81)90154-4; BAICI A, 1987, BIOCHEM J, V244, P793, DOI 10.1042/bj2440793; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BIETH JG, 1980, CLIN RES PROC, V16, P183; Bieth JG, 1986, REGULATION MATRIX AC, P217; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BOUDIER C, 1981, J BIOL CHEM, V256, P256; BRAUN NJ, 1987, BIOL CHEM H-S, V368, P299, DOI 10.1515/bchm3.1987.368.1.299; BRODRICK JW, 1980, BIOCHEMISTRY-US, V19, P4865, DOI 10.1021/bi00562a025; BRUCH M, 1986, BIOCHEM J, V238, P269, DOI 10.1042/bj2380269; CAMPBELL EJ, 1988, J CELL BIOL, V106, P667, DOI 10.1083/jcb.106.3.667; CAMPBELL EJ, 1986, AM REV RESPIR DIS, V134, P435; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CASU B, 1990, HAEMOSTASIS, V20, P62; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CLARK JG, 1983, INT REV CONNECT TISS, V10, P249; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DANISHEFSKY I, 1979, BIOCHEM BIOPH RES CO, V91, P862, DOI 10.1016/0006-291X(79)91959-4; DUSWALD KH, 1985, SURGERY, V98, P892; EGBRING R, 1977, BLOOD, V49, P219; GAST A, 1990, AM REV RESPIR DIS, V141, P880, DOI 10.1164/ajrccm/141.4_Pt_1.880; GAUTHIER F, 1982, BIOCHIM BIOPHYS ACTA, V700, P178, DOI 10.1016/0167-4838(82)90095-4; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; HEINEGARD D, 1984, EXTRACELLULAR MATRIX, P277; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HORL WH, 1985, KIDNEY INT, V28, P791, DOI 10.1038/ki.1985.199; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JANOFF A, 1983, AM REV RESPIR DIS, V127, P531; JORDAN RE, 1987, SCIENCE, V237, P777, DOI 10.1126/science.3649921; MAROSSY K, 1981, BIOCHIM BIOPHYS ACTA, V659, P351, DOI 10.1016/0005-2744(81)90061-9; MARTODAM RR, 1979, PREP BIOCHEM, V9, P15, DOI 10.1080/00327487908061669; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; OGUSHI F, 1988, AM REV RESPIR DIS, V137, P364, DOI 10.1164/ajrccm/137.2.364; PADRINES M, 1989, AM REV RESPIR DIS, V139, P783, DOI 10.1164/ajrccm/139.3.783; POWERS JC, 1984, J BIOL CHEM, V259, P4288; RAO NV, 1990, AM REV RESPIR DIS, V142, P407, DOI 10.1164/ajrccm/142.2.407; REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515; SCHNEBLI HP, 1989, ELASTIN ELASTASES, V2, P137; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; STEIN PL, 1989, J BIOL CHEM, V264, P15441; STRAUS SD, 1985, BIOCHEM BIOPH RES CO, V130, P1177, DOI 10.1016/0006-291X(85)91739-5; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; Taylor JC, 1987, PULMONARY EMPHYSEMA; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TYAGI SC, 1990, BIOCHEMISTRY-US, V29, P9970, DOI 10.1021/bi00494a030	49	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15356	15362						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869557				2022-12-25	WOS:A1991GB09700079
J	CAI, DY; TIEN, M				CAI, DY; TIEN, M			LIGNIN PEROXIDASE OF PHANEROCHAETE-CHRYSOSPORIUM - EVIDENCE FOR AN ACIDIC IONIZATION CONTROLLING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COMPOUND-I FORMATION; HORSERADISH-PEROXIDASE; HYDROGEN-PEROXIDE; COMPLEX-FORMATION; KINETIC-ANALYSIS; STEADY-STATE; ENZYME; CHLOROPEROXIDASE; OXIDATION	The active site amino acid residues of lignin peroxidase are homologous to those of other peroxidases; however, in contrast to other peroxidases, no pH dependence is observed for the reaction of ferric lignin peroxidase with H2O2 to form compound I (Andrawis, A., Johnson, K. A., and Tien, M. (1988) J. Biol. Chem. 263, 1195-1198). Chloride binding is used in the present study to investigate this reaction further. Chloride binds to lignin peroxidase at the same site as cyanide and hydrogen peroxide. This is indicated by the following. 1) Chloride competes with cyanide in binding to lignin peroxidase. 2) Chloride is a competitive inhibitor of lignin peroxidase with respect to H2O2. The inhibition constant (K(i)) is equal to the dissociation constant (K(d)) of chloride at all pH values studied. Chloride binding is pH dependent: chloride binds only to the protonated form of lignin peroxidase. Transient-state kinetic studies demonstrate that chloride inhibits lignin peroxidase compound I formation in a pH-dependent manner with maximum inhibition at low pH. An apparent pK(a) was calculated at each chloride concentration; the pK(a) increased as the chloride concentration increased. Extrapolation to zero chloride concentration allowed us to estimate the intrinsic pK(a) for the ionization in the lignin peroxidase active site. The results reported here provide evidence that an acidic ionizable group (pK(a) almost-equal-to 1) at the active site controls both lignin peroxidase compound I formation and chloride binding. We propose that the mechanism for lignin peroxidase compound I formation is similar to that of other peroxidases in that it requires the deprotonated form of an ionizable group near the active site.	PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIEHS NIH HHS [1-P42ES04922-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004922] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; ANDRAWIS A, 1988, J BIOL CHEM, V263, P1195; ANDRAWIS A, 1989, BIOCHEM BIOPH RES CO, V162, P673, DOI 10.1016/0006-291X(89)92363-2; ARAISO T, 1981, J BIOL CHEM, V256, P99; ARAISO T, 1980, BIOCHEM BIOPH RES CO, V94, P1177, DOI 10.1016/0006-291X(80)90543-4; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; Cleland W W, 1979, Methods Enzymol, V63, P103; CONROY CW, 1978, BIOCHIM BIOPHYS ACTA, V537, P62, DOI 10.1016/0005-2795(78)90602-5; DEBOER HA, 1987, GENE, V60, P93, DOI 10.1016/0378-1119(87)90217-4; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; DUNFORD HB, 1979, BIOCHEM BIOPH RES CO, V89, P764, DOI 10.1016/0006-291X(79)90695-8; FERSHT A, 1985, ENZYME STRUCTURE MEC, P3; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; HARBURY HA, 1957, J BIOL CHEM, V225, P1009; IKEDASAITO M, 1987, BIOCHEMISTRY-US, V26, P4344, DOI 10.1021/bi00388a024; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; Kolthoff I.M., 1957, VOLUMETRIC ANAL, V3, P75; LAMBEIR AM, 1983, J BIOL CHEM, V258, P3558; LAMBEIR AM, 1983, J INORG BIOCHEM, V19, P291, DOI 10.1016/0162-0134(83)80002-6; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LOO S, 1975, BIOCHEMISTRY-US, V14, P3467, DOI 10.1021/bi00686a027; MILLIS CD, 1989, BIOCHEMISTRY-US, V28, P8484, DOI 10.1021/bi00447a032; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; PERRIN DD, 1969, PURE APPL CHEM, V20, P168; RENGANATHAN V, 1987, BIOCHEMISTRY-US, V26, P5127, DOI 10.1021/bi00390a035; SONO M, 1986, BIOCHEMISTRY-US, V25, P347, DOI 10.1021/bi00350a011; TIEN M, 1988, METHOD ENZYMOL, V161, P238; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; Tien M, 1987, NATURE, V326, P520, DOI 10.1038/326520a0; TIEN M, 1990, APPL ENVIRON MICROB, V56, P2540, DOI 10.1128/AEM.56.8.2540-2544.1990; YAMADA H, 1974, ARCH BIOCHEM BIOPHYS, V165, P728, DOI 10.1016/0003-9861(74)90301-4	33	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14464	14469						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860854				2022-12-25	WOS:A1991FZ35100057
J	MAVROVOUNIOTIS, ML				MAVROVOUNIOTIS, ML			ESTIMATION OF STANDARD GIBBS ENERGY CHANGES OF BIOTRANSFORMATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Contributions and corrections for the estimation of standard Gibbs energies are given. The group contribution method, applicable to both cyclic and acyclic compounds, permits the approximate estimation of the standard Gibbs energy of a biotransformation, given the stoichiometry and structures of the metabolites involved. Estimated standard Gibbs energies of formation for a number of acyclic biochemical compounds are provided.	UNIV MARYLAND,DEPT CHEM ENGN,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park	MAVROVOUNIOTIS, ML (corresponding author), UNIV MARYLAND,SYST RES CTR,AV WILLIAMS BLDG,COLLEGE PK,MD 20742, USA.							Barman T. E, 1969, ENZYME HDB, V2; Barman T.E., 1969, ENZYME HDB, VI; BARMAN TE, 1974, ENZYME HDB S, V1; Benson S.W., 1968, THERMOCHEMICAL KINET; EDSALL JT, 1983, BIOTHERMODYNAMICS; Lehninger A.L, 1975, BIOCHEMISTRY-US; Lehninger A L, 1982, PRINCIPLES BIOCH; Luscher-Mattli M., 1986, THERMODYNAMIC DATA B; MAVROVOUNIOTIS ML, 1990, BIOTECHNOL BIOENG, V36, P1070, DOI 10.1002/bit.260361013; MAVROVOUNIOTIS ML, 1990, IND ENG CHEM RES, V29, P1943, DOI 10.1021/ie00105a029; Reid R.C., 1987, PROPERTIES GASES LIQ; Sober HA, 1970, HDB BIOCH; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; 1976, J BIOL CHEM, V251, P6879	14	179	211	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14440	14445						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860851				2022-12-25	WOS:A1991FZ35100053
J	BRAND, B; BOOS, W				BRAND, B; BOOS, W			MALTOSE TRANSACETYLASE OF ESCHERICHIA-COLI - MAPPING AND CLONING OF ITS STRUCTURAL GENE, MAC, AND CHARACTERIZATION OF THE ENZYME AS A DIMER OF IDENTICAL POLYPEPTIDES WITH A MOLECULAR-WEIGHT OF 20,000	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOGALACTOSIDE TRANSACETYLASE; BINDING-PROTEIN; RESISTANCE ELEMENTS; ACTIVE-TRANSPORT; LACTOSE OPERON; RECONSTITUTION; EXPRESSION; SEQUENCE; MUTANTS; SYSTEM	malQ mutants, lacking amylomaltase, cannot grown on maltose. However, when maltose is present in the medium, it can be accumulated to high internal levels. In a subsequent slow reaction, accumulated maltose becomes acetylated and leaks back into the medium. The enzyme responsible for this acetylation uses acetyl-CoA as acetyl donor and can be measured in crude extracts (Boos, W., Ferenci, T., and Shuman, H. A. (1981) J. Bacteriol. 146, 725-732). The structural gene for the enzyme, which we named mac, was mapped at 10.4 min on the Escherichia coli linkage map. We cloned a 3.4-kilobase pair PstI-EcoRI DNA fragment containing the mac gene. Cell-free extracts of a strain harboring the multicopy plasmid were used to purify the maltose-transacetylating activity to apparent homogeneity. On sodium dodecyl sulfate-polyacrylamide gels the enzyme exhibited a molecular weight of 20,000. Using molecular sieve chromatography, a molecular weight of 40,000 was determined for the native enzyme. Therefore, the enzyme is a dimer of two identical subunits. At a sugar concentration of 100 mM the enzyme acetylates glucose, maltose, mannose, galactose, and fructose in decreasing relative rate of 1, 0.55, 0.20, 0.07, 0.04. Maltotriose and other oligosaccharides were acetylated with 2% of the rate determined for glucose. The K(m) for glucose and maltose were 62 and 90 mm, and the V(max) was 0.20 and 0. 11 mmol/min x mg enzyme, respectively.	UNIV CONSTANCE,DEPT BIOL,POB 5560,W-7750 CONSTANCE,GERMANY	University of Konstanz								ADELBERG EA, 1965, BIOCHEM BIOPH RES CO, V18, P788, DOI 10.1016/0006-291X(65)90855-7; ALPERS DH, 1965, J BIOL CHEM, V240, P10; ANDREWS KJ, 1976, J BACTERIOL, V128, P510, DOI 10.1128/JB.128.1.510-513.1976; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BIRKENBIHL RP, 1989, NUCLEIC ACIDS RES, V17, P5057, DOI 10.1093/nar/17.13.5057; BOOS W, 1990, J BACTERIOL, V172, P3450, DOI 10.1128/jb.172.6.3450-3461.1990; BOOS W, 1981, J BACTERIOL, V146, P725, DOI 10.1128/JB.146.2.725-732.1981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER E, 1988, J BACTERIOL, V170, P108, DOI 10.1128/jb.170.1.108-116.1988; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DEAN DA, 1990, J BIOL CHEM, V265, P21005; FOWLER AV, 1985, BIOCHIMIE, V67, P101, DOI 10.1016/S0300-9084(85)80235-2; FREUNDLIEB S, 1982, ANN INST PASTEUR MIC, VA133, P181; HARAYAMA S, 1983, J BACTERIOL, V153, P408, DOI 10.1128/JB.153.1.408-415.1983; HEDIGER MA, 1985, P NATL ACAD SCI USA, V82, P6414, DOI 10.1073/pnas.82.19.6414; HENGGE R, 1983, BIOCHIM BIOPHYS ACTA, V737, P443, DOI 10.1016/0304-4157(83)90009-6; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; KLECKNER N, 1977, J MOL BIOL, V116, P125, DOI 10.1016/0022-2836(77)90123-1; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MEAGHER RB, 1977, CELL, V10, P521, DOI 10.1016/0092-8674(77)90039-3; Miller J.H., 1972, EXPT MOL GENETICS; MUSSO RE, 1973, BIOCHEMISTRY-US, V12, P553, DOI 10.1021/bi00727a031; Reeve J, 1979, Methods Enzymol, V68, P493; Schwartz M, 1987, ESCHERICHIA COLI SAL; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SINGER M, 1989, MICROBIOL REV, V53, P1; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; ZABIN I, 1962, J BIOL CHEM, V237, P253	33	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14113	14118						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856235				2022-12-25	WOS:A1991FY02700100
J	HORST, M; HARTH, N; HASILIK, A				HORST, M; HARTH, N; HASILIK, A			BIOSYNTHESIS OF GLYCOSYLATED HUMAN LYSOZYME MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ASPARAGINE-LINKED OLIGOSACCHARIDES; LYSOSOMAL-ENZYMES; ESTABLISHED HUMAN; LOCALIZATION; EXPRESSION; PROTEINS; CHAINS; MONOCYTES; LINES	Complementary DNA encoding human lysozyme was subjected to oligonucleotide-directed mutagenesis. At one of three selected positions, amino acid residues 22, 68, or 118, the signal for N-linked glycosylation was created. The mutant DNAs were inserted into a eucaryotic vector and transfected into cultured hamster cells. The three mutant cDNAs directed synthesis of lysozyme mutants, which were named LI, LII, and LIII. The mutant lysozymes LI and LII comprised mixtures of glycosylated and nonglycosylated forms. The glycosylated and nonglycosylated forms of mutant LI were found to have an enzymatic activity similar to normal human milk lysozyme. The usage of the glycosylation sites in the mutants was similar in Chinese hamster ovary (CHO) and baby hamster kidney cells. Approximately two of every three molecules in mutant LI, approximately one of every eight molecules in mutant LII, and practically no molecules in mutant LIII became glycosylated. In CHO cells, the processing of the oligosaccharide side chains yielded several larger products than in baby hamster kidney cells. This size variability of glycosylated lysozyme from CHO cells may be explained by the presence of biantennary and triantennary endo-beta-N-acetylglucosaminidase H-resistant oligosaccharides with N-acetyllactosamine repeats of variable length and by the presence of hybrid oligosaccharides, as suggested by affinity to several lectins and sensitivity to endo-beta-galactosidase. In both cell types, the majority of the glycosylated forms were secreted and thus behaved similarly to nonglycosylated lysozyme. A small proportion of mutant LI lysozyme remained associated with the cells. The retained lysozyme was recruited predominantly from the molecules bearing high mannose oligosaccharides. These molecules were targeted to lysosomes, and their carbohydrate was trimmed to an endo-beta-N-acetylglucosaminidase H-resistant form. Owing to the small size of mutant LI lysozyme, minor changes in the size of its carbohydrate moiety result in detectable changes in the electrophoretic mobility of the whole glycoprotein. We suggest that this novel glycoprotein could be used as a reporter in studies on processing and segregation of glycoproteins.	UNIV MUNSTER,INST PHYSIOL CHEM & PATHOBIOCHEM,WALDEYERSTR 15,W-4400 MUNSTER,GERMANY	University of Munster								ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; CASTANON MJ, 1988, GENE, V66, P223, DOI 10.1016/0378-1119(88)90359-9; CULLY J, 1989, EXP CELL RES, V180, P440, DOI 10.1016/0014-4827(89)90070-0; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; Fleming A, 1922, P R SOC LOND B-CONTA, V93, P306, DOI 10.1098/rspb.1922.0023; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GRASSEL S, 1988, ANAL BIOCHEM, V180, P72; GUPTA DK, 1987, CLIN CHIM ACTA, V165, P73, DOI 10.1016/0009-8981(87)90220-8; GUPTA DK, 1985, BIOCHIM BIOPHYS ACTA, V847, P217, DOI 10.1016/0167-4889(85)90023-0; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LI E, 1980, ARCH BIOCHEM BIOPHYS, V199, P393, DOI 10.1016/0003-9861(80)90295-7; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; Maniatis T., 1982, MOL CLONING; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MINAMITAKE Y, 1990, J BIOCHEM-TOKYO, V107, P292, DOI 10.1093/oxfordjournals.jbchem.a123041; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUTASA HCF, 1989, EUR J CELL BIOL, V49, P319; OSSERMAN EF, 1966, J EXP MED, V124, P921, DOI 10.1084/jem.124.5.921; PAWEL B, 1989, ACTA HAEMATOL-BASEL, V81, P101; PETERS CWB, 1989, EUR J BIOCHEM, V182, P507, DOI 10.1111/j.1432-1033.1989.tb14857.x; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528; ROGERS JC, 1971, BIOCHEM BIOPH RES CO, V45, P622, DOI 10.1016/0006-291X(71)90462-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SHEARES BT, 1988, J BIOL CHEM, V263, P12778; SMITH DF, 1990, J BIOL CHEM, V265, P6225; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	43	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13914	13919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856221				2022-12-25	WOS:A1991FY02700072
J	SCHMID, PC; JOHNSON, SB; SCHMID, HHO				SCHMID, PC; JOHNSON, SB; SCHMID, HHO			REMODELING OF RAT HEPATOCYTE PHOSPHOLIPIDS BY SELECTIVE ACYL TURNOVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER IN-VIVO; FATTY-ACIDS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; DEACYLATION-REACYLATION; DIFFERENTIAL TURNOVER; INITIAL INCORPORATION; PRIMARY CULTURE; PHOSPHATIDYLETHANOLAMINE; GLYCEROLIPIDS; METABOLISM	Acyl turnover of rat hepatocyte phospholipids and triacylglycerols was assessed by incubating the cells in media containing 40% H-2 O-18 and measuring the time-dependent incorporation of O-18 into ester carbonyls by gas chromatography-mass spectrometry of hydrogenated methyl esters. Incorporation of O-18 into 22-carbon acyl groups was low in phosphatidylcholine, phosphatidylinositol, and phosphatidylserine, whereas in phosphatidylethanolamine, it was about the same as in the other acyl groups. Incorporation of O-18 into individual molecular species of phosphatidylcholine and phosphatidylethanolamine was determined after phospholipase C hydrolysis, derivatization to dinitrobenzoates, and separation by high-performance liquid chromatography. In most molecular species, acyl groups at the sn-1 and sn-2 positions became O-18-labeled at drastically different rates, indicating remodeling through deacylation-reacylation. Molecular species expected to arise de novo from acylation of glycerophosphate exhibited similar rates of O-18 incorporation at the sn-1 and sn-2 positions. The data suggest that hepatocyte phospholipids are continually synthesized, remodeled bv deacylation-reacylation at specific turnover rates up to 10-15%/h, and degraded. This acyl turnover probably does not involve the majority of intracellular unesterified fatty acids whose O-18 incorporation was found to be very low. In contrast, the oxygens of extracellular unesterified fatty acids were readily exchanged with the media. This exchange was enzyme-catalyzed, possibly by lipases released into the media from damaged cells. Incorporation of O-18 into exogenously added fatty acids was also rapid and resulted in enhanced uptake of O-18-labeled fatty acids into cellular lipids, primarily triacylglycerols and phosphatidylcholine, without drastic change of the intracellular free fatty acid pool.	UNIV MINNESOTA,HORMEL INST,801 16TH AVE NE,AUSTIN,MN 55912	University of Minnesota System					NHLBI NIH HHS [HL08214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL008214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; AKESSON B, 1976, BIOCHIM BIOPHYS ACTA, V441, P453, DOI 10.1016/0005-2760(76)90242-3; AKESSON B, 1970, BIOCHIM BIOPHYS ACTA, V218, P44, DOI 10.1016/0005-2760(70)90091-3; AKESSON B, 1970, BIOCHIM BIOPHYS ACTA, V210, P15, DOI 10.1016/0005-2760(70)90057-3; AKESSON B, 1970, BIOCHIM BIOPHYS ACTA, V218, P57, DOI 10.1016/0005-2760(70)90092-5; ARVIDSON GA, 1968, EUR J BIOCHEM, V4, P478, DOI 10.1111/j.1432-1033.1968.tb00237.x; ARVIDSON GA, 1968, EUR J BIOCHEM, V5, P415, DOI 10.1111/j.1432-1033.1968.tb00385.x; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CHAMBAZ J, 1986, BIOCHIM BIOPHYS ACTA, V878, P310, DOI 10.1016/0005-2760(86)90238-9; CURSTEDT T, 1974, BIOCHIM BIOPHYS ACTA, V369, P196, DOI 10.1016/0005-2760(74)90251-3; FOLCH J, 1957, J BIOL CHEM, V226, P497; FOX PL, 1982, BIOCHIM BIOPHYS ACTA, V712, P605, DOI 10.1016/0005-2760(82)90289-2; GEELEN MJH, 1980, DIABETES, V29, P1006, DOI 10.2337/diab.29.12.1006; GROENER JEM, 1978, BIOCHIM BIOPHYS ACTA, V529, P88, DOI 10.1016/0005-2760(78)90106-6; HILL EE, 1968, J BIOL CHEM, V243, P4440; HOLUB BJ, 1971, CAN J BIOCHEM CELL B, V49, P1347, DOI 10.1139/o71-195; HOLUB BJ, 1971, J LIPID RES, V12, P699; HOLUB BJ, 1971, LIPIDS, V6, P307, DOI 10.1007/BF02531820; HOLUB BJ, 1971, CAN J BIOCHEM CELL B, V49, P1005, DOI 10.1139/o71-147; INFANTE JP, 1987, TRENDS BIOCHEM SCI, V12, P131, DOI 10.1016/0968-0004(87)90062-4; KANOH H, 1977, BIOCHIM BIOPHYS ACTA, V486, P511, DOI 10.1016/0005-2760(77)90101-1; KANOH H, 1969, BIOCHIM BIOPHYS ACTA, V176, P756; KANOH H, 1973, BIOCHIM BIOPHYS ACTA, V306, P203; Krebs H.A., 1974, REGULATION HEPATIC M, P726; KUWAE T, 1987, BIOCHEM BIOPH RES CO, V142, P86, DOI 10.1016/0006-291X(87)90454-2; KUWAE T, 1990, J BIOL CHEM, V265, P5002; LAMB RG, 1983, BIOCHIM BIOPHYS ACTA, V753, P356, DOI 10.1016/0005-2760(83)90059-0; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; LANDS WEM, 1965, J BIOL CHEM, V240, P1905; MILLER MA, 1986, J BIOL CHEM, V261, P9753; OKUYAMA H, 1975, J BIOL CHEM, V250, P1710; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; SAMBORSKI RW, 1990, J BIOL CHEM, V265, P18322; SARZALA M G, 1970, Biochimica et Biophysica Acta, V202, P106, DOI 10.1016/0005-2760(70)90222-5; SCHLENK H, 1960, ANAL CHEM, V32, P1412, DOI 10.1021/ac60167a011; SCHMID PC, 1988, CHEM PHYS LIPIDS, V46, P165, DOI 10.1016/0009-3084(88)90018-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUNDLER R, 1974, BIOCHIM BIOPHYS ACTA, V337, P248, DOI 10.1016/0005-2760(74)90206-9; SUNDLER R, 1974, J BIOL CHEM, V249, P5102; SUNDLER R, 1973, BIOCHIM BIOPHYS ACTA, V306, P218, DOI 10.1016/0005-2760(73)90227-0; SUNDLER R, 1975, BIOCHEM J, V146, P309, DOI 10.1042/bj1460309; SUNDLER R, 1972, BIOCHIM BIOPHYS ACTA, V280, P559, DOI 10.1016/0005-2760(72)90136-1; SUNDLER R, 1974, FEBS LETT, V43, P303, DOI 10.1016/0014-5793(74)80667-8; TAKAMURA H, 1986, LIPIDS, V21, P356, DOI 10.1007/BF02535701; THOMAS G, 1988, BIOCHEM J, V256, P641, DOI 10.1042/bj2560641; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TIJBURG LBM, 1989, BIOCHEM BIOPH RES CO, V160, P1275, DOI 10.1016/S0006-291X(89)80141-X; TINOCO J, 1967, LIPIDS, V2, P479, DOI 10.1007/BF02533175; TINOCO J, 1970, LIPIDS, V5, P412, DOI 10.1007/BF02532107; TREWHELLA MA, 1973, BIOCHIM BIOPHYS ACTA, V296, P34, DOI 10.1016/0005-2760(73)90041-6; TREWHELLA MA, 1973, BIOCHIM BIOPHYS ACTA, V296, P51, DOI 10.1016/0005-2760(73)90042-8; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE JE, 1988, BIOCHIM BIOPHYS ACTA, V963, P70, DOI 10.1016/0005-2760(88)90339-6; VANDENBOSCH H, 1974, ANNU REV BIOCHEM, V43, P243; VANGOLDE LM, 1969, BIOCHIM BIOPHYS ACTA, V176, P635, DOI 10.1016/0005-2760(69)90231-8; VANGOLDE LMG, 1977, LIPID METABOLISM MAM, V1, P35; VEREYKEN JM, 1972, BIOCHIM BIOPHYS ACTA, V260, P70, DOI 10.1016/0005-2760(72)90075-6; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; WEISS SB, 1958, J BIOL CHEM, V231, P53	60	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13690	13697						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856202				2022-12-25	WOS:A1991FY02700038
J	TU, GF; ACHEN, MG; ALDRED, AR; SOUTHWELL, BR; SCHREIBER, G				TU, GF; ACHEN, MG; ALDRED, AR; SOUTHWELL, BR; SCHREIBER, G			THE DISTRIBUTION OF CEREBRAL EXPRESSION OF THE TRANSFERRIN GENE IS SPECIES-SPECIFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CHOROID-PLEXUS; GROWTH FACTOR-II; TRANSCRIPT PREVALENCE LEVELS; TRANSTHYRETIN MESSENGER-RNA; MOLECULAR TITRATION ASSAY; ACID-PROTEIN TRANSFERASE; CEREBROSPINAL-FLUID; PLASMA-PROTEINS; ENZYMATIC MODIFICATION; NUCLEOTIDE-SEQUENCE	Various plasma proteins, for example, transferrin, are synthesized not only in the liver, but also in the brain. The proportion of transferrin mRNA in total RNA from different regions of brains from various mammalian species was studied by Northern blot analysis. Absolute amounts of transferrin mRNA were determined in brain, choroid plexus, and liver from rats, sheep, and pigs by hybridization in solution followed by ribonuclease protection assay. Corrections for differences in yields of RNA were made using internal RNA standards. Large proportions of transferrin mRNA in total RNA and high absolute levels of transferrin mRNA in choroid plexus were found only in rats. Small proportions of transferrin mRNA were observed in RNA from choroid plexus from mice, dogs, and rabbits, while no transferrin mRNA at all was detected in choroid plexus from humans, sheep, pigs, cows, and guinea pigs. In further analysis of sheep and pigs, various amounts of transferrin mRNA were found in many parts of the brain, in contrast to the absence of transferrin mRNA from choroid plexus. In conclusion, a striking species specificity was observed for the pattern of cerebral expression of the transferrin gene.	UNIV MELBOURNE,RUSSELL GRIMWADE SCH BIOCHEM,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne				Achen, Marc/0000-0002-3791-803X; Southwell, Bridget Rae/0000-0003-3439-9366				ALDRED AR, 1987, J BIOL CHEM, V262, P5293; ALDRED AR, 1984, BIOCHEM BIOPH RES CO, V122, P960, DOI 10.1016/0006-291X(84)91185-9; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALDWIN GS, 1988, NUCLEIC ACIDS RES, V16, P8720, DOI 10.1093/nar/16.17.8720; BLOCH B, 1987, BRAIN RES BULL, V18, P573, DOI 10.1016/0361-9230(87)90122-5; BLOCH B, 1985, P NATL ACAD SCI USA, V82, P6706, DOI 10.1073/pnas.82.19.6706; BRADBURY M, 1979, CONCEPT BLOOD BRAIN, P1; BRIGHTMAN MW, 1975, CHOROID PLEXUS HLTH, P86; COLE T, 1989, EUR J BIOCHEM, V186, P35, DOI 10.1111/j.1432-1033.1989.tb15174.x; DICKSON PW, 1985, BIOCHEM BIOPH RES CO, V127, P890, DOI 10.1016/S0006-291X(85)80027-9; DICKSON PW, 1986, NEUROSCI LETT, V66, P311, DOI 10.1016/0304-3940(86)90037-6; DICKSON PW, 1987, J BIOL CHEM, V262, P13907; DICKSON PW, 1985, J BIOL CHEM, V260, P8214; DICKSON PW, 1986, J BIOL CHEM, V261, P3475; DILLNERCENTERLIND ML, 1979, EUR J IMMUNOL, V9, P942, DOI 10.1002/eji.1830091207; DUAN W, 1989, NUCLEIC ACIDS RES, V17, P3979, DOI 10.1093/nar/17.10.3979; DZIEGIELEWSKA KM, 1985, DEV BRAIN RES, V23, P259, DOI 10.1016/0165-3806(85)90048-3; DZIEGIELEWSKA KM, 1980, J PHYSIOL-LONDON, V300, P457, DOI 10.1113/jphysiol.1980.sp013172; DZIEGIELEWSKA KM, 1986, DEV BIOL, V115, P93, DOI 10.1016/0012-1606(86)90231-9; DZIEGIELEWSKA KM, 1984, INT J DEV NEUROSCI, V2, P215, DOI 10.1016/0736-5748(84)90015-7; DZIEGIELEWSKA KM, 1982, COMP BIOCHEM PHYS A, V73, P327, DOI 10.1016/0300-9629(82)90079-2; EVANS HE, 1973, ANAT HISTOL EMBRYOL, V2, P11, DOI DOI 10.1111/J.1439-0264.1973.TB00253.X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FELGENHAUER K, 1974, KLIN WOCHENSCHR, V52, P1158, DOI 10.1007/BF01466734; FUNG WP, 1988, J BIOL CHEM, V263, P480; GOYA N, 1972, BLOOD-J HEMATOL, V40, P239, DOI 10.1182/blood.V40.2.239.239; GROSS PM, 1987, J CEREBR BLOOD F MET, V7, P663, DOI 10.1038/jcbfm.1987.120; HEILMEYER L, 1961, DEUT MED WOCHENSCHR, V86, P1745, DOI 10.1055/s-0028-1113001; HERBERT J, 1986, NEUROLOGY, V36, P900, DOI 10.1212/WNL.36.7.900; HURLEY JV, 1981, J PATHOL, V134, P57, DOI 10.1002/path.1711340107; HYNES MA, 1988, MOL ENDOCRINOL, V2, P47, DOI 10.1210/mend-2-1-47; ICHIMIYA Y, 1988, MOL BRAIN RES, V4, P167, DOI 10.1016/0169-328X(88)90009-5; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P3723, DOI 10.1073/pnas.83.11.3723; II I, 1982, DEV BIOL, V94, P366, DOI 10.1016/0012-1606(82)90354-2; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; KATO M, 1986, DIFFERENTIATION, V31, P228, DOI 10.1111/j.1432-0436.1986.tb00402.x; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAURELL CB, 1947, ACTA CHEM SCAND, V1, P770, DOI 10.3891/acta.chem.scand.01-0770; LAURELL CB, 1952, PHARMACOL REV, V4, P371; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LEIBOWITZ JM, 1971, J BIOL CHEM, V246, P5207; LEIBOWITZ MJ, 1970, J BIOL CHEM, V245, P2066; LEVIN MJ, 1984, BIOCHEM BIOPH RES CO, V122, P212, DOI 10.1016/0006-291X(84)90461-3; LINDVALLAXELSSON M, 1988, EXP NEUROL, V99, P362, DOI 10.1016/0014-4886(88)90154-9; Maniatis T., 1982, MOL CLONING; MERCER JFB, 1985, NUCLEIC ACIDS RES, V13, P7929, DOI 10.1093/nar/13.22.7929; MITA S, 1986, J BIOCHEM-TOKYO, V100, P1215, DOI 10.1093/oxfordjournals.jbchem.a121826; MOLLGARD K, 1979, NEUROSCI LETT, V14, P85, DOI 10.1016/0304-3940(79)95349-7; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; MORGAN EH, 1969, J BIOL CHEM, V244, P4193; New H, 1983, Int J Dev Neurosci, V1, P369, DOI 10.1016/0736-5748(83)90018-7; OH TH, 1982, J NEUROSCI RES, V8, P535, DOI 10.1002/jnr.490080239; OZAWA E, 1983, MUSCULAR DYSTROPHY B, P53; PLOESER JM, 1949, J BIOL CHEM, V178, P431; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBE.G, 1969, EUR J BIOCHEM, V10, P355, DOI 10.1111/j.1432-1033.1969.tb00698.x; SCHREIBER G, 1966, CANCER RES, V26, P2357; SCHREIBER G, 1990, AM J PHYSIOL, V258, pR338; SCHREIBER G, 1979, J BIOL CHEM, V254, P2013; Schreiber G, 1978, Rev Physiol Biochem Pharmacol, V82, P27, DOI 10.1007/BFb0030497; SCHREIBER G, 1981, ARCH BIOCHEM BIOPHYS, V212, P319, DOI 10.1016/0003-9861(81)90372-6; SHIMOOKA T, 1986, J CELL PHYSIOL, V126, P341, DOI 10.1002/jcp.1041260304; SOFFER RL, 1973, J BIOL CHEM, V248, P8424; SOFFER RL, 1966, BIOCHEM BIOPH RES CO, V23, P252, DOI 10.1016/0006-291X(66)90537-7; SOFFER RL, 1968, BIOCHIM BIOPHYS ACTA, V155, P228, DOI 10.1016/0005-2787(68)90352-3; SOFFER RL, 1971, J BIOL CHEM, V246, P1602; SOFFER RL, 1969, J MOL BIOL, V43, P163, DOI 10.1016/0022-2836(69)90086-2; SOFFER RL, 1970, J BIOL CHEM, V245, P731; SOFFER RL, 1969, COLD SPRING HARB SYM, V34, P529, DOI 10.1101/SQB.1969.034.01.060; STAUDER AJ, 1986, J HISTOCHEM CYTOCHEM, V34, P949, DOI 10.1177/34.7.3458812; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMAS T, 1989, DEV BIOL, V134, P38, DOI 10.1016/0012-1606(89)90076-6; THOMAS T, 1988, DEV BIOL, V128, P415, DOI 10.1016/0012-1606(88)90303-X; TSENG LYH, 1989, MOL ENDOCRINOL, V3, P1559, DOI 10.1210/mend-3-10-1559; TSUTSUMI M, 1989, J BIOL CHEM, V264, P9626; TU GF, 1989, NUCLEIC ACIDS RES, V17, P6384, DOI 10.1093/nar/17.15.6384; URBAN J, 1974, ANAL BIOCHEM, V58, P102, DOI 10.1016/0003-2697(74)90446-1; UZAN G, 1984, BIOCHEM BIOPH RES CO, V119, P273, DOI 10.1016/0006-291X(84)91648-6; WAKASUGI S, 1986, J BIOCHEM-TOKYO, V100, P49, DOI 10.1093/oxfordjournals.jbchem.a121705; WALSH MJ, 1984, J NEUROCHEM, V43, P1277, DOI 10.1111/j.1471-4159.1984.tb05384.x; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; YANG FM, 1984, P NATL ACAD SCI-BIOL, V81, P2752, DOI 10.1073/pnas.81.9.2752	84	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6201	6208						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1848850				2022-12-25	WOS:A1991FE37300033
J	BURGESS, GM; BIRD, GSJ; OBIE, JF; PUTNEY, JW				BURGESS, GM; BIRD, GSJ; OBIE, JF; PUTNEY, JW			THE MECHANISM FOR SYNERGISM BETWEEN PHOSPHOLIPASE-C-LINKED AND ADENYLYLCYCLASE-LINKED HORMONES IN LIVER - CYCLIC AMP-DEPENDENT KINASE AUGMENTS INOSITOL TRISPHOSPHATE-MEDIATED CA2+ MOBILIZATION WITHOUT INCREASING THE CELLULAR-LEVELS OF INOSITOL POLYPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HEPATOCYTES; CYTOSOLIC CALCIUM; 1,4,5-TRISPHOSPHATE RECEPTOR; FURA-2-LOADED HEPATOCYTES; STIMULATED HEPATOCYTES; RAT HEPATOCYTES; RELEASE; CELLS; CAMP; VASOPRESSIN	The ability of cAMP-dependent hormones to modulate the actions of Ca2+-mobilizing hormones was studied in single fura-2-injected guinea pig hepatocytes. In 91% of cells the cAMP-linked hormone, isoproterenol, applied alone, did not alter cytosolic Ca2+ concentration. In 78% of cells which had been pre-exposed to a low concentration of angiotensin II, isoproterenol was able to increase cytosolic Ca2+. Isoproterenol did not, however, increase inositol 1,4,5-trisphosphate or inositol tetrakisphosphate on its own, or in the presence of angiotensin II. Isoproterenol was also able to raise cytosolic Ca2+ concentration in cells microinjected with inositol 2,4,5-triphosphate or a photoactivatable derivative of inositol 1,4,5-trisphosphate. The elevation of cytosolic Ca2+ concentration induced by isoproterenol in angiotensin II-treated cells and cells injected with caged inositol 1,4,5-trisphosphate was blocked by heparin, implying that the effect was mediated by an inositol 1,4,5-trisphosphate receptor agonist. In permeabilized hepatocytes, inositol 1,4,5-trisphosphate-induced Ca2+ release was enhanced by 8-bromo-cAMP and the catalytic subunit of cAMP-dependent kinase. Cyclic AMP-dependent kinase shifted the dose-response curve for inositol 1,4,5-trisphosphate-mediated Ca2+ release to the left by a factor of 4 and increased the total amount of Ca2+ released by 25%. These results indicate that increased sensitivity of the intracellular Ca2+ releasing organelle to inositol 1,4,5-trisphosphate is responsible for synergism between phospholipase C- and adenylylcyclase-linked hormones in the liver.	SANDOZ INST MED RES,LONDON WC1E 6BN,ENGLAND	Novartis; Sandoz	BURGESS, GM (corresponding author), NATL INST ENVIRONM HLTH,CALCIUM REGULAT SECT,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709, USA.		Bird, Gary/AAI-8186-2021; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James/0000-0002-3379-4789				BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BURGESS GM, 1986, MOL PHARMACOL, V30, P315; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; BURGESS GM, 1984, BIOCHEM J, V224, P741, DOI 10.1042/bj2240741; CAPIOD T, 1989, Pfluegers Archiv European Journal of Physiology, V414, pS162, DOI 10.1007/BF00582283; CAPIOD T, 1990, J PHYSL, V427, P22; CHENG HC, 1986, J BIOL CHEM, V261, P989; COCKS TM, 1984, BRIT J PHARMACOL, V83, P281, DOI 10.1111/j.1476-5381.1984.tb10144.x; DEAN NM, 1987, BIOCHEM J, V242, P361, DOI 10.1042/bj2420361; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FIELD AC, 1987, J PHYSIOL-LONDON, V392, P493, DOI 10.1113/jphysiol.1987.sp016793; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; JENKINSON DH, 1977, BRIT J PHARMACOL, V59, P163, DOI 10.1111/j.1476-5381.1977.tb06991.x; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; MAUGER JP, 1989, J BIOL CHEM, V264, P8821; MINTA A, 1989, J BIOL CHEM, V264, P8171; MONCK JR, 1988, J BIOL CHEM, V263, P4569; MORGAN NG, 1984, P NATL ACAD SCI-BIOL, V81, P4208, DOI 10.1073/pnas.81.13.4208; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PITTNER RA, 1989, BIOCHEM J, V257, P455, DOI 10.1042/bj2570455; POGGIOLI J, 1986, BIOCHEM J, V235, P663, DOI 10.1042/bj2350663; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; WALAAS SI, 1986, J NEUROSCI, V6, P954; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619	38	171	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4772	4781						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848225				2022-12-25	WOS:A1991FC21700019
J	SUZUKI, H; HOSOKAWA, Y; NISHIKIMI, M; OZAWA, T				SUZUKI, H; HOSOKAWA, Y; NISHIKIMI, M; OZAWA, T			EXISTENCE OF COMMON HOMOLOGOUS ELEMENTS IN THE TRANSCRIPTIONAL REGULATORY REGIONS OF HUMAN NUCLEAR GENES AND MITOCHONDRIAL GENE FOR THE OXIDATIVE-PHOSPHORYLATION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-DEPENDENT GENES; DNA; SEQUENCE; IDENTIFICATION; EXPRESSION; UPSTREAM; ORGANIZATION; GENOME; YEAST; INITIATION	Our previous study indicated that nuclear protein factors of HeLa cells specifically bind to three nuclear Mt elements, Mt1, Mt3, and Mt4, located in the 5'-flanking regions of the human nuclear genes for cytochrome c1 and for ubiquinone-binding protein, both of which are subunits of mitochondrial cytochrome bc1 complex (Suzuki, H., Hosokawa, Y., Toda, H., Nishikimi, M., and Ozawa, T. (1990) J. Biol. Chem. 265, 8159-8163). In this study, we examined whether the same nuclear factors could recognize a set of the Mt3 and Mt4 elements that were found in the displacement loop and the promoter region of mammalian mitochondrial genomes. Gel retardation experiments disclosed that the same nuclear protein factors specifically bind to those Mt elements in the human mitochondrial genome as well as to the nuclear Mt3 and Mt4 elements of the two genes, and that the coexistence of both the elements is required for the efficient binding. The nuclear protein factors which recognize the Mt elements located in the regulatory regions of the nuclear and mitochondrial genes may play an important role in coordinate expression of the two physically separated genes during mitochondrial biogenesis.	NAGOYA UNIV,FAC MED,DEPT BIOMED CHEM,TSURUMA CHO 65,SHOWA KU,NAGOYA,AICHI 466,JAPAN; INST APPL BIOCHEM,MITAKE,GIFU 50101,JAPAN	Nagoya University								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BROWN GG, 1986, J MOL BIOL, V192, P503, DOI 10.1016/0022-2836(86)90272-X; CHANG DD, 1986, MOL CELL BIOL, V6, P1446, DOI 10.1128/MCB.6.5.1446; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHEN SJ, 1989, ONCOGENE, V4, P195; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; DORSMAN JC, 1988, NUCLEIC ACIDS RES, V16, P7287, DOI 10.1093/nar/16.15.7287; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KING TC, 1987, J BIOL CHEM, V262, P6204; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; LIU HT, 1985, MOL CELL BIOL, V5, P2936, DOI 10.1128/MCB.5.11.2936; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; NAJARIAN D, 1987, MOL CELL BIOL, V7, P185, DOI 10.1128/MCB.7.1.185; OHTA S, 1988, J BIOL CHEM, V263, P11257; OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TANAKA M, 1989, BIOCHEM BIOPH RES CO, V164, P156, DOI 10.1016/0006-291X(89)91696-3; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TOPPER JN, 1989, MOL CELL BIOL, V9, P1200, DOI 10.1128/MCB.9.3.1200; VANTUYLE GC, 1981, J BIOL CHEM, V256, P2772; YAMAMOTO A, 1989, BIOCHEM BIOPH RES CO, V159, P1100, DOI 10.1016/0006-291X(89)92222-5; zawa T, 1987, BIOENERGETICS STRUCT, P101	32	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2333	2338						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1846623				2022-12-25	WOS:A1991EV51500050
J	MORRISON, RS				MORRISON, RS			SUPPRESSION OF BASIC FIBROBLAST GROWTH-FACTOR EXPRESSION BY ANTISENSE OLIGODEOXYNUCLEOTIDES INHIBITS THE GROWTH OF TRANSFORMED HUMAN ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLIOMA-CELLS; ENDOTHELIAL-CELLS; FACTOR CDNA; NUCLEOTIDE-SEQUENCE; HUMAN KERATINOCYTES; GENE AMPLIFICATION; MESSENGER-RNA; B-CHAIN; PDGF-A; RECEPTOR	Basic fibroblast growth factor (bFGF) is a heparin-binding protein expressing potent mitogenic and angiogenic properties. Elevated levels of bFGF have recently been described in human glioma cell lines. The high degree of vascularity and invasiveness which characterize human gliomas suggest that activated expression of bFGF or similar proteins may be related to the aberrant growth patterns of these tumors. The influence of endogenous bFGF on glioma cell growth in vitro was evaluated in the present study by down-regulating bFGF expression using antisense oligonucleotide primers. The addition of 50-mu-M bFGF-specific antisense primer to the human glioma cell line SNB-19 resulted in an 80% inhibition in glioma growth. This effect was saturable and specific. Antisense primers directed to two different sites of bFGF mRNA were effective in suppressing SNB-19 growth, whereas sense strand primer was ineffective. Furthermore, only the antisense primer significantly reduced the specific activity of bFGF protein in SNB-19 cell extracts. Neither antisense or sense primers inhibited the growth of non-transformed human glia. bFGF mRNA was detected in both transformed and nontransformed human glia by polymerase chain reaction analysis suggesting that alterations in bFGF isoform content or activity may be specifically related to abnormal growth control in human gliomas.	GOOD SAMARITAN HOSP, CTR COMPREHENS CANC, PORTLAND, OR 97209 USA		MORRISON, RS (corresponding author), GOOD SAMARITAN HOSP, ROBERT S DOW NEUROL SCI INST, PORTLAND, OR 97209 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026125] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26125-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BIGNER SH, 1988, J NEUROPATH EXP NEUR, V47, P191, DOI 10.1097/00005072-198805000-00001; BLAM SB, 1988, ONCOGENE, V3, P129; BOHLEN P, 1985, FEBS LETT, V185, P177, DOI 10.1016/0014-5793(85)80765-1; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; CHODAK GW, 1988, CANCER RES, V48, P2083; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; COURTY J, 1986, BIOCHEM BIOPH RES CO, V136, P102, DOI 10.1016/0006-291X(86)90882-X; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIDSON JM, 1985, J CELL BIOL, V100, P1219, DOI 10.1083/jcb.100.4.1219; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GROSS JL, 1988, CANCER RES, V48, P291; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1988, ONCOGENE RES, V3, P177; HATTEN ME, 1988, DEV BIOL, V125, P280, DOI 10.1016/0012-1606(88)90211-4; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; JANET T, 1987, NEUROSCI LETT, V80, P153, DOI 10.1016/0304-3940(87)90645-8; JANET T, 1988, J NEUROSCI RES, V19, P195, DOI 10.1002/jnr.490190204; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISON RS, 1981, P NATL ACAD SCI-BIOL, V78, P7205, DOI 10.1073/pnas.78.11.7205; MORRISON RS, 1990, CANCER RES, V50, P2524; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; PAULUS W, 1990, ACTA NEUROPATHOL, V79, P418, DOI 10.1007/BF00308718; PETTMANN B, 1986, NEUROSCI LETT, V68, P175, DOI 10.1016/0304-3940(86)90137-0; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SATO Y, 1989, MOL ENDOCRINOL, V3, P744, DOI 10.1210/mend-3-4-744; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SHAPIRO JR, 1986, SEMIN ONCOL, V13, P4; SHIPLEY GD, 1989, J CELL PHYSIOL, V138, P511, DOI 10.1002/jcp.1041380310; SLACK JMW, 1989, DEVELOPMENT, V105, P147; STERNFELD MD, 1988, J CELL PHYSIOL, V136, P297, DOI 10.1002/jcp.1041360212; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WESTPHAL M, 1988, CANCER LETT, V38, P283, DOI 10.1016/0304-3835(88)90020-1; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	59	165	185	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					728	734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845992				2022-12-25	WOS:A1991ET17700011
J	WU, LNY; GENGE, BR; LLOYD, GC; WUTHIER, RE				WU, LNY; GENGE, BR; LLOYD, GC; WUTHIER, RE			COLLAGEN-BINDING PROTEINS IN COLLAGENASE-RELEASED MATRIX VESICLES FROM CARTILAGE - INTERACTION BETWEEN MATRIX VESICLE PROTEINS AND DIFFERENT TYPES OF COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND ALKALINE-PHOSPHATASE; HUMAN VONWILLEBRAND-FACTOR; MOLECULAR WEIGHT COLLAGEN; GROWTH PLATE CARTILAGE; MEDIATED MINERALIZATION; EPIPHYSEAL CARTILAGE; POLYACRYLAMIDE GELS; MEMBRANE-PROTEIN; HYALURONIC-ACID; ANCHORIN-CII	Recent evidence indicates that matrix vesicles (MV) interact with cartilage-specific collagens and other matrix proteins. Both type II and X collagens bind to and cosediment with MV. Our companion study shows that MV also are tightly coupled to proteoglycan link proteins (LP) and hyaluronic acid-binding region (HABR) in cartilage matrix. Here we sought to identify proteins responsible for the nexus between MV and matrix collagens using affinity chromatography with types I, II, and X collagen-Sepharose columns. Elution with NaCl step-gradients in the presence of nonionic detergent was used to assess the affinity between the MV proteins and the covalently attached collagens. Several MV proteins were found to bind to native type I, II, and X collagens but none bound to denatured type I collagen. Alkaline phosphatase, proteoglycan LP and HABR, and the 33- and 67-kDa annexins, bound with varying affinities to the native type I, II and X columns. In particular, LP and HABR, the 67-kDa annexin, and alkaline phosphatase bound with high affinity to the cartilage-specific collagens, although LP, HABR, and a 37-kDa protein also bound less tightly to native type I collagen. Thus, several MV proteins bind specifically to native type II and X collagens and should promote interaction between MV and the extracellular matrix. Such interactions may be important in MV formation, or in MV-mediated mineralization.	UNIV S CAROLINA,DEPT CHEM,BIOMINERALIZAT RES LAB,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NIAMS NIH HHS [AR18983] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018983] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; BLAKESLEY RW, 1977, ANAL BIOCHEM, V82, P580, DOI 10.1016/0003-2697(77)90197-X; BONUCCI E, 1969, Z ZELLFORSCH MIKROSK, V103, P192; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; CAMPBELL RD, 1984, PHILOS T ROY SOC B, V306, P367, DOI 10.1098/rstb.1984.0097; CHANDRASEKHAR S, 1983, J BIOL CHEM, V258, P6226; CHANDRASEKHAR S, 1986, P NATL ACAD SCI USA, V83, P5126, DOI 10.1073/pnas.83.14.5126; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; CYBORON GW, 1981, J BIOL CHEM, V256, P7262; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1988, J BIOL CHEM, V263, P18513; GENGE BR, 1989, THESIS U S CAROLINA; HAIGLER HT, 1989, TRENDS BIOCHEM SCI, V14, P48, DOI 10.1016/0968-0004(89)90041-8; HARDINGHAM TE, 1974, BIOCHEM J, V139, P565, DOI 10.1042/bj1390565; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HASCALL VC, 1974, J BIOL CHEM, V249, P4232; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1987, METHOD ENZYMOL, V145, P336; HEWITT AT, 1982, J BIOL CHEM, V257, P2330; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHTO VP, 1980, BIOCHEM BIOPH RES CO, V95, P909, DOI 10.1016/0006-291X(80)91559-4; LOW MG, 1987, BIOCHEM J, V244, P1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; OIDA S, 1984, ANAL BIOCHEM, V140, P117, DOI 10.1016/0003-2697(84)90141-6; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; SAJDERA S, 1969, J BIOL CHEM, V244, P77; SCHMID TM, 1982, J BIOL CHEM, V257, P2451; SCHMID TM, 1982, J BIOL CHEM, V257, P2444; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SUDHOF TC, 1985, J NEUROCHEM, V44, P1302, DOI 10.1111/j.1471-4159.1985.tb08757.x; SUDHOF TC, 1984, BIOCHEMISTRY-US, V23, P1103; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSONIS PA, 1988, BIOCHEM J, V254, P623, DOI 10.1042/bj2540623; VANDERREST M, 1985, J BIOL CHEM, V260, P220; WU LNY, 1989, J BIOL CHEM, V264, P21346; WU LNY, 1991, J BIOL CHEM, V266, P1187; WU LNY, 1989, BONE MINER, V7, P113, DOI 10.1016/0169-6009(89)90069-X; Wuthier R.E., 1982, CLIN ORTHOP RELAT R, V169, P219; WUTHIER RE, 1988, ISI ATLAS-BIOCHEM, V1, P231; WUTHIER RE, 1985, J BIOL CHEM, V260, P5972	49	137	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1195	1203						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1845989				2022-12-25	WOS:A1991ET17700080
J	AIKENS, J; DIX, TA				AIKENS, J; DIX, TA			PERHYDROXYL RADICAL (HOO.) INITIATED LIPID-PEROXIDATION - THE ROLE OF FATTY-ACID HYDROPEROXIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE-INDUCED AUTOXIDATION; LINOLEIC-ACID; XANTHINE-OXIDASE; HYDROGEN-ATOM; SUPEROXIDE; REACTIVITY; MECHANISM; REARRANGEMENT; PURIFICATION; METABOLITES	It is demonstrated that the perhydroxyl radical (HOO., the conjugate acid of superoxide (O2-)), initiates fatty acid peroxidation (a model for biological lipid peroxidation) by two parallel pathways: fatty acid hydroperoxide (LOOH)-independent and LOOH-dependent. Previous workers (Gebicki, J. M., and Bielski, B. H. J. (1981) J. Am. Chem. Soc. 103, 7020-7025) demonstrated that HOO., generated by pulse radiolysis, initiates peroxidation in ethanol/water fatty acid dispersions by abstraction of the bis-allylic hydrogen atom from a polyunsaturated fatty acid. Addition Of O2 to the fatty acid radicals forms peroxyl radicals (LOO.s), the chain-propagating species of lipid peroxidation. In this work it is demonstrated that HOO., generated either chemically (KO2) or enzymatically (xanthine oxidase), is a good initiator of fatty acid peroxidation in linoleic acid ethanol/water dispersions; O2- serves only as the source of HOO., and HOO. initiation can be observed at physiologically relevant pH values. In contrast to the previous results, the initiating effectiveness of HOO. is related directly to the initial concentration of LOOHs in the lipids to be peroxidized. This defines a LOOH-dependent mechanism for fatty acid peroxidation initiation by HOO., which parallels the previously established LOOH-independent pathway. Since the LOOH-dependent pathway is much more facile than the LOOH-independent pathway, LOOH is the kinetically preferred site of HOO. attack in these systems. Experiments comparing HOO./LOOH-dependent fatty acid peroxidation with transition metal- and peroxyl radical-initiated peroxidation rule out the participation of the latter two species as initiators, which defines the HOO./LOOH initiation system as mechanistically unique. LOOH product studies are consistent with either a direct or indirect hydrogen atom transfer between LOOH and HOO. to yield LOO.s, which propagate peroxidation. The LOOH-dependent pathway of HOO.-initiated fatty acid peroxidation may be relevant to mechanisms of lipid peroxidation initiation in vivo.	UNIV CALIF IRVINE, DEPT CHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine					NIGMS NIH HHS [GM40338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUDI RL, 1983, J LIPID RES, V24, P485; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BEHAR D, 1970, J PHYS CHEM-US, V74, P3209, DOI 10.1021/j100711a009; BENSON SW, 1971, ORGANIC PEROXIDES, V1, P132; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BIELSKI BHJ, 1983, J BIOL CHEM, V258, P4759; BORS W, 1979, FEBS LETT, V107, P403, DOI 10.1016/0014-5793(79)80417-2; BRAWN K, 1980, ACTA PHYSIOL SCAND, P9; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; CHAN HWS, 1979, CHEM PHYS LIPIDS, V24, P245, DOI 10.1016/0009-3084(79)90030-6; CHENIER JHB, 1975, CAN J CHEM, V53, P623, DOI 10.1139/v75-088; DIX TA, 1985, J BIOL CHEM, V260, P5351; FANTONE JC, 1982, AM J PATHOL, V107, P397; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; FRIDOVICH I, 1988, OXYGEN RADICALS TISS, P1; FUNK MO, 1976, LIPIDS, V11, P113, DOI 10.1007/BF02532660; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GEBICKI JM, 1981, J AM CHEM SOC, V103, P7020, DOI 10.1021/ja00413a066; GIBIAN MJ, 1979, J AM CHEM SOC, V101, P1291, DOI 10.1021/ja00499a047; HALLIWELL B, 1988, OXYGEN RADICALS TISS; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hendry D. G., 1974, Journal of Physical and Chemical Reference Data, V3, P937, DOI 10.1063/1.3253151; INGOLD KU, 1969, ACCOUNTS CHEM RES, V2, P1, DOI 10.1021/ar50013a001; Kagan V. E, 1988, LIPID PEROXIDATION B; LOKESH BR, 1986, TOXICOL LETT, V34, P75, DOI 10.1016/0378-4274(86)90147-5; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MILAS NA, 1959, J AM CHEM SOC, V81, P3358, DOI 10.1021/ja01522a050; NAKAMURA S, 1969, BIOCHIM BIOPHYS ACTA, V189, P29, DOI 10.1016/0005-2728(69)90221-7; OBERLEY LW, 1985, SUPEROXIDE DISMUTASE; PETERS JW, 1976, J AM CHEM SOC, V98, P873, DOI 10.1021/ja00419a058; PORTER NA, 1984, J AM CHEM SOC, V106, P2626, DOI 10.1021/ja00321a022; PORTER NA, 1986, ACCOUNTS CHEM RES, V19, P262, DOI 10.1021/ar00129a001; PORTER NA, 1981, J AM CHEM SOC, V103, P6447, DOI 10.1021/ja00411a032; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; PRYOR WA, 1976, FREE RADICALS, V1; SAWYER DT, 1983, INORG CHEM, V22, P2577, DOI 10.1021/ic00160a022; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SAWYER DT, 1988, CHEM RES TOXICOL, V1, P97, DOI 10.1021/tx00002a002; SINGAL PK, 1988, OXYGEN RADICALS PATH; Sosnovsky G., 1971, ORGANIC PEROXIDES, V2, P153; STANLEY JP, 1980, J ORG CHEM, V45, P1413, DOI 10.1021/jo01296a014; SUTHERLAND MW, 1982, ARCH BIOCHEM BIOPHYS, V214, P1, DOI 10.1016/0003-9861(82)90001-7; THOMAS MJ, 1982, J BIOL CHEM, V257, P8343; THOMAS MJ, 1978, BIOCHEM BIOPH RES CO, V83, P927, DOI 10.1016/0006-291X(78)91484-5; THOMAS MJ, 1984, ARCH BIOCHEM BIOPHYS, V233, P772, DOI 10.1016/0003-9861(84)90505-8; VILE G F, 1986, Journal of Free Radicals in Biology and Medicine, V2, P393, DOI 10.1016/S0748-5514(86)80041-1; WEISS SJ, 1982, LAB INVEST, V47, P5	48	166	172	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15091	15098						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869544				2022-12-25	WOS:A1991GB09700047
J	DYER, CA; SMITH, RS; CURTISS, LK				DYER, CA; SMITH, RS; CURTISS, LK			ONLY MULTIMERS OF A SYNTHETIC PEPTIDE OF HUMAN APOLIPOPROTEIN-E ARE BIOLOGICALLY-ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; T-LYMPHOTROPIC VIRUS; AMINO-ACID-SEQUENCE; LYMPHOCYTE-PROLIFERATION; BINDING DOMAIN; INHIBITION; CHOLESTEROL; SURFACE; LIVER	Plasma apolipoprotein E (apoE) is a ligand for the cellular uptake of cholesterol-rich plasma lipoproteins. ApoE also inhibits mitogen-stimulated lymphocyte proliferation and gonadotropin-stimulated ovarian theca/interstitial cell androgen production. To address the mechanism(s) by which apoE is active and to understand its interaction with the target cells, we prepared and examined the inhibitory activity of a series of apoE synthetic peptides. ApoE peptides representing amino acid residues 93-112, 141-155, 161-171, 172-182, and 174-193 were not active in either bioassay. However, specific inhibition of both lymphocyte proliferation and ovarian androgen production was observed with a self-conjugate of peptide-(141-155). Furthermore, a synthesized dimeric peptide representing two repeats of sequence-(141-155) (i.e. (141-155)-(141-155)) was active as well. In both bioassays, the inhibition observed was not a result of direct cell killing. Furthermore, these apoE peptides exhibited activities with characteristics that were shared with those of native apoE. The results indicate that amino acid residues 141-155 of apoE are responsible for the biological activity of apoE. Furthermore, the results suggest that dimers or multimers of native apoE may be a biologically important species.	JOHNSON & JOHNSON BIOTECHNOL CTR, LA JOLLA, CA 92038 USA	Johnson & Johnson	DYER, CA (corresponding author), Scripps Res Inst, RES INST, DEPT IMMUNOL, IMM-17, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-32497] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1989, ATHEROSCLEROSIS, V3, P293; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; CARDIN AD, 1988, BIOCHEM BIOPH RES CO, V154, P741, DOI 10.1016/0006-291X(88)90202-1; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; CURTISS LK, 1984, J IMMUNOL, V133, P1379; CURTISS LK, 1988, J BIOL CHEM, V263, P13779; CURTISS LK, 1987, J CLIN INVEST, V80, P367, DOI 10.1172/JCI113081; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; DRISCOLL DM, 1985, J BIOL CHEM, V260, P9031; DYER CA, 1988, J BIOL CHEM, V263, P10965; DYER CA, 1983, FED PROC, V42, P316; EDGINGTON TS, 1983, DIETARY FATS HLTH, P901; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FUNAHASHI T, 1989, J BIOCHEM-TOKYO, V105, P582, DOI 10.1093/oxfordjournals.jbchem.a122708; GIULIAN GG, 1985, FED PROC, V44, P686; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIRS C, 1954, J BIOL CHEM, V241, P941; HOARE DG, 1967, J BIOL CHEM, V242, P2447; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LENARD J, 1967, J AM CHEM SOC, V89, P181, DOI 10.1021/ja00977a057; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCONATHY WJ, 1989, FEBS LETT, V251, P250, DOI 10.1016/0014-5793(89)81464-4; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PEPE MG, 1986, J IMMUNOL, V136, P3716; PITAS RE, 1980, J BIOL CHEM, V255, P5454; RALL SC, 1982, J BIOL CHEM, V257, P4171; RUEGG CL, 1989, J VIROL, V63, P3257, DOI 10.1128/JVI.63.8.3257-3260.1989; RUEGG CL, 1989, J VIROL, V63, P3250, DOI 10.1128/JVI.63.8.3250-3256.1989; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; SODROSKI J, 1984, SCIENCE, V225, P421, DOI 10.1126/science.6204380; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348	46	40	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15009	15015						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869538				2022-12-25	WOS:A1991GB09700034
J	JANSSEN, GMC; MORALES, J; SCHIPPER, A; LABBE, JC; MULNERLORILLON, O; BELLE, R; MOLLER, W				JANSSEN, GMC; MORALES, J; SCHIPPER, A; LABBE, JC; MULNERLORILLON, O; BELLE, R; MOLLER, W			A MAJOR SUBSTRATE OF MATURATION PROMOTING FACTOR IDENTIFIED AS ELONGATION FACTOR-1-BETA-PSI-DELTA IN XENOPUS-LAEVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYPEPTIDE-CHAIN ELONGATION; PROGESTERONE-INDUCED MATURATION; PROTEIN-SYNTHESIS; FACTOR-I; SILK GLAND; PIG LIVER; M-PHASE; PURIFICATION; OOCYTES; ARTEMIA	Protein synthesis is believed to be under control of the cell cycle during meiosis and mitosis. Any relationship between substrates for cdc2 kinase and components of the protein synthetic apparatus would therefore be of prime importance. During meiosis of Xenopus laevis oocytes one of the substrates for this kinase is a p47 protein, which is complexed to two other proteins, P36 and P30. Judged from partial amino acid sequence data on P47 and P30, the P30 and P47 proteins were reported to resemble the protein synthetic elongation factors (EF) 1-beta and 1-gamma from Artemia salina (Belle, R., Derancourt, J., Poulhe, R., Capony, J. P., Ozon, R., and Mulner-Lorillon, O. (1989) FEBS Lett. 255, 101-104). This paper shows that the complex composed of P30, P47, and P36 from Xenopus is identical to the complex of EF-1-beta, EF-1-gamma, and EF-1-delta from Artemia according to two criteria. 1) Both stimulate elongation factor 1-alpha-mediated transfer RNA binding to ribosomes and exchange of guanine nucleotides on elongation factor 1-alpha to a comparable degree. 2) Each of the three subunits of the protein complex P30.P47.P36 from Xenopus shows a structural homology with one of the corresponding subunits of EF-1-beta-gamma-delta from Artemia. Presumably the phosphorylation of EF-1-gamma, which associates with tubulin at least in vitro, is important in processes following the onset of meiosis which is accompanied by a rise of protein synthesis.	UNIV PARIS 06,INRA,PHYSIOL REPROD LAB,CNRS,UNITE 555,F-75252 PARIS 05,FRANCE; CTR RECH BIOCHIM MACROMOLEC,CNRS,UNITE PROPRE RECH,INSERM,U249,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	JANSSEN, GMC (corresponding author), LEIDEN UNIV,SYLVIUS LAB,DEPT MED BIOCHEM,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.		labbe, jean-claude/B-2277-2009	Morales, Julia/0000-0003-1632-5419				BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; BELLE R, 1978, BIOL CELLULAIRE, V32, P97; BELLE R, 1990, International Journal of Developmental Biology, V34, P111; CARVALHO JF, 1984, ARCH BIOCHEM BIOPHYS, V234, P591, DOI 10.1016/0003-9861(84)90309-6; CATSIMPOOLAS N, 1968, ANAL BIOCHEM, V26, P480, DOI 10.1016/0003-2697(68)90219-4; CRECHET JB, 1986, EUR J BIOCHEM, V161, P635, DOI 10.1111/j.1432-1033.1986.tb10488.x; EJIRI S, 1983, J BIOCHEM-TOKYO, V94, P319, DOI 10.1093/oxfordjournals.jbchem.a134348; EJIRI S, 1978, FEBS LETT, V95, P277, DOI 10.1016/0014-5793(78)81010-2; EJIRI S, 1978, FEBS LETT, V92, P251, DOI 10.1016/0014-5793(78)80764-9; EJIRI S, 1989, INT S MOL ORG BIOL S, P238; GIULIAN GG, 1984, ANAL BIOCHEM, V142, P421, DOI 10.1016/0003-2697(84)90486-X; GRASMUK H, 1978, EUR J BIOCHEM, V92, P479, DOI 10.1111/j.1432-1033.1978.tb12770.x; IWASAKI K, 1976, J BIOL CHEM, V251, P1843; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JANSSEN GMC, 1990, RIBOSOMES PROTEIN SY, P51; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAESSEN GDF, 1986, FEBS LETT, V208, P77, DOI 10.1016/0014-5793(86)81536-8; MAESSEN GDF, 1987, FEBS LETT, V223, P181, DOI 10.1016/0014-5793(87)80532-X; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MULNERLORILLON O, 1989, FEBS LETT, V251, P219, DOI 10.1016/0014-5793(89)81458-9; MURAKAMI K, 1983, J NEUROCHEM, V40, P866, DOI 10.1111/j.1471-4159.1983.tb08060.x; OZON R, 1987, MOL REGULATION NUCLE, P111; RICHTER JD, 1982, DEV BIOL, V89, P159, DOI 10.1016/0012-1606(82)90304-9; SLOBIN LI, 1978, EUR J BIOCHEM, V84, P69, DOI 10.1111/j.1432-1033.1978.tb12142.x; SLOBIN LI, 1979, EUR J BIOCHEM, V96, P287, DOI 10.1111/j.1432-1033.1979.tb13039.x; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; WASSERMAN WJ, 1982, DEV BIOL, V89, P152, DOI 10.1016/0012-1606(82)90303-7; ZASLOFF M, 1971, P NATL ACAD SCI USA, V68, P3059, DOI 10.1073/pnas.68.12.3059	34	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14885	14888						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869528				2022-12-25	WOS:A1991GB09700015
J	MATTINGLY, RR; STEPHENS, LR; IRVINE, RF; GARRISON, JC				MATTINGLY, RR; STEPHENS, LR; IRVINE, RF; GARRISON, JC			EFFECTS OF TRANSFORMATION WITH THE V-SRC ONCOGENE ON INOSITOL PHOSPHATE-METABOLISM IN RAT-1 FIBROBLASTS - D-MYO-INOSITOL 1,4,5,6-TETRAKISPHOSPHATE IS INCREASED IN V-SRC-TRANSFORMED RAT-1 FIBROBLASTS AND CAN BE SYNTHESIZED FROM D-MYO-INOSITOL 1,3,4-TRISPHOSPHATE IN CYTOSOLIC EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; ROUS-SARCOMA VIRUS; 1,4,5-TRISPHOSPHATE 3-KINASE ACTIVITY; INDUCED CA-2+ MOBILIZATION; AGONIST-INDUCED REGULATION; AR42J PANCREATOMA CELLS; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL METABOLISM; TETRAKISPHOSPHATE ISOMERS	Rat-1 fibroblasts transformed with the v-src oncogene show a 6-fold increase in the apparent amount of an inositol polyphosphate which has a high performance liquid chromatography (HPLC) elution characteristic of the D/L-myo-inositol 1,4,5,6-tetrakisphosphate enantiomeric pair (Johnson, R. M., Wasilenko, W. J., Mattingly, R. R., Weber, M. J., and Garrison, J. C. (1989) Science 246, 121-124). By chemical and enzymatic analysis, the structure of this compound produced in both normal and v-src-transformed rat-1 fibroblasts has been determined to be principally D-myoinositol 1,4,5,6-tetrakisphosphate (D-Ins(1,4,5,6)P4). Chronic stimulation with endothelin-1 in the presence of Li+ significantly increased the amount of D/L-Ins(1,4,5,6)P4 only in the v-src-transformed rat-1 cells, suggesting that production of this compound may be remotely coupled to long term agonist-induced phosphatidylinositol turnover. Further evidence for such a link is provided by the progressive loss of D-Ins(1,4,5,6)P4 from the normal cells deprived of serum stimulation. To define a possible synthetic pathway for D-Ins(1,4,5,6)P4, cytosolic extracts of normal and v-src-transformed cells were incubated with [H-3]inositol polyphosphates, and the reaction products were identified by HPLC elution and chemical analysis. Although inositol 1,3,4-trisphosphate 6-kinase activity was prominent in extracts of both normal and transformed cells, only the cytosol from v-src-transformed cells ultimately formed measurable amounts of D-Ins(1,4,5,6)P4 from [H-3]inositol 1,3,4-trisphosphate. Approximately 6% of 0.1-mu-M inositol 1,3,4-trisphosphate was converted to D-Ins(1,4,5,6)P4 during a 2-h incubation at 37-degrees-C. Inositol pentakisphosphate was identified as a likely intermediate in this conversion, and extracts of both normal and transformed cells converted [H-3]inositol 1,3,4,5,6-pentakisphosphate to D-Ins(1,4,5,6)P4. The synthetic pathway described is consistent with the long term regulation of D/L-Ins(1,4,5,6)P4 levels in rat-1 fibroblasts seen in response to src transformation, serum withdrawal, and chronic endothelin treatment, and identifies several new potential interactions between the pathways of inositol polyphosphate metabolism and those of src transformation.	UNIV VIRGINIA, SCH MED, CANC RES CTR, CHARLOTTESVILLE, VA 22908 USA; AFRC, INST ANIM PHYSIOL, DEPT BIOCHEM, CAMBRIDGE CB2 4AT, ENGLAND	University of Virginia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	MATTINGLY, RR (corresponding author), UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA.			stephens, len/0000-0002-2771-3487	NCI NIH HHS [CA-40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLA T, 1989, J BIOL CHEM, V264, P9386; BALLA T, 1987, BIOCHEM BIOPH RES CO, V148, P199, DOI 10.1016/0006-291X(87)91095-3; BALLA T, 1989, J BIOL CHEM, V264, P13605; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIDEN TJ, 1988, BIOCHEM J, V256, P697, DOI 10.1042/bj2560697; BIDEN TJ, 1988, BIOCHEM J, V251, P435, DOI 10.1042/bj2510435; CHIARUGI V, 1987, ONCOGENE, V2, P37; DIRINGER H, 1977, CANCER RES, V37, P2979; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GRAY GM, 1989, ONCOGENE, V4, P1213; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; IMBODEN JB, 1987, J CLIN INVEST, V79, P1538, DOI 10.1172/JCI112986; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACARA IG, 1985, AM J PHYSIOL, V248, pC3, DOI 10.1152/ajpcell.1985.248.1.C3; MARTINS TJ, 1989, J CELL BIOL, V108, P683, DOI 10.1083/jcb.108.2.683; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PITTET D, 1989, J BIOL CHEM, V264, P18489; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; SIM SS, 1990, J BIOL CHEM, V265, P10367; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; Stephens L. R., 1990, METHODS INOSITIDE RE, P9; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; WHITMAN M, 1989, BIOCHIM BIOPHYS ACTA, V948, P327, DOI 10.1016/0304-419X(89)90005-X	39	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15144	15153						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1869546				2022-12-25	WOS:A1991GB09700053
J	HARLAN, DM; GRAFF, JM; STUMPO, DJ; EDDY, RL; SHOWS, TB; BOYLE, JM; BLACKSHEAR, PJ				HARLAN, DM; GRAFF, JM; STUMPO, DJ; EDDY, RL; SHOWS, TB; BOYLE, JM; BLACKSHEAR, PJ			THE HUMAN MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) GENE (MACS) - ANALYSIS OF ITS GENE-PRODUCT, PROMOTER, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; PROMINENT CELLULAR SUBSTRATE; MAJOR SPECIFIC SUBSTRATE; MESSENGER-RNA LEVELS; PHORBOL ESTERS; PROTEIN-PHOSPHORYLATION; FACTOR-ALPHA; 3T3 CELLS; INDEPENDENT PATHWAYS; NUCLEOTIDE-SEQUENCE	The expression of a major cellular substrate for protein kinase C, the MARCKS protein, is regulated in a cell-, tissue-, and developmental stage-specific fashion; in addition, this expression can be stimulated acutely by various cytokines in certain cell types. We have begun to characterize the human gene in order to elucidate the genetic elements responsible for this highly regulated expression. We first cloned a human MARCKS cDNA, which encoded a predicted protein of 332 amino acids (M(r) 31,600) that was approximately 89, 74, and 59% identical to the bovine, mouse, and chicken proteins, respectively. Regions conserved at the amino acid level included the amino-terminal myristoylation consensus sequence, the site of intron splicing, and the phosphorylation site domain. The human cDNA was used to demonstrate that tumor necrosis factor-alpha could rapidly stimulate MARCKS gene transcription in the human promyelocytic leukemia cell line HL60. Genomic clones were then isolated; sequence analysis identified a putative promoter region that had no TATA box and contained multiple transcription initiation sites in a region spanning 57 base pairs (bp). This was followed by a 5'-untranslated region of approximately 400 bp, which displayed a complex predicted secondary structure with a DELTA-G of -73.4 kcal/mol. Plasmid constructions containing between 52 and 1453 bp of the human MARCKS promoter linked to the human growth hormone gene were then used in transient expression experiments. Constructions containing 52 and 110 bp of the MARCKS promoter did not exhibit promoter function while the larger constructions all exhibited promoter function; the 248-bp fragment of the MARCKS promoter was 80% as effective as the human ferritin promoter in stimulating expression of human growth hormone in intact cells. Using an insert from the human genomic clone as a probe, we identified human chromosome 6, q21-qter, as the location of the MARCKS gene; this has been assigned the gene symbol MACS.	DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & GENET,DIABET & METAB SECT,BOX 3897,DURHAM,NC 27710; HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263; CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT BIOCHEM GENET,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND	Duke University; Duke University; Roswell Park Cancer Institute; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NICHD NIH HHS [HD05196] Funding Source: Medline; NIGMS NIH HHS [GM20454] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020454] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BISHOP R, 1985, MOL CELL BIOL, V5, P2231, DOI 10.1128/MCB.5.9.2231; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BLACKSHEAR PJ, 1986, MECHANISMS INSULIN A, P211; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOYLE JM, 1990, HUM GENET, V84, P455; BOYLE JM, 1988, HUM GENET, V81, P88, DOI 10.1007/BF00283737; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P264; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GOODFELLOW PN, 1982, P NATL ACAD SCI-BIOL, V79, P1190, DOI 10.1073/pnas.79.4.1190; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GRZESCHIK KH, 1978, CYTOGENET CELL GENET, V22, P412, DOI 10.1159/000130985; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; JAMES G, 1989, J BIOL CHEM, V264, P20928; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LANGRIDGE J, 1980, ANAL BIOCHEM, V103, P264, DOI 10.1016/0003-2697(80)90266-3; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LIN JX, 1987, J BIOL CHEM, V262, P11908; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Maniatis T., 1982, MOL CLONING; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MCALPINE PJ, 1989, CYTOGENET CELL GENET, V51, P13, DOI 10.1159/000132780; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P2556, DOI 10.1073/pnas.83.8.2556; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OUIMET CC, 1990, J NEUROSCI, V10, P1683; PATEL J, 1987, J BIOL CHEM, V262, P16686; PAULSSON Y, 1989, EXP CELL RES, V180, P490, DOI 10.1016/0014-4827(89)90075-X; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; PFIZENMAIER K, 1987, J IMMUNOL, V138, P975; REIS LFL, 1989, J BIOL CHEM, V264, P16351; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1984, P NATL ACAD SCI USA, V81, P2975; SAKAGUCHI AY, 1984, MOL CELL BIOL, V4, P989, DOI 10.1128/MCB.4.5.989; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH BM, 1988, J BIOL CHEM, V263, P6424; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STUMPO DJ, 1989, NUCLEIC ACIDS RES, V17, P3987, DOI 10.1093/nar/17.10.3987; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WILLISON K, 1987, EMBO J, V6, P1967, DOI 10.1002/j.1460-2075.1987.tb02459.x; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	73	94	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14399	14405						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860846				2022-12-25	WOS:A1991FZ35100046
J	JEANSONNE, NE; JAZWINSKI, SM; DONOSO, LA				JEANSONNE, NE; JAZWINSKI, SM; DONOSO, LA			A 48-KDA, S-ANTIGEN-LIKE PHOSPHOPROTEIN IN YEAST DNA-REPLICATIVE COMPLEX PREPARATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-PRIMASE COMPLEX; SIGNAL TRANSDUCTION; PROTEIN; ARRESTIN; RECEPTOR; DROSOPHILA; RETINA; PARTICIPATION; PHOTORECEPTOR; SUBUNIT	A 48-kDa protein from the budding yeast Saccharomyces cerevisiae is antigenically and structurally similar to S-antigen from retina. Eight anti-S-antigen monoclonal antibodies, directed against distinct epitopes, cross-reacted with a yeast 48-kDa protein. Structural similarity between the bovine and yeast proteins was further demonstrated by comparison of tryptic peptide fragments containing one of these epitopes. This 48-kDa yeast protein appears to be a component of the replicative complex of the cell. It was found associated with immunoaffinity-purified yeast DNA polymerase I-primase and with yeast DNA-replicative complex. The 48-kDa protein was phosphorylated by a protein kinase activity endogenous to the replicative complex preparation. This phosphorylation was dependent on the cell division cycle gene CDC7. In addition, authentic bovine S-antigen, when added to yeast DNA polymerase I-primase, stimulated polymerase activity. These findings suggest that the yeast S-antigen-like protein may play a role in replication, and they raise the possibility that it may be involved in traversal of the G1/S boundary of the cell cycle.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70112 USA; WILLS EYE HOSP & RES INST, PHILADELPHIA, PA 19107 USA	Louisiana State University System; Jefferson University					NATIONAL EYE INSTITUTE [R01EY005095] Funding Source: NIH RePORTER; NEI NIH HHS [EY5095, EY5520] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; DONOSO LA, 1987, AM J OPHTHALMOL, V103, P57, DOI 10.1016/S0002-9394(14)74170-4; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; DONOSO LA, 1985, INVEST OPHTH VIS SCI, V26, P561; FAURE JP, 1990, CURR EYE RES, V9, P163, DOI 10.3109/02713689008999437; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; HArgrave PA, 1982, PROGR RET RES, V1, P1; HERSKOWITZ I, 1987, CELL, V50, P995, DOI 10.1016/0092-8674(87)90162-0; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JAZWINSKI SM, 1990, UCLA SYM BI, V123, P189; JAZWINSKI SM, 1985, J BIOL CHEM, V260, P4995; JAZWINSKI SM, 1988, P NATL ACAD SCI USA, V85, P2101, DOI 10.1073/pnas.85.7.2101; JAZWINSKI SM, 1982, P NATL ACAD SCI-BIOL, V79, P3428, DOI 10.1073/pnas.79.11.3428; JAZWINSKI SM, 1987, BIOCHEM J, V246, P213, DOI 10.1042/bj2460213; JAZWINSKI SM, 1984, J BIOL CHEM, V259, P6852; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KNOSPE V, 1989, CURR EYE RES, V7, P1137; LOSHE J, 1990, SCIENCE, V248, P1547; MIRSHAHI M, 1989, FEBS LETT, V258, P240, DOI 10.1016/0014-5793(89)81663-1; PERENTES E, 1987, AM J OPHTHALMOL, V103, P647, DOI 10.1016/S0002-9394(14)74324-7; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PLEVANI P, 1988, BIOCHIM BIOPHYS ACTA, V951, P268, DOI 10.1016/0167-4781(88)90096-6; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SHINOHARA T, 1988, PROGR RETINAL RES, V8, P51; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671	34	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14675	14680						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860866				2022-12-25	WOS:A1991FZ35100086
J	MITSUBUCHI, H; NOBUKUNI, Y; ENDO, F; MATSUDA, I				MITSUBUCHI, H; NOBUKUNI, Y; ENDO, F; MATSUDA, I			STRUCTURAL ORGANIZATION AND CHROMOSOMAL LOCALIZATION OF THE GENE FOR THE E1-BETA SUBUNIT OF HUMAN BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP URINE DISEASE; LIVER-TYPE ARGINASE; NUCLEOTIDE-SEQUENCE; PROMOTER REGION; MOLECULAR-CLONING; E1-ALPHA SUBUNIT; CDNA SEQUENCE; MESSENGER-RNA; LINKED GENE; COMPLEX	A defect in the E1-beta-subunit of the branched chain alpha-keto acid dehydrogenase (BCKDH) complex is one cause of maple syrup urine disease (MSUD). In an attempt to elucidate the molecular basis of MSUD, we isolated and characterized the cDNA of the E1-beta-subunit of BCKDH. Using the cDNA as a probe, a chromosomal gene related to E1-beta-subunit of human BCKDH was isolated from human gene libraries. The gene of E1-beta-subunit is over 100 kilobases long and is split into 10 exons. All of the splice donor and acceptor sites conform to the GT/AG rule. The transcription initiation site was determined by nuclease S1 mapping and primer extension and was located 47 bases upstream from the initiation codon. A "CAAT" box and its reverse complement sequences were present at 39 bases and 75 bases upstream from the cap site, but there was no "TATA" box-like sequence. There were three sets of sequences resembling the transcription factor Sp1-binding sites and two sets of sequences resembling the enhancer core sequence. We also analyzed the chromosomal localization of the gene for the E1-beta-subunit of BCKDH. The gene was mapped to chromosome 6. Knowledge of the gene structure of human BCKDH E1-beta-subunit will facilitate further studies on the expression and regulation of this gene and provide necessary information for analyses of mutations in patients with MSUD.	KUMAMOTO UNIV, SCH MED, DEPT PEDIAT, HONJO 1-1-1, KUMAMOTO 860, JAPAN	Kumamoto University								AGARWAL KL, 1981, J BIOL CHEM, V256, P1023; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRIGGS MR, 1989, SCIENCE, V245, P371; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUANG JL, 1990, FEBS LETT, V262, P305, DOI 10.1016/0014-5793(90)80215-5; DANNER DJ, 1989, J BIOL CHEM, V264, P7742; Danner DJ, 1989, METABOLIC BASIS INHE, P671; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER CW, 1989, J BIOL CHEM, V264, P3448; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HATA A, 1988, J BIOCHEM-TOKYO, V103, P302, DOI 10.1093/oxfordjournals.jbchem.a122265; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HUMMEL KB, 1988, J BIOL CHEM, V263, P6165; IIZUKA M, 1990, CANCER RES, V50, P3345; INDO Y, 1988, HUM GENET, V80, P6, DOI 10.1007/BF00451447; INDO Y, 1987, J CLIN INVEST, V80, P63, DOI 10.1172/JCI113064; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JINNO Y, 1985, J BIOCHEM-TOKYO, V98, P1395, DOI 10.1093/oxfordjournals.jbchem.a135407; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIM SH, 1986, NUCLEIC ACIDS RES, V14, P3103, DOI 10.1093/nar/14.7.3103; LAU KS, 1988, BIOCHEMISTRY-US, V27, P1972, DOI 10.1021/bi00406a025; LEWIN B, 1983, GENES, P174; Maniatis T., 1982, MOL CLONING; MARTINI G, 1986, EMBO J, V5, P1849, DOI 10.1002/j.1460-2075.1986.tb04436.x; MATSUDA I, 1990, BIOCHEM BIOPH RES CO, V172, P646, DOI 10.1016/0006-291X(90)90723-Z; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MITSUBUCHI H, 1991, J CLIN INVEST, V87, P1207, DOI 10.1172/JCI115120; NOBUKUNI Y, 1990, J CLIN INVEST, V86, P242, DOI 10.1172/JCI114690; NOBUKUNI Y, 1991, J CLIN INVEST, V87, P1862, DOI 10.1172/JCI115209; NOBUKUNI Y, 1990, BIOCHEMISTRY-US, V29, P1154, DOI 10.1021/bi00457a009; NOBUKUNI Y, 1989, BIOCHEM BIOPH RES CO, V161, P1035, DOI 10.1016/0006-291X(89)91347-8; OHTAKE A, 1988, J BIOL CHEM, V263, P2245; OLSON S, 1990, AM J HUM GENET, V46, P340; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; PONS G, 1988, P NATL ACAD SCI USA, V85, P1422, DOI 10.1073/pnas.85.5.1422; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; TAKIGUCHI M, 1987, P NATL ACAD SCI USA, V84, P6136, DOI 10.1073/pnas.84.17.6136; TAKIGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8789, DOI 10.1093/nar/16.18.8789; Tanaka K, 1983, METABOLIC BASIS INHE, P440; TANOUE A, 1990, J BIOL CHEM, V265, P11306; TIU A B, 1988, American Journal of Human Genetics, V43, pA17; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VANOMMEN GJ, 1983, NUCLEIC ACIDS RES, V11, P2273; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WILKS A, 1981, GENE, V16, P249, DOI 10.1016/0378-1119(81)90081-0; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; YOSHIDA MC, 1975, P JPN ACAD, V51, P184, DOI 10.2183/pjab1945.51.184; ZHANG B, 1988, GENE, V69, P159, DOI 10.1016/0378-1119(88)90390-3	53	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14686	14691						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860867				2022-12-25	WOS:A1991FZ35100088
J	MURATA, M; KAGIWADA, S; TAKAHASHI, S; OHNISHI, SI				MURATA, M; KAGIWADA, S; TAKAHASHI, S; OHNISHI, SI			MEMBRANE-FUSION INDUCED BY MUTUAL INTERACTION OF THE 2 CHARGE-REVERSED AMPHIPHILIC PEPTIDES AT NEUTRAL PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; AMPHIPATHIC PEPTIDE; AMINO-ACID; LIPOSOMES; MECHANISM; MELITTIN; PROTEIN; BINDING; DESTABILIZATION; SEQUENCE	An anionic amphiphilic peptide and the charge-reversed cationic peptide are synthesized. They contain 20 amino acids with the same sequence except for 5 Glu residues for the anionic versus 5 Lys residues for the cationic peptides. Fusion of egg phosphatidylcholine large unilamellar vesicles is assayed with the fluorescent probes by the lipid mixing and the internal content mixing at neutral pH. The peptide mixture causes a rapid and efficient membrane fusion, in spite of no fusions with each peptide by itself. Each peptide takes nearly random coils with a small amount of helix, but the peptide mixture has an ordered helical structure. The equimolar peptide mixture forms a much more hydrophobic complex than those of different molar ratios of peptides and also that of each peptide itself. The equimolar peptide mixture causes the most efficient fusion. Preincubations of two peptides before addition to vesicles cause the slower rates of fusion. The fusion is greatly reduced at higher ionic strength and nearly zero at 800 mM NaCl and 40 mM sodium phosphate. Each peptide and the peptide mixture show the same alpha-helical structure, interact with vesicles, but do not induce fusion at higher ionic strengths. These results suggest that the two peptides interact mutually through the electrostatic Coulombic interaction between the charged groups. The electrically neutralized hydrophobic complex aggregates the separate vesicles together and interacts with the hydrocarbon region of lipid bilayers to cause fusion.	KYOTO UNIV, INST CHEM RES, UJI, KYOTO 611, JAPAN	Kyoto University	MURATA, M (corresponding author), KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 606, JAPAN.							BONDESON J, 1990, BIOCHIM BIOPHYS ACTA, V1026, P186, DOI 10.1016/0005-2736(90)90063-T; BORDIER C, 1981, J BIOL CHEM, V256, P1604; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; DUZGUNES N, 1987, CELL FUSION, P241; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LUCY JA, 1984, FEBS LETT, V166, P223, DOI 10.1016/0014-5793(84)80085-X; MURATA M, 1987, BIOCHEMISTRY-US, V26, P4056, DOI 10.1021/bi00387a047; MURATA M, 1987, J BIOCHEM-TOKYO, V102, P957, DOI 10.1093/oxfordjournals.jbchem.a122137; Ohnishi Shun-Ichi, 1988, Curr Top Membr Transp, V32, P257, DOI 10.1016/S0070-2161(08)60137-9; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; PORTIS A, 1979, BIOCHEMISTRY-US, V18, P780, DOI 10.1021/bi00572a007; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; SHEN DF, 1982, BIOCHIM BIOPHYS ACTA, V689, P31, DOI 10.1016/0005-2736(82)90185-7; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TAKAHASHI S, 1990, BIOCHEMISTRY-US, V29, P6527; TOURNOIS H, 1990, BIOCHEMISTRY-US, V29, P8297, DOI 10.1021/bi00488a014; VOGEL H, 1981, FEBS LETT, V134, P37, DOI 10.1016/0014-5793(81)80545-5; WALTER A, 1986, BIOCHIM BIOPHYS ACTA, V861, P319, DOI 10.1016/0005-2736(86)90434-7; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011	26	36	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14353	14358						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1860844				2022-12-25	WOS:A1991FZ35100039
J	MENDOZA, JA; ROGERS, E; LORIMER, GH; HOROWITZ, PM				MENDOZA, JA; ROGERS, E; LORIMER, GH; HOROWITZ, PM			UNASSISTED REFOLDING OF UREA UNFOLDED RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; CONFORMATIONAL-CHANGES ACCOMPANY; CHLORIDE-DENATURED RHODANESE; NON-COVALENT AGGREGATION; BOVINE LIVER RHODANESE; GUANIDINIUM CHLORIDE; OXIDATIVE INACTIVATION; LACTIC-DEHYDROGENASE; ENZYME RHODANESE; ATP HYDROLYSIS	In vitro refolding after urea unfolding of the enzyme rhodanese (thiosulfate:cyanide sulfurtransferase, EC 2.8.1.1) normally requires the assistance of detergents or chaperonin proteins. No efficient, unassisted, reversible unfolding/folding transition has been demonstrated to date. The detergents or the chaperonin proteins have been proposed to stabilize folding intermediates that kinetically limit folding by aggregating. Based on this hypothesis, we have investigated a number of experimental conditions and have developed a protocol for refolding, without assistants, that gives evidence of a reversible unfolding transition and leads to > 80% recovery of native enzyme. In addition to low protein concentration (10-mu-g/ml), low temperatures are required to maximize refolding. Otherwise optimal conditions give < 10% refolding at 37-degrees-C, whereas at 10-degrees-C the recovery approaches 80%. The unfolding/refolding phases of the transition curves are most similar in the region of the transition, and refolding yields are significantly reduced when unfolded rhodanese is diluted to low urea concentrations, rather than to concentrations near the transition region. This is consistent with the formation of "sticky" intermediates that can remain soluble close to the transition region. Apparently, nonnative structures, e.g. aggregates, can form rapidly at low denaturant concentrations, and their subsequent conversion to the native structure is slow.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284; DUPONT CO,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	University of Texas System; University of Texas Health San Antonio; DuPont			Rogers, Elizabeth/AAB-3643-2021; Rogers, Elizabeth E/D-2087-2009	Rogers, Elizabeth/0000-0002-0545-4744; Rogers, Elizabeth E/0000-0002-0545-4744	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, BIOCHIM BIOPHYS ACTA, V956, P30, DOI 10.1016/0167-4838(88)90294-4; Ellis R J, 1990, Semin Cell Biol, V1, P1; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ P, 1987, J BIOL CHEM, V262, P5587; HOROWITZ PM, 1988, J BIOL CHEM, V263, P10278; HOROWITZ PM, 1986, J BIOL CHEM, V261, P13887; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; OGATA K, 1989, J BIOL CHEM, V264, P2718; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; Ploegman J.H., 1978, NATURE, V273, P1245; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUDOLPH R, 1979, BIOCHEMISTRY-US, V18, P5572, DOI 10.1021/bi00592a008; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1990, J BIOL CHEM, V265, P5967; TANDON S, 1987, J BIOL CHEM, V262, P4486; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	30	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13587	13591						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856195				2022-12-25	WOS:A1991FY02700023
J	WANG, LX; KADUCE, TL; SPECTOR, AA				WANG, LX; KADUCE, TL; SPECTOR, AA			MYRISTIC ACID UTILIZATION AND PROCESSING IN BC3H1 MUSCLE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; GLYCOSYL-PHOSPHATIDYLINOSITOL; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; DIACYLGLYCEROL PRODUCTION; PROTEOLIPID PROTEIN; STRUCTURAL PROTEINS; ACYLATED PROTEINS; CELLULAR PROTEINS; ENDOTHELIAL-CELLS	Because myristic acid (14:0) is important in regulating cell function, we have studied its utilization in BC3H1 muscle cells. Phosphatidylcholine contained 70-80% of the [9,10-H-3]14:0 radioactivity incorporated into the cell phospholipids. In both myoblasts and myocytes, however, large amounts of radioactivity also accumulated in a labile neutral lipid pool consisting mostly of triacylglycerol. Therefore, radioactive lipid products formed when BC3H1 cells labeled with 14:0 are stimulated are not necessarily derived only from phosphatidylcholine. Elongation of [9,10-H-3]14:0 occurred rapidly in the myoblasts and myocytes, and extensive desaturation also occurred in the myoblasts. Thus, even after short periods of labeling, substantial amounts of radioactivity are contained in fatty acids other than 14:0. The labeling of proteins with [9,10-H-3] myristic acid was generally similar in the myoblasts and myocytes. A number of lipid-soluble, polar radioactive metabolites were released into the medium during incubation of [9,10-H-3]14:0 with the cells. [1-C-14 14:0 was not converted to these compounds, indicating that they are chain-shortened 14:0 derivatives. Based on chemical analysis, two of the major products appear to be hydroxylated fatty acids. This oxidation process shows some specificity for 14:0 because similar compounds were not produced from palmitic, oleic, or linoleic acids. The myocytes formed larger amounts of the metabolites than the myoblasts, suggesting that differentiation may increase the activity of this 14:0 oxidative pathway.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Spector, Arthur/AAG-9860-2020		NIDDK NIH HHS [DK 28516] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028516] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIZZOZERO OA, 1986, J NEUROCHEM, V46, P630, DOI 10.1111/j.1471-4159.1986.tb13013.x; BURNS CP, 1978, LIPIDS, V13, P666, DOI 10.1007/BF02533743; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHRISTENSEN E, 1989, BIOCHIM BIOPHYS ACTA, V1004, P187, DOI 10.1016/0005-2760(89)90267-1; Crain P F, 1975, Methods Enzymol, V35, P359, DOI 10.1016/0076-6879(75)35176-8; DOERING TL, 1990, J BIOL CHEM, V265, P611; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; GORDON JA, 1990, J CLIN INVEST, V85, P1173, DOI 10.1172/JCI114550; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HUANG CF, 1990, J BIOL CHEM, V265, P17468; IOZZO RV, 1990, J BIOL CHEM, V265, P19980; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JAMES G, 1989, J BIOL CHEM, V264, P20998; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KOJIMA I, 1990, J BIOL CHEM, V265, P16846; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES MB, 1972, ANAL BIOCHEM, V47, P184, DOI 10.1016/0003-2697(72)90291-6; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MATO JM, 1987, J BIOL CHEM, V262, P2131; MATTIEU JM, 1989, NEUROCHEM RES, V14, P91; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MORRISON WR, 1964, J LIPID RES, V5, P600; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; ROMERO G, 1990, P NATL ACAD SCI USA, V87, P1476, DOI 10.1073/pnas.87.4.1476; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1988, SCIENCE, V239, P268; STANDAERT ML, 1984, J BIOL CHEM, V259, P2337; TAKEDA A, 1990, SCIENCE, V250, P676, DOI 10.1126/science.2146743; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WANDERS RJA, 1988, J NEUROL SCI, V88, P1, DOI 10.1016/0022-510X(88)90203-1; WANG YC, 1988, J CELL BIOL, V106, P797, DOI 10.1083/jcb.106.3.797; WELSH CJ, 1990, LIPIDS, V25, P675, DOI 10.1007/BF02544033; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; WILCOX CA, 1987, BIOCHEMISTRY-US, V26, P1029, DOI 10.1021/bi00378a008	45	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13883	13890						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856220				2022-12-25	WOS:A1991FY02700068
J	ROSS, TS; WHITELEY, B; GRAHAM, RA; MAJERUS, PW				ROSS, TS; WHITELEY, B; GRAHAM, RA; MAJERUS, PW			CYCLIC HYDROLASE-TRANSFECTED 3T3 CELLS HAVE LOW-LEVELS OF INOSITOL 1,2-CYCLIC PHOSPHATE AND REACH CONFLUENCE AT LOW-DENSITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PHOSPHOLIPID-BINDING-PROTEINS; MOUSE PANCREATIC MINILOBULES; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; BOVINE BRAIN; C ENZYMES; STIMULATION; METABOLISM; 4,5-TRISPHOSPHATE	The cDNA that encodes inositol-1,2-cyclic phosphate 2-phosphohydrolase (cyclic hydrolase), an enzyme that converts inositol 1,2-cyclic phosphate (cIns(1,2)P) to inositol 1-phosphate, was expressed in 3T3 cells to investigate the function of inositol cyclic phosphates. Cells with increased cyclic hydrolase activity had lower levels of cIns(1,2)P and grew to a lower density at confluence than control cells. This relationship was strengthened by the demonstration that several cell types with differences in cyclic hydrolase activity had levels of cIns(1,2)P and saturation densities that also correlated inversely with cyclic hydrolase activity. In addition, cyclic hydrolase activity is higher in cells at confluence compared to subconfluence. These results suggest that cellular cIns(1,2)P levels are determined by cyclic hydrolase activity and play a role in the control of cell proliferation.	FOX CHASE CANC INST,NUCL MAGNET RESONANCE LAB,PHILADELPHIA,PA 19111	Fox Chase Cancer Center	ROSS, TS (corresponding author), WASHINGTON UNIV,SCH MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110, USA.			Ross, Theodora/0000-0002-9166-1802	NHLBI NIH HHS [HLBI 16634, HLBI 14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R37HL016634, P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BINDER H, 1985, ANAL BIOCHEM, V148, P220, DOI 10.1016/0003-2697(85)90649-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONNOLLY TM, 1986, J BIOL CHEM, V261, P122; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAWSON MC, 1973, BIOCHEM J, V134, P59; DAWSON RMC, 1972, BIOCHEM J, V127, P113, DOI 10.1042/bj1270113; DIXON JF, 1987, BIOCHEM BIOPH RES CO, V149, P1208, DOI 10.1016/0006-291X(87)90536-5; DIXON JF, 1985, J BIOL CHEM, V260, P6068; DIXON JF, 1987, J BIOL CHEM, V262, P13892; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P238; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GRAHAM RA, 1987, J BIOL CHEM, V262, P35; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAIGLER HT, 1989, TRENDS BIOCHEM SCI, V14, P48, DOI 10.1016/0968-0004(89)90041-8; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; ISHII H, 1986, P NATL ACAD SCI USA, V83, P6397, DOI 10.1073/pnas.83.17.6397; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KIM JW, 1989, BIOCHEM BIOPH RES CO, V163, P177, DOI 10.1016/0006-291X(89)92117-7; KOCH MA, 1974, BIOCHEM BIOPH RES CO, V58, P361, DOI 10.1016/0006-291X(74)90373-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOSATA M, 1982, P NATL ACAD SCI-BIOL, V79, P7654, DOI 10.1073/pnas.79.24.7654; LIN G, 1990, BIOCHEMISTRY-US, V29, P2747, DOI 10.1021/bi00463a018; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MICHELL RH, 1981, PHILOS T R SOC B, V296, P123, DOI 10.1098/rstb.1981.0177; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKAR MC, 1987, J BIOL CHEM, V262, P340; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHAYMAN JA, 1986, BIOCHIM BIOPHYS ACTA, V886, P171; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TARVER AP, 1987, J BIOL CHEM, V262, P17268; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILSON DB, 1985, P NATL ACAD SCI USA, V82, P4013, DOI 10.1073/pnas.82.12.4013	60	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9086	9092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851165				2022-12-25	WOS:A1991FM03800066
J	KNOWLTON, KU; BARACCHINI, E; ROSS, RS; HARRIS, AN; HENDERSON, SA; EVANS, SM; GLEMBOTSKI, CC; CHIEN, KR				KNOWLTON, KU; BARACCHINI, E; ROSS, RS; HARRIS, AN; HENDERSON, SA; EVANS, SM; GLEMBOTSKI, CC; CHIEN, KR			CO-REGULATION OF THE ATRIAL-NATRIURETIC-FACTOR AND CARDIAC MYOSIN LIGHT CHAIN-2 GENES DURING ALPHA-ADRENERGIC STIMULATION OF NEONATAL RAT VENTRICULAR CELLS - IDENTIFICATION OF CIS SEQUENCES WITHIN AN EMBRYONIC AND A CONSTITUTIVE CONTRACTILE PROTEIN GENE WHICH MEDIATE INDUCIBLE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGESTIVE HEART-FAILURE; DNA-BINDING PROTEIN; MYOCARDIAL-CELLS; CYCLIC-AMP; ALPHA-1-ADRENERGIC STIMULATION; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; POLYPEPTIDE GENE; MESSENGER-RNA; MUSCLE-CELLS	To study the mechanisms which mediate the transcriptional activation of cardiac genes during alpha-adrenergic stimulation, the present study examined the regulated expression of three cardiac genes, a ventricular embryonic gene (atrial natriuretic factor, ANF), a constitutively expressed contractile protein gene (cardiac MLC-2), and a cardiac sodium channel gene. Alpha-1-adrenergic stimulation activates the expression and release of ANF from neonatal ventricular cells. As assessed by RNase protection analyses, treatment with alpha-adrenergic agonists increases the steady-state levels of ANF mRNA by greater than 15-fold. However, a rat cardiac sodium channel gene mRNA is not induced, indicating that alpha-adrenergic stimulation does not lead to an increase in the expression of all cardiac genes. Studies employing a series of rat ANF luciferase and rat MLC-2 luciferase fusion genes identify 315- and 92-base pair cis regulatory sequences within an embryonic gene (ANF) and a constitutively expressed contractile protein gene (MLC-2), respectively, which mediate alpha-adrenergic-inducible gene expression. Transfection of various ANF luciferase reporters into neonatal rat ventricular cells demonstrated that upstream sequences which mediate tissue-specific expression (-3003 to -638) can be segregated from those responsible for inducibility. The lack of inducibility of a cardiac Na+ channel gene, and the segregation of ANF gene sequences which mediate cardiac specific from those which mediate inducible expression, provides further insight into the relationship between muscle-specific and inducible expression during cardiac myocyte hypertrophy. Based on these results, a testable model is proposed for the induction of embryonic cardiac genes and constitutively expressed contractile protein genes and the noninducibility of a subset of cardiac genes during alpha-adrenergic stimulation of neonatal rat ventricular cells.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED M-013C,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,DEPT KINESIOL,LOS ANGELES,CA 90024; SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOLEC BIOL,SAN DIEGO,CA 92182	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Los Angeles; California State University System; San Diego State University; California State University System; San Diego State University			Evans, Sylvia/G-1980-2015		NHLBI NIH HHS [HL-36139, HL26-H] Funding Source: Medline; NINDS NIH HHS [NS-25037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAI H, 1988, CIRC RES, V62, P926, DOI 10.1161/01.RES.62.5.926; ARGENTIN S, 1985, J BIOL CHEM, V260, P4568; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BLOCH KD, 1986, CELL, V47, P695, DOI 10.1016/0092-8674(86)90512-X; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAY ML, 1987, HYPERTENSION, V9, P485, DOI 10.1161/01.HYP.9.5.485; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDWARDS BS, 1988, J CLIN INVEST, V81, P82, DOI 10.1172/JCI113314; EPPENBERGER HM, 1964, DEV BIOL, V10, P1, DOI 10.1016/0012-1606(64)90002-8; FEINBERG AP, 1989, ANAL BIOCHEM, V132, P6; FIELD LJ, 1988, SCIENCE, V26, P953; FRANCH HA, 1988, CIRC RES, V62, P31, DOI 10.1161/01.RES.62.1.31; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GLEMBOTSKI CC, 1987, ENDOCRINOLOGY, V12, P843; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUSTAFSON TA, 1986, CIRC RES, V59, P194, DOI 10.1161/01.RES.59.2.194; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HENDERSON SA, 1988, NUCLEIC ACIDS RES, V16, P4722, DOI 10.1093/nar/16.10.4722; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; IWAKI K, 1990, J BIOL CHEM, V265, P13809; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KIM D, 1987, CIRCULATION, V76, P252; KUMAR CC, 1986, J BIOL CHEM, V261, P2866; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LATTION AL, 1986, AM J PHYSIOL, V251, pH980; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINER JH, 1990, P NATL ACAD SCI USA, V87, P4089; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROSEN MR, 1977, CIRC RES, V40, P390, DOI 10.1161/01.RES.40.4.390; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEI CA, 1990, J BIOL CHEM, V265, P7166; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; SEN A, 1988, J BIOL CHEM, V263, P19132; SHIELDS PP, 1989, J BIOL CHEM, V264, P9322; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SILLS MN, 1989, J CLIN INVEST, V84, P331, DOI 10.1172/JCI114158; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WU JP, 1989, J BIOL CHEM, V264, P6472; WU JP, 1988, AM J PHYSIOL, V255, pE388, DOI 10.1152/ajpendo.1988.255.3.E388	65	244	246	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7759	7768						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850419				2022-12-25	WOS:A1991FJ34200071
J	BRINTON, BT; CADDLE, MS; HEINTZ, NH				BRINTON, BT; CADDLE, MS; HEINTZ, NH			POSITION AND ORIENTATION-DEPENDENT EFFECTS OF A EUKARYOTIC Z-TRIPLEX DNA MOTIF ON EPISOMAL DNA-REPLICATION IN COS-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; EARLY SV40 MUTANTS; SYNTHESIS INVITRO; SEQUENCES; TERMINATION; REGION; INITIATION; FRAGMENTS; SUPPORT; INVIVO	A cluster of simple repeated sequences composed of 5'-(GC)5(AC)18(AG)21(G)9(CAGA)4GAGGGAGAGAGGCAGAGAGGG(AG)27-3' located near the origin of replication associated with the Chinese hamster dhfr gene has been shown to adopt multiple Z-form and triplex DNA structures under various experimental conditions (Bianchi, A., Wells, R. D., Heintz, N. H., and Caddle, M. S. (1990) J. Biol. Chem. 265, 21789-21796). Thus, we refer to the cluster of alternating repeats as a Z-triplex DNA motif. Primer extension studies indicate that DNA polymerases traverse the Z-triplex sequence more readily in the Z to triplex direction than in the triplex to Z direction. To examine the effect of these sequences on replication fork travel in living cells, the Z-triplex motif was cloned in both orientations on the early and late side of the SV40 origin of replication in the vector pSV011. Test constructs were cotransfected along with pSV011 into COS-7 cells, and plasmid replication was monitored by the accumulation of DpnI-resistant replication products. A single copy of the Z-triplex motif reduced plasmid replication after 48 h by 20-50%, depending upon the position and orientation of the insert relative to the SV40 origin sequences. The replication of plasmids containing two copies of the Z-triplex motif, in different orientations on either side of the SV40 origin, was reduced by 85-95% as compared to the cotransfected control. Two-dimensional gel analysis of replication intermediates failed to show absolute termination of replication fork travel at the Z-triplex sequenced, but rather indicated that the Z-triplex region causes replication intermediates to accumulate during the late phases of replication. These results indicate that the dhfr Z-triplex region has complex effects on both replication fork movement and the termination phases of episomal DNA synthesis in animal cells.			BRINTON, BT (corresponding author), UNIV VERMONT,COLL MED,DEPT PATHOL,PROGRAM CELLULAR & MOLEC BIOL,BURLINGTON,VT 05405, USA.				NIGMS NIH HHS [GM 32859] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032859] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; BARN N, 1987, MOL CELL BIOL, V7, P2636; BEDINGER P, 1989, J BIOL CHEM, V264, P16880; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; BURHANS WC, 1986, P NATL ACAD SCI USA, V83, P7790, DOI 10.1073/pnas.83.20.7790; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.ge.19.120185.000333; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIELDSBERRY SC, 1989, NUCLEIC ACIDS RES, V17, P3261, DOI 10.1093/nar/17.8.3261; FINER MH, 1987, J BIOL CHEM, V262, P13323; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HEINTZ NH, 1983, NATURE, V302, P439, DOI 10.1038/302439a0; HEINTZ NH, 1988, MOL CELL BIOL, V8, P1923, DOI 10.1128/MCB.8.5.1923; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Maniatis T., 1982, MOL CLONING; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; RAO BS, 1988, NUCLEIC ACIDS RES, V16, P8077, DOI 10.1093/nar/16.16.8077; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STRAUSS BS, 1981, DNA REPAIR LABORATOR, P319; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WEISMANSHOMER P, 1989, BIOCHEM BIOPH RES CO, V164, P1149, DOI 10.1016/0006-291X(89)91789-0; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	38	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5153	5161						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848241				2022-12-25	WOS:A1991FC21700071
J	OSAWA, S; JOHNSON, GL				OSAWA, S; JOHNSON, GL			A DOMINANT NEGATIVE G-ALPHA-S MUTANT IS RESCUED BY SECONDARY MUTATION OF THE ALPHA-CHAIN AMINO TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENYLYL CYCLASE; G-PROTEINS; TRANSDUCIN; DOMAIN; STIMULATION; RECEPTORS; SUBUNIT; P21	The G(s) protein alpha-subunit, alpha-s, stimulates the activity of adenylyl cyclase. The sequence 223Asp-Val-Gly-Gly-Gln227 in the alpha-s polypeptide is predicted to interact with the gamma-phosphate of GTP and mediate the conformational change involved in alpha-s activation. Mutation of the alpha-s polypeptide within this region at Gly225 --> Thr had two demonstrative phenotypic effects when expressed in COS-1 cells: the mutant alpha-s chain was ineffective in activating adenylyl cyclase and inhibited in a concentration-dependent manner the beta-adrenergic receptor stimulation of cAMP synthesis. Thus, the Gly225 --> Thr mutation alters the ability of GTP to activate the alpha-s chain and when overexpressed the mutant polypeptide exerts a dominant negative phenotype. Mutation at the amino terminus which creates a constitutively active alpha-s rescued the inhibited state of the Gly225 --> Thr mutant when both mutations were encoded in the same polypeptide. This finding defines the amino terminus as a functional regulatory domain controlling the properties of the GTP/GDP binding site of G protein alpha-subunit polypeptide chains.	NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, 1400 JACKSON ST, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOSCH L, 1989, GUANINE NUCLEOTIDE B; CHEE WW, 1989, J BIOL CHEM, V264, P5687; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HINGORANI VN, 1988, J BIOL CHEM, V263, P19804; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KELLEHER DJ, 1986, MOL PHARMACOL, V30, P603; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; OSAWA S, 1990, MOL CELL BIOL, V10, P2931, DOI 10.1128/MCB.10.6.2931; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SIGAL IS, 1988, COLD SPRING HARB SYM, V53, P863, DOI 10.1101/SQB.1988.053.01.099; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; WOON CW, 1989, BIOCHEMISTRY-US, V28, P4547, DOI 10.1021/bi00437a006	26	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4673	4676						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1848223				2022-12-25	WOS:A1991FC21700004
J	SAKURAI, T; KUROKAWA, H; NONOMURA, Y				SAKURAI, T; KUROKAWA, H; NONOMURA, Y			THE CA2+-DEPENDENT ACTIN FILAMENT-SEVERING ACTIVITY OF 74-KDA PROTEIN (ADSEVERIN) RESIDES IN ITS NH2-TERMINAL HALF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; BINDING PROTEINS; PLASMA GELSOLIN; VILLIN; DOMAIN; IDENTIFICATION; END; POLYPHOSPHOINOSITIDES; POLYMERIZATION; PURIFICATION	Calcium sensitive actin severing protein, adseverin, with M(r) 74,000, was cleaved into two fragments of M(r) 42,000 and M(r) 39,000 by V8 protease and trypsin, and both fragments were purified by high performance (pressure) liquid chromatography ion-exchange column chromatography. To understand how adseverin can sever actin filaments, we identified the actin-binding domains. The NH2 termini of native adseverin and the M(r) 42,000 fragment were confirmed to be blocked by amino acid sequencing. Twelve amino acids of the M(r) 39,000 fragment were sequenced from the NH2 terminus; the sequence of this part had a homology to the hinge region between segments 3 and4 of gelsolin and villin. Thus, the M(r) 42,000 fragment is the NH2-terminal half (N42), and the M(r) 39,000 fragment is the COOH-terminal half (C39). Each fragment was examined for actin-severing, -nucleating, -capping, and phospholipid binding activities with and without calcium. N42 contained a calcium-dependent actin-severing activity regulated by phospholipid. C39 bound to G-actin in a calcium-dependent manner, but had no severing activity. The sequence homology and similar functional domain structure suggest a common structural basis for the calcium- and phospholipid-regulated actin-severing properties shared by adseverin, gelsolin, and villin.	UNIV TOKYO,FAC MED,DEPT PHARMACOL,TOKYO 113,JAPAN	University of Tokyo								ASHINO N, 1987, J BIOCHEM-TOKYO, V101, P609, DOI 10.1093/jb/101.3.609; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; DELCASTILLO AR, 1990, EMBO J, V9, P43, DOI 10.1002/j.1460-2075.1990.tb08078.x; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V96, P613, DOI 10.1093/oxfordjournals.jbchem.a134876; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TILNEY LG, 1981, J CELL BIOL, V90, P485, DOI 10.1083/jcb.90.2.485; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WYA M, 1988, J MOL BIOL, V203, P1127; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805	30	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4581	4585						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847925				2022-12-25	WOS:A1991FA69400086
J	WATANABE, K; NARIMATSU, S; YAMAMOTO, I; YOSHIMURA, H				WATANABE, K; NARIMATSU, S; YAMAMOTO, I; YOSHIMURA, H			OXYGENATION MECHANISM IN CONVERSION OF ALDEHYDE TO CARBOXYLIC-ACID CATALYZED BY A CYTOCHROME-P-450 ISOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIVER; DEHYDROGENASE; PURIFICATION; MICROSOMES; OXIDATION; ESTERASE	The oxygenation of an aldehyde, 11-oxo-DELTA-8-tetrahydrocannabinol to a carboxylic acid, DELTA-8-tetrahydrocannabinol-11-oic acid was catalyzed by cytochrome P-450 MUT-2 purified from hepatic microsomes of male ddN mice. The oxygenation mechanism was confirmed by the incorporation of oxygen-18 from molecular oxygen into the carboxylic acid formed. An aldehyde form but not a hydrated form of 11-oxo-DELTA-8-tetrahydrocannabinol may be a substrate for the cytochrome P-450. The oxygenation of aldehyde catalyzed by cytochrome P-450 might be a common metabolic reaction in biological systems, and should be considered as an additional role of cytochrome P-450 in biotransformation of endogenous compounds and xenobiotics.	HOKURIKU UNIV,FAC PHARMACEUT SCI,DEPT HYG CHEM,3-HO,KANAZAWA,ISHIKAWA 92011,JAPAN; KYUSHU UNIV,FAC PHARMACEUT SCI,DEPT HYG & FORENS CHEM,FUKUOKA 812,JAPAN	Hokuriku University; Kyushu University								Bell R., 1966, ADV PHYS ORG CHEM, V4, P1, DOI DOI 10.1016/S0065-3160(08)60351-2; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FUNAE Y, 1985, BIOCHIM BIOPHYS ACTA, V842, P119, DOI 10.1016/0304-4165(85)90193-X; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HANIU M, 1984, ARCH BIOCHEM BIOPHYS, V235, P304, DOI 10.1016/0003-9861(84)90202-9; INAYAMA S, 1974, CHEM PHARM BULL, V22, P1519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCHE JL, 1976, J CHEM SOC, P976; OMURA T, 1964, J BIOL CHEM, V239, P2370; SHEPHARD EA, 1983, ANAL BIOCHEM, V129, P430, DOI 10.1016/0003-2697(83)90573-0; WATANABE K, 1990, BIOCHEM BIOPH RES CO, V166, P1308, DOI 10.1016/0006-291X(90)91008-G; WEINER H, 1976, J BIOL CHEM, V251, P3853; WEINER H, 1979, BIOCH PHARMACOLOGY E, V1, P107; YAMAMOTO I, 1990, EISEI KAGAKU, V36, P149, DOI 10.1248/jhs1956.36.149; YAMAMOTO I, 1988, BIOCHEM BIOPH RES CO, V153, P779, DOI 10.1016/S0006-291X(88)81163-X; YANG CS, 1987, MAMMALIAN CYTOCHROME, V2, P1	17	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2709	2711						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847130				2022-12-25	WOS:A1991EX60000008
J	ORNING, L; KRIVI, G; FITZPATRICK, FA				ORNING, L; KRIVI, G; FITZPATRICK, FA			LEUKOTRIENE-A4 HYDROLASE - INHIBITION BY BESTATIN AND INTRINSIC AMINOPEPTIDASE ACTIVITY ESTABLISH ITS FUNCTIONAL RESEMBLANCE TO METALLOHYDROLASE ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-ENDOTHELIAL CELLS; ARACHIDONIC-ACID; POLYMORPHONUCLEAR LEUKOCYTES; BIOSYNTHESIS; NEUTROPHILS; ADHESION; FAMILY	Bestatin, an inhibitor of aminopeptidases, was also a potent inhibitor of leukotriene (LT) A4 hydrolase. On isolated enzyme its effects were immediate and reversible with a K(i) = 201 +/- 95 nM. With erythrocytes it inhibited LTB4 formation > 90% within 10 min; with neutrophils it inhibited LTB4 formation by only 10% during the same period, increasing to 40% in 2 h. Bestatin inhibited LTA4 hydrolase selectively; neither 5-lipoxygenase nor 15-lipoxygenase activity in neutrophil lysates was affected. Purified LTA4 hydrolase exhibited an intrinsic aminopeptidase activity, hydrolyzing L-lysine-p-nitroanilide and L-leucine-beta-naphthylamide with apparent K(m) = 156-mu-M and 70-mu-M and V(max) = 50 and 215 nmol/min/mg, respectively. Both LTA4 and bestatin suppressed the intrinsic aminopeptidase activity of LTA4 hydrolase with apparent K(i) values of 5.3-mu-M and 172 nM, respectively. Other metallohydrolase inhibitors tested did not reduce LTA4 hydrolase/aminopeptidase activity, with one exception; captopril, an inhibitor of angiotensin-converting enzyme, was as effective as bestatin. The results demonstrate a functional resemblance between LTA4 hydrolase and certain metallohydrolases, consistent with a molecular resemblance at their putative Zn2+-binding sites. The availability of a reversible, chemically stable inhibitor of LTA4 hydrolase may facilitate investigations on the role of LTB4 in inflammation, particularly the process termed transcellular biosynthesis.	MONSANTO CO,CORP RES,ST LOUIS,MO 63198	Monsanto	ORNING, L (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,4200 E 9TH AVE,DENVER,CO 80262, USA.				NIAID NIH HHS [R01 AI26730] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACH M, 1983, PROSTAGLANDINS, V23, P759; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; BOKOCH GM, 1981, J BIOL CHEM, V256, P5317; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; COREY EJ, 1982, J AM CHEM SOC, V104, P1752, DOI 10.1021/ja00370a058; EDENIUS C, 1988, BIOCHEM BIOPH RES CO, V157, P801, DOI 10.1016/S0006-291X(88)80320-6; EVANS J, 1985, J BIOL CHEM, V269, P10966; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GIMBRONE MA, 1984, J CLIN INVEST, V74, P1552, DOI 10.1172/JCI111570; HOOVER RL, 1984, P NATL ACAD SCI-BIOL, V81, P2191, DOI 10.1073/pnas.81.7.2191; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; Marcus A., 1988, INFLAMMATION BASIC P, P129; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; OHISHI N, 1987, J BIOL CHEM, V262, P10200; ORNING L, 1990, J BIOL CHEM, V265, P14911; PRESCOTT SM, 1984, J BIOL CHEM, V259, P7615; RADMARK O, 1984, J BIOL CHEM, V259, P2339; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; STENSON WF, 1984, J BIOL CHEM, V259, P1784; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WILKES SH, 1985, J BIOL CHEM, V260, P3154; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	33	140	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1375	1378						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846352				2022-12-25	WOS:A1991EU49700006
J	MISRA, R; PETERSON, A; FERENCI, T; SILHAVY, TJ				MISRA, R; PETERSON, A; FERENCI, T; SILHAVY, TJ			A GENETIC APPROACH FOR ANALYZING THE PATHWAY OF LAMB ASSEMBLY INTO THE OUTER-MEMBRANE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FOLDING MUTATIONS; SIGNAL SEQUENCE; PROTEIN; EXPORT; K-12; LOCALIZATION; POLYPEPTIDE; SITES	Results presented in this study demonstrate that a mutation which inserts an additional tyrosine between the 2 tyrosines at residues 118 and 119 of mature LamB protein results in a temperature-dependent assembly defect. This defect leads to the accumulation of an intermediate at the restrictive temperature that is most likely an assembly-defective monomer. These monomers are rapidly degraded in the wild type (htrA+) strain, and the biphasic kinetics of this degradation indicate that the mutation affects the assembly process and not the final product, i.e. stable trimers. In addition, our data show that the temperature-dependent assembly defect in the mutant strain is reversible, and therefore the accumulated monomers represent a true assembly intermediate. Fractionation studies show that the monomers, which can be accumulated in htrA (degP) mutants at the restrictive temperature, are associated with the outer membrane, indicating that trimerization of LamB is not a prerequisite for localization.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544; UNIV SYDNEY,DEPT MICROBIOL,SYDNEY,NSW 2006,AUSTRALIA	Princeton University; University of Sydney			Ferenci, Tom/A-1177-2010	Silhavy, Thomas/0000-0001-7672-5153				BAKER K, 1987, PROG BIOPHYS MOL BIO, V49, P89, DOI 10.1016/0079-6107(87)90010-1; BENSON SA, 1984, P NATL ACAD SCI-BIOL, V81, P3830, DOI 10.1073/pnas.81.12.3830; BOSCH D, 1988, J BIOL CHEM, V263, P9952; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; HEINE HG, 1988, J BACTERIOL, V170, P1730, DOI 10.1128/jb.170.4.1730-1738.1988; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; KLOSE M, 1988, J BIOL CHEM, V263, P13291; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; NIKAIDO H, 1984, P NATL ACAD SCI-BIOL, V81, P1048, DOI 10.1073/pnas.81.4.1048; NIKAIDO H, 1990, EXPERIENTIA, V46, P174; RANDALLH.L, 1973, J BACTERIOL, V116, P1436, DOI 10.1128/JB.116.3.1436-1446.1973; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; Silhavy T.J., 1984, EXPT GENE FUSIONS; STADER J, 1986, J BIOL CHEM, V261, P5075; SZMELCMAN S, 1975, J BACTERIOL, V124, P112, DOI 10.1128/JB.124.1.112-118.1975; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; VOORHOUT W, 1988, J GEN MICROBIOL, V134, P599; VOSSCHEPERKEUTER GH, 1984, J MOL BIOL, V175, P511, DOI 10.1016/0022-2836(84)90182-7; YU MH, 1988, J BIOL CHEM, V263, P1424	21	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13592	13597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1856196				2022-12-25	WOS:A1991FY02700024
J	BERRY, EA; HUANG, LS; DEROSE, VJ				BERRY, EA; HUANG, LS; DEROSE, VJ			UBIQUINOL-CYTOCHROME C OXIDOREDUCTASE OF HIGHER-PLANTS - ISOLATION AND CHARACTERIZATION OF THE BC1 COMPLEX FROM POTATO-TUBER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART MITOCHONDRIA; POLYACRYLAMIDE-GEL ELECTROPHORESIS; OXIDATION-REDUCTION POTENTIALS; SACCHAROMYCES-CEREVISIAE; RESPIRATORY-CHAIN; PARACOCCUS-DENITRIFICANS; B-C1 COMPLEX; AFFINITY-CHROMATOGRAPHY; CARDIAC CYTOCHROME-C1; DENSITY GRADIENTS	A procedure is described for isolation of active ubiquinol-cytochrome c oxidoreductase (bc1 complex) from potato tuber mitochondria using dodecyl maltoside extraction and ion exchange chromatography. The same procedure works well with mitochondria from red beet and sweet potato. The potato complex has at least 10 subunits resolvable by gel electrophoresis in the presence of dodecyl sulfate. The fifth subunit carries covalently bound heme. The two largest ("core") subunits either show heterogeneity or include a third subunit. The purified complex contains about 4-mu-mol of cytochrome c1, 8-mu-mol of cytochrome b, and 20-mu-mol of iron/g of protein. The complex is highly delipidated, with 1-6 mol of phospholipid and about 0.2 mol of ubiquinone/mol of cytochrome c1. Nonetheless it catalyzes electron transfer from a short chain ubiquinol analog to equine cytochrome c with a turnover number of 50-170 mol of cytochrome c reduced per mol of cytochrome c1 per s, as compared with approximately 220 in whole mitochondria. The enzymatic activity is stable for weeks at 4-degrees-C in phosphate buffer and for months at -20-degrees-C in 50% glycerol. The activity is inhibited by antimycin, myxothiazol, and funiculosin. The complex is more resistant to funiculosin and diuron than the beef heart enzyme. The optical difference spectra of the cytochromes were resolved by analysis of full-spectrum redox titrations. The alpha-band absorption maxima are 552 nm (cytochrome c1), 560 nm (cytochrome b-560), and 557.5 + 565.5 nm (cytochrome b-566, which has a split alpha-band). Extinction coefficients appropriate for the potato cytochromes are estimated. Despite the low lipid and ubiquinone content of the purified complex, the midpoint potentials of the cytochromes (257, 51, and -77 mV for cytochromes c1, b-560, and b-566, respectively) are not very different from values reported for whole mitochondria. EPR spectroscopy shows the presence of a Rieske-type iron sulfur center, and the absence of centers associated with succinate and NADH dehydrogenases. The complex shows characteristics associated with a Q-cycle mechanism of redox-driven proton translocation, including two pathways for reduction of b cytochromes by quinols and oxidant-induced reduction of b cytochromes in the presence of antimycin.	UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB, DIV CHEM BIODYNAM, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	BERRY, EA (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB, DIV CELL & MOLEC BIOL, BERKELEY, CA 94720 USA.			Huang, Li-Shar/0000-0003-1427-2544	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM036884] Funding Source: NIH RePORTER; NCRR NIH HHS [S07RR05918-05] Funding Source: Medline; NIGMS NIH HHS [GM36884] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDO K, 1969, J ANTIBIOT, V22, P189, DOI 10.7164/antibiotics.22.189; ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; BEATTIE DS, 1986, BIOCHEMISTRY-US, V25, P1395, DOI 10.1021/bi00354a031; BERDEN JA, 1972, BIOCHIM BIOPHYS ACTA, V267, P7, DOI 10.1016/0005-2728(72)90133-8; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BERRY EA, 1986, METHOD ENZYMOL, V126, P305; BILL K, 1982, BIOCHIM BIOPHYS ACTA, V679, P28, DOI 10.1016/0005-2728(82)90251-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN GG, 1977, BIOCHEMISTRY-US, V16, P4449, DOI 10.1021/bi00639a019; Brumby P.E., 1967, METHOD ENZYMOL, V10, P463, DOI DOI 10.1016/0076-6879(67)10078-5; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; Clark W. M., 1960, OXIDATION REDUCTION; COLSON AM, 1977, EUR J BIOCHEM, V74, P521, DOI 10.1111/j.1432-1033.1977.tb11419.x; CONVENT B, 1978, EUR J BIOCHEM, V82, P473, DOI 10.1111/j.1432-1033.1978.tb12041.x; DEGLIESPOSTI M, 1985, PLANT PHYSIOL, V77, P758; DIOLEZ P, 1985, BIOCHIM BIOPHYS ACTA, V806, P56, DOI 10.1016/0005-2728(85)90081-7; DIRAGO JP, 1990, FEBS LETT, V263, P93, DOI 10.1016/0014-5793(90)80713-S; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; DOUCE R, 1972, BIOCHIM BIOPHYS ACTA, V275, P148, DOI 10.1016/0005-2728(72)90035-7; DUCET G, 1978, PLANT SCI LETT, V11, P217, DOI 10.1016/0304-4211(78)90006-8; DUPONT J, 1984, STRUCTURE FUNCTION M, P197; Dutton P L, 1978, Methods Enzymol, V54, P411; DUTTON PL, 1970, BIOCHEMISTRY-US, V9, P5077, DOI 10.1021/bi00828a006; DUTTON PL, 1971, PLANT PHYSIOL, V47, P282, DOI 10.1104/pp.47.2.282; ENGEL WD, 1980, BIOCHIM BIOPHYS ACTA, V592, P211, DOI 10.1016/0005-2728(80)90182-6; ESPOSTI MD, 1986, COMP BIOCHEM PHYS B, V85, P543, DOI 10.1016/0305-0491(86)90044-1; GABELLINI N, 1988, J BIOENERG BIOMEMBR, V20, P59, DOI 10.1007/BF00762138; GERTH K, 1980, J ANTIBIOT, V33, P1474, DOI 10.7164/antibiotics.33.1474; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HATEFI Y, 1962, J BIOL CHEM, V237, P1681; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HAWKESFORD MJ, 1987, PLANT MITOCHONDRIA S, P251; KAMEN MD, 1983, FED PROC, V42, P2815; KIM CH, 1987, BIOCHEMISTRY-US, V26, P1955, DOI 10.1021/bi00381a025; KIM CH, 1987, J BIOL CHEM, V262, P8103; KRIAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70, DOI 10.1016/S0005-2728(89)80190-2; Kroger A, 1978, Methods Enzymol, V53, P579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOWITZ AM, 1974, J BIOL CHEM, V249, P2428; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRES CAM, 1985, BIOPHYS J, V47, pA196; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; MENDELHARTVIG I, 1981, BIOCHIM BIOPHYS ACTA, V636, P91, DOI 10.1016/0005-2728(81)90079-7; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOREAU F, 1982, PLANT PHYSIOL, V70, P1380, DOI 10.1104/pp.70.5.1380; NAKAJIMA T, 1984, AGR BIOL CHEM TOKYO, V48, P3019, DOI 10.1080/00021369.1984.10866629; NELSON BD, 1977, BIOCHIM BIOPHYS ACTA, V460, P157, DOI 10.1016/0005-2728(77)90162-1; NEUBURGER M, 1982, ARCH BIOCHEM BIOPHYS, V217, P312, DOI 10.1016/0003-9861(82)90507-0; PASQUALI P, 1981, J BIOENERG BIOMEMBR, V13, P141, DOI 10.1007/BF00763836; PEIFFER WE, 1990, BIOCHEMISTRY-US, V29, P8696, DOI 10.1021/bi00489a027; PUMPHREY AM, 1960, BIOCHEM J, V76, P61, DOI 10.1042/bj0760061; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; RIESKE JS, 1964, J BIOL CHEM, V239, P3023; RIESKE JS, 1964, BIOCHEM BIOPH RES CO, V15, P338, DOI 10.1016/0006-291X(64)90171-8; SALERNO JC, 1989, J BIOL CHEM, V264, P15398; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRAGER RI, 1982, ANAL CHEM, V54, P1147; SHEPARD JF, 1980, SCIENCE, V208, P17, DOI 10.1126/science.208.4439.17; SIDHU A, 1982, J BIOL CHEM, V257, P7879; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; SONE N, 1987, J BIOL CHEM, V262, P15386; STERNBERG JC, 1960, ANAL CHEM, V32, P84, DOI 10.1021/ac60157a025; STRONG FM, 1960, J AM CHEM SOC, V82, P1513, DOI 10.1021/ja01491a070; TAKAMIYA K, 1982, PLANT CELL PHYSIOL, V23, P987; TERVOORT MJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P245, DOI 10.1016/0005-2728(81)90163-8; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TSAI A, 1986, BIOCHIM BIOPHYS ACTA, V852, P100, DOI 10.1016/0005-2728(86)90061-7; TSAI AL, 1983, J BIOL CHEM, V258, P2122; VANBREUKELEN EWM, 1977, EUPHYTICA, V26, P263, DOI 10.1007/BF00026987; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; VANNESTE WH, 1966, BIOCHIM BIOPHYS ACTA, V113, P175, DOI 10.1016/S0926-6593(66)80132-7; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WAN YP, 1975, BIOCHEM BIOPH RES CO, V63, P11, DOI 10.1016/S0006-291X(75)80003-9; WEISS H, 1979, EUR J BIOCHEM, V99, P139, DOI 10.1111/j.1432-1033.1979.tb13240.x; WEISS H, 1978, EUR J BIOCHEM, V88, P17, DOI 10.1111/j.1432-1033.1978.tb12418.x; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3; WYCKOFF M, 1977, ANAL BIOCHEM, V78, P459, DOI 10.1016/0003-2697(77)90107-5; YANG XH, 1986, J BIOL CHEM, V261, P2282; YONETANI T, 1961, J BIOL CHEM, V236, P1680; YU CA, 1974, J BIOL CHEM, V249, P4905; YU CA, 1972, J BIOL CHEM, V247, P1012; YU CA, 1975, J BIOL CHEM, V250, P1383; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008; YU CA, 1979, ARCH BIOCHEM BIOPHYS, V198, P314, DOI 10.1016/0003-9861(79)90424-7; ZAUGG WS, 1962, BIOCHEM BIOPH RES CO, V9, P213, DOI 10.1016/0006-291X(62)90060-8	91	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9064	9077						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1851164				2022-12-25	WOS:A1991FM03800064
J	LEGRAND, AB; LAWSON, JA; MEYRICK, BO; BLAIR, IA; OATES, JA				LEGRAND, AB; LAWSON, JA; MEYRICK, BO; BLAIR, IA; OATES, JA			SUBSTITUTION OF 15-HYDROXYEICOSATETRAENOIC ACID IN THE PHOSPHOINOSITIDE SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; HYDROXYEICOSATETRAENOIC ACIDS; 15-LIPOXYGENASE PRODUCTS; FATTY-ACIDS; DIACYLGLYCEROL; ACTIVATION; SN-1,2-DIACYLGLYCEROLS; SPECIFICITY	Consideration of how 15-hydroxyeicosatetraenoic acid (15-HETE) might exert its biological actions led us to investigate the consequences of it incorporation into bovine pulmonary arterial endothelial cell (BPAEC) phospholipids. [H-3]15(S)-HETE was incorporated mainly (89%) into phosphatidylinositols, predominantly as 1-stearoyl-2-(15-HETE) phosphatidylinositol. By contrast 5(S)- and 12(S)-HETE are incorporated largely into phosphatidylcholine. 15-HETE had a long persistence in the phosphatidylinositols of BPAEC with a half-life of 12 h; its uptake was concentration-dependent, and it accumulated so that 2-(15-HETE) phosphatidylinositol accounted for 10.9% of total phosphatidylinositol after four sequential 1-h incubations of cells with 1-mu-M 15(S)-HETE. After incubating BPAEC with 15(S)-HETE, stimulation of the cells with bradykinin led to an increase in the levels of 15-HETE. Following addition of bradykinin to cells exposed to [H-3]15(S)-HETE, a radiolabeled diacylglycerol was isolated. A mass spectrum of its pentafluorobenzoyl (PFBO) trimethylsilyl (Me3Si) derivative obtained with direct electron capture negative ion chemical ionization mass spectrometry (DNICI/MS) revealed a molecular anion and fragment ions that were identical with those observed with the PFBO/Me3Si derivative of authentic 1-stearoyl-2-(15-HETE) diacylglycerol. There was a lesser quantity of 1-oleoyl-2-(15-HETE) diacylglycerol. An increase in the quantity of 1-stearoyl-2-(15-HETE) diacylglycerol from 6 +/- 1.4 pmol/10(7) cells in the basal state to 12.7 +/- 3.5 after bradykinin was measured by DNICI/MS utilizing a deuterium-labeled analog as an internal standard. Thus, incorporation of 15(S)-HETE into the phosphatidylinositol of these cells led to the release of altered second messengers.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34208] Funding Source: Medline; NIGMS NIH HHS [GM-15431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDYOPADHYAY GK, 1988, J BIOL CHEM, V263, P7567; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOEYNAEMS JM, 1981, LIPIDS, V16, P246, DOI 10.1007/BF02535024; BONI LT, 1985, J BIOL CHEM, V260, P819; BURHOP KE, 1988, CIRC RES, V62, P687, DOI 10.1161/01.RES.62.4.687; CAPDEVILA JH, 1987, BIOCHEM BIOPH RES CO, V146, P638, DOI 10.1016/0006-291X(87)90576-6; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COREY EJ, 1979, J AM CHEM SOC, V101, P1586, DOI 10.1021/ja00500a035; DELEBASSEE S, 1988, ANN INST PASTEUR IMM, V139, P383, DOI 10.1016/0769-2625(88)90065-7; FOGH K, 1989, PROSTAGLANDINS, V37, P213, DOI 10.1016/0090-6980(89)90058-0; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; HAMBERG M, 1980, ACTA PHYSIOL SCAND, V110, P219, DOI 10.1111/j.1748-1716.1980.tb06656.x; HEYMANS F, 1987, FEBS LETT, V218, P35, DOI 10.1016/0014-5793(87)81013-X; HUGHES H, 1986, ANAL BIOCHEM, V152, P107, DOI 10.1016/0003-2697(86)90127-2; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; JOHNSON HG, 1985, AM REV RESPIR DIS, V131, P919; KOSHIMOTO A, 1980, J BIOL CHEM, V255, P2273; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; MATHUR SN, 1988, BIOCHEM J, V256, P807, DOI 10.1042/bj2560807; MICHELL RH, 1979, TRENDS BIOCHEM SCI, V4, P128, DOI 10.1016/0968-0004(79)90443-2; MOORE SA, 1988, J CELL PHYSIOL, V137, P75, DOI 10.1002/jcp.1041370109; MORI T, 1982, J BIOCHEM, V91, P427, DOI 10.1093/oxfordjournals.jbchem.a133714; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NOMURA H, 1986, BIOCHEM BIOPH RES CO, V140, P1143, DOI 10.1016/0006-291X(86)90754-0; PAWLOWSKI NA, 1982, J EXP MED, V155, P1653, DOI 10.1084/jem.155.6.1653; PREISS J, 1986, J BIOL CHEM, V261, P8597; RABIER M, 1988, NEUROENDOCRINOLOGY, V47, P323, DOI 10.1159/000124932; RANDO RR, 1984, BIOCHEM BIOPH RES CO, V122, P818, DOI 10.1016/S0006-291X(84)80107-2; RICHARDS CF, 1989, PROSTAGLANDINS, V38, P565, DOI 10.1016/0090-6980(89)90150-0; RYAN JW, 1978, TISSUE CELL, V10, P555, DOI 10.1016/S0040-8166(16)30348-2; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SHEN XY, 1988, BIOCHEMISTRY-US, V27, P996, DOI 10.1021/bi00403a024; SHIKI Y, 1987, AM J PHYSIOL, V252, pC436, DOI 10.1152/ajpcell.1987.252.4.C436; SMITH RJ, 1987, BIOCHEM BIOPH RES CO, V148, P636, DOI 10.1016/0006-291X(87)90924-7; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; STENSON WF, 1983, PROSTAGLANDINS, V26, P253, DOI 10.1016/0090-6980(83)90093-X; TURK J, 1982, J BIOL CHEM, V257, P7068; VANDERHOEK JY, 1988, ANN NY ACAD SCI, V524, P240; YANNI JM, 1989, INT ARCH ALLER A IMM, V90, P307, DOI 10.1159/000235043	42	86	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7570	7577						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850411				2022-12-25	WOS:A1991FJ34200041
J	VISSE, R; DERUIJTER, M; BROUWER, J; BRANDSMA, JA; VANDEPUTTE, P				VISSE, R; DERUIJTER, M; BROUWER, J; BRANDSMA, JA; VANDEPUTTE, P			UVR EXCISION REPAIR PROTEIN COMPLEX OF ESCHERICHIA-COLI BINDS TO THE CONVEX SIDE OF A CISPLATIN-INDUCED KINK IN THE DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); ABC EXCINUCLEASE; ACTION MECHANISM; PSORALEN CROSSLINK; DEFINED POSITION; UNIQUE SITE; ADDUCTS; NUCLEASE; IDENTIFICATION; QUANTITATION	The Escherichia coli UvrABC endonuclease is capable of initiating the repair of a wide variety of DNA damages. To study the binding of the UvrAB complex to the DNA at the site of a lesion we have constructed a synthetic DNA fragment with a defined cis-diamminedichloroplatinum(II) (cis-Pt).GG adduct. The cis-Pt.GG is the major adduct after treatment of DNA with the antitumor agent cisplatin. Binding to the DNA at the site of the defined lesion was studied with DNase I and MPE.Fe(II) hydroxyl radical footprinting. The results indicate that the UvrAB complex binds to the convex side of the kink in the DNA caused by the cis-Pt.GG adduct. Concerted incisions of the damaged strand by the UvrABC endonuclease were at the 8th phosphodiester bond 5' to and at the 4th bond 3' of the adjacent guanines. An additional incision was found at the 15th phosphodiester bond 5' to the damaged site. This extra incision was stimulated by a high concentration of UvrC.			VISSE, R (corresponding author), LEIDEN STATE UNIV,GORLAEUS LABS,DEPT BIOCHEM,MOLEC GENET LAB,POB 9502,2300 RA LEIDEN,NETHERLANDS.							BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; COMESS KM, 1990, BIOCHEMISTRY-US, V29, P2102, DOI 10.1021/bi00460a020; FICHTINGERSCHEPMAN AMJ, 1987, CANCER RES, V47, P3000; FICHTINGERSCHEPMAN AMJ, 1985, CHEM-BIOL INTERACT, V55, P275, DOI 10.1016/S0009-2797(85)80135-6; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; JONES BK, 1990, J BIOL CHEM, V265, P3489; KOZELKA J, 1986, INORG CHEM, V25, P1075, DOI 10.1021/ic00228a002; Maxam A M, 1980, Methods Enzymol, V65, P499; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PAGE JD, 1990, BIOCHEMISTRY-US, V29, P1016, DOI 10.1021/bi00456a026; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; SANCAR A, 1984, P NATL ACAD SCI-BIOL, V81, P7397, DOI 10.1073/pnas.81.23.7397; SELBY CP, 1988, BIOCHEMISTRY-US, V27, P7184, DOI 10.1021/bi00419a004; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; VANHOUTEN B, 1988, J BIOL CHEM, V263, P16553; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VANHOUTEN B, 1986, J BIOL CHEM, V261, P14135; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1988, NUCLEIC ACIDS RES, V16, P4539, DOI 10.1093/nar/16.10.4539; YOAKUM GH, 1981, NATURE, V292, P171, DOI 10.1038/292171a0	29	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7609	7617						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1850413				2022-12-25	WOS:A1991FJ34200047
J	BECK, KA; KEEN, JH				BECK, KA; KEEN, JH			INTERACTION OF PHOSPHOINOSITIDE CYCLE INTERMEDIATES WITH THE PLASMA MEMBRANE-ASSOCIATED CLATHRIN ASSEMBLY PROTEIN AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; COATED VESICLES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CHOLINERGIC STIMULATION; INOSITOL POLYPHOSPHATE; CHROMAFFIN CELLS; HUMAN-PLATELETS; PC12 CELLS; POLYPEPTIDES; RECEPTOR	Several components of the phosphoinositide cycle have been found to interact specifically and at physiological concentrations with the plasma membrane-associated clathrin assembly (adaptor) protein AP-2. These include phosphatidylinositol 4,5-bisphosphate and inositol 1,4,5-trisphosphate, which are present at the plasma membrane, as well as other polyphosphoinositols. ATP and other polyphosphate molecules compete with the polyphosphoinositols, however, they are at least 80-fold less potent. Also, the effect of ATP, unlike the polyphosphoinositols, is blocked by physiological concentrations of Mg2+. Photoaffinity labeling of AP-2 by [alpha-P-32]8-azidoadenosine 5'-triphosphate and its competition by polyphosphoinositols has been used to identify the alpha-subunit of the AP-2 complex as the site of specific interaction with the polyphosphoinositols and to confirm direct ultrafiltration binding experiments. Proteolytic dissection of the labeled AP-2 demonstrated that binding occurred exclusively on the N-terminal portion of the alpha-subunit. Interaction of purified AP-2 with sub-mu-M concentrations of polyphosphoinositols has inhibitory effects on a novel AP-2 self-association described in the accompanying paper (Beck, K. A., and Keen, J. H., J. Biol. Chem. 266, 4437-4441), and at higher concentrations on the binding of AP-2 to dissociated clathrin trimers as well as AP-2-mediated clathrin coat assembly. Review of the literature shows that several physiological stimuli that are known to result in increased coat pit formation in intact cells correlate with increased phosphoinositide turnover. These in vivo correlations and the in vitro observations reported here suggest that coated membrane and phosphoinositide cycles may be interdependent within cells.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,3420 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIGMS NIH HHS [GM-28526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BALLA T, 1989, J BIOL CHEM, V264, P13605; BECK KA, 1990, J BIOL CHEM, V266, P4437; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; DANIEL JL, 1987, BIOCHEM J, V246, P109, DOI 10.1042/bj2460109; DANIEL JL, 1986, FEBS LETT, V206, P299, DOI 10.1016/0014-5793(86)81000-6; DOWNES P, 1982, CELL CALCIUM, V3, P467, DOI 10.1016/0143-4160(82)90031-8; EBERHARD DA, 1987, J NEUROCHEM, V49, P1634, DOI 10.1111/j.1471-4159.1987.tb01037.x; FISHER GW, 1983, DEV BIOL, V99, P456, DOI 10.1016/0012-1606(83)90295-6; FREEMAN D, 1987, BIOCHIM BIOPHYS ACTA, V927, P350, DOI 10.1016/0167-4889(87)90099-1; GEISOW MJ, 1985, EUR J CELL BIOL, V38, P51; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; GUPTA RK, 1980, J BIOL CHEM, V255, P3987; GUPTA RK, 1980, P NATL ACAD SCI-BIOL, V77, P2487, DOI 10.1073/pnas.77.5.2487; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; GUSOVSKY F, 1988, NEUROPHARMACOLOGY, V27, P95, DOI 10.1016/0028-3908(88)90206-7; HENDRICKSON HS, 1969, BIOCHEMISTRY-US, V8, P4855, DOI 10.1021/bi00840a031; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; ILES RA, 1985, BIOCHEM J, V229, P141, DOI 10.1042/bj2290141; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KHAN MMT, 1966, J AM CHEM SOC, V88, P668; LASSING I, 1988, EXP CELL RES, V174, P1, DOI 10.1016/0014-4827(88)90136-X; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; MORGENSTERN E, 1982, EUR J CELL BIOL, V26, P315; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SUGUIRA Y, 1981, BIOCHIM BIOPHYS ACTA, V641, P148; THOMAS AP, 1984, J BIOL CHEM, V259, P5574; TONER M, 1988, BIOCHEMISTRY-US, V27, P7435, DOI 10.1021/bi00419a039; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; VIRSHUP DM, 1988, J CELL BIOL, V106, P39, DOI 10.1083/jcb.106.1.39; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	47	127	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4442	4447						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1847920				2022-12-25	WOS:A1991FA69400066
J	HARADA, S; YANAGI, K				HARADA, S; YANAGI, K			AMINO-ACID-SEQUENCE HOMOLOGY OF EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-2 TO ADENOVIRUS E1A, HUMAN PAPILLOMA VIRUS-16 E7 AND SV40 LARGE T-ANTIGEN IN THE FUNCTIONAL DOMAINS FOR GROWTH TRANSFORMATION	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; SEPARATE DOMAINS; PHOSPHORYLATION; ACTIVATION; PROTEINS; BINDING				HARADA, S (corresponding author), NATL INST HLTH,DEPT VIROL & RICKETTSIOL,2-10-35 KAMIOSAKI,SHINAGAWA KU,TOKYO 141,JAPAN.							BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; KIEFF E, 1990, VIROLOGY, P1889; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1989, EMBO J, V8, P111; MILLER G, 1990, VIROLOGY, P1921; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	14	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					461	462						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849247				2022-12-25	WOS:A1991FT34400017
J	SUGIYAMA, M; TSUZUKI, K; OGURA, R				SUGIYAMA, M; TSUZUKI, K; OGURA, R			EFFECT OF ASCORBIC-ACID ON DNA DAMAGE, CYTOTOXICITY, GLUTATHIONE-REDUCTASE, AND FORMATION OF PARAMAGNETIC CHROMIUM IN CHINESE-HAMSTER V-79 CELLS TREATED WITH SODIUM CHROMATE(VI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SINGLE-STRAND BREAKS; HEXAVALENT CHROMIUM; CARCINOGEN CHROMATE; VITAMIN-E; CALCIUM CHROMATE; MAMMALIAN-CELLS; LESIONS; MUTAGENICITY; INVITRO; MECHANISM	The effect of pretreatment with ascorbic acid (vitamin C) on chromate-induced DNA damage, cytotoxicity, and enzyme inhibition as well as on the cellular reduction of chromium(VI) was investigated using Chinese hamster V-79 cells. Cellular pretreatment with nontoxic levels of 1 mM ascorbic acid for 24 h prior to exposure resulted in a significant increase (1.7-fold) in cellular levels of this vitamin. Alkaline elution assays demonstrated that this pretreatment decreased cellular levels of Na2CrO4-induced alkali-labile sites while the numbers of DNA-protein cross-links produced by chromate increased. In colony-forming assays, pretreatment with ascorbic acid enhanced the cytotoxicity of chromate. However, the inhibition of glutathione reductase attributed to Na2CrO4 was attenuated by this pretreatment. Under the same experimental condition, the uptake of chromate in pretreated cells was found to increase. ESR studies revealed that cellular pretreatment with ascorbic acid reduced the level of chromium(V) intermediate and increased the level of chromium(III) complex, indicating that cellular reduction of chromium(VI) to chromium(III) was accelerated by this vitamin. These results suggest that ascorbic acid decreases chromate-induced alkali-labile sites and chromium inhibition of glutathione reductase, but it enhances DNA-protein cross-links and cytotoxicity caused by this metal through its ability to directly reduce chromium(VI).			SUGIYAMA, M (corresponding author), KURUME UNIV, SCH MED, DEPT MED BIOCHEM, 67 ASAHI MACHI, KURUME, FUKUOKA 830, JAPAN.							BANKS RB, 1986, BIOCHEM BIOPH RES CO, V137, P8; BIANCHI V, 1983, MUTAT RES, V117, P279, DOI 10.1016/0165-1218(83)90128-3; CANTONI O, 1984, CARCINOGENESIS, V5, P1207, DOI 10.1093/carcin/5.9.1207; CONNETT PH, 1983, STRUCT BOND, V54, P93; COSTA M, 1984, PROGR CLIN BIOCH MED, V1, P1; CUPO DY, 1985, P NATL ACAD SCI USA, V82, P6755, DOI 10.1073/pnas.82.20.6755; De Flora S, 1989, LIFE CHEM REPORTS, V7, P169; DEFLORA S, 1985, CANCER RES, V45, P3188; DEFLORA S, 1984, CARCINOGENESIS, V5, P505, DOI 10.1093/carcin/5.4.505; DOLL R, 1981, Environmental Health Perspectives, V40, P11; ENTERLINE PE, 1974, J OCCUP ENVIRON MED, V16, P523; FORNACE AJ, 1981, CHEM-BIOL INTERACT, V36, P345, DOI 10.1016/0009-2797(81)90077-6; FRADKIN A, 1975, CANCER RES, V35, P1058; FURST A, 1969, PROG EXP TUMOR RES, V12, P102; GANTT R, 1985, ANAL BIOCHEM, V149, P365, DOI 10.1016/0003-2697(85)90584-6; GOODGAME DML, 1986, J INORG BIOCHEM, V26, P219, DOI 10.1016/0162-0134(86)80044-7; HORNIG D, 1975, ANN NY ACAD SCI, V258, P103, DOI 10.1111/j.1749-6632.1975.tb29271.x; JAGOTA SK, 1982, ANAL BIOCHEM, V127, P178, DOI 10.1016/0003-2697(82)90162-2; Jennette K W, 1979, Biol Trace Elem Res, V1, P55, DOI 10.1007/BF02783843; JENNETTE KW, 1982, J AM CHEM SOC, V104, P874, DOI 10.1021/ja00367a050; KAWANISHI S, 1986, J BIOL CHEM, V261, P5952; KITAGAWA S, 1988, INORG CHIM A-BIOINOR, V152, P251, DOI 10.1016/S0020-1693(00)91477-4; KORALLUS U, 1984, INT ARCH OCC ENV HEA, V53, P247, DOI 10.1007/BF00398817; KOUTRAS GA, 1964, J CLIN INVEST, V43, P323, DOI 10.1172/JCI104917; KOUTRAS GA, 1965, BRIT J HAEMATOL, V11, P360, DOI 10.1111/j.1365-2141.1965.tb06596.x; LEONARD A, 1980, MUTAT RES, V76, P227, DOI 10.1016/0165-1110(80)90018-4; MAJONE F, 1979, MUTAT RES, V67, P231, DOI 10.1016/0165-1218(79)90017-X; MILLER CA, 1988, MOL CARCINOGEN, V1, P125; NORSETH T, 1981, ENVIRON HEALTH PERSP, V40, P121, DOI 10.2307/3429226; SHI XL, 1989, BIOCHEM BIOPH RES CO, V163, P627, DOI 10.1016/0006-291X(89)92183-9; STAAL GEJ, 1969, BIOCHIM BIOPHYS ACTA, V185, P39, DOI 10.1016/0005-2744(69)90280-0; SUGIYAMA M, 1988, CANCER RES, V48, P1100; SUGIYAMA M, 1986, CANCER RES, V46, P4547; SUGIYAMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1080, DOI 10.1016/0006-291X(89)92219-5; SUGIYAMA M, 1986, MOL PHARMACOL, V29, P606; SUGIYAMA M, 1989, BIOL TRACE ELEM RES, V21, P399, DOI 10.1007/BF02917281; SUGIYAMA M, 1987, CANCER LETT, V38, P1, DOI 10.1016/0304-3835(87)90193-5; SUGIYAMA M, 1989, CARCINOGENESIS, V10, P737, DOI 10.1093/carcin/10.4.737; SUGIYAMA M, 1989, CANCER RES, V49, P6180; SUZUKI Y, 1990, ARCH TOXICOL, V64, P169, DOI 10.1007/BF02010721; TSAPAKOS MJ, 1981, J BIOL CHEM, V256, P3623; TUDA H, 1977, MUTAT RES, V46, P87	42	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3383	3386						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1847372				2022-12-25	WOS:A1991EY68200008
J	JAY, SD; SHARP, AH; KAHL, SD; VEDVICK, TS; HARPOLD, MM; CAMPBELL, KP				JAY, SD; SHARP, AH; KAHL, SD; VEDVICK, TS; HARPOLD, MM; CAMPBELL, KP			STRUCTURAL CHARACTERIZATION OF THE DIHYDROPYRIDINE-SENSITIVE CALCIUM-CHANNEL ALPHA-2-SUBUNIT AND THE ASSOCIATED DELTA-PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; BETA-SUBUNIT; RECEPTOR; SEQUENCE; PROTEINS; PURIFICATION; EXPRESSION; MEMBRANES; CLEAVAGE	Upon disulfide bond reduction, the alpha-2-subunit of the dihydropyridine-sensitive Ca2+ channel undergoes a characteristic mobility shift on sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis with the concurrent appearance of the three delta-peptides delta-1 (25,000 Da), delta-2 (22,000 Da), and delta-3 (17,000 Da). Densitometric scanning of Coomassie Blue-stained gels shows a stoichiometric ratio of 1.0:0.31:0.47:0.08 for the alpha-2-subunit and the delta-peptides 1, 2, and 3, respectively. Characterization of the delta-peptides using antibodies, photoincorporation of a hydrophobic probe, and lectin staining shows them to be antigenically similar hydrophobic glycoproteins. Amino-terminal sequence analysis of the delta-peptides reveals three identical sequences that match the predicted amino acid sequence of the alpha-2-subunit starting at Ala935. Enzymatic deglycosylation of the reduced alpha-2.delta-complex produces individual core peptides of 105,000 and 17,000 Da, respectively. Treatment of skeletal muscle membranes with high pH in the presence of reducing agents is able to extract the larger amino-terminal peptide but not the smaller carboxyl (delta) peptide, consistent with a single transmembrane domain in the carboxyl (delta) region. The data support a model of the alpha-2-subunit in which the propeptide is processed into two chains that remain attached through disulfide linkages.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,400 ECKSTEIN MED RES BLDG,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; SALK INST BIOTECHNOL IND ASSOCITES INC,LA JOLLA,CA 92037	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Salk Institute				Kahl, Steven/0000-0001-7085-9556; Campbell, Kevin/0000-0003-2066-5889	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039265] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39265, HL-14388] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARHANIN J, 1987, EUR J BIOCHEM, V164, P525, DOI 10.1111/j.1432-1033.1987.tb11158.x; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BURGESS AJ, 1988, EUR J BIOCHEM, V178, P527, DOI 10.1111/j.1432-1033.1988.tb14479.x; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOSSET M, 1983, J BIOL CHEM, V258, P6086; GLOSSMANN H, 1983, N-S ARCH PHARMACOL, V323, P1, DOI 10.1007/BF00498821; GLOSSMANN H, 1988, ISI ATLAS-PHARMACOL, V2, P202; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCLESKEY EW, 1986, J EXP BIOL, V124, P177; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SHARP AH, 1989, J BIOL CHEM, V264, P2816; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; VENTER JC, 1987, STRUCTURE PHYSL SLOW; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	32	198	214	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3287	3293						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847144				2022-12-25	WOS:A1991EX60000092
J	SURETTE, MG; HARKNESS, T; CHACONAS, G				SURETTE, MG; HARKNESS, T; CHACONAS, G			STIMULATION OF THE MU-A-PROTEIN-MEDIATED STRAND CLEAVAGE REACTION BY THE MU-B-PROTEIN, AND THE REQUIREMENT OF DNA NICKING FOR STABLE TYPE-1 TRANSPOSOSOME FORMATION - INVITRO TRANSPOSITION CHARACTERISTICS OF MINI-MU PLASMIDS CARRYING TERMINAL BASE PAIR MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; BACTERIOPHAGE-MU; TARGET IMMUNITY; MECHANISM; ENDS; DISTANCE; ENHANCER; SITE	We have examined the effects of a T --> C point mutation at the terminal nucleotide of the Mu ends in a mini-Mu plasmid on the early steps in the in vitro transposition reaction. These mutations inhibit the introduction of nicks at the Mu ends in a reaction with Mu A, HU, and integration host factor proteins. The presence of the point mutation at either the left end or the right end is sufficient to block the nicking reaction at both ends, indicating that the reaction is normally concerted. Addition of Mu B and ATP, however, dramatically stimulates the reaction of mutant mini-Mu plasmids carrying the mutation at one end but not at both ends. The data suggest that the Mu B protein mediates its effect through direct interaction with Mu A and that Mu B may play a role in an earlier step in the transposition process than previously proposed. In the presence of Mu B, two products are observed with the left end or right end mutant mini-Mu plasmids, a normal protein-DNA intermediate (Type 1 complex) which contains nicks at both Mu ends and an abortive product composed of free relaxed plasmid which is nicked only at the wild-type end. Furthermore, stable protein-DNA complexes characteristic of the first step in the in vitro transposition reaction are not observed in the absence of nicking or when only one end is a nicked; the introduction of nicks at both Mu ends is a prerequisite for stable transpososome assembly.			SURETTE, MG (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.			Harkness, Troy/0000-0002-8271-7229				ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1987, STRUCTURE EXPRESSION, V3, P97; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLINGAME RP, 1986, P NATL ACAD SCI USA, V83, P6012, DOI 10.1073/pnas.83.16.6012; CHACONAS G, 1988, BIOESSAYS, V9, P205, DOI 10.1002/bies.950090606; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; FAELEN M, 1978, NATURE, V271, P580, DOI 10.1038/271580a0; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Pato ML, 1989, MOBILE DNA, P23; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SYMONDS N, 1987, PHAGE MU, P1; WIJFFELMAN C, 1977, MOL GEN GENET, V151, P169, DOI 10.1007/BF00338691	24	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3118	3124						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1847140				2022-12-25	WOS:A1991EX60000068
J	COHEN, FE; STREWLER, GJ; BRADLEY, MS; CARLQUIST, M; NILSSON, M; ERICSSON, M; CIARDELLI, TL; NISSENSON, RA				COHEN, FE; STREWLER, GJ; BRADLEY, MS; CARLQUIST, M; NILSSON, M; ERICSSON, M; CIARDELLI, TL; NISSENSON, RA			ANALOGS OF PARATHYROID-HORMONE MODIFIED AT POSITION-3 AND POSITION-6 - EFFECTS ON RECEPTOR-BINDING AND ACTIVATION OF ADENYLYL CYCLASE IN KIDNEY AND BONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMORAL HYPERCALCEMIA; BIOLOGICAL-ACTIVITY; SYNTHETIC PEPTIDE; SECONDARY STRUCTURE; PLASMA-MEMBRANES; ALPHA-HELICES; 1-34 FRAGMENT; HUMAN-TUMOR; PROTEIN; MALIGNANCY	Predictive and spectroscopic methods were used to develop a model of the structures of the 1-34 peptides of parathyroid hormone (PTH) and the PTH-related protein (PTHrP). Circular dichroism (CD) studies of bovine PTH-(1-34) and human PTHrP-(1-34)amide in the presence of trifluoroethanol suggest the presence of 24-26 alpha-helical residues. For both peptides, interactions between amino- and carboxyl-region alpha-helices are predicted to result in a hydrophobic core with externally facing hydrophilic residues that include probable determinants of receptor binding and activation. Two such residues, Ser3 and Gln6, are conserved in all known members of the PTH/PTHrP family. We have synthesized 13 novel analogues of bovine PTH-(1-34) monosubstituted at positions 3 and 6 and have determined their biological activities in renal and bone cell radioreceptor and adenylyl cyclase assays. Position 3 analogues displayed biological activity that was reduced in direct proportion to the volume of the substituent side-chain. Position 6 analogues also displayed reduced biological activity, but no simple correlation with side-chain volume or hydrophobicity was evident. The analogues fully displaced labeled PTH from binding sites in renal membranes and bone cells, but [Phe3]bPTH-(1-34), [Tyr3]bPTH-(1-34), [Phe6] bPTH-(1-34), and [Ser6]bPTH-(1-34) were only partial agonists in one or both adenylyl cyclase assays. Of these, [Phe3]bPTH-(1-34) and [Phe6]bPTH-(1-34) were tested for antagonist activity and were found to inhibit the activation of adenylyl cyclase in response to bPTH-(1-34) or hPTHrP-(1-34)amide. These results indicate that positions 3 and 6 contribute important determinants of PTH receptor binding and activation. Modification at these positions represents a novel approach to the development of antagonists of PTH action.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; VET ADM MED CTR,ENDOCRINE UNIT,SAN FRANCISCO,CA 94121; KARA BIO AB,CALCIUM & BONE SECT,S-14104 HUDDINGE,SWEDEN; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035323] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA034738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039900] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34738] Funding Source: Medline; NIADDK NIH HHS [AM 35323] Funding Source: Medline; NIGMS NIH HHS [GM 39900] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; BURTIS WJ, 1987, J BIOL CHEM, V262, P7151; CHAN SDH, 1990, MOL ENDOCRINOL, V4, P638, DOI 10.1210/mend-4-4-638; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CODDINGTON JM, 1989, MOL ENDOCRINOL, V3, P749, DOI 10.1210/mend-3-4-749; COHEN FE, 1979, J MOL BIOL, V132, P275, DOI 10.1016/0022-2836(79)90260-2; CORPORATE L, 1985, PEPTIDES STRUCTURE F, P663; COTTER R J, 1988, Analytical Chemistry, V60, P781; DRAPER MW, 1982, J BIOL CHEM, V257, P3714; EPAND RM, 1985, INT J PEPT PROT RES, V25, P594; FISKIN AM, 1977, J BIOL CHEM, V252, P8261; FRELINGER AL, 1984, J BIOL CHEM, V259, P5507; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLOVER I, 1983, BIOPOLYMERS, V22, P293, DOI 10.1002/bip.360220138; HENDERSON JE, 1990, J BONE MINER RES, V5, P105, DOI 10.1002/jbmr.5650050203; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HONG BS, 1986, PEPTIDES, V7, P1131, DOI 10.1016/0196-9781(86)90143-9; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; LEE SC, 1989, BIOPOLYMERS, V28, P1115, DOI 10.1002/bip.360280606; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; NISSENSON RA, 1985, METHOD ENZYMOL, V109, P48; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; NISSENSON RA, 1979, J BIOL CHEM, V254, P1469; NISSENSON RA, 1983, ASSAY CALCIUM REGULA, P247; PARSONS JA, 1975, CALCIUM REGULATING H, P34; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; ROSENBLATT M, 1977, ENDOCR RES COMMUN, V4, P115, DOI 10.3109/07435807709073917; ROSENBLATT M, 1980, ENDOCRINOLOGY, V107, P545, DOI 10.1210/endo-107-2-545; ROSENBLATT M, 1976, J BIOL CHEM, V251, P159; ROSENBLATT M, 1982, ENDOCRINOLOGY CALCIU, P103; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SHAH GV, 1987, MOL CELL ENDOCRINOL, V49, P203, DOI 10.1016/0303-7207(87)90214-0; STEWART AF, 1988, J CLIN INVEST, V81, P596, DOI 10.1172/JCI113358; STEWART JM, 1972, PROGR PEPTIDE RES, P59; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; TEITELBAUM AP, 1982, ENDOCRINOLOGY, V111, P1524, DOI 10.1210/endo-111-5-1524; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P4605, DOI 10.1073/pnas.85.13.4605; THOMPSON DD, 1988, P NATL ACAD SCI USA, V85, P5673, DOI 10.1073/pnas.85.15.5673; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406; ZULL JE, 1987, MOL CELL ENDOCRINOL, V51, P267, DOI 10.1016/0303-7207(87)90037-2; ZULL JE, 1980, P NATL ACAD SCI-BIOL, V77, P3791, DOI 10.1073/pnas.77.7.3791; ZULL JE, 1990, J BIOL CHEM, V265, P5671	58	80	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1997	2004						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1846369				2022-12-25	WOS:A1991EU49700093
J	DUAN, DSR; PAZIN, MJ; FRETTO, LJ; WILLIAMS, LT				DUAN, DSR; PAZIN, MJ; FRETTO, LJ; WILLIAMS, LT			A FUNCTIONAL SOLUBLE EXTRACELLULAR REGION OF THE PLATELET-DERIVED GROWTH-FACTOR (PDGF) BETA-RECEPTOR ANTAGONIZES PDGF-STIMULATED RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; LIGAND-BINDING; DIMERIZATION; TRANSFECTION; ESTABLISHES; ACTIVATION; PROTEINS; OCCURS	The platelet-derived growth factor beta-receptor (PDGFr) is a 180-kDa transmembrane glycoprotein which binds BB-PDGF with high affinity. We have expressed the extracellular region of the receptor in Chinese hamster ovary cells using an expression vector that carries a dihydrofolate reductase gene as an amplifiable marker. Upon amplification of the receptor cDNA sequences by methotrexate a 110-kDa soluble form the receptor extracellular region (XR) was secreted at 12 mg/liter. The soluble XR protein fully retained the high affinity specific binding of the intact PDGFr for BB-PDGF (apparent dissociation constant, 0.4 nM). In the presence of ligand the soluble XR protein formed complexes that migrated on sodium dodecyl sulfate gels at the size expected for dimers of the protein. When added to fibroblast cultures the soluble XR protein blocked the ability of BB-PDGF to stimulate DNA synthesis but did not alter the mitogenic effect of AA-PDGF. The XR fragment also inhibited the binding of BB-PDGF to PDGFr and the activation of PDGFr tyrosine kinase by BB-PDGR. Thus, the soluble extracellular region protein of the PDGFr binds BB-PDGF with high affinity and functions as a specific antagonist of BB-PDGF actions.	UNIV CALIF SAN FRANCISCO,DEPT MED,HOWARD HUGHES MED INST,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; COR THERAPEUT INC,S SAN FRANCISCO,CA 94080	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Pazin, Michael/0000-0002-7561-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL032898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008120] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL32898-07, P01 HL43821] Funding Source: Medline; NIGMS NIH HHS [5T32GM-08120] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BASU M, 1986, J BIOL CHEM, V261, P2879; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; DOWER SK, 1989, J IMMUNOL, V142, P4314; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; HANNINK M, 1989, BIOCHIM BIOPHYS ACTA, V989, P1, DOI 10.1016/0304-419X(89)90031-0; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	28	85	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					413	418						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845970				2022-12-25	WOS:A1991EQ33900060
